<SEC-DOCUMENT>0001640334-21-000483.txt : 20210302
<SEC-HEADER>0001640334-21-000483.hdr.sgml : 20210302
<ACCEPTANCE-DATETIME>20210301204636
ACCESSION NUMBER:		0001640334-21-000483
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210302
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Skye Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		21700776

	BUSINESS ADDRESS:	
		STREET 1:		5910 PACIFIC CENTER BLVD, SUITE 320
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(949) 480-9051

	MAIL ADDRESS:	
		STREET 1:		5910 PACIFIC CENTER BLVD, SUITE 320
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Emerald Bioscience, Inc.
		DATE OF NAME CHANGE:	20190325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>skye_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html><head><title>skye_10k.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM 10-K</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&#9746;&nbsp;&nbsp;&nbsp;&nbsp; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the fiscal year ended <strong><u>December 31, 2020</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&#9744;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from __________ to __________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File Number: <strong><u>000-55136</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:45%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">Skye Bioscience, Inc.</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;"><strong>Nevada</strong></p></td> <td style="width:10%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;"><strong>45-0692882</strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;">(State or other jurisdiction </p> <p style="MARGIN: 0px; text-align:center;">of incorporation or organization)</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">(I.R.S. Employer</p> <p style="MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong>5910 Pacific Center Blvd.</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Suite 320, </strong><strong>San Diego, CA </strong></p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;"><strong>92121</strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;">(Address of principal executive offices) </p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">(Zip Code) </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number, including area code: <strong><u>(949) 480-9051</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;">Title of each class:</p></td> <td style="width:10%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;">Name of each exchange on which registered:</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong>None</strong></p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;"><strong>None</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(g) of the Act:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Common Stock, Par Value $0.001</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Title of Class)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746; No </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746; No </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. &#9746;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;"> <p style="MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td> <td style="width:20%;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="width:30%;"> <p style="MARGIN: 0px; text-align:justify;">Accelerated filer</p></td> <td style="width:20%;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">Non-accelerated filer</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&#9746;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Smaller reporting company</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&#9746;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Emerging growth company</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746; No </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $29,109,240 as of June 30, 2020, based upon the closing price of $0.16 per share of the registrant&#8217;s common stock on the OTCQB on June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of February 23, 2021, there were 350,007,749 shares of the registrant&#8217;s common stock issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="toc"><strong>TABLE</strong><strong> OF CONTENTS</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:9%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="MARGIN: 0px; text-align:center;"><strong>PAGE</strong></p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="5"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#p1">PART I</a></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i1">Item 1. </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i1">Business</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">3</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i1a">Item 1A.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i1a">Risk Factors</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">20</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i1b">Item 1B. </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i1b">Unresolved Staff Comments</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i2">Item 2. </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i2">Properties</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i3">Item 3.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i3">Legal Proceedings</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i4">Item 4.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#i4">Mine Safety Disclosures</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="5" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#p2">PART II</a></strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i5">Item 5.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i5">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">35</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i6">Item 6.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i6">Selected Financial Data</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">36</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i7">Item 7.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">36</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i7a">Item 7A.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i7a">Quantitative and Qualitative Disclosures About Market Risk</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">44</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i8">Item 8.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i8">Financial Statements and Supplementary Data</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">44</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i9">Item 9.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">44</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i9a">Item 9A.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i9a">Controls and Procedures</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">44</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i9b">Item 9B.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i9b">Other Information</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">45</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="5" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#p3">PART III</a></strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i10">Item 10.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i10">Directors, Executive Officers and Corporate Governance</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">46</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i11">Item 11.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i11">Executive Compensation</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">50</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i12">Item 12.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">54</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i13">Item 13.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i13">Certain Relationships and Related Transactions, and Director Independence</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">56</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i14">Item 14.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i14">Principal Accountant Fees and Services</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">59</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="5" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#p4">PART IV</a></strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i15">Item 15.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i15">Exhibits, Financial Statement Schedules</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">60</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i16">Item 16.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="#i16">Form 10-K Summary</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">63</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="p1"><strong>PART</strong><strong> I</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>As used in this report, unless otherwise indicated, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221; and &#8220;Skye Bioscience&#8221; refer to Skye Bioscience, Inc., a Nevada corporation formerly known as Emerald Bioscience, Inc., together with its wholly owned subsidiaries, Nemus, a California corporation, and EMBI Australia Pty Ltd, an Australian proprietary limited company.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i1"><strong><u>Item</u></strong><strong><u> 1. Business</u></strong><strong>. </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>History</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We were incorporated in the State of Nevada on March 16, 2011 in the transportation and logistics business. We are presently a biopharmaceutical company focused on the discovery, development and commercialization of cannabinoid-based therapeutics.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective March 25, 2019, we changed our name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc. and effective January 19, 2021, we changed our name to Skye Bioscience, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2019, we formed a new subsidiary in Australia, EMBI Australia Pty Ltd. in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia Pty Ltd. is to conduct clinical trials for our product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">As of December 31, 2020, we have devoted substantially all of our efforts to securing product licenses, carrying out research and development activities, planning clinical development, building infrastructure and raising capital. We have not yet realized revenue from our planned principal operations and is a number of years away from potentially being able to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Business Overview</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a biopharmaceutical company targeting the discovery, development and commercialization of cannabinoid-based therapeutics through a number of license agreements with the University of Mississippi (&#8220;UM&#8221;). We continue to be a development and commercialization partner of UM working to bring UM&#8217;s proprietary cannabinoid molecules through the development process.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>UM 5050 Prodrug Agreements and UM 8930 Analog Agreements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">In July 2018, we renewed our ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, related to an analog formulation of cannabidiol (&#8220;CBD&#8221;). On May 24, 2019, the ocular delivery licenses were replaced by &#8220;all fields of use&#8221; licenses for both UM 5050 and UM 8930 (collectively, the &#8220;License Agreements&#8221;). Pursuant to the License Agreements, UM granted us an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, the intellectual property related to UM 5050 and UM 8930 for all fields of use.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The License Agreements contain certain milestone payments, annual maintenance, royalty and sublicensing fees payable by us, as defined therein. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each License Agreement continues, unless earlier terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of our payment obligations under the License Agreements. UM may early terminate each License Agreement, by giving written notice of termination, upon our material breach of the License Agreements, including failure to make material payments without cure, material breach of covenants, representations or warranties without cure, material noncompliance of the license grant, a bankruptcy event, our dissolution or cessation of operations, our failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside our control, or our failure to meet certain pre-established development milestones. We may terminate each License Agreement upon 60 days&#8217; written notice to UM.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>UM 5070 License Agreement</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2017, we entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, the intellectual property related to a platform of cannabinoid-based molecules (&#8220;UM 5070&#8221;), to research, develop and commercialize products for the treatment of infectious diseases. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The License Agreement contains certain milestone payments, annual maintenance, royalty and sublicensing fees payable by us, as defined therein. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The License Agreement continues, unless earlier terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of our payment obligations under the License Agreement. UM may early terminate each License Agreement, by giving written notice of termination, upon our material breach of the License Agreement, including failure to make material payments without cure, material breach of covenants, representations or warranties without cure, material noncompliance of the license grant, a bankruptcy event, our dissolution or cessation of operations, our failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside our control, or our failure to meet certain pre-established development milestones. We may terminate the License Agreement upon 60 days&#8217; written notice to UM.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our Product Candidates</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cannabinoids are a class of chemically diverse compounds that are mainly found in extracts from the cannabis plant. These compounds express their physiological response by binding to cannabinoid (CB1 and CB2) and certain other receptors found throughout the human body. Some cannabinoids have been observed to exert multiple effects on the human body, including, but not limited to impacting the immune response, nervous system function and repair, gastrointestinal maintenance and motility, motor function in muscles, pancreatic functionality, tissue repair, blood sugar regulation, and integrity of function in the eye (including the optic nerve). Cannabis and specific cannabinoids have been studied widely and the results suggest that there may be a potential for these compounds to be used in treating many disorders or alleviating disease-associated symptoms.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are focused on the development of proprietary, synthetic cannabinoid-derived molecules that have been bioengineered to improve solubility, bioavailability and pharmacology of natural cannabinoids, while also providing the Company with strong intellectual property protection. The following table summarizes certain information regarding our cannabinoid product candidates:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:20%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Product Candidate</strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Indication</strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Development Status</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">THCVHS</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Glaucoma</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Preclinical</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">CBDVHS</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Multiple Targets</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Preclinical</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cannabinoid Cocktail</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Anti-infective</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Research</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>THCVHS</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our lead compound initially being developed to treat ocular disease is THCVHS, a prodrug of THC. A prodrug is a medication or compound, that after administration is metabolized into a pharmacological active drug. The molecule has been designed to make the usually lipophilic THC more hydrophilic to allow for improved transport across the membranes of the eye. In 2013 and 2014, UM conducted studies of the formulation in the rabbit ocular model which showed that THCVHS was able to penetrate all chambers of the eye which could potentially broaden the proposed therapeutic indications of interest for THCVHS to diseases of the eye that affect the retina and the optic nerve, such as glaucoma, macular degeneration or diabetic retinopathy. These studies also revealed that THCVHS was able to achieve potentially therapeutic concentrations in the anterior compartment, vitreous humor, and posterior compartment of the normal rabbit eye, which is very similar to the human eye in anatomy and physiology.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Glaucoma is an ocular neuropathy associated with the initiation of programmed cell death, known as apoptosis, of the retinal ganglion cells (&#8220;RGCs&#8221;) of the optic nerve, resulting in the progressive and irreversible loss of vision. Intraocular pressure (&#8220;IOP&#8221;) has been identified as an important risk factor in the pathogenesis of this disease. Elevated IOP can lead to damage of RGC axons through vascular ischemia by compromising blood flow to the cells, and physical crush injury as the elevated ocular pressure compresses these delicate cells. Cannabinoid receptors are highly concentrated in the eye, especially in the anterior compartment that helps regulate IOP, and the posterior compartment in the area of the retina and optic nerve. Stimulation of cannabinoid receptors by THC has been previously shown to lower IOP in both animal and human studies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Additional studies using an alpha-chymotrypsin induced glaucoma model in rabbits were performed by UM in 2013 and 2014 under a grant from the National Institutes of Health (the &#8220;NIH&#8221;). Those studies showed that THCVHS was able to reduce IOP by 45% to 50%. Reduction in IOP was successful in an almost linear dose-responsive manner, with greater decline in IOP associated with higher dosage concentration. The decline in IOP observed in the rabbit model correlated to historical human data when patients were exposed to systemically administered THC via inhalational methods. The human studies were conducted by the NIH and the U.S. Army in the 1970&#8217;s where glaucoma patients for the NIH study and normal volunteers for the U.S. Army study were exposed to THC by smoking marijuana. Patients tested by the NIH exhibited a decline in IOP ranging from 35% to as high as 65%, correlated to the amount of THC in the plasma. Normal volunteers in the U.S. Army study also showed a decrease in IOP of approximately 10% to 20% in a setting of normotension. While THC from smoking marijuana was able to reduce IOP in humans, the effect was short lived given the short half-life of the THC molecule. The half-life of the THCVHS used in the rabbit glaucoma model was considerably longer; however, we intend to formulate THCVHS in order to lengthen the half-life to the degree that it would be effective when dosed once a day.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We examined the THCVHS in further testing using a nanoparticle delivery system to prolong the drug&#8217;s half-life in late 2015 and 2016. The studies were conducted by UM and placed THCVHS into a solid lipid-nanoparticle system (&#8220;SLN&#8221;) to deliver the drug to the eye using topical drop administration. The SLN delivery of THCVHS was administered to rabbits that underwent elevated IOP inducement using the alpha-chymotrypsin model. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Data from that experiment confirmed previous studies that showed administration of THCVHS resulted in a 45% reduction in IOP from baseline with a half-life consistent with five to six-times per day dosing. When THCVHS was administered via SLN delivery in normotensive animals, a lower concentration of THCVHS (0.4% equivalent THC) exhibited a decrease in IOP of approximately 20% while a higher concentration of THCVHS (0.6% equivalent THC) lowered IOP up to 38%. The use of SLN technology lengthened the half-life of THCVHS equivalent to dosing the drug two to three times a day. The formulation we are developing for human studies will encapsulate THCVHS in a nanoemulsion including the emulsifier, Carbopol, to increase the residence time of the drug in the eye. Testing of this formulation in a normotensive animal models revealed statistically significant lowering of the IOP when compared to both latanoprost and timolol, the current standard-of-care in the treatment of IOP, as well as extended pharmacologic activity time that could support once daily dosing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Further animal experimentation conducted in 2016-2017 examined both the penetration and concentration of THCVHS in key organs of the eye. The data revealed that IOP declined in a concentration-time dependent manner and could be correlated to the concentration of THC in organs regulating IOP, such as the trabecular meshwork in the anterior compartment and the retina-choroid in the posterior compartment. The data was important for demonstrating a direct causal relationship between the penetration and concentration of THC with IOP-lowering capability and the presence of THC in multiple compartments of the eye. Additionally, neither free-THC nor 11-hydroxy-THC (the main active metabolite of THC) was detected in the peripheral circulation of the test animals, indicating that the topical dosage of the test compound remained restricted to the eye, an enclosed organ.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2019, UM completed experiments showing that THCVHS was statistically superior in lowering IOP compared to the prostaglandin-based therapy, latanoprost, the current standard-of-care for treating glaucoma. Significance was reached across multiple timepoints during a seven-day course of dosing using a validated rabbit normotensive ocular model and THCVHS exerted pharmacologic activity consistent with once-daily to twice-daily dosing. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, we worked with Glauconix Biosciences Inc. (&#8220;Glauconix&#8221;) to complete a pilot study to research the mechanism of action and IOP-lowering ability of THC when administered into an ex vivo model of a 3D-human trabecular meshwork using both healthy and glaucomatous-derived tissues. The Glauconix study validated the mechanism of action of THCVHS in lowering IOP, a defining disease process of hypertensive glaucoma. Moreover, biomarkers associated with inflammation and fibrosis in both normal and tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states; and data revealed that biomarkers associated with neovascularization, a disease process of new blood vessel formation that can damage the retina in a variety of ocular diseases, was also inhibited by THC, prompting further study for the utility of this drug in diseases of the retina.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The rabbit ocular model is an accepted animal model for regulatory agencies when considering a candidate drug for human testing and this data will be submitted as part of our investigational new drug application (&#8220;IND&#8221;) to the Food and Drug Administration (&#8220;FDA&#8221;). The manufacturing of the active pharmaceutical ingredient THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but may utilize regulatory-accepted excipients sourced from countries outside the United States, such as China. The recent COVID-19 pandemic may impact our ability to source specific materials that are part of the eye drop formulation and could possibly impact volunteer and/or patient recruitment in Australia for our Phase I clinical studies of THCVHS. The pandemic has resulted in a shift of our first in-human studies, from the second half of 2020 to the third quarter of 2021. Our first-in-human studies are to be conducted in healthy volunteers and patients with glaucoma and ocular hypertension in Australia (the &#8220;THCVHS Clinical Trial&#8221;). Initially, we plan to conduct a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single-ascending dose (&#8220;SAD&#8221;) and multiple-ascending dose (&#8220;MAD&#8221;) study to establish a safe and tolerable dosing window of THCVHS in humans that can be used in the design of subsequent clinical trials.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subsequently, we may advance THCVHS into a Phase 2 clinical trial provided that data from the Phase 1 clinical trial demonstrates that the topical delivery of THCVHS is safe and well-tolerated, and IOP is markedly different between THCVHS and the placebo. Design of a subsequent Phase 2 clinical trial will be dependent upon the advice of our Advisory Board, the FDA and other regulatory bodies.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>CBDVHS</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have embarked on research exploring the utility of different formulations of CBDVHS, our proprietary CBD analog. Early studies of CBDVHS demonstrated analgesic, anti-inflammation, anti-fibrotic, anti-seizure properties, including the potential treatment and management of several eye diseases, such as uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. Data we presented at the American Association of Pharmaceutical Scientists (&#8220;AAPS&#8221;) meeting held in November 2017, revealed that an ocular formulation of CBDVHS was able to penetrate multiple compartments of the eye, including reaching the retina and the optic nerve. Further testing will need to be conducted to further evaluate the possible utility of this compound as a therapeutic agent and we continue to advance our research studies related to CBDVHS to explore different therapeutic applications. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Cannabinoid Cocktail</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cannabinoid molecules have been shown in in vitro studies conducted by third parties to possess anti-infective activity against a variety of bacterial strains. We entered into a research agreement with UM to explore this area in 2015 and have tested a variety of cannabinoids in various strengths, combinations, and delivery systems against a variety of bacterial species found in community, healthcare, and institutional settings such as nursing homes, correctional facilities, and military quarters. As discussed above in &#8220;UM 5070 License Agreement,&#8221; in January 2017, we entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Other Potential Products</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We continue to work with UM to explore other potential indications and associated routes of administration based on the expanded UM 5050 and UM 8930 all fields licenses. Our decision to advance another potential therapeutic candidate will be influenced by a number of criteria, including but not limited to research, preclinical data, synthesis and formulation capability as well as prevailing market conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our Competitive Strengths</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cannabis is subject to strict regulation in the United States. Cannabis and cannabis extracts are classified by the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;), as a Schedule I substance, which means that, under federal law, it has no established medicinal use and may not be marketed or sold in the United States. In addition, the United States is a party to the Single Convention on Narcotic Drugs, which imposes certain requirements and restrictions on member parties with respect to the cultivation and wholesale trade in cannabis. Since 1968, UM has held the only contract with the Federal Government to cultivate cannabis on its behalf for research purposes and holds the requisite DEA registrations authorizing it to engage in that activity. The contract, which is open for competitive bidding at periodic intervals, is administered by the National Institute on Drug Abuse (&#8220;NIDA&#8221;), an agency within the NIH. UM&#8217;s current contract was awarded in 2015 and runs for a base year of one year with four one-year options. As the sole contract holder since 1968, UM has developed significant expertise in the extraction, separation, processing and manufacture of cannabinoids. UM has also engaged in the cultivation of cannabis and the extraction of cannabinoids for purposes of developing drug product candidates apart from its role as NIDA contractor. We have entered into several research and license agreements with UM and view this collaborative association as a significant strategic advantage in the marketplace.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The only cannabinoid products that are currently approved as drugs in the United States and, to our knowledge, all cannabinoid products in late-stage development, are predominantly orally delivered products. Cannabinoids, when ingested orally, are subject to significant first pass metabolism by the liver and potential drug-drug interactions, resulting in very high inter-patient and intra-patient variation in bioavailability which can potentially compromise both efficacy and safety. This has been published in the literature and in product labeling by regulatory agencies worldwide. These independent assessments correlate with highly variable response rates and safety profiles which, in some cases, have been deemed to have marginal clinical utility. We have licensed from UM the rights to THCVHS, a pro-drug formulation of THC. Data from UM supports the delivery of the pro-drug through absorptive routes other than the gastrointestinal tract, which we believe has the potential to mitigate the issue of first-pass metabolism by the liver, potentially enhancing drug bioavailability and predictive pharmacokinetics. We are also working with UM and other parties on methods to formulate and deliver CBDVHS and a variety of other pharmaceutical-grade cannabinoids to better manage symptoms and/or treat diseases. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our Business Strategy</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Our goal is to become a premier developer of synthetic cannabinoid-derived medicines for global markets to treat significant unmet medical needs. Our current operating strategy includes:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">selection and licensing of potential clinical targets based on internal and external published data, access to appropriate cannabinoids, and the impact of both developmental and market conditions&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">prioritization of product candidates based on the potential clinical utility and market of associated target indications&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">development and execution of an intellectual property strategy&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">Clinical development and advancement of our current product pipeline&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">outsourcing services, such as use of Clinical Research Organizations (&#8220;CROs&#8221;) and contract manufacturers for the active pharmaceutical ingredient, where possible and cost effective&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">obtaining regulatory direction and approval from the FDA, European Medicines Agency (&#8220;EMA&#8221;), and other regulatory agencies for our product candidates&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">research and development of additional indications for our product candidates&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">partnering, out-licensing, or selling our product candidates to pharmaceutical companies to maximize profits and to bring our state-of-the-art therapeutics to patients in need.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Sales and Marketing</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not established a sales, marketing or product distribution infrastructure because our lead product candidates are still in research, discovery or preclinical development stages. If and when we obtain approval to market any of our product candidates, we will evaluate what we believe to be the optimal commercialization path for the Company, the respective product candidate, and patients. Commercialization paths may include licensing, selling, or partnering with other commercial partners. We may also choose to build a commercial sales and marketing team for some or all of our product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Manufacturing</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities for final manufacture. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture of any products that we may commercialize.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">For all of our future product candidates, we aim to identify and qualify manufacturers to provide the API and fill-and-finish services prior to submission of a New Drug Application (&#8220;NDA&#8221;) to the FDA. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Intellectual Property</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The success of most of our product candidates will depend in large part on our ability to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">obtain and maintain patent and other legal protections for the proprietary technology, inventions and improvements we consider important to our business&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">prosecute our patent applications and defend any issued patents we obtain&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">preserve the confidentiality of our trade secrets&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">operate without infringing the patents and proprietary rights of third parties.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We intend to continue to seek patent protection for certain of our product candidates, drug delivery systems, molecular modifications, as well as other proprietary technologies and their uses by filing patent applications in the United States and other selected global territories. We intend for these patent applications to cover, where possible, claims for composition of matter, medical uses, processes for isolation and preparation, processes for delivery and formulations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of the date of this Annual Report, we have licensed from UM three inventions, which include U.S. patents as well as a number of foreign counterparts, including the European Union, Japan, Canada and Australia. The patents that we license, cover composition of matter and preparation of prodrug of THC, analog of cannabidiol, and platform of cannabinoids for the treatment of infectious diseases, and their methods of use. These patents are expected to expire in 2039. Additionally, in March 2020, we were notified by the United States Patent and Trademark Office, that a notice of allowance has been issued for the proprietary analog of cannabidiol, CBDVHS. The official issuance date for the CBDVHS US patent was July 2020. The expiration date of the US patent for CBDVHS is January 2037. Under our license agreements, UM retains ownership over the licensed patents and control over the maintenance and prosecution of the licensed patents and patent applications. We also rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees and selected consultants, scientific advisors and collaborators. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed through a relationship with a third party.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Competition</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, such as pharmaceutical companies, including generic drug companies, biotechnology companies, drug delivery companies and academic and research institutions. Many of our potential competitors may have substantially greater financial, scientific, technical, intellectual property, regulatory and human resources than we do, and greater experience than we do commercializing products and developing product candidates, including obtaining FDA and other regulatory approvals for product candidates. Consequently, our competitors may develop products for indications we pursue that are more effective, better tolerated, more widely prescribed or accepted, more useful and less costly, and they may also be more successful in manufacturing and marketing their products. We also face competition from third parties in recruiting and retaining qualified personnel, establishing clinical trial sites and enrolling patients for clinical trials and in identifying and acquiring or in-licensing new products and product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Government Regulation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. A failure to comply with such laws and regulations or prevail in any enforcement action or litigation related to noncompliance could have a material adverse impact on our business, financial condition and results of operations and could cause the market value of our common stock to decline.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Regulation of Cannabis and Cannabinoids</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>DEA Regulation</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cannabis, cannabis extracts and some cannabinoids are regulated as &#8220;controlled substances&#8221; as defined in the Controlled Substances Act (the &#8220;CSA&#8221;), which establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements administered by the DEA. The DEA is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, of controlled substances in order to prevent loss and diversion into illicit channels of commerce.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Cannabis, cannabis extracts and some cannabinoids are listed by the DEA as Schedule I controlled substances under the CSA. Consequently, their manufacture, shipment, storage, sale and use are subject to a high degree of regulation. Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages, surveillance cameras and inventory reconciliations. The registered entity must maintain records for the handling of all controlled substances and must make periodic reports to the DEA. These include, for example, distribution reports for Schedule I and II controlled substances, Schedule III substances that are narcotics, and other designated substances. The registered entity must also report thefts or losses of any controlled substance and obtain authorization to destroy any controlled substance. In addition, special authorization and notification requirements apply to imports and exports.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, a DEA quota system controls and limits the availability and production of controlled substances in Schedule I or II. Distributions of any Schedule I or II controlled substance must also be accompanied by special order forms, with copies provided to the DEA. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. To meet its responsibilities, the DEA conducts periodic inspections of registered establishments that handle controlled substances. In the event of non-compliance, the DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The DEA has conducted a scientific review of the chemical structure of CBDVHS and determined that CBDVHS is not a regulated chemical nor controlled substance under the CSA. This decision by the DEA should help the Company expand the network of clinical testing sites, permit a greater cross-section of patients to participate in studies of this drug, as well as speed the initiation of clinical trials. THCVHS remains a Schedule I, controlled substance, pending a request to re-schedule THCVHS after a drug approval by the FDA.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>U.S. Food and Drug Administration</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDA regulates drugs under the Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject us to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with good laboratory practice (&#8220;GLP&#8221;) regulations&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">approval by an institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug for each indication&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">submission of an NDA to the FDA&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">FDA review and approval of the NDA.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Preclinical Studies</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA unless, before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND does not always result in the FDA allowing clinical trials to commence.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Clinical Trials</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical trials involve the administration of the investigational new drug candidate to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov website.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Marketing Approval</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of reviewing and responding to a submission within ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity. This review typically takes at least twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision. However, if issues arise during the review, the FDA may request additional information and the review period may be extended to permit the applicant to provide and the FDA to review that information, which may significantly extend this time period.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;), as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that is adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA also may require submission of REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept a NDA for filing. In this event, the application must be resubmitted with the additional information requested. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The testing and approval process for a NDA requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. For some products, such as our product candidates, an additional step of DEA review and scheduling is required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Post-Approval Requirements</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA may impose a number of post-approval requirements as a condition of approval of a NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other potential consequences include, among other things:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">fines, warning letters or holds on post-approval clinical trials&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">product seizure or detention, or refusal to permit the import or export of products&#894; or</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">injunctions or the imposition of civil or criminal penalties.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Exclusivity and Approval of Competing Products</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Hatch Waxman Act</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#8217;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Hatch Waxman Patent Exclusivity</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In seeking approval for a drug through a NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ANDA or 505(b)(2) NDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the required patent information has not been filed&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the listed patent has expired&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration&#894; or</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except when the ANDA or 505(b)(2) NDA applicant challenges a listed drug. A certification that the proposed product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all the listed patents claiming the referenced product have expired.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Hatch Waxman Non-Patent Exclusivity</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to patent issues, market and data exclusivity provisions under the FDCA can delay the submission or the approval of certain applications for competing products. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that references the previously approved drug. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a Paragraph IV certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA, or supplement to an existing NDA or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for other versions of a drug. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Orphan Drug Designation and Exclusivity</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a disease or condition that affects populations of fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a NDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication than that for which the orphan product has exclusivity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Federal and State Fraud and Abuse and Data Privacy and Security Laws and Regulations</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state fraud and abuse laws restrict business practices in the pharmaceutical industry. These laws include anti-kickback and false claims laws and regulations as well as data privacy and security laws and regulations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. A violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-covered, uses. In addition, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The federal HIPAA also created federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pharmaceutical companies are also subject to the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other health care providers. The Patient Protection and Affordable Care Act, as amended by the ACA, signed into law on March 2010, created new federal requirements for reporting, by applicable manufacturers of covered drugs, payments and other transfers of value to physicians and teaching hospitals. Applicable manufacturers are also required to report annually to the government certain ownership and investment interests held by physicians and their immediate family members. In addition, certain states require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other health care professionals and entities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act (&#8220;HITECH&#8221;) and its implementing regulations, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Coverage and Reimbursement</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and reimbursement from third party payors. Third party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third party payor not to cover our products, if approved, could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. By way of example, in the United States, the ACA contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign Regulation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In order to market any product outside of the United States, we must comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales and distribution of our products. While our management and many of our consultants are familiar with and have been responsible for gaining marketing approval in many countries, we have not reviewed the specific regulations in countries outside of the United States, as it pertains to cannabinoids.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Additional Regulation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a reporting company with the Securities and Exchange Commission (the &#8220;SEC&#8221;), and, therefore, subject to the information and reporting requirements of the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley Act&#8221;). In addition, our financial reporting is subject to United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), and U.S. GAAP is subject to change over time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are also subject to federal, state and local laws and regulations applied to businesses generally. We believe that we are in conformity with all applicable laws in all relevant jurisdictions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employees</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of the date of this Annual Report, we have a total of six full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We have not experienced any work stoppages and we consider our relations with our employees to be good.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We anticipate that we will need to hire additional employees or independent contractors for our continued development efforts. We also intend to utilize independent contractors and outsourced services, such as CROs, and third party manufacturers, where possible and appropriate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Website</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Internet website, which is located at <u>http://www.skyebioscience.com</u>, describes our company and our management and provides information about cannabis-based therapeutics. Information contained on our website is not incorporated by reference into, and should not be considered a part of, this Annual Report.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORWARD-LOOKING STATEMENTS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Statements in this Annual Report on Form 10-K that are not descriptions of historical facts are forward-looking statements that are based on management&#8217;s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially and negatively affected. In some cases, you can identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section below titled &#8220;Risk Factors,&#8221; including, without limitation, risks relating to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the early stage of our product candidates presently under development&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to retain or hire key scientific or management personnel&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">our dependence on University of Mississippi, third party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to develop successful sales and marketing capabilities in the future as needed&#894;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">competition in our industry&#894; </p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the duration and impact of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">regulatory developments in the United States and foreign countries.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, such as the COVID-19 outbreak and associated business disruptions including delayed clinical trials and laboratory resources, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i1a"><strong><u>Item</u></strong><strong><u> 1A. Risk Factors.</u></strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Any investment in our common stock involves a high degree of risk. Investors should carefully consider the risks described below and all of the information contained in this Annual Report on Form 10-K before deciding whether to purchase our common stock. Our business, financial condition or results of operations could be materially and adversely affected by these risks if any of them actually occur. Our common stock is quoted on the OTCQB under the symbol &#8220;SKYE.&#8221; This market is extremely limited, and the prices quoted are not a reliable indication of the value of our common stock. As of the date of this Annual Report, there has been very limited trading of shares of our common stock. If and when our common stock is traded, the trading price could decline due to any of these risks, and an investor may lose all or part of his or her investment. Some of these factors have affected our financial condition and operating results in the past or are currently affecting us. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described below and elsewhere in this Annual report. </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to our Business and Capital Requirements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We currently have no product revenues and no products approved for marketing and need substantial additional funding to continue our operations. </strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect to need substantial additional funding to pursue the clinical development of our product candidates and launch and commercialize any product candidates for which we receive regulatory approval. We need to bring in additional capital in the near term and expect to incur additional costs associated with operating as a public company. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may increase our capital needs. As noted in our audited financial statements for the years ended December 31, 2020 and 2019, the uncertainties surrounding our ability to fund our operations raise substantial doubt about our ability to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To date, we have financed our operations entirely through debt and equity financings. We may seek additional funds through public or private equity or debt financing, via strategic transactions or collaborative arrangements. Additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms, or at all. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are no assurances that future funding will be available on favorable terms or at all. If additional funding is not obtained, we may need to reduce, defer or cancel preclinical and lab work, planned clinical trials, or overhead expenditures, which could have a material adverse effect on our business, financial condition and results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. Any of these events could significantly harm our business, financial condition and prospects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. </strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our historical financial statements have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting firm has issued a report on our audited financial statements for the years ended December 31, 2020 and 2019 that included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity financing or other capital, attain further operating efficiencies, reduce expenditures, and, ultimately, generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. However, if adequate funds are not available to us when we need it, we will be required to curtail our operations which would, in turn, further raise substantial doubt about our ability to continue as a going concern. The doubt regarding our potential ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue as a going concern, our stockholders may lose some or all of their investment in us.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We rely heavily on UM for our research and development programs, and UM is a joint owner of the intellectual property resulting from its preclinical research and development.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We rely heavily on our relationship with UM for our research and development programs. Under the terms of our agreements with UM, we are required to fund preclinical and clinical trials required for cannabinoid-based products developed by UM. If UM were to terminate one or more of our agreements, we may be required to return or destroy certain materials or data developed during our partnership that is confidential to UM and face substantial delays or possible termination of the affected program. In addition, the agreements provide that all intellectual property rights (including any patents and non-manufacturing related know-how) that are conceived by both UM and us during the course of the collaboration are to be jointly owned by UM and us, and we may need to seek UM&#8217;s consent to pursue, use, license and/or enforce some of these intellectual property rights in the future. An unexpected deterioration in our relationship with UM may have a material adverse effect on our business, reputation, results of operations and financial condition.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are heavily dependent on the success of our early-stage product candidates, which will require significant additional efforts to develop and may prove not to be viable for commercialization.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have no products approved for sale and all of our product candidates are in preclinical development, including the development of cannabinoid-based formulations. Further preclinical testing is ongoing and if successful, will be part of a regulatory filing to satisfy Investigational New Drug (&#8220;IND&#8221;) requirements that need to be met in order for the candidate compounds and routes of administration to enter testing in humans. Our business depends entirely on the successful development, clinical testing, and commercialization of these and any other product candidates we may seek to develop in the future, which may never occur. The success of our product candidates will depend on several factors, which we may not be able to successfully complete, such as:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">receipt of necessary controlled substance registrations from the DEA&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">successful completion of preclinical studies and clinical trials&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">receipt of marketing approvals from the FDA and other applicable regulatory authorities;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">obtaining, maintaining and protecting our intellectual property portfolio&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">identifying, making arrangements and ensuring necessary registrations with third party manufacturers, or establishing commercial manufacturing capabilities for applicable product candidates&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">launching commercial sales of the products, if and when approved&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="margin:0px">acceptance of our products, if and when approved, by patients, the medical community and third party payors&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">obtaining and maintaining healthcare coverage and adequate reimbursement of our products&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">maintaining a continued acceptable safety profile of our products following approval.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. We expect to conduct clinical trials for certain of our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We conduct certain research and development operations through our Australian wholly owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2019, we formed a wholly owned Australian subsidiary, EMBI Australia, to conduct various clinical activities for our product candidates in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor, develop and commercialize our lead product candidate in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our product candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals. In addition, current Australian tax regulations provide for a refundable R&amp;D tax credit equal to 43.5% of qualified expenditures. If our subsidiary loses its ability to operate in Australia, or if we are ineligible or unable to receive the R&amp;D tax credit, or the Australian government significantly reduces or eliminates the tax incentive program, our business and results of operation may be adversely affected.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We expect to face intense competition, often from companies with greater resources and experience than we have.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The highly competitive pharmaceutical industry continues to rapidly expand and evolve as an increasing number of competitors and potential competitors enter the market, many of which have substantially greater financial, technological, managerial and research and development resources and experience than we have. Our pipeline products, if successfully developed, will compete with product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than we or our collaboration partners have. If we are unable to compete successfully, we may be unable to grow and sustain our revenue.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The current volatility of global financial conditions could negatively impact our business and financial condition.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Current global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot guaranty that debt or equity financing, and the ability to borrow funds or cash generated by operations will be available or sufficient to meet or satisfy our initiatives, objectives, or requirements. Our inability to access sufficient amounts of capital on terms acceptable to us for our operations will negatively impact our business, prospects, liquidity and financial condition.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>If we are not able to attract and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our success depends in large measure on our key personnel, including Mr. Punit Dhillon, our Chief Executive Officer. The loss of the services of Mr. Dhillon could significantly hinder our operations. We do not currently have key person insurance in effect for Mr. Dhillon. In addition, the competition for qualified personnel in the pharmaceutical industry is intense and there can be no assurance that we will be able to continue to attract and retain all personnel necessary for the development and operation of our business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Breach of any of the license agreements with UM could result in the loss of such license rights that are important to our business and our operations could be materially harmed.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We licensed from UM the use, development and commercialization rights for our product candidates. As a result, our current business plans are dependent upon our maintenance of the license agreements and the rights we licensed under it. If we breach the terms of our license agreement with UM, or any future license agreement on which our business or product candidates are dependent, UM or other licensors may have the right to terminate the applicable agreement in whole or in part and thereby limit or terminate our rights to the licensed technology and intellectual property and/or any rights we have acquired to develop and commercialize certain product candidates. The loss of the rights licensed to us under our license agreement with UM, or any future license agreement that we may enter granting rights on which our business or product candidates are dependent, would harm, or even eliminate, our ability to further develop the applicable product candidates and would materially harm our business, prospects, financial condition and results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our operating activities may be restricted as a result of covenants related to the outstanding indebtedness under our Credit Agreement.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We could default on the payment of our indebtedness under our Amended and Restated Multi-Draw Credit Agreement entered into with Emerald Health Sciences, Inc. (&#8220;Emerald Health Sciences&#8221;), a related party, on April 1, 2020 (the &#8220;Credit Agreement&#8221;), when it comes due which may result in acceleration of all amounts outstanding under our Credit Agreement. Additionally, our Credit Agreement restricts, among other things, our ability to incur debt and requires us to comply with certain covenants. We may not be able to comply with these restrictions and covenants in the future, which could result in an event of default under our Credit Agreement and result in the acceleration of the maturity of the indebtedness under the Credit Agreement. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In that case, we may be required to delay, limit, reduce or terminate our product candidate development or commercialization efforts or grant others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We engage in transactions with related parties which present possible conflicts of interest that could have an adverse effect on us.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have entered, and may continue to enter, into transactions with Emerald Health Sciences and its affiliates and other related parties for financing, corporate, business development and operational services. Such transactions may not have been entered into on an arm&#8217;s-length basis, and we may have achieved more or less favorable terms because such transactions were entered into with our related parties. We rely, and will continue to rely, on our related parties to maintain these services. If the pricing for these services changes, or if our related parties cease to provide these services, including by terminating agreements with us, we may be unable to obtain replacements for these services on the same terms without disruption to our business. This could have a material effect on our business, results of operations and financial condition. The details of certain of these transactions are set forth in &#8220;Certain Relationships and Related Party Transactions.&#8221; Related party transactions create the possibility of conflicts of interest with regard to our management, we may enter into contracts between us, on the one hand, and related parties, on the other, that may not result in arm&#8217;s-length transactions, including that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our executive officers and directors that hold positions of responsibility with related parties may be aware of certain business opportunities that are appropriate for presentation to us as well as to such other related parties and may present such business opportunities to such other parties&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our executive officers and directors that hold positions of responsibility with related parties may have significant duties with, and spend significant time serving, other entities and may have conflicts of interest in allocating time.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Such conflicts could cause an individual in our management to seek to advance his or her economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest created by related party transactions could impair the confidence of our investors. Our audit committee reviews these transactions. Notwithstanding this, it is possible that a conflict of interest could have a material adverse effect on our liquidity, results of operations and financial condition.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are expecting delays to our THCVHS clinical trial because of the COVID-19 pandemic and unpredictable business disruptions could seriously harm our future revenues and financial condition, increase our costs and expenses, and impact our ability to raise capital.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our operations could be subject to unpredictable events, such as earthquakes, power shortages, telecommunications failures, water shortages, medical epidemics such as the COVID-19 outbreak and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Notably, we rely on third party manufacturers to produce our product candidates. In connection with the recent COVID-19 pandemic, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we have shifted our first-in-human studies of the lead drug candidate, THCVHS, from the second half of 2020 to the third quarter of 2021. Additionally, COVID-19 has caused significant disruptions to the global financial markets which could impact our ability to raise additional capital. The ultimate impact on us and our significant suppliers and manufacturers is unknown, but our operations and financial condition could suffer, and any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, results of operations, financial condition and cash flows from future prospects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to Controlled Substances</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The product candidates we are developing will be subject to U.S. controlled substance laws and regulations, and failure to comply with or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, and our financial condition.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The product candidates we plan to develop will contain controlled substances as defined in the CSA. Controlled substances that are pharmaceutical products are subject to a high degree of regulation under the CSA, which establishes, among other things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements administered by the DEA. The DEA classifies controlled substances into five schedules: Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, no currently &#8220;accepted medical use&#8221; in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. While cannabis, cannabis extracts, and some cannabinoids are Schedule I controlled substances, products approved for medical use in the United States that contain cannabis, cannabis extracts or some cannabinoids must be placed on Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved by the FDA, we expect the finished dosage forms of our cannabinoid-derived drug product candidates to be listed by the DEA as a Schedule II or III controlled substance. Consequently, their manufacture, importation, exportation, domestic distribution, storage, sale and legitimate use will be subject to a significant degree of regulation by the DEA. In addition, the scheduling process may take one or more years, thereby delaying the launch of the drug product in the United States. Furthermore, if the FDA, DEA, or any foreign regulatory authority determines that any of our drug product candidates may have potential for abuse, it may require us to generate more clinical or other data than we currently anticipate establishing whether or to what extent the substance has an abuse potential, which could increase the cost and/or delay the launch of the drug product.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Obtaining the necessary registrations may result in delay of the manufacturing, development, or distribution of our product candidates. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings. Individual states have also established controlled substance laws and regulations. While some states automatically schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product. We or our partners or clinical sites must also obtain separate state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To conduct clinical trials with our product candidates in the United States prior to approval, each of our research sites must obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense the product candidate and to obtain the product. If the DEA delays or denies the grant of a research registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Manufacturing of our product candidates is, and, if approved, our commercial products will be, subject to the DEA&#8217;s annual manufacturing and procurement quota requirements, if classified as Schedule II. The annual quota allocated to us or our contract manufacturers for the controlled substances in our product candidates may not be sufficient to meet commercial demand or complete clinical trials. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&#8217;, procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If, upon approval of any of our product candidates, the product is scheduled as Schedule II or III, we would also need to identify wholesale distributors with the appropriate DEA registrations and authority to distribute the product to pharmacies and other health care providers. The failure to obtain, or delay in obtaining, or the loss of any of those registrations could result in increased costs to us. Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended to reduce prescription drug abuse, such as the requirement that physicians consult a state prescription drug monitoring program may make physicians less willing to prescribe, and pharmacies to dispense, our products, if approved.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Our ability to research, develop and commercialize our drug product candidates is dependent on our ability to obtain and maintain the necessary controlled substance registrations from the DEA.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the United States, the DEA regulates activities relating to the cultivation, possession and supply of cannabis for medical research and/or commercial development, including the requirement to obtain annual registrations to manufacture or distribute pharmaceutical products derived from cannabis extracts. The National Institute on Drug Abuse (&#8220;NIDA&#8221;) also plays a role in oversight of the cultivation of cannabis for medicinal research. We do not currently handle any controlled substances, but we plan to partner with third parties to engage in the research and development of cannabis-derived compounds for medical purposes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The cultivation of cannabis is strictly regulated in the United States under a complex legal framework and our partners may be unable to obtain or maintain the necessary authorizations to cultivate cannabis for the research and development of cannabis-derived compounds.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are partnering with UM to research and develop cannabis-derived drug products. Pursuant to that partnership, UM plans to cultivate cannabis and make extracts to conduct or enable our third party laboratories to conduct early investigations into proof-of-concept studies on the activity of these cannabinoids in various medical conditions. The regulation of cannabis is complex and subject to stringent controls. If UM cannot obtain or maintain the necessary regulatory authorizations that we anticipate will be required for the contemplated development program, our business may suffer, and we may not be able to pursue the discovery, research and development of cannabinoids. While UM conducts research using cannabinoids derived from the plant, all of the Company&#8217;s candidate molecules are synthetic derivatives and therefore may not fall under the DEA&#8217;s definition of a controlled substance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to Government Regulation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>If we fail to demonstrate the safety and efficacy of any product candidate that we develop to the satisfaction of the regulatory authorities, we may incur additional costs or experience difficulty in completing, the development and commercialization of such product candidate.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are not permitted to commercialize, market, promote, or sell any product candidate in the United States without obtaining marketing approval from the FDA or in other countries without obtaining approvals from comparable foreign regulatory authorities, such as the European Medicines Agency (the &#8220;EMA&#8221;), and we may never receive such approvals. To gain approval to market a drug product, we must complete extensive preclinical development and clinical trials that demonstrate the safety and efficacy of the product for the intended indication to the satisfaction of the FDA or other regulatory authority.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not previously submitted a new drug application (&#8220;NDA&#8221;) to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. If we do not receive regulatory approval for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA or any foreign regulatory bodies could delay, limit or deny approval of our product candidates for many reasons, including our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that the product candidate is safe and effective for the requested indication, the regulatory agency&#8217;s disagreement with the interpretation of data from preclinical studies or clinical trials, or our inability to demonstrate that the clinical and other benefits of the product candidate outweigh any safety or other perceived risks. The FDA or applicable regulatory body could also require additional preclinical or clinical studies, deny approval of the formulation, labeling or the specifications of the product candidate, or the manufacturing processes or facilities of third party manufacturers with which we contract. The policies of the applicable regulatory agencies could also significantly change in a manner rendering our clinical data insufficient for approval.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Even if we eventually complete clinical testing and receive approval of a NDA or foreign regulatory filing for a product candidate, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials. The FDA or the applicable foreign regulatory agency also may approve the product candidate for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve the labeling that we believe is necessary or desirable for the successful commercialization of the product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of the product candidate and would materially adversely impact our business and prospects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical testing is expensive and can take several years to complete, and its outcome is inherently uncertain. Moreover, obtaining sufficient quantities of product for clinical testing is subject to regulation by DEA and, in some cases, NIDA. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. A failure of one or more clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or subsequently to commercialize our product candidates, including:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">FDA, DEA or NIDA may not authorize the use and distribution of sufficient quantities of product for clinical testing&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">regulators or independent institutional review boards (IRBs) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">regulators or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the cost of clinical trials of our product candidates may be greater than we anticipate&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Our pool of suitable patients may be smaller for some of our product candidates, which will impact our ability to enroll a sufficient number of suitable patients. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including the severity of the disease under investigation, the eligibility criteria for the study in question, the perceived risks and benefits of the product candidate, the patient referral practices of physicians, the ability to monitor patients adequately during and after treatment, and the proximity and availability of clinical trial sites for prospective patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether, which could result in increased development costs and cause the value of our company to decline and limit our ability to obtain additional financing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our development and commercialization strategy for THCVHS, may depend, in part, on published scientific literature and the FDA&#8217;s prior findings regarding the safety and efficacy of dronabinol, based on data not developed by us, but upon which the FDA may rely in reviewing our NDA.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Hatch-Waxman Act added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), Section 505(b)(2) permits the filing of a NDA where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The FDA interprets Section 505(b)(2) of the FDCA, for purposes of approving a NDA, to permit the applicant to rely, in part, upon published literature or the FDA&#8217;s previous findings of safety and efficacy for an approved product. The FDA may also require companies to perform additional clinical trials or measurements to support any deviation from the previously approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. The label, however, may require all or some of the limitations, contraindications, warnings or precautions included in the listed product&#8217;s label, including a black box warning, or may require additional limitations, contraindications, warnings or precautions. Depending on guidance from the FDA, we may decide to submit a NDA for THCVHS under Section 505(b)(2) relying, in part, on the FDA&#8217;s previous findings of safety and efficacy from investigations for the approved drug product Dronabinol for which we have not received a right of reference and published scientific literature. Even though we may be able to take advantage of Section 505(b)(2) to support potential U.S. approval, the FDA may require us to perform additional clinical trials or measurements to support approval. In addition, notwithstanding the approval of many products by the FDA pursuant to Section 505(b)(2), over the last few years some pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&#8217;s interpretation is successfully challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) NDAs that we submit. Such a result could require us to conduct additional testing and costly clinical trials, which could substantially delay or prevent the approval and launch of our product candidates, including THCVHS.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Once regulatory approval has been granted, the approved product and its manufacturer are subject to continual review by the FDA, DEA and/or non-U.S. regulatory authorities and such approval may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing follow-up studies or surveillance. In addition, we will be subject to extensive and ongoing regulatory requirements with regard to labeling, packaging, adverse event reporting, storage, distribution, advertising, promotion, recordkeeping and submission of safety and other post-market information. Manufacturers of our products and manufacturers&#8217; facilities are required to comply with current good manufacturing practice (&#8220;cGMP&#8221;) regulations, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA and to comply with requirements concerning advertising and promotion for our products. If we, any future collaboration partner or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the collaboration partner, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any DEA registrations that we receive may also be subject to limitations such as the DEA&#8217;s annual manufacturing and procurement quota requirements. The annual quota allocated to us or our contract manufacturers for the controlled substances in our product candidates may not be sufficient to meet commercial demand. Our facilities that handle controlled substances, and those of our third party contractors, will also be subject to registration requirements and periodic inspections. Additionally, if approved by the FDA, the finished dosage forms of our drug product candidates will be subject to the DEA&#8217;s rescheduling process, which may delay product launch and impose additional regulatory burdens. Failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings. For additional information, see Risk Factor, &#8220;<em>The product candidates we are developing will be subject to U.S. controlled substance laws and regulations and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, both during non-clinical and clinical development and post-approval, and our financial condition.</em>&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and regulatory requirements. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Widely publicized events concerning the safety risk of certain drug products have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the imposition by the FDA of risk evaluation and mitigation strategies (&#8220;REMS&#8221;), to ensure that the benefits of the drug outweigh its risks. In addition, widely publicized events concerning the safety risk of certain drug products have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the imposition by the FDA of REMS to ensure that the benefits of the drug outweigh its risks. In addition, because of the serious public health risks of high-profile adverse safety events with certain products, the FDA may require, as a condition of approval, costly REMS programs.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or any future collaboration partner are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, will not be permitted to market our future products and our business will suffer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Serious adverse events or undesirable side effects or other unexpected properties of any of our product candidates may be identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Serious adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us, an IRB, or regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label, the imposition of distribution or use restrictions or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. If any of our product candidates are associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Undesirable side effects or other unexpected adverse events or properties of any of our other product candidates could arise or become known either during clinical development or, if approved, after the approved product has been marketed. If such an event occurs during development, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates. If such an event occurs after such product candidates are approved, a number of potentially significant negative consequences may result, including withdrawal of regulatory approval, requirements for additional warnings on the label, use or distribution restrictions, requirements to conduct post-market studies, requirements to create a medication guide outlining side effects, and liability for harm caused to patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We expect to rely on third parties, such as CROs, to conduct some or all of our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize any of our product candidates.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct our preclinical and clinical studies on our product candidates in compliance with applicable regulatory requirements. These third parties will not be our employees and, except for restrictions imposed by our contracts with such third parties, we will have limited ability to control the amount or timing of resources that they devote to our programs. Although we expect to rely on these third parties to conduct our preclinical studies and clinical trials, we will remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and the applicable legal, regulatory, and scientific standards, and our reliance on these third parties will not relieve us of our regulatory responsibilities. These entities must maintain and comply with valid DEA registrations and requirements. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as current good clinical practices (&#8220;cGCPs&#8221;), for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. If we or any of our third party contractors fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, we are required to report certain financial interests of our third party investigators if these relationships exceed certain financial thresholds and meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by principal investigators who previously served or currently serve as scientific advisors or consultants to us from time to time and receive cash compensation in connection with such services. Our clinical trials must also generally be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Some of the third parties with whom we contract may also have relationships with other commercial entities, some of which may compete with us. If the third parties conducting our preclinical studies or our clinical trials do not perform their contractual duties or obligations or comply with regulatory requirements, we may need to enter into new arrangements with alternative third parties. This could be costly, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated, and we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, or to commercialize such product candidate being tested in such studies or trials. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third party contractors or to do so on commercially reasonable terms. Though we plan to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We rely on, and expect to continue relying on, third party contract manufacturing organizations to manufacture and supply product candidates for us, as well as certain raw materials used in the production thereof. If one of our suppliers or manufacturers fails to perform adequately, we may be required to incur significant delays and costs to find new suppliers or manufacturers.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We currently have no experience in, and we do not own facilities for, manufacturing our product candidates. We rely on, and expect to continue relying upon, third party manufacturing organizations to manufacture and supply our product candidates and certain raw materials used in the production thereof. Some of our key components for the production of our product candidates may have a limited number of suppliers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We expect that we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements, for manufacture of our drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, DEA or others, they will not be able to secure and/or maintain DEA registrations and regulatory approval for their manufacturing facilities. In addition, we expect that we will have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if DEA does not register these facilities for the manufacture of controlled substances, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We do not have any commercial supply agreements with our suppliers. In the event that we and our suppliers cannot agree to the terms and conditions for them to provide clinical and commercial supply needs, we would not be able to manufacture our product or candidates until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, our product candidates. The failure of third party manufacturers or suppliers to perform adequately or the termination of our arrangements with any of them may adversely affect our business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Healthcare reform measures could hinder or prevent our products candidates&#8217; commercial success, if approved.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the United States, there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably if approved. In the United States, the Federal government passed the Patient Protection and Affordable Care Act in 2010, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;). The ACA:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">increases the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">requires collection of rebates for drugs paid by Medicaid managed care organizations&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">requires manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect that state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates if approved, or additional pricing pressure. The implementation of cost containment measures or other healthcare reform initiatives may prevent us from being able to generate revenue, attain profitability, or commercialize any products for which we may obtain regulatory approval. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect our ability to set a price we believe is fair for our products, to generate revenues and achieve or maintain profitability, to raise capital, and to obtain timely approval of our products.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third party payors that are false or fraudulent&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">HIPAA, which created federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and as amended by the Health Information Technology and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the federal physician sunshine requirements under the ACA, which require manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">state law equivalents of each of the above federal laws, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We may be subject to requests for access to our product candidates. Demand for compassionate use of our unapproved therapies could strain our resources, delay our drug development activities, negatively impact our regulatory approval or commercial activities, and result in losses.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are developing product candidates to treat conditions for which there are currently limited therapeutic options. If we experience requests for access to unapproved drugs, we may experience significant disruption to our business which could result in losses. We are a small company with limited resources, and any unanticipated trials or access programs resulting from requests for access could deplete our drug supply, increase our capital expenditures, and otherwise divert our resources from our primary goals.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, legislation referred to as &#8220;Right to Try&#8221; laws have been introduced at the local and national levels, which are intended to give patients access to unapproved therapies. Patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and generally have exhausted all other available therapies. The risk for serious adverse events in this patient population is high and could have a negative impact on the safety profile of our product candidate, which could cause significant delays or an inability to successfully commercialize our product candidate and could materially harm our business. In addition, in order to perform the controlled clinical trials required for regulatory approval and successful commercialization of our product candidates, we may also need to restructure or pause any ongoing compassionate use and/or expanded access programs, which could prompt adverse publicity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to our Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our stock price may be volatile, which may result in losses to our stockholders.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The stock markets have experienced significant price and trading volume fluctuations, and the market prices of companies quoted on the OTCQB, where our shares of common stock will be quoted, generally have been very volatile and have experienced sharp share-price and trading-volume changes. The trading price of our common stock is likely to be volatile and could fluctuate widely in response to factors which may be out of our control, such as variations in our operating results, changes in expectations of our future financial performance, changes in operating and stock price performance of other companies in our industry, additions or departures of key personnel, and future sales of our common stock. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Domestic and international stock markets often experience significant price and volume fluctuations. These fluctuations, as well as general economic and political conditions unrelated to our performance, may adversely affect the price of our common stock. In the past, following periods of volatility in the market price of a public company&#8217;s securities, securities class action litigation has often been initiated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our common shares are thinly-traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices or at all.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We cannot predict the extent to which an active public market for our common stock will develop or be sustained due to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors, and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The market for our common shares may be characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile than a seasoned issuer for the indefinite future. The potential volatility in our share price is attributable to a number of factors. First, as noted above, our common shares may be sporadically and/or thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. Secondly, an investment in us is a speculative or &#8220;risky&#8221; investment due to our lack of revenues or profits to date. As a consequence of this enhanced risk, more risk-averse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We cannot assure you that our common stock will become eligible for listing or quotation on any exchange and the failure to do so may adversely affect your ability to dispose of our common stock in a timely fashion.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In order for our common stock to become eligible for listing or quotation on any exchange, reverse merger companies must have had their securities traded on an over-the-counter market for at least one year, maintained a certain minimum closing price for not less than 30 of the most recent 60 days prior to the filing of an initial listing application and prior to listing, and timely filed with the SEC all required reports since the consummation of the reverse merger, including one annual report containing audited consolidated financial statements for a full fiscal year commencing after the date of filing of the Current Report on Form 8-K which discloses the reverse merger. We may not be able to meet all of the filing requirements above and may not be able to satisfy the initial standards for listing or quotation on any exchange in the foreseeable future or at all. Even if we are able to become listed or quoted on an exchange, we may not be able to maintain a listing of the common stock on such stock exchange.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We do not anticipate paying any cash dividends.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We presently do not anticipate that we will pay any dividends on any of our capital stock in the foreseeable future. The payment of dividends, if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any dividends will be within the discretion of our Board. We presently intend to retain all earnings, if any, to implement our business plan; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Our common stock is subject to penny stock rules, which may make it more difficult for our stockholders to sell their common stock.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Broker-dealer practices in connection with transactions in &#8220;penny stocks&#8221; are regulated by certain penny stock rules adopted by the SEC. Penny stocks generally are equity securities with a price of less than $5.00 per share. The penny stock rules require a broker-dealer, prior to a purchase or sale of a penny stock not otherwise exempt from the rules, to deliver to the customer a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We will need additional capital, and the sale of additional shares or other equity securities could result in additional dilution to our stockholders.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We require additional capital for the development and commercialization of our product candidates and may require additional cash resources due to changed business conditions or other future developments, including any investments or acquisitions we may decide to pursue. If our resources are insufficient to satisfy our cash requirements, we will seek to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our principal stockholder owns a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our principal stockholder, Emerald Health Sciences, owns a significant percentage of our outstanding capital stock. As of February 23, 2021, Emerald Health Sciences owned 31.8% of our outstanding shares of common stock. As such, Emerald Health Sciences may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers for our common stock that some of our stockholders may believe is in their best interest.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We have a substantial number of authorized common shares available for future issuance that could cause dilution of our stockholders&#8217; interest and adversely impact the rights of holders of our common stock.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have a total of 5,000,000,000 shares of common stock authorized for issuance and up to 50,000,000 shares of preferred stock with the rights, preferences and privileges that our Board may determine from time to time. As of February 23, 2021, we have reserved; 22,050,000 shares for issuance upon the exercise of outstanding options, 18,984,109 shares for issuance under our 2014 equity incentive plan, 5,179,223 shares underlying the Amended Credit Agreement, and 95,580,001 shares for issuance upon the exercise of outstanding warrants. As of February 23, 2021, we had no outstanding preferred stock. As of February 23, 2021, we had 4,508,198,918 shares of common stock unreserved and available for issuance. We may seek financing that could result in the issuance of additional shares of our capital stock and/or rights to acquire additional shares of our capital stock. We may also make acquisitions that result in issuances of additional shares of our capital stock. Those additional issuances of capital stock would result in a significant reduction of your percentage interest in us. Furthermore, the book value per share of our common stock may be reduced. This reduction would occur if the exercise price of any issued warrants, the conversion price of any convertible notes is lower than the book value per share of our common stock at the time of such exercise or conversion.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The addition of a substantial number of shares of our common stock into the market or by the registration of any of our other securities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), may significantly and negatively affect the prevailing market price for our common stock. The future sales of shares of our common stock issuable upon the exercise of outstanding warrants may have a depressive effect on the market price of our common stock, as such warrants would be more likely to be exercised at a time when the price of our common stock is greater than the exercise price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The issuance of shares upon exercise of outstanding warrants and options may cause immediate and substantial dilution to our existing stockholders.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the price per share of our common stock at the time of exercise of any warrants, options, or any other convertible securities is in excess of the various conversion or exercise prices of these convertible securities, conversion or exercise of these convertible securities would have a dilutive effect on our common stock. As of February 23, 2021, we had outstanding (i) warrants to purchase up to 95,580,001 shares of our common stock at exercise prices ranging from $0.06 to $5.00 per share, and (ii) options to purchase up to 22,050,000 shares of our common stock at exercise prices ranging from $0.045 to $0.31 per share. Further, any additional financing that we secure may require the granting of rights, preferences or privileges senior to those of our common stock and which result in additional dilution of the existing ownership interests of our common stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. In general, an &#8220;ownership change&#8221; occurs if the aggregate stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. During 2018, pursuant to the Emerald Financing transaction, the Company underwent a significant ownership change which likely triggered a limitation under Section 382. If we experience ownership changes as a result of future transactions in our stock, our ability to use our net operating loss carryforwards and other tax attributes to offset U.S. federal taxable income may be subject to further limitations, which could potentially result in increased future tax liability to us.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="i1b">Item 1B. Unresolved Staff Comments.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="i2">Item 2. Properties.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Our principal executive and corporate offices are located at 5910 Pacific Center Blvd. Suite 320, San Diego, CA 92121.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i3"><strong><u>Item</u></strong><strong><u> 3. Legal Proceedings.</u></strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i4"><strong><u>Item</u></strong><strong><u> 4. Mine Safety Disclosures.</u></strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="p2"><strong>PART</strong><strong> II</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i5"><strong><u>Item</u></strong><strong><u> 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u></strong><strong>. </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Market Information.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock has been quoted on the OTCQB, under the symbol &#8220;SKYE&#8221;. Previously, it traded under the symbols &#8220;EMBI&#8221; until January 19, 2021 and prior to that it traded under the symbol &#8220;NMUS&#8221; until March 25, 2019. There can be infrequent trading volume, which precipitates wide spreads in the &#8220;bid&#8221; and &#8220;ask&#8221; quotes of our common stock, on any given day. On February 23, 2021, the last reported sale price of our common stock on the OTCQB was $0.12 per share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth, for the quarters indicated, the high and low bid prices per share of our common stock on the OTCQB, reported by the Financial Industry Regulatory Authority Composite Feed or other qualified interdealer quotation medium. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Quarter Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>High</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Low</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">December 31, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.06</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.03</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">September 30, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.16</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">June 30, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.20</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 31, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.20</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">December 31, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.49</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">September 30, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.45</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">June 30, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.17</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.28</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 31, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.90</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.30</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">December 31, 2018</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.60</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">September 30, 2018</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.39</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.18</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">June 30, 2018</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.34</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.22</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 31, 2018</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.48</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.14</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Holders.</strong> As of February 23, 2021, there were 63 stockholders of record. The number of stockholders of record does not include beneficial owners of our common stock, whose shares are held in the names of various dealers, clearing agencies, banks, brokers and other fiduciaries.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Dividends.</strong> We have never declared or paid a cash dividend on our common stock. We do not expect to pay cash dividends on our common stock in the foreseeable future. We currently intend to retain our earnings, if any, for use in our business. Any dividends declared in the future will be at the discretion of our Board and subject to any restrictions that may be imposed by our lenders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Sales of Unregistered Securities. </strong>None.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Issuer Purchases of Equity Securities. </strong>None during the fiscal year ended December 31, 2020 covered by this Annual Report.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Penny Stock Regulation. </strong>Shares of our common stock will probably be subject to rules adopted by the SEC that regulate broker-dealer practices in connection with transactions in &#8220;penny stocks.&#8221; Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in those securities is provided by the exchange or system). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, deliver a standardized risk disclosure document prepared by the SEC, which contains the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading&#894;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a description of the broker&#8217;s or dealer&#8217;s duties to the customer and of the rights and remedies available to the customer with respect to violation to such duties or other requirements of securities&#8217; laws&#894;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a brief, clear, narrative description of a dealer market, including &#8220;bid&#8221; and &#8220;ask&#8221; prices for penny stocks and the significance of the spread between the &#8220;bid&#8221; and &#8220;ask&#8221; price&#894;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a toll-free telephone number for inquiries on disciplinary actions&#894;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">definitions of significant terms in the disclosure document or in the conduct of trading in penny stocks&#894; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">such other information and is in such form (including language, type, size and format), as the SEC shall require by rule or regulation.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to effecting any transaction in penny stock, the broker-dealer also must provide the customer the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the bid and offer quotations for the penny stock&#894;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the compensation of the broker-dealer and its salesperson in the transaction&#894;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock&#894; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">monthly account statements showing the market value of each penny stock held in the customer&#8217;s account.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for a stock that becomes subject to the penny stock rules. Holders of shares of our common stock may have difficulty selling those shares because our common stock will probably be subject to the penny stock rules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i6"><strong><u>Item</u></strong><strong><u> 6. Selected Financial Data</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i7"><strong><u>Item</u></strong><strong><u> 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements for the years ended December 31, 2020 and 2019 together with notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Unless otherwise provided in this Annual Report, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;Skye Bioscience&#8221; in this discussion and analysis refer to Skye Bioscience, Inc., a Nevada corporation formerly known as Emerald Bioscience, Inc., together with its wholly owned subsidiaries, Nemus, a California corporation, and EMBI Australia Pty Ltd., an Australian proprietary limited company.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a biopharmaceutical company targeting the discovery, development, and the commercialization of cannabinoid-based therapeutics, through a number of license agreements with the University of Mississippi (&#8220;UM&#8221;). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective March 25, 2019, we changed our name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc. and effective January 19, 2021, we changed our name to Skye Bioscience, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2019, we formed a new subsidiary in Australia, EMBI Australia, in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for our product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Events and Significant Contracts</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Expansion of UM 5050 and UM 8930 Licenses from Ocular Delivery Only to All Fields of Use</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 24, 2019, we executed two restated and amended license agreements with UM which expanded our use of UM 5050, a prodrug of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, an analog of cannabidiol (&#8220;CBD&#8221;), this expanded our scope of field of use from ocular delivery only to all fields of use. Pursuant to these license agreements, we have exclusive, perpetual, worldwide licenses related to UM 5050 and UM 8930. Additionally, with the prior written consent of UM, we have the right to sublicense the licensed intellectual property.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The exclusive license for tetrahydrocannabinol-valine-hemisuccinate (&#8220;THCVHS&#8221;), the proprietary prodrug of THC, is expected to allow us to explore related uses for the active moiety of the prodrug, namely THC. Independent <em>in vitro</em> and <em>in vivo</em> studies have demonstrated the potential use of THC in a variety of potential indications based on the ability of the cannabinoid to act as an anti-inflammatory, anti-fibrotic, and/or inhibitor of neovascularization. The Company has generated data related to these effects using an <em>ex vivo</em> human tissue model of the eye. The prodrug technology employed in THCVHS is designed to enhance the pharmacokinetic and pharmacodynamics of the active part of the molecule, once introduced into the body through various routes of administration being considered by the development team.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The exclusive license of cannabidiol-valine-hemisuccinate (&#8220;CBDVHS&#8221;), the analog of CBD, is expected to permit us to expand research and development into organ systems outside of the current ocular space. Potential disease targets over time could involve the central nervous system, the gastrointestinal tract, the endocrine/metabolic system, reproductive system diseases, or as yet unrecognized opportunities. This bioengineered version of CBD is expected to enlarge the disease target pool by virtue of new routes of administration into the body, thereby enhancing bioavailability. The determination by the DEA that CBDVHS is not a controlled substance permits us to enlarge the potential pool of clinical test sites and a more diverse patient pool in the study of disease. We expect to develop strategic collaborations to identify and advance these applications.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>THCVHS</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">THCVHS, our lead ocular compound, is a prodrug of THC. We have delayed our first-in-human studies of THCVHS, from the second half of 2020 to the third quarter of 2021. The first-in-human Phase 1 trials are expected to be conducted in both normal subjects and patients with glaucoma or ocular hypertension in Australia (the &#8220;Clinical Trial&#8221;). We are eligible under the AusIndustry research and development tax incentive program to obtain a cash incentive from the Australian Taxation Office. The tax incentive is available to us based on specific criteria with which we must comply and is based on our eligible research and development spend in Australia. Prior to August 2020, we executed several agreements, and the work underlying those agreements was subsequently delayed. After August 2020, we have been focused on clinical enabling activities, notably: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">formulation and manufacturing of drug product to supply our GLP toxicology studies and first-in-human Phase 1 clinical trial;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">initiating and completing GLP toxicology studies to support our first-in-human Phase 1 clinical trial;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">initiating and completing validation of a pharmacokinetic assay for both animal and human samples to support our pre-clinical and clinical studies; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">engaging our vendors and contractors to support the finalization of study-related materials for our Phase 1 study, including the finalization of the clinical study protocol.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of COVID-19 there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>CBDVHS</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CBDVHS is our proprietary CBD analog. We have embarked on studies with UM exploring the utility of our drug candidate CBDVHS as a topical formulation for the potential treatment and management of several ocular diseases, including but not limited to, uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In July 2019, we engaged Glauconix to conduct research as to whether CBD or CBDVHS is associated with an increase in IOP and, if so, what the potential mechanism of action would be by exposing the 3D-human trabecular meshwork tissue constructs to these molecules. In December 2019, we announced that data generated by Glauconix Biosciences, Inc. showed significant anti-inflammatory and anti-fibrotic activity in ocular tissue with CBDVHS when compared to CBD, indicating therapeutic potential as a neuroprotectant, especially in diseases of the retina. Additionally, CBD was associated with biomarkers related to the elevation of IOP while CBDVHS was not associated with elevating IOP at anti-fibrotic concentrations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the second quarter of 2019, UM also completed preclinical experiments showing that CBDVHS exhibited an ability to penetrate multiple chambers of the eye and reach the optic nerve. These findings support the therapeutic potential to provide ocular neuroprotection of retinal ganglion cells, an important goal in treating diseases that lead to vision loss. The data were published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics in a paper entitled, &#8220;Analog Derivatization of Cannabidiol for Improved Ocular Permeation&#8221; (2019&#894; volume 35 (5): 1-10). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In July 2019, we engaged StemoniX to evaluate CBD and CBDVHS in a human <em>in vitro</em> neural model that has application for epilepsy. The series of experiments are designed to provide insight into how these cannabinoids stabilize neuronal cells. In November and December 2019, we also executed additional preclinical research agreements with StemoniX related to CBDVHS.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In February 2019, we entered into the Purisys Agreement to provide manufacturing and product development services for our analog formulation of CBD. We made an upfront payment and additional payments will be made upon Purisys&#8217;s shipment of the active pharmaceutical ingredient.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, we announced data generated by StemoniX, that CBDVHS was both pharmacologically and therapeutically distinct from CBD when studied in an <em>in vitro</em> human neural tissue model mimicking chemically induced seizure-like hyperactivity. Additionally, CBDVHS was observed to gain potency in anti-seizure-like activity over the seven-day observation period, whereas the suppressive effect afforded by CBD dissipated by day three. In the assessment of safety parameters of CBDVHS, the molecule was not found to be toxic to the neurologic cells tested in multiple assays, both in acute and longer-term exposure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We plan to continue to work with UM to explore other potential indications and associated routes of administration based on the expanded UM 8930 exclusive licenses. Our decision to advance a potential therapeutic candidate will be influenced by several criteria, including but not limited to, preclinical data, synthesis and formulation capability as well as prevailing market conditions. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our consolidated financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described at relevant sections in this discussion and analysis and in the notes to the consolidated financial statements included in this Annual Report on Form 10-K. We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Fair Value Measurements</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 2: Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The carrying values of our financial instruments, with the exception of the Credit Agreement (as defined below) and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2019, the aggregate fair value of the advances under the Amended Credit Agreement was $1,877,938, the carrying amount of the liability on December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in our Consolidated Balance Sheets. As of December 31, 2020, we estimate that the fair value of the Amended Credit Agreement to be materially consistent with the fair value estimate as of December 31, 2019, plus the non-convertible advances made in 2020. This determination was based on the following considerations: (i) we have not experienced any significant change in our credit worthiness or operations year over year, (ii) there have been no repayments or convertible draws (iii) the facility is closer to maturity, and (iv) the embedded conversion feature on the convertible advances is out-of-the-money at the reporting date. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Convertible Instruments</em></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We account for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We account for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, <em>Debt with Conversion and Other Options</em> (&#8220;ASC 470-20&#8221;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When we determine that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We also follow ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#8220;ASC 480-10&#8221;) when evaluating the accounting for our hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">When determining the short-term vs. long-term classification of derivative liabilities, we first evaluate the instruments&#8217; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, we carefully evaluate all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. We evaluate our derivative liabilities at each reporting period end and make updates for any changes in facts and circumstances that may impact classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Warrants Issued in Connection with Financings</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other expense (income) in the Consolidated Statements of Comprehensive (Loss) Income.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation Expense </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. We use the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and our actual stock volatility adjusted for periods in which significant financial variability is identified.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends in the foreseeable future.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net (Loss) Income Per Share of Common Stock</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We apply FASB ASC No. 260, <em>Earnings per Share</em>. Basic net (loss) income per share of common stock is computed by dividing (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net (loss) income per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recently Issued and Adopted Accounting Pronouncements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Note 2 to the accompanying Consolidated Financial Statements included in Part IV, Item 15 of this Annual Report on Form 10- K for information on recently issued accounting pronouncements and recently adopted accounting pronouncements. While we expect certain recently adopted accounting pronouncements to impact our estimates in future periods, the impact upon adoption was not significant to our current estimates and operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operations</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>For the years ended December 31, 2020 and 2019</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenues. </strong>To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Operating expenses. </strong>For the year ended December 31, 2020, our total operating expenses were $6,289,013 as compared to $6,632,578 for the year ended December 31, 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Research and development</u>. Research and development expenses for the year ended December 31, 2020 were $1,944,411, which consisted of salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees paid to UM, fees related to contract manufacturing and formulation, a $200,000 license fee incurred under the UM 8930 Analog Agreement for the receipt for the first United States Patent and Trademark Office notice of allowance and the annual license maintenance fee for UM 5070.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development expenses for the year ended December 31, 2019 were $2,237,956, which consisted of upfront payments for the all fields of use licenses for UM 5050 and UM 8930, the annual license maintenance fee for UM 5070, salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees including fees for manufacturing and formulation, regulatory consulting fees, in preparation of the Clinical Trials.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the year ended December 31, 2020, research and development expenses decreased by $293,545, as compared to the year ended December 31, 2019. The decrease is primarily due to an overall decline in contracted development costs as the Company moved its focus towards exploring new strategic initiatives in 2020. Contracted development costs were lower during 2020 as compared to 2019, due to a lack of cash on hand through the second quarter and the delay of our clinical trials due to COVID-19.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>General and administrative</u>. General and administrative expenses for the year ended December 31, 2020 were $4,344,602 which primarily consisted of salaries, consulting fees, stock-based compensation expense and professional fees associated with our costs of being a public company. General and administrative expenses for the year ended December 31, 2019 were $4,394,622, which primarily consisted of the same components. General and administrative expenses remained relatively constant year over year.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other expense (income). </strong>For the year ended December 31, 2020, we had non-operating expense of $270,086, which was comprised primarily of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$436,270 of other income from the change in fair value of derivative liabilities which represents an overall decrease in the fair value of our derivative liabilities. The derivatives marked-to-market include the Series B and Emerald Health Sciences warrant liabilities and the derivative bifurcated from the Credit Agreement (as defined below). Several assumptions go into the valuations for each of these instruments however the decrease in our stock price, modification of the Credit Agreement and valuation assumptions were all contributing factors to the decrease in the fair value of these instruments during the year ended December 31, 2020;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">We incurred interest expense of $706,385 during the year ended December 31, 2020 due to the amortization of the debt discount and interest payments associated with the outstanding balance under the Credit Agreement. Interest expense declined by $294,328, when comparing the year ended December 31, 2020 and December 31, 2019, due to the partial pre-payment of amounts outstanding under the Credit Agreement, which resulted in a lower average outstanding balance during 2020 as compared to 2019. </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the year ended December 31, 2019, we had non-operating income of $7,686,003, which was comprised primarily of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">$9,734,759 of other income from the change in fair value of derivative liabilities which represents an overall decrease in the fair value of our derivative liabilities. The derivatives marked-to-market include the Series B and Emerald Health Sciences warrant liabilities and the compound derivative bifurcated from the Credit Agreement (as defined below). Several assumptions go into the third party valuations for each of these instruments however the decrease in our stock price and valuation assumptions were all contributing factors to the decrease in the value of these instruments during the year ended December 31, 2019;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$322,644 of other expense was related to drawdowns initiated under the Credit Agreement which required us to bifurcate compound embedded derivatives and record an additional charge for the fair value of such instruments in excess of proceeds;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">We incurred interest expense of $1,000,713 during the year ended December 31, 2019 due to the amortization of the debt discount and interest payments associated with the outstanding balance under the Credit Agreement which was entered into during the fourth quarter of 2018; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$725,425 loss on extinguishment related to the prepayment of the Credit Agreement.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Net (loss) income. </strong>For the year ended December 31, 2020, we had a net loss of $6,560,699 as compared to net income of $1,051,825 for the year ended December 31, 2019. The net income generated during 2019 was driven by other income primarily related to a non-cash adjustment in derivative liabilities from the decrease in our stock price. We expect to incur net losses for the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have incurred operating losses and negative cash flows from operations since our inception and as of December 31, 2020, had an accumulated deficit of $38,733,981, stockholders&#8217; equity of $450,786 and working capital of $1,877,186. We anticipate that we will continue to incur net losses into the foreseeable future in order to advance and develop potential drug candidates into preclinical and clinical development activities and support our corporate infrastructure, which includes the costs associated with being a public company. We had unrestricted cash of $2,469,410 as of December 31, 2020, as compared to $1,829,977 as of December 31, 2019. The increase was primarily attributable to the proceeds received in the August 2020 Financing. Without additional funding, management believes that we will not have enough funds to meet our obligations beyond one year after the date the Consolidated Financial Statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 5, 2018, we secured a Credit Agreement with Emerald Health Sciences (the &#8220;Credit Agreement&#8221;), providing us with a credit facility of up to $20,000,000. Under the Credit Agreement, we may draw a remaining amount of up to $13,550,000 in advances from Emerald Health Sciences from time to time. However, we do not consider the facility available until advance requests are approved, drawn down and funded. Through the third quarter of 2019, we effected three drawdowns under the Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $6,000,000 in advances, and issued Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock at an exercise price of $0.50 per share. On December 20, 2019, we entered into a Warrant Exercise Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences has exercised 40,800,000 of such warrants and paid the aggregate exercise price of approximately $4,080,000 for the related warrant shares in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement. Upon consummation of the transactions under the Warrant Exercise Agreement, the total outstanding principal amount excluding discounts under the Credit Agreement was $2,014,500.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 22, 2020, we entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#8220;PPP Loan&#8221;) from City National Bank. The PPP Loan was obtained pursuant to the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act administered by the U.S. Small Business Administration. We used the proceeds of the PPP loan for payment of payrolls and rent for our office space.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 29, 2020, we entered into an Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, as reported in the current report on the Form 8-K filed with the SEC on April 29, 2020. The Amended Credit Agreement provides for a credit facility to us in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment. During the year ended December 31, 2020, we received the fourth and fifth advances of $150,000 and $300,000 pursuant to the Amended Credit Agreement. The advances bear interest at 7% per annum and mature on October 5, 2022.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On July 28, 2020, we filed a registration statement on Form S-1/A, which has been declared effective as of July 31, 2020, and on July 31, 2020, we filed a related registration statement on a Form S-1MEF that became effective under Rule 462(b). On July 31, 2020, we sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant, which securities were registered under the foregoing registration statements under a securities purchase agreement, as reported in our current report on the Form 8-K filed with the SEC on August 5, 2020. The net proceeds from the transaction were $6,085,589. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. We are using the net proceeds from the offering for general corporate purposes, including working capital.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During March 2020, we approved a plan to defer up to 50% of the members of senior management&#8217;s compensation and 100% of the Board of Director and committee fees indefinitely. In August 2020, subsequent to closing the August 2020 Financing, our Board of Directors determined that we had been sufficiently financed and authorized us to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">From January 1, 2021 through February 23, 2021, we received $3,019,800 in proceeds from the exercise of warrants.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread around the world and throughout the United States and Australia, where we have operations and conduct laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment, and significant economic disruptions to the global financial markets. These disruptions could impact our ability to raise additional capital and obtain the necessary funds.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notably, we rely on third party manufacturers to produce our product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent COVID-19 pandemic, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we have shifted the expected start of our first-in-human studies of the lead drug candidate, THCVHS, from the second half of 2020 to the third quarter of 2021.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ultimate impact on us and overall delay in our drug product research and development is unknown, but our operations and financial condition will suffer in the event of business interruptions, delayed clinical trials, production or a lack of laboratory resources due to the pandemic. As of the date of this filing, we are aware of the impact on our business as a result of COVID-19 but uncertain as to the extent of this impact on our consolidated financial statements. There is uncertainty as to the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Going Concern</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our independent registered public accounting firm has issued a report on our audited consolidated financial statements for the fiscal year ended December 31, 2020 that includes an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Off-Balance Sheet Arrangements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i7a"><strong><u>Item</u></strong><strong><u> 7A. Quantitative and Qualitative Disclosures About Market Risk</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i8"><strong><u>Item</u></strong><strong><u> 8. Financial Statements and Supplementary Data</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our consolidated financial statements and the report of our independent registered public accounting firm are included in this report on pages F-1 through F-30.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i9"><strong><u>I</u></strong><strong><u>tem 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i9a"><strong><u>Item</u></strong><strong><u> 9A. Controls and Procedures</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Evaluation of Disclosure Controls and Procedures</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Management&#8217;s Annual Report on Internal Control over Financial Reporting</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of the company&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183; </font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management, with the supervision and participation of our Chief Executive Officer and Interim Principal Accounting Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2020, based on criteria for effective internal control over financial reporting set forth by the Committee of Sponsoring Organizations of the Treadway Commission in <em>Internal Control-Integrated Framework - 2013 (COSO 2013 Framework).</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on their assessment, our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As we are a smaller reporting company, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Changes in internal control over financial reporting</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There was no change in our internal control over financial reporting during the fourth quarter ended December 31, 2020 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i9b"><strong><u>Item</u></strong><strong><u> 9B. Other Information</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="p3"><strong>PART</strong><strong> III</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i10"><strong><u>Item</u></strong><strong><u> 10. Directors, Executive Officers and Corporate Governance</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth certain information as of the date of this Annual Report, with respect to our directors, executive officers and significant employees.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;"><strong>Name</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Age</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Position</strong></p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Punit Dhillon</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:bottom;white-space: nowrap;"> <p style="MARGIN: 0px; text-align:center;">40</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">Chief Executive Officer, Chairman, Director</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="width:25%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Richard Janney</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2" style="width:9%;vertical-align:bottom;white-space: nowrap;"> <p style="MARGIN: 0px; text-align:center;">62</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">Interim Principal Accounting Officer</p></td> <td style="width:1%;">&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Margaret Dalesandro</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:bottom;white-space: nowrap;"> <p style="MARGIN: 0px; text-align:center;">74</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">Director</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Jim Heppell</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:bottom;white-space: nowrap;"> <p style="MARGIN: 0px; text-align:center;">65</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">Director</p></td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Biographies of Directors, Executive Officers and Significant Employees</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Punit Dhillon. </strong>Mr. Dhillon was appointed as a member of our Board in connection with the consummation of the investment in us by Emerald Health Sciences in 2018. On December 17, 2019, Mr. Dhillon was appointed as Chairman of our Board. Mr. Dhillon is currently a board member of Emerald Health Pharmaceuticals, Inc., Emerald Health Therapeutics, Inc. (EMH), a TSX Venture Exchange listed company, and Arch Therapeutics Inc. (OTCQB: ARTH). Mr. Dhillon is a Co-founder and Director of OncoSec Medical Incorporated (NASDAQ: ONCS) and was formerly the CEO through March 2018. Prior to OncoSec, Mr. Dhillon was the Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc. (NASDAQ: INO) from September 2003 until March 2011. Mr. Dhillon has also previously been a consultant and board member for several TSX Venture Exchange listed early-stage life science companies, which matured through advances in their development pipelines and subsequent M&amp;A transactions. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk and worked with MDS Capital Corp. (now Lumira Capital Corp.). Mr. Dhillon is an active member in his community and places great value on helping future leaders overcome challenges through mentorship and education and is a co-founder and board member of Young Entrepreneurship Leadership Launchpad (YELL), a not-for-profit and charity organization based in Canada. Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University. Mr. Dhillon&#8217;s experience in the biotechnology and pharmaceutical industry, and his experience with publicly traded companies were the primary qualifications that the Board considered in appointing him as a director of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Jim Heppell. </strong>Mr. Heppell was the founder, CEO and director of BC Advantage Life Sciences I Fund, which won the Canadian Venture Capital Deal of the Year Award for having the highest realized return (23.4x its investment in Aspreva Pharmaceuticals) of any venture capital fund in Canada. Mr. Heppell has a Bachelor of Science degree in Microbiology and a law degree from the University of British Columbia. After being called to the Bar, he worked for six years with Fasken Martineau DuMoulin, during which time he was seconded to the BC Securities Commission for six months. Mr. Heppell then became President and Chief Executive Officer of Catalyst Corporate Finance Lawyers, a boutique corporate finance law firm that focused on building life science and technology companies. He is a past member of the Securities Policy Advisory Committee to the BCSC and is Past-Chairman of the Securities Section of the Canadian Bar Association (B.C. Branch). Mr. Heppell taught corporate finance and corporate governance courses at the University of British Columbia, Simon Fraser University and at a number of biotechnology conferences for numerous years. He is currently a director of a number of public and private life science companies, including Emerald Health Sciences. The Board considered Mr. Heppell&#8217;s significant experience with life science and technology companies and the public markets in making the decision to appoint him as a director of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Dr. Margaret Dalesandro. </strong>Dr. Margaret Dalesandro currently serves on the board of OncoSec Medical Incorporated, a company listed on NASDAQ and a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. In addition, Dr. Dalesandro is currently the President of Brecon Pharma Consulting LLC. Dr. Dalesandro has over twenty-five years of experience leading strategic product development in the pharmaceutical, biotechnology and diagnostics industries. She has previously served as a Business Director of Integrative Pharmacology at Corning, Incorporated, as a Vice President of Project, Portfolio and Alliance Management at ImClone Systems Inc., as an Executive Director of Project and Portfolio Management at GlaxoSmithKline, and as a Senior Consultant at Cambridge Pharma Consultancy over the course of her career. Dr. Dalesandro earned her Ph.D. in Biochemistry from Bryn Mawr College and completed a NIH Post-Doctoral Fellowship in Molecular Immunology at the Wake Forest University School of Medicine. The Board considered Dr. Dalesandro&#8217;s significant experience with life science and technology companies in making the decision to appoint her as a director of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Richard Janney. </strong>Mr. Richard Janney currently is an independent contractor at RoseRyan, Inc. (&#8220;RoseRyan&#8221;), a professional services firm which provides accounting and financial advisory services to the Company on a regular basis. Mr. Janney currently serves as the acting Chief Financial Officer of Pinnacle Engines and Tempathic, Inc. on a part-time basis. Prior to Tempathic, Inc., Mr. Janney served as the Chief Financial Officer of Thinc, Inc. from September 2018 to August 2019, and as the Chief Executive Officer of AFFARI, LLC from 2011 to 2019. Mr. Janney also served as the principal accounting officer of several public and private companies, including Trident Microsystems, Inc., a NASDAQ listed company, and Asyst Technologies, Inc., a NASDAQ listed company. Mr. Janney&#8217;s experience also includes being a manager at PricewaterhouseCoopers. Mr. Janney received a B.S. degree from California Polytechnic University San Luis Obispo in Business Administration with an emphasis in Finance and Accounting.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 16(a) Beneficial Ownership Reporting Compliance</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>S</strong>ection 16(a) of the Exchange Act requires our directors, executive officers, and any persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. SEC regulation requires executive officers, directors and greater than 10% stockholders to furnish us with copies of all Section 16(a) forms they file. Based solely on our review of the copies of such forms received by us, or written representations from certain reporting persons, we believe that during the year ended December 31, 2020, our executive officers, directors, and greater than 10% stockholders complied with all applicable filing requirements on a timely basis, except that a Form 4 was filed late by Margaret Dalesandro, resulting in one transaction not being reported on a timely basis. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Family Relationships</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are no family relationships among our directors or executive officers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Term of Office of Directors</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our directors are elected at each annual meeting of stockholders and serve until the next annual meeting of stockholders or until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Directors and Officers Involvement in Certain Legal Proceedings</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the past ten years, our directors and executive officers have not been involved in any of the legal proceedings set forth in Item 401(f) of Regulation S-K promulgated by the SEC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Board and Committee Meetings</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">During 2020, our Board met four times (including telephonic meetings) and took action by written consent 17 times. Each director attended at least 75% of the meetings held by the Board and by each committee on which she or he served while she or he was a director, either in person or by teleconference, during the year.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Director Attendance at Annual Meetings</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Although we do not have a formal policy regarding attendance by members of our Board at each annual meeting of stockholders, we encourage all of our directors to attend. All of our directors attended our most recent annual general meeting of stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Audit Committee and Financial Expert</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On February 23, 2015, our Board established an audit committee that operates under a written charter that has been approved by our Board. The members of our audit committee are Mr. Jim Heppell and Dr. Margaret Dalesandro. Mr. Jim Heppell serves as chairman of the audit committee and our Board has determined that he is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules. The Board has determined that Mr. Jim Heppell and Dr. Margaret Dalesandro are independent directors as that term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules, and we have determined that both Mr. Jim Heppell and Dr. Margaret Dalesandro as audit committee members meet the more stringent requirements under Rule 5605(c)(2) of the Nasdaq Listing Rules. Our audit committee met two times (including telephonic meetings) and took action by written consent one time in 2020 as compensation matters were handled directly by our Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our audit committee is responsible for: (1) selection and oversight of our independent accountant&#894; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters&#894; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters&#894; (4) engaging outside advisors&#894; and, (5) approving fees for the independent auditor and any outside advisors engaged by the audit committee. The Audit Committee Charter is filed as Exhibit 99.1 to our Report on Form 8-K filed on February 27, 2015.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Compensation Committee</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 31, 2015, our Board established a compensation and compliance committee which operated under a written charter that was approved by the Board. In 2018, the Board dissolved the former compensation and compliance committee and established a new compensation committee which operates under a written charter approved by the Board. The members of our compensation committee are Mr. Jim Heppell and Dr. Margaret Dalesandro. Mr. Jim Heppell serves as chairman of the compensation committee. Our compensation committee did not meet or take action by written consent during 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our compensation committee is responsible for the oversight of, and the annual and ongoing review of, the Chief Executive Officer, the compensation of the senior management team, and the bonus programs in place for employees, which includes: (1) reviewing the performance of the Chief Executive Officer and such other senior officers as the Board may request, and determining the bonus entitlement for such officer or officers on an annual basis and recommending the same to the Board for approval&#894; (2) determining the proposed annual compensation of our executive officers for each fiscal year and recommending the same to the Board for approval&#894; (3) reviewing and discussing the bonus plan proposed for our senior management team with the Chief Executive Officer&#894; (4) reviewing and discussing the terms and conditions of proposed grants of stock options to directors, employees, consultants and advisors with the Chief Executive Officer&#894; (5) reviewing and recommending to the Board the compensation of the Board and committee members&#894; (6) reviewing and discussing with the Chief Executive Officer the standard forms of employment and consulting contracts used by us&#894; (7) reviewing and discussing with the Chief Executive Officer the general benefit plans in place for employees&#894; (8) engaging and setting the compensation for independent counsel and other advisors and consultants&#894; and (9) reviewing and assessing the adequacy of its Charter and submitting any recommended changes to our Board for its consideration and approval.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Nomination and Corporate Governance Committee</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2018, our Board established a nominating and corporate governance committee that operates under a written charter approved by the Board. The members of our nomination and corporate governance committee are Mr. Jim Heppell and Dr. Margaret Dalesandro. Dr. Margaret Dalesandro serves as chairman of the nomination and corporate governance committee. Our nomination and corporate governance committee met once during 2020 (including telephonic meetings) and took action by written consent one time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our nominating and corporate governance committee is responsible for assisting the Board in (1) identifying qualified individuals to become Board members, consistent with criteria approved by the Board, (2) determining the composition of the Board and its committees, (3) selecting the director nominees for the next annual meeting of shareholders, (4) monitoring a process to assess Board, committee and management effectiveness, (5) aiding and monitoring management succession planning and (6) developing, recommending to the Board, implementing and monitoring policies and processes related to our corporate governance guidelines.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Finance and Business Development Committee</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2018, our Board established a finance and business development committee which operates under a written charter approved by the Board. The members of our finance and business development committee are Mr. Punit Dhillon and Mr. Jim Heppell. Mr. Punit Dhillon serves as chairman of the finance and business development committee. Our finance and business development committee did not meet but took action by written consent three times in 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our finance and business development committee is responsible for assisting the Board in (1) matters affecting our balance sheet, including capital structure strategies, debt and equity financings and working capital (2) analysis and assessment of financial and strategic aspects of major acquisitions and divestitures, collaborations and joint ventures, (3) formulating and recommending for approval to the Board our financial policies, including management of the financial affairs of the Company, (4) developing and maintaining relationships with investment banks, financial institutions and other investors and monitor developments in the capital markets and financing trends, and (5) evaluating and making recommendations to the Board concerning business development opportunities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Nominations to the Board of Directors</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We do not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. Our Board believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. We do not currently have any specific or minimum criteria for the election of nominees to the Board. The Board, with the help of its nomination and corporate governance committee, will assess all candidates and make recommendations for election or appointment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stockholder Communications</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We do not have a formal policy regarding stockholder communications with our Board. A shareholder who wishes to communicate with our Board may do so by directing a written request addressed to our Chief Executive Officer, at the address appearing on the first page of this filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Code of Ethics</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 31, 2014, we adopted a formal code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, as well as our other officers, directors and employees. A copy of our code of ethics is available on our website at <u>http://www.skyebioscience.com</u>. We intend to disclose any future amendments to provisions of our code of ethics, or waivers of provisions required to be disclosed under the rules of the SEC, on a current report on Form 8-K or at the same location on our website identified in the preceding sentence. Any amendment or waiver disclosed on our website will remain available on our website for at least 12 months after the initial disclosure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i11"><strong><u>Item</u></strong><strong><u> 11. Executive Compensation</u></strong><strong>. </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Summary Compensation Table </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth information concerning the compensation earned for services rendered to us for the fiscal years ended December 31, 2020 and 2019 of our named executive officers as determined in accordance with SEC rules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="35"> <p style="MARGIN: 0px; text-align:center;"><strong>SUMMARY COMPENSATION TABLE</strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Name and </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>Principal </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>Position</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Year</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Salary</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Bonus</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Stock </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($) <sup>(1)</sup></strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Option </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($) <sup>(1)</sup></strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Non-Equity Incentive Plan Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Nonqualified Deferred Compensation Earnings</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>All </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Other Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Richard Janney</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">52,425</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">52,425</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Interim PAO <sup>(2)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">160,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">387,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">547,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">CEO</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Brian S. Murphy, </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">247,026</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,750</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">195,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">448,776</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former CEO/ CMO <sup>(3)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">390,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">390,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Elena Traistaru,</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">41,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">130,571</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">171,571</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former Interim PFA<sup>(4)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Douglas Cesario,</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">95,192</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">220,192</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former CFO<sup>(5)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">250,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">250,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Dennis Kim,</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">308,404</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,712</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">164,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">478,116</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former CMO<sup>(6)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">119,812</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">164,985</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">284,797</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Avtar Dhillon, </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">120,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">127,387</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">247,387</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former Executive Chairman <sup>(7)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">117,890</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">117,890</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">___________</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Amounts reflect the full grant date fair value of stock options and awards, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">For the year ended December 31, 2020, other compensation consists of consulting fees charged to the Company by RoseRyan, Inc. for Mr. Richard Janney&#8217;s services.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(3)</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Dr. Brian Murphy separated from us, effective August 7, 2020, pursuant to a Separation and Release Agreement between us and Dr. Murphy. For the year ended December 31, 2020, other compensation consists of severance payable under Mr. Murphy&#8217;s Separation and Release Agreement.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(4)</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Ms. Elena Traistaru resigned as Interim Principal Accounting Officer, effective September 25, 2020. For the year ended December 31, 2020, other compensation consists of consulting fees charged to the Company by Ms. Traistaru&#8217;s consulting company.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(5)</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Mr. Douglas Cesario separated from us, effective May 15, 2020, pursuant to a Separation and Release Agreement between us and Mr. Cesario. For the year ended December 31, 2020, other compensation consists of severance payable under the Separation and Release Agreement.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(6)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Dr. Dennis Kim resigned as Chief Medical Officer, effective November 6, 2020. </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(7)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Dr. Avtar Dhillon resigned as Chairman and member of our Board of Directors, effective December 17, 2019. For the year 2020, other compensation consists of consulting fees earned under the Independent Contractor Agreement (defined below). See &#8220;Director Compensation&#8221; below. For the year 2019, other compensation represents fees earned for services rendered as a member of our Board of Directors.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment and Severance Arrangements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Employment Agreement</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On August 7, 2020, we entered into an employment agreement with Mr. Punit Dhillon, our Chief Executive Officer. The agreement provides for an annual base salary of $400,000 per year and an annual discretionary bonus up to fifty percent (50%) of his base salary based on Mr. Punit Dhillon&#8217;s achievement of annual corporate milestones agreed to by the Board. Mr. Punit Dhillon will also receive the normal benefits available to other similarly situated executives and will be entitled to severance pay under the circumstances described below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Mr. Punit Dhillon&#8217;s employment with the Company is at-will. Except for termination of Mr. Punit Dhillon&#8217;s employment for &#8220;Cause,&#8221; &#8220;By Death&#8221; or &#8220;By Disability&#8221; (as such terms are defined in his employment agreement), Mr. Punit Dhillon will be entitled to a minimum six months&#8217; severance if he is terminated by the Company without cause. Under his employment agreement, Mr. Punit Dhillon will be eligible to receive a 12-months&#8217; severance if he is employed by the Company for at least 12 months commencing on August 10, 2020, or a 24 months&#8217; severance if he is employed by the Company for at least 24 months commencing on August 10, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">In connection with his appointment, the Company granted Mr. Punit Dhillon options to purchase 9,000,000 shares of the Company&#8217;s common stock at an exercise price of $0.045 per share (the then market price of the Company&#8217;s shares), with 10% of such options vested immediately upon grant and the remaining 90% vesting equally on each six-month anniversary of the grant date over four and a half years.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The foregoing description of the employment agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the employment agreements attached hereto as an exhibit and incorporated by reference herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Severance Arrangements</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&#8217;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon resignation for a good reason (as each term is defined in the plan).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In either such event, and provided the executive timely executes and does not revoke a general release of claims against us, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months&#8217; of the executive&#8217;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to the length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&#8217;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 29, 2020, we entered into a Separation and Release Agreement with Mr. Douglas Cesario. Mr. Cesario&#8217;s separation was effective May 15, 2020. Pursuant to the Separation and Release Agreement, Mr. Cesario agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation and Release Agreement. As consideration, we agreed to provide Mr. Cesario compensation and benefits in accordance with his Employment Agreement as follows: (i) through the Separation Date, an annualized base salary at the rate in effect for him as of the date of the Separation and Release Agreement; (ii) a gross payment of $125,000 in consideration for the restrictive covenants contained in the Separation and Release Agreement; and (iii) a continuation of health insurance benefits for reimbursement for a period of six months following the Separation Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 7, 2020, we entered into a Separation and Release Agreement with Dr. Brian Murphy, pursuant to which, Dr. Murphy resigned as the Company&#8217;s Chief Executive Officer and a member of the Board, effective August 7, 2020. Pursuant to the Separation and Release Agreement, Dr. Murphy has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as set out in the Separation and Release Agreement. As consideration, we have agreed to provide Dr. Murphy with certain compensation and benefits in accordance with his Employment Agreement as follows: (i) an aggregate gross sum of $195,000, less federal and state withholdings, as salary continuation over six months in accordance with the Company&#8217;s standard biweekly payroll practice; and (ii) Company&#8217;s healthcare benefits (for similarly situated executives as amended from time to time), for a period of six months from the Separation Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The foregoing descriptions of the separation and release agreements do not purport to be complete and are qualified in their entirety by reference to the full text of such separation and release agreements attached hereto as exhibits and incorporated by reference herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Outstanding Equity Awards at Fiscal Year-end</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2020, our named executive officers held the following outstanding Company equity awards. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="15"> <p style="MARGIN: 0px; text-align:center;"><strong>Option Awards</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="3"> <p style="MARGIN: 0px; text-align:center;"><strong>Stock Awards</strong></p></td> <td style="width:1%;">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="margin:0px"><strong>Name</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Grant</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Securities</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Underlying Unexercised</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Options (#)</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Securities</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Underlying</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Unexercised</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Options (#)</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Un-</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>exercisable </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Option</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Option</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Expiration</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Stock Not</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Vested (#)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Market</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares Not</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Vested ($)<sup>(1)</sup></strong></p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon,</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><sup>(2)</sup>10/10/2018</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.305</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">10/10/2028</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">CEO/Chairman</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><sup>(3)</sup>8/7/2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,100,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.045</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">8/7/2030</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">___________&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The market value of shares that have not vested is calculated based on the per share closing price of our common stock on December 31, 2020.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The options specified above vest as follows: 1/12 each month on the anniversary of the grant date.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(3)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The options specified above vest as follows: 10% of total vests on the grant date and 1/10 vests semi-annually on the anniversary of the grant date thereafter.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Exercises of Options</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no exercises of stock options by our named executive officers during the year ended December 31, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Director Compensation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since October 2018, our policy for the compensation of our non-employee directors has been as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each non-employee director receives a cash retainer of $40,000 on an annual basis, and an executive chair of the Board, if one is appointed as such and is a non-employee director, receives an additional $40,000 retainer annually.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon election to the Board, non-employee directors receive a one-time award of 200,000 stock options which vest in twelve equal monthly installments. In subsequent annual periods, each non-employee director receives a grant of 100,000 common stock options which vest in twelve equal monthly installments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Non-employee directors who serve as members of special committees of the Board receive additional compensation as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Audit Committee: $5,000 per year ($20,000 for the chair)</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Compensation Committee: $2,500 per year ($10,000 for the chair)</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Nominating and Corporate Governance Committee: $1,000 per year ($5,000 for the chair)</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">Finance and Business Development Special Committee: $40,000 per year for a non-employee member (no compensation for employee members)</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our directors received the following compensation for their service as our directors during the fiscal year ended December 31, 2020. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="29"> <p style="MARGIN: 0px; text-align:center;"><strong>DIRECTOR COMPENSATION <sup>(1)</sup> </strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Name</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fees</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Earned</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>or Paid</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>in Cash</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Stock </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($) <sup>(2)</sup> </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Option </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)<sup> (2)</sup></strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Non-Equity</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Incentive Plan Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Non-Qualified</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Deferred Compensation Earnings</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>All </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Other Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p> <p style="MARGIN: 0px; text-align:center;"></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p> <p style="MARGIN: 0px; text-align:center;"></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">68,082</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">68,082</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Jim Heppell</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">83,527</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">40,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">123,527</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Margaret Dalesandro</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">21,028</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31,028</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">___________&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Does not include compensation received for services provided as executive officers.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Each non-employee director is entitled to an annual grant of 100,000 common stock options, all of which vest in twelve equal monthly installments. However, no annual option grants were approved by the Board of Directors in 2020. Amounts reflect the full grant date fair value of restricted stock awards and stock options, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of restricted stock awards and options granted to our directors in Note 2 and 6 to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i12"><strong><u>Item</u></strong><strong><u> 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</u></strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Securities Authorized for Issuance under Equity Compensation Plans</strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The table below includes the following information as of December 31, 2020 for the Company&#8217;s 2014 Omnibus Incentive Plan. Shares available for issuance under the 2014 Omnibus Incentive Plan can be granted pursuant to stock options, stock appreciation rights, restricted stock, restricted stock unit awards, performance awards and other stock-based or cash-based awards, as selected by the plan administrator. For additional information about the 2014 Omnibus Incentive Plan, refer to Note 6 in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="13"> <p style="MARGIN: 0px; text-align:center;"><strong>Equity Compensation Plan Information</strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Plan category</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>shares of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>common</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>stock to be issued upon exercise of outstanding options, warrants and rights</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(a)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>average exercise price of outstanding options, warrants and rights</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(b)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of shares of common stock remaining available for future</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>issuance</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>under equity</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>plans (excluding shares of common stock reflected in column (a))</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(c)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Equity compensation plans approved by security holders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,050,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.06</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,790,775</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>22,050,000</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.06</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>12,790,775</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Security Ownership of Certain Beneficial Owners and Management</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth certain information with respect to beneficial ownership of our common stock, by:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">each person known to be the beneficial owner of 5% or more of our outstanding common stock&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">each executive officer&#894;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">each director&#894; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="margin:0px">all of the executive officers and directors as a group.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon exercise of an option or warrant) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table does not necessarily reflect the person&#8217;s actual voting power at any particular date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The information set forth in the table below is based on 350,007,749 shares of our common stock issued and outstanding on February 23, 2021.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. Unless otherwise indicated, the address of each beneficial owner listed below is 5910 Pacific Center Blvd. Suite 320, San Diego, CA 92121.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Name and Address of Beneficial Owner</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:20%;vertical-align:bottom;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Beneficial</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Ownership</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Percent</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>of Class</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Health Sciences, Inc.<sup> (1)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">124,066,474</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(2)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:7%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">34.2</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">3,000,000</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(3)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Brian S. Murphy</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">1,275,000</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(6)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Richard Janney</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">-</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Elena Traistaru</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">-</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(9)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Douglas Cesario</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">643,501</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(7)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Dennis Kim</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">-</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(10)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Jim Heppell</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">1,025,000</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(4)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Margaret Dalesandro</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">81,250</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(5)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:7%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Avtar Dhillon</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">2,475,000</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;"><sup>(8)</sup></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:7%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All executive officers and directors as a group (9 persons)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:18%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">8,499,751</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:7%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">2.4</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;">%</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">_________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">*Denotes less than 1% of our outstanding shares of common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The address of Emerald Health Sciences is 8262, The Landing, 200 - 375 Water St., Vancouver, British Columbia, Canada V6B 0M9.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Includes (i) 111,387,251 shares of common stock, (ii) 7,500,000 shares issuable on exercise of warrants and (iii) 5,178,244 shares issuable upon the conversion of outstanding principal and accrued interest associated with the Amended Credit Agreement.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(3)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Includes 2,000,000 shares of common stock underlying options that may be exercised within 60 days of February 23, 2021.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(4)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Includes 525,000 shares of common stock underlying options that may be exercised within 60 days of February 23, 2021.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(5)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Includes 81,250 shares of common stock underlying options that may be exercised within 60 days of February 23, 2021.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(6)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Brian Murphy separated from us, effective August 7, 2020, pursuant to a Separation and Release Agreement between us and Dr. Murphy.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(7)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Mr. Douglas Cesario separated from us, effective May 15, 2020, pursuant to a Separation and Release Agreement between us and Mr. Cesario.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(8)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Includes 1,975,000 shares of common stock underlying options that may be exercised within 60 days of February 23, 2021. Dr. Avtar Dhillon resigned as Chairman and member of our Board of Directors, effective December 17, 2019.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(9)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Ms. Elena Traistaru resigned as Interim Principal Accounting Officer, effective September 25, 2020.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(10)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Dennis Kim resigned as Chief Medical Officer, effective November 6, 2020.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Changes in Control</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management is not aware of any arrangements which may result in &#8220;changes in control&#8221; as that term is defined by the provisions of Item 403(c) of Regulation S-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i13"><strong><u>Item</u></strong><strong><u> 13. Certain Relationships and Related Transactions, and Director Independence</u></strong><strong>. </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Transactions with Related Persons</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as specified below, there have been no other transactions with related persons in the last two fiscal years, or any currently proposed transaction, in which we were or are to be a participant and the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets as of December 31, 2020 and 2019, and in which any related person had or will have a direct or indirect material interest.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Health Sciences</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2018, we entered into a securities purchase agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences purchased a majority of the outstanding equity in us, resulting in a change in control of the Company. As part of the transaction, the members of Board of the Company, with the exception of Dr. Brian Murphy, our former CEO, tendered their resignation, and Emerald Health Sciences appointed two nominees to the Board. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, CEO and President of Emerald Health Sciences, as the Executive Chairman of the Board. On December 17, 2019, the Board accepted the resignation of Dr. Avtar Dhillon, who offered his resignation as the Executive Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. The Board also appointed Punit Dhillon, an existing member of the Board, as Chairman of the Board and as Chairman of the Finance and Business Development Committee of the Board, to fill the vacancies in such offices created by the resignation of Dr. Avtar Dhillon. On August 7, 2020, Mr. Punit Dhillon was appointed the CEO of the Company and tendered his resignation as Chairman of the Audit Committee and a member of the Compensation Committee and the Nomination and Corporate Governance Committee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On February 1, 2018, we entered into an Independent Contractor Agreement (the &#8220;Independent Contractor Agreement&#8221;) with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursements for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services may include, but are not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of ten years and specified compensation to be agreed upon between the Company&#8217;s chief executive officer and Emerald Health Sciences&#8217; CEO on a month-to-month basis. The fee due under this agreement was payable on a monthly basis; however, if we were unable to make payments due to insufficient funds, then interest on the outstanding balance is accrued at a rate of 12% per annum, calculated semi-annually. Under this agreement, the Company incurred expenses of $542,000 during the year ended December 31, 2019. As of December 31, 2019 and 2020, $7,032 remains unpaid. The Independent Contractor Agreement was terminated effective December 31, 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On October 5, 2018, we entered into the Credit Agreement with Emerald Health Sciences. The Credit Agreement provides for a credit facility to us of up to $20,000,000 and is unsecured. Advances under the Credit Agreement bear interest at an annual rate of 7% (payable quarterly in arrears) and mature on October 5, 2022. At Emerald Health Sciences&#8217; election, advances and unpaid interest may be converted into Common Stock at a fixed conversion price of $0.40, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. In connection with each advance under the Credit Agreement, we agreed, if requested by Emerald Health Sciences, to issue Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have an exercise price of $0.50 per share, a term of five years and will be immediately exercisable upon issuance. The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to our shareholders. On November 1, 2018, we affected an initial draw under the Credit Agreement in the amount of $2,000,000 and issued Emerald Health Sciences a warrant to purchase 2,500,000 shares of common stock at an exercise price of $0.50 per share, in accordance with the terms of the Credit Agreement. On February 1, 2019, we affected the second draw under the Credit Agreement in the amount of $2,000,000 and issued Emerald Health Sciences a warrant to purchase 2,500,000 shares of common stock at an exercise price of $0.50 per share, in accordance with the terms of the Credit Agreement. On March 29, 2019, we affected the third draw under the Credit Agreement in the amount of $2,000,000 and issued Emerald Health Sciences a warrant to purchase 2,500,000 shares of common stock at an exercise price of $0.50 per share, in accordance with the terms of the Credit Agreement. On December 20, 2019, we entered into a Warrant Exchange Agreement, pursuant to which Emerald Health Sciences exercised 40.8 million of such warrants and paid the aggregate exercise price of approximately $4.08 million for the related warrant shares in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement. Upon consummation of the transaction under the Warrant Exchange Agreement, the total outstanding principal amount excluding discounts under the Credit Agreement was $2,014,500. On April 29, 2020, we entered into an Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, as reported in the current report on the Form 8-K filed with the SEC on April 29, 2020. The Amended Credit Agreement provides for a credit facility to us in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment. During the year ended December 31, 2020, we received the fourth and fifth advances of $150,000 and $300,000 pursuant to the Amended Credit Agreement. The advances bear interest at 7% per annum and mature on October 5, 2022. The Amended Credit Agreement is still in place; however, there is no guarantee of continued funding under the Amended Credit Agreement. A portion of the proceeds raised in this offering may be used to pay, in whole or in part, the principal and accrued interest on our Amended Credit Agreement. See &#8220;Use of Proceeds.&#8221; The net proceeds of each advance shall be used for general corporate purposes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On December 19, 2019, we entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Avtar Dhillon will provide ongoing corporate finance and strategic business advisory services to us. In exchange for his services, Dr. Dhillon initially received a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#8217;s completion of a material financing. On March 30, 2020, we amended the Independent Contractor Services Agreement by agreeing to defer payment of 100% of Dr. Dhillon&#8217;s consulting fees until the Board of Directors determined that we had been sufficiently financed to make such payments at which point we would pay Dr. Dhillon all his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. After the August 2020 Financing Dr. Dhillon continues to receive a monthly fee of $10,000 per month for his services. The Board reviews the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and automatically renews thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party. Under this agreement, for the years ended December 31, 2020 and 2019, we incurred fees of $127,387 and $3,871, respectively. As of December 31, 2020, we have accrued $10,000 in expense related to the Independent Contractor Services Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On December 19, 2019, we entered into a Board Observer Agreement with Emerald Health Sciences, our largest shareholder. The Board Observer Agreement gives a right to Emerald Health Sciences to designate one observer to our Board for so long as Emerald Health Sciences maintains ownership of any securities in the Company. Under the Board Observer Agreement, the board observer will be permitted to attend all meetings (whether in person, telephonically or otherwise) of the Board in a non-voting, observer capacity. Emerald Health Sciences appointed Dr. Avtar Dhillon as its board observer. The Board Observer Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Health Biotechnology Espa&#241;a, S.L.U.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2021, we entered into a Collaborative Research Agreement with Emerald Health Biotechnology Espa&#241;a, S.L.U, a subsidiary of Emerald Health Research, Inc. which is 100% owned by Emerald Health Sciences. Under the agreement, Emerald Health Biotechnology Espa&#241;a, S.L. will provide research and development services pursuant to an agreed upon project plan for the research and development of CBDVHS. The term of the agreement is initially for a one-year period. The agreement will terminate upon delivery and acceptance of the final deliverable under the project plan or if either party is in breach of the terms of the contract and such breach remains uncured for 45 days. Payment for services rendered will be based on time and materials billable at reasonable market rates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Douglas Cesario</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">In April 2020, we entered into a Separation and Release Agreement with Mr. Douglas Cesario, our former Chief Financial Officer. Mr. Cesario&#8217;s separation was effective May 15, 2020. Pursuant to the agreement, Mr. Cesario agreed to certain ongoing cooperation obligations and to provide certain releases and waivers to us as set out in the agreement. As consideration, we agreed to provide Mr. Cesario compensation and benefits in accordance with his Employment Agreement as follows: (i) through May 15, 2020, an annualized base salary at the rate in effect for him as of the date of the agreement; (ii) a gross payment of $125,000 in consideration for the restrictive covenants contained in the agreement; and (iii) a continuation of health insurance benefits for a period of six months following May 15, 2020. In addition, 325,929 unvested stock options granted to Mr. Cesario were cancelled on May 15, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Dr. Brian Murphy</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 7, 2020, we entered into a Separation and Release Agreement with Dr. Brian Murphy, pursuant to which, Dr. Murphy resigned as the Company&#8217;s Chief Executive Officer and a member of the Board, effective August 7, 2020. Pursuant to the Separation and Release Agreement, Dr. Murphy agreed to certain ongoing cooperation obligations and to provide certain releases and waivers to us as set out in the Separation and Release Agreement. As consideration, we have agreed to provide Dr. Murphy with certain compensation and benefits as follows: (i) an aggregate gross sum of $195,000, less federal and state withholdings, as salary continuation over six months in accordance with our standard biweekly payroll practice; and (ii) a continuation of health insurance benefits (for similarly situated executives as amended from time to time), for a period of six months from the Separation Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Review, Approval and Ratification of Related Party Transactions</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Given our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification of transactions, such as those described above, with our executive officers, directors and significant stockholders, other than all related party transactions must be approved by directors independent of the parties involved. However, all of the transactions described above were approved and ratified by the independent members of our Board. In connection with the approval of the transactions described above, our Board took into account several factors, including their fiduciary duties to the Company, the relationships of the related parties described above to the Company, the material facts underlying each transaction, the anticipated benefits to the Company and related costs associated with such benefits, whether comparable products or services were available, and the terms we could receive from an unrelated third party.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional directors so that such transactions will be subject to the review, approval or ratification of our Board, or an appropriate committee thereof. On a moving forward basis, our Board will continue to approve any related party transaction based on the criteria set forth above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Conflicts Related to Other Business Activities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The persons serving as our officers and directors have existing responsibilities and, in the future, may have additional responsibilities, to provide management and services to other entities in addition to us. As a result, conflicts of interest between us and the other activities of those persons may occur from time to time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will attempt to resolve any such conflicts of interest in our favor. Our officers and directors are accountable to our shareholders and us as fiduciaries, which requires that such officers and directors exercise good faith and integrity in handling our affairs. A shareholder may be able to institute legal action on our behalf or on behalf of that shareholder and all other similarly situated shareholders to recover damages or for other relief in cases of the resolution of conflicts in any manner prejudicial to us.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Director Independence</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have determined that Jim Heppell and Dr. Margaret Dalesandro are independent members of our Board, as that term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Insider Trading Policy</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 31, 2014, our Board adopted an Insider Trading Policy applicable to all directors and officers. Insider trading generally refers to the buying or selling of a security in breach of a fiduciary duty or other relationship of trust and confidence while in possession of material, non-public information about the security. Insider trading violations may also include &#8216;tipping&#8217; such information, securities trading by the person &#8216;tipped,&#8217; and securities trading by those who misappropriate such information. The scope of insider trading violations can be wide reaching. As such, our Board has adopted an Insider Trading Policy that outlines the definitions of insider trading, the penalties and sanctions determined, and what constitutes material, non-public information. Illegal insider trading is against our policy as such trading can cause significant harm to the reputation for integrity and ethical conduct of our company. Individuals who fail to comply with the requirements of the policy are subject to disciplinary action, at our sole discretion, including dismissal for cause. All members of our Board and all executive officers are required to ratify the terms of this policy on an annual basis. Our Insider Trading Policy is available on our website at <u>http://www.skyebioscience.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i14"><strong><u>Item</u></strong><strong><u> 14. Principal Accounting Fees and Services</u></strong><strong>. </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Audit Fees</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The aggregate fees billed in each of the fiscal years ended December 31, 2020 and 2019, for professional services rendered by Mayer Hoffman McCann P.C. for the audit of our annual consolidated financial statements included in our Annual Report on Form 10-K and quarterly reviews of the unaudited interim condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for 2020 and 2019 were $392,402 and $328,514, respectively. Substantially all MHM&#8217;s personnel, who work under the control of MHM shareholders, are employees of wholly owned subsidiaries of CBIZ, Inc., which provides personnel and various services to MHM in an alternative practice structure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Tax Fees </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>All Other Fees</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pre-Approval Policies and Procedures</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to engaging Mayer Hoffman McCann P.C. to perform a particular service, our Board obtains an estimate for the service to be performed. All of the services described above were approved by the members of the Audit Committee of the Board in accordance with its procedures.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="p4"><strong>PART</strong><strong> IV</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i15"><strong><u>Item</u></strong><strong><u> 15. Exhibits, Financial Statement Schedules</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial Statements. The following consolidated financial statements of Skye Bioscience, Inc., together with the report thereon of Mayer Hoffman McCann P.C., an independent registered public accounting firm, are included in this Annual Report on Form 10-K:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">60</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><a href="#toc"><em>Table of Contents</em></a></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="toc2">SKYE BIOSCIENCE, INC. AND SUBSIDIARIES INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="MARGIN: 0px; text-align:center;"><strong>Page No.</strong></p></td> <td style="width:1%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#re">Report of Independent Registered Public Accounting Firm </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-2</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#bs">Consolidated Balance Sheets as of December 31, 2020 and 2019 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-3</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#sop">Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-4</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#cf">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-5</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#eq">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2020 and 2019 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-6</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#n">Notes to the Consolidated Financial Statements </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-7</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="re"><strong>REPORT</strong><strong> OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the Board of Directors and </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stockholders of Skye Bioscience, Inc. and Subsidiaries:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Opinion on the Financial Statements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have audited the accompanying consolidated balance sheets of Skye Bioscience, Inc., formerly known as Emerald Bioscience, Inc., and Subsidiaries&nbsp;(&#8220;Company&#8221;) as of December 31, 2020 and 2019,&nbsp;and the related consolidated statements of comprehensive (loss) income, stockholders&#8217; equity, and cash flows for each of the two years in the&nbsp;period ended December 31, 2020,&nbsp;and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of&nbsp;the Company as of December 31, 2020 and 2019,&nbsp;and the results of its operations and its cash flows for each of the two years in the period ended&nbsp;December 31, 2020,&nbsp;in conformity with accounting principles generally accepted in the United States of America.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern Uncertainty</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred recurring operating losses and is dependent on additional financing to fund operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are described in Note 1 to the financial statements. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis for Opinion</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">These financial statements are the responsibility of the&nbsp;Company&#8217;s&nbsp;management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to&nbsp;the Company&nbsp;in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.&nbsp;The Company&nbsp;is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Audit Matters</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Mayer Hoffman McCann P.C.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have served as the Company's auditor since 2014.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Irvine, California</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">March 1, 2021</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong><a name="bs">SKYE BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong>CONSOLIDATED</strong><strong> BALANCE SHEETS</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>ASSETS</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current assets</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,469,410</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,829,977</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Restricted cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,566</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0px; text-align:justify;">Prepaid expenses </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">190,134</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,695</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Other current assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">275</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,550</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total current assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,664,385</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,994,760</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Property and equipment, net </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,341</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,983</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,671,726</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current liabilities </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Accounts payable </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">364,340</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,809</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Accounts payable - related party </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,032</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Accrued interest - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,087</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Other current liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">259,111</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,406</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Derivative liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,567</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,603</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: 0px;vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">PPP loan current</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">64,062</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Total current liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">787,199</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">970,818</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Noncurrent liabilities </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">PPP loan non-current</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,638</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Convertible multi-draw credit agreement - related party, net of discount </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">931,103</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">387,070</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Derivative liabilities, non-current </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Total liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,220,940</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,448,685</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Stockholders&#8217; equity</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at December 31, 2020 and December 31, 2019 </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Common stock, $0.001 par value; 500,000,000 shares authorized; 288,074,415 and 182,895,247 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,074</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,895</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Additional paid-in-capital </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,896,693</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,538,445</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Accumulated deficit </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(38,733,981</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,173,282</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total stockholders&#8217; equity </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">450,786</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">548,058</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total liabilities and stockholders&#8217; equity </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,671,726</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="9" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the consolidated financial statements. </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="sop">SKYE BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSOLIDATED </strong><strong>STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31, </strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Operating expenses</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Research and development</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,944,411</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,237,956</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">General and administrative</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,344,602</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,394,622</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Total operating expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,289,013</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,632,578</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Operating loss</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,289,013</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,632,578</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Other expense (income)</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Change in fair value of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(436,270</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,734,759</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Loss on extinguishment of debt - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">725,425</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Interest expense </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">706,385</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,713</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Interest income</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(29</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Total other expense (income), net</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">270,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,686,003</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>(Loss) income before income taxes</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,559,099</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,053,425</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Provision for income taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net (loss) income and comprehensive (loss) income </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6,560,699</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>(Loss) earnings per common share:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.03</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.03</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.05</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Weighted average shares of common stock outstanding used to compute (loss) earnings per share:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">230,746,878</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">135,154,931</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">231,420,973</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">169,560,265</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="9"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="9" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the consolidated financial statements.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="cf"><strong>SKYE BIOSCIENCE, INC. AND SUBSIDIARIES</strong> </a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSOLIDATED</strong><strong> STATEMENTS OF CASH FLOWS</strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from operating activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Net (loss) income </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,560,699</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Adjustments to reconcile net (loss) income to net cash used in operating activities:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Depreciation</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,872</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,462</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">302,742</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">680,455</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Change in fair value of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(436,270</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,734,759</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Loss on extinguishment of debt - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">725,425</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Amortization of debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">544,033</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">629,293</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Changes in assets and liabilities:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Prepaid expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(37,439</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(59,502</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Other current assets</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,275</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,941</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Accounts payable</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234,531</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,212</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Accounts payable &#8211; related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,032</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Accrued interest &#8211; related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,087</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Other current liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(161,295</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,945</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:justify;">Net cash used in operating activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,054,131</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,027,941</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from investing activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Purchases of property and equipment</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,230</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:justify;">Net cash used in investing activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,230</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from financing activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Proceeds from the issuance of common stock and warrants - net of $854,078 and $80,628 of issuance costs in 2020 and 2019, respectively</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,085,589</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,919,372</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Proceeds from warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,533</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,080,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Proceeds from PPP loan</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,700</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs in 2020 and 2019, respectively</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,990,699</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Prepayment of convertible multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,985,500</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:justify;">Net cash provided by financing activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,700,822</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,004,571</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net increase (decrease) in cash and restricted cash</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">639,461</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(23,370</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash and restricted cash</strong>,<strong> beginning of year</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,857,885</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash and restricted cash, end of year</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,473,976</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Supplemental disclosures of cash-flow information:</em></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Reconciliation of cash and restricted cash:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Cash</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,469,410</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,829,977</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Restricted cash</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,566</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">Total cash and restricted cash shown in the consolidated statements of cash flows</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,473,976</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cash paid during the year for:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Interest</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,459</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,420</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Income taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Supplemental disclosures of non-cash financing activities:</em></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Beneficial conversion feature on convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,414</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Reclassification of warrant liabilities to equity from exercise of warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,077,698</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="9" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the consolidated financial statements. </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="eq">SKYE BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSOLIDATED</strong><strong> STATEMENTS OF STOCKHOLDERS' EQUITY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Stockholders' Equity</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Additional</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>Paid-In </strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Total </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Stockholders'</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Amounts</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Capital </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Equity</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, December 31, 2018</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>133,907,747</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>133,908</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>17,528,947</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(33,225,107</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(15,562,252</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">680,455</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">680,455</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Issuance of common stock and warrants, net of issuance costs of $80,628</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,911,372</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,919,372</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Warrants issued in connection with convertible multi-draw credit agreement, related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Series B warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,188</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,375</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Exercise of Emerald financing warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,800,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,800</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,972,523</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,013,323</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Net income for the year ended December 31, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, December 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,895,247</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,895</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>32,538,445</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(32,173,282</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>548,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">302,742</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">302,742</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Issuance of common stock and warrants, net of issuance costs of $854,078</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,333,334</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,333</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,029,256</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,085,589</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Exercise of pre-funded warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,533,334</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,533</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,533</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">312,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">313</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,563</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss for the year ended December 31, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,560,699</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,560,699</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, December 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>288,074,415</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>288,074</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>38,896,693</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(38,733,981</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>450,786</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See accompanying notes to the consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="n">SKYE BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Nature of Operations and Business Activities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Nature of Operations</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Skye Bioscience, Inc. (the &#8220;Company&#8221;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#8220;Merger&#8221;) pursuant to which Nemus, a California corporation (&#8220;Nemus Sub&#8221;), became the Company&#8217;s wholly owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub to form a Nevada company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald Health Sciences&#8221;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &#8220;Emerald Financing&#8221;). As part of the transaction, the Company&#8217;s Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s former CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#8217;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective March 25, 2019, the Company changed its name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc. Effective January 19, 2021, the Company changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#8220;EMBI Australia&#8221;), in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#8217;s product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#8217;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 11 - Related Party Matters for additional information.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a biopharmaceutical company located in San Diego, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#8220;UM&#8221;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Liquidity and Going Concern</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Company has incurred operating losses and negative cash flows from operations since inception and as of December 31, 2020, had an accumulated deficit of $38,733,981. The Company anticipates that it will continue to incur operating losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of December 31, 2020, the Company had unrestricted cash in the amount of $2,469,410. From January 1, 2021 through February 23, 2021, the Company received $3,019,800 in proceeds from the exercise of warrants (Note 13).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. As the Company approaches its first clinical trial, it expects to ramp up research and development spending and to increase cash used in operating activities. However, based on the Company&#8217;s expected cash requirements, without obtaining additional funding by the second half of 2021, management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#8220;Credit Agreement&#8221;) with Emerald Health Sciences (See Note 4). On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &#8220;Amended Credit Agreement&#8221;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000 and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of the Company&#8217;s common stock, in accordance with the terms of the Credit Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. Emerald Health Sciences elected that the fourth and fifth advances are not convertible into shares of Common Stock and no warrants were issued with the advances. The Company used the proceeds from the advances for general corporate and working capital purposes. As of December 31, 2020, the Company may draw down up to the remaining amount under the Amended Credit Agreement. However, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place, however, there is no guarantee of continued funding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#8220;PPP Loan&#8221;) from City National Bank (the &#8220;PPP Loan Lender&#8221;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (&#8220;SBA&#8221;) (Note 4).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 31, 2020, the Company entered into the August 2020 Financing (Note 5), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction were $6,085,589. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company is using the net proceeds of the offering for general corporate purposes, including working capital.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#8217;s compensation and 100% of the Board of Director and committee fees indefinitely. Upon the closing of the August 2020 Financing, the Company&#8217;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread around the world and throughout the United States and Australia, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&#8217;s ability to raise additional capital and obtain the necessary funds.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notably, the Company relies on third party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of THCVHS from the second half of 2020 to the third quarter of 2021.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. Summary of Significant Accounting Policies</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Basis of Presentation</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#8217;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Risks and Uncertainties</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#8217;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#8217;s ability to attract new funding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Cash, Cash Equivalents and Restricted Cash</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2020, and 2019, the Company has no cash equivalents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted cash on the balance sheet represents a certificate of deposit held by the Company&#8217;s bank as collateral for the Company&#8217;s credit cards.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Fair Value Measurements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#8220;exit price&#8221;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:6%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 1:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 2:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 3:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The carrying values of the Company&#8217;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2019, the fair value of the advances under the Amended Credit Agreement was $1,877,938, the carrying amount of the liability on December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#8217;s Consolidated Balance Sheets. As of December 31, 2020, the Company estimates the fair value of the Amended Credit Agreement to be materially consistent with the fair value estimate as of December 31, 2019, plus the non-convertible advances made in 2020. This determination was based on the following considerations: (i) the Company has not experienced any significant change in its credit worthiness or operations year over year, (ii) there have been no repayments or convertible draws, (iii) the facility is closer to maturity, and (iv) the embedded conversion feature on the convertible advances is out-of-the-money at the reporting date. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Income Taxes</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &#8220;NOLs&#8221;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#8217;s Consolidated Statements of Comprehensive (Loss) Income in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&#8217;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020 and 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive (Loss) Income to offset pre-tax losses.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Convertible Instruments</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, <em>Debt with Conversion and Other Options</em> (&#8220;ASC 470-20&#8221;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company also follows ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#8217; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Warrants Issued in Connection with Financings</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Consolidated Statements of Comprehensive (Loss) Income.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Debt Issuance Costs and Interest</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Research and Development Expenses and Licensed Technology</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third party contract research organizations and investigative sites, third party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#8217;s preclinical and clinical drug development activities; facilities expense, and other expenses; and equipment and laboratory supplies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock-Based Compensation Expense </strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#8217;s actual stock volatility adjusted for periods in which significant financial variability was identified.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividends - The dividend yield assumption is based on the Company&#8217;s history and expectation of paying no dividends in the foreseeable future.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Comprehensive (Loss) Income</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Comprehensive (loss) income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 <em>Comprehensive Income</em> requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2020 and 2019, the comprehensive (loss) income was equal to net (loss) income.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Net (Loss) Income Per Share of Common Stock</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net (loss) income per share. Basic net (loss) income per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net (loss) income per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net (loss) income per share, see Note 7 &#8220;Net (Loss) Income per Share of Common Stock.&#8221; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Recent Accounting Pronouncements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU 2020-06, <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</em>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The adoption of ASU 2020-06 will likely impact the way the Company calculates its (loss) earnings per share, result in expanded disclosures around convertible instruments and remove the requirement to assess and record beneficial conversion features. The impact from adoption will depend on whether the Company elects to early adopt this ASU. The Company currently plans to adopt the provisions of this ASU on the effective date. However, it reserves the right to early adopt these provisions. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU No. 2019-12, <em>Income Taxes (Topic 740)</em>: <em>Simplifying the Accounting for Income Taxes</em>. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. Because the Company&#8217;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Recently Adopted Accounting Pronouncements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) intended to improve the effectiveness of disclosures around fair value measurements in the notes to financial statements. The ASU affects all entities that are required to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The Company early adopted certain provisions of this ASU upon issuance during the third quarter of 2018 and revised its disclosures to omit the disclosures removed by this ASU on a retrospective basis. As provided by the ASU, the Company elected to delay adoption of the additional disclosures until January 1, 2020, which include the range and weighed average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty until their effective date. Upon the effective date, the additional disclosures have been included on a prospective basis in the Company&#8217;s financial statements, as applicable. Because much of this information was disclosed prior to adoption this guidance did not have a substantial impact to the Company's disclosures in the notes to its financial statements and had no impact on the Company&#8217;s consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. Warrants and Derivative Liabilities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Warrants</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s warrants. These judgments and estimates include assumptions regarding the Company&#8217;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants vested and outstanding as of December 31, 2020 are summarized as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Vested and</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Source</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>(Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Pre 2015 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">6-10</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,110,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2015 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">5-10</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Common Stock Warrants to Service Providers</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.15</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Series C Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Series D Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Common Stock Warrants to Service Provider</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.41</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2018 Emerald Financing Warrants </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Multi-Draw Credit Agreement Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2019 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.35</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2020 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.06</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,666,668</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2020 Common Stock Warrants to Placement Agent</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.075</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.99</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,166,667</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2020 Pre-Funded Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.001</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> <p style="MARGIN: 0px; text-align:right;">Indefinite</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,800,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total warrants vested and outstanding as of December 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>157,513,335</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>August 2020 Financing Warrants </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the August 2020 Financing (Note 5), the Company issued 116,666,668 common stock warrants, 8,166,667 common stock warrants to the placement agent and 60,333,334 pre-funded warrants. The warrants were equity classified at issuance and of the $6,939,667 in gross proceeds, the Company allocated $2,767,767 and $2,146,997 of the gross proceeds to the common stock warrants and pre-funded warrants on a relative fair value basis, respectively. The remaining $2,024,903 was allocated to the common stock. The warrants issued to the placement agent were valued at $261,333 and recorded as equity issuance costs within equity. The warrants vested immediately and were valued utilizing the Black-Scholes option pricing model with the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock Warrants</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Pre-funded</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Placement Agent Warrants</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91.64</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.86</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91.64</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.52</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.99</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>2019 Common Stock Warrants</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company issued 8,000,000 fully vested common stock warrants to investors, in conjunction with the November 2019 Common Stock Offering discussed below (See Note 5). The warrants are equity classified at issuance and the Company allocated an aggregate of $722,208 of the gross proceeds to the warrants on a relative fair value basis. The warrants vested immediately and had an estimated aggregate fair value of $1,130,400 utilizing the Black-Scholes option pricing model with the following assumptions: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.08</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.62</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.22</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Multi-Draw Credit Agreement Warrants </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes option pricing model with the following assumptions: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">91.6-92.1</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">2.23-2.51</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">$0.33-0.69</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Derivative Liabilities</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following tables summarize the activity of derivative liabilities for the periods indicated: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31, 2020</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair value of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>of Derivatives</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>to Equity </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2020,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Financing - warrant liability <sup>(2)</sup> </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,024</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(237,457</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,567</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability <sup>(3)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134,579</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(108,016</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,563</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>501,400</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(436,270</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(26,563</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>38,567</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>410,603</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>38,567</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31, 2019</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, 2018, Fair</strong> <strong>Value of</strong> <strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair Value of Derivative Liabilities Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair value of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong> <strong>of Derivatives</strong> <strong>to Equity or Extinguishment</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, 2019, Fair</strong> <strong>Value of</strong> <strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219,453</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">516,058</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(484,147</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(160,567</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)*</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Financing - warrant liability <sup>(2)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,251,413</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,042,066</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,933,323</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,024</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability <sup>(3)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">487,500</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(208,546</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(144,375</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134,579</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,958,366</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>516,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(9,734,759</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(6,238,265</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>501,400</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,738,913</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>410,603</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#8217;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes Option Pricing model for each payment period. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. During the year ended December 31, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Financing Warrant Liability (2)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contained an anti-dilution protection feature that provided the investors with price protection if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. In connection with the August 2020 Financing, this provision was waived, and the exercise price was permanently set to $0.10. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of </strong><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90.9</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.5</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.14</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.62</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="margin:0px">0.04</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Series B Warrant Liability (3)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Common Stock Warrants originally exercisable at a price of $1.15 per share. The warrants were exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B Common Stock Warrants also had a &#8220;down-round&#8221; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and the strike price was permanently reset to $0.00 on January 19, 2018, as a result of the Emerald Financing. However, because the remaining warrant holders still had certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B Common Stock Warrant agreements, the warrants continued to require liability classification. After the Emerald Financing repricing occurred, the warrants were valued using a Black Scholes Option Pricing Model. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.2</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.60</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.64</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Common Stock Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options was reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#8217;s common stock on the exercise dates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2020, the remaining Series B Common Stock Warrants expired unexercised. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. Debt</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Multi-Draw Credit Agreement- Related Party</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Debt with Emerald Health Sciences consists of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;" colspan="2"></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of</strong> <strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Conversion</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value of convertible debt&#8212;related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,079,821</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,622,344</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt issuance costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,576</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Carrying value of total convertible debt - related party</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>931,103</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value of non-convertible debt&#8212;related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">n/a</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,381,103</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 11). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. As of August 2020, interest is no longer being deferred as a result of the August 2020 Financing. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Amended Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&#8217; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of December 31, 2020, the unused portion of the credit facility is $13,550,000. The Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place; however, there is no guarantee of continued funding under the Amended Credit Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#8217;s stockholders (See Note 3).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#8217;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision were remeasured at fair value in subsequent periods in the Company&#8217;s Consolidated Balance Sheets.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. Emerald Health Sciences has elected that the fourth and fifth advances will not be convertible into shares of the Company&#8217;s common stock and gave notice to the Company that no warrants will be issued in connection with the advances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the years ended December 31, 2020 and 2019, the effective interest rate related to the convertible portion of the Amended Credit Agreement was 98.01% and 32.05%, respectively. As of December 31, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 1.76 years. As of December 31, 2020, the fair value of the shares underlying the convertible advances under the Amended Credit agreement was $201,450. As of December 31, 2020, the if-converted value did not exceed the principal balance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>PPP Loan</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing on the date the amount of forgiveness determined under section 1106 of the CARES Act is remitted to the Company, but in no event ten months after the last day of the covered period if the Company fails to apply for loan forgiveness. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before October 9, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 40% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Interest Expense</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s interest expense consists of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Related party interest expense &#8211; stated rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161,546</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,420</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">PPP loan interest expense &#8211; stated rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">806</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Non-cash interest expense:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Amortization of debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">542,523</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">616,383</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Amortization of transaction costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,510</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,910</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>706,385</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,000,713</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. Stockholders&#8217; Equity and Capitalization</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Common Stock</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>August 2020 Financing</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 31, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the issuance and sale of securities, with H.C. Wainwright &amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and 60,333,334 pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, in a registered public offering which closed on August 4, 2020 (the &#8220;August 2020 Financing&#8221;). The common units and pre-funded units were sold at a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The common stock warrants have a term of five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full (Note 3). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the August 2020 Financing, the Company incurred issuance costs of $854,078, for net proceeds of $6,085,589. Additionally, the Company issued warrants to purchase 8,166,667 shares of common stock to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>November 2019 Common Stock Offering</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In November 2019, the Company sold in a registered direct offering an aggregate of 8,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 8,000,000 shares of common stock (Note 3). The aggregate net proceeds of the transaction were $1,919,372.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Warrant Exercises</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, the Pre-Funded Warrant holders exercised 48,533,334 warrants with an intrinsic value of $2,104,667, which resulted in the issuance of 48,533,334 shares of common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, the Series B Warrant holders exercised 312,500 warrants with an intrinsic value of $26,563, which resulted in the issuance of 312,500 shares of common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, Emerald Health Sciences exercised 40,800,000 2018 Emerald Financing Warrants with an intrinsic value of $4,284,000, which resulted in the issuance of 40,800,000 shares of common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Series B Common Stock Warrant holders exercised 187,500 warrants with an intrinsic value of $144,375, which resulted in the issuance of 187,500 shares of common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. Stock-Based Compensation </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock Incentive Plan</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 31, 2014, after the closing of the Merger, the Board approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. In August 2020, the Company approved Amendment No. 2 to the 2014 Plan, which increased the share reserve by an additional 7,876,835 shares over the 10% of the number of issued and outstanding shares of common stock and removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of December 31, 2020, the shares available for future grant under the 2014 Plan are as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares Available for Grant</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Available as of December 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>13,128,381</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Share pool increase </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,394,752</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Forfeited</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,837,407</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cancelled</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,830,235</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,400,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Available as of December 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>12,790,775</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock Options </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Options granted under the 2014 Plan expire no later than ten years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&#8217;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to five years from the date of grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is a summary of option activities under the Company&#8217;s 2014 Plan for the year ended December 31, 2020: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average Remaining</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value*</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Outstanding, December 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>3,317,642</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.33</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>8.34</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,400,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cancelled</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,830,235</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Forfeited</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,837,407</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.26</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Outstanding, December 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>22,050,000</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.06</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>9.52</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Exercisable, December 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,465,000</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.15</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>8.88</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Vested and expected to vest, December 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>22,050,000</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.06</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>9.52</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#8217;s stock exceeded the exercise price of the stock options at December 31, 2020 for those stock options for which the quoted market price was in excess of the exercise price (&#8220;in-the-money options&#8221;). </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2020 and 2019 was $0.04 and $0.22, respectively. The total fair value of the stock options that vested during the years ended December 31, 2020 and 2019 was $168,168 and $473,030, respectively.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31,</strong> </p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">0.28-0.46</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> <p style="margin:0px">%</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.49</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">5.65-6.13</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">92.51-107.87</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> <p style="margin:0px">%</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.72</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 30, 2020, 643,501 restricted stock awards (&#8220;RSAs&#8221;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. As of December 31, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There was no restricted stock award (&#8220;RSA&#8221;) activity under the Company&#8217;s 2014 Plan during the year ended December 31, 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Awards Granted Outside the 2014 Plan</strong></em> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Options</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&#8217;s former CFO. As of December 31, 2020, an additional 869,144 options vested and outstanding with a weighted average exercise price of $0.25 were cancelled unexercised. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There was no option activity outside of the 2014 Plan during the year ended December 31, 2019. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The total fair value of stock options that vested during the years ended December 31, 2020 and 2019 were $18,252 and $54,756, respectively.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is a summary of RSA activity outside of the Company&#8217;s 2014 Plan during the year ended December 31, 2020: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Grant </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Date Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, December 31, 2019</strong></p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;"><strong>450,000</strong></p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="margin:0px"><strong>$</strong></p></td> <td style="width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;"><strong>0.19</strong></p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">-</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">-</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Released</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">(450,000</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="margin:0px">)</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;">0.19</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, December 31, 2020</strong></p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;"><strong>-</strong></p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="margin:0px"><strong>$</strong></p></td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:right;"><strong>-</strong></p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock-Based Compensation Expense</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. The Company recognized stock-based compensation expense, including compensation expense for RSAs discussed above, in its Consolidated Statements of Comprehensive (Loss) Income as follows: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Research and development </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,545</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">General and administrative</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">209,197</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">680,455</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>302,742</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>680,455</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The total amount of unrecognized compensation cost was $688,410 as of December 31, 2020. This amount will be recognized over a weighted-average period of 3.79 years.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7. Net (Loss) Income Per Share of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net (loss) income per share computations:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Year Ended</strong> <strong>December 31, 2020</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Loss</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Numerator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Denominator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Per-Share</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,560,699</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Basic EPS</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Loss available to common stockholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6,560,699</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">230,746,878</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.03</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Effect of Dilutive Securities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants &#8211; liability classified</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(345,473</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">674,095</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Diluted EPS</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Loss available to common stockholders + assumed conversions</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6,906,172</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">231,420,973</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.03</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Year Ended</strong> <strong>December 31, 2019</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Income</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Numerator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Denominator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Per-Share</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net income</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Basic EPS</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Income available to common stockholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">135,154,931</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.01</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Effect of Dilutive Securities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unvested restricted stock</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">858,856</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Options</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">392,784</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">447,431</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants &#8211; liability classified</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,250,612</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,706,263</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Diluted EPS</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Loss available to common stockholders + assumed conversions</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(8,198,787</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">169,560,265</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.05</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock options </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,050,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,119,931</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unvested restricted stock</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234,645</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Common shares underlying convertible debt</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,126,343</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,036,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">145,039,240</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,712,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. Income Taxes </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The components of (loss) income before the income tax provision consist of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">United States</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,556,280</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,120,521</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Foreign</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,819</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(67,096</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Pre-tax (loss) income from operations </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(6,559,099</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,053,425</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is subject to taxation in the United States, California and Australia. The Company&#8217;s tax years for 2017 (federal), 2016 (California) and 2019 (Australia) and forward are subject to examination by the United States, California and Australia tax authorities. However, to the extent allowed by law, the taxing authorities may have the right to examine periods where NOLs and credits were generated and carried forward and make adjustments up to the amount of the NOL and credit carryforwards.&nbsp; The Company is not currently under examination by any jurisdiction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At December 31, 2020, the Company had federal and California NOLs aggregating $30,475,657 and $30,310,672, respectively. If not used, $13,213,037 of Federal NOLs and $30,310,672 of state NOLs will begin to expire in 2033. $17,262,620 of federal NOLs will carry forward indefinitely subject to an 80% limitation against taxable income. At December 31, 2020, the Company had Australia NOLs aggregating $43,349 which do not expire.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">At December 31, 2020, the Company had federal and California research credit carryforwards of approximately $76,632 and $40,528, respectively. The federal research credit carry forwards will begin to expire in 2040, unless previously utilized and the California research credits will carry forward indefinitely. The Company&#8217;s NOLs and research credit carryforwards are subject to a reserve.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Utilization of the domestic NOL will be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. While the Company has not performed a Section 382 study, multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company&#8217;s effective tax rate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current deferred tax assets/(liabilities): </strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">State taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Amortization</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Research and development credits</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,324</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Other</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,056</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112,222</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Net operating loss</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,679,216</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,434,544</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Gross deferred tax assets</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>7,817,112</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>6,547,102</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Valuation allowance</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,590,215</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,206,450</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net deferred tax assets </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>226,897</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>340,652</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Deferred tax liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Note discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(226,897</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(340,652</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total deferred tax liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(226,897</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(340,652</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net deferred tax assets</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2020 and 2019, due to the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected income tax benefit at federal statutory tax rate </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,377,411</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">221,219</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">State income taxes, net of federal benefit</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(415,249</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(434,881</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Change in fair value of warrants </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(72,549</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,874,873</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Change in valuation allowance</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="margin:0px">1,383,765</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,469,187</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Uncertain tax positions</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">470,838</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">436,145</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Change in compound derivative</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(101,671</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Loss on extinguishment of debt</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,925</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,198</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock compensation</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,273</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,289</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Rate adjustment</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(108,649</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,338</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Other permanent difference</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"> <p style="margin:0px">22,657</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,351</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Provision for income taxes</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,600</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,600</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company&#8217;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses. During the year ended December 31, 2020, the valuation allowance increased by $1,383,765.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 22, 2020, when the Company entered into the PPP Loan with the PPP Loan Lender (Note 4). In accordance with the Consolidated Appropriations Act, 2021 enacted on December 27, 2020, certain qualified expenses used with the funds of the PPP Loan are fully deductible for Federal income tax purposes. Additionally, should the Company receive forgiveness of the PPP loan in the future, the amount will not be considered taxable for Federal income tax purposes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the FASB&#8217;s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unrecognized tax positions, beginning of the year </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">552,082</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Gross increase - current period tax positions</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">585,812</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">552,082</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Gross decrease &#8211; prior period tax positions</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,721</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unrecognized tax positions, end of year</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,134,173</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>552,082</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If recognized, none of the unrecognized tax positions would impact the Company&#8217;s income tax benefit or effective tax rate as long as the Company&#8217;s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company&#8217;s unrecognized tax positions within the next twelve months.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had no accrual for interest or penalties on the Company&#8217;s Balance Sheets at December 31, 2020 and 2019 and has not recognized interest and/or penalties in the Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. Other Current Liabilities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other current liabilities consist of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of </strong><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Accrued payroll liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,547</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,830</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Accrued research and development costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,888</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,006</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Accrued legal expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,596</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,237</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Accrued board fees</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,625</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,395</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total other accrued liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,455</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">77,938</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>259,111</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>420,406</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10. Significant Contracts - University of Mississippi</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>UM 5050 Prodrug and UM 8930 Analog Agreements</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">In July 2018, the Company renewed its ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, related to an analog formulation of cannabidiol (&#8220;CBD&#8221;). On May 24, 2019, the ocular delivery licenses were replaced by &#8220;all fields of use&#8221; licenses for both UM 5050 and UM 8930 (collectively, the &#8220;License Agreements&#8221;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, the intellectual property related to UM 5050 and UM 8930 for all fields of use.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The Company made upfront payments for UM 5050 and UM 8930 of $100,000 and $200,000, respectively. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">i)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application (&#8220;NDA&#8221;) to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product; </p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">ii)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">iii)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#8217;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#8217;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#8217;s dissolution or cessation of operations, the Company&#8217;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#8217;s control, or the Company&#8217;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#8217; written notice to UM.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>UM 5070 License Agreement</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#8220;UM 5070&#8221;), to research, develop and commercialize products for the treatment of infectious diseases. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company paid UM an upfront license fee of $65,000 under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees of $25,000 that will be credited against any royalties incurred, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#8217;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#8217;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#8217;s control. The Company may terminate the license agreement upon 60 days&#8217; written notice to UM.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2020, none of the milestones under this license agreement have been met.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>11. Related Party Matters</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Emerald Health Sciences</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of ten years and specified compensation to be agreed upon between the Company&#8217;s Chief Executive Officer and Emerald Health Sciences&#8217; CEO on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of December 31, 2020, and 2019, the Company has accrued $7,032 reimbursable expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the year ended December 31, 2020. Under this agreement, for the year ended December 31, 2019, the Company incurred expenses of $542,000.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon initially received a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#8217;s completion of a material financing. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to defer payment of 100% of Dr. Dhillon&#8217;s consulting fees until the Board of Directors determined that the Company had been sufficiently financed to make such payments at which point the Company agreed to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. Subsequent to the August 2020 Financing Dr. Dhillon continues to receive a monthly fee of $10,000 per month for his services. The Board reviews the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and automatically renews thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party. Under this agreement, for the years ended December 31, 2020 and 2019, the Company incurred fees of $127,387 and $3,871, respectively. As of December 31, 2020, the Company has accrued $10,000 in expense related to the Independent Contractor Services Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, on August 10, 2020, Emerald Health Sciences, Inc. transferred to Dr. Avtar Dhillon 500,000 shares of the Company&#8217;s common stock at a deemed price of $0.10 in exchange for the cancellation of $50,000 of debt.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2020, Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. As of December 31, 2020, Jim Heppell is also a board member of Emerald Health Sciences, Inc. The Company&#8217;s CEO, Punit Dhillon also served as a board member of Emerald Health Sciences, Inc. until he tendered his resignation from such board on August 10, 2020. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company shares the same office location as Emerald Health Pharmaceuticals. However, the Company&#8217;s workforce is remote, there is no written rental agreement with Emerald Health Pharmaceuticals, and no rent is being charged. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 10, 2020, Emerald Health Sciences, Inc. extinguished debt of $186,667 by transferring 1,566,666 shares of the Company&#8217;s common stock at a deemed price of $0.10 per share to certain officers, employees and directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>2. <strong>Contingencies</strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><font style="font-style:italic">General Litigation and Disputes</font></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">From time to time, in the normal course of operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Company&#8217;s operations or financial position, liquidity or results of operations. As of December 31, 2020, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&#8217;s financial position or results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>13. Subsequent Events</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Emerald Health Biotechnology Espa&#241;a, S.L.U</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2021, the Company entered into a Collaborative Research Agreement with Emerald Health Biotechnology Espa&#241;a, S.L.U, a subsidiary of Emerald Health Research, Inc. which is 100% owned by Emerald Health Sciences. Under the agreement, Emerald Health Biotechnology Espa&#241;a, S.L. will provide research and development services pursuant to an agreed upon project plan for the research and development of CBDVHS. The term of the agreement is initially for a one-year period. The agreement will terminate upon delivery and acceptance of the final deliverable under the project plan or if either party is in breach of the terms of the contract and such breach remains uncured for 45 days. Payment for services rendered will be based on time and materials billable at reasonable market rates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Warrant Exercises</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From January 1, 2021 through February 23, 2021 11,800,000 pre-funded warrants were exercised in exchange for 11,800,000 shares of common stock for gross proceeds of $11,800.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From January 1, 2021 through February 23, 2021 50,133,334 common stock warrants were exercised in exchange for 50,133,334 shares of common stock for gross proceeds of $3,008,000.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Increase to Authorized Shares of Capital Stock </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 5, 2021, the Company increased its authorized shares of common and preferred stock to 5,000,000,000 and 50,000,000, respectively. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-30</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The following exhibits are filed with this Annual Report on Form 10-K.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:10%;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Exhibit </strong><strong>Number </strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Description of Exhibit</strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex31.htm">3.1 *</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex31.htm">Articles of Incorporation of Registrant, as amended </a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex32.htm">3.2*</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex32.htm">Amended and Restated Bylaws of Registrant </a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-3_1.htm">3.3 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-3_1.htm">Certificate of Designation of the Relative Rights and Preferences of the Series B Preferred Stock filed with the Secretary of State of Nevada on August 19, 2015 <sup>(4)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-1.htm">4.1</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-1.htm">Form of Warrants issued by Nemus to certain security holders to purchase an aggregate of 3,000,000 shares of commons stock <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-2.htm">4.2</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-2.htm">Form of Warrants issued by Nemus to certain security holders to purchase an aggregate of 1,000,000 shares of commons stock <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000237/ex_4-1.htm">4.3</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000237/ex_4-1.htm">Form of Common Stock Purchase Warrant to certain security holders to purchase shares of common stock <sup>(3)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-3.htm">4.4</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-3.htm">Form of Warrant dated April 25, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 100,000 shares of common stock <sup>(4)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-4.htm">4.5</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-4.htm">Form of Warrant dated April 29, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 90,000 shares of common stock <sup>(5)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-5.htm">4.6</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-5.htm">Form of Warrant dated April 26, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 6,000 shares of common stock <sup>(5)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000037/ex4-6.htm">4.7</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000037/ex4-6.htm">Form of Warrant dated June 8, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 10,000 shares of common stock <sup>(6)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-4_1.htm">4.8</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-4_1.htm">Form of Warrant to certain security holders to purchase shares of common stock <sup>(4)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-2.htm">4.9</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-2.htm">Registration Rights Agreement, dated January 7, 2015, by and between Nemus Bioscience, Inc. and certain investors <sup>(7)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000379/nemus_ex410.htm">4.10</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000379/nemus_ex410.htm">Form of Warrant<sup>(30)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">4.11</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">Form of Warrant <sup>(34)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex41.htm">4.12</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex41.htm">Form of Common Warrant<sup>(38)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex42.htm">4.13</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex42.htm">Form of Pre-Funded Warrant<sup>(38)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-1.htm">10.1&#8224; </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-1.htm">Nemus Bioscience, Inc. 2014 Omnibus Incentive Plan <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-2.htm">10.2&#8224;</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-2.htm">Form of Stock Option Agreement under 2014 Omnibus Incentive Plan <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-3.htm">10.3</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-3.htm">Memorandum of Understanding, dated July 31, 2013, between Nemus and University of Mississippi, National Center for Natural Products Research <sup>(2)</sup></a></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:10%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-9.htm">10.9 **</a></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-9.htm">License Agreement, dated September 29, 2014, between Nemus and the University of Mississippi, School of Pharmacy <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-10.htm">10.10 **</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-10.htm">License Agreement, dated September 29, 2014, between Nemus and the University of Mississippi, School of Pharmacy <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-11.htm">10.11 **</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-11.htm">License Agreement, dated September 29, 2014, between Nemus and the University of Mississippi, School of Pharmacy <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-12.htm">10.12</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-12.htm">Lease Agreement dated September 1, 2014 between University of Mississippi Research Foundation, Inc. and Nemus <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-13.htm">10.13 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-13.htm">Center Tower Lease dated October 13, 2014, by and between Nemus and Center Tower Associates LLC. <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-1.htm">10.17</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-1.htm">Common Stock Purchase Agreement, dated January 7, 2015, by and between Nemus Bioscience, Inc. and certain investors <sup>(7)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000010/ex_10-1.htm">10.19 &#8224;</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000010/ex_10-1.htm">Form of Indemnification Agreement <sup>(8)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000113/ex10_1.htm">10.20 &#8224;</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000113/ex10_1.htm">Nemus Bioscience, Inc. Officer Change in Control Severance Plan <sup>(9)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-10_2.htm">10.21</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-10_2.htm">Form of Registration Rights Agreement between Nemus Bioscience, Inc. and certain investors (4) 10.22&#8224; Form of Restricted Stock Award Agreement under 2014 Omnibus Incentive Plan <sup>(10)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_1.htm">10.23 **</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_1.htm">License Agreement, dated December 14, 2015, between Nemus and the University of Mississippi, School of Pharmacy <sup>(11)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_2.htm">10.24 **</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_2.htm">License Agreement, dated December 14, 2015, between Nemus and the University of Mississippi, School of Pharmacy <sup>(11)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416000847/ex-10_25.htm">10.25 ** </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416000847/ex-10_25.htm">Letter Agreement with Albany Molecular Research Inc. dated February 5, 2016 <sup>(12)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex101.htm">10.26</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex101.htm">Form of Securities Purchase Agreement between Nemus Bioscience, Inc. and certain investors <sup>(13)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex102.htm">10.27 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex102.htm">Form of Registration Rights Agreement between Nemus Bioscience, Inc. and certain investors <sup>(13)</sup></a></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">61</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:10%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001861/nmus_ex101.htm">10.28 </a></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001861/nmus_ex101.htm">Form of Lock-up Agreement between Nemus Bioscience, Inc. and certain shareholders <sup>(14)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex101.htm">10.29</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex101.htm">Form of Securities Purchase Agreement between Nemus Bioscience, Inc. and certain investors <sup>(15)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex102.htm">10.30 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex102.htm">Form of Registration Rights Agreement between Nemus Bioscience, Inc. and certain investors <sup>(15)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000043/nmus_ex101.htm">10.31</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000043/nmus_ex101.htm">Form of Lock-up Agreement between Nemus Bioscience, Inc. and certain shareholders <sup>(16)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000139/nmus_ex101.htm">10.32 **</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000139/nmus_ex101.htm">License Agreement, dated January 10, 2017, between Nemus and the University of Mississippi, School of Pharmacy <sup>(17)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000851/nemus_ex101.htm">10.33</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000851/nemus_ex101.htm">Securities Purchase Agreement, dated May 3, 2017, between Nemus Bioscience, Inc. and Schneider Finance LLC <sup>(18)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417001379/nemus_ex991.htm">10.34</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417001379/nemus_ex991.htm">Financial Guarantee dated May 3, 2017 <sup>(19)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex101.htm">10.35</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex101.htm">Form of Securities Purchase Agreement <sup>(20)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex102.htm">10.36</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex102.htm">Form of Registration Rights Agreement (20) 10.37&#8224; Form of Restricted Stock Agreement <sup>(21)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000161/nemus_ex101.htm">10.38</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000161/nemus_ex101.htm">Securities Purchase Agreement <sup>(21)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000036/nemus_ex101.htm">10.39</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000036/nemus_ex101.htm">Convertible Bridge Promissory Note <sup>(22)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000482/nmus_ex1040.htm">10.40</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000482/nmus_ex1040.htm">Independent Contractor Termination Agreement and Release (23) 10.41* Independent Contractor Agreement <sup>(23)</sup></a></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:10%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001127/nmus_ex101.htm">10.42&#8224;</a></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001127/nmus_ex101.htm">Employment Agreement, dated May 25, 2018, between Nemus Bioscience, Inc. and Douglas Cesario (24) 10.43&#8224; Stock Option Agreement, dated May 25, 2018, between Nemus Bioscience, Inc. and Douglas Cesario <sup>(24)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001486/nemus_101.htm">10.44 ** </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001486/nemus_101.htm">Letter Agreement, dated July 31, 2018, by and between Nemus Bioscience, Inc. and Albany Molecular Research Inc. <sup>(25)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex101.htm">10.45</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex101.htm">Multi-Draw Credit Agreement, dated October 5, 2018, by and between Nemus Bioscience, Inc. and Emerald Health Sciences, Inc. <sup>(26)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex102.htm">10.46</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex102.htm">Registration Rights Agreement, dated October 5, 2018, by and between Nemus Bioscience, Inc. and Emerald Health Sciences, Inc. <sup>(26)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex103.htm">10.47 &#8224;</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex103.htm">Amendment No. 1 to 2014 Omnibus Incentive Plan <sup>(26)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000347/nemus_ex101.htm">10.48 **</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000347/nemus_ex101.htm">Master Development and Clinical Supply Agreement, dated February 26, 2019, by and between Nemus Bioscience, Inc. and Noramco, Inc. <sup>(29)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex101.htm">10.49</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex101.htm">Restated and Amended License Agreement, dated as of May 24, 2019, by and between the Company and University of Mississippi, School of Pharmacy <sup>(31)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex102.htm">10.50</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex102.htm">Restated and Amended License Agreement, dated as of May 24, 2019, by and between the Company and University of Mississippi, School of Pharmacy <sup>(31)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001557/embi_ex101.htm">10.51</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001557/embi_ex101.htm">First Amendment to Master Development and Clinical Supply Agreement, dated as of August 7, 2019, by and between the Company and Noramco, Inc. <sup>(32)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">10.52</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">Start-Up Agreement, dated as of August 23, 2019, by and between the Company and Novotech <sup>(33)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">10.53</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">Master Services Agreement, dated as of September 20, 2019, by and between EMBI Australia and Novotech (Australia) Pty Limited <sup>(34)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">10.54 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">Form of Securities Purchase Agreement, dated as of November 20, 2019, between the Company and certain purchasers set forth in the signature page thereto <sup>(35)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">10.55 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">Warrant Exercise Agreement, dated as of December 20, 2019, between the Company and Emerald Health Sciences <sup>(36)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">10.56 </a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">Independent Contractor Services Agreement, dated as of December 19, 2019, between the Company and Dr. Avtar Dhillon. <sup>(36)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex101.htm">10.57</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex101.htm">Amended and Restated Multi-Draw Credit Agreement, dated April 29, 2020, by and between Emerald Bioscience, Inc. and Emerald Health Sciences, Inc. Sciences, Inc.<sup>(37)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex102.htm">10.58</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex102.htm">Separation and Release Agreement, dated April 29, 2020, between Emerald Bioscience, Inc. and Douglas Cesario<sup>(37)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex101.htm">10.59</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex101.htm">Form of Securities Purchase Agreement, dated as of July 31, 2020, between the Company and certain purchasers set forth in the signature page thereto<sup>(38)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex101.htm">10.60</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex101.htm">Separation and Release Agreement, dated August 7, 2020, by and between Emerald Bioscience, Inc. and Brian Murphy<sup>(39)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex102.htm">10.61</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex102.htm">Employment Agreement, dated August 10, 2020, by and between Emerald Bioscience, Inc. and Punit Dhillon<sup>(39)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex103.htm">10.62</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex103.htm">Amendment No. 2 to 2014 Omnibus Incentive Plan<sup>(39)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex1063.htm">10.63*</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><a href="skye_ex1063.htm">Collaborative Research Agreement, dated January 2021, by and between Skye Bioscience, Inc. &nbsp;and Emerald Health Biotechnology Espa&#241;a, S.L.,</a></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">62</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#ffffff"> <td style="width:10%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_21-1.htm">21.1 </a></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_21-1.htm">Subsidiaries of the Registrant <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex231.htm">23.1*</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex231.htm">Consent of Independent Registered Public Accounting Firm</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex311.htm">31.1*</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex312.htm">31.2*</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex312.htm">Certification of Principal Financial and Accounting Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 </a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex321.htm">32.1***</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex321.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex322.htm">32.2***</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="skye_ex322.htm">Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">101.ins&#8224;&#8224;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Instance Document</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">101.sch&#8224;&#8224; </p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">XBRL Taxonomy Schema Document</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">101.cal&#8224;&#8224;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">XBRL Taxonomy Calculation Linkbase Document 101.def&#8224;&#8224; XBRL Taxonomy Definition Linkbase Document 101.lab&#8224;&#8224; XBRL Taxonomy Label Linkbase Document</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">101.pre&#8224;&#8224;</p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">XBRL Taxonomy Presentation Linkbase Document</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">____________ </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on November 3, 2014.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(3)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed April 7, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(4)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed August 20, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(5)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Quarterly Report on Form 10-Q filed May 13, 2015</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(6)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Quarterly Report on Form 10-Q filed August 14, 2015</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(7)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on January 9, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(8)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on January 12, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(9)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on February 27, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(10)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on October 22, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(11)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on December 18, 2015.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(12)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Annual Report on Form 10-K filed on March 21, 2016.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(13)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on October 26, 2016</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(14)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on October 27, 2016.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(15)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on December 29, 2016.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(16)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on January 10, 2017.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(17)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K/A filed on January 20, 2017.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(18)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on May 4, 2017.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(19)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on July 11, 2017.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(20)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on November 2, 2017.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(21)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on January 22, 2018.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(22)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on January 3, 2018.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(23)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Annual Report on Form 10-K filed on March 19, 2018.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(24)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on June 1, 2018.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(25)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on August 1, 2018.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(26)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on October 12, 2018.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(29)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on March 4, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(30)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Annual Report on Form 10-K filed on March 14, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(31)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on May 29, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(32)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on August 8, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(33)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on August 27, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(34)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Quarterly Report on Form 10-Q filed on September 30, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(35)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on November 21, 2019.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(36)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on December 20, 2019.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">(37)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on April 29, 2020.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">(38)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on August 5, 2020</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">(39)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Included as exhibit to our Current Report on Form 8-K filed on August 12, 2020</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">_________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Filed Herewith</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">** Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">*** Furnished Herewith</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#8224; Management contract or compensatory plan or arrangement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#8224;&#8224; In accordance with Regulation S-T, XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, and is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not otherwise subject to liability under these sections.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="i16"><strong><u>Item</u></strong><strong><u> 16. Form 10-K Summary</u></strong><strong>.</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">63</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;"><strong>Skye</strong> <strong>Bioscience, Inc. </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>a Nevada corporation</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:35%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:10%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 1, 2021</p></td> <td style="vertical-align:top;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon </em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Chief Executive Officer, Chairman</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(Principal Executive Officer)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 1, 2021</p></td> <td style="vertical-align:top;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Richard Janney</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="margin:0px">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Richard Janney</p> <p style="MARGIN: 0px; text-align:justify;">Interim Principal Accounting Officer</p> <p style="MARGIN: 0px; text-align:justify;">(Principal Financial and Accounting Officer)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:justify;">By: </p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon </em></p></td> <td style="width:10%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">March 1, 2021</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Chief Executive Officer, Chairman</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(Principal Executive Officer)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Richard Janney</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 1, 2021</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Richard Janney</p> <p style="MARGIN: 0px; text-align:justify;">Interim Principal Accounting Officer</p> <p style="MARGIN: 0px; text-align:justify;">(Principal Financial and Accounting Officer)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Margaret Dalesandro</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 1, 2021</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Margaret Dalesandro</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Director</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Jim Heppell</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">March 1, 2021</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Jim Heppell </p> <p style="MARGIN: 0px; text-align:justify;">Director</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">64</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>skye_ex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head><title>skye_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 3.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img14.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img15.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img16.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img17.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img18.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img19.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img20.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img21.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img22.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img23.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img24.jpg">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="skye_ex31img25.jpg"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;">&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>skye_ex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<html><head><title>skye_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: justify; FONT: 10pt Times New Roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 3.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">AMENDED AND RESTATED BYLAWS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">of</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">SKYE BIOSCIENCE, INC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(a Nevada corporation)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE I<br>OFFICES</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 1.1 <u>Principal Office</u>. The principal office and place of business of Skye Bioscience, Inc., a Nevada corporation (the &#8220;<u>Corporation</u>&#8221;), shall be established from time to time by resolution of the board of directors of the Corporation (the &#8220;<u>Board</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 1.2 <u>Other Offices</u>. Other offices and places of business either within or without the State of Nevada may be established from time to time by resolution of the Board or as the business of the Corporation may require. The street address of the Corporation&#8217;s registered agent is the registered office of the Corporation in Nevada.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE II<br>STOCKHOLDERS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.1 <u>Annual Meeting</u>. The annual meeting of the stockholders of the Corporation shall be held on such date and at such time as may be designated from time to time by the Board. At the annual meeting, directors shall be elected, and any other business may be transacted as may be properly brought before the meeting pursuant to these Amended and Restated Bylaws (as further amended from time to time, these &#8220;<u>Bylaws</u>&#8221;). Except as otherwise restricted by the Amended and Restated Articles of Incorporation of the Corporation (as further amended from time to time, the &#8220;<u>Articles of Incorporation</u>&#8221;) or applicable law, the Board may postpone, reschedule or cancel any annual meeting of stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.2 <u>Special Meetings</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) Special meetings of the stockholders may only be called in the manner provided in the Articles of Incorporation. Stockholders shall have no right to request or call a special meeting except as otherwise provided in the Articles of Incorporation. Except as otherwise restricted by the Articles of Incorporation or applicable law, the Board may postpone, reschedule or cancel any special meeting of stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) No business shall be acted upon at a special meeting of stockholders except as set forth in the notice of the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.3 <u>Place of Meetings</u>. Any meeting of the stockholders of the Corporation may be held at the Corporation&#8217;s registered office in the State of Nevada or at such other place in or out of the State of Nevada and the United States as may be designated in the notice of meeting. A waiver of notice signed by all stockholders entitled to vote thereat may designate any place for the holding of such meeting. The Board may, in its sole discretion, determine that any meeting of the stockholders shall be held using, or shall be held solely by means of, electronic communications or other available technology in accordance with <u>Section 2.14</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.4 <u>Notice of Meetings; Waiver of Notice</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) The chief executive officer, the president, any vice president, the secretary, any assistant secretary, or any other individual designated by the Board shall sign and deliver or cause to be delivered written notice of any stockholders&#8217; meeting to the stockholders entitled to vote at such meeting (unless applicable law requires notice be given to all stockholders of record, in which case such notice shall be given in accordance with such law) not less than ten days, but not more than sixty days, before the date of such meeting. The notice shall state the place, date and time of the meeting, the means of electronic communication, if any, by which the stockholders entitled to vote or the proxies thereof shall be deemed to be present and vote and, in the case of a special meeting, the purpose or purposes for which the meeting is called. The notice shall be delivered in accordance with and shall contain or be accompanied by such additional information as may be required by the Nevada Revised Statutes (as amended from time to time, the &#8220;<u>NRS</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) In the case of an annual meeting, subject to <u>Section 2.13</u>, any proper business may be presented for action, except that (i) if a proposed plan of merger, conversion or exchange is submitted to a vote, the notice of the meeting must state that the purpose, or one of the purposes, of the meeting is to consider the plan of merger, conversion or exchange and must contain or be accompanied by a copy or summary of the plan; and (ii) if a proposed action creating dissenter&#8217;s rights is to be submitted to a vote, the notice of the meeting must state that the stockholders are or may be entitled to assert dissenter&#8217;s rights under NRS 92A.300 to 92A.500, inclusive, and be accompanied by a copy of those sections.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) A copy of the notice of any meeting of stockholders shall be personally delivered, mailed postage prepaid to each stockholder of record entitled to vote at such meeting (unless applicable law requires notice be given to all stockholders of record, in which case such notice shall be given in accordance with such law), at the address appearing on the records of the Corporation or as otherwise allowed under the NRS. Upon mailing, service of the notice is complete, and the time of the notice begins to run from the date upon which the notice is deposited in the mail or otherwise delivered. If the address of any stockholder does not appear upon the records of the Corporation or is incomplete, it will be sufficient to address any notice to such stockholder at the registered office of the Corporation. Notwithstanding the foregoing and in addition thereto, any notice to stockholders given by the Corporation pursuant to Chapters 78 or 92A of the NRS, the Articles of Incorporation or these Bylaws may be given pursuant to the forms of electronic transmission listed herein, if such forms of transmission are consented to in writing by the stockholder receiving such electronically transmitted notice and such consent is filed by the secretary in the corporate records. Notice shall be deemed given (i) by facsimile when directed to a number consented to by the stockholder to receive notice, (ii) by e-mail when directed to an e-mail address consented to by the stockholder to receive notice, (iii) by posting on an electronic network together with a separate notice to the stockholder of the specific posting on the later of the specific posting or the giving of the separate notice or (iv) by any other electronic transmission as consented to by and when directed to the stockholder. The stockholder consent necessary to permit electronic transmission to such stockholder shall be deemed revoked and of no force and effect if (A) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with the stockholder&#8217;s consent and (B) the inability to deliver by electronic transmission becomes known to the secretary, any assistant secretary, transfer agent or other agent of the Corporation responsible for the giving of notice.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(d) The written certificate of an individual signing a notice of meeting, setting forth the substance of the notice or having a copy thereof attached thereto, the date the notice was mailed or personally delivered to the requisite stockholders and the addresses to which the notice was mailed, shall be prima facie evidence of the manner and fact of giving such notice and, in the absence of fraud, an affidavit of the individual signing a notice of a meeting on behalf of the Corporation that the notice thereof has been given by a form of electronic transmission shall be prima facie evidence of the facts stated in the affidavit.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(e) Any stockholder may waive notice of any meeting by a signed writing or by transmission of an electronic record, either before or after the meeting. Such waiver of notice shall be deemed the equivalent of the giving of such notice.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.5 <u>Determination of Stockholders of Record</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) For the purpose of determining the stockholders entitled to (i) notice of and to vote at any meeting of stockholders or any adjournment thereof, (ii) receive payment of any distribution or the allotment of any rights, or (iii) exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than sixty days nor less than ten days before the date of such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) If stockholder action by written consent is permitted under the Articles of Incorporation and these Bylaws, the Board may adopt a resolution prescribing a date upon which the stockholders of record entitled to give written consent must be determined. The date set by the Board must not precede or be more than ten days after the date the resolution setting such date is adopted by the Board. If the Board does not adopt a resolution setting a date upon which the stockholders of record entitled to give written consent must be determined, and (i) no prior action by the Board is required by the NRS, then the date shall be the first date on which a valid written consent is delivered to the Corporation in accordance with the NRS, the Articles of Incorporation and these Bylaws; or (ii) prior action by the Board is required by the NRS, then the date shall be the close of business on the date that the Board adopts the resolution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) If no record date is fixed, the record date for determining stockholders: (i) entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; and (ii) for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at any meeting of stockholders shall apply to any postponement of any meeting of stockholders to a date not more than sixty days after the record date or to any adjournment of the meeting; <u>provided</u> that the Board may fix a new record date for the adjourned meeting and must fix a new record date if the meeting is adjourned to a date more than sixty days later than the meeting date set for the original meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.6 <u>Quorum; Adjourned Meetings</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) At any meeting of the stockholders, and unless the Articles of Incorporation require a different proportion, stockholders holding at least a majority of the voting power of the Corporation&#8217;s capital stock entitled to vote at such meeting, represented in person or by proxy (regardless of whether the proxy has authority to vote on all matters), are necessary to constitute a quorum for the transaction of business at such meeting. If, on any issue, voting by classes or series is required by the laws of the State of Nevada, the Articles of Incorporation or these Bylaws, at least a majority of the voting power, represented in person or by proxy (regardless of whether the proxy has authority to vote on all matters), within each such class or series is necessary to constitute a quorum of each such class or series.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) If a quorum is not represented, a majority of the voting power represented or the person presiding at the meeting may adjourn the meeting from time to time until a quorum shall be represented. At any such adjourned meeting at which a quorum shall be represented, any business may be transacted which might otherwise have been transacted at the adjourned meeting as originally called. When a stockholders&#8217; meeting is adjourned to another time or place hereunder, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. However, if a new record date is fixed for the adjourned meeting, notice of the adjourned meeting must be given to each stockholder of record as of the new record date. The stockholders present at a duly convened meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the departure of enough stockholders to leave less than a quorum of the voting power.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.7 <u>Voting</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) Unless otherwise provided in the Articles of Incorporation, or in the resolution providing for the issuance of preferred stock (or any series of preferred stock) adopted by the Board pursuant to authority expressly vested in it by the provisions of the Articles of Incorporation (including any certificate of designation relating to any series of preferred stock) if such authority is so vested, each stockholder of record, or such stockholder&#8217;s duly authorized proxy, shall be entitled to one (1) vote for each share of voting stock standing registered in such stockholder&#8217;s name at the close of business on the record date or the date established by the Board in connection with stockholder action by written consent, as applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) Except as otherwise provided in these Bylaws, all votes with respect to shares (including pledged shares, unless in the pledge the pledgor has expressly empowered the pledgee to vote the stock) standing in the name of an individual at the close of business on the record date (or the date established by the Board in connection with stockholder action by written consent) shall be cast only by that individual or such individual&#8217;s duly authorized proxy. With respect to shares held by a representative of the estate of a deceased stockholder, or a guardian, conservator, custodian or trustee, even though the shares do not stand in the name of such holder, votes may be cast by such holder upon proof of such representative capacity. In the case of shares under the control of a receiver, the receiver may vote such shares even though the shares do not stand of record in the name of the receiver but only if and to the extent that the order of a court of competent jurisdiction which appoints the receiver contains the authority to vote such shares. If shares stand of record in the name of a minor, votes may be cast by the duly appointed guardian of the estate of such minor only if such guardian has provided the Corporation with written proof of such appointment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) With respect to shares standing of record in the name of another corporation, partnership, limited liability company or other legal entity on the record date, votes may be cast: (i) in the case of a corporation, by such individual as the bylaws of such other corporation prescribe, by such individual as may be appointed by resolution of the Board of such other corporation or by such individual (including, without limitation, the officer making the authorization) authorized in writing to do so by the chairman of the Board, the chief executive officer, the president or any vice president of such corporation; and (ii) in the case of a partnership, limited liability company or other legal entity, by an individual representing such stockholder upon presentation to the Corporation of satisfactory evidence of her or his authority to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(d) Notwithstanding anything to the contrary contained in these Bylaws and except for the Corporation&#8217;s shares held in a fiduciary capacity, the Corporation shall not vote, directly or indirectly, shares of its own stock owned or held by it, and such shares shall not be counted in determining the total number of outstanding shares entitled to vote.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(e) Any holder of shares entitled to vote on any matter may cast a portion of the votes in favor of such matter and refrain from casting the remaining votes or cast the same against the proposal. If such holder entitled to vote does vote any of such stockholder&#8217;s shares affirmatively and fails to specify the number of affirmative votes, it will be conclusively presumed that the holder is casting affirmative votes with respect to all shares held.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(f) With respect to shares standing of record in the name of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, spouses as community property, tenants by the entirety, voting trustees or otherwise and shares held by two or more persons (including proxy holders) having the same fiduciary relationship in respect to the same shares, votes may be cast in the following manner:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(i) If only one person votes, the vote of such person binds all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(ii) If more than one person casts votes, the act of the majority so voting binds all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(iii) If more than one person casts votes, but the vote is evenly split on a particular matter, the votes shall be deemed cast proportionately, as split.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(g) If a quorum is present, unless the Articles of Incorporation, these Bylaws, the NRS or other applicable law provide for a different proportion, action by the stockholders entitled to vote on a matter, other than the election of directors, is approved by and is the act of the stockholders if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, unless voting by classes or series is required for any action of the stockholders by the laws of the State of Nevada, the Articles of Incorporation or these Bylaws, in which case the number of votes cast in favor of the action by the voting power of each such class or series must exceed the number of votes cast in opposition to the action by the voting power of each such class or series.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(h) If a quorum is present, directors shall be elected by a plurality of the votes cast.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.8 <u>Proxies</u>. At any meeting of stockholders, any holder of shares entitled to vote may designate, in a manner permitted by the laws of the State of Nevada, another person or persons to act as a proxy or proxies. If a stockholder designates two or more persons to act as proxies, then a majority of those persons present at a meeting has and may exercise all of the powers conferred by the stockholder or, if only one is present, then that one has and may exercise all of the powers conferred by the stockholder, unless the stockholder&#8217;s designation of proxy provides otherwise. Every proxy shall continue in full force and effect until its expiration or revocation in a manner permitted by the laws of the State of Nevada.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.75pt; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.9 <u>Stockholder Action Without A Meeting</u>. Any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation may be taken without a meeting if, before or after the action, a written consent thereto is (a) signed by stockholders holding at least a majority of the voting power of the outstanding capital stock of the Corporation entitled to vote on such action (except that if a greater proportion of the voting power would be required for such an action at a meeting, then that proportion of written consents is required), and (b) delivered to the Corporation by delivery to its registered office in the State of Nevada, its principal place of business, or an officer or agent of the Corporation having custody of the books in which proceedings of meetings of stockholders are recorded. Any such delivery made to the Corporation&#8217;s registered office shall be made by hand, overnight courier or by certified or registered mail, return receipt requested. In no instance where action is duly and properly authorized by written consent need a meeting of stockholders be called or, unless otherwise required by applicable law or any certificate of designation relating to any series of Preferred Stock, notice given.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.10 <u>Organization</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) Meetings of stockholders shall be presided over by the chairman of the Board, or, in the absence of the chairman of the Board, by the vice chairman of the Board, if any, or if there be no vice chairman or in the absence of the vice chairman, by the chief executive officer, if any, or if there be no chief executive officer or in the absence of the chief executive officer, by the president, or, in the absence of the president, or, in the absence of any of the foregoing persons, by a chairman designated by the Board, or by a chairman chosen at the meeting by the stockholders entitled to cast a majority of the votes which all stockholders present in person or by proxy are entitled to cast. The person acting as chairman of the meeting may delegate any or all of her or his authority and responsibilities as such to any director or officer of the Corporation present in person at the meeting. The secretary, or in the absence of the secretary, an assistant secretary, shall act as secretary of the meeting, but in the absence of the secretary and any assistant secretary, the chairman of the meeting may appoint any person to act as secretary of the meeting. The order of business at each such meeting shall be as determined by the chairman of the meeting. The chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts and things as are necessary or desirable for the proper conduct of the meeting, including, without limitation, (i) the establishment of procedures for the maintenance of order and safety, (ii) limitation on the time allotted for consideration of each agenda item and for questions or comments by meeting participants, (iii) restrictions on entry to such meeting and (iv) the opening and closing of the voting polls. The Board, in its discretion, or the chairman of the meeting, in her or his discretion, may require that any votes cast at such meeting shall be cast by written ballot.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) The chairman of the meeting may appoint one or more inspectors of elections. The inspector or inspectors may (i) ascertain the number of shares outstanding and the voting power of each; (ii) determine the number of shares represented at a meeting and the validity of proxies or ballots; (iii) count all votes and ballots; (iv) determine any challenges made to any determination made by the inspector(s); and (v) certify the determination of the number of shares represented at the meeting and the count of all votes and ballots.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) Only such persons who are nominated in accordance with the procedures set forth in <u>Section 2.12</u> shall be eligible to be elected at any meeting of stockholders of the Corporation to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in <u>Section 2.12</u>. If any proposed nomination or business was not made or proposed in compliance with <u>Section 2.12</u> (including proper notice under <u>Section 2.13</u> and including whether the stockholder or beneficial owner, if any, on whose behalf the nomination or proposal is made solicited (or is part of a group which solicited) or did not so solicit, as the case may be, proxies in compliance with such stockholder&#8217;s representation pursuant to <u>clause (a)(iv)(D)</u> of <u>Section 2.13</u>), then, unless otherwise provided in the Articles of Incorporation, the chairman of the meeting shall have the power to declare that such nomination shall be disregarded or that such proposed business shall not be transacted. If the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this <u>Section 2.10</u>, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or authorized by a writing executed by such stockholder (or a reliable reproduction or electronic transmission of the writing) delivered to the Corporation prior to the making of such nomination or proposal at such meeting by such stockholder stating that such person is authorized to act for such stockholder as proxy at the meeting of stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.11 <u>Consent to Meetings</u>. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person objects at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called, noticed or convened and except that attendance at a meeting is not a waiver of any right to object to the consideration of matters not included in the notice, to the extent such notice is required, if such objection is expressly made at the time any such matters are presented at the meeting. Neither the business to be transacted at nor the purpose of any regular or special meeting of stockholders need be specified in any written waiver of notice or consent, except as otherwise provided in these Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.12 <u>Director Nominations and Business Conducted at Meetings of Stockholders</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) Except as otherwise provided in the Articles of Incorporation, nominations of persons for election to the Board and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders only (i) by or at the direction of the Board or the chairman of the Board, or (ii) by any stockholder of the Corporation who is entitled to vote on such matter at the meeting and who (A) has complied with the notice procedures set forth in <u>Section 2.13</u> and (B) was a stockholder of record at the time such notice is delivered to the secretary of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) Except as otherwise provided in the Articles of Incorporation, nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation&#8217;s notice of meeting (i) by or at the direction of the Board or the chairman of the Board, or (ii) by any stockholder of the Corporation who is entitled to vote on such matter at the meeting and who (A) has complied with the notice procedures set forth in <u>Section 2.13</u> and (B) was a stockholder of record at the time such notice is delivered to the secretary of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.13 <u>Advance Notice of Director Nominations and Stockholder Proposals by Stockholders</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) For nominations or other business to be properly brought before an annual meeting by a stockholder and for nominations to be properly brought before a special meeting by a stockholder in each case pursuant to <u>Section 2.12</u>, the stockholder of record must have given timely notice thereof in writing to the secretary of the Corporation, and, in the case of business other than nominations, such other business must be a proper matter for stockholder action. To be timely, a stockholder&#8217;s notice shall be delivered to the secretary of the Corporation at the principal executive offices of the Corporation not later than the close of business on the 90<sup>th</sup> day nor earlier than the close of business on the 120<sup>th</sup> day prior to the first anniversary of the preceding year&#8217;s annual meeting; <u>provided</u> that in the event that the date of the annual meeting is more than 30 days before or more than 70 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120<sup>th</sup> day prior to such annual meeting and not later than the close of business on the later of the 90<sup>th</sup> day prior to such annual meeting or the 10<sup>th</sup> day following the day on which public announcement (as defined below) of the date of such meeting is first made by the Corporation. In no event shall the public announcement of an adjournment or postponement of an annual meeting commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above. The notice must be provided by a stockholder of record and must set forth:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(i) as to each person whom the stockholder proposes to nominate for election or re-election as a director all information relating to such person that is (i) required by paragraphs (a), (e) and (f) of Item 401 of Regulation S-K adopted by the Securities and Exchange Commission, and (ii) required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), including such person&#8217;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(ii) as to any other business that the stockholder proposes to bring before an annual meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the Bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting and any substantial interest (within the meaning of Item 5 of Schedule 14A under the Exchange Act) in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(iii) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made or the business is proposed: (A) the name and address of such stockholder, as they appear on the Corporation&#8217;s books, and the name and address of such beneficial owner, (B) the class and number of shares of stock of the Corporation which are owned of record by such stockholder and such beneficial owner as of the date of the notice, and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such meeting of the class and number of shares of stock of the Corporation owned of record by the stockholder and such beneficial owner as of the record date for the meeting, and (C) a representation that the stockholder intends to appear in person or by proxy at the meeting to propose such nomination or business;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(iv) as to the stockholder giving the notice or, if the notice is given on behalf of a beneficial owner on whose behalf the nomination is made or the business is proposed, as to such beneficial owner, and if such stockholder or beneficial owner is an entity, as to each director, executive, managing member or control person of such entity (any such person, a &#8220;<u>control person</u>&#8221;): (A) the class and number of shares of stock of the Corporation which are beneficially owned (as defined below) by such stockholder or beneficial owner and by any control person as of the date of the notice, and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such meeting of the class and number of shares of stock of the Corporation beneficially owned by such stockholder or beneficial owner and by any control person as of the record date for the meeting, (B) a description of any agreement, arrangement or understanding with respect to the nomination or other business between or among such stockholder or beneficial owner or control person and any other person, including without limitation any agreements that would be required to be disclosed pursuant to Item 5 or Item 6 of Exchange Act Schedule 13D (regardless of whether the requirement to file a Schedule 13D is applicable to the stockholder, beneficial owner or control person) and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting, (C) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder&#8217;s notice by, or on behalf of, such stockholder or beneficial owner and by any control person or any other person acting in concert with any of the foregoing, the effect or intent of which is to mitigate loss, manage risk or benefit from changes in the share price of any class of the Corporation&#8217;s stock, or maintain, increase or decrease the voting power of the stockholder or beneficial owner with respect to shares of stock of the Corporation, and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting, (D) a representation whether the stockholder or the beneficial owner, if any, and any control person will engage in a solicitation with respect to the nomination or business and, if so, the name of each participant (as defined in Item 4 of Schedule 14A under the Exchange Act) in such solicitation and whether such person intends or is part of a group which intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding stock required to approve or adopt the business to be proposed (in person or by proxy) by the stockholder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(v) a certification that the stockholder giving the notice and the beneficial owner(s), if any, on whose behalf the nomination is made or the business is proposed, has or have complied with all applicable federal, state and other legal requirements in connection with such stockholder&#8217;s and/or each such beneficial owner&#8217;s acquisition of shares of capital stock or other securities of the Corporation and/or such stockholder&#8217;s and/or each such beneficial owner&#8217;s acts or omissions as a stockholder of the Corporation, including, without limitation, in connection with such nomination or proposal.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) The Corporation may require any proposed nominee to furnish such other information as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as a director of the Corporation, including information relevant to a determination whether such proposed nominee can be considered an independent director.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) For purposes of <u>Section 2.13(a)</u>, a &#8220;<u>public announcement</u>&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act. For purposes of <u>clause (a)(iv)(A)</u> of this <u>Section 2.13</u>, shares shall be treated as &#8220;beneficially owned&#8221; by a person if the person beneficially owns such shares, directly or indirectly, for purposes of Section 13(d) of the Exchange Act and Regulations 13D and 13G thereunder or has or shares pursuant to any agreement, arrangement or understanding (whether or not in writing): (i) the right to acquire such shares (whether such right is exercisable immediately or only after the passage of time or the fulfillment of a condition or both), (ii) the right to vote such shares, alone or in concert with others and/or (iii) investment power with respect to such shares, including the power to dispose of, or to direct the disposition of, such shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(d) This <u>Section 2.13</u> shall not apply to notice of a proposal to be made by a stockholder if the stockholder has notified the Corporation of her or his intention to present the proposal at an annual or special meeting only pursuant to and in compliance with Rule 14a-8 under the Exchange Act and such proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(e) If the stockholder does not provide the information required under <u>clause (a)(iii)(B)</u> and <u>clauses (a)(iv)(A)-(C)</u> of this <u>Section 2.13</u> to the Corporation within the time frames specified, or if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. The chairman of the meeting shall have the power to determine whether notice of a nomination or of any business proposed to be brought before the meeting was properly made in accordance with the procedures set forth in this <u>Section 2.13</u>. Notwithstanding the foregoing provisions hereof, a stockholder shall also comply with all applicable requirements of the Exchange Act, and the rules and regulations thereunder with respect to the matters set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 2.14 <u>Meetings Through Electronic Communications</u>. Stockholders may participate in a meeting of the stockholders by any means of electronic communications, videoconferencing, teleconferencing or other available technology permitted under the NRS (including, without limitation, a telephone conference or similar method of communication by which all individuals participating in the meeting may hear each other). If any such means are utilized, the Corporation shall, to the extent required under the NRS, implement reasonable measures to (a) verify the identity of each person participating through such means as a stockholder and (b) provide the stockholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to communicate, and to read or hear the proceedings of the meeting in a substantially concurrent manner with such proceedings. Participation in a meeting pursuant to this <u>Section 2.14</u> constitutes presence in person at the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE III<br><u>DIRECTORS</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.1 <u>General Powers; Performance of Duties</u>. The business and affairs of the Corporation shall be managed by or under the direction of the Board, except as otherwise provided in the NRS or the Articles of Incorporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.2 <u>Number, Tenure, and Qualifications</u>. The Board shall consist of at least two individuals and not more than nine individuals, with the number of directors within the foregoing fixed minimum and maximum established and changed from time to time as provided by resolutions adopted by the Board. Each director shall hold office until her or his successor shall be elected or appointed and qualified or until her or his earlier death, retirement, disqualification, resignation or removal. No reduction of the number of directors shall have the effect of removing any director prior to the expiration of her or his term of office. No provision of this <u>Section 3.2</u> shall restrict the right of the Board (or, to the extent permitted under the Articles of Incorporation, the stockholders) to fill vacancies or the right of the stockholders entitled to vote thereon to remove directors, each as provided in the Articles of Incorporation or these Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.3 <u>Chairman of the Board</u>. The Board shall elect a chairman of the Board from the members of the Board, who shall preside at all meetings of the Board and stockholders at which she or he shall be present and shall have and may exercise such powers as may, from time to time, be assigned to her or him by the Board, these Bylaws or as provided by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.4 <u>Vice Chairman of the Board</u>. The Board may elect a vice chairman of the Board from the members of the Board who shall preside at all meetings of the Board and stockholders at which she or he shall be present, and the chairman is not present and shall have and may exercise such powers as may, from time to time, be assigned to her or him by the Board, these Bylaws or as provided by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.5 <u>Elections</u>. The directors shall be elected in accordance with the Articles of Incorporation and the NRS.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.6 <u>Removal and Resignation of Directors</u>. Any director may be removed from such position as provided in, and in accordance with, the Articles of Incorporation and the NRS. Any director may resign effective upon giving written notice, unless the notice specifies a later time for effectiveness of such resignation, to the chairman of the Board, the president or the secretary, or in the absence of all of them, any other officer of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.7 <u>Vacancies; Newly Created Directorships</u>. Vacancies on the Board, including vacancies resulting from newly created directorships, shall be filled as provided in, and in accordance with, the Articles of Incorporation and the NRS.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.8 <u>Annual and Regular Meetings</u>. Within five business days after the conclusion of the annual meeting of the stockholders or any special meeting of the stockholders at which directors are elected, the Board, including directors newly elected, shall hold its annual meeting without call or notice, other than this provision, to transact such business as may be necessary or appropriate. The Board may provide by resolution the place, date, and hour for holding regular meetings between annual meetings, and if the Board so provides with respect to a regular meeting, notice of such regular meeting shall not be required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.9 <u>Special Meetings</u>. Subject to any rights of the holders of preferred stock, if any, and except as otherwise required by law or the Articles of Incorporation, special meetings of the Board may be called only by the chairman of the Board, or if there be no chairman of the Board, by the chief executive officer, or by the president or the secretary, and shall be called by the chairman of the Board, the chief executive officer, the president, or the secretary upon the request of a majority of the Board. If the chairman of the Board, or if there be no chairman of the Board, each of the chief executive officer, the president, and the secretary, fails for any reason to call such special meeting, a special meeting may be called by a notice signed by a majority of the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.10 <u>Place of Meetings</u>. Any regular or special meeting of the Board may be held at such place as the Board, or in the absence of such designation, as the notice calling such meeting, may designate. A waiver of notice signed by the directors may designate any place for the holding of such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.11 <u>Notice of Meetings</u>. Except as otherwise provided in <u>Section 3.8</u>, there shall be delivered to each director at the address appearing for her or him on the records of the Corporation, at least twenty-four hours before the time of such meeting, a copy of a written notice of any meeting (i) by delivery of such notice personally, (ii) by mailing such notice postage prepaid, (iii) by overnight courier or (v) by electronic transmission or electronic writing, including, without limitation, e-mail. If mailed to an address inside the United States, the notice shall be deemed delivered five business days following the date the same is deposited in the United States mail, postage prepaid. If mailed to an address outside the United States, the notice shall be deemed delivered seven business days following the date the same is deposited in the United States mail, postage prepaid. If sent via overnight courier, the notice shall be deemed delivered the business day following the delivery of such notice to the courier. If sent by electronic transmission (including, without limitation, e-mail), the notice shall be deemed delivered when directed to the e-mail address of the director appearing on the records of the Corporation, and otherwise pursuant to the applicable provisions of the NRS. If the address of any director is incomplete or does not appear upon the records of the Corporation, it will be sufficient to address any notice to such director at the registered office of the Corporation. Any director may waive notice of any meeting, and the attendance of a director at a meeting shall constitute waiver of notice of the meeting unless such director objects, prior to the transaction of any business, that the meeting was not lawfully called, noticed or convened. Attendance for the express purpose of objecting to the transaction of business thereat because the meeting was not properly called or convened shall not constitute presence or a waiver of notice for purposes hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.12 <u>Quorum; Adjourned Meetings</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) A majority of the directors is necessary to constitute a quorum for the transaction of business at any meeting of the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) At any meeting of the Board where a quorum is not present, a majority of those present may adjourn, from time to time, until a quorum is present, and no notice of such adjournment shall be required. At any adjourned meeting where a quorum is present, any business may be transacted which could have been transacted at the meeting originally called.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.13 <u>Manner of Acting</u>. The affirmative vote of a majority of the directors present at a meeting at which a quorum is present is an act of the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.14 <u>Meetings Through Electronic Communications</u>. Members of the Board or of any committee designated by the Board may participate in a meeting of the Board or such committee by any means of electronic communications, videoconferencing, teleconferencing or other available technology permitted under the NRS (including, without limitation, a telephone conference or similar method of communication by which all individuals participating in the meeting can hear each other). If any such means are utilized, the Corporation shall, to the extent required under the NRS, implement reasonable measures to (a) verify the identity of each person participating through such means as a director or member of the committee, as the case may be, and (b) provide the directors or members of the committee a reasonable opportunity to participate in the meeting and to vote on matters submitted to the directors or members of the committee, including an opportunity to communicate, and to read or hear the proceedings of the meeting in a substantially concurrent manner with such proceedings. Participation in a meeting pursuant to this <u>Section 3.14</u> constitutes presence in person at the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.15 <u>Action Without Meeting</u>. Any action required or permitted to be taken at a meeting of the Board or of a committee thereof may be taken without a meeting if, before or after the action, a written consent thereto is signed by all of the members of the Board or the committee, except that such consent need not be signed by any director who is not required to sign pursuant to the NRS. The written consent may be signed manually or electronically (or by any other means then permitted under the NRS), and may be so signed in counterparts, including, without limitation, email counterparts, and shall be filed with the minutes of the proceedings of the Board or committee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.16 <u>Powers and Duties</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) Except as otherwise restricted by the NRS or the Articles of Incorporation, the Board has full control over the business and affairs of the Corporation. The Board may delegate any of its authority to manage, control or conduct the business of the Corporation to any standing or special committee, or to any officer or agent, and to appoint any persons to be agents of the Corporation with such powers, including the power to subdelegate, and upon such terms as it deems fit.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) The Board, in its discretion, or the chairman presiding at a meeting of stockholders, in her or his discretion, may submit any contract or act for approval or ratification at any annual meeting of the stockholders or any special meeting properly called and noticed for the purpose of considering any such contract or act, provided a quorum is present.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) The Board may, by resolution passed by a majority of the Board, designate one or more committees, each committee to consist of one or more of the directors of the Corporation, provided that the Board may also appoint additional natural persons who are not directors to serve on any committee. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Subject to applicable law and to the extent provided in the resolution of the Board, any such committee shall have and may exercise all the powers of the Board in the management of the business and affairs of the Corporation as the Board delegates. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board. The committees shall keep regular minutes of their proceedings and report the same to the Board when requested.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.17 <u>Compensation</u>. The Board, without regard to personal interest, may establish the compensation of directors for services in any capacity. If the Board establishes the compensation of directors pursuant to this <u>Section 3.17</u>, such compensation is presumed to be fair to the Corporation unless proven unfair by a preponderance of the evidence.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 3.18 <u>Organization</u>. Meetings of the Board shall be presided over by the chairman of the Board, or in the absence of the chairman of the Board by the vice chairman, or in her or his absence by a chairman chosen at the meeting. The secretary, or in the absence of the secretary, an assistant secretary, shall act as secretary of the meeting, but in the absence of the secretary and any assistant secretary, the chairman of the meeting may appoint any person to act as secretary of the meeting. The order of business at each such meeting shall be as determined by the chairman of the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE IV<br><u>OFFICERS</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.1 <u>Election</u>. The Board shall elect or appoint a president, a secretary, a treasurer or the equivalents of such officers. Such officers shall serve until their respective successors are elected and appointed and shall qualify or until their earlier resignation or removal. The Board may from time to time, by resolution, elect or appoint such other officers and agents as it may deem advisable, who shall hold office at the pleasure of the Board, and shall have such powers and duties and be paid such compensation as may be directed by the Board. Any individual may hold two or more offices.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.2 <u>Removal; Resignation</u>. Any officer or agent elected or appointed by the Board may be removed by the Board with or without cause. Any officer may resign at any time upon written notice to the Corporation. Any such removal or resignation shall be subject to the rights, if any, of the respective parties under any contract between the Corporation and such officer or agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.3 <u>Vacancies</u>. Any vacancy in any office because of death, resignation, removal or otherwise may be filled by the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.4 <u>Chief Executive Officer</u>. The Board may elect a chief executive officer who, subject to the supervision and control of the Board, shall have the ultimate responsibility for the management and control of the business and affairs of the Corporation and perform such other duties and have such other powers which are delegated to her or him by the Board, these Bylaws or as provided by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.5 <u>President</u>. The president, subject to the supervision and control of the Board, shall in general actively supervise and control the business and affairs of the Corporation. The president shall keep the Board fully informed as the Board may request and shall consult the Board concerning the business of the Corporation. The president shall perform such other duties and have such other powers which are delegated and assigned to her or him by the Board, the chief executive officer, these Bylaws or as provided by law. The president shall be the chief executive officer of the Corporation unless the Board shall elect or appoint different individuals to hold such positions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.6 <u>Vice Presidents</u>. The Board may elect one or more vice presidents. In the absence or disability of the president, or at the president&#8217;s request, the vice president or vice presidents, in order of their rank as fixed by the Board, and if not ranked, the vice presidents in the order designated by the Board, or in the absence of such designation, in the order designated by the president, shall perform all of the duties of the president, and when so acting, shall have all the powers of, and be subject to all the restrictions on the president. Each vice president shall perform such other duties and have such other powers which are delegated and assigned to her or him by the Board, the chief executive officer, the president, these Bylaws or as provided by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.7 <u>Secretary</u>. The secretary shall attend all meetings of the stockholders, the Board and any committees thereof, and shall keep, or cause to be kept, the minutes of proceedings thereof in books provided for that purpose. She or he shall keep, or cause to be kept, a register of the stockholders of the Corporation and shall be responsible for the giving of notice of meetings of the stockholders, the Board and any committees, and shall see that all notices are duly given in accordance with the provisions of these Bylaws or as required by law. The secretary shall be custodian of the corporate seal, if any, the records of the Corporation, the stock certificate books, transfer books and stock ledgers, and such other books and papers as the Board or any appropriate committee may direct. The secretary shall perform all other duties commonly incident to her or his office and shall perform such other duties which are assigned to her or him by the Board, the chief executive officer, the president, these Bylaws or as provided by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.8 <u>Assistant Secretaries</u>. The Corporation may have one or more assistant secretaries. An assistant secretary shall, at the request of the secretary, or in the absence or disability of the secretary, perform all the duties of the secretary. He or she shall perform such other duties as are assigned to him or her by the Board, the chief executive officer, if any, the president, these Bylaws or as provided by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.9 <u>Treasurer</u>. The treasurer, subject to the order of the Board, shall have the care and custody of, and be responsible for, all of the money, funds, securities, receipts and valuable papers, documents and instruments of the Corporation, and all books and records relating thereto. The treasurer shall keep, or cause to be kept, full and accurate books of accounts of the Corporation&#8217;s transactions, which shall be the property of the Corporation, and shall render financial reports and statements of condition of the Corporation when so requested by the Board, the chairman of the Board, the chief executive officer, or the president. The treasurer shall perform all other duties commonly incident to her or his office and such other duties as may, from time to time, be assigned to her or him by the Board, the chief executive officer, the president, these Bylaws or as provided by law. If a chief financial officer of the Corporation has not been appointed, the treasurer may be deemed the chief financial officer of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 4.11 <u>Execution of Negotiable Instruments, Deeds and Contracts</u>. All (i) checks, drafts, notes, bonds, bills of exchange, and orders for the payment of money of the Corporation, (ii) deeds, mortgages, proxies, powers of attorney and other written contracts, documents, instruments and agreements to which the Corporation shall be a party and (iii) assignments or endorsements of stock certificates, registered bonds or other securities owned by the Corporation shall be signed in the name of the Corporation by such officers or other persons as the Board may from time to time designate. The Board may authorize the use of the electronic signatures of any such persons. Any officer of the Corporation shall be authorized to attend, act and vote, or designate another officer or an agent of the Corporation to attend, act and vote, at any meeting of the owners of any entity in which the Corporation may own an interest or to take action by written consent in lieu thereof. Such officer or agent, at any such meeting or by such written action, shall possess and may exercise on behalf of the Corporation any and all rights and powers incident to the ownership of such interest.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE V<br><u>CAPITAL STOCK</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.1 <u>Issuance</u>. Shares of the Corporation&#8217;s authorized capital stock shall, subject to any provisions or limitations of the laws of the State of Nevada, the Articles of Incorporation or any contracts or agreements to which the Corporation may be a party, be issued in such manner, at such times, upon such conditions and for such consideration as shall be prescribed by the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.2 <u>Stock Certificates and Uncertificated Shares</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) Every holder of stock in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by (i) the chief executive officer, the president, or a vice president, and (ii) the secretary, an assistant secretary, the treasurer or the chief financial officer of the Corporation (or any other two officers or agents so authorized by the Board), certifying the number of shares of stock owned by him, her or it in the Corporation; <u>provided</u> that the Board may authorize the issuance of uncertificated shares of some or all of any or all classes or series of the Corporation&#8217;s stock. Any such issuance of uncertificated shares shall have no effect on existing certificates for shares until such certificates are surrendered to the Corporation, or on the respective rights and obligations of the stockholders. Whenever any such certificate is countersigned or otherwise authenticated by a transfer agent or a transfer clerk and by a registrar (other than the Corporation), then a facsimile of the signatures of any corporate officers or agents, the transfer agent, transfer clerk or the registrar of the Corporation may be printed or lithographed upon the certificate in lieu of the actual signatures. In the event that any officer or officers who have signed, or whose facsimile signatures have been used on any certificate or certificates for stock cease to be an officer or officers because of death, resignation or other reason, before the certificate or certificates for stock have been delivered by the Corporation, the certificate or certificates may nevertheless be adopted by the Corporation and be issued and delivered as though the person or persons who signed the certificate or certificates, or whose facsimile signature or signatures have been used thereon, had not ceased to be an officer or officers of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner thereof a written statement certifying the number and class (and the designation of the series, if any) of the shares owned by such stockholder in the Corporation and any restrictions on the transfer or registration of such shares imposed by the Articles of Incorporation, these Bylaws, any agreement among stockholders or any agreement between the stockholders and the Corporation, and, at least annually thereafter, the Corporation shall provide to such stockholders of record holding uncertificated shares, a written statement confirming the information contained in such written statement previously sent. Except as otherwise expressly provided by the NRS, the rights and obligations of the stockholders of the Corporation shall be identical whether or not their shares of stock are represented by certificates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) Each certificate representing shares shall state the following upon the face thereof: the name of the state of the Corporation&#8217;s organization; the name of the person to whom issued; the number and class of shares and the designation of the series, if any, which such certificate represents; the par value of each share, if any, represented by such certificate or a statement that the shares are without par value. Certificates of stock shall be in such form consistent with law as shall be prescribed by the Board. No certificate shall be issued until the shares represented thereby are fully paid. In addition to the foregoing, all certificates evidencing shares of the Corporation&#8217;s stock or other securities issued by the Corporation shall contain such legend or legends as may from time to time be required by the NRS, the Exchange Act or such other federal, state or local laws or regulations then in effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.3 <u>Surrendered; Lost or Destroyed Certificates</u>. All certificates surrendered to the Corporation, except those representing shares of treasury stock, shall be canceled and no new certificate shall be issued until the former certificate for a like number of shares shall have been canceled, except that in case of a lost, stolen, destroyed or mutilated certificate, a new one may be issued therefor. However, any stockholder applying for the issuance of a stock certificate in lieu of one alleged to have been lost, stolen, destroyed or mutilated shall, prior to the issuance of a replacement, provide the Corporation with his, her or its affidavit of the facts surrounding the loss, theft, destruction or mutilation and, if required by the Board, an indemnity bond in an amount not less than twice the current market value of the stock, and upon such terms as the treasurer or the Board shall require which shall indemnify the Corporation against any loss, damage, cost or inconvenience arising as a consequence of the issuance of a replacement certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.4 <u>Replacement Certificate</u>. When the Articles of Incorporation are amended in any way affecting the statements contained in the certificates for outstanding shares of capital stock of the Corporation or it becomes desirable for any reason, in the discretion of the Board, including, without limitation, the merger of the Corporation with another Corporation or the conversion or reorganization of the Corporation, to cancel any outstanding certificate for shares and issue a new certificate therefor conforming to the rights of the holder, the Board may order any holders of outstanding certificates for shares to surrender and exchange the same for new certificates within a reasonable time to be fixed by the Board. The order may provide that a holder of any certificate(s) ordered to be surrendered shall not be entitled to vote, receive distributions or exercise any other rights of stockholders of record until the holder has complied with the order, but the order operates to suspend such rights only after notice and until compliance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.5 <u>Transfer of Shares</u>. No transfer of stock shall be valid as against the Corporation except on surrender and cancellation of any certificate(s) therefor accompanied by an assignment or transfer by the registered owner made either in person or under assignment. Whenever any transfer shall be expressly made for collateral security and not absolutely, the collateral nature of the transfer shall be reflected in the entry of transfer in the records of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.6 <u>Transfer Agent; Registrars</u>. The Board may appoint one or more transfer agents, transfer clerks and registrars of transfer and may require all certificates for shares of stock to bear the signature of such transfer agents, transfer clerks and/or registrars of transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.7 <u>Miscellaneous</u>. The Board shall have the power and authority to make such rules and regulations not inconsistent herewith as it may deem expedient concerning the issue, transfer, and registration of certificates for shares of the Corporation&#8217;s stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 5.8 <u>Inapplicability of Controlling Interest Statutes</u>. Notwithstanding any other provision in the Articles of Incorporation or these Bylaws to the contrary, and in accordance with the provisions of NRS 78.378, the provisions of NRS 78.378 to 78.3793, inclusive, or any successor statutes, relating to acquisitions of controlling interests in the Corporation, shall not apply to the Corporation or to any acquisition of any shares of the Corporation&#8217;s capital stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE VI<br><u>DISTRIBUTIONS</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Distributions may be declared, subject to the provisions of the laws of the State of Nevada and the Articles of Incorporation, by the Board and may be paid in money, shares of corporate stock, property or any other medium not prohibited under applicable law. The Board may fix in advance a record date, in accordance with and as provided in <u>Section 2.5</u>, prior to the distribution for the purpose of determining stockholders entitled to receive any distribution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE VII<br><u>RECORDS AND REPORTS; CORPORATE SEAL; fiscal year</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 7.1 <u>Records</u>. All original records of the Corporation shall be kept at the principal office of the Corporation by or under the direction of the secretary or at such other place or by such other person as may be prescribed by these Bylaws or the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 7.2 <u>Corporate Seal</u>. The Board may, by resolution, authorize a seal, and the seal may be used by causing it, or a facsimile, to be impressed or affixed or reproduced or otherwise. Except when otherwise specifically provided in these Bylaws, the Board may authorize any officer of the Corporation the authority to affix the seal to any document requiring it.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 7.3 <u>Fiscal Year-End</u>. The fiscal year-end of the Corporation shall be such date as may be fixed from time to time by resolution of the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE VIII<br><u>INDEMNIFICATION</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 8.1 <u>Indemnification and Insurance</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(a) <u>Indemnification of Directors and Officers</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(i) For purposes of this Article, (A) &#8220;<u>Indemnitee</u>&#8221; shall mean each director or officer who was or is a party to, or is threatened to be made a party to, or is otherwise involved in, any Proceeding (as hereinafter defined), by reason of the fact that she or he is or was a director, officer, employee, consultant or agent (including, without limitation, as a trustee, fiduciary, administrator or manager) of the Corporation or any predecessor entity thereof, or is or was serving in any capacity as a director, officer, employee, consultant or agent (including, without limitation, as a trustee, fiduciary, administrator, partner, member or manager) of, or in any other capacity for, another corporation or any partnership, joint venture, limited liability company, trust, or other enterprise; and (B) &#8220;<u>Proceeding</u>&#8221; shall mean any threatened, pending, or completed action, suit, petition or proceeding (including, without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative, or investigative.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(ii) Each Indemnitee shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the laws of the State of Nevada, against all expense, liability and loss (including, without limitation, attorneys&#8217; fees, judgments, fines, taxes, penalties, and amounts paid or to be paid in settlement) reasonably incurred or suffered by the Indemnitee in connection with any Proceeding; provided that such Indemnitee either is not liable pursuant to the NRS or acted in good faith and in a manner such Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any Proceeding that is criminal in nature, had no reasonable cause to believe that her or his conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of <em>nolo contendere</em> or its equivalent, does not, of itself, create a presumption that the Indemnitee is liable pursuant to the NRS or did not act in good faith and in a manner in which she or he reasonably believed to be in or not opposed to the best interests of the Corporation, or that, with respect to any criminal proceeding she or he had reasonable cause to believe that her or his conduct was unlawful. The Corporation shall not indemnify an Indemnitee for any claim, issue or matter as to which the Indemnitee has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the Corporation or for any amounts paid in settlement to the Corporation, unless and only to the extent that the court in which the Proceeding was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the Indemnitee is fairly and reasonably entitled to indemnity for such amounts as the court deems proper. Except as so ordered by a court and for advancement of expenses pursuant to this Section, indemnification may not be made to or on behalf of an Indemnitee if a final adjudication establishes that her or his acts or omissions involved intentional misconduct, fraud or a knowing violation of law and was material to the cause of action. Notwithstanding anything to the contrary contained in these Bylaws, no director or officer may be indemnified for expenses incurred in defending any threatened, pending, or completed action, suit, petition or proceeding (including without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative or investigative, that such director or officer incurred in her or his capacity as a stockholder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(iii) Indemnification pursuant to this Section shall continue as to an Indemnitee who has ceased to be a director or officer of the Corporation or who has ceased to serve as a director, officer, employee, agent, trustee, fiduciary, administrator, partner, member or manager of, or in any other capacity for, another corporation or any partnership, joint venture, limited liability company, trust, or other enterprise, and such indemnification shall inure to the benefit of such Indemnitee&#8217;s heirs, executors and administrators.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1.5in; text-align:justify;">(iv) The expenses of Indemnitees must be paid by the Corporation or through insurance purchased and maintained by the Corporation or through other financial arrangements made by the Corporation, as such expenses are incurred and in advance of the final disposition of the Proceeding, upon receipt of an undertaking by or on behalf of such Indemnitee to repay the amount if it is ultimately determined by a court of competent jurisdiction that she or he is not entitled to be indemnified by the Corporation. To the extent that an Indemnitee is successful on the merits or otherwise in defense of any Proceeding, or in the defense of any claim, issue or matter therein, the Corporation shall indemnify her or him against expenses, including attorneys&#8217; fees, actually and reasonably incurred in by her or him in connection with the defense.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(b) <u>Indemnification of Employees and Other Persons</u>. The Corporation may, by action of its Board and to the extent provided in such action, indemnify employees and other persons as though they were Indemnitees.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(c) <u>Non-Exclusivity of Rights</u>. The rights to indemnification provided in this <u>Article VIII</u> shall not be exclusive of any other rights that any person may have or hereafter acquire under any statute, provision of the Articles of Incorporation or these Bylaws, agreement, vote of stockholders or directors, or otherwise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(d) <u>Insurance</u>. The Corporation may purchase and maintain insurance or make other financial arrangements on behalf of any Indemnitee for any liability asserted against her or him and liability and expenses incurred by her or him in her or his capacity as a director, officer, employee, member, managing member or agent, or arising out of her or his status as such, whether or not the Corporation has the authority to indemnify her or him against such liability and expenses.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(e) <u>Other Financial Arrangements</u>. The other financial arrangements which may be made by the Corporation may include the following (i) the creation of a trust fund; (ii) the establishment of a program of self-insurance; (iii) the securing of its obligation of indemnification by granting a security interest or other lien on any assets of the Corporation; and (iv) the establishment of a letter of credit, guarantee or surety. No financial arrangement made pursuant to this subsection may provide protection for a person adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable for intentional misconduct, fraud, or a knowing violation of law, except with respect to advancement of expenses or indemnification ordered by a court.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 1in; text-align:justify;">(f) <u>Other Matters Relating to Insurance or Financial Arrangements</u>. Any insurance or other financial arrangement made on behalf of a person pursuant to this <u>Section 8.1</u> may be provided by the Corporation or any other person approved by the Board, even if all or part of the other person&#8217;s stock or other securities is owned by the Corporation. In the absence of fraud, (i) the decision of the Board as to the propriety of the terms and conditions of any insurance or other financial arrangement made pursuant to this <u>Section 8.1</u> and the choice of the person to provide the insurance or other financial arrangement is conclusive; and (ii) the insurance or other financial arrangement is not void or voidable and does not subject any director approving it to personal liability for his action; even if a director approving the insurance or other financial arrangement is a beneficiary of the insurance or other financial arrangement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Section 8.2 <u>Amendment</u>. The provisions of this <u>Article VIII</u> relating to indemnification shall constitute a contract between the Corporation and each of its directors and officers which may be modified as to any director or officer only with that person&#8217;s consent or as specifically provided in this <u>Section 8.2</u>. Notwithstanding any other provision of these Bylaws relating to their amendment generally, any repeal or amendment of this <u>Article VIII</u> which is adverse to any director or officer shall apply to such director or officer only on a prospective basis, and shall not limit the rights of an Indemnitee to indemnification with respect to any action or failure to act occurring prior to the time of such repeal or amendment. Notwithstanding any other provision of these Bylaws (including, without limitation, <u>Article X</u>), no repeal or amendment of these Bylaws shall affect any or all of this <u>Article VIII</u> so as to limit or reduce the indemnification in any manner unless adopted by (i) the unanimous vote of the directors of the Corporation then serving, or (ii) the stockholders as set forth in <u>Article X</u>; <u>provided</u> that no such amendment shall have a retroactive effect inconsistent with the preceding sentence.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE IX<br><u>CHANGES IN NEVADA LAW</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">References in these Bylaws to the laws of the State of Nevada or the NRS or to any provision thereof shall be to such law as it existed on the date these Bylaws were adopted or as such law thereafter may be changed; <u>provided</u> that (i) in the case of any change which expands the liability of directors or officers or limits the indemnification rights or the rights to advancement of expenses which the Corporation may provide in <u>Article VIII</u>, the rights to limited liability, to indemnification and to the advancement of expenses provided in the Articles of Incorporation and/or these Bylaws shall, to the extent permitted by law, continue as in effect prior to such change; and (ii) if such change permits the Corporation, without the requirement of any further action by stockholders or directors, to limit further the liability of directors or limit further the liability of officers or to provide broader indemnification rights or rights to the advancement of expenses than the Corporation was permitted to provide prior to such change, then liability thereupon shall be so limited and the rights to indemnification and the advancement of expenses shall be so broadened to the extent permitted by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ARTICLE X<br><u>AMENDMENT OR REPEAL</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Except as otherwise provided in the Articles of Incorporation: (a) the Board is expressly authorized (in furtherance and not in limitation of the powers conferred by statute) to amend, repeal or rescind any provision of these Bylaws or to adopt new bylaws; or (b) the affirmative vote of the holders of at least a majority of the outstanding voting power of the Common Stock (as defined in the Articles of Incorporation) shall be required in order for the stockholders of the Corporation to amend, repeal or rescind, in whole or in part, any provision of these Bylaws (including, without limitation, this <u>Article X</u>) or to adopt any new provision of these Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.63
<SEQUENCE>4
<FILENAME>skye_ex1063.htm
<DESCRIPTION>EX-10.63
<TEXT>
<html><head><title>skye_ex1063.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.63</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>&nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COLLABORATIVE RESEARCH AGREEMENT</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">THIS COLLABORATIVE RESEARCH AGREEMENT (this &#8220;<strong>Agreement</strong>&#8221;) effective as of January 2021 (the &#8220;<strong>Effective Date</strong>&#8221;), is entered into between EMERALD BIOSCIENCE INC. (&#8220;<strong>EMBI</strong>&#8221;), with a place of business at 5910 Pacific Center Blvd., #320 San Diego, CA, 92121, United States and EMERALD HEALTH BIOTECHNOLOGY ESPA&#209;A, S.L. a limited liability company incorporated under the laws of Spain(&#8220;<strong>EHBE</strong>&#8221;), having a place of business at Parque Cientifico Tecnologico de Cordoba, Rabanales 21, c/ Astronoma Cecilia Payne, Edifico Centauro, 14014, Cordoba, Spain.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>WHEREAS:</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">A. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">EMBI has discovered and developed a new chemical entity based on CBD (CBD-VAL- HS) that may be effective in the treatment of human diseases.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">B. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">EMBI desires to sponsor certain research by EHBE as further described in the Project Plan (as defined below) and EHBE desires to conduct such research in accordance with the terms and conditions of this Agreement (Exhibit A).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>NOW, THEREFORE, </strong>in consideration of the foregoing premises and he mutual covenants herein contained; the parties hereby agree as follows:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Definitions</u>. For the purposes of this Agreement, the following terms shall have the respective meanings set forth below:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.1 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Confidential Information</strong>&#8221; means, with respect to a party (the &#8220;<strong>Discloser or EMBI</strong>&#8221;), any and all proprietary or confidential data and information disclosed by EMBI to the other party (the &#8220;<strong>Recipient or EHBE</strong>&#8221;), whether in writing, or in oral, graphic, electronic or any other form, or obtained by or on behalf of the Recipient through inspection or observation of the foregoing. Confidential Information shall not include any information that</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">is or becomes publicly known through no act or omission of the Recipient.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">was rightfully known by Recipient before receipt from the Discloser.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">becomes known to Recipient by a third party without confidential or proprietary restriction from the Discloser; or</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">is independently developed by Recipient without the use of or reference to the Confidential Information of Discloser. The terms and conditions of this Agreement shall constitute Confidential Information of both parties.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 1 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.2 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Collaborator Materials</strong>&#8221; mean, collectively, all information and materials provided by or on behalf of EHBE to EMBI in connection with materials described in the Project Plan.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.3 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Collaborator Technology</strong>&#8221; means, collectively, the Collaborator Materials, together with (a) all parts, compositions, formulations, modifications, derivatives, improvements and enhancements thereof and thereto, (b) all methods specific to the manufacture thereof, and (c) all uses thereof.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.4 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Initial Project Plan</strong>&#8221; means the Project Plan set out in Exhibit A.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.5 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Initial Project Plan Budget</strong>&#8221; means the Budget set out in Exhibit A to the Initial Project Plan.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.6 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Intellectual Property Rights</strong>&#8221; mean:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">any and all proprietary rights, in any jurisdiction in the world, provided under (i) patent law, (ii) copyright law, (iii) trade-mark law, (iv) design patent or industrial design law, (v) plant breeders&#8217; rights or plant variety rights law; or (vi) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in ideas, formulae, algorithms, concepts, inventions, inventors&#8217; notes, research data, works or know-how, or the expression or use thereof, and including all past, present and future causes of action, rights of recovery, and claims for damage, accounting of profits, royalties, or other relief relating, referring or pertaining to any of the foregoing; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">any and all applications, registrations, licenses, sublicenses, collaboration agreements, technology transfer agreements, and other agreements or other evidence of a right in any of the foregoing.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.7 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Principal Investigator</strong>&#8221; shall mean, with respect to a Project, the principal investigator identified in the Project Plan for such Project.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.8 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Project</strong>&#8221; means the project described in a Project Plan.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.9 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Project Plan</strong>&#8221; means, a written project plan mutually agreed in writing by the parties and includes the Initial Project Plan.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.10 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#8220;<strong>Results</strong>&#8221; mean all data, information and other deliverables and results derived from a Project or use of the Collaborator Technology</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2. </p></td> <td style="vertical-align:top;"><u>Conduct of Projects</u>.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.1 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Projects</u>. EMBI engages EHBE to conduct each Project on the terms and conditions of this Agreement, including, without limitation, the applicable Project Plan. EHBE accepts such engagement and should conduct each Project and otherwise act in strict accordance with the terms and conditions of this Agreement, including, without limitation, the applicable Project Plan.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 2 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.2 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Initial Project Plan</u>. EMBI engages EHBE to conduct the activities contemplated under the Project Plan</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.3 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Project Plan</u>. It is contemplated that the parties shall from time to time enter into new Project Plans. Upon mutual agreement, due execution and delivery of a Project Plan for a Project, such Project Plan automatically shall be incorporated into this Agreement; provided, however, that to the extent any term or condition of such Project Plan conflicts with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall control unless otherwise expressly stated in the applicable Project Plan that such conflicting term or condition is specifically intended to supersede the terms and conditions of this Agreement, and expressly referencing the specific terms and conditions to be superseded.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.4 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Principal Investigator.</u> EHBE shall conduct each Project under the direction of the Principal Investigator identified in the applicable Project Plan. The Principal Investigator for a Project shall be responsible for the supervision and administration thereof.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.5 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Research Procedures</u>. EHBE shall conduct the Project in good scientific manner, and in compliance with all applicable Collaborator policies and procedures as detailed in the applicable Project Plan, all requirements of applicable laws and regulations, the highest professional industry standards and good laboratory and/or clinical practices, including, without limitation, any quality assurance, quality control and other standards set forth in the applicable Project Plan. EHBE shall proceed diligently with the work set out in the applicable Project Plan for such Project, including, without limitation, by allocating sufficient time and effort and using personnel with sufficient skills and experience, together with sufficient equipment and facilities, to conduct such Project and to accomplish the goals set out therein.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.6 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Records</u>. EHBE shall maintain complete and accurate records, appropriate for patent and Intellectual Property Rights protection purposes, of all work in connection with the Project.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.7 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Reports</u>.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">At such times as described in the applicable Project Plan for a Project and otherwise at EMBI&#8217;s reasonable request, EHBE shall prepare and deliver to EMBI such reports (in such form as reasonably requested by EMBI), including, without limitation, a report (in such form as reasonably requested by EMBI) describing in reasonably sufficient detail the Results derived as of the date of such report, activities conducted under such Project and all resulting Project Technology and EMBI Technology, and accounting for the use of the funding provided by EMBI for such Project.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 3 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(b) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unless otherwise set forth in the applicable Project Plan, within forty- five (45) days after completion or termination of such Project, EHBE shall prepare and deliver to EMBI a final report (in such form as reasonably requested by EMBI) describing in reasonably sufficient detail all Results of such Project, all methodologies, techniques and other activities used in conducting such Project and all resulting Project Technology and EMBI Technology, and accounting for the use of the funding provided by EMBI for such Project.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.8 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Term</u>. The term of each Project shall commence on Project Effective Date (as defined in the applicable Project Plan) and, unless terminated earlier in accordance with this Agreement or the pa1iies otherwise mutually agree in writing, shall terminate upon delivery by EHBE and acceptance by EMBI of the final deliverable for such Project as described in the applicable Project Plan.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.9 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Insurance</u>. EHBE shall at all times maintain comprehensive personal injury and property damage insurance applicable to the operations of EHBE that will include without limitation personal injury liability, product liability, and contractual liability, and any other forms of insurance, all of which must be in such reasonable amounts and with such reasonable deductions as would be obtained by a prudent person acting reasonably in similar circumstances.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3. </p></td> <td style="vertical-align:top;"><u>Collaborator Materials; Collaborator Technology</u>.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.1 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Collaborator Materials</u>. EMBI may provide EHEB with the compound to be investigated.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.2 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Ownership</u>. EHBE hereby acknowledges that, as between EMBI and EHBE, EMBI is the sole owner or licensee of the EMBI Technology, together with all Intellectual Property Rights therein and thereto, and hereby assigns to EMBI, all right, title and interest in and to the foregoing.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.3 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Patent Rights</u>. EMBI shall control, at its sole cost, the filing, preparation, prosecution, maintenance and enforcement of all patent applications and patents claiming or covering the EMBI Technology. Upon EMBI&#8217;s reasonable request, EHBE and its employees and consultants shall assist EMBI, shall execute, acknowledge and deliver such further documents and instruments, and shall perform all such other acts as may be necessary or appropriate in preparing, filing, prosecuting, maintaining or enforcing all such patent applications and patents.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.4 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>No Warranties</u>. EHBE hereby acknowledges that the EMBI Materials are experimental in nature and that they are provided on an &#8220;AS IS&#8221; basis. COLLABORATOR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE EMBI MATERIALS OR THE USE THEREOF. EMBI DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE ORNON- INFRINGEMENT.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 4 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">4. </p></td> <td style="vertical-align:top;"><u>Results and Project Technology</u>.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">4.1 </p></td> <td style="vertical-align:top;"><u>Ownership and Assignment</u>.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">EMBI shall be the exclusive owner of all rights, title and interests, including without limitation the Intellectual Property Rights, in and to the Results and Project Technology, regardless of whether they were made or conceived (a) solely by employees or others acting on behalf of EHBE, (b) solely by employees or others acting on behalf of EMBI or (c) jointly by employees or others acting on behalf of EMBI and by employees or others acting on behalf of EHBE. EMBI shall have the right, subject to the provisions of this Agreement, to freely exploit, transfer, license or encumber its rights in any Results and Project Technology, and the Intellectual Property Rights therein, without the consent of, or payment or accounting to, EHBE.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">4.2 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosure. EHBE promptly shall disclose to EMBI any Results and Project Technology made or conceived by or on behalf of EHBE and provide EMBI with copies of all information available to EHEB regarding such Results and Project Technology.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Financial Terms</u>. With respect to each Project Plan entered into between the parties on mutual agreement, EMBI shall pay to EHBE such amounts as set forth in the budget of the applicable Project Plan, at such times an in accordance with such other terms and conditions as set forth in such Project Plan. EHBE will provide services to EMBI at reasonable market rates. EHBE shall use funds received from EMBI solely to conduct the applicable Project and for no other purpose.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">6.</p></td> <td> <p style="margin:0px"><u>Confidential Information</u>.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">6.1 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Confidential Information</u>. EHBE shall hold all Confidential Information of the EMBI in confidence and shall not disclose such Confidential Information to any third party. EHBE shall disclose Confidential Information of the Discloser only to its employees, in each case who need to know such Confidential Information, to the extent such disclosure is reasonably necessary performance of its obligations or the exercise of its rights under this Agreement, and who are bound by restrictions regarding disclosure and use of such Confidential Information no less restrictive than those set forth herein. EHBE shall not use, or grant the use of, any Confidential Information of EMBI for the benefit of itself or any third party or for any purpose other than the performance of its obligations or the exercise of its rights under this Agreement. The obligations of this section 6 with respect to any item of Confidential Information or with respect to any discussions or agreements between the parties shall survive for five (5) years following the termination or expiration of this Agreement.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 5 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">6.2 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Ownership</u>. All Confidential Information (including, without limitation, all copies, extracts and portions thereof) is and shall remain the sole property of EMBI. EHBE does not acquire (by license or otherwise, whether express or implied) any Intellectual Property Rights or other rights under this Agreement or any disclosure hereunder, except the limited right to use such Confidential Information in accordance with the express provisions of this Agreement.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">7. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>No Implied Rights</u>. Except as expressly set forth in this Agreement, this Agreement shall not be construed to grant any license or other rights to either party in or to any patent or other intellectual property rights of the other party.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">8. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Term and Termination</u>.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">8.1 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Term</u>. This Agreement will commence on the Effective Date and, unless sooner terminated as provided in this Agreement, will remain in full force and effect for a term of 1 year (the &#8220;Initial Term&#8221;).</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">8.2 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Termination</u>. Any party shall have the right to terminate the Agreement in its entirety upon or after the material breach of this Agreement by EMBI or EHBE if the breaching party has not cured such breach within thirty (45) days after notice thereof by the other party.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">8.3 </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Effects of Termination</u>.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Promptly upon the completion or termination of any individual Project, unless the parties otherwise mutually agree in writing, the Recipient shall destroy or return to EMBI (as requested by the EMBI) all tangible items regarding the Confidential Information of the EMBI relating to such Project and all copies thereof, except that (i) EHBE shall have the right to retain one (1) copy for its legal files for the sole purpose of determining its obligations hereunder, and (ii) EHBE shall return to EMBI all remaining Technology relating to such Project.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Promptly upon the expiration or termination of this Agreement in its entirety, unless the parties otherwise mutually agree in writing, (i) EHBE shall destroy or return to the EMBI (as requested by the EMBI) all tangible items regarding the Confidential Information of the EMBI and all copies thereof; provided, however, that the EHBE shall have the right to retain one (1) copy for its legal files for the sole purpose of determining its obligations hereunder, and (ii) EHBE shall return to EMBI all remaining EMBI Technology.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">9. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Governing Law</u>. This Agreement shall be governed by, interpreted and construed in accordance with the laws of California, without regard to the conflicts of law principles thereof. Any legal action or other proceeding to resolve any dispute arising from or relating to this Agreement shall be brought only in the courts of California</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 6 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">10. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Notices</u>. All reports, notices and other documents that a party is required or may want to deliver to any other party shall be delivered in writing and either by personal delivery or by registered or certified mail at the address for the receiving party set out on page 1 of this Agreement, or as varied by any notice.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">11. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>No Waiver</u>. No condoning, excusing or overlooking by any party of any default, breach or non-observance by any other party at any time or times regarding any terms of this Agreement (including any Project Plans) shall operate as a waiver of that party&#180;s rights under this Agreement. A waiver of any term or right under this Agreement shall be made in writing signed by the party entitled to the benefit of that term or right and is effective only to the extent set out in the written waiver.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">12. </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><u>Severability</u>. Any part of this Agreement that is indefinite, invalid, illegal or otherwise void or unenforceable may be severed from this Agreement and the balance of this Agreement will continue in full force and effect.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Remainder of page left intentionally blank. Signature page follows.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">- 7 -</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2"> <p style="margin:0px"><strong>EMERALD HEALTH BIOTECHNOLOGY ESPA&#209;A</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:3%;">&nbsp;</td> <td style="width:35%;">&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>By:</td> <td style="BORDER-BOTTOM: black 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Authorized Signatory</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td colspan="2"> <p style="margin:0px"><strong>EMERALD BIOSCIENCE INC.</strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">By:&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Authorized Signatory</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT A</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Project Development for CBD-Val-HS</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Investigators: Emerald Biotechnology Espa&#241;a</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>AIM OF PROJECT</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The aim of this project is to study the activity of CBD-Val-HS and CDB.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>1. </strong></p></td> <td style="vertical-align:top;"><strong>Synthesis and Stability of drug substance and drug product (Galchimia and Ardena)</strong></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>2. </strong></p></td> <td style="vertical-align:top;"><strong>Solubility and Formulation of CBD-Val-HS (Galchimia and Ardena)</strong></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>3. </strong></p></td> <td style="vertical-align:top;"><strong>PK analysis (Eurofins)</strong></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4. </strong></p></td> <td style="vertical-align:top;"><strong>Toxicology (minimum for go/non-go decision)</strong></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5. </strong></p></td> <td style="vertical-align:top;"><strong>Bioactivity in vitro related to the endocannabinoid system</strong></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6. </strong></p></td> <td style="vertical-align:top;"><strong>Bioactivity in vitro unrelated to the endocannabinoid system</strong></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px;text-indent:30px"><strong>&nbsp;</strong></p></td> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>7. </strong></p></td> <td style="vertical-align:top;"><strong>Efficacy in Animal model of autoimmune disease with skin and fibrotic components (as example)</strong></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CHRONOGRAM AND BUDGET</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:50%;vertical-align:top;"> <p style="margin:0px"><strong>EHBE/EMBI CRA</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Q1</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Q2</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Q3</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Q4</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#0080ff"> <td style="BORDER-TOP: #000000 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong>Objective 1</strong></p></td> <td style="BORDER-TOP: #000000 1px solid;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">1.1. Synthesis and Stability of drug substance and drug product</p></td> <td style="BORDER-TOP: #000000 1px solid; background-color:#80ff00;" rowspan="3"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px; text-align:right;">30.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">1.2. Solubility and Formulation of CBD-Val-HS</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">20.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">1.3.PK analysis</p></td> <td style="BORDER-TOP: #000000 1px solid; background-color:#80ff00;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">20.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">1.4. Toxicology (genotoxicity and cardiotoxicity)</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">20.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#0080ff"> <td style="BORDER-TOP: #000000 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong>Objective 2 (in vitro)</strong></p></td> <td style="BORDER-TOP: #000000 1px solid;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">2.1.Bioactivity in vitro related to the endocannabinoid system</p></td> <td style="BORDER-TOP: #000000 1px solid; background-color:#80ff00;" rowspan="2" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">10.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">2.2. Bioactivity in vitro unrelated to the endocannabinoid system</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">10.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#0080ff"> <td style="BORDER-TOP: #000000 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong>Objective 3 (in vivo)</strong></p></td> <td style="BORDER-TOP: #000000 1px solid;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid;" colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">3.1.Efficacy in Animal model</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; background-color:#80ff00;" colspan="3"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">35.000</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">80.000</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">40.000</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">15.000</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">10.000</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">145.000</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="color:red"><strong>* If CBD-VAL is provided by EMBI (1.1) reduce 20.000 &#8364;</strong></font></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>PROTOCOLS (in house)</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>1. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cell cultures</strong>. The different cell lines used in this project will be maintained in supplemented DMEM medium containing 10% FBS and 1% antibiotics penicillin/streptomycin (DMEM complete medium) at 37&#186;C in a humidified atmosphere of 5% CO2.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>2. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>CB1 and CB2 functional assays</strong>. 293T-CB1 and 293T-CB2 cells (stably transfected with CB1 and CB2 cDNAs) are incubated in 24-well plates (1x105 cell/ml) and transiently transfected with 0,1 mg/ml of the plasmid CRE-luc that contains six consensus cAMP responsive elements (CRE) linked to firefly luciferase. Transient transfections are performed with Rotifect (Carl Roth GmbH, Karlsruhe, Germany) according to the manufacturer&#8217;s instructions and harvested 24 h after transfection. For agonistic activity of CB1 the cells are treated with the compounds for 6 h. For antagonistic activity of CB1 the transfected cells are incubated with increasing concentrations of the test compounds for 15 min and then with WIN-55, 212-2 (positive control for CB1), during 6 h and then luciferase activity measured in the cell lysates. Forskolin is an adenylate cyclase activator that is used at 10 mM as a positive control of cAMP signaling pathway activated by a CB1R-independent mechanism. For CB2 agonistic activity we treated 293T-CB2-CRE-luc cells either with increasing concentrations of the test substances or with WIN-55, 212-2 (positive control for CB2), for 15 min and then with Forskolin (10 mM). After six hours of stimulation the cells will be lysed in 25 mM Tris-phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol and luciferase activity measured using TriStar2 Berthold/LB942 multimode reader (Berthold Technologies) following the instructions of the luciferase assay kit (Promega, Madison, WI). The background obtained with the lysis buffer will be subtracted in each experimental value, and the specific transactivation expressed as fold induction over basal levels (CRE-Luc).</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>3. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Binding assays</strong>. CB1 and CB2 receptor binding affinities will be determined by competition studies using [3H]CP55940 as radioligand and commercial membrane preparations of HEK293 EBNA cells stably expressing the respective receptor type (Perkin-Elmer Life and Analytical Sciences, Boston, MA), following a procedure previously described by us. Initially, compounds will be screened at 40 &#956;M and, in those cases in which the inhibition of radioligand binding will be at least about 70%, competition curves using a broad range of compound concentrations will be performed to calculate Ki values. Competition binding data are analyzed by using GraphPad Prism&#174; version 5.01 (GraphPad Software Inc., CA, USA).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>4. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cytotoxicity assays</strong>. Briefly, NIH-3T3 cells will be seeded at a density of 1 x 103 cells/well in 96-well plates and treated with increasing concentrations of the compounds for 24 hours. After that, 50 &#956;l of 3-MTT (4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium bromide) (5 mg/ml) from a mixture solution of MTT: DMEM (1:2) per well will be added and cells will be incubated for 4 hours at 37&#186; C in darkness. Then, supernatant will be removed and 100 &#956;l DMSO will be added to each well for 10 min, in gentle shaking. Absorbance will be measured at 550 nm using a TriStar LB 941 (Berthold Technologies, GmbH &amp; Co. KG). The mean concentration in each set of three wells will be measured. The absorbance of untreated controls will be considered as 100% survival.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>5. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Nrf2 activity assays</strong>. The HaCaT-ARE-Luc cell line contains the Nqo1 Antioxidant Response Element (ARE)-Luc reporter plasmid. The ARE is activated by all members of the CNC family of factors (Nrf1, Nrf2, Nrf3 and p45 NF-E2). The cells are cultivated in 24 well plates at the concentration of 2x104 cells/well in a CO2 incubator at 37&#186;C. For induction of Nrf2 activation the cells will be treated with increasing concentrations of the test substances for 6 h. As a positive control the cells will be treated with 0.2 mM Tert-butyl-hydroquinone (TBHQ). For inhibition of Nrf2, the cells are preincubated with increasing concentrations of test substances for 15 min and then treated with 0.2 mM TBHQ for 6 h. Then the cells are will behed twice in PBS and lysed in 25 mM Tris-phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100 and 7% glycerol during 15 min at RT in a horizontal shaker. After centrifugation, the supernatant are used to measure luciferase activity using an Autolumat LB 9510 (Berthold) following the instructions of the luciferase assay kit (Promega, Madison, WI, USA). The protein concentration in the cell extracts is measured by the Bradford method (BioRad). The RLU/mg is calculated, and the results are expressed as percentage of induction/inhibition of ARE-luc activity.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>6. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cellular antioxidant activity</strong>. The intracellular accumulation of ROS is detected by fluorimetry using 2&#180;,7-&#180;dihydrofluorescein-diacetate (DCFH-DA). The HaCaT cells (1X 105 cells/well) are cultured in a 12-well plate in DMEM supplemented with 10% FBS; culture medium is renewed when the cells reached 80% confluence. After preincubation with the test substances for 24 h the cells are incubated with 10 mM DCFH-DA in the culture medium at 37&#186;C for 30 min and then treated with 0.2 mM Tert-butyl-hydroquinone (TBHQ). The acetate groups on DCFH-DA are removed by an intracellular esterase, trapping the probe inside the HaCaT cells. The cells are then will behed with warm PBS buffer. The production of ROS can be measured by changes in fluorescence due to the intracellular accumulation of DCF caused by the oxidation of DCFH. Intracellular ROS, as indicated by DCF fluorescence is detected using a TECAN Pro plate reader (excitation, 485 nm; emission, 530 nm).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>7. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Determination of Col1A2 gene transcription</strong>. The COL1A2-luciferase construct contains sequences from -353 to +58 bp of the human COL1A2 promoter fused to the luciferase reporter gene. NIH3T3 fibroblast cells will be cultivated at a density of 5 x 104 cells/ml for 24 h at 37&#186;C and transfected with the COL1A2-luc plasmid using Roti-Fect (Carl Roth) following the manufacturer&#180;s recommendations. Twenty-four h later the cells will be treated with the test compounds at several concentrations and TGF&#946;1 (10 ng/ml) as positive control for 12h. The cells will be will behed with PBS and lysed in 100&#181;l lysis buffer containing 25 mM Trisphosphate (pH 7.8), 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol during 15 min. Luciferase activity and protein concentration will be measured in the cell lysates to calculate the RLU/mg of protein and the results expressed as the percentage of induction considering the value obtained with TGF&#946;1 as 100% activation.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>8. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Miofibroblast differentiation</strong>. To induce myofibroblast differentiation MEFs will be plated on glass coverslips with the appropriate medium. After serum starvation for 24 h, the cells will be preincubated with the test compounds for 1 h and stimulated with TGF&#946;1 (10 ng/ml) for another 24 h. Coverslips will be collected, will behed with PBS and fixed with 4% paraformaldehyde. After antigen retrieval non-specific binding will be reduced by blocking with IHC select blocking reagent (Merck Millipore, MA, USA) at room temperature for 30 min. Coverslips will be placed in a humidified chamber and incubated overnight at 4 &#186;C with a primary antibody &#945;-SMA (1:50, sc-32251, Santa Cruz). Then, coverslips will be will behed three times with 0.1% PBS-Tween 20 and incubated with the secondary antibody goat anti-rat Alexa 488 (Merck Millipore). Finally, coverslips will be mounted in VectaShield Mounting Medium with DAPI and analyzed using a Leica DM2500 microscope and a Leica DFC420c camera.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>9. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>In vitro cell migration assays</strong>. The modulation of cell migration will be analyzed by wound- healing assays. Briefly, NHDFs will be seeded in a 96-well Essen ImageLock plate (Essen BioScience) and will be grown to confluence. After 24 h, the scratches will be made using the 96-pin WoundMaker (Essen BioScience), followed by incubation of the cultures in media with 10 ng/ml of mitomycin C to block cell proliferation. VCE-004.8 and TGFb1 or rhIL-4 (10 ng/ml) will be added, and wound images will be taken every 60 min for 36 h, and the data analyzed by the integrated metric Relative Wound Density part of the live content cell imaging system IncuCyte HD (Essen BioScience).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>10. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>NF-kB assays in fibroblasts</strong>. The NIH3T3-KBF-Luc cells has been stably transfected with the plasmid KBF-Luc plasmid, which contains three copies of NF-&#954;B binding site (from major histocompatibility complex promoter), fused to a minimal simian virus 40 promoter driving the luciferase gene. Cells (1x104 for NIH3T3-KBF-Luc) are seeded the day before the assay on 96-well plate. Then the cells are treated with the test compounds for 15 min and then stimulated with 30 ng/ml TNF&#945;. After 6 h, the cells are will behed twice with PBS and lysed in 50&#181;l lysis buffer containing 25 mM Tris-phosphate (pH 7.8), 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol during 15 min at RT in a horizontal shaker. Luciferase activity is measured using a TriStar2 Berthold/LB942 multimode reader (Berthold Technologies) following the instructions of the luciferase assay kit (Promega, Madison, WI, USA). The RLU is calculated and the results are expressed as percentage of inhibition of NF-&#954;B activity induced by TNF&#945; (100% activation). The experiments for each concentration of the test items will be done in triplicate wells.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>11. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Animals and experimental protocols </strong>Six- to eight-week-old female BALB/c mice will be purchased from Harlan laboratories (Barcelona, Spain) and housed in our animal facilities (University of C&#243;rdoba, C&#243;rdoba, Spain) under controlled conditions (12h light/dark cycle; temperature 20&#186;C (&#177;2&#186;C) and 40&#8211;50% relative humidity) with free access to standard food and water. All experiments will be performed in accordance with European Union guidelines and approved by the Animal Research Ethics Committee of the C&#243;rdoba University (2014PI/016). Bleomycin-induced skin and lung fibrosis will be developed by daily subcutaneous injections of 100 &#181;L bleomycin (20 &#956;g/mL) diluted in phosphate buffered saline (PBS) (Mylan Pharmaceuticals, Barcelona, Spain) into well-defined areas (1cm2) of the shaved backs of mice for 6 weeks. During the last 3 weeks, the mice will be treated daily by oral gavage with either CBD or CBD-Val-HS formulated in sesame oil. After 6 weeks, all animals will be sacrificed by cervical dislocation and dissected for tissue processing. Skin and lung samples will be divided into two pieces, one maintained in RNA-later (Sigma-Aldrich, St. Louis, MO, USA) cooled in dry ice and stored at -80oC for transcriptomic analysis, and the second piece fixed in fresh 4% paraformaldehyde (0.1M, PBS) (AppliChem, Darmstadt, Germany) for histochemical analysis. Six to eight animals will be analyzed in each experimental group.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>12. </strong></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Histochemical analysis</strong>. Five mm-thick tissue sections of skin or lung sections will be embedded in paraffin and then stained with Masson's trichrome (Merck Millipore, Darmstadt, Germany). Skin collagen will be also detected by picrosirius red staining (Sigma-Aldrich, St. Louis, MO, USA). Three random fields of each skin or lung biopsy will be photographed by standard brightfield microscopy and digitalized using a Leica DFC420c camera and analyzed using Image J software (http://rsb.info.nih.gov/ij/) in a blinded manner by two independent observers. The Ashcroft score will be used to determine the degree of fibrosis in lung specimens.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>13.</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><strong>Confocal microscopy analyses</strong>. Skin sections (5 &#181;m-thick) will be deparaffinized and boiled for 10 min in sodium citrate buffer (10mM, pH 6.0) (Sigma-Aldrich, St. Louis, MO, USA) for antigen retrieval. Nonspecific binding will be blocked with 3% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, USA) in PBS and sections will be incubated overnight at 4&#186;C with the following primary antibodies: monoclonal anti-Tenascin (TNC) (1:100 dilution, #MAB2138, RD system, Mineapolis, MN, USA), and anti-&#945;-Smooth muscle actin (SMA) monoclonal antibody Alexa-488 (1:100 dilution, #53-9760-80, Thermo Fischer, Waltham, MA, USA). Next, slides will be incubated with secondary antibodies for 1h at room temperature in the dark. All images will be acquired using a spectral confocal laser-scanning microscope LSM710, (Zeiss, Jena, Germany) with a 25&#215;/0.8 Plan-Apochromat oil immersion lens and quantified in 10 to 15 randomly chosen fields using ImageJ software (http://rsb.info.nih.gov/ij/).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ADDENDUM</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">THIS ADDENDUM (this &#8220;<strong>ADDENDUM</strong>&#8221;) is entered into between SKYE BIOSCIENCE, formerly known as EMERALD BIOSCIENCE INC., (&#8220;<strong>EMBI</strong>&#8221;), with a place of business at 5910 Pacific Center Blvd., #320 San Diego, CA, 92121, United States and EMERALD HEALTH BIOTECHNOLOGY ESPA&#209;A, S.L. a limited liability company incorporated under the laws of Spain (&#8220;<strong>EHBE</strong>&#8221;), having a place of business at Parque Cientifico Tecnologico de Cordoba, Rabanales 21, c/ Astronoma Cecilia Payne, Edifico Centauro, 14014, Cordoba, Spain, which ADDENDUM is effective as of January 2021 (the &#8220;<strong>Effective </strong><strong>Date</strong>&#8221;).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>WHEREAS:</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">A.<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The Parties entered into a Collaborative Research Agreement having an effective date of January 2021 (the &#8220;CRA&#8221;). </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">B.<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The Parties wish to clarify certain aspects of the CRA, and, thus, agree to add this ADDENDUM to the CRA.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>NOW, THEREFORE, </strong>in consideration of the foregoing premises and he mutual covenants herein contained; the parties hereby agree as follows:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">1.<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>All rights and obligations of the CRA will remain unless explicitly amended by the Parties herein.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In Exhibit A of the CRA, the Parties agree to the following:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 75px; text-align:left;">2.1<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp; </font>All payments will be converted to US dollars based on the exchange rate from the January 25, 2021 Wall Street Journal published exchange rate: 1.2175:1 (US dollar:Euro).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 75px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 75px; text-align:left;">2.2<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp; </font>The Chronogram and budget relate to calendar year 2021.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 75px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 75px; text-align:left;">2.3<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp; </font>The language in the asterisk shall be replaced in its entirety with the following language:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 75px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 75px; text-align:left;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#8220;If CBD-VAL is provided by EMBI (1.1), then reduce by 20,000 Euros&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 75px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 75px; text-align:left;">2.4<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp; </font>Payment.&nbsp; EHBE shall invoice EMBI upon the initiation of an objective outlined and budgeted in the Chronogram, and EMBI shall remit payment net 45 days from receipt of such invoice.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3.<font style='font:7pt times new roman'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><u>Entire Agreement</u>. This ADDENDUM, along with the CRA, represents the final and entire agreement and understanding between the Parties related to this subject matter, and is the complete and exclusive statement of its terms.&nbsp; This contract supersedes all prior agreement and understandings, whether oral or written.&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>EMERALD HEALTH </strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>BIOTECHNOLOGY ESPA&#209;A</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Authorized Signatory</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>EMERALD BIOSCIENCE INC.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Authorized Signatory</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-size:8pt">&nbsp;</font></p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>skye_ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head><title>skye_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">As independent registered public accountants, we hereby consent to the incorporation by reference in Registration Statement Nos. 333-227860, 333-223439, 333-226259, 333-245177, 333-240226 and 333-239826 of our report dated March 1, 2021, relating to the consolidated financial statements of Skye Bioscience, Inc., formerly known as Emerald Bioscience, Inc., and Subsidiaries, which report includes an explanatory paragraph relating to the uncertainty of the Company&#8217;s ability to continue as a going concern, for the years ended December 31, 2020 and 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>/s/ Mayer Hoffman McCann P.C.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Irvine, California</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">March 1, 2021</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>skye_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head><title>skye_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Certification of Principal Executive Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>As Adopted Pursuant To Section 302 of the Sarbanes--Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">I, Punit Dhillon, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of Skye Bioscience, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Ru1es 13a-15(e) and 15d-15(e )) and internal control over financial reporting (as defined in Exchange Act Ru1es 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particu1arly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;"> <p style="margin:0px">Date: March 1, 2021</p></td> <td style="width:65%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="margin:0px"><em>/s/ Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Punit Dhillon, Chief Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">(Principal Executive Officer)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>skye_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head><title>skye_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Certification of Principal Financial and Accounting Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>As Adopted Pursuant To Section 302 of the Sarbanes--Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">I, Richard Janney, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of Skye Bioscience, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Ru1es 13a-15(e) and 15d-15(e )) and internal control over financial reporting (as defined in Exchange Act Ru1es 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particu1arly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;"> <p style="margin:0px">Date: March 1, 2021</p></td> <td style="width:65%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="margin:0px"><em>/s/ </em><em>Richard Janney</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Richard Janney</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">(Principal Financial and Accounting Officer)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>skye_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head><title>skye_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Certification of Principal Executive Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Section 906 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">In connection with the Annual Report of Skye Bioscience, Inc., a Nevada corporation (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Punit Dhillon, Chief Executive Officer of the Company, hereby certify, that, to my knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to&#167; 906 of the Sarbanes-Oxley Act of 2002:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to Skye Bioscience, Inc., and will be retained by Skye Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Punit Dhillon</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Chief Executive Officer</p> <p style="margin:0px">(Principal Executive Officer) </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">March 1, 2021</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>skye_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head><title>skye_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Certification of Principal Financial and Accounting Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:center;"><strong>Section 906 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">In connection with the Annual Report of Skye Bioscience, Inc., a Nevada corporation (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Richard Janney, Interim Principal Accounting Officer of the Company, hereby certify, that, to my knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to&#167; 906 of the Sarbanes-Oxley Act of 2002:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to&nbsp;Skye Bioscience, Inc., and will be retained by Skye Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="margin:0px"><em>/s/ </em><em>Richard Janney</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Richard Janney</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Interim Principal Accounting Officer </p> <p style="margin:0px">(Principal Financial and Accounting Officer)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">March 1, 2021</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>skye-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
 <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:skye="http://www.emeraldbio.life/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink">























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  <link:schemaRef xlink:href="skye-20201231.xsd" xlink:type="simple"></link:schemaRef>
  <context id="C_20200101to20201231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20210223">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2021-02-23</instant>
    </period>
  </context>
  <context id="C_20201231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20181231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200401to20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:AmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-04-29</endDate>
    </period>
  </context>
  <context id="C_20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:AmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-29</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapTypeOfArrangementAxis_skyeFourthAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:FourthAmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapTypeOfArrangementAxis_skyeFifthAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:FifthAmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200422_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgramPromissoryNoteMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">skye:PaycheckProtectionProgramPromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-22</instant>
    </period>
  </context>
  <context id="C_20200701to20200731_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200731_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200801to20200831">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="C_20210101to20210223_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2021-01-01</startDate>
      <endDate>2021-02-23</endDate>
    </period>
  </context>
  <context id="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="C_20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-10-05</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20181101to20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-11-01</startDate>
      <endDate>2018-11-30</endDate>
    </period>
  </context>
  <context id="C_20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-30</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200401to20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">skye:PaycheckProtectionProgrammeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-04-24</endDate>
    </period>
  </context>
  <context id="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">skye:PaycheckProtectionProgrammeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-24</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191101to20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-11-01</startDate>
      <endDate>2019-11-30</endDate>
    </period>
  </context>
  <context id="C_20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-11-30</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_srtTitleOfIndividualAxis_skyePlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">skye:PlacementAgentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_srtTitleOfIndividualAxis_skyePlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">skye:PlacementAgentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20141031_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2014-10-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20141001to20141031_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">skye:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapConvertibleDebtSecuritiesMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapConvertibleDebtSecuritiesMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_skyeDilutedSecuritiesAxis_skyeWarrantsLiabilityClassifiedMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="skye:DilutedSecuritiesAxis">skye:WarrantsLiabilityClassifiedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeUnvestedRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="skye:DilutedSecuritiesAxis">skye:UnvestedRestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeOptionsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="skye:DilutedSecuritiesAxis">skye:OptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="skye:DilutedSecuritiesAxis">skye:WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeWarrantsLiabilityClassifiedMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="skye:DilutedSecuritiesAxis">skye:WarrantsLiabilityClassifiedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20170101to20170110_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:Um5070LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-01-01</startDate>
      <endDate>2017-01-10</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeOptionAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:OptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone3Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:Um5050ProdrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:MilestonePaymentsPayableAxis">skye:Milestone3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone2Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:Um5050ProdrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:MilestonePaymentsPayableAxis">skye:Milestone2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone1Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:Um5050ProdrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:MilestonePaymentsPayableAxis">skye:Milestone1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20170110_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:Um5070LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-01-10</instant>
    </period>
  </context>
  <context id="C_20170101to20170110_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:Um5070LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-01-01</startDate>
      <endDate>2017-01-10</endDate>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">skye:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">skye:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">skye:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200801to20200810_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeOfficersEmployeeAndDirectorsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">skye:OfficersEmployeeAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-10</endDate>
    </period>
  </context>
  <context id="C_20191201to20191219_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">skye:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-12-01</startDate>
      <endDate>2019-12-19</endDate>
    </period>
  </context>
  <context id="C_20200301to20200330_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">skye:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">skye:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-03-01</startDate>
      <endDate>2020-03-30</endDate>
    </period>
  </context>
  <context id="C_20210205_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2021-02-05</instant>
    </period>
  </context>
  <context id="C_20210223_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2021-02-23</instant>
    </period>
  </context>
  <context id="C_20210101to20210223_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2021-01-01</startDate>
      <endDate>2021-02-23</endDate>
    </period>
  </context>
  <context id="C_20210101to20210223_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2021-01-01</startDate>
      <endDate>2021-02-23</endDate>
    </period>
  </context>
  <context id="C_20210223_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2021-02-23</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyPreFundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyPreFundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyPreFundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyPreFundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeAugustTwoThousandAndTwentyFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:AugustTwoThousandAndTwentyFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PlacementAgentWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PlacementAgentWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PlacementAgentWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PlacementAgentWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PlacementAgentWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOfferedPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOfferedPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOfferedPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20181231_deiLegalEntityAxis_skyeEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20181231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">skye:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">skye:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="skye:PricingModelAxis">skye:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="C_20180216_usgaapClassOfWarrantOrRightAxis_skyeEmeraldWarrantLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_skyeEmeraldWarrantLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="C_20180201to20180216_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">skye:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-16</endDate>
    </period>
  </context>
  <unit id="USD">


        <measure>iso4217:USD</measure>
  </unit>
  <unit id="USD_per_Share">


        <divide>



              <unitNumerator>


                    <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>


                    <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">


        <measure>pure</measure>
  </unit>
  <unit id="shares">


        <measure>shares</measure>
  </unit>
  <skye:InitialTermOfAgreement contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" id="Fxbrl_20200506114236417">P10Y</skye:InitialTermOfAgreement>
  <dei:EntityCentralIndexKey contextRef="C_20200101to20201231" id="Fdei_EntityCentralIndexKey_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">0001516551</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="C_20200101to20201231" id="Fdei_EntityCurrentReportingStatus_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers contextRef="C_20200101to20201231" id="Fdei_EntityVoluntaryFilers_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">No</dei:EntityVoluntaryFilers>
  <dei:CurrentFiscalYearEndDate contextRef="C_20200101to20201231" id="Fdei_CurrentFiscalYearEndDate_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory contextRef="C_20200101to20201231" id="Fdei_EntityFilerCategory_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer contextRef="C_20200101to20201231" id="Fdei_EntityWellKnownSeasonedIssuer_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:AmendmentFlag contextRef="C_20200101to20201231" id="Fdei_AmendmentFlag_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">false</dei:AmendmentFlag>
  <dei:DocumentFiscalYearFocus contextRef="C_20200101to20201231" id="Fdei_DocumentFiscalYearFocus_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="C_20200101to20201231" id="Fdei_DocumentFiscalPeriodFocus_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntitySmallBusiness contextRef="C_20200101to20201231" id="Fdei_EntitySmallBusiness_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany contextRef="C_20200101to20201231" id="Fdei_EntityEmergingGrowthCompany_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityShellCompany contextRef="C_20200101to20201231" id="Fdei_EntityShellCompany_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">false</dei:EntityShellCompany>
  <dei:DocumentType contextRef="C_20200101to20201231" id="F22_10K">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="C_20200101to20201231" id="F31_December31">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="C_20200101to20201231" id="F49_NemusBiosc">Skye Bioscience, Inc.</dei:EntityRegistrantName>
  <dei:EntityInteractiveDataCurrent contextRef="C_20200101to20201231" id="Fxbrl_20200312193409162">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityPublicFloat contextRef="C_20200630" decimals="0" id="F200_16326892" unitRef="USD">29109240</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding contextRef="C_20210223" decimals="INF" id="F202_133907747" unitRef="shares">350007749</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:Cash contextRef="C_20201231" decimals="0" id="F7313" unitRef="USD">2469410</us-gaap:Cash>
  <us-gaap:Cash contextRef="C_20191231" decimals="0" id="F7319" unitRef="USD">1829977</us-gaap:Cash>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20201231" decimals="0" id="F7329" unitRef="USD">4566</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20191231" decimals="0" id="F7336" unitRef="USD">4538</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20201231" decimals="0" id="F7346" unitRef="USD">190134</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20191231" decimals="0" id="F7353" unitRef="USD">152695</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20201231" decimals="0" id="F7363" unitRef="USD">275</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200312110300768" unitRef="USD">7550</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20201231" decimals="0" id="F7380" unitRef="USD">2664385</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20191231" decimals="0" id="F7387" unitRef="USD">1994760</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200655598_7380" unitRef="USD">7341</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200655598_7387" unitRef="USD">1983</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="C_20201231" decimals="0" id="F7451" unitRef="USD">2671726</us-gaap:Assets>
  <us-gaap:Assets contextRef="C_20191231" decimals="0" id="F7457" unitRef="USD">1996743</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent contextRef="C_20201231" decimals="0" id="F7545" unitRef="USD">364340</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="C_20191231" decimals="0" id="F7551" unitRef="USD">129809</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200720878_7380" unitRef="USD">17032</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200720878_7387" unitRef="USD">10000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <skye:AccruedInterestRelatedParty contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200715486_7380" unitRef="USD">44087</skye:AccruedInterestRelatedParty>
  <skye:AccruedInterestRelatedParty contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200715486_7387" unitRef="USD">0</skye:AccruedInterestRelatedParty>
  <us-gaap:OtherLiabilitiesCurrent contextRef="C_20201231" decimals="0" id="F7578" unitRef="USD">259111</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="F7585" unitRef="USD">420406</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20201231" decimals="0" id="F7595" unitRef="USD">38567</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="F7602" unitRef="USD">410603</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20181231" decimals="0" id="Fxbrl_20210218161147771_xbrl_20201102153703270_xbrl_20200810100806908_xbrl_20200506171810074" unitRef="USD">15738913</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:OtherLongTermDebtCurrent contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200710806_7380" unitRef="USD">64062</us-gaap:OtherLongTermDebtCurrent>
  <us-gaap:OtherLongTermDebtCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200710806_7387" unitRef="USD">0</us-gaap:OtherLongTermDebtCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20201231" decimals="0" id="F7629" unitRef="USD">787199</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20191231" decimals="0" id="F7636" unitRef="USD">970818</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherLoansPayableLongTerm contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200701477_7380" unitRef="USD">52638</us-gaap:OtherLoansPayableLongTerm>
  <us-gaap:OtherLoansPayableLongTerm contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200701477_7387" unitRef="USD">0</us-gaap:OtherLoansPayableLongTerm>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200705059_7380" unitRef="USD">450000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200705059_7387" unitRef="USD">0</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20201231" decimals="0" id="F7685" unitRef="USD">931103</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200312110850425" unitRef="USD">387070</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859221_xbrl_20210218164004505_xbrl_20210218163944319_xbrl_20210218163910695_xbrl_20210218163703795" unitRef="USD">450000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859221_xbrl_20210218164004505_xbrl_20210218163944319_xbrl_20210218163910695_xbrl_20210218163835101" unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20201231" decimals="0" id="F7702" unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20191231" decimals="0" id="F7709" unitRef="USD">90797</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20181231" decimals="0" id="Fxbrl_20210218161147756_xbrl_20201102153703266_xbrl_20200810100806901_xbrl_20200506171802173" unitRef="USD">219453</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="C_20201231" decimals="0" id="F7738" unitRef="USD">2220940</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="C_20191231" decimals="0" id="F7745" unitRef="USD">1448685</us-gaap:Liabilities>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20191231" decimals="3" id="Fxbrl_202003121123093570" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20201231" decimals="3" id="Fxbrl_20200312112309357" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_202003121123528860" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20201231" decimals="INF" id="Fxbrl_20200312112352886" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20210205_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20210218200743850" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="C_20191231" decimals="0" id="Fxbrl_202003121127021822" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="C_20201231" decimals="0" id="Fxbrl_202003121127021821" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200923713" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="C_20191231" decimals="0" id="Fxbrl_20210218200941373" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20191231" decimals="3" id="Fxbrl_202001201406380850" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20201231" decimals="3" id="Fxbrl_20200120140638085" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_202102190403344990" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20201231" decimals="INF" id="Fxbrl_20210219040334499" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20210205_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20210218200737010" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20201231" decimals="INF" id="Fxbrl_202102190405448630" unitRef="shares">288074415</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20191231" decimals="INF" id="Fxbrl_202102190406038540" unitRef="shares">182895247</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="C_20201231" decimals="INF" id="Fxbrl_20210219040544863" unitRef="shares">288074415</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="C_20191231" decimals="INF" id="Fxbrl_20210219040603854" unitRef="shares">182895247</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="C_20210223_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="INF" id="Fxbrl_20210224011517961" unitRef="shares">11800000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="C_20210223_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="INF" id="Fxbrl_20210224011842294" unitRef="shares">50133334</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="C_20201231" decimals="0" id="F8016" unitRef="USD">288074</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="C_20191231" decimals="0" id="F8023" unitRef="USD">182895</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20201231" decimals="0" id="F8033" unitRef="USD">38896693</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20191231" decimals="0" id="F8040" unitRef="USD">32538445</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20201231" decimals="0" id="F8067_33225107" unitRef="USD">-38733981</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20191231" decimals="0" id="F8073_14030871" unitRef="USD">-32173282</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="C_20201231" decimals="0" id="F8082_15562252" unitRef="USD">450786</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231" decimals="0" id="F8088_3569506" unitRef="USD">548058</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_47" unitRef="USD">133908</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_411" unitRef="USD">17528947</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_415" unitRef="USD">-33225107</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231" decimals="0" id="Fxbrl_20210218214323196_419" unitRef="USD">-15562252</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_207" unitRef="USD">182895</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_2011" unitRef="USD">32538445</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218215938955" unitRef="USD">-32173282</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_327" unitRef="USD">288074</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_3211" unitRef="USD">38896693</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218220258648" unitRef="USD">-38733981</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20201231" decimals="0" id="F8096" unitRef="USD">2671726</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20191231" decimals="0" id="F8102" unitRef="USD">1996743</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20200101to20201231" decimals="0" id="F8185" unitRef="USD">1944411</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190101to20191231" decimals="0" id="F8191" unitRef="USD">2237956</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20210218141511090" unitRef="USD">93545</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20210218141544681" unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20200101to20201231" decimals="0" id="F8201" unitRef="USD">4344602</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190101to20191231" decimals="0" id="F8208" unitRef="USD">4394622</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20210218141604378" unitRef="USD">209197</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20210218141654717" unitRef="USD">680455</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="C_20200101to20201231" decimals="0" id="F8237" unitRef="USD">6289013</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20190101to20191231" decimals="0" id="F8244" unitRef="USD">6632578</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="C_20200101to20201231" decimals="0" id="F8274_4692523" unitRef="USD">-6289013</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20190101to20191231" decimals="0" id="F8280_3859229" unitRef="USD">-6632578</us-gaap:OperatingIncomeLoss>
  <skye:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20200101to20201231" decimals="0" id="F8328" unitRef="USD">-436270</skye:ChangeInFairValueOfDerivativeLiabilities>
  <skye:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20190101to20191231" decimals="0" id="F8335_767198" unitRef="USD">-9734759</skye:ChangeInFairValueOfDerivativeLiabilities>
  <skye:FairValueOfDerivativeLiabilityInExcessOfProceeds contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218201619302" unitRef="USD">-322644</skye:FairValueOfDerivativeLiabilityInExcessOfProceeds>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20200101to20201231" decimals="0" id="F8378" unitRef="USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312123233029" unitRef="USD">-725425</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218161345990" unitRef="USD">-725425</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:InterestExpense contextRef="C_20200101to20201231" decimals="0" id="F8395" unitRef="USD">706385</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20190101to20191231" decimals="0" id="F8402" unitRef="USD">1000713</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="C_20200101to20201231" decimals="0" id="F8412_84" unitRef="USD">29</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312124246651" unitRef="USD">26</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218202238385" unitRef="USD">-270086</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219053347802" unitRef="USD">7686003</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="C_20200101to20201231" decimals="0" id="F8448_19192594" unitRef="USD">-6559099</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="C_20190101to20191231" decimals="0" id="F8454_3092698" unitRef="USD">1053425</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20200101to20201231" decimals="0" id="F8482" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20190101to20191231" decimals="0" id="F8489" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20201231" decimals="0" id="F8518_19194236" unitRef="USD">-6560699</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20191231" decimals="0" id="F8523_3094298" unitRef="USD">1051825</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_187" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_1811" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_1815" unitRef="USD">1051825</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_307" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_3011" unitRef="USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_3015" unitRef="USD">-6560699</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic contextRef="C_20200101to20201231" decimals="2" id="Fxbrl_20200312124625825" unitRef="USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20190101to20191231" decimals="2" id="Fxbrl_20200312124631312" unitRef="USD_per_Share">0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20200101to20201231" decimals="2" id="Fxbrl_20200312124643696" unitRef="USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20190101to20191231" decimals="2" id="Fxbrl_20200312124648130" unitRef="USD_per_Share">-0.05</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312124659683" unitRef="shares">230746878</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312124705756" unitRef="shares">135154931</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312124715242" unitRef="shares">231420973</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312124724475" unitRef="shares">169560265</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:Depreciation contextRef="C_20200101to20201231" decimals="0" id="F8738" unitRef="USD">1872</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="C_20190101to20191231" decimals="0" id="F8745" unitRef="USD">1462</us-gaap:Depreciation>
  <us-gaap:ShareBasedCompensation contextRef="C_20200101to20201231" decimals="0" id="F8789" unitRef="USD">302742</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20190101to20191231" decimals="0" id="F8796" unitRef="USD">680455</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20210218141713259" unitRef="USD">302742</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20210218141730321" unitRef="USD">680455</us-gaap:ShareBasedCompensation>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20201231" decimals="0" id="F8823" unitRef="USD">-436270</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231" decimals="0" id="F8830_767198" unitRef="USD">-9734759</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20210218155102939" unitRef="USD">1130400</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20210218153838898" unitRef="USD">1830573</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161017164_xbrl_20200810100656150_xbrl_20200506162036611" unitRef="USD">-90797</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161017200_xbrl_20200810100656174_xbrl_20200506162054372" unitRef="USD">-237457</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161017235_xbrl_20200810100656193_xbrl_20200506162107929" unitRef="USD">-108016</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161712021" unitRef="USD">-484147</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161147665_xbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164300542" unitRef="USD">-9042066</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161147691_xbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164309192" unitRef="USD">-208546</us-gaap:FairValueAdjustmentOfWarrants>
  <skye:FairValueOfDerivativeLiabilityExcessOfProceeds contextRef="C_20200101to20201231" decimals="0" id="F8839" unitRef="USD">0</skye:FairValueOfDerivativeLiabilityExcessOfProceeds>
  <skye:FairValueOfDerivativeLiabilityExcessOfProceeds contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312143650887" unitRef="USD">322644</skye:FairValueOfDerivativeLiabilityExcessOfProceeds>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20200101to20201231" decimals="0" id="F8907" unitRef="USD">544033</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312143953353" unitRef="USD">629293</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20200101to20201231" decimals="0" id="F8960" unitRef="USD">37439</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20190101to20191231" decimals="0" id="F8967_121273" unitRef="USD">59502</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C_20200101to20201231" decimals="0" id="F8993_2609" unitRef="USD">-7275</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C_20190101to20191231" decimals="0" id="F8999" unitRef="USD">4941</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20200101to20201231" decimals="0" id="F9009_85324" unitRef="USD">234531</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20190101to20191231" decimals="0" id="F9015_173729" unitRef="USD">124212</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218203106542" unitRef="USD">7032</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="C_20190101to20191231" decimals="0" id="F9024" unitRef="USD">10000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218203152167" unitRef="USD">44087</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210219124453531" unitRef="USD">-161295</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219124458315" unitRef="USD">225945</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20200101to20201231" decimals="0" id="F9056_3943014" unitRef="USD">-6054131</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20190101to20191231" decimals="0" id="F9062_3331285" unitRef="USD">-6027941</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218203217608" unitRef="USD">7230</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218203241301" unitRef="USD">-7230</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <skye:ProceedsFromIssuanceOfCommonStockAndWarrantNet contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210219182929845" unitRef="USD">854078</skye:ProceedsFromIssuanceOfCommonStockAndWarrantNet>
  <skye:ProceedsFromIssuanceOfCommonStockAndWarrantNet contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219182937037" unitRef="USD">80628</skye:ProceedsFromIssuanceOfCommonStockAndWarrantNet>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312144510319" unitRef="USD">6085589</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312144515614" unitRef="USD">1919372</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="0" id="Fxbrl_20210218204324111" unitRef="USD">6085589</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312144456974" unitRef="USD">48533</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312144754042" unitRef="USD">4080000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20210101to20210223_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20210224012258304" unitRef="USD">3019800</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20210101to20210223_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20210224011614457" unitRef="USD">11800</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20210101to20210223_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20210224011621448" unitRef="USD">3008000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromOtherShortTermDebt contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218203323969" unitRef="USD">116700</us-gaap:ProceedsFromOtherShortTermDebt>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210219182953118" unitRef="USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219183014582" unitRef="USD">9301</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="0" id="Fxbrl_20210218204305415" unitRef="USD">854078</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218203347932" unitRef="USD">450000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218203422379" unitRef="USD">3990699</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <skye:RepaymentOfConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219125225245" unitRef="USD">3985500</skye:RepaymentOfConvertibleMultiDrawCreditAgreement>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20200101to20201231" decimals="0" id="F9243" unitRef="USD">6700822</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20190101to20191231" decimals="0" id="F9250" unitRef="USD">6004571</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="C_20200101to20201231" decimals="0" id="F9280" unitRef="USD">639461</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="C_20190101to20191231" decimals="0" id="F9287" unitRef="USD">-23370</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20191231" decimals="0" id="F9317" unitRef="USD">1834515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20181231" decimals="0" id="F9323" unitRef="USD">1857885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20201231" decimals="0" id="F9352" unitRef="USD">2473976</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:InterestPaidNet contextRef="C_20200101to20201231" decimals="0" id="F9528" unitRef="USD">117459</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312145202788" unitRef="USD">371420</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid contextRef="C_20200101to20201231" decimals="0" id="F9562" unitRef="USD">1600</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid contextRef="C_20190101to20191231" decimals="0" id="F9568" unitRef="USD">1600</us-gaap:IncomeTaxesPaid>
  <skye:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement contextRef="C_20200101to20201231" decimals="0" id="F9734" unitRef="USD">0</skye:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement>
  <skye:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312145244988" unitRef="USD">1584850</skye:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement>
  <skye:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20200101to20201231" decimals="0" id="F9683" unitRef="USD">0</skye:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement>
  <skye:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312145331970" unitRef="USD">716110</skye:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement>
  <skye:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210219181021897" unitRef="USD">0</skye:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement>
  <skye:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219181026415" unitRef="USD">193414</skye:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement>
  <skye:ExerciseOfWarrants contextRef="C_20200101to20201231" decimals="0" id="F9700" unitRef="USD">26250</skye:ExerciseOfWarrants>
  <skye:ExerciseOfWarrants contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312145337033" unitRef="USD">6077698</skye:ExerciseOfWarrants>
  <us-gaap:SharesIssued contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_43" unitRef="shares">133907747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_203" unitRef="shares">182895247</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_323" unitRef="shares">288074415</us-gaap:SharesIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_67" unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_611" unitRef="USD">680455</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_615" unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218214323196_619" unitRef="USD">680455</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_227" unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_2211" unitRef="USD">302742</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_2215" unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218214323196_2219" unitRef="USD">302742</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <skye:ShareIssuanceCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219182455373" unitRef="USD">80628</skye:ShareIssuanceCosts>
  <skye:ShareIssuanceCosts contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210219182841605" unitRef="USD">854078</skye:ShareIssuanceCosts>
  <skye:StockIssuedDuringPeriodSharesNetOfIssuanceCosts contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210219061846422" unitRef="shares">8000000</skye:StockIssuedDuringPeriodSharesNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodSharesNetOfIssuanceCosts contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_243" unitRef="shares">56333334</skye:StockIssuedDuringPeriodSharesNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_87" unitRef="USD">8000</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_811" unitRef="USD">1911372</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_815" unitRef="USD">0</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218214323196_819" unitRef="USD">1919372</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_247" unitRef="USD">56333</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_2411" unitRef="USD">6029256</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_2415" unitRef="USD">0</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218214323196_2419" unitRef="USD">6085589</skye:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_107" unitRef="USD">0</skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_1011" unitRef="USD">716110</skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_1015" unitRef="USD">0</skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218214323196_1019" unitRef="USD">716110</skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" decimals="0" id="Fxbrl_20210218155051794" unitRef="USD">722208</skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20210218153826446" unitRef="USD">716110</skye:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_127" unitRef="USD">0</skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_1211" unitRef="USD">1584850</skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_1215" unitRef="USD">0</skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218214323196_1219" unitRef="USD">1584850</skye:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <skye:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_143" unitRef="shares">187500</skye:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_283" unitRef="shares">312500</skye:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_147" unitRef="USD">187</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_1411" unitRef="USD">144188</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_1415" unitRef="USD">0</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218214323196_1419" unitRef="USD">144375</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_287" unitRef="USD">313</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_2811" unitRef="USD">26250</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_2815" unitRef="USD">0</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218214323196_2819" unitRef="USD">26563</skye:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <skye:FinancingSharesWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_163" unitRef="shares">40800000</skye:FinancingSharesWarrantExercise>
  <skye:FinancingValueWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_167" unitRef="USD">40800</skye:FinancingValueWarrantExercise>
  <skye:FinancingValueWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_1611" unitRef="USD">9972523</skye:FinancingValueWarrantExercise>
  <skye:FinancingValueWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_1615" unitRef="USD">0</skye:FinancingValueWarrantExercise>
  <skye:FinancingValueWarrantExercise contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218214323196_1619" unitRef="USD">10013323</skye:FinancingValueWarrantExercise>
  <skye:StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20210218214323196_263" unitRef="shares">48533334</skye:StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants>
  <skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20210218214323196_267" unitRef="USD">48533</skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants>
  <skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20210218214323196_2611" unitRef="USD">0</skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants>
  <skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20210218214323196_2615" unitRef="USD">0</skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants>
  <skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218214323196_2619" unitRef="USD">48533</skye:StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="C_20200101to20201231" id="F89bda070-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1. Nature of Operations and Business Activities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Skye Bioscience, Inc. (the &amp;#x201c;Company&amp;#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &amp;#x201c;Merger&amp;#x201d;) pursuant to which Nemus, a California corporation (&amp;#x201c;Nemus Sub&amp;#x201d;), became the Company&amp;#x2019;s wholly owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub to form a Nevada company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&amp;#x201c;Emerald Health Sciences&amp;#x201d;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &amp;#x201c;Emerald Financing&amp;#x201d;). As part of the transaction, the Company&amp;#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&amp;#x2019;s former CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&amp;#x2019;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Effective March 25, 2019, the Company changed its name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc. Effective January 19, 2021, the Company changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&amp;#x201c;EMBI Australia&amp;#x201d;), in order to qualify for the Australian government&amp;#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&amp;#x2019;s product candidates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&amp;#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 11 - Related Party Matters for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company is a biopharmaceutical company located in San Diego, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&amp;#x201c;UM&amp;#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The Company has incurred operating losses and negative cash flows from operations since inception and as of December 31, 2020, had an accumulated deficit of $38,733,981. The Company anticipates that it will continue to incur operating losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of December 31, 2020, the Company had unrestricted cash in the amount of $2,469,410. From January&amp;#160;1, 2021&amp;#160;through February 23, 2021, the Company received $3,019,800 in proceeds from the exercise of warrants (Note 13).&lt;/p&gt;
    &lt;/div&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company&amp;#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. As the Company approaches its first clinical trial, it expects to ramp up research and development spending and to increase cash used in operating activities. However, based on the Company&amp;#x2019;s expected cash requirements, without obtaining additional funding by the second half of 2021, management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &amp;#x201c;Credit Agreement&amp;#x201d;) with Emerald Health Sciences (See Note 4). On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &amp;#x201c;Amended Credit Agreement&amp;#x201d;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to &lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$20,000,000,&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:black"&gt;which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000 and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of the Company&amp;#x2019;s common stock, in accordance with the terms of the Credit Agreement.&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;During the year ended December 31, 2020, the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. Emerald Health Sciences elected that the fourth and fifth advances are not convertible into shares of Common Stock and no warrants were issued with the advances. The Company used the proceeds from the advances for general corporate and working capital purposes. As of December 31, 2020, the Company may draw down up to the remaining amount under the Amended Credit Agreement. However, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place, however, there is no guarantee of continued funding.&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &amp;#x201c;PPP Loan&amp;#x201d;) from City National Bank (the &amp;#x201c;PPP Loan Lender&amp;#x201d;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &amp;#x201c;PPP&amp;#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;CARES Act&amp;#x201d;) administered by the U.S. Small Business Administration (&amp;#x201c;SBA&amp;#x201d;) (Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On July 31, 2020, the Company entered into the August 2020 Financing (Note 5), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction were $6,085,589. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company is using the net proceeds of the offering for general corporate purposes, including working capital.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&amp;#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely. Upon the closing of the August 2020 Financing, the Company&amp;#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In December 2019, a novel strain of coronavirus (&amp;#x201c;COVID-19&amp;#x201d;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread around the world and throughout the United States and Australia, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&amp;#x2019;s ability to raise additional capital and obtain the necessary funds.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;&lt;/div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Notably, the Company relies on third party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of THCVHS from the second half of 2020 to the third quarter of 2021.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


  </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218130053522" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218114024436" unitRef="USD">6000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218155143304" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <skye:DrawDownsLoansInAggregatePrincipalAmount contextRef="C_20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218114712851" unitRef="USD">6000000</skye:DrawDownsLoansInAggregatePrincipalAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="INF" id="Fxbrl_20210218114819114" unitRef="shares">7500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_srtTitleOfIndividualAxis_skyePlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="0" id="Fxbrl_20210218204309454" unitRef="shares">8166667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="INF" id="Fxbrl_20200312151856612" unitRef="shares">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember" decimals="INF" id="Fxbrl_20210218202541944" unitRef="shares">48533334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="INF" id="Fxbrl_20210218202537430" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20200312154432742" unitRef="shares">40800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="INF" id="Fxbrl_20210219162130851" unitRef="shares">187500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember" decimals="INF" id="Fxbrl_202102191552246260" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_skyeEmeraldWarrantLiabilityMember" decimals="INF" id="Fxbrl_20210219155224626" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200429_usgaapTypeOfArrangementAxis_skyeAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218115002557" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" decimals="2" id="Fxbrl_20210218122757561" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" decimals="3" id="Fxbrl_20210218122934105" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218155840458" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218160230868" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218160904997" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="2" id="Fxbrl_20210218204246807" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="3" id="Fxbrl_20210218204251008" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember" decimals="2" id="Fxbrl_20210218151556326_xbrl_20191101141039417" unitRef="USD_per_Share">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember" decimals="2" id="Fxbrl_20210218151556345_xbrl_20201102173818937" unitRef="USD_per_Share">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="Fxbrl_20210218151556366_xbrl_20191101140403604" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="2" id="Fxbrl_20210218151556383_11042" unitRef="USD_per_Share">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="2" id="Fxbrl_20210218151556402_11065" unitRef="USD_per_Share">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="Fxbrl_20210218151556419_11088" unitRef="USD_per_Share">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="2" id="Fxbrl_20210218151556441_xbrl_20200810164306721" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20210218151556464_xbrl_20201102192846053" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" decimals="2" id="Fxbrl_20210218151556485_xbrl_20200810153549838" unitRef="USD_per_Share">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember" decimals="2" id="Fxbrl_20210218151556507_xbrl_20201102155538627" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="3" id="Fxbrl_20210218151556529_xbrl_20201102155548364" unitRef="USD_per_Share">0.075</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyPreFundedWarrantsMember" decimals="3" id="Fxbrl_20210218152043286" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember" decimals="2" id="Fxbrl_202102191552386560" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_skyeEmeraldWarrantLiabilityMember" decimals="2" id="Fxbrl_20210219155238656" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="2" id="Fxbrl_20210218163604535" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="2" id="Fxbrl_20210218163709707" unitRef="USD_per_Share">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="C_20200101to20201231_usgaapTypeOfArrangementAxis_skyeFourthAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218115603218" unitRef="USD">150000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="C_20200101to20201231_usgaapTypeOfArrangementAxis_skyeFifthAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218115627757" unitRef="USD">300000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20200422_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgramPromissoryNoteMember" decimals="0" id="Fxbrl_20210218121635210" unitRef="USD">116700</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160727601" unitRef="USD">4000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" decimals="0" id="Fxbrl_20210218162648212" unitRef="USD">116700</us-gaap:DebtInstrumentFaceAmount>
  <skye:NumberOfCommonStockUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" decimals="INF" id="Fxbrl_20210218122111658" unitRef="shares">56333334</skye:NumberOfCommonStockUnitsSold>
  <skye:NumberOfCommonStockUnitsSold contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="0" id="Fxbrl_20210218204117044" unitRef="shares">56333334</skye:NumberOfCommonStockUnitsSold>
  <skye:NumberOfPreFundedUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" decimals="INF" id="Fxbrl_20210218122314674" unitRef="shares">60333334</skye:NumberOfPreFundedUnitsSold>
  <skye:NumberOfPreFundedUnitsSold contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="0" id="Fxbrl_20210218204159012" unitRef="shares">60333334</skye:NumberOfPreFundedUnitsSold>
  <skye:GrossProceedsOfUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" decimals="0" id="Fxbrl_20210218122501874" unitRef="USD">6085589</skye:GrossProceedsOfUnitsSold>
  <skye:GrossProceedsOfUnitsSold contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="0" id="Fxbrl_20210218204235123" unitRef="USD">6939667</skye:GrossProceedsOfUnitsSold>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200731_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" id="Fxbrl_20210219060446205">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" id="Fxbrl_20210218204256110">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_srtTitleOfIndividualAxis_skyePlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" id="Fxbrl_20210219164025122">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218153945121_xbrl_20201102162641982_xbrl_20191101172810291">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218153945121_xbrl_20201102162710884_xbrl_20191101172810291">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218153945121_xbrl_20201102162729726_xbrl_20191101172810291">P4Y11M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218155119929_xbrl_20210218152443861_xbrl_20191101172810291">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218152443861_xbrl_20191101172810291">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218163525280_xbrl_20201102195350002">P2Y1M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20210218163525280_xbrl_20201102195452829">P3Y1M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember" id="Fxbrl_20210218163744112_xbrl_20200506143246008">P0Y7M20D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <skye:SeniorManagementCompensationPlanDescription contextRef="C_20200101to20201231" id="Fxbrl_20210218123820950">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&amp;#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely.</skye:SeniorManagementCompensationPlanDescription>
  <skye:SeniorManagementCompensationPlanDescription contextRef="C_20200801to20200831" id="Fxbrl_20210218123700586">Upon the closing of the August 2020 Financing, the Company&amp;#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.</skye:SeniorManagementCompensationPlanDescription>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20200101to20201231" id="F89bda071-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2. Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;em&gt;&lt;strong&gt;Cash, Cash Equivalents and Restricted Cash&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2020, and 2019, the Company has no cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Restricted cash on the balance sheet represents a certificate of deposit held by the Company&amp;#x2019;s bank as collateral for the Company&amp;#x2019;s credit cards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr style="height:15"&gt;
              &lt;td style="width:7%" valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:93%" valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).&lt;/p&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As of December 31, 2019, the fair value of the advances under the Amended Credit Agreement was $1,877,938, the carrying amount of the liability on December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Consolidated Balance Sheets. As of December 31, 2020, the Company estimates the fair value of the Amended Credit Agreement to be materially consistent with the fair value estimate as of December 31, 2019, plus the non-convertible advances made in 2020. This determination was based on the following considerations: (i) the Company has not experienced any significant change in its credit worthiness or operations year over year, (ii) there have been no repayments or convertible draws, (iii) the facility is closer to maturity, and (iv) the embedded conversion feature on the convertible advances is out-of-the-money at the reporting date. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).&lt;/p&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &amp;#x201c;NOLs&amp;#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&amp;#x2019;s Consolidated Statements of Comprehensive (Loss) Income in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&amp;#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020 and 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive (Loss) Income to offset pre-tax losses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Convertible Instruments&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815,&amp;#160;&lt;em&gt;Derivatives and Hedging Activities&lt;/em&gt;&amp;#160;(&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also follows ASC 480-10,&amp;#160;&lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt;&amp;#160;(&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Consolidated Statements of Comprehensive (Loss) Income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Debt Issuance Costs and Interest&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Research and Development Expenses and Licensed Technology&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third party contract research organizations and investigative sites, third party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, and other expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock-Based Compensation&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;em&gt;&lt;strong&gt;Expense&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr style="height:15"&gt;
              &lt;td style="width:4%"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:4%" valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividends - &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px 0px 0px 0in"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Comprehensive (Loss)&amp;#160;&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Income&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Comprehensive (loss) income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220&amp;#160;&lt;em&gt;Comprehensive Income&lt;/em&gt;&amp;#160;requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2020 and 2019, the comprehensive (loss) income was equal to net (loss) income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Net (Loss) &lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Income &lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&amp;#160;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Per Share of Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies FASB ASC No. 260,&amp;#160;&lt;em&gt;Earnings per Share&lt;/em&gt;&amp;#160;in calculating its basic and diluted net (loss) income per share. Basic net (loss) income per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net (loss) income per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net (loss) income per share, see Note 7 &amp;#x201c;Net (Loss) Income per Share of Common Stock.&amp;#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2020, the FASB issued ASU 2020-06,&amp;#160;&lt;em&gt;Debt&amp;#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#x2014;Contracts in Entity&amp;#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&amp;#x2019;s Own Equity&lt;/em&gt;. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The adoption of ASU 2020-06 will likely impact the way the Company calculates its (loss) earnings per share, result in expanded disclosures around convertible instruments and remove the requirement to assess and record beneficial conversion features. The impact from adoption will depend on whether the Company elects to early adopt this ASU. The Company currently plans to adopt the provisions of this ASU on the effective date. However, it reserves the right to early adopt these provisions.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, the FASB issued ASU No. 2019-12,&amp;#160;&lt;em&gt;Income Taxes (Topic 740)&lt;/em&gt;:&amp;#160;&lt;em&gt;Simplifying the Accounting for Income Taxes&lt;/em&gt;. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. Because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Recently Adopted Accounting Pronouncements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) intended to improve the effectiveness of disclosures around fair value measurements in the notes to financial statements. The ASU affects all entities that are required to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The Company early adopted certain provisions of this ASU upon issuance during the third quarter of 2018 and revised its disclosures to omit the disclosures removed by this ASU on a retrospective basis. As provided by the ASU, the Company elected to delay adoption of the additional disclosures until January 1, 2020, which include the range and weighed average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty until their effective date. Upon the effective date, the additional disclosures have been included on a prospective basis in the Company&amp;#x2019;s financial statements, as applicable. Because much of this information was disclosed prior to adoption this guidance did not have a substantial impact to the Company's disclosures in the notes to its financial statements and had no impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

  </us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172222083">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="C_20200101to20201231" id="Fxbrl_20200312172232079">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:UseOfEstimates>
  <skye:RisksAndUncertaintiesPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172236390">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </skye:RisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20200101to20201231" id="Fxbrl_20200312172242668">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;em&gt;&lt;strong&gt;Cash, Cash Equivalents and Restricted Cash&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2020, and 2019, the Company has no cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Restricted cash on the balance sheet represents a certificate of deposit held by the Company&amp;#x2019;s bank as collateral for the Company&amp;#x2019;s credit cards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172259843">
      &lt;div&gt;
        &lt;p style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr style="height:15"&gt;
              &lt;td style="width:7%" valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:93%" valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).&lt;/p&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As of December 31, 2019, the fair value of the advances under the Amended Credit Agreement was $1,877,938, the carrying amount of the liability on December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Consolidated Balance Sheets. As of December 31, 2020, the Company estimates the fair value of the Amended Credit Agreement to be materially consistent with the fair value estimate as of December 31, 2019, plus the non-convertible advances made in 2020. This determination was based on the following considerations: (i) the Company has not experienced any significant change in its credit worthiness or operations year over year, (ii) there have been no repayments or convertible draws, (iii) the facility is closer to maturity, and (iv) the embedded conversion feature on the convertible advances is out-of-the-money at the reporting date. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).&lt;/p&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="C_20191231" decimals="0" id="Fxbrl_20210218142732027" unitRef="USD">1877938</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172311249">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &amp;#x201c;NOLs&amp;#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&amp;#x2019;s Consolidated Statements of Comprehensive (Loss) Income in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&amp;#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020 and 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive (Loss) Income to offset pre-tax losses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:DerivativesPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172318650">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Convertible Instruments&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815,&amp;#160;&lt;em&gt;Derivatives and Hedging Activities&lt;/em&gt;&amp;#160;(&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also follows ASC 480-10,&amp;#160;&lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt;&amp;#160;(&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:DerivativesPolicyTextBlock>
  <skye:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172323957">
      &lt;div&gt;
        &lt;p style="margin:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Consolidated Statements of Comprehensive (Loss) Income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </skye:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172327653">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Debt Issuance Costs and Interest&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:DebtPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20200101to20201231" id="Fxbrl_20200312172333574">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Research and Development Expenses and Licensed Technology&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third party contract research organizations and investigative sites, third party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, and other expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_20200101to20201231" id="Fxbrl_20200312172343509">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock-Based Compensation&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;em&gt;&lt;strong&gt;Expense&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr style="height:15"&gt;
              &lt;td style="width:4%"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:4%" valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="height:15"&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividends - &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172350180">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Comprehensive (Loss)&amp;#160;&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Income&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Comprehensive (loss) income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220&amp;#160;&lt;em&gt;Comprehensive Income&lt;/em&gt;&amp;#160;requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2020 and 2019, the comprehensive (loss) income was equal to net (loss) income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172355667">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Net (Loss) &lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Income &lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&amp;#160;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Per Share of Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies FASB ASC No. 260,&amp;#160;&lt;em&gt;Earnings per Share&lt;/em&gt;&amp;#160;in calculating its basic and diluted net (loss) income per share. Basic net (loss) income per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net (loss) income per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net (loss) income per share, see Note 7 &amp;#x201c;Net (Loss) Income per Share of Common Stock.&amp;#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312172415604">
      &lt;div&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2020, the FASB issued ASU 2020-06,&amp;#160;&lt;em&gt;Debt&amp;#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#x2014;Contracts in Entity&amp;#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&amp;#x2019;s Own Equity&lt;/em&gt;. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The adoption of ASU 2020-06 will likely impact the way the Company calculates its (loss) earnings per share, result in expanded disclosures around convertible instruments and remove the requirement to assess and record beneficial conversion features. The impact from adoption will depend on whether the Company elects to early adopt this ASU. The Company currently plans to adopt the provisions of this ASU on the effective date. However, it reserves the right to early adopt these provisions.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, the FASB issued ASU No. 2019-12,&amp;#160;&lt;em&gt;Income Taxes (Topic 740)&lt;/em&gt;:&amp;#160;&lt;em&gt;Simplifying the Accounting for Income Taxes&lt;/em&gt;. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. Because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Recently Adopted Accounting Pronouncements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) intended to improve the effectiveness of disclosures around fair value measurements in the notes to financial statements. The ASU affects all entities that are required to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The Company early adopted certain provisions of this ASU upon issuance during the third quarter of 2018 and revised its disclosures to omit the disclosures removed by this ASU on a retrospective basis. As provided by the ASU, the Company elected to delay adoption of the additional disclosures until January 1, 2020, which include the range and weighed average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty until their effective date. Upon the effective date, the additional disclosures have been included on a prospective basis in the Company&amp;#x2019;s financial statements, as applicable. Because much of this information was disclosed prior to adoption this guidance did not have a substantial impact to the Company's disclosures in the notes to its financial statements and had no impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="C_20200101to20201231" id="F89bf9c41-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4. Debt&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px 0px 0px 0in"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;em&gt;Multi-Draw Credit Agreement- Related Party&lt;/em&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;The Company&amp;#x2019;s Debt with Emerald Health Sciences consists of the following:&lt;/p&gt;
        &lt;div&gt;
          &lt;div&gt;

              &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%"&gt;&amp;#160;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of&lt;/strong&gt; &lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Conversion&lt;/strong&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Total principal value of convertible debt&amp;#x2014;related party&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.40&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,014,500&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,014,500&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Unamortized debt discount&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,079,821&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,622,344&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Unamortized debt issuance costs&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(3,576&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(5,086&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Carrying value of total convertible debt - related party&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;931,103&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Total principal value of non-convertible debt&amp;#x2014;related party&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;n/a&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;450,000&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Total carrying value of advances under the multi-draw credit agreement&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,381,103&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;

            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 11). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. As of August 2020, interest is no longer being deferred as a result of the August 2020 Financing. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Amended Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&amp;#x2019; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of December 31, 2020, the unused portion of the credit facility is $13,550,000. The Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place; however, there is no guarantee of continued funding under the Amended Credit Agreement..&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&amp;#x2019;s stockholders (See Note 3).&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&amp;#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision were remeasured at fair value in subsequent periods in the Company&amp;#x2019;s Consolidated Balance Sheets.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;During the year ended December 31, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;During the year ended December 31, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. Emerald Health Sciences has elected that the fourth and fifth advances will not be convertible into shares of the Company&amp;#x2019;s common stock and gave notice to the Company that no warrants will be issued in connection with the advances.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;/div&gt;&lt;/div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;For the years ended December 31, 2020 and 2019, the effective interest rate related to the convertible portion of the Amended Credit Agreement was 98.01% and 32.05%, respectively. As of December 31, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 1.76 years. As of December 31, 2020, the fair value of the shares underlying the convertible advances under the Amended Credit agreement was $201,450. As of December 31, 2020, the if-converted value did not exceed the principal balance.&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;em&gt;PPP Loan&lt;/em&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing on the date the amount of forgiveness determined under section 1106 of the CARES Act is remitted to the Company, but in no event ten months after the last day of the covered period if the Company fails to apply for loan forgiveness. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before October 9, 2020.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 40% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;em&gt;Interest Expense&lt;/em&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;The Company&amp;#x2019;s interest expense consists of the following:&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Related party interest expense &amp;#x2013; stated rate&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;161,546&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;371,420&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;PPP loan interest expense &amp;#x2013; stated rate&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;806&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Non-cash interest expense:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px 0px 0px 30px;text-align:justify"&gt;Amortization of debt discount&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;542,523&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;616,383&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px 0px 0px 30px;text-align:justify"&gt;Amortization of transaction costs&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;1,510&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;12,910&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;706,385&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,000,713&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;



    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218165258023">
              &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%"&gt;&amp;#160;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of&lt;/strong&gt; &lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Conversion&lt;/strong&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Total principal value of convertible debt&amp;#x2014;related party&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.40&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,014,500&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,014,500&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Unamortized debt discount&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,079,821&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,622,344&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Unamortized debt issuance costs&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(3,576&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(5,086&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Carrying value of total convertible debt - related party&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;931,103&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;Total principal value of non-convertible debt&amp;#x2014;related party&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;n/a&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;450,000&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Total carrying value of advances under the multi-draw credit agreement&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,381,103&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
            </us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="2" id="Fxbrl_20210218164859188_xbrl_20210218163436643" unitRef="USD_per_Share">0.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="2" id="Fxbrl_20210218163617519" unitRef="USD_per_Share">0.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859188_xbrl_20210218163607287" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859188_xbrl_20210218163644168" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859200_xbrl_20210218163703795" unitRef="USD">1079821</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859200_xbrl_20210218163835101" unitRef="USD">1622344</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859207_xbrl_20210218163910695_xbrl_20210218163703795" unitRef="USD">3576</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859207_xbrl_20210218163910695_xbrl_20210218163835101" unitRef="USD">5086</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859214_xbrl_20210218163944319_xbrl_20210218163910695_xbrl_20210218163703795" unitRef="USD">931103</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859214_xbrl_20210218163944319_xbrl_20210218163910695_xbrl_20210218163835101" unitRef="USD">387070</us-gaap:ConvertibleDebtCurrent>
  <skye:CurrentConvertibleDebtExcludingNoncurrentPortion contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859229_xbrl_20210218164031497_xbrl_20210218164004505_xbrl_20210218163944319_xbrl_20210218163910695_xbrl_20210218163703795" unitRef="USD">1381103</skye:CurrentConvertibleDebtExcludingNoncurrentPortion>
  <skye:CurrentConvertibleDebtExcludingNoncurrentPortion contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember" decimals="0" id="Fxbrl_20210218164859229_xbrl_20210218164031497_xbrl_20210218164004505_xbrl_20210218163944319_xbrl_20210218163910695_xbrl_20210218163835101" unitRef="USD">387070</skye:CurrentConvertibleDebtExcludingNoncurrentPortion>
  <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218152244626" unitRef="USD">5000000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
  <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease contextRef="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218155044520" unitRef="USD_per_Share">0.25</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="C_20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218155247598" unitRef="pure">0.07</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:DebtInstrumentMaturityDate contextRef="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" id="Fxbrl_20210218155319577">2022-10-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="C_20200401to20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" id="Fxbrl_20210218162549319">2022-04-24</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218155402688" unitRef="USD">13550000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
  <skye:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase contextRef="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218155743483" unitRef="pure">0.50</skye:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase>
  <us-gaap:WarrantExercisePriceDecrease contextRef="C_20181001to20181005_deiLegalEntityAxis_skyeEmeraldFinancingMember_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20210218155920202" unitRef="USD_per_Share">0.35</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="C_20181101to20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160016371" unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160619370" unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="C_20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160148345" unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="INF" id="Fxbrl_20210218160829949" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <skye:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="C_20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160323712" unitRef="USD">1684920</skye:AllocationOfDebtOnBasisOfRelativeFairValue>
  <skye:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160927956" unitRef="USD">3283890</skye:AllocationOfDebtOnBasisOfRelativeFairValue>
  <skye:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="C_20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160410162" unitRef="USD">315080</skye:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <skye:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218161017119" unitRef="USD">716110</skye:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="C_20181101to20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160446018" unitRef="USD">90080</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218161048473" unitRef="USD">1584850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DerivativeLiabilities contextRef="C_20181130_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218160511891" unitRef="USD">204102</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218161122053" unitRef="USD">516058</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161017164_xbrl_20200810100656150_xbrl_20200506151738328" unitRef="USD">90797</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161017164_xbrl_20200810100656150_xbrl_20200506162919091" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161017200_xbrl_20201102194617241" unitRef="USD">276024</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161017200_xbrl_20200810100656174_xbrl_20200506162930332" unitRef="USD">38567</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161017235_xbrl_20201102194730737" unitRef="USD">134579</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161017235_xbrl_20200810100656193_xbrl_20200506162943171" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20210218161017270_xbrl_20201102194840835" unitRef="USD">501400</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20201231" decimals="0" id="Fxbrl_20210218161017270_xbrl_20200810100656211_xbrl_20200506162955205" unitRef="USD">38567</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161646888" unitRef="USD">219453</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161147665_xbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164212355" unitRef="USD">15251413</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161147691_xbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164223242" unitRef="USD">487500</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231" decimals="0" id="Fxbrl_20210218161147724_xbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164357066" unitRef="USD">15958366</us-gaap:DerivativeLiabilities>
  <skye:FairValueOfWarrantLiabilityInExcessForProceeds contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218161153565" unitRef="USD">322644</skye:FairValueOfWarrantLiabilityInExcessForProceeds>
  <us-gaap:ProceedsFromWarrantExercises contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218161227687" unitRef="USD">3985500</us-gaap:ProceedsFromWarrantExercises>
  <skye:CreditFacilityEffectedFourthAdvance contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20210218161448497" unitRef="USD">150000</skye:CreditFacilityEffectedFourthAdvance>
  <skye:CreditFacilityEffectedFifthAdvance contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20210218161527443" unitRef="USD">300000</skye:CreditFacilityEffectedFifthAdvance>
  <skye:ConvertibleMultiDrawCreditAgreementIssuanceCosts contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218161632292" unitRef="USD">63007</skye:ConvertibleMultiDrawCreditAgreementIssuanceCosts>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="C_20201231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="4" id="Fxbrl_20210218162136798" unitRef="pure">0.9801</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="C_20191231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="4" id="Fxbrl_20210218162158346" unitRef="pure">0.3205</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <skye:UnamortizedDebtDiscountPeriod contextRef="C_20200101to20201231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" id="Fxbrl_20210218161752223">P1Y9M3D</skye:UnamortizedDebtDiscountPeriod>
  <skye:FairValueOfSharesUnderlyingConvertibleDebt1 contextRef="C_20201231_usgaapTypeOfArrangementAxis_skyeMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20210218162247394" unitRef="USD">201450</skye:FairValueOfSharesUnderlyingConvertibleDebt1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" decimals="4" id="Fxbrl_20210218162739517" unitRef="pure">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <skye:PayrollCostExcludeCompensation contextRef="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" decimals="0" id="Fxbrl_20210218162821783" unitRef="USD">100000</skye:PayrollCostExcludeCompensation>
  <skye:PercentageOfForgivenessAmountForNonPayrollCost contextRef="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" decimals="2" id="Fxbrl_20210219134152708" unitRef="pure">0.40</skye:PercentageOfForgivenessAmountForNonPayrollCost>
  <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" decimals="0" id="Fxbrl_20210218162900524" unitRef="USD">100000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
  <skye:PercentOfReductionInAnnualSalary contextRef="C_20200424_usgaapDebtInstrumentAxis_skyePaycheckProtectionProgrammeMember" decimals="2" id="Fxbrl_20210218162845559" unitRef="pure">0.25</skye:PercentOfReductionInAnnualSalary>
  <skye:ScheduleOfInterestExpenseTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218165134976">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Related party interest expense &amp;#x2013; stated rate&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;161,546&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;371,420&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;PPP loan interest expense &amp;#x2013; stated rate&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;806&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Non-cash interest expense:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px 0px 0px 30px;text-align:justify"&gt;Amortization of debt discount&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;542,523&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;616,383&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px 0px 0px 30px;text-align:justify"&gt;Amortization of transaction costs&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;1,510&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;12,910&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;706,385&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,000,713&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        </skye:ScheduleOfInterestExpenseTableTextBlock>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218164120443" unitRef="USD">161546</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218164215766" unitRef="USD">371420</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseDebt contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218164243035_xbrl_20210218164120443" unitRef="USD">806</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218164243035_xbrl_20210218164215766" unitRef="USD">0</us-gaap:InterestExpenseDebt>
  <skye:AmortizationOfDebtDiscount contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218164309675_xbrl_20210218164243035_xbrl_20210218164120443" unitRef="USD">542523</skye:AmortizationOfDebtDiscount>
  <skye:AmortizationOfDebtDiscount contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218164309675_xbrl_20210218164243035_xbrl_20210218164215766" unitRef="USD">616383</skye:AmortizationOfDebtDiscount>
  <skye:AmortizationOfTransactionCosts contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218164333251_xbrl_20210218164309675_xbrl_20210218164243035_xbrl_20210218164120443" unitRef="USD">1510</skye:AmortizationOfTransactionCosts>
  <skye:AmortizationOfTransactionCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218164333251_xbrl_20210218164309675_xbrl_20210218164243035_xbrl_20210218164215766" unitRef="USD">12910</skye:AmortizationOfTransactionCosts>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_20200101to20201231" id="F89bfc350-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;5. Stockholders&amp;#x2019; Equity (Deficit) and Capitalization&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;em&gt;Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;em&gt;August 2020 Financing&lt;/em&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On July 31, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the issuance and sale of securities, with H.C. Wainwright &amp;amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and 60,333,334 pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, in a registered public offering which closed on August 4, 2020 (the &amp;#x201c;August 2020 Financing&amp;#x201d;). The common units and pre-funded units were sold at a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The common stock warrants have a term of five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full (Note 3).&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;In connection with the August 2020 Financing, the Company incurred issuance costs of $854,078, for net proceeds of $6,085,589. Additionally, the Company issued warrants to purchase 8,166,667 shares of common stock to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years.&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;November 2019 Common Stock Offering&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;In November 2019, the Company sold in a registered direct offering an aggregate of 8,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 8,000,000 shares of common stock (Note 3). The aggregate net proceeds of the transaction were $1,919,372.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;em&gt;Warrant Exercises&lt;/em&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;During the year ended December 31, 2020, the Pre-Funded Warrant holders exercised 48,533,334 warrants with an intrinsic value of $2,104,667, which resulted in the issuance of 48,533,334 shares of common stock.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;During the year ended December 31, 2020, the Series B Warrant holders exercised 312,500 warrants with an intrinsic value of $26,563, which resulted in the issuance of 312,500 shares of common stock.&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2019, Emerald Health Sciences exercised 40,800,000 2018 Emerald Financing Warrants with an intrinsic value of $4,284,000, which resulted in the issuance of 40,800,000 shares of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;During the year ended December 31, 2019, the Series B Common Stock Warrant holders exercised 187,500 warrants with an intrinsic value of $144,375, which resulted in the issuance of 187,500 shares of common stock.&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" id="Fxbrl_20210218204344355">each consisting of one share of common stock and one warrant to purchase one share of common stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" id="Fxbrl_20210218204353268">each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <skye:CommonUnitSoldPricePerUnit contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="2" id="Fxbrl_20210218204243272" unitRef="USD_per_Share">0.06</skye:CommonUnitSoldPricePerUnit>
  <skye:PreFundedUnitSoldPricePerUnit contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="3" id="Fxbrl_20210218204238989" unitRef="USD_per_Share">0.059</skye:PreFundedUnitSoldPricePerUnit>
  <skye:PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering contextRef="C_20200701to20200731_deiLegalEntityAxis_skyeInstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_srtTitleOfIndividualAxis_skyePlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapTypeOfArrangementAxis_skyeSecuritiesPurchaseAgreementMember" decimals="2" id="Fxbrl_20210218204312907" unitRef="pure">0.07</skye:PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="C_20191101to20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="INF" id="Fxbrl_20200312151658410" unitRef="shares">8000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="C_20210101to20210223_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="INF" id="Fxbrl_20210224011652007" unitRef="shares">11800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="C_20210101to20210223_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="INF" id="Fxbrl_20210224011718708" unitRef="shares">50133334</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare contextRef="C_20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="3" id="Fxbrl_20200312151838053" unitRef="USD_per_Share">0.001</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="C_20191101to20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="0" id="Fxbrl_20200312151938092" unitRef="USD">1919372</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <skye:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember" decimals="INF" id="Fxbrl_20210218202513503" unitRef="shares">48533334</skye:ClassOfWarrantOrRightWarrantsExercise>
  <skye:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="INF" id="Fxbrl_20210218202525076" unitRef="shares">312500</skye:ClassOfWarrantOrRightWarrantsExercise>
  <skye:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20200312154250875" unitRef="shares">40800000</skye:ClassOfWarrantOrRightWarrantsExercise>
  <skye:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="INF" id="Fxbrl_20210219162111504" unitRef="shares">187500</skye:ClassOfWarrantOrRightWarrantsExercise>
  <skye:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember" decimals="0" id="Fxbrl_20201102204740774" unitRef="shares">40800000</skye:ClassOfWarrantOrRightWarrantsExercise>
  <skye:IntrinsicValueOfWarrantExercises contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember" decimals="0" id="Fxbrl_20210218202555288" unitRef="USD">2104667</skye:IntrinsicValueOfWarrantExercises>
  <skye:IntrinsicValueOfWarrantExercises contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="0" id="Fxbrl_20210218202550985" unitRef="USD">26563</skye:IntrinsicValueOfWarrantExercises>
  <skye:IntrinsicValueOfWarrantExercises contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="0" id="Fxbrl_20200312154321711" unitRef="USD">4284000</skye:IntrinsicValueOfWarrantExercises>
  <skye:IntrinsicValueOfWarrantExercises contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="0" id="Fxbrl_20210218203509398" unitRef="USD">144375</skye:IntrinsicValueOfWarrantExercises>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_20200101to20201231" id="F89bfc351-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;6. Stock-Based Compensation&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On October 31, 2014, after the closing of the Merger, the Board approved the Company&amp;#x2019;s 2014 Omnibus Incentive Plan (the &amp;#x201c;2014 Plan&amp;#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. In August 2020, the Company approved Amendment No. 2 to the 2014 Plan, which increased the share reserve by an additional 7,876,835 shares over the 10% of the number of issued and outstanding shares of common stock and removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of December 31, 2020, the shares available for future grant under the 2014 Plan are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares Available for Grant&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Available as of December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;13,128,381&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Share pool increase&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;18,394,752&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,837,407&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5,830,235&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(26,400,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Available as of December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;12,790,775&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;Stock Options &lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options granted under the 2014 Plan expire no later than ten years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&amp;#x2019;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to five years from the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The following is a summary of option activities under the Company&amp;#x2019;s 2014 Plan for the year ended December 31, 2020:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                  &lt;tbody&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Average Remaining&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Intrinsic&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Value*&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Outstanding, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;3,317,642&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.33&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;8.34&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;26,400,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(5,830,235&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(1,837,407&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Outstanding, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;22,050,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.06&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;9.52&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Exercisable, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;3,465,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.15&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;8.88&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Vested and expected to vest, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;22,050,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.06&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;9.52&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                  &lt;/tbody&gt;
                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&amp;#x2019;s stock exceeded the exercise price of the stock options at December 31, 2020 for those stock options for which the quoted market price was in excess of the exercise price (&amp;#x201c;in-the-money options&amp;#x201d;).&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2020 and 2019 was $0.04 and $0.22, respectively. The total fair value of the stock options that vested during the years ended December 31, 2020 and 2019 was $168,168 and $473,030, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                  &lt;tbody&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2"&gt;
                        &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.28&amp;#x2014;0.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2"&gt;
                        &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.65&amp;#x2014;6.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2"&gt;
                        &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;92.51&amp;#x2014;107.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;93.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                  &lt;/tbody&gt;
                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;

    &lt;/div&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;Restricted Stock Awards &lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 30, 2020, 643,501 restricted stock awards (&amp;#x201c;RSAs&amp;#x201d;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. As of December 31, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;There was no restricted stock award (&amp;#x201c;RSA&amp;#x201d;) activity under the Company&amp;#x2019;s 2014 Plan during the year ended December 31, 2019.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;&lt;strong&gt;Awards Granted Outside the 2014 Plan&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;Options&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&amp;#x2019;s former CFO. As of December 31, 2020, an additional 869,144 options vested and outstanding with a weighted average exercise price of $0.25 were cancelled unexercised.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;There was no option activity outside of the 2014 Plan during the year ended December 31, 2019.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The total fair value of stock options that vested during the years ended December 31, 2020 and 2019 were $18,252 and $54,756, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;Restricted Stock Awards&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The following is a summary of RSA activity outside of the Company&amp;#x2019;s 2014 Plan during the year ended December 31, 2020:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div&gt;&amp;#160;&lt;/div&gt;
      &lt;div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="FONT-SIZE:10pt" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Date Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.19&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Released&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(450,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Unvested, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. The Company recognized stock-based compensation expense, including compensation expense for RSAs discussed above, in its Consolidated Statements of Comprehensive (Loss) Income as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

          &lt;div&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
              &lt;tbody&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;&amp;#160;&lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;93,545&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;209,197&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;680,455&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;302,742&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;680,455&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/tbody&gt;
            &lt;/table&gt;
          &lt;/div&gt;

        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The total amount of unrecognized compensation cost was $688,410 as of December 31, 2020. This amount will be recognized over a weighted-average period of 3.79 years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="C_20141031_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F19992_3200000" unitRef="shares">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <skye:PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares contextRef="C_20141001to20141031_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="Fxbrl_20210218113135917" unitRef="pure">0.10</skye:PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="C_20141001to20141031_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20210218113322989" unitRef="shares">7876835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="F8a09ebb0-2de8-11ea-add8-41ed81237e2f">
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares Available for Grant&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Available as of December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;13,128,381&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Share pool increase&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;18,394,752&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,837,407&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5,830,235&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(26,400,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Available as of December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;12,790,775&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated contextRef="C_20191231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20014_870000" unitRef="shares">13128381</us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated>
  <us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated contextRef="C_20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20067_9142273" unitRef="shares">12790775</us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="C_20200101to20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20026" unitRef="shares">18394752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C_20200101to20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20036" unitRef="shares">1837407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20281_427000" unitRef="shares">1837407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="C_20200101to20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20046" unitRef="shares">5830235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20251_48000" unitRef="shares">5830235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20200101to20201231_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20056_2393501" unitRef="shares">26400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20220" unitRef="shares">26400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20200313125351664">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                  &lt;tbody&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Average Remaining&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Intrinsic&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Value*&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Outstanding, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;3,317,642&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.33&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;8.34&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;26,400,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(5,830,235&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(1,837,407&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:1px solid;width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Outstanding, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;22,050,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.06&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;9.52&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Exercisable, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;3,465,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.15&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;8.88&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Vested and expected to vest, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;22,050,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.06&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;9.52&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                  &lt;/tbody&gt;
                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&amp;#x2019;s stock exceeded the exercise price of the stock options at December 31, 2020 for those stock options for which the quoted market price was in excess of the exercise price (&amp;#x201c;in-the-money options&amp;#x201d;).&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C_20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20150_1130000" unitRef="shares">3317642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20313_2405000" unitRef="shares">22050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C_20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="F20159_060" unitRef="USD_per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="F20322_033" unitRef="USD_per_Share">0.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20200312110611626">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20200312110624774">P9Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="F20227" unitRef="USD_per_Share">0.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="F20257" unitRef="USD_per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="F20287" unitRef="USD_per_Share">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="F20341_182000" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="INF" id="F20355_859417" unitRef="shares">3465000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="F20364_037" unitRef="USD_per_Share">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20210219125922473">P8Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="F20383_36458" unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20210218114905319_20355_859417" unitRef="shares">22050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="C_20201231" decimals="INF" id="Fxbrl_20210218130741783" unitRef="shares">869144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="Fxbrl_20210218114905319_20364_037" unitRef="USD_per_Share">0.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="C_20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20210218125053538" unitRef="USD_per_Share">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20210218114905319_xbrl_20200312110807381">P9Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="C_20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20210218114905319_20383_36458" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="3" id="Fxbrl_20200312101835309" unitRef="USD_per_Share">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="2" id="Fxbrl_20200312110908864" unitRef="USD_per_Share">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20200312121607438" unitRef="USD">168168</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20200312121620696" unitRef="USD">473030</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218130917632" unitRef="USD">18252</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218131055219" unitRef="USD">54756</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210219193621452">
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                  &lt;tbody&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px"&gt;
                      &lt;td&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2"&gt;
                        &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.28&amp;#x2014;0.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2"&gt;
                        &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.65&amp;#x2014;6.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                      &lt;td valign="top"&gt;
                        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="2"&gt;
                        &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;92.51&amp;#x2014;107.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                        &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap"&gt;
                        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;93.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                  &lt;/tbody&gt;
                &lt;/table&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20200312112447768" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20200312113028285" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20210219024655575" unitRef="pure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20210219024826890" unitRef="pure">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20210219130205161" unitRef="pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20210219025013906">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20210219025216309">P6Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" id="Fxbrl_20200312113356167">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20210219025447435" unitRef="pure">0.9251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20210219025456665" unitRef="pure">1.0787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_skyeOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20210219130142620" unitRef="pure">0.9372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20210218124526207" unitRef="shares">643501</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="C_20200101to20201231" decimals="INF" id="Fxbrl_20210218130415138" unitRef="shares">325929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="C_20200101to20201231" decimals="2" id="Fxbrl_20210218130447094" unitRef="USD_per_Share">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="C_20201231" decimals="2" id="Fxbrl_20210218130844839" unitRef="USD_per_Share">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210219193829619">
          &lt;div&gt;
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="FONT-SIZE:10pt" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Date Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.19&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Released&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(450,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Unvested, December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20200312104751322" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="F20827_900000" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20200312104716108" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="F20836_019" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="F20792" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="F20799" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="F20809_1600000" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="F20815" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218142052985">
          &lt;div&gt;
            &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
              &lt;tbody&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;&amp;#160;&lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;93,545&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;209,197&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;680,455&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;302,742&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;680,455&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/tbody&gt;
            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="C_20201231" decimals="0" id="F20845_748616" unitRef="USD">688410</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20200101to20201231" id="Fxbrl_20200312113821221">P3Y9M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EarningsPerShareTextBlock contextRef="C_20200101to20201231" id="F89bfc352-2de8-11ea-add8-41ed81237e2f">
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;7. Net (Loss) Income Per Share of Common Stock&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net (loss) income per share computations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;div&gt;
      &lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Loss&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,560,699&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basic EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,560,699&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;230,746,878&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(0.03&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Effect of Dilutive Securities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants &amp;#x2013; liability classified&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;(345,473&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;674,095&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss available to common stockholders + assumed conversions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,906,172&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;231,420,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong style="font-family:Times New Roman, Times, serif;font-size:10pt"&gt;0.03&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basic EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;135,154,931&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;0.01&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Effect of Dilutive Securities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;858,856&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;392,784&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;447,431&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants &amp;#x2013; liability classified&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(9,250,612&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,706,263&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss available to common stockholders + assumed conversions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(8,198,787&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;169,560,265&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(0.05&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;

    &lt;/div&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;22,050,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,119,931&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;234,645&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Common shares underlying convertible debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,126,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,036,250&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;145,039,240&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,712,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
      &lt;/div&gt;

  </us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200318174619197">
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Loss&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,560,699&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basic EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,560,699&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;230,746,878&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(0.03&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Effect of Dilutive Securities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants &amp;#x2013; liability classified&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;(345,473&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;674,095&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss available to common stockholders + assumed conversions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,906,172&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;231,420,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong style="font-family:Times New Roman, Times, serif;font-size:10pt"&gt;0.03&lt;/strong&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                &lt;tbody&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basic EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td colspan="2" style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;135,154,931&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;0.01&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Effect of Dilutive Securities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;858,856&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;392,784&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;447,431&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants &amp;#x2013; liability classified&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(9,250,612&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32,706,263&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:9%"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                    &lt;td valign="top"&gt;
                      &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss available to common stockholders + assumed conversions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(8,198,787&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;169,560,265&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="width:1%;white-space:nowrap"&gt;
                      &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(0.05&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/tbody&gt;
              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218144358037_xbrl_20200318165704226" unitRef="USD">-6560699</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218144846033_xbrl_20210218144358037_xbrl_20200318165704226" unitRef="USD">1051825</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:DilutiveSecurities contextRef="C_20200101to20201231_skyeDilutedSecuritiesAxis_skyeWarrantsLiabilityClassifiedMember" decimals="0" id="Fxbrl_20210219162746346" unitRef="USD">-345473</us-gaap:DilutiveSecurities>
  <us-gaap:DilutiveSecurities contextRef="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeWarrantsLiabilityClassifiedMember" decimals="0" id="Fxbrl_20210218165006926_xbrl_20210218144846033_xbrl_20210218144358037_xbrl_20200318165716853" unitRef="USD">-9250612</us-gaap:DilutiveSecurities>
  <skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20200101to20201231_skyeDilutedSecuritiesAxis_skyeWarrantsLiabilityClassifiedMember" decimals="0" id="Fxbrl_20200318174247813" unitRef="shares">674095</skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeUnvestedRestrictedStockMember" decimals="INF" id="Fxbrl_20210218144950096" unitRef="shares">858856</skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeOptionsMember" decimals="INF" id="Fxbrl_20210218145001674" unitRef="shares">392784</skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeWarrantsMember" decimals="INF" id="Fxbrl_20210218145006178" unitRef="shares">447431</skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_skyeDilutedSecuritiesAxis_skyeWarrantsLiabilityClassifiedMember" decimals="0" id="Fxbrl_20210218165006926_xbrl_20210218144846033_xbrl_20210218144358037_xbrl_20200318165732625" unitRef="shares">32706263</skye:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <skye:NetLossAdjustedBalance contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200318165704226" unitRef="USD">-6906172</skye:NetLossAdjustedBalance>
  <skye:NetLossAdjustedBalance contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218165009663_xbrl_20210218144846033_xbrl_20210218144358037_xbrl_20200318165704226" unitRef="USD">-8198787</skye:NetLossAdjustedBalance>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_20200101to20201231" id="F8a219260-2de8-11ea-add8-41ed81237e2f">
      &lt;div&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;22,050,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,119,931&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;234,645&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Common shares underlying convertible debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,126,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,036,250&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;145,039,240&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,712,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" decimals="0" id="F20972" unitRef="shares">22050000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" decimals="0" id="F20979" unitRef="shares">4119931</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockMember" decimals="0" id="F20989" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockMember" decimals="0" id="F20996" unitRef="shares">234645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapConvertibleDebtSecuritiesMember" decimals="0" id="F21006" unitRef="shares">5126343</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapConvertibleDebtSecuritiesMember" decimals="0" id="F21013" unitRef="shares">5036250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" decimals="0" id="F21040" unitRef="shares">145039240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" decimals="0" id="F21047" unitRef="shares">20712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20200101to20201231" id="F89bfea60-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;8. Income Taxes &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The components of (loss) income before the income tax provision consist of the following:&lt;/p&gt;
    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
              &lt;tbody&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Year Ended &lt;/strong&gt;&lt;/p&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;United States&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(6,556,280&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,120,521&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Foreign&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(2,819&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(67,096&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Pre-tax (loss) income from operations &lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;(6,559,099&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,053,425&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/tbody&gt;
            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The Company is subject to taxation in the United States, California and Australia. The Company&amp;#x2019;s tax years for 2017 (federal), 2016 (California) and 2019 (Australia) and forward are subject to examination by the United States, California and Australia tax authorities. However, to the extent allowed by law, the taxing authorities may have the right to examine periods where NOLs and credits were generated and carried forward and make adjustments up to the amount of the NOL and credit carryforwards. &amp;#160;The Company is not currently under examination by any jurisdiction.&lt;/p&gt;
    &lt;/div&gt;
    &lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2020, the Company had federal and California NOLs aggregating $30,475,657 and $30,310,672, respectively.&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;If not used, $13,213,037 of Federal NOLs and $30,310,672 of state NOLs will begin to expire in 2033.&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt; $17,262,620&amp;#160;&lt;/span&gt;&lt;/span&gt;of federal NOLs will carry forward indefinitely subject to an 80% limitation against taxable income. At December 31, 2020, the Company had Australia NOLs aggregating&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt; $43,349 which do not expire.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;At December 31, 2020, the Company had federal and California research credit carryforwards of approximately $76,632 and $40,528, respectively. The federal research credit carry forwards will begin to expire in 2040, unless previously utilized and the California research credits will carry forward indefinitely.&amp;#160;The Company&amp;#x2019;s NOLs and research credit carryforwards are subject to a FIN 48 reserve.&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;Utilization of the domestic NOL will be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, respectively.&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;In general, an &amp;#x201c;ownership change&amp;#x201d; as defined by Section 382 of the Code&amp;#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&amp;#x2019;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. While the Company has not performed a Section 382 study, multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company&amp;#x2019;s effective tax rate.&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Current deferred tax assets/(liabilities): &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;State taxes&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;336&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;336&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;Amortization&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;180&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Research and development credits&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;54,324&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Other&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;83,056&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;112,222&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Net operating loss&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;7,679,216&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;6,434,544&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Gross deferred tax assets&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;7,817,112&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;6,547,102&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Valuation allowance&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(7,590,215&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(6,206,450&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Net deferred tax assets &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;226,897&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;340,652&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Deferred tax liabilities&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Note discount&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(226,897&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(340,652&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Total deferred tax liabilities&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;(226,897&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;(340,652&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Net deferred tax assets&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2020 and 2019, due to the following:&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Expected income tax benefit at federal statutory tax rate&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,377,411&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;221,219&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;State income taxes, net of federal benefit&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(415,249&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(434,881&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Change in fair value of warrants&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(72,549&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,874,873&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Change in valuation allowance&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,383,765&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,469,187&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Uncertain tax positions&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;470,838&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;436,145&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Change in compound derivative&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(101,671&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Loss on extinguishment of debt&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;33,925&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;117,198&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Stock compensation&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;64,273&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;121,289&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Rate adjustment&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(108,649&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;49,338&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Other permanent difference&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;22,657&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(1,351&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Provision for income taxes&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,600&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,600&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company&amp;#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses. During the year ended December 31, 2020, the valuation allowance increased by $1,383,765.&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&amp;#x201c;GILTI&amp;#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On April 22, 2020, when the Company entered into the PPP Loan with the PPP Loan Lender (Note 4). In accordance with the Consolidated Appropriations Act, 2021 enacted on December 27, 2020, certain qualified expenses used with the funds of the PPP Loan are fully deductible for Federal income tax purposes. Additionally, should the Company receive forgiveness of the PPP loan in the future, the amount will not be considered taxable for Federal income tax purposes.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;Under the FASB&amp;#x2019;s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
              &lt;tbody&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Unrecognized tax positions, beginning of the year&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;552,082&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Gross increase - current period tax positions&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;585,812&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;552,082&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Gross decrease &amp;#x2013; prior period tax positions&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(3,721&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:9%"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Unrecognized tax positions, end of year&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,134,173&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;552,082&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/tbody&gt;
            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If recognized, none of the unrecognized tax positions would impact the Company&amp;#x2019;s income tax benefit or effective tax rate as long as the Company&amp;#x2019;s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company&amp;#x2019;s unrecognized tax positions within the next twelve months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The Company had no accrual for interest or penalties on the Company&amp;#x2019;s Balance Sheets at December 31, 2020 and 2019 and has not recognized interest and/or penalties in the Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019.&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312180511770">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
              &lt;tbody&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Year Ended &lt;/strong&gt;&lt;/p&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;United States&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(6,556,280&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,120,521&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Foreign&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(2,819&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(67,096&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Pre-tax (loss) income from operations &lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;(6,559,099&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,053,425&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/tbody&gt;
            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218201433597_xbrl_20200312142741160" unitRef="USD">-6556280</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218201433597_xbrl_20200312143007351" unitRef="USD">1120521</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312142741160" unitRef="USD">-2819</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312143007351" unitRef="USD">-67096</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:OperatingLossCarryforwards contextRef="C_20201231" decimals="0" id="Fxbrl_20200312145242432" unitRef="USD">30475657</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="C_20191231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember" decimals="0" id="Fxbrl_20210218200644504" unitRef="USD">17262620</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="C_20201231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember" decimals="0" id="Fxbrl_20200312145421108" unitRef="USD">43349</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="C_20201231" decimals="0" id="Fxbrl_20200312145334442" unitRef="USD">30310672</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200725566" unitRef="USD">13213037</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <skye:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal contextRef="C_20201231" decimals="0" id="Fxbrl_20210218200741145" unitRef="USD">30310672</skye:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="C_20201231" decimals="0" id="Fxbrl_20210218201023819" unitRef="USD">76632</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="C_20201231" decimals="0" id="Fxbrl_20210218201030896" unitRef="USD">40528</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="C_20200101to20201231" id="Fxbrl_20200312183033777">In general, an &amp;#x201c;ownership change&amp;#x201d; as defined by Section 382 of the Code&amp;#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_20200101to20201231" id="F8a1b9ef0-2de8-11ea-add8-41ed81237e2f">
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Current deferred tax assets/(liabilities): &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;State taxes&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;336&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;336&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;Amortization&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;180&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Research and development credits&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;54,324&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Other&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;83,056&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;112,222&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Net operating loss&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;7,679,216&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;6,434,544&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Gross deferred tax assets&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;7,817,112&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;6,547,102&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Valuation allowance&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(7,590,215&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(6,206,450&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Net deferred tax assets &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;226,897&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;340,652&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Deferred tax liabilities&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:9%"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify"&gt;Note discount&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(226,897&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(340,652&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Total deferred tax liabilities&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;(226,897&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;(340,652&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Net deferred tax assets&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsStateTaxes contextRef="C_20201231" decimals="0" id="F21134" unitRef="USD">336</us-gaap:DeferredTaxAssetsStateTaxes>
  <us-gaap:DeferredTaxAssetsStateTaxes contextRef="C_20191231" decimals="0" id="F21140" unitRef="USD">336</us-gaap:DeferredTaxAssetsStateTaxes>
  <skye:DeferredTaxAssetsAmortization contextRef="C_20201231" decimals="0" id="Fxbrl_20210218201658397_21134" unitRef="USD">180</skye:DeferredTaxAssetsAmortization>
  <skye:DeferredTaxAssetsAmortization contextRef="C_20191231" decimals="0" id="Fxbrl_20210218201658397_21140" unitRef="USD">0</skye:DeferredTaxAssetsAmortization>
  <skye:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts contextRef="C_20201231" decimals="0" id="Fxbrl_20210218201731676_xbrl_20210218201658397_21134" unitRef="USD">54324</skye:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
  <skye:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts contextRef="C_20191231" decimals="0" id="Fxbrl_20210218201731676_xbrl_20210218201658397_21140" unitRef="USD">0</skye:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
  <us-gaap:DeferredTaxAssetsOther contextRef="C_20201231" decimals="0" id="F21167" unitRef="USD">83056</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="C_20191231" decimals="0" id="F21174" unitRef="USD">112222</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="C_20201231" decimals="0" id="F21184" unitRef="USD">7679216</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="C_20191231" decimals="0" id="F21191" unitRef="USD">6434544</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsGross contextRef="C_20201231" decimals="0" id="F21201" unitRef="USD">7817112</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="C_20191231" decimals="0" id="F21208" unitRef="USD">6547102</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="C_20201231" decimals="0" id="F21218_5302481" unitRef="USD">7590215</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="C_20191231" decimals="0" id="F21224_4015487" unitRef="USD">6206450</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet contextRef="C_20201231" decimals="0" id="Fxbrl_20200312151224507" unitRef="USD">226897</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="C_20191231" decimals="0" id="Fxbrl_20200312151258630" unitRef="USD">340652</us-gaap:DeferredTaxAssetsNet>
  <skye:DeferredTaxLiabilitiesNoteDiscount contextRef="C_20201231" decimals="0" id="Fxbrl_20200312161635596" unitRef="USD">226897</skye:DeferredTaxLiabilitiesNoteDiscount>
  <skye:DeferredTaxLiabilitiesNoteDiscount contextRef="C_20191231" decimals="0" id="Fxbrl_20200312162645121" unitRef="USD">340652</skye:DeferredTaxLiabilitiesNoteDiscount>
  <us-gaap:DeferredTaxLiabilities contextRef="C_20201231" decimals="0" id="Fxbrl_20200312161638082" unitRef="USD">226897</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20200312162823168" unitRef="USD">340652</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="C_20201231" decimals="0" id="Fxbrl_20210218201946940_xbrl_20200312161638082" unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="C_20191231" decimals="0" id="Fxbrl_20210218201946940_xbrl_20200312162823168" unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_20200101to20201231" id="F8a2032d0-2de8-11ea-add8-41ed81237e2f">
      &lt;div&gt;
        &lt;div&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
            &lt;tbody&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px"&gt;
                &lt;td&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                  &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Expected income tax benefit at federal statutory tax rate&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,377,411&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;221,219&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;State income taxes, net of federal benefit&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(415,249&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(434,881&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Change in fair value of warrants&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(72,549&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(1,874,873&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Change in valuation allowance&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,383,765&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,469,187&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Uncertain tax positions&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;470,838&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;436,145&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Change in compound derivative&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(101,671&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Loss on extinguishment of debt&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;33,925&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;117,198&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Stock compensation&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;64,273&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;121,289&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Rate adjustment&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;(108,649&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="text-align:right;width:9%" valign="bottom"&gt;49,338&lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;Other permanent difference&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;22,657&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(1,351&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                &lt;td valign="top"&gt;
                  &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Provision for income taxes&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,600&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,600&lt;/strong&gt;&lt;/td&gt;
                &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                  &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/tbody&gt;
          &lt;/table&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="C_20200101to20201231" decimals="0" id="F21284_4030454" unitRef="USD">-1377411</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="C_20190101to20191231" decimals="0" id="F21289_1082444" unitRef="USD">221219</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="C_20200101to20201231" decimals="0" id="F21298_319816" unitRef="USD">-415249</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="C_20190101to20191231" decimals="0" id="F21304_208619" unitRef="USD">-434881</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <skye:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218202303348_21298_319816" unitRef="USD">-72549</skye:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant>
  <skye:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218202303348_21304_208619" unitRef="USD">-1874873</skye:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="C_20200101to20201231" decimals="0" id="F21329" unitRef="USD">1383765</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="C_20190101to20191231" decimals="0" id="F21336_344321" unitRef="USD">1469187</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <skye:IncomeTaxReconciliationUncertainTaxPositions contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312170814104" unitRef="USD">470838</skye:IncomeTaxReconciliationUncertainTaxPositions>
  <skye:IncomeTaxReconciliationUncertainTaxPositions contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312171349214" unitRef="USD">436145</skye:IncomeTaxReconciliationUncertainTaxPositions>
  <skye:IncomeTaxReconciliationChangeInCompoundDerivative contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218202451461_xbrl_20200312170814104" unitRef="USD">0</skye:IncomeTaxReconciliationChangeInCompoundDerivative>
  <skye:IncomeTaxReconciliationChangeInCompoundDerivative contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218202451461_xbrl_20200312171349214" unitRef="USD">-101671</skye:IncomeTaxReconciliationChangeInCompoundDerivative>
  <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312170918935" unitRef="USD">33925</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
  <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312171600177" unitRef="USD">117198</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="C_20200101to20201231" decimals="0" id="F21345" unitRef="USD">64273</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="C_20190101to20191231" decimals="0" id="F21352" unitRef="USD">121289</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312170954380" unitRef="USD">-108649</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312171616781" unitRef="USD">49338</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210219103812307_21345" unitRef="USD">22657</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210219103812307_21352" unitRef="USD">-1351</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218201222733" unitRef="USD">1383765</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20200312180558013">
      &lt;div&gt;
        &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
              &lt;tbody&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px"&gt;
                  &lt;td&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                    &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Unrecognized tax positions, beginning of the year&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;552,082&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Gross increase - current period tax positions&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;585,812&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="text-align:right;width:9%" valign="bottom"&gt;552,082&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Gross decrease &amp;#x2013; prior period tax positions&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;(3,721&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;)&lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:1px solid;width:9%"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                  &lt;td valign="top"&gt;
                    &lt;p style="MARGIN:0px;text-align:justify"&gt;Unrecognized tax positions, end of year&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;1,134,173&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;552,082&lt;/strong&gt;&lt;/td&gt;
                  &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/tbody&gt;
            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:UnrecognizedTaxBenefits contextRef="C_20191231" decimals="0" id="Fxbrl_20200312173048837" unitRef="USD">552082</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="C_20181231" decimals="0" id="Fxbrl_20200312173142466" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="C_20201231" decimals="0" id="Fxbrl_20200312173117546" unitRef="USD">1134173</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20200312173104891" unitRef="USD">585812</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312173216019" unitRef="USD">552082</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218202712940" unitRef="USD">3721</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <skye:SignificantContractsTextBlock contextRef="C_20200101to20201231" id="F89bfea61-2de8-11ea-add8-41ed81237e2f">
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;10. Significant Contracts - University of Mississippi&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;em&gt;UM 5050 Prodrug and UM 8930 Analog Agreements&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In July 2018, the Company renewed its ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&amp;#x201c;THC&amp;#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&amp;#x201c;CBD&amp;#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &amp;#x201c;all fields of use&amp;#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &amp;#x201c;License Agreements&amp;#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, the&amp;#160;intellectual property related to UM 5050 and UM 8930 for all fields of use.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. &lt;/span&gt;The Company made upfront payments&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;for &lt;/span&gt;UM 5050 and UM 8930 of&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;$100,000 and&amp;#160;$200,000,&amp;#160;&lt;/span&gt;respectively.&lt;span style="font-family:Times New Roman,Times,serif"&gt; In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="FONT-SIZE:10pt" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr style="HEIGHT:15px"&gt;
              &lt;td style="width:4%" valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$100,000 paid within 30 days following the submission of the first Investigational New Drug Application (&amp;#x201c;NDA&amp;#x201d;) to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:4%" valign="top"&gt;&amp;#160;&lt;/td&gt;
              &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="HEIGHT:15px"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ii)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="HEIGHT:15px"&gt;
              &lt;td&gt;&amp;#160;&lt;/td&gt;
              &lt;td&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="HEIGHT:15px"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;iii)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td valign="top"&gt;
                &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&amp;#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&amp;#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&amp;#x2019;s dissolution or cessation of operations, the Company&amp;#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&amp;#x2019;s control, or the Company&amp;#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;&lt;/div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;em&gt;UM 5070 License Agreement&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&amp;#x201c;UM 5070&amp;#x201d;), to research, develop and commercialize products for the treatment of infectious diseases.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;The Company paid UM an upfront license fee of $65,000 under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees of $25,000 that will be credited against any royalties incurred, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;$700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&amp;#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/p&gt;


    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&amp;#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&amp;#x2019;s control. The Company may terminate the license agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2020, none of the milestones under this license agreement have been met.&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </skye:SignificantContractsTextBlock>
  <skye:AnnualMaintenanceFeePayable contextRef="C_20201231" decimals="0" id="Fxbrl_20200312142403636" unitRef="USD">75000</skye:AnnualMaintenanceFeePayable>
  <skye:AnnualMaintenanceFeePayable contextRef="C_20170110_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember" decimals="0" id="Fxbrl_20210219154322479" unitRef="USD">25000</skye:AnnualMaintenanceFeePayable>
  <skye:PaymentForUpfrontFees contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeOptionAgreementMember" decimals="0" id="Fxbrl_20200312142536312" unitRef="USD">100000</skye:PaymentForUpfrontFees>
  <skye:PaymentForUpfrontFees contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218160858708" unitRef="USD">200000</skye:PaymentForUpfrontFees>
  <skye:AnnualFeesForLicenseAgreement contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218160919766" unitRef="USD">200000</skye:AnnualFeesForLicenseAgreement>
  <skye:AnnualFeesForLicenseAgreement contextRef="C_20170101to20170110_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember" decimals="0" id="Fxbrl_20210219154326200" unitRef="USD">65000</skye:AnnualFeesForLicenseAgreement>
  <skye:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone1Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember" decimals="0" id="Fxbrl_20210219141256951" unitRef="USD">100000</skye:AggregateMilestonePaymentsIfMilestonesAchieved>
  <skye:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone2Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember" decimals="0" id="Fxbrl_20210219141242114" unitRef="USD">200000</skye:AggregateMilestonePaymentsIfMilestonesAchieved>
  <skye:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone3Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember" decimals="0" id="Fxbrl_20210219141227591" unitRef="USD">400000</skye:AggregateMilestonePaymentsIfMilestonesAchieved>
  <skye:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20170101to20170110_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember" decimals="0" id="Fxbrl_20200312140730836" unitRef="USD">700000</skye:AggregateMilestonePaymentsIfMilestonesAchieved>
  <skye:TermOfAgreement contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone1Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember" id="Fxbrl_20210219141334236">P30D</skye:TermOfAgreement>
  <skye:TermOfAgreement contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone2Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember" id="Fxbrl_20210219141402449">P30D</skye:TermOfAgreement>
  <skye:TermOfAgreement contextRef="C_20180701to20180731_deiLegalEntityAxis_skyeUniversityOfMississippiMember_skyeMilestonePaymentsPayableAxis_skyeMilestone3Member_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5050ProdrugAndUm8930AnalogAgreementsMember" id="Fxbrl_20210219141415172">P30D</skye:TermOfAgreement>
  <skye:NoticePeriodForTermination contextRef="C_20170101to20170110_deiLegalEntityAxis_skyeUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_usgaapTypeOfArrangementAxis_skyeUm5070LicenseAgreementMember" id="Fxbrl_20200312141129527">P60D</skye:NoticePeriodForTermination>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20200101to20201231" id="Fb4c27c40-fb9e-11e9-95c3-eb6626f9f922">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;strong&gt;11. Related Party Matters&lt;/strong&gt;&lt;/p&gt;
            &lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;
            &lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;&lt;strong&gt;Emerald Health Sciences&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
            &lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;
            &lt;div&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of &lt;span style="-sec-ix-hidden:Fxbrl_20200506114236417"&gt;ten&lt;/span&gt; years and specified compensation to be agreed upon between the Company&amp;#x2019;s Chief Executive Officer and Emerald Health Sciences&amp;#x2019; CEO on a month-to-month basis.&amp;#160;The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of December 31, 2020, and 2019, the Company has accrued $7,032 reimbursable expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the year ended December 31, 2020. Under this agreement, for the year ended December 31, 2019, the Company incurred expenses of $542,000.&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.&lt;/p&gt;
            &lt;/div&gt;
            &lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;
            &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon initially received a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&amp;#x2019;s completion of a material financing. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to defer payment of 100% of Dr. Dhillon&amp;#x2019;s consulting fees until the Board of Directors determined that the Company had been sufficiently financed to make such payments at which point the Company agreed to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. Subsequent to the August 2020 Financing Dr. Dhillon continues to receive a monthly fee of $10,000 per month for his services. The Board reviews the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and automatically renews thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&amp;#x2019; prior written notice to the other party. Under this agreement, for the years ended December 31, 2020 and 2019, the Company incurred fees of $127,387 and $3,871, respectively. As of December 31, 2020, the Company has accrued $10,000 in expense related to the Independent Contractor Services Agreement.&lt;/p&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;
            &lt;div&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;In addition, on August 10, 2020, Emerald Health Sciences, Inc. transferred to Dr. Avtar Dhillon 500,000 shares of the Company&amp;#x2019;s common stock at a deemed price of $0.10 in exchange for the cancellation of $50,000 of debt.&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As of December 31, 2020, Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. As of December 31, 2020, Jim Heppell is also a board member of Emerald Health Sciences, Inc. The Company&amp;#x2019;s CEO, Punit Dhillon also served as a board member of Emerald Health Sciences, Inc. until he tendered his resignation from such board on August 10, 2020.&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Company shares the same office location as Emerald Health Pharmaceuticals. However, the Company&amp;#x2019;s workforce is remote, there is no written rental agreement with Emerald Health Pharmaceuticals, and no rent is being charged.&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On August 10, 2020, Emerald Health Sciences, Inc. extinguished debt of $186,667 by transferring 1,566,666 shares of the Company&amp;#x2019;s common stock at a deemed price of $0.10 per share to certain officers, employees and directors of the Company.&lt;/p&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <skye:AccruedExpenseUnderAgreement contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_202005061142570850" unitRef="USD">7032</skye:AccruedExpenseUnderAgreement>
  <skye:AccruedExpenseUnderAgreement contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200506114257085" unitRef="USD">7032</skye:AccruedExpenseUnderAgreement>
  <skye:AccruedExpenseUnderAgreement contextRef="C_20201231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200506114901777" unitRef="USD">10000</skye:AccruedExpenseUnderAgreement>
  <skye:TotalExpenseIncurredUnderAgreement contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20210219164448542" unitRef="USD">0</skye:TotalExpenseIncurredUnderAgreement>
  <skye:TotalExpenseIncurredUnderAgreement contextRef="C_20190101to20191231_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200506114314106" unitRef="USD">542000</skye:TotalExpenseIncurredUnderAgreement>
  <skye:MonthlyFee contextRef="C_20191201to20191219_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20210219152050539" unitRef="USD">10000</skye:MonthlyFee>
  <skye:MonthlyFeePaidEachMonthInExchangeOfServices contextRef="C_20191201to20191219_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20210219152104782" unitRef="USD">5000</skye:MonthlyFeePaidEachMonthInExchangeOfServices>
  <skye:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices contextRef="C_20191201to20191219_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20210219152118826" unitRef="USD">5000</skye:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices>
  <skye:PercentageOfAccruedConsultingFee contextRef="C_20200301to20200330_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="2" id="Fxbrl_20210219152135583" unitRef="pure">1</skye:PercentageOfAccruedConsultingFee>
  <skye:PercentageOfBonusForAccruedConsultingFee contextRef="C_20200301to20200330_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="2" id="Fxbrl_20210219152145128" unitRef="pure">0.10</skye:PercentageOfBonusForAccruedConsultingFee>
  <skye:FeesIncurredUnderAgreement contextRef="C_20200101to20201231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200810095241152" unitRef="USD">127387</skye:FeesIncurredUnderAgreement>
  <skye:FeesIncurredUnderAgreement contextRef="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeAvtarDhillonMember_usgaapTypeOfArrangementAxis_skyeIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200810095334198" unitRef="USD">3871</skye:FeesIncurredUnderAgreement>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="C_20200801to20200810_deiLegalEntityAxis_skyeEmeraldHealthSciencesIncMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_skyeOfficersEmployeeAndDirectorsMember" decimals="0" id="Fxbrl_20201102145306180" unitRef="USD">186667</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:SubsequentEventsTextBlock contextRef="C_20200101to20201231" id="F89c03880-2de8-11ea-add8-41ed81237e2f">
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;13. Subsequent Events&lt;/strong&gt;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;&lt;strong&gt;Emerald Health Biotechnology Espa&amp;#xf1;a, S.L.U&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In January 2021, the Company entered into a Collaborative Research Agreement with Emerald Health Biotechnology Espa&amp;#xf1;a, S.L.U, a subsidiary of Emerald Health Research, Inc. which is 100% owned by Emerald Health Sciences. Under the agreement, Emerald Health Biotechnology Espa&amp;#xf1;a, S.L. will provide research and development services pursuant to an agreed upon project plan for the research and development of CBDVHS. The term of the agreement is initially for a one-year period. The agreement will terminate upon delivery and acceptance of the final deliverable under the project plan or if either party is in breach of the terms of the contract and such breach remains uncured for 45 days. Payment for services rendered will be based on time and materials billable at reasonable market rates.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;strong&gt;&lt;em&gt;Warrant Exercises&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;From January 1, 2021 through February 23, 2021 11,800,000 pre-funded warrants were exercised in exchange for 11,800,000 shares of common stock for gross proceeds of $11,800.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;From January 1, 2021 through February 23, 2021 50,133,334 common stock warrants were exercised in exchange for 50,133,334 shares of common stock for gross proceeds of $3,008,000.&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;strong&gt;&lt;em&gt;Increase to Authorized Shares of Capital Stock&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On February 5, 2021, the Company increased its authorized shares of common and preferred stock to 5,000,000,000 and 50,000,000, respectively.&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
  <skye:WarrantsAndDerivativeLiabilitiesTextBlock contextRef="C_20200101to20201231" id="Fb4c22e22-fb9e-11e9-95c3-eb6626f9f922">
    &lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3. Warrants and Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&amp;#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Warrants vested and outstanding as of December 31, 2020 are summarized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Vested and&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Pre 2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,110,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2016 Common Stock Warrants to Service Providers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;480,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2017 Common Stock Warrants to Service Provider&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2018 Emerald Financing Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,400,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2019 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2020 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;116,666,668&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2020 Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.075&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8,166,667&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2020 Pre-Funded Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Indefinite&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,800,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total warrants vested and outstanding as of December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;157,513,335&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;August 2020 Financing Warrants&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In connection with the August 2020 Financing (Note 5), the Company issued 116,666,668 common stock warrants, 8,166,667 common stock warrants to the placement agent and 60,333,334 pre-funded warrants. The warrants were equity classified at issuance and of the $6,939,667 in gross proceeds, the Company allocated $2,767,767 and $2,146,997 of the gross proceeds to the common stock warrants and pre-funded warrants on a relative fair value basis, respectively. The remaining $2,024,903 was allocated to the common stock. The warrants issued to the placement agent were valued at $261,333 and recorded as equity issuance costs within equity. The warrants vested immediately and were valued utilizing the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Common Stock Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Pre-funded&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Placement Agent Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;91.64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;93.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;91.64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;2019 Common Stock Warrants&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the year ended December 31, 2019, the Company issued 8,000,000 fully vested common stock warrants to investors, in conjunction with the November 2019 Common Stock Offering discussed below (See Note 5). The warrants are equity classified at issuance and the Company allocated an aggregate of $722,208 of the gross proceeds to the warrants on a relative fair value basis. The warrants vested immediately and had an estimated aggregate fair value of $1,130,400 utilizing the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;93.08&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the year ended December 31, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;91.6&amp;#x2014;92.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2.23&amp;#x2014;2.51&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$0.33&amp;#x2014;0.69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following tables summarize the activity of derivative liabilities for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="18" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2020,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability&amp;#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Financing - warrant liability&amp;#160;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(237,457&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;38,567&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability&amp;#160;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(108,016&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(26,563&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(436,270&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(26,563&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;38,567&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;38,567&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="18" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2018, Fair&lt;/strong&gt;&amp;#160;&lt;strong&gt;Value of&lt;/strong&gt;&amp;#160;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair Value of Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&amp;#160;&lt;strong&gt;of Derivatives&lt;/strong&gt;&amp;#160;&lt;strong&gt;to Equity or Extinguishment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2019, Fair&lt;/strong&gt;&amp;#160;&lt;strong&gt;Value of&lt;/strong&gt;&amp;#160;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability&amp;#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;516,058&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(484,147&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(160,567&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Financing - warrant liability&amp;#160;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(9,042,066&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(5,933,323&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability&amp;#160;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(208,546&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(144,375&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(9,734,759&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(6,238,265&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&amp;#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes Option Pricing model for each payment period.&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. During the year ended December 31, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Emerald Financing Warrant Liability (2)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision.The warrants contained an anti-dilution protection feature that provided the investors with price protection if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. In connection with the August 2020 Financing, this provision was waived, and the exercise price was permanently set to $0.10. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, &lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt;, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, &lt;em&gt;Derivatives and Hedging/Contracts in Entity&lt;/em&gt;&lt;em&gt;&amp;#x2019;&lt;/em&gt;&lt;em&gt;s Own Equity&lt;/em&gt;, and determined that the warrants also meet the definition of a derivative. With the assistance of a third party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, &lt;em&gt;Fair Value Measurement&lt;/em&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="6" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of&amp;#160;&lt;/strong&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Series B Warrant Liability (3)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Common Stock Warrants originally exercisable at a price of $1.15 per share. The warrants were exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B Common Stock Warrants also had a &amp;#x201c;down-round&amp;#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and the strike price was permanently reset to $0.00 on January 19, 2018, as a result of the Emerald Financing. However, because the remaining warrant holders still had certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B Common Stock Warrant agreements, the warrants continued to require liability classification. After the Emerald Financing repricing occurred, the warrants were valued using a Black Scholes Merton Option Pricing Model.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the year ended December 31, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Common Stock Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options was reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&amp;#x2019;s common stock on the exercise dates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2020, the remaining Series B Common Stock Warrants expired unexercised.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </skye:WarrantsAndDerivativeLiabilitiesTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218151539507">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Vested and&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Pre 2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,110,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2016 Common Stock Warrants to Service Providers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;480,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2017 Common Stock Warrants to Service Provider&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2018 Emerald Financing Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,400,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2019 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2020 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;116,666,668&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2020 Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.075&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;8,166,667&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2020 Pre-Funded Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Indefinite&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;11,800,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total warrants vested and outstanding as of December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;157,513,335&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember" id="Fxbrl_20210218151635403">P6Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember" id="Fxbrl_20210218151847508">P10Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember" id="Fxbrl_20210218152859262">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember" id="Fxbrl_20210218152339415">P10Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20210218151556366_xbrl_20191101140300168">P10Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="Fxbrl_20210218151556383_xbrl_20191101140457103">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="Fxbrl_20210218151556402_xbrl_20191101140706851">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20210218151556419_xbrl_20191101140714179">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember" id="Fxbrl_20210218151556441_xbrl_20191107103627372">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20210218151556464_xbrl_20191101172324097">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" id="Fxbrl_20210218151556485_xbrl_20200506171055008">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember" id="Fxbrl_20210218151556507_xbrl_20201102155937119">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" id="Fxbrl_20210218151556529_xbrl_20201102155723823">P4Y11M26D</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20180201to20180216_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_202102191552579450">P5Y</skye:TermOfWarrant>
  <skye:TermOfWarrant contextRef="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_skyeEmeraldWarrantLiabilityMember" id="Fxbrl_20210219155257945">P5Y</skye:TermOfWarrant>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyePre2015CommonStockWarrantsMember" decimals="INF" id="Fxbrl_20210219020748545" unitRef="shares">1110000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandFifteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20210218151556345_10962" unitRef="shares">100000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="Fxbrl_20210218151556366_11033" unitRef="shares">40000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="INF" id="Fxbrl_20210218151556383_11056" unitRef="shares">125000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="INF" id="Fxbrl_20210218151556402_11079" unitRef="shares">480000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="Fxbrl_20210218151556419_11102" unitRef="shares">125000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20210218151556441_11125" unitRef="shares">3400000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="Fxbrl_20210218151556464_11148" unitRef="shares">7500000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20210218151556485_xbrl_20200506171102006" unitRef="shares">8000000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20210218151556507_xbrl_20201102160134130" unitRef="shares">116666668</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="INF" id="Fxbrl_20210218151556529_xbrl_20201102160146768" unitRef="shares">8166667</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyPreFundedWarrantsMember" decimals="INF" id="Fxbrl_20210218151556549_xbrl_20201102160150704" unitRef="shares">11800000</skye:WarrantsVestedAndOutstanding>
  <skye:WarrantsVestedAndOutstanding contextRef="C_20200101to20201231" decimals="INF" id="Fxbrl_20210218153023613" unitRef="shares">157513335</skye:WarrantsVestedAndOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember" decimals="0" id="Fxbrl_20210218154034102" unitRef="shares">116666668</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="0" id="Fxbrl_20210218154153659" unitRef="shares">8166667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember" decimals="0" id="Fxbrl_20210218154217624" unitRef="shares">60333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20210218155041754" unitRef="shares">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="Fxbrl_20210218153815774" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="0" id="Fxbrl_20210218163638473" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <skye:GrossProceedsOfWarrant contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218164453235" unitRef="USD">6939667</skye:GrossProceedsOfWarrant>
  <skye:GrossProceedsOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeCommonStockWarrantsMember" decimals="0" id="Fxbrl_20210218154246160" unitRef="USD">2767767</skye:GrossProceedsOfWarrant>
  <skye:GrossProceedsOfWarrant contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember" decimals="0" id="Fxbrl_20210218154315345" unitRef="USD">2146997</skye:GrossProceedsOfWarrant>
  <skye:ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="0" id="Fxbrl_20210218154348675" unitRef="USD">261333</skye:ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity>
  <skye:FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock contextRef="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeAugustTwoThousandAndTwentyFinancingWarrantsMember" id="Fxbrl_20210218153915666">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Common Stock Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Pre-funded&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Placement Agent Warrants&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;91.64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;93.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;91.64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;
    </skye:FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock>
  <skye:FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock contextRef="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" id="Fxbrl_20210218154648246">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;93.08&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;
    </skye:FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218153945066_xbrl_20201102162641966_xbrl_20191101141525787" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218153945066_xbrl_20201102162710867_xbrl_20191101141525787" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218153945066_xbrl_20201102162729714_xbrl_20191101141525787" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20210218153945086_xbrl_20201102162641975_xbrl_20201102160422267" unitRef="pure">91.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20210218153945086_xbrl_20201102162710873_xbrl_20201102160422267" unitRef="pure">93.86</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20210218153945086_xbrl_20201102162729718_xbrl_20201102160422267" unitRef="pure">91.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218153945101_xbrl_20201102162641979_xbrl_20201102160724487" unitRef="pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218153945101_xbrl_20201102162710878_xbrl_20201102160724487" unitRef="pure">0.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218153945101_xbrl_20201102162729722_xbrl_20201102160724487" unitRef="pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218155119909_xbrl_20210218152443839_xbrl_20201102174227211" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20210218155119914_xbrl_20210218152506574" unitRef="pure">93.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218155119924_xbrl_20210218152540849" unitRef="pure">1.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218152443839_xbrl_20201102174227211" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="1" id="Fxbrl_20210218152506574" unitRef="pure">91.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="1" id="Fxbrl_20210218152514061" unitRef="pure">92.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218152540849" unitRef="pure">2.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218152548327" unitRef="pure">2.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218163525242_xbrl_20200506145117729" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20210218163525242_xbrl_20200506145325597" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="1" id="Fxbrl_20210218163525254_xbrl_20200506145134245" unitRef="pure">90.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="1" id="Fxbrl_20210218163525254_xbrl_20201102195712975" unitRef="pure">79.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218163525267_xbrl_20201102194927027" unitRef="pure">0.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20210218163525267_xbrl_20201102195821980" unitRef="pure">1.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember" decimals="2" id="Fxbrl_20210218163744095_xbrl_20200506143011880" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember" decimals="1" id="Fxbrl_20210218163744099_xbrl_20200506143049096" unitRef="pure">79.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember" decimals="2" id="Fxbrl_20210218163744105_xbrl_20200506143126941" unitRef="pure">1.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandAndTwentyCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember" decimals="2" id="Fxbrl_20210218153945136_xbrl_20201102162641984_xbrl_20201102160619455" unitRef="USD_per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePrefundedWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember" decimals="2" id="Fxbrl_20210218153945136_xbrl_20201102162710890_xbrl_20201102160619455" unitRef="USD_per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20201231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyePlacementAgentWarrantMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember" decimals="2" id="Fxbrl_20210218153945136_xbrl_20201102162729731_xbrl_20201102160619455" unitRef="USD_per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandNineteenCommonStockWarrantsMember" decimals="2" id="Fxbrl_20210218155119934_xbrl_20210218152603910" unitRef="USD_per_Share">0.22</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20210218152603910" unitRef="USD_per_Share">0.33</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20210218153311966" unitRef="USD_per_Share">0.69</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20210218163525293_xbrl_20200506145205245" unitRef="USD_per_Share">0.04</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember_skyePricingModelAxis_skyeMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20210218163525293_xbrl_20200506145256042" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_skyePricingModelAxis_skyePricingModelMember_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember" decimals="2" id="Fxbrl_20210218163744119_xbrl_20200506143224958" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20210218152416766">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;91.6&amp;#x2014;92.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2.23&amp;#x2014;2.51&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$0.33&amp;#x2014;0.69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_20210218163502134">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="6" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of&amp;#160;&lt;/strong&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20201231_usgaapStatementClassOfStockAxis_skyeSeriesBWarrantMember" id="Fxbrl_20210218163727937">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218161223329">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="18" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2020,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability&amp;#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Financing - warrant liability&amp;#160;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(237,457&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;38,567&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability&amp;#160;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(108,016&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(26,563&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(436,270&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(26,563&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;38,567&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;38,567&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%"&gt;
          &lt;tbody&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="18" style="text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2018, Fair&lt;/strong&gt;&amp;#160;&lt;strong&gt;Value of&lt;/strong&gt;&amp;#160;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair Value of Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&amp;#160;&lt;strong&gt;of Derivatives&lt;/strong&gt;&amp;#160;&lt;strong&gt;to Equity or Extinguishment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2019, Fair&lt;/strong&gt;&amp;#160;&lt;strong&gt;Value of&lt;/strong&gt;&amp;#160;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability&amp;#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;516,058&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(484,147&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(160,567&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Emerald Financing - warrant liability&amp;#160;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(9,042,066&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(5,933,323&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability&amp;#160;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(208,546&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(144,375&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(9,734,759&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(6,238,265&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#ffffff"&gt;
              &lt;td valign="top"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:9%"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:1%;white-space:nowrap"&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
          &lt;/tbody&gt;
        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <skye:FairValueOfWarrantsIssued contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161017164_xbrl_20200810100656150_xbrl_20200506161519971" unitRef="USD">0</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161017200_xbrl_20200810100656174_xbrl_20200506161535400" unitRef="USD">0</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161017235_xbrl_20200810100656193_xbrl_20200506161554205" unitRef="USD">0</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218161017270_xbrl_20200810100656211_xbrl_20200506161618939" unitRef="USD">0</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161658427" unitRef="USD">516058</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20190101to20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161147665_xbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164238992" unitRef="USD">0</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161147691_xbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164249140" unitRef="USD">0</skye:FairValueOfWarrantsIssued>
  <skye:FairValueOfWarrantsIssued contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218161147724_xbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164404505" unitRef="USD">516058</skye:FairValueOfWarrantsIssued>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218161017164_xbrl_20200810100656150_xbrl_20200506162752874" unitRef="USD">0</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20201231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161017200_xbrl_20200810100656174_xbrl_20200506162211890" unitRef="USD">0</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161017235_xbrl_20200810100656193_xbrl_20200506162146359" unitRef="USD">-26563</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218161017270_xbrl_20200810100656211_xbrl_20200506162129574" unitRef="USD">-26563</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20210218162440139" unitRef="USD">-160567</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231_deiLegalEntityAxis_skyeEmeraldFinancingMember" decimals="0" id="Fxbrl_20210218161147665_xbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164318857" unitRef="USD">-5933323</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantMember" decimals="0" id="Fxbrl_20210218161147691_xbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164328141" unitRef="USD">-144375</skye:ReclassificationOfDerivativesToEquity>
  <skye:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20210218161147724_xbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164426888" unitRef="USD">-6238265</skye:ReclassificationOfDerivativesToEquity>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="C_20200101to20201231" decimals="0" id="Fxbrl_20210218163438355" unitRef="USD">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <skye:AggregateExercisePriceOfOutstandingCreditAgreements contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_skyeEmeraldFinancingWarrantsLiabilityMember" decimals="0" id="Fxbrl_20200810110513593" unitRef="USD">4080000</skye:AggregateExercisePriceOfOutstandingCreditAgreements>
  <skye:ValueOfCommonStockCalledByWarrants contextRef="C_20201231_usgaapClassOfWarrantOrRightAxis_skyeSeriesBWarrantsMember" decimals="0" id="Fxbrl_20210218163658614" unitRef="USD">26563</skye:ValueOfCommonStockCalledByWarrants>
  <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218162954352">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;9. Other Current Liabilities&lt;/strong&gt;&lt;/p&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
              &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Other current liabilities consist of the following:&lt;/strong&gt;&lt;/p&gt;

                &lt;div&gt;
                  &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                    &lt;tbody&gt;
                      &lt;tr style="HEIGHT:15px"&gt;
                        &lt;td&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                          &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px"&gt;
                        &lt;td&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                          &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                          &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued payroll liabilities&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;61,547&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;43,830&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued research and development costs&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;93,888&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;148,006&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued legal expense&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;57,596&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;92,237&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued board fees&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;40,625&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;58,395&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Total other accrued liabilities&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;5,455&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;77,938&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                        &lt;td&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;259,111&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;420,406&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/tbody&gt;
                  &lt;/table&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OtherLiabilitiesDisclosureTextBlock>
  <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210218164112449">
                &lt;div&gt;
                  &lt;p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;
                    &lt;tbody&gt;
                      &lt;tr style="HEIGHT:15px"&gt;
                        &lt;td&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                          &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px"&gt;
                        &lt;td&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                          &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;
                          &lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued payroll liabilities&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;61,547&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;43,830&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued research and development costs&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;93,888&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;148,006&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued legal expense&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;57,596&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;92,237&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Accrued board fees&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;40,625&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="text-align:right;width:9%" valign="bottom"&gt;58,395&lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;
                        &lt;td valign="top"&gt;
                          &lt;p style="MARGIN:0px;text-align:justify"&gt;Total other accrued liabilities&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;5,455&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;77,938&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;
                        &lt;td&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;259,111&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;420,406&lt;/strong&gt;&lt;/td&gt;
                        &lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;
                          &lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/tbody&gt;
                  &lt;/table&gt;
                &lt;/div&gt;
              </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:AccruedSalariesCurrent contextRef="C_20201231" decimals="0" id="Fxbrl_20210218163703866" unitRef="USD">61547</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20210218163710166" unitRef="USD">43830</us-gaap:AccruedSalariesCurrent>
  <skye:AccruedResearchAndDevelopmentCosts contextRef="C_20201231" decimals="0" id="Fxbrl_20210218163741571_xbrl_20210218163703866" unitRef="USD">93888</skye:AccruedResearchAndDevelopmentCosts>
  <skye:AccruedResearchAndDevelopmentCosts contextRef="C_20191231" decimals="0" id="Fxbrl_20210218163741571_xbrl_20210218163710166" unitRef="USD">148006</skye:AccruedResearchAndDevelopmentCosts>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="C_20201231" decimals="0" id="Fxbrl_20210218163744177_xbrl_20210218163703866" unitRef="USD">57596</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20210218163744177_xbrl_20210218163710166" unitRef="USD">92237</us-gaap:AccruedProfessionalFeesCurrent>
  <skye:AccruedBoardFees contextRef="C_20201231" decimals="0" id="Fxbrl_20210218163747701_xbrl_20210218163703866" unitRef="USD">40625</skye:AccruedBoardFees>
  <skye:AccruedBoardFees contextRef="C_20191231" decimals="0" id="Fxbrl_20210218163747701_xbrl_20210218163710166" unitRef="USD">58395</skye:AccruedBoardFees>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="C_20201231" decimals="0" id="Fxbrl_20210218163750219_xbrl_20210218163703866" unitRef="USD">5455</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20210218163750219_xbrl_20210218163710166" unitRef="USD">77938</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="C_20200101to20201231" id="Fxbrl_20210219200350839">
      &lt;div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;2.&amp;#160;&lt;strong&gt;Contingencies&lt;/strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&lt;strong&gt;&lt;em&gt;&lt;span style="font-style:italic"&gt;General Litigation and Disputes&lt;/span&gt;&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;From time to time, in the normal course of our operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Company&amp;#x2019;s operations or financial position, liquidity or results of operations. As of December 31, 2020, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&amp;#x2019;s financial position or results of operations.&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:LegalMattersAndContingenciesTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>skye-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:skye="http://www.emeraldbio.life/20201231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" targetNamespace="http://www.emeraldbio.life/20201231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals" id="Consolidatedbalancesheetsparentheticals">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" id="CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsOFCASHFLOWSParentheticals" id="CONSOLIDATEDSTATEMENTSCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsOFCASHFLOWSParentheticals">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit" id="ConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>0007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals" id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals">
        <link:definition>0008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities" id="NatureOfOperationsAndBusinessActivities">
        <link:definition>0009 - Disclosure - Nature of Operations and Business Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities" id="WarrantsAndDerivativeLiabilities">
        <link:definition>0011 - Disclosure - Warrants and Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty" id="ConvertibleDebtRelatedParty">
        <link:definition>0012 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization" id="StockholdersEquityDeficitAndCapitalization">
        <link:definition>0013 - Disclosure - Stockholders' Equity and Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock" id="NetIncomeLossPerShareOfCommonStock">
        <link:definition>0015 - Disclosure - Net (Loss) Income Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
        <link:definition>0017 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi" id="SignificantContractsUniversityOfMississippi">
        <link:definition>0018 - Disclosure - Significant Contracts - University of Mississippi</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters" id="RelatedPartyMatters">
        <link:definition>0019 - Disclosure - Related Party Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/Contingencies" id="Contingencies">
        <link:definition>0020 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0021 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0022 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables" id="WarrantsAndDerivativeLiabilitiesTables">
        <link:definition>0023 - Disclosure - Warrants and Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables" id="ConvertibleDebtRelatedPartyTables">
        <link:definition>0024 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>0025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables" id="NetIncomeLossPerShareOfCommonStockTables">
        <link:definition>0026 - Disclosure - Net (Loss) Income Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/Incometaxestables" id="Incometaxestables">
        <link:definition>0027 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
        <link:definition>0028 - Disclosure - Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals" id="NatureOfOperationsAndBusinessActivitiesDetailTextuals">
        <link:definition>0029 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals" id="SummaryOfSignificantAccountingPoliciesDetailTextuals">
        <link:definition>0030 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails" id="WarrantsAndDerivativeLiabilitiesDetails">
        <link:definition>0031 - Disclosure - Warrants and Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1" id="WarrantsAndDerivativeLiabilitiesDetails1">
        <link:definition>0032 - Disclosure - Warrants and Derivative Liabilities (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2" id="WarrantsAndDerivativeLiabilitiesDetails2">
        <link:definition>0033 - Disclosure - Warrants and Derivative Liabilities (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6" id="WarrantsAndDerivativeLiabilitiesDetails6">
        <link:definition>0034 - Disclosure - Warrants and Derivative Liabilities (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3" id="WarrantsAndDerivativeLiabilitiesDetails3">
        <link:definition>0035 - Disclosure - Warrants and Derivative Liabilities (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4" id="WarrantsAndDerivativeLiabilitiesDetails4">
        <link:definition>0036 - Disclosure - Warrants and Derivative Liabilities (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals" id="WarrantsAndDerivativeLiabilitiesDetailTextuals">
        <link:definition>0037 - Disclosure - Warrants and Derivative Liabilities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails" id="ConvertibleDebtRelatedPartyDetails">
        <link:definition>0038 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1" id="ConvertibleDebtRelatedPartyDetails1">
        <link:definition>0039 - Disclosure - Debt (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals" id="ConvertibleDebtRelatedPartyDetailTextuals">
        <link:definition>0040 - Disclosure - Debt (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals" id="StockholdersEquityDeficitAndCapitalizationDetailTextuals">
        <link:definition>0041 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
        <link:definition>0042 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1" id="StockBasedCompensationDetails1">
        <link:definition>0043 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2" id="StockBasedCompensationDetails2">
        <link:definition>0044 - Disclosure - Stock-Based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4" id="StockBasedCompensationDetails4">
        <link:definition>0045 - Disclosure - Stock-Based Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails5" id="StockBasedCompensationDetails5">
        <link:definition>0046 - Disclosure - Stock-Based Compensation (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals" id="StockBasedCompensationDetailTextuals">
        <link:definition>0047 - Disclosure - Stock-Based Compensation (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1" id="StockBasedCompensationDetailTextuals1">
        <link:definition>0048 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails" id="NetIncomeLossPerShareOfCommonStockDetails">
        <link:definition>0049 - Disclosure - Net (Loss) Income Per Share of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1" id="NetIncomeLossPerShareOfCommonStockDetails1">
        <link:definition>0050 - Disclosure - Net (Loss) Income Per Share of Common Stock (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>0051 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>0052 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>0053 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails3" id="IncomeTaxesDetails3">
        <link:definition>0054 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals" id="IncomeTaxesDetailTextuals">
        <link:definition>0055 - Disclosure - Income Taxes (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
        <link:definition>0056 - Disclosure - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals" id="SignificantContractsUniversityOfMississippiDetailTextuals">
        <link:definition>0057 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetails" id="RelatedPartyMattersDetails">
        <link:definition>0058 - Disclosure - Related Party Matters (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
        <link:definition>0059 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="skye-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="skye-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="skye-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="skye-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedBoardFees" id="skye_AccruedBoardFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedExpenseUnderAgreement" id="skye_AccruedExpenseUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AccruedInterestRelatedParty" id="skye_AccruedInterestRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedResearchAndDevelopmentCosts" id="skye_AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdditionalConversionLiability" id="skye_AdditionalConversionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateExercisePriceOfOutstandingCreditAgreements" id="skye_AggregateExercisePriceOfOutstandingCreditAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateMilestonePaymentsIfMilestonesAchieved" id="skye_AggregateMilestonePaymentsIfMilestonesAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AlbanyMolecularResearchIncMember" id="skye_AlbanyMolecularResearchIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AllocationOfDebtOnBasisOfRelativeFairValue" id="skye_AllocationOfDebtOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AllocationOfWarrantOnBasisOfRelativeFairValue" id="skye_AllocationOfWarrantOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmendedAndRestatedMultiDrawCreditAgreementMember" id="skye_AmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfDebtDiscount" id="skye_AmortizationOfDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmortizationOfTransactionCosts" id="skye_AmortizationOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmountOfEachWarrantOutstanding" id="skye_AmountOfEachWarrantOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmountOfPassThroughExpensesAndConsultingFees" id="skye_AmountOfPassThroughExpensesAndConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeeForAgreement" id="skye_AnnualFeeForAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeesForLicenseAgreement" id="skye_AnnualFeesForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualMaintenanceFeePayable" id="skye_AnnualMaintenanceFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualMaintenanceFees" id="skye_AnnualMaintenanceFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="August2020FinancingMember" id="skye_August2020FinancingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AugustTwoThousandAndTwentyFinancingWarrantsMember" id="skye_AugustTwoThousandAndTwentyFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AvtarDhillonMember" id="skye_AvtarDhillonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AwardsGrantedOutside2014PlanMember" id="skye_AwardsGrantedOutside2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AwardsGrantedOutsideThe2014PlanMember" id="skye_AwardsGrantedOutsideThe2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" id="skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock" id="skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock" id="skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CashPaidDuringPeriodForAbstract" id="skye_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInFairValueOfDerivativeLiabilities" id="skye_ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChangeInFairValueOfWarrantLiability" id="skye_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightWarrantsAggregateExercisePrice" id="skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ClassOfWarrantOrRightWarrantsExercise" id="skye_ClassOfWarrantOrRightWarrantsExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonSharesUnderlyingConvertiblePreferredStockMember" id="skye_CommonSharesUnderlyingConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockAggregatePurchasePrice" id="skye_CommonStockAggregatePurchasePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockIssuedForServices" id="skye_CommonStockIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CommonStockWarrantsMember" id="skye_CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockWarrantsToSeriesBStockholdersMember" id="skye_CommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonUnitSoldPricePerUnit" id="skye_CommonUnitSoldPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingAgreementMember" id="skye_ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContractPayableDue" id="skye_ContractPayableDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionLiabilityIntoCommonStockPerShare" id="skye_ConversionLiabilityIntoCommonStockPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" id="skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" id="skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" id="skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" id="skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" id="skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesCPreferredStockToCommonStockShares" id="skye_ConversionOfSeriesCPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesCPreferredStockToCommonStockSharesValue" id="skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStock" id="skye_ConversionOfSeriesDPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStockShares" id="skye_ConversionOfSeriesDPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockShares" id="skye_ConversionOfSeriesFPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockValue" id="skye_ConversionOfSeriesFPreferredStockToCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionPrice" id="skye_ConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionPricePerShare" id="skye_ConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertedRate10000001Member" id="skye_ConvertedRate10000001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertedRate100001Member" id="skye_ConvertedRate100001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertedRateAxis" id="skye_ConvertedRateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ConvertedRateDomain" id="skye_ConvertedRateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleDebtRelatedPartyTextBlock" id="skye_ConvertibleDebtRelatedPartyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleMultiDrawCreditAgreementIssuanceCosts" id="skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CouponInterestExpense" id="skye_CouponInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CreditFacilityEffectedFifthAdvance" id="skye_CreditFacilityEffectedFifthAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CreditFacilityEffectedFourthAdvance" id="skye_CreditFacilityEffectedFourthAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrentConvertibleDebtExcludingNoncurrentPortion" id="skye_CurrentConvertibleDebtExcludingNoncurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="December2015Member" id="skye_December2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock" id="skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock" id="skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsAmortization" id="skye_DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal" id="skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxLiabilitiesNoteDiscount" id="skye_DeferredTaxLiabilitiesNoteDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DerivativeLiabilitiesLineItems" id="skye_DerivativeLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativeLiabilitiesTable" id="skye_DerivativeLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DerivativesLiabilitiesTable" id="skye_DerivativesLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DilutedSecuritiesAxis" id="skye_DilutedSecuritiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="DilutedSecuritiesDomain" id="skye_DilutedSecuritiesDomain" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" id="skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DocumentAndEntityInformationAbstract" id="skye_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DouglasCesarioMember" id="skye_DouglasCesarioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DrawDownsLoansInAggregatePrincipalAmount" id="skye_DrawDownsLoansInAggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" id="skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EmeraldConvertiblePromissoryNoteConversionLiabilityMember" id="skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingIssuanceCosts" id="skye_EmeraldFinancingIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EmeraldFinancingMember" id="skye_EmeraldFinancingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantsLiabilityMember" id="skye_EmeraldFinancingWarrantsLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldHealthSciencesIncMember" id="skye_EmeraldHealthSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" id="skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldWarrantLiabilityMember" id="skye_EmeraldWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityLineItems" id="skye_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityTable" id="skye_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="EstimatedAgreementFeesAndExpenses" id="skye_EstimatedAgreementFeesAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EstimatedInitialPaymentForContract" id="skye_EstimatedInitialPaymentForContract" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExerciseOfWarrants" id="skye_ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairMarketValueOfSharesGranted" id="skye_FairMarketValueOfSharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairMarketValueOfStockOptions" id="skye_FairMarketValueOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" id="skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfCommonStockWarrantsIssued" id="skye_FairValueOfCommonStockWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" id="skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfDerivativeLiabilitiesRollForward" id="skye_FairValueOfDerivativeLiabilitiesRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfDerivativeLiabilityExcessOfProceeds" id="skye_FairValueOfDerivativeLiabilityExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfDerivativeLiabilityInExcessOfProceeds" id="skye_FairValueOfDerivativeLiabilityInExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfSharesUnderlyingConvertibleDebt1" id="skye_FairValueOfSharesUnderlyingConvertibleDebt1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfUnderlyingShares" id="skye_FairValueOfUnderlyingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantLiabilityInExcessForProceeds" id="skye_FairValueOfWarrantLiabilityInExcessForProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssued" id="skye_FairValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfWarrantsIssuedInConnectionWithFinancings" id="skye_FairValueOfWarrantsIssuedInConnectionWithFinancings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FeesAndExpensesForServicesProvided" id="skye_FeesAndExpensesForServicesProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FeesIncurredUnderAgreement" id="skye_FeesIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FifthAmendedAndRestatedMultiDrawCreditAgreementMember" id="skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancingSharesWarrantExercise" id="skye_FinancingSharesWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancingValueWarrantExercise" id="skye_FinancingValueWarrantExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FixedAssetsProvidedToUniversityInLieuOfCash" id="skye_FixedAssetsProvidedToUniversityInLieuOfCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FourthAmendedAndRestatedMultiDrawCreditAgreementMember" id="skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GlauconixBiosciencesIncMember" id="skye_GlauconixBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrossProceedsOfUnitsSold" id="skye_GrossProceedsOfUnitsSold" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="GrossProceedsOfWarrant" id="skye_GrossProceedsOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="GuarantorFailedToPay" id="skye_GuarantorFailedToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxReconciliationChangeInCompoundDerivative" id="skye_IncomeTaxReconciliationChangeInCompoundDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxReconciliationUncertainTaxPositions" id="skye_IncomeTaxReconciliationUncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseChangeInFairValueOfWarrantLiability" id="skye_IncreaseChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDepositsAndOtherAssets" id="skye_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncrementalAgreementFeesAndExpenses" id="skye_IncrementalAgreementFeesAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IndependentContractorAgreementMember" id="skye_IndependentContractorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InitialTermOfAgreement" id="skye_InitialTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember" id="skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IntrinsicValueOfWarrantExercises" id="skye_IntrinsicValueOfWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfPreferredStockNetOfIssuanceCosts" id="skye_IssuanceOfPreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfPreferredStockNetOfIssuanceCostsShares" id="skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares" id="skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue" id="skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="K2CIncMember" id="skye_K2CIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeaseAgreementMember" id="skye_LeaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LetterAgreementMember" id="skye_LetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementMember" id="skye_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseFee" id="skye_LicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LiquidationProvisionCommonStockEquivalentShares" id="skye_LiquidationProvisionCommonStockEquivalentShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidationProvisionCommonStockEquivalentValue" id="skye_LiquidationProvisionCommonStockEquivalentValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossOnCommonStockIssuanceFromConversionOfAccruedInterest" id="skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LumpSumPaymentInAgreement" id="skye_LumpSumPaymentInAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterServiceAgreementMember" id="skye_MasterServiceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone1Member" id="skye_Milestone1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone2Member" id="skye_Milestone2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone3Member" id="skye_Milestone3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentsPayableAxis" id="skye_MilestonePaymentsPayableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MilestonePaymentsPayableDomain" id="skye_MilestonePaymentsPayableDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MinimumLitigationJudgementAmount" id="skye_MinimumLitigationJudgementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonteCarloSimulationsMember" id="skye_MonteCarloSimulationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthAndYearOfAgreementAxis" id="skye_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MonthAndYearOfAgreementDomain" id="skye_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthlyFee" id="skye_MonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" id="skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MonthlyFeePaidEachMonthInExchangeOfServices" id="skye_MonthlyFeePaidEachMonthInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MultiDrawCreditAgreementMember" id="skye_MultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesAbstract" id="skye_NatureOfOperationsAndBusinessActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesLineItems" id="skye_NatureOfOperationsAndBusinessActivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesTable" id="skye_NatureOfOperationsAndBusinessActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="NetLossAdjustedBalance" id="skye_NetLossAdjustedBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonCashInterestExpenseAbstract" id="skye_NonCashInterestExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoramcoAgreementMember" id="skye_NoramcoAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoticePeriodForTermination" id="skye_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonStockIssuedUponConversionOfPreferredStock" id="skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonStockUnitsSold" id="skye_NumberOfCommonStockUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfInvestors" id="skye_NumberOfInvestors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfLicenseAgreements" id="skye_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfPreFundedUnitsSold" id="skye_NumberOfPreFundedUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercisable" id="skye_NumberOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="skye_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OctoberTwoThousandFifteenMember" id="skye_OctoberTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OfficersEmployeeAndDirectorsMember" id="skye_OfficersEmployeeAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OmnibusIncentivePlan2014Member" id="skye_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OneTimeUpfrontPayment" id="skye_OneTimeUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OptionAgreementMember" id="skye_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionsMember" id="skye_OptionsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaycheckProtectionProgrammeMember" id="skye_PaycheckProtectionProgrammeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaycheckProtectionProgramPromissoryNoteMember" id="skye_PaycheckProtectionProgramPromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentForUpfrontFees" id="skye_PaymentForUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentOfUpfrontLicenseFee" id="skye_PaymentOfUpfrontLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PayrollCostExcludeCompensation" id="skye_PayrollCostExcludeCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PercentageOfAccruedConsultingFee" id="skye_PercentageOfAccruedConsultingFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAccruedInterestOnOutstandingBalance" id="skye_PercentageOfAccruedInterestOnOutstandingBalance" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" id="skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfBonusForAccruedConsultingFee" id="skye_PercentageOfBonusForAccruedConsultingFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfConversionAmount" id="skye_PercentageOfConversionAmount" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfForgivenessAmountForNonPayrollCost" id="skye_PercentageOfForgivenessAmountForNonPayrollCost" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" id="skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" id="skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfSharesToBeRedeemed" id="skye_PercentageOfSharesToBeRedeemed" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentOfReductionInAnnualSalary" id="skye_PercentOfReductionInAnnualSalary" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" id="skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PharmaceuticalsInternationalInc.AgreementMember" id="skye_PharmaceuticalsInternationalInc.AgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentMember" id="skye_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentWarrantMember" id="skye_PlacementAgentWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Pre2015CommonStockWarrantsMember" id="skye_Pre2015CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreferredStockPutOptionLiability" id="skye_PreferredStockPutOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PreFundedUnitSoldPricePerUnit" id="skye_PreFundedUnitSoldPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreFundedWarrantMember" id="skye_PreFundedWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrefundedWarrantsMember" id="skye_PrefundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelAxis" id="skye_PricingModelAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="PricingModelDomain" id="skye_PricingModelDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelMember" id="skye_PricingModelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" id="skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromConvertibleMultiDrawCreditAgreement" id="skye_ProceedsFromConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromEmeraldFinancingNetOfIssuanceCosts" id="skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" id="skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfCommonStockAndWarrantNet" id="skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProvisionForConversionOfPreferredStock" id="skye_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReclassificationOfDerivativesToEquity" id="skye_ReclassificationOfDerivativesToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RedemptionAmountPercentage" id="skye_RedemptionAmountPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" id="skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RemainingDrawDownsLoans" id="skye_RemainingDrawDownsLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepaymentOfConvertibleMultiDrawCreditAgreement" id="skye_RepaymentOfConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ResearchAgreementMember" id="skye_ResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedStockAgreementsMember" id="skye_RestrictedStockAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAndUncertaintiesPolicyTextBlock" id="skye_RisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RrdInternationalAgreementMember" id="skye_RrdInternationalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" id="skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" id="skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfInterestExpenseTableTextBlock" id="skye_ScheduleOfInterestExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondDrawOnMultiDrawCreditFacilityMember" id="skye_SecondDrawOnMultiDrawCreditFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuredPromissoryNoteAndSecurityAgreementMember" id="skye_SecuredPromissoryNoteAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementMember" id="skye_SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" id="skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeniorManagementCompensationPlanDescription" id="skye_SeniorManagementCompensationPlanDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAndReleaseAgreementMember" id="skye_SeparationAndReleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBCommonStockWarrantMember" id="skye_SeriesBCommonStockWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBPreferredStockConversionLiabilityMember" id="skye_SeriesBPreferredStockConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantMember" id="skye_SeriesBWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantsMember" id="skye_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesFPreferredStockPutOptionLiabilityMember" id="skye_SeriesFPreferredStockPutOptionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareAndWarrantsIssuanceCosts" id="skye_ShareAndWarrantsIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareIssuanceCosts" id="skye_ShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SignificantContractsAbstract" id="skye_SignificantContractsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantContractsLineItems" id="skye_SignificantContractsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantContractsTable" id="skye_SignificantContractsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SignificantContractsTextBlock" id="skye_SignificantContractsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" id="skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockBasedCompensationForNonEmployeesPolicyTextBlock" id="skye_StockBasedCompensationForNonEmployeesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuanceCosts" id="skye_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants" id="skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" id="skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNetOfIssuanceCosts" id="skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" id="skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesSeriesBWarrantExercises" id="skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants" id="skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueNetOfIssuanceCosts" id="skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" id="skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueSeriesBWarrantExercises" id="skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SubsequentFinancingPurchasePriceDescription" id="skye_SubsequentFinancingPurchasePriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfAgreement" id="skye_TermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrant" id="skye_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrants" id="skye_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermsOfAgreementRenewed" id="skye_TermsOfAgreementRenewed" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalExpenseIncurredUnderAgreement" id="skye_TotalExpenseIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TwoThousandAndTwentyCommonStockWarrantsMember" id="skye_TwoThousandAndTwentyCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" id="skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandAndTwentyPreFundedWarrantsMember" id="skye_TwoThousandAndTwentyPreFundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandEighteenEmeraldFinancingWarrantsMember" id="skye_TwoThousandEighteenEmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenCommonStockWarrantsMember" id="skye_TwoThousandFifteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" id="skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" id="skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandNineteenCommonStockWarrantsMember" id="skye_TwoThousandNineteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5050ProdrugAndUm8930AnalogAgreementsMember" id="skye_Um5050ProdrugAndUm8930AnalogAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5070LicenseAgreementMember" id="skye_Um5070LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnamortizedDebtDiscountPeriod" id="skye_UnamortizedDebtDiscountPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsLineItems" id="skye_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsTable" id="skye_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="UniversityOfMississippiMember" id="skye_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnvestedRestrictedStockMember" id="skye_UnvestedRestrictedStockMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UpfrontPayment" id="skye_UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ValueOfCommonStockCalledByWarrants" id="skye_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity" id="skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsAndDerivativeLiabilitiesAbstract" id="skye_WarrantsAndDerivativeLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndDerivativeLiabilitiesTextBlock" id="skye_WarrantsAndDerivativeLiabilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" id="skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsLiabilityClassifiedMember" id="skye_WarrantsLiabilityClassifiedMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsMember" id="skye_WarrantsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsVestedAndOutstanding" id="skye_WarrantsVestedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WorkingCapitalDeficit" id="skye_WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>skye-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetails1" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetails2" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#OtherCurrentLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedInterestRelatedParty" xlink:label="loc_skye_AccruedInterestRelatedParty_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaap_OtherLongTermDebtCurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLoansPayableLongTerm" xlink:label="loc_us-gaap_OtherLoansPayableLongTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_Liabilities_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LiabilitiesCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_skye_AccruedInterestRelatedParty_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_12" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_OtherLongTermDebtCurrent_13" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_17" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_OtherLoansPayableLongTerm_18" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_PreferredStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_skye_ChangeInFairValueOfDerivativeLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_OperatingExpenses_2" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_skye_ChangeInFairValueOfDerivativeLiabilities_6" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_InterestExpense_10" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockIssuedForServices" xlink:label="loc_skye_CommonStockIssuedForServices_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_skye_IncreaseDecreaseInDepositsAndOtherAssets_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_24"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_25"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RepaymentOfConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt_27"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_skye_CommonStockIssuedForServices_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_skye_IncreaseDecreaseInDepositsAndOtherAssets_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14" order="130" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15" order="140" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_16" order="150" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_17" order="160" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_18" order="170" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_23" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_24" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" xlink:to="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_25" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" xlink:to="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_26" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" xlink:to="loc_us-gaap_ProceedsFromOtherShortTermDebt_27" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsAmortization" xlink:label="loc_skye_DeferredTaxAssetsAmortization_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxLiabilitiesNoteDiscount" xlink:label="loc_skye_DeferredTaxLiabilitiesNoteDiscount_9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_skye_DeferredTaxAssetsAmortization_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredTaxLiabilities_9" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9" xlink:to="loc_skye_DeferredTaxLiabilitiesNoteDiscount_9" order="0" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" xlink:label="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncomeTaxReconciliationChangeInCompoundDerivative" xlink:label="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10" order="90" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedBoardFees" xlink:label="loc_skye_AccruedBoardFees_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedResearchAndDevelopmentCosts" xlink:label="loc_skye_AccruedResearchAndDevelopmentCosts_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_skye_AccruedBoardFees_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_skye_AccruedResearchAndDevelopmentCosts_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedSalariesCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5" order="40" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>skye-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationTables" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails6" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockholdersEquityDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails4" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#RelatedPartyMattersDetails" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetailTextuals" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NetIncomeLossPerShareOfCommonStockDetails" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NetIncomeLossPerShareOfCommonStockDetails1" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails3" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails5" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails5"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuanceCosts" xlink:label="loc_skye_StockIssuanceCosts_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_skye_StockIssuanceCosts_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FinancingValueWarrantExercise" xlink:label="loc_skye_FinancingValueWarrantExercise_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FinancingSharesWarrantExercise" xlink:label="loc_skye_FinancingSharesWarrantExercise_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_StockholdersEquity_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_SharesIssued_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_FinancingValueWarrantExercise_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_skye_FinancingSharesWarrantExercise_23" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_NetIncomeLoss_24" order="160" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativeLiabilitiesLineItems" xlink:label="loc_skye_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativesLiabilitiesTable" xlink:label="loc_skye_DerivativesLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_skye_EmeraldFinancingWarrantsLiabilityMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_skye_DerivativesLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_skye_EmeraldFinancingWarrantsLiabilityMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_skye_SeriesBWarrantMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_17" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AwardsGrantedOutside2014PlanMember" xlink:label="loc_skye_AwardsGrantedOutside2014PlanMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_skye_AwardsGrantedOutside2014PlanMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MultiDrawCreditAgreementMember" xlink:label="loc_skye_MultiDrawCreditAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" xlink:label="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_29"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_33"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RemainingDrawDownsLoans" xlink:label="loc_skye_RemainingDrawDownsLoans_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_35"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfCommonStockUnitsSold" xlink:label="loc_skye_NumberOfCommonStockUnitsSold_36"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfPreFundedUnitsSold" xlink:label="loc_skye_NumberOfPreFundedUnitsSold_37"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfUnitsSold" xlink:label="loc_skye_GrossProceedsOfUnitsSold_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_39"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeniorManagementCompensationPlanDescription" xlink:label="loc_skye_SeniorManagementCompensationPlanDescription_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_41"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_MultiDrawCreditAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9" xlink:to="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_CommonStockWarrantsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_PrefundedWarrantsMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_18" xlink:to="loc_us-gaap_SubsequentEventMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_Cash_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_26" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_27" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_28" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_29" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_30" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_33" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_RemainingDrawDownsLoans_34" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_35" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_NumberOfCommonStockUnitsSold_36" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_NumberOfPreFundedUnitsSold_37" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_GrossProceedsOfUnitsSold_38" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_39" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_skye_SeniorManagementCompensationPlanDescription_40" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_41" order="190" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentWarrantMember" xlink:label="loc_skye_PlacementAgentWarrantMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PrefundedWarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PlacementAgentWarrantMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_PricingModelAxis_8" xlink:to="loc_skye_PricingModelDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_PricingModelDomain_8" xlink:to="loc_skye_PricingModelMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_PricingModelAxis_8" xlink:to="loc_skye_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_12" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_16" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_12" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_20" xlink:to="loc_srt_RangeMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20" xlink:to="loc_srt_MinimumMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20" xlink:to="loc_srt_MaximumMember_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_27" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativeLiabilitiesLineItems" xlink:label="loc_skye_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativesLiabilitiesTable" xlink:label="loc_skye_DerivativesLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantsIssued" xlink:label="loc_skye_FairValueOfWarrantsIssued_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ReclassificationOfDerivativesToEquity" xlink:label="loc_skye_ReclassificationOfDerivativesToEquity_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_skye_DerivativesLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_skye_SeriesBWarrantMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_0" xlink:to="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilities_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_skye_FairValueOfWarrantsIssued_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_skye_ReclassificationOfDerivativesToEquity_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EquityLineItems" xlink:label="loc_skye_EquityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EquityTable" xlink:label="loc_skye_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuritiesPurchaseAgreementMember" xlink:label="loc_skye_SecuritiesPurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember" xlink:label="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBCommonStockWarrantMember" xlink:label="loc_skye_SeriesBCommonStockWarrantMember_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantsMember" xlink:label="loc_skye_SeriesBWarrantsMember_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_24"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentMember" xlink:label="loc_skye_PlacementAgentMember_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_skye_ClassOfWarrantOrRightWarrantsExercise_33"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IntrinsicValueOfWarrantExercises" xlink:label="loc_skye_IntrinsicValueOfWarrantExercises_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_36"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_skye_SubsequentFinancingPurchasePriceDescription_37"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingIssuanceCosts" xlink:label="loc_skye_EmeraldFinancingIssuanceCosts_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_39"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" xlink:label="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_40"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfCommonStockUnitsSold" xlink:label="loc_skye_NumberOfCommonStockUnitsSold_41"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfPreFundedUnitsSold" xlink:label="loc_skye_NumberOfPreFundedUnitsSold_42"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonUnitSoldPricePerUnit" xlink:label="loc_skye_CommonUnitSoldPricePerUnit_43"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_44"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PreFundedUnitSoldPricePerUnit" xlink:label="loc_skye_PreFundedUnitSoldPricePerUnit_45"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfUnitsSold" xlink:label="loc_skye_GrossProceedsOfUnitsSold_46"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_48"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_49"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" xlink:label="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_51"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_52"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_EquityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_SecuritiesPurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" xlink:to="loc_us-gaap_IPOMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" xlink:to="loc_us-gaap_PrivatePlacementMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" xlink:to="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_skye_PrefundedWarrantsMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_skye_SeriesBCommonStockWarrantMember_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_skye_SeriesBWarrantsMember_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_skye_CommonStockWarrantsMember_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_24" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_24" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_24" xlink:to="loc_skye_PlacementAgentMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_24" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_31" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_ClassOfWarrantOrRightWarrantsExercise_33" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_IntrinsicValueOfWarrantExercises_34" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_BridgeLoan_36" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_SubsequentFinancingPurchasePriceDescription_37" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_EmeraldFinancingIssuanceCosts_38" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_39" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_40" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_NumberOfCommonStockUnitsSold_41" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_NumberOfPreFundedUnitsSold_42" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_CommonUnitSoldPricePerUnit_43" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_44" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_PreFundedUnitSoldPricePerUnit_45" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_GrossProceedsOfUnitsSold_46" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_48" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_49" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_51" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_52" order="240" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RestrictedStockAgreementsMember" xlink:label="loc_skye_RestrictedStockAgreementsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_K2CIncMember" xlink:label="loc_skye_K2CIncMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_ChiefFinancialOfficerMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_skye_RestrictedStockAgreementsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_dei_LegalEntityAxis_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_skye_K2CIncMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_RestrictedStockExpense_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_27" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DouglasCesarioMember" xlink:label="loc_skye_DouglasCesarioMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RestrictedStockAgreementsMember" xlink:label="loc_skye_RestrictedStockAgreementsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairMarketValueOfStockOptions" xlink:label="loc_skye_FairMarketValueOfStockOptions_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_10" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_skye_DouglasCesarioMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_10" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14" xlink:to="loc_skye_RestrictedStockAgreementsMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_skye_FairMarketValueOfStockOptions_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_27" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_28" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_29" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_30" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_31" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_33" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_34" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_35" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_36" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37" order="200" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_skye_UniversityOfMississippiAgreementsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiAgreementsTable" xlink:label="loc_skye_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OptionAgreementMember" xlink:label="loc_skye_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LicenseAgreementMember" xlink:label="loc_skye_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Um5070LicenseAgreementMember" xlink:label="loc_skye_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Um5050ProdrugAndUm8930AnalogAgreementsMember" xlink:label="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiMember" xlink:label="loc_skye_UniversityOfMississippiMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementAxis" xlink:label="loc_skye_MonthAndYearOfAgreementAxis_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementDomain" xlink:label="loc_skye_MonthAndYearOfAgreementDomain_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_December2015Member" xlink:label="loc_skye_December2015Member_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OctoberTwoThousandFifteenMember" xlink:label="loc_skye_OctoberTwoThousandFifteenMember_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementDomain" xlink:label="loc_skye_MonthAndYearOfAgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableAxis" xlink:label="loc_skye_MilestonePaymentsPayableAxis_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableDomain" xlink:label="loc_skye_MilestonePaymentsPayableDomain_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone1Member" xlink:label="loc_skye_Milestone1Member_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone2Member" xlink:label="loc_skye_Milestone2Member_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone3Member" xlink:label="loc_skye_Milestone3Member_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableDomain" xlink:label="loc_skye_MilestonePaymentsPayableDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualMaintenanceFeePayable" xlink:label="loc_skye_AnnualMaintenanceFeePayable_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfAgreement" xlink:label="loc_skye_TermOfAgreement_29"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaymentForUpfrontFees" xlink:label="loc_skye_PaymentForUpfrontFees_30"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfLicenseAgreements" xlink:label="loc_skye_NumberOfLicenseAgreements_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NoticePeriodForTermination" xlink:label="loc_skye_NoticePeriodForTermination_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualFeesForLicenseAgreement" xlink:label="loc_skye_AnnualFeesForLicenseAgreement_33"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_OptionAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_LicenseAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_Um5070LicenseAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_skye_UniversityOfMississippiMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_skye_MonthAndYearOfAgreementAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_MonthAndYearOfAgreementAxis_12" xlink:to="loc_skye_MonthAndYearOfAgreementDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_MonthAndYearOfAgreementDomain_12" xlink:to="loc_skye_December2015Member_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_MonthAndYearOfAgreementDomain_12" xlink:to="loc_skye_OctoberTwoThousandFifteenMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_MonthAndYearOfAgreementAxis_12" xlink:to="loc_skye_MonthAndYearOfAgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_skye_MilestonePaymentsPayableAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_MilestonePaymentsPayableAxis_17" xlink:to="loc_skye_MilestonePaymentsPayableDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_MilestonePaymentsPayableDomain_17" xlink:to="loc_skye_Milestone1Member_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_MilestonePaymentsPayableDomain_17" xlink:to="loc_skye_Milestone2Member_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_MilestonePaymentsPayableDomain_17" xlink:to="loc_skye_Milestone3Member_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_MilestonePaymentsPayableAxis_17" xlink:to="loc_skye_MilestonePaymentsPayableDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23" xlink:to="loc_us-gaap_IntellectualPropertyMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_AnnualMaintenanceFeePayable_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_TermOfAgreement_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_PaymentForUpfrontFees_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_NumberOfLicenseAgreements_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_NoticePeriodForTermination_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_AnnualFeesForLicenseAgreement_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_34" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IndependentContractorAgreementMember" xlink:label="loc_skye_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AvtarDhillonMember" xlink:label="loc_skye_AvtarDhillonMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OfficersEmployeeAndDirectorsMember" xlink:label="loc_skye_OfficersEmployeeAndDirectorsMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_InitialTermOfAgreement" xlink:label="loc_skye_InitialTermOfAgreement_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TotalExpenseIncurredUnderAgreement" xlink:label="loc_skye_TotalExpenseIncurredUnderAgreement_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFee" xlink:label="loc_skye_MonthlyFee_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAccruedConsultingFee" xlink:label="loc_skye_PercentageOfAccruedConsultingFee_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfBonusForAccruedConsultingFee" xlink:label="loc_skye_PercentageOfBonusForAccruedConsultingFee_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FeesIncurredUnderAgreement" xlink:label="loc_skye_FeesIncurredUnderAgreement_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedExpenseUnderAgreement" xlink:label="loc_skye_AccruedExpenseUnderAgreement_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_IndependentContractorAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_skye_AvtarDhillonMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_skye_OfficersEmployeeAndDirectorsMember_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_InitialTermOfAgreement_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_TotalExpenseIncurredUnderAgreement_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_MonthlyFee_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_PercentageOfAccruedConsultingFee_19" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_PercentageOfBonusForAccruedConsultingFee_20" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_FeesIncurredUnderAgreement_21" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_skye_AccruedExpenseUnderAgreement_22" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_23" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_ForeignCountryMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesAxis" xlink:label="loc_skye_DilutedSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesDomain" xlink:label="loc_skye_DilutedSecuritiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UnvestedRestrictedStockMember" xlink:label="loc_skye_UnvestedRestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OptionsMember" xlink:label="loc_skye_OptionsMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsMember" xlink:label="loc_skye_WarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsLiabilityClassifiedMember" xlink:label="loc_skye_WarrantsLiabilityClassifiedMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesDomain" xlink:label="loc_skye_DilutedSecuritiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" xlink:label="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" xlink:to="loc_skye_DilutedSecuritiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_DilutedSecuritiesAxis_1" xlink:to="loc_skye_DilutedSecuritiesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_UnvestedRestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_OptionsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_WarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_WarrantsLiabilityClassifiedMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_DilutedSecuritiesAxis_1" xlink:to="loc_skye_DilutedSecuritiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_0" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9" xlink:to="loc_us-gaap_DilutiveSecurities_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9" xlink:to="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonSharesUnderlyingConvertiblePreferredStockMember" xlink:label="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_14" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_PricingModelAxis_18" xlink:to="loc_skye_PricingModelDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_PricingModelDomain_18" xlink:to="loc_skye_PricingModelMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_PricingModelAxis_18" xlink:to="loc_skye_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonteCarloSimulationsMember" xlink:label="loc_skye_MonteCarloSimulationsMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_PricingModelAxis_8" xlink:to="loc_skye_PricingModelDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_PricingModelDomain_8" xlink:to="loc_skye_MonteCarloSimulationsMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_PricingModelAxis_8" xlink:to="loc_skye_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_skye_EmeraldFinancingMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MinimumMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_skye_PricingModelAxis_9" xlink:to="loc_skye_PricingModelDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_skye_PricingModelDomain_9" xlink:to="loc_skye_PricingModelMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_skye_PricingModelAxis_9" xlink:to="loc_skye_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_skye_SeriesBWarrantMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18" xlink:to="loc_srt_RangeMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18" xlink:to="loc_srt_MinimumMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18" xlink:to="loc_srt_MaximumMember_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Pre2015CommonStockWarrantsMember" xlink:label="loc_skye_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyPreFundedWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfWarrant" xlink:label="loc_skye_TermOfWarrant_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsVestedAndOutstanding" xlink:label="loc_skye_WarrantsVestedAndOutstanding_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_Pre2015CommonStockWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_11" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_12" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MinimumMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_TermOfWarrant_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_WarrantsVestedAndOutstanding_23" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_skye_PrefundedWarrantsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_skye_CommonStockWarrantsMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_15" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_skye_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldWarrantLiabilityMember" xlink:label="loc_skye_EmeraldWarrantLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantsMember" xlink:label="loc_skye_SeriesBWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentWarrantMember" xlink:label="loc_skye_PlacementAgentWarrantMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_25"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfWarrant" xlink:label="loc_skye_GrossProceedsOfWarrant_26"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ValueOfCommonStockCalledByWarrants" xlink:label="loc_skye_ValueOfCommonStockCalledByWarrants_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity" xlink:label="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfWarrant" xlink:label="loc_skye_TermOfWarrant_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_35"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AggregateExercisePriceOfOutstandingCreditAgreements" xlink:label="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_36"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_skye_ClassOfWarrantOrRightWarrantsExercise_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_EmeraldFinancingWarrantsLiabilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_EmeraldWarrantLiabilityMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_SeriesBWarrantsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_CommonStockWarrantsMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PrefundedWarrantsMember_11" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PlacementAgentWarrantMember_12" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_16" xlink:to="loc_us-gaap_EquityComponentDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_WarrantMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_16" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_20" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_20" xlink:to="loc_dei_EntityDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_20" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_20" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_GrossProceedsOfWarrant_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_ValueOfCommonStockCalledByWarrants_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_29" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_TermOfWarrant_32" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_34" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_35" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_36" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_skye_ClassOfWarrantOrRightWarrantsExercise_37" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38" order="140" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_16" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MultiDrawCreditAgreementMember" xlink:label="loc_skye_MultiDrawCreditAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IndependentContractorAgreementMember" xlink:label="loc_skye_IndependentContractorAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaycheckProtectionProgrammeMember" xlink:label="loc_skye_PaycheckProtectionProgrammeMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_25"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_26"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CreditFacilityEffectedFourthAdvance" xlink:label="loc_skye_CreditFacilityEffectedFourthAdvance_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CreditFacilityEffectedFifthAdvance" xlink:label="loc_skye_CreditFacilityEffectedFifthAdvance_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_35"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantLiabilityInExcessForProceeds" xlink:label="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_36"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UnamortizedDebtDiscountPeriod" xlink:label="loc_skye_UnamortizedDebtDiscountPeriod_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_38"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfSharesUnderlyingConvertibleDebt1" xlink:label="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PayrollCostExcludeCompensation" xlink:label="loc_skye_PayrollCostExcludeCompensation_42"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfForgivenessAmountForNonPayrollCost" xlink:label="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_43"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_44"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentOfReductionInAnnualSalary" xlink:label="loc_skye_PercentOfReductionInAnnualSalary_45"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_skye_MultiDrawCreditAgreementMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_skye_IndependentContractorAgreementMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_11" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_11" xlink:to="loc_skye_PaycheckProtectionProgrammeMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_11" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_22" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_24" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_25" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_26" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_27" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_CreditFacilityEffectedFourthAdvance_28" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_CreditFacilityEffectedFifthAdvance_29" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_30" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilities_31" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_32" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_33" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_34" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_35" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_36" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_UnamortizedDebtDiscountPeriod_37" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_38" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_39" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_40" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_PayrollCostExcludeCompensation_42" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_43" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_44" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_skye_PercentOfReductionInAnnualSalary_45" order="300" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>skye-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedBoardFees" xlink:label="loc_skye_AccruedBoardFees_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedExpenseUnderAgreement" xlink:label="loc_skye_AccruedExpenseUnderAgreement_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedInterestRelatedParty" xlink:label="loc_skye_AccruedInterestRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedResearchAndDevelopmentCosts" xlink:label="loc_skye_AccruedResearchAndDevelopmentCosts_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AdditionalConversionLiability" xlink:label="loc_skye_AdditionalConversionLiability_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AggregateExercisePriceOfOutstandingCreditAgreements" xlink:label="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmortizationOfDebtDiscount" xlink:label="loc_skye_AmortizationOfDebtDiscount_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmortizationOfTransactionCosts" xlink:label="loc_skye_AmortizationOfTransactionCosts_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmountOfEachWarrantOutstanding" xlink:label="loc_skye_AmountOfEachWarrantOutstanding_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmountOfPassThroughExpensesAndConsultingFees" xlink:label="loc_skye_AmountOfPassThroughExpensesAndConsultingFees_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualFeeForAgreement" xlink:label="loc_skye_AnnualFeeForAgreement_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualFeesForLicenseAgreement" xlink:label="loc_skye_AnnualFeesForLicenseAgreement_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualMaintenanceFeePayable" xlink:label="loc_skye_AnnualMaintenanceFeePayable_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualMaintenanceFees" xlink:label="loc_skye_AnnualMaintenanceFees_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_August2020FinancingMember" xlink:label="loc_skye_August2020FinancingMember_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AvtarDhillonMember" xlink:label="loc_skye_AvtarDhillonMember_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AwardsGrantedOutside2014PlanMember" xlink:label="loc_skye_AwardsGrantedOutside2014PlanMember_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AwardsGrantedOutsideThe2014PlanMember" xlink:label="loc_skye_AwardsGrantedOutsideThe2014PlanMember_23"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_24"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_25"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock" xlink:label="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_26"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock" xlink:label="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_skye_ChangeInFairValueOfDerivativeLiabilities_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ChangeInFairValueOfWarrantLiability" xlink:label="loc_skye_ChangeInFairValueOfWarrantLiability_29"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice" xlink:label="loc_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_30"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_skye_ClassOfWarrantOrRightWarrantsExercise_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonSharesUnderlyingConvertiblePreferredStockMember" xlink:label="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockAggregatePurchasePrice" xlink:label="loc_skye_CommonStockAggregatePurchasePrice_33"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockIssuedForServices" xlink:label="loc_skye_CommonStockIssuedForServices_34"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_35"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_skye_CommonStockWarrantsToSeriesBStockholdersMember_36"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonUnitSoldPricePerUnit" xlink:label="loc_skye_CommonUnitSoldPricePerUnit_37"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConsultingAgreementMember" xlink:label="loc_skye_ConsultingAgreementMember_38"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ContractPayableDue" xlink:label="loc_skye_ContractPayableDue_39"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionLiabilityIntoCommonStockPerShare" xlink:label="loc_skye_ConversionLiabilityIntoCommonStockPerShare_40"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_41"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" xlink:label="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_42"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" xlink:label="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_43"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" xlink:label="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_44"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" xlink:label="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_45"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSeriesCPreferredStockToCommonStockShares" xlink:label="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_46"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue" xlink:label="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_47"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSeriesDPreferredStockToCommonStock" xlink:label="loc_skye_ConversionOfSeriesDPreferredStockToCommonStock_48"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSeriesDPreferredStockToCommonStockShares" xlink:label="loc_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_49"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSeriesFPreferredStockToCommonStockShares" xlink:label="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_50"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionOfSeriesFPreferredStockToCommonStockValue" xlink:label="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_51"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionPrice" xlink:label="loc_skye_ConversionPrice_52"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConversionPricePerShare" xlink:label="loc_skye_ConversionPricePerShare_53"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertedRate10000001Member" xlink:label="loc_skye_ConvertedRate10000001Member_54"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertedRate100001Member" xlink:label="loc_skye_ConvertedRate100001Member_55"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertedRateAxis" xlink:label="loc_skye_ConvertedRateAxis_56"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertedRateDomain" xlink:label="loc_skye_ConvertedRateDomain_57"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertibleDebtRelatedPartyTextBlock" xlink:label="loc_skye_ConvertibleDebtRelatedPartyTextBlock_58"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_59"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CouponInterestExpense" xlink:label="loc_skye_CouponInterestExpense_60"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CreditFacilityEffectedFifthAdvance" xlink:label="loc_skye_CreditFacilityEffectedFifthAdvance_61"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CreditFacilityEffectedFourthAdvance" xlink:label="loc_skye_CreditFacilityEffectedFourthAdvance_62"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_63"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_December2015Member" xlink:label="loc_skye_December2015Member_64"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock" xlink:label="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_65"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock" xlink:label="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_66"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsAmortization" xlink:label="loc_skye_DeferredTaxAssetsAmortization_67"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_68"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal" xlink:label="loc_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_69"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxLiabilitiesNoteDiscount" xlink:label="loc_skye_DeferredTaxLiabilitiesNoteDiscount_70"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativeLiabilitiesLineItems" xlink:label="loc_skye_DerivativeLiabilitiesLineItems_71"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativeLiabilitiesTable" xlink:label="loc_skye_DerivativeLiabilitiesTable_72"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativesLiabilitiesTable" xlink:label="loc_skye_DerivativesLiabilitiesTable_73"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesDomain" xlink:label="loc_skye_DilutedSecuritiesDomain_74"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" xlink:label="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_75"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DouglasCesarioMember" xlink:label="loc_skye_DouglasCesarioMember_76"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_77"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" xlink:label="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_78"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_79"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingIssuanceCosts" xlink:label="loc_skye_EmeraldFinancingIssuanceCosts_80"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_81"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_skye_EmeraldFinancingWarrantsLiabilityMember_82"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_83"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_84"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldWarrantLiabilityMember" xlink:label="loc_skye_EmeraldWarrantLiabilityMember_85"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EquityLineItems" xlink:label="loc_skye_EquityLineItems_86"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EquityTable" xlink:label="loc_skye_EquityTable_87"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EstimatedAgreementFeesAndExpenses" xlink:label="loc_skye_EstimatedAgreementFeesAndExpenses_88"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EstimatedInitialPaymentForContract" xlink:label="loc_skye_EstimatedInitialPaymentForContract_89"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ExerciseOfWarrants" xlink:label="loc_skye_ExerciseOfWarrants_90"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairMarketValueOfSharesGranted" xlink:label="loc_skye_FairMarketValueOfSharesGranted_91"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairMarketValueOfStockOptions" xlink:label="loc_skye_FairMarketValueOfStockOptions_92"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_93"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfCommonStockWarrantsIssued" xlink:label="loc_skye_FairValueOfCommonStockWarrantsIssued_94"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_95"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_96"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_97"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_98"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfSharesUnderlyingConvertibleDebt1" xlink:label="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_99"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfUnderlyingShares" xlink:label="loc_skye_FairValueOfUnderlyingShares_100"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantLiabilityInExcessForProceeds" xlink:label="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantsIssued" xlink:label="loc_skye_FairValueOfWarrantsIssued_102"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantsIssuedInConnectionWithFinancings" xlink:label="loc_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_103"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FeesAndExpensesForServicesProvided" xlink:label="loc_skye_FeesAndExpensesForServicesProvided_104"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FeesIncurredUnderAgreement" xlink:label="loc_skye_FeesIncurredUnderAgreement_105"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_106"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FinancingSharesWarrantExercise" xlink:label="loc_skye_FinancingSharesWarrantExercise_107"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FinancingValueWarrantExercise" xlink:label="loc_skye_FinancingValueWarrantExercise_108"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FixedAssetsProvidedToUniversityInLieuOfCash" xlink:label="loc_skye_FixedAssetsProvidedToUniversityInLieuOfCash_109"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_110"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GlauconixBiosciencesIncMember" xlink:label="loc_skye_GlauconixBiosciencesIncMember_111"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfUnitsSold" xlink:label="loc_skye_GrossProceedsOfUnitsSold_112"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfWarrant" xlink:label="loc_skye_GrossProceedsOfWarrant_113"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GuarantorFailedToPay" xlink:label="loc_skye_GuarantorFailedToPay_114"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncomeTaxReconciliationChangeInCompoundDerivative" xlink:label="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_115"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_116"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncreaseChangeInFairValueOfWarrantLiability" xlink:label="loc_skye_IncreaseChangeInFairValueOfWarrantLiability_117"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_skye_IncreaseDecreaseInDepositsAndOtherAssets_118"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncrementalAgreementFeesAndExpenses" xlink:label="loc_skye_IncrementalAgreementFeesAndExpenses_119"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IndependentContractorAgreementMember" xlink:label="loc_skye_IndependentContractorAgreementMember_120"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_InitialTermOfAgreement" xlink:label="loc_skye_InitialTermOfAgreement_121"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember" xlink:label="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_122"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IntrinsicValueOfWarrantExercises" xlink:label="loc_skye_IntrinsicValueOfWarrantExercises_123"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IssuanceOfPreferredStockNetOfIssuanceCosts" xlink:label="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_124"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares" xlink:label="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_125"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares" xlink:label="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_126"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue" xlink:label="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_127"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_K2CIncMember" xlink:label="loc_skye_K2CIncMember_128"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LetterAgreementMember" xlink:label="loc_skye_LetterAgreementMember_129"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LicenseAgreementMember" xlink:label="loc_skye_LicenseAgreementMember_130"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LicenseFee" xlink:label="loc_skye_LicenseFee_131"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LiquidationProvisionCommonStockEquivalentShares" xlink:label="loc_skye_LiquidationProvisionCommonStockEquivalentShares_132"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LiquidationProvisionCommonStockEquivalentValue" xlink:label="loc_skye_LiquidationProvisionCommonStockEquivalentValue_133"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_134"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LumpSumPaymentInAgreement" xlink:label="loc_skye_LumpSumPaymentInAgreement_135"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MasterServiceAgreementMember" xlink:label="loc_skye_MasterServiceAgreementMember_136"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone1Member" xlink:label="loc_skye_Milestone1Member_137"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone2Member" xlink:label="loc_skye_Milestone2Member_138"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone3Member" xlink:label="loc_skye_Milestone3Member_139"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableAxis" xlink:label="loc_skye_MilestonePaymentsPayableAxis_140"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableDomain" xlink:label="loc_skye_MilestonePaymentsPayableDomain_141"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MinimumLitigationJudgementAmount" xlink:label="loc_skye_MinimumLitigationJudgementAmount_142"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonteCarloSimulationsMember" xlink:label="loc_skye_MonteCarloSimulationsMember_143"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementAxis" xlink:label="loc_skye_MonthAndYearOfAgreementAxis_144"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementDomain" xlink:label="loc_skye_MonthAndYearOfAgreementDomain_145"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFee" xlink:label="loc_skye_MonthlyFee_146"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_147"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_148"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MultiDrawCreditAgreementMember" xlink:label="loc_skye_MultiDrawCreditAgreementMember_149"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesAbstract_150"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_151"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_152"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NetLossAdjustedBalance" xlink:label="loc_skye_NetLossAdjustedBalance_153"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NoramcoAgreementMember" xlink:label="loc_skye_NoramcoAgreementMember_154"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NoticePeriodForTermination" xlink:label="loc_skye_NoticePeriodForTermination_155"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xlink:label="loc_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_156"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfCommonStockUnitsSold" xlink:label="loc_skye_NumberOfCommonStockUnitsSold_157"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfInvestors" xlink:label="loc_skye_NumberOfInvestors_158"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfLicenseAgreements" xlink:label="loc_skye_NumberOfLicenseAgreements_159"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfPreFundedUnitsSold" xlink:label="loc_skye_NumberOfPreFundedUnitsSold_160"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfWarrantsExercisable" xlink:label="loc_skye_NumberOfWarrantsExercisable_161"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfWarrantsExercised" xlink:label="loc_skye_NumberOfWarrantsExercised_162"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OctoberTwoThousandFifteenMember" xlink:label="loc_skye_OctoberTwoThousandFifteenMember_163"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OfficersEmployeeAndDirectorsMember" xlink:label="loc_skye_OfficersEmployeeAndDirectorsMember_164"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_165"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OneTimeUpfrontPayment" xlink:label="loc_skye_OneTimeUpfrontPayment_166"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OptionAgreementMember" xlink:label="loc_skye_OptionAgreementMember_167"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OptionsMember" xlink:label="loc_skye_OptionsMember_168"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaycheckProtectionProgrammeMember" xlink:label="loc_skye_PaycheckProtectionProgrammeMember_169"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_170"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaymentForUpfrontFees" xlink:label="loc_skye_PaymentForUpfrontFees_171"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaymentOfUpfrontLicenseFee" xlink:label="loc_skye_PaymentOfUpfrontLicenseFee_172"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PayrollCostExcludeCompensation" xlink:label="loc_skye_PayrollCostExcludeCompensation_173"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAccruedConsultingFee" xlink:label="loc_skye_PercentageOfAccruedConsultingFee_174"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAccruedInterestOnOutstandingBalance" xlink:label="loc_skye_PercentageOfAccruedInterestOnOutstandingBalance_175"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_176"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfBonusForAccruedConsultingFee" xlink:label="loc_skye_PercentageOfBonusForAccruedConsultingFee_177"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfConversionAmount" xlink:label="loc_skye_PercentageOfConversionAmount_178"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfForgivenessAmountForNonPayrollCost" xlink:label="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_179"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_180"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" xlink:label="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_181"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfSharesToBeRedeemed" xlink:label="loc_skye_PercentageOfSharesToBeRedeemed_182"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentOfReductionInAnnualSalary" xlink:label="loc_skye_PercentOfReductionInAnnualSalary_183"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" xlink:label="loc_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_184"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PharmaceuticalsInternationalInc.AgreementMember" xlink:label="loc_skye_PharmaceuticalsInternationalInc.AgreementMember_185"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentMember" xlink:label="loc_skye_PlacementAgentMember_186"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentWarrantMember" xlink:label="loc_skye_PlacementAgentWarrantMember_187"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Pre2015CommonStockWarrantsMember" xlink:label="loc_skye_Pre2015CommonStockWarrantsMember_188"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PreferredStockPutOptionLiability" xlink:label="loc_skye_PreferredStockPutOptionLiability_189"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PreFundedUnitSoldPricePerUnit" xlink:label="loc_skye_PreFundedUnitSoldPricePerUnit_190"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PreFundedWarrantMember" xlink:label="loc_skye_PreFundedWarrantMember_191"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_192"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_193"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_194"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_195"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts" xlink:label="loc_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_196"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_197"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:label="loc_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_198"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProvisionForConversionOfPreferredStock" xlink:label="loc_skye_ProvisionForConversionOfPreferredStock_199"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ReclassificationOfDerivativesToEquity" xlink:label="loc_skye_ReclassificationOfDerivativesToEquity_200"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RedemptionAmountPercentage" xlink:label="loc_skye_RedemptionAmountPercentage_201"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" xlink:label="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_202"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RemainingDrawDownsLoans" xlink:label="loc_skye_RemainingDrawDownsLoans_203"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RepaymentOfConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_204"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ResearchAgreementMember" xlink:label="loc_skye_ResearchAgreementMember_205"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RestrictedStockAgreementsMember" xlink:label="loc_skye_RestrictedStockAgreementsMember_206"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_skye_RisksAndUncertaintiesPolicyTextBlock_207"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RrdInternationalAgreementMember" xlink:label="loc_skye_RrdInternationalAgreementMember_208"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" xlink:label="loc_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_209"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" xlink:label="loc_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_210"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_skye_ScheduleOfInterestExpenseTableTextBlock_211"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecondDrawOnMultiDrawCreditFacilityMember" xlink:label="loc_skye_SecondDrawOnMultiDrawCreditFacilityMember_212"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_skye_SecuredPromissoryNoteAndSecurityAgreementMember_213"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuritiesPurchaseAgreementMember" xlink:label="loc_skye_SecuritiesPurchaseAgreementMember_214"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" xlink:label="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_215"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeniorManagementCompensationPlanDescription" xlink:label="loc_skye_SeniorManagementCompensationPlanDescription_216"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeparationAndReleaseAgreementMember" xlink:label="loc_skye_SeparationAndReleaseAgreementMember_217"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBCommonStockWarrantMember" xlink:label="loc_skye_SeriesBCommonStockWarrantMember_218"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_skye_SeriesBPreferredStockConversionLiabilityMember_219"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_220"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantsMember" xlink:label="loc_skye_SeriesBWarrantsMember_221"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesFPreferredStockPutOptionLiabilityMember" xlink:label="loc_skye_SeriesFPreferredStockPutOptionLiabilityMember_222"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ShareAndWarrantsIssuanceCosts" xlink:label="loc_skye_ShareAndWarrantsIssuanceCosts_223"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ShareIssuanceCosts" xlink:label="loc_skye_ShareIssuanceCosts_224"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsLineItems" xlink:label="loc_skye_SignificantContractsLineItems_225"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsTextBlock" xlink:label="loc_skye_SignificantContractsTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_227"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_228"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuanceCosts" xlink:label="loc_skye_StockIssuanceCosts_229"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_230"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" xlink:label="loc_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_231"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_232"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_233"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_234"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_235"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_236"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_237"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_238"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_skye_SubsequentFinancingPurchasePriceDescription_239"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfAgreement" xlink:label="loc_skye_TermOfAgreement_240"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfWarrant" xlink:label="loc_skye_TermOfWarrant_241"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfWarrants" xlink:label="loc_skye_TermOfWarrants_242"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermsOfAgreementRenewed" xlink:label="loc_skye_TermsOfAgreementRenewed_243"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TotalExpenseIncurredUnderAgreement" xlink:label="loc_skye_TotalExpenseIncurredUnderAgreement_244"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_245"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_246"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyPreFundedWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_247"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_248"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_249"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_250"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_251"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_252"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_253"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_254"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_255"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_256"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_257"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Um5050ProdrugAndUm8930AnalogAgreementsMember" xlink:label="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_258"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Um5070LicenseAgreementMember" xlink:label="loc_skye_Um5070LicenseAgreementMember_259"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UnamortizedDebtDiscountPeriod" xlink:label="loc_skye_UnamortizedDebtDiscountPeriod_260"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_skye_UniversityOfMississippiAgreementsLineItems_261"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiAgreementsTable" xlink:label="loc_skye_UniversityOfMississippiAgreementsTable_262"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiMember" xlink:label="loc_skye_UniversityOfMississippiMember_263"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UnvestedRestrictedStockMember" xlink:label="loc_skye_UnvestedRestrictedStockMember_264"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UpfrontPayment" xlink:label="loc_skye_UpfrontPayment_265"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ValueOfCommonStockCalledByWarrants" xlink:label="loc_skye_ValueOfCommonStockCalledByWarrants_266"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity" xlink:label="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_267"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_skye_WarrantsAndDerivativeLiabilitiesTextBlock_268"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_269"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_270"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsLiabilityClassifiedMember" xlink:label="loc_skye_WarrantsLiabilityClassifiedMember_271"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsMember" xlink:label="loc_skye_WarrantsMember_272"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsVestedAndOutstanding" xlink:label="loc_skye_WarrantsVestedAndOutstanding_273"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WorkingCapitalDeficit" xlink:label="loc_skye_WorkingCapitalDeficit_274"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_275"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_276"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_277"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_278"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_279"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_280"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_281"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_282"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_283"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_284"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_286"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_287"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_288"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_289"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_290"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_291"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_292"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_295"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_296"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_298"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_299"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_300"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_301"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_302"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_304"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_305"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_306"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_308"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_309"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_310"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_311"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_312"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_313"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_314"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_316"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_317"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_318"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_319"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_320"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_321"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_322"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_323"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_324"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_325"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_326"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_327"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_328"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLoansPayableLongTerm" xlink:label="loc_us-gaap_OtherLoansPayableLongTerm_329"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_330"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_331"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_332"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_333"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_334"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_335"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_336"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_337"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_362"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AlbanyMolecularResearchIncMember" xlink:label="loc_skye_AlbanyMolecularResearchIncMember_363"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CashPaidDuringPeriodForAbstract" xlink:label="loc_skye_CashPaidDuringPeriodForAbstract_364"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesAxis" xlink:label="loc_skye_DilutedSecuritiesAxis_365"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DocumentAndEntityInformationAbstract" xlink:label="loc_skye_DocumentAndEntityInformationAbstract_366"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LeaseAgreementMember" xlink:label="loc_skye_LeaseAgreementMember_367"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NonCashInterestExpenseAbstract" xlink:label="loc_skye_NonCashInterestExpenseAbstract_368"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_369"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_370"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsAbstract" xlink:label="loc_skye_SignificantContractsAbstract_371"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsTable" xlink:label="loc_skye_SignificantContractsTable_372"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_skye_WarrantsAndDerivativeLiabilitiesAbstract_373"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_374"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_375"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_376"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_377"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_378"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_379"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_380"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_381"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_382"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_383"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_384"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_385"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_386"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_387"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_388"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_389"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_390"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_391"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_392"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_393"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_394"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_396"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_397"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_398"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_399"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_400"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_401"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_402"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_403"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_404"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_405"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_406"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_407"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_408"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_409"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_410"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_411"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_412"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_414"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_415"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_416"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_417"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_418"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_419"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_420"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_421"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_422"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_423"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_424"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_425"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_426"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_427"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_428"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_429"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_430"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_431"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_432"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_433"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_434"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_435"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_436"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_437"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_438"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_439"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_440"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_441"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_442"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_443"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_444"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_445"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_446"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_447"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_449"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_450"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_451"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_452"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_453"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_454"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_455"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_456"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_457"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_458"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_459"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_460"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_461"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_462"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_463"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_464"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_465"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_466"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_467"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_468"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_469"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_470"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_471"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_472"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_473"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_474"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_475"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_476"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_477"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_478"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_479"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_480"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_481"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_482"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_483"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_484"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_485"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_486"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_487"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_488"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_489"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_490"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_491"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_492"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_493"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_496"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_497"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_498"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_499"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_500"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_501"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_502"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_503"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_504"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_505"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_506"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_507"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_508"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_509"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_510"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_511"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_512"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_513"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_514"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_515"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_516"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_517"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_518"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_519"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_520"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_521"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_522"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_523"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_524"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_525"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_526"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaap_InterestExpenseOther_527"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_528"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_529"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_530"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_531"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_532"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_534"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_535"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_536"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_537"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_538"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_539"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_540"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_541"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_542"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_543"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_544"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_545"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_546"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_547"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_548"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_549"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_550"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_551"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_552"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_553"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_554"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_555"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_556"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_557"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_558"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_559"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_560"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_561"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_562"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_563"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_564"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_565"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_566"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_567"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_568"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_569"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_570"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_571"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_572"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_573"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_574"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_575"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_576"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_577"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_578"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaap_OtherLongTermDebtCurrent_579"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_580"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_581"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_582"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_583"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_584"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_585"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPriceDecrease_586"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_587"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_588"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_589"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_590"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_591"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_592"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_593"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_594"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_595"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_596"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_597"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_598"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_599"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt_600"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_601"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_602"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_603"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_604"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_605"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_606"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_607"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_608"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_609"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_610"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_611"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_612"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_613"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_614"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_615"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_616"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_617"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_618"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_619"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_620"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_621"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_622"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_623"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_624"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_625"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_626"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_627"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_628"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_629"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_630"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_631"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_632"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_633"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_634"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_636"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_639"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_640"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_641"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_642"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_643"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_644"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_645"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_646"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_647"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_648"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_649"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_650"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_651"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_653"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_654"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_655"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_656"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_657"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_658"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_659"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_660"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_662"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_663"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_664"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_665"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_666"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_667"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_668"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_669"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_670"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_671"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_672"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_673"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_674"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_675"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_676"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_677"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_678"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_679"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_680"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_681"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_682"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_684"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_685"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_686"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_687"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_688"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_690"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_691"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_692"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_693"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_694"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_695"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_696"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_697"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_698"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_699"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_700"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_701"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_702"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_703"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_704"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_705"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_706"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_707"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_708"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_709"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_710"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_711"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_712"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_713"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_714"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_715"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_716"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_717"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_718"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_719"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_720"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_721"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_722"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_723"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_724"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_725"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_726"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_727"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_728"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_729"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_730"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_731"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_732"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_733"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_734"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AccruedBoardFees_0" xml:lang="en-US">Amount of accrued board fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AccruedBoardFees_1" xml:lang="en-US">Accrued Board Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AccruedBoardFees_2" xml:lang="en-US">Accrued board fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AccruedExpenseUnderAgreement_0" xml:lang="en-US">Represents total accrued expense under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AccruedExpenseUnderAgreement_1" xml:lang="en-US">Accrued expense Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AccruedExpenseUnderAgreement_2" xml:lang="en-US">Accrued expense under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AccruedInterestRelatedParty_0" xml:lang="en-US">Amount of accrued interest to related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AccruedInterestRelatedParty_1" xml:lang="en-US">Accrued Interest Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AccruedInterestRelatedParty_2" xml:lang="en-US">Accrued interest - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AccruedResearchAndDevelopmentCosts_0" xml:lang="en-US">Amount of accrued research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AccruedResearchAndDevelopmentCosts_1" xml:lang="en-US">Accrued Research And Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AccruedResearchAndDevelopmentCosts_2" xml:lang="en-US">Accrued research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AdditionalConversionLiability_0" xml:lang="en-US">Threshold number of specified trading days that common stock price to additional conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AdditionalConversionLiability_1" xml:lang="en-US">Additional Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AdditionalConversionLiability_2" xml:lang="en-US">Additional conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AggregateExercisePriceOfOutstandingCreditAgreements_0" xml:lang="en-US">Information about aggregate exercise price of outstanding credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AggregateExercisePriceOfOutstandingCreditAgreements_1" xml:lang="en-US">Aggregate Exercise Price Of Outstanding Credit Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AggregateExercisePriceOfOutstandingCreditAgreements_2" xml:lang="en-US">Aggregate exercise price of outstanding credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AggregateMilestonePaymentsIfMilestonesAchieved_0" xml:lang="en-US">This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AggregateMilestonePaymentsIfMilestonesAchieved_1" xml:lang="en-US">Aggregate Milestone Payments If Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AggregateMilestonePaymentsIfMilestonesAchieved_2" xml:lang="en-US">Aggregate milestone payments if milestones achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AllocationOfDebtOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of debt on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AllocationOfDebtOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Debt On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AllocationOfDebtOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of debt on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of warrant on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Warrant On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of warrant on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents information of amended and restated multi draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AmortizationOfDebtDiscount_0" xml:lang="en-US">Amount of amortization expense attributable to debt discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AmortizationOfDebtDiscount_1" xml:lang="en-US">Amortization Of Debt Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AmortizationOfDebtDiscount_2" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AmortizationOfTransactionCosts_0" xml:lang="en-US">Amount of amortization of transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AmortizationOfTransactionCosts_1" xml:lang="en-US">Amortization Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AmortizationOfTransactionCosts_2" xml:lang="en-US">Amortization of transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AmountOfEachWarrantOutstanding_0" xml:lang="en-US">Amount of each warrant outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AmountOfEachWarrantOutstanding_1" xml:lang="en-US">Amount of each warrant outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AmountOfEachWarrantOutstanding_2" xml:lang="en-US">Amount of each warrant outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AmountOfPassThroughExpensesAndConsultingFees_0" xml:lang="en-US">Represent the amount of pass through expenses and consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AmountOfPassThroughExpensesAndConsultingFees_1" xml:lang="en-US">Amount Of Pass Through Expenses And Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AmountOfPassThroughExpensesAndConsultingFees_2" xml:lang="en-US">Amount of pass through expenses and consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AnnualFeeForAgreement_0" xml:lang="en-US">Represents amount of annual fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AnnualFeeForAgreement_1" xml:lang="en-US">Annual Fee For Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AnnualFeeForAgreement_2" xml:lang="en-US">Annual fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AnnualFeesForLicenseAgreement_0" xml:lang="en-US">Represents annual fees for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AnnualFeesForLicenseAgreement_1" xml:lang="en-US">Annual Fees For License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AnnualFeesForLicenseAgreement_2" xml:lang="en-US">Annual fees for license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AnnualMaintenanceFeePayable_0" xml:lang="en-US">Represents the amount of annual maintenance fee payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AnnualMaintenanceFeePayable_1" xml:lang="en-US">Annual Maintenance Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AnnualMaintenanceFees_0" xml:lang="en-US">Information about annual maintenance fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AnnualMaintenanceFees_1" xml:lang="en-US">Annual Maintenance Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_August2020FinancingMember_0" xml:lang="en-US">August 20202 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_August2020FinancingMember_1" xml:lang="en-US">August 2020 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_0" xml:lang="en-US">August Two Thousand And Twenty Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_1" xml:lang="en-US">August Two Thousand And Twenty Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_2" xml:lang="en-US">August 2020 Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AvtarDhillonMember_0" xml:lang="en-US">Name of board member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AvtarDhillonMember_1" xml:lang="en-US">Avtar Dhillon[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_AvtarDhillonMember_2" xml:lang="en-US">Dr. Avtar Dhillon</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AwardsGrantedOutside2014PlanMember_0" xml:lang="en-US">Represents awards Granted Outside the 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AwardsGrantedOutside2014PlanMember_1" xml:lang="en-US">Awards Granted Outside 2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AwardsGrantedOutside2014PlanMember_2" xml:lang="en-US">Awards Granted Outside the 2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_AwardsGrantedOutsideThe2014PlanMember_0" xml:lang="en-US">Information about awards granted outside the 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AwardsGrantedOutsideThe2014PlanMember_1" xml:lang="en-US">Awards Granted Outside the 2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AwardsGrantedOutsideThe2014PlanMember_2" xml:lang="en-US">Awards Granted Outside the 2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Beneficial conversion feature on convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_0" xml:lang="en-US">Amount of increase (decrease) resulting from beneficial conversion feature Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_1" xml:lang="en-US">Beneficial Conversion Feature Upon Issuance of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_2" xml:lang="en-US">Beneficial conversion feature upon issuance of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_0" xml:lang="en-US">Amount of increase (decrease) resulting from beneficial conversion feature series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_1" xml:lang="en-US">Beneficial Conversion Feature Upon Issuance of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_2" xml:lang="en-US">Beneficial conversion feature upon issuance of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ChangeInFairValueOfDerivativeLiabilities_0" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ChangeInFairValueOfDerivativeLiabilities_1" xml:lang="en-US">Change In Fair Value Of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ChangeInFairValueOfDerivativeLiabilities_2" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ChangeInFairValueOfWarrantLiability_0" xml:lang="en-US">Amount of expense (income) related to warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ChangeInFairValueOfWarrantLiability_1" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ChangeInFairValueOfWarrantLiability_2" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_0" xml:lang="en-US">Represents amount of aggregate exercise price of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_1" xml:lang="en-US">Class Of Warrant Or Right, Warrants Aggregate Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_2" xml:lang="en-US">Warrants aggregate exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ClassOfWarrantOrRightWarrantsExercise_0" xml:lang="en-US">Represents number of warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ClassOfWarrantOrRightWarrantsExercise_1" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ClassOfWarrantOrRightWarrantsExercise_2" xml:lang="en-US">Warrants exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_0" xml:lang="en-US">Represents common shares underlying convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_1" xml:lang="en-US">Common Shares Underlying Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_2" xml:lang="en-US">Common shares underlying convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CommonStockAggregatePurchasePrice_0" xml:lang="en-US">Represents common stock aggregate purchase price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CommonStockAggregatePurchasePrice_1" xml:lang="en-US">Common Stock Aggregate Purchase Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CommonStockAggregatePurchasePrice_2" xml:lang="en-US">Aggregate purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CommonStockIssuedForServices_0" xml:lang="en-US">Represents amount related to common stock issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CommonStockIssuedForServices_1" xml:lang="en-US">Common stock issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CommonStockWarrantsMember_0" xml:lang="en-US">Common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CommonStockWarrantsMember_1" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CommonStockWarrantsMember_2" xml:lang="en-US">Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Type of member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Common Stock Warrants to Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CommonUnitSoldPricePerUnit_0" xml:lang="en-US">Common Unit Sold Price Per Unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CommonUnitSoldPricePerUnit_1" xml:lang="en-US">Common Unit Sold Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CommonUnitSoldPricePerUnit_2" xml:lang="en-US">Common units sold price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConsultingAgreementMember_0" xml:lang="en-US">Consulting Agreement that involves two or more parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConsultingAgreementMember_1" xml:lang="en-US">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConsultingAgreementMember_2" xml:lang="en-US">Consulting Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ContractPayableDue_0" xml:lang="en-US">Represent information related amount payable under research agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ContractPayableDue_1" xml:lang="en-US">Contract Payable Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ContractPayableDue_2" xml:lang="en-US">Payments due for aggregate amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionLiabilityIntoCommonStockPerShare_0" xml:lang="en-US">Represents conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionLiabilityIntoCommonStockPerShare_1" xml:lang="en-US">Conversion Liability Into Common Stock Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionLiabilityIntoCommonStockPerShare_2" xml:lang="en-US">Conversion liability into common stock per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0" xml:lang="en-US">Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1" xml:lang="en-US">Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2" xml:lang="en-US">Conversion of outstanding preferred stock subject to redemption into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.80 and $0.40 per share for December 31, 2016 and $0.25 and $0.15 per share for December 31, 2017 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3" xml:lang="en-US">Conversion of Series A and Series B Preferred Stock and conversion liability into common stock at $0.80 per share and $0.80 and $0.40 per share for 2015 and 2016, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series C Preferred Stock To Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series C Preferred Stock to common stock at $0.25 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_3" xml:lang="en-US">Conversion of Series C Preferred Stock to common stock at $0.40 and $0.25 per share for December 31, 2016 and 2017 respectively (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion of series C preferred stock to common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_1" xml:lang="en-US">Conversion Of Series C Preferred Stock To Common Stock Shares Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_2" xml:lang="en-US">Conversion of Series C Preferred Stock to common stock at $0.25 per share for December 31, 2017</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion of series D preferred stock to common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock,Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_0" xml:lang="en-US">Number of shares of series F preferred stock converted during the period into common stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_0" xml:lang="en-US">Value of shares of series F preferred stock converted into common stocks during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionPrice_0" xml:lang="en-US">Represents conversion price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionPrice_1" xml:lang="en-US">Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionPrice_2" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConversionPricePerShare_0" xml:lang="en-US">Represents the value related to conversion of Series A Preferred Stock and conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConversionPricePerShare_1" xml:lang="en-US">Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConversionPricePerShare_2" xml:lang="en-US">Conversion of preferred stock price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConvertedRate10000001Member_0" xml:lang="en-US">Converted rate 1,000,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConvertedRate10000001Member_1" xml:lang="en-US">Converted Rate 1,000,0001 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConvertedRate10000001Member_2" xml:lang="en-US">Converted rate of 1,000,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConvertedRate100001Member_0" xml:lang="en-US">Converted rate 10,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConvertedRate100001Member_1" xml:lang="en-US">Converted Rate 10,0001 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConvertedRate100001Member_2" xml:lang="en-US">Converted rate of 10,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConvertedRateAxis_0" xml:lang="en-US">Information by type of converted rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConvertedRateAxis_1" xml:lang="en-US">Converted Rate [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConvertedRateDomain_0" xml:lang="en-US">Converted rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConvertedRateDomain_1" xml:lang="en-US">Converted Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConvertibleDebtRelatedPartyTextBlock_0" xml:lang="en-US">The entire disclosure for convertible debt - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConvertibleDebtRelatedPartyTextBlock_1" xml:lang="en-US">Convertible Debt Related Party [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ConvertibleDebtRelatedPartyTextBlock_2" xml:lang="en-US">Convertible Debt - Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1" xml:lang="en-US">Convertible Multi Draw Credit Agreement Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2" xml:lang="en-US">Convertible multi-draw credit agreement issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CouponInterestExpense_0" xml:lang="en-US">Amount of interest expense classified as coupon interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CouponInterestExpense_1" xml:lang="en-US">Coupon Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_CouponInterestExpense_2" xml:lang="en-US">Interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CreditFacilityEffectedFifthAdvance_0" xml:lang="en-US">Credit facility effected fifth advances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CreditFacilityEffectedFifthAdvance_1" xml:lang="en-US">Credit Facility Effected Fifth Advance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CreditFacilityEffectedFifthAdvance_2" xml:lang="en-US">Credit facility effected fifth advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CreditFacilityEffectedFourthAdvance_0" xml:lang="en-US">Credit facility effected fourth advances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CreditFacilityEffectedFourthAdvance_1" xml:lang="en-US">Credit Facility Effected Fourth Advance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CreditFacilityEffectedFourthAdvance_2" xml:lang="en-US">Credit facility effected fourth advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_0" xml:lang="en-US">The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_1" xml:lang="en-US">Current Convertible Debt Excluding Noncurrent Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_2" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_3" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_4" xml:lang="en-US">Total carrying value of advances under the multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_December2015Member_0" xml:lang="en-US">Represents December 2015 as agreement month and year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_December2015Member_1" xml:lang="en-US">December 2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_December2015Member_2" xml:lang="en-US">December 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_0" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from dividends conversion of series D preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_1" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_2" xml:lang="en-US">Deemed Dividend From Beneficial Conversion Feature Of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_3" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_0" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from dividends conversion of series F preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_1" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_2" xml:lang="en-US">Deemed Dividend From Beneficial Conversion Feature Of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_3" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DeferredTaxAssetsAmortization_0" xml:lang="en-US">It represents deferred tax assets amortizaton.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DeferredTaxAssetsAmortization_1" xml:lang="en-US">Deferred Tax Assets Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DeferredTaxAssetsAmortization_2" xml:lang="en-US">Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_1" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2" xml:lang="en-US">Research and development credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates state and local.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_1" xml:lang="en-US">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration State And Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_2" xml:lang="en-US">Expired in California net operating loss carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DeferredTaxLiabilitiesNoteDiscount_0" xml:lang="en-US">Represents amount of notes discount related to deferred tax liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_DeferredTaxLiabilitiesNoteDiscount_1" xml:lang="en-US">Note discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DeferredTaxLiabilitiesNoteDiscount_2" xml:lang="en-US">Deferred Tax Liabilities Note Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DeferredTaxLiabilitiesNoteDiscount_3" xml:lang="en-US">Note discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DerivativeLiabilitiesLineItems_0" xml:lang="en-US">Line item represents derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DerivativeLiabilitiesLineItems_1" xml:lang="en-US">Derivative Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DerivativeLiabilitiesTable_0" xml:lang="en-US">A table or schedule providing information about derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DerivativeLiabilitiesTable_1" xml:lang="en-US">Derivative Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DerivativesLiabilitiesTable_0" xml:lang="en-US">Derivatives Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DerivativesLiabilitiesTable_1" xml:lang="en-US">Derivatives Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DilutedSecuritiesDomain_0" xml:lang="en-US">Information by type of diluted security.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DilutedSecuritiesDomain_1" xml:lang="en-US">Diluted Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_0" xml:lang="en-US">Number of shares for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_1" xml:lang="en-US">Dilutive Securities Effect on Basic Earnings Per Share shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_2" xml:lang="en-US">Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DouglasCesarioMember_0" xml:lang="en-US">Represents the Douglas Cesario.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DouglasCesarioMember_1" xml:lang="en-US">Douglas Cesario [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_DouglasCesarioMember_2" xml:lang="en-US">Douglas Cesario, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_DrawDownsLoansInAggregatePrincipalAmount_0" xml:lang="en-US">Represents draw downs loans in aggregate principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DrawDownsLoansInAggregatePrincipalAmount_1" xml:lang="en-US">Draw Downs Loans In Aggregate Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DrawDownsLoansInAggregatePrincipalAmount_2" xml:lang="en-US">Draw downs loans In aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_0" xml:lang="en-US">Represents amount related to Change in fair value of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_1" xml:lang="en-US">Change in fair value of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_2" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Fair Value Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3" xml:lang="en-US">Change in fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0" xml:lang="en-US">Information about emerald convertible promissory note - conversion liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3" xml:lang="en-US">Emerald Convertible Promissory Note - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldFinancingIssuanceCosts_0" xml:lang="en-US">Cost incurred for Emerald Financing, issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldFinancingIssuanceCosts_1" xml:lang="en-US">Emerald Financing Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldFinancingIssuanceCosts_2" xml:lang="en-US">Emerald financing issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldFinancingMember_0" xml:lang="en-US">Represents Emerald financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldFinancingMember_1" xml:lang="en-US">Emerald Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldFinancingMember_2" xml:lang="en-US">Emerald financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EmeraldFinancingMember_3" xml:lang="en-US">Emerald Financing - Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldFinancingWarrantsLiabilityMember_0" xml:lang="en-US">Information regarding Emerald Financing Warrants Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldFinancingWarrantsLiabilityMember_1" xml:lang="en-US">Emerald Financing Warrants Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldFinancingWarrantsLiabilityMember_2" xml:lang="en-US">Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldHealthSciencesIncMember_0" xml:lang="en-US">Information by Emerald Health Sciences, Inc. ("Emerald").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldHealthSciencesIncMember_1" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldHealthSciencesIncMember_2" xml:lang="en-US">Emerald Health Sciences Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EmeraldHealthSciencesIncMember_3" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0" xml:lang="en-US">Represents information about Emerald Multi Draw Credit Agreement - compound derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement - compound derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2" xml:lang="en-US">Emerald Multi Draw Credit Agreement Compound Derivative Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_3" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_4" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EmeraldWarrantLiabilityMember_0" xml:lang="en-US">Represents the information about Emerald Warrant Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EmeraldWarrantLiabilityMember_1" xml:lang="en-US">Emerald Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_EmeraldWarrantLiabilityMember_2" xml:lang="en-US">Emerald Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EmeraldWarrantLiabilityMember_3" xml:lang="en-US">Emerald Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EquityLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EquityLineItems_1" xml:lang="en-US">Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EquityTable_0" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EquityTable_1" xml:lang="en-US">Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EstimatedAgreementFeesAndExpenses_0" xml:lang="en-US">Represent a estimated agreement fees and expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EstimatedAgreementFeesAndExpenses_1" xml:lang="en-US">Estimated Agreement Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EstimatedAgreementFeesAndExpenses_2" xml:lang="en-US">Estimated agreement fees and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_EstimatedInitialPaymentForContract_0" xml:lang="en-US">Estimated Initial Payment For Contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_EstimatedInitialPaymentForContract_1" xml:lang="en-US">Estimated Initial Payment For Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_EstimatedInitialPaymentForContract_2" xml:lang="en-US">Estimated initial payment for contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ExerciseOfWarrants_0" xml:lang="en-US">Represents the fair value of derivative liabilities reclassified to equity upon the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ExerciseOfWarrants_1" xml:lang="en-US">Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ExerciseOfWarrants_2" xml:lang="en-US">Reclassification of warrant liabilities to equity from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairMarketValueOfSharesGranted_0" xml:lang="en-US">Fair value of shares granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairMarketValueOfSharesGranted_1" xml:lang="en-US">Fair Market Value Of Shares Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairMarketValueOfSharesGranted_2" xml:lang="en-US">Fair market value of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairMarketValueOfStockOptions_0" xml:lang="en-US">Represents the fair market value of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairMarketValueOfStockOptions_1" xml:lang="en-US">Fair Market Value Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairMarketValueOfStockOptions_2" xml:lang="en-US">Fair market value of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_0" xml:lang="en-US">Fair Value Measurement Input And Valuation Techniques Derivative Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_1" xml:lang="en-US">Fair Value Measurement Input And Valuation Techniques Derivative Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_2" xml:lang="en-US">Schedule of input and valuation technique used to value warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfCommonStockWarrantsIssued_0" xml:lang="en-US">Represents the fair value of the common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfCommonStockWarrantsIssued_1" xml:lang="en-US">Fair value of common stock warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfCommonStockWarrantsIssued_2" xml:lang="en-US">Fair value of common stock warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfDerivativeLiabilitiesRollForward_0" xml:lang="en-US">Represents the amount of derivative liabilities at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfDerivativeLiabilitiesRollForward_1" xml:lang="en-US">Fair Value Of Derivative Liabilities [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_0" xml:lang="en-US">Represents amount of fair value of derivative liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_1" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_2" xml:lang="en-US">Fair Value Of Derivative Liability Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_3" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_0" xml:lang="en-US">Amount of expense (income) related to fair value of derivative liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_1" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_2" xml:lang="en-US">Fair Value Of Derivative Liability In Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_3" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds recorded as other expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_0" xml:lang="en-US">Fair value of shares underlying convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_1" xml:lang="en-US">Fair Value Of Shares Underlying Convertible Debt1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_2" xml:lang="en-US">Fair value of shares underlying convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_3" xml:lang="en-US">Total principal value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfUnderlyingShares_0" xml:lang="en-US">Fair value of the underlying shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfUnderlyingShares_1" xml:lang="en-US">fair value of underlying shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfUnderlyingShares_2" xml:lang="en-US">Fair value of underlying shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_0" xml:lang="en-US">Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_1" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_2" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_3" xml:lang="en-US">Fair Value Of Warrant Liability In Excess For Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_5" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfWarrantsIssued_0" xml:lang="en-US">The fair value of warrants issued in noncash investing or financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_skye_FairValueOfWarrantsIssued_1" xml:lang="en-US">Initial fair value of Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfWarrantsIssued_2" xml:lang="en-US">Fair Value Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfWarrantsIssued_3" xml:lang="en-US">Fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FairValueOfWarrantsIssued_4" xml:lang="en-US">Fair Value of Derivative Liabilities Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_0" xml:lang="en-US">Amount of fair value of warrants issued in connection with financings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_1" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_2" xml:lang="en-US">Fair value of warrants issued in connection with financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FeesAndExpensesForServicesProvided_0" xml:lang="en-US">Represents amount of fees and expenses for services provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FeesAndExpensesForServicesProvided_1" xml:lang="en-US">Fees And Expenses For Services Provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FeesAndExpensesForServicesProvided_2" xml:lang="en-US">Fees and expenses for the initial evaluation and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FeesIncurredUnderAgreement_0" xml:lang="en-US">Represents the total fees incurred under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FeesIncurredUnderAgreement_1" xml:lang="en-US">Fees Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_FeesIncurredUnderAgreement_2" xml:lang="en-US">Fees incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents Fifth Amended And Restated Multi Draw Credit Agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Fifth Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Fifth amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FinancingSharesWarrantExercise_0" xml:lang="en-US">Represents number of shares related to exercise of emerald financing warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FinancingSharesWarrantExercise_1" xml:lang="en-US">Financing shares Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FinancingSharesWarrantExercise_2" xml:lang="en-US">Exercise of Emerald financing warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FinancingValueWarrantExercise_0" xml:lang="en-US">Represents amount related to Exercise of emerald financing warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FinancingValueWarrantExercise_1" xml:lang="en-US">Financing Value Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FinancingValueWarrantExercise_2" xml:lang="en-US">Exercise of Emerald financing warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FixedAssetsProvidedToUniversityInLieuOfCash_0" xml:lang="en-US">Represents amount of fixed assets provided to university in lieu of cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FixedAssetsProvidedToUniversityInLieuOfCash_1" xml:lang="en-US">Fixed Assets Provided To University In Lieu Of Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FixedAssetsProvidedToUniversityInLieuOfCash_2" xml:lang="en-US">Fixed assets provided to university in lieu of cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents Fourth Amended And Restated Multi Draw Credit Agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Fourth Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Fourth amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_GlauconixBiosciencesIncMember_0" xml:lang="en-US">Represents information regarding Glauconix biosciences, inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_GlauconixBiosciencesIncMember_1" xml:lang="en-US">Glauconix Biosciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_GlauconixBiosciencesIncMember_2" xml:lang="en-US">Glauconix Biosciences, Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_GrossProceedsOfUnitsSold_0" xml:lang="en-US">Represents the amount of gross proceeds of units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_GrossProceedsOfUnitsSold_1" xml:lang="en-US">Gross Proceeds Of Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_GrossProceedsOfUnitsSold_2" xml:lang="en-US">Gross proceeds of units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_GrossProceedsOfWarrant_0" xml:lang="en-US">Represents the gross proceeds of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_GrossProceedsOfWarrant_1" xml:lang="en-US">Gross Proceeds Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_GrossProceedsOfWarrant_2" xml:lang="en-US">Gross proceeds of warrants on a relative fair value basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_GuarantorFailedToPay_0" xml:lang="en-US">Represents information the guarantor failed to pay within 90 days of notice of purchaser.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_GuarantorFailedToPay_1" xml:lang="en-US">Guarantor Failed To Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_GuarantorFailedToPay_2" xml:lang="en-US">Guarantor failed to pay within 90 days of notice of purchaser</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IncomeTaxReconciliationChangeInCompoundDerivative_0" xml:lang="en-US">Represents amount of Income Tax Reconciliation change in compound derivative related to the income tax reconciliation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IncomeTaxReconciliationChangeInCompoundDerivative_1" xml:lang="en-US">Income Tax Reconciliation Change in compound derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IncomeTaxReconciliationChangeInCompoundDerivative_2" xml:lang="en-US">Change in compound derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IncomeTaxReconciliationUncertainTaxPositions_0" xml:lang="en-US">Represents amount of uncertain tax positions related to Income Tax Reconciliation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IncomeTaxReconciliationUncertainTaxPositions_1" xml:lang="en-US">Income Tax Reconciliation Uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IncomeTaxReconciliationUncertainTaxPositions_2" xml:lang="en-US">Uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IncreaseChangeInFairValueOfWarrantLiability_0" xml:lang="en-US">Amount increase of expense (income) related to warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IncreaseChangeInFairValueOfWarrantLiability_1" xml:lang="en-US">Increase Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_IncreaseChangeInFairValueOfWarrantLiability_2" xml:lang="en-US">Increase change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IncreaseDecreaseInDepositsAndOtherAssets_0" xml:lang="en-US">Represents amount of increase (decrease) in deposits and other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_IncreaseDecreaseInDepositsAndOtherAssets_1" xml:lang="en-US">Deposits and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IncreaseDecreaseInDepositsAndOtherAssets_2" xml:lang="en-US">Increase Decrease In Deposits And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IncrementalAgreementFeesAndExpenses_0" xml:lang="en-US">Represent a incremental agreement fees and expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IncrementalAgreementFeesAndExpenses_1" xml:lang="en-US">Incremental Agreement Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IncrementalAgreementFeesAndExpenses_2" xml:lang="en-US">Incremental agreement fees and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IndependentContractorAgreementMember_0" xml:lang="en-US">Represents name of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IndependentContractorAgreementMember_1" xml:lang="en-US">Independent Contractor Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IndependentContractorAgreementMember_2" xml:lang="en-US">Independent contractor agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_InitialTermOfAgreement_0" xml:lang="en-US">Represents the initial term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_InitialTermOfAgreement_1" xml:lang="en-US">Initial Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_InitialTermOfAgreement_2" xml:lang="en-US">Initial term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_0" xml:lang="en-US">Institutional Investor And HC Wain Wright And Company LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_1" xml:lang="en-US">Institutional Investor And Hc Wain Wright And Company Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_2" xml:lang="en-US">Institutional investors and H.C. Wainwright &amp; Co., LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IntrinsicValueOfWarrantExercises_0" xml:lang="en-US">Represents intrinsic value of warrant exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IntrinsicValueOfWarrantExercises_1" xml:lang="en-US">Intrinsic Value Of Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_IntrinsicValueOfWarrantExercises_2" xml:lang="en-US">Intrinsic value of warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_0" xml:lang="en-US">Represents issuance cost of preferred cost net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_1" xml:lang="en-US">Issuance Of Preferred Stock Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of Series F Preferred Stock net of issuance costs of $118,855 and $103,364 put option liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_0" xml:lang="en-US">Represents issuance of preferred stock Series net of issuance costs shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance Of Preferred Stock Net Of Issuance Costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of Series F Preferred Stock net of issuance costs of $118,855 and $103,364 put option liability (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_0" xml:lang="en-US">Represents issuance of Preferred Stock Series net of issuance costs shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance Of Preferred Stock Series Net Of Issuance Costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of Series D Preferred Stock net of issuance costs of $183,343 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_0" xml:lang="en-US">Represents issuance of Preferred Stock Series net of issuance costs value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_1" xml:lang="en-US">Issuance Of Preferred Stock Series Net Of Issuance Costs Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_2" xml:lang="en-US">Issuance of Series D Preferred Stock net of issuance costs of $183,343</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_K2CIncMember_0" xml:lang="en-US">Represents name of party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_K2CIncMember_1" xml:lang="en-US">K2C Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_K2CIncMember_2" xml:lang="en-US">K2C, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LetterAgreementMember_0" xml:lang="en-US">Represents letter agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LetterAgreementMember_1" xml:lang="en-US">Letter Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_LetterAgreementMember_2" xml:lang="en-US">Letter agreement ("Agreement")</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LicenseAgreementMember_0" xml:lang="en-US">Represents license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LicenseAgreementMember_1" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_LicenseAgreementMember_2" xml:lang="en-US">UM 8930 analogue agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_LicenseAgreementMember_3" xml:lang="en-US">License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LicenseFee_0" xml:lang="en-US">Information about license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LicenseFee_1" xml:lang="en-US">License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LiquidationProvisionCommonStockEquivalentShares_0" xml:lang="en-US">Represents liquidation provision common stock equivalent shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LiquidationProvisionCommonStockEquivalentShares_1" xml:lang="en-US">Liquidation Provision Common Stock Equivalent Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_LiquidationProvisionCommonStockEquivalentShares_2" xml:lang="en-US">Liquidation provision common stock equivalent shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LiquidationProvisionCommonStockEquivalentValue_0" xml:lang="en-US">Represents liquidation provision common stock equivalent value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LiquidationProvisionCommonStockEquivalentValue_1" xml:lang="en-US">Liquidation provision common stock equivalent value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_0" xml:lang="en-US">Amount of loss on common stock issuance from conversion of accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_1" xml:lang="en-US">Loss On Common Stock Issuance From Conversion Of Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_2" xml:lang="en-US">Loss on common stock issuance from conversion of accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_LumpSumPaymentInAgreement_0" xml:lang="en-US">The amount related to lump sum payment in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LumpSumPaymentInAgreement_1" xml:lang="en-US">Lump Sum Payment In Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_LumpSumPaymentInAgreement_2" xml:lang="en-US">Lump sum payment in agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MasterServiceAgreementMember_0" xml:lang="en-US">Represents information regarding master service agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MasterServiceAgreementMember_1" xml:lang="en-US">Master Service Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_MasterServiceAgreementMember_2" xml:lang="en-US">Master service agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_Milestone1Member_0" xml:lang="en-US">It represents milestone 1 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_Milestone1Member_1" xml:lang="en-US">Milestone 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_Milestone1Member_2" xml:lang="en-US">Milestone 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_Milestone2Member_0" xml:lang="en-US">It represents milestone 2 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_Milestone2Member_1" xml:lang="en-US">Milestone 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_Milestone2Member_2" xml:lang="en-US">Milestone 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_Milestone3Member_0" xml:lang="en-US">It represents milestone 3 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_Milestone3Member_1" xml:lang="en-US">Milestone 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_Milestone3Member_2" xml:lang="en-US">Milestone 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MilestonePaymentsPayableAxis_0" xml:lang="en-US">It represents milestone payments payable axis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MilestonePaymentsPayableAxis_1" xml:lang="en-US">Milestone Payments Payable [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MilestonePaymentsPayableDomain_0" xml:lang="en-US">It represents milestone payments payable domain.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MilestonePaymentsPayableDomain_1" xml:lang="en-US">Milestone Payments Payable [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MinimumLitigationJudgementAmount_0" xml:lang="en-US">Represents minimum litigation judgement amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MinimumLitigationJudgementAmount_1" xml:lang="en-US">Minimum Litigation Judgement Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_MinimumLitigationJudgementAmount_2" xml:lang="en-US">Value of final judgment rendered against company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MonteCarloSimulationsMember_0" xml:lang="en-US">Represents monte carlo simulations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MonteCarloSimulationsMember_1" xml:lang="en-US">Monte Carlo Simulations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_MonteCarloSimulationsMember_2" xml:lang="en-US">Monte Carlo simulations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MonthAndYearOfAgreementAxis_0" xml:lang="en-US">Information regarding month and year of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MonthAndYearOfAgreementAxis_1" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MonthAndYearOfAgreementDomain_0" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MonthAndYearOfAgreementDomain_1" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MonthlyFee_0" xml:lang="en-US">Represents amount of monthly fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MonthlyFee_1" xml:lang="en-US">Monthly Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_MonthlyFee_2" xml:lang="en-US">Monthly fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0" xml:lang="en-US">Represents amount of monthly fees accruing from the effective date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1" xml:lang="en-US">Monthly Fee Accruing From Effective Date In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2" xml:lang="en-US">Monthly fee accruing from effective date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MonthlyFeePaidEachMonthInExchangeOfServices_0" xml:lang="en-US">Represents amount of monthly fee paid in exchange of services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MonthlyFeePaidEachMonthInExchangeOfServices_1" xml:lang="en-US">Monthly Fee Paid Each Month In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_MonthlyFeePaidEachMonthInExchangeOfServices_2" xml:lang="en-US">Monthly fee paid each month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_MultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents the information about Multi-Draw Credit Agreement (the "Credit Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_MultiDrawCreditAgreementMember_1" xml:lang="en-US">Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_MultiDrawCreditAgreementMember_2" xml:lang="en-US">Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NatureOfOperationsAndBusinessActivitiesAbstract_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NatureOfOperationsAndBusinessActivitiesAbstract_1" xml:lang="en-US">Nature Of Operations And Business Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NatureOfOperationsAndBusinessActivitiesLineItems_1" xml:lang="en-US">Nature Of Operations And Business Activities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NatureOfOperationsAndBusinessActivitiesTable_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xml:lang="en-US">Nature Of Operations And Business Activities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NetLossAdjustedBalance_0" xml:lang="en-US">Adjusted balance of net loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NetLossAdjustedBalance_1" xml:lang="en-US">Net Loss Adjusted Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_NetLossAdjustedBalance_2" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NetLossAdjustedBalance_3" xml:lang="en-US">Loss available to common stockholders + assumed conversions, Income (Numerator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NoramcoAgreementMember_0" xml:lang="en-US">Represents information of noramco agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NoramcoAgreementMember_1" xml:lang="en-US">Noramco Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NoramcoAgreementMember_2" xml:lang="en-US">Noramco Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NoticePeriodForTermination_0" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NoticePeriodForTermination_1" xml:lang="en-US">Notice Period For Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NoticePeriodForTermination_2" xml:lang="en-US">Notice period for termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_0" xml:lang="en-US">Represents number of common stock issued upon conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_1" xml:lang="en-US">Number Of Common Stock Issued Upon Conversion Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_2" xml:lang="en-US">Number of common stock issued upon conversion of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfCommonStockUnitsSold_0" xml:lang="en-US">Represents the number of common stock units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfCommonStockUnitsSold_1" xml:lang="en-US">Number Of Common Stock Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfCommonStockUnitsSold_2" xml:lang="en-US">Number of common stock units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfInvestors_0" xml:lang="en-US">Represents the number of investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfInvestors_1" xml:lang="en-US">Number Of Investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfInvestors_2" xml:lang="en-US">Number of investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfLicenseAgreements_0" xml:lang="en-US">Represents number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfLicenseAgreements_1" xml:lang="en-US">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfLicenseAgreements_2" xml:lang="en-US">Number of license agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfPreFundedUnitsSold_0" xml:lang="en-US">Number of pre funded units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfPreFundedUnitsSold_1" xml:lang="en-US">Number Of Pre Funded Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfPreFundedUnitsSold_2" xml:lang="en-US">Number of pre-funded units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfWarrantsExercisable_0" xml:lang="en-US">Number of warrants exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfWarrantsExercisable_1" xml:lang="en-US">Number Of Warrants Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfWarrantsExercisable_2" xml:lang="en-US">Number of warrants exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_NumberOfWarrantsExercised_0" xml:lang="en-US">Represents the number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_NumberOfWarrantsExercised_2" xml:lang="en-US">Shares issued, price per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_NumberOfWarrantsExercised_3" xml:lang="en-US">Number of stock sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_OctoberTwoThousandFifteenMember_0" xml:lang="en-US">Represents agreement date of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_OctoberTwoThousandFifteenMember_1" xml:lang="en-US">October Two Thousand Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_OctoberTwoThousandFifteenMember_2" xml:lang="en-US">October 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_OfficersEmployeeAndDirectorsMember_0" xml:lang="en-US">This member stands for officers, employee and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_OfficersEmployeeAndDirectorsMember_1" xml:lang="en-US">Officers, Employee And Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_OfficersEmployeeAndDirectorsMember_2" xml:lang="en-US">Officers, employees and directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_OmnibusIncentivePlan2014Member_0" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_OmnibusIncentivePlan2014Member_1" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_OmnibusIncentivePlan2014Member_2" xml:lang="en-US">2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_OmnibusIncentivePlan2014Member_3" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_OneTimeUpfrontPayment_0" xml:lang="en-US">This element represents amount of one-time upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_skye_OneTimeUpfrontPayment_1" xml:lang="en-US">One time up front payment payable in four equal monthly installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_OneTimeUpfrontPayment_2" xml:lang="en-US">One Time Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_OneTimeUpfrontPayment_3" xml:lang="en-US">One-time up-front option payment under University of Mississippi option agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_OneTimeUpfrontPayment_4" xml:lang="en-US">One time up front payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_OptionAgreementMember_0" xml:lang="en-US">Represents information regarding option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_OptionAgreementMember_1" xml:lang="en-US">Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_OptionAgreementMember_2" xml:lang="en-US">UM 5050 pro-drug agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_OptionAgreementMember_3" xml:lang="en-US">Option Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_OptionsMember_0" xml:lang="en-US">Represent the information of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_OptionsMember_1" xml:lang="en-US">Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_OptionsMember_2" xml:lang="en-US">Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PaycheckProtectionProgrammeMember_0" xml:lang="en-US">Paycheck Protection Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PaycheckProtectionProgrammeMember_1" xml:lang="en-US">Paycheck Protection Programme [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PaycheckProtectionProgrammeMember_2" xml:lang="en-US">Paycheck Protection Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PaycheckProtectionProgramPromissoryNoteMember_0" xml:lang="en-US">Represents information of Paycheck protection program promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PaycheckProtectionProgramPromissoryNoteMember_1" xml:lang="en-US">Paycheck Protection Program Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PaycheckProtectionProgramPromissoryNoteMember_2" xml:lang="en-US">Paycheck Protection Program Promissory Note (PPP Note)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PaymentForUpfrontFees_0" xml:lang="en-US">It represents payment for upfront fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PaymentForUpfrontFees_1" xml:lang="en-US">Payment For Upfront Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PaymentForUpfrontFees_2" xml:lang="en-US">Payment for upfront fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PaymentOfUpfrontLicenseFee_0" xml:lang="en-US">Represents cash outflow of payment of upfront license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PaymentOfUpfrontLicenseFee_1" xml:lang="en-US">Payment Of Upfront License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PaymentOfUpfrontLicenseFee_2" xml:lang="en-US">Payment of upfront license fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PayrollCostExcludeCompensation_0" xml:lang="en-US">Payroll costs exclude compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PayrollCostExcludeCompensation_1" xml:lang="en-US">Payroll Cost Exclude Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PayrollCostExcludeCompensation_2" xml:lang="en-US">Excess payroll costs exclude compensation of an individual employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfAccruedConsultingFee_0" xml:lang="en-US">Represents percentage of accrued consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfAccruedConsultingFee_1" xml:lang="en-US">Percentage Of Accrued Consulting Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PercentageOfAccruedConsultingFee_2" xml:lang="en-US">Percentage of accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfAccruedInterestOnOutstandingBalance_0" xml:lang="en-US">Represents percentage of interest on accrued the outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfAccruedInterestOnOutstandingBalance_1" xml:lang="en-US">Percentage Of Accrued Interest On Outstanding Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentageOfAccruedInterestOnOutstandingBalance_2" xml:lang="en-US">Percentage of accrued interest on outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0" xml:lang="en-US">Percentage of amount need to be issued against warrant purchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1" xml:lang="en-US">Percentage Of Amount Need To Be Issued Against Warrant Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2" xml:lang="en-US">Warrant coverage on the debt facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfBonusForAccruedConsultingFee_0" xml:lang="en-US">Represents percentage of bonus for accrued consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfBonusForAccruedConsultingFee_1" xml:lang="en-US">Percentage Of Bonus For Accrued Consulting Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentageOfBonusForAccruedConsultingFee_2" xml:lang="en-US">Percentage of bonus for accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfConversionAmount_0" xml:lang="en-US">Represents percentage of conversion amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfConversionAmount_1" xml:lang="en-US">Percentage Of Conversion Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentageOfConversionAmount_2" xml:lang="en-US">Percentage of conversion amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfForgivenessAmountForNonPayrollCost_0" xml:lang="en-US">Percentage of forgiveness amount for non payroll cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfForgivenessAmountForNonPayrollCost_1" xml:lang="en-US">Percentage Of Forgiveness Amount For Non Payroll Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentageOfForgivenessAmountForNonPayrollCost_2" xml:lang="en-US">Percentage of forgiveness amount for nonpayroll costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_0" xml:lang="en-US">Percentage of share reserve of the number of issued and outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_1" xml:lang="en-US">Percentage Of Share Reserve Of Number Of Issued And Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_2" xml:lang="en-US">Percentage of share reserve of the number of issued and outstanding shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_0" xml:lang="en-US">Percentage of total shares of common stock and pre-funded warrants sold in the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_1" xml:lang="en-US">Percentage Of Shares Of Common Stock And Prefunded Warrants Sold In Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_2" xml:lang="en-US">Percentage of total shares of common stock and pre-funded warrants sold in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentageOfSharesToBeRedeemed_0" xml:lang="en-US">Represents percentage of shares to be redeemed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentageOfSharesToBeRedeemed_1" xml:lang="en-US">Percentage Of Shares To Be Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PercentageOfSharesToBeRedeemed_2" xml:lang="en-US">Percentage of shares to be redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PercentOfReductionInAnnualSalary_0" xml:lang="en-US">Percent of reduction in annual salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PercentOfReductionInAnnualSalary_1" xml:lang="en-US">Percent Of Reduction In Annual Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PercentOfReductionInAnnualSalary_2" xml:lang="en-US">Percentage of reduction in annual salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1" xml:lang="en-US">Period Of Discretionary Annual Bonus Payable To Contractor After Each Fiscal Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PharmaceuticalsInternationalInc.AgreementMember_0" xml:lang="en-US">Represents information regarding Pharmaceuticals International, Inc. agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PharmaceuticalsInternationalInc.AgreementMember_1" xml:lang="en-US">Pharmaceuticals International, Inc. Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PharmaceuticalsInternationalInc.AgreementMember_2" xml:lang="en-US">Pharmaceuticals International, Inc. Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PlacementAgentMember_0" xml:lang="en-US">Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PlacementAgentMember_1" xml:lang="en-US">Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PlacementAgentMember_2" xml:lang="en-US">Placement agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PlacementAgentWarrantMember_0" xml:lang="en-US">Placement agent warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PlacementAgentWarrantMember_1" xml:lang="en-US">Placement Agent Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PlacementAgentWarrantMember_2" xml:lang="en-US">Placement agent warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_Pre2015CommonStockWarrantsMember_0" xml:lang="en-US">Represents Pre 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_Pre2015CommonStockWarrantsMember_1" xml:lang="en-US">Pre 2015 Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_Pre2015CommonStockWarrantsMember_2" xml:lang="en-US">Pre 2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PreferredStockPutOptionLiability_0" xml:lang="en-US">Represents the value of preferred stock put option liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PreferredStockPutOptionLiability_1" xml:lang="en-US">Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PreferredStockPutOptionLiability_2" xml:lang="en-US">Series F put option liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PreFundedUnitSoldPricePerUnit_0" xml:lang="en-US">Represents the price per unit of pre-funded units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PreFundedUnitSoldPricePerUnit_1" xml:lang="en-US">Pre Funded Unit Sold Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PreFundedUnitSoldPricePerUnit_2" xml:lang="en-US">Pre-funded units sold price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PreFundedWarrantMember_0" xml:lang="en-US">Information about pre-funded warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PreFundedWarrantMember_1" xml:lang="en-US">Pre Funded Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PrefundedWarrantsMember_0" xml:lang="en-US">Prefunded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PrefundedWarrantsMember_1" xml:lang="en-US">Prefunded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PrefundedWarrantsMember_2" xml:lang="en-US">Pre-funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_PricingModelMember_0" xml:lang="en-US">Represents option pricing model,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PricingModelMember_1" xml:lang="en-US">Pricing Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_PricingModelMember_2" xml:lang="en-US">Black Scholes Merton Option Pricing Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_PricingModelMember_3" xml:lang="en-US">Black-Scholes option pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds From Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_3" xml:lang="en-US">Proceeds from convertible multi-draw credit agreement - related party, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_0" xml:lang="en-US">Amount of Proceeds from Emerald Financing, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds From Emerald Financing, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from Emerald Financing, net of $154,092 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0" xml:lang="en-US">Represents the amount related to proceeds from financing between the conversion liability and the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1" xml:lang="en-US">Proceeds From Financing Between Conversion Liability And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2" xml:lang="en-US">Proceeds from financing between conversion liability and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_0" xml:lang="en-US">Represents the proceeds from issuance of common stock and warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_1" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrant Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_2" xml:lang="en-US">Proceeds from the sale of common stock and warrants net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ProvisionForConversionOfPreferredStock_0" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ProvisionForConversionOfPreferredStock_1" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ProvisionForConversionOfPreferredStock_2" xml:lang="en-US">Fair value of the conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ProvisionForConversionOfPreferredStock_3" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ReclassificationOfDerivativesToEquity_0" xml:lang="en-US">Amount of derivatives reclassified to equity or the statement of operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ReclassificationOfDerivativesToEquity_1" xml:lang="en-US">Reclassification Of Derivatives To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ReclassificationOfDerivativesToEquity_2" xml:lang="en-US">Reclassification of Derivatives to Equity or Extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ReclassificationOfDerivativesToEquity_3" xml:lang="en-US">Reduction of equity liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_RedemptionAmountPercentage_0" xml:lang="en-US">Represents redemption amount percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_RedemptionAmountPercentage_1" xml:lang="en-US">Redemption Amount Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_RedemptionAmountPercentage_2" xml:lang="en-US">Redemption amount percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_0" xml:lang="en-US">Amount of reduction to APIC from the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_1" xml:lang="en-US">Reduction To Additional Paid In Capital From The Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_2" xml:lang="en-US">Reduction to APIC from the issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_RemainingDrawDownsLoans_0" xml:lang="en-US">It represents remaining draw downs loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_RemainingDrawDownsLoans_1" xml:lang="en-US">Remaining Draw Downs Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_RemainingDrawDownsLoans_2" xml:lang="en-US">Remaining draw downs loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Represents amount related to prepayment of convertible multi-draw credit agreement - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Prepayment of convertible multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Repayment of Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ResearchAgreementMember_0" xml:lang="en-US">Represents information regarding research agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ResearchAgreementMember_1" xml:lang="en-US">Research Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ResearchAgreementMember_2" xml:lang="en-US">Research Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_RestrictedStockAgreementsMember_0" xml:lang="en-US">Information of Restricted Stock Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_RestrictedStockAgreementsMember_1" xml:lang="en-US">Restricted Stock Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_RestrictedStockAgreementsMember_2" xml:lang="en-US">Restricted Stock Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_RisksAndUncertaintiesPolicyTextBlock_0" xml:lang="en-US">Represents policy for Risks and Uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_RisksAndUncertaintiesPolicyTextBlock_1" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_RisksAndUncertaintiesPolicyTextBlock_2" xml:lang="en-US">Risks and Uncertainties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_RrdInternationalAgreementMember_0" xml:lang="en-US">Represents information regarding RRD International agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_RrdInternationalAgreementMember_1" xml:lang="en-US">Rrd International Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_RrdInternationalAgreementMember_2" xml:lang="en-US">RRD International Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0" xml:lang="en-US">Represent Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1" xml:lang="en-US">Schedule Of Adjustment For Difference Between Fair Value Of Warrant Liabilities And Total Proceeds Received Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2" xml:lang="en-US">Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_0" xml:lang="en-US">Tabular disclosure of Schedule of Assumptions Used to compute the fair value of the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_1" xml:lang="en-US">Schedule Of Assumptions Used To Compute Fair Value Of Warrants Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_2" xml:lang="en-US">Schedule of Assumptions Used to compute the fair value of the warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ScheduleOfInterestExpenseTableTextBlock_0" xml:lang="en-US">Tabular disclosure of interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ScheduleOfInterestExpenseTableTextBlock_1" xml:lang="en-US">Schedule Of Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_ScheduleOfInterestExpenseTableTextBlock_2" xml:lang="en-US">Schedule of interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SecondDrawOnMultiDrawCreditFacilityMember_0" xml:lang="en-US">Represents information regarding second draw on multi draw credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SecondDrawOnMultiDrawCreditFacilityMember_1" xml:lang="en-US">Second Draw On Multi Draw Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SecondDrawOnMultiDrawCreditFacilityMember_2" xml:lang="en-US">2nd Draw on Multi Draw Credit Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SecuredPromissoryNoteAndSecurityAgreementMember_0" xml:lang="en-US">Represents Secured Promissory Note and Security Agreement for a convertible loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SecuredPromissoryNoteAndSecurityAgreementMember_1" xml:lang="en-US">Secured Promissory Note And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_SecuredPromissoryNoteAndSecurityAgreementMember_2" xml:lang="en-US">Secured Promissory Note and Security Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SecuritiesPurchaseAgreementMember_0" xml:lang="en-US">Represents information regarding securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SecuritiesPurchaseAgreementMember_1" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_SecuritiesPurchaseAgreementMember_2" xml:lang="en-US">Securities Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SecuritiesPurchaseAgreementMember_3" xml:lang="en-US">Securities purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_0" xml:lang="en-US">Securities Purchase Agreement with H C Wainwright And Co LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_1" xml:lang="en-US">Securities Purchase Agreement With Hc Wainwright And Co Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_2" xml:lang="en-US">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeniorManagementCompensationPlanDescription_0" xml:lang="en-US">Represents description of senior management compensation plan description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeniorManagementCompensationPlanDescription_1" xml:lang="en-US">Senior Management Compensation Plan Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SeniorManagementCompensationPlanDescription_2" xml:lang="en-US">Description of senior management's compensation plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeparationAndReleaseAgreementMember_0" xml:lang="en-US">Represents separation and release agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeparationAndReleaseAgreementMember_1" xml:lang="en-US">Separation And Release Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SeparationAndReleaseAgreementMember_2" xml:lang="en-US">Separation and release agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeriesBCommonStockWarrantMember_0" xml:lang="en-US">Information about series b common stock. Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeriesBCommonStockWarrantMember_1" xml:lang="en-US">Series B Common Stock Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_SeriesBCommonStockWarrantMember_2" xml:lang="en-US">Series B Common Stock Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeriesBPreferredStockConversionLiabilityMember_0" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeriesBPreferredStockConversionLiabilityMember_1" xml:lang="en-US">Series BPreferred Stock Conversion Liability Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SeriesBPreferredStockConversionLiabilityMember_2" xml:lang="en-US">Series B Preferred Stock - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeriesBWarrantMember_0" xml:lang="en-US">Represents information regarding Series B warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeriesBWarrantMember_1" xml:lang="en-US">Series B Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_SeriesBWarrantMember_2" xml:lang="en-US">Series B - warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SeriesBWarrantMember_3" xml:lang="en-US">Series B Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeriesBWarrantsMember_0" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeriesBWarrantsMember_1" xml:lang="en-US">Series B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SeriesBWarrantsMember_2" xml:lang="en-US">Series B Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SeriesFPreferredStockPutOptionLiabilityMember_0" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SeriesFPreferredStockPutOptionLiabilityMember_1" xml:lang="en-US">Series F Preferred Stock Put Option Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SeriesFPreferredStockPutOptionLiabilityMember_2" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ShareAndWarrantsIssuanceCosts_0" xml:lang="en-US">Represents amount related to share and warrants issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ShareAndWarrantsIssuanceCosts_1" xml:lang="en-US">Share and warrants Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ShareAndWarrantsIssuanceCosts_2" xml:lang="en-US">Shares and warrants issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ShareIssuanceCosts_0" xml:lang="en-US">Represents costs related to issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ShareIssuanceCosts_1" xml:lang="en-US">Share Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ShareIssuanceCosts_2" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SignificantContractsLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SignificantContractsLineItems_1" xml:lang="en-US">Significant Contracts [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SignificantContractsTextBlock_0" xml:lang="en-US">Represents entire disclosure for significant contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SignificantContractsTextBlock_1" xml:lang="en-US">Significant Contracts [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_SignificantContractsTextBlock_2" xml:lang="en-US">Significant Contracts - University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SignificantContractsTextBlock_3" xml:lang="en-US">University of Mississippi Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_0" xml:lang="en-US">Number of preferred stock and warrants for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_1" xml:lang="en-US">Stock And Warrants Issued During Period Shares Preferred Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_2" xml:lang="en-US">Number of preferred stock and warrants sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_0" xml:lang="en-US">Represents policy for stock based compensation for Non Employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_1" xml:lang="en-US">Stock Based Compensation For Non Employees [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_2" xml:lang="en-US">Stock-Based Compensation for Non-Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuanceCosts_0" xml:lang="en-US">Represents amount of stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuanceCosts_1" xml:lang="en-US">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuanceCosts_2" xml:lang="en-US">Issuance costs (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_0" xml:lang="en-US">Exercise of pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_1" xml:lang="en-US">Stock Issued During Period Shares For Exercise Of Pre Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_2" xml:lang="en-US">Exercise of pre-funded warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0" xml:lang="en-US">Number of shares issued in lieu of cash for Stock based compensation expense contributed to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1" xml:lang="en-US">Stock Issued During Period Shares Issued For Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2" xml:lang="en-US">Stock-based compensation expense (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0" xml:lang="en-US">Number of shares of stock issued during the period net of issuance costs value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_0" xml:lang="en-US">Represents number of shares related to issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_1" xml:lang="en-US">Stock Issued During Period shares Net Of Issuance Costs and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_2" xml:lang="en-US">Issuance of common stock and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0" xml:lang="en-US">Number of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Shares Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_0" xml:lang="en-US">Exercise of pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_1" xml:lang="en-US">Stock Issued During Period Value For Exercise Of Pre Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_2" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0" xml:lang="en-US">Value of shares of common stock issued during the period net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_0" xml:lang="en-US">Represents amount related to issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_1" xml:lang="en-US">Stock Issued During Period Value Net Of Issuance Costs and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_2" xml:lang="en-US">Issuance of common stock and warrants, net of issuance costs of $80,628</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0" xml:lang="en-US">Value of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Value Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_SubsequentFinancingPurchasePriceDescription_0" xml:lang="en-US">Represents subsequent financing purchase price description to protect against anti-dilution.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SubsequentFinancingPurchasePriceDescription_1" xml:lang="en-US">Subsequent Financing Purchase Price Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_SubsequentFinancingPurchasePriceDescription_2" xml:lang="en-US">Subsequent financing purchase price, description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TermOfAgreement_0" xml:lang="en-US">Represents term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TermOfAgreement_1" xml:lang="en-US">Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TermOfAgreement_2" xml:lang="en-US">Term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TermOfWarrant_0" xml:lang="en-US">Represents term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TermOfWarrant_1" xml:lang="en-US">Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TermOfWarrant_2" xml:lang="en-US">Term of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TermOfWarrant_3" xml:lang="en-US">Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TermOfWarrants_0" xml:lang="en-US">Represents term of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TermOfWarrants_1" xml:lang="en-US">Term Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TermOfWarrants_2" xml:lang="en-US">Term of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TermsOfAgreementRenewed_0" xml:lang="en-US">Represents tem of agreement renewed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TermsOfAgreementRenewed_1" xml:lang="en-US">Terms Of Agreement Renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TermsOfAgreementRenewed_2" xml:lang="en-US">Terms of agreement renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TotalExpenseIncurredUnderAgreement_0" xml:lang="en-US">Represents total expense incurred under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TotalExpenseIncurredUnderAgreement_1" xml:lang="en-US">Total Expense Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TotalExpenseIncurredUnderAgreement_2" xml:lang="en-US">Total expense incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandAndTwentyCommonStockWarrantsMember_0" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandAndTwentyCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TwoThousandAndTwentyCommonStockWarrantsMember_2" xml:lang="en-US">2020 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_0" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants To Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_1" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants To Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_2" xml:lang="en-US">2020 Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandAndTwentyPreFundedWarrantsMember_0" xml:lang="en-US">Two Thousand And Twenty Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandAndTwentyPreFundedWarrantsMember_1" xml:lang="en-US">Two Thousand And Twenty Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandAndTwentyPreFundedWarrantsMember_2" xml:lang="en-US">2020 Pre-Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_0" xml:lang="en-US">Represents 2018 Emerald Financing Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_1" xml:lang="en-US">Two Thousand Eighteen Emerald Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_2" xml:lang="en-US">2018 Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0" xml:lang="en-US">Information about 2018 emerald multi-draw credit agreement warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement - compound derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2" xml:lang="en-US">Two Thousand Eighteen Emerald Multi Draw Credit Agreement Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandFifteenCommonStockWarrantsMember_0" xml:lang="en-US">Represents 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandFifteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandFifteenCommonStockWarrantsMember_2" xml:lang="en-US">2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Common Stock Warrants to Series B Stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Common Stock Warrants To Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">2015 series B financing Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2" xml:lang="en-US">2015 Series B financing Placement Agent Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandNineteenCommonStockWarrantsMember_0" xml:lang="en-US">Represents 2019 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandNineteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Nineteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_TwoThousandNineteenCommonStockWarrantsMember_2" xml:lang="en-US">2019 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand seventeen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Seventeen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2017 Common Stock Warrants to Service Provider</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand sixteen Series D Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Seventeen Series D Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2" xml:lang="en-US">2017 Series D Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand sixteen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Sixteen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2016 Common Stock Warrants to Service Providers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents 2016 Series C Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Sixteen Series C Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2" xml:lang="en-US">2016 Series C Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_0" xml:lang="en-US">It represents UM 5050 Pro-Drug and UM 8930 Analog Agreements member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_1" xml:lang="en-US">Um 5050 Prodrug And Um 8930 Analog Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_2" xml:lang="en-US">Um 5050 Pro-Drug And Um 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_Um5070LicenseAgreementMember_0" xml:lang="en-US">UM 5070 license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_Um5070LicenseAgreementMember_1" xml:lang="en-US">Um 5070 License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_Um5070LicenseAgreementMember_2" xml:lang="en-US">UM 5070 license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_UnamortizedDebtDiscountPeriod_0" xml:lang="en-US">Period of unamortized discount of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_UnamortizedDebtDiscountPeriod_1" xml:lang="en-US">Unamortized Debt Discount Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_UnamortizedDebtDiscountPeriod_2" xml:lang="en-US">Unamortized debt discount period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_UniversityOfMississippiAgreementsLineItems_0" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_UniversityOfMississippiAgreementsLineItems_1" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_UniversityOfMississippiAgreementsTable_0" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_UniversityOfMississippiAgreementsTable_1" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_UniversityOfMississippiMember_0" xml:lang="en-US">Represents information regarding university of mississippi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_UniversityOfMississippiMember_1" xml:lang="en-US">University Of Mississippi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_UniversityOfMississippiMember_2" xml:lang="en-US">University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_UnvestedRestrictedStockMember_0" xml:lang="en-US">Represent the information of unvested restricted stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_UnvestedRestrictedStockMember_1" xml:lang="en-US">Unvested Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_UnvestedRestrictedStockMember_2" xml:lang="en-US">Unvested restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_UpfrontPayment_0" xml:lang="en-US">This element represents amount of upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_UpfrontPayment_1" xml:lang="en-US">Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_UpfrontPayment_2" xml:lang="en-US">Upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ValueOfCommonStockCalledByWarrants_0" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ValueOfCommonStockCalledByWarrants_1" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ValueOfCommonStockCalledByWarrants_2" xml:lang="en-US">Value of common stock called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_0" xml:lang="en-US">Value Of Warrants Issued recorded as equity issuance costs within equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_1" xml:lang="en-US">Value Of Warrant Issued Recorded As Equity Issuance Costs Within Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_2" xml:lang="en-US">Value of warrants issued recorded as equity issuance costs within equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WarrantsAndDerivativeLiabilitiesTextBlock_0" xml:lang="en-US">The entire disclosure for Warrants and Derivative Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsAndDerivativeLiabilitiesTextBlock_1" xml:lang="en-US">Warrants And Derivative Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_WarrantsAndDerivativeLiabilitiesTextBlock_2" xml:lang="en-US">Warrants and Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents warrants issued in connection with convertible multi draw credit agreement related party value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Warrants issued in connection with convertible multi draw credit agreement related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_3" xml:lang="en-US">Warrants issued in connection with convertible multi-draw credit agreement, related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for warrants issued in bundled transactions with other financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1" xml:lang="en-US">Warrants Issued In Connection With Financings [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2" xml:lang="en-US">Warrants Issued in Connection with Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WarrantsLiabilityClassifiedMember_0" xml:lang="en-US">Represent the information of warrants - liability classified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsLiabilityClassifiedMember_1" xml:lang="en-US">Warrants liability classified [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_WarrantsLiabilityClassifiedMember_2" xml:lang="en-US">Warrants - liability classified</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WarrantsMember_0" xml:lang="en-US">Represent the information of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsMember_1" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_WarrantsMember_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WarrantsVestedAndOutstanding_0" xml:lang="en-US">Represents warrants vested and outstanding as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsVestedAndOutstanding_1" xml:lang="en-US">Warrants Vested And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_WarrantsVestedAndOutstanding_2" xml:lang="en-US">Amount Vested and Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_WarrantsVestedAndOutstanding_3" xml:lang="en-US">Number of Warrants Vested and Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_skye_WorkingCapitalDeficit_0" xml:lang="en-US">Represent working capital deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_skye_WorkingCapitalDeficit_1" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WorkingCapitalDeficit_2" xml:lang="en-US">Working Capital Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_WorkingCapitalDeficit_3" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_0" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_0" xml:lang="en-US">Less, noncurrent portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US">Convertible multi-draw credit agreement - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_2" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_3" xml:lang="en-US">Convertible multi-draw credit agreement - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_4" xml:lang="en-US">Total principal value of non-convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_0" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_1" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_3" xml:lang="en-US">Issuance costs related to warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_0" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_1" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_2" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes_0" xml:lang="en-US">State taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes_1" xml:lang="en-US">Deferred Tax Assets, State Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes_2" xml:lang="en-US">State taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1" xml:lang="en-US">Derivative Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2" xml:lang="en-US">Derivative liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2" xml:lang="en-US">Change in fair market of the warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3" xml:lang="en-US">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_4" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_5" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_6" xml:lang="en-US">Change in Fair value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0" xml:lang="en-US">Loss on disposal of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0" xml:lang="en-US">Loss on extinguishment of debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US">Loss on extinguishment of debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3" xml:lang="en-US">Loss on extinguishment of secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Provision (Benefit) for Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Provision for Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense_1" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense_2" xml:lang="en-US">Net income (loss) and comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpense_3" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_1" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_2" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_0" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_1" xml:lang="en-US">Warrant liability, issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_2" xml:lang="en-US">Payments of Derivative Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_3" xml:lang="en-US">Payments of derivative issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_4" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xml:lang="en-US">Purchases of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Less: Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Common stock gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Proceeds from the issuance of common stock and warrants - net of $854,078 and $80,628 of issuance costs in 2020 and 2019, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5" xml:lang="en-US">Proceeds from stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3" xml:lang="en-US">Retained earnings during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2" xml:lang="en-US">Number of unrestricted stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3" xml:lang="en-US">Number of restricted common stock vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xml:lang="en-US">Options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" xml:lang="en-US">Aggregate number of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity_4" xml:lang="en-US">Stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_5" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity_6" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0" xml:lang="en-US">Gross decrease - prior period tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2" xml:lang="en-US">Gross decrease - prior period tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities_0" xml:lang="en-US">Total deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities_1" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities_2" xml:lang="en-US">Total deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants to purchase an aggregate shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US">Number of common stock called by warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xml:lang="en-US">Total number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Warrants to purchase an aggregate shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Number of common stock called by warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_2" xml:lang="en-US">Total number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_3" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_4" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_5" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_6" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_5" xml:lang="en-US">Net (loss) income and comprehensive (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_6" xml:lang="en-US">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash_0" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash_1" xml:lang="en-US">Cash, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash_3" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Cash_4" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash_5" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and restricted cash, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash and restricted cash, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3" xml:lang="en-US">Common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_0" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_1" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities_2" xml:lang="en-US">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_3" xml:lang="en-US">Derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_2" xml:lang="en-US">Convertible preferred stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_3" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue_0" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue_1" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue_2" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue_3" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue_4" xml:lang="en-US">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at December 31, 2020 and December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Unvested, December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Unvested, December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_2" xml:lang="en-US">Shares Held in Employee Stock Option Plan, Allocated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_3" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_4" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued_2" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued_3" xml:lang="en-US">Number of additional shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_0" xml:lang="en-US">Unrecognized tax positions, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1" xml:lang="en-US">Unrecognized tax positions, beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_2" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent_0" xml:lang="en-US">Accrued payroll liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent_1" xml:lang="en-US">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent_2" xml:lang="en-US">Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent_3" xml:lang="en-US">Accrued payroll and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_0" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_2" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_3" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_4" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_5" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2" xml:lang="en-US">Conversion price, per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3" xml:lang="en-US">Initial conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0" xml:lang="en-US">Draw downs in aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_2" xml:lang="en-US">Principal amount of promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Income available to common stockholders, Per-Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">Net income (loss) per share - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_3" xml:lang="en-US">Earnings Per Share, Basic, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_4" xml:lang="en-US">Basic (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_0" xml:lang="en-US">Loss available to common stockholders, Per-Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_2" xml:lang="en-US">Net loss per share - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_3" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_4" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Loss available to common stockholders + assumed conversions, Per-Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2" xml:lang="en-US">Net loss per share - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3" xml:lang="en-US">Diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0" xml:lang="en-US">Income available to common stockholders, Income (Numerator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3" xml:lang="en-US">Net loss applicable to common shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_3" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OtherLoansPayableLongTerm_0" xml:lang="en-US">PPP loan non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLoansPayableLongTerm_1" xml:lang="en-US">Other Loans Payable, Long-term, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted-average fair value of stock options granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Vested and expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3" xml:lang="en-US">Expected to vest, September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Weighted average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_2" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_3" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Loss available to common stockholders + assumed conversions, Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted average common shares outstanding - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3" xml:lang="en-US">Diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0" xml:lang="en-US">Loss available to common stockholders, Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3" xml:lang="en-US">Weighted average shares of common stock outstanding: basic and diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Income available to common stockholders Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted average common shares outstanding - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4" xml:lang="en-US">Basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_0" xml:lang="en-US">Funding of remaining bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_1" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_2" xml:lang="en-US">Payments received from convertible bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_3" xml:lang="en-US">Funds received under the Secured Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0" xml:lang="en-US">Proceeds from Common stock issuance, net of $80,628 and 154,092 of issuance costs in 2019 and 2018, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2" xml:lang="en-US">Aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3" xml:lang="en-US">Proceeds from preferred stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag_1" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CoverAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate_1" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus_1" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus_1" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate_1" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType_1" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey_1" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory_1" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName_1" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_LegalEntityAxis_1" xml:lang="en-US">UM 5050 Pro-Drug and UM 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol_1" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_AlbanyMolecularResearchIncMember_0" xml:lang="en-US">Albany Molecular Research Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_AlbanyMolecularResearchIncMember_1" xml:lang="en-US">AMRI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_CashPaidDuringPeriodForAbstract_0" xml:lang="en-US">Cash Paid During Period For Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_CashPaidDuringPeriodForAbstract_1" xml:lang="en-US">Cash paid during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DilutedSecuritiesAxis_0" xml:lang="en-US">Diluted Securities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_LeaseAgreementMember_0" xml:lang="en-US">Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_skye_LeaseAgreementMember_1" xml:lang="en-US">Lease Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_NonCashInterestExpenseAbstract_0" xml:lang="en-US">Non Cash Interest Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_skye_NonCashInterestExpenseAbstract_1" xml:lang="en-US">Non-cash interest expense:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PricingModelAxis_0" xml:lang="en-US">Pricing Model [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_PricingModelDomain_0" xml:lang="en-US">Pricing Model [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SignificantContractsAbstract_0" xml:lang="en-US">Significant Contracts [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_SignificantContractsTable_0" xml:lang="en-US">Significant Contracts [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_skye_WarrantsAndDerivativeLiabilitiesAbstract_0" xml:lang="en-US">Warrants And Derivative Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_1" xml:lang="en-US">Cosmas N. Lykos</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_2" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_1" xml:lang="en-US">Dr. Brian S. Murphy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_2" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_1" xml:lang="en-US">Elizabeth Berecz, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_2" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_2" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1" xml:lang="en-US">Accounts payable - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_2" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Total other accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_2" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_0" xml:lang="en-US">Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_1" xml:lang="en-US">Accrued legal expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_0" xml:lang="en-US">Accrued Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_1" xml:lang="en-US">Amount of salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional paid-in-capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional Paid-In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_0" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_1" xml:lang="en-US">Value of warrants issued to purchase shares of common stock for consulting services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1" xml:lang="en-US">Beneficial conversion feature upon issuance of Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_1" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_2" xml:lang="en-US">Amortization of convertible debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_1" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_2" xml:lang="en-US">Amortization of warrants and stock issued for services (1)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Anti-dilutive excluded from the calculation of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfLand_0" xml:lang="en-US">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfLand_1" xml:lang="en-US">Area of corporate office headquarters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AreaOfLand_2" xml:lang="en-US">Area of land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets_2" xml:lang="en-US">Total Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent_2" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoan_0" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoan_1" xml:lang="en-US">Aggregate gross proceeds secured by all of Nemus' assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BridgeLoan_2" xml:lang="en-US">Aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoanMember_0" xml:lang="en-US">Bridge Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoanMember_1" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xml:lang="en-US">Net increase (decrease) in cash and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1" xml:lang="en-US">Reconciliation of cash and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US">Supplemental disclosures of non-cash financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_1" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US">Number of warrant issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">Commitments and contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US">Number of shares reserved for future grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Par value of common stock issued (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Common stock, $0.001 par value; 500,000,000 shares authorized; 288,074,415 and 182,895,247 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xml:lang="en-US">Comprehensive Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_1" xml:lang="en-US">Number of shares converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_1" xml:lang="en-US">Number of shares issued in conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt_0" xml:lang="en-US">Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ConvertibleDebt_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember_0" xml:lang="en-US">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember_1" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_0" xml:lang="en-US">Convertible Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_1" xml:lang="en-US">Common shares underlying convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_1" xml:lang="en-US">Schedule of convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_2" xml:lang="en-US">Schedule of convertible and non-convertible advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_1" xml:lang="en-US">Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis_0" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1" xml:lang="en-US">Beneficial conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1" xml:lang="en-US">Total principal value of convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2" xml:lang="en-US">Total principal value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_2" xml:lang="en-US">Reduction in conversion price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1" xml:lang="en-US">Unamortized debt discount period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1" xml:lang="en-US">Number of trading days as of financing close date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xml:lang="en-US">Effective interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2" xml:lang="en-US">Bridge loan interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US">Bridge loan maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_2" xml:lang="en-US">Maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US">Debt Issuance Costs and Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2" xml:lang="en-US">Total deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1" xml:lang="en-US">United States</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_2" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_1" xml:lang="en-US">Current deferred tax assets/(liabilities):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" xml:lang="en-US">Net operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1" xml:lang="en-US">California net operating loss carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1" xml:lang="en-US">Expired in net operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1" xml:lang="en-US">Deferred tax carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1" xml:lang="en-US">California research deferred tax carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_0" xml:lang="en-US">Derivative Contract [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_0" xml:lang="en-US">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_1" xml:lang="en-US">Current balance of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_2" xml:lang="en-US">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_1" xml:lang="en-US">Convertible Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecurities_0" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DilutiveSecurities_1" xml:lang="en-US">Income (Numerator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DilutiveSecurities_2" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_0" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_1" xml:lang="en-US">Effect of Dilutive Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">Stock-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1" xml:lang="en-US">Schedule of shares available for future grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromRelatedParties_0" xml:lang="en-US">Due from Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromRelatedParties_1" xml:lang="en-US">Amount of payments due under the contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_0" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_1" xml:lang="en-US">Basic net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_2" xml:lang="en-US">Basic EPS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1" xml:lang="en-US">(Loss) earnings per common share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_0" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_1" xml:lang="en-US">Diluted net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_2" xml:lang="en-US">Diluted EPS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems_0" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Net Income (Loss) Per Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_1" xml:lang="en-US">Net Income (Loss) Per Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Recognized weighted average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" xml:lang="en-US">Recognized period of non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Total amount of unrecognized compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US">Stock Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract_0" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityAbstract_1" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain_1" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_0" xml:lang="en-US">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_0" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Income Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_1" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" xml:lang="en-US">Schedule of input and valuation technique used to value warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1" xml:lang="en-US">Fair Value Measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember_0" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCountryMember_1" xml:lang="en-US">Australia</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xml:lang="en-US">Pre-tax (loss) income from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xml:lang="en-US">(Loss) income before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3" xml:lang="en-US">Income (loss) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract_1" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_1" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_0" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1" xml:lang="en-US">Reduction in deferred tax asset balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1" xml:lang="en-US">Tax Cuts and Jobs Act</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Expected income tax benefit at federal statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Other permanent difference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2" xml:lang="en-US">Other permanent difference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1" xml:lang="en-US">Stock Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_1" xml:lang="en-US">Rate adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1" xml:lang="en-US">Accounts payable - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_3" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_0" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1" xml:lang="en-US">Decrease in derivative liability through an adjustment to change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1" xml:lang="en-US">Accounts payable - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1" xml:lang="en-US">Changes in assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1" xml:lang="en-US">Accrued interest - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember_0" xml:lang="en-US">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntellectualPropertyMember_1" xml:lang="en-US">Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt_0" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt_1" xml:lang="en-US">PPP loan interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseOther_0" xml:lang="en-US">Interest Expense, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseOther_1" xml:lang="en-US">Other interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseRelatedParty_0" xml:lang="en-US">Interest Expense, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseRelatedParty_1" xml:lang="en-US">Related party interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet_0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet_1" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestorMember_0" xml:lang="en-US">Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestorMember_1" xml:lang="en-US">Accredited Investor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember_0" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember_1" xml:lang="en-US">Direct offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense_0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseAndRentalExpense_1" xml:lang="en-US">Lease expenses per month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_1" xml:lang="en-US">Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">Noncurrent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1" xml:lang="en-US">Maximum amount that can be borrowed over the life of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_2" xml:lang="en-US">Credit facility advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1" xml:lang="en-US">Unused portion of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xml:lang="en-US">Principal amounts of borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1" xml:lang="en-US">Fair value of advance under credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_1" xml:lang="en-US">Amount of capital raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1" xml:lang="en-US">Interest rate percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2" xml:lang="en-US">Interest rates per annum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_0" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_1" xml:lang="en-US">Principal amount of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US">Maximum borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2" xml:lang="en-US">Maximum borrowing capacity of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Maximum Month-end Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_1" xml:lang="en-US">Credit facility advances per month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember_0" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember_1" xml:lang="en-US">Closing price per share of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_1" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_0" xml:lang="en-US">Measurement Input, Offered Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_1" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_2" xml:lang="en-US">Weighted-average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_1" xml:lang="en-US">Volatility factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1" xml:lang="en-US">Other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_0" xml:lang="en-US">Nonoperating Income (Expense) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments_0" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments_1" xml:lang="en-US">Number of reportable segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_0" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_0" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_1" xml:lang="en-US">Rent expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US">Operating loss carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_0" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_0" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" xml:lang="en-US">Nature of Operations and Business Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">Total other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_2" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_0" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1" xml:lang="en-US">Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebtCurrent_0" xml:lang="en-US">Other Long-term Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebtCurrent_1" xml:lang="en-US">PPP loan current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent_0" xml:lang="en-US">Other Long-term Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent_1" xml:lang="en-US">Multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2" xml:lang="en-US">Stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_0" xml:lang="en-US">Payments to Acquire Furniture and Fixtures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_1" xml:lang="en-US">Value of furniture lease payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConversionBasis_0" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockConversionBasis_1" xml:lang="en-US">Preferred stock, conversion rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_1" xml:lang="en-US">Reduction of conversion price of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_0" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1" xml:lang="en-US">Liquidation preference value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1" xml:lang="en-US">Preferred stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2" xml:lang="en-US">Preferred stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_2" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_2" xml:lang="en-US">Preferred Stock, Shares Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_3" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember_1" xml:lang="en-US">Private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs in 2020 and 2019, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_2" xml:lang="en-US">Proceeds from convertible debt issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs in 2020 and 2019, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from convertible debt issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1" xml:lang="en-US">Proceeds from triggering transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1" xml:lang="en-US">Proceeds from issuance of preferred stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_2" xml:lang="en-US">Proceeds received from the Series B financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_2" xml:lang="en-US">Proceeds from warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_0" xml:lang="en-US">Proceeds from Other Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_1" xml:lang="en-US">Amount of cash inflow from convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherShortTermDebt_0" xml:lang="en-US">Proceeds from Other Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherShortTermDebt_1" xml:lang="en-US">Proceeds from PPP loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_1" xml:lang="en-US">Proceeds from related party debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_2" xml:lang="en-US">Proceeds from Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Net equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US">Net equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US">Estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends_0" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends_1" xml:lang="en-US">Less: Preferred deemed dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends_2" xml:lang="en-US">Preferred deemed dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">Related Party Matters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development Expenses and Licensed Technology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockExpense_0" xml:lang="en-US">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockExpense_1" xml:lang="en-US">Stock compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember_0" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_1" xml:lang="en-US">Unvested restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_2" xml:lang="en-US">Restricted stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US">Revenue Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1" xml:lang="en-US">Net proceeds from the transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction_0" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction_1" xml:lang="en-US">Common stock and pre-funded stock units sold description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1" xml:lang="en-US">Shares issued, price per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2" xml:lang="en-US">Number of warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_1" xml:lang="en-US">Common stock, par value (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of anti-dilutive securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" xml:lang="en-US">Schedule of components of income (loss) before the income tax provision (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule for significant portions of deferred income tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xml:lang="en-US">Schedule summary of the activity of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_0" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1" xml:lang="en-US">Schedule of RSA activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_1" xml:lang="en-US">Schedule of stock-Based compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of summary of stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of fair value assumptions of stock option granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_0" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US">Schedule of warrants vested and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of reconciliation of beginning and ending amounts of unrecognized tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1" xml:lang="en-US">Segment Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_1" xml:lang="en-US">Convertible Series A Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_2" xml:lang="en-US">Series F Preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_1" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_2" xml:lang="en-US">Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_1" xml:lang="en-US">Convertible Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_2" xml:lang="en-US">Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_1" xml:lang="en-US">Convertible Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_2" xml:lang="en-US">Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesEPreferredStockMember_0" xml:lang="en-US">Series E Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesEPreferredStockMember_1" xml:lang="en-US">Series E Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_0" xml:lang="en-US">Series F Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_1" xml:lang="en-US">Convertible Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_2" xml:lang="en-US">Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_2" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US">Restricted stock vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1" xml:lang="en-US">Description of stock option agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xml:lang="en-US">Number of restricted common stock granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Weighted-average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Dividend Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xml:lang="en-US">Number of additional shares reserved for future grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, additional disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2" xml:lang="en-US">Aggregate intrinsic value of the awards exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Options to purchase shares of common stock, exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xml:lang="en-US">Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted-average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1" xml:lang="en-US">Number of forfeiture of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted average exercise price of forfeiture of shares (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1" xml:lang="en-US">Share pool increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2" xml:lang="en-US">Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value of the awards expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xml:lang="en-US">Aggregate intrinsic value of options exercisable, and vested and expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price of vested and outstanding (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value of options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2" xml:lang="en-US">Aggregate Intrinsic Value, Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xml:lang="en-US">Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xml:lang="en-US">Expected to vest, September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US">Fair value of stock options vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US">Options vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2" xml:lang="en-US">Number of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US">January 18, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2" xml:lang="en-US">Immediate vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1" xml:lang="en-US">November 21, 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">October 20, 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Stock-Based Compensation for Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2" xml:lang="en-US">Stock-Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems_0" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_0" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_1" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1" xml:lang="en-US">Common stock warrants issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2" xml:lang="en-US">Value of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">Stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2" xml:lang="en-US">Stockholders' equity (deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">Stockholders' Equity (Deficit) and Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1" xml:lang="en-US">Number of notes converted into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1" xml:lang="en-US">Common stock issued for services (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2" xml:lang="en-US">Number of common shares issued to founders and one board member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1" xml:lang="en-US">Common stock issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2" xml:lang="en-US">Issuance of common stock for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_1" xml:lang="en-US">Tax credit limitation on use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_0" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_1" xml:lang="en-US">Liquidation preference value (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_1" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_1" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1" xml:lang="en-US">Gross increase - current period tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Deferred tax assets increase in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_1" xml:lang="en-US">Reduced exercise price of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_2" xml:lang="en-US">Decrease in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_2" xml:lang="en-US">Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_1" xml:lang="en-US">Value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1" xml:lang="en-US">Warrants and rights outstanding measurement input (in percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2" xml:lang="en-US">Measurement input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1" xml:lang="en-US">Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2" xml:lang="en-US">Warrants and rights outstanding term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1" xml:lang="en-US">Weighted average shares of common stock outstanding used to compute (loss) earnings per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedBoardFees_1" xlink:to="lab_skye_AccruedBoardFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedBoardFees_1" xlink:to="lab_skye_AccruedBoardFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedBoardFees_1" xlink:to="lab_skye_AccruedBoardFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedExpenseUnderAgreement_2" xlink:to="lab_skye_AccruedExpenseUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedExpenseUnderAgreement_2" xlink:to="lab_skye_AccruedExpenseUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedExpenseUnderAgreement_2" xlink:to="lab_skye_AccruedExpenseUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedInterestRelatedParty_3" xlink:to="lab_skye_AccruedInterestRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedInterestRelatedParty_3" xlink:to="lab_skye_AccruedInterestRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedInterestRelatedParty_3" xlink:to="lab_skye_AccruedInterestRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedResearchAndDevelopmentCosts_4" xlink:to="lab_skye_AccruedResearchAndDevelopmentCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedResearchAndDevelopmentCosts_4" xlink:to="lab_skye_AccruedResearchAndDevelopmentCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AccruedResearchAndDevelopmentCosts_4" xlink:to="lab_skye_AccruedResearchAndDevelopmentCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AdditionalConversionLiability_5" xlink:to="lab_skye_AdditionalConversionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AdditionalConversionLiability_5" xlink:to="lab_skye_AdditionalConversionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AdditionalConversionLiability_5" xlink:to="lab_skye_AdditionalConversionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_6" xlink:to="lab_skye_AggregateExercisePriceOfOutstandingCreditAgreements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_6" xlink:to="lab_skye_AggregateExercisePriceOfOutstandingCreditAgreements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_6" xlink:to="lab_skye_AggregateExercisePriceOfOutstandingCreditAgreements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_7" xlink:to="lab_skye_AggregateMilestonePaymentsIfMilestonesAchieved_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_7" xlink:to="lab_skye_AggregateMilestonePaymentsIfMilestonesAchieved_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_7" xlink:to="lab_skye_AggregateMilestonePaymentsIfMilestonesAchieved_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_8" xlink:to="lab_skye_AllocationOfDebtOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_8" xlink:to="lab_skye_AllocationOfDebtOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_8" xlink:to="lab_skye_AllocationOfDebtOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_9" xlink:to="lab_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_9" xlink:to="lab_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_9" xlink:to="lab_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_10" xlink:to="lab_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_10" xlink:to="lab_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_10" xlink:to="lab_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmortizationOfDebtDiscount_11" xlink:to="lab_skye_AmortizationOfDebtDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmortizationOfDebtDiscount_11" xlink:to="lab_skye_AmortizationOfDebtDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmortizationOfDebtDiscount_11" xlink:to="lab_skye_AmortizationOfDebtDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmortizationOfTransactionCosts_12" xlink:to="lab_skye_AmortizationOfTransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmortizationOfTransactionCosts_12" xlink:to="lab_skye_AmortizationOfTransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmortizationOfTransactionCosts_12" xlink:to="lab_skye_AmortizationOfTransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmountOfEachWarrantOutstanding_13" xlink:to="lab_skye_AmountOfEachWarrantOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmountOfEachWarrantOutstanding_13" xlink:to="lab_skye_AmountOfEachWarrantOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmountOfEachWarrantOutstanding_13" xlink:to="lab_skye_AmountOfEachWarrantOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmountOfPassThroughExpensesAndConsultingFees_14" xlink:to="lab_skye_AmountOfPassThroughExpensesAndConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmountOfPassThroughExpensesAndConsultingFees_14" xlink:to="lab_skye_AmountOfPassThroughExpensesAndConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AmountOfPassThroughExpensesAndConsultingFees_14" xlink:to="lab_skye_AmountOfPassThroughExpensesAndConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualFeeForAgreement_15" xlink:to="lab_skye_AnnualFeeForAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualFeeForAgreement_15" xlink:to="lab_skye_AnnualFeeForAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualFeeForAgreement_15" xlink:to="lab_skye_AnnualFeeForAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualFeesForLicenseAgreement_16" xlink:to="lab_skye_AnnualFeesForLicenseAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualFeesForLicenseAgreement_16" xlink:to="lab_skye_AnnualFeesForLicenseAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualFeesForLicenseAgreement_16" xlink:to="lab_skye_AnnualFeesForLicenseAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualMaintenanceFeePayable_17" xlink:to="lab_skye_AnnualMaintenanceFeePayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualMaintenanceFeePayable_17" xlink:to="lab_skye_AnnualMaintenanceFeePayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualMaintenanceFees_18" xlink:to="lab_skye_AnnualMaintenanceFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AnnualMaintenanceFees_18" xlink:to="lab_skye_AnnualMaintenanceFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_August2020FinancingMember_19" xlink:to="lab_skye_August2020FinancingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_August2020FinancingMember_19" xlink:to="lab_skye_August2020FinancingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_20" xlink:to="lab_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_20" xlink:to="lab_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_20" xlink:to="lab_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AvtarDhillonMember_21" xlink:to="lab_skye_AvtarDhillonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AvtarDhillonMember_21" xlink:to="lab_skye_AvtarDhillonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AvtarDhillonMember_21" xlink:to="lab_skye_AvtarDhillonMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AwardsGrantedOutside2014PlanMember_22" xlink:to="lab_skye_AwardsGrantedOutside2014PlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AwardsGrantedOutside2014PlanMember_22" xlink:to="lab_skye_AwardsGrantedOutside2014PlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AwardsGrantedOutside2014PlanMember_22" xlink:to="lab_skye_AwardsGrantedOutside2014PlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AwardsGrantedOutsideThe2014PlanMember_23" xlink:to="lab_skye_AwardsGrantedOutsideThe2014PlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AwardsGrantedOutsideThe2014PlanMember_23" xlink:to="lab_skye_AwardsGrantedOutsideThe2014PlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AwardsGrantedOutsideThe2014PlanMember_23" xlink:to="lab_skye_AwardsGrantedOutsideThe2014PlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_24" xlink:to="lab_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_24" xlink:to="lab_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_24" xlink:to="lab_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_25" xlink:to="lab_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_25" xlink:to="lab_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_25" xlink:to="lab_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_26" xlink:to="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_26" xlink:to="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_26" xlink:to="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_27" xlink:to="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_27" xlink:to="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_27" xlink:to="lab_skye_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ChangeInFairValueOfDerivativeLiabilities_28" xlink:to="lab_skye_ChangeInFairValueOfDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ChangeInFairValueOfDerivativeLiabilities_28" xlink:to="lab_skye_ChangeInFairValueOfDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ChangeInFairValueOfDerivativeLiabilities_28" xlink:to="lab_skye_ChangeInFairValueOfDerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ChangeInFairValueOfWarrantLiability_29" xlink:to="lab_skye_ChangeInFairValueOfWarrantLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ChangeInFairValueOfWarrantLiability_29" xlink:to="lab_skye_ChangeInFairValueOfWarrantLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ChangeInFairValueOfWarrantLiability_29" xlink:to="lab_skye_ChangeInFairValueOfWarrantLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_30" xlink:to="lab_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_30" xlink:to="lab_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_30" xlink:to="lab_skye_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ClassOfWarrantOrRightWarrantsExercise_31" xlink:to="lab_skye_ClassOfWarrantOrRightWarrantsExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ClassOfWarrantOrRightWarrantsExercise_31" xlink:to="lab_skye_ClassOfWarrantOrRightWarrantsExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ClassOfWarrantOrRightWarrantsExercise_31" xlink:to="lab_skye_ClassOfWarrantOrRightWarrantsExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_32" xlink:to="lab_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_32" xlink:to="lab_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_32" xlink:to="lab_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockAggregatePurchasePrice_33" xlink:to="lab_skye_CommonStockAggregatePurchasePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockAggregatePurchasePrice_33" xlink:to="lab_skye_CommonStockAggregatePurchasePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockAggregatePurchasePrice_33" xlink:to="lab_skye_CommonStockAggregatePurchasePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockIssuedForServices_34" xlink:to="lab_skye_CommonStockIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockIssuedForServices_34" xlink:to="lab_skye_CommonStockIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockWarrantsMember_35" xlink:to="lab_skye_CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockWarrantsMember_35" xlink:to="lab_skye_CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockWarrantsMember_35" xlink:to="lab_skye_CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockWarrantsToSeriesBStockholdersMember_36" xlink:to="lab_skye_CommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockWarrantsToSeriesBStockholdersMember_36" xlink:to="lab_skye_CommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonStockWarrantsToSeriesBStockholdersMember_36" xlink:to="lab_skye_CommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonUnitSoldPricePerUnit_37" xlink:to="lab_skye_CommonUnitSoldPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonUnitSoldPricePerUnit_37" xlink:to="lab_skye_CommonUnitSoldPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CommonUnitSoldPricePerUnit_37" xlink:to="lab_skye_CommonUnitSoldPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConsultingAgreementMember_38" xlink:to="lab_skye_ConsultingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConsultingAgreementMember_38" xlink:to="lab_skye_ConsultingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConsultingAgreementMember_38" xlink:to="lab_skye_ConsultingAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ContractPayableDue_39" xlink:to="lab_skye_ContractPayableDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ContractPayableDue_39" xlink:to="lab_skye_ContractPayableDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ContractPayableDue_39" xlink:to="lab_skye_ContractPayableDue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionLiabilityIntoCommonStockPerShare_40" xlink:to="lab_skye_ConversionLiabilityIntoCommonStockPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionLiabilityIntoCommonStockPerShare_40" xlink:to="lab_skye_ConversionLiabilityIntoCommonStockPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionLiabilityIntoCommonStockPerShare_40" xlink:to="lab_skye_ConversionLiabilityIntoCommonStockPerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_41" xlink:to="lab_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_41" xlink:to="lab_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_41" xlink:to="lab_skye_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_42" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_42" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_42" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_42" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_43" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_43" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_43" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_43" xlink:to="lab_skye_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_44" xlink:to="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_44" xlink:to="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_44" xlink:to="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_45" xlink:to="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_45" xlink:to="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_45" xlink:to="lab_skye_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_46" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_46" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_46" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_46" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_47" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_47" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_47" xlink:to="lab_skye_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStock_48" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStock_48" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStock_48" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStock_48" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_49" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_49" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_49" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_49" xlink:to="lab_skye_ConversionOfSeriesDPreferredStockToCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_50" xlink:to="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_50" xlink:to="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_50" xlink:to="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_51" xlink:to="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_51" xlink:to="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_51" xlink:to="lab_skye_ConversionOfSeriesFPreferredStockToCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionPrice_52" xlink:to="lab_skye_ConversionPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionPrice_52" xlink:to="lab_skye_ConversionPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionPrice_52" xlink:to="lab_skye_ConversionPrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionPricePerShare_53" xlink:to="lab_skye_ConversionPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionPricePerShare_53" xlink:to="lab_skye_ConversionPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConversionPricePerShare_53" xlink:to="lab_skye_ConversionPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRate10000001Member_54" xlink:to="lab_skye_ConvertedRate10000001Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRate10000001Member_54" xlink:to="lab_skye_ConvertedRate10000001Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRate10000001Member_54" xlink:to="lab_skye_ConvertedRate10000001Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRate100001Member_55" xlink:to="lab_skye_ConvertedRate100001Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRate100001Member_55" xlink:to="lab_skye_ConvertedRate100001Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRate100001Member_55" xlink:to="lab_skye_ConvertedRate100001Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRateAxis_56" xlink:to="lab_skye_ConvertedRateAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRateAxis_56" xlink:to="lab_skye_ConvertedRateAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRateDomain_57" xlink:to="lab_skye_ConvertedRateDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertedRateDomain_57" xlink:to="lab_skye_ConvertedRateDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertibleDebtRelatedPartyTextBlock_58" xlink:to="lab_skye_ConvertibleDebtRelatedPartyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertibleDebtRelatedPartyTextBlock_58" xlink:to="lab_skye_ConvertibleDebtRelatedPartyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertibleDebtRelatedPartyTextBlock_58" xlink:to="lab_skye_ConvertibleDebtRelatedPartyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_59" xlink:to="lab_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_59" xlink:to="lab_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_59" xlink:to="lab_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CouponInterestExpense_60" xlink:to="lab_skye_CouponInterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CouponInterestExpense_60" xlink:to="lab_skye_CouponInterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CouponInterestExpense_60" xlink:to="lab_skye_CouponInterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CreditFacilityEffectedFifthAdvance_61" xlink:to="lab_skye_CreditFacilityEffectedFifthAdvance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CreditFacilityEffectedFifthAdvance_61" xlink:to="lab_skye_CreditFacilityEffectedFifthAdvance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CreditFacilityEffectedFifthAdvance_61" xlink:to="lab_skye_CreditFacilityEffectedFifthAdvance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CreditFacilityEffectedFourthAdvance_62" xlink:to="lab_skye_CreditFacilityEffectedFourthAdvance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CreditFacilityEffectedFourthAdvance_62" xlink:to="lab_skye_CreditFacilityEffectedFourthAdvance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CreditFacilityEffectedFourthAdvance_62" xlink:to="lab_skye_CreditFacilityEffectedFourthAdvance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_December2015Member_64" xlink:to="lab_skye_December2015Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_December2015Member_64" xlink:to="lab_skye_December2015Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_December2015Member_64" xlink:to="lab_skye_December2015Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_65" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_65" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_65" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_65" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_66" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_66" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_66" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_66" xlink:to="lab_skye_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsAmortization_67" xlink:to="lab_skye_DeferredTaxAssetsAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsAmortization_67" xlink:to="lab_skye_DeferredTaxAssetsAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsAmortization_67" xlink:to="lab_skye_DeferredTaxAssetsAmortization_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_68" xlink:to="lab_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_68" xlink:to="lab_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_68" xlink:to="lab_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_69" xlink:to="lab_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_69" xlink:to="lab_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_69" xlink:to="lab_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxLiabilitiesNoteDiscount_70" xlink:to="lab_skye_DeferredTaxLiabilitiesNoteDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxLiabilitiesNoteDiscount_70" xlink:to="lab_skye_DeferredTaxLiabilitiesNoteDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxLiabilitiesNoteDiscount_70" xlink:to="lab_skye_DeferredTaxLiabilitiesNoteDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DeferredTaxLiabilitiesNoteDiscount_70" xlink:to="lab_skye_DeferredTaxLiabilitiesNoteDiscount_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_71" xlink:to="lab_skye_DerivativeLiabilitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_71" xlink:to="lab_skye_DerivativeLiabilitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DerivativeLiabilitiesTable_72" xlink:to="lab_skye_DerivativeLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DerivativeLiabilitiesTable_72" xlink:to="lab_skye_DerivativeLiabilitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DerivativesLiabilitiesTable_73" xlink:to="lab_skye_DerivativesLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DerivativesLiabilitiesTable_73" xlink:to="lab_skye_DerivativesLiabilitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DilutedSecuritiesDomain_74" xlink:to="lab_skye_DilutedSecuritiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DilutedSecuritiesDomain_74" xlink:to="lab_skye_DilutedSecuritiesDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_75" xlink:to="lab_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_75" xlink:to="lab_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_75" xlink:to="lab_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DouglasCesarioMember_76" xlink:to="lab_skye_DouglasCesarioMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DouglasCesarioMember_76" xlink:to="lab_skye_DouglasCesarioMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DouglasCesarioMember_76" xlink:to="lab_skye_DouglasCesarioMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_77" xlink:to="lab_skye_DrawDownsLoansInAggregatePrincipalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_77" xlink:to="lab_skye_DrawDownsLoansInAggregatePrincipalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_77" xlink:to="lab_skye_DrawDownsLoansInAggregatePrincipalAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_78" xlink:to="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_78" xlink:to="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_78" xlink:to="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_78" xlink:to="lab_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_79" xlink:to="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_79" xlink:to="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_79" xlink:to="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_79" xlink:to="lab_skye_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingIssuanceCosts_80" xlink:to="lab_skye_EmeraldFinancingIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingIssuanceCosts_80" xlink:to="lab_skye_EmeraldFinancingIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingIssuanceCosts_80" xlink:to="lab_skye_EmeraldFinancingIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingMember_81" xlink:to="lab_skye_EmeraldFinancingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingMember_81" xlink:to="lab_skye_EmeraldFinancingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingMember_81" xlink:to="lab_skye_EmeraldFinancingMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingMember_81" xlink:to="lab_skye_EmeraldFinancingMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingWarrantsLiabilityMember_82" xlink:to="lab_skye_EmeraldFinancingWarrantsLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingWarrantsLiabilityMember_82" xlink:to="lab_skye_EmeraldFinancingWarrantsLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldFinancingWarrantsLiabilityMember_82" xlink:to="lab_skye_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldHealthSciencesIncMember_83" xlink:to="lab_skye_EmeraldHealthSciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldHealthSciencesIncMember_83" xlink:to="lab_skye_EmeraldHealthSciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldHealthSciencesIncMember_83" xlink:to="lab_skye_EmeraldHealthSciencesIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldHealthSciencesIncMember_83" xlink:to="lab_skye_EmeraldHealthSciencesIncMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_84" xlink:to="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_84" xlink:to="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_84" xlink:to="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_84" xlink:to="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_84" xlink:to="lab_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldWarrantLiabilityMember_85" xlink:to="lab_skye_EmeraldWarrantLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldWarrantLiabilityMember_85" xlink:to="lab_skye_EmeraldWarrantLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldWarrantLiabilityMember_85" xlink:to="lab_skye_EmeraldWarrantLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EmeraldWarrantLiabilityMember_85" xlink:to="lab_skye_EmeraldWarrantLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EquityLineItems_86" xlink:to="lab_skye_EquityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EquityLineItems_86" xlink:to="lab_skye_EquityLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EquityTable_87" xlink:to="lab_skye_EquityTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EquityTable_87" xlink:to="lab_skye_EquityTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EstimatedAgreementFeesAndExpenses_88" xlink:to="lab_skye_EstimatedAgreementFeesAndExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EstimatedAgreementFeesAndExpenses_88" xlink:to="lab_skye_EstimatedAgreementFeesAndExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EstimatedAgreementFeesAndExpenses_88" xlink:to="lab_skye_EstimatedAgreementFeesAndExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EstimatedInitialPaymentForContract_89" xlink:to="lab_skye_EstimatedInitialPaymentForContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EstimatedInitialPaymentForContract_89" xlink:to="lab_skye_EstimatedInitialPaymentForContract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_EstimatedInitialPaymentForContract_89" xlink:to="lab_skye_EstimatedInitialPaymentForContract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ExerciseOfWarrants_90" xlink:to="lab_skye_ExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ExerciseOfWarrants_90" xlink:to="lab_skye_ExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ExerciseOfWarrants_90" xlink:to="lab_skye_ExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairMarketValueOfSharesGranted_91" xlink:to="lab_skye_FairMarketValueOfSharesGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairMarketValueOfSharesGranted_91" xlink:to="lab_skye_FairMarketValueOfSharesGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairMarketValueOfSharesGranted_91" xlink:to="lab_skye_FairMarketValueOfSharesGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairMarketValueOfStockOptions_92" xlink:to="lab_skye_FairMarketValueOfStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairMarketValueOfStockOptions_92" xlink:to="lab_skye_FairMarketValueOfStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairMarketValueOfStockOptions_92" xlink:to="lab_skye_FairMarketValueOfStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_93" xlink:to="lab_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_93" xlink:to="lab_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_93" xlink:to="lab_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfCommonStockWarrantsIssued_94" xlink:to="lab_skye_FairValueOfCommonStockWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfCommonStockWarrantsIssued_94" xlink:to="lab_skye_FairValueOfCommonStockWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfCommonStockWarrantsIssued_94" xlink:to="lab_skye_FairValueOfCommonStockWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_95" xlink:to="lab_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_95" xlink:to="lab_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_95" xlink:to="lab_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_96" xlink:to="lab_skye_FairValueOfDerivativeLiabilitiesRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_96" xlink:to="lab_skye_FairValueOfDerivativeLiabilitiesRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_97" xlink:to="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_97" xlink:to="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_97" xlink:to="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_97" xlink:to="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_97" xlink:to="lab_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_98" xlink:to="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_98" xlink:to="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_98" xlink:to="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_98" xlink:to="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_98" xlink:to="lab_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_99" xlink:to="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_99" xlink:to="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_99" xlink:to="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_99" xlink:to="lab_skye_FairValueOfSharesUnderlyingConvertibleDebt1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfUnderlyingShares_100" xlink:to="lab_skye_FairValueOfUnderlyingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfUnderlyingShares_100" xlink:to="lab_skye_FairValueOfUnderlyingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfUnderlyingShares_100" xlink:to="lab_skye_FairValueOfUnderlyingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101" xlink:to="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101" xlink:to="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101" xlink:to="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101" xlink:to="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101" xlink:to="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_101" xlink:to="lab_skye_FairValueOfWarrantLiabilityInExcessForProceeds_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssued_102" xlink:to="lab_skye_FairValueOfWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssued_102" xlink:to="lab_skye_FairValueOfWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssued_102" xlink:to="lab_skye_FairValueOfWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssued_102" xlink:to="lab_skye_FairValueOfWarrantsIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssued_102" xlink:to="lab_skye_FairValueOfWarrantsIssued_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_103" xlink:to="lab_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_103" xlink:to="lab_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_103" xlink:to="lab_skye_FairValueOfWarrantsIssuedInConnectionWithFinancings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FeesAndExpensesForServicesProvided_104" xlink:to="lab_skye_FeesAndExpensesForServicesProvided_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FeesAndExpensesForServicesProvided_104" xlink:to="lab_skye_FeesAndExpensesForServicesProvided_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FeesAndExpensesForServicesProvided_104" xlink:to="lab_skye_FeesAndExpensesForServicesProvided_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FeesIncurredUnderAgreement_105" xlink:to="lab_skye_FeesIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FeesIncurredUnderAgreement_105" xlink:to="lab_skye_FeesIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FeesIncurredUnderAgreement_105" xlink:to="lab_skye_FeesIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_106" xlink:to="lab_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_106" xlink:to="lab_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_106" xlink:to="lab_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FinancingSharesWarrantExercise_107" xlink:to="lab_skye_FinancingSharesWarrantExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FinancingSharesWarrantExercise_107" xlink:to="lab_skye_FinancingSharesWarrantExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FinancingSharesWarrantExercise_107" xlink:to="lab_skye_FinancingSharesWarrantExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FinancingValueWarrantExercise_108" xlink:to="lab_skye_FinancingValueWarrantExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FinancingValueWarrantExercise_108" xlink:to="lab_skye_FinancingValueWarrantExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FinancingValueWarrantExercise_108" xlink:to="lab_skye_FinancingValueWarrantExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FixedAssetsProvidedToUniversityInLieuOfCash_109" xlink:to="lab_skye_FixedAssetsProvidedToUniversityInLieuOfCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FixedAssetsProvidedToUniversityInLieuOfCash_109" xlink:to="lab_skye_FixedAssetsProvidedToUniversityInLieuOfCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FixedAssetsProvidedToUniversityInLieuOfCash_109" xlink:to="lab_skye_FixedAssetsProvidedToUniversityInLieuOfCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_110" xlink:to="lab_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_110" xlink:to="lab_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_110" xlink:to="lab_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GlauconixBiosciencesIncMember_111" xlink:to="lab_skye_GlauconixBiosciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GlauconixBiosciencesIncMember_111" xlink:to="lab_skye_GlauconixBiosciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GlauconixBiosciencesIncMember_111" xlink:to="lab_skye_GlauconixBiosciencesIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GrossProceedsOfUnitsSold_112" xlink:to="lab_skye_GrossProceedsOfUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GrossProceedsOfUnitsSold_112" xlink:to="lab_skye_GrossProceedsOfUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GrossProceedsOfUnitsSold_112" xlink:to="lab_skye_GrossProceedsOfUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GrossProceedsOfWarrant_113" xlink:to="lab_skye_GrossProceedsOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GrossProceedsOfWarrant_113" xlink:to="lab_skye_GrossProceedsOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GrossProceedsOfWarrant_113" xlink:to="lab_skye_GrossProceedsOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GuarantorFailedToPay_114" xlink:to="lab_skye_GuarantorFailedToPay_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GuarantorFailedToPay_114" xlink:to="lab_skye_GuarantorFailedToPay_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_GuarantorFailedToPay_114" xlink:to="lab_skye_GuarantorFailedToPay_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_115" xlink:to="lab_skye_IncomeTaxReconciliationChangeInCompoundDerivative_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_115" xlink:to="lab_skye_IncomeTaxReconciliationChangeInCompoundDerivative_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_115" xlink:to="lab_skye_IncomeTaxReconciliationChangeInCompoundDerivative_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_116" xlink:to="lab_skye_IncomeTaxReconciliationUncertainTaxPositions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_116" xlink:to="lab_skye_IncomeTaxReconciliationUncertainTaxPositions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_116" xlink:to="lab_skye_IncomeTaxReconciliationUncertainTaxPositions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncreaseChangeInFairValueOfWarrantLiability_117" xlink:to="lab_skye_IncreaseChangeInFairValueOfWarrantLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncreaseChangeInFairValueOfWarrantLiability_117" xlink:to="lab_skye_IncreaseChangeInFairValueOfWarrantLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncreaseChangeInFairValueOfWarrantLiability_117" xlink:to="lab_skye_IncreaseChangeInFairValueOfWarrantLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncreaseDecreaseInDepositsAndOtherAssets_118" xlink:to="lab_skye_IncreaseDecreaseInDepositsAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncreaseDecreaseInDepositsAndOtherAssets_118" xlink:to="lab_skye_IncreaseDecreaseInDepositsAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncreaseDecreaseInDepositsAndOtherAssets_118" xlink:to="lab_skye_IncreaseDecreaseInDepositsAndOtherAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncrementalAgreementFeesAndExpenses_119" xlink:to="lab_skye_IncrementalAgreementFeesAndExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncrementalAgreementFeesAndExpenses_119" xlink:to="lab_skye_IncrementalAgreementFeesAndExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IncrementalAgreementFeesAndExpenses_119" xlink:to="lab_skye_IncrementalAgreementFeesAndExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IndependentContractorAgreementMember_120" xlink:to="lab_skye_IndependentContractorAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IndependentContractorAgreementMember_120" xlink:to="lab_skye_IndependentContractorAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IndependentContractorAgreementMember_120" xlink:to="lab_skye_IndependentContractorAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_InitialTermOfAgreement_121" xlink:to="lab_skye_InitialTermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_InitialTermOfAgreement_121" xlink:to="lab_skye_InitialTermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_InitialTermOfAgreement_121" xlink:to="lab_skye_InitialTermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_122" xlink:to="lab_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_122" xlink:to="lab_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_122" xlink:to="lab_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IntrinsicValueOfWarrantExercises_123" xlink:to="lab_skye_IntrinsicValueOfWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IntrinsicValueOfWarrantExercises_123" xlink:to="lab_skye_IntrinsicValueOfWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IntrinsicValueOfWarrantExercises_123" xlink:to="lab_skye_IntrinsicValueOfWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_124" xlink:to="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_124" xlink:to="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_124" xlink:to="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_125" xlink:to="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_125" xlink:to="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_125" xlink:to="lab_skye_IssuanceOfPreferredStockNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_126" xlink:to="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_126" xlink:to="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_126" xlink:to="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_127" xlink:to="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_127" xlink:to="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_127" xlink:to="lab_skye_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_K2CIncMember_128" xlink:to="lab_skye_K2CIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_K2CIncMember_128" xlink:to="lab_skye_K2CIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_K2CIncMember_128" xlink:to="lab_skye_K2CIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LetterAgreementMember_129" xlink:to="lab_skye_LetterAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LetterAgreementMember_129" xlink:to="lab_skye_LetterAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LetterAgreementMember_129" xlink:to="lab_skye_LetterAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LicenseAgreementMember_130" xlink:to="lab_skye_LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LicenseAgreementMember_130" xlink:to="lab_skye_LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LicenseAgreementMember_130" xlink:to="lab_skye_LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LicenseAgreementMember_130" xlink:to="lab_skye_LicenseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LicenseFee_131" xlink:to="lab_skye_LicenseFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LicenseFee_131" xlink:to="lab_skye_LicenseFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LiquidationProvisionCommonStockEquivalentShares_132" xlink:to="lab_skye_LiquidationProvisionCommonStockEquivalentShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LiquidationProvisionCommonStockEquivalentShares_132" xlink:to="lab_skye_LiquidationProvisionCommonStockEquivalentShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LiquidationProvisionCommonStockEquivalentShares_132" xlink:to="lab_skye_LiquidationProvisionCommonStockEquivalentShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LiquidationProvisionCommonStockEquivalentValue_133" xlink:to="lab_skye_LiquidationProvisionCommonStockEquivalentValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LiquidationProvisionCommonStockEquivalentValue_133" xlink:to="lab_skye_LiquidationProvisionCommonStockEquivalentValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_134" xlink:to="lab_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_134" xlink:to="lab_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_134" xlink:to="lab_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LumpSumPaymentInAgreement_135" xlink:to="lab_skye_LumpSumPaymentInAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LumpSumPaymentInAgreement_135" xlink:to="lab_skye_LumpSumPaymentInAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LumpSumPaymentInAgreement_135" xlink:to="lab_skye_LumpSumPaymentInAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MasterServiceAgreementMember_136" xlink:to="lab_skye_MasterServiceAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MasterServiceAgreementMember_136" xlink:to="lab_skye_MasterServiceAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MasterServiceAgreementMember_136" xlink:to="lab_skye_MasterServiceAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone1Member_137" xlink:to="lab_skye_Milestone1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone1Member_137" xlink:to="lab_skye_Milestone1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone1Member_137" xlink:to="lab_skye_Milestone1Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone2Member_138" xlink:to="lab_skye_Milestone2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone2Member_138" xlink:to="lab_skye_Milestone2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone2Member_138" xlink:to="lab_skye_Milestone2Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone3Member_139" xlink:to="lab_skye_Milestone3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone3Member_139" xlink:to="lab_skye_Milestone3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Milestone3Member_139" xlink:to="lab_skye_Milestone3Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MilestonePaymentsPayableAxis_140" xlink:to="lab_skye_MilestonePaymentsPayableAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MilestonePaymentsPayableAxis_140" xlink:to="lab_skye_MilestonePaymentsPayableAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MilestonePaymentsPayableDomain_141" xlink:to="lab_skye_MilestonePaymentsPayableDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MilestonePaymentsPayableDomain_141" xlink:to="lab_skye_MilestonePaymentsPayableDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MinimumLitigationJudgementAmount_142" xlink:to="lab_skye_MinimumLitigationJudgementAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MinimumLitigationJudgementAmount_142" xlink:to="lab_skye_MinimumLitigationJudgementAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MinimumLitigationJudgementAmount_142" xlink:to="lab_skye_MinimumLitigationJudgementAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonteCarloSimulationsMember_143" xlink:to="lab_skye_MonteCarloSimulationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonteCarloSimulationsMember_143" xlink:to="lab_skye_MonteCarloSimulationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonteCarloSimulationsMember_143" xlink:to="lab_skye_MonteCarloSimulationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthAndYearOfAgreementAxis_144" xlink:to="lab_skye_MonthAndYearOfAgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthAndYearOfAgreementAxis_144" xlink:to="lab_skye_MonthAndYearOfAgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthAndYearOfAgreementDomain_145" xlink:to="lab_skye_MonthAndYearOfAgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthAndYearOfAgreementDomain_145" xlink:to="lab_skye_MonthAndYearOfAgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFee_146" xlink:to="lab_skye_MonthlyFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFee_146" xlink:to="lab_skye_MonthlyFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFee_146" xlink:to="lab_skye_MonthlyFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_147" xlink:to="lab_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_147" xlink:to="lab_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_147" xlink:to="lab_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_148" xlink:to="lab_skye_MonthlyFeePaidEachMonthInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_148" xlink:to="lab_skye_MonthlyFeePaidEachMonthInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_148" xlink:to="lab_skye_MonthlyFeePaidEachMonthInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MultiDrawCreditAgreementMember_149" xlink:to="lab_skye_MultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MultiDrawCreditAgreementMember_149" xlink:to="lab_skye_MultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_MultiDrawCreditAgreementMember_149" xlink:to="lab_skye_MultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesAbstract_150" xlink:to="lab_skye_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesAbstract_150" xlink:to="lab_skye_NatureOfOperationsAndBusinessActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_151" xlink:to="lab_skye_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_151" xlink:to="lab_skye_NatureOfOperationsAndBusinessActivitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_152" xlink:to="lab_skye_NatureOfOperationsAndBusinessActivitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_152" xlink:to="lab_skye_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NetLossAdjustedBalance_153" xlink:to="lab_skye_NetLossAdjustedBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NetLossAdjustedBalance_153" xlink:to="lab_skye_NetLossAdjustedBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NetLossAdjustedBalance_153" xlink:to="lab_skye_NetLossAdjustedBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NetLossAdjustedBalance_153" xlink:to="lab_skye_NetLossAdjustedBalance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NoramcoAgreementMember_154" xlink:to="lab_skye_NoramcoAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NoramcoAgreementMember_154" xlink:to="lab_skye_NoramcoAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NoramcoAgreementMember_154" xlink:to="lab_skye_NoramcoAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NoticePeriodForTermination_155" xlink:to="lab_skye_NoticePeriodForTermination_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NoticePeriodForTermination_155" xlink:to="lab_skye_NoticePeriodForTermination_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NoticePeriodForTermination_155" xlink:to="lab_skye_NoticePeriodForTermination_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_156" xlink:to="lab_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_156" xlink:to="lab_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_156" xlink:to="lab_skye_NumberOfCommonStockIssuedUponConversionOfPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfCommonStockUnitsSold_157" xlink:to="lab_skye_NumberOfCommonStockUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfCommonStockUnitsSold_157" xlink:to="lab_skye_NumberOfCommonStockUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfCommonStockUnitsSold_157" xlink:to="lab_skye_NumberOfCommonStockUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfInvestors_158" xlink:to="lab_skye_NumberOfInvestors_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfInvestors_158" xlink:to="lab_skye_NumberOfInvestors_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfInvestors_158" xlink:to="lab_skye_NumberOfInvestors_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfLicenseAgreements_159" xlink:to="lab_skye_NumberOfLicenseAgreements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfLicenseAgreements_159" xlink:to="lab_skye_NumberOfLicenseAgreements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfLicenseAgreements_159" xlink:to="lab_skye_NumberOfLicenseAgreements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfPreFundedUnitsSold_160" xlink:to="lab_skye_NumberOfPreFundedUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfPreFundedUnitsSold_160" xlink:to="lab_skye_NumberOfPreFundedUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfPreFundedUnitsSold_160" xlink:to="lab_skye_NumberOfPreFundedUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercisable_161" xlink:to="lab_skye_NumberOfWarrantsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercisable_161" xlink:to="lab_skye_NumberOfWarrantsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercisable_161" xlink:to="lab_skye_NumberOfWarrantsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercised_162" xlink:to="lab_skye_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercised_162" xlink:to="lab_skye_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercised_162" xlink:to="lab_skye_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NumberOfWarrantsExercised_162" xlink:to="lab_skye_NumberOfWarrantsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OctoberTwoThousandFifteenMember_163" xlink:to="lab_skye_OctoberTwoThousandFifteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OctoberTwoThousandFifteenMember_163" xlink:to="lab_skye_OctoberTwoThousandFifteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OctoberTwoThousandFifteenMember_163" xlink:to="lab_skye_OctoberTwoThousandFifteenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OfficersEmployeeAndDirectorsMember_164" xlink:to="lab_skye_OfficersEmployeeAndDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OfficersEmployeeAndDirectorsMember_164" xlink:to="lab_skye_OfficersEmployeeAndDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OfficersEmployeeAndDirectorsMember_164" xlink:to="lab_skye_OfficersEmployeeAndDirectorsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OmnibusIncentivePlan2014Member_165" xlink:to="lab_skye_OmnibusIncentivePlan2014Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OmnibusIncentivePlan2014Member_165" xlink:to="lab_skye_OmnibusIncentivePlan2014Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OmnibusIncentivePlan2014Member_165" xlink:to="lab_skye_OmnibusIncentivePlan2014Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OmnibusIncentivePlan2014Member_165" xlink:to="lab_skye_OmnibusIncentivePlan2014Member_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OneTimeUpfrontPayment_166" xlink:to="lab_skye_OneTimeUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OneTimeUpfrontPayment_166" xlink:to="lab_skye_OneTimeUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OneTimeUpfrontPayment_166" xlink:to="lab_skye_OneTimeUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OneTimeUpfrontPayment_166" xlink:to="lab_skye_OneTimeUpfrontPayment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OneTimeUpfrontPayment_166" xlink:to="lab_skye_OneTimeUpfrontPayment_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionAgreementMember_167" xlink:to="lab_skye_OptionAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionAgreementMember_167" xlink:to="lab_skye_OptionAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionAgreementMember_167" xlink:to="lab_skye_OptionAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionAgreementMember_167" xlink:to="lab_skye_OptionAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionsMember_168" xlink:to="lab_skye_OptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionsMember_168" xlink:to="lab_skye_OptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_OptionsMember_168" xlink:to="lab_skye_OptionsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaycheckProtectionProgrammeMember_169" xlink:to="lab_skye_PaycheckProtectionProgrammeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaycheckProtectionProgrammeMember_169" xlink:to="lab_skye_PaycheckProtectionProgrammeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaycheckProtectionProgrammeMember_169" xlink:to="lab_skye_PaycheckProtectionProgrammeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_170" xlink:to="lab_skye_PaycheckProtectionProgramPromissoryNoteMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_170" xlink:to="lab_skye_PaycheckProtectionProgramPromissoryNoteMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_170" xlink:to="lab_skye_PaycheckProtectionProgramPromissoryNoteMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaymentForUpfrontFees_171" xlink:to="lab_skye_PaymentForUpfrontFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaymentForUpfrontFees_171" xlink:to="lab_skye_PaymentForUpfrontFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaymentForUpfrontFees_171" xlink:to="lab_skye_PaymentForUpfrontFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaymentOfUpfrontLicenseFee_172" xlink:to="lab_skye_PaymentOfUpfrontLicenseFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaymentOfUpfrontLicenseFee_172" xlink:to="lab_skye_PaymentOfUpfrontLicenseFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PaymentOfUpfrontLicenseFee_172" xlink:to="lab_skye_PaymentOfUpfrontLicenseFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PayrollCostExcludeCompensation_173" xlink:to="lab_skye_PayrollCostExcludeCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PayrollCostExcludeCompensation_173" xlink:to="lab_skye_PayrollCostExcludeCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PayrollCostExcludeCompensation_173" xlink:to="lab_skye_PayrollCostExcludeCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAccruedConsultingFee_174" xlink:to="lab_skye_PercentageOfAccruedConsultingFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAccruedConsultingFee_174" xlink:to="lab_skye_PercentageOfAccruedConsultingFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAccruedConsultingFee_174" xlink:to="lab_skye_PercentageOfAccruedConsultingFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAccruedInterestOnOutstandingBalance_175" xlink:to="lab_skye_PercentageOfAccruedInterestOnOutstandingBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAccruedInterestOnOutstandingBalance_175" xlink:to="lab_skye_PercentageOfAccruedInterestOnOutstandingBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAccruedInterestOnOutstandingBalance_175" xlink:to="lab_skye_PercentageOfAccruedInterestOnOutstandingBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_176" xlink:to="lab_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_176" xlink:to="lab_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_176" xlink:to="lab_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfBonusForAccruedConsultingFee_177" xlink:to="lab_skye_PercentageOfBonusForAccruedConsultingFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfBonusForAccruedConsultingFee_177" xlink:to="lab_skye_PercentageOfBonusForAccruedConsultingFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfBonusForAccruedConsultingFee_177" xlink:to="lab_skye_PercentageOfBonusForAccruedConsultingFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfConversionAmount_178" xlink:to="lab_skye_PercentageOfConversionAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfConversionAmount_178" xlink:to="lab_skye_PercentageOfConversionAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfConversionAmount_178" xlink:to="lab_skye_PercentageOfConversionAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_179" xlink:to="lab_skye_PercentageOfForgivenessAmountForNonPayrollCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_179" xlink:to="lab_skye_PercentageOfForgivenessAmountForNonPayrollCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_179" xlink:to="lab_skye_PercentageOfForgivenessAmountForNonPayrollCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_180" xlink:to="lab_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_180" xlink:to="lab_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_180" xlink:to="lab_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_181" xlink:to="lab_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_181" xlink:to="lab_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_181" xlink:to="lab_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfSharesToBeRedeemed_182" xlink:to="lab_skye_PercentageOfSharesToBeRedeemed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfSharesToBeRedeemed_182" xlink:to="lab_skye_PercentageOfSharesToBeRedeemed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentageOfSharesToBeRedeemed_182" xlink:to="lab_skye_PercentageOfSharesToBeRedeemed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentOfReductionInAnnualSalary_183" xlink:to="lab_skye_PercentOfReductionInAnnualSalary_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentOfReductionInAnnualSalary_183" xlink:to="lab_skye_PercentOfReductionInAnnualSalary_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PercentOfReductionInAnnualSalary_183" xlink:to="lab_skye_PercentOfReductionInAnnualSalary_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_184" xlink:to="lab_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_184" xlink:to="lab_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_184" xlink:to="lab_skye_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PharmaceuticalsInternationalInc.AgreementMember_185" xlink:to="lab_skye_PharmaceuticalsInternationalInc.AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PharmaceuticalsInternationalInc.AgreementMember_185" xlink:to="lab_skye_PharmaceuticalsInternationalInc.AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PharmaceuticalsInternationalInc.AgreementMember_185" xlink:to="lab_skye_PharmaceuticalsInternationalInc.AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PlacementAgentMember_186" xlink:to="lab_skye_PlacementAgentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PlacementAgentMember_186" xlink:to="lab_skye_PlacementAgentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PlacementAgentMember_186" xlink:to="lab_skye_PlacementAgentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PlacementAgentWarrantMember_187" xlink:to="lab_skye_PlacementAgentWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PlacementAgentWarrantMember_187" xlink:to="lab_skye_PlacementAgentWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PlacementAgentWarrantMember_187" xlink:to="lab_skye_PlacementAgentWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Pre2015CommonStockWarrantsMember_188" xlink:to="lab_skye_Pre2015CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Pre2015CommonStockWarrantsMember_188" xlink:to="lab_skye_Pre2015CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Pre2015CommonStockWarrantsMember_188" xlink:to="lab_skye_Pre2015CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreferredStockPutOptionLiability_189" xlink:to="lab_skye_PreferredStockPutOptionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreferredStockPutOptionLiability_189" xlink:to="lab_skye_PreferredStockPutOptionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreferredStockPutOptionLiability_189" xlink:to="lab_skye_PreferredStockPutOptionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreFundedUnitSoldPricePerUnit_190" xlink:to="lab_skye_PreFundedUnitSoldPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreFundedUnitSoldPricePerUnit_190" xlink:to="lab_skye_PreFundedUnitSoldPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreFundedUnitSoldPricePerUnit_190" xlink:to="lab_skye_PreFundedUnitSoldPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreFundedWarrantMember_191" xlink:to="lab_skye_PreFundedWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PreFundedWarrantMember_191" xlink:to="lab_skye_PreFundedWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PrefundedWarrantsMember_192" xlink:to="lab_skye_PrefundedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PrefundedWarrantsMember_192" xlink:to="lab_skye_PrefundedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PrefundedWarrantsMember_192" xlink:to="lab_skye_PrefundedWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PricingModelMember_193" xlink:to="lab_skye_PricingModelMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PricingModelMember_193" xlink:to="lab_skye_PricingModelMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PricingModelMember_193" xlink:to="lab_skye_PricingModelMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PricingModelMember_193" xlink:to="lab_skye_PricingModelMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_194" xlink:to="lab_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_194" xlink:to="lab_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_194" xlink:to="lab_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_195" xlink:to="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_195" xlink:to="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_195" xlink:to="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_195" xlink:to="lab_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_196" xlink:to="lab_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_196" xlink:to="lab_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_196" xlink:to="lab_skye_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_197" xlink:to="lab_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_197" xlink:to="lab_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_197" xlink:to="lab_skye_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_198" xlink:to="lab_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_198" xlink:to="lab_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_198" xlink:to="lab_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProvisionForConversionOfPreferredStock_199" xlink:to="lab_skye_ProvisionForConversionOfPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProvisionForConversionOfPreferredStock_199" xlink:to="lab_skye_ProvisionForConversionOfPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProvisionForConversionOfPreferredStock_199" xlink:to="lab_skye_ProvisionForConversionOfPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ProvisionForConversionOfPreferredStock_199" xlink:to="lab_skye_ProvisionForConversionOfPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReclassificationOfDerivativesToEquity_200" xlink:to="lab_skye_ReclassificationOfDerivativesToEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReclassificationOfDerivativesToEquity_200" xlink:to="lab_skye_ReclassificationOfDerivativesToEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReclassificationOfDerivativesToEquity_200" xlink:to="lab_skye_ReclassificationOfDerivativesToEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReclassificationOfDerivativesToEquity_200" xlink:to="lab_skye_ReclassificationOfDerivativesToEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RedemptionAmountPercentage_201" xlink:to="lab_skye_RedemptionAmountPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RedemptionAmountPercentage_201" xlink:to="lab_skye_RedemptionAmountPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RedemptionAmountPercentage_201" xlink:to="lab_skye_RedemptionAmountPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_202" xlink:to="lab_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_202" xlink:to="lab_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_202" xlink:to="lab_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RemainingDrawDownsLoans_203" xlink:to="lab_skye_RemainingDrawDownsLoans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RemainingDrawDownsLoans_203" xlink:to="lab_skye_RemainingDrawDownsLoans_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RemainingDrawDownsLoans_203" xlink:to="lab_skye_RemainingDrawDownsLoans_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_204" xlink:to="lab_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_204" xlink:to="lab_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_204" xlink:to="lab_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ResearchAgreementMember_205" xlink:to="lab_skye_ResearchAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ResearchAgreementMember_205" xlink:to="lab_skye_ResearchAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ResearchAgreementMember_205" xlink:to="lab_skye_ResearchAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RestrictedStockAgreementsMember_206" xlink:to="lab_skye_RestrictedStockAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RestrictedStockAgreementsMember_206" xlink:to="lab_skye_RestrictedStockAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RestrictedStockAgreementsMember_206" xlink:to="lab_skye_RestrictedStockAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RisksAndUncertaintiesPolicyTextBlock_207" xlink:to="lab_skye_RisksAndUncertaintiesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RisksAndUncertaintiesPolicyTextBlock_207" xlink:to="lab_skye_RisksAndUncertaintiesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RisksAndUncertaintiesPolicyTextBlock_207" xlink:to="lab_skye_RisksAndUncertaintiesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RrdInternationalAgreementMember_208" xlink:to="lab_skye_RrdInternationalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RrdInternationalAgreementMember_208" xlink:to="lab_skye_RrdInternationalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_RrdInternationalAgreementMember_208" xlink:to="lab_skye_RrdInternationalAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_209" xlink:to="lab_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_209" xlink:to="lab_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_209" xlink:to="lab_skye_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_210" xlink:to="lab_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_210" xlink:to="lab_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_210" xlink:to="lab_skye_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfInterestExpenseTableTextBlock_211" xlink:to="lab_skye_ScheduleOfInterestExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfInterestExpenseTableTextBlock_211" xlink:to="lab_skye_ScheduleOfInterestExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ScheduleOfInterestExpenseTableTextBlock_211" xlink:to="lab_skye_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecondDrawOnMultiDrawCreditFacilityMember_212" xlink:to="lab_skye_SecondDrawOnMultiDrawCreditFacilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecondDrawOnMultiDrawCreditFacilityMember_212" xlink:to="lab_skye_SecondDrawOnMultiDrawCreditFacilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecondDrawOnMultiDrawCreditFacilityMember_212" xlink:to="lab_skye_SecondDrawOnMultiDrawCreditFacilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuredPromissoryNoteAndSecurityAgreementMember_213" xlink:to="lab_skye_SecuredPromissoryNoteAndSecurityAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuredPromissoryNoteAndSecurityAgreementMember_213" xlink:to="lab_skye_SecuredPromissoryNoteAndSecurityAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuredPromissoryNoteAndSecurityAgreementMember_213" xlink:to="lab_skye_SecuredPromissoryNoteAndSecurityAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementMember_214" xlink:to="lab_skye_SecuritiesPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementMember_214" xlink:to="lab_skye_SecuritiesPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementMember_214" xlink:to="lab_skye_SecuritiesPurchaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementMember_214" xlink:to="lab_skye_SecuritiesPurchaseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_215" xlink:to="lab_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_215" xlink:to="lab_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_215" xlink:to="lab_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeniorManagementCompensationPlanDescription_216" xlink:to="lab_skye_SeniorManagementCompensationPlanDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeniorManagementCompensationPlanDescription_216" xlink:to="lab_skye_SeniorManagementCompensationPlanDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeniorManagementCompensationPlanDescription_216" xlink:to="lab_skye_SeniorManagementCompensationPlanDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeparationAndReleaseAgreementMember_217" xlink:to="lab_skye_SeparationAndReleaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeparationAndReleaseAgreementMember_217" xlink:to="lab_skye_SeparationAndReleaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeparationAndReleaseAgreementMember_217" xlink:to="lab_skye_SeparationAndReleaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBCommonStockWarrantMember_218" xlink:to="lab_skye_SeriesBCommonStockWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBCommonStockWarrantMember_218" xlink:to="lab_skye_SeriesBCommonStockWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBCommonStockWarrantMember_218" xlink:to="lab_skye_SeriesBCommonStockWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBPreferredStockConversionLiabilityMember_219" xlink:to="lab_skye_SeriesBPreferredStockConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBPreferredStockConversionLiabilityMember_219" xlink:to="lab_skye_SeriesBPreferredStockConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBPreferredStockConversionLiabilityMember_219" xlink:to="lab_skye_SeriesBPreferredStockConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantMember_220" xlink:to="lab_skye_SeriesBWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantMember_220" xlink:to="lab_skye_SeriesBWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantMember_220" xlink:to="lab_skye_SeriesBWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantMember_220" xlink:to="lab_skye_SeriesBWarrantMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantsMember_221" xlink:to="lab_skye_SeriesBWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantsMember_221" xlink:to="lab_skye_SeriesBWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesBWarrantsMember_221" xlink:to="lab_skye_SeriesBWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesFPreferredStockPutOptionLiabilityMember_222" xlink:to="lab_skye_SeriesFPreferredStockPutOptionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesFPreferredStockPutOptionLiabilityMember_222" xlink:to="lab_skye_SeriesFPreferredStockPutOptionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SeriesFPreferredStockPutOptionLiabilityMember_222" xlink:to="lab_skye_SeriesFPreferredStockPutOptionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ShareAndWarrantsIssuanceCosts_223" xlink:to="lab_skye_ShareAndWarrantsIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ShareAndWarrantsIssuanceCosts_223" xlink:to="lab_skye_ShareAndWarrantsIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ShareAndWarrantsIssuanceCosts_223" xlink:to="lab_skye_ShareAndWarrantsIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ShareIssuanceCosts_224" xlink:to="lab_skye_ShareIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ShareIssuanceCosts_224" xlink:to="lab_skye_ShareIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ShareIssuanceCosts_224" xlink:to="lab_skye_ShareIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsLineItems_225" xlink:to="lab_skye_SignificantContractsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsLineItems_225" xlink:to="lab_skye_SignificantContractsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsTextBlock_226" xlink:to="lab_skye_SignificantContractsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsTextBlock_226" xlink:to="lab_skye_SignificantContractsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsTextBlock_226" xlink:to="lab_skye_SignificantContractsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsTextBlock_226" xlink:to="lab_skye_SignificantContractsTextBlock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_227" xlink:to="lab_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_227" xlink:to="lab_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_227" xlink:to="lab_skye_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_228" xlink:to="lab_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_228" xlink:to="lab_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_228" xlink:to="lab_skye_StockBasedCompensationForNonEmployeesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuanceCosts_229" xlink:to="lab_skye_StockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuanceCosts_229" xlink:to="lab_skye_StockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuanceCosts_229" xlink:to="lab_skye_StockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_230" xlink:to="lab_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_230" xlink:to="lab_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_230" xlink:to="lab_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_231" xlink:to="lab_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_231" xlink:to="lab_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_231" xlink:to="lab_skye_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_232" xlink:to="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_232" xlink:to="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_232" xlink:to="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_233" xlink:to="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_233" xlink:to="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_233" xlink:to="lab_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_234" xlink:to="lab_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_234" xlink:to="lab_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_234" xlink:to="lab_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_235" xlink:to="lab_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_235" xlink:to="lab_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_235" xlink:to="lab_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_236" xlink:to="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_236" xlink:to="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_236" xlink:to="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_237" xlink:to="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_237" xlink:to="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_237" xlink:to="lab_skye_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_238" xlink:to="lab_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_238" xlink:to="lab_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_238" xlink:to="lab_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SubsequentFinancingPurchasePriceDescription_239" xlink:to="lab_skye_SubsequentFinancingPurchasePriceDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SubsequentFinancingPurchasePriceDescription_239" xlink:to="lab_skye_SubsequentFinancingPurchasePriceDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SubsequentFinancingPurchasePriceDescription_239" xlink:to="lab_skye_SubsequentFinancingPurchasePriceDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfAgreement_240" xlink:to="lab_skye_TermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfAgreement_240" xlink:to="lab_skye_TermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfAgreement_240" xlink:to="lab_skye_TermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrant_241" xlink:to="lab_skye_TermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrant_241" xlink:to="lab_skye_TermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrant_241" xlink:to="lab_skye_TermOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrant_241" xlink:to="lab_skye_TermOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrants_242" xlink:to="lab_skye_TermOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrants_242" xlink:to="lab_skye_TermOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermOfWarrants_242" xlink:to="lab_skye_TermOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermsOfAgreementRenewed_243" xlink:to="lab_skye_TermsOfAgreementRenewed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermsOfAgreementRenewed_243" xlink:to="lab_skye_TermsOfAgreementRenewed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TermsOfAgreementRenewed_243" xlink:to="lab_skye_TermsOfAgreementRenewed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TotalExpenseIncurredUnderAgreement_244" xlink:to="lab_skye_TotalExpenseIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TotalExpenseIncurredUnderAgreement_244" xlink:to="lab_skye_TotalExpenseIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TotalExpenseIncurredUnderAgreement_244" xlink:to="lab_skye_TotalExpenseIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_245" xlink:to="lab_skye_TwoThousandAndTwentyCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_245" xlink:to="lab_skye_TwoThousandAndTwentyCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_245" xlink:to="lab_skye_TwoThousandAndTwentyCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_246" xlink:to="lab_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_246" xlink:to="lab_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_246" xlink:to="lab_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_247" xlink:to="lab_skye_TwoThousandAndTwentyPreFundedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_247" xlink:to="lab_skye_TwoThousandAndTwentyPreFundedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_247" xlink:to="lab_skye_TwoThousandAndTwentyPreFundedWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_248" xlink:to="lab_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_248" xlink:to="lab_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_248" xlink:to="lab_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_249" xlink:to="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_249" xlink:to="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_249" xlink:to="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_249" xlink:to="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_249" xlink:to="lab_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_250" xlink:to="lab_skye_TwoThousandFifteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_250" xlink:to="lab_skye_TwoThousandFifteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_250" xlink:to="lab_skye_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_251" xlink:to="lab_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_251" xlink:to="lab_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_251" xlink:to="lab_skye_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_252" xlink:to="lab_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_252" xlink:to="lab_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_252" xlink:to="lab_skye_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_253" xlink:to="lab_skye_TwoThousandNineteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_253" xlink:to="lab_skye_TwoThousandNineteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_253" xlink:to="lab_skye_TwoThousandNineteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_254" xlink:to="lab_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_254" xlink:to="lab_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_254" xlink:to="lab_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_255" xlink:to="lab_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_255" xlink:to="lab_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_255" xlink:to="lab_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_256" xlink:to="lab_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_256" xlink:to="lab_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_256" xlink:to="lab_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_257" xlink:to="lab_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_257" xlink:to="lab_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_257" xlink:to="lab_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_258" xlink:to="lab_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_258" xlink:to="lab_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_258" xlink:to="lab_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Um5070LicenseAgreementMember_259" xlink:to="lab_skye_Um5070LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Um5070LicenseAgreementMember_259" xlink:to="lab_skye_Um5070LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_Um5070LicenseAgreementMember_259" xlink:to="lab_skye_Um5070LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UnamortizedDebtDiscountPeriod_260" xlink:to="lab_skye_UnamortizedDebtDiscountPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UnamortizedDebtDiscountPeriod_260" xlink:to="lab_skye_UnamortizedDebtDiscountPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UnamortizedDebtDiscountPeriod_260" xlink:to="lab_skye_UnamortizedDebtDiscountPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_261" xlink:to="lab_skye_UniversityOfMississippiAgreementsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_261" xlink:to="lab_skye_UniversityOfMississippiAgreementsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_262" xlink:to="lab_skye_UniversityOfMississippiAgreementsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_262" xlink:to="lab_skye_UniversityOfMississippiAgreementsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiMember_263" xlink:to="lab_skye_UniversityOfMississippiMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiMember_263" xlink:to="lab_skye_UniversityOfMississippiMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UniversityOfMississippiMember_263" xlink:to="lab_skye_UniversityOfMississippiMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UnvestedRestrictedStockMember_264" xlink:to="lab_skye_UnvestedRestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UnvestedRestrictedStockMember_264" xlink:to="lab_skye_UnvestedRestrictedStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UnvestedRestrictedStockMember_264" xlink:to="lab_skye_UnvestedRestrictedStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UpfrontPayment_265" xlink:to="lab_skye_UpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UpfrontPayment_265" xlink:to="lab_skye_UpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_UpfrontPayment_265" xlink:to="lab_skye_UpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ValueOfCommonStockCalledByWarrants_266" xlink:to="lab_skye_ValueOfCommonStockCalledByWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ValueOfCommonStockCalledByWarrants_266" xlink:to="lab_skye_ValueOfCommonStockCalledByWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ValueOfCommonStockCalledByWarrants_266" xlink:to="lab_skye_ValueOfCommonStockCalledByWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_267" xlink:to="lab_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_267" xlink:to="lab_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_267" xlink:to="lab_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsAndDerivativeLiabilitiesTextBlock_268" xlink:to="lab_skye_WarrantsAndDerivativeLiabilitiesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsAndDerivativeLiabilitiesTextBlock_268" xlink:to="lab_skye_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsAndDerivativeLiabilitiesTextBlock_268" xlink:to="lab_skye_WarrantsAndDerivativeLiabilitiesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_269" xlink:to="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_269" xlink:to="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_269" xlink:to="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_269" xlink:to="lab_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_270" xlink:to="lab_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_270" xlink:to="lab_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_270" xlink:to="lab_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsLiabilityClassifiedMember_271" xlink:to="lab_skye_WarrantsLiabilityClassifiedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsLiabilityClassifiedMember_271" xlink:to="lab_skye_WarrantsLiabilityClassifiedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsLiabilityClassifiedMember_271" xlink:to="lab_skye_WarrantsLiabilityClassifiedMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsMember_272" xlink:to="lab_skye_WarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsMember_272" xlink:to="lab_skye_WarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsMember_272" xlink:to="lab_skye_WarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsVestedAndOutstanding_273" xlink:to="lab_skye_WarrantsVestedAndOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsVestedAndOutstanding_273" xlink:to="lab_skye_WarrantsVestedAndOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsVestedAndOutstanding_273" xlink:to="lab_skye_WarrantsVestedAndOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsVestedAndOutstanding_273" xlink:to="lab_skye_WarrantsVestedAndOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WorkingCapitalDeficit_274" xlink:to="lab_skye_WorkingCapitalDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WorkingCapitalDeficit_274" xlink:to="lab_skye_WorkingCapitalDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WorkingCapitalDeficit_274" xlink:to="lab_skye_WorkingCapitalDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WorkingCapitalDeficit_274" xlink:to="lab_skye_WorkingCapitalDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_275" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_275" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_275" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_276" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_276" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_276" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_276" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_276" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_277" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_277" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_277" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_278" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_278" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_278" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_278" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_279" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_279" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_279" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes_280" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes_280" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes_280" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_281" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_281" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_281" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_282" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_282" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_282" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_282" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_283" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_284" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_284" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_284" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_285" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_286" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_286" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_286" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_286" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_286" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_287" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_287" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_288" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_288" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_289" xlink:to="lab_us-gaap_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_289" xlink:to="lab_us-gaap_InterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_289" xlink:to="lab_us-gaap_InterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_289" xlink:to="lab_us-gaap_InterestExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_290" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_290" xlink:to="lab_us-gaap_InvestmentIncomeInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_290" xlink:to="lab_us-gaap_InvestmentIncomeInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_291" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_291" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_291" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_291" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_291" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_292" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_292" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_292" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_293" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_294" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_295" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_295" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_295" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_295" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_296" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_296" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_296" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_298" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_298" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_298" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_298" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_298" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_299" xlink:to="lab_us-gaap_StockholdersEquity_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_300" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_300" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_300" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_301" xlink:to="lab_us-gaap_DeferredTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_301" xlink:to="lab_us-gaap_DeferredTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_301" xlink:to="lab_us-gaap_DeferredTaxLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_302" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_302" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_302" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_304" xlink:to="lab_us-gaap_CommonStockSharesIssued_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_305" xlink:to="lab_us-gaap_NetIncomeLoss_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_306" xlink:to="lab_us-gaap_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_306" xlink:to="lab_us-gaap_Cash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_306" xlink:to="lab_us-gaap_Cash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_306" xlink:to="lab_us-gaap_Cash_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_306" xlink:to="lab_us-gaap_Cash_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_306" xlink:to="lab_us-gaap_Cash_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_308" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_308" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_308" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_308" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_308" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_309" xlink:to="lab_us-gaap_DerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_309" xlink:to="lab_us-gaap_DerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_309" xlink:to="lab_us-gaap_DerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_309" xlink:to="lab_us-gaap_DerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_310" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_310" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_310" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_310" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_311" xlink:to="lab_us-gaap_PreferredStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_311" xlink:to="lab_us-gaap_PreferredStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_311" xlink:to="lab_us-gaap_PreferredStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_311" xlink:to="lab_us-gaap_PreferredStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_311" xlink:to="lab_us-gaap_PreferredStockValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_312" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_312" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_312" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_312" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_313" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_313" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_313" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_314" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_314" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_314" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_316" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_316" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_316" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_317" xlink:to="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_317" xlink:to="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_317" xlink:to="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_317" xlink:to="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_317" xlink:to="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_318" xlink:to="lab_us-gaap_SharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_318" xlink:to="lab_us-gaap_SharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_318" xlink:to="lab_us-gaap_SharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_318" xlink:to="lab_us-gaap_SharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_319" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_319" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_319" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_320" xlink:to="lab_us-gaap_AccruedSalariesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_320" xlink:to="lab_us-gaap_AccruedSalariesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_320" xlink:to="lab_us-gaap_AccruedSalariesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_320" xlink:to="lab_us-gaap_AccruedSalariesCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_321" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_321" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_321" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_321" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_321" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_321" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_322" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_322" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_322" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_322" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_323" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_323" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_323" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_324" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_324" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_324" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_324" xlink:to="lab_us-gaap_EarningsPerShareBasic_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_324" xlink:to="lab_us-gaap_EarningsPerShareBasic_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_325" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_325" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_325" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_325" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_325" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_326" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_326" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_326" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_326" xlink:to="lab_us-gaap_EarningsPerShareDiluted_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_327" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_327" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_327" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_327" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_327" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_328" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_328" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_328" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_328" xlink:to="lab_us-gaap_OperatingIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLoansPayableLongTerm_329" xlink:to="lab_us-gaap_OtherLoansPayableLongTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLoansPayableLongTerm_329" xlink:to="lab_us-gaap_OtherLoansPayableLongTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_330" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_330" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_330" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_330" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_331" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_331" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_331" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_331" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_332" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_332" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_332" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_332" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_333" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_333" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_333" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_333" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_334" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_334" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_334" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_334" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_335" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_335" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_335" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_335" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_335" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_336" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_336" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_336" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_336" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_337" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_337" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_337" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_337" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_338" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_338" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_338" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_338" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_339" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_339" xlink:to="lab_dei_AmendmentFlag_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_340" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_340" xlink:to="lab_dei_CoverAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_341" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_341" xlink:to="lab_dei_CurrentFiscalYearEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_342" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_342" xlink:to="lab_dei_DocumentFiscalPeriodFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_343" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_343" xlink:to="lab_dei_DocumentFiscalYearFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_344" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_344" xlink:to="lab_dei_DocumentPeriodEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_345" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_345" xlink:to="lab_dei_DocumentType_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_346" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_346" xlink:to="lab_dei_EntityCentralIndexKey_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_347" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_347" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_348" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_349" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_350" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_351" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_352" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_352" xlink:to="lab_dei_EntityFilerCategory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_353" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_354" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_355" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_355" xlink:to="lab_dei_EntityRegistrantName_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_356" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_357" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_358" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_359" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_360" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_360" xlink:to="lab_dei_LegalEntityAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_361" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_362" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_362" xlink:to="lab_dei_TradingSymbol_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AlbanyMolecularResearchIncMember_363" xlink:to="lab_skye_AlbanyMolecularResearchIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_AlbanyMolecularResearchIncMember_363" xlink:to="lab_skye_AlbanyMolecularResearchIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CashPaidDuringPeriodForAbstract_364" xlink:to="lab_skye_CashPaidDuringPeriodForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_CashPaidDuringPeriodForAbstract_364" xlink:to="lab_skye_CashPaidDuringPeriodForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DilutedSecuritiesAxis_365" xlink:to="lab_skye_DilutedSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DocumentAndEntityInformationAbstract_366" xlink:to="lab_skye_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_DocumentAndEntityInformationAbstract_366" xlink:to="lab_skye_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LeaseAgreementMember_367" xlink:to="lab_skye_LeaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_LeaseAgreementMember_367" xlink:to="lab_skye_LeaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NonCashInterestExpenseAbstract_368" xlink:to="lab_skye_NonCashInterestExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_NonCashInterestExpenseAbstract_368" xlink:to="lab_skye_NonCashInterestExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PricingModelAxis_369" xlink:to="lab_skye_PricingModelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_PricingModelDomain_370" xlink:to="lab_skye_PricingModelDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsAbstract_371" xlink:to="lab_skye_SignificantContractsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_SignificantContractsTable_372" xlink:to="lab_skye_SignificantContractsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_skye_WarrantsAndDerivativeLiabilitiesAbstract_373" xlink:to="lab_skye_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_374" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_374" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_374" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_375" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_375" xlink:to="lab_srt_ChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_375" xlink:to="lab_srt_ChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_376" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_376" xlink:to="lab_srt_ChiefFinancialOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_377" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_377" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_377" xlink:to="lab_srt_MaximumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_378" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_378" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_378" xlink:to="lab_srt_MinimumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_379" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_380" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_381" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_382" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_383" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_383" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_384" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_384" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_385" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_385" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_385" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_386" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_386" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_386" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_387" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_388" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_388" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_389" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_389" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_390" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_390" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_391" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_391" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_392" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_392" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_393" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_393" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_394" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_394" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_396" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_396" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_396" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_397" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_397" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_397" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_398" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_398" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_399" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_400" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_401" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand_402" xlink:to="lab_us-gaap_AreaOfLand_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand_402" xlink:to="lab_us-gaap_AreaOfLand_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand_402" xlink:to="lab_us-gaap_AreaOfLand_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_403" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_404" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_404" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_404" xlink:to="lab_us-gaap_Assets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_405" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_405" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_406" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_406" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_406" xlink:to="lab_us-gaap_AssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_407" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_407" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_408" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_409" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_409" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_410" xlink:to="lab_us-gaap_BridgeLoan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_410" xlink:to="lab_us-gaap_BridgeLoan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_410" xlink:to="lab_us-gaap_BridgeLoan_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_411" xlink:to="lab_us-gaap_BridgeLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_411" xlink:to="lab_us-gaap_BridgeLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_412" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_412" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_412" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_414" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_414" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_415" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_415" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_416" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_416" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_417" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_418" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_419" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_419" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_420" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_421" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_421" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_422" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_422" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_423" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_424" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_424" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_425" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_426" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_426" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_427" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_427" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_428" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_428" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_429" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_429" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_429" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_430" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_430" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_431" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_431" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_432" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_432" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_433" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_433" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_434" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_434" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_435" xlink:to="lab_us-gaap_ConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_435" xlink:to="lab_us-gaap_ConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_436" xlink:to="lab_us-gaap_ConvertibleDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_436" xlink:to="lab_us-gaap_ConvertibleDebtMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_437" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_437" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_438" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_438" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_438" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_439" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_440" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_440" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_441" xlink:to="lab_us-gaap_DebtInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_442" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_442" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_443" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_443" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_443" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_444" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_444" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_444" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_445" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_445" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_446" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_446" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_447" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_447" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_449" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_450" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_450" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_450" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_451" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_452" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_453" xlink:to="lab_us-gaap_DebtPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_453" xlink:to="lab_us-gaap_DebtPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_454" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_454" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_455" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_455" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_455" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_456" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_456" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_457" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_457" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_457" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_458" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_458" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_459" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_459" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_460" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_460" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_461" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_461" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_461" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_462" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_462" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_463" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_463" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_464" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_464" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_465" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_465" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_466" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_466" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_467" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_467" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_468" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_469" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_469" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_469" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_470" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_470" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities_471" xlink:to="lab_us-gaap_DilutiveSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities_471" xlink:to="lab_us-gaap_DilutiveSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities_471" xlink:to="lab_us-gaap_DilutiveSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_472" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_472" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_473" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_474" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_474" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_475" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_475" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_476" xlink:to="lab_us-gaap_DueFromRelatedParties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_476" xlink:to="lab_us-gaap_DueFromRelatedParties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_477" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_478" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_478" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_478" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_479" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_479" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_480" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_480" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_480" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_481" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_482" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_482" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_483" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_483" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_484" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_484" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_485" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_485" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_485" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_486" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_486" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_486" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_487" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_487" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_487" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_488" xlink:to="lab_us-gaap_EquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_488" xlink:to="lab_us-gaap_EquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_489" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_489" xlink:to="lab_us-gaap_EquityComponentDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_490" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_491" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_491" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_492" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_492" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_493" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_493" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_496" xlink:to="lab_us-gaap_ForeignCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_496" xlink:to="lab_us-gaap_ForeignCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_497" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_497" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_497" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_498" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_498" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_498" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_498" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_499" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_499" xlink:to="lab_us-gaap_IncomeStatementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_500" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_501" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_502" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_503" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_504" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_504" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_505" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_505" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_506" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_506" xlink:to="lab_us-gaap_IncomeTaxesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_507" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_507" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_508" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_508" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_509" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_509" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_510" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_510" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_511" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_511" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_512" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_512" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_512" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_513" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_513" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_514" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_514" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_515" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_515" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_516" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_516" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_517" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_517" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_517" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_517" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_518" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_518" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_519" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_519" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_520" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_520" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_520" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_521" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_521" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_522" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_522" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_523" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_523" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_524" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_525" xlink:to="lab_us-gaap_IntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_525" xlink:to="lab_us-gaap_IntellectualPropertyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_526" xlink:to="lab_us-gaap_InterestExpenseDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_526" xlink:to="lab_us-gaap_InterestExpenseDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther_527" xlink:to="lab_us-gaap_InterestExpenseOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther_527" xlink:to="lab_us-gaap_InterestExpenseOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty_528" xlink:to="lab_us-gaap_InterestExpenseRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty_528" xlink:to="lab_us-gaap_InterestExpenseRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_529" xlink:to="lab_us-gaap_InterestPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_529" xlink:to="lab_us-gaap_InterestPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_530" xlink:to="lab_us-gaap_InvestorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_530" xlink:to="lab_us-gaap_InvestorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_531" xlink:to="lab_us-gaap_IPOMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_531" xlink:to="lab_us-gaap_IPOMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_532" xlink:to="lab_us-gaap_LeaseAndRentalExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_532" xlink:to="lab_us-gaap_LeaseAndRentalExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_533" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_533" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_534" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_534" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_535" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_535" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_535" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_536" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_536" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_537" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_537" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_538" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_538" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_539" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_539" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_540" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_540" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_540" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_541" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_541" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_542" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_542" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_543" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_543" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_544" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_544" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_545" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_545" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_545" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_546" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_546" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_547" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_547" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_547" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_548" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_548" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember_549" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember_549" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_550" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_550" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_551" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_551" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_552" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_552" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_552" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_553" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_553" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_554" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_554" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_555" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_556" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_557" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_557" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_558" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_558" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_559" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_559" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_560" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_560" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_561" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_561" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_561" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_562" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_562" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_563" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_563" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_564" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_564" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_565" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_565" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_566" xlink:to="lab_us-gaap_NumberOfReportableSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_566" xlink:to="lab_us-gaap_NumberOfReportableSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_567" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_567" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_567" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_568" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_568" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_569" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_570" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_570" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_571" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_571" xlink:to="lab_us-gaap_OperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_573" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_574" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_574" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_575" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_575" xlink:to="lab_us-gaap_OtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_576" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_576" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_577" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_577" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_577" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_578" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_578" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtCurrent_579" xlink:to="lab_us-gaap_OtherLongTermDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtCurrent_579" xlink:to="lab_us-gaap_OtherLongTermDebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent_580" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent_580" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_581" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_581" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_581" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_582" xlink:to="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_582" xlink:to="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_583" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_584" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis_585" xlink:to="lab_us-gaap_PreferredStockConversionBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis_585" xlink:to="lab_us-gaap_PreferredStockConversionBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPriceDecrease_586" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPriceDecrease_586" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_587" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_587" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_588" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_588" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_588" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_589" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_589" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_589" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_590" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_590" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_590" xlink:to="lab_us-gaap_PreferredStockSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_590" xlink:to="lab_us-gaap_PreferredStockSharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_591" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_591" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_592" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_592" xlink:to="lab_us-gaap_PrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_593" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_593" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_593" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_594" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_594" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_594" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_595" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_595" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_596" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_596" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_596" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_597" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_597" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_597" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_598" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_598" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_598" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_599" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_599" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherShortTermDebt_600" xlink:to="lab_us-gaap_ProceedsFromOtherShortTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherShortTermDebt_600" xlink:to="lab_us-gaap_ProceedsFromOtherShortTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_601" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_601" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_602" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_602" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_602" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_603" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_604" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_604" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_604" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_604" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_605" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_605" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends_606" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends_606" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends_606" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_607" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_608" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_609" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_610" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_611" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_611" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_612" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_612" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_612" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_613" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_613" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_614" xlink:to="lab_us-gaap_RestrictedStockExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_614" xlink:to="lab_us-gaap_RestrictedStockExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_615" xlink:to="lab_us-gaap_RestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_615" xlink:to="lab_us-gaap_RestrictedStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_615" xlink:to="lab_us-gaap_RestrictedStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_616" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_616" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_617" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_617" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_618" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_618" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction_619" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction_619" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_620" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_621" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_621" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_621" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_622" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_622" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_623" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_624" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_624" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_625" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_625" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_626" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_626" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_627" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_627" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_628" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_628" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_629" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_630" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_630" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_631" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_631" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_632" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_633" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_634" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_636" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_636" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_639" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_640" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_640" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_641" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_641" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_642" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_642" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_643" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_643" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_643" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_644" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_644" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_644" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_645" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_645" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_645" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_646" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_646" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_646" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember_647" xlink:to="lab_us-gaap_SeriesEPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember_647" xlink:to="lab_us-gaap_SeriesEPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_648" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_648" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_648" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_649" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_649" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_649" xlink:to="lab_us-gaap_ShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_650" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_650" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_650" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_651" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_651" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_653" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_653" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_653" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_654" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_654" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_655" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_655" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_656" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_656" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_657" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_657" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_658" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_658" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_659" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_659" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_660" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_660" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_662" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_662" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_663" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_663" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_664" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_664" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_664" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_665" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_665" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_665" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_666" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_666" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_667" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_667" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_668" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_668" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_669" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_669" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_670" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_670" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_671" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_671" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_672" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_672" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_673" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_673" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_673" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_674" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_674" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_675" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_675" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_675" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_676" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_676" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_676" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_677" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_677" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_678" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_678" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_678" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_680" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_680" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_681" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_681" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_682" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_682" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_682" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_684" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_684" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_685" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_685" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_685" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_687" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_687" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_687" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_688" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_688" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_690" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_690" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_690" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_691" xlink:to="lab_us-gaap_ShortTermDebtLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_692" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_693" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_694" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_694" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_695" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_696" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_696" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_697" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_698" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_698" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_699" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_699" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_700" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_701" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_702" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_702" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_702" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_703" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_703" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_703" xlink:to="lab_us-gaap_StockholdersEquityAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_704" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_704" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_705" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_705" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_706" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_706" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_706" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_707" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_707" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_707" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_708" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_708" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_708" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_709" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_710" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_710" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_711" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_712" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_712" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_713" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_714" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_715" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_716" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_717" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_717" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_718" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_718" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_719" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_719" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_720" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_720" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_721" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_721" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_722" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_722" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_723" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_724" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_724" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_725" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_725" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_726" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_726" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_727" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_728" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_728" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_728" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_729" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_729" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_729" xlink:to="lab_us-gaap_WarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_730" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_731" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_731" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_731" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_732" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_732" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_732" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_733" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_733" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_733" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_734" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_734" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>skye-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NatureOfOperationsAndBusinessActivities" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilities" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockholdersEquityDeficitAndCapitalization" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensation" roleURI="http://www.emeraldbio.life/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NetIncomeLossPerShareOfCommonStock" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxes" roleURI="http://www.emeraldbio.life/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SignificantContractsUniversityOfMississippi" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#RelatedPartyMatters" roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SubsequentEvents" roleURI="http://www.emeraldbio.life/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationTables" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#Incometaxestables" roleURI="http://www.emeraldbio.life/role/Incometaxestables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NetIncomeLossPerShareOfCommonStockTables" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails6" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockholdersEquityDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails4" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#RelatedPartyMattersDetails" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetails1" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetails2" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetailTextuals" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NetIncomeLossPerShareOfCommonStockDetails" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#NetIncomeLossPerShareOfCommonStockDetails1" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails3" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetails" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#IncomeTaxesDetails3" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#StockBasedCompensationDetails5" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails5"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#WarrantsAndDerivativeLiabilitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedParty" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedPartyTables" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedPartyDetails1" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#OtherCurrentLiabilities" roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#OtherCurrentLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#OtherCurrentLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#Contingencies" roleURI="http://www.emeraldbio.life/role/Contingencies"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#CONSOLIDATEDSTATEMENTSCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsOFCASHFLOWSParentheticals" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsOFCASHFLOWSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="skye-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFilerCategory_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityPublicFloat_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityExTransitionPeriod_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityShellCompany_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedInterestRelatedParty" xlink:label="loc_skye_AccruedInterestRelatedParty_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaap_OtherLongTermDebtCurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLoansPayableLongTerm" xlink:label="loc_us-gaap_OtherLoansPayableLongTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_skye_AccruedInterestRelatedParty_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_OtherLongTermDebtCurrent_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_OtherLoansPayableLongTerm_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_Liabilities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_PreferredStockValue_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommonStockValue_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquity_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_skye_ChangeInFairValueOfDerivativeLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_skye_ChangeInFairValueOfDerivativeLiabilities_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InterestExpense_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_EarningsPerShareBasic_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_EarningsPerShareDiluted_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockIssuedForServices" xlink:label="loc_skye_CommonStockIssuedForServices_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RepaymentOfConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CashPaidDuringPeriodForAbstract" xlink:label="loc_skye_CashPaidDuringPeriodForAbstract_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_42"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_43"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_44"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ExerciseOfWarrants" xlink:label="loc_skye_ExerciseOfWarrants_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_skye_FairValueOfDerivativeLiabilityExcessOfProceeds_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_skye_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_skye_CommonStockIssuedForServices_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromOtherShortTermDebt_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_skye_RepaymentOfConvertibleMultiDrawCreditAgreement_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_35" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_35" xlink:to="loc_us-gaap_Cash_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_35" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_35" xlink:to="loc_skye_CashPaidDuringPeriodForAbstract_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_CashPaidDuringPeriodForAbstract_39" xlink:to="loc_us-gaap_InterestPaidNet_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_CashPaidDuringPeriodForAbstract_39" xlink:to="loc_us-gaap_IncomeTaxesPaid_40" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_35" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" xlink:to="loc_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" xlink:to="loc_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_43" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" xlink:to="loc_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_44" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42" xlink:to="loc_skye_ExerciseOfWarrants_45" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants" xlink:label="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FinancingValueWarrantExercise" xlink:label="loc_skye_FinancingValueWarrantExercise_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FinancingSharesWarrantExercise" xlink:label="loc_skye_FinancingSharesWarrantExercise_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_SharesIssued_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_FinancingValueWarrantExercise_20" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_skye_FinancingSharesWarrantExercise_21" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_NetIncomeLoss_22" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockholdersEquity_23" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_SharesIssued_24" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_skye_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_skye_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_skye_WarrantsAndDerivativeLiabilitiesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsAbstract" xlink:label="loc_skye_SignificantContractsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsTextBlock" xlink:label="loc_skye_SignificantContractsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_SignificantContractsAbstract_0" xlink:to="loc_skye_SignificantContractsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMatters">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_skye_RisksAndUncertaintiesPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_skye_RisksAndUncertaintiesPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_skye_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativesLiabilitiesTable" xlink:label="loc_skye_DerivativesLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_skye_EmeraldFinancingWarrantsLiabilityMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativeLiabilitiesLineItems" xlink:label="loc_skye_DerivativeLiabilitiesLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_skye_DerivativesLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_skye_EmeraldFinancingWarrantsLiabilityMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_skye_SeriesBWarrantMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_skye_DerivativeLiabilitiesLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_11" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_11" xlink:to="loc_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_11" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_11" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AwardsGrantedOutside2014PlanMember" xlink:label="loc_skye_AwardsGrantedOutside2014PlanMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_skye_AwardsGrantedOutside2014PlanMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Incometaxestables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MultiDrawCreditAgreementMember" xlink:label="loc_skye_MultiDrawCreditAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember" xlink:label="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_23"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_24"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RemainingDrawDownsLoans" xlink:label="loc_skye_RemainingDrawDownsLoans_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_30"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfCommonStockUnitsSold" xlink:label="loc_skye_NumberOfCommonStockUnitsSold_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfPreFundedUnitsSold" xlink:label="loc_skye_NumberOfPreFundedUnitsSold_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfUnitsSold" xlink:label="loc_skye_GrossProceedsOfUnitsSold_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_34"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeniorManagementCompensationPlanDescription" xlink:label="loc_skye_SeniorManagementCompensationPlanDescription_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_36"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesAbstract_0" xlink:to="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_MultiDrawCreditAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_AmendedAndRestatedMultiDrawCreditAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_skye_PaycheckProtectionProgramPromissoryNoteMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_skye_CommonStockWarrantsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_skye_PrefundedWarrantsMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_15" xlink:to="loc_us-gaap_SubsequentEventMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_Cash_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_ProceedsFromConvertibleMultiDrawCreditAgreement_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_DrawDownsLoansInAggregatePrincipalAmount_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_RemainingDrawDownsLoans_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_NumberOfCommonStockUnitsSold_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_NumberOfPreFundedUnitsSold_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_GrossProceedsOfUnitsSold_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_skye_SeniorManagementCompensationPlanDescription_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentWarrantMember" xlink:label="loc_skye_PlacementAgentWarrantMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PrefundedWarrantsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PlacementAgentWarrantMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelAxis_7" xlink:to="loc_skye_PricingModelDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelDomain_7" xlink:to="loc_skye_PricingModelMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_10" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativesLiabilitiesTable" xlink:label="loc_skye_DerivativesLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DerivativeLiabilitiesLineItems" xlink:label="loc_skye_DerivativeLiabilitiesLineItems_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantsIssued" xlink:label="loc_skye_FairValueOfWarrantsIssued_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ReclassificationOfDerivativesToEquity" xlink:label="loc_skye_ReclassificationOfDerivativesToEquity_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_skye_DerivativesLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_skye_SeriesBWarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativesLiabilitiesTable_1" xlink:to="loc_skye_DerivativeLiabilitiesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DerivativeLiabilitiesLineItems_8" xlink:to="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_skye_FairValueOfWarrantsIssued_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_skye_ReclassificationOfDerivativesToEquity_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilities_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EquityTable" xlink:label="loc_skye_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SecuritiesPurchaseAgreementMember" xlink:label="loc_skye_SecuritiesPurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember" xlink:label="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBCommonStockWarrantMember" xlink:label="loc_skye_SeriesBCommonStockWarrantMember_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantsMember" xlink:label="loc_skye_SeriesBWarrantsMember_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentMember" xlink:label="loc_skye_PlacementAgentMember_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EquityLineItems" xlink:label="loc_skye_EquityLineItems_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_skye_ClassOfWarrantOrRightWarrantsExercise_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IntrinsicValueOfWarrantExercises" xlink:label="loc_skye_IntrinsicValueOfWarrantExercises_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_30"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_skye_SubsequentFinancingPurchasePriceDescription_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingIssuanceCosts" xlink:label="loc_skye_EmeraldFinancingIssuanceCosts_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_33"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" xlink:label="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_34"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfCommonStockUnitsSold" xlink:label="loc_skye_NumberOfCommonStockUnitsSold_35"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfPreFundedUnitsSold" xlink:label="loc_skye_NumberOfPreFundedUnitsSold_36"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonUnitSoldPricePerUnit" xlink:label="loc_skye_CommonUnitSoldPricePerUnit_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_38"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PreFundedUnitSoldPricePerUnit" xlink:label="loc_skye_PreFundedUnitSoldPricePerUnit_39"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfUnitsSold" xlink:label="loc_skye_GrossProceedsOfUnitsSold_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_43"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_44"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" xlink:label="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_46"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_skye_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_SecuritiesPurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8" xlink:to="loc_us-gaap_IPOMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8" xlink:to="loc_us-gaap_PrivatePlacementMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8" xlink:to="loc_skye_AugustTwoThousandAndTwentyFinancingWarrantsMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_PrefundedWarrantsMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_SeriesBCommonStockWarrantMember_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_SeriesBWarrantsMember_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_skye_CommonStockWarrantsMember_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_20" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20" xlink:to="loc_skye_PlacementAgentMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityTable_1" xlink:to="loc_skye_EquityLineItems_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_ClassOfWarrantOrRightWarrantsExercise_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_IntrinsicValueOfWarrantExercises_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_BridgeLoan_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_SubsequentFinancingPurchasePriceDescription_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_EmeraldFinancingIssuanceCosts_32" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_34" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_NumberOfCommonStockUnitsSold_35" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_NumberOfPreFundedUnitsSold_36" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_CommonUnitSoldPricePerUnit_37" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_PreFundedUnitSoldPricePerUnit_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_GrossProceedsOfUnitsSold_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_42" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_43" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_44" order="210" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_45" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_EquityLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_46" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4" xlink:to="loc_srt_RangeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4" xlink:to="loc_srt_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4" xlink:to="loc_srt_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8" xlink:to="loc_us-gaap_PlanNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RestrictedStockAgreementsMember" xlink:label="loc_skye_RestrictedStockAgreementsMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_K2CIncMember" xlink:label="loc_skye_K2CIncMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_ChiefFinancialOfficerMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4" xlink:to="loc_us-gaap_PlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" xlink:to="loc_skye_RestrictedStockAgreementsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_dei_LegalEntityAxis_13" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_13" xlink:to="loc_dei_EntityDomain_13" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13" xlink:to="loc_skye_K2CIncMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_RestrictedStockExpense_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OmnibusIncentivePlan2014Member" xlink:label="loc_skye_OmnibusIncentivePlan2014Member_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DouglasCesarioMember" xlink:label="loc_skye_DouglasCesarioMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_RestrictedStockAgreementsMember" xlink:label="loc_skye_RestrictedStockAgreementsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairMarketValueOfStockOptions" xlink:label="loc_skye_FairMarketValueOfStockOptions_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_skye_OmnibusIncentivePlan2014Member_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8" xlink:to="loc_skye_DouglasCesarioMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11" xlink:to="loc_skye_RestrictedStockAgreementsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_skye_FairMarketValueOfStockOptions_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_26" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_27" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_28" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_29" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensation_30" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_31" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SignificantContractsAbstract" xlink:label="loc_skye_SignificantContractsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiAgreementsTable" xlink:label="loc_skye_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OptionAgreementMember" xlink:label="loc_skye_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_LicenseAgreementMember" xlink:label="loc_skye_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Um5070LicenseAgreementMember" xlink:label="loc_skye_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Um5050ProdrugAndUm8930AnalogAgreementsMember" xlink:label="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiMember" xlink:label="loc_skye_UniversityOfMississippiMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementAxis" xlink:label="loc_skye_MonthAndYearOfAgreementAxis_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthAndYearOfAgreementDomain" xlink:label="loc_skye_MonthAndYearOfAgreementDomain_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_December2015Member" xlink:label="loc_skye_December2015Member_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OctoberTwoThousandFifteenMember" xlink:label="loc_skye_OctoberTwoThousandFifteenMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableAxis" xlink:label="loc_skye_MilestonePaymentsPayableAxis_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MilestonePaymentsPayableDomain" xlink:label="loc_skye_MilestonePaymentsPayableDomain_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone1Member" xlink:label="loc_skye_Milestone1Member_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone2Member" xlink:label="loc_skye_Milestone2Member_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Milestone3Member" xlink:label="loc_skye_Milestone3Member_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_skye_UniversityOfMississippiAgreementsLineItems_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualMaintenanceFeePayable" xlink:label="loc_skye_AnnualMaintenanceFeePayable_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfAgreement" xlink:label="loc_skye_TermOfAgreement_23"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaymentForUpfrontFees" xlink:label="loc_skye_PaymentForUpfrontFees_24"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NumberOfLicenseAgreements" xlink:label="loc_skye_NumberOfLicenseAgreements_25"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NoticePeriodForTermination" xlink:label="loc_skye_NoticePeriodForTermination_26"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AnnualFeesForLicenseAgreement" xlink:label="loc_skye_AnnualFeesForLicenseAgreement_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_SignificantContractsAbstract_0" xlink:to="loc_skye_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_OptionAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_LicenseAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_Um5070LicenseAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_Um5050ProdrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_skye_UniversityOfMississippiMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_skye_MonthAndYearOfAgreementAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MonthAndYearOfAgreementAxis_10" xlink:to="loc_skye_MonthAndYearOfAgreementDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MonthAndYearOfAgreementDomain_10" xlink:to="loc_skye_December2015Member_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MonthAndYearOfAgreementDomain_10" xlink:to="loc_skye_OctoberTwoThousandFifteenMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_skye_MilestonePaymentsPayableAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MilestonePaymentsPayableAxis_14" xlink:to="loc_skye_MilestonePaymentsPayableDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MilestonePaymentsPayableDomain_14" xlink:to="loc_skye_Milestone1Member_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MilestonePaymentsPayableDomain_14" xlink:to="loc_skye_Milestone2Member_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_MilestonePaymentsPayableDomain_14" xlink:to="loc_skye_Milestone3Member_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_us-gaap_IntellectualPropertyMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_skye_UniversityOfMississippiAgreementsLineItems_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_AnnualMaintenanceFeePayable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_TermOfAgreement_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_PaymentForUpfrontFees_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_NumberOfLicenseAgreements_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_NoticePeriodForTermination_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_AnnualFeesForLicenseAgreement_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_skye_AggregateMilestonePaymentsIfMilestonesAchieved_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IndependentContractorAgreementMember" xlink:label="loc_skye_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AvtarDhillonMember" xlink:label="loc_skye_AvtarDhillonMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OfficersEmployeeAndDirectorsMember" xlink:label="loc_skye_OfficersEmployeeAndDirectorsMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_InitialTermOfAgreement" xlink:label="loc_skye_InitialTermOfAgreement_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TotalExpenseIncurredUnderAgreement" xlink:label="loc_skye_TotalExpenseIncurredUnderAgreement_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFee" xlink:label="loc_skye_MonthlyFee_13"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_14"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAccruedConsultingFee" xlink:label="loc_skye_PercentageOfAccruedConsultingFee_16"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfBonusForAccruedConsultingFee" xlink:label="loc_skye_PercentageOfBonusForAccruedConsultingFee_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FeesIncurredUnderAgreement" xlink:label="loc_skye_FeesIncurredUnderAgreement_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedExpenseUnderAgreement" xlink:label="loc_skye_AccruedExpenseUnderAgreement_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_skye_IndependentContractorAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_skye_AvtarDhillonMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_skye_OfficersEmployeeAndDirectorsMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_InitialTermOfAgreement_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_TotalExpenseIncurredUnderAgreement_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_MonthlyFee_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_MonthlyFeePaidEachMonthInExchangeOfServices_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_PercentageOfAccruedConsultingFee_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_PercentageOfBonusForAccruedConsultingFee_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_FeesIncurredUnderAgreement_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_skye_AccruedExpenseUnderAgreement_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsAmortization" xlink:label="loc_skye_DeferredTaxAssetsAmortization_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxLiabilitiesNoteDiscount" xlink:label="loc_skye_DeferredTaxLiabilitiesNoteDiscount_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_skye_DeferredTaxAssetsAmortization_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_skye_DeferredTaxLiabilitiesNoteDiscount_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxLiabilities_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" xlink:label="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IncomeTaxReconciliationChangeInCompoundDerivative" xlink:label="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_skye_IncomeTaxReconciliationUncertainTaxPositions_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_skye_IncomeTaxReconciliationChangeInCompoundDerivative_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal" xlink:label="loc_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_ForeignCountryMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesAxis" xlink:label="loc_skye_DilutedSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutedSecuritiesDomain" xlink:label="loc_skye_DilutedSecuritiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UnvestedRestrictedStockMember" xlink:label="loc_skye_UnvestedRestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_OptionsMember" xlink:label="loc_skye_OptionsMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsMember" xlink:label="loc_skye_WarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsLiabilityClassifiedMember" xlink:label="loc_skye_WarrantsLiabilityClassifiedMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" xlink:label="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NetLossAdjustedBalance" xlink:label="loc_skye_NetLossAdjustedBalance_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" xlink:to="loc_skye_DilutedSecuritiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DilutedSecuritiesAxis_1" xlink:to="loc_skye_DilutedSecuritiesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_UnvestedRestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_OptionsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_WarrantsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_DilutedSecuritiesDomain_1" xlink:to="loc_skye_WarrantsLiabilityClassifiedMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7" xlink:to="loc_us-gaap_DilutiveSecurities_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7" xlink:to="loc_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_13" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_13" xlink:to="loc_us-gaap_EarningsPerShareBasic_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_17" xlink:to="loc_skye_NetLossAdjustedBalance_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_17" xlink:to="loc_us-gaap_EarningsPerShareDiluted_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonSharesUnderlyingConvertiblePreferredStockMember" xlink:label="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_skye_CommonSharesUnderlyingConvertiblePreferredStockMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_15"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8" xlink:to="loc_srt_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_12" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelAxis_15" xlink:to="loc_skye_PricingModelDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelDomain_15" xlink:to="loc_skye_PricingModelMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MonteCarloSimulationsMember" xlink:label="loc_skye_MonteCarloSimulationsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelAxis_7" xlink:to="loc_skye_PricingModelDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelDomain_7" xlink:to="loc_skye_MonteCarloSimulationsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_skye_EmeraldFinancingMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelAxis" xlink:label="loc_skye_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelDomain" xlink:label="loc_skye_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PricingModelMember" xlink:label="loc_skye_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantMember" xlink:label="loc_skye_SeriesBWarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_skye_PricingModelAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelAxis_8" xlink:to="loc_skye_PricingModelDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_PricingModelDomain_8" xlink:to="loc_skye_PricingModelMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_skye_SeriesBWarrantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MinimumMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MaximumMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_Pre2015CommonStockWarrantsMember" xlink:label="loc_skye_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyPreFundedWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfWarrant" xlink:label="loc_skye_TermOfWarrant_20"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsVestedAndOutstanding" xlink:label="loc_skye_WarrantsVestedAndOutstanding_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_Pre2015CommonStockWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandEighteenEmeraldFinancingWarrantsMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyPreFundedWarrantsMember_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MinimumMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MaximumMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" xlink:to="loc_skye_TermOfWarrant_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_19" xlink:to="loc_skye_WarrantsVestedAndOutstanding_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_skye_PrefundedWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_skye_CommonStockWarrantsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_CommonStockSharesIssued_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_skye_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldWarrantLiabilityMember" xlink:label="loc_skye_EmeraldWarrantLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_SeriesBWarrantsMember" xlink:label="loc_skye_SeriesBWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CommonStockWarrantsMember" xlink:label="loc_skye_CommonStockWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_10"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PrefundedWarrantsMember" xlink:label="loc_skye_PrefundedWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PlacementAgentWarrantMember" xlink:label="loc_skye_PlacementAgentWarrantMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_18"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_GrossProceedsOfWarrant" xlink:label="loc_skye_GrossProceedsOfWarrant_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ValueOfCommonStockCalledByWarrants" xlink:label="loc_skye_ValueOfCommonStockCalledByWarrants_23"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity" xlink:label="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_TermOfWarrant" xlink:label="loc_skye_TermOfWarrant_28"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AggregateExercisePriceOfOutstandingCreditAgreements" xlink:label="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_skye_ClassOfWarrantOrRightWarrantsExercise_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_34"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_EmeraldFinancingWarrantsLiabilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_EmeraldWarrantLiabilityMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandFifteenCommonStockWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_SeriesBWarrantsMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_CommonStockWarrantsMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandNineteenCommonStockWarrantsMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PrefundedWarrantsMember_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_skye_PlacementAgentWarrantMember_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15" xlink:to="loc_us-gaap_WarrantMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_18" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_GrossProceedsOfWarrant_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_ValueOfCommonStockCalledByWarrants_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_TermOfWarrant_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_31" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_AggregateExercisePriceOfOutstandingCreditAgreements_32" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_skye_ClassOfWarrantOrRightWarrantsExercise_33" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_21" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_34" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_skye_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_skye_ScheduleOfInterestExpenseTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_12"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_skye_CurrentConvertibleDebtExcludingNoncurrentPortion_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_2"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_NonCashInterestExpenseAbstract" xlink:label="loc_skye_NonCashInterestExpenseAbstract_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmortizationOfDebtDiscount" xlink:label="loc_skye_AmortizationOfDebtDiscount_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AmortizationOfTransactionCosts" xlink:label="loc_skye_AmortizationOfTransactionCosts_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseDebt_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_skye_NonCashInterestExpenseAbstract_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NonCashInterestExpenseAbstract_3" xlink:to="loc_skye_AmortizationOfDebtDiscount_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_skye_NonCashInterestExpenseAbstract_3" xlink:to="loc_skye_AmortizationOfTransactionCosts_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpense_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldFinancingMember" xlink:label="loc_skye_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_EmeraldHealthSciencesIncMember" xlink:label="loc_skye_EmeraldHealthSciencesIncMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_MultiDrawCreditAgreementMember" xlink:label="loc_skye_MultiDrawCreditAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_IndependentContractorAgreementMember" xlink:label="loc_skye_IndependentContractorAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PaycheckProtectionProgrammeMember" xlink:label="loc_skye_PaycheckProtectionProgrammeMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_17"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_22"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_23"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CreditFacilityEffectedFourthAdvance" xlink:label="loc_skye_CreditFacilityEffectedFourthAdvance_24"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_CreditFacilityEffectedFifthAdvance" xlink:label="loc_skye_CreditFacilityEffectedFifthAdvance_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_27"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfWarrantLiabilityInExcessForProceeds" xlink:label="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_32"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_UnamortizedDebtDiscountPeriod" xlink:label="loc_skye_UnamortizedDebtDiscountPeriod_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_34"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_FairValueOfSharesUnderlyingConvertibleDebt1" xlink:label="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PayrollCostExcludeCompensation" xlink:label="loc_skye_PayrollCostExcludeCompensation_38"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentageOfForgivenessAmountForNonPayrollCost" xlink:label="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_40"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_PercentOfReductionInAnnualSalary" xlink:label="loc_skye_PercentOfReductionInAnnualSalary_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_skye_EmeraldHealthSciencesIncMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_skye_MultiDrawCreditAgreementMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_skye_IndependentContractorAgreementMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9" xlink:to="loc_skye_PaycheckProtectionProgrammeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_AllocationOfDebtOnBasisOfRelativeFairValue_22" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_AllocationOfWarrantOnBasisOfRelativeFairValue_23" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_CreditFacilityEffectedFourthAdvance_24" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_CreditFacilityEffectedFifthAdvance_25" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_26" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DerivativeLiabilities_27" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts_28" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_29" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_30" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_FairValueOfWarrantLiabilityInExcessForProceeds_32" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_UnamortizedDebtDiscountPeriod_33" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_34" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_FairValueOfSharesUnderlyingConvertibleDebt1_35" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_36" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_PayrollCostExcludeCompensation_38" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_PercentageOfForgivenessAmountForNonPayrollCost_39" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_40" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_skye_PercentOfReductionInAnnualSalary_41" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/OtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedResearchAndDevelopmentCosts" xlink:label="loc_skye_AccruedResearchAndDevelopmentCosts_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_AccruedBoardFees" xlink:label="loc_skye_AccruedBoardFees_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_AccruedSalariesCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_skye_AccruedResearchAndDevelopmentCosts_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_skye_AccruedBoardFees_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/OtherCurrentLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsOFCASHFLOWSParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:label="loc_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="skye-20201231.xsd#skye_ShareIssuanceCosts" xlink:label="loc_skye_ShareIssuanceCosts_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_skye_ShareIssuanceCosts_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>skye_ex31img14.jpg
<TEXT>
begin 644 skye_ex31img14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]P17M'A5?^$#OKS0_$7B:76-5U_6I)K"2X,?VFY1H4.2B8 5!&X)"J,(, 9
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MDS.+O&+ZLS8?B]X@NO'=E\/;?P39#Q<;,W]_:S:UMMK&/JJ^<L#&20@KE53
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M @)(+_0=O65&C1NJSU[*Z_X+/%<Z]>SCJN[_ *L:DFK/%H-I?V=E:VTTMQ+
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MJ=FWE?:8X@DLD9^4H[]6&2I[=#CJ<YDBJY"26J-<*BQ08C!"D$ '# AL+G@
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MW$+JKR(SE&8]3A^2H/H.@Z$5Y(OCW1X=-OI-'TN"WOQ-]H@,Z^89 \F9 =H
M"C<H"YZ#.2179_#R^\07\%Y=^(;6"/3X6_T6&6(H\CGH@!/,:CG)&3P,GFL<
M%1PV I>SHJRW_ICGC5C:D5?F;[)V,'XL+;ZA:?9X;:2!)I1<6^X_*A5 "RXR
M3\QX(QG&#TQ7CD5_=/X@^UW.N"XN]1C^U7ILP8WA*L2\9X5<A 7(7@[5&3BO
M6/'UQ<W'BV4W#,VV-=I;N",D_F3^5>2ZEYC)!%YFG0V]AJH&U<"[D:0*[,W=
MD^7'IU%=N$Q4Y5&UT5U\C;$4(J*C\G\SOUDU_4M7;4KFRNK/3(H_*AM[E6"S
M*S 'DC#,6(D;_=/0 "O;_@+J'F> +O17D+OH^H36P+=T8B0$>V78?A7SG%#8
MVT:WTFJ7QU.6 ,=Z1H [1;OO%RQ7G!.!Z=\5[=\#;GR_&7C/3E!V>59S =@=
MKAOQ/'Y5[F805^9;-+\-#QLMFU4Y9;ZGO-%%%>*?2!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <=X\\1W_ (=T.T72(8Y]8U6]BTZQ$^?*260G
MYWQSM50S$#&=N.,UDW-UKG@21-4\0>++[Q)8SH+:.Q^R6Z7,][(ZB.. 1H@V
MXW\.Q(ZLQ R.F\4>%]/\6:4EA?37%LT,R7-O=6DFR:VF0Y21"01D>X(()!!!
MK$O?AU'J5O8#4/%WB"YOK*]%]'?-- LNX1O%L"+$(D79(PRB*V<'=D U*T^_
M\ _KYF!;_'/1;N6SM[?PCXGEN;U+EX+>*U@EE;R)A#*-J3$\-DYZ$ X.>*U(
M?BMITVGQW:^&M=$EY>O8:?:%+<SZC*A<2>6@F_=A/+8L9O+P,9H\-_"/0_"]
MJT>FZQK#S_V6VD0W<DL?G6T32/*SQLL8Q(7DSN.?NKZ',!^$&FGRKC_A+/$0
MU6.ZFNFU19K=;AS-"L,B'$.Q041>516R-V[))JOZ_$#/;X^^$E:W']D:VQGM
MH+H;88CL22X-O\W[W@K*"I]>-N[(KI/&&N:ROB+0O!OAN9+/4-7$T\U_)$)1
M9VT(7>RJ>&D+.BKG(&22#C!SG^#7A$?N[.2_L8Q+8.J6\B (EF=T40+(24+$
MLV26+'.171>)/!]KXBOM.U--6U#1]5TUG^RW^GM&)$5P Z%9$=&5MJY#*>5!
M&#1I^+^[H'^7XG(WWB3Q!X(\36NAZMJ][XABODGN[>5[.U,OV>WA+S+(4>!4
MD9F4*^QDP%! )+5/X8^*PUBTBCU;PQJFEZE)%97*P.L!$D-W,8XI$*S-D#'S
M9VL,$[>U6M6^%.E:W(9M0\1Z]-<-I5SI+S&XC+/'<$&5^8R%<X&-H"@  +Q6
M?H/@O59M9D\4W^FOIFI6&F_V/I=K/=QR[Q&TGEW,C1H5#,'X 4[ S<9. EIO
MK_7_  P/7;^MO^"=IXRN+JS\#:U>66H3:?<V]G)-'<0)&[HRJ6&%D5E.2,8(
M/6O+E\6>)?$'A[3YW\47_AC4M(T^_D\0065O:R!;BVV*1^^B?:&9MZXX*'Z$
M>AZAX6U/7O!-AH6L>)KV&]C6$WE[810(;N1 "V5DB=0C,,D!1Z=,@Q:A\./#
M^HW/BJZS<VMUXIL4L+^>W=5;8J,FY,J0'*M@D@@[5XXI26]F--:'._#V7QIK
MECX9U/4_&%[<QVVG)+JT;6MJJ7=U,BN(P5B!01!N=I&<J"20U<M>?$3QC;^,
M/%]Y97CWMCH]G=WMO8>1%]EN;9(E$4L$@7S9'$X=9,,4 &.#MS[3HFBV'A[0
M+/0]-C9+.TB$2!CN9O5F/4L3DD]2237):5\+['1COT[Q/KD4T%L;&PE9[=VT
MZV,@=H80T)!!VJ"T@=\* &&*<MW;8F.VN^AQOAKQ;J^M:-XLF7XDW&H:/HK6
M\G]OV%G:-),Y@+S6\ \LQ$!S&!N1V^8KDG##.USQC\0='TZ\MSXDD2Y\+V5G
M<:A++;6[OJ%[=3?N[1ML84(J?*6C5&)8'(YKUVU\$:#9Z58Z39PR0VEK>"_9
M ^XW4X);?,S99SO(<DG)95YP,50U#X;Z%JGC9?$UU<7Q/G074M@)$%K//"I6
M&9QMWEE!X&[;E5)4D U5U>_H+6UB&PU;6+SXWZSI$>IS2:+IVD6TDMHT<>Q+
MJ61\$.$#_<CY!8CYN@KO.<BN6\-^#(O#OB'7];_M_5-5NM;DCDG%]Y&V,HNU
M0GEQ(0 N!@D],]22>K[TNP^HM%%% PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)50YR&Q@J<'GH1S7BJA*FVK:,]A5(R=]';RO^96FBU74GC:_?1F?+HAMD2V
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MD\I@!5MZ,\ <1N5;Y@6&00,$8%6= T*UT*WN?+/G7M],UU>W+#YKB8@ L?0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M]TU\@^-O#*Z3XR\0
M>%MBJ)9?[3TX;L$I)D[0.X4ATQZ MVKZ_KRKXO\ @:X\1:-#K^C$G6M%5Y8X
MA'N^UQ<%XN.2>,KUYR/XB1M1FX2T=O\ /H<>+H^UIVM<^7U\*ZI<^#[CQ,(
M^E1R?9I65QO4G ^[_P "X)XR/IG-TVZ;3T>\A.G:>NFPQQW4 F;SM1RYVRJC
M C(60= , ^IK5U2W^TV\.IZ>Q:PNVWE-WRQ2'@Y[#..O'3L,9H>+?"MO8ZL-
M+;5[:Z 2-Q>V<@=-K ,1QGU/YYY%>YBX1Q5+VJUONENK?JF?/X*K]7G[)Z+H
MWM=_H>HZ3';ZGH$DDOV:2U:%6B5I-Z2@L.-NP#U.>G%=4_ANZO\ 18+&"Z^R
MZ==1%4MI5V;0020F!G;_ '>?PK"\.^!VMM!LS+JD&B6UP':QS)O6<!3)F3J$
M0)&Y+YR21UQ@^CW)GAN5A:Z?1M02?S&CGA$AG4\!(')VX)QG W 'H#7YOBJE
M6C)*GUZGVL%<\BU#1=1DU.S@6XOKF]LG#P>2!)(I&> %0Y7KP.HZ\9!ZO1Y]
M7MY);[Q)#J4\MPT<*K/92J"5SM)/E@=R.OX#OTFK:/<M<_VCILBBX>7S6WPB
M17*@@A5.!U/(]ATP:J1:=JGB*QN+J:6&);,E',$'V<\ ,P(R>=I[],BNVE7]
MI&W-=]2;69EWFFZ;;P7.F6>E-8W%Q<R7$RJFTO*X(8C>023G/'!R,=:Y#Q5I
M*++=VT?AK4].^V2O=7$JV;'SI'15+<N0.%' ...G6NCEU9;AEACMKO4IY2%6
M--5FW2-T^5 KC'X'U)ZFKY\.:I<#[&]U'IFLSQG[-I<5P\H(&21+(2%#E=V$
MX+8.?E#8IU+Z1U'S,\5UJXM+YGO;^RU%_#L=P(;V:W*1R"5U9T1=Q()^7=CM
MCGK5/PGX8U;Q+??V9IO[ZZ,?FL9WVB.-!M4$\@;5/MU*]0*9XC\/+HGBF\M9
M'!)PT]H)-\8F#-\S8.#P00OOSZ-KW/AFZL=9L;6TU:WNY)[9+MI[:8-Y&X9P
MQ!SNY'^\6 &<U]?EE!0IJK)\J5W=]7W]$?*YGB'.;IKWGHG;MV]2/2XWTNPO
M-1>,FZS]FMD5=SF0_P!WWR.O((##J17V'X#\._\ ")^!=(T$X\VV@S,0<@RL
M2\A'MO9L>U>'_"?P5;>)_$*:Y<(_]A>'I0EF@^[=70PQ<^JKP>, MCIA@?I@
M=ZY,96=6HV]V[O\ 1';E^']E33^[]1U%%%<1ZH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "5YU\:DCN?@]KNFM:0WDVIB+3[>&;D---*D<9Z'!
M#,&! )&,]J]&K(U?PYX>\11P1Z_H.GZNEN_FPK?6J3B)_P"\N\'!]Q2W&M#Q
MXQQ_#R.U:P\%^$?!OB/46N(A<VRE[2WT^!%DDFF9!"TQ) P"$.7'3!)?X:^)
M7CS5M8\%Z;J5SX:LG\3:5_:9Q:3[K7# B/:9OF,B-\I)7!5C\V-I]?U;P]H6
MN?9SKFAV&IFV8M!]LMDF\HD8)7<#M)''%4K/P5X/TT0C3O">C68MYQ<Q""PB
MC\N4+M\Q<+PVWC<.<<4T^Y+6FAA:M<7&O_%*'P=,"-%L]-&HWR?\_3R2-'#&
M3UVCRY&([D+VSGE--\*?#^S\.>(_%K>$-._L>\"6]I906JK]OAB?]WOP/WS3
M3<C?NW QYSS7K!TFS;6VU4J?/:W^RR#C;(F[<-PQS@EL?[S5+_9]A]DM[46,
M'V>W*&&'RUV1%,;-HQ@;<#&.F.*26@V]?(\2\3>"](\.^ /#VGQ6>C37=CJD
M%U=>'_L<#VE_-=2A'40E?EVAG\M@/E"=\''>>$M4DO/'?CQ+>)AI5A<VT$;*
MORM<+;CS@OK@>4OU%=+>>'=%N=6_MO\ LRTCUH0FWCU1;:,W4*'/"R,I( R3
M@Y'M5C2M+LM%TZ/3]/A\J%&9CDY9V8EF=CU9F8DDGDDDT^C_ *["ML?-NE^(
M;[4KFXUCQ2UI?7WBC3GN-+N8%Q=>'OM$RVEM LC,5C#"0L654;*29WX%4#J]
MQX+^#GB32;6QFLKN::ZM+Z71M/N'L8IH(T@"Q/&K!'G?86=RF"9.C@9^DX_"
M'A.&QU"PA\,:3%9ZFQ>]@2RB$=VQZM*NW#GW;-65\/Z%'HD>AQ:+8)I,6WR[
M%;9! FUMRXCQM&& (XX(S2LK-=U;_(J^J?9W.,\,S>&;/X>6W@F]M]2ALM+T
M6..\>ZTN\LX#$L2[_P!\\:J203E0V[[V1P<<3XA\,Z1HWP"\2?8_#6F:3=^,
M9HH8]/BLXX4B,\B16Z;% &]$(<\9#[C7N]Q:V]Y;2VMU;1W%O(NUXI5#JX]"
M#P16;K7A?PUXD^SCQ%X>TW6!;DM"+^UCN/*)QDKO!VDX'3TIO5W?7<F/NI>1
MYS\1M&VZS\/]/_L6VETJ'4K>W6]CN"+JS="'3R8B-H4^4 [@E@A<8QDUS_@.
M&UU7XY-XF!C:/6+2?6M-ND^:ZDMCY=N;>X8'Y8U8!T3!Y)R0RL#[1'X;\/0>
M()O$4.A:?%K,J".34%M4%PZX VF0#<1@ 8SV%.TSP[H&BW5Y=:+H5AIL]Z_F
M74MI;)$UP^2=SE0"QR3R<]31%V?W@UI]QKT444#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;BL+Q7
MJ5UHW@W5]6M+JUM)[*UDN5FNXFEA38I8[E5D)& >C#^E;U?.?[5GQ!T_0_AA
M<^$+358!K>MO'"ULL@,D5OG<\C <JIV[<GKDXZ&HG>UENRHJ[5R+X=_%#XO_
M !#\'0ZEIZ^$H=8O)"UM8M87)CBME?8T\\@N,H"RN$4*2Q0XX!*['Q;^)'Q$
M^&VA>%(;"X\.:OXAUJ\^PM:G39T25R>&C_TG*A<HI!W9+9^7[M>/>#]2\)?!
M?]I?2=.T_P 3V%SX;UO0K:WNKN*Z62&&8QC:[,"0H9T#9/ $V>E=1K7BCPU\
M2/VSO"NGV^N:?<:+X:@::&9+E#'<W9^8+&V<.=WE\+D_(WO6K5Y12V>_RW,U
M=)M]%I\SMOC3\3/B)\*?!6CZK:R^'M5U.5F%["=.G2,*"!YJ?Z3E54O&A!W9
M+@Y'2MCQ9\95\+? 32_'4MM#<:WJNF175K9H&\LRM&K,Q&<B)"W.3W5<Y85Q
M/Q0U?P_\2_"WQ,7P[KECK+:1I,-K;0VDZRNS><L\TB@9W*2L* CC*$9KRCXE
M?\4_\(/"_P /-8\0V'_"9:D;2QO[?SUVZ/8QA62&3G$>7,<CDXW$?W57&>LH
MM=;JWHR^J;Z)W/;[+XH?$9?V;;SXKZ_+X;T^[, NK.S73KAD*;RBJY^TY)D)
M3!&-H/(;/&=IWQD^)$.N_#>QU&R\/ZO-XOB6>[TS3;6>&ZTV%MNV5F::0%=K
M;LLJ_=(]ZP/C_KWA)M \"?!W2_$&G1V<]Y:K?2?;$6.TLXT4(9&SA P8.,]0
MN>XJ7P[?Z'%^T]'>_"46^G^ [#36'B6\L@(M*=D1RK;AB,LN4^<?[1Z;B;6L
MG;:_X)=2'\"OO:_W['>?%3XE^./"_P 5?!W@SP>-#NI/$C^6T5]93226BA@#
M*6290RX+'&!C8>3GCO=''Q$C\5-;ZWJGAW4]#%L^Z?3["6UGBN0R;497N)05
M*LQ]>.W&?F73?%'@/X@?M4>)_%GBCQ=:Z9X?T*S^QZ7<#6'L'E8':6BDCD1V
M!_?'Y3R''7->E:9\4O!/@[X!ZUJ7A_67GL[![JWTN\OWVRZO='+ED5SO<!Y
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M(X$)_A4.[,<>N1GT%?.-K\<OB=?6?Q)U.UF\)2:9X)8HMR^FW*#4&WLNU?\
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MUY+X5T?P_I&IW^FZUKNL6UC9W&GWDMM)%EMTKDQL"RB)7R#D=#C(%8MYJ?\
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ME D+CO\ +G ;U6RDN9M/MY;NW^RW+QJTL D$@B<C)7<,;L'(SWIV87+E%%%
MPHHHH **** "BBB@ HHHH **** "BBB@ HHKA_$_Q'T+PSXETWPNMM?:UXBU
M)2]OI&F1H\YC'61B[(D:#!Y=AT..AI>0';45P.C_ !0TG6-8U?PZNCZK9>*-
M+A\^30;M88[J9.S1-YIA<'CD28&1DBL#0/CE:>*=!U/6_#_P[\6ZA8Z9+);W
M3Q)8[TD0 LH0W0=B 1]T'/:F%CUZBO*/^%U64GCJ/P7:^!?$]UK,MF-0ABC^
MPJLMN>D@9[D  ^APWM5;Q%\>=+\*Z4NI:_X$\66<)U Z8RM#:%DN-H=5(%QR
M&4Y##*D=Z /3M5T72M<L'L-8T^WO[5_O0W$8=<^N#W]Z\WU#X#>#Y=[Z->ZK
MH3L=Q%I=%T;V(D#''L"*Z#Q%\2]%\,+I%KJ>GZDVO:P/]#T&WC2>]D/<$(YC
M '=B^W@_-Q4L?CW-V=,G\(Z];:T;62[CTV6.WWS1HRJVR43& G+K\OFY&>0*
M:DTM'H9RIPG;F5SSRX^!GB:/Y=.\?0^7G[L^EKN _P!X/R?P%10_ _QD90+C
MQ_:*G<KI8<_D7%;FA?';3_$WA*[\7:'\/_%M[HUH[QSW$<=EE&3!;]W]JWG
M()PIX^E>JWNH66FZ9/J=_=1VEE;QF::>5@J1H!DL2>@ J_:22N[+Y(Q^JTF[
M6_$\DLO@)IK'=KWBG5=1!'SPP%;:%_7*@$_DPKOO#O@3PGX4YT'0K>SEP1YY
MS),1Z&1R7Q[9Q7(?\+RT$^&3XN7PMXE;PD)-G]NBTB^S[<X\WR_-\_R\\;O*
MQ5KQA\9- \&VN@W\FCZKK6F:^\<5A?:5]FDAFDDSM3YYD8$@9SC;SUSD"7.3
MT_ UC2IPUBOF>FCBESS7(Z+XPN-3\2G0=0\'Z[H-S]E:[C>_%LT4J*RJ0KP3
M2#<"PX..#7,^-/C1IG@.UU#4=:\'>))-*LKQ;)M1MX[4Q2RE00$#SK(PYQNV
M8R",\5!J>J8HQ7E^N?&&#PWX=U;7-<\!^*+*VTD0/<AELV81RDA)%*W)5UW#
M:=I)!(R,9(H:Y\>-'T#P/H7C/4O!?B:/2-<:-+215LV8F12T891<Y&Y02/3O
M@\4_(/,]@I#7EFJ?&2#2/'&E>"KWP#XG_MS5H3/9VRFQ(E4*6;Y_M6T%=K Y
M(Y'&003U_ACQ.WB(ZE#-X>U70KG3YQ#+;ZDL09B5#!D,4DBLI!ZANH-"UU#R
M.EHHHH **** "BBB@ HHHH **** "BBB@#B/%.M>*=(\2Z NGQZ9/I=_?Q6,
MMJZ2&Z<,&9Y4<,%41A=Q4JV0&Y7'-'_A)/&MKXPUW29--T_5DM]*;4+."P#1
MRI)O98X)7D?:QD"Y#83&UA@XS6B/#GBAO&UQKTOB;3I+7RWBM+7^RGWP*5P%
M,AG(*[L,VU$9BJC<  *HZ;X4\<Z;I5Z@\:Z8^JW-S'.UY_8C;'QG?YB&X+,6
M&U00ZA0BA5&.4'7[CG[7XB>([[PWX:M].NM,O?$/B*ZG2.273I;6'3HH!_I!
MFA,[LS1L"F!(N69>F.;5_P#$+7F_9\@^(&FQ6$6LSVL,D<,\+RV\DKR+&%"J
MZMAB>/F)&1UZ%^J?"62;3],AT3Q1+I=Y;0WMO=7C6HEDN%O'5[AU 95CD++E
M6PP7)&T\8T?$WP^O=1\-^'?#GAG6+'1=,T2>WG6&ZT][L2_9RK0H=LT6%!4$
M]2<#D<Y?ZM?<"Z?,U-8\9:5X'T*QN/'.L01WDD;&1[*SF97*+ND=8E\QUC4<
MEB2%'4C-3Z-XZ\-Z]JYTG2+B[NKA88YW9;"X$4:O&LB!Y3&(T8HRG86#<]*X
M/Q)\)_%_BB349]3^(EHESJ.FR:7(UOHFQ887<.5B!G)4-MPV69F[,N!CJO"_
M@_7M#\3WNMZQXEM=16>V%K';VFF_8U"+(S1F3]Z_F,BMY:D!3MZ[CS1ON)Z+
M0Q=;\7>,K3XBZ_H.FW&C2V=EI$-U:QR6$KSO=SM)'#"S"=58%HRQ(5?E..,%
MJTX_B7X;T4C2?%GB.S&MVL+-?RVEI.MFDB)OD17(90P!!V%R_(XY J[8>!DM
M?B?K7CBZU)[I[^*"*WM/+VI:^6A4MG)WL=S8.!M#,!U)/E?B/X4-X:T37KC[
M3=:\-8GG@1H=-FNIK!;F?S6G=5D=W\M@"%@6+)PS GYA.R2?]=BK7?W?\$](
MC^+O@.2TO;O^TK^)+.X6TE2;2+R*3SF0OY:QM$'=@@W$*#M7YC@'-7]'^(OA
M/Q#J%C8Z+?W=]+?6R7D30Z=<F-87W;'D?R]L6[8V-Y4G''45YGHOPYU?Q'H,
M5Y83'P=<0C4;;SYK2XN9KW[2D8-Y_I3K-'+\I3][N;;D#&01VG@_X?:YX;UW
M3;R^\56U[9:9IW]F6]M;:7]E9H@(PBR/YK[U0HQ7Y009&^8@XJ^NO]:$7TT,
M'XC?$O7O"?CMM#TS6O#EJO\ 9!OX+/4;266YO;CS?+2WBV3J6:3G&$8C;T.>
M-2W^)S6GQ%GT/Q$8]/L6AT^"%%LYY)(K^Y#'R))EW1C "X+!,[^IQ53Q-\)]
M>\5:YK\VH>,+2+2M<^S0SV\&DL+F.W@=G2*.9IRJDLQ)?R\YZ!:M7_PGN=4M
M/%%K=^*#$-;U>UU6&X@L]L]H8&CVH':1@WRPJ =JX))(;.*E;*_]?U^A3ZV&
M>.?BWI6D^%)9?"^I0S>()BJ6=M=:=<R(9#/Y(695V&'<ZNJEV7)!QNQBM7QM
MXTO_  ;K'A:6?[--I-_=?9=2Q"_F6X8 +<!]^%C5V0,&4\.#D8YYV;X*2?\
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M>21L?Q,S,3]:HG>QT5%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M6CHL4SB158;G6>.1)"=[$[E.2<]>:X>3P1XFM/B=8:CI_A82QZ4T%G8ZA?\
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M'$N !&@^;<< \\G.J?!>CM\1!XYE:XEU-+%;"&-W'DPH&9MRKC[YWL-Q)X)
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MRK@8P"...E8EQ\-/!]YIEKI]S97LL=L\KI,VIW7V@^8,2!Y_-\QU8  JS%2
M!C &![MH%HE<\>UW5-<NO#'A"+2_%VI7=G':1K>ZG;7TT/V.6\=/L,\SC#W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:]%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>-4^%.I>%X;*:PM#>+?P:@9UD3Y"HV&%"I(<9Y."".>M>LTM[/N/JT+1113
M**** "BBB@ I,5Q^M>/M#T7Q[X=\$/*)]9UQY-D".-T,21NYE<>A*;1ZDGT-
M=@*.EP\A:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M92_NGL-+N;M((?)E0L6BC89W,!M^]SG&*]BHXI=O(?\ E8 <J*6BBF 4444
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M_P"(J>!M4U[^WI]5TN74+"[N[>.%HIHF"R1L(54&,[U9>"PPP);@T+6UNO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8\\A>:^B>M&!5/7?O<2TM;H?,Z^$_B(/C?:^,C\/]2_LV+PJ-(8?;K'S//\
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M^,O#/BV748_#>L0ZG_9LH@N6@#%$<C( ;&&X[J2*Q/"FE1MXTUOQE>+]FO\
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M3BMNB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0B-$4;2=O"CISDY-?.?CCP1XPU7XM^*-2M_'GCSP5'<2PI;QZ7I=]J$-\BQ
M"026K*D8SN&Q^1R<C.![W\.;/Q9!\+M&L_&=Y*VO_9RMQ.=ID!W'86Z@N%VY
MZC(.<TH_P_,)?'Y?\,>%?".UM;W]JWXPV=Y;1W%O.K+)%(H9'4R#((/!!K!^
M#FN>+?#6B?&70_!?V>\M?#UXS:3'?W"QP0$RR*Q+N0H&Q V"0,KU&37LVE_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF5 3N# @X!Z9Z<T^XCT&BH89HKB".>%Q)%(H='7D,",@BIJ>P!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #<
M5\W_ +5^GZMXA\&Z#H.A>'M9UJ]CU*.\E2PTR>X180DBDET0IG)'RYSSG&*^
MD#UHI=4^S!.QYYI.@^$O#W@G6]9\)^'[C2[74[=II+"WTN6!RZJ4^6U\L2*Q
MX^4+S@$#G)^2I?"_B_\ X91T3PF/!7B4ZW!XG:\DL_[%NMZ0B-OG/[O&/F'Z
M^AK[XI>]"^)R]/P!;)?UL?,=J-0_X:XUOQ8?#?B%=#E\/-;1WK:'>!'E6-&*
M#]UG.%( QR?E&20#XU8^&?&5O\$/"^@OX'\4QZK9>+FU*6$:'=YCM_+4>9D1
MXZ]ASP>*_0&BG'W7=?UK<3U5OZVL?&GQN\3^&_!WQEUVXDDUW2Y/$^@)8WLZ
MZ6ETEQ$X"GREDFA,;A4 ))<9R"@(R?H/X)ZCX1U'X.:"/!$UW)HUI$;9/MH
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M@*,:IIU_KWB;6/$LFF2>?8QZD+54MY=I3S ((8]S;6(R^[&<C!YIKSVM_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU 89]1UKQGP=\%?$OA#4/&EW#XYTZ]/BYI);M9-$=1#*WF$%,77W093E3DD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIIDC;3;B6&..[5=O[Q)A%&D9PV-I50<$YZ5U=(H**** "BBB@ HHHH ****
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MV/+,S$L2>I)K7HHV&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^^(EE8ZYX(O]/3P7JAN;/4;S<\5Y&(<(Z.1ABSLK8!8CRLL02!7KM%%];O\
MIB_KY$<BEHF56*$@@,N,CW&>*Y[POX6E\,K?K)XFU77/MDYN&_M$6_[MV)+%
M?)ACX)/0Y QQCG/34AH&>::]\%O!>N^"-<\(^7=:9IFM:@-2G2QE6,QS_)DH
M"I4 E 2I!&2<8XQ!IGP4T'1_%&K>)=.\0Z[#J>JZ8NF7,ID@<% BH' :$@.
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MW!]<BJOA_P"(WQ$UKXS?$;2DTK3);'P[;QPQVAU.2!4XD82*WD/O=^ 20H4
M8W8Y+VU\K_<%OT/H2BOFGX?_ !IL],^!FD:Q):ZQJNIZKK+Z7IUIJNK?:[BX
MF9AC?<&)=L8W?W#@8'.:Z^]^-LVG:%XZ^U^%XE\1^"Q'+?:8NHDPS0O@B2*?
MRLGY3G!C4YP#C.:&K;@M=CV>BO$/"WQYFUWQ;X-T+5/"0TI/%VGM?V5PFH"<
MH5W91U\M<9V'!!/49 Y ZCXT0S)\&O$NHVFH:CIU[IUE+=VUQ87TUJZ2*AP2
M8F7</]ELCVX%$O=5V$?>DHGHU&*^/;2Z\7Z?^R3I7Q<TCQOX@7Q+9DS7+7NI
MS7<%Y']J,6UX9F9!@;<%0#P?6O6[?XV&X\*^ I[/0ENM=\86TDT%M+.UO;1M
M$FZ4&41R$<@A1M/;.!S3:M>_1V$O>M;S_ ]HHXS7S-XJ_: U?5_V9KKXA>$M
M)72KN2Z.FSBXN-[V;G WQ$)B0_,,$[<=<'&#V6O?&0^#8_#?A_7+31X_$FK6
MS7&RZUOR+*&%%.'DNI(0=SXP%\LY;(SCFCN/MY_H>SXHQ7DEA\8KC7O!?A'Q
M1X4\#ZIKMMKM\+*ZCMV&=, 8J\CD @J"#@_*".25R!7K=%FMQ7"C->*?%&S\
M9Z7XZ\/:[\/=1O9-7E^T23Z1<W\QLM0CBC4F(1,WEQN1G#*!\W)ZYHNO$&B?
M$FV\$:YI.HZS8K=:J^G7]G;:I=6,D#+;SN\$R0R*-ZNB\D9P.#@\BU'_ )'M
M5+GI7E>J?%6^M-.USQ!HWA3^UO#'A^XDM=0O!?".X8Q<3/#"4(D5.<EI$)VM
M@'@ETGQ2U"\^(0\(>'/"@U SZ.-:L[^YU%+>"YB)4 _*LCJIW$9*YR!\NT[@
MN@MMSU+K17C\?QST2X\$^&M<5=,TZ^UY)FCMM9U9+&W@,+;)=\[*<X; 7:A+
M9S@ $CJOAO\ $#3_ (B^%Y=9L8D@DMKJ2RNHH[A;B-)4(SLE7B1"""K#&01P
M*=GJ%[6\SMZ***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5X_^T)H/BCQ?\);_P )>%?#ESJ]_J+QD.EQ;PQPB.5'.\RR
M(>0#C:&Z<XKV"BI:ON-.QXEX=_X3;1/"_A[2]-^%>HV>NBRL-)U#5;F]L!%#
M#%\K2 )<.TFW=(5&P$Y_"O/?$GP\^)%U\3OBYK5EX'O+FP\4:0VF:?(+RR7>
MX6) [!IP50[&(R,XQD \5]6T4WK+F_K44?=T7]6/EEOAC\03X&^#&WPQ(;_P
M;J6_4K W=L)/+\Q6WHWF;&&%Z;@>1Q6\W@?QQ??M/:_XMG\+36NA:EH;Z5'>
MFZMV193&HWE1)YFPE2 =F[D94<X^B*,\T/6_S_$$[6_KS/!OA5X.NO#GP"/P
MX^)=G;Z+]KEGTY3/>0D7C3NY41[6.201@'#$@_+QD]#\!O"NK^%OA?:V>O7X
MO[P/);PR@<+:QR.L*@]UP6<9[28[5W/B?PEX=\96-M8^(M/^VPVMPEW 5E>)
MX9D^ZZO&RL",GH:V+>W@M+6*VMXEB@A0)&B#"HH&  .P JKMW?5V)M:R6VK.
M)\86GB&ZUJ%8_#%IXG\+26<D>HZ7/)&))7WJ4,22XC8@;LAV08(YR,5Y?X>^
M#6J:?I'Q2&BZ,?#&G^*=/-IINA7-TLIBD\M@9)#&SHFYFX"LV >HX%?1M':I
MM9-=R[GS&O@OXIP_!WX<>%K;P9!'/I5\@U1VN+22\M8E?)EMG9BD;%2V'5MX
MXQBLS0?@]X_M_@[\5_!UQH?D7VM7QN],>6]BE2Z4.& W[RP8A>K@<GD]:^L*
M.U-ZWOU_X EI:W0^;O&'P^\=ZS\+/A9'9>&V?5O"=Y92W>F&[@$KI%&JN5<O
MY><KP-_0@]<@1^%_ OCJV\:_%:\UKX>Q7&G>+)X)+>"\OK=H)H1*1(DA1RZ/
MY<A8$*0"IY/&[Z4XS2T7U;[_ *_\,*VB7;]#PCP%X2^('@#PMXVC\,:9=&SP
MC^&M!UV^BF:"0*?,4O'(RB,L1M&\'Y>=I)->O^&YM>N?"VF7'B:Q@L=:DMT:
M]M[=]\<4I'S*IR<@'W/U/6MFBC_@!8X_Q_=>)+?PA<0^%-#N]6U*Z_T=?LLT
M$36RMPTV99$!*C) !Y;&<#)'F?C;X:W6E^'?#.K?#GPYKVH>(=%O+>>SL[W7
MY)8K:-0!)$RW%R8U!3*?NP><8^7FO>N@H]*5K.Z'NK'BFKP_$[1?B(GQ \*>
M!!K$6MZ=#9:CHMYJ5O:W%E)$[E)/-!=&7#G(4L?Z:\^B^,&^,GAKQA/H<4L)
MT6>PO1;72;+.5YHY.2^UG4*K ,JG+ 9"@Y'JM':A:6^?X@]?P_ \4\%>#-:U
M3P?\1O#?C'PS=:);>(M6O+RW::XMY2T4X&T_NI'VNA4$YXZ8)YQ=3P3XL\3?
M _5M%\5-;VGBO5[18IBS"6)7B55C#%<@HQ3>PYQYK#FO7J*5M+?(.M_.YY7\
M,M#GL;M[K4?@SH/@74(H#%+>Z<UJ3<G(R(_)7<(SC=AR".!@]1ZK115;B"BB
MB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/T'
MPY^)UK^T+JWQ473O"UQ!?67V$:=)J]PI"A47<7^R$<[,[=O?&3C)[:*V^+D.
MFZW<1VOA:+49FB@TNQ2^N#:64"JV69O(R\F6Z!%! 7IC!]*[4<9I6]WEZ!UY
MCP'P'\.O'7PYU+Q<@;15\$ZH);N.S2_FFN+.7R^74F!%8,1RN1@8P3CGR?X5
M?#SQ!\4_V=/#GAB.\TJT\.P:[)=WMP9)#=J$)S$L84J2=V=Q=< CY3C)^RKZ
MQLM2L)]/U*SAO;2X4QS6]Q&)(Y5/4,IR"#Z&L_0_"OACPP9U\->'-+T43X\X
M:?9QV_FXSC=L SC)QGU--:-M]DON!ZI6[MGD=W\,O'J_'W7/B)8PZ!)I]YI+
MZ7;6TFH3)*/D 1WQ;L!DJ,@$X!ZG&#M_!;P#XL^'/PIE\(ZS<Z9]NBEEDM;J
MQEDF0[^065XTQANPSD>E>NTE*VC7=?U^8NWE_P ,?+5E\!?B4WB7P=XHU[6M
M#U37='U>2_U"\DNIS)>1,R%%#&+Y=H0@)@*,\=37>Z5\-/%WA_XH_$/Q5IMQ
MI%Y9>*8$,$5Q-+%)'*J$;&VQL N6SO!8X'W>>/:.*6CI;U_$?6_I^!\P>'OV
M>O%FE_"K0]"O+[1D\1>&M=&M:=/#/+);S\J6BES$K(#M'(#=!]*W=2^#'BC5
M-/\ B3K4\NDCQ1XVB2T2W%U*;2QA4 ?ZWRM\C84'_5J,@#CK7T$>E)3>H+2U
MCYHT+X*_$;3_ !G\,=:O&\.&V\'6?V&=8M0G+W"DN"Z@VX (5P=I/)&,CK7L
M'Q0T+Q#XJ^&^K>&?#<.GO<ZI ]H\E_=/ D*,I!<;(I"Q!Q\OR_7C![>@&B7O
M*S!:2YCYNM/@U\2KKX'Z9\'M2O\ P_I>D1,?MVIV=S/=3W"><90B1-#&J<GD
MEVZ=.:ZKQ7\*O$=TO@CP[X3U*RA\%:&@BU#2;R21/M@4 (6**?-'4E&PI/7.
M>/9^]&:3UOYN[%L?+]E^SQXPC_9OUGX876K:.-1FU0:A9W*22F%ERGRR9C!0
M_*>@;K79>)/A=XRNO'G@KXD>'[S2(_$>AVWV*]L+F65+6Y@(8%5E",P(#L,E
M.>#@8P?;Z.].[O<+?UZG#^*-/^)E_%X=?POKFDZ1+%?)+J\<L1F66V_BBC9D
M))[9PA/7*]*[FBB@9PWB+3O%UUX_\.ZKI.FZ1/IFF^;YKW.HRPS-YJ[6VHMN
MZ_*!D9<;CQ\O6L75/A/ _P 8M%^(6A7G]GNDYDU>R&1%?$0R)'+@#'FKYA&3
MU!/.1SZEQBBC:P;W1XTOPW\7Z98>+O".AW6DGPQXEN+BX6YN9)5NM-^T#$ZK
M$$*3#DE<NF">=V*6U\ ^+M#^+-MXBT+3]$?0M-\.#0+*"?49HYV"D.COBW91
M\P"D G ^;)/RU[)2=ZG_ (;] >NY\[Z!\(_B=X9\'^&9M"U;P]8^+?#DEW"A
MDDFN++4+6XE$K1RGRT>,AL8V@].HSQ[3X6B\61:$I\9WNG7&L2-ND&EPO';0
MC &Q-Y+MT)W-U)Z 8%=#15AN[A1112 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKBOB!XYB\$:18216/]I:OJ]['INF60D$8GN)/N
M[FYVH.26P<#ZT =K17GUQ<?%72=/&H7(\.ZVQ=/-L;&UN+=X4+@.RR-))YQ5
M23C9'G'X5T_B*37TT*?_ (1F*U;5F9%A-XI:% 74,[@,I(52QP&!..*0;FS1
M7C5MXD^*EW\5-8\"QZ[X4$FG:;#J"W;:%<@2F1F4(5^V_+C;][)Z]*]+L-0N
M[7PC;:IXG2"QNXK-9[\1G,4+A,R;3D_*#G')XIW5KAUY39]Z/>O+_"_BCQ[X
M^T2/Q9H/]BZ'H-RS-8P:A:2W5S=1!B [LDT:P[L<#$F 03Z4NK_$C6="T31;
M/4?#L2>,==U&73;'2TN&,.5D8><TI4$Q",*Y8+DY P,\%GMU#S/4.U%>5^)/
M&7C+X<Z;!XC\92:+JWAWSHX;Z33;.:TFT\.P428>643(&(!QL..0#TJ#6?%G
MC[_A<FG^"]$U;P]%IVIZ;+J5O<W&DSSO&J,J["5ND#YW9W +CT/6A:_U\P>A
MZU2UY?X&\:>)?%UEXKT>\BT[3O$?AV].GR7<4,D]G,^ P=8RZ-TZIOR./FKA
MK'XO?$.U^#-G\6M8C\/7VD>>4O-,M;.:WN$C^T&#='*T\BNV<':4'7&:/^!^
M(O\ ,^B?2BO-/^$XUKQ3XYU7PIX$6QMUT-8O[2U74H))XTED&Y88X4>,NP ^
M8EUV],&C3?'&NQ>.KKX;^)/[.M?$DMBU]I>H6\,C6MY&"5),)?<C*1DIYAR.
MC"D,]+[T8YKY]M/B7\4&^'?BKQO+<>%;BW\,ZA=VL]A_9]Q;M<QV[89EF-RX
M1F'12C#/&:]MT'5X]=\,Z9KJ0R6\5_:QW:Q2C#1AT#8;W&:.EP>CL:M%>7>!
M_B5J'B7X@Z]X<U/3H;.V%O'J6ARH&W7MB6:,RMDGG>H(P!\KKQWIOQ%\0_$C
MPQH'BGQ1IEQH$&DZ/;^?:6]W833S78$8+DR)<H$&XE1\A/&?3)LKC6KL>HD<
MYI>U>76^H?%8Z&FK2:IX8EM9]*-ZLZ:3.GV>8;'$;(;LF160N-P*X*@D'H</
M1OBYKD/PE\,^)M<M].U/Q!XMGBMM)TRPA>U02/QB1VDE)5<%F< 8&!MS3=]?
ME^.Q-]O,]MI:\L\3>+/'?P]T+_A+/%#:)K&A0.@U"+3;2:UGLHV8+YB,\L@G
M"EAD;8R1R/2LKQ1\6-8\#^.M)DUI;'4_ NK6S7(U"PM9$GTU-\:I),3(RR1D
MR+EE5<;NG&"EJ[?U<?2Y[317!:YK7BA?&WAFQ\/ZMHHT?6$DD8SZ?)<2%8U#
MDI(EPBX92 /E..OS=*M_$OQD? 'P[U3Q4EF+Q[0(J1MD)N=U0,Y )"C=DGT%
M#T6H+78[&DK@=%U3QQ<RZ4TE[X>UW2]2CD<:OI4$J1P,$)0>699!(A;^,2+T
MQM!((Q/"WC/QM!\6-5\%?$.YT*W"6?VS3)+"RFA74(@?G</).X4I_%'M)YSN
MP.3R%NM#UJBO)(?&GCC2O 7B/X@>(O[)U#1+*VGN=-M-/T^:WN+J)?\ 5RNS
MS2!%8#. I^4AB1RM:/A?Q+XTU:Q\/:PMUX<\0:-JT@\^;28Y8S8*8V;J9)!+
MA@$)_=X)^[V!N/8]*.**\5\5^*_BQX9_X1EKB\\,1'Q!KD>E+;-I,\C6:2%R
MKLXNP)&"J,@!1DG!XJ3Q[XJ^*?@7X<Z_XCNKGPU=3:7/$8'739UCO(9"B8*?
M:BT3J[-SN8$8P!UH6OWV#K8]FHKS]+CXAV>N:/;WGB#PWJ,5W(6FM+?2)[6;
MR0/GD1VNY%^4LF05Y!..<5SG@OXE>)+CXM:SX!\:1:;\A<:5J%A;R6Z7C1!3
M-&R/+)AP)$8 -TR::U=NO^0KZ<Q['BC%>1?$7XC>(M$^(7A;P9X4BT]9-6NA
M;WM]?V\EPEJ75FC5422,LQ$;D_-P-O\ >%>L1>=Y*"5E:3 W%5V@GO@9./S-
M):ZC>CL34444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9!Z' &X-C=R">*U+'Q9-H_A[4?&3>-H?%_@RSTV6Z6]1(/M!F4@E&:$*AXX
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M*@M]X\FJ7PDT[Q3I&O>-6U_PCJ&D0:UK,VJVL\]Q:R+Y;*BB-A%,[!^">A7
M^]7KII:+ZW\K"MI;SN>)Z$OC/1/B_P"//%$WPUUVYT_719):^1=:=O\ W$;(
MQ8-=K@$D$=3CJ!TKT3P>^J/HSQWWAD^&[6&4Q65A)-'+*D"@89S&[H"3G"JQ
MP,<UT]%+96&]7<\3\3Z_\6W\<%]/^"LNNZ)IKYL3-X@L[42RCC[0R$N>/X 2
M,9)(W8V[-UI'BG1_'MCX_M= _MFZO=&33-6TZQFCB>*5&\Q)(S,ZJ4!9U(W
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M,-R#STQ6/X[_ +=;7?"LND^$]2UJ'3]0^W7$MI-:H$7R)HMN)IHR6S(IX&,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%<8_Q4^&,<C1R_$;PNCH2K*VKVX((Z@C?1#\4/AY<Z
MMIFDZ?XRTK4;W59&BM(K&X6Y\UE&2,Q[@N .IP*%KL#T.SHHHH ***A::)9D
MA:5%DDR44L 6QUP.^,B@":BH8YHIGD6.57,3;'"L#M; .#Z'!!_$5-0 45A>
M)_%7A[P;H4NM^)]6ATO3HR%,TV>6/10 "6)YX )K6AN(KFUBN(6WQ2J'1L8R
M",@\T;@3]J**Y[6?&7AG0-;TG1=7UB"UU+6)?)L;4Y:2=L@<  X&2.3@>]'D
M!T-%%<\WC#PS_P )H/!:ZQ WB#[.;DV* LZ1C'S-@87J, D$YXH\@.AHHHH
M**** "BBB@ HHJ'SXO/-OYB^:%WF/<-VW.,X]* )J*S(=8TVZUJZT>VNUFOK
M1%>XCC!;R=WW0S 85B.0I.<<XQS1=ZSIMAJ5CIU[=+;W-^S+;+("%E91DH&Q
MMW8Y"YR0"0#@X -.BBB@ HHHH **** "BN7\2>//#'A.39KE_+$RQ&XD2WM)
MKEH8@<>;((D8QQYR-[87(ZU1'Q3\ MX;TCQ%_P )'"-,UFX^RZ?,T<@:YEWE
M-JH5W'YAUQCOTYH6NP/0[6EHK/U?6-,T'1[G5]9OHK&PMD\R:XF;:J+[FDW;
M<#0HK,T76]-\1:'9ZYHUT+K3[V(36\P5E\Q#T.& (_$5I&GY +16?JFJ66BZ
M/>:QJ4_DV5E"]Q/+M+;$4$L<*"3@ \ $TD&JZ?<6-M?1W<8M[F'[1%(YV;H]
MH;=AL'&""?3O2 T:*P/#/B[P[XSTN35?#&J1ZI8QS-;F>$,$+KC(!(&>HY&1
M[UOT]@"BN;O_ !MX4T[7M'T&[URW74]9&;"V0EVN%P3N&T'"X!^8X'O729H\
MP"BBL6Q\3^'-6U:\T?3/$&FWVI61(NK.VNXY)H,'!WHI++@\<@<T ;5%8%YX
MR\(Z=KL7A_4/%&D6>KS%%CL)KZ)+ARW"@1EMQSVXYK?I>8!1113 **R=>U[2
M/#.AW.N:[J$.GZ=:@-+<3MM5<D ?B20 .Y-3:5JEEK>CV6L:9-Y]C?0I<6\N
MTKOC90RMA@",@C@@&C<#0HHK"F\7>%;?7#H5QXFTJ+5PN\V#WD:SA<9SY9;=
MC'/2@#=HIJLKH&5@RD9!'((IU !1110 45#YT;7#6_F*944.R;OF .0"1Z'!
M_(U-0 4444 %%%5+Z^L],TZ?4=0NH[6SMHVEFFE8*D: 9+$GH * +=%<WX?\
M:>'O$U[>V.DW5PUW8A&G@NK.>UD57SL8+,BEE;!PPR#CK6S>7MII]E+>7UU#
M:6T*EY)IY B(OJ6/ 'UH>FX+4MT5D:3XD\.^((5N-!U[3M6@;=MDLKJ.=3MP
M&P4)Z;AGTR/6M&":*>/S(9%D3)7<C C(."./0@C\* )J*AFFA@C,DTJQH" 6
M9@ ,G Y/O4U !114,T\-O ]Q<2I#%&I9Y'8*J@=22>@H FHKG])\9^$=>:5-
M"\5:/JK1,JR+97T4Q0L<*#M8X)/ ]3704 %%%% !1110 4444 %%96NZ[I?A
MG0KK7-<NOLFG6BAIIO+9]@) '"@D\D=!6FI#*&'(/- #J*Y^?Q=X;M?&-GX.
MFUB%=?NX6GBL1EI&C4$EC@84<'KC..*Z"@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3D2!QR<8S23_  5\(7UGXHL]5FU34H?$S1S7BW-R#MF15 EC*J-KY4'N!R%
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M,20C)1%5K8XV%L@DDG'S%N<XJ_ C2(_ -EX(C\:>*(])L;[[?"%DM!(L@?S
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MV_/[L!.,# S]XEC5G^!'AF]L_$%IJVNZ[J2:Y>KJ4CRS01O;7:\+/"T42%&
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MK4A7ZBT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I#G:<<GWXI::Q"J68X Y.>U)@>/V
M7Q+\>:CJWBW2[3X?Z1/-X7>-+M(_$4FZ;?'Y@\G=: $[?[Q3GOWKM/"OCS0/
M%7P\LO'4%TMAI%S"9GDO76,0;6*N'8G PP(SG'%?/MCYOC3Q]\7;?P'\0(5O
M;J>UFM]/M+R#RM6B2!1(OF*IE4=4WQ.H4MSFM'Q#XP\+W'PS\+'P8]YI&E>%
MM1C;6]&L(8YK_28U21-SPS)(&$<I!+LK D;@<C(+Z)O>R_X(6U]+GT19>(M
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M*9& \X9)*CC!6M:?Q;X<2Z73XO$VCKJ<]J;NWMI;V/=)%M+"4+NW&/ )W#C
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M[VXT7X>WGA&YO/%'B[1_ )T66QT_5Y=-@GEB<SLQ699;5RBR1E-@$:L54 C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD&BRVFA3^++-+"[_ +2?==1^:?FEM@ @#; R,2[ #HF[!]3^,/B+7?"_P?\
M$.N^'%M_M]K;DB2=RODJ>"ZX4[F&> <#/4\8*V5WWM^0TKR4>YZ#WHKSA?&G
MB82V?AZP\-:?J7B>/3QJ%Y;_ -K.EO#$6*QXF,&YI'*G"F, 8.6 P3T?@OQ9
M8^-/"EMK]C!-;+*SQ2V\X DMY48I)&V.,AE(XZT[$7V.FHHHH*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ),/GA/*\P '*;MP]*3]Y_*PEHM#S:P^'GQ&L[7X5P-;^&V_X0P,ETPU&?\
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M#9.3Q@8R?3Z*7;R#OYGCMUX+\?MX\\?:Y;6N@-:>(M,BL+-)-0G5XVC5U5I
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M:O4*0]:+[,5M+'"_%7PSKWC'X7:SX7\/_8!>ZE&(/,OIGBCC3();Y$<D\<#
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MX KW&DJ=+6'=WN>,6G@?XC6/Q+T;Q2MMX<N8=.\.G1O*_M">)I')#AO^/=@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^%=N/AS\3O%'PCD8KI4O_$]T#>?^6$AQ-"O^XXX'7DGO0![?,S)!(ZKN95)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'/@#X@7^M>$/%NGZE;ZVL0U+4?$4+W&H1E6);RBA56#9'WB.@ZXK1U/2-/\
M"/[17PHTOP]:+9V<FD:GIK0Q<!8(D21 ?7Y^>>I.>M>Y4 ?/7PI^"OB30/'5
MWXF\<ZE!=Q6%]>3Z+8V[;D1[AR9+E^!\Y7  Y('T%:OQ%_9UT#QYXCOO$-KX
MDU;P]>ZFJ)J"6DF8;P*H4;D..< #KCVSS7N%% 'CW@7]G/X:^!89S;Z?/JMW
M=6DEE<W&H2E_.B?&]=@P@!QV&?>I-)_9O^#FC:S%JMKX066>!M\:75U-/$I_
MW'8J?Q!KUVB@#QCQ%^SSX3U;Q3<>)?#^L:YX,U.X&9WT&Z%O',W]YDP>?7&
M>O7-9W_#/^O3$QWOQT\=S6YZHE[L8CZ\_P J]XHH XKP!\-/"OPWTB:P\.VL
MIDNI/.NKRZE\VXNG_O._?OP,#D\<FNUHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;4DO[J.W5SZ N0":S+WXB> -.\O^T/''A^S\WF/S]3@CWC ;C+<\,I^C#UH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6:,K+<=G<N9U.[.X J00,4)W_KU_R$]/Z_KN>XS?#WP!-;RV\W@7P_+!-/\
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M?=QTKP&Z^/7CF"#7;BSL- U"*WLH]0LI_*N((FC:\^S\%G+S#E?FV0@D-@$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M');75J_@C06M[R03W$1TV$I/(,X=QMPS#)Y//)JYH_A'PKX>%R- \,Z5I(O
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>skye_ex31img15.jpg
<TEXT>
begin 644 skye_ex31img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M\=I?^&1?BUC[NC=^!>'_ .)K]!Z.U2!^>0_9*^+Q_P"732Q];X?X4T_LF_&
M=+'36YQQ?+7Z'T50'YVR?LH?&)?NZ5I[\?PWR?UQ4!_97^,W_0OVO_@PA_\
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M1GX>ZYR<<6;'^E-;X,_%@?\ -/==_P# )_\ "OU* Q2T ?E?_P *<^*@R/\
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ME?FP*_2G]FQ@W[.OA;'9)Q_Y'DH ]=HHHH *AG_X]Y/]TU-4,_\ Q[R?[IH
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MF^+GBY-3NK=[J&/^S]/V21HP5R)/L.S(++E=V?F!Q@UK?\(=XB_Z*QXJ_P#
M;2O_ )"KQNZ\'?$N](F;1/% -K-JEOIK/X@B2\MX[@0-;N\ZW#,T:/$^Y2S'
ME1M8<5%J_A#X[M<>)#+JFN:A<RVTL=D^F7J6\$K%(_*8,U['Y+(ZDG;;C<"X
M9G# 4+I?M?\ X ?YV/:O^$-\1?\ 16/%7_@-I7_R%1_PAOB+_HK'BK_P&TK_
M .0JW=!LVLM!L[=A>!Q&&D%[<&XF#M\S!G+-D@D]"5'1> *UNU&PD[G&?\(;
MXB_Z*QXJ_P# ;2O_ )"H_P"$-\1?]%8\5?\ @-I7_P A5V=% SC/^$-\1?\
M16/%7_@-I7_R%1_PAOB+_HK'BK_P&TK_ .0J[.B@#C/^$-\1?]%8\5?^ VE?
M_(5'_"&^(O\ HK'BK_P&TK_Y"KLZ* .,_P"$-\1?]%8\5?\ @-I7_P A5DWE
MGXD\-^+_  <DGC[6M9M=5U26RN;6_M[%8V06-U,"##;1N"'A0_>QC((.:])K
MB_&7_(W?#C_L8)?_ $U7] ':4444 %%%% !1110!XU^T1;)=?#O3D8Q+C4XV
M_>MM'^JE]CS15/\ :9"M\,M-SS_Q-H^./^>,U% 'YTK7Z6_LXQ^5^SMX4&T+
MF*5N.^9G.:_--:_3#]G7/_#/'A//_/"3K_UU>@#U:BBB@ J*;_4/]#4M0W'_
M ![R?[IH&2BEI%Z4M @HHHH **** "BBB@ HHHH **** "BBB@!,<YI:** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **.]% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7&?#3_D4;[_ +&#6_\ TZW5=G7COA/QS9^&='U&UUK1]92T.N:R
M\-_9:?->Q2DZK=Y0B!69&!'\0 .1@GD  Z_Q?KNJ6DBZ3H<T%I<_99;ZZO[B
M/S([&WCZMLR-SL>%!('RNQSMVG9\+7U]J?@W1-2U-!%?75C!/<(HVA9&C5F
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MB+_HD_BK_P "=*_^3:/^$R\1?]$G\5?^!.E?_)M '9T5QG_"9>(O^B3^*O\
MP)TK_P"3:/\ A,O$7_1)_%7_ ($Z5_\ )M '9T5QG_"9>(O^B3^*O_ G2O\
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MTWQRLFUG*!<@%2WS =<]ZSHKR73XKN2WU*S L)T\A%=PTS'($L61P1USP<4
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MP/0@]Q0!+1110 45RT7CWPG-XBU/0$UE!J&F0O<72O%(D<:)C>?,*A&V[EW
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M$)4$JRGH " ,5]D8HQ1<370\9_X:B^!/_0]?^4R\_P#C-'_#4?P)_P"AZ_\
M*9>?_&:]GHI#/&/^&H_@3_T/7_E,O/\ XS1_PU'\"?\ H>O_ "F7G_QFO9Z*
M /&/^&H_@3_T/7_E,O/_ (S1_P -1_ G_H>O_*9>?_&:]GHH \8_X:C^!/\
MT/7_ )3+S_XS1_PU'\"?^AZ_\IEY_P#&:]GHH \8_P"&H_@3_P!#U_Y3+S_X
MS1_PU'\"?^AZ_P#*9>?_ !FO9Z* /&/^&H_@3_T/7_E,O/\ XS5-/C)\-_B)
M\2/ &B>#_$G]IW\&L3W4D7V.>';$--O5+9DC4=748SGFO<ZXOQE_R-WPX_[&
M"7_TU7] ':4444 %%%% "#K2'K3J0F@#YB_;-=1\+-!# _\ (87_ -$2T4S]
MLQR/ACH"[MJ_VN#S_P!<9/\ Z]%4!\,CK7ZA_!$?\6(\&_)L_P");%QC':OR
M\'6OU%^">1\"O!H(Y_LV+^52!Z%1110 5#/_ ,>\G^Z:FJ&?_CWD_P!TT 2K
MTI:0=*6@ HHHH **** "H+B:*UMY+B>18X8U+N[' 4#DDU/VKP7]I+QU'H/@
M5?"EO,JW_B &)COP8K<8\QC['[N?<]<4T!\^_&+XCW/Q.\83MIZS7.@:4#]B
MCAZ2 'YKA@>GISVQ[UQWVNST_2R]C>27-K)_K;"_MU82 A1)MD7H00,=".#U
MQ4UC')ING6TU]I\$]M<+EH;M/)8*,[725N#U)(&02<$'-9!Q=;V:TORLB_9[
M22UB!!N5"E$8X 8XP6QR>.O6J 9H]KY]Q8W0M4U")[CRFTF"5DN77!YW 95?
M>O8/#_PM;^PK&U\474CVT4[7$-A:R)&("_&UY0-S<<=?7%1>&(=8T#XGQ6^N
MZ/?6MUJ]K)(U]=PA?MDVU6^3Y?E VMQWX]J]<CBMU>!KABJ3-Y:LP^1RN<A>
M.2.>F<4[ :?A_P"&?@_3!#;V'ARQ1QC#R1"1STY+-DC\Z] C\">&3;LDND6;
MB3'F+Y"@./0TF@WMC/#$H5E<Y*L8V ?! X)'N!^==0)(U.&?#8SC//Y4F!Y+
MXD_9_P#AWKL,@72WTF63AGT]_)SZ94?*?RKYU^)'PC\1^$KG5=9N+637+618
MUM[ZUVPBUVX4M+&% ;Y1C(X[GK7W$3'\PQ@GYLL".:YSQ*ME+I9W^7*?3J&!
M_'D4+4#\_P"/4SIDE_ILEU;W3&(1O=61$HG C&U2S9^09Y&!RH] 1%)#J,ZO
MJTD<H;S-WFG"R;@N_P Q<#@ <YX_2O2/B9X7M=&N;B]LYY;;PK<7!N;F&TME
M9H+HH0K#/\+' ()&,G'6O.].G!B:VU:[DLQ;[)_L@MM\UP0" O*X "'OQ@]#
M3 ^Q_@'\5+CQSH%QHNO2Q_V_I04.P;)N8> LOUSPV.^/6O;J_-SPSXMG\">/
M+#Q/H[W$,$<P\V&5,!HF(\V/_: Z \'@' K]&K&\M]0T^WOK619;>XC66-U/
M#*PR#^1J6!:[UGZO<:?:Z+>W&K-&MA'"[W!E&4$84EMWMC-:%<YXUCEF\!:]
M%#HYUEWL95_L\2>6;D%"#&&P<$C@>]2!Y;X(USX$ZUXOLK'P[X4L-*ULI]HL
MC/HOV5YE SOB8H,\<YR#7K>G^'= TO39],TW2+.SLIV=IK>"%420O]XLH&"3
MWKY-\(RZX?'7AF'P'_PDFL);6MP)K;Q/IP<Z*/+P!%<,JX)(487@\9[@0_#<
M^/FO[Q])U35SKHT.];4K>:TN<F[P1&)'FDV>;NQM*#&./I5@/K71_"WAOP_Y
MPT31;/3_ #52*7[/"J;U0813@<@#@#M6)>?"KX;ZA:6MK>>#=*FM[3?Y$;6Z
MXBWMN;'IEN:^:8=8D_X5SXB7PK<>.7U=?#L3:A+<33>5'>^:BM@.-PE)S]PX
MVYXI_P 0-/\ %'A!O"5@OB+7XM OM->[N;J[N[N3-^R<JS1'>.Q53QDGWHL!
M]$MX4^%FDW>D^$5T'2+6::<ZC9V*0!2TD7)FP!U7@9/KBNBUSPEX;\27%M<:
MWI-O?2VJ2QPO*N3&LB[9 #Z,O!]J^30EWI_C#X:>)O'&I:[<7G]B7!CN )X9
MIYEE8P1$')#,&4'/#<9'-5/ OC+Q5)K&LRKK>K>5-X6OKCRI;ZYG9+I1E=QD
M55$H'/[L8HL!]<7G@WPQJ%EI5C>:1;R6^CR)+8I@C[,R#"E,'C J2R\(^';#
M0;S0[72+:/3KYI6N;<+E)C)GS"V>N[)S7SE>W'B?X:_"[P=\4X?%'B#76G6)
MM4L[^\>6,B> JNU#C&V3;C/->Q^'X?%VE? *.::XNK_Q8=*EN\SG?)]I=6D5
M,,2/E8A0.G I =)=>#?"LG@M?"=QI,!T"%4VV>2J*$8.O0YP& -<U8R?"OXK
M7_\ ;.GFVURYT(O:BZC\Q/*WJ0RAOEW@C/J*\"\.^*M8UJ]\,V>D>,O$>K7^
MI:;>?\)5;SSOLLB(VY7*@0L&R%QQP/Q]4_9_TQ=-_9PLKDB]O!=P3SO;M+N/
M5ALC&/ER%Z>II@=9X7\??">X>U\!>&_$6F3FVB%G!8I(6#(HQL4MP_ [$YIO
MA?X7_"G3/$4OB'PQH]DU_:2R0^9%<-,EK(>755+%8VYZ  C-?,OAR[TO3]3\
M!6GAS6X/%4 U-%A\.WFG>5J&D;F)D?S8\$E3R2W!X..*DTOQ0G@WP)J6FZ?X
MRU=-7O/%-S!-:QZA#;F)%9\/)+(A\O?@$OSN(XP,T6 ^C+SX-_"JWU(WUS8R
MV=U?7AEW+JMQ#YL[MN("B0#)/8"M#Q%\'? WBC6)=8U#3[FWOYU6.XFL;R6V
M-RBC 60(P#<>HS[U\S6NN:IXJTCX=Z[XF\<7]M':^*;JS:[-S&1 BKN1C+M
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M8],*3QCMV[>=>/H]>UCXQ7-\O@J?3[G3]=M9I9;;3IIY9XT8*9_M!X"<#"*
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M]2TW5;(7VFWL-Y;,2!-!('0XZ\CBOD[3/A;KVJ:CX0_M/P1<6?AJX\3WE_\
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M?_0Y>%?_  F;G_Y/H_L[XI_]#EX5_P#"9N?_ )/H [2BN+_L[XI_]#EX5_\
M"9N?_D^C^SOBG_T.7A7_ ,)FY_\ D^@#M**XO^SOBG_T.7A7_P )FY_^3Z/[
M.^*?_0Y>%?\ PF;G_P"3Z .THKB_[.^*?_0Y>%?_  F;G_Y/H_L[XI_]#EX5
M_P#"9N?_ )/H [2BN+_L[XI_]#EX5_\ "9N?_D^C^SOBG_T.7A7_ ,)FY_\
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MO"O_ (3-S_\ )] ':5Q?C+_D;OAQ_P!C!+_Z:K^C^SOBG_T.7A7_ ,)FY_\
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MW1(]:AUW[/-_Q_1$E#A<-@G)Z@D\D<UAWD.FPJJ6-S*Z>4OF&4 %9.K 8SD
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ML9[;S(U"E K!&7*DG<"02,4@*=[\0'\+S1?%(_ _4!J&J6+R:E?I<;C:HC[
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MLX9[7@>3)&&3 ((X/'! _*K@&!@<"EHH **** "BBB@ HHHH **** "BBB@
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MN=0N4BT6X"M%;V2F&!./]6W<L,8^8GU%<C_PD2+HUOIZA'FA@ELC(HW&2%I
MZ@+ZJP)!XZBN[\-_!WXI^-+?;8Z+)I>G2QH!/JK&WC8)@ [ "Q/<'&.*5P//
M9-7F_L-;":S@2$2M,)EC'G,Q&,$]=O3CH.:^AO@9\"KC6+FV\:>-;%[;3X9!
M)8Z7."&F93GS)%(^[G&%/7'/'7TOX;?LZ>&_"4D.L>(VC\0ZZK%UDDCQ!">,
M%(SG)&/O'GTQ7NJJ$0+V'%2 D:JJA5  '0#M3Z**0!7&?$W6=9\._#36=>T%
M(9+S3HA=;)D+*T:,&D&!WV!L5V=4-8TV/6-#OM*FQY5Y ]N^1GY64J?YT >
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MQ7)_&#7[#2?%WQ%T[4-$TR^OM;TJU99+N\B$VG.(0#&H8!F.<,/+SDXYZX+
M?6=]XM\,:6]FNI>(-.LFOL&V$]TB&?/39D_-^%7/[6T[SKF'[=;^9:*'N%\Q
M<PJ02"PS\HP#R?2OFG4O!/BBRN]6N)?A[_PF$?B#P[9V-E,7A5M,DC@V,K>8
M<J"Q#[E]/6I/%WPC\>PW/A?3_#;M*FMZ3;Z'XJNHI@F8XFC)E)."<H'3/)(X
MQS0!].0S17$"3P2+)$ZAD=#E6!Y!!'45-56SM8+"Q@L[6,1001K%'&O1548
M'X"K5( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BD%+0 4444 %%%% !1_.BDQS0 O-%%% !1110 4444 %%%% !1110
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MGFX'_/Q*,?\ D*GK^U_KF?G^%-Q@#G%X_P#\9KZU\F/',:G\*/)B'2-?RIW
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MZW$P/_H?O3 KQ_M-?!E\_P#%6%<?WK*<?^R583]I'X-2(&'C*)?9K6<'_P!
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MU?B%>#_MS4C_ -#IG_#&4(''Q$N1C_IP'_QRD!]9?;+4]+B,_P# A3OM-O\
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M>._#>I>'[NTUB]:Y^SVDB_/+NA0+@9[D$?A3H?A_XM;]AV3PF="N(]>4M/\
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MO!7A"W\&>(O &HGQ'I,"V2#=M64H-JE@1D< =,YZCK73:=I/Q>\<?LU^,O\
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M.3UP.:[7QO\ %CXB_#OX$:1)XHLH(/'FIS/9HPV2( O/G$+\N[:5XZ9/3'%
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MWS^0KT;:*=P/SAN?!OB#6/AE!I.B_!+5K?6]/D$FI:S)%,TL^"0%1&ZYW D
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M"*[FY6U@0RR[?[Q4=![FOEKX6>&]*^%G[2C>$OB!IL5U?2G&CZK(2(]QSL<
M\9;[N>JL,>]3LOB:?]L/QC]AT_1+W555Q:PZY(4C\O"!3'@$EMN,8[%J>X'U
MAX7^(GA+QAX:D\1:%K,$^G0AC/(YV&#:"3O#8*\#//:N1/[1_P 'EU/^S_\
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M;=2^&O@2/]B^'Q5%IMLNN"TCN_[2QB1I6E *9SR,$KCIWKWG]FW(_9X\+_\
M7.;_ -'R4@/1O$^NVGAKPIJGB"]($&GVTEPX)QG:I./QZ?C7SA\!/V@O$GQ
M^(UQX;\5)8I'/:M+:-!'Y9WJ1E>ISE<G_@-2?M>^-6TWPCIG@JTD(N-7D\ZX
M5.ODH1@8]VQ_WR:\"\1?$/P]:^(O .N>#]*O].N/#,$5M.;N!(Q<!#NSE#R3
ME\Y]: /T3O=2T_38TDU"^M[1';:K3R! Q]!D\FN-\8_%7PIX1\,ZWJW]J66H
MW.DINDL+>ZC,Q8D +C.1R?2O%_VKM0AUKX.^$KRP;,%]J44L3#H5:!ROTX-8
M?Q#_ &?/!7@KX%:[XFC^V:AK,=I;R"XGE^Y+O =U '1MYR#GH* /78_BCX@\
M1?L__P#"=>$].TU]?E4,NGRW 9(LS;,,Q*\[>>2.:]&\-:KJ%UX(TK5/$<=O
M9ZA-:I+=I$X\N-RN6 .2,#ZFOD23PGHVA?L*7>NV$$D=_K@MI;R0R$^85NL+
MP>  /2F?$B[U#6/"/P/^'_VZ:PTK6;.V%T8WVB3=Y:#([X!)&>YH ^S--US2
M-8B:32M3M+Y%.&:WF60 ^^TFO,O"_P 4]5UW]HCQ3\-;C3;:*QT:U-Q'<HS>
M8YS%P1T_Y:'\A7*V/[/VD^$/BEHGB/P+XI?P[! %^TZ?*6F^V , R@E@<,#C
MO@X(%<#8:S=:#^TS\9]<LR&NK#0KB>(LNX;E\C&0/<4P/K>;6--@O8[&6^MT
MNI/NPF50Y_X#G-6GGC2/>[!5QDD] *_.31+/PQX@\ ZEK>M:9XTU3QK=22S0
M:G:6[20+(/N N"<\CDXR,^U=OXEA^*?C']F_PG-)8ZQ>#2[JY@U2##K<3Q@K
MY;D$98!2PS@X//K1H!]NVFIV&H;OL%W%<A3AC$X< ^^#5ZO@_P"&&K_#>/XP
M:%<^']1U[P!>AT@FT^Y'VF"]<MM\LN6!7=G'S+@'I@U]V;P%);@#O2 DHS7D
M,OQ4UR\;1D\,^$X;YM8%[-;_ &O4!; V]O(J"7.QOO[LA>P(J?PO\6O^$D\6
M:/X?&AM:SW<=\+EA=+*L$EM(J,%(&)%8MPV1]*+ >KT=:\4O/C5J":U_9&D^
M$TO;U]9O-(C2;45@0_9T5S)N*$#(;I[4?\+QW>'6G;PTT>M+K)T,VDE]&MN)
MPI?/V@C;L(&,XSDXQ18#VNBO--+^(E]-=:)9:OX5NM,U#4M4?2W1IQ)$I6W>
M<2QN!B5"$ R ,$G/2K6O?$FUT*W\7O)I<\[^'?LR+'&V6O)9U!CC08X)+*O?
MK18#T&BO(]6^.'A_1? WA;QA>V5PMAKMTMK)@C=9-\V_>.^PJP./0UK:U\1+
MRQU;5['0_"UQKS:5#!<SO!=1QKY<J2,&!<\X$?;KNHL!Z-17 >$O'6M^*O#$
M^O'P1>Z?$ULES8Q2W43->AE+ +@_+_#]['WO:L'3_C#?W.L:G9:EX#U'2K?1
ML'5;J:[@9+)3%YH8[6RPV<\9HL!Z[17D^C?&%=2O-*GO?"&KZ3H&LRI#I^KW
M/E^7*S_ZO>H8M&'.-I/7(]:Z'Q'\1M#\+^.O#OA35O,BN->$GV>? \M64J K
M'U8M@4 =OFBO*+[XR:?;:A]@T_PSK&K7K:E=:6MO:K'N9[=%9VRS@;<-QSGK
M4W_"Y-$/A0ZR-#U?[8NI#1SI'DJ+K[41GR\;MOW><[L8HL!ZC17'^$?&L7BR
MRU&3^Q]1TJ^TV8P75A>QA98WVAA@@E6!4@@@XYKG;'XS:+<7.IPZAX>\0:-_
M9E@^HW#:C8^4%A7C/WB22> ,<D'TI >HYH[UQW@OQWIWC2&^6VL-0TR]L)%C
MN;+48/)FCW+N0[<D8(Z'-/O?B'X4T_Q#J>AW>J)'=Z78'4KS@E;>$$#+-T!Y
MSCKB@#KZ*\JL_CAX.O/#UWJR0ZJLEM-%#_9[6+_:Y#+S$5CZL' )!Z<<XKH=
M&^(WAK7)-&6RFN VK_:%MQ- T962 @2Q.#RD@Y.T]0I]* .THI <@&EH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY^_
M:V8CX*0KV;5;<'\GKZ!KYZ_:X)_X4W9 =&U>W'_CLE 'N>AC'AW31QQ;1=.G
MW!6E5+2@%T:R5>@@0#_OD5=H **** "BCO10!\/_ +9\J_\ "?>&8BV"NG.V
M/K*?\**9^V=M_P"%B^&_O _V6>1T/[UJ* /E^'_7IT^\.M?KW;<6<../D7^5
M?D+;C=<1J.I8#]:_7NV7;:0J>R <_2@"9>E+2"EH *AN/^/>3_=-35#/_P >
M\G^Z: )5Z4M(O2EH *^=?VH<O:?#Z'&=_B*'OCG'_P!>OHJOG7]IK#7_ ,,X
M6/W_ !%%QZ\K_C0!]$CI2T#I10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %'>BB@ HHJM>7EM8V4UY=SI!;P(9)))&"JB@9))/
M08H LUR>F_#[PKI/CK4?&UAIOE:[J2>7<W/FN?,7Y>-N=H^ZO;M7F>I?M5?"
MG3]1>SCO-0OEC;:UQ:VNZ+\"Q!/UQ7I_@WQWX8\>Z*=7\+ZDE];*VR3 *O&V
M,X93R.M,"AXX^%W@[XAM82>)]/>>;3W+V\T,S121YQD;E(..!^58_CCX&^ _
M'UW;7VLV=S!J-NJQB^M)C',ZJ, ,W.[ZGGWJK+\?OAVOQ '@>&\N[G5#=BQW
M06S-$)BVTJ6]FX)P10W[07PT_P"$V_X1&/5II]0\_P"S%HK9WB\P'!&X#L0>
M>G% &QX3^$'@7P;X6O\ P]I>D"6SU%2E\UTWFO<@C&')[8)X& ,FN&;]E?X<
M&Y9([W78-,>3S6TR.^/V=CQV()QQZY]^*]5\'^-_#?CW2)=6\+ZA]NLHIFMV
MD\MX\. "1A@#T(KIJ0'G?BGX0^#/%7PYM_ EQ9O9:39E7M19ML:W900&7.<_
M>;.<YR:Y*Y_9J\#W_P /[/PI>7^JW!LIWN+;4))P9X6<*&4<8VG8ORD<8KW#
M/-+F@#Q#2/V:_ NCZKI&M1WVL3:SIETMT+^6[W23%2"%?(QMXZ#'?FK7C7X!
M^'_&7Q"A\;KKFJZ/J05%G-C(%\X*,#DC*\  ]B.U>R]JYFQ\<>%-2\7W?A&R
MUJ";7+-2\]D P>,#&2<C'\0_.@#SGQW^SWX<\7>)SXHTO6=2\,ZS*-MQ<:<^
MT3CH21Q\Q'&0>>X-;_@_X*^!_"'@?4?"EO8&_@U5-NHSW1W27?&.3VQDX Z'
MGKS7IM% 'S7#^REIOV"]T2\\=ZW<: 2SV6G;\1VKD@[\9VL1S_".M>S_  ^\
M&0> ? FF>%+>\>]BT]759Y$"LP9V;D#_ 'JT]>\3^'_"^G_VAXBUBTTJUW;1
M+=2B,%O09ZGZ5EZ#\2/ GBB^^P^'_%FFZC=8)$$-PI<@=<+U-,#D]8^#%GKW
MQRL/B=J6M33?V?&BV^FF%3&I56P=V<_>;=TZUT/Q+^'NG_$?P)>^%[V06OGE
M)(KI(U=H9%;(8 _D?8FNQEN;> (9IDCWL$7<P&YCT ]S5BD!X)XB^ -YXA^$
M?ACP)<>+LR:!<B:.\>USYB!6 0KOXQN SGH.E>F^.O!MMXU^'.J^#Y[@VZ7U
MOY2S 9*.""K8[X8 X[UUU1B:-I&C5U+KC<H/(S0!\WZ;^SYXP'P7UGX>:UXZ
MANX[EH#88A9HK)4D+LH!(SN)_#%=)XS^ \'BOX9>%O#Z:TUEK_ABWCCLM4C0
M@;E4 Y&<@$JIX.00*]PHHN!\Y>$O@'XKF^(.G^+OBIXS3Q-)I2 6-O$&"JX;
M*EB0. <G&.3C/3GH]$^#$UE\9_&OC+5M0MKW2?$UF]H;-5974.4W!CTZ*?SK
MVJB@#Y2;]GCXJZ+9ZAX3\'_$J&S\'7<K,MO.&\Y$;[RY"_G@@'VR:[/Q3\ [
MB]\":!I'A;QAJ&G:UH;-)#?SSNPN&9MQ\P _W@"#SC&.:]ZHIW ^9]+^!/C_
M ,2?$/1_$_Q9\4Z=J46C,LEO%IT>QI&5@PWG8O&1SUZ=LU](3P+-:2VY8A9$
M*$_48JQ33@<T >(>&?ALNMV'@ZV\4Z3;SV?A6RO-)FM+Z'<9I \2QS)G@J4C
M+ _[0]\;?B/X?:GIOB'PWXB^&MGH]G-HL-Q:?V9<*8+>2*8J6(,:DJP9<].>
M:]5&,<4IZ4@/ ]-^"6I75[H-[XR_LG5F75=0U75;<*S0N]P@5%C##G;M7KBI
M6^%_C31_#UUH.@MH%]H=IJC75CI.HP[H;BUD!9H9CM."CG*,,].:]WHIW \"
MTWX8^.-&T6UU;2H='M=8L=>;5[314F<64$+0&!X%?&02K,V0H&>U3M\,O&WB
MCQ$-0\675OIUE?:B-0O;72[V0/'Y, CME60*"3NRY;CE5XKW8447 \&7X.:M
M;^)+'3XI(KSPE9ZXVJ+'?7#32F.6V=)D;<#NS(<\G^(UK^ _ACK7@V7QO9G4
M?MFGZE%%!I!EE+20PJD@6-SC@*7P#SP/:O8J* .=\&Z3=:)X!T#1;X*+JQT^
M"VEV-D;TC"G![\BN-;X?ZAJFK?%*'43';Z=XLCAAMI$8,R@6@A9B.V&[>U>J
M44@/$K7P]\3->T[P]X2\4:+IMEIVDW=O/>:K#=B4WJV[!XQ'%MRA8JF[=TYQ
M6[XR^'LGB_X@6=QJ%JDFB#1KFRED\S#QS/)&R,HZ@C9D,.A KU"D-.X'S?X8
M^"_B9Y-&M_' ^WQVVK:E?7=Q%=F)Y!(B+%(#&0V6*DD9XSS5X?#KQ1H_@NZ\
M*Q^%;#7M)M-:>Z,,TR"75;5\E6$A(9)XR5&YB-VWK7T'2=J+@>8_"?0/$&AV
M&LKK%G<Z7I]Q="33=+NKW[9+9Q; &!DR?O,"P4$XK.U+P5XDU#P-\09/)3_A
M(/$%Q,L*-*/GM4PD46[HH:-6^AE)/->O_2BBX'B7PY\.:]X3FUJXLO!M[HFG
M:S<6T,-A)>QW4MF5B99+IV+G*YV#:&)XZ5Q<GP/^(EO)K]FVM:;J@U/0[F&2
M]^Q^3+=7+RB0+(VXDDE?O'@#@8KZBHQ2 \#L;?QTVKZ]XXN? -W''=6-GI)T
M@72)=M$AD\Z6,H^ 07&WYE) )!!Q5/2=)NM/L_"?A9].N+"[N/%+ZQIVGW<H
MFN+.QC)>5I7!/4LPY9C^]49)XKZ(Q5;[-;M=+=- AG52BR[1N"D@D ]<$@?D
M* +"]*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3G/M2T4 '>B
MBB@ HHHH *.U%% "9KYY_:Z_Y(_IRDXW:S /_')*^AZ^=_VMS_Q:W1(\D;]=
M@''_ %SDH ]]TP!=)LU'00I_Z"*MU!:KMM(5'0(H_2IZ "BBB@ I.U+10!\-
M_MG-_P 7(\.+NP!I9X_[:M147[9O_)4M ^;'_$H''_;:2B@#YGM3MNX3Z./Y
MU^OD/,$9_P!D?RK\AM/4-J5JIZ&51^HK]>X\"-?H* '8I:** "HIO]1)_NFI
M:AN/^/>3_=- $J]*6D7I2T %?.G[2ASXA^%<8_B\11_^A1]OQKZ+KYQ_:28?
M\)K\(XV&0=?4X[\20]_QH ^CJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HI,BEH **** "BC-(#F@!:*** "O"OVI]7N]+^!-]%:R/']NNH;61
MD.#L))8?0A<?C7N>1UKSWXP>!/\ A8_PQU/PW!.(+M]LUM(P^7S4.Y0?8]">
MV: ,CX2_#OPKH_P>T6Q71;*Y^W6<=Q=R21K*;B1U!))(Y'.!Z#BO#_"=EJG@
M?]ISQSX%\!W$%D-1TV62RC?F&"?RQ)'G.>%+,.G0U<\+?%+XO_#?PG!X)UCX
M3:KK-[81M!;74._84'W1E$8, .X8<8KKO@+\._%B^+M=^+/Q#MVL]=U8M%#9
MNI1HD)!9BN>,X 4'D >]4!XK\$K#XK77B_QK/X/N-'%]%,RZB][&IW3YE*%/
ME.!O!/&.U7_V=8?&S>)/$^H6]OI<VDQ22G5Y)XE>3S!'(4\OC.-W7%>I?LVZ
M#KVC^+/B9<:QHE]IXN[Y6@DNK9HEF'F39VY !ZCIQR*H_LZ:/KNC^&?B8NJ:
M+J%G<SW#-$LULR-+\DGW01\W)[9ZB@";X6?%+^P?V:?$7CJ_TO3X9+"^FCAM
MK*V6VCE<B-4!5?5F&3Z?2L"U^*7[2*^%]/\ B))H-EJ'AZ]F4K86UJ3,8B>"
M%&7"G'#9/4'H:J>#?AYXE\0?L>>)/#?]D7EGJ[:F]Y!:W,+1/,4\MMH# =0I
M [9J3P[\=/%GA_X::'X%\/\ PYU2?Q?8+'9-'=6DABVKP&P,-DCL< =: /1/
MB=\9/%6GWOA;PK\/=%$OB?Q';K>+%>QG-M$02 RDC!X;)/ "'UJ'X<_%;XA+
M\5Q\-OBMIMI:ZC=0&>QN;-<++M!)'!(((#=,$%<$5P'QV\)ZM%XZ\'^/O%VB
MWVHZ8VGI::PNANRO;3#<3M;DA<OQG@[2,C-0_!K0O#/B#XW6NL>%_"WB--*T
M>(RKJ^K7I^\5("[-A!SN.%#=,F@">Z_:"^,>J>//$OA+PEX9LM5N=/O)UA$-
MNSM'!%(RDO\ -@DC:,\<GCDBNTT7PCKW@#QOXO\ CAXN-KLFT19FMK=V\P3B
M.,RJ5(( W(0/F/6LW]G&QN(/C-\5KNZLY8_,OW$<DD3(&'VB4G&1]*]_\</-
M#X%UF2WT'_A('^S.#IH;:;I2,,F<'DC/&.>E(#YDTOX\?';6?#;^,-)\,^']
M1TB*7;):6A,ERJ[L<H)"X^N/?&*^J_#^K'7/#FGZPUG<6+7ENDYMKE"DL)90
M2K*>A%?G5>V?PXB\/2ZMX>U3Q'X9\81,430VC:8*X;  E"J0.._()Z<5][?"
MT^()/A5X<D\5+*-9-E']H\[/F9QQOSSNQC/OF@#YI_:HCNK?XH^%-9\1Z==:
MEX*AC"R002%%9]Y,B[A]UF79SQD#@\<4M!TGX)^,/'GAC5_AGXF_X0?6K*=)
M'L+N%S]I8$$*I9]N>", \YZ5Z%\7OBAXF\ _%:VLO%/A^'4OAM?0A7_T-9=[
M%2""S<9##.T]17A'Q&O_ (;^.O%WA^T^#'A>[M-<EN%WM;PB&)B2-OR \$'D
MMP /T8'8?&+QQXYMOVH='BAT*YN5TB:-M+TT,X2_Y/[T+ZDEER!_ /2O6_'/
MQP\7:+KFC^%/"'@E]:\375DEY>V\@;9:Y7)08QDCG))P..N:\[^+^K6OA?\
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MADMDYSC!SFM+X@:/'H_[.7PXLXI+Y[:ZU.XNH/ML"POY;\CY0S8!SD<]&IV
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MQM]"Q-(#WC<OK2%U4\L!7RA%;>+-/T+7=4T33_&6B:-%X;O)+Q]=O_-$T_E
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MM% 'SUI/_(;L?^OB/_T(5^O"_=%?D5H?_(PZ;_U]1?\ H0K]=5^Z* '4444
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M+AW4G!&!QQ]:]W7Q;X4?F/Q)I;#KD7D9_P#9JF3Q)X=DP$US3WW'C%RAS^M
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M7:*6B@!-HHV@]12T4 -"*.@I=JYSBEHH ;L7/2CRTS]T4ZB@!-HH*J>HI:*
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M<'(ZUX9X5DUR'XG7GB3Q%$TT][XRETF%K?5KC$ 2&4E?+X1HQM7&1SDY P*
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M\2-7\4W=Q##;:18W1MK.$6TB2J Q 9W;Y6) Y4?=/7K0 O\ PNK6%Y?X.>.
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M4]?C]\(F"_\ %:V@S_>CE'_LM>C?V?9GK:PG'3]V*:=-T]L;K*!L="8U/]*
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M8L/D;A6!8X([5ZEX;\.P^'_"-GX>^TRWZ01&.2:<#=,3DL2!P,DG@<#I6?\
M\(WXL4%8_B%?8[&2QMF(_)!3AX=\7!"/^$^NB>Q.GV__ ,33 \W7]G?14ATV
MV&K2^3:ZW+J4H"$&6W8*%M,[N$ CB'N%Z>FUXO\ A/?>(U\47-CKL=E>ZK<V
M%Y:,\&];>2T^Z&&?F!/Y>]=?_8/B]44#QR[$'DMIT.6'X8YJ-M!\;^8=GCM
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MU ];I!C]: .CHKG!XZ\&-]WQ7I)_[?8_\:3_ (3KP5Q_Q5VCX/\ T_1__%4
M=)16!'XT\'S#]SXJTB3_ ';Z(_\ LU3+XH\,OG9XATUL=<7<9Q^M &S166OB
M+P_(,IKFGL/47*'^M.&O:&5W#6+(KZBX3'\Z -*@\"FJRL RG(/<4Z@#R.^;
M/[6NBKZ>%;G_ -*4KURO(KL@_M=:4H[>$YR?_ I:]=H **** $(I,<>].HH
M_/W]KHC_ (7NNTDG^RX,CT^9Z*3]K@_\7Y'3_D%V_3_>>B@#QCP;QX]\/?\
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M1;@/UWAD4^G4=#0!O/\ $.:P\0W^BZ_H?]F36VDG58I#=*Z7"@[713M'S*<
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M@9]NT!BP .<<^G-:5OXZ\/W&OPZ/%<RM-<32VT,OD.(99H@3)&LF-I88;O\
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M >5> =Q^)?A<+RW]JVN,_P#75:_6.OR=^'P)^)OA;"[C_:UKQZ_O5K]8ATH
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M#U'<M&Y?6O,X9OA>9&BBL[F-L8(%I=I_[**B2;X6&9%472.2 HVWBGC/;\Z
M/4=R^M&Y:\PS\+8R4^UW4>X\_P"D7B\_7-2O/\,X2N_6+F+R1N#'4;M< ].=
M_(H ]*W"C<*\WMY_AG]R'Q),,#H=:NACMWDIS2_#2'*MXJF7?S@^(+KG_P C
M4 >C;A2YK@%F^':/M_X2QU8C.&\03]OK+4BW'P_/W?%V1_V,4W;_ +;4 =UD
M4M<5%<>!B=T?BK?U/_(?E;IQ_P ]:D6Z\&*5"^*1DGY0=<D.2>G_ "TI =C1
M7-+<>&&.Q/$ )'8:JY/_ *'4RR:%CY=;)W=/^)@Q_P#9J -^LW7'V>'=2?\
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MI&)_VU]J].7X9^"ET>XTD:&C6ES9K82J\LC,T"NSJNXMGAG8@YSSUX%8VF^
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M#Z]Z0'BVJ_%3XC7?BWQ#<^&].NYM.T+4)=.338M%>XCO/+QO9[A7!C8\[<#
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M:SM6QNMHCCU058HH I_V;I^[=]AM\^OE+_A3/['TG=N_LRUSUSY*_P"%7Z*
M,]M%T=L[M)LSGKF!>?TIA\/Z&QRVC6)/_7NG^%:=% &6WAW0&/S:)8'ZVR?X
M5C:_X9\-P^&-4DCT+3HF2UF8.MJ@*G8>>!FNMK(\3?\ (I:QP3_H4W3K]PT
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M:*P_]J4P/6Z3%>4_V+\>E7Y?&WA5S_M:1*/QXDJ%M*_:$4#;XM\',3U#:=,
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MO[=Q_LRJ?ZUR/_"0_">3_F,>%GSQ_K[<_P!:='J7PJD;$5]X69C_ '9+?/\
M.BP'7B]LR"1=0D#_ &Q69XDN8?\ A$=8*S1L?L4W&\<_NS63YGPUD#J'\.L'
M&& ,'S#WH2S^&I;=';^'MQ/\(AZT6 ZZ+)A3(QP.*DJ@FL:2P^34K4_29?\
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MT-^->-J+>X\1O'%$HF\O[,UB(L$%<<@EN0V:+ ?86U:"$#9Z&O(?AGHUQ?\
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M>1()3#$Z\_*K.A;GL>U2V.H>/_%_C3PEJNGZAIVCZAJ.A:A=J]Q9-*L%F]Q
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MXX_%:3G'VG3UY'I:BO5Z\L^'^T_%SXIR#G_B86:]>>+1.WX_YQ7J= !1112
M0]>*0C*FE]Z:3F@#\SOV@@\?[0GBX3;\_:4//7!B0C\,44?M!22-^T)XN8DE
MA<HO(QP(D _E15 5O@.D;_'WP<LBY7[<#CW"L1^N*_3I<X]*_,;X#+N^/W@X
M>E\#^2L:_3I>!4@.HHHH *BF_P!1)_NFI:AG_P"/>3_=- $J]*6D7I2T %<7
MX@\?Z7X>N=52:WN;B/2+'[=?20 $0@G$<?7EWP<#H ,DC(SVG:O&[R.]77_B
M;H]OIMIJNK7WV6^M]/N\;;VT,"1/'S@=8IE] 6!/!I@=;X?\;7>JZP-)U;PG
MJ6A326YNH9)VCFAD0$ CS(V8*PR/E.#CD5-J/Q&\*VGAC6?$%AJUMJ]OHT;2
M74>GS)*ZX&=N < _4BO';;P?XFNT\0:?X"T7Q!X5T2\T6ZMI;/6KG]W]K90(
MOLZEW*8RVY@0IS[5SMK\/]>N/#OB5M+\/^(DN?[!.G>3>65I9++(73]VBQ*/
M-"[6.\GV&=U.R ^GAX@T4ZE!I3ZG:)J,\?FI9M,OG,N,Y"9R13;SQ'H-A+<P
MW>K6D<]M"UQ+"9E\Q8P"2VW.<8!_*OF6?X>>)O\ A9%XMQ9Z\]_/KJ7UO>VM
MA;F$6X92K?:V&]-BC:8\\@8 P:V4\,1-;7?AK5?A;>ZSXKEO+VXFUJ2%4BDC
M<R;9?M&2'&QT7RLGTP,460'T!X=\1:5XL\-V'B'1IO/T^^C$T+XP<>X[$<@C
MJ#5V#4K"Z21[:\@F6)MLA20,$/H<=#7DO@W2-4;]E:/0M%TJYT?7!HLMJ()8
M#:2BZV%2V#CEGYW]\YKSC6O#4>K:)JX\#> ]5T33GT>&PO[8V;VS75S]JA(P
MN/G9$$N9 /XNII ?4R75M)&TD<R.J'#,K9 ^M9U]K^EZ=_9[75R!%J%PMK#*
MOS)YC E02.F2,#W('4U\]?$#P!J&D7WB*Q\$:--I^@S0Z7->6]K:R2Q3A9I1
M+B-6'F$+Y995()'7K6?HNC7VG?##Q2MO<7!M=4U/3XM&@;2WTZ/[4)8_GAB9
MBP&0"3@?<)'K1H!]7=:,4U/N#/6G4@$VT8%+10 FT48'I2T4 &**** "BBB@
M#RZYRW[4>G# PGA:8DCWNDQG]<?C7J->82?-^T_;_P"QX5?K[W:]/R_E7I],
M HHHI %%%% !1110 4444 %07%O!=6[V]U"DT,@*O'(H96![$'@U/7G_ ,5-
M5\0:7X6L%\-:DNFZC?ZK:6"7+0K*(UED"L=K<' ^E '50:!HEKI']CVNCV,&
MG9W?9([=%BSNW?< QUYZ=:FGTG3+H7/VK3;6;[4JI/YD*MYRK]T-D?,!DXST
MKYSU[Q9\4K37]7T'1?$6KWC>%X8HI)[;0X;G^T)VC$I:;D>6I#!0%'09S4'B
MCXG_ !.2XLM5:[G\,:8NEVUU((=(&H0"=E)D6Y927A7.,8'*\T[ ?1-UX7\.
MWFN6^NW>AV%SJML-L-Y);(TT8YX5R,CJ>]0?\(EX4D\4#Q%_8.FMKD0Q]M^S
M)YZY&/OXSTKR;6O%7Q$UVY\5:MX-\3:9INE>%H8W6":U$PU(FW6=BSDY1"K
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M8/RL"K@X/<'Z]E\-_$/BZ^UKQ1X8\9R6%UJ&A2P!;RQC:-)TE0N,JQ.",8H
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M=<\+:;:O/'HBHMS?K(AC\U@#Y8 .[(!Y.,9!%=.NJ::U\=/6_MS> 9, E7S
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M8XQDMN(<DD]3CTJC+\)O'<FE?\("?$&E#P%]M^TAEA?[?Y7G>:(.NS&>-W7
M%>BK\4_A_)X5?Q.OBFR.DI,+=[C<0(Y#T1EQD'V(KB+_ /:$\.LGBH:";?4'
MT73HKZW9I3&+O<?F&",J%RF?]ZGJ!LS_  _UY?AUXFT*QO-.&H:GJMS?Q?:H
M//MWBDN/,\J56'.Y,J2.F<CI3?@_\/=4\"Z?K)U2#3;&34KI9ET_2FD:UM@J
M!<KYG.6.2>W2NL\+^/O"7BZ2X@\.^(+/4[BU56GC@?)0'O[C.>1Q7'^*/C3I
M7AW7?%6AE+=M0T&TM[I(YIMGVDR$EP.. B["3S][M2U \TUKX#>.=4\1ZE.\
M?AN\:;5/MZ:U>-,]ZZ>:'$6/N1@*-ORCH/>NE\1?#+XCR0>(_"_AV^T<^&]>
MU'^TY)[PO]HB9F5I(0H!4J2O!Z@$_6O6M!\=^#_$R7KZ#XDL-16Q&ZY,$ZL(
MAS\S<\#@\].*=X?\<^$?%-Q/;>'?$=AJDT W21VTZNRCUP.WO1J!Y/JWPV^(
MJ_\ "5^$]#GT;_A%O%5Y+=37<Y<7-F)L><JJ 0Y.#@D\9_"L2#PQX^NO%/Q(
M\,>$%TE=$OI[;2[B[OF?S[=18PHSH N'^1L8)X->P7'Q$T2W^*</P_EN;=+Z
M2Q:\W-, <@C$>WKDKN;Z+5K3O'G@?4I;U=+\4Z5=26B//="&Z1FC11\SM@]
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M^2,MY?F#;OZ=ZYK0?C1J5KX)\.Q3:;)XJ\3:FMU</''/#:!8([EXP[,V%7@
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M ,T@.HHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !10** "BBB@
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MV@W&M3,9]1M@S2VEM$ SNH4$Y9MB XQ\YHL!U#?"OX:MG=X!\/G/7_B6P_\
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MW-O<+:/I5Q9.M[YS*61!%C)+*"01QP>>*>H$'_"I+W<2/BKXX'.0/[0CX_\
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M(F0)#D9VKE1\QS@?A7KM%%P.'\7>%M0U[Q9X,U6TEA2#0]0DO+A9"=SJ8'C
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M1()HFVX#,!\I^8=,T6?QMU;4)4T?7_"5QX8DUS1I]0T6Y-TLQFVQ,YSM V'
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M %%%% !1110 4444 %%%% !111WH **#10 4444 %%%% "=32TG>EH ****
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M%6.&<=4#?=+>P.:P_A[\3)O'?C#Q796ZV"Z5HMP;:$QM(9Y"#@R,"-H4D-@
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M!%J-['J3V1TM4A6Q$&[SAA<2"3/'WNF.W6D!O44=J*0!BBBB@ HHHH ****
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MEZ7I6HZG=7:?9].A>>XV,&,:HI8Y'K@=* $?P[HLGAF3PR--MTTB2!K9K2-
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MZS1_X5]U5\+?L9;O^%G>(#AL#22#Z?ZY.O\ GUK[IH 0FE%%% !4,_-O(/\
M9-35%-_J'_W30!(O2EI%Z4M &9K5I)?:!J-C$D4LEQ;R1*D^?+8LI #;>=O/
M..<5\T:7\*_B#)X:U;1O[)FTNS73(($M9]0CE:::*Y279;S %XX657 5SP67
MTS7U2: JCH*=P/F:+X;^+KZ&3Q(GA[4X[JSU.PNQINM:LES-J,=N9&9,CY$P
M9#LW$Y(YP*W&T/Q;=>+]$\5S?#*ST^!=3F9[6UDA^UA)+;RQ-.=VPD-_=8D
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M;?-8[3M,1/48Z8QJZI\.9K?X,>%8Y/"-['JUM>/<7CZ=;0SW,+$RX>2!AMN
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MNX]*^AVT32&6W5M+M6^S2F>',*_NI#G+KQ\K<GD<\TMQH^E7E]#?W>FVT]W
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M/&SPRJ5=)-$RKJW!!RV""*6#]H/PI:VJ06W@/QG#!$HC1$T4JJ@<!0-W'TH
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M9!&"=N1^>/0UY+J^AZU<:/X7@UP75IX(1=1_L]-1TZZNF@_?DVXECB=7!,.
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MH2,>/-!P>_\ :$7_ ,54J_%#X<OC;XXT(Y_ZB$7_ ,519@=A17)?\+*^'O\
MT.VA?^#"+_XJE'Q)^'[9V^-M".#@_P#$QA_^*HLP.LHKDV^(W@()N_X370N>
M!_Q,8O\ XJD7XD> RVT>-="/TU&'_P"*HLP.MHKF?^$^\$GD>+]%(]M0B_\
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M:H;C_CWD_P!TT 2KTI>](M+0 4444 %%%% !1110 4444 %%(#D4M !1110
M4444 %%%% !1110 4C=*6D;I0!Y%\ _^1.\2-MQGQ+J)Z8)_>]Q7H)\5: +F
M6W_M*(RQ9WJ,G&,_X'\J\^^ 7/@/7'[/XAU%O_(Q[]Z\S^(%UK<?CG3H/A*U
MRWQ"\FZ;4HXF#0_9 [[?-W_+O#$;/K]*8'T?!XHT"XGAMXM4@:69ML:9P7/H
M,]ZVJ\6^%)\/R?"71YM+N;R>Y?5(VU*34-WGF^\P>:'!Z'=P,<8Q[U[52 YK
MQSXE'@_P'K'B3[,;IK"W:5(0<>8_15_%B!7 QZ3\;M,N+#7I/%&G>(&FEC%[
MH?V-;:&&)B-YAER6++_M9R,\=J]%\7^';?Q=X,U;PW=.8XM0MG@WKU0D?*P^
MAP?PKS&/2_CGKEOIWAW6I]*T2SLY8WNM;TZZ=I[Q8V!"HF!LW8PV21UI@;.H
M_&OPMI?BBYTB>QU:6SLKA;2\U>*T+6=K,2!L>3/8D D# -8OCSXZVGAU?$EC
MHGAS6M1U#1E:.2ZCL_,LX9/+#J7<,,+ALGOQ]*X_4_@=XF'BK7K>S\/Z#J>G
MZQJ1OX]7U"YE+VB.^^2-H%($ASG!SWY/IW5[\/\ Q%-X,^)VEQ1VHNO$$\DF
MGE7VAU^SQHN_^[\R&@#'\5?&#4=/\#:YXBTRWU".YCTFTGM[*XT_:UJ\\DD8
ME<[SN'R XQQQR=U7_"_Q4BT;P3JFI^.-:GOKBPG@@V?V2UK</)+$LB1"+>VY
MSN[8_K5?5?!'CCQ#X=\175]I%I9ZIJVDZ?:+:+=B14EAGD9QNP!C:P(^I%)X
MB^'7BJ3Q5J_BW1[6WGO;77;35]/M9I@JWB1VBPR(3@[&/S8)[@4P.@7XX^"?
M^$7&M>5J@G^V&P.E_86-Z)PNXH8AS]WG/3%9VJ?'?PW'X>T/6=/L[Z2/4-7&
MF7-O+9R>?:D*6<,@YW8VX'<'VQ6)XBT7XO:PMKK-WH*K:27KO+H6D:BEI=I'
MY05&:Z&-QW D@'H1UQ5/P]X+\?Z!H+7TGA-Y+M/%::PFGKJRW$K0-;^409I#
M\S*3SN/.#CM1H!Z$?C)X#7QJOA-KRX-T;@6?VD6KFU$_'[KS<;=V2!CUXKK/
M$GBC0_"GAVXU[7KT6=A  6D*DDD]  .23V YKY_A^%OB*WU&;PS/X0U"_M)M
M7-VNIG7Y([%8&G\[+VZR F1<D8"X) .:]8^*GAW6M8T;1-0T&RCU"]T#58=4
M6QDD"?:U0,#&&/ ;YL@GC(I <OXL_: \+V/PPN?%7AN0WMVMY'IZ6UU;2QM#
M,QS^]7&X *&8=-V, YKT_P /ZH][X*T_6=0GA9IK-+F6:.)XHSE Q8*_S*/8
M\UXIK?A+QMXSM?$VOS>$Y-(FU2[TB*VTZ:XB:416USODFDVG;T<\9SA?S])^
M*>E:_P"(? Y\+:##)OU>XAL[RX1@IMK5C^^DYZ_*"N!D_-3 ROAS\5!XROM;
MAU+3?[-6VC74+$Y)^TV#Y"2XQU^0Y SU%.A^/GPCN6N!'XNMB((/M#%HG 9>
M!A<K\S<CY1D\]*Y_4OA;J'A/5=*UKPK>:UKC?9I-'N+:[O%D$-H\3;-F0,!9
M%C_ GBH/#?@#5+;3?@Y'?^'0'T:.8ZCO5";9C;L%W<]=^.F>: /0)OBO\/(/
M!EMXPF\2VJ:-=L8X9CG=(XZH$QN+#N,9%2:C\2?AYI_A[3]>U'Q)IT6FZC&S
MVL[ME9@N-P7U(R..M>$W_P /O%&GW]GXBD\-ZS+8V.O:M(UKI#QK=I%.ZF*>
M-2=I'RD8'.#74>$?A[=VNN^";VX\,WT-B+W5-0N(=2E2=[9I8U$;2;5"JS$9
MVC."3SFC0#U.Z\=^ [3PG:>*KK7-/CT6\VB"Z9AMD+= .^>N1VP<XQ6'H/Q,
M\&ZIH%]KVKW6EZ;IL>I7&GVUQ-*ACNEB&X.I('5<G'M7G<.@ZQX4N]"\17O@
MV^U72--U+7$;3K.V$LT"SW1>&=(CC*[5Q[!P>]6/"'A.^NXO#G]I>"I].LSX
MMU'4C8W,"XMH6AE\IF'( W%<8[XQ1H!Z5;^-/A1J5WIEG:ZYH-Q<:D<V<2-&
MS3')' ]<Y'UJ_-K'P[;Q(OAN>^T,ZR>EDSQ>=ZXV]<]\5Y)=?#YK7P;KOV'P
MCY%^_C2.YMV2U'F>0+J(B1=HSLVANG09KSMO NO6NJ?\(SJ-EXIFUG^W1>_Z
M'I]N]M*IFWBY%V4W+@$9RV1R.E*P'TX-6^&ZZTFBK?: -3DE:);3?#YID!P5
MV]<YXQ5/POXB\&^+-<\0Z5I]IIYN]#O&LI(QY;.X 4EP!R%W,5^J&O+K_P "
MK)X8\1ZP/"K-K4_C=+J&X-F9)VA%]&-ZG&[9LW'CC&:[;X:PZ;IOQ$^(6E#1
M)++4Y-5:]\_[&426W>*+9MEQ@_-O.W/4D^M&@&K8:[\/-:U_Q+IDUKHZ3>'Y
MO*N7F$/3RU9G]0 6VDG'*D5L:5I_P_URU-UHECH.I6X8J9+:*&501U&5!YKQ
M#QEI5G%XF\:V_P#PB=S>/'KMCK%Y#!8$_;M.$<(D57 P_P"]5F*9YVDXZUV?
MPO73=2^('B'Q)X0T631O"L]G;VNQK,VBW-TK.S2)&0",*RJ3CG\*=@+_ ,1M
M:^'/P[ATJ;5/!=G>G4+CRR+>QC8Q1#!DF;(^ZN5S]:Z>^TGX;Z5$JZEI?ARS
M\WYU$T,$>_GJ,@=S^9KR?5/"_C7XH^//%FI6>L)X?TBRAD\.0QWVG?:/M*8W
M3N@8C:&;: PZA1Z54\*:&OB[QWX0L_&N@_;Y= T.^L;C[=;%H6GAN8HE< C!
M)3G)SUXZ4M /0-&F^'7B)89=$\':/=0/J4VFRN8+=?*,>_Y\=65C'P ,D$'I
M6IJ&F_#6QTS5;F+P]H5U-I5O)<SVUO;PM( H+$;>Q..]>&:?I5O;Q66A>$])
M&GZW9^*-4BN-EJ83$7@N_LQ+[<%=A7!Y &!3M!7P9'X731M%\#W\/C/2]$OH
M=8N!"\;VLGD,',S=)][_ '0"W7(Q560'NMK8?#*?1=*U2[T'0+*/4X8Y8$NK
M:!&(90P49')&>U7KSPS\-[.2&._\/^'8))FQ$LUK I<^V1S^%?+_ (WT^UAU
MJ&?QAJD>G6=YX?L(M)^V:(VHA\0XDBCPP\J3?C/0G</2JOQ$T^RTE=!E\07,
MDVI1>'[:+[/XATII4U';G"1-$S/!,.C#(R<$GK2L!]:-X \!!2[>#-"QU).G
MP_\ Q-8&JZ)\*-,\,ZGXD?PGX=N+'3XI)IF@L8'/R+DJ./O=L>XK'^(+:G>?
ML]A_[/N+5C:V4M_:0%C+';!HVN4'(;(CWCU.#7BVK6G@CQ#%XNN_AGI)/A.'
MPI<?VEY4,D5LUXN'M\(P ,JXSG'XTK >UZ38?#K4/AO<^--0^%NDZ;;PV\MT
MUM)86LDC1HI;(*97) Z9SZUKZ=X3^%>I:!8:P_@?P];0WL$=PBS:= K*) "H
M/R]>:KZCI.GZ#^SIJNGZ/IZ6-LF@3LL$*[0&:!F;CU+$G\:\[L_!WA_QAXFT
MF#Q+I:W]K:>!+*2%)2P1'+2?-QWXXSTY]:+(#UJ?X<?"VWC66;P1X:C7( 9]
M/@ ]NJU#-\-/A8C1I<>!_#:O(=J Z= ,_3Y:^=;2Z\(2V/AJ7XQRS7'AUO"5
ML-):8RM"9QD3A=G6;;Y?OC&.U2:VW@%9->;X@PZQ:ZL^FV@\+1:@TCW*0_9E
M\ORRA(\WS@VXDYSC-.P'T+)\*OA.K!)? ?AT,YX!L(1D_E2)\)_A0[M'%X$\
M/,0,D"RC)&?PKR?PUX5_M[Q'KFJ^.+22Y\2:'X>TQD>:0_Z-<-!*SL #C?E0
M3[UP_@,Z*VG^%I?A7=W<OC,Z3=_VUEY&_P"78[/,#''$QC"=O3(HL!]&CX1?
M"621XU\!Z"[I]X"TCR/R%,_X5!\(QOSX"T+Y1EO]%7Y>/TKQ3P0?!</B?P&_
MP]U"XN?%5QN_X2)6DE>5H?(8S&X#' (FV8'KTJ@NB^$]!^!GA[6[S3_.O?$E
M\(KZ\N]1E@MVVM,Z+<.F3Y8VX"@<D+Z46 ]FUGX<_!'1+2VGU'P/HJ175U%:
M1%+4'=)(X5!Q[FFZ/\+?@[JS:F(/AK9VWV*Z>UD-U9&,2,H!+1D_>0YX8<'F
MO -*A\.ZKX#U/^U)+%]!TSQA8L'LYY_LL$$BHLA1G(8*><DX&>1VK:N[RUEU
M"6WU_5KJV\#7'C34$U.:&X9(FQ!&8$D<'(C+9XZ?I3L![L?@A\(&0M_P@6DX
M)[1X_K3%^!7P?=05\!Z81G.0&_QKP2VL['7]5L?"FE:QJ-SX%E\6Q0:=.MU)
M\\?V21IHHY"=Q0.,=>,^M>Z?"2SBT>7QGX=LVN#IVE:X\%I'/*TIB0PQ.5!8
MDXW,WYU-@.9U[X?_  !\/OK8U#P7;-_8UBM_>^4LC"*)B0O1OO':V!UP/?G
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MD)=64LR)L(4G'S$XKBO"NEKXB\;?#'5-5U2_O/)_M5;&Y:[D#7-O;S 6[G!
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M&3P..36-X@^#G@_Q+K]]J]Z^J6[:B@2^MK.^D@@O<+M#2HI&X@<=>W->DT4
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M8UZU6RU6;0+HW$:,I4.(G!*[6(P<9')QFN7N?%WQ(\(:3';MJ&F^()'T$:Y
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MA$CKDX(QDCTKG?B+\2O&/A&3P]J'C#33HUK::U'YSZ3<F>+48#!(QCP0K9#
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M6Q F$6<Q$YP&! *G@\'TKA&^/?@[RH[KSUCL1K$ND7%Q-($6$I&[B3H<AMF
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MW^VKS5;^V@D9DA62S^SQ)&2HWD;5+$@=3CISNM\:O!4UA?S:=<7EW);6LMU
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M$ELY"*.G7 'Q?U[1V\67^JV=K<V8UR#3M(5K@QA!)!&X\P[#A A\PGYCEF4
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M>3_=- $J]*6D7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.T\>E>EZQX!O]2^&&A>#VUCSI].ET]Y[NX4L;@6\D;OD9)RP0]^O>L:'XZZ
MMKJLVJ>']<TA]/L1J7DW4,?F30%PFY0KG!RPX;!JO-\?=!LI;Y=3\,^)+)=/
M,3WK36("VL4APDKD,?E)],G@\<&C4"WK7PMU'4F\;R0ZM C^([^PNH=R']PM
MN8MP/J3Y9Q]17)ZE\%/%6H>//[8FO]&E@BUR+5X[^8SR7IB657%N 3L154$
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MBB@ HHH[4 %%%% !6/XF;9X/UEST6RF/_D,UL5A>,6"^ O$#-T&G7&?^_34
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MPCCQSH/_ (,8?_BJ-0.$U#X":1J7@3PYX5N-=O/+T6YED^T1QHCW$,KEI8&
MX"MD X_NCBM'7OA-<:IJ^NMI?BF;2-&\1Q10ZKI\=JDAE"((SY;DYCW1@*>#
M76_\+%\ XW?\)MH6/7^T8?\ XJE;XA^ U0/_ ,)GHF#T_P")A#_\51J [POX
M5M_#4^MO;3%X]3OOM@C*X$.(8H@H]>(@<^]<AX@^%^IZIJGB%=)\5'2]&\3;
M?[6M39K+(Y$8C8Q2$C9N0 '(;&,CK78+X^\#M]WQAHI^E_%_\53SXY\%@X/B
MW1Q];Z+_ .*HU H>%/!,/A76_$NH6]X9HM9N(9DA*8\@1PK$%SGG[N>U<[IG
MPPO[+Q!8WTVNQ2V=AKUYK5O MKM;%PDBF-FW'.#*2#CM79?\)QX+X_XJW1O_
M  /B_P#BJ4>-O!S$!?%>CDGM]NB_^*HU \O\0? N/4=7_M^RU&QN-1^W7EQY
M.JV"W5LT=P02A3(.Y"HPP([Y%=CIG@"32_A'/X'M]5$$\UM/#]ML[=+<1O*6
M)9(TP%P6X[\=<\UT'_"9>$<@?\)1I)S_ -/L?_Q52#Q9X68_+XDTL_2\C_QH
MU \&MOV=M66SU6%M5T>Q:^TO^SB-/LY$#'SHY/-=F<LS'8P.>.1BNZ\5_"V^
M\00^.E@U*" >)+*RMH0T9/D& L3G'4'->B+XE\.LNY-=T]E]1<H?ZU(->T-N
MFL61_P"WA/\ &C4#PS4_@)<W'C"^NK5= FTS4KU+Z:XOK%I;RW(VEXXSG8RL
M5/4?+N/6NNF^&E_+H=WI_P#:$&9_%2:_D*0/*%PDAC_WL*1Z9Q7HXUK1R<#5
M+0GT$ZG^M/75--;[NH6Q^DJ_XT:@>'67PD\=0W?A/1[K6](D\.>%KJ26U>.&
M07,Z,C(HD_ARH8CCKG-==X>^'FH:-<^ FDNK>5/#FDSZ?/M4CS'=8@&7CI^[
M/7U%>BKJ%BWW;R$_20?XU(+NU/2XC/\ P,4:@?-5Q\ M?LSIM]90Z+K%V-.%
MA=VU_/<0QQL)'=98VB()P'P5/7';-=58?"/6M.\'>-]#@N+#S-:T.VTVS,8*
M(DD=L\39&#M4LV1R>#7MGGP?\]4_[Z%.\V+_ )Z+^= '!>%/#.N:#\0/%U_,
MEHVD:PUM<P2I(?-21($B9"N,8^3(.>_2O+]8^$/C%[:5H=+TK4Y&U[4M11?M
M\MG-"D[J8I$F09##;\R\@\=<5]';XST8?G2[E]10!Q/@G3O%V@Z1HNAZ[);W
MZ6NFJMSJ/G%I'N0V-@! RNW^(\\=*W;V1!-J0:=H0MF&:0$KL'S_ #!NQX/T
MQ6SE<=:SWWI>S2&W,T<D:IP1V+9R#CUH ^6O"]SJ&K1?#W[?\1-?8>(M&U&7
M4B-492Q@(:/;_<Q\P)!!(4Y/6NE\+>*;CQ#8^'[7Q9XOO-/MIO"L=Y;7B7AM
MOM%T'=9G9P1N=%6,[3D<DD5[O]ET]/**:&@\M2L96.(; >H'/&<G]:BN-+T:
MZM8+2Z\.0SV]LX>&.2")D1O503QUZTP/"M'U+QMXBO+.2\\3ZG;:E8>%8-9.
MFV<B1_:[D22;?,3;D!U";EX^\/:MWX-ZWJ6L:Q;7]Q\1(-;6]TE99](0O));
MSAEW2/N)\KDE=@P#C@<5["L-FM\VH+I&V[:/RS.(TWE!_#NSG'M5?3M-T71[
MB[GTO08;&:[?S+A[>!$:9_5B.IY/7UI7 \&\=7-LB_%RSFUZ1+V34M-2&VEN
M=WE1E;0[TC)_O.?;C%6=5\2W_AOQ+J/A.Y\=ZI=&/5X$M4FEA2>X#V?FF-IR
M%$,8?#;L$XRH!SBO:+_P_P"&=2N;J;4O"UK>R7803R3VL;F4(<IN)ZX/3TJO
MJ'@_P9JAE;4O!]C=-)+'<2&2S1B\B#:C'CDJ"0/;-.X'B?A7Q9XN\:Z1X-L[
MCQQ=Z?+=P:N+V:Q,#.QMY5$1+&,@$ ]0!D=N<UZUX.U6Z\4?!#1M2US6/LEW
MJFF()[^(K&4=UV[UR-H;)XXQGM6A:^#?!-G*)K7PC9P/B;E;,9'F_P"M[<;N
M_K4\GAWPO-X3;PC)H,9T(Q^5]@%N1$%SG  Z<\_6@#YPU/3M1\(:;XJ\ M]B
MU'1K*;29Y-5BM(X9FM9+I0\5P8P V%#')Y*G)ZUV.J>&=0\1_$?XAZ5H8@_L
MY/['NIK:9BEM<RQ_.T3E1D!HU7. ?X<UZ_9>&O"NG:#/X?L]!BBTRZ4K-;?9
MV*R@C!W9'/  YI-%T#PWX>T:XT?2=,:UM)MQF01R%I"5 )+'))Q@9SP !VHN
M!\_:-J5]'\1[_7],T_2KS[-:SZ@NJWB&*!(PQC:2)5Y;S&4Q(2?NQEOX^?J:
M%FDMXW==C,H)7T/I7*3>%O!]U<:==3Z!&TNEQB&U_P!'<")%/RKM P5!4$ @
M@'D5TXO(L#Y9.F?]6W^%)Z@6:*JM?0J/F$G_ '[;_"C[=!_M_P#?MO\ "D!:
MHS59;J)ON[O^^2/Z4OVF$2;-WS8SC!_SWH "I^W(W'W&'ZK7G'QXV_\ "G[T
M-@@WUB#G_K[BKT,2A[]=I)"HP;CH25Q7G/QX_P"24RC.-VI:>/\ R:CH ]14
M_**6FJ, 4Z@ HHHH *\X^.4C)\!_&9&?^0;(/SXKT>O-OCLVWX!^,B5R/[.<
M8^I H _,$]:*#UHH ^X_V+U_XMYXC;_J)@?^0EKZDKY<_8O'_%NO$1W?\Q0<
M?]LDKZCH **** "H;C_CWD_W34U0W'_'M+_NG^5 T2KTI:1>E+0(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HYHHH *YWQT=OPX\2MTQI=R>/
M^N35T5<O\0VV_"WQ8WII-W_Z):@"/X<H5^%'A->F-)M?_1*U-H>G6-Q!=W%Q
M96TDK7]S\YC4DXE91SZX _*D^'XV_"_POTR-*M?I_JEI;7^W-,CGACTE+M'N
M99E=;A5^5Y&;H1UP: (_$^E:?_8IFCT^ 3I/ R.D8#*?-49!&"."?PS75#I7
M*ZHVNZG;)8_V(($::%VE-TI"A9%8\8YX%=5VH XCXG^)-2\+> +O4-'2-M3F
MDAL[5I?N1RS2+$KM[ OG'M7G7B[P[XJ^%_A63Q]IOC_6M<O--V3:C9:I,KVU
M[%N <*N!Y1 8E<'CIS7KGB[PS9>,/"6H>'KZ1XHKN/:)8_OPN#E)%]U8 CZ5
MYS-\,_B!XGCAT3QYXZM-1\.6\R3-%96/D3WVQMRI,Q) 7(!( .?:F!Y/X^^(
M'Q.;Q/\ $&XTRWU&VLM,%GIULUM?QI':K.RD2["N7DD!&".4W8KT+P_X\OO"
M>BZGIUSI^LZWKT6I6^FV^FW>HQSRO*]LDI02[%4*J[B2<Y*DYY%=#K/PGN]4
MN?&TBZU'$GB6^TZZ1?*.;=;8QY'7DMLX/;-&L_"_5I]3U?7M&UJVM]8DUF+6
M-.::$F.)EMU@>.7!RRLH;I@C(]*=P*6H?&VYT>SCL]6\#WMEXEFNVMH=,FNH
MXXI55 YE6X;"% "!GKDXJ-OCO;7'A33M2T[PG?:AJEWJS:+)I,4\?F17"H7Q
MO^ZRD '(.,'VJGK'P?\ %NO/:^*->US1]8\46=P\L%E>6;/IB1,@1H0A);G
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MZUN:U)XUU+1_$WBBT\'ZKI2W^O6=PH>R2ZOH+9;5(Q-%$Y*[PP7..5W,.HX
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M7Z7T_P#\77L5% 'C?_#,OP=Q@>&YQSG(U"?_ .+IK?LR_"-AA=$O$^FHS_\
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M44 %0W'_ ![R?[IJ:H9_^/>3_=- $J]*6D7I2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<I\2'\OX3>+WZ8T>[Z_]<6KJZY'XF_\
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M88.0#FH5^+GPS>[>U7QQI'G)$TS+]I485<[N>F1@\=:\'T3P]XWE\0>#6O\
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M(D?ERC]XQ/W<[1S[4 >D[DSUK/OM5M=/O+&TF6X:6^D,47EP/(H(&26(!"#
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M44*H  ' %>??$R\N[/3?#36TFQIO$.GPO\JM\K3 $?,#^8P?>O)='\0>/O\
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M/^CIR/3I4!\)^&&QN\.Z8<9QFTCXS^% &QYT1Z2*?QI=Z?WA6+_PB/A;)/\
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MM^!GC(]?^)9,./\ =KOZ\[^-K;?@5XP.,YT]Q^>!0!W6G?\ (+M!_P!,4_\
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M=*@U;1[Z*^L;@%HIX6W(X!(.#]0: +$%K;6[3-;V\<33/YDA10I=L ;CCJ<
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M@KM&",=*+@>%>,5UC4M0N+)?$#VIM/'6F62S):P;YC]G@(=ODP64Y89X[=
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MQ,&1@&!4\CH11H!XMI7QZ\2OIOBRWN+/0-6U'1K:"YM9M*DE^S3F281"-C(
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M;.X0H#GKG:*0%NBBB@ HHHH **** (V9MVU5R>O)IZDE02,'TJ-5;SF9@,8
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M9?A:G4_:K]NO_3J?\:]1KRWQL0_QQ^&$?(*MJ+_E;@?UH ]2HHHH 0THHHH
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M=^SGX3_ZYSC_ ,F)*]<KR?\ 9T4I^SOX2!&/W$IY]YY#7K% !1110 5#<?\
M'O)_NFIJAG_X]Y?]T_RH&2KTI:1>E+0(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\O^,/,7@9?7Q9I_'K\S'^E>H5Y=\8,FY^'J#&&\
M6V6<^RR&@#U =*6D'2EH **** "BBB@ HHHH *QI(]3CUN>ZM[>":"2WCC^>
M8HRLK2$\!3_>7O6S63-?7W]J26=G9Q2B*)9&>68IRQ8  !3_ '3^= "+<ZVV
MX2:7 H[8NB<\?[@[_P">U6M.MY+?2;2VF(\R*%48@YY P>:KO=:TB;SIEL<
MD@71_P#B*MP723:?#>-B-)(Q(<GA01GK0!SVC^$O[)D\4N+[S3K]Z]YGR]OD
M[H4CV]><;,YXZURT7PAA7PSX&T&?6&D@\+K(KLL(4W0>!X3W^7[^>_2NET_X
MD^ M6UO^Q=.\7:7=7Y;8L,=PI+MZ+SAC[#-;]QJ^F6JSM=7]O"+?892\@'E[
MSA<^F3P/6@#RWPC\)=8\.ZGI$-[KVE7FD:,0;?R='CBNY\+A!++D\+URH!)
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MWLO!MG#I,_AJR\0PZPNH/<,L[P_:O/:+R\'YE/\ $3R/T]Z^WV.81]LAS/\
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MZGPMX$O;/Q-:IJ7AR[D@L_ ?V:(WL*R%)VN)&,.5&S>%(& ,X..E?2>*,47
M^3=!L[GPG9:-)XR^'NJZW!?^$[;3+<)8F9K:<-*7MV3JA8,ASQ]VLK_A'=9T
M73_ .J:E!J^FV,?AP6N^VT1=1:VF,C,R/'(C%-RNHSCG:17V/BC%.X'S#I5G
M;^#[?P9K/C#P]J>IZ,=*O((4N--$TEK/+.)55X8P0A>/A1_#]VO1?@U,-%^&
M?AS1[K2;W2Y[^XOFAM)K=P;=1<2N%<XPGRD8SC/:O6,#TI<4F[@%'-%%( HH
MHH *0YQ2T4 <]X+P? ^D-_>MU)^IZT_7R?MNA;3C.H#/./\ EE)3+;PV]G;1
M6MGK5]!!$ L<:E"% [<KFI/["=KRSN9]4NKC[)*951]F&)5EYPO8,:8'G/PU
M;0!>>/%UA[,:T-?O#?"Y*^8("P\G.[GRS'MQVXKEK.]TG6?$7A[X?^ =?O?#
MO@Z>RO\ 4?M5E)Y<EQ*ESL,43R X0%F;Y>V,<"O7M?\ AQX&\5:BFH^(/"VG
M:C>* OGS0@N0.@)ZD>QJ76/ '@[7]'LM'U;P[8W-A8X^S0&(*L'&,+C&T8["
M@#QC2]6\8^*-3\.>$O\ A.KN*%+_ %:SFU:R2-9+^&V\L1MDJRALL02!U!IV
M@?$+7O#^E:)KGB?7FNM$MM6U/0;V>9%42&,L;>=B ,']TR'IG=7N%CX4\.Z8
M^G/I^C6MH=-CDBM!#&$$"R$%PH' W%1FJ-WX \(W_ARY\.WF@6LVE7-RUY+;
M,#M:8OYA?UR6Y_\ K<47 \(U;QI\2);'PE8Q'6[FZURRN-:N(](C@6XCC9U\
MJ)?,&T*JL-W!8GOS6QX=\2?$?QA>>#M%N_$$WAZXN+/4)[UX[>%Y)Q!.B1D\
M,JD[@& ]&Z9KV+Q)X#\*^+K:TAU[1X;L6?\ Q[L"T;Q XR%92" <#(S@XJ?3
M?!_AO1Y].FTK1[>S;3;:2TM?)&T11.P9U Z<LH))YS]33N!X3HWC[QM#\4;>
MS\4:W?6EE>ZC+:P&.PAFTJ[CRPBCCG3YEDXY+$\Y!%6_ GB#QIXMTWP_H.E:
M];^&DBT8ZE-+:V4+M.S7$D:(B%=BHHCR<#)W#IUKT^S^$O@.Q\2KXAM=!CAO
MDF:XC"ROY4<ASEUBSL5N<Y ZT[4?A1X)U+3]*L9=*>"+2D:&V-M<RP.D;'+)
MN1@Q4D X)-*X'G&A^,/B%XUU?PUH=EXBM=&FET^^EU"[ALUF\YK>Y6$/&&X4
M,>>XZ^U>H_#/7-3\1?#C2]5UF6.:_<S132Q)L60QS/'N"]LA,X]ZNZ=X-\.Z
M3J6GWVF::EK-IUDVGV_EDA4@9E8ICIU4'/7\ZT-!T/3O#NBQ:1I<+0V<3.R(
MSEL%W+MR>?O,: -6BBBD 4444 %%%% !1110 4444 %%%% !7EGB#:?VEO!:
M_P 0T;43_P"/15ZG7E.LMN_:@\*KC[OA^^//;,L0H ]6'2BBB@ HHHH ,5\P
M?MFL1\,O#Z*V VJ@D>N(7KZ?/2OEW]LXX^&_AU3P3JA/_D)Z /ADGFBCO10!
M^F7[._\ R;SX1_Z]Y/\ T<]>K5Y9^SVH7]GOP@._V5SQ[RO7J= !1110 5#<
M?\>\G^Z:FJ&X_P"/>3_=- $J]*6D7I2T %%%% !1110 4444 %%%% !1110
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MUH 6BDW"C<I'6@!:*3(]:-R^M "T4F1ZT9'K0 M%)D>M+0 4449% !11D44
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M[C_?_P#915BH(?\ 73]?O_T% $_>BBB@ HHHH **** "BBB@ HHHH **.M%
M!1110 4444 )P>U+BBB@ Q1BBB@ HHHH **** "BBB@ Q1BBB@ Q1BBB@!-H
MS1M7TI:* $VBC:*6B@!-HI-J^E.HH ;L7TH,:-]Y0:=10 WRTQC:*;Y$.,>6
MOY5)10!'Y$/'[M?RH,,9.3&I/3)%244 1>3$3GRUSZXI/LT&[=Y29]<5-10!
M'Y,1&/+&/I1Y,8QA<8J2B@"/R4]/UI/)0>OYFI:* &>6N._YFCRU]_S-/HH
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MH\Y$T03YF9'"' YQD\]*\>O=$UB^\(>);.2U\0>(_"=M)I]Q:'Q!9.]ZCK<
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M@'TK[2O9M.T^VGU.[6.-($:627;DJJ@DGUZ5%I[:1J6FI?V,4$EIJ,2S!_+
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M_+E>H&5.#[>U03>#/"T\>I(^BV^-2MDL[O:"IFA12JQDC^$ D8%%P/F?QO\
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MN=P^@(S5G_A<O@H>*O\ A'FDU$3C4/[+:Y^PR?9DN>@C,N-N3D8^OI7FNL?
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M&<#:I;C&2.HH5P/,OB5X;;2['XA>)KQ[73?GT[4-%GDD53+=6R$[0 <[F(V
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MD>X_M'6=)\7ZSK6MWEOK.H>'=%DFMGD4 R.ZYDV8XVD9&.A8^M=7XLU_Q?\
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M4\.K;SN4]?6MGP7X0NO"MI?_ -H:P=5N[Z83.\=LEM%& H4+'&O"C@GJ22:
M.*T_XUR:K)$[^$=1TW3+RXN-/M=5ED1HGNHPY"[0=VT[#AB.HQ67#\=+S1/
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MM$?!N4X7QQ;+_OP3+_-*](?2]+E!$FGVSYZ[HE/]*B;0=$?[VD639]8%/]*
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M22@?\5_X5?UW::P_D* /:\T5XF=&_:62,[?&'@V4\8W6<J_R%*NG_M+JR_\
M$^\#..^ZVN!C\J0'M6:7->+F#]IE/^7[X?R9]8[H8IW_ !DNA(S\/91_V]BF
M![+VHKQU9_VDD;Y['P!(/427:_TIRWW[1:=?#W@9_=+RX'\UI >PT5Y!'JO[
M0Q+!O"?@U<=&_M"?G_QVGC6/V@%?;)X-\(R#U34YA_-* /7**\F&N_'@$;_
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M  T!\)^K>)Y%'^UI]R/_ &G0!ZE17EW_  O_ .$:G#>,(U/^U:3C_P!ITO\
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M#]6\-:+H4D=[:1:("ME/9W3Q3Q*1AEWCG!&,CV%7]+^&_A;1I?#<FG6DMO\
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M6A'4&0=3CD>]:,OP?OQ]LT.U\721^#K^^%]<Z3):!Y2=X=XUGW9".XR>">2
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MB>TE@$T1.!)&74!USQD9[>HKK:0!1110 4444 -*U\7_ +:A_P")YX.7(/\
MH]T>G3YH^]?:1Z5\6?MJ _V_X.;L;:Y&/^!1T ?)?-%'-% 'ZQ> ^/AKX8&T
M _V7:\#M^Y6NEKG/ W'P\\-C&W&F6W'_ &R6NCI@%%%%( J&?_CWD_W34U0S
M_P#'O)_NF@"5>E+2+TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!-HSFEHHH **** "BBB@ J.6*.:)HI$5T8896&01Z5)10
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MVD%F5Y "1@<T6 ]*\)_!S1?#D=]J<UK9W/B:>[O+F+4F5I!$99'*$(QP"JN
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M(]JTJ* .?\.>$?#OA.SEL_#NDPZ=#*P9UBS\Q P,D\\  #T'2N@HHH ****
M"BBB@!IZ5\2_MI'_ (K3PJO.?L$I]O\ 6"OMK;DU\3?MIL?^$Q\*+@8^PRG/
M_;0?X4 ?*5%%% 'ZX^&1M\(:.,8Q90\?\ %:]9?A]=OAK2EQC%I$,'_<%:E
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M+"/=:*\07]JGX,-U\07:_73YO_B:F_X:D^"O_0TS?^"^X_\ B*+ >TT5XO\
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M3"Z]SCZT[(]: %HI*,\4 +11FDR* %HHHH **3(-+F@ I#2TF10 M%(#0>:
M%HI!]:7- !1110 44F12YH **** "BBB@ [4444 %%%(3Q0 M%%% !111F@
MHHHH **** "BBB@ HHHH **** "BC-% !1110 4AYI:* "OA;]LXC_A9^@<<
M_P!DCO\ ]-I*^Z37PC^V8V[XL:&N[IHZ<?\ ;:6@#YEHHHH 2BBB@!/2@=:*
M* %HHHI '>BBBK *.]%%2 4=Z** #O1110 =Z*** $]:6BB@ HR<4450!FBB
MB@ R:,GFBB@ R<TM%%2 F3FE[&BB@ W&C)P*** #)S1DT44  8TN3110 9-)
MDYHHH ,G!HW&BB@!<FDW-BBB@!0QS1N-%% !DT;C@444 *&-.W-RNXX],T44
M $<\RMN25T9/F4JQ!!J2.\O%RL=U*@QNPKD<^M%% $@UC55!5=2N@,=!,W^-
M2IKVN#&W6;Y=W7%PXS^M%%4!9C\4^)DRL?B+4T"YP%NY!C]:4^*O%'GEO^$E
MU7?_ 'OMDF?SS114@+%XS\7PY$/BK6(@<9V7THZ=.C>PI\WC;QDX_>>+-9?:
M.-U_*<?^/444 6H_B'\0(\>7XZ\0)QM^74IAQ_WU4X^)GQ(A<-'\0/$8*],Z
MG-Q_X]115$B'XH?$HON/Q \1YY_YBD__ ,54D?Q4^)L;*R_$'Q$".G_$SF_^
M*HHH*)_^%P?%.-5Q\0=>.WIF^D/]:D'QE^*VUO\ BX&M_>S_ ,?3444P'K\9
MOBLL>T>/]:(][IC_ #J9?CC\7-I_XK_5ON_\]?\ ZU%%("9?CS\8%Z>/M2/U
M*G^:T]?V@/C'A7_X3R_SZ;8\?^@T44P'_P#"_P#XQ2M\WCN]'TCB'_LE./[0
M7QD4+CQW>'ZPPG_V2BBD2(O[1'QG4!1XZNR/>"$_S2I3^TA\:E_YGB;\;.W_
M /C=%% $R_M+?&S<3_PFS]/^?&V_^-U-'^TU\:P_/C -SWT^V_\ C=%% $T?
M[4/QHWR9\3PD8Z&P@Q_Z!4J_M1_&3R03KUH3[V$/_P 3113*)$_:K^,2#G5K
M!^OWK&/^E3P_M:_%[Y<W&E'ZV?\ ]E115+8DD3]K;XMAQ^\T<@GH;,XZ_P"]
M3_\ AKKXL%2"NB=!_P N;>O^_110 MO^U]\6-K[X-"D_WK-_0^DE6#^V!\5%
MO&C%CX?*[NAM)?\ X[110!?T_P#:X^)URF9=.\/$Y[6LH[?]=:Z>U_:=^($E
MZ(6TW0MO'2WESU_ZZT44 7X_VD_';^;G3=#^4<8@E]?^NM;-O\?O&4IVMI^C
MXR.D,OM_TTHHH*-BT^-GBJ:4JUAI6..D4G_QRMNP^*OB*YN989+73PJQ(XQ&
MX.2>?XZ**1)N#Q]K.T?Z/9]#_ WI_O5=T_QIJMS<I')!:@,>2$;/_H5%%(T.
MA@UJZD16:.+))Z _XUI+=2G/W>GI112,P^U2_P"ST':E%U)M_A_*BBF!,LSM
M'SBGB1MO:BBD,57:E#';114@)N.&I2>3]***H8K'@4QF.T444 *A.!3\G-%%
M2 TDYIPZ?A113 3<<TN3BBBD 'I0*** %-&:** &;C2@G!HHJ@$'WA3^]%%)
A@(?N5\'_ +97_)7M$7)Q_8L?'_;>6BB@#YIHHHI$G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>skye_ex31img16.jpg
<TEXT>
begin 644 skye_ex31img16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M@NS;O^$&M_PN9_\ XNHS^S9\%FSGP1",^EW<#_VI7KM'>E8#R)?V:_@HN/\
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M7_QRO8\4 4P/'/\ AF/X)<?\47W_ .@C=?\ QVE_X9C^"0_YDOO_ -!"Z_\
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M<_\ "+S@>@U&X_\ BZ]KHH \4_X9:^"N<_\ "+S_ /@QN/\ XNE_X9;^"O\
MT*LW_@QN/_BZ]JHH \1_X98^"^3_ ,4Y<X/;^T)^/_'Z;_PRK\&=Q/\ 8-YC
MT^WS?_%5[A10!XA_PRO\%\G_ (IVZ/'3^T)O_BJC;]E/X--TT6]7Z:A+_C7N
M=% 'A3?LH_!TXQI-^OTOY/\ &F-^R=\'VS_Q+=17/I?OQ7O%%4!X)_PR7\(/
M^?'4_P#P.;_"D/[)GP?/2QU1?<7S?X5[Y10!X(/V2_A#MP;/5"?7[<W^%,_X
M9(^$1_Y8:O\ ^!O_ -C7OU%2!X%_PR3\(<#_ $75<C_I^//Z4A_9(^$.!FVU
M;_P./^%>_44[ > G]DGX1?PVNJK_ -OI_P *:/V1OA+GF+5_PO?_ +&OH"BB
MP'S_ /\ #(WPCQCR]7!]?MO_ -C1_P ,C?"3_GEJ_P#X&_\ V-?0%%(#Y]_X
M9$^$O_4:_P# T?\ Q%'_  R+\)3VUH<_\_H_^)KZ"HH ^?#^R'\)O76O_ U?
M_B*3_AD3X2@G)UH@C_G\7C_QROH2D(Y]JH#\^_VCO@[X1^%UMX=;PT;]CJ#S
MB8W4PD'R!,8PHQ]XT5Z3^VIG^S?!>T\>==_RBHJ@.^_9)&/@-"?74+C^8KWZ
MO /V2<?\*&B 8G_B87&1Z?=KW^D 4444@"H9O]7_ ,"7^8J:H9O]7_P)?YBF
MAHFHHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHYS0 444
M4 %%%% !12,2%) R?2E'2@ HHHH **** "BBB@ HHHH **** "BBC/.*  ]*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*!
M110 4&BB@#Y#_;6++IG@O^Z9KO\ /;%13?VUVVV/@KYN/,O./PBHJ@/0/V2<
M?\*%AX(_XF%QU[_=KWZO /V2"3\!XO0:A<?^RU[_ %(!1110 5#-_J_^!+_,
M5-4,W^K_ .!+_,4T-$U%%%(04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'[P]U)%=^"".*0"T444 %%%% !13=RYQN'YTNY<9R,4 +12;E R6&*;YD?\
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M49U^X>Z&EW%PS22R2/G>N22IW#C&,8XHN!Z78V]K9V,%G8QI';01K'%&G15
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M3::AJ8OW^ZJ[A("< XZ>N?6O1ZY?P?X+TWP7I]Q8Z7>:C<Q3S><QO[Q[EE.
M, N20..E=12 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** #I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110:
M"BBDQ0 M%%% !112 4 +11S2<Y- !D4<9H.<>M&* %Q12<TM !FBDQ2T %%%
M% !1110 &BBB@ HHHH **** "CM10>E 'Q_^VP/W/@=MV/FO1_Z)HH_;6.(_
M _R@_->\_P#?BBF!WO[)##_A0ZJ.HU*XS_X[7T$.E?/O[(W/P*'MJ5Q_):^@
MZ0!1110 #I4,_P#JO^!+_,5,.E0S_P"J_P"!+_,4T-$U%%%(04444 %5-0O;
M73=.N;^\F$-M;QM+*YZ*JC)/Y5;KP[]IKQ!<:3\*$TRUD:.36+I;5RF<F(*S
MN./7:%_X%30'RMXBUZX\9^-]4\7:HES/#<R,X6*,,8(!Q'\A." %&5[X;UK'
MU);&VBD:WE26>[D_UV L84!2HV #RF+ \9X4].AJUIC+%=>=!<:<KPQ>=LNV
M>(AE^4+'+G[Q7)SD+@D&JUI!=:PT]\\FF75U<R"Q2TO&+W#&1<^8HX'RC@-V
MYJ@'VMK86EY"-4DMX?)O7M9KFQNBS7H?;F/(./+53SV/(ZFOI""QL[:Q2QTN
M.*WLHV 1+?/EX.3P>I^IZUT?@[X1^"[SX866A:QX>LW>Y@V33J,3!LYW*^-P
M.>>,"MC1_!&C6$5]I-U))(\(%M&2^QHD ^7&W@94*<__ *J$ OAG3[9CLFFV
ME\,BOG))'3\.*],LXEAACC./E&,#.!Z5R,.G^&]+6XF.EHD *I)+*QW[3QNR
M3GU]_2BTU'5-1U-85F&EZ;;Y*2RC=//UVC:>@Q@YY/TH>H';NL1!!(*^AK/U
M2V22RE544G;CYQD?_JJO;WUFP-JL@N2HS)<CY5#<8R>S'T'\JY_Q(NN1F-;#
M4GCS#(9 P'ESOQM ./E49/(]:2 ^;OB=\.;2UG.N>&]+CNEMX9-^EEW2,,1C
MSXU!&'[D#@D=#7CVFSWFBZB]F)+2ZNT7D13KY+[D(&77MA\8R.>.,5]@:S:Z
M#;:-++KNH7=E?*H\EU.0V>R*,D^GS?I7RMXZT!-"UG48K1]/@LPQOK5I$*RW
M +*'A4C.<$AL?6J: QKR*;2[B&XMM6C74;6?)DMI%S%(N"K(5 [#!QD CKS7
MW[\*?&B^.OAMI>O.8A>,AANXXSQ',G##';L?H17P+%"FI:?'9VND,+FZ^62[
MDB(2%0<A4VCCH,L<^P')/O/[*?BF:S\0ZKX,O/DBNXC?01G)VRH=DOY\?E4@
M?7@H/0TM!Z5('Q+\3+7P_9^-_'^I:/KNAR7$DW_$TT7Q3:A996"Y!M9/O;3V
MVD'..>E,\3?$;QO_ &A+'9:M>>$X=-T;3[K2[$:A%#'\\2EO,$@+SCDK@$G@
M9KWOQCXW^"$'CR#2_%D6E7FN6\B1-<36(F%HQY0/+M(3Z$\9[5=O_&GPDUCX
MF6?A/4H[&_\ $-G,8[9Y[/>D4VW<8UE*[0^,<9_6F!Y5)XSU2Z\:ZM>>,OB3
M>^$K[2/[.6STFS >*Z$D:/(3$.9MS,5X^Z#[4S5-6\>+9_%7QI9>,]6V^';^
M>RL--!40QKMCS(002=@?(]-N>YKU2U^('PA\5?$ZTT5%L[_Q+9RRPVES)9$A
M9$!+K',5QD 'H:Z#5_%?@?PMXLT[PAJ,<-G?>)WD>-1;CR[F0\-O(&"S<#GK
MQ3 ^3_$&I>*?$'PG\=VMYXHN]3TBPAL+Q"^IPWCK(TP0H[QC!1@=^WLR#\;?
MQ+^(VI:0LEIX.^(>OW4NAV-H$E:^MXX)-W+/@?-<L<X.!\N#G@5]0^%?^%>W
MT7B7P[X;T6QM[:RO'L]3MEM%CBDE*@MD8PXP16S_ ,(?X-80/_PC>E'R(O)B
M/V6/Y(_[HXZ>U%P/ D@\>>._&WQ ;2_B%J^GG1K2UDT^RLY0D3RRV8<9_P!G
M=Z>N:Z7X&^+O$_Q&UC4?%6I7UTFEV.GVNF+:,-J27@4/<28]0V!]&KNO$WB+
MP?HMMXBTR#58M'U:#2&O[B2Q@5KB"!%*++C!#;1]T'T]*/A#H/A_P_\ ##28
M?#MU+>VEZG]H-=W"[9;EY<,9&'8D$#'8 "D!Y+\2?%&I_P#"R/&5KJ'Q&O/"
M$7A[38;G1K.WF2$:A*T3.20P/F_. NT?_KB^'6DWFM_M)_\ "1^(+ZY.ICPO
M9:E):R*FV*25=K1XVY"J22!P<GO7JWQ)\2?#/PQ=:5?>--/M+_5 Q?3HELQ<
MW19><Q@ D<]^!FMSP?XF\&^,]//BSPV]M<-(OV>:8QA)XRO_ "RDS\P(ST/K
M0!X#\8[;0;CXP:C<6GB32-*\00Z7'#/9^*+1387L!R?W4C9VOS@X&>OO7':#
M?6K>,?A1X@N-1F\)Z?#H][Y<,$FZ%#%))Q'O)+"3C*Y)(P :^PM:\->&?$2P
M?\)!HMCJ8@;?%]K@638>G&13;KPUX8U#^S_MFB6%Q_9K![,20*?LY P-G'R\
M>E%P/DOPAX\\3>*/$NKZ-'XXUN\TO5?#]]<K+=2V_F^8N=I2)-WDC&1M)R>3
MQQ6-I_BWQ-H_@7P!X?T/QM>QZ;=V$]W<2VUW;P-#,O2V\R3"J% #%2<G>?48
M^RK#PEX2TNY,VF^'=+M)V+L7AM8T8EN&Y [XYJD/AUX &D/HW_"(Z1]@:<W)
MMC:H4\TXR^,=>!^5%P*WPMU;7-<^%7A_5O$C1R:G<VH>:6)E*R\G#C;Q\RX/
M''/:NWKE_%GC'PQ\/O#T6J>(+Q+"QWK;PI'&6+N0<(B*"2< \#TK)T7XM> ]
M=\-7_B"WUV.VLM-(6]^U*T+VI/0.K $9S@>IZ4@.^HJ".XBDA6:-@8V 8-G@
M@\YJ7S%W;<\T .I.<^U4=2U;3]'TN?5-2NH[:RMT,DT\C +&HZDFK%O<175O
M%<0.'AE4.C@\,I&010!/1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4=Z** "BBB@ HHHH **** "BBB@ HHHH *.U%&* "BBB@ H
MHHH **** "BB@=* "BBB@ HHHH **** "BBB@ HHHH *3H:6CO0 G/I2T4#@
M4 %%%% !1110 4444 %%%% !1110 8YS1110!\?_ +:[)Y7@A3MSNO3SU_Y8
MT4G[:T<9'@=G)W9O0/I^XHI@>@?LCX_X40O_ &$KC_V6OH&OG[]D8?\ %B$]
M]1N/_9:^@:0!1110 #I4,W^K_P"!+_,5,.E0W'^K_P"!+_,4T-$U%%%(04AI
M:* "OD[]K.Y:37_!U@V?*6.YFQV+9C _+%?6-?(O[6,+1^,_!]T?F1K>= N.
MI#*?ZBF@/ )9-<M;&YTU]09=.7#2P^8'B!9AG !/0GG;WX-;_A7R[/Q#X?6_
MM-,AACBENHIH6W2R[L@>9DX! X[=!G-95\ROH:(NK"[9&5HX8],\O;E@2!)@
M;>2#@9!Q5WPSHK7FKZ7"VG2:']LLV2&Z(+K<RJ^TOZ+Z=^GO5 ?:GP[GW^%K
M?]YM,#-'R.0 <X_S[U8\0?:H?%L1@%M#!J"I&D]U\Z22 /E H_B"J#Z$?2O'
M?@WX_P ^)[SP/<6MPT<4KK#>O*#YS1_*W'_ 6.037LGBB?2M2TV?PU+K,%CJ
MDQ!L6+!7BG'*,N>O.,@=F(/6@!=8MK6S^QR->VT^HF-@!<,L:L-N>,8VC(7I
MDBLV_P#$&D7UJNXV%M+D)'++AD(89_=X.&^Z>,]CFO&FA^*VDZD\=YK=]%=K
M-YTAN5MQ#.5 ^5&*_=;  QCGK@BLC5(/'^NPO#8:3H]HUS=&67'DJ&(6--HR
MS%2JJ^<'OT!IZ >WSZ5J4ESYNG75D]B8FW1F%@P/RXP V&)_#K63;^();SPQ
M9ZA;ZI:S-M*1VJKN:27S-NQ1N4AMV5.>!@]A7GG@76?$?AWS[CQA!!YPM)I[
M(VDT;QV\(C7<Q4-T^0'TSQU-8?@?2-8\0^%[K5-'LX;4^>[?:;K<LCEFWX78
MI& '7/;K^(![[JNGMI'A6^FG:&[U*[_=33JF.&PNQ>I"J!TSZGJ:^?/B-I;O
M8Z#(UM87$T5\(!'??+$0ZX^<@CIP?P^M=KJVC^+]!@MYWUB.2WN8@6BBN3DO
MP=H# 9P<\\<8KS#QI</K.BZ9+$LVJI<WL2I8LQ'GG)W*2#D'CM]: //;&SC2
MV9]6O;E4L9RBK PDC7MGG/WF4 $ C\AGN_@S<2:=^T/X<EAE<B>YGMY TJR$
MB2%CRPX//< <UYQ:P6$D]Q<7<DNG6R3LBQQIYQC))PIY'0#KGFNX^$-O!#\?
MO"D4)$J+?L%D"8##RG.3W!]JD#]#%&!Q0QPII>U!Z5('R+\5/&OA_7/B=-X,
MU#0[_3?#-I?)/JES8:;YDVK749&U-PZ(!_%R3CZ5)&ES/XRMOAV-+OH]<MO'
M;Z^UP8&$8L3ND$GF8QR"%Q^%>R>,?C5X'\%:[+HEY]NO]0MXQ-=1:=:&?[,A
M_BD(X7U^AKN=&UK1M>T>SU[2[N.XL[V)9(9@?O*>1_\ J[&F!\V>%/%^F^,O
MVA].CNM+U#1[+1[JY71K&WT_9#/*R/YMQ.^, D9P!^?)K>^-O@F;QY\8O!FB
MQS7%E(NF7TT-[$IQ!,NUHR3C& P'I7T3NA5L9 /ZTBR0NQVL"1P>>E 'Q! ?
M%U_\-]<U7Q)IFJ064WC*-O$,%A'(DK6XA57*]RNX#/X5.='O=5\,:Y:>$H]<
MM/ ]_P"*-,@TI9/-$J*0RSNF[E4^88/T]Z^U_,MVW*"#_>]OK2KY.0BX]0!1
M=@?%OC3P)X<\!_$SQ5I-C8:I(EQX/N&TTL9I]]PRR;LMSD;5;@\?C74?#3PF
M_A'XK?"^;3EU*)=;\.23ZH)Y92K2B($;E8X7!( 7MQ7NWCOXC^%OA^EFVMO<
M37EZQ6WL[*$S3R@?>(4=AGDFJ>D?%KP?X@T&RUK26O;J*YU)-),2VK>;;3L<
M 2KU1>Y/3!H XWQ]J$O@'XZV'Q"U71;[4O#]WHITEKBS@\][*82F3)4<@,#C
M-><_$CQ#)XC\&:#?WGP_G\.Z/JNLW$J[VEC2<!<QS7,4"B0L^3@9S\I.2#7T
M]H?BK0/$LNI)HU^MVVF7;V%SM4@),H!9,D<XR.E;FV.3WQZ'I0!\=>&O#=WX
MQ\(?"SPKKTVL)9G4-5AO0&EBD5%5F1&)Y P!U[<"L-+&XT/]H:*UT_\ M?4K
MZVUY(8;>9KB*ZCMP<#]X-T30;<$YPQ&>F:^N?$?C3PWX5UK0M'UJY:VN-;G-
MM9L8R4+@#@MT&<@?C5O1_$NCZUKFMZ79,[7>BSI;W>Y, ,R!Q@]Q@B@#Y,MS
MJW_"?VH$WB$?%-_%!6X5O-%K_9X?T^[Y.P#'?K[5,OA>Z?0]?\>1WNL#6].\
M<_9[0?:9!'%";B,-A.F#O.3[#TK[) B9]X +=,^U(PA"G=@ G]:+@>)_M&?V
M>W@[1FUBQU<V,.I)(VIZ2V)M,<*P67;@[AR1CCG'.<5X3J4NL^*/A)\1HVGN
M?$NB6!LKBRUR;3S9W-TXD"L&P,RA$+9+9QC-?<+- %Y(QTY-8WACQ'HOBOPS
M;Z[HTK2Z?<,ZQM(A0DHY1OE/3E30!\S:#H$7B76?$NK>#]2UIX]!T"TFT* W
M,H1[@PR %D;[QW+WKD/A_>>,9+37)/"&O7UUJS>')WU&V(NG9;KLQ>3Y5FSR
M-OO7VU=7ECIFG7&H74R6]I;1M++*W"HBC))]@*X#P[\9OAMXDL]9O-)UC$6E
MP?:[MYK=X?W7/[P!@"PX[>U/4#Y;TW3I/$7@3QBNG:O>WVGQ:"MY=6L+797[
M8K[MS/,<%_O;D'!&".17U_\ #1M$;X::$?#MU+=:8+<+%+,SLQP2&Y?YN&!'
M/8"N=L_CC\,+SPIJ'B2UUH_V?8R1Q70-K()$,G"$IMW;3ZXQQ2Z;\<_AA?>'
M=6UJQUX?V?HRQF[;[/(IC\PD( I4%B2", $T:L#U.BN-T7XC>#]=\$W'C'3=
M:CET:V#F>=E*&+9RP96 (/MCG(QUK=T#7--\2^';'7M(F,UA?0K-!(5*EE/3
M@\BI U:*Y^\\6:!8^+=/\*W6I)'K.H1//;VN#N9$&6;T X/7T/I6!H/Q>^'O
MB;Q+=^'M$\207.H6P9F3:RJP4X8JQ 5L>Q- '?T5QGA'XF>"/'%Y>6GAC7X-
M1N+/)EC565@H.-PW ;ER?O#BM30_%6A^([O5+;1=06\?2KHV=WL4XCE"@E<]
M#C/.._% &_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !110.E !1110 4444 %%%% !2=S2T4
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MZF28]D-J=TB;D. I+%551A<##5G:??16%G!J5I_:)U&&?=+-M5K>.VD!7 #
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M -$44P/0_P!D?_D@R_\ 82N/Y+7T%7S]^R./^+$*<==2N/QX6OH&D 4444
MZ5#/_JO^!+_,5,.E0S_ZK_@2_P Q30T2@TM(*6D(**** "D/0TM% 'Q;^TE\
M/F\,^-%\9V%JPT76B1>"+("7(YY/;?U'NI]:\4L+"UGM+FX_MBVTZ:TA\RWC
MDSOG;(&Q>/0G\O>OTF\1:!I7BC0+O0]:M$NK&Z7;)&XS[@CW! (]Q7P5\4/A
M+JGPT\3G[1Y]WX:F;%KJ0&=F?^6<G8-G'/<?D&@,/PC)K&H^(-.L] A\W7KA
MVBCD8[VA4X.Y >%7).>P!;BOJ'7/ =UXGU!5NM5>ZL;=85=X5((='.Y70 90
ME#TZ^V*^3K>XTZQTZ"2T2Y@UR.??#>)*/+CC"]L8;=N7KGVKV_P+\>M1L+03
M^*]&FOQ:,L/V[3PIDS)E5WH3\S$J?F!R<U2 [.XU;Q+8:7;Z9#'I"ZD9Q)LL
M78B$KCY<G.]F5B3TQ[]]R#X@P^"-'6U\2K!$UO#O=WG(?@=A@DX/'KQ[U5T[
MQ1\/_&OV -K&C:I")E#27Q^S7:%<#G.TDEE'U_&DUSX0^!O$<L6I7NE3WCVG
ME)"$U-F5D7 QSG/&2?7%/4#G+'Q'<ZOX^O+_ %'0[P:7>PQ2+'>+L62)6/EL
M/,_AX## &2:[^'Q5<W4+:3HOAL6-H "U[&ZB.#G!<;,!B!SA>35OQ#?>%M,D
MDU#5M0T;3[F.(6Z27,HE=8E^< (3ZEN /2O+/%WQX\,QI=MX2T^[UN:+:XN9
M5VVML6.T\_?*GIMX!Z9H Y3XZOXE6[M+F^G-_P"&97#V\TZ;9$?R\,F!R"&S
MCIC/XUXQ;68OM)N]0N+Z%)[8I^YG/[^Y9B<L/[V.22<]JUM;\5:CXO\ $+ZO
MXTOKK4E*.L<5K(J+%Q\NP'A5!P2,9Q[\UF:)HVL>*/$-CHFB6+WVHW!/E01L
M%  Y+.>P'<_A2 T_ ?@F_P#B!X\LO#>G*R+/A[B<?,+:!<!W/N1@#W(K]&]%
MTBST'0K'1M/C\NTL84@B7T51@5Q'PC^%^G?#7PO]E#+=:S>?O+^\QS(_]U?1
M%Z ?CWKTFI8!2-T-+2-P*0'A7@>2^T3XB_&M_L)N=52YBOK>(*=]Q&8&,2CN
M1D;1COFK-E8^)O!W[,%Q<Z187=QXNO+-KZ6-86,YN[AMSG8!G*E^F.-M9OB+
MXW>'_#5CXG\63^%0WB#1M5'AV2%9@'N$#,Z-OV_=(#L!CUKJ-&^,VDZMXFM=
M->S6SL#X>BU^ZU">X"QVHD("Q-D=>>N1]*8''>/O L&D?!/P=HMQX2U+Q'I>
MDSPS:C::=,4NBQ1MT@51\_[QR3R",YSUKE;'3=:LO ?P]T74+6\T^ZO_ !O'
M>:38WK%[FQLD+/M?/)(7/7H'%>V:O\6_"=GX03Q3I.J66KZ<+^WLIY8;D!8/
M,D5"['!P%#;N<9 J>3Q=\+M2@A\=2:_HUQ%HY>"/4C.I%L9,!E!SP6"CW(Z4
M:@<#^T)X9O\ 5+OP?X@CTO7-4T[2Y[B.]MM"<K=[944*RXYQN0 ^S5YQKWAW
MQW<> ? 4WC;0_$>J6=JM]O321NU.V#C%NLC@9P5X;\,],5]#7_Q)T=M)T75O
M#=WINM6.HZG'I[3"_2)8]P))4G[[C'W."<UG>&?C9X$\26_B*Z&K0:?::%=F
MVEGO)T19%Z+*O/W&.0,\G!H \%\0?"OXKZM\$=#:ZAL;B#2-':*+07MG^T)*
M7($@5.#,(MHR>A+<9.:]D70/BW)X'MK6ZU;1VA&C/;W.E0V;+)++Y3*$68N=
MO\ SM/()]*]"MO&?A.\TZQU&T\1:?/9W]P+2UF2X4K-,>D:G/+<=.M;D\\-K
M;R7,\@CBB4N[L<!5 R2: /F#X(Z%J>D^.%OM#\'^(_#.A6NC&'4K?5G=A=7@
M;(\I3UQAN0 .>@SS:OOA]XDU;]E_6[E]+N6\7^(+L:W>VKIMF=Q.'$0!Y&(U
M "G_ .M7O4/C+PK<2:?'#XAT^1]1C::T5;A2;A%SN9.?F P<X]#56W^(G@6\
MTZ[U"U\6:5-:V2HUQ*ETA6$,<*6.?ER>F: /F3Q%H_C+QAIGCGQQ;^"]6L=/
MU272[>33GB\N^D@M\&5XU(^\&"X/H#Z5[!\ =.U"QT'Q'--IFJZ?IMYJ[W%B
MNLJ1>R(8T!:4GD\C SS@5Z&WC7PDNJVND-XCTX:A=JC06WVE/,E#C*E5SDY'
M3UJRGBCPXZ!TURQ8&\_L\$7"G-S_ ,\>OW_]GK1J!MT5B:OXI\-^'W1-<UVP
MTUW1I%6ZN$B+*,9(W$9 R*+/Q-X>U*2WBL-<L;N2YA-Q"L-PCF6,'!=0#R >
M,CO2 VZ*Y:?XA>!;8VXN/%^CP_:,^5OO8QOP<''/KQ5W4?%GAC2+R"SU3Q#I
MUC<3X\J*XNDC:3/3 )R: -RBL*\\6^%].U&#3;[Q%IMK?7 4Q6\UU&DDF[[N
M%)R<]O6M*\OK/3K&6^O[J*UMHEW233.$1!ZDG@4 6Z*Q;+Q1X<U"WGN+#7M/
MNH;>,2RR0W*.L:'.&8@\#@\GT--M?%7AJ]L3?V?B#3KBT$@B\^*ZC9-Y. NX
M'&2>U &Y15)=2L9-2?38[R!KR.,2O;B0&14)P&*]0,]ZNT %%%% !1110 44
M44 %%%':@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ H[T4=Z "BBB@ HHHH **3!I: "BBB@
M HHHH **** "D'4TM% !1110 4444 %%%% !1110 4444 %%%% 'Q_\ ML,-
MO@9=N3F].?\ OQ13?VV'PO@8;5/-]R>O_+"BJ ]!_9%S_P *'7/_ $$I_P"2
MU] UX!^R.P/P&0#'&I7&?_':]_J0"BBB@ '2H9_]5_P)?YBIATJ&?_5?\"7^
M8IH:)%IU-6G'I2$%%>27/[1/PAL[NXM)_%B^;;R-$^RUF8;@<'!"8/U%1K^T
MK\&C_P S< ?0V<__ ,13L!Z_17D:_M)?!EFVCQDF?^O2?_XBGK^T=\&V_P"9
MTB_\!9__ (BBP'K-4=1TVQU:QDL-2LX+VUEX>&>,2(W.>0>#TKS(?M(?!EC@
M>-(O_ 6?_P"(IW_#1WP:P#_PFD6#_P!.L_\ \118#Q_XD_LOW-O)<ZU\/;CS
MK<LTK:/.0"N>T38[?W3Z#FO 8[G4?#4VH:'J6CO974L;6S07@,3QLQ5EDY[J
M54CH/SK[?_X:+^#6<?\ ":V_XV\W_P 16+XA^+7[.WBJT6V\1ZYI6IQ#[HN+
M*5RO?@[,CIVIZ@?&TSV7]A):P!4N5A.X20G,A=R6V]5X 7YN",#'4U==-/NI
M;&*QD@MC*D<MQM_=B!D1E89/'S!=WU(KV?5]'_9+U20-8^,)M';N+1KC:1])
M$;'X5RUWX,_9_FN,6_QIO(D! C$MFS\>Y\L9_P#UTP.!U!M)BU6]GLYH4AU.
MS\Z,1CS#:2DB01]RN'0KU^Z?>JK:_;6^KW%S8VB))<A$*-& K@8\P-&.H<Y^
M7C[U>O:;X4_9DMY$_M+XI7^H.",@[XD8XP?NQ_UKT_PWXL_99\)7276AWVC6
M]VG"W+VTTLHXQ]]E)'YT,#Q7P#\!_&7CR5;RXMF\.Z0&#"ZO(2DLJL02$BSG
M@$X8X'%?7_@+X:^%?AWI7V/P_8!9G \^[E^::<X&2S?AG XK#7]H#X.YP/'%
MET!_U<@_]EIX_: ^#Q!QXZL3C_8D_P#B:G4#T^BO,?\ A?\ \'\X_P"$ZL<_
M[DG_ ,32CX^_!\]/'5A_WS)_\30!Z;0>17F7_"_/A .OCJP]>C__ !-+_P +
M[^$''_%=Z?S[/_\ $T@.4U?X-WFH?M'VWC+9;R^%I8UN[VUD8'?>)&\:-LQS
MPP.>QS7$V7[._BE/A5XRT62^A_MJ_O(8].9Y_D-G;N#&C$*2N1GY>0"%KV$?
M'OX/G_F>M/Q]'_\ B:!\>OA 1_R/6G_D_P#\33 \CL_@OXR_X1'7)3HT:ZG>
MZAI\R6-_JHN4N(X'#-YK! HSC P"<<'WL^)/A)XR\51>)M:D\*:;IUQ?WED]
MOI<&HE'C6WCD4S)*@V"0F3 W*1@'/:O5/^%\_"'/_(]:?_X__P#$T@^/'P@Q
MQXZT[ _WO_B:-0/)?#WP;^(EEX<T*SOXK8FU\86^M-#)<(TJ6ZH5=I)%4"1R
M<>IP*I:O\%O'=Q;^(]/M=#ME@7Q0VO6<D-^D)O(&+ 0_</EE0=P)X!)&.]>T
MGX\?"$'GQUIOYM_A2CX[?"-NGCK33^+?X4 <Q\/? NO>$?#ULMUX6@O+K4/$
M'VZXBO=06=K"/:1]H5M@4RC'10/O=:]KDC62)HW0,K*593T(]*\\'QT^$;$J
M/'>F9')RS?X4K?'+X2KC=XZTSGT=C_2@#Y_U']F_XAO%JLFFZE;PRZ7=?9_#
MH^T8"V3O*9 W'!Q*.#Z$>E=GXT^ %YJFK^%M/\/&*U\/O90:=KX638TL5NRM
M&5'.6/S#.?2O35^.?PC;IX[TO_OL_P"%+_PO'X2G_F>]*_&0_P"% 'C^F? O
MQC:_#35[N\:WF\>Q7EK-I-P)^(H[0*D*EN@RF_/'<9]K/P^^"GC'P]\2- OM
M:G2XT.TA.L74;3AMVK21E'P/;@@].*]7_P"%W?";C/CS21GUEQ_2G?\ "[OA
M.#@^/=('_;:@# F\)^(O%OQ/\+>*O%?A6RMK?3K&^MYK9KA+E8Y&=1$PR!NR
MH)Z<9KS=?@O\0+/X2:$NAK%IGC'2+Z]6,+*@!M+EF5@7!P,*0P ].F:]I/QK
M^$XZ^/='_P"_XI__  NCX4XS_P )]HW_ ($B@#Y_^(?P#\1QZC:VO@O02]J-
M-@LQ<07<02:1.";B*4'ZY7.?3-;>O_"WQQ:ZEXG/_"%Z7XJ?Q+I5M90WAGCB
M&F2I (V 5QQ&&&Y=F#P/P]D_X71\*,X_X3W1L_\ 7R*3_A=7PGS_ ,C]HW_@
M2* /GGQ%\$_B#;:W81:1I/VZX6TTZ!K[SXI;2=X54,9XY?G7&WC:3D =S7IG
MQLCU?4? <]MJUC9V%GI>IZ?);FYO52WUKG+PL,'RESP-Q[ G@5WO_"Y/A42,
M>/=%.>G^E+574OB?\'=6T^?3]5\7>'[VSE&V2"XF1T<>X/!HU \#A\.ZMX^\
M2?$6#P_H&EZ:VW2+@Z7;72-;W"Q,[-"\D8V;F4<CH.,^M=?8?"W4_&5QXUO+
MCP?#X(TW5])AL[&P#IN^U1L76X98SA2K  8YQ7HVA^/O@EX>L6L_#_B3PQIE
ML3N:.TEBB4GU(7O6H?B]\+QG_BO-$ ][Q/\ &@#GO@YX-\1:/:ZMXJ\=JA\6
M:S(J7!5@_E01*(XU!''(!8_[PSTKURN%3XO?"]E##QYHF/\ K\3_ !JQ'\4O
MAQ(%V>.=#.[I_IT8_K0!V5%<D/B5\/R%/_"::+\PR/\ 3H^?UIQ^)'@$*&_X
M3+1L'O\ ;8_\:+,#JZ*YC_A87@7.!XOT?_P-C_QH7X@^!67<OB_1B.>1>Q]O
MQHLP.GHKFQX\\%,>/%FD?^!D?^-*GCGP;(<)XJTECUXO(_\ &BS Z.BL#_A-
M/".,_P#"3Z5C_K\C_P :>OB[PJR[E\2:61[7<?\ C2 W**PAXP\*GIXDTP_]
MO<?^-2+XJ\,MT\0:<?I=)_C0!LT5CCQ1X;8$KK^G$?\ 7RG^-./B7P^!DZY8
M8_Z^4_QH UJ*RO\ A)/#^[:-<L-WI]I3_&G_ -O:'G']L66?^NZ_XT :5%9?
M_"1:#S_Q.K'C_IX3_&E_M_0^,:Q9'_MNO^- &G16:->T1@"-7LR#W\]?\:5=
M<T=_NZK:-])E_P : -&BJ']LZ3N*_P!IVN?3SE_QIW]K:9G']H6WT\U?\: +
MM%4O[6TS_H(VW_?U?\:7^U-.W;?MUOG_ *ZK_C0!<HJD-5TX]+^W/_;5?\:;
M_:^F%MHU"V+>GFK_ (T[ 7Z*HKJVFMG;J%LQ'I*I_K0=6TT=;^W'UE7_ !HL
M!>HJB=8TM3AM0MA_VU7_ !I/[8TK./[2M<^GFK_C2 OT50_MC2\C_B96W/\
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M?_PH#X/EE;_A!; $>[X_]"I1\ ?@_G_D1=/(Z<[_ /XJO3Z* /+F_9]^#S
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M[]*- .Y\)?L[? _QIX9M?$6@_P!LSZ=<LXBD:Z9-X1RA."N<94^E.\2?LX?
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M7WY?N**H#T;]D;=_PH=,]/[2N,?3Y:^@*\ _9('_ !86(Y/.HW'7M]VO?ZD
MS1110 #I4,_^J_X$O\Q4PZ5#/_JO^!+_ #%-#1*M-?\ U;?0TY:;)_JF^AI"
M/GK]DU5'@+Q.R]#KLW/_  !*^B*^=OV3?^1!\3<D_P#$\FZ]?N)7T30 4444
M %%%% !1110 4444 %%%% !1110 4444 %%(6"]32*ZM]TYH =1110 4444
M%%)N%)O7^\* '4ASCB@,#T-+0 4444 %%&:* "BBB@ HHI-P% "T4 Y%)NH
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M.M 'QI^VPQ^W>"%*9_=WIS^,-%+^VP<W_@@?],[SCTYAHJ@/3_V2^/@%;?\
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MQM(QEAQ7D^J:=X1UO2[6R\)^ _$^C?$-I45K.W5OLR29^<J')=1U(Z;?7 H
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MS><Y_P")O/\ 7[L=?0E?/?[)'_)&+OWU:?\ #Y8Z^A* "BBB@ HHHH ****
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M2ZH"/)CM@TC[,D_*!M7U)XYK9T+XY?"_Q-KJZ'H_BVVEOW;;''(CQB4^B,P
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MWJG[1NBK\:]!\,:;K.C'PE<6[3WVK^=N"N4D*QYR G*IGJ?F[5TUCK_B:?\
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M_@45%)^VQG^U/!?RY_=7?/XQ450'JG[)VW_A05I@8/VZX/U^85[W7@?[)O\
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M8K7=5(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7SW^S3DW7Q+8Y.?$DW).<]>]?0E?/?[,OS+\1F]?$L_;'Z=J
M/H2BBB@ HHHH **** /C']M<G^UO!6.GDW?/K\T5%._;54_VMX*8?\\;P=?]
MJ&BJ ]1_9/P/@%9=>;VYZ_[]>]]J\#_9.W?\*"M/3[=<?^A5[YVI, HHHI
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M.[D+]*]2^)GQ?\6Z=\2+#X9?#71+74O$,\0FGFO,^7 IY P".BC<23P".":
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MX/Y4 7:*IP:E87,3R6U[#,B?>9) P7ZXZ5%'K6DS2>7#J=K(Q. %F4DGVYH
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M0V>GW-S+#=VOF)%&SLN(&&3@<<\9K*_LC]L??N_M2V;;TW&S/\TI6TO]LK:
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MB]WQ_P!.MU_\336_:7^+4;!9/@W<HQZ P7(_]DI ?7-%?(Y_:>^**)N;X.7
M_P"V=Q_\13!^U)\2=^#\(93VP!<9!_[XIV ^NZ*^1O\ AJ;XC!<M\'[C@9/^
MOQ_Z+IO_  U9X^#E3\(9]P[;YL_^BZ+ ?7=%?(K?M9>-D&9/A%<*.G,TP_\
M:5(/VM?&&TL?A'/M]?M$N!_Y"HL!]=T5\A']KSQ.JDO\)YE]S=2#_P!I4O\
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MM::D<%=213QG]P#G]:7[+J6TC^T4)YY,'3_QZM&B@#,^QZGG_D)1_P#@/_\
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MYG\-\'QK\3&'_0?4=/\ IU@KTL]*\V^&ASXM^)3<_P#(PD<^UK * /2J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3\: %KG_&'B.W\
M(^#=5\1W49E2Q@:01+UE?HB#W9B%'UKH*X_XD^';KQ7\-]:T*Q95O)X0]OO^
MZ9482(#[%D _&@#D-1^,EEX0$FD^*--U+4-8TRUM[K5I],LLV]JDN?G.6R%7
MIW/UYK3L?C'X;NEO/M&FZOITEM):JL5Y:>6\Z7,GEPRHN<["WK@CN >*Y]O
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MIG_C'S2^O_'U<_\ HPU[I7A/[*9_XQ^TSIQ=7/\ Z,->[4@"BBBD #I4,_\
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M2Q8\P2#.U,;EZM_$/>D;XU>&VTO1;RSTG6]0N-8DN(8+&UL]]PDD! E1EW
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MV(-<[XQ^)E[H?Q:T/PA:_9[33S:R:AJMY=VLS*D"8X1UPJ\;LLV0.!UX)J!
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M*GBC!W?!SQ;QUP+?_P".4H^*GB3;N;X/>+^G01V^?_1M>JT4@/*1\6->(/\
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M.\;2ZHU[H-C,^I6<7DF76YDATV01 /&(DPLAW@L'(_BYZ5T-Q\)/$%KXSO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O*OA>4/C_XHE54'^W5!(Z_\>\?6O5:\L^%^YO&_Q/8@
M@?V^ ,X_Y]X_2@#U.BBB@ HHHH *0D8Y.*6D/W: /B;]M,?\5=X3(Z?8YO\
MT-:*/VTA_P 5;X3./^7.;M_MK15 >T_LJG/[/.D<=+FY_P#1K5[C7AO[*C9_
M9[TD9^[<W(_\BM7N52 444&@ '2H9_\ 5?\  E_F*F'2H9_]5_P)?YBFAHD6
MN5^(?A*+QS\.]9\*R2^2;^ I'(<X1P0R$X[!@*ZI:221(HVDD8(BC+,3@ 4A
M'@NGP_'Z^3P[X5ETZQ\-V>DRQ"^UR*[6X^VQ1J!M2/&1NQSG\Q69XL^&/B[4
M_ WQ/L;/2(I;_7=?AO;(&9/WT*F$[L]L;7X/OCMGW=?$_AU]*EU=-=L&TZ%M
MDEV+E#$AXX+9P#R/SI[^(M!AL8;Z36K)+2<9BG:X0)(/]DYP?PIZ@?+?Q4^&
M/Q6\2>)?$4-MIMY?Z=<VEL+ VE_';VX\M0769.LKY!"YXYS].[M? 7B23XGZ
MMJUYHN^TF\&QZ9&\C1L#<8PT>?S!/2O:[?7=%NKTV-MJUI-<A2QACG5G !P3
M@'/!XJ6+5=-FO9[&'4+:6ZMQF:!95+QCU9<Y'4=:-0/E.VTO7OA_XA^&5Q-I
MUC>:U;>'9;"?2;R_BMV@)9F\U6<$=R&QGH?6N<\.^"_$WB;X+:9KF@6,MS-I
M'BJ[OI;/3KA8I)4.U28).GRD<''T]_JCQ1I/PW\76"R^++?1=3MK*3:);J1"
M(6/;=GC/'&>:;#XB\'^%);+PGHMO#%G3IM0M+.P5 C0QE<[>0,L6X]>230!X
M':_"WQA:>#[?Q0OAJ_N-2MO$\.LRZ3?WR7%S>1(NS<2 %$AW9QD]/PKJ/#.G
M^,;37OBSXRU3X9R%=8ALWL]%GDC?[8$1E=3C<-V""1@\G'.*]VM-<LKBSL)I
MIDM);Z-9(K>>1!)\P!VX!.2,]LU<:^M%G6!KJ(2LVT(7&XGCC'XC\Q0!S'B6
MQU'6OA%JNG6MG]AU&\T>2*.V4C]S(T) C!&!P3BO.;/7;NS\2>#_ !AI'A'5
M]:TJX\+"T4:; C&"0R1L$8,X"X"$'GJ*]N%U;-=&V$R&=5W&,,-P'KCKBJT,
M6E:+9B"%+;3[<R,P4;8UWNQ9CZ9+$D^I)H \%O/"_B)KG_A8VL>$+JZ^V>(5
MU*ZT"+9//':I9M;PL4SM:0,0Y4$XSQR*J^'/A_JT_CKPUK%[X2DLM#N=5U;4
METVXA0KI\<MNB1K(HRJEF5FVCH6QVKZ-DN;>(A9)XT8X #,!UX'YUFV'B+3]
M1\0:MHD#.+G2FB2?>N%)DC\Q=I[_ "]: /G+3_AAXBM_ W@>TTCPZVF:L+;6
M8;J4*(FA>:%UB:1AR,D)CTXJGX5\!:W<P7%O<:%XE8VGAVZL9[2ZM;?38Y)'
M"@012Q+F3)4D,<@8!/WC7TM-XFTNW\56GANXF,5[>P/-;EAA)MC .BMW=<@E
M>N#GL<;W:B[ ^2=-\,^(8?!>J27O@>ZO=,L]4TJZ@>;2$@O[I(I5$JM"A(8)
M'\H8 %@3VK;7P_K&F^(+;QAK/@W4-6\/0ZMJKMI,=KYTRF=E\F?R3PPP"OMF
MOINBBX'(?#N);?P#81Q^%V\+P9D:'2V?<T$9D8KN_ND@ABO\.<=JZ^BBD =J
M\T^%?_(5^(9]?%%SSG_IG%7I?:O,OA0VZ^^('&,>*;L=/]B.@#TVBBB@ HHH
MH #TKG[6YUC4+_45@NK.&"UN# JM SL?D1LDAP/XCQBN@/2L'0V6.[UH,V"U
M^Q&3_P!,HZ &7LVNZ?92WLU[82QQ8)1;5U)&0#\WF''?M5O6KC6+?1)Y]!L[
M>]U%5'DP7$YAC<Y'5PK8X]C4'BC;-X8O8E<;F4 <]?F'%;:D;: /(?#OQ!^)
M.M>*]4T6?P)I5K%HUU';:A.NL%R@:-9-R+Y0W_*P].36_P"!/BEX;\:6-C"N
MJ6$&O7$)FETM+E7EBP3D8X)P!D^E,\'Z3J=GXS^(M[=6<L%OJ&HQ26DCJ )E
M6UC0LOMN4C\*\ZT/X?:I:^%_A@;3P_\ 8-3M)+W[;.(@DEN9;>8!G/7ERGXX
MI@>T67C'POJ7B&?P_8>(+"YU:VSYUI%.K2)CKE0>W?TJUKGB'0_#>G'4=>U6
MUTRU#!?.N91&I)Z#)ZGVKYT^'WA35K75/!VB:CX1U=-0T&Y,ES=26XAMX"-V
MZ59P_P"^#Y^[@]>1Q79_&71-6G\7>$?$D>GWFH:1IJ74=REE9B[E@>0)LD\H
MD%A\I!(Y&?>@#TZZ\8^%K'2;;5[SQ%IUOI]T"T%S)<HL<H S\K$X/ )XK$UW
MXI>$M%TO1-6_MFQN=.UB^6RBNDND$:]=SELXVKC!]"1FO+/#G@>XGN/!HOO"
MET-,&O7E]);W\ 'E(T#;9&BRPC!?!"\8)Z4FJ>&9-)MKF[F\(7-QIECX[.H+
M:6UCYI^RF#:72,#YE+D=!0!Z-<?%OP_IOB73-"UJXL[.?4[JZAAE6^C:)(X?
MNNYR-I?H%Z@Y!Z5VT>NZ+,NGO'JMHZZES9L)EQ=?+N_=\_/\O/&>*^?E\.S0
M^,_#.MZKX5N[K35\1:RTG_$O:1HTF;]P[+C(7/(/0=>U:/PM\-WD?Q2U;2]2
MA672_ @DL=(+9(C-R_G KQU6$QQ\EB.V,T >V:QXBT/0@AUK6;'3A("R?:KA
M(MP&,D;B,X)'YBFWGB?P[I^D0ZQ?Z[86NG3X,5U+<HL4F1D;6)P<CTKB_%WA
MN'7_ (Q>#Y-4T)-3TNTL;\R-/")88Y&,(3(((R1NQGT->*:QH/B+2_#_ (-M
M8].N],L[2YU91+'X?75&A#71\J,0LIV!DY#<<+B@#Z>?Q/X=CTRWU*37;!+*
MY!:&X:Y01R  DE6S@X )X]*2#Q3X;N[NVM;77M/GGNQN@BCND9I1SRH!R1P>
M1Z&OGSP7X-OKRU\%6'B+PS,]E#XHU.ZEM[RP$:(A@E:)FC *("Q4@= >.U74
M^']K9^'IK[2?"B6>L+XY,MO-!:[)8[<7FW<K  K'Y>>GRX^M&@'O\6N:--JS
MZ3%JUG)J$?W[59U,J]^4SD?E69XC\66GAO4]"M;Q0L.JW3VQG>0(D 6"28NQ
M/;]WC\:^3/!OA758?$GA;2]0FU)?$5EJT<EU;1^&DC:)A*S/*][E2\;)NYR=
MPXVGI7T;\1M!M/$'B7P!8ZGI:ZE8KJ\LD\4D6^, 6<Y4N.F-VWKWH [O^V-+
M;2QJBZE:FQ(S]I\Y?*QTSNSC]::NN:1)IK:E'JEH]DOWKA9E,8QURV<?K7S#
MXOT6?3?!5YH<&E?V;IP\:W,L=U)IINH-/BV;D?[/L8.C%B!QM!/:L/3?#[1_
M"WQ/:ZQ#??9_[<M[VWU-= V01+]G&+EK(85HN"I&TXW!BM.P'V):WEK?6JW-
MG<Q7,#?=DB<.K?0CBN7\(>/-*\66<TT>+.>.\N+1;::1?,<PR,A8#K@[<UQ'
M[.\-Y;_#B_2Z6.2%M3EDM[R&T^R1WB%4)D6+8FP;MRXQCY3CBO'-(L_#[:/J
M.@V_A6]C^)%QXEEEL;QK&17VB[W><LV,"-8PP(SCKP<YI ?7[:C9K?+9&[A^
MTL-PA\P;R/7;UI'U*R2]6R:[A%RR[EB,B[R/4+G-?$TWA;66\;WUKJOB2ZMO
M%<NN--'91>'Q-=R#S@4DCN^"(MF#]\  $8IFK:!JTWC;6;35O$]Q:>)WUIY;
M>UM_#WVB]D0RYBDAN0%.S;@\.  "/:G9 ?;C:E8I,L+7D(D9MH0R#<3Z8]:L
MR2)%$TDCJB*,EB< "OF77?!>EZAH?Q3\0W6BB[UZUU9/LMZ8F\Y-D5L08R.G
M)8\=>]=Q^T#<1Q_#2UM[BT,D5Q?PQM<R&0P6> 3YLRJK;XP1@JRE22,TK >M
MQW]G);^?'=1/%G;O1P5SZ9]:$O[.1$D2ZB:-VVJP<$,?05\3Z%ID=UH&O:2E
MP-7T^\UW0?WEGIS6,$B&9Q(4154;<#!< 9KKO%'@+PS;7/QGBLO#\<4>C:;:
MW&EQPAMMI*T#,SQ@'"L6522.:=@/JZ2ZMX9$CDF1'D^ZK, 6^GK1)<V\3JDD
MR(S$ !F )-?#_C33KV^\::Y<^*?%7]DZA-%;_P!FQ7&D-=3SH84*_9G"_*P8
MD84@[LY/>O1;[P=9:W;_ !*U+Q1ILFI:MIGA^S-K=W*,)$F6Q8LZ@'A]Z@G&
M<'C-%@/I#5]7M='TRYO[IODMX9)R@(W.$4L0H/4X%1:7K5IJ>A:;K"GR(M1M
MX[B))6 8!U# =<9P>U?+_C";PMY/B@_$FVEN=;NM$M6\.O-'*[-_H8W+"5&
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M9+.UM%+&&<S2KU5% W,1[ TL_P 4_ -MX<L?$$WB2W^P7[M';,JNSRNOWE"
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M;6TUY%EW'"CS8)HD8G_?=1]6KT38.U9NL:-I_B#29M)U:V%U938\R,DC.&#
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MO@F]T;QOJ%R=::4>1.D.EM"TYE%QYAC."%/(Z[J^Q=HSFC:":=P/FC4?"'B
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M7PD;<?'1_P"IJO\ Z=5KTWM7F/PB'[OQNV0<^*M0Z?[RCF@#TZBBB@ HHHH
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M'?:790RW=Q+:7=S'<2M&'")Y0)0;>2SYY/3C-;&F?%SQ9XA\16-KIVB6.F6
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M^G_$ <9'BB[Z'/\ "GY5Z=7F'PER=0^()R"/^$IN\8&/X4H ]/HHHH ****
M"DI:#0!\2?MI*5\9^%&'0V,H_P#(@HIO[:$C-XS\*IO(5;"4[?0F3K^GZ450
M'N'[+0'_  SOH7 SYUUG_O\ O7MM>)?LM_\ )NV@_P#76Z_]*'KVVD 4448I
M %0S?ZK_ ($O\Q4U0S?ZO_@2_P Q30T34444A!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !VKS3X1 ?9/&; $9\4ZCU_WQ7I=>9_"%O\
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M1C>1TZ\XKA]4USQ-X$M?%FAZG\0;^_D2+3YK:^>S2>Z62X>1'BAC4!<MY?R
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M'%>M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHA1$QGY0%8CC'6M*;5=-MI!'<7UO"[,(PLDJJ2QZ+R>O3CWJX9%5-S-@=<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS2^(?A))JGAGP=:VEUILNJ^%[=;:)]3LOM-M<H8U1U>,MD9V@@@Y&* *EO\
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MQ1XY\ >(U74?&#>++)O#-[JQA>U@C(G@"D$&-0?+.[CGLW)XPOPV\7?$"_\
M%^@6^M2:Y>6&JV4LUVVI:7#:PP2A0ZF!XSN*\E<-DX(.:+ >Z&\M5U!=/:XB
M%TT9E6 N-Y0$ L%ZX!(&?<5;KQ7QII_B+5OVAM"M/#OB'^P)E\.W;S7:VJ3N
M8_/B&U0X*YW;3R.@/K7-2?$/QI>:%X4MCXK>SO[BVN7OO[)T@W][</'.T2NL
M6PI'$=I)8]^!18#Z*\J(R>9Y:[^F['/YTYV2-&9V"JHR2> !7S$/B3\2]1\$
M>%;VWN[N#S6OHM3N]/TJ.YO%,,YCB9K4M\JG:=^T'!!Z9%>Q^%/$$OB3X01:
MQ=ZC::I<264JW%Q9QM'&[J&5AL<!E.1@@C@YH [>&:&X@2:&19(W4,KH<JP/
M0@]Q4V:^=/!.O^./!_@OX?ZEK.M6NKZ)JNF^2-.@M522U"6K31%7!R_R1[6S
MP"1BJG@[XJ>/[_4_#^LZA_:6H:1JVYKJU_L%K>"SC,;,KQW.?G (4<]1D\46
M ^EJ3BOFCP=\5OB)K6O:!JLT-[=Z5K5V(I;%=!DC@LX7)"NMUG#E>-Q/!YQ6
MKX+\<?$>XUSP7J/B#5]-N]'\3WE[9+9PV?EO;^2)"C^9GDGRR",8QCOR"P'O
M-U8V=XBI=VL-PJG<HEC#@'UY[U9& OH!7EOQ9\6:QX=&BV>C^(+316OI)?,D
M:PDO[EU100(8$!W<D9)X&17">%?B7X^\7Z=I_ANSU6ULM<N=6OK-M6N-.*8@
MMHT?)MV(P[>8HP>G-%@/HI)8Y,[&5L'!P<X/I0LD;E@C!BIPP!Z&OF[P?KGC
MB"TF\*Z=J.GV_B76/%6I1W.IO"98(UA16D9(]W5CMPI/&3Z55B\=>+O".E:Y
M83SP-XDU?Q=-9O>V=A)<Q0JEM$S2) I+,=BC"YX).>!3L!]/U&LD;.R*REE^
M\ >17SSIOQ2\?76BP>'_ "E7Q#?ZT-+LM8OM-EM(6B:(S><8'P=P"LNWIG'-
M=!\'9-?'Q ^)EOXGN[>]U2WOK2*2YMT*1R@6_P K!23M)7!(' )-*P'M50QP
MQP@B.-4!8L0HQDDY)^I-344@"BBB@ HHHH **** "BBB@ HP*** "BBB@ HQ
M110 4444 %)BEHH ,48HHH 3 /:C:,TM% !BC%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>=_"8 :/XF(QSXFU/./^OAJ]$KSOX2C_B1>
M(O?Q)JGX?Z2U 'HE%%% !1110 4A%+10!\.?MF[A\1/#?"D?V:W)Z_ZT_I_]
M>BC]M)4'Q!\--_%_9K \=O-;_P"O15 >_P#[,I'_  SEX8VY_P"7GD_]?,M>
MR5X[^S*,?LX>%\]?])_]*9:]BJ0"BBB@ '2H9_\ 5?\  E_F*F'2H9_]5_P)
M?YBFAHE6EHHI""BBB@ HHHH **** "BD QFEH **** "BBB@ HHHH **** "
MBBB@ [5YS\'5_P"*$NB#UUO5#]/]-FKT:O/?@_QX"GZ_\AC5.O\ U_34 >A4
M444 %%%% !63_8EJHF\N6YB$KF1A'<.HW%BQ(P>,DUK'I6'9RZM?)+/'>6T<
M8FEB"&W8D;)"G7>/[OIWH E70K52-]Q=R@2+(%EN7<95@PX)]0*EUK1=-\0Z
M+=:-K%FEY87<9CF@DZ.OX52O9]8TY(;B:\M9HFN(8606Q4G?(J<'><?>ST/I
M[UNEL)N)Q0!EVN@:39ZW<ZW;V,<>H74,=O+.,[GC3.Q3]-QK*OOA]X0U+2-6
MTF^T*VGLM7N3=WD39Q),0 9.O#?*.1BJ7@?XC:3XXO-:M=/MY[=M,N#&IF7
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M" 0".QP1Q3 \+^&'PEU#3_%MUKGB3PO;:-:#3)-+2R.J2:BUPLC*6RSDA(P
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MJRLFO#X5L4ADUK3;G4GNI"&WBWC0A4<' 9B<DXZ#K]CE5)Z<TAC0G.T9]<4
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MM2UC1&LBPGG\IU:+>58KD$$'G/2BP'TA169HMMJEKI,-OK&I)J5\@(DN8X!
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M_F*:&B:BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[]JE#*D8W,,8ZFH+_']G7.[IY;9YQVKS+XM:+KFI'PYJ&BZ;:^(%T:>2[NM
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M:*H#Z:_9S '[.OA''/[B7_T?)7J]>4?LZ<_L[>$?^N$H_P#(\E>KU(!1110
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M?-Y^ZWY4 >967P>L;'7]*OX?$VK_ -GZ1?2WUEI1:,V\#2!MRCY-Q'SMC).
M<#%;OBKP%:>*O$7AO6[K4;F";0+AKF".((4E9@%._*DD;<CC'6NP\S_9;\J/
M,&?NM^5 'E=_\$-!GAO[72]8U+1K6>[CU&UM[-T$=A>)G]_$"I*DY.5SM.3Q
M4^L?"9M9T/\ LN^\7:A=_:$E2_DNXHIA=^9L&X(5VQLFSY"@&W<>I))].,@'
M9O\ ODTGFCT;\J /)=2^"=G>WNIRVGB?4;&WOK6QA^SJL<BA[0CRG8L#O&
M5/!YSVQ9MOA']GVR'Q7>S7"ZZ-<29X(<JYA,+I@*!AE8\XXXQSR?4/.7'1O^
M^30)%[9_(TP/)M,^"MO8Z)?^&+OQ9JE]X8FCGBM=+8(BVJR@AOG R^W<=H/
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M=*9X1C,B_G2N!':_:/L4/VS8;G8OFF,$+OQSC/.,U8J/SHL?ZQ?SH6:-L;9
M?H: )**89(QU<#\:/,3^]0 ^BF>;'_>!_&CS8\_>% #Z*9YB?WA2AU(R&R*
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M;^5<-\%QCX'^$?\ KP3MCUH ] HHHH **** "C%%% !1110 8HQ110 4444
M%&*** "BBB@!,"EQ110 8HQ110 8HQ110 8%&*** $. *S-)UK2];LGO=+NE
MNK997A\U =I=&*M@]P"",CCBL[Q[-?6_PV\33Z8&-]'IERT&S[V\1-MQ[YKY
MW\?WFG+I_@WP_;ZE)9V5KX;2YA$NLMIMLQ*JJN/*1GFE&/N#CGWII7 ^F;W7
M-'T]YX[[4K>W>"V:\E620*4A4X:0^B@]ZO)-')&DD;!T<!E9>00>]?&>J6%O
MKWAE-;UK6-2DU.[^'GVA2+V1?M4D;88$9^<  ,R_4D4SX@:^([._.@^*K^)=
M!TFR6QEF\0O$2QA#AX(8U)N"W=F8#@] *=@/M+<M4=)U;3=<TX:AI5TEU:M(
M\8D3H61BC#\&4C\*^;+77-.U/4[GQ-XN^(.L:/KVG:A90V&G65UE9H7CA*E;
M;!\T2EW).#P?:CX;QS:1X@\$ZUI^L:H4\2:IJ\%Q92W#-;+$CRNJI&>%8,F<
M]<L?6E8#ZB) Q5/4=1L=)TRZU+4;A+:TM(VFFF?[L:*,EC]!7@/QMUV1O%CZ
M3'K%_8FPTH7@4:T-+B5W9PLBD*S3N-N-G0<>IKA?%WB&\\1?#_5;CQAXRO-*
M>#PI97&F0PW/E1ZG)-"?.9TQ^]RV%(_A!SWS18#ZRN=;TFST(:Y=7T4.FF-)
M?M+G";6QM/XY'YU'#XAT2:X>WCU2V:5+EK,IY@#><J[S&!U+!><>G-?*.N7]
MOJOA'5[K6O&NH66IZ9<:=9:?HB7/E0R0,D##]UUDW;G.[MM]JZ+5FEU3XEZ/
M>ZEKVH6\=GXXO+:)EN-B1JMF'5<=.6&WZ,P[T[ ?3&GZA8ZIIUOJ.GW$=S:7
M,8EBFC.5=3R"*M97/2OE;2]6NM=T?3T\2?$'4_#L.E^%[;4[![>]$)NYV\S?
M(Y/$NTJB[.?O>](UYXJ\96_BS5M4\8:[H]YHGAC3M6CMM/N/)C6Z>VDD8LH'
M(R@XXZFE8#ZJW+C(Z52L=4T_4S<_V?=17/V6=K:;RVSY<JXW(?<9%?)'BKXA
M>*GO;KQ-I_B74X9M-N;"V$4E]%;VXD81&1%M0"TX;>26)4 #C@5[=\/)I(_#
M_P 0IU?RY%\0ZDZL%Y7A<'WHL!ZL64=:,U\D>%/&6M:5X=\(>*I/B1J6N7FL
M6MY_:FFS2).L$<4$K"5$XV,AC7.3\Q)J+2?&_C30F\1P6VN:A=-)X5DU1?MV
MI17TD4JNBB9508A^5RWEY;H.>*=@/KS*DU!<7-O9VLMU<RK#!$I>21SA44#)
M)/8 5\G^(/&GB3P;?:UIOA3XB7GB2T_L^P9;F\N(Y3:M/<%';S-N =I!!.=N
M[VJY#J/B2X@U#P1X@UI=1T2XU;2X9#-J27T\,<TI,D<DJJJE'V# QD!R.]%@
M/J*UNK:]LX;ZUG2:VGC66.5#E74C(8'T(-1Z?J>GZMI\6H:9=Q7EI+DI-"VY
M6P<'!'N"*^?=:\2:_I'QBFOI?$5[)H%IJUKIZVVG7,/EVRR*@\F:U=0[$L^?
M,5C@$''&*]%^'RK8^-_B'HUH-NFV^J13PH!\L<DUNDDJCL/F.<>K&E8#IKOQ
MQX0L8[2:[\1Z?"EY<M9V[-.N)9E;:T:^I#<'T-=)N4BOF'PO;7WB'XF^"-0O
MM8O@T5WKQ6)/+52(KO@$;>K!@&[X4=.<]KX^C\1:O\1;K0]/\7:GX?LK3PX^
MH!=/*@O.LI"DD@G '88S[46 ]JXI,KFOD"^^('Q'UR6VD7Q$VDIIWARRU..0
MWT5E'<S2(&>64.A,J;OE*#&/QKKI/$VL:M=ZWKWB;XDS>$)M!2S:&SL2LEM,
MKPQRO(T97=,'9F08QTXYIV ^D2RYQ1E>G6OE'PYXZ^(NL>*M.\2/K@@@N-??
M3)K"YOH4@6$.5\H6^SS!*  V[<2?I46E^.?&FFQZQ)J?C*X2\U+2KFYL+V::
M&XT]WC9<3)L7?" & V,I]3G%%@/K/*D9X(H.W&:^3;+Q]XNTW1-2\+ZCXB\1
M1:Y/<6*6HS:7<C"7S"PBN 50!]C?,XRH' -6?#?B;Q]KUXG@IO%NHV 7Q(+%
MKLR0W%VD)LY9WC:55V,0R8! R.G:BP'U+++#! \TKK'&@+,[' 4#J2:9:W%M
M>6L5U:S1SP3*'CEC8,KJ1D$$=017@>E^,/%J?$RW^$-QJUW=:A9:LUY<:E+&
MNZ?2UC65 V% )9F$9(QT/K79_!HO;:3XFT))/-L-%\07=C9$_P $(VN$^BF1
ME'H!BD!ZCM%&U?2EHI )M%)L7NHIU% #=JGJH_*CRT_NC\J=10 WRX_[@_*C
MRX_[@_*G44 ,\F+/^K7\J3R8LY\M<_2I.]% #?+3^Z/RIJPQ+]V-1]!4E% #
M/)CX_=KQ[4&&,]47\J?10!'Y,9ZHOY4GV>'&/+7\JEHH B^SPXQY:X_W:#;P
MGK&O7/2I:* (OL\.21&H)]J3[-#S^[7GKQ4U% $1MXB,;!^5(;:$D$QCCVJ:
MB@"(6\(& @ ]J40QJ00N".E244 ,D.(V/L:\V^!7_)%-$;^])=-CZW,M>DR?
MZIL^AKS;X$C'P1T+'3=<_P 6[_EYD[T >F4444 %(..*6B@ I#2TAH ^#OVQ
M]O\ PN/2/7^Q8O\ T?-11^V0S'XPZ.K  #18\?\ ?^:BJ ^GOV>V_P",>_"(
M/7[*W7_KJ]>J5Y9^SWM/[/7A#8,#[*_Y^:^:]3J0"BBB@ J&;_5_\"7^8J:H
M9O\ 5_\  E_F*:&B7M7G6H_$K4=.U&YL_P#A67B^Z6"4QB>VM8GCE&<!E/F\
M@]?YXKT:N-\>_$#1?A[I%I>ZM#=W<U[<"UL[.RB\R:XE/(55X]*0C$'Q8OCU
M^%?C8?\ ;C%_\=IK?%R="5D^%_C@$#/&FH?Y25T/@/QUI'Q!\,#7M'CN(8UF
M>"6"ZCV2PR+U5ASSR.GK3?'GCW1OA_H<&J:PEU<&XN$M;:ULX_,FN)6Z*HR!
MV/4_KBF!SQ^,#*^UOAEXY'_<*!_]GIQ^,"C&?AMXYP>>-'S_ .ST[P_\7M%U
MZ#Q#&-$UK3]6T&'[1<Z3=6NVZ:/;E2B@D-GH!GKCUKM]+UB'4]%L-4:":Q6]
MC218+M1'*FX9"LN>&]N: .$_X7)'@'_A6_CH@]_[&/\ \52/\9;6-MK_  ]\
M<J?^P(W^->G>;$ /F&*030M'Y@D4I_>!XI >9?\ "Y]-4XD\#^-HSZ-H<G]#
M0WQLTA"-_@OQJJXSN.A2X%=EXF\6:#X0\-7/B+7+Q;?3[?:&<#<69B%55 ZD
MD@5MK)&ZJRG.X9'TH \P?XY>'8PI;POXO ;H?["G_P *9_PO3PV#\WACQ>BY
MP&.A38/Z5ZIN3U%(6CR%XR>@]: /+?\ A?'A$#+:-XI7ZZ'<?_$T?\+X\'[=
MQTGQ.,=1_8=QQ_X[7J8"Y(Q3MHH \H;X^>!U*[K/Q$,]#_8ES_\ $TU/V@/
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M[[P1?^$K+3K31K&]&[_0(DA,<H(*RKM ^9652#["L4? ?X5 Y_X1?_R<N/\
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M);V.UB2YE 6298P'<#H">IJU2 **** "BBB@ HHHH S=>;9X;U-R,[;64_\
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MY;;NF>%2YVG*\D9X/(]*=P/!/#;^(O$WB71-/D\3:I;6D8UB^>*UG$1N'AU
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MMIIC*UG$.5@*J54KZ8!(_&LS5_ /@O7O$-KXAUK0+.\U.T 6*XE3) !R >S
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M":,@D,#@XKY:U;P%KFAZ7;V?@72=2M+V\\$NMV8=ZB6X$D!*LQ./.*F4#O\
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M!+_,5-44W^K_ .!+_,4T-$M%%%(04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!R/Q../A'XN([:3=?^BFK0\)_N_ 6@A1G;IUOQ_VS6LOX
MJ.8_@[XP8#)_LBZX_P"V35L>$QCP5H0/46$'_HM: /F?QAX-\8?&_P 3^)/%
M5O#?:+!X80V_AV">W:"2ZF4AS(=XZ,1@$=/E]#7MWPA\6ZWXP^'UK>>)]'N]
M+UNU8VUW'<VK0>8Z_P#+10W8@CIT.17H>T#M2%?E(Z4 +FC->7-\'RTK2?\
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M<@G01S_Y$IO_  C7QYR,?$S02/?0_P#[.@#URC->1'P]\?ADK\1/#9] =&8
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MUQZV#\T =+17/_\ "3P\?\2?5^?^G%^/TIC^*[:-0SZ5K 4G:,:?*W?T"YH
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M1110 4444 %%%)WH XCXNG'P6\8'./\ B57'?_8-=#X9_P"11T?C'^AP]/\
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M+2#,?E^7$R1@R DY&#T&: /IP=*7%(OW12T@#%&*** $VBEQ110 FT48I:*
M$VBC:*6B@!-HI-HIU% ";11M7TI:* $VBC:*6B@!NQ<8Q2@8%+10!PGQ@;;\
M$O&+$9_XE5QQG'\!K1^'*&/X4^$T/4:3:Y_[\K67\9#CX(>,>"?^)7-T./X:
MU_A[G_A6'A8,,'^RK7C_ +8K0!T]%%% !1110 4A-+24 ?G]^UUM_P"%ZQY(
M'_$J@R1W.^2BH?VM23\>Y%^]MTVW&/3[U%4!]A_ _P#Y(/X,_P"P;%U^E>BU
MY[\$O^2$>#.<_P#$KA_E7H52 4444  Z5%/_ *O_ ($O\Q4HZ5#-_J_^!+_,
M4T-$U%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y]
M\:VV_ OQB>!_Q+91R<=JR?'&D_$35/ 'AV'X<ZM!87D1@EG,[; \:(&"Y /5
ME4$="&.>*T/CHVWX">,#_P!.##GZBNXT8!=!T]1C MXQQ_NB@#Y[\9:OXYAM
M/%&AV%]-=7+:OH^G23K?M;/'YD,&_P LA2$WN2"1C&XG!KU#Q;XGN?A[X2TJ
M.TM[>ZD)2U\[5=46&*(!.7EF?+-T[*22:OWWP^TJ_P!1U&]FN+C??ZE9ZG(H
M*X$EL$" <=#Y8S_2H/'GP]MO'#:3<-JESI5]I$[36MS;*CE=R[6!5PRGC'.,
MCM3 XG1?C=JWB;3-)30/"<%]JVH7M[8&,:EMMT:W56,@D\OYD(8$< _6M'3?
MC;9MI\%YX@T5](1]/O[J0^>) LUG+Y<\(P!D_P 0/<=JV?#'PHT?POJ=IJ%O
MJ6HWMQ:W=W>*]U(K%GN$19-Q"C/W,CZGVKE/%GPE348O"/A*VT^:^TFWURXU
MB]U&>5!Y4;O)(\&!AFWF0+P,87)Z4: =GKWCZXT'X21>.Y]"DEG>"UF.G),
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MJ ^QO@JQ/P,\&-@#.EP=.GW17H5>>_!7'_"C/!>!@?V5!T_W!7H52 4444
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MOFR,> 2=W<UQ]U\(4D\;^ =)MM+F;PYX0\Z]&HW-PI:9WDWK!L')PZJQ) &
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MO'?$EIK?PMFM=%T^^B&H7_A][&ZDETV:X@N#YTS(L#1C/F@R,-C +C!SVHT
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M#PG?:M=-)X=E;Q*+N6XD039BV%Q*2%E\S?P.V>,5]?Z"NWPWIB]A:Q#G_<%
M&E1112 ***.] !1ZT4=J /SU_:TS_P +[FW'(_L^WP!V^]12_M;<_'N;_L'V
M_P#[-13 ^R/@NK#X&>"]W_0*@_\ 0!7H-<%\&^?@?X*[_P#$HMO_ $6*[VD
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M9&G6X.!_O44W]K$?\7]N".IT^W)_(T50'V;\',CX(>"L]3H]M_Z+%=]7#?"
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M:1[% "H Q/'.2>:Z'QWX-?QGH46G1:Q-ICQ3"8,L2312X!&R6)QMD3GH?04
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MTMYG+"UMB=L:("<*"!NX]118#RYOV/+%<;?B)J?XVR__ !5,/['<.#M^).H
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M"6F?%&^BT,^$-1U(6BZ:B.+J*%I3&'WYP6!4\8Y]NR^*/BU\6+.;Q_JVB?V
MNB>#[^.!H[BWD,UPK%>,AL<9SGCK1KW QG\!_M;PH3_PGUHP]?MB_P!8J:/
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M2-Q_Q3U@V?FP%MCCV^_7UCBDP*5V!\I#Q1^U\',9\&Z<Q'\6(/\ X[2'Q?\
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M^%/?#)M;DUS_ (0[3SJ+W0O#<!3N\X'.X<\<\X'&:\N\3/J4T^E>'[?XK?\
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MQG_B=:?_ .E"UZPOW17E'Q\!;X<V*AMN[7-/&?\ MX6O5UZ4 +1110 4444
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MTM%;^M>RXHQ0!X[%\;-0<?O/@[X^3Z:6"/\ T*E_X7==*^V3X1>/T]QI(/\
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M.!WK?;X:_#QFW'P+H!/_ &#H?_B:0_#/X=G.? OA_G_J&P__ !- '+Z7X?\
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MR6 HR*\H_P"%%Z #E/%_C-#QTUZ;_&D/P+T?C9XX\;IZXUZ7F@#UG-%>2?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M57*_#A=OPI\(KC&-'M./^V*UU52 4444  Z5#<?ZO_@2_P Q4PZ5%/\ ZO\
MX$O\Q30T2T444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"+V//^'RGOXMLO_09*]0H **** "BBB@ I#2TUCZ4 ?G!^TZV[]HWQ)O!
M"VP'_@/'13/VF\_\-&>)"X(&VVQG_KWCHJ@/T%\&?\B%X>Y_YAMM_P"BEK?K
M!\'#;X$\/KZ:=;]?^N:UO5(!1110 5#/_JO^!+_,5-4%P,P_\"7^8IH:)Z**
M*0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFHHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"%PZEG!^$OC@'VL8S_ .U*]6)7&[M3%EA9=RL",]12 \I;XSW:D;OA1XZ
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MUJY^S64156<1LY+,P55"J"222  !5JPO+;5-,M=1M=S074:S1[XRC;6&1E6
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M/KL%(;&S+;C:PD^NP4@/-?\ AH3X/_\ 0Z0_C;3_ /Q%!_:%^#H//C6W]?\
MCWF_^(KTC[!8\_Z'"<_],Q_A2-IFGMC-C;G'3]VO^% 'G(_:"^#K+N'CBT_[
M]2Y_] I1^T!\'R<?\)O:?]^I?_B:]$.E::3DZ?;$_P#7)?\ "C^R=-_Z!]M_
MWZ7_  H \^'Q^^$!_P"9XLA]4D'_ ++33^T#\'@?^1YLO^_<G_Q->@MH^DN
M'TRU;'3,*G'Z4TZ'HIZZ39GZP+_A0!P0^/WP?)Q_PG5AG_=D_P#B:D7X\?")
M@"/'6G<^[?X5W']@Z+VT>RQ_U[I_A2'P_H3?>T6Q/;FW3_"@#B!\>/A$<?\
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M_"\?A+_T/VD?]_ZZK_A$?"O_ $+>E_\ @''_ /$TQO!OA-A@^%])(_Z\X_\
MXF@#FA\;_A*1QX^T?_P(%._X7;\)L?\ (_:-_P"!(KHO^$+\'_\ 0JZ1Z?\
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M HHHH **** "BBB@ HHHH **** "BBB@ H[T44 %%%% !1110 4444 %%%%
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M;M7?RY975I&.!@JH&4]0<$UO>-]<\0Z)J'AS^R]/LYK*]U2"SNYYY</$KN%
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MZSI)?+*L/D*WVCD+BW'IZ6L6?7YO6F!=D^)G@B(77F^((5^RR&*4,C@A@7!
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M/[0'C#(Q_IO?_<6B@#],[/\ X\H#_P!,U_E5BJ]F?]#@'_3->OTJQ0 4444
M%0S_ .J_X$O\Q4U0S_ZK_@2_S%-#1-1112$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%'>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3I2T4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2-TI::_ STH _,'XW@?\+\\988-_Q,'Y'X44WXWRF3X\
M^,9#C_D(.O'M@?THH _3NW7_ $>+_='\JGJ*!AY*8_NBI: "BBB@!.U13_ZK
M_@2_S%2]JAN?]5_P)?\ T(4UN-$XHIJGK3LTA!111F@ HHHH **** "BBB@
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0_)<?&7_84F_]"HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>skye_ex31img17.jpg
<TEXT>
begin 644 skye_ex31img17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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MW_\  JX_^.4?\,Y?!7_H0[;_ ,"9_P#XY7K-% 'DZ_LY?!5?^9$M3];B<_\
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MDP_9Q^"X/_(BV_\ X$S_ /QRE_X9R^"O_0B6_P#X%3__ !RO6** /)F_9O\
M@J?^9&@_\"KC_P".4W_AF[X*_P#0C0?^!5Q_\<KUNB@#R4?LW_!7'_(C0?\
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M?_':7_AF'X(XY\%_^5&Z_P#CM>R44 >-?\,P_!')_P"*-/\ X,;K_P".TO\
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M&-Q_\73&_98^"V>/#=R!_P!A"?\ ^+KW"C% 'A__  RQ\%^/^*=N1_W$)_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **.]% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ3YLSRK:W$'WH@6/ 93D =P!3L!]!E@O4TGF)_>KY[N=<NO&W[0>A0&_N_\
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M0&!!!]*YGPUX\UO6/!>N^!?&4\VD^.-.TYYH[B"5H?ML6S,=Q$X(]MW3GKW
M=@/?*,U\T:?;ZM>?$WX=^'Y?&'B(66K>&CJ-\@U696FF"@[L[CCKT&!Q77-J
M_B'P!\:/#OA2XUV[UKP[XG2=8%OSYL]G/&-V!( "R$$?>R<@\T6 ]IR!1FO(
M?CK>W^D^%-$U+3]>O=&8ZU:6LTMO<F(&&20*^>QP.1GIS6;X"U_4=1^+VJ:9
MX9\57OBCP7!8C[3=W;"5;6]W "**8 %\KR1DX]: /<,T5\UV'B+3+3Q!X\C\
M5_$S7-/31M5DBM;=+\AE@$2L.-I+<EL9],=JU?'WB#6?!EYX'L]?\3:O%X0D
M@>/4=<M(]LS7& (C*X!**0<G'4CTR*+ >_YHKRO0="\1ZYI*R-\2KV\TR/4I
M)[>\L&A,EY:^6H2-W5<#:^_.!DXKGOAG8^*O$^EZCJDWC_6UN-.\17%JJR-'
M)%+;03;?+9-H^\N06!!SS[4 >Z]Z,UXO\7_B9K'@^_T^/P_";F+3)(M1UTH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU7PCIVL:3<V$L>J:+#-$OENTG[M(S)A7V)\IR0#U'.*]>Q28H \K^$?@O4?
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MFT;LAF)#!MP(XZ?C7EWCIO#]]^T1HL.O?:?[.M-$N(YI(_.15D:1"J;H\<D
MFNZ^'=QX?@BU30O"D=U+I=C,9C<7#2-NFF9I'0%QN8+D<Y/WL<D&@#-UKQ?X
MV7XP-X%T&+1A$VD'5$N+Q)<CYS'L.UL?> .>P[&J.E_%/6]4\&>.+B32;2R\
M1>#VE2YB,C2VLS(A<%6&#@JI]QFN>\6QZ!>_M-J^N2WL%G!X;\C[1;--"$E,
MQ;:9(\<[3G&>]<WX2L4T'P1\7[;28[YO"4T4ATV\OK9Q<7<[PL) "5#2#=M
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MH **** /E+]M/_D3_"G.#]NE_P#18HIO[:CA?"/A/Y,_Z;-S_P!LQ15(#?\
MV.1_Q9G4??69O_1,-?2%?-_['1;_ (4QJ/7_ )#$W_HJ*OI"DP"BBBD #I44
M_P#J_P#@2_S%2CI44_\ J_\ @2_S%-#1+1112$%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !BDQ2T4 )M%&!2T4 )M4T!0O2EHH 3:,YQS2;1Z4Z
MB@!-HQBD"*!\HQ3J* &>6I()&:5E5AM89'O3J* &>4F,;>/2CRHQ_"/RI]%
M#!$@).T9-.5548 P*6B@!"JL"",@TU8T485<?2GT4 1F&)A@H#^%9,_A^QNM
M?M-8N#+)/9*1;Q[\1Q,059PH_B*G'.>*VJ* (VA1L?*,CIQ0L<:L650">I J
M2B@!-H!)[FHS!$9/,\M=_P#>QS4M% #=B[]^/FZ9IU%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1WHHH **** "BBB@ HHHH **** "@]*** /E']M#_D5O"0W<?;)N/^
M +13?VU./"_A' .?MD_3_<6BK0'0_L=Y_P"%+7__ &&)O_145?1]?.'['?/P
M6O\ _L,3?^BHJ^CZ@ HHHH *AF_U?_ A_,5-4,W^K_X$O\Q30T34444A!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2H 6BBB@ J*;_5_\"7^8J6H9O]7_ ,"7^8IH:)J***0@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :[!$+'@ 9KY]UBQN?C)
M?^*;S0[_ $2YT.VM9=!MY+G?(4D(#RS)M. <E #S_J^.#7T&RAE*L,@U7M[.
MUM8S':VT<"$Y*QJ%!/X4P/D[Q+\0M*\5?LJ0V>IZS:KKMA>VNGWB-(N_S(IE
M'F <]57=G&.M=3H=Q:>$/V@+B^\>ZFNI)K%J!X>\274H$?E<9MAM C#<YR -
MV?>O?_[#T;DG2K3D[C^X7D^O2GW&F:9=0)#=6-O/%&=RI)$K!3Z@$4[@>0_%
M_4])A\>?"R.?4;6%EUU92)' (3RV ;V&< 'IG%1_&K4=,M_&/PMCN[VWAQXB
M25EED52$$;#=S_#D@9]2*]AN-,TN\F2:ZL;>XECX5Y859E[\$CBEN-+TR]9&
MN[&WN63[C2Q*Y7Z9'%(#Q?POJ%CX)^.WCN'Q9J,.GCQ"UO>:;<W<@CCN(U4H
MR(QP"RD@;1SC%2_&SQ5X;U3X&>+3I>IP7(6.*$W$+ H[><N8U?HQ&#D G KV
M.^TW2]3B6WU*QMKV-3N5+B)9 #Z@,#S3)=)TF>RCL9M-M9+6(Y2!X5**1TPI
M&!UHN!@6OC?PJBZ1IL&O6-W>WNR&"WM[A'D<[<DA0<X !)/85XSH TG6/&_Q
M5AA^(TOAV.;40J&TN;=$?-NH9_G4MD$$$J1]:^@[71-#LYQ<6>E65M,,C?%
MBL,]>0*CD\,^'9G:230]/=VY):V0D_I0!3\+Z[I>M^%H=1TR^6[L$#0K=YPD
MNP["P.>F5/->>?L[W$,WP_U58IEEVZY?'Y9 _!E)!XZ _KUZ&O7HK6UAM%M8
M;=(X$7:L2J H'3 '3%1V>FZ?IZNNGV4%H'.YA#&J;CZG YI 7:*** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1CG-%% !1110 4444 %%%%
M!1110 =Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0 M%%%
M !1110!\B?MLMMTKP5Q_RVN__08J*/VV/^09X)_Z[7G\HJ*I ==^Q[_R1.Z_
M["\__HN*OHT5\Y_L>\?!*[Y_YB\W_HN*OHRI **** "H9O\ 5_\  E_F*FJ&
M;_5_\"7^8IH:)J***0@HHHH **** #O1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%(<T +1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 )NYZ4M%% !1110 4444 %%%%
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M*N/M?BWN;PS?:CX:NK+0O$\RV^GW[3*YWN,Q>9&!\@<<CDX[XH ]1:15(!8
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M'M3 ]9HKR&U^-VFW4-GY/A7Q EQ?^=):P7$$<)EACC5VFR[A0F'&#GDU1O\
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M3*_,V<GL/;!KVME\0/"GBB>_L_A_<>(+#7])L[:X@-S;QO:7$$9C*R98KY;
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M6)().X\8 7UHM]%\2:QX)^'WA:^\+:A8:CX4OH;J\NFC'E".W5Q^Z?/SF3Y
M /4YQBN\M/V??A?9V:VR:/>, -I<ZI<AC^4@'Z59;X$_#3(QHU[QT U:['_M
M6BX'F>D>'?$UE^S1+H2>$YHM?CU O-;RVT,LS1-=B1I(@Q*LP0@C/0KQT%4H
MO#7B>XL?BW:6_A378D\0:;#]BDU*Y2629TA*E6;>V&+,<*.!T^7@5ZN/@/\
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MO^NMW_**BJN!VW[(/'P,EYZZK/Q_P&.OH:OGC]D#_DATW_85G_\ 0(Z^AZD
MHHHH !TJ&?\ U7_ E_F*F'2H9O\ 5_\  E_F*:&B44M%%(04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %'>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBC- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !WHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BB@]* /D+]MAC]B\%#C_ %EW_**BF?MJ
MKBU\$X!QOO/Y0T55@.Y_9!4_\*,D;UU6?_T&.OH>OGK]D/GX%/C_ *"D^?\
MOE*^A:D HHHH *AF_P!7_P "7^8J:H9_]5_P)?YBFAHFHHHI""BBB@ HHHH
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M05Z0B[4"]<#'-/HI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'Q]^VQ_J? Z_[5Z?\ T311^VN1_P 4/\N>;WG_ +\455P.
M^_9'('P)&.O]I7!_1:^@Z^??V1_^2%+D=-2N.?P6OH*I ****  =*AF_U?\
MP)?YBIATJ*?_ %?_  )?YBFAHEHHHI""BBB@ HHHH **** "BBB@ HHHH **
M** "BBL;6/$WAWP^85US7+'3&FSY8N[A8B^,9QN(SC(H V:*Y:W^(7@2Z8K;
M>,M$F(1I"$U"(_*!DM][H!R3VK<TW4[#6-,@U/2[R*\LKA=\4\+;D=?4'O0!
M=HHH[4 %%8%UXR\)V.I'3;WQ)IEM> X,$MTBNI]"">*V89X;B!)[>598G4,C
MH<JP/0@]Q0!-1110 4444 %%%5+Z]M--T^?4-0NHK6UMT,DLTK!4C4<EB3T
MH MT56M;JWO;2&[M)DGMYT$D<D;;E=2,A@1U!%6: "BBB@ HHHH **** "BB
ML]]8TJ/4ETV34[5;YQN6V,RB1AZA<Y- &A1110 4444 %%,>2.-&DD8(BC)9
MC@ 4JLK*&5@5/(([T .HHHH **** "BBB@ HI-R[MN>?2EH **** "BBD#*3
MP: %HHHH **3<,]:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,B@!:*
M3<,XSS2T %%)D"EH **** "BBC- !1110 4444 %%%% !1110 4444 %%%%
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M2.8, [+N51CDDJ"<#T/I4GQ'T[4-7^&7B+2-)L?MU]?6,MM#"75 6=2H.6(
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MQI.I>-X_B;J7PFOM6U-V^W)JEKK#LQ8Z8!N:/.?O;PL6?]ICV&?H7[J=<XI
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MHH^4+P2%&2<U4\4_"?Q1X@U#3+6>'1YAIRV8M/$7FR1:A:>4$\TA57$FXJY
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M^9I%R0N,<X["OI J,4;>*=P.<\7-XAC\*7<OA6U2\UF/RWMX)'"+*0ZDJ6/
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MR!)<EMS;L?)T&X<9X'2O<=HI<47 ****0!1110 4444 %%%% !1110 4444
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M_,4T-$U%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD:9W(^\?EX'.3[5[:O2EHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO;*\3_99Q_PSIH/KYUU_Z/>O;*D HHHH !TJ&?\ U7_ E_F*F'2H;C_5_P#
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M6>D:QHGACXN2:QHKV%I>FYN[29Y4E\^(6@CR=K$@_N\X..& K \,^%-6\>>
MOA?9W&E2Z9I>CV N9+YY(W:0FV\N-8]K%N=^XYQC:!UI >DQ_%GPNT^G/(M]
M;Z;JDYM;'59H-MK<R\@*K9R,X.TL &[$UFV_QV\"W U"1_[6MK;33,MU<SZ;
M*L4+1 %E8XX8Y&%/)].1GB=/\!^-]9^'/AGX:>(-!^P1:%J4,DNJK-$T,]K
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MRY4C(6V13^14BN;^,NH6,'Q5\,0W\(LT.F7JC49;9[D-OVKY,48!4R' Y8'
M/2I ]JOO$WA_3-,BU/4M<L+.RFQY=Q/<(D;YY&&)P>*RY/'_ (5C\9V'A/\
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MFC6YMK"T3RX8=[/L7.<98D_K7@7AWQ5XLNOB;X>A_P"$CO\ 4-.UNZU*WFN
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M'NW[+O\ R;EX=X_Y:77_ *4R5[37B_[+XQ^SCX</_32Z_P#2F2O:*D HHHH
M!TJ*;[G_  (?S%2CI44W$?\ P)?YBFAHEHHHI""BBB@ HHHH **** ,C7?#^
MC^*-%GT;7M/AU"PGQO@F7*G!R#[$$=16-_PK7P/_ ,(VGAT>&[1=-CF^T)$%
M.Y)>T@?.X./[P.?>NPHH XV?X:^"[KP_=Z'=:,MQ8WLJS72R2R,]RZ@!6D?=
MN?  ZD]*Y_Q;X*OM5\<>!#9:2TNA:&9Q/*EX8I(@\7EIMPP8D=2<Y_&O4J*
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M?;WTPNKW2;:[*6EU,#DNZ]3D\D9P>_6MWP7X'_X0TZQM\07^K#5;Q[YUNUC
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MCL#\DI]652ZCV:N!NO@3>S:AJDD/CZ]@M;K7$UZ"$643M%,&R0SMDN.@'0#
MR#7N5%%P/$-9^"&K7Y\26&G?$*[T_0_$4AN+NP-BDN)FVEW1R05W,N2.G.!3
M-4^!FL:@-=MQ\1+J.TUEK>:=3IT+.98@@4[^NWY!\@P!SZU[E11<#F]+T;7;
M/Q#/?W_BB:_LGLXH([)K=(U252=\V1R2V1QT&*Z,=.>:6BD 44=Z* "BBB@
MHHI-M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5( &/UIC^"O%'A_QQJWB+P/J6GK:ZZRS:CIVIHY03JNT2Q.G() &5((..HH
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MFO+RYO1<203'RVE<MTS\V"3U-=[9Z9JEAX,32X]2&H:I';>7]LNU)$LI'+L
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M&;_5_P# E_F*FJ&;_5_\"7^8IH:)J***0@HHHH **** "BBB@ HHHH ****
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MT,KJF0_EDD L.JCC/2N?UCXA>-M#739=0\&6,4>J:LNDVJMJ;;]S,X61AY.
MI"YX)//2J?BWQ?X<\;>&=*T'PGJ46L:C>W]E(+>V.]X$CGCD=Y1UC"JI^]CG
M [TGQLUO2=)NOA_'J.HV]J5\36MRPD< K$@<,_LH+#)Z#- &EXB^(7BGPKHC
M:EJW@VWW+J4&GA8M0)1Q+M"2JQB' 9MI! (P>M:OC#QKJWA2Z\-6YT*&];6[
MQ-/)2[*^1*P)_P">?S+\IYX^E<I\?=4TJ'X=:/\ :-4CMX[K6;!XYDFVML$R
MLTB$=<+SGMUS6+\1QH>A:]\-Y6\97=XL_B"VG5+W45EC,6Q_WO/;)&&Z<T >
MB'QY/JGC#4_"_A72?[5N=)C4W]U-/Y%M!(W*Q;MK%GQR0%P!C)YK(/Q<B&@^
M*[F30YH-9\**7U/2IIE5DC"LRR)( 59649!X[_CS?P\OK+X=^//'F@>,=2CT
MV75=6?6+"\O95CCO()%'"NV 60K@C/&1VKC?$4\>IZI\7OB)'(UCX=N]!72K
M"[ES''J4NPY>,-CS.1M4C@YXS0!ZQ;_%2[AOO"L/B#PO-I5MXF*QV=TERLZ)
M*R;UCD  921QG!&:TT\?7C_%N?P#_81S#8C4&OOM V^46VC";<EL@\5XKINW
MPGK7@'QYXGU:36_!,FEPVT$TTAEBT6\\L*'PH"[3AEWD$J3CCBNQL_%'AU_V
MJ-4OH]=LI+?_ (16,+(MRI0[96D;&#SA?F/M0!N>)/BSJWACPU#KVH>"95@N
M[A+>SMQ>I]INF=MJ!8]O4CG&>!6CX@^(^J:'XP\/>%8_"4EYJ.O6\DL 6\1%
MB:-0TBN2.V>HSFN!\.>(_"?CCQY<?$SQ5XITN'2-(DD@\/6$]VB!%7A[MT9L
M[V.0N1D  XZ&H?'6M:/X@^,_PIO!KKZ-#/97ET9A.D,L2/$"F=V0-WN.>: /
M0=8^(_B#P[X=U_5]:\#SVR:-%'<,%O(V2>)BP8H^,%EV\J<'D?C!=_%>[T+0
M;'Q)XJ\'WVF:!=+$SZA#/'<K:K(!M:55(8#) ) ..*XGQIK'AO2/@W\0]"@\
M='Q'<RP2W+S3W"2M 9<)'#E?ESE3@<'KQ5[QMXS\+S_L]IX;T[4+;6=;U;1H
M[.RTNRD\^::1H@O"(2V%ZD]MM 'N*ZC9R:0NK1W4;630BX$^[Y#'C=NSZ8YK
MSV/XI7-_X?O?%6@^$-0U;PW;[V2\BEC22Y1,[I(HF(+)P<$D$XX%-3PKKUO^
MS.?""2,^MKX?-F-O4R^3MV\^_%9/PM\9^$]-^"^BZ=JVIVNG7FE6JV-]IURP
M2>*9?E:,QM\Q)/08YR,4 >H_VY8KX7'B"63R;+[)]L9W_ACV;LG\*S/"?C"Q
M\:>!++Q7HL;20WD1>.%V4-N&04)Z Y&*X?XB3W?B*;0_AWX773UEN474+VSO
M)F@7[''@"%E0%AO8@8 QA&!XKFOA9>77@#XH>)/AWXDN--LH[\?VUIL%I,3!
M"&8^;$FX# !&[&!@ F@#HK?XXP_\(W_PD^J>$M3T_0DOVTZ:],L,@@D$GEDN
MH;=MW<9 /TK5?XIM'XOU_P -_P#",7\S:)8_VA)<0RQN)XBI,?EKG)9L8QQ@
MUP'PS\%Z-X^^'%U9ZCXBN[G2$U^[N9-,MI8A%+MN79!(P7>5/#8W 'BNC\-W
MFGC]JKQE9PW4'F#1K&-8@ZY)7<2,=<@$?G3 V4^)VN2>,6\(CP%>+JZZ<-3,
M37UOCRBVT#.[[VX$8]J["W\46;>!XO%FH1R:9:FS%Y*EUA6A7;N*M[CI7GJ7
M]F?VN)K?[=%O_P"$52/R]R@[_M+';UR3CG'I4_Q(N+WQ3XBTWX?^'YK&>2+&
MIZI;7,I16A1AY43;<G#R8.,<A#V-(#MO#OBNU\5>!+#Q5H,;7,=_;^?#"S*K
M9[H3T!!R#[BLWX>^.I/'VA/K<6BW&FV8FDMT,\T;L[HQ5^$)P 00.><9Z8)\
MQ^$&NR>"_''BOX5^);FPLS9S-JFFI#<9B2WE.]HE+ $!"<\\\GL,UI?!7QAX
M8TGX+->:CK]E;K;WU_-)YDJ(P4W,C#Y<]P1@>_% 'M5_>V^FZ9<ZA>2B&VM8
MFFED;HB*"23] *X*S^(UY<R:!/<>$]2MM-\0.%L;L20R  QM(&E4-F/*J2!\
MWIP:ZB^U2RN/ UWK%Y:R/8/8O<2P.OSM%L+%2,]2.,9KY\TEYO /BCP0/A_X
MN'B;P;XAOUA&BW,J7$E@KC.^!@=RJ@)R#]WOG.0(#U*3XK7D.I>'M-E\!ZS'
M=^(5D>QCDEMD)5%#MO!D^3Y2#@\]NM:-S\1K>QT"TN;_ $74K?5;Z\?3[72"
ML;7,\RL0=N&V%< L6W;0._:N>\>WME#\>OA7%-=1QR!]1;#.!C-N%'YG@57^
M)"OH_P ;?AUXQU.Y$/A^V:ZL)I9.$MYIHR(V8]@Q&W)Z8'K0!UEM\0X[?Q5I
M_AGQ/HEWH&HZHK-8F9DEAN"O5 Z$@.!@[3CKP33W\>_;/$VHZ#X<T2]UN?2R
MJ7TT+Q1PP.PR(]SL-SXY(4'&1G%</\6;RQ\4>,_ 7A/0K@7NL0ZQ#JLAM2'-
MK;1@EG<@_*&R ,]>V>E0?!;5+'PO/XS\)^)[^+3M>AURXO9$NI@K3PR[2DJE
MC\RX&,CIWH Z&[^,]C9Z-;:I+X;U51+K!T)[=_*66&ZS@*XWX .1@Y/;UKI&
M\;[_ !HGA?3]%O-0N8XTEO9H&C\JQ#9PLA+#YN#@#)->2_'?4M U;P7H']BZ
ME!9BZ\4VH^WPJ -X!W3*>CXR,MR.,=JT?AMXOC\"^)+CX:^/([33=2D8W-CK
M)8A-;0G_ %C,Q.)>F03[#H,@'OBYQS2TU65E#*<@]Z=2 **** "CO110 444
M4 %%%% !1110 4444 )1VI:* #-%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 G:D.<4ZD[<T ?#7[9K+_P +&\.=2?[,/_HU
MJ*;^V=Q\3?#_ /V"O_:KT50'T1^S2C)^SIX6SCE;@\?]?$E>P5Y!^S7G_AG/
MPK_NW'_I1+7K]2 4444 %0S?ZO\ X$O\Q4U0S?ZO_@2_S%-#1-1112$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !11VHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_NF@#L:*B,T8;;N&<9QWK+U7Q!I.C06LVH7B0"[N([6 $\R2.P55 [\G\*
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M* #O1110 4AI:#0!\*?MF?\ )4=!_P"P2/\ T=)12_MF8_X6CH.T\_V2,_\
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M)LW,\TI)*]&^]][U/4]\UM6_PV\'V6MW&LV>F20WMS:BQD>.ZE4&$ *$"[L
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M\W_"BM'*ZO>F\O/&\:?:+B42M$XO74. P/S'J<YR>3Z5O:SXL\7> _\ A/\
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M[.OA+'_/&;_T?)7K->3?LXY_X9V\);O^>,W_ */DKUFI **** "HIO\ 5_\
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MVT.26"9)E^S2 VZ>9YN26=A\I'UZUOWGQETBRA?5)-)O_P#A&HM0.G2:YA#
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M68D'G(X/-6/"\VM?#K1?"OA36O#LE[=>*;VZ?49[:Z1OLD\S-)C;U<!3@LO
MVY[T <[!\0?%L'@;1OC#/K$TEGJ6K"UET4JH@2R>9HDV#&[S00&W9YR1C&,3
M:]XX\77NF^/O'^E:U)96G@Z_:QL],55:&[6(IYS3<9);<0N"-N/7-067PZ\7
M3>!/#_PHOM)DAL=*U@74VK[XS!+:1RM*@4!MV]MRK@CC!.3QFYK7@/QA;Z1X
M\\"Z3I#SV7C'5&O+;5$E18;*.7;YPE'W@1M. JMNW#GK0!>C\5^)/B3XM\06
M/A[7+C0['0-)M;R 0*H>XNYXC*@D+9S&HP"HQG/6I+#XCZU)\-_"7Q8N+@1:
M==&*RUG3]OR+OF,)GC/52LF"0<@KQP1DDWA'Q1X%\8^*-0\,Z"^LV.OZ/;VE
MNMM(D;6US!$8EW[V "$$'<,XP>/6IXE\+?\ ",_L]^'?A0MTEQK.HSVEE&(^
M=[_:%EFD /.Q0')/'&.F: /7_$_BC3O"NFV]YJ"S2-=7$=I;00+NDGF<X5%!
M(&>IY(& :\H\5?$:-_$?@'Q+8WFL66F#4;^SO]-,.'E>*&3Y&C&26#K@#/?/
MH:[3XI:,-?\ "UGI4WA.;Q+92W($ZVLZ17%F C;9XB[*-ZM@8R.I^E>9Z)X9
M^(5C>?#U]:T?4M7M]*U:^N&FN9(&GM[:1&C@,V&^:3YMQQGOSGBA >CV/Q@\
M-:GX:M-7L;/5)9[J^DTZ/33 $NOM$:LSQE68 $*I8Y;I[\5!-\;/!MMX0TOQ
M/<#45M=2NFLHXQ:,TD4RN49' ^Z00>,\]LUYXOA_QQ;:_?QR^#=5N-(N?%MS
MJDR6L\"27$#0A8L,9!A-ZC>,KD8'.2*K:3X5\;V?@WP[HLG@*\MSIGC ZL4A
MN+=T%MYTC\9D!X#@#UZT: >@-\=?"/\ 8<>L16>MW$(@-U=1Q6)WV409EWS*
M3\H)1B.O S6UJOQ6\/Z9?_9HK'4]42.&WGFN+" 210).<1%B6'7KP#@<G%>>
M^+?"VN67Q>U'7)/AA;>.M&UNUMXT:0P^;8R(I4H1)T0X!)[<<\8JMX[\%^*+
MO5;?4/#'A>^T?Q-9PV<-KJ&E7$:V,\8 $D$Z%P?+0[L?+T QGI3T ]Q\1>)-
M*\+:#/K>LW)M[2# 9@I=F8G"JJCEF)(  ZYKE]/^*FAZH^KV4.FZO!K&E0+<
M3:3<6A2Z:-ONLBYPP^AX[UG_ !H\+^(/%'@>Q'AR%+K4=*U.WU1+1F"BY$1)
M*9/ )SD9QR*R8=,U_5?B[<?$)_"]]86-GH1TV.WE$8N;N9Y Y&T.5"ITR2,G
M.,BI @^#\WB3QA%8_$&\\2:W!'<++]KTNZC7['-EF\OR.A4(, D=2.<\UU$?
MQC\(MXKM= 1;_%W>2:?;Z@UN1:37"?>C63/)R",XP2#@FCX0:9JVE_"#1]!U
MG3;K2KZT@:&2*7;E268Y4J2",$5PWP\T_P"(GA71HOA[=>"H[G^R[R22#7;B
M1&MI(6D9PX&=YE.XC&.,Y..E,#OO#GQ8\->)-?@T;3X+^%[N":ZLY[B#9%>1
MQ/L=HSG)YYY )'/>L'_AHCX=?:TMVGU*-/MK6,MQ)8ND5O(" /,8XV D\9YX
M/'%</X'\-^-;3X@>"M?U?P?JT$]M;WMMJ<\]Q$8HY'(*F-%?"1=0, 9[@XS6
M7I=EJ7BKP)\4/ VEZ#/<W6K>*KJ%;PQC[/!F5"9'8G/R!<X )Z8ZT[ =MJ/Q
M.M_#-U\2?$-CJ&L>(3I)MU_LQ[?RX+-RNT;&/)4D99O<8SG-=+J'QH\/Z+;6
MW]JZ;JZWO]G_ -I75O':;GM(-VWS)!N^5<@XY)QVKSS5_!?BBX_X6UIMEX<N
MW34;"QCT^:3"K=F"-5<*=W4E>,]:J^.--\;>+M1U,R> _$'V2^\.F"P@AFCM
MPL^'S]K*N"Q'!1"2O/3+&EH!Z%K6N:H?CS\/8M/UNX_L35["\EDLE($<FV,,
MCGC)/S#KZ5VGB[QGI?A%-/6^M[RZN]0E:*UM+*+S)I2JEVP,C@*"3S7FEAI?
MB:;XC?"O4IO"]_:6NE:3<6]\TA1EMV>-44':3SE.W0$>]=!\7=)AUJ/1;.X\
M.ZQ?())7BU/1F87.ES!0$==I!PV6![=,T@$TOXQZ=K7C?1/#^FZ)JLEOJME)
M>+<O;E?+VNJ;2O4 $G<3@ X'-:<?Q8\*MXCAT??>^5/=M80ZD;5A9R7(X,2R
M]"V<CT)XSFO/O"^F^/=)U[P)J'B31;^_NI=&O-*N[BW5 ;9WN(WCDF^; ^1,
MD@D[L\$UGZ;X;\12_##3OA!<^&-1CU'3]6C9M4,6+1H$NQ.;@2G@EDR-H^;<
M<$"GH!ZGK'Q7\*:/XC_L6ZFO#MNHK*>\CMF:VMIY!E(Y)!P&.1QVR,XKCO"W
MQ&N-!N_&R^,]9O=5%IXC.F:?&EJ'F8&-66-$B7GJ3TZ#)JKH\/C#PIXC\2^$
M9O 5QK]MJNL/JNGZL-AM(_,96_?;CE3&5SP"21QC@UQ&FZ-XYT'XJ^(/B7IW
MA/5;R(ZW)'+IDD!#3V<H0>= #T<%.?5< XI ?5\4GF1*Y5ER,X88(KSGQ;\:
MO ?@W7;G0M:U"Y74K>!;EK>&TD<E"< @@8/KP>@-:6C^//[2^(-WX1E\/ZA8
M-#8I?QW=RH5)D8@%<=58$XP?0UYYXCUB'1?VKX+F31[[4MWA7;ML;<SO'_I)
MYVCD ],^XH2 Z^[^-W@*VTC3M5CO;N\M[^U>^C%K:22LD"'#R. /E"G@YIVO
M?&WX=>'$LFU#6V"W]E_:%L8[>1O-AQD$<=3Z=>N<5X1=>$?&FGP-8-X0U;^S
MM7TW4[I+?38$\V&:>:1X[:>;(*1JA1B@."V1AJZ+PII.N?\ "4?!K^T_!NK0
M1Z1I%S97<DUEE(':-44M@D*"5/7G!&0,T: >Y^)/'OAWPGX0@\6:S<3QZ/+Y
M9$\<#R;0XRI8*"0#QR>Y [U7OOB3X7TS[))J5U-:P76FMJJS2P.J+ NW)8X^
M4_.ORGG) K?UK1['6_#M[HE["K6EY UNZ;01M9<<"OGZQ\-^/]-^"'B:]UK2
M!J7B.VM$TBRMKB(7'FVEO(0)/*((=FRS@'.[:G- 'I<_Q*TOQ)X0\5GPKJ-S
MI^M:1I[W.V\LFBDAS&S1OLE4;E.WKR*I^ OB?8W_ (:\)Z7XAOYYO$VI:(FI
MOBU<"X 3+E2J[2W7Y1^5>1>';?6M/UGQY<KX8\730ZKX96&&ZO[-VEFF6-@0
M5S\N2P"H.F.@YK2T6WUSP[;?"3Q/-X3UNZATW1)M*N;:"S;[1#.RJ%#(V-JD
MJ?F.!ZXIV ]DB^+7@>X\)VOB:UU.>XL;N<VMNL5I*TTTH^\BQ!=[$8.<#C!K
MHO#?B;1_%F@PZUH-XMW939"N,@J1P58'E6!X(/(KY(TG0_$5CX7\'^(M8\!Z
M]>:;HNK:DNH:?'&T5R4N&!26-%(9@.AQ@<=<<U]*_#"ST^U\&O-I/A.?PU9W
M=Q)<16=R3Y[!L?/("259L=,G QGG-(#R_P (?$3X@^,/&NJKI^MV0ETJ:*.[
MT*6S"")?M4D<@$A8-N$2J^[)&3C K;UCXB>,KF3QSX@T&:S@T/P7,;=[.2'S
M)-0>-0\^7S^[ !PN >1SZ5YWXBCOO%_Q;L=9\,^'];\/>-(([17$=J\48Q/*
MMP9I"H5T\L#:Q^]@ >E=/JEIJ^@Z=\3?AZFDWUQ?>*KJ6ZTF>WM7>"5;I0C[
MY ,)L;=NW$<=.HI@>Q:MXSL].^%]QXZC0RVD>G?V@B;AEP4W*N1QSD#-</9^
M//%_AOQ%X6L_'5Q8W5MXHLYI8S9VYA^Q7$:"3RCN8[E*'&XD'<#P!47B"REN
M?A]=_ ^QL+U[]/"Z_9]0:$I:RL@"!-_."649![&L*:.X^+'BGP1%;:9?:?!X
M?LKB;4VOK62$13R0B%85+ !SNW$E>,#J"10!IVGQ.\5V>F^$/&>N+9GP]XJU
M".RCL8HF6:P6;=Y#F0M^\)V_-P!\W'2NK/BWQ-'^T!#X+FBLET*?1Y-0B= Q
MG+K(B?,<X R3P!SZUY;:VNI^+/"GPY^&K6-Y:ZIX:U6"759+BVD6*&*RW+E7
M*A6\SY-NTG.?8UW%]?K_ ,-8Z3_HUSY2>'9K8W MW,0E:97";\;<[5)Z^@ZG
M%)@>F:]XDT3POH\NK>(-1AT^RBP&FF;"Y)P!]2>U9VB_$#P;X@FU*+1?$MC?
M/I?-YY4P(A'/)/3'!Y''%<K^T L/_"A?$S31^8@CA)&,G F2O,/&N@VWC*[U
MR_\ AKHKQ06OA:2SN-ED]I]I9IHW2W56526\N*0=.-RCO0![=:?%#P#>:=?:
MC#XKL!:6&W[0\LOE>7N&5)#X)#?PD<-VS6SH'BSP[XH2Z?P_K%MJ2VDGE3-;
MON$;XS@_A7S!>7/@G5OA[XOUS0O#GBA-2;P[)ILEQJ[7$IA=FQ';)O+;CD$Y
M7A0.VZOI#P'I^@VGA#3KK0--M[*&[M87?RK<0M(1&%!<8!R ,<^E# ZNBBBD
M 4444 %%%% !1110 4444 %(:6FL0!0!\)?MED?\+;T7/7^QT_\ 1TM%-_;)
M;=\7-&]/['3_ -'2T50'TU^SH/\ C';PEG_GA+_Z/DKU>O*OV=_^3>/"(_Z=
MY/\ T<]>JU(!1110 #I4-QS%_P "7^8J8=*AF_U?_ E_F*:&B44M%%(04444
M %%%% "!<=R?K2T44 (S!1DG%<?K7BR&Q^('A_P==:4\\>N0W$D=T64HAB4,
M5*GGH1S[UA_%^TO+[0M(AT[5-/M[]=066WL-2D,=OJ;+&Y,#,,$'&6'NHKRK
M24T+Q/KWPMTVXL[G2K1AKB36AU!RP<2*'C652"\98,!@\KQ3 ^FVCM_(\ME3
MRB,;2.,4D,5O;1"."-(HQT5% 'Z5\L:9K-F=#T?P[=ZVUU'9^(=6M[1-3U Q
MV9@A^[Y\G+OL#C8F<GOP.+&E:C9^(_ ?PIL)O%<S3MKD^GW+V.I-&[1;+C"$
MJ^1D",#)+888/-%@/J3S%_O5'/;6]U&8[B!)D/\ #(H8?D:^79K&Q3QKXG\'
MZM\0I_#3:&;1=':^E+S"W5$<21.SJ&9GW \'.<<@8KZ.L->T>XU$Z''K%O<:
MO!"LLUMYBB=5('SM'U7.1V[BBP&LBQP((XU"*.@ P!4FY:\'\7:EX?U+XL^(
M_#?CGQ+)H5K#I,#:0YO/LBH7W^;,C9 :0,$ SG&.G7.9H]U:>+/%_CO2_%6O
M:BJ:/86XTEYKE[1UMS#N-T NW+E^2Q'' P.E%@/HO<!WHW"OFK2Q?>+_ !A\
M.X/$NM:K"=4\*RW-];V^IRVZSNICVL51A@D'<<8)QSTJK#)KVI?#7PS#I>O#
M6+JQU'48_P"Q[K47@DU2WBFDC $P8,71=I!)QTSG%%@/H2;6+J'Q7::+'HMW
M+;3V[SOJ*[?(A*D 1MSG<<\8']<:\DT<432.X55!8D] !7SUX#UNWO\ QUX%
METK5M:.G7'AV^WV^J732.CQSHH+KG:S [ANQD@#FN4M(=0BT[6M,\57=SJDU
M[HVI7FGZQI^K22VVIQ@!]TB;LQNAVXP ""1]2P'TC?>)&A_L&72])NM8M=6F
M5/M-IM*6\3(6$SDG[N/Y_2NCW#&:^<Y+BUL/#OP272-:GCBFO+>"X2&^?9)N
MMRSJX#$'YL<'ITXS7,ZH=2M? 'C+Q=;>+-:&H:+XN>WL0VI2&.*/[1&A383A
M@58C#9'3&,FBP'UEN%+FOFKQ[J6J7WB[QIH<&K7BZH;:S_L22TU+[.MF[*-^
MX!AC))9F(.5_*O3/B%J&K^#O@5K-]H5Q<7&H6%A\ER[&61>@:7)ZE02WX>E%
M@/2-PYK@+3XDV^H^)I=+TGP_J=_8P:D^D7&HPQJ8K>X49;<N=P0="^,9KDH8
MFTGXH^"8?#.KWM]I.OZ;<_VC%)>2W",D<:,EP"S':2S!21C.ZF_ 33=/@TSQ
MA<V4DA?_ (2._AP9WD4*)!CAC@G'\74^M%@/38_%&G7'B^7PO9LUS?6L7G78
MC&5M5.-@<]BV3@=2 3VK4U&^:QTV>]CM9;LPQF3R( #(X SA02,GVKQ+1-5C
MTSX2?$_Q'J&JW&F71UC5%EOK:,-/"5?RH@OJ0 @7..HZ=:J_"O7-37XOWF@W
M=_-'8SZ#;WD=I<ZFUZYFWD%V8L0KE1EE4XZ&BP'M^A:YI?B30[36='NUN[&Z
M3?'*O&>Q!!Y!!!!!Y!!!KE_$WQ'@T#4[[3]/\/ZIXAN--@CN;Z/345FMXW)"
M\,078X)VKDX&:P/A$JVOB'XD:1:-_P 2RS\12-;J.%C:2-))%4=@')_,UA^&
M]#LC^T'\4=EU?PRK:6;1R)?290R1/D\G'!^Z#D+V H ]>\,ZVWB+PW9:S)I=
M[I37*%C9WT7ES1<D89>QXS]"*VMR^M?,]EK&L:3\%/AU\3+KQ!J=S!IURO\
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MD8YKAO"VH^,]/^+=MX=U[Q.-:L=0T(ZF$-JD/D2B94(3;SMPW\1-9OQ,\/\
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M(7!"_+C'7)Z5R>L^-KC0?CGKFGVM_;Z??^(['2K5=6*^9:VC;9B9"2,'.0J
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M10 #I4,_^J_X$O\ ,5,.E0W'^K_X$O\ ,4T-$HI:!12$%%%% !1110 4444
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M3@H3DJ > ">2!C/>O-+CXE>-(= T#0KG2;C2/%WB+5Y-.1KZ-"D$:\R7$:C
M9%!^4-R>IW=^S_X1_P ::)J^@S:;XNU#6[$W.W5(-06#+Q%&_>(RHI7#;?E'
M4?3D T6^&'@&2STRS;PKI_V?2G,EG&(L"!B02RX[Y Y]J5_ACX"?3+G2V\+V
M1L;NX%U/;[#LDE'1R,]?>J=_\5_!^FWYM[VXNX[9;S^SVU#[*YM5N/\ GF9
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MD9KCO'_CJ]TOXOZ+X1U#Q'+X5T:_L6F@U"*)&^T76\@1,TBE54  ].21R :
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M.U=KZ=Q'#C&W:7(/0=0>@]!46L>%[T?$'3O&>B/ MVMN=.OX9B56XMBP<$$
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M,M)EN95=UC6Z3)"YW'KVP?RS6;KOC_2=0^'E]KG@[QEH=N4D\B+4;R0-;1R
MC*M@]<'@>XHU M:3\,/#&BZY;:I8K=9M&F>SM99V>"S:7_6&)#]W.2/8$@8S
M61I?P@T6/3/$VEZJTL]EKFJ'4EA$[DVKA@RLC\$-N&[CIG'(J_>>(]?A^,>E
M>%XI[7^S+W1+B]SY+%O.22-0<YY7#]!@^_2N?\.^.O$6L>!_"FI7FN:#INJW
M^K/;74=R"@NHDEDC,<"[L[SA,<G'>@#M-+\ >']-T35])ECFU*/6BS:C-?2>
M;+=EE"?.W' 4!0   !4?ASX=Z!X;CO5A:\OWO+>.SD?4)S.PMT!"0C/ 0;FX
M[DDG-:.K>,?"VA:A#INL:]96-Y-M"0SSJKG<< X)X!/&3Q4>J^.O!VAR2Q:Q
MXGTRQDAV>9'/=1JR;ONY!.1G'% &5X=^&^A^$KQ-2L9+^_GL[9K6QCNYA(+.
M$D$Q1<# )51DY. !G%,\%^$[[3=<U[Q?KCJ=:U]X_,@C;=':P1@B*)3_ !$
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M:K(-RDL &&,\>O%/4#SS1OA+9Z9JNC--KEU?Z-H$DDVE:7-&NRVD;[K%NK[
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M $8]>IUY;^SZNW]G[PCZ_9&_]&-7J52 4444  Z5#/\ ZK_@2_S%3#I4,_\
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MC/3%L=:@D;RRS0S0RM%+ Q4J65E((.&/L>X-4]%^'/A#0O"-UX6L]*673;Q
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M,O\ 9J W2O#ND7(Y3.">Y''-9_A_QS\3[S3=)^(,SV]QX4N(Y;C4(&DA"QQ
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M_'X@@NO"'@63X7ZFWA[1K_Q(;:XL);/YH9FD>5HV 8856!^0<$$<@8KUS5O
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M$BDLV"K:1 #]W,Q8C>,\].M>,:->W.EZ3\%=6O/#^L_9=.M)]/N +&1I(YC
MB*&0#(4LK $@=,].:IWUEK&N?#OXD6V@Z+?2W"^+/[2-D]N\)O;99(RRKN #
M9$;<#^HRP/?[?QKX1NM.O-3M_$NG26=C@W,PN4VP ]"QSP#VSU[5/IOBKPUK
M&I2Z;I>OZ??WL48ED@M[E)'5#C#%020.1^=?/?C:/_A+;SQ)XW\-:5?QZ,GA
M&;39T^PR))>74F?*C$>W<QCW#+8P,XSC)K:T1;6U^+/PK-CIEU;*OAZ>VN7C
MT^2)=VQ-JR'9@<H_!/!^O*L![=XBURQ\.>';[6M0E2*"UA:0[F"[B 2%!/<G
M@>]<!X0\=:E?Z39>+?$/B;PR/#=[8QR2>43#)9W;[6$)9G96 5CG.ULCI@UU
M7Q!O8[/X;>(9)8YI=UC-$J00-,S.R%5 502>2/IWKR*UU+^RS\(O$UY:W3^'
M+'2Y--NS]FD_T&Z:&-5DD3;D#Y'3<1@9ZX- 'N'_  E'AO\ LZVU+^WM/^QW
M1Q!/]I3RY3_LMG!_"K]C?6>I6,5[I]U%=6LR[HYHF#(X]01P:^7]2TJS$T-[
M?::6\.ZUX\AO;*UELW9!;A-LTI7;\J._.#P1SWKZ>L-/L=+L(K#3K.&SM8AB
M.&",(B#.>%' Y)H HS^*/#EKJ+:;<Z]I\-Z@):WDND610!G)4G/0$U8CUW1Y
MDLWBU2TD6^S]E99U(GQUV<_-^&:^;[$6L/Q?ACT2%=;L;_Q'<-<Z/?VI6ZTB
MX'F"2\CD YA;:3\W!RHZ],_0O$&GQZ!\*?#*:;J(U+P[X@>'4(H[*0FU;9<#
M:?E[[@<#/"GTHL!]/_V[HW]K_P!C_P!JVG]I8S]D\]/-QC/W,YZ<]*Y+P?XZ
M;4KK7+'Q)>:787MEK<^F6T*3;#.B*C*0&.6;Y^<"O*O &K>'WN-/\$^)?#=_
M<>.-(UZXNMYM9%!=II#]J,P^4IY;'J<':  ?EKG];?PK=> ?B1JYBMCJG_"8
M(;>[\K,RCS8"K1MC(&U9,8X(!]:+ ?6W:J']L:7_ &D=+_M&V^W 9^S><OF8
M]=N<U(DRWFG+<64JLLL>Z*0<@@C(-?+WP\U#PS>:+I'AB[\.7A^)VCW=U^\-
MO(K1SLS[KB64 *4(.<$GH  >* /IJ/6M(EU)],AU.UDOD!9K99E,@ ZDKG--
M?7=%218VU:T5VE\@*9T!,G]SK][D<=:^8M/CL-<^'GPXTCPU&MIX]TS5H&OT
M"F.YMBFX73SG&[:W<GABRCG-97BR/PC)\,?BMJME'9G6HO$NZTN$0>=$/-B(
M,9QD D2GCKS18#ZUFU?2K:]CL;C4K6&[E&8X))E5W[<*3DUFZ#JFK3C6I->&
MGPPVM])';/:S[P;<*I5I,_=?DY%> >([BSA^(T^NZ9J&F>((;VYTN&]T*\4)
M=F7;$89[20 E@ 0Q[</^&=J6IVL/A+Q-/I\(N?#MMX_$VL6]JA8?8ALW910<
MH67G/!P:+ >Z:#XYFUKXHZ_X9C;3YM,TZQM[J&YM9O-9S(SJP8C@8V=/?K76
MIK6D31SR1ZI:.EN<3,LZD1?[W/'XU\MZ]K.C^(-4^*2?#-C(UUX=LS%_9<9C
M,VR21I@HP 6V-@XYY(ZYK#\1O\.=2^&GBG7/#VL:KJ5VV@QVUP;FVCAA@8W$
M?EHRK&@,V0^",X"GMBG8#[!EUG2H('N)M2M8X4?RVD:90H;T)SU]JR]8\:>'
M-$N=*MM0U2!)M6F$%H@=29"03NZ_= ')Z=/45X5XRM?!6@GP;8Z3IUEIEOJ%
MG<W4>H?9C<02R-"B%5A48EG<8P3T )PV<5SOA>]T)/A3\';_ %>-3;Z9K<MK
M=R3VQ8Q-MFVH1M/<IP.^.XHL!],:!J6MWFH:XNKPZ?'9VUWY=BUI<>:SQ; =
MTG]ULD\>WT)U[75+"^1WLKV"X5#AC%(KA?K@\5\SW4OVOP=\;(?!O[^8ZQ%.
MT%@"'E@*1"8)MYY"S#CWKJ[.X\(WWQ:T/6O!4EDNB)X?NCK+VB*EN(?W?D+)
M@;0XR_RM@@ YZ8HL![9#JFGSSI!!?02RNGFJB2J69/[P /(]ZN,RHA9C@#DD
MU\I>![;PKI?ASX'ZI8K8V>JW5_+%/.F%FE4PSAE9NI&\H,'N0!7MOQEO+2P^
M#/B2:^LY[NU:V$4D4+LC$.ZIDLH)"C=EN#\H-(#M+?4["]A::RO(+B)#M9XI
M%<*?0D'BG6.I6.I6_GZ?>0W<6<;X9 ZY^HKY1T?6O##:O\3-,O/$T"Z?JFA6
MI6XTK3C% H5'1VBCY#*F5&2>>1GBO5O@??-/'XGLI+71YI;.\BCDUC11MM=3
M;R5PX7H)%4*'"\9HL!ZU>:A9:?&LE[=Q6R,VU6E<("?3)KAO^$]NX_C--X-N
MX;*#2%T7^U8[XRG<Q\U8]ISA0.3W/:N)^-9MH_$VF746L:/!J%GIES)_9NOQ
M V=_ SQ[U5R?DE!48VC//I7)Z6OA#Q1\6]&37M)M$LK;P#%-]@O@)5M3O4A3
MO'54)Y/./2FD!],3ZEI]I%'+=7D$,<I"H\DBJ')Z $GFN/U_QGJ6C?$WPGX8
MBT^VFT_7UN,W33$/&T2;L!0N"#D<Y]?Q^6H-?\.7G@>QTVX>V@U&W\'30Q7%
MY&UR)?WD@6&WB''F>KDD@8P,9->A^&?$6DWVJ? )!J<4DJ:==(V7!^<6Z)M.
M>?O*P^H(HL![+\-_&&I>,M)UBXU33X;&XTW5[G3"D#EU81-C=D\\Y]J=XF\7
M:AH'CGPGH:V=J]CKD\T,MS),0\12%I.%QCG;US^%<S\"KRSNM$\7_9;B.7_B
MJ-0<[6R<-)\I/ID#CVJI\9K70[OQA\.(_$T<3:1_:5Q]H-SQ#_Q[-M5STP6
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MO'()/M0!RFL?"GQ%XDM=0O/$/BBQGUR72IM&M)H+!D@MXI<"60IYFYI& /\
M%@=AUSB_$JUNO#/PV^'OA?\ MRQ_MFSUC3(89Y8BL<GE,!YC1[B=H^4GG\17
MH?@'QQ_PE7@BWU_6(K729Y+FXMC")]RAHYFCX9@,GY?2NO6>TGF:%9(Y)8\%
ME!!*9Z9':@#QK5?@SJWB22?Q/K/B"WA\:K=075C>6<)%O:"#=Y<6UB2ZG>Q8
MGDD^U0>+?@_XL\7Z-K5WJ7B#2T\1ZO!;6+O#:R"VM[:*0R[%&XLS,YR6;C
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M+J3S"LL:QDQY09X0'G')/IS;^&G@[XE>&)[/0=>N]!E\/:.C16EW:PM]LNT
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M[')8G P>F:;\4OAO\1/&7B7Q!%9VFDW^C7^EK!8O?7#@V,HY?9&!C>Y ^;G
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MSKI.N "TU&+""1=Q^[*HP5.">OH:];LO#>GV?B6^\0(KO?WJ)$[M@!8UZ*
M._.3D^_2KU[I.EZD8_[1TVUO#'RGGPK)M^F1Q2 ^:M)M_!'B?Q=X)T_7+2&'
M3HO!18:??7&3$=\6U7Y!8A<L,CL&QQFO.[77O#VK^#O#^BZIK-L&M/#E\5FU
M6;S+9/WSJ@BBSEK@!0 =PPO0&OMMM-L&N/M+6-N9]NSS#$N[;Z9QG'M5==!T
M2,Q^7I%DICW;-MN@V;N&QQQGOZT[@?-NB^(+&\A_9^>?5H;B=4G$LDEP"P86
MQ3!YZYXY[\5Z=\&;NSNX_'+6UXEQ_P 51>M\C C!V8(QV/KWYKT0Z!H9%O\
M\2>RQ;<PC[.G[KO\O'R_A4]GI>G::)%T^PM[-9&W.((E0.?4X')I7 \/\6:/
MX1UO]HZXT_Q%Y-Q;-X6:2:VEN"$=Q/P60,.0HS^O;-<=\.+_ $G6I?!6B>-)
MXK[0)_#4J6:WTH>%KE)_G!SQO6(*!GD &OI^71M)FO'OIM,M)+IXS$TS0*79
M#_"6QDCVJNWAKP[)8QV+:'I[6D;;T@-JGEJWJ%QC/O1<#YC%OI7_  A7P^U#
MQ2T4FCVGC&>VL[W4""/L&9O*W._\'RKCM@+7T)X\DMS\(/%$MKMDA.C731^5
MRK+Y#8QCM7076DZ7>V,=A>:;:W-I&5*02PJR*5Y7"D8&.WI5PQH4*%1M(Q@C
MBD!\KQZ/;Z9J?P^U3X6N\NKW6C7$VK-:SM*LD:VPVM*"Q&?-*@#UXQQQ-\(7
M\.ZMXE\'Z]9^.?M/B$V\L5]IMO9%)YV\O]XUVV\D[2/E=A@DC%?2MCH^D:2C
MKI>FVEBKG+"WA6,,?? YHM-'TBQNY[RRTNTMKFX.99H8%1Y#U^8@9/XT[@>7
M?&B[TM9?"&G:M);1Q76HN?\ B92A; A8'W>>#]\ -E5R,L!SQ7F_A^:/6O@-
M8:58^*-/%W'XFECM5NFW6ER%EE=+:558[(G120I)_AZY%?3E[IFGZBL:ZA8V
M]VL3B1%GB60(P_B&1P>3S563PYH$UK):R:+826\K^9)$ULA5VQC<01@GWHN!
M\S>=:ZWX4TFQLUT[2M5L=7U,GP[?W)DTW4G3'FJLJX&%W@IZ'=QQD4-7UC2?
M$VO:;9Z]XE3P=H-_X7MGTF+5+9;J)2-PD*LS +(,)A_O$ 8/8_4]UX:\.WEM
M%;7FAZ?<6\.?+BEM49$SUP",#-2W6B:-?);K>:79W*VIS")8581'&,KD?+QZ
M4[@?,GC.%+?3+34UOX?%UMI?AJV^V:?JDK6EV("6(O(&R=LK!<$=> "3P#8U
MBYLK?XBR>-&=-;TJ?4-+B-N;AXM2T28I&4"J20Z-N7<O&<M_=S7T;J'AOPWJ
MES#=:IH>G7MQ 08Y;BV21XR.F"1D8I3X:\/OK0UI]$L&U(# NS;)YH''\>,]
MA^5%P/E7PYKNCV_Q.^'VL6FNV\5O?ZAJ E>XOC)?2QMOQ]J.=N-V JXXP.2<
MT[4M!T&;P=\0/$-K>3VOC"T\57"Z8T%Y(DBRF9"BI'N ^;G)QT&>U?5'_",^
M&Q,)O[ TX2B;[0'^RQ[A)TWYQ][GKUH_X1O01K1UK^Q;+^TSUN_LZ^:>WW\9
M[FBX'SAXGUC6[/0?C->Z'=2IJ4=U8">:TDW211B&-92,'C W>_6NP^$=EH">
M.+K4O#GCJVU>&]TM))M,L(=D,9W#;*XWMMDZKC@\'->RPZ'HUM+=26^DV<+W
M?_'PT<"J9O\ ?('S=>],TGP[H.@121Z'HUEIB2-N=;2W6(.?4[0,T7 \Q^-^
MGZ%?3> QK$<#;_$EM!^]. T;*^Y3[$A?TKC=0M_#>JZI\5;7Q9.EIJ6AJ#I)
M>=D:SMA;!HI8 ",9?<Q*]SBOH*_T/1=7>"75-)L[Y[9MT37$"R&,^JY'!^E5
M[WPKX9U._@U#4M T^\N[==D4\]LCNB\\ D9 Y/%*X'SOX3T%O&'Q2T6'QM>7
MO]HMX4M+ZX@COY(RUQYO#,%8<[0,CIS^->D_'B_MK#X=VL5U=3VZW>IVULOE
MW'V>.0EL[)GYVQ$ [C@\=J]$7PYH*ZT-:71;$:F!@7GV=/.Z8^_C/3CK4VJ:
M1I>M6#V&KZ?;:A:/@M!=1+*A(Y'#<47 ^2%U6%?AA\:-+M]:M8A:7*364.FW
MCK%&-J;O)^;.W=UQQFNRTKPSIJ_%31-!6^O#8^(_!KM?K)?R.T\H* 2?,Q(8
M \?3CH:]P/@7P8UO/;MX4TAH;@*LR&RC*R!?N[ACG';/2L_6O!=A'I=S=>#]
M+T;1_$D=L8-/U V$9-L0,*.!G;@D8]^AZ47 \H^%FF:O/K=MX!U>S(B\ WDS
MW-VTA)OGDW-;-UR1L9F(/=5_#K_VAE\OX.7MRM]<6+PW5MMFM[AH2NZ9%;)4
MCC:3UR!U[5UO@3P[J>@:%-)X@U*/5-?U"8W6H7<<?EH\FT*JH,<*J*JCZ9[U
MD?%[PIKWCCP&WAK03IJR3W$4DKZ@S; B.'P%53NR0!CC@T=0/(-9\.V_A[7O
MB'H/AS4+^^T9_";ZI=137DDOV6^#-Y;*['*LRJ6Z]O3&-:RUG2=6^*OPWM[;
M7_M$MSX7E6\$-XP+$Q(4) ;[WWO]K\N/<=$\,:+H^E2VMCHEAIZW0W7$-I"J
MH[$8.< ;OQJE;_#?P!:+&MOX,T6(1A@FVQC&T,,-CCN.M.X'S)#X91?V:7\=
M#Q1X@.L7-PD#3+JTVV./^T-F N['0GKGDD]:TO&T6K_#3Q!XE@\$ZWK-QIMW
MHL5YJ3RW;W+V1:Y$9F1F)(8Q[SZ\9^GL7Q!^&JZC\,)_!W@/2-&TM+B[AGDB
M=/)@PDBR-\J*<DE .G>NPT?PEX=TK29K*U\/Z99I>(%NXK:W58YCMVD$8Y&.
M,'MQ2N!XW=6L7AOXCW&G^$]:DTW1-5\*7-W<R-.\D=K,K 1W623@_-R<\[3U
MQ7!7NN:QX/\ "VO:=*USH^KK::8+F_MK^2[M9K9I]ANU;<&C=AD$<$@YSWKZ
MAT[P=X0TBTN[/3?#NG6MO=IY=Q%%;J%E3GY6&.5^8\'CDTRR\!^"]/L+RPL?
M#&F06M]&(KF%+5 DR#HK#&"!Z4[@>8_#N33_  MXHUJ]OOB;IM]H]Y;PS164
M<SM;VK$[5<2R2O@N0?ESR?I7I?CW5(]'^&WB#57U">P6VL99/M5L@>2'Y3AD
M!(!([<CZUAZW\)?"5[X&OO">C:+INBV=_*DDQALU.<,"2!QAL9PW\)YQ79#1
MM/.@#0IK=;C3_(^S-#,-ZO'MV[6SUX]:0'@7PWFO+;XI76AW.I26]K=^%HKC
M[.NJR7+R2ER#,S'[LI!).PX'&":YG0QK&G>#?A=XP3Q5KEYJNJ:V+*X6?4))
M$>W)ES'L)VG[@))!.2>>@KZ&L/AC\/M+N([C3_!VD6TL<30*\=H@8(W49QWH
M'PR\ BTL[-?"NGBWL9?/MHA%A89/[RCL>.M.X'SY=-;:UX,\ ^,M0URZO-<O
M?%UO]J26\D9+8F20>2(L[5"8&.,@Y/0U]#?$;SO^%6>)IK:^N+&>+39Y8[BV
MD,<D;+&6!##IR*JW7PH^&]]J<NI7?@S2IKN683R2-;CYY,YW$="3W]>]=-JF
MCZ9K&C3Z-J5JEQ87$?E20'(5T_NG':E<#YI\*WGB#PW=?#[7AXHUW7I]>\.W
MEQ<V=]>-)$\D4"R)M!& <\<Y///>I;;5=9M_A[\-_B'I_C'4K_6]5UBWM[^W
MDNF:&]$[X>#R\[$V8.W@8P:]WM?AYX.LKG2;JWT.".;1HC#8."V;9#U5>>E1
MV'PW\#Z9JJZI8^&K."Z2=KF-E4[8Y6&#(BD[58^H -%P*_Q/76I/AKJD/AW6
M8='U67RX[:XFF\D,YD4>6'_A9^4!]6%>!37$6N:EX=TN]N/$5CJ-CXSAMKNP
MOK^1VL\VY.R.4-\Z$H65_O $G@')^H-<T'2?$FD2Z/KEC%?6$V"\,HRK$'(/
MU! -<_<?##P+>:))HEUX?AELY+H7KAG<NTP&!(7W;RV.,YZ<4 >7ZC/JOB2^
M^)KQ^+M6TF]\+!8=,AM[EHEA5;=91,Z_\M=[;A\V1M!Q63X=\4Z[\4+BRTC6
M/%%]X:OCX5AU&V:SE:#S;EW=6N&"D;E78I"$[<.>.A'LVH?#'P1JM\+Z]T.-
M[@6ZV;&.62(20J,+&ZJP#@ ]&S3O$GPR\#>+KBPG\0^';6]DT]?+MV^9-B?W
M/E(RO'W3D=>.:=P/!?&WBZZ\._%>%_[5E%IJGAW3["^\2PQ8^QJ\TP-QM! 4
ML1P>BYS@\ _3>C6T=GHUI:I?3WRQQ*HN+B4RR2\?>9NY/6N=OOAGX*U*\U"Z
MO=%2234+,6%P!+(JO .0FT-@ 'G@#GFM[0]#T_PYHT&D:3'+'90#;%')/),5
M'H&=B<>@S@4@-:BBBD 4444 %%%% !1110 4444 %(>E+2'I0!^?G[74@;XZ
M@8^[IEN/U<_UHJ+]K7_DO4G7_D'6_P#[-13N!]A_ _/_  HGP;G_ *!L7\J]
M&KSWX)C'P+\&>G]EP?\ H->A4@"BBB@ J*;_ %?_  )?YBI:AG_U7_ E_F*:
M&B:BBBD(**** "BBB@ HHHH \X^(FH7>F^*O +1V.G74%SK(M7:ZMS)+"6B<
MAXFS\API!..]<[IGQ"\6W7Q!N=#N&T^WN8I+S_B2W-L\$[Q(&^SRPRLVV8.5
M7=M'&[MBN\\5^#T\4ZEH%W)J]W8_V+>K?QQPK&5ED *C=N4G&&8<$=?I7/?\
M*GMYM6LK[4O$VJ7YTV2ZET]93&&M6G5E.'"[F"ACM!/'OBF@//H/C#XPG\(:
M[K2W^CKJ&E:4U[<Z7<6,D%Q9W"NH:)D:3<T94G$@[C\*]$;QMJUG\3+;1;PV
MK:1/X>?6&=(R)$=)$4C);!7#'L*A;X/Z=?"Y;Q%K5]K4\VD-HHGE6.-U@8@E
MB44;GR <GTZ<FC1_A+]A\56GB+5/&&LZW=PZ>^FNEV(1'+"QSM(5 1V.0<DC
MD]J>@'):;\6?&LL-AXMN/#\DWA*ZL)[VZ?[&8OL2JK/&5E,A\T$8!^4<\CT%
M9KCQ#K'Q2^$'B'Q#_9RR:C'=S+';1%&@S;%A'O+'>,'K@<Y]:ZS1?@GI^DVL
M^BS>*-8O_"Q65(-#G=?)A$@((W@!V W':">/>F:/\%Y-+U7PU>2>.]:O(_#4
MC_8()DAPL3+M,;$)EACC)[ 8Q1<#7^(7C#6_#FIZ/9Z6^G6T%VD[3W5V&FD!
M104CB@1@\C,3VS@?6N5N?B]K ^%'@WQ=]GMM.76I-FH7LEK+<06("MEBBL&P
M2O4GCOFNS\6?#V7Q%XMTSQ+8>)K[0[RSM9;)_LR1R"6*0@D8D5@IR.H&?RK,
MT?X6ZAX?\*:5X?TKQO?"'37E5!<VL,J20N,>4R8&0.H.<_AQ1H!U7A+5M4US
MP+I^J7TUB-0N82[26;>9;DY(#+ACE<8/WOQKY]TV36-+L=4\7:Q:Z!J\]KXV
M,*RSV4GGK(\Z0[XY/-^4*K?*I!Z5]!^$/"=KX,\'6?AK39WDBM ^V64#)9F+
MDX   RQX':N/7X1N?".O>'YO$UQ(-4U$ZM#<);HC6ESY@D# #AE#*ORGWI:
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MF]]/M_\ V:BF?M:'_B_4_(_Y!]O_ ":BG<#[,^"R[?@7X+[?\2J _FHKT&N
M^#/_ "0[P6,8_P")3;_^@"N_I %%%% !4,W^K_X$O\Q4U0S_ .J_X$O\Q30T
M34444A!1110 4444 %%%% %+4-2T_2K,W>IWT%E;@A3+<2"- 3T&3Q7->,O'
MFD^$_ MQXH^T07L6U1:JDRA;EV8*H5LXQDC)&<#)KCOB'<?V7\9_ ^L:^I;P
MNL%W;/-(NZ"VNW \MI.RY7*ACTR>>:X'7DT>T^$OC:<K#!X>O?$\,FCPR183
MRQ+ )FB3^X768C'&,GH:8'O/AC5/$FH/?G7+#3X[:-D:RO-/N3-'=HRY)P1E
M2IX]^U9NM>,]1TOXH^'O!L6C13PZS#/.+LW14Q"(*7RFPY^\,<_E77V/V-K"
M%M/\HVK*&C,.-A4\@C'&*\H\6:II\?[2G@"WDND5X]/U%'4_PLXBV@^F=K?E
M0!Z@=:TA98HFU2U$DLAAC0S+EY!U0#/+#TZT^;5-,MKV&QN-1MHKN?\ U4#R
MA7D_W5)R?PKY1U&U\'P_#SQKKUO;V*ZG:>-1]DN0H#PC[5$1Y>/N@KOY'! .
M>E=%)KGA5?'OBSPOX[TVXO?$5WK-O?:+Y$+-)=PJ(S;K#(!A I# \@?,V>].
MP'T7<ZOI=G=06MYJ5M;7$YQ%%+*JM(<X^4$Y/X4^XU+3[:3R[B]@A8 $B20*
M1DX'7U/%?.-W+H3S_%G1OB)#"=<GE>72_M"@S2VQC @%L3R2'7HO1J;X>\*^
M&?$/QBL='\<6MI>ZS'X4LI;J&23#-=J_S%L$$N !^!HL!]'MJ>GI,L+7T"R.
M_EJID +/C.T#/)QVI9M1L;>[BM9KR&.>7_5QO(H9_H"<G\*^1]8T3P!)X4^*
M$;1VJ^+K?7YUTJ**3%Q'(60PB!1SRV<[1VYZ5LLNEMX1^).E_$+R_P#A.58/
M:/-C[4X\E/LOV8_>/[U> G\1/K18#ZAEO[.%@DUU%&Y(4*[@$D]!^--74;%I
MY;=+R%I85W2() 60>I&<C\:^</"/AW0M4^)VHGQE:V^H>)=,T#2[V6))3YHN
MXU<NV <EQA,_7WKEOAGK?AMOB'X NK>\TV""ZL]0MY[*.-GF5WP0ES,?];(Q
M&=N!C'0Y!HL!]'ZEXV^T>"[S7? ]I#XHN()?*6V2Z2$.1)L<[SP,88^^..HK
MJI+ZUMUB6\N(;=Y3A5D<#<?09ZU\EZQ<>$(_V3M3L;5M.AU.PU14N84Q')'(
M+YMJMT.?+W8']VNKNKGPG<_$GXBVOQ':U='TZ";1YKIPP^Q>5S]GSD;A)SE?
MF+?046 ^C);RUM\^?<1Q +N)=@./6I(I(Y8UDB<2(PRK*<@CV-?*7AC1])U;
MQ?X"LOB (KBX/A"9[B*_?&\"4>4)0V,D1\X;TSVS7JW[/%Y'=?!#2XXKA)A:
MW%U;A4D#^6JSOL4^GRE>/0C'&*5@.]\2^)M-\*Z:MYJ,C;IY5M[:",;I+F9O
MNQHO=C_B3P*OVM^&M[0:AY5G>3H&-L90Q#8Y4'^+'J*\\\>-)'\7OA?)<;OL
M'VN]3KA1<&V/EY[=!(!]:\2^,GB'0YM:^(J+<1V>KZ?)8+']M8RSN5VM_HHP
M/)3YB6;)R>PHL!]<2W5M RK-/'&6^[N8#/TJQVKY=^*EQH=]K]_XBM]2T[Q!
M%!H5N;G1KR38SPN[,D]E-R!+D= #NP/4"OIJVE\ZTBE\MHMZ*VQQAER.A]Z&
MK 8&O^+K+2K'6_L7EZCJ>D61OI;!90C[,,5R3PN=C=?2K/A?7X_$GA/2-<\D
M6S:C9Q7?V??O,0=0V,X&<9ZX%>->)I/"NC_%+XC_ &U-.L]2O/#4,EJ71!+*
MVRZ61D[DX"@XZX&:Q?">EZ'H&I_"/4_#[06^IZQH=Q'=2+-N>Z9;5&4-SAL.
M./3&!VH ^F%FB:0QB12XY*@\BI:^5?A.FDZEXE\*ZI=^-9!XLMY9X;[28M/6
M*[DF97\W[2X.YHP5)#,,?=Z$BOJD_=I -\R/<5WC([4"1#G# XZU\E:IK&F>
M$M5U*\OD?6;;4[?5Y;+7M)G,5XH^;S8;A6[H2%5^V!@5<\.W6C+JOBS1WU31
M[:TO_"$;K#I=Y\ID7S06+97?*%P68 4[ ?5 E0G <&G>8NW=N^7UKY7T+PSH
M+:U\)$-U=!O$.ASQZK_ILF;T"WC8*YW=,] ,#C%4I=2FTSX1:/I<FM&Q\/1>
M,+RPNKIPT\5O;))+Y,<B[P3&6" @GIC\2P'ULK!AD'-!8 <G%>7?!K3[72_#
MFJVNG^+D\360U&1XIX(MEO!N56,47SL"JDGH< DCM47Q\98_@SJ\_P!KEM)(
MW@,;Q3M$V3,H/*D$\$\<BD!ZJ''K2[A7S-KG@W0HO'/C+2X]1U%;&'PW'JOV
M8ZI,5:ZS*!,WSY)P%ZG'/2N<\8:XNM>#K 3:F9M4LO \=](U]?F"&*1E!$T0
M4[I+@E2.2 ..I.*JP'UYN%+7S/?ZA/HOAKX=?&:&XO-9C6RALM6MXIV=9C+"
M$27;G&]9<*3U^;VKW#P+HMQH'@VQL;QG:]<-<7.Z0OMED)=E!)/RJ3M'L!2
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MR8)(/0*, \<#-9^N67C#2M&^);0?$KQ(R>$)8[JQWW*EI6>%)2)6QEU&2 G
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MKY%S?-'$(8PC/YD0C.[>"Y#;AU &,5]#03+)&-K*Y &=K9&:+6 E=UC4LQ
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MC9K*%FQB-I?+4N<G' )(SQG&>,UTSWWQHT7PCXMCNF_M&>+R)=)D#0R7QB+
M3C8@",P7<4XY)QSTHL![V**\R^#_ (BN/$GAG4KFX\17.MM#J#1*;VU6VNK5
M1''F&9%  <-OY'!!%6?B5XFU;2)_"^@Z+=+87GB/4Q8_;I$#_9HPC.[*IX+D
M* H((R>12 ]"8JHW,< 5SNC>-?"?B#5;C2M#\0V&H7MNN^2&"978+P-V!U7)
M R.*\DU35_%LFD_$SP+JGB2:YN]$TL7]MJL=O'')-!)"Y,;J!M#90C<H!P>,
M8KN?A-H"V'P\\-ZA>7$=_>R:5;K%<M:QQO#"8U(A#* 2H//)))YI@>BL"RD
MX/K2CIS112 ****  T444 %%%% !1110 4A/%+2'K0!^>O[67S?'V?;U&GV^
M?R-%)^UF-OQ]N/\ KPM_Y&B@#[1^#HQ\#O!7_8'MO_18KNZX;X/\?!#P2,?\
MP:U_]%+7<T %%%%  .E13_ZO_@2_S%2CI4,W^K_X$O\ ,4T-$U%%%(04444
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M@NY_.DA592!%N+'.W&.N/3B@#O\ 6M!T3Q'8?V?KNEVFIVFX2>3=1+(H8=&
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MKRSTW4[&*"8PC^T+5K<S?*#O0'DJ<\&N,^-(\56WAW3;[P3J]S8:\=2@MK=
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M[L*PRV>=QR>O/)J&7X7>!9[;5[6?1?-AUJ59K]'N9B+AP<@GY_IT]!Z5P/\
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M@#[7^$/_ "1#P3_V!K3_ -%+7<5P_P (N/@CX)[?\26T_P#1*UW%, HHHI
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MKSJRW*.VT;5'3G=U.?EZ4 :FC:7K"^![?2/$$UF^H&U,$S6<;"$97;\H8Y(
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M-N(XF?#Y)_A(QD>V3P*Y_4=(\)>+OC7XHMKM;;4-.M_"MN8(XYB8EP[D$*A
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M2 85B0IQUP!GJ:X;Q;IEK:7OQZNOM%S)(=*@(6:ZD<#?;N2-N<8!Z#'RY.,
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MN'9E+*/F<=0.,5SNF_"R+6M(UN\^(&@Z1>^(]4FG+3Q2/(@C(VQ+E@,;5PO
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M-0ECVQ/, <@\Y_BQT[&LG38/B!J7P];3;WX0VL&O:#HTNG1W=^4D6X&S9Y<
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M?=)[5VFA>![;Q?X=^*WAR^TN[TQ+G79;_3);FWDMD1P@\N:/<HXW*<X[=>M
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M*H&!G!Y(KPS7?#MC9^-=3^'MUXN&EZ;9Z+'<Z7)K5U-*59Y9&EFC;S$S(AV
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M5\3?B)X+U#Q-X9FN=,U2_P!-L;?5+34'MC&)8I)EA:-XU? 8,PPP., Y'H6
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M\ X/9LUFZ[XO\?\ @[P_-;ZY'9:GJ5_JT.G:3=6<>WS$E7)D:$OU3#@+O^;
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MIFL)!I$AM7UBVN!;!)U8!MF&#.JGY6/3ZXKVNQDD.AVLB@RR>0K8)P6.WUI
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M(V2>,=?N.Q1L'.UPIQVSQ5[QUXWO_">K>&]/M-!N=0_MF_2T,T93:G#,5 +
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M4 '. Q'7OUPOC#4O$VD^$?BCK%CXPU*.?1+R,6)Q&R0*T,$A7&SD9E8<]L4
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MJ0OH-4>+2=4C:- 8+F3B&8%0 ,L CC.,L".G(!?7X+^&F\'S^&KB^U2XCDU
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M4M=#4@%%%%  .E0S?ZO_ ($O\Q4PZ5%/_J_^!+_,4T-$M%%%(04444 %%%%
M!1110!YGXC\=>++'XB3^#]!\-V-\XT?^U4N;F]:)1B0H58!&[CC&<^U5O _Q
M0O\ QC?:)&-%AM;?5]%EU2-O/9FCDBF6)XS\N"I+ @CMVK8U#P+J%Y\0[OQ?
M#XA,#3Z4=*6U^R*P1,LP;=NR2';/TXKF]'^#VH^'M.\,P:+XVGL[K1;>>QDN
MELHV-S;2R"4IM8D*P91AA[\&F!2L_C-KVI>'O"%_8>#[>>Z\1:A<Z;Y7]H;5
MADA9QG)3E2(V.>H]":BA^-'B9=,O-2O_  7!#:Z1K2Z+JCQWY<B1I5C#0C9\
MX&]2=VT\\>UW0_@M>:#;>%+6V\8RW$/AW4KC446XLD8RF7<&7(88X=^>>6SV
M IMQ\&-2N/#/B/1?^$N11KFN+K3R_P!G#,;"19/+ \S!&Y!S3T Y_4-3\0>'
M_P!H_P :7WA/PQ!K$W]@VEQ<1R7/D9"LW(^4[G(& /;DUMM\=H]3TZWN?"GA
MZ?59I-*74Y(?+F<H6+*L'[J-_G)1QN.!P*Z"^^'.L/XTO?%&E>*/L=SJMA%I
M^HH]KO5U3/SQ?,/+;ENNX<]*SI?@W-H^H:3??#[Q5<^&)+.P33+@&W2Y6ZA4
MDJQ#8 <$D[O?I2 5OBEXKO/%$.A:'\.9[F:73(-4*W=ZEK)''(VUE=&&592"
M,=\=J]&U[7;+PYX;O]>U)BMI80/<2E1DE5&< >I[5R^D>!=2TKXE3>*?[>^T
MV<FFQZ;]EF@+2D(Y<.9=W)RQ[=^V*Z?Q'H=GXE\,ZEH&H*3::A;O;R  $@,,
M9&>,CJ/>@#DK;Q_JD/B/P_IGB#P_%I\/B.)VT^Y@O#*!*$\P0R@HNUBF2"-P
MR"*X_P !Z#_PF/B[Q3K'BK1[.>YTOQ))]COH[IS<6[0K&%C0A5_=8[9 .3E>
M<UUFC^ ]>74M"N?%'B*#6%\.JXT]8K,PEW*>6)9LNVY@A(&T*,DGZ7_ /A#6
M/"<FNMJ.M6NI+JVHRZEB"S,'E/)C(YD;(X'^)H J>/OB._@BY:)]-MY(EL);
M[S[R\^S1R%"!Y,9VMOD.<XXXJ;3_ (BKJ6N^%-/@TPK#XETR748)FEYBV*A*
M,N/^F@Y![5D>.OAGK?BSQ<=6T_Q);Z?:W&E2:9-%<V(N7B#%LO"20$9@Q#'G
M( _"HOPM\3V&F^#9-(\86Z:UX;MWL1<SV&8I;9PBLHC#\,!&N"2><^V #(\0
M_%3Q1J'A_P ,7?AW2;>RFU+Q(='N$FNLD>5(P8 [/NMY9YQD#MS6/:>,M2^'
MVO?%/6+7PO+JFF66K1SWK+=+&(5,,6XH""6)+%L<8'>M]?@SXAB\&Z?I4?B^
MW?5=.U]M<@NI-/'E[F=R59 W/WR>O!]L5-J'PG\67_AWQ]HTGB73]OBRX6;S
MA9N##\JJV1OP<A%_7Z4 =)=?$B>ZO=2M_"VA#6#I5E#?7?F7'D,!(I=8T&T[
MGV#/.!R!GKC @^-D^M7VF6GA#P7?:\VHZ6FJ1E;F*'9&93&ZMN/!5@1UYQ^-
M36_PR\5:/K+ZKX?\26<$NIZ=!I^K13VA>)FBCV+/$ P(8#(VG(YJ7PI\+M4\
M&>.-+O-'U2V;P_8Z,NDFWFC9KB3$C2F0L"%R7;TP!P!3T 3PKKZQW'CF?P[X
M/NFU>'6UAN[:2^#":1E3,@8Y"*%.2H]ZCA^-EM]G\2WUYHABTO072V>_@N/-
MBN+EG">3'\H+8)P6' J-OASX^@TOQW#I?BRPL+WQ-??:H;F.U?-LI4(R_>Z[
M%7!'0Y-58_A/XHO_ (>KX%U/6-*TW1[:V46ATNVD\U;E)$DCF8R,<X*$D=]Y
M]!1H!HV_QIMO.U6VO_#E_!<VK01V:Q*S1ZB\K!$2-W5 &#, P(XZY(!K/\.3
M:I-^U1K']I6']FR'PW"[0)=M<1R'SL"1>  <#:1@<KGG.3/=?#CX@^(?!TMK
MXJ\;6LNN6LL-QIDEE:;((9H6#I)(#DN6( /0 $X%7O"?@CQY:_$P^-_%GB#2
M[F>;2UTZ:TL+1T0;7+*59F/<Y)Q[8%+0#J_'7C2S\!^'$UB^A,L<MQ':KE_+
MC1G. TCG(1!R2QKR_7_%&J:AXW^'VN0^';P7WVV_M5LHKL-%<JL)VR(Q*HR'
M(8/UQ^5>F^/M%\2:[H,-EX;NM-C;SP;NVU. RV]Y!M8-"P'(!R.1Z5YUX9^$
M'B3PQJGAR\LM1TN.VTV_O+^2Q59?+A^T+L,,!)X15P1D9)SVXH0'26OQ8^UZ
M$MX/#=Q!>)J4^EW<,TP6&SDB5B[23 %0GR@ ]RP%4YOC99CPIX8\067A75-1
M7Q!<O90P6KQ,R3J64IDL V2C88<8&217+GX/?$!-0.H1:QX?E<Z_<ZQ]DNH)
M9+<^: %8KD9>/&5[9[U8L?A/X_TVR\):>-6T.\M= UN74\M'+$SHS.0,#(W?
MO'/8 X'/6GH!T6I?&JQTJQ<WV@7=OJ=K9K>7FFS2QI-"&+;8UR<.Y"$X'8CG
MFM'4/BQI]O/!;:;I-UJ5U-IL6J+:AEAF>&0D#8CD%V&#E1TXZYK,\2>"_B#9
M_$JX\5?#W4]'BAUFWAM]3M]5B=PABR$ECV\D[6(VD@<?EF_$'X9^*O&%S!9,
MNCWD,-M"MIK%RSQ7NGW*M^\E38/F!PI"[@,TM /9Y+F*"T:ZN&$,2(7=GX"
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M7OV58KB>,8W2;,,P_')KP32_ ?C>'X70_""[\.L;>UU5&771/%Y+6BW(N/,
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M9YQSCG[33-6L_A!XR^%VM>'-0G\4ZEJLTELZ6CO'=^9*K)<><%V  CDLPQM
M..E.R ^AO^%@^#Q<ZQ;'7;?SM%&[4$YS:CU;C@5>A\5:#<WFF6<.I123:K ;
MFR49_P!(C #;EXZ8(->1^./!GB:'XFV%YX5M66W\6::VCZW<)@"V"8*S[NI;
M874>N!TJ]\%?#'B;34N/^$KA*-X?630=++9S+;*^[SN>NX>6H_ZYGUI: =UX
MQ^(/AWP/)I46NW1CEU2Y2UMT"DY)8 L2!@!0<G/IQ7)Z+\5+.U^('BWP_P",
MO$.D:?%97T$&F*[>2\B21A^=S<\LHSQS]:L?&1Q;6?@_5IK&YN;73?$=K=7
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M@L#_ (0'P]CC_B6VW3_KDM;]8'@Y-G@70%Z8TZW'_D-:WZ "BBB@ J*7[G_
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M=%T>WO+J\M])LX;F[XN)D@57F_WB!EOQKB8?BSH]Q'X-FATK43!XN#?89"J
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M2ZN;6!D5UM8P[#<P4$Y( &2.:8'B,WPY^)<GPQUCP_\ V'IOV[4/$YU@8O\
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M:638A=@H&3A1DGIT S1<#QNQT'QO9^(_A9<3>%&>+0-)FM;]X+F+;"[Q)&%
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M!C^\5QN^=1U'N,]-\*_'NK>-?[0DO[[1KJ"".%E-@LD4T,K%Q)%/#(2R,I
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MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A>_C+;G']HR=:* /T\LQBR@QT\M?Y58JO:Y^RP_[@_E5B@ HHHH !TJ&?\
MU7_ E_F*F'2H9_\ 5?\  E_F*:&B44M-6G4A!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%'>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *1NE+VI.QH _+OXVY_P"%Z^,LC'_$SE_G12?&S(^.GC+/
M_03EZ_6B@#]0;=<6\?\ NC^52U'#Q"@_V14E !1110 #I4-QS%_P)?YBIATJ
M&;_5_P# E_F*:&B4#%+112$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %'>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **/PHH **** "
MDYSTI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *:WW33J1ONF@#\NOC2V[XZ^,FVA?^)G,,#_>HI/C,=_QT\9\Y_P")
MI,./9L44 ?J'%_J4^@J2F1_ZI/H*?0 4444  Z5#<?ZO_@2_S%3#I4,W^K_X
M$O\ ,4T-$U%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %'>BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[II:
M1NE 'Y:_&8D_&_QD3_T%)_\ T(T4GQCQ_P +O\9X;/\ Q-KCG_@9HH _4F/[
MB_04^HX_N+]*DH ****  =*AG_U7_ E_F*F'2H9_]5_P)?YBFAHF%%(!2TA!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4A^Z:6D;[IH _++XNC'QM\9
MC'_,7N?_ $8:*3XO$M\;?&A/)_MBZ_\ 1AHH _4R/[H^E/IB$8'TI] !1110
M G:HI_\ 5?\  E_F*EJ&X_U7_ E_F*%N-$]%-!Q2Y% A:**,T %%%% !111F
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CO110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4E&: %HI,T9H 6BC-&: "BBB@ HHHH **** "BBB@ HHHH **** "BBD*@]1
MF@!:*** "BBB@ HHHH **** "BBB@ HHHH *0]#2TC'Y30!^5WQ98_\ "ZO&
MA;D_VQ=#_P BM12?%1@_QH\:,/\ H,W?_HYJ* -)?CG\75&T>/M5QC_GH/\
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M>8V:7>W-%% !O;=1N:BBD I8\TW>W%%%- .W'B@L<444 (';/X4QI&QVHHH
M [9/-.W-O-%%,!8V)4_4T_)YHHJ6 M,W&BBF!(.E,9C114@(Q.ZHE=CU-%%5
MT D+&F;FW-]***$ W>VX+GBI QQ^-%%# 7<:5&+ 9HHH =G^='I114@+WH!H
MHH ,TF>E%% "9.?QI>QHHH ;D[A2[CQ115 +DT9HHJ0#)I>U%% #03DT^BB@
M H[T44 (.IH[BBB@ HS110 W)W4N3110 ZHY.A^E%%- ?E9\4?\ DL?C3_L-
*WG_H]Z***8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>skye_ex31img18.jpg
<TEXT>
begin 644 skye_ex31img18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M* /(_P#AFOX)?]"-%_X&W/\ \<II_9I^"1/_ "(\?_@=<_\ QRO7J* /(/\
MAF?X(YS_ ,(.G_@?=?\ QVC_ (9I^"//_%#1_P#@==?_ !RO7Z* /(_^&:O@
MC_T(T7_@;<__ !RF_P##-/P2Q_R(\?\ X'7/_P <KUZB@#R$_LT_!,_\R/'^
M%]<__'*7_AFKX)_]"/'_ .!MS_\ '*]=HH \@_X9I^"?_0D1_P#@=<__ !RE
M'[-/P3Y_XH>/G_I^N?\ XY7KU% 'D/\ PS1\$<Y_X0=/_ ^Z_P#CM)_PS/\
M!$G/_"$)_P"!]U_\=KU^BE8#QUOV8_@BPQ_PA7O_ ,A&[_\ CM(/V8O@?C_D
M2O\ RI7?_P =KV.BF!XY_P ,P_ _'_(E'_P97?\ \=H_X9A^!^/^1*/_ (,K
MO_X[7L=% 'C7_#+_ ,#\_P#(EM_X,KO_ ..TC?LO_!$]/!K?^#*[_P#CM>S4
M4 >,K^R_\$.,^#&_\&5W_P#':=_PR_\  _\ Z$L_^#*[_P#CM>R44 >-G]F#
MX'G_ )DLCZ:E=_\ QVC_ (9?^!__ $);?^#*[_\ CM>R44 >-_\ #,'P/QC_
M (0L_P#@RN__ ([2?\,O_ _.?^$-;_P97?\ \=KV6B@#QK_AE_X'Y_Y$QA_W
M$KO_ ..T?\,O_!#_ *$U_P#P97?_ ,=KV6B@#QK_ (9?^"'_ $)K?^#*[_\
MCM+_ ,,P_ __ *$L_P#@RN__ ([7LE% 'C/_  R]\$/^A.?_ ,&5W_\ ':&_
M9?\ @@W_ #)KC_N)7?\ \=KV:B@#Q@?LO?!#_H37_P#!E=?_ !VC_AEWX(YS
M_P (A)_X,KK_ ..5[/10!XL?V6_@EV\)2_\ @RNO_CE'_#+?P2)S_P (E+]/
M[2NO_CE>TT4 >*_\,M_!+'_(I2_^#*Z_^.4O_#+?P0_Z%&7_ ,&5U_\ '*]I
MHH \7'[+GP1 _P"1/D/_ '$KK_XY3Q^R_P#! ?\ ,FN?^XE=_P#QVO9:* /&
MA^R_\$ ?^1-8_P#<2N__ ([2_P##,'P/_P"A+/\ X,KO_P".U[)10!XY_P ,
MQ?!#'_(EG_P8W?\ \=H'[,7P/_Z$L_\ @RN__CM>QT4 >-_\,P?!#/\ R)9_
M\&5W_P#':#^S!\#S_P R6W_@RN__ ([7LE% 'C0_9@^!_P#T)C?CJ5W_ /':
M7_AF'X'_ /0EG_P97?\ \=KV2B@#QO\ X9@^"&,#P8WU_M*[_P#CM-_X9?\
M@C_T)S_^#*Z_^.U[-10!XW_PS!\#_P#H2V_\&5W_ /':3_AE_P"!_P#T)K?^
M#*[_ /CM>RT4 >,_\,O? _&/^$-?Z_VE=_\ QVC_ (9>^!^,?\(:_P#X,KO_
M ..U[-10!XN?V7/@CV\'N/\ N)77_P <H_X9>^".!_Q1S_\ @RNO_CM>T44
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M/^@9J/\ X'O7N]% '@__  R;\'<?\@W4OK]O>E_X9.^#O_0+U'/K]O>O=Z*
M/"/^&3O@[_T"]1_\#WII_9-^#V/^0?J7_@<U>\T4 >"_\,E_![_GQU0?]OS?
MX4P_LD_"'/\ QZ:J/^WX_P"%>^T$9H \!'[)/PAR?]%U7_P-/^%+_P ,D?"'
M_GVU;_P./^%>^T4 > _\,D_"$G_CVU;'_7Z?\*4_LD?"'_GVU;_P./\ A7OM
M% 'RQXX_9B^&>@Z%!=:9;ZF9GN1&2UYGY2K'^[Z@45[7\4@6\+6N-W_'XOW?
M]Q_8T4P/"/V*]W_"->+N1M^UP8'OL;_ZU?6=?)?[%+?\4_XP7TNK<_\ CCU]
M:4@"BBB@ J*;_42?[IJ6HIO]1)_NF@!Z_P!*=35Z?A3J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH X;XG('\+VPP3_IBGAL?P/14/Q6#GPK:[
M Y_TQ?NKN_@>BF!X3^Q0?^)#XQ7_ *>;;_T&2OK6ODK]BD?\2'QBWK<VP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "+GO2T44 %%%% 'FWQD ;P;9YS
M_P ?R=/^N<E%)\8VE'@ZT\K!;[<G4@<>7)ZT4P/$_P!BD?\ $C\8GG_CXMOI
M]UZ^MJ^2?V*#_P 23QD/^GBV_P#09*^MJ0!1110 5%-_J)/]TU+4,_\ Q[R?
M[IH D7^E.IJ=!]*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'F/QJ?R_!-D?+,F=03H,_P#+.3W%%5?CPTR^ +'[.K,W]I)G'IY4M%,#R']B
MC_D">,C_ -/%M_Z#)7UM7R3^Q5C^P?&)W<_:;;C_ ("]?6U( HHHH *BF_U$
MG^Z:EJ*;_42?[IH D7H*6FKT%.H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#RKXZ9'@2QP ?^)BG?'_+*2BHOCY,8?A_8$#/_ !,D'_D*6BF!
MY%^Q2O\ Q)/&)[_:+;_T&2OK<# Q7R3^Q3_R!/&1[_:+;_T&2OK:D 4444 %
M13?ZB3_=-2U%-_J)/]TT /7I3J:O0?2G4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4449H **** "BBB@ HHHH **** "BBB@ HHHSSB@ HH
MHH **** "BD!!'%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /(/V@/-_P"%>V'E*"W]IQ]<#CRI?6BH_P!H
M9WC^'>GLF/\ D*1CG_KE+13 \M_8I_Y /C'_ *^;;_T%Z^M:^2OV*QCP_P",
M&SR;FW&,?[#U]:T@"BBB@ J*;_4O_NFI:AG_ ./>3_=- $J]!2TU.@^E.H *
M*** "BBB@ HHHH Y3XB>)SX+^&^O>*%C$DEA:M)$A&0TA^5 ?;<5KFH_!GBR
M[^'DDS>-=5B\8W5EO^UBXVV\4Y7(40@; @/&0N['.<UV?BWPY9^+O!VJ^&=0
M9DMM2MV@9T^\F1PP]P<'\*XC1&^,%CH,'AJ^TO2)[JW MQKYO&V/$,*)3!MW
M&3')7<%SW[4P-W4O']KIM_J.GV^CZEJTNCP)-J3V*1E;4,NX [W4LVT%MJ@G
M&/4 Y"_&'0[K5[/3-(T37-6-[9PZA#-96@=&MY7""3)8$ $G.1G@\&J=UX;\
M:>'_ !IXIU+PY8VNM67B>")W%W<B$VEU'%Y18@*=T;*$) Y!!P*K>!OA_P"(
M/!WC6QVP6DN@V?A^#2%N?M#><[H[2%_+VX +.1C)['VIZ 6KGXWZ#8IJMQ-X
M;\0BQT:]:QU&]^QKY-HX(&6._)7+#[H. <D"MF^^*&BVMMJ6H0Z?J%YH^E2"
M.^U.WB4PP'"D\%@[A0P)*J0/P./+]'T_Q+XLM/B?X-T[2[+^R]3\2W5O/J,E
MSA[=&V"4^7M.X[!\N#U/.,5OW'@/QEIVA>+_  'H^GV=UX>\02LT&HSWA26T
M29%28-'M.\KABN#SD T: =6OQ7TJ3Q;>>&[?0=;N;FR>$74T-JK0P1RY*2L0
M^=A SG&<=JET/XG:1K^I:;96VFW\#:Q9R7VFO,L8%Y$F-Q #DH?F!&\+U^M9
M7ACPEXITGQIXQN6MK6ST_4[2UMM.G2<RO$8(3&I=2HS][/7M7&>#? 'Q&TGQ
M=X3US4?#^B6\VGQW%MJ5W_:$DUS>>8%W3,?+Z_*2J9P,]0.*- -QOB$NO?"A
M/$FO6^OZ);2:U]FBDTN2,386[,<:L58_*=JH_KDXSUKLM4^)&EZ5/K*Q:7J>
MI0:$ VIW%I$C):93S.=SJ7(0@D(&P"*\XF\"?$6/X5W'@R/1M.G:#6UO+:==
M0VF:+[8UP68%,+QA<9)Y)[5NW'AGQYI6I>,+?1-'L;_3?%:?:,W%YL:PNGB$
M4FX;?GCP 1MYXQCG(- .ENOBGH*:GIUCIMCJ6L3:GIW]IV7V" .MQ%D#ABP
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MK->6]Q-9MJ%O%<V,T37,"C+/&"N7QD<#YN>E>;WW@_Q9XJOOBM:W.@W&D_\
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M;;G )(W8ZUXHG@/QKJFH^/[>R\):OIZ:[H]F+2XU:XBF>26%MQ25_,;!?&W
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MDDRIPIZL<@ <]-XOMM=T/XX^'O&T.B7>LZ&=,ETJZ^QQF:2R=I ZR>6,L0<
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MLKN8D<D' !P,\CS?QMJ?B35_AC\0O#.L:X\TOAW5+.!+Z&.)#>12M$ZK*-N
M5W<E0N<#MG(![GH/C+0O$AU)=.N)HY=,<)=PW<$EO)!D$J660 @$#(/0BK$?
MBC19/%S^%$NS_;"6WVMH#&P_=9 W;L;3RPXSFO,/CC9ZI8_!P+;^(;R.Y-]:
M13W*I$CW0:=5VOA ,#/08S@ Y&<KX@T[Q%)\:].L]'\2BQO8?"LQDU&:U2:5
M\7"<[.$!)QD[<=0!Z 'ME%?.^G?$CQUXHTGP3HVE/'#J^K:--J-U=1")"[QN
M(P$6167&<LP STQ@5Z-I^H>.8_@_>WGB"XTVU\4VEM.S36H$T 9-Q4D9 R0!
MD=CGZ4 >@\4<5\]6OC#XFZ=:> -2U+Q!IM_;^,8%@:!=/\LV,K6YD652&._I
M\P.!Z8!XAM?'WQ"T7X(6OQ#US7+#4Y-7@MX+.T2Q\E+6:638)7<-E@ <D8'(
MXHL!]%_E44\T5M;R7$S!(XU+NQZ*!R37CNI:C\1=+\<6W@BW\30W@US2+BZL
M-1GLX_,M+F'9D,J@*T;;QVR,]>.8?!?CS7O'&G^'X['4/)O[32I[C7&EM5*+
M<@F%(R."I\Q)'P"#M3G[U%@/5?#WB/2/%?AZUU_0;L7>FW8+0S!&3> Q4\,
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MTO2[;3X9)94MXUB5YGWN5 P,GO0!XK/INMZ99?"OQ;I_A?4)HM!MVL=2TQ8
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M3^E%,#FOV+-O_"*>+.>?MD/'_;,U]7+7RG^Q:H/A'Q6=O)O8N?7]V:^K1@#
MI +1110 5#/_ ,>\G^Z:FJ&?_CWD_P!TT 2)T'TIU-3H/I3J "BBB@ HHHH
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M<YMG6"YB$,(9!-C82VUU S_6F![?H'CCPGXHFEAT'7;2^FB42-'&_P VP]'
M/53_ 'AD>]9]YX]T#4(-9TWP[XDTZ77+*UEE6+=Y@4ID$X!&X!E(.#QWQ7C]
MYINJ^//$7A>]\,Z/J&C7&E^'+ZQOY)[9[00S20!([?YP-Q60DY7<!BI?!NH
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M,EXN1EAC .>N>.O.>&-(O6^*WB^3X:VM^_AW4M&D,^H:B)1NU AA&(I9AO8
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MLTX+*8Q*N[*@%AC.> 1GZBOEV&2UU#X0VOAI2+?XL6>N*9 (R+Y+DW>6G/\
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MC)L,>T8WA0,DX%3W9T$_&FRB_P")3XLL-6UZYB>"5 -1TZY\MTD20=9+? R
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MB+P9JOB:Y\$ZG"='U1-)O+430LPF+*C%<-E@&= .,G<,<9(NCXMWJ6.O+?\
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ME4X<\$Y<=,UT>X4 >#6/PI\96OP^@\.K=Z7%=:#KG]L:-*'D*3D3O)MF&W*
MB0K@;B.N3TKMO#WAG6IOB1J'CSQ#;VUE=RZ;#I=M9VTQF\N-7:5V=RJ@L78#
M ' 7.><#T/(]J.*+@>8V_A;Q=I/Q3\8>(-.BTZ[TOQ!9V^!<3O'+'-#&R*F
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ME[29W=^#GCMBOF72K/38?V=?#.G6^H-!<?\ "8PQSA;PR-;'^T9%4KNSL(4
M]!G!)!R:^JM-TW3])TV'3=,LX;*R@79%! @1(U] HX K"N/AYX%NEE6Z\(Z3
M.LUT;Z026B-OG/60Y'+'UH \'\0ZMK_@P^.?#^A^)+^#2X-;TN)[R]NI+E]/
MM[E/W["1FWJN<<ALC)P5/->F?"RUDL=4UZSA^(47BFQ/DSP6T/F2KIX8-E1,
M\DA8-C(4L2H';-=C'X$\'1/JLD?AK3E?6%*7["W7-TIZASCYA]:L^'O"OAWP
MGIIT[PWHUKI5J6W-';1A S>I]3[FBX'E7B6#5[C]JC3(=$U:VTVZ;PK,#++;
M_: 5^TKQLWK@]"#D].E8^M^!I_!UQX'\.:3XPUFT;7]<G;5;FVN/(-V\D3R2
M,% PARH P...XS7LK>"/"<GBP>+)/#]DVN#I?F(><,# ^;Z4_6O!OAGQ%J5C
MJ&N:-;7]SIY+6LDR[C"<@Y7T/ HN!XAXB75&\7ZIX#_X6=+H#Z/IUM+I]UJ5
MY()I5VNSSLRR1B4@C!#AA@=.N=C5M+M]1^.'PSN;C6+RZN9M%NYFEANY8%F9
M%A(8(K84,225Z' !SBO3]?\  '@WQ1J%EJ'B+PY9:G=V./L\UQ&&:, YQ[C/
M.#Q3[OP-X3OO$L'B6\T.VFUBWV^5=L#YB;>1@YXHN!X1X/U'7O$']E^)KCXK
M0Z=J']J26VHZ7NDE<EI2@MA"7V*0,894R.220#5"X_X2BV_9LU/Q_P#\+"\2
M+J\7GP*OVU3$ M\44XVY!"@C((//H *]]A^&W@:W\57/BF'PO81ZU<JRRW:Q
M_,VX88^@)R<G&340^%_@)?"TOA5/#=LFBRS"=[,%O+9\YSC/J*=P/*?%5QKW
MAO6?!O@Z/QQ>+8>)&N;JXU/5;HAO-$:>7 DL>PQJ220!CGC..*LZ?=:U'K?A
M;X?^(/B%/J5O<M?M-J5B[0/.\6PQVQFSNRJNQ)!W';@]#7K&K> O"6N^%(?"
M^K:';7FCP*JPVT@)$0487:<Y7 XR#TJK?_#'P)J7A.T\+7GA>S?1[,YM[95V
M"$^JE2"">YSSWS2N!QW[/\*P>$O$]NMW)=B+Q)?IYTK L^''S$C&2>N<"LCQ
M9H.LVWC7Q3XO^$OB*%/$5MY2ZWH=^-UO=[8@R$$X*,4. 00#SR.:]6\,^"?"
M_@VVN;?PQHMMI45U)YTRP+C>W/7.>F3@=!VQ6?JGPQ\#:QK%WJ^H:"C7UZ-M
MU-%+)$URNT+MDV,-ZX &TY'M1<#Q_19[/Q%\0/A#XB1;K2(KS1KJ1=/@NG2&
M%HA& B+G&TG(/]X8S3O^$I\3:C\(=:^*$6M:E:>)=-U*2,:0LV;>,)<",6K0
M$8)9"/F(W[FR#T%>V:AX%\(ZI+HLE]H-K,VA,&TX;=HM<  ;0,#' X/' ]*K
MS?#SP?-XCD\02:*AOI9DN9")'$<LJ?<D:,'8SCC#$9X%%P/-%UK4?$>M>-Y=
M0\:3^%=1\-ZA&EO$LG[F&U6-)-\D.0)?,_>#)Z<8QCGB;+Q)+:_&[Q?X>U'4
M+[0?#VJ:]&7UFT?RV:X$$?EVQ?GRU<;B6/)Q@8Y(]^UCX9^!_$'BJT\4:UX<
MM+W5[10L=Q*">AR,KG:V.VX'':JLWPH^']S;:K;S^'8IDU:=;F\#R2'SI5)*
MN<MU!)Q^72G<#KH;NQ^U-I\=W&US$@9H3(&D5>S$9S^)KR_XGZ?]L^)WPTW:
MKJ%JDFHSJ8K>X,:?+;2,&Q_>[9]"1WK?T_X;Z3I_Q1/CBU1()ETT::$0NSS*
M-F&D9F.2H0*,#/<D\8WO$OA'P]XNM[2#Q#IBWT=G.+F$,S+LD (SE2#T)&.A
MS2 \1O/$_BB_^$_B;XD6WB2_LM=T74YXHM,4J+9%BGV+ \3+EBR$<GYLL,8Z
M5[Y- =3T,PS--:-<0C<T+%)(B1S@]016!<?#?P?=:]+K4VD W<TT=S*JS2+#
M++']R1H@VQF&!R1G@>@KI[NSAO;*:SG\P12H8V\N1HVP1@X92"#[@@T ?,^D
MW&J>&OV:O"VK:/XBU"WN)M9AA?,JNK1M?.C(,@D @DDKC)]N*V/B+KVO^%/B
M2VG6OC&Y70-96&.^G<%CX<9Y/EE#@;5$@W*H?H>3E1BO3O\ A4O@3_A&;?PS
M_8\W]C6TXN8K7[=<;$D'0CY_4DXZ9YZU:N?AKX/O-.UNPNM*>:WUYTDU!7NI
MC]H9,!23NR, #ICI3N!M7%BLGA2;3X[VYVM:F-;A)?WOW<;@_P#>[Y]>:^9-
M+MYA^R[X(D;5;MKN]\1VCM-,XD:)S>L-RJV1UYYZG)/I7U%I>D6.C:':Z+IT
M31V5I$(88WD:0J@& ,L23QZFN-7X,_#D:8VFIX=\JT-Y]O\ *CNIE F'1AA^
M,9. .!DXZFDF!YGXF\5^+/ :^-]-M?$]QJ*VMSI2PWVIO&6M%N25E)(3"J-N
M0=I STKN/A_#XRL?&.JV?B#Q/IVHZ==6R75C917;7,]N,X+ERBDHQ/?//2NI
M_P"%=^$6N-9N)M+-R^MPB"_%S<23+<(,X!#L1QDXQT[4_P (?#_PGX$@N(?"
M^CQZ>MQM$K!WD=PN=H+.2<#)P.@R:=P.!\7QZW??''3O#-KXPU32=+O=!N+F
M2"S:.,I(CHH9&*$Y.>>XQP17*> O%WBC4-9^%IU/Q%>3QZO9:E!?H\B^7,T#
M,$?.!\^!R1UQFO:K[P)X9U#Q9'XJN[&1]9C@-JER+F5=L1!!7:&"X.3VZX/4
M5DGX/_#V30[+0W\/AM.L+AKFU@-Q*1 [#YMIW9"G/*YP>XHN!Y1#XE\57WP3
MO=0B\8:A%>VOBHZ='=0M'*[0&[6)5)*\X5NO?OD4S6_^$KTU/BC:6OQ&\1!/
M"=O!J-BS/#O:22%G*NVSYH\KPHP!D]:]:'P<^'(T1]%7PS##ITEW]N>W@EDC
M5INS':PSCL.@[ 5:O/A9X'U!]:>[TF21M<"#4#]LG'VD)]T-A^@]*+@><:Y8
MWOBKXP>#HT\0WVC3W7A2XN)+O32BR,3) <*65L GG@9P,9Y-<;I/C3XE>)/$
M-OX#C\106]Q!#?I%J4\_V1]1:&X:%'#+&X+*%R5 P<'->^WWPX\*7T.F12V,
ML;Z5";:SGANI8YHHB,&/S%8.5([$D<#TJOKGPH^'_B/0],T;5O#D$EGI7_'F
ML3-$T /4*R$-@XYYYZT7 \KDN/B#J7B3X?>%[KXD/%/J]CJ,6H7FC)$T,DEO
M@!XRR9W=F/J#C&:];\>:SJ?A#X4ZYKNGAKW4-,TYYHVE7.]U7[[!0./XB!CH
M>E*_PW\&MK>BZQ'I+07>AQ"#3_(N98DMXQ_"$5@N"#@Y'(P#D5U5S:P7EG-:
M74*S6\Z&.2-QE74C!!'<$4K@>,6EYKNB>-/ 5K:^*-2UJP\6V=Q]M^U,C^4R
MP"59XB% C&3C RN".*N_!+16LX/%EY)JU[=Y\1:C'Y,T@9,B;&_&T'>=O)]S
M79:%\.O"GARY2XTG3I8FAA>WMQ)=2RK:Q.0SI$'8B,$@?=QT Z 58\+^!_#O
M@XW?_"/V]S;B]E::=9;R:</(3EGQ([88GDD<GO1<#SKXLZMXLT/Q+#JEK?:E
M!X7M=/+74^DF)Y]/F+$"XEB<$R0A0<@?W2>HS7'W\NIW>K?&#Q;X9\77FEC3
M+:SU* V2Q;+LK8AT\S>A)4@=!CK7MGB#X=>&_%&LG5M5BNVN6MOL<GD7DL*3
M09)\MU1@KKEFZ@]:AD^%_@V6/7U;3YPOB%%CU%5O9U$R*  H ?Y0%&W"XXXZ
M<4 >(_$/XB^+M/>XUK0->NF:Q&F>;#!$BVMF9L;TEW F5GW @+]T \COZ';'
MQ9JGQOU_34\:7MOI6D06.H1V*00E91)YN^(MLW;3L'.=WOTK6N_@;\-[[SS>
M:%).9HHH6+WLY)$8Q&V2_P!]1P&Z@<9Q6[H?P_\ #?AWQ#>:]I-M/%?WD$=O
M+))>32AD0 ("'<C@#CCN?4T[@>/^!_$'Q1\27'A_QFWB#38M%O+QHKVVGO5,
M;(SE!%'&(0R2J< 9D8GOUK2\"^*O$X^*D&B^,->OX;R\-V]O;&&*33]1B!+1
MO;3(N5*(!E6//)//7N]-^#W@'2/%[>*M-T7[/J+2O/@3R&%9&!#.(MVP-R><
M<=JLZ)\+O"'A_5[+4M/L[CS=/65;-)[N6:.T\TYD\M'8A<YQP.G%%P,;QMK^
MJS?%+PMX!L=:DT.#5;:YNY[J"-&FF\O;B&-G#*I(+$G:3@#&*\L\:>(/$NO?
M!/XHZ#K.L323>%]0%F+Z*&-/[0B+(0L@VX# $;MFWMV)%>^^*/!&@^+C82ZM
M;RB[TZ7SK.[MIFAFMV[[74@\XY!X-9M]\+?!^I>#KGPG=V5R=,NYS=706[E6
M2ZE)R7ED#;G).#R3T'H*0'1Z%I[6&BVT<MY+?3>6NZYG5!(XZ@'8JCC.!Q7S
MAIWA;Q=XWT;XE>$=)M=(AT;4?%MTMS?7,[^="!(C,4B"$$_*,$L.<_6OIBST
MZ.RTB#38III(X8Q$))I"\A &,ECR3[U@>%? >C>#[G4IM'FOLZE.UU<)<73S
M*\K?>?#$X)XSCT% 'F]A_P )U%\3M;\+V/C(PZ%X;L]/N%MVL8Y);B,HV^,N
M>1N"'YN3DC&,<Y7@7Q7\5O%2^&?%[W]D?#^J7#1WUO+-;B.-&;:BP@*)!(#P
M0S-G.,5Z_8^!M'T_QOJ/C"":^_M+4$$=P'NF:)U7[HV=..<>F36'HGP8\#>'
M?$G]M:39W4!68W,=G]KD:VBF.?WBQ$[0WS''8=@*=P/$K/5-5\(>'?'VN17R
MZI=-XU>Q@COX83'%.SQJ+K=M&' Z8PH/;O74^(O$?QD\+^&]9NKK4K.-1>V
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MG>M';F<,K&4)@C<2O/;VR 1Z=;0K;VL5N'=Q&@3<[%F; QDD\D^]("Q1112
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M*%=/,Y6.-<$R/L!?' QMYR:X75O$6I>%?CGXBOM$\*W^NRW.@6MU+;I=+&$
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MI1Q74AC2;R9-Q3<%;:3ZX- %;7?B:ND:I>V-GX8U365TF!+C5IK,QD6*LI8
M@L"[A06*IDXQZBNYTO4K+6=(M-6TVX6YLKR%9X)4Z.C#*L/J#7E"^#?&GA[Q
M-XQN_#]C8:E8^*X5N'2>\,7V.\\O8_\ RS.Z,\'(Y[8KT3P5X=7PCX$T3PRL
M_G_V99QVQEQCS"J@%L=LG)Q[T <SXN^*^G>$O%L'AB3PYKNJZC<VK7<$>G6H
ME\X*P#*OS#)&<G.  .N>*PYOC_X8CT[2+B#P_P"(;NZU4SQPV4%COF6:'/F0
MLH/#@CG&0,@DXYJ#QA=:I;?M)^&&TFQBOYSH%Z#$]P(,CS8SPQ4Y.0./K6;I
MOPT\9Z?X_P##?B)K739$@U+4M5U$)=$;'NUV".,>7\P10I+'&3GI0!TE]\<_
M#.GW, NM+U.*TWV\-Y=.D:K82S*&6*5"X?<-R[MJL%SR:V+CXF6,'BY_#\.@
MZM=1Q7L6G3ZC;QHUO!/(H95?YPX&&7+;<9(&<UR;^!_&NE>//$4FCZ/X=U#2
M-=O%OHK_ %#FXTZ0HJR_)L/F#*;E&X#-0:YX!\5:M\3H/$.GZ;;Z%>6^IQ.V
ML6=[M^WV2[=T<\(7+M@$#)QR.>HHT ZI?B[H)UVUL6TW5!I]W>OIMKJXA4VM
MS<J#F-,-O/*L VS:2IP:Q+GXO^%_%7AK7;:&Q\46-DFGW;2ZE!I[IY7E,8W$
M;_\ /09W 8X[X((JKX3\,_%7PG8_\(A;+I,NAV5Z]Q9ZHTI:8VQD,GD>5MP'
M.2N\M@ D\X%7= \,^+K7X'Z]X9OM'MXM7O/MXAB6\4H?M$CL,OMXV^9SU^[1
MH!QUSXO;P_XV^&>I65]XHU?1;WPW+*E@N^YGNV5$V,T:<-(0Y+$G P#D8KT:
MW^,WAB^\-Z;J^EV>I7\VH22PIIL4*K=1R1#,JNCLH7;QGGN,9S7(6'@SQQH>
MH_#37%\/PWTGAO1Y=)O;..]1'W,B*LB%L*1\G/.>:K7WPM\5V6L6'C.TT+2-
M<U*?4;RZU'1;J4&%8[CRP!'(ZXW((4R2O.6P.E&@'LGA/Q7HOC3PU;>(O#]U
M]IL;G.UBI5@0<%6!Y!!&,5SWB3QY>:-\1_#7A&'P[?7B:NDTDEU"BLB! .!E
MAT+ L>PZ9SQM^"]/U'3?#B0ZI9V%A<R2/+]CT] L-NK,2J @#<0.K8&3FL+Q
M=HOB*;XD^#?$>BZ=!?6^G"ZM[M9;CR3$DRQCS!\IW8V'@<_S !Q7@WXEV'AN
M\\0:3XBNM9U'9XFN;$:A+;M+%:H9%2)99>%4$\ #IZ#-=WX@^*/AOPW?7<-]
M'>26UA)%#?WT$.^"R>3&T2-G.<,I. <!USC->?7_ (+\<77PZ\6:,OAR/[9J
MOB4ZK;H;R,CR?M$<WS'/!Q&1CGDBG7/@?QA:^-O$5S;^ _#^OZ?XBE2\BN]2
M:(RZ;,8T5ED4J?,12N0%Z^HS0![RKAXPZ\@C(QWKB[+XC:/?>)/$>@_8KZUN
MO#\(GNFN(A&K(=Q5D)/S A20>GKBNSB4I"B,<D #.,9KROXA?#O5O$OCK0M8
MT6^6QMIXGTS7B -UQ8DB0(,]<LI3U E)[4 :,GQ<\/K! ]OIVKWLLEDFHS6]
MK9F66SMW^[),H/RY'(4$L0"<50'Q;M[[XH>'_#&BZ7=7^F:KI[7ZZC%'NC="
MRA&0Y^Z,G>2..*HR^&_%7A+XM>)/%&BZ%'KND^([.WC-O#-'%+:SPIL3/F,%
M,9&>A)!QQQSC>%_AMXL\$^+/ MU9V-IJEK8://IM_(EP(OL\DLXF9U##YU&2
M!C!/M1H!T>C?$#PQH.@:_KU]KVM7UH?$4EFYOK63=:2N4 A5=H*1+N&"V.OJ
M0#O:?\4?"U[HNNZM+)>6$&@D?;4OK22"6-67<C!&&XAATXR:\XOO"OCB7PMX
MHLX_",KW&H>+H=8@3[3;@&W66%SGY^N(2,?[0QQG#OB)IVJ6ME\3-0U+2%2R
MUZTL+.P::XC7SIUS&J_*Q*G?(I!/&5.2!0!Z;X?^(>B>(?$-QX=BM]0LM8MX
M!<R6=Y:M&RQ'&UR1E0#GCG/7TKI=4U.TT;2;K5;YG2UM8VFE9(VD(4#)PJ@D
M_@*\A^&[ZK9_$6\'BOP_JL.OZG8@1WUY=6LRB" @>6JP\J-TNXDCDGKTKU;Q
M*RIX3U9V.%6SF)/3 V&A[@<3H'QI\$>(]:TW3-/GO(Y-4A\VRFN+22&&Y.W<
MT:.PP7'.0.XQDU<_X6UX174K2V:>Z%G>79L+?4_LS&SEN =OEB4<9W C/W20
M<&O+O!6@Z]XW^&7PNTZ;PY-IFF:,L5_)J4T\1,NR%A&(E0EOF+ G<%P!CGK4
MUG\/O&DGPKL?@_?:(LD-AJ$3#71,@MWM4G$NX+N\P2D?+MVX[[J>@'I5Q\6/
M#-K;>(KBXM=41?#LRQ:@OV)R\6[)#[1R4P-VX<8(-7-3^)'AO1[BRAO&N?\
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M7U12 **** "H9_\ CWD_W34U13?ZB3_=- #TZ#Z4ZFKT'TIU !1110 4444
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MB'13\V /ICJ?4TEU\-_!=]::%976B+-;Z <Z<C32'R. ,9W988 X;(X%8O\
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M,.<@@\9X-=13N!X[J6A^,M0^)?P\UR\T%6CTA;V2_DM9H_*@,T>U(T#$,^W
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MK.2UC2((!*HRSD$%MP+,?T'J&B_"W0[==/U#63=7NO6^FC3)+\7UPI>+;AE
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MEEV%B,.K%,C<,CG%>AQ?#'P7'H6KZ%)I3W6G:Q.;J\AN;F6;S9202^78E6R
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MP<]1CD/"?B7XA?$+Q)X9M&\97F@+?^'6U"X6"U@*F6.X$0=-RYP^-Q!Z9P,
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M:C#GKGH#DY')KN=8TBWUK0[W2+B66*&\A:"1HB X5A@X)! .#Z4 >0:CXO\
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M&/,M;B,Y1P#P>_!X(/XUEV_P\N8YM;U:?Q!)-XCUBU2REU'[.H6&%0<)'%G
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MZ4ZFKT'TIU @HHHH **** "BBB@#/U+4[+2+&74-2N4MK6+!>61L!<\#\S@
M=22*R8/''A:XTV]U"/685@L)5AN1+NC>&1L;59& 8,VX8&.<C%8OQ6T_5KOP
M2EYHMF^H7>DW]KJ@LH_O72P3+(T8]20O YY KSGQ7_:OCOP;)XPT;P#J%C#8
M:G::E-874?V:_P!72$,LBX0[AM4C9DY)4X'0$ ]1D^)_@.'3&U"X\2V=M EU
M]B?SV,3)-U\ME8!E..<$#BLNV^,'A'4_&.FZ!H^IQ:@EY;33O=P[FCA*.B!<
M@8.2S<YP-O)Y%>0>+;.SU+X>'4?#_P ,?$&GP:AKEA//!<VLL]Y=I Q,C21[
MG*H% "DD%N1C !/H^LRMH_QP\+Z]#X=O[C2;[1+FR#V=H6\B1I8YB9%X*C:K
M'GDG( )XI@2:I\0CX=^"VI^+E\1V?B6Y22=+.\M[?9"S^8RQH0N1\O ))&2#
MSS3/#6N:]+\1K&TN?B=INIZ7=6LES'I3V(AO' &"V1C"*P."1R/7K7!R/>1_
MLQ^*](7P_K1U"ZU:\6*U&F7'FN)+LRHVW9G:4(^;H.F<\5L>-/MOB;XH>%VT
MG2-7C6?PWJ%O]KDT^9$MI+B,"(.VT;6^5L@D8X[F@#UBQ^('@[4;Z6RL_$-E
M+-'&\I!EP&C3[[JQX=5[E20.^*9:_$3P?>6]W-9:U%<BTM_M4BQ!F;R>TBKC
M+*>Q4$'M7CWA_6=4UCP?;^'V^$,Q\1^&]&GL9Y=3MPENH$.WRX7&3)YI5,J,
M#&>?6I\.Y+YOB;I-R- \3M#>>&9+,W>H67DQ)*)0Q4+P(HUQM48&?]KK3T ]
M?T#XF^&M:\#67BZ>\2QL[MRD:R$EBV3M4#&68K@X /Z5TVC:]I/B#2H]4T;4
M(+^RD)"S0ON7(."/8@]0>17S-;QZK9?"[X<ZO?>%->NK#PC+-9ZK90!X+G<R
M;/.B"L&=4.1U ()[9Q[!X)T>VG^'6M1^'_#UUX4AU>2>:V2]>0W+-)&%\^56
M8E&+9.,YP >I-(#J+?QYX1O-:31;7Q#92W\C,D<2RC]ZR_>5#T<CN%)([XK@
M+GQIX@\5_$+7/#?@SQ'8:=)HXM3$ES:F5;QFW/*&.05 4 #&.>_IP6CV.I:A
MX"\#_#F3P[?6WB?PSK$$MY-);NL%M'%*7><3%=KAT.  <DL?0UZ!X#U:*X^-
M?Q QI^HV\5\;,VLMQ8RQ1S"*$HY5V4# .._.>* .R\8^,-&\-Z7<0WGB"RTS
M47MWEA-Q^\VX'WR@(.W) SP.>M8/A7XG:5#\+O#>O>-->M+>_P!1L%NY6QL!
M!^\VT?=4$@9/&2.>:Y#6M0O_  ;\7O&-QK/A_5M9L_$NGPKI<MA:&Z">7&RO
M;L!]W+,6YP#DYKS/P_I\VA#1K[QMX%\57^D:GX=MM*5+$2I+%-&SAH9(XW4E
M7!R-U 'U!J?C_P 'Z.+<ZGXBLK?[5$LT1,H(:-CA7R,@*3P&. :IV.OLWCK7
M[:3Q-I<VFZ?:0R/8IQ/9.=Y9Y7S@ @# /8=N_AGC+3TTF]TMM!T'6M#UJVT:
M"WATN*SEOK#48&DD(L9\ A67/+%L#=[5L>*-UUXH^*L=YI.HK!=>$X8C+%;.
ML3/&DK.B2,-K$>8N.>>>N*=D![+8_$+P9J5R;6T\1V+7 C,PA>8([1@$EU#8
MW+@$[AQQUINF_$?P+K&HVNG:5XKTN\O+L%H8(;I'>0#K@ ^Q/T!->,_#[QCI
MNJ>/[/4/$D5_:ZS:Z$^FVMN^BSVZR*N))>6+;F^084>AQG-8NA21V/PO^%,8
M\.ZK#>:?X@\VZ"Z7-YD0S*6+83."9%Y[Y]J+(#Z%A\>>#[K5)=)M]?LIKR(2
MEHDE!)\O_6 ?WBO\0&<=ZXR;XIZ7XF\'ZG?>&/%>F:%-;:BMI%=:H#L=1(H;
M"-M)+#>% YR/R\I\*7.L2?$CP'>7/AG7;06.I:A;W-E#I_EV.GM(LH41G^+/
MWFD)(/;' IVK7DL/P<\<>%)-!U87\/BAIEVV#R(ZM?+-E2 =WR*3^(%%@/H_
M6?%_AOPW)!%KVMVEA),I=5GD"G:" 6/HH)&6/ ]:-3\9>%-&>&/5/$6G6;SP
MFXB6:Z12\8&2XR>5]^E>3W^M1^%_BYX@USQ%I]_=Z+XFTFUCTZ6*QEG(,:R;
M[8JJDJ6W[L' .?6N=\.Z7-H/B+X-:'XBTNZGNM.TV\:XW6KS1VKRJ/*0M@@$
M8*]>-OO2 ^A-.\0Z-JVAKKFFZE;7FF,K.+N&4/&54D,=PXXP<_2LR'X@>"[B
M"PF@\4:;+'J,QM[1EN5(N)<@>6A[MDCCKS7'? ^YAN/#.OVZVMQ;[==OIDCG
MMG@_=23%T*A@."#GBO/]9^'WC#_BK?#FCQ_8M&T+4F\3:/*@.;BX8"5+90!D
M*KB7.TYRR8[Y /7=:\71GQIH^BZ/XL\/VTR7GE:E87<NZZD4IE4B4-PW(/(Z
M'\\/Q%\6K%M#\<#PCJ%G-JWA>U\\^>ID20A2S*%#*3C@9SC)[UY[J]Q<KJ'P
MKU[6M-N+?6M8U_\ MB\2*VDE^RQO%Y:1L0N1A3"N#C)!/;-'BO4H].N?CAH-
MUINH?:]5MTN+5H[222.1#:K&/G"XY?C'U]#3 ]\T'Q/H.N--::9K5C?WEH%%
MU%;3J[0L?[P!)'.>M1ZCXX\(:3J+:?JGBC2K.[7;N@GO(T=<G RI.1G(KR_2
MIM)M_P!HG0/[+L6MK1_"QM5,-FT<>\RK(J$A0H^0,1^76JXM-!U+]KO5H]2T
M>*]3_A'XH4>:S,D8G67S#\Q7;N"[3FD!Z\WB[PVOB%?#K:W8KJ[#(LC<IYQX
MSPN<].?I3(_&GA2;4+G3XO$>FO=VJL\T(NDWQ!?O%AG@#N>U?.VBKI)\;7/@
MWQ-HWB.Z\56_B274+5('D2VF0S,Z76[[JJ$)SSSMQSP!-X N%'C"WL/#_P#Q
M._#\]OJ,C6^HVICO/#X)RT3/G#I(^,9Y(&1T)IV ^A+'QAX7U*]AL;#Q%IMS
M=31^;'#%=QN[I_> !R1[BI(?%7ANXUR30H-<T]]4CSOLUN4,RX]4!SZU\N^#
MK'P]XB^'7PKTGP=:01^*++4X[Z\N(82LEM$A8S/(V,[7^11GAB0!P*T/AK'H
M=QKFA^%-8T_Q2_C70KZ:62*3>MM!)EM]SOQMV.">"?F+8Y!!HL@/HZ3Q?X8C
MU.;2W\0:<M] K/+;FZ3S(PHRV5SD8')]!57POXY\/>+_  _-KVD:C#+8P331
M/+YBX CD9-YYX5@NX9[$&O$OAIKFBR2:+X#U_P +WUQXYT'5+B5F-LZJA>1]
M]VTGW2K(Q/).XX SP:[CX#7-HWPWN=",+QWVEZG?0WD,D+((V:ZE=5R1@_*5
M/&<9%(#K/"/Q&\,>,/#ESKNGZE;I96]Q+"\CS* %21D$AY^56V[AG'!%=-8Z
ME8:I9)>:;?6][:O]V:WE61&^C D&OCWPGJ L_ _@%[BUF.D>%_$MS_PD<36[
M!+622:3R)).,$1_>/7;N4G&17M/PLALKCXI?$;7_  [\_AF^GM%@EB_X]Y[E
M(V\^2+L1EE!8<$]S0!ZA<>(M!M;XV%UK-C!=C_EA)<(LG3/W<YZ4]=>T66*V
MD35K)DNV*6["X0B9@<$)S\Q!]*^=S=V5G\79I-%U"SUNWO?%7E7>B7D06]TZ
MY"[6NH9 2S187.&&W''K7/MXIT&Q\&>%_"MRTRZMH_CGS;Q/LTA^R)]NDD#,
MRKM&Y6! SR,XZ'#L!]4R:UI::BNF-J-LM\XRMN9E$A_X#G-<=X-\=7.JZMXD
MTWQ(^FV%QIFKMIMLL4Q'GCRT=?OD$M\_0"O*M)UWPM%XPUGPAXLTB[O/&B^*
MSJFGQQQ.'G4L#!,) ,+&D?4,<!5(]!7,^)?^$/O/!WQKUF1],N-3BUD"SN69
M#*A"Q%?+;J/F1^G4HWI18#ZWN;JWM+=[FZGC@A09:21@JK]2>E5#K6EBP-^;
M^W%H#M\_S5V9_P![.*\T^+S:+J_PUTF2Z\2+I$5Q?VLMGJ/EB>W$HR\9E!.#
M&2.OT/2O(;W6X[71/!^I:V5\-^&[;6-1M[K4="VSVOVD\)<HDD<B^6Q\W'!V
MY.#2L!]4MK&F+#',VH6RQ2)YB2&90KKUR#GD8'6L_3-2U:Z\2ZM;W$5D-)A2
M![*:&??++N4ERZ_PC(&WUYKYAM=#^&=UXL^&.EVL\FJ:#=WVJ!9=7V(;E&C^
M4*H5<1&7=L&!DYQUKI?%-I9:2WQ?T7P=;1V\EMH>F*;>P($GE()!(!_M"(8Y
M!/2G8#Z/M]1L+I))+6\@G2,X=HY%8*??'2EM+^RO59K2[AN OWC%('Q]<5\M
MV-Q\+[SPUXLUS2_&FLWL%]HB6FH3Q64,:6*-($0O''%&"^YCQR=JMSTKI? 7
MC?0_!.H>*Y/&$FCVHM180S:YI 8VU]OWB,F- 0DG4MC/4=@*+ ?0TDT4*[I)
M%1<XRQP,U#]OLB)6%W"1"=LA\P?(?0^E>6?'^VTV_P#@O>7%ZL36\=U9RB=O
M^62FXC!<'J/E9NG8UX]\2O#OA2SU'Q;-X,6SB\/+X5/]I):R+]F-V91]F;(X
M,W4^N .[<I(#ZQ;4+%8))Y+J!(HSM9VD "GT)[&I#=VJQ)*9HUC?&UMPPV>F
M/K7SM?:/X0\+_$[P )M/M(O!FJ6]Q-O9M]M)J3(@627=D9*+A23]XD]<UP^N
MZ?81_#36)9P__"*P^/(5TAW)\N&T\P"7RB?NQY#@8]#CK18#["BO+:=&DAGC
MD1>"R,"!2)>6LD+317$<D8X+*P(%?(WC/2K+0]>^(1^'*S6_A5-)T\ZJNDG?
M&DGVI#*$ RI;[.'+#T8YZU6UVP^'<WP[\6:YX9\67.J17@T_[0?*BL[6WD,Z
M %5C1,3;/,R ,X)SU%.P'TCXB\8W^D?$+PAX=M[&">QU^6XADN3.0\#Q1&3
M7&#G&.3^%=BMY;&,R"XC* XW!ABO$-8T?PEX0^)/PKTSPY'!96=UJ=]=%5N"
M_F,UHR[OF8D[CM&?7W-9[>%7L_BIK'PQL=#A'AK7KFW\2S3E,K%$C*)H.<Y+
M2QIQT"RO[4@/H22:.)-\CJB_WF.!6!K&IZW;ZKHD.CZ7#?V-W<-'?7#7 3[+
M'L)#A?X\L ,#U_&N%^--K'?:9X:LTU;3]/OAJ0FLX=6B\RRNI$B?]U*.W!)!
MYY45Y]IMSI,ME\)M0_LNUT:X'B2\@,4,^^)5'VG>(VX!C+X*^F5%.P'TQ]HA
MW^7YBE\?=SS^5(US N=TJKC&<MTSTKY2B7P[XGUF[\/7VIZ$-3C\7RWC7]Y<
MQ+</;I/S#Y9^<DC]V%S@CGIBM77_  ]X1U/QC\;GU"SM+A['2K>> .>(9OLL
MA,BC. X;'S=1GW-%@/IF2>&+;YDBIN.%R<9-9'B;69M$\-:AJ=G;Q75S;0/)
M%;RS>4LK 9V[L''Y&OF3Q#<^']?US3+#QOXNBTG3;SPI9_8+JXMXIXY&^83E
M6<'9+NVG(P>.O2K-K?\ AG^T?%.D>/[@W<<'AVU7PZ^N(@DG@\D[GC1A_K6D
M"D\;L@#M18#Z*\$^(I/%7@'1/$]Q:K9OJ=HERT&_<(]PSC/>MN&]M+B)I+>X
MBE16VLT;!@#^%>&Z/K&FQ?L86][(TUU:P^'_ ")19R;9 VW8P#8.W!SDX. "
M>:X+3-0\-QZQ\1M*DU3P\;:^\**\=MI0"VIE1)3@$_ZQU &7 'T&*+ ?6*W5
MN\AA6>-I NXJ&!./7'I7$>+O'5UX=\8>$]$L],BOHM<OC9S3&Y"M;?(6!V8Y
MR%;N.GTKP^"VT3P[K7PEOO!C6D&J:CH%Z+AXI\M>2"T4QK(<Y?\ >Y !Z$8&
M,<9^GZ[X!F3X+ZE#>V U^/4PFK338%R)FB82>=_%DRD8+<9/IFE8#Z1\;>+3
MX3TFTEAMX[J^U&^ATZTADE\M#+(V 6;!PH&2>.WO7)V?CKXC(?$[:UX"M;2#
M1K22XMITU166_9.?E&W<JE03DCKQ]*WQLM_#]P? JZS#8N3XEM(_]*53F,[B
MZ\_PG"Y'0X&:XZ\.B:7\;?B5':O:VD1\'KB,,%4D*V<#I]T#CTIV ]P\(^)%
M\2> M%\43PI9#4K*&[,1DW"/>@;;N(&<9QG%;5Q<I%!YA90,9!9MH]LG\J^2
M;K5+3^P?@Q8ZUK\>E^'+CP^T;7%Q"L]J+H1HH$H8[,A=P!/*D]JN>&+CP;8>
M*_#/AOQ-XD;7O"$-C>-IEYJ\9BM+BZ%QA@-YVN$0$(>1R<=118#W_P"'?C"X
M\;>%Y=:NM/73Y$O+BT:!9O-"F*0H?GVKG.W/3O78?:(=VWS4SZ;A7C?[/\FA
MWOPMO]-TVXMKBVBU6_B:*&7<$C:=R@QG*@H01Z@Y[UY1HWA_1U^$_AKQ!X=F
M9?&J>)C;VKBY=G/^FR*T)7=A4\DEF& ,<GKFE8#Z]\Q,9W+CZTS[1%NV[U)S
MC@]#7RE>:MX5T[P!XBTFZOK*VU.U\=EK2 RK');H+R')4'!5?+W>V#79>&_"
M_A+6OC7X[U>:XDF?2;NQO+/R;URL9-ON9PJMR"3SGCBBP'OOGPDX\Q?SIWF)
M_?7\Z^,I-)CL_ &MV<\&EZW/=>'+R^TW6M-.)+F-9(FW7,9&X3)E=KY/&X5V
M^O>+_"L/B9-0M]>!4>!;G[1+I5TAN X,1!4YQYBKO(SS3L!]*B6,_P :_G09
M8P"2PX]Z^/O"-WH]GXXFLUU#3+6TU#P0[21V5X2TLP(*M*X(WW&,L2 #R>N,
MU)X/T+1+73/@YJZR^9?:Y#>6NI&2Z,ANXC!)^Z=&)!7.!C&!]<46 ^J]&US2
M]?TU=2TF[6[M'9T65,[6*L5;'XJ1^%&EZ[IFL17$FFW2W,=O<26LCKG"R(VU
MES['BO*_V=K/P_\ \*2T^'3X[4W$HD^WI&07WEW&)!V..Q[5Y/:W&E^&/@?(
MFCO'923^*C:ZRUK)Y<\%C]L=2&VD,H*A5SQP:0'U^)%8<,#^-<AXC\<V.BZ#
MXEU"RC_M:Z\.P>?=V4,@1E&S?C<> =OS>N.W(KCO">FV>@?'34=)\)S*GAVY
MT2.\NK.&3=#!<^;LC91G"%TW9 QG;FN"-CX=TV;X_P :QVEMJ'E3F&+<%<QM
M9!V*C.<%B2?K0!]">&-:'B'PEI.O&$6_]HVL5UY0?=LWJ&VYP,XSZ5L%QM^5
M@2>G-?)EOYWA&X^'E]X7U&\:_P!2\(7LUPLUX\HG>*U5XOD+%1M88&   ,5O
M_#".TF\5>$?$EA\1;>\FU.T>&ZTNV@E,EZXC+-)<%IGPZ$??VCL!UHL!ZII_
MQ.T^3XF7/P^UK3;C1-86(SV?VF2,QW\>YANB*D]ESM.#UXX-2ZMX\O\ 3?%>
MIZ##X1O[YK'3UU+SH9X0)HRQ7"AG4YRK\'T]Q7&^-/ .F_$3XD>(K&>Y>QU2
MQTO3I].U"$CS+.82W15ACG&<9&>1Z'!K,\$^)M;UKQSXILO%5B]EK^@>'EL+
MXYQ'.WF2,LT9/\+KAOQH W='^/.EZC9Z+JVH>$=;T?0M:F%M:ZK<B%H?,+;0
M'V.60%@0"1CBNP\4>/(O#NKV&AV&@W^OZQ>Q27"V=@8PR1(0&D=I&55&6 '.
M2>*^8=!M]5M?!7PHOO&&I/>_#>6X!EBMU6,6EYYK^29VZO%GJ<@9SGMGVSXE
M^$[/QEXTTJ/0/$UQX<\;Z99/>:?>1-F.6(OM:-USEAD<X' /?.* .^\$^,;/
MQMHL^J6>GWNG?9[J2SEM[Z,)*DD> P(!/0G'6NJKR/X3^.I-2\-WL?BU=(TG
M5[369M)FDMI%2&_N5VDO'D_,S9Y'7(_ >N Y%( HHHH **** "BBB@ HHHH
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M!\9Z1X;\1MH^H/XBL9I]/N;."2)+>XC3>T4@+L73!&&&#UXHL![#L4YXZ]:
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M$Y_.F:/\8(_$EKIMCI_AF[3Q#J+3K_9MW)Y*Q)%@/*TN#\GS*%(4DD]!R06
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MR0!;I@)G.SI]W/..F:\-\*>+X_"?BKXKZ_KEA<V;1ZA8PK9&X$V9)(PJA7/
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MV!S^-0VOA/PS9JL=EX?TZU1(WA58K6-0J.<LHP.A/4=#7!O\:[&ZLM"F\/\
MA+7-;?7;.:[M8K:.-6'E,%D1PS@JPSUZ'C!).*J:/XY\+:#J7Q%UZ]L]:TZ7
M3I[4ZA%J$XD#2.F(U@7>54'*]QR><8H ] C\"^#8HXHXO"NDQI%&\2*MC& $
M;[RXV]#W'>I(_!?@^)K1H_"VDQM9'-J5LHP8/FW?)\OR_,<\=^:\]L_C_P"%
M)X=?^T6<\$VC68OVCCN(+A9XB0HV21R,N[) ()&,^G-=UX0\6'Q7:74S:3-I
M[6[HOS313)*&0.K(\3,K#!_.@#6TO0M&T-;A=(TNTT\7,AFF%M"L?F.>K-M
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M@IE0.A)SGCI5_7O!/Q8\4>!KO3==UW0'U2>>V*1P),EK$D,BR[N[,[LHSG
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M,J*6(12S$ 9X Y)]A6'X0\7:3XT\.KKNCBX6T::6 "YC,;[HW*-E3R.0>O-
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M18Y"$ );"LQQCG%>->%/#=CI_C/7(OAA/J,G@Z]T:XDO-.F646\%TPQ$L0D
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M 4444 %%%% !1110!P'Q8UKQ#H/@&74/#8M1=_:K:%VN)&3:DDR1G:0#\WS
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M6=H\*RE\   @GDG'%=SX/L_$5EH/D^)=935[GSG,-R+?R': G]V)%  W@=<
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M,O)/?&>M=G\5-"\,^+;71?#6N7EQIM_>W+/I6HVS!);6=$+95L]2 1CO^&0
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M*9.UL'! ./2@#T+ I:\ \4?%CQ1H/Q+73$ELI[1-:M=.:QMK5Y@+>8 >9+<
MXCEW'B/&<+T(.:]^'W12 6BBB@ HHHH **** "BBB@ HHHH #TI.W-+10!\L
M?MGY_P"$&\,<'']HOT_ZYFBF?MH%3X)\+(9%0G4)#SU_U?\ ]>BF!?\ V,E_
MXM1KC8ZZRXS_ -L(:^FZ^9/V,E/_  J?7&YP=9?_ -$0U]-T@"BBB@ J&?\
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M$?EF)W5RQ& H.<D#%8NB^(M7U+]I 6EQ9ZWI-F?#3SG3[V4&%G^T1A955'9
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MUI/BAX'AT[4+ZXUY8(M-94O$EAD26V+?=+QE=Z@]B1@UIR>+] AU.VTV>_\
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M[E49&6( YK(O?BIX4MO%6@:!#=&\DUJ-IH+B!&>+RPN0P<*0V20.#QU/;+U
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MGC66*6-@RNC#(8$=010!QOQ<T_4=4^$/B32=)TZ?4;Z]LWMX;>#&XLW /)
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MC!5 Y). *;;S07$*S6\J2QM]UT8,#^(H GHHHI %%%% !1110 4444 %%%%
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MC6VOZEIT*^$[AWGM+H_:''FV_P HE.YE&X@Y!Z+CI7J.G_#?P+IANFL?"]C
MUY:&QN&$>3-">J,3USGDGD]Z;I7PT\%Z+=6MUI.C?8YK2!K:%XIY04C8Y9?O
M=SU^@]!@ \A\#^)M<\37?@OP?KNM7ZVLVGZC<2WT=RT,]])!<M B&1"&RJ#>
M<$$D#/&0<Q;SQIKFN^'O#,GCO6;)5U[4]"DO+29 ]U##$SI*3MYE&=A/JN<9
MYKV]/AIX+ATFRTNWT406UA<-=6IBGE22WD8Y9DD#;UR2<@$ ]ZF7X=^#X[C1
M9H]&6.30V:2P*2R+Y#,26; ;DL2<DYSGFBX'&Z7::W'\0O%_A:Y\9:K-:CP_
M9M%<S.H-I(_G1M*F /F_=AL^N>>!7+Z1K>O36WB?XCZ7J>IIX8TNPN8M'LKV
M\>8:M/&KEK@AB3L^4A0.N"> *]>NO 7A6\U'5]0N=-:2YUFW^R7SFXE_?18(
M"$;L  $XQC':HM/^'?A32[FPFL]/F_XEZ&.UCEO)IHH%*;"%C=RH^4E>G0T7
M \IL]8\;>%_#E[X_F\26FJZ2_AU[J+3WU![M[FY50_GKE%$8[,BY7TQ20V;C
MXJ?!S6IO$%]J\^I6MY<2F>0O$7:TW%XUZ1@YQM&!@#ODGU3P[\,_ OA66[D\
M/^&[6S-VC12_><%&.60!B=JD]5&![53TOX0?#K1M1LM1TWPU#!=:?*TUJ_FR
M-Y#'KM!8@#VQCVH I?$W4;ZVO/"^D:=JMY;S:E>NC65@ L]ZBQLQ42DCRE4X
M9GZX'&2<'R>R\2>-]:^'/@&8^,K^RO[OQ3-I-Q-$T>9HEDE"[R5^8@1@#H&S
MR#Q7OOB;P5X;\7OI[>(-.^UMI\QFMF$CQLC$8(RI!P1U'0\9K%M?@_\ #VQA
MMH;+03;1VM]_:,*Q74RB.?\ O@!^,<X'09/')H \N_X3#Q-X7@\4>%9O$U[>
M"#Q-8Z/;:O?*KS6L5S&KNQ; 5B,MC(XW#/%=1X$TG^Q_VB?'=NM_=WJMI>GN
MCWDK2NH/F#;O;DC()]LXKMYOAKX+N/[=^U:(MR-?97U%9Y9)%G9>%;#,0I'8
MK@CM2>&OAEX+\(ZQ+K&A:2T.HS0BWDN9;B69V0'(!+L?;\A0!S.LZGJB?M Q
M>'X]4NH=+O?"\]Q) LFU4E68*)$]& )Z>V:\_P!)UKQAKWPL^%%TOC34K.]U
MG5)K.[N4".\R'SR"21]Y0@QVSU!Q7M_B'P'X5\5:K8ZGKVDI=7=BK)#+YCH=
MC$$HVTC>A(^ZV1[<U2M?A;X'T^PTFSLM%-M!I$QN;-(KB5?)E(P7X;DXXR<\
M47 \BL?$?B.S\03?#JZ\6:B\4OBHZ>FJSN&N4MQ:K/Y._& S$[00 1SCG%9D
MVH:OX#USXN_V7K4\ERU_HUI'J-_(9'M4F4+O=B#D('P"0>@SGO[7=?"?P)?6
MVKP7FBF9=7N5N[HO<RLQF7.V126RC#/5<< #H!19?"3X>Z?#JUO!X<B>/6(5
MAOA/+)-]H4=-Q=B<YYW=<\YS1<#BVT_XE:7H7B;3[7Q):WDEU%!/I5L^I-+=
MH-ZK*JSO&H'F#(0D':["N9A\3:O)H=I-8>)/$=G/;>+K*PN]+U55,\$<AC#0
M.YR77JRN",ASG->L:=\)? 6E^';S0-/T,P6-Y)'),5N)?-8QN'CQ+NW@(P!4
M X';J:?/\*_!MQ9+:7%G>3 7:W[2OJ%P99)U ".\F_<Q4* N2<8XQ3N!P/CS
M7O$7_"5^+])T_5-4MM4M=-M)/#]OIP9DEE<R99P 5)+J%(?@* 1CK5O4K#QC
M=_%W2?"Z_$#5;"TG\.O=7"PQ0%C*DL2,5;9P3NSGDCG&,U6\3?#O6-6^(NKZ
ME<^#GU%+UXUM-3LO$,NGB&)8E7$L:8+,&#'< V0P'&*[W1OA]8VO]E:KJ]U>
M7WB*TTQ=.EO_ +9,/,7:H?Y=P R5#9P#GGK1<#R!?%'BS7O!WABQB\37\NJ'
M2[^2>'3I8X9YGAF\I+B69AM5 %.1_$S#@\XDT>YU3Q3\0O@YK6H:Y?"XO?#T
M]W.D,VV.25%CR=F,?-N(;'4<5Z;;_!?X>V[:>R:/(WV!9(XQ)=ROOC=BS1OE
MOG3<2=K9&2?6K5M\)_!=G!X=AM[&X0>'69K%A=R[E#$$JS;LLN0/E/' &,<4
MK@>;:+K7Q*\2:G/XRTO7[6STO3]<N+2[L;NY_<O:Q/Y?EB/RB5E. P;?R6],
M"L[4+K6/%G@7P3\0+[Q-<R_;_$EC(^E(%^RPH;D*L6 N[<A RQ.2<]L >OK\
M+?!*^-9?%W]DG^TYI%GD'GR>2TJXQ*8L["XP.<=>>O-9)^!OP\^U32BPO4AE
MNUOA:1ZA/';Q3!MVY(U<*I)]!],47 Z3QVWB8> M4_X1!HEUPQ 6ID8*-Q8
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MU2:15R#( 223M7H2<C8D^#5B_P *3\.5\6:W_9@G$R3'R#,JA]_EY\L KO\
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M(J2HT>]BI4L,-DC!Z5I6?P9LYO!VK^'?%?BK6/%']I0I;_:;R0!K9$Y3RP.
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ME^.;KQ%J!M+^S8W.DW-HJQB4L"KPMM5MH&1QD-QW%8NO?$^_UKX7^/M4T/\
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MLE;='.$:1@,("0<%B,UC7WC273O%F@O)+!>>%_$3+:6=Y"IW0W1!958YPR2
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M0?6N=MTL9_'?C?QGI=M)%X8O-$BM[B0VSJM[> L0X0J"Q5"JY .2V.H-=?\
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MH:T*D HHHH ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\G?MJ?\ (K^$<'_E\G^7_@"\T4G[
M:;8\-^$ P.PW=P?QV)_]>BF!N_L:AO\ A3NKYSM_MN7'_?B"OI6OFW]CE2/@
MUJ1W$@ZU-P>W[F&OI*A@%%%%( J*;_42?[IJ6HIO]1)_NF@!Z]!3J:O04Z@
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M=1)$<#>A8 ,,D X)P>#@T =A17*>,O\ A*#I$<?AK5-/TABQ:XU&_C\U+>,
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MO6NEWXDC9V022!2H&1L8 ]QT(I >KT5F:?KFD:I=7MGINHP7<]A)Y-TD+AC
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MQ(7(RYP,G@'%;WASQ5->^'KS4O$UBGAV6RNYK6=+BX!1=C8#AR%!5A@@].:
M.NHK+CU[19=+&J0ZM9R6!.!<I<(8R<X^\#CKQ2/X@T)8;F9M9L5CM6V3N;A
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MO 6A^)+J.'3I]7C:1+0S;R,.5P"0"W0=N].P':45!-<0V]N\]Q*D42#<SNV
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M/PA!K1DU!KJ JIC$+B&=T(R(Q)@@L!_"?2O9&6&XC#<.I&01R"#3S&K#!S3
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M374WA%H;H1W08.RB%D5AG&X9D..O4FO<[?0M%M+YKZUTFTANV01M/' BN5
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M@#J?V/'!^"=XN""-8G_']W%7T;7SE^QZBCX)7;#DG5YL^W[N*OHVFP"BBBD
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M[AMM0SA?.# E;?CDJ,@G&[CGV^W??;QLTBR,R@[DZ-QU'M7GVJ_";2]0N/\
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MX+74=2U":QN[)[@DV7D^9YI)VC<1Y8[#)<?6L'2_CE-K6N:9'I?A:[N])O\
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MRY\-ZQIDFLH\EG)=I#LD54WDDI(Q4X[$ ^U=9I^I6&IP23V%REQ%'*\+.AR
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MAR2QCU?48;66_G6WMXWD56E=CC@$]!U)[ 5?DU33H;V&QEOH$NYP3% TBAY
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M4KZ%J0"BBB@ J*;_ %$G^Z:EJ*;_ %$G^Z: 'KT'TIU-7I3J "BBB@ HHHH
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M3L;F[U1E>ZE=3N=@0=PY^4DCDC&>^:TX? 7A:W\2Q^(H=+":I%#]GBN%D?\
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M_#4+6]E:6JQ&((R!&#;T).5 '7C&>O-=\. !0 M%%%( HHHH ***,T %%%%
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MC<$)!'%<YKVCWD?PPL;30?AW=Z7]KUZVU'^S+4(9(8XYXY'>8[MH=MAX!..
M3P:R/^$5NE\7>)M/USX5S^);;7=0.I:?J#2*(8PZJ=EP&<%!&1V!)QQGC* ]
M7U'XM_#S2?$<GA[4/%%I!J<<Z6SP'=E)'!(!.,#IR<X'&<9ING_&#X<ZM;W=
MSI_BFUN(K.!;B9EW?*K,47C&2Q88VCG)7CD5B>&[>XM_C#X]U2]\,W_V>ZCM
M/LMX]NK)*(8L,J'KRQR!WQGTKS9?!7B=_@#X32'PA<MJ7AW66OK[1IAY$M[#
MYLK$(0>3MD!'/8]2,%Z >ZV'Q&\&:EX9O?$=OKD*Z;8NT=U),K1-;NO571@&
M#>@QD]LUR/@'XB77B[XN^+='M=3%WH>G6MO);QM9/;R0R.6W*V\;FZ#G@<\"
MN'U3PIJ5QX;@\2>$OAG=Z0EKKUGJEQI5TZ&\U*.)6#L4+L 06^52V3M)[BNM
M\#?VOJ'QT\5^);GPCJ^D:9J6G6D4,U]'''EX]V<J')SR,<9&.<<4,!;CQ]K&
MI_%GQ%X+TWQ!I^AZAI4<9L;*]LVE_M#=&&,C-O7Y06P N#P2<]!+)\7'\-W7
M@?PYXQT^>#Q'KD(DOEC@;R[8A3G!4-N.X ;03@<G'&<WQ]I.F^,)=<T?Q=\/
M]3NI[:4KHFJZ?:;W(,:$8D5MR$2%OO[4.![UBVOA_P =:&OP<O?$&DW^NW^D
M"[BU)[5EF>W,J8BWDGG P"V<?*3GID ]??XB>#X/$$>@3:U$E^\_V558-L\[
M /E>9C9OP1\N<\]*-:^(7@_0-731]8UJ&VNFV!E(9A#O.$,A (C#'@%R,UX7
M)X0\67'P:NOA/<>'KQ]?&L&>/4S%BU$;7/G?:?-SC(4D;?O9XQ6U!IOBGPQX
MT\=Z/>_#N;Q=9>)+V.]L+MTBDMBP10$N-[914(!S@]#@=*+(#K/#_P 0;NQ\
M7?$&W\6ZJK:5H=]:6]FT=L=RB9 0F$RSL6=1W/ZUZ1?ZUIVE:'/K6IW0L[&W
MB\Z66<% BXSR#R#[=<\5\W#PWXYL?CEKOQ @T/4+FVM=0M]VG>4HBO8C"L,D
ML.3Q(A&5)QE<\\U[+\2O[7U'X3ZFVAZ"U_?3Q1[;.>%7D52ZEB(V.&=1E@I.
M"RBD!.GQ6\#-HNJZQ+K'V6TTEU2]-U!) \!;[@*.H;YL\<<TL/Q5\"7.CR:I
M9Z]'=P)<O:?Z+&\SM*@RRJB*6; YR 1@@]#7A.H>'?$TVC_$JSM/!_B>8Z]I
M=BMK-J3)++/)&2&W'S&P3G.T<  Y"\5VWCC0[R#Q;X/\86_@_4M6TB.QEM+N
MPTUC!<VLDGELLNU&7)PFTC/I[8>@'L.B:]I?B#0[;6M'O([RPN4\R*>-OE8?
MT]QVQ6##\4O ,[WBIXFM!]DB>>0R$QJ8T.UG1F #J#P64D5D:7X7N)O@]JF@
MZ5H8\*RZA!=+:VC2EG@,@8*TARV&.<D G!)KRG1-%F_X0F.ROOA3KD'B/1M&
MN;.2\NI9)859K=HL6PWD/YA*_*H  )Y^490'MNE_%#P%K6LKH^D^)K2\OY+8
M7:0Q,2SQE=V1QR=O.WJ!VKA_^%S:3XH\':GJFA^);3PTUIJBVD%UJ4+,MP@9
M<[4(!8L-X"C)&,G%<QX=T?4+;4/@8@\*ZG;?V)9W,6HLUDR"WD:W6/YR!U+@
MGW')]LF;1]>_X5+XQ\)OX.U>34CXH:]BD^R%TFC-ZDF]#_%\BDY  P>.],#V
ME_B-I=W\0M0\ 6,LB:K;V7G>>T#M&LC9PO P< 9)R!V!SG&?X1^)5M#\(?#W
MBKQOJ<<5UJ"/N:.%B9&#/]V- 3PJY.,X )-4O-OM)^.6JZW)H>I3Z;JV@P)!
M<V]JSJAB:1G5\<AOG7"X))->96/A[Q!HGASX<ZSJWA/Q#?6&DV-U8:CI^GM+
M#=VSR.&64*C*77 P<'^5(#Z!N?'?A6+PO;^)#KEM_9EV0MO<1DR"9CD!5"\L
M>#P.>#TQ6#\(O%FH>,O#VLZCJ&I6FIK;:O<6=O<V<)BCDA0(5(4LQYW$\DUY
MM_9=_P"%_$7@7Q5I/@75H/"UF+Y&TN)3<W5I).?DN&0L3EAUP?EW<]:U_!7B
MFZ\$Z=K$^L>"O$%G9ZMXJG,9^R(%MHYBNV1P&X3/!(SR>,T >S:SKFE>'],?
M4M8OHK*T0A3)*V 2> !ZD]@.37(:EXZL=2M_#=]X9\7:3!:W^J);L+E2[WBC
M.^"->"LF2 <CY>]8GQHTO5;JW\+:UIVD7^M6VDZIY]Y8Z=*\=P\;1.F^,H0V
MY=V0 ><_6N*GTBQ6V\*:CX?\!ZYI4,GBN#4IOM4,T]S(BJ5DN)0=[)DLHP3E
ML$XQ0@.RU3XN6FJ:%X]A\'WD*:MX8A>2-KF-G64QQAW.S*G'5<YZ\\]*Z/P+
M\0M!\3Z1I]DWB"QO/$*Z?!=7]M X#1L\:LWR]AD\CMD XKS;45U6P;XTZ/\
M\(UK,\VLK)-8S6]DTD4P>T2)0K <G?Q@9Q@DXP:P;OPQJ\]_X%L]!\/W^G2Q
M^#KO3Y;A;"2)(+F6$*JNVT!3O#<GN<]\TP/>;/XA>";ZXNX;/Q-ITKVB^9-B
MY0!$!P6R3RH(Y(X%7-"\7^&?$[W$?A_7++4WME1IA;3+)Y8<90G'J.E?._AO
M1=/NM"M)G^&WBFWUS2=)N+2>749+AXK;]R4*0HS,)=[8 55P!SQ@5['\']#T
MW1_A=H'V?08]*U)M.@BOLV?V>9Y43#>9D L0Q;DYZGUI,#HE\9>%G\2'PW'K
MUE_;&XK]C$R^86"[BN.Y Y(ZXI++QQX2U#4;S3[+Q'I\UU9*SW$2W"[HE4X9
MCST!X)Z"O ]:T+Q--XQU:+P5%J41U6^U 3V&HZ>RQV5QY,B"^MKDJ  _'&3G
M?^5OX=:3H]_-X<%YX&\3VWB'1+&2VG.JM/\ 9+)?**.8_,)C?><851T.?X:-
M /;[/Q[X+U#5[?2K#Q1I=W?7*L\,$%VCO(H."0 >>0?R/I4MAXS\*ZIJ5SIN
MF^(-/N[RV4M-!#<(SH!P20#T'?TKY?\  FFZ7JGP6\"6WA[PW+)XJM=8%^]T
MFGM&?+BN'>0FXV[<,B[ -QR<#MP>"UOAX_\ ASJ4^BZY;6=JE_;W%A'HDR6V
MFEU($*DJ6<9/S.2V>.1R*=D!]/P>-O!]P)3;^*-*E$,1GD*WD9"1ABI<\\+N
M!&>F:R/$'Q2\&:#X&NO&#:Q;WVFPGRT>UF5_/E[1H<X+>V>.IP.:\$M-$L-$
M_9OMM0MOA^'UV2_\B]FFTR59K2(W9D$K( LDBH%C(4'G"YXR*CU"SU"]^%'Q
M4TL6&NZC<SZK;:I#/?:7+$UU"1;EF5=BC/R.=@&0!R*0'TK-XV\)VMA9W]YX
MDTRVMKU=UO++=HJ2]!\I)P>3VK#F\9WMK\5_[!NI=/C\/'09-7%T6(=2DJ(=
MS$[=FUB<X_&O&/&3:9J/Q)35_$5CXJ/A+7="BLK*?3K24'=OD,D4D>S>N\8(
M& 3P>G(ZCP=I^FZ3\5/#WAXZ/J%G8Q>$9++[)?(T_E[[A7$<D@!3=L!R,X'2
M@#V,>*O#36<-ZNO:>UM/+Y$4RW2%)),9V*<X+>PYK;!R,UX#\/O!NI:1\0]1
M\'2V\<GA3PO>/JNEL[;L-<J?*C [>5^_/K\RGKS7OPH 6BBBD 4444 %%%%
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M\8"A1NVXP"IXKJOAK:^*;/Q7++J?C*QU;1]1TY9[>RCU"6\DWAQF9&D&0A#
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MOG%O<*_EK_>.#P/?I1J!P\WP8T_4K5X/$?B/4]:;^R9-&CFE6*.1('*$DLB
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M1M/\1:#JUU-::7K5C?7$'^MBM[A)&CYQ\P4G'/K5C4=5TW1[)K[5;ZWL;5"
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M>V#TV@W6J7WA^QN]:TS^R]1EA5KBT$HE$+]UW#AOK0!JT444@"BBB@ HHHH
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M,&V8CYGR7#1,,8 P,D^OLNO^)='\-VL%YK%Q)!#+,ENK)!)+F1CA5^12022
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MP;:R.K*>1Z?R%%P.:^ T7A^#X=S0Z%JD>HLU_//=M%;O L4TAWF,+( ^%#
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MC?="NW!)R3DU[#K'A/PWXBNK.[US1;34;BR;=;23QAFA.<Y4]CP.14FO>&=
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MI4Z$$=B"01T(-9=GX"TFR\;:OXM6[OI;W6(DAO(99MT$B*NU5V8QP"<?4^M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %-89Q3J* /B_P#;6W#6?!>-N/)N^O7[T5%)^VL?^)[X-_O?9[K\MT=%
M4!ZU^RB/^,?].Y_Y?+G_ -&5[O7A?[*0Q^SYIA];NY_]&&O=*D HHHH *BF_
MU$G^Z:EJ*;_42?[IH >O0?2G4U>GX4Z@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH S+[6-/TVXM+>]NEAFO)1#;QG[TKGLH')P
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M36(&G+*I#.&B^=L !5SD#CCO7T;11<#-T73FTG1+/3'OKF_:VB6(W-V^^67
MQN<X&2:TJ**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(+CL&P<XZ9[UGV.@^,KWQ5J'CG5M*L+34AI)TRQTQ+PNO+[W>24)QE@N %.
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M1@Z[@.HRH!]JXT^$/&?C?6[#4?%NFVV@2:5I5U8QO#.MPUS/<1B-Y!M "Q@
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MO.!CGC2\'_%+PKXP\-ZAK]G>Q6EE82R).;F>,&)58J'?#$*K;202>E>8>#M
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MNX-UO886-U"KN90G'W<X( XJIX/\96GC'2K_ %"VLKFR6ROYM/DCNU"N)(R
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MMM81&:2*SC$DA4=2 2!QU.3P :L:1K<&M>%[#Q!:PRK!>VJ7<<;J-X5T# $
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M@_PYU/XG:AK/AKQ%K&JP7F@:[:LUS'-<PX24H9(_LZH@;C# J68XR<\5[S0
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MJK@LX4=,LHQD9S]2%UWX-KXD@DU74O$ES!XL^UPWEOJ]E$(A;-$I6-%B+-E
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\/_ +:/_(^^&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;JMYI>FZ->ZU>:? ES>1690&"-]VW[S#<QV-A1S],C/A5]J^ER>!M=\)VOQ
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M;6FL:/XAT*&P>'4M2BNFGF-RF H1QPZ]02PW<9/->D5(!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %'>BB@ HHHH **** "BBB@ HHHH *.:**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(: /AO\
M;0*_\+(\.>O]EG_T<]%)^V;Q\3?#O_8)_P#:ST50'T5^S>NW]G/PER.8ISQ[
MW$E>N5Y+^SCM_P"&=/"6W/\ JINO_7>2O6JD HHHH *@N/\ CUE_W3_*IZ@N
M/^/:3_=--#1*G0?2G4U.@^E.I""BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D8;@12T4 (JA1Q1M&=V.:6B@!-H/49HVKZ"EHH 3:O]T4
MGEI_='Y4ZB@"/RH_^>:_E0;>$_\ +-?RJ2B@" VENW6%/^^:!:VH_P"7>/\
M[Y%3T4 5S9VI/-K$3_N"FMI]BWWK. _6,5:HH J'3=//WK&W/UB7_"F?V3I>
M,'3;4CWA7_"KU% $,$$-O&(K>%(8QT1%"@?@*FHI%! Y.: %HHHH **** "B
MBB@ HHHH **** "BBCG/M0 4444 %%%% !1110 44=Z* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "CO110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0:**
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M02J@R!R4X^O%<MX'T[Q!H,OPENM0\(ZUC3[74M/ND%F2UK)+(AC+_P!U"O\
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M>%A!Y<,4F8@5X<[B"S;NN<=JM?\ "0^-8_A/I7E>+;G^TK;Q=_8SW[PH[74
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M3TKU&@ HHHI %%%% !1110 4444 %%%% !1110!\*?MF;O\ A;.A=<?V,O\
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MV,D CN;>%6*LTB.RXY!P!DG' -7A\4/#=TFE#1VN=9NM5LCJ-O:V,8:3[."
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M1HX>,_,P.%X]:Y7XBPZ?J'P<O+?Q%:ZC!:7$,*SQZ<GF3VY++R ,[@C8)Z\
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MN->T:SU*'3+K5K."^F_U=M).JR2<X^52<GDB@Z]HBBZ9M7L@+1@MQF=?W)/
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M60 A0V 6Z9[<YK&OO%OC";X7:M\7K#Q5+'-9:A+MT1HXQ:K;QS^5Y#?*6,A
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MNUXFC!5QZ$=#1+INGW$7E36,$L?'R/$I''3@BKE% %1-/L8Y_/2TA6;&/,"
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MC&^.<9'\)!]ZSV^$_AR;X5+\.+N>_O-'4(JO//NE0(X90K8P -H  '2O1**
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M-/(;P]<27CO?6?VE[RXDW;W8AU !W,-HX&>.@KU^BD!Y!J'PAOFN_$%EX?\
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MBB@ HHIK,JC+,%'J30 ZBHDFCD4-'(K@]U.14BG(H 6BBF%T5U1F 9N@)Y-
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MMI!9>*?W=K+:SO(UM.4WI%+E<'<,_,O (Z8YJO-\*M5U3Q-;7VN^(+2\TPZ
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M#5_"?BG5-4DTVQ\/Z;>6<,;:5IUW)/ ]T&)DN%5E C!!50H]#FO7*D HHHH
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M.D?"[PC\0(O"^B^3!XOM]'CAD7$@>6V!!W'^ DMR<?-^%>K4@"BBB@ HHHH
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M]!]*=35Z"G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !111WH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)
MQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P
M!^V!S\<K;@K_ ,2B#D]_WDM%)^U\V[XZ0[AM TF#!]?GDHJ@/LGX1_\ )$?!
M QC_ (DEG_Z)6NWKB/A+Q\%/ XSG_B1V?_HE:[>I **** "HIO\ 42?[IJ6H
MIO\ 42?[IH D7H*6FKT%.H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH .]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!^?_[7_P#R72#@#_B4P?\ H<E%,_:^/_%]8^/^85!_Z%)13 ^S/A*N
MWX*>",CG^Q+/_P!$I7;UQ7PGRWP4\$;N3_8=ES_VP2NUI %%%% !44W^HD_W
M34M13?ZB3_=- #UZ#Z4ZFKT'TIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "8YS2T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'Y^_M=_P#)>5[_ /$KM^/3YGHIG[71V_'?KUTRW_F]%,#[
M2^%8V_!OP2!G']AV7_HA*[.N/^%I/_"FO!6[[W]AV7_HA*["D 4444 %13?Z
MB3_=-2U#<?\ 'O)_NF@"1>@^E.IJ=!]*=0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %(W2EHH _/G]KAMWQV^FF6X_5Z*;^UQ@?'I^G_(-M_\ V:BJ
M ^U_A=N7X/\ @M6R3_8EGR1_TP2NQKD?AB,?"#P;W_XDMG_Z(2NNJ0"BBB@
MJ"X_X]I/]TU/4%Q_Q[2?[IIH:)5^Z*=35^Z*=2$%%%% !1110 4444 %%%%
M!1110 4457N(Y6"-"Y#(V<=F'H: +%%(,XYI: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BCO10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$TM-(H _/O]KC_DO1YR
M/[,@_FU%1_M;?\E[E_[!UO\ ^S450'VY\,#GX/\ @SC'_$EL_P#T0E==7(_#
M+CX1>#1_U!;/_P!$)775(!1110 5#/\ \>TO^Z?Y5-4,_P#Q[R?[I_E3&B1/
MNTZFKT'TIU(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\>TG^Z:!HD7[HIU-7[HIU @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BCO10 4F:6B@!".*,4M% !1110 444
M4 %%%% !1110 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB
M@ HHHH *0TM% 'YZ?M9\_'^X_P"P?;_R-%)^UG_R7ZYW=/L%OC\C10!]R?#W
M'_"L/">#D?V1:?\ HE:ZBN7^'^/^%9>%57H-)M/_ $2M=10 4449H *AN/\
MCWD_W34V:AG_ ./:7_=/\J$-$B=!]*=35^X/I3J!!11FB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *,T4=Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0GF@!:*
M09HSB@!:**,T )SFEI,\4;A0 M%%% !1110 4444 %%%% !1110 4A]*6D-
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M $+3>O\ SSD]?]^BBJ&/'Q:\2;S_ *'IW3_GG)_\75V/XH>(&4$VEA_W[?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>skye_ex31img19.jpg
<TEXT>
begin 644 skye_ex31img19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M.$(_D>*]+HI >9+\!/A!MY\ Z9_WRW^-)_PH/X/X_P"1!TW\F_\ BJ].HIV
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M)J]3HH \L_X9Z^#>T+_P@EE@>DDO_P 73U_9_P#@ZO\ S(6G_BTA_FU>H44
M>8_\* ^#N1_Q06G<?[__ ,51_P *"^#^"/\ A M-Y]F_QKTZBI \N_X9]^#I
M()\!V&1Z-(/_ &:G+^S_ /!T?\R#IW''\?\ \57I]%4!YG_PH/X/_P#0@Z9^
M3?XT'X"_!\_\R#IGX*W^->F44K >8+\ ?@\H./ 6G'Z[S_[-2']G[X.DY_X0
M/3_P+_\ Q5>H446 \P'[/_P=_P"A#T_\Y/\ XJD;]G[X.,H7_A K#CT:0?\
MLU>H446 \M'[/OP;"E?^$#L,'_:DS^>ZD_X9Y^#.<_\ "!V6?^NDO_Q=>IT4
MP/+C^SY\&_\ H0K#_OJ3_P"*IA_9Z^#3  ^ K'CIAY1_[-7JE% 'E+?L[_!D
MG)\!V7IQ+*/_ &>E;]GGX,^64_X0.R /I)+G\]]>JT4 >4#]G7X,[LGP):>G
M^NF_^+IP_9W^# (_XH.SX&.993_[/7JM% 'E7_#._P &/^A#LO\ O[+_ /%T
M-^SO\&&'_(AV7X2RC_V>O5:* /+&_9Z^#9(/_"!V.1Z/(/\ V:HF_9W^#38_
MXH6S&/2:8?\ L]>L'I2=\Y_"@#RU?V>_@X!C_A!+$X&.7D_^*IW_  SY\',Y
M_P"$#L?^^Y/_ (JO4:* /,!\ ?@Z%*CP%IV#_OY_]"II_9[^#?\ T(=C_P!]
MR?\ Q5>HT4K >7']GWX.'KX#L/P:0?\ LU-_X9Y^#7_0AV7_ '\E_P#BZ]3H
MHL!Y>O[/WP<7./ 6G_BTA_\ 9J&_9]^#CG)\!V ^C2#_ -FKU"BBP'E9_9Y^
M#1.?^$$LOPDE'_L]'_#/?P; _P"1#LNN>9)?_BJ]4HHL!Y:/V?/@WS_Q0=CS
M_MR?_%4G_#/?P;QC_A!++_OY+_\ %5ZG118#R_\ X9^^#I7!\!V'_?4G_P 5
M3!^SW\&P0?\ A [+_OY+_P#%5ZG13 \K;]GKX-DD_P#""663QQ)+_P#%4\?L
M^?!L$'_A [#C_;D_^*KU&B@#RQOV>?@V?^9%L_\ OY+_ /%T+^SS\&U_YD2R
M/_;27_XNO4Z* /+/^&>?@UQ_Q0=EQ_TTE_\ BZ7_ (9Z^#?/_%!V7_?R7_XN
MO4J*5@/*_P#AGCX,\Y\"6?/_ $VF_P#BZ/\ AG?X,8Q_P@EI_P!_IO\ XNO5
M**8'D_\ PSE\%Q_S(UM_X$S_ /Q='_#.?P6R?^*%MN?^GB?_ .+KUBBE8#R;
M_AG+X+9S_P (+!_X%3__ !RF-^S?\%F8D^!X>?2ZN!C_ ,B5ZY13 \C_ .&:
M_@GW\#Q?^!ES_P#'*#^S7\$S_P R/%_X&W/_ ,<KURB@#R _LT?!(_\ ,DI_
MX'7/_P <IA_9E^"6_=_PA8^G]H76/_1M>Q44 >.G]F3X),/^1+ ^FH77_P =
MI#^S'\$BV[_A"L?34;K_ ..U['10!X]_PS+\$N?^**'/_40NO_CM,/[,/P1(
M_P"1,/\ X,;K_P".U[)10!XU_P ,P_!'_H3#_P"#&Z_^.TT_LO\ P1W9_P"$
M/?'I_:5U_P#'*]GHH \8;]E_X(GIX/<?]Q*Z_P#CM,/[+OP3[>$Y?_!E=<?^
M1*]JHH \8'[+_P $1Q_PA[GZZE=?_'*1OV7?@F<D>$9%]AJ5U_\ '*]HH[4
M?+'Q3^ GPC\+>%+:_P!,\-S0327JPEA?7#_*8W..7/=117IOQZ4-X!L<L1_Q
M,DZ9_P">4OH110!I_ UE_P"%"^#<*5_XET?##'K7H]><? UBWP%\&EN3_9T8
MZ8]:]'H **** "J\O^N@_P!__P!E-6*KR?ZV#_?_ /930-%BBBB@04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 -8D8PN<G\J=110 4444 %%%% !11WHZ"@#RCXZ75Q9^!+&
M6WABF8ZBBD2KN&/*DYZCGBBH_CU.D/@.Q9CC.HQ]21_RRE]Q13 O_ C/_"@/
M!WSA_P#05Y'^\:],KS;X%;O^%">#MR[?^)>F!G/&3S7I-( HHHH *K3?ZVW_
M -__ -E-6:KR?ZV#_?\ _930-%BBBB@04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !WHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI.<C'2EHH **** "D/ZTM% 'A_[2TOD_#736:W28'58QACC'[F;V-%7/VB(Q
M+\.=/4]M4C/_ )!EHI@;/P)?/P"\&_\ 7@H_4UZ5UKS;X%8;X">#F";?^)>@
MQC&<$\UZ3CBD M%%% !5>3_6P?[_ /[*:L56D_UEO_O_ /LIH&BS1110(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **3/S 4M !110: "BD%+0 4E+10 4444 >*_M'7$%O\-].:
M:]6T!U6,;BI;)\F7CBBJG[3HE_X5AIGE/L/]KQ_P!N/)F]113 ZGX#NLGP"\
M'&,8 L57\02#7IE>:_ G8/@'X.\M2H_L],@^N3G]:]*I %%%% !5:3_66_\
MO_\ LIJS5>3_ %L'^_\ ^RF@:+%%%% @HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !WHHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX;2]M[&_CL+R0W@2YBW $SBWVY:$9'S9_#'-%@/7:*13E0:6D 4444 %%%%
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M5D7GB#0].OH]/OM8LK6\E&8X)KA$=\G PI.3SQ7(>&?B!)>^+O%NB>(KC3+
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M!,=SC':O(]7@O='\"S>%M6TS4]/UI?"L:1RP6;74M]'O=A"201"L61OP WN
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M1V@98&D'3:'SR> 2.17G6I1:7;?#GXV7=A);#PM>Y&DJA'DO/]F'FF$=#F3
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M'<,,>.1GF'0/"G@_7OBUX<T/4[RXUNV'A03!K^4QRW;+<#RF= V3^[ (!_A
M)KZDO=+TW4A&-0T^WO!&=R">%7VGU&1Q3?[+TS[>-0_L^V%XHVBX\E?, Z8W
M8STHN!\D7MOX1L/@Q\2-/1=-M=4L/$DYB@CV1S1(+M5CV@8.T+N !R,#TKN?
M&NF^$?$'[2WAZ#Q9);2Z3+X7D=4FN?+BF;S20.HW<'=U[ ]J]YET'1+AIY)]
M'LI7N65YB]NC&1E^Z6R.2.V>E+>:'H=[;PP7VCV-Q#!_JHY;='6/_=!''X47
M ^4? <US8^+?A;9WU[*;2+5=;BTR2[E.^2UV*L6,\E200/7C'&*IZ!_97B+4
MX+W7?'LFE^,M/\1LK64%DG]H2MYY58U?=YCQ;2!C[H"]..?KR;2=(NKJ"ZN-
M,M)KB  1220*S1@<_*2,C\*:NAZ-'JK:LNE6:Z@PPUT(%$I'3[V,]*+@<'\>
M([>3X"^*S<2;-EF7C.XJ=X(*]/<=*\RU#2]!\0?&WX?VVIN+JSO_  JYN(/M
M3>7-M4%0P!P1R3[XSVKZ2O;&QU*S:TO[2"\MG^]%/&'1OJ#Q51/#VA1W$-S'
MHUDDT$?E12+;H&C3&-H..!CC% 'QYX-C\-CQ#\+[G5_L7V6TU+6K/S[APR+'
M&VZ",L>RELJ#SSZ&M+5KR'5OAI\2-;\07\UGX[T77I#IT_F$7%NN^/R(X<'.
MQAQQP<Y]*^KO^$9\-^7%'_8&G[(9OM$:_94PDG]\<<-[]:DGT'1;C5$U2XTF
MREOT "W+P*95P<C#8SQ1<#,\+>)M/U6!=);5+:YURPMXAJ-M%(&>"0J,A@.G
M.:\\^(LRWGQL\&>'?$C1CPI>6ET_E22%8[F[  59.<':IRH]2?:O0=-\'Z=I
M_C/5O%2JIO\ 446'<D:QE8QC@D<L21G<>< #MSL:GH^EZU:K;:MIMMJ%N&#B
M.YA610PZ$!AP?>@#Y->T@N/[!T&ZU6YDT2#Q[-IEC(;Y]S67E\Q;P>4#Y4'.
M>HSFOJK1]%M?#?AF#1='5Q;6</EP++(9#@#C+,<G\:#X7\-O%9PMH.G-'8_\
M>JFU3$'.?DX^7D=JV!BBX'R1\-8['Q!>^&/$.H?$&*+Q!]IGM]4TU(&-W=NQ
M;S(IOWAS&!R"%PHR>,$U;\#M9Z?\3=)\,ZY<7$_@X7EY=^$KR:0A9Y P#1NV
M[)5</LW<-D'G(KZ23PKX;CU&[U%/#^G1W=XK)<3K:H'F4\$,<98$=<U6E\#>
M#YK:PM9O"^ERP:=G[)&]I&5M\\G8,?+^%%P/FW1]OB?7CJVL>/(-*U[3/$TL
M%Q:K"XO)4\_:MNI\T Q,A4<)V)YVYJ71M,?3_A/X_P#&^E:QJ]]K6G7.I6,#
M-?22>1 )>2J%B-P&6!.3DY]*^D)/!OA5]>;7F\-Z8=68<WAM(S,>,??QGIQ4
MFF>%/#NBVEU9:3H-A8VUX2UQ%;VZHLQ(P=P P<\]:=P/(=*L?!MO:Z]/X.\3
MW5S!J'APS&SAN69(6C!(G9PVY)&+@=03M)Y[<-X@EU>;X3>"]:21]8M+'PLL
MU]IT>H26]S&I"?Z9$0<.Z;6!#?AU-?1MAX#\&Z5I=[IFG>%]+M;*^S]I@AM4
M5)P>S#&"/8\57F^&O@&XAM()?!^D&*S4K;I]C3;$I.2 ,8P3SBE<#Y>U#7?[
M1MKCQ1H.N:C<16%YH\,-Y?WYADMP1"&BCB5B'W!R9&; .3C.":]%\7:'IWBG
M]I:ZL[_6+W3[8>$O,66RNFMR2+@X;<I!8+][&<9 R*]<O?AG\/\ 4;N>[O?!
MFC3W%PBQRR/91EG5<8!..V!^0J?4_A_X*UJ2TDU3PMIET]G'Y,#/;+F./^X.
M/N\GY>G-%P/G?X=ZUK6M>-_A5JVN7#7>H'0=3"SR[B]RJR$(WN2H!YZ\GK4O
M@.ZU7Q#;>$_'+?$>#3KQ]4\O4K)KB>62YD>0 VK0M(57'\("C:#FOHR7P=X5
MFUJRUJ7P_8/J-A&(K6Y-NN^!!T5#CY0,]JJV/@#P5IOB>;Q+8^%].M]9F8L]
MXENHD+'J<]B<\D=>].X'4K]T4M%%2 4444 %%%% !1110 9HHHH *0],FEI&
MZ4 ?-7[9++_PIS1=V2?[<BZ#_IWGHIO[9*E?@YHNW ']N1>W_+O/15 >F? 6
M/R_@#X.!7&;$-^;$UZ97F'P#;?\ L_\ @]E!XL\<^S-7IU2 M%%% !5>3_6P
M?[__ +*:L57D_P!;!_O_ /LIH&BQ1110(**** "BBB@ HHHH **** "BBB@
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MPX\?:>?A+YNDZ:P\(":.\9;\DL'7R]RYC';YL>O';-&@'M_B3Q!IOA;PS?\
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M\[59T*@G';F@#S;P%\6M'GL_#7AO6;76K&_N=*BEAO=2M72*^9(0TA61N6.
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MIZ@J_$'PW\)?".IR^']'.G3ZB;NR8,\@1RJPQLP(X;<QQS@ <"@#VW<#WH+
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MNV27R_IN!Q7#^(_C)HWAN)IIM,NKB.VMH;O4-LL2/9)*,J"CL&=@.2J@X'U
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MT5VE5%<FQCRP4@KDX[8'Y5HZ7X+\*Z-K4^M:5H%C9:A.@CDGAA",R@  <=L
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M\ 8Q[UAO\<O"-KI.IWNJ6VI:?/I5Q#!>V<D >6W\W_5NVPLNP_WLXXQUP*+
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M*]THHN!\[^,/A[\13J?Q$M_#]G9:K;>,M/ME:]N+D0-#+%%Y3)Y8!R6'S Y
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M8'S<,"1Z_2LOB+0K?Q#;>'IM6M8]6N8S-#9&0>:Z#.6"]<<'GIP:Y?Q/\(_
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MZQH\>B^-_$F@^/-'\4:K9ZW8V<=G+HBR&&[,<"HT+A. Q<,>3CYN<5T_P_\
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MU/6+>YNH8X=1AMKLQ1:D$  ,Z@?-E1M., CZF@#D;[Q7\3(O%?C74%U[3X]
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M_#?@"VT#Q)+XDN]6O-:U>2RCT\7=X(PXA1BV#L5026.2QY.!3=7\ K>^,?\
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M#YA_;/Q_PJG0#G!_MA?_ $1+13OVSO+_ .%5:""</_;"X^GD2Y_I13 ]1^!
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MAXL\SP_=26\LUA/9+)+&T8 +0S9!B+[1G XYQC)KU+S$P,,.>G/6@2 D+WH
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MSQ1N!2\6_##7=7\3:GJOACQD_AZ'6[3[-JMN;1+A;@JA2-UW8V$ X..2,="
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MTQA<5]6KX;\/_P!L'6ET6P74VZW@MT\T_P# \9JE)X#\%RK=K+X3TAQ>-ON
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M+2KN^G4+)/-:H[. <C.1R<]^M6[_ ,$^$M4UFSUG4?#NG76H60 M[F6W5GC
MZ8..W;THN!\Z^(M&M]4\2_$ZXNM>U29-+\/6M_;E;R:%1/Y+NLNP'CYE#;>
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MV/I7#>(/AY\2-6M_&5O#H^DK_;>NVVIPL^H$!(H?+ ! C/S$1_K[5O:YX?\
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M#+NP S R,J_,P7H,>M0>#_#OBC3?C%XZ\0:IIL$&E:XMI]EECN [ PQ["&7
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MZU\"P?\ A0O@[(P?[/3^M>D"O.O@?N'P'\&Y4#_B6Q?RKT:D 4444 %5Y?\
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M".0.AK%O/$'@?X<:59Z-<74.D6EO ?)MHXWD\J%>"Y"AB%'=CQZFO'E^)OQ
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M %02?ZR#_?\ _934]5Y/];!_O_\ LIH&BQ1110(**** "BBB@ HHHH ****
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M[MBL%SGJ<<]ZEG^"_P .[MM<:XT.20ZX5-[ONYB)"IRA W_*5(X*XQVXKA?
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M^V=N_P"%>>&\1[Q_:C?^BF_^O14?[:!7_A7WAE64G_B9,>/^N344P/8/@?\
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M13?VSQYG@CPL>_\ :$G_ *+HJ@/9_@JNWX$^"\KC_B50'_QT5Z%7GOP68O\
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MJ'AC4OBR=8NM,FTOQ!<Z4EI;6S:+)8P[8CF1E+D@O@@<8PH YYP@/HVBBBD
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ME,FYFQ@,\GS$(,A@%(W>NW&" >AT444@"BBB@ HHHH **** "BBB@ HHH[4
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MJQ3H)$$L31O@],JP!'T(!KSG0_'WA_0_!^JZ_K_CUM8L!JUQ"MY)8M#]G.X
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M)$.&0D=&!ZBM':O'R]*5P/D5K1KKX8'X?W]E*?B7:^)3-#*(6+M(USO^V;\
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MMTB@MB8VWF=Q&"X9P2H+%MQYZ&OK%H8FD60Q@NO1B.12+;PQRM*D:K(_WF
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M  EX^"G@C_L"6?;_ *8K7;5Q/PE_Y(IX)&<_\26SY_[8K7;4 %%%% !5:?\
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M * -S'IDEB231<#BO&/B/XE-\6(_!/@^;1+6&?2&U%;F^CD9HBLH0Y .&SD
M=.I)S@"N+D^+_CB]\/6EI!)8Z9KMH^H6FHF.T:]::YMF4 10JV[RV!)9SPN/
MSZSQ)8ZKJG[2.F?V;?:KI")H$UNU]#8^9"7,RN(R[H4R0">O8#/.*O-\#]$A
MN[*[TOQ#K.EW4=K<VEW<0O&TM^L\GF2M(60C>7YW*!V'0"@#)M?&6J:]+\'M
M:O=*TQAKWFR3R20[Y;>3[,S_ +DD_(#M.3UQ@=JY?XGZ]XD\<_"WQ'KFFWMC
M!X7L]16P^Q2VA>>?RKF-#+OW?)\^["X.5QR":]*T_P"$<&EV7@VSM?%6K>5X
M3D=[7>L3&56!78_R= A*C';WJCJ?P-TV^AUS3K/Q;K>EZ)K5R+VXTNU\GREG
MWJY="R%ERR@X!QGVXIW0'I.M:G#H7AN_UFX5F@T^U>ZD Y)5%+''O@&O&4^(
M_CS2;?P=XNUN;2KKP[XMN(;<6=O"R2Z<9TW0GS-Q$G.0W [8KVN33X;C1GTN
M]+7<,T)@E,N,RJ1ALXP.1GI7 Z3\(=.TVVT73;GQ!J6I:7X?F\_2K2Y$>+9Q
MN"$LJAGV!L*"<>H/%) <-I_Q*^)SV.F>)K^/03H9\0-HMS;VZOYTBFX, =6)
MP-IYQW_&IKJ[\4Z1>?&#6/!"6W]IV6HVUUY,\>]9T6SC:10!T8C)'J?K75CX
M-VR^$8/#8\5:F8(=8&LB5HX2_F"3S=N-F N\D]/T&*GOM+;X<GQ+XMMK76O%
M4NN74+3Z=;0QNP;:(@4  . H7.<\#/K0 O@3QEJ7C34[.^TW4(+GP_'I$$MT
M_P!FVN]Y)D[0=Q"[5 ++SC<.>]/^*NI76FCP:(=/TV]@N_$-K;2_;8A*T.[<
M5DB!X#C'!ZC/%7_A9X3C\(^ H;'^S(]-N;JXFOKBUC8,(7E<OY>1Q\BE4X_N
M]ZO>,_!<'C)=%6?5;K3QI&H1ZE']G2,EY(P=N=ZG@;CTHZ@>+Z]\4/BM:IX_
MU&P70$T[P;J 219(I/,N8L [%^8@'#9W>XP*^B-/O5OM(M+[;L^TPI*%SG&X
M9QG\:\XNO@MIMWI?C+3YO$VJLGBZ83WK;8<H1CA/DX& !SFO1--TX:?HMIIG
MVF2X%M"L(FE WL%7&XX &?H!0!\[W_CWQ-XBC\6:!X@O=,M0NE:D;GP]+:M'
M<V^Q&\AXW8XG5E&XL ,$CBK?@WQMX]\.MX"T;5K?1FT76]";[#!#(PFA:"W5
MPTDC?+\P(SQ@9Z]SUUU\#K'4FM&U/Q?K-])8V-S86LTZP&2..=2KY;9ER%.T
M;LXJ?5/@O8ZM:>&K6X\3:HL6@V4UA$$CA7S8I8?*?=A.NW&/3'K570'+^!_B
M9XXUCQ?;Z7?3Z=>IJVBSZE;A+*2&*VF1E7RQ+N(G3+8+KG/&/>KI'Q/^)T/P
MY'Q"UZTT6>POX8;;3K&T602F[DN!$&<G@)U..O09KL=+^#LFFZQI&J+XZUN6
M;2+%].MD:.W"+ 0H5"!'@XV*<G).!DUH0_"31I/A#_PK35M1O=1TP+M2=MB3
M1X?>I4J,9#<@D470'(Q>.OBQIOAKQ5-J7AM[V:Q@BGTZ\6P,/F[CB4& 2,S;
M.6&#R!@XR*['X4>*[[Q;X:OKZ\U_3-=CAO&A@N["!K<E BG$L3DM'(&+9![8
M(ZU!:?"NY@TJ:&?QYK]YJC>0L.IS/&9;=(I-ZHJ[=I!.=Q8$L.":Z#PEX,@\
M*3:O??;GO=0UFX6YNYVC6(,RQJ@VHO &%R>Y)))]$[ <EX@\6>--6\:Z]X;\
M#W&EV3>';.*>XDU&W>7[3/*&9(5PZ[5V@9?DY88'!KD$^*_Q-\77OAN#P%HV
MA1#7=)?4%_M)Y=T#Q2*DH8KC(W948'<$D=*]*UCX<"Z\8W_BK1O$-YH>H:G9
MK97ODQ1R),J9V/AP<.H) /3':JNA_"BR\.^*=!U;2M9N8K/1-..FV]D\2,&C
M8@L6?[Q8L-V?4FD!O^,?%!\&_#O4O%-Y;^?)86WF-#">'DX 4'T+$"O);?XN
M?$+0UU:]\5>%9+K38[%;FWNTL9+%4N6<(MLPD9MP)9</QWX->U>*/#NG^+/"
MFI>&M45S9:A"T$OEMM8 ]P?4'!_"O-HO@?%=>&KK0_$_C+6O$$#V9L;5KAEC
M:U0D$M\H_>/E5^9\],="<B H77C3XE:+XQN?#^JWFA3R-X>N-9B>*TD"Q3(P
M'E']YET'/S<$YZ<5IV/Q&\07&H_"WS;>P%IXOL7FO(UC</%(+43#RVW8VY.,
M$$X[UREAX?O-,^/UIH?B+7M7\2+<^&9['[=<V?EA-\@Q&&C3;G8K$EB3[]JZ
M72_@I>6.H^%;ZZ^(6K78\+!H]/B^RP*$B*!-C':2<J ">N.F#S3 X;Q%XD\4
MQ_ ;QG?:%%IOAK4K7Q-)9W3:7&RB0&>.-G4Y!\QBP)8XR,]#TZ[_ (6-XP\*
M?$/_ (1SQU)I2Z9+I,E_97]G;2)]JDC&7C :1OF R=O4C'(Z5JW/P:2\^'_B
MKPE>>)II5\0Z@VI_:1;*K02F59<8R0R[D'![$U@:QI<7C#QIX:\!ZIH^JZM>
M>&+R.]N]?O;,10R((MQ",N%.]S&I7&,*>NW-(#U/P?=>);SP=I]YXJAMH-9N
M(O-FAM594BR257!).0I //4&O&]6^(&O^"]&^(VNZ/X5T*"^T[Q!;P7'EL^+
MI94C'F,>-TGSKZ#D]<<_1&SY,#KVKR+7O@O/KMGXKLY?%LL47B74(+^?%FI,
M1BV[57YNGR+U]* .=UWXA_$S3(?'.CZK'HVGZG8: VNZ;<69>18X@SJ5?>.7
M^7CC'\JIV_Q0\<:=X7\->&]*LUU?Q*WA^+5II_LLUPLL97;&ORG.]FZL>!@]
M<UWVM?"G_A(/$^L:OJ7B*9H=5T-M#EMUMD&R-LG>K'.#N);G/8=JQU^">HVK
MZ'JFE_$*_P!/\1Z39?V;_:<=G$1<6H/RQO&?E.,\,<G//6G<"CK7Q3^(QO\
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M%-[Y#^0&.!YFT[<_CBOD?28/#M_\+/!/]B!;?XCVOB"-;A0Q^U^=YS?:3/\
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MDT4K?:H7$JK;Q1#KY95L!5X.2>O-?6FC->OH-@VI+LO3;QF=>.)-HW=..N:
M*-UXHTN+Q _AV&Z2;6?LC7B66[#,@.!ST&3QS_0UA_#+Q\GQ!\%P^(9+ :7+
M-/-"+4S"1@(W*YS@9Z>E>;7MKX9L_P!LM[O4H;6WN9/#B36\D^U=\XEV[ESU
M8)QZX'M7D?AG3=)L? '@+QI;WC+K)\9?91.URWRP-,X9,9V@$<DXYR?6G8#[
M9^T1^8L>X!V&0I(S^5*T\:%59@I;IDU\BZQ_9NI^!/B5XCU^^EL/'FBZU(;2
M9IBL]L$8?98X1_SS93C ZY)YXJSXV6:U\47?BK6VM_$212Z7%?VMO,T&HZ-.
M!$?W&1AE=F!*C!.XXQR:5@/K+SH_,">8N_&<9YQ4O:OD[PBNF^(O%=GK^L>,
M[;3?&%AXFD2>S$1%[./-9!;G][@Q&/:,A, *>^<_5RL?*R>M#0"E@, GK7&>
M,O&TWAJ]TG2=+T2;7-;U7SFM;))EA!2)=TC,[<  $ =<EA]:\4UNUMO%ES\7
M;KQ;?W%AKGAV8MI,D=R8FL8$B\R"2/!_C926/4YQ5^/1[3Q%\3/A#?>+M-C;
M6KW09Y[X.Q1VF2.!E+ $8(8MQ]1SB@#W?PUK%QKWAJRU>ZT>[T>>Y0L]E>KM
MEA()&&'X9^A%87C3XB:;X1\-:YJT5O)JTVB+&UU:6K /&'(QDG@<'/<X[5VJ
MJ%7:.U?(WBK1_#EC:_':6-8H-0$T20(UQM<(T,3,50MTW,?FQQT'I0!]:PW"
MS0I(.C*&_.I0P-?,5Y!?_#GQCXLC\,ZKJEZ9?!4FJLM[<M.XN4D95D7=G!QV
MQ6Q\*=/L8/%^D:]I/Q!MM236M,WW6EP&65IG&&\YS)*YC8%L'A>I&!18#Z&H
MI!TI:0!1110 4444 %%%% !1WHHH #2,:6FNNX4 ?)?[:Q_XISP<1N(^U7(R
M.GW$HIO[:: ^'?!\AW*PNKD<#CE$_P !15 ?0WPKP/@SX* ! _L2RX)R?]0E
M=E7%?"G_ )(MX)['^Q++C_M@E=H#FI 6BBB@ JK<?ZZV_P"NG_LIJUWJM.,S
M6_\ UT_]E--#19%%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444AZ<4 8FM>*?#GAPP_V_KECI?GY\K[5,L?F8QG&3SC(_,5;T[5
M=,UB*2;2[ZVOH4;8SV\BR*IP#@D'K@@_0BO'/A(Z^*O'OQ%U[Q%#%=ZI9:S)
MI=N)@CFUMHQ\L:C' )))]36EJT,7P[U2R\-^!O)L;WQKK$DP-P@>"RVP[IF1
M 5ZA.%SC<Q/3BG8#V'%&*^=/%7Q7\=>%]!\=:6TFGW6O^%6M;J.]-N5BN[2=
M@!E WRR#.#SBI[SQK\8X?$FN^&%F\."_M])77(;D0RF.*$LP,)&<NV5P&..,
MG':BP'T+@4G%?/C_ !/^(6L6WPR;P\FCPOXPLY3,+M'(AF1-Q8;3]T>G?ID5
MAV_Q<^*%OH":YJ2Z&UMIGB/_ (1Z_6..027;>;M,B<X0 $<')//2BP'T_@4$
M BO!-6^*'C*[L/&'BKPN=/\ [$\(7ILYK&ZB8RZAY6//82!@(Q@_+\ISCD\U
M'>_$7XD:OXON--\)-HEOI\GA^'7K>34(I6>-&ZHP!^9B>.P'7VHL!ZAHO@33
M=%\9ZSXK^VWU]?:BY*"[G,B6:$#='"#]Q20"?H!T K9NO$?A^QU%=-O=;L;:
M]==RV\UPJ2$<\A2<]C^58OPU\53^-OAGH7BJ[MEMI]0@\R2),[58,5.,\XR#
MCVKP7Q%;7G@C6/&DWC'PR/&7@KQ'=32R:YI\:3W6F$@CRW!R0L>  <@+CUXH
M ^J0P8 CD'O3L5X):>*_$.E_%>[1O$EO<^#-+\+#5HH%M2)'A.0.=P_>?(#N
M(QC@*,DUIZ?\0/&EE)X/USQ%#IDOA_Q;(L,,5HCK/8/+&9(0S%B)054@D!<'
MVHL![*Y506? 4#))[53T_4]-U:T%YIE]!>VQ8J);>0.A(.",CC@UY5X>\8?$
M#Q9/IOB&STS2KGP=JEW/;-:Y(N;>!&9!.SEMK99#E . PY/..)^"?B#4FM1X
M'\'R:;"^FZM>W.L"ZA8>7;M<.(TB"L!N.WME5&._%%@/IKH*KI<V\LSPQRJ\
MD>-Z Y*9Y&?2N4^)GBJ;P7\+O$'B:V3=<V5HS09&0)#\J$CN Q!/M7(S:M)\
M/_ 7A72])CCN?$GB6>&W%U=,666Y=-\L\K<,^ #@=_E P.@![!Q2;5QMP,>E
M?/?B+XN^./"<OB+0-1TG3+W7]*6VNX)X3)'!=VLTJQ#"DDI(&8#!;!Z]J]?\
M'W/BZXT2=O&5C8V6H"X<1K8RM)&T/&PY/.>H_"D!TVT>@_*F/&C*05'0UXIJ
M?Q0\16OQ4G\-1_V796UE=PQR6>H;TNKNV9,O<0.6"-@G 0 G@YIGA?XL^)=5
MUFTOKWP[,/"NH6D]XMS'97"-8HB>8GF2./+DWH.JX^8XYX)=@+NE?!K5K1QI
M&H?$"_U+PBDA9='EM8@73=N$;S8WE<]<8R..*]BC18XEC5<*HP .PKQS2/&_
MQ,U:&SUB#P_IAT'6M/EO+&97DWV+!=\:W.2-V]2/N#@YZT:#\3O$6K:5\.-2
METVR6#Q7)-!=*KN&@D2.1UV'G@F,]<T >OSR0PPM/<,B1Q@NSO@!0.I)/2A6
MMYXA-'LE2100XP0P/3GN*^?)OB%\0O$WA'Q<VJ?#_3)M T^'4+.^SJ3 2O$#
ME5P-V-O&< D\_+6K)XD\60:]\)M'\,KINGZ)J^GM/):D2?P6X/EY_N .,=]P
M&>*+ >U6\UG/YGV>2*4QL8WV$':PZJ<=#[5/Y4>X-Y:Y' ..E> Z+\0[/PQX
M?\?ZM#X32SU./Q.^G_9;:XEF^VW;A '8[21G.<*O08 )ZVH?C'XGL_#'B>\U
MCPC.MQHWEM#>I:W,-G<I(ZJ7Q(@D'E[LN #D D>Q8#W/R8O^>:YW;N@Z^M+Y
M4?G"38N\#&[;SCZUQ?P\\3:CXHT*YOKZ;3+N..X\NWO-*G,L%U'L4[P#DKR6
M4J>05K U'XB^*+C4M>;P;X7BUS3_  _>QV%V/M)6>>4[3((E (_=JXSN(R<^
MG)8#U)88ED>18U#OC<P')QTS3/LMJ(A%]GB" [@NP8!]<5Y3JGQ-\1W>I^*(
M_!?AVWU2V\*@+?M=79A:>79O:.$*K<JO4L1SQCO64_QB\3:QXFLM'\&>$;>_
M6_T*/7;>XO+_ ,I?*;&X. A(()VX&>2.@S@L![;]GM]ZR>2FY1A3M&0*1;:V
MCF:9((TD;[SA "?J:\6T;XS:QJVO>!4F\.PZ?H?BNVD>.]DN2QCG0,6A("@9
MRO!SR#Z@@33_ !BO8[32]FD+-<:]>7?]F-$)I$%E <?:)%1&?YN" JD?,.11
M8#V#[-9R*R^3$REMQ&P8W>OUI\D,#,CR1(S)]TE02OTKPB'XT^,[U/#=O8_#
MF>/5-8FNK7[->3-;_O($#%EWH#Y9!SN..XQQFK7A'QA\2]:^)OB[2=:T[3H(
M=,TRVD73$N&^261&8+YFTY.<JQX P, ]:+ >RK_9LMQ%=JMNTSC;'* I8CK@
M'\ZLR31P)NE=43^\QP!Z5\NR7>?#WP7U[P?X5BAO#<W<-II;79PN8Y<J97ZC
M<-Q8@GK@<UK>-/&-_P"-/@_XMTWQ'X<71M?\/:I8Q7%L)UG1&:>)D=6&,@HQ
M^OXT6 ^C$AA4EHXT4MU(7K3(K6TME8PV\40Y)V(%Z]>E>->,/C-?Z)XAU/3O
M#_AN76DT::*&\2%)GEE9\%EBV1LNY5.2'89S[5Z\9I)M(-Q#;L\C0[UAD^0D
M[<A3GIZ>U%@)88;)C)-##"3+]]U4?/\ 4]ZE6"&,#;$B[>F% Q7@?ASQ_-X;
M^&/@7_A%?!(6#6]2GT]; Z@6-O+YDI(WL"7R4<[CP/?BG:_\4/'$WPWN+S3[
M&RTO7;'Q%%H=\IF,L2DRQC,;;1D$. 21P"2.U.P'O L[;#_Z/%\[;F^0?,?4
M^]*]M;R/&\D,;M']PLH)7Z>E>57OQ%\5M)XCCT'P]9:@WA>%?[2#W;J9I_+\
MQHH/DYPN/F;&20,5Z!X5\1:?XL\)Z;XDTO>;/4(%GC#C# $="/4=*0&FUI;.
MS,]O$S-C<2@)..F:>MO"DAD6)%<C&X* :Y+QKXND\-R:+INGVBWNL:Y>?8[*
M"67RTR%+N[MR=JJI/ ))P!UKSWQ!\;=5\,IXDT^_\,QSZ[X?DMC+;PW9\JX@
MG9565&*9ZL 5(X-%@/=2,BJJV-FES)<+:PK-)]^01@,WU/>L?PIJGB'5-"^U
M>)?#W]@7_G.OV3[2MP-@/RMO7CD?K7E^I?'*9==GCT'PU<:UIMGJG]E7)MEF
M:XW+P\J*L90JI(X+@GT'% 'M45K;0,S0P1QEN6**!FIZ\8UCXM>)-'\77WA*
MY\( :S*4.A()W,6JJ6^?Y_+Q&47#,#TYYJGXC^-NIZ5J^K6.E>%CK+:+)%!>
M)!)-OEE8 ND.V,JVP%<[BN<T[ >V1VUO#(\D4$<;R<N44 L??UIBV=G'</<I
M:PI-(,/((P&8>YZFO([KXM^(5\<W/A^R\#R3VEK:VNHSWDEXL1@M9?OR.C*"
M&4 _)U.TU;\._$GQ%XEO-#NK7P;*_A[78IWM=1CN"S0^7D S+MQ&'_APQ//3
M/%*P'HZZ5HDZR!=-LI%+Y;]RA!8>O'6L'QEX,A\0>"];T72H[&PO-3M7M/M;
MVP;8KC:QPN"?ESQGT[<5Y%X<^(MAX-^%6J>(=-\*_P!GAO%$NGSP3ZB\L:2L
MX#322E253/H#V[FNBU#XN^(-/T.VOKGPK9Q2S-<G[1)JA6P\N+;M99_+.XR[
M@$7:,X.<4[ =WX+\+Q>$_"6E:'="SN+NSM4M)+F&W$0G"K@9!)/(&3DFMS^R
M-#AC3&DV2JN50"! !N/(''?]:\"\1^+;SQ#>_"'Q]H/AZ6[U;4GN/+L#<A P
M,#Y4N>,*<G=C./RI?%?C*3QEX5@AU?1)]"\0>'_%6G6MW:&X$@3?*F&#+PZL
MIX_SDL!]!#1](^Q/8C2[3[*YW-#Y"["?=<8J1=,TZ-9UCL;=1<#$P$2CS.,?
M-QSQZUY%XJ^-T/AW7]6T_3=$;58M'EB@O%25Q<,[;2PA01LK[0X)RR]#QQD^
ML3:M9VNARZQ=N;>SAMS<R/)QL0+N)/T%*P!%HND0V36,.E6<=HYW- D"A&/J
M5QCL*671=)GL5L)M+M);1#E8'A5D4^RD8KS6T^*^I-_PC&H:AX3DL]%\3RB#
M3[K[6'D#NI:$2Q[1LW@#HS8)YJ;P#\3?$'CC4A_Q0=SIVD*UQ!)J#7D<BI-%
M(4*;1@D''7USV&: /44C2-%2-0JJ,!5& !Z56O=-T_45C74+.WNUB<2(L\2N
M$8=&&1P1ZUYQXY^+,/@_6VT*UTS^U-1BLC?S1O*T06/)"HI5'W.Q5L# &!R1
M6;>_&VWTVW\,ZOJVBW.E^'M?@9EU"YRC6TP!(BD3;D9Q\K9PW)Z46 ]3DT'1
M9-174Y-)LWOEP%N6@4R#'3YL9K0W*IV]*\Q'Q)UA=+\.I<>%&MM?\0RR"RTN
M6\ Q%&F]GD?;\GR_PX)Y7W Y;QEXGU;4(/ 'B!O#FIV&K1^(WM)=+\X*9"L<
MP*[CA70E%(8\8.:+ >TW.CZ7>7<5Y=Z?;3W,2LD<TD*LZ*000&(R 03GUS5+
M_A$O"XMDMQX>TT0(YD6,6L>U6/5@,8!X'/M7GMI\7[^31[EKCPC<0ZU::O\
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M 1W%Q:H\B '( )&>M2W/AGPWJ&L6^LW>B6-QJ5MCRKN2W5I8\<C#$9'6O(O
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M*6]NK95@BDB;:8RX8C=],^G8X+ >G#I12+TI:0!1110 4444 %%%% !1110
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M1V?AGPYKFH:7<:'X4N!/87$)<3W9B0I;B5<80*&R=K'.W'>NI^%/A3Q%X/\
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M_AZ=9\'/#GB7PSX<U/3_ !-I5O8S3:G<WL1@N!+N6:0O@D <CI[C'I7J&X4
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M?%L>KR+90W$@6<0)Y8@\I>NPIDG'!)8FOK2WM;>UMDM;6"."%!M6.- JJ/0
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M,M7O/C#>^!?[&N5TV+25NFO(Y8PP+NRB0?," -K+QDYYP ,TO@?1_$6F>/\
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M4("QVOD?\M/[WJ3GKF@#U>BBBD 4444 %%%% !1110 4444 %)GCTI:3O[T
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MB7:0>"I9NAR<BKG[1UC-=>&O"DD>IW5J/^$ALXO+AVX8N_#\J?F7&1VYY!H
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M:O\ 1?[%T[5+W3#%;V<D<TIB8*L@)D8*,YXYX[^BL!Z_1112 **** "BBB@
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M[0VH>6!AG+!63.1M&TX)'+#&,=0#9F^'7@F[\.-X?N/#]M+IDDPN9(&W$2R
MY#N<Y<Y]2:9KGPU\"^);VQO-=\-6=_<6*B.&29"6"#HK<_.OLV1U]:X#X2?%
MC3[[PEX2T7Q#J&H7.NZE')&MY/:2>5<2JS'9YN-I?:.@]#]*[.;XJ>$K?5X=
M.FNKE?/NI+*&Y%LYAEN$SNB5@#EA@C'<@@9-&H'4ZEH>EZMH,^A7UFDFFW$?
MDR6ZY12G]WY<8%8J_#KPBD^B3+I9$F@IY>G-]HE)ME]%^;IVYSQQTXKGM/\
MCC\/=4$TEKJUPD,,,LS2RVDB(?+<(R E>7RR_*.>1ZBM:T^)WA&X&MK<W[Z;
M+H2++?QW\30- C#*L0W4'MC/-&H"2_"GP#-8S6$V@(\$U[_:4@,TF3<<YDW;
ML[CDYYY'7-6=0^'/@O5-8;4[O18S=/&L,WEN\:7$:_=25%(611Z,".*CTWXA
M^']7OKO3(%OX[^WM!??8Y[*6.66 G =%*Y8$\<<Y[5Y#8>+O%VIZ%>_%+3]8
MUD1:+=WDU]HMS;[+2XL8YI%V1$H )5C3.02=P(.* /68? %E#\5Y/'T>VWN3
M8?V?LAR/-7(.7'3Y0H"XQP3G/%:WB'P9X=\475C>:QIYDN[ L;:YAFD@FAW#
M#!9(V5@".HS@UJ:?JEEJ6B6VLVLZO97,*W$<A. 49=P/Y&N5TWXI>#]5U2QT
M^WOIXGU)7?3Y;BUEBBOE7[QA=E"O@8/!Y!!&10!-+\,O!4QTC=HYA_L9VDL?
ML]S+#Y+L<L_R.,L>[').3DG)KIM1TW3]7TR;3-4LH;VSG79)!/&'1QZ$'@UY
M\/CI\-/[0CLO^$@82M>'3WW6DRB&;. LA*83)X&<=#Z&NS\0>)-+\-VEM<ZI
M</&MU<):P)'&TCS2MG:BJH)).#^5%@.;L?@_\/--T>YTFQ\.I!:W17S0MQ+O
M<*VY4W[]VP'G;G'M6O)X%\+S>*+OQ+-I:RZG>6_V.XD>1RLT.,;&CW;&7'8C
MWJWX8\4Z/XMTJ34=%FDDAAGDM95EA:)XI4.'1E8 @@^U<IXA^-7P]\+ZQ>Z1
MJVM21WU@%:XACM)I&12,[OE7&T=VZ#(]:-0)]-^#?PYTFPU*PL?#D<-OJ2-%
M<*LTN3&QR8U.[*)GG:N!P/2M;4/A_P"$=3\%P^#=2T9+S0X%58K::1W,>W[N
MURVX$= 0<@<=*JZM\2/"VCV=K>2WDUW#<V?]H*;*VDN"+;&?.8(#M3GJ<>E9
M.I?&[X<Z3=6]M=:^S23V\-W'Y5M(X:*5E"."%P0=PZ=.?I2L!I'X4^ SHMCH
MZZ'Y5G8W2WL2Q7$J,9UZ2,X8,[#U8GH*FNOAMX0N]=GUB\TU[B>YDCFFBDN9
M3!-(BJJ.\6[8S (O)4]!71ZIK&G:/HUUK&IW26MC:1M--,YP$11DD_E7E7Q!
M^(T=W\+O%USX3U:_T?6=%M(;MFN+%H'5'8[2%F3D,$<9'YYI@=!9_!?X;V%_
M;7EGX=6&6TN_ML&VXEQ%)WVC=@*<\J/E/<5?NOAAX,O-:N]5GTDM)>RB>[MQ
M/(+>ZD&,/)"&V.>!U7G'-4=(^+O@?4(M0C&O!)=*LQ>7;3PO$!$.&D4LH#KN
MR,KGFK5C\4O!UY;ZQ(M]<0MH\<<MY'<6<T4D22<HVQEW,#Z@&BS T;?P'X8M
M/$^H^(X=/8:AJ4(M[IFGD:.6,# 4QEBF /\ 9[GU-1>$_AUX0\#M=-X:TA+-
MKH_.Q=G(7.=B[B=JY/W1@5CZ7\:?AUK5K<7&DZZ;WR&B0QPVLK2.TH)143;N
M<X5LA0<;3G&*ZKPYXETCQ9HW]J:)=-+!YCPMOC:-XY$.&1T8 JP/4$4 9^N^
M /#7B/68M:OK:>+4(XC;M<6ES+;O+%G/EN8V4LN><&B+X?\ A6V\1:7KUKII
MMKW2K7['9B"9XXX8>Z",,%Q^'8>E>;^&_B_HGAK7?%.A^/O%SRW47B&:ULWD
MMFVQP^7$41C&FU/F+@;L9P:[V[^*/@RQU\:'<ZHZ7?VI+%G%O(T*7#J&6(RA
M=@8@CC- '1:YH.D>)-%N=&URQAO]/N5VRP3+E6'4?B#R#VKEK'X2^ ]/\*WG
MAJTT4Q6%Z5-R!<2^9,%/RJTF[>5'0+G&.W)JUJ/Q*\(Z7XE/AVZU"0WR30V\
MJPVTDB022_ZI9&52$+<8R16'X;\8:786'C'7=4\;2:MIUIJSQ$/9O']@)V!;
M91C=(<NH!'4D8Z\EF!T4WP[\*3>)[GQ+-IC2:C=6WV.X9IY#'-#M*^6\9;8R
MX)X(]^M96E_!SX?:+9:G9Z9H?V:'4HF@F"7$N5C8Y9$.[**2.0N,]ZZ7PWXJ
MTGQ3:W-QIAN ;2X:UGCN+=X'CE4 E2K@'HP/XUB:W\4_!F@:K/I^I:E(C6TD
M<5U-';220VKOC8LLBJ50G(ZGC(SBC4!K_"WP3)'I$,^G3S)I%O):6:27LS+'
M$ZX=,%\,"."#G@ = *CTSX1> =%OK+4M.T9X;RRMVM8;C[7,76(_PDE^0.V?
MN\8QBN8^(GC"\G^(>@^ -+U#6=)^WVUQ<3WNG6#RR @*L.T[&!3<Y+,.F "5
MS6MKWCJY^&?AGPM9>)OM6O:MJ$\-A)=6EFY61^-[[5!PQ&2$'+'.. < &E'\
M)O!$.DP:5'87@M8+[^THT&HW.5N,[O,SYF<YYZ]23UYKR[5/A7XIO_$VM7!\
M-*M_>WDLL6NVGB.>UC57^XS6ZC.Y% &/XBO7!K9;XJV7@_XL^+K?QOXID31A
M;6$VG6S6IW6_F"0N-J*6., DGI7H6O\ Q*\)^&[:*XO]2DECDM?MV;.VEN=E
MO_SV?RU.U.OS' .#Z&GJ!0N/@_X'U#7K3Q#JND_;-6BACCGG:5U6[*  -,@(
M60\?Q U6N/@I\.KK49[Z;29_,FOAJ11+V9(TGSDNJ!]J[N<X'-=7JWB[1=)\
M$77C&2[6?28+0WGG0_,)$V[AM]<\8^M>:Z4GQ@\4^"?^$TL?%EGIE]J5M]KT
MW1A9QR6T4;C=&LDC#>SE<98$*">A I =CJ7PM\'ZIK5UK$UG=17%_&D-Z+>]
MFB2\C485)45P'&..1_,U:C^'/A2+QE!XLBL)8M3M[46,/EW$BQ1P 8\H1!M@
M7OC&,\]:K77C_2_"_AW2&\83R6VKW%FLT]I! \\JE4!E<I$&(123EONCUIFH
M?%KX>:7H^EZM>>*;2.QU;<;.<;F67;][H#C'?..>.M $7ASX0^!?"GB%]<T/
M1S;W&YGB1IG>*W9LAC&C$JA()&0.A(Z&MCQ?X$T#QS:65KX@CNI(K*<7,*P7
M4D&V0?=;Y",D=L]*Y>W^/7PINFM5A\60EKN?[.BM!*I5]P7#@K^[!)X+8!Y]
M#6CX@^,'P]\+ZK>Z5K?B>"UOK(*9K=4>1TW#(X53VY]AR>*+,"SJWPO\*ZQJ
MW]K7$=Y#?26XL[F:UO)(6O(1C]W*58;QQU//O4EG\-?"EAXML?%%C9S6E]86
M8L+=(KAUAC@ (""/.W'.>G7GK4.B_%;P#XB\31^&]'\1P7FHR0_:(XXU;:Z;
M0QP^-I(!!(!R/P-/M/B?X)O?$L7AZWUI3?SR20V^Z-UBN)(SATCD*['93P0I
M)H U?%GA/2/&6AG2=:BD:%9DN(I(9&CDAE0Y5T9>5(]1[UC/\,/#G]JZIJ4<
M^IPSZI8+IMQLOI,&%1@ 9)P>3\W7D^IJE=?&OX96>KC1[CQ=:+>&Z:R,85V"
MR@@%6(&%&6 R3CKSP:W/B!XDNO"?PZUSQ+8V?VRXT^T>:.'!(+ <$X[#J?8'
MI0!S%Q\"_ UQ!HT47]IV<VD6_P!D@N;6_DBF>#_GD[J02OM7;7WAC2;[P=/X
M3:!H-)EM39>5 Q0I$5VX4CD8'2O,O"'BSQ=?MHOB&+Q=IWBKPK=QS2:A)::=
MY4UBRQ,ZKA78XR N""V<#G-=#X9^,'@_Q%X-O_%8OC9:;83/'-)/&RX42LD;
M<CDO@$ 9.3CKQ0!7F^"GA.[M91J-UJVHZB[PLFJ7%XQNX1"VZ-4D&-H!)/OG
MG/%2-\%O!R:/X@TJV?4[6W\0;3>[+Z1F8A0"06)Y;'S$Y)^G%=)HOCWPGK^D
MZAJNF:Q%):Z:S+>-(&B-N5&3O5@"..<XKAO'7Q1MKKX6>*-9^'OB*!=5T2%)
MI!/;MN5201\D@'WAG#8(HU Z"U^%FAV>NQZW%JFLM>1Z;_92L]X2!#@=!C@Y
M4'COSBL^Y^"/A*Z\&:)X8%YJT,>ARF73[Z&[*75ODDE5D X4@XQCH!Z"N@/B
M:WU66_\ "^AZQ!%XJMK)9F26W9U@9E!1G P",D94-FK'@GQ0?%/A^2XN+;[)
MJ5C=2Z??VX.1%<1-M< ]U/# _P!UA0!;\/\ AG3_  QX?CT73&G:%"S-+<3-
M++*['+.[L<LQ))S7&GX+>'6\,7F@MK6NM!=ZI_:\DC78,AGWA^NWIN /3KS7
MJ-%(#R_Q)\%_#'B?6=5O[S4=8MH]7MTAOK2TN_*ANF0;5E=0/F8# ZXX'%6(
M?A)H\&H7%]#KFMJ\VCC1<-=!]D Z8+*3NSSDD\D]N*](HH \QT_X/Z/I;^$C
M:Z]K93PJ'6SC>="KA@0P?Y.?E.WC''YTNC?![1=%NX8X=:U:?1;>\.H0:-/(
MC6T<Y8MN^YO(#'< 6(SS7IM% 'E4?P1\.VWB:ZU:RUG7+.RN[K[;-H\%YLLG
MFSNWE ,_>YQG'M70^!_ D'@:'5;>UUO4=4CU*\>^D%[Y?R2N27*[$7[Q/(/'
M'&.:[2B@ HHHH **** "BBB@ HHHH ***3- "T49I.] 'R-^VOC[!X(_>;?W
MEYQ^$-%-_;7)-CX(4#(\R\.<>T-% 'TG\/"[_"_PJSG+?V3:9([_ +E:ZFN9
M\!)Y?PV\,)NSMTNU7.,9_=+734V 4444@"J\G^M@_P!__P!E-6*KR?ZV#_?_
M /930-%@44"B@0#I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2,,C%+10!\^+\-_&UCX6\1?"^WL+6Y\-ZOJ#W$&LO<*&MK>6022(T6-S
M2#!"D<$D$XQ7;Z9IGBN'XUZEK4V@QQ:#+ID.G0W0O$:0F-W?<4Z@'S",9SQ[
M\>F44P/*_BGX9U+Q)<:7%%X3AU^PACF9WCO!:7=I/\GE20RDC;T8-SZ=<8KF
MM"\'_$/2?B!X.UC5-.76$TC0)=.NKO[<A=YG(<<-@MC:$+=\YKWFBBX'ROIW
MP_\ BU;V6DZ;?^%[.\TZ-=02:R;51% DD\K2),^S/FJ VW801D9XZUM>#?!_
MQ-TB?X9QZGX7M5@\,0W5K<M'J$;-LE54#8QR1@DX/3WS7T=BBBX'SM??#OQ[
MIWQ$\16^D>'?#NL:#XCNOMRZIJT4<LNER-@/\C F3'55Z' Y'-:6J>"/$U]\
M2H=:TWPZ='U"'5H6.O6EU'''=Z>FW<EQ"&R['!"_+V!R ,'W>BBX'F/Q>LV7
M1O#_ (E*R&#P[K=IJ5QL7=L@#%)6('95<L>#PIK.U*Q\3Z#\5+GQOX:T3_A)
M=)U[3(;::.WNHTDAEBWM%("Y"F-@^"02<G.*]<=%DC:-U#*PP0>015:PL+/3
M;"*QL+>.VMHAA(HUVJ@SG '84 >(:=X*\6^'=1^&$5OX??4H=%>\N-4FCN8E
M6*2ZSN5-S L$+MT'( KV;6I+JWT.Z>PL)+ZY$3".WB94:0D= 6(4?B16K11<
M#YLT'POX]L=+^$FGS^![E#X:N96U!S=6["-61HPR_/\ -]_=Z_+CO5?XE>"?
MB)XBUGQE%;^$FU6WN9+232[L:@D$<<<>QG7RLC=(65OF;MC! KZ;HHN!X5JF
MF_$O0/B5JGB'0/!]MX@L?%&GVT5Y:S7L<8LYHE9<$MPR$,<X!J]#HOC70_BM
M=:U_82:O::AX?@LYKJWE2)8)H3(618V()#%AC'2O9Z*+@?/FB>$O&NB>"?AG
MJ2>'99-5\*3S0WVF>='OD@E5T:1#NVEAE6 W#@D5%XG\$^+]4\(^/-4LO#TO
M]J>*-3L9(=+,L2M'!;F(;G;=M#,%<D \?+[U]$447 \RT[3==_X7YJ.OS:'<
M0:7+H,%G'>.\95I5F=V7 8MT<<X['VJE=V'B33OCQJFNVOA^>]TG4="BMOM<
M3IB.6*25BA5F!);>H&..?K7K5%%P/G31?#OBVT\#?"C39O"-]]IT/5C<WZL8
MQY";)5W</R,R@\9. >.QI>%_!GB+1?$TND:C\+[6^>RU>6^M/$TTB.# TS2[
MMF[=YV"57L"03P.?IC%! (YHN!\WKX"\6ZA\ O$6B1Z#+::Z-;FU.VM+MT O
M%^U"=5+*V/F7Y>2.1VZU7N_ ^N^-?AWXBCTOX;Q>"=3EM[9D^U2JTFH30R>8
M8S@G$>5P"W4MG&!7TQ11<#QRSCUC7OB9I7CFX\,ZGI4&A:-/;S0SQ*LUU/(4
M/E(NX[E4*QSG&2.>M8>DRZEHW[-/B;3=9T&]TR_D745AMKN-<SR74TQAC4 G
M<Q\Q!CU.*]_K,OM'TW4;^QO+VV$\UA(9K<L3B-RI7=CH3@D GIDXHN!Q>G^#
M=07]GJ'P&;G[/J)T'^SO-#?ZN4P[.OH"?RKSRWT/Q1XPTKX9:%J7A*^T.]\)
MW\%UJ-S.JB%8[="@6)PQ+^80G"\#G/3GZ*HH ^5-:\/>)+KX3>,=(M_!>LF_
MU/Q>VI10_9P&> W"R!QSTVH1UZD5ZS\55UBZ\/>'9M+T74]1A75(IKQ=.A3[
M;!%Y,GSQ;_N/N*@D88!F&1FO4J* /(_@MI^L:/I_B:RU;P]J>C1R:U/=V_\
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MVDUK+;VBQF,[ RN JOYF %3/0G&.:S;6UU^U^&^DV?\ PBVL2?\ "+^*&O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\?_MM#_1O O"GYK[K
MUZ044_\ ;:S]@\#X(_UE[_*&BF!]+> 763X:>&"IW#^RK7IW_<K73UR_@ [_
M (9^%WQ@MI5J2 <C_4K744, HHHI %5Y/];!_O\ _LIJQ5>3_6P?[_\ [*:!
MHL4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#!\6^(K/PCX0U7Q+J&XVVG6[3LJ_>? X4>Y. /<UQW]C
M_$+Q'X1TE_\ A+V\/W=]NO+^6UMUDDA#+F.WB#K@*N1N8_,=IZ;N-#XQ^'[_
M ,4?!SQ+H>EQM+>SVN^&-6P9&1@X3\=N/Q[=:Q==\6^*)_ GAVX\#>&+W68]
M2A4W,UG-#')91A!N4"1@/,SE>AVD'/.!0!2\)W/Q!U'X?>(K&7Q!'?\ B#0-
M6FM;/4C&J1Z@L6UMDJJ, '+1G'((SU'/I?A?7K3Q1X4TOQ%8\6^H6Z3JI.2F
M1RI]P<@^XKBO!6J7&A?#W4[C6O!TG@S2='C=XK>YNUGEE0(7DD=E)&2Q/).2
M<D]:T/@[H-[X:^#?A[2M1R+M8&GE0_\ +,RNTNS_ (#OQ^%,"K\7_%?B#PSX
M/*>#K;[5XAG5YH4PI$<,(#S2$-Q@+A?JZULR?$'P[9_#6U\?:A=/!HTUK%=&
M5(FE**X!&0H)[XKE]-T'4O&'CWQ!KOB"TUK0EL"=-TSRYQ$LUKU>0;2<EW&3
MG& L?<&O-ET;QE8_ [QY\+[?P9K,T%O++#H4SJA,]M)+E5)W=5Y/T(_$ ]ET
M_P"+'@G5'O([._N6DM;$:FR-93*TMM_SUC!7]XO;*YJS8_$KPEJ6EZ!J=E>S
MS6OB"X-K8.MO)F5P"3QC( "L23P,&N$L;#5/^%Y>&=7D\,W]MI4/A4V,]Q)"
MJQ0R%@^QSGL%(^I%6/AKX/.D_$#Q)%'(L_AS1+MQH<:@%;9[E%EN%4]?E)"C
ML Q'K0!ZCKFNZ5X<T6XUC6KV.RLK8 O-(>!DX  ZDDD  <DG KRJQ\<7ES\8
M/%=K+KFHP:%9:"MY]GN-/:-K*0R%2X7;N<!5W9Y!S[&NB^,'AW7=>\(Z=+X?
MM4O;S1]4M]5^PNV!>+"2QB],GC&>,@5Q^FZAXHU#XKZ]XKNOA[K6GZ;-X:6V
MC\U4\V619'?9M#$[CN( Z\9[B@#M?#7C#2],^'7AB[U#Q#=>(I=2A"07L5F_
MFWS!69F$2@D8523QV]3SG6?QH\/ZGXUL-#TVUOY]/NM+DU0W_P!DD"A X0?*
M5W8SNR<=1CO7$VNC:E)\'/A_IFJ>&?$UI?Z<KI]KTU-E[IDR(RJ^T?>1\D$'
M@@C/M7\,V?C_ ,/^./#.N>)/"5Y?R3^&9-/N)-/AC @E^TF3]X%(524VD@=6
M)QGF@#L-=^,7@7Q#X+UE?"_CX:5<PVJ3?VDEA),+8&0*#M*\G/&.VX&F:]\0
MT\#?&7[+XI\42KX=GT 745N;4-LG$P4M^[7<<J">>!S[5R.E^'=7M?V.;OPX
MOA/4H-<^SRP-8K;;9W=IR^X#JPP>OZ"NPUF2ZTSXN:=XMN/"VJ7^EW7ALV ^
MS61GDBF,PD\MT'*94XR>,]3Q0!W.F^/_  KJU_966G:J+J:_LCJ%KLC;;/ "
M 65L8)!8 C.1W K'O/BQX8C_ .$=;3S=W\6O7LEE!)!:R$*T8??GY>H*$8Z]
M^@->8:'X9\2?#G5? ^L3>&=0U.WCTZ_M9[+2T65[*6>X6>-",@;0!M+9QE?2
MDT2P\5Z?X.\$7EYX+U3SM*\6WMQ<V<*J\OES?:0LB\CY-TR@DX&!GIS0!ZWX
M>UZ.;7/&%Q<>*8[ZPT^X0&W:V\C^S L(+JS$#=GEL]@:NZ7\0/"NL74MK9ZD
MXGCM?MWES6\D+/;\?O4#J-R<CD9ZUY9K/AWQ#XB@^,>FZ;I-Y9W.K/:R6+W$
M)CCN_+@C5T#'@Y*,N?1JU()+CQ?\1?"7BRV\.ZMI$>@:?>#4?MEFT#EI$15M
ME!&9,$,WRY7CKS0!V>C_ !2\ ^(-8L])T;Q);WEY>JS6Z(K8DV@D@,1C< "=
MN<X'2NKU"_LM*TVYU+4+E+6SM8VFFFD.%C11DL3Z "OGO0;*_A\)?"2'_A%M
M6MKC3M;DEO5.G2(ULA292[C;@*3*G.<=>NTUZC\7-*U?6/AEJ5MH=E_:%Y'+
M;W(LO^?I(IDD>+WW*I&._3GI0!S^D_$.ZU?]H)M LM:,OAW_ (1PZ@;:6S,#
M1R^<BB3<ZAF4H<CMS7;:/X]\*:[J#6&EZLLUR+?[6$:-X_,AR5\U-X&],C&Y
M<BO$-:?7_B'\0+^\T;PCXAT>/4/!=YI,=SJ%C]F$=PT@959B<@#D<=^1D<U6
M\,^'6\4:2]I:_#G7=!\2VFAW6G/J>J3S"*"1H3&L<&^3E223PI"X]P: /;D\
M<>']>@NM.\/:\@U*2SEN+63R6(95^7SH]P"RJ&QRI(/XUB>%OB9I$7PT\+ZI
MXNUN/^U-0TF.^G$<1=F 0&24I&IVH">3@*.E<EX(U^ZU32M/M;_X8ZEI>L^'
M-)>QOKZ[L]GE8BQY=LPRTF]D!PHP!WY&>!DM?$Y\*>&-+;P=KB1'P8U@L]AI
M^VZEN@,/:SNXS%#P&QQO/0G[M 'T!K7Q8^'?A\6K:QXJL[475N+J$DEO,B(!
M## /!!&/7(JY??$7P7IM];65[K\$,USY/EDABG[W/E;G VKNP<9(SBO"O"FE
MW=YXI^#2:MX.U5;?3-!GLKS[;IKF.&4QJB[SM(&2K<-C&1TS5O7O#[6_Q$\6
MZ+X@^'>M^)+;7+J"YTJ6QGF2S8+$BA)RCJD81HQ@D$@>O% 'IGQ2\=VOAKP;
MKT6F^($T[7[2Q-U$_P!E:Y$620F\ $*'*E06^O.*[#PO>7.H^#-%U"\??<W-
MC!-*P &7:,,3@<=37A'B.3Q#X;E^*WA^]\(ZWK;^)XGETN]L;(W*.C6WE")V
M!^4(0.#ZD@>OMG@5KAOAUX?6ZL;BQG33X8WM[E-DD;*@4AAVZ4 >?>&OBYHN
ME^(/$VA>//&5C#?V^O36=C'*@B(@VH4!P, 9)&YL9(/->@V_CCPO=?VSY&IA
M_P"P]W]H_NG'V; W'=D>@S].:\0U71Y+K3?BIX.N/"-Y=Z_K^J2R::[6+&*5
M)$012BXQL41D,W+#&.Y.*TO$G@W5=-^*WA_2=&O1<6'BW3Q8>(=ZY>6.U5<S
MXSC+H?*).1\PZDT >\VUW;WEC#?6[^9!,BR1N ?F4C(..O0UX;XR^,ES??#K
MQ#KW@FZ;3I=!UF&QEEN[4E9XC*D;,-X 7YF(YR?D/'->]%1Y>T#C'2ODC7;7
M7%^'OQ+\)S>$]=N+NZ\7-?1%-/DFCN('N8V!4J,-E%;VQWYQ0@/H_0O'_@_Q
M)_: T7Q!:WC:: ;O:^/)!SACG'RG!YZ<58T#QCX:\4W%U!H6JQW<UH$::,*R
M,@==R-A@#M8$$$<$5\_>.-!UKQ!\0OB!I7AO2;Z(W_A6"UM6-I)!#+(DN\Q!
MR HRG') YQZUW?PE@TV]UNZ\067@?6- NC91V=[=ZO-,9)I5Q^Z19'.57^]@
M9R .].P&G\8O$7BSP[_PB3>&-4CL1J>M0:9<^9:K, DN[Y^>F-OZTW2/%'BS
M2/C+;^!/$&IV6NVFHZ?)?6]S;V_D36IC8 K(H)!4YX;CFLGX_1R75KX)MUT.
M_P!6@@\16M[=K:6<DXCMX]P=FV _W@ .IYQ638Z!;W7QPTK6OA[H>JZ19FSN
M;?7+VZMIK>&567]R$67!9Q)SE1@#K1T ]9C\?^$)M:CTF'7(6NY+EK-  VQY
MU!+1!\;2XP?E!SP:%^('A&3Q GA]=<A.HO.]JD>UMKS(,M&'QM+CNH.17A5K
MI.N7_P )_#OPM70]3L?%6DZM"TEVUK*L,:QW!=[M+C&P[EW8(;<2V,5EJ?$<
MGB+1[R7P?XBBGTSQ?)=7=E;6 %G#&[2CS8VQNF9MRL7R0,MT&!18#Z L_B9X
M#U'Q&OAZR\3VD^JO)+&MJI._=&NYQTXP,Y^A'4&N)UWXH_:/BGX!TCPGXCMK
MC3-7N9XKR%;4L)D5&(=)2,$;A@[2><?0YVCZ#=ZMH/Q8ALO#\]EK=[?WSZ;<
MW=JT+R"2V6-&1W QDAAP>,\]:YBUUB^UK7/A%!9^ -?LYO#EPT-\)--:-+;_
M $?RR YXVYYSG! &>>*0'TS<7%O:VLEU<RK%#"I>21R J*!DDD]!BN;TGXB>
M#-<FO(=,\06\TEG!]IF1@T96'_GI\P&4_P!H<>]97Q@T'6O%'P=\1:+H#$ZC
M<6W[N,-CSMK!FC[?>4%?QKC+:X_X2_XC>#_%FG:!J>F0Z'IEV-7-S820-AXU
M5+4*R@R$.&;"Y V^I%"0'=Z5\5OA[KVLVFCZ1XLL;R_NPQ@AC8DR;<Y'3&?E
M)QU(&175:KJVFZ'I-SJNK7D=G8VR;YII6PJ+ZFOG+PQ:-9_#GX<0-X7U:&_@
M\4/=W0_LB8/$GFS?O'(3Y1MDC&3VS_=./5_C&UZOPJU3^S]%.LN6AW6ZVYN"
M$\U2T@C_ (RH&X+T) SQ0!TOAWQ=X>\4K=-H.HK=FT<1W";&1XF(W ,K $9!
MR..:EU_Q-H?AC3UOM<U%+*!W\M2X+%VP3@* 2> 3P.@)Z"O*/A.+Z+XH^,YK
MC3?$0AU*"RFBOM8MQ&9@B.I)P %.>BX!P.@K>^+T5O+:Z#NN]:TF^ANI)K/6
M-*LFO/L4@B8?O8U5MR.&*XQR2.E'4"IX@^)D.E^./"&I1^*].3P1K%O=R2N\
M0Y,2<,)<]"S*,8ZCJ<X'8-\1_!"^'+3Q$?$MH=+O7\NVG5\^<V2"JJ/F)&#D
M8R,5XWH4NJ7^O_"9/%7AF9+FUBU":Z^SZ9+]FB,@/E.PV;49L;MO&TMVX%<E
MI-SJ$&NVL:^$]8ATIO$NK7$&H6NDRM<V:2C]TL0D3""0'!9E./;J'8#Z1O/B
M1X#T_3+#4;[Q9IEM:ZC&TMI+)<*!.JC)9>>0/_K5'=_$WP#8VUC=7GBJPAM[
M^)9[>1I/E>-CA7)_A!/ )QSQ7S3H%K,OA#X3Z/K'A/6<Z/XBN6O8[G2I) B&
M1R&)"D%09$YZ$@G'%;WB+PW8Z3\3_%ND^+?!_B&^\.Z_';#2$T+S?(D6.(+]
MG9(B%7:06&>!UZ<TK ?5"R(R!U;*GH1WKF5\?^#6\1+X>7Q'9G5'D,*V_F<F
M0#)CSTWX_ASGVK3T>VDM?#EC9B$VKQ6J1A#)YIC(4#!8_>QZGK7S=86.H7/P
MCL/AG<:/??\ "<6>NQS/*+9QM9;P2M>^;C:5,9;YMV22!U- '?>*/'7B#5OB
M%J?@[P3XGTO2=2TVWA,,=]!YBWUR[.6B)ZJ%2/JH)R_M79>/_'<?@/P?!JUQ
M9-J.H7<\5C:6=NVW[1<R?=0,>@X)SZ"N?\.W4(_:%\9+);W(\ZPL(H9GMI!&
M[1B8N%?;M.-Z]^_M3/CGX5U[Q%X2T?4O#5H;[5/#VK0:M': @&X6/.Y1G@MS
MD#OC'>@"9IOC!I/]DW^HWVAZK#<7EM%?6=G8RHUM')(JNT;[SO"[CDL!QSVK
ML9O&GA6W\0Q^'IM>LTU:1Q&MH9!O+D;@N.Q(YQUKG-'^*>A>(C;6/A^VU&ZU
M5V59K.>QF@:UZ;C*S*%4+GU.3@#->2:HM]>>!_&7P[N-+O?^$UEU][O3Y/LS
MYN%:[5X;I90-H5$QDY^54QZ"@#W?4?B#X)TB:Y@U/Q1IMK+:R)%.DEPH,3OG
M:K#/!.#Q[&KEEXN\,ZCJ=WI>G:[975[9QB6X@AF5VB0]&(!X%>%>*+/1Y?%7
MQ@6\T5[J]E\/0QVTS:<[M-(L+JVQ@I!;<T6<'/0]!P>'?[%TOXA_#&6UTB:S
MB/AR>VO)(M/E1?-98B$D.P<Y63KDY^H-%@/:H?'_ ()N;JVM8/%6ER372220
MH+I,R*A(<CGD JV?H?2M#2_$V@:UI#ZQI&L6=]IR%E:Y@F5XU*_>!8' Q7RK
M)I^@-\.?AW&OAUFN8O&#RZ@#ID@?[.99B2^$R5V-%QT(QZ<:&L6&HW&@_%O3
M/"NC73V\>NVEX=.BM7C%U;KY?G+&A4!LE6R!]X#OGDL!]):?XT\)ZM8WE]IO
MB/3KNULO^/F:*Y1D@XS\YS\O'K2Z7XR\*ZWJ!T_1_$6G:A=B(3F&VN4D?RST
M; .<=.?<>M>#:Q)I.O>-+_QKX3M&_P"$?B\(W-OJ,R6K1I+,1F"+:5^:1<@G
M@E>![5E>$8]'TFZ^ \UOI[65W]GNH[^1+5XV+O $Q*Q7G+KCGTXXIV ]T^*'
MCG_A7O@>77S:K<.T\=K'YC[(HWD;:'D;!P@ZG\N]5-*\4>*+'6+G_A,)-&_L
M!=/^WQ:W9%XX!\R@HY<D#AL@[N1@X%6?B9J>GZ9X/5=8\/OKNDWMS'9WMLD+
M2LL4F0T@502=O!XYZXYQ7F?PUTRSTGXB7OA_P/K5[KO@"33))9;6Z!E@L+GS
M%V1([#.2I8[#DCC/:D!ZKX<^(WA#Q'X1?Q19ZW:Q:9$[)-+/.B"'#;1OYPF1
M@@'!PPK>M]>T2ZT/^W;75[.?2MI?[;'<(T.T=3O!VX&#SFOE[PE>65CX2^%T
M]]8R)HFA7]S;^(!-:,J6]T5D2%I=RX(1L@MR%)'3BM?5"+'3/&/BG2[&:Z\"
MGQ)IM\;:. F*XA41FZDC3&60R;6) P=A/3-%@/4_&_Q!FTS2_#6K>$+G2]8L
M-2UJVTVXF2;S0$D?:3&4."PYZGBNZL]:TG4;RZLK#4[6ZNK-@ES##,KO QS@
M.H.5/!Z^AKY?\?:EX6G\()J/@"&71X]7\46-W'?3P2"*6X7.^9877A$&PD@
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MX'"D#'&#WS3?%_Q,\6VMGJ^K:)J&]M,T^PO'M;6*-H+5I-ID2X=QDE@?E$;
MA02<<9=@/;CXFT@>*9O#7VAO[3AL_MS0B)S^YW;=P.,'GC YJ7P_K^E^*-"M
M]<T6X-Q87&[RY"C(6VL5/# $<J17&+('_:(C+#YCX5)X;@_Z4/\ .:7X'?\
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MHY XJB?@GKA\!S^$SXXB9)M:_MDSMIGS*WF>;L \SIOYS^%>U^8H.&8 T\L
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M=L^DRP);OY<0$;.R@$*58=<#\:[CX\*)_@=XCM([22\N+F%8H(8H6E9W+C&
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M05B^%1_Q1VB]C]A@X_[9BMJDP"BBBD 56G_UUO\ ]=/_ &4U9JM-S-!_O_\
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MF<'C@'C QBI-)^#%C9ZK;7&J>)M5UNTT^.YCTZUNF0?9!."LF'50S_*2!N)
M],TP.1\.Z]\2+'PS\+_#^G:_I<\WB/29)!<WMF[-;^7;HZ9P_P Y ;G.,D=N
ME=?+K'B*'XKP^&M5.FW$,GAB2[DEAM]LGGK(J,-Q))0DDA<#WS5/0O@>-#U#
MPU=1>/O$%Q_PCAD6TCF>-E$;JJF/[G"[5QBNLN/ 7VKXF1>-I-=O=\=B^G_8
M L?DF)B">=N[.X ]>WIQ0!Y!X2U[X@>$_A[\/+X:AI=QX<U9;?35LUM&\^V,
MB-LEW[R'P1R, 8Z>M;.F_$WQE>?#SX<>(WN+#SM=UI=+U!/LQ"NC3/&&3YOD
M.$]^3V KL/#?PEL]!N]+^T^(M1U?3-%R=+T^[$?EVC$$;LJH+D D+GH#W/-8
M4/[/NC6[VT<?BSQ MG8:F-3L+1;K$=FV\N548YR21DY//7DT <78^(_&>F?#
MKXI:]-J]GK-SIOB&2W,6H6>^-XU\I. &P,@C /"X]S7J%]XD\2:Y\0=3\'^&
M]0L]';2-/ANY9[BV^T&:24ML0+N7" +R>I)&,8YS;_X&Z;=6WBJSMO%6MV5G
MXFNOMEU;1S(T22$@OM#*?O$#)SG  Z5N:[\.9]1U;3]<TOQ7?:-K-O:FQN+V
M&*)VO("0=KJ5VY##*D#@D\<T <58?$SQSXDL? ,NC1Z3IT^OW%[8WJW5M),D
M4MNLA+H5D7*DQG Z\]:D_P"%B^.[7P+KLUQ9QZGJFA^('TJZNM,LF<_9E"L9
MU@+Y8@. 5#>I[5U1^$]G!=>$FTG7K_3;?PON:UMXEC997=2LDDA9"69@S9.>
MK$]:I+\([NW_ +1FLO'FK6UU=ZP=;CF6*$^5,4*%<;<,A4@$'L.V30!TGPV\
M1S>*_!4.M2ZW8:RLLTJQW5A"T*,@<A0T;$E' QD$FLOXR>+O$7@GX?CQ!X;6
MSDN4O+>!X[N)W5EDD"<;6!!RP]?I70>"_"-OX-T*738;R:^FN;J6\N;J8*K3
M32-N=MJ@*OT QQ7#_M#66I:M\)Y-*TG3]0O;RXO;9E6Q@:5T"RJS-\H., 'K
M0!A>)/'_ ,2?!MYJVEZ[=>&Y9Y+%=0T^^5)888%$R12)(A9BY'FJ5 .6QCG.
M FD_$3XB:YHGCNSTA;:;7/#;136IN=-D@-W&T7F;#%YF5<X('/ID#-;U]\'1
MXDT>\E\0>,-1U'6+I8/L>IF"."33UC?S$$:JH );!8GEL#I@8JVW@J?X57FM
M>.(]2\5>-+O43#%<6$1CD>1^$\W;A!Q]< ?3(8#-/^)NN^(/#K^(_#MUI;Z?
M9: ;V\%[F/\ TQ@VV,OOQ&%*,6!'H 1G(;X.\>ZWXL;QCX?UZ-;F"STN*ZAN
M&TV2S,BRK(&!B=F)7*<'C([5K:/\,K74/A%KGAK4;4Z/)XEGN+V>*$J6M&E?
M<BY'!* (.XR" <4[PW\([C0O%]YXDOO'&LZY+?6*V=U%=%%68C<%8[0,!0YP
MHZ$D\FD!PG@?QAX\\'^#/AFVM0Z3?>&-=BL]+ACM$D6ZMB\0\MW+-M;H=V ,
M=L]W^&_&&H>$?A-I-GH6GBYU+6/$>HV,"+'O\H"XG=F";EW%0IPNY1[UW?AG
MX4W.BG1[?4O%4NLV/AV-H]'MY;1(Q;DKL5W(/[QD3*J>.I[],R3X'^?\,6\'
MW'BV[%Y!J#ZI8ZK! (I;6=G9R< _,,N_<<'&>,T =A\.]7\9:II=ZOC;1!IM
MY;73102*%474& 4D*!WV$\Y&X\BM/QO<3V?@'7[RVM+6\F@L)I%M[P%H9<(3
MM<#J#C&*J^!_"-QX3T>6WO\ Q!>>(;^XD\R>_O,!W(4*% '10!P,GJ?6M3Q+
MI,^O^%=3T6"^-B]];O;_ &@1B0QAU*D[3C/!I >96WC+QM-JGA#P]X=T_0K.
M+6/#G]I*TZ2K';N@B!154_='F#"]<=QCGL/ACXMOO&G@.UUK5+6&WOO-FMYU
M@SY9>*5HRR9YVG;GOC.,FL?2?AMJ^EZ]X:UB;Q=]J?0=+DTH1_8503QMMPQP
MW#9C3IUQ[UJ?#/P-?^ ?#,NAWFO_ -LJUU+=))]F$!C,C%F7 8Y&XD_C3 O_
M ! \0:GX5\":EKVDZ<VHW5H$;R50N0A<!WVCEMJEFP,9VXR.M>(^(O&%[XT\
M/>$]6L[S1M6N+?QC:PV<T*/;C_5D[9D8NT3;B0PR>!D5[MXRT+4/$?AB;2]+
MUR30[TRPS17L<?F&,QR*_P!W(W [<$9Z&O.;CX)WUQJ,6J?\):D&H/KD6N73
MPZ>%2:2)=L:!=_R@#.3DDDDT("NWQ0\9:=9^)M.U>WT)=5T34[>S:[61X[<0
MS('$GELV]V .-BMECTJE'\9O%EQ\.[77K/1=.FOAXE&@2I*984F!DV+(JG+(
M2<9#$XYZ]*N:Y\#]<U;7]3UZ+Q[]EOKK4[?5+<KIRE;>2%"B]7^<;<=>XS52
M/X#^)+?0I]+C^(N]9->375:?35;$JL6.<.,Y.TGH..E/0"]KGQ-\>:;JL'@^
MWT&RNO%B:>VH7/V2&:YML%V2- ,HPW8&6)(7G@U'K7Q<\5:5I'AN;4M!MO"]
MUJMG))*^L)(UO%=*V%MV="!'O&6#,>F!BMSQU\*]4\1>,=-\:>%_%LOACQ%:
MVYLYKB.W\Z.X@Y.TH2.0Q)'/?Z4S5OACXDNM&M])L_&@FM9-,ET[4%U.S^TB
MZ>1BQN -X <%CC.1CKG%&@'I&BW5S>Z#87=XL2W,T"22"%PZ!BH)VL.",]#W
MKEO$/B[58_'VG>"/#D-I_:=S92:C-<7NXQ0P(X0852"S,S>H  )YZ5T7AC1(
M?#7A/2O#]O-)-%IUM';++)C<X10N3CC)QVKG?%G@K4-4\8Z+XP\.:M!IFLZ9
M%+:O]I@::*Z@DP?+<*RD88!@0?6D!Y)\0?'FM>,O@MK<,5M;Z??:5K\6BZO#
M)N>*1EN$7]V>"8VRN<C."1[U[EX9\*Z;H+7E_#IEA9ZIJ;+)?RV,1C2=UR =
MI)QP?U->?:W\'=2O?AY)X:T?Q%;6-]?:L=:U&_ELS(9[@RB7*J'&T A1C)^5
M0/>O6[..\CLH5OY8YKH*/->%"B,W<A220/;)H8'COQ/OI-=^,W@+X;7NU="U
M#S]1O8V_Y>S"A9(3V*Y&2._%=7J'P]\,Z?XLT;QII]O#HTVB1SF5+.$(ES$T
M17:X7&=O!'7T[U/\1/ /_":6VF7.GZJVB:_H]T+O3]22/S#$W1E9<C<C#@C/
MI]"[3O#WBZ]U.*^\9ZY8W$-LI$5EI<$D$,C$8+2;W8MP2 O3GO0!PMS\9=:T
M[P5HWQ$OM#M7\*ZI=K!Y4,K_ &NVB=BJ2MD;6R1RHQC(Y/9NN_%WQCI%KXBU
MA?"^F3:7X?UE-+G47[^=.KF,*4'EA ?WJDY;CD=LU)8?!35H=!L_!6H>);>Z
M\&6&J+J-O:FU/VAD63S%MG8L5\L,3D[<D>E/USX3^,-4T+Q5I<7BC3(UUW6(
M]64FQ<F H4PG^LY!\I.<?WO7@ T(?B+XOANO&>EZKH.F)JF@Z;'JENL%XYAF
MC8.=K.4!R-A&0,'VZUBZ3\5OB!JMWX7MX_#.B(_BO3'O=//VZ3$#(JLQF^3.
MW#<!<_7O6K<_#;QK=^(O$VL2>)-)5M=T==*:,64I6/:& 89DZ?.YQ[CWS'H_
MPK\6:3J/@>X_X2;39!X5TZ;3P/L;C[0KJ%!/[S@@(OZT] *_AOXP:QXITSPS
M9V.CV=OXAUN>]A=)9W-O;+:MB1^!N;.5PO')ZC'-+4OC5XATK0/%"W'AZR?7
M_#&I6UE>0+<,L,\4S 1RQ'&><_=/3U.,4[1?@CXET71=*>U\7V::]H^K7&H6
M=VMD_EM%./WT$B^9DJQYSGL.M6]:^#&LZIX4UR#_ (2*U'B#Q#J4%_J%^UJS
M1A82#%%$F[(5=H&223D^V#0#I/"'CGQ!J7Q%U_P/XFT>RL[[3K6&^AFL;AIH
MWBD) 4[E!W CKCGGCU]%N%9X'C1_+9E(#_W3ZUYWH_@?Q%I_QAU3QU>:W936
MNH:?#8M:16[(R^7R&W%B.I;MT(],UZ)/%YT+QYQN!%(#Y-L8=/\ !+:/X'^*
MWATV]Z^J1W6G>,=/'F1W<OGAU\V4_,I.,$9P%]  :]"LOB1XAT7Q'\4]4\37
M$$^@^&'C\JWMXR)0#&&0+D_Q;N2>_3BM!?A7XLNO"&E^!]>\5V.K:!:3PR2W
M#V3)=R)%('6/.\J.@7?UQ[\U:;X3W-SXL\;S:AJUO<^&_%L0\^P^S?O4D$8C
M#>86(XQD8&<XZ8Y '0_$'Q+I'B#PW!XKTVP72_$L+-;7-B[[K258C+Y<F\#<
M"@.&&.0>*K0^)?&7BKPW'>7_ (:TZ3PEKVD7-R9$F)EM5*$Q)(K</O4C.T<$
MGTR;WA[X<^((KKPVOB_7;+5[3PQ"T=@L%NT;S.4\H2REF(R(\@ #JQ.>*P?#
MWP=\9:%!-I+?$0W6@6<=Q'I&GR6G$(D!"F5PP+[ QPO3Z=*>@%3]G[Q3?Z_X
M!\-Z1H(M'TG1[);?5)Y2PF6XQN$<:CM@C+'\.0:]\4Y'7->'^"?@UXA\#ZMX
M<U'2_$EC$UE9'3]51+-@NHQAR8V(W\.H.-W/Y<5UWPOM?'%K8:Y%XUU5M4)U
M)VL;B2'R7,!4?+L[*&W 9_EBDP-;XA>,;7P#X'O_ !3=6KW:6FQ5A1@ID=W"
M*N3TY8<]AFN+U+XB^-/#>KP:;KNBZ7+)J6F3WNGRVT\BH)H8_,>"3<"<;>CC
MKCH,UW7CSPA9^.O FJ>%KZ5H(KZ+:)E7<T3A@R.!WPP!Q7!GX8^,-0A@E\0>
M*K"[O--TFXTS3C%8LJ!Y4$;7$@+DE]H(PI Y_"A ;_PN\6>,/&?AV'Q#XAT*
MQTRPOK>*XL?LUPTKN&!W;P0-O8C&>#73>+M9N/#O@S6==M;%[^?3[22Y2V3.
M92JD[> 3SCT-4_A]X;O_  ?X TCPQJ&H1:A)ID(MUN(H3$'1>%RI)YQCO6EX
METW4=6\+ZCI^DZH=+U">$I;WBKN\E^S8[\T >/'XVWMOX/EU^.'2]:2XN+6R
ML#ILLC,\\N[<DL>"Z%,#CDGM4ME\9O$W]AZHVJ>"[JWU*._MM/TV2>"6T@OW
MG;:AQ*NY-O5AST]Q46K? K4?$:>(+[5=>M--UO4FLY+:YTFU,4<$MN2PE92V
M6<EB,YX '-7+GX-^(_$'@#6-&\;>.I=7UF]:%K6^BM_)CL3$<QE$4C)))W'J
M>/3FM -'7?'7COPKIMQ<:[X?TYDCU.RM(;F&=A%<QSLJ,0#ED9&/4\'C I?$
M'Q*U_1[CX@V\&DV-TWA?3H=2@+SL@GC=69@W!P1L;&.O'2J#?"/Q=JW@'4-+
M\4>//[3\0S26TMG?_9=L5GY$@DC C!&XDYW,>3GV%5+CX1>.[Q_&5UJ'C;3[
MN[\4Z6NGS*=-98X< KE,29X!.,YZ\^ZT I:UXE\3:BG@;4O''@31/LM_KMG_
M &>Z7SS/;/)&2KE0@!8<CKC..N,U!#XF\5ZA8_&0^)+73M<TG17>W_LYII(D
M:-8@2H.&P"F2>Y;T[=CX@\ ^,M<\/>"K)=<TJ*[\/7L-[/(;:39.T0*J% ;C
M*DY]^F*SKCX5>+H]1^(9TSQ391:9XN1V%O+:DO#,\8C+%\] -V !UQ[@H#%7
MXO/H6A>&/#OA7PKNEDT"'4EMH8Y[B.WC*@)"/*1V[$;VP!CN>*MZM\;-:M8?
M"\;>&XM!O-<L9+E4UZ1X%6=&V_9<[/E9NH9L<$<<XJ.[^#'C2SC\*ZMX5\96
MFC>(]&TU=(N9UM2\%U;@_+E&).5Z\YR<=*UM7^&7C:ZTN/2(?%%CJUA+I4MC
M?1ZS T@FN'9F^TJ%.%(+' [#CL#0!ZSIMQ+=:5:W-Q"L,TL2.\:OO",0"1N'
M7'K7*>+/%6J:;XFT3POH%K;7&JZJD\P-W*4BABB"[F.T%B<NH '7GD8KH/#.
MCIX>\)Z5H,<S3IIUK%:B5^#($0+N([9QFN*^)W@#7?%=]X?\0>$-=BT/Q%H<
MTC0W,T7F))%(H#QL,<@X'MU^H *</Q$\57%]H7A5O#5II_BS48)[F:WN;LF"
MWBB?;YF44LV_@J,#'.>E8TWQJUB/PI'?1^%8IM5MO$ \.:A9B\(5)RV \;;/
MF4Y!&0N,^U7Y/ACXLMM3\->++;Q%:7_B[3?.COY[M&C@O89228P%R4"G&T<C
MCI5:]^%'B1O#MG9V>J:6=3G\1CQ+J4TL<@1YA(&$<8!SM  7).< =,\/0"6X
M^)OC:Q\.>-IKWPOIS:SX3\N::UM[R1XKBW>/S,JWEYW!<]L<5/K'QB32].?5
M[>PBU'2(='@U":>WE)/G3OLBA ([\DD] .G:NCT/PIK5E\0?%>N:E<V4^FZ[
M';JMO%NWQ&*/9@Y&"&!)_ >M<AH_P(L-/^#6N_#NXU)V74[J2XCNX\EH '!@
MZ]=H1,C@'GUHT HVOQL\2M:^*&NO!$I;1]/_ +2AG!FM[>X48\R/?+$NUESP
M<$-@],$U7U'XC?$R_P#!GA[68_#-GHT>KZMIT=N[7AD:>*5E<@@+E <;3D'A
MN!6A;_#GXJ7W@K6]&\6>,-,U:YN=,;3+)5CD2)5;;OEEQR[X7CCUYY-;6I>
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M8I%,1V@&)F88<X&<KD#/7G [;Q!H\'B'PQJFA7;%;?4;66UD9>H5U*DC\#2
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MC\.?$75?!FEO9^'[_2K6Q46MFZ17MZ)2VZ- O(6,@%P,9..W !]'ZAXM\/\
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MW*_>#G/RD=P:Y'QS\0)]&\%6'BCPC)IFLV,U_;6\LS3%D\N658R4*<$_-W(
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M7AW0?BSXFTOPS=#2;*\\#O)(+$?(9P7/F\'+2!,-GJ0>O-<[\,[WPOXA\2>
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MSFMYW#!L*K"16'!0YX/MZY%=0ES!)$)(Y59#SN!R*\1^)OB32M2;PE>2,9O
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MN7VD:7JBHNI:;:WH0Y43PK)M/MD<4W6=4M=$T&^UJ\WBVL8'N9=BEFV(I9L
M=3@&O,KWXU)I?A>Z\2:CX3OTL(;>VNTD@N(9EFAF<H"K!MN]3C<F<\C&>M(#
MU.:PLKBP:QGM8I+5EV-"R H5],=,56;0]&.GKIS:7:&R7I;F)3&.<_=QCJ2:
MY+5?BCH^A:[K^FZU9W5E%HVEIJSW3!62:%F*@* <[MPQ@XYKE_$'Q!D\1>&O
M%/AN31]<\+:K'H$FK6\S.L;>3M.UA(C'8X. 4/(Y]*8'J;^']!F.Y](LG.SR
M\F!"=G]WIT]JB7PIX95HV7P_IH,7,>+6/Y.<\<<<\UY7\)_B>U]I'@KPIJVE
M:NEYJ6DK);:K>8>.^>*-3+\VXMG'.6'->LZ]K=AX=T&^US5)A%964+33-U.T
M>@[D] .Y(% %5O!_A)E*-X;TK:7#E?L<>"WJ>.M79M$T:YO+:^GTRTEN;48@
MF:%6>(?[)QD?A7BLGB;6+SXZ637>E^(]*LY_#5U<G3I+I&$@#)M:.-'(64?,
M#GD''-=#X<\<V&E_#SP3!H]CK6O7&L6SM:QWD\1NI$C7=(TCLX4O@CY0<G/3
M . #TB;0=%N+QKN?2;.6Z=2K3/;HSLI&""2,D8XJ:QTVPTN$PZ?9P6<18ML@
MC6-<GJ<"O)I/BWK,_P 2?#FC:?X1O_[,U+1WU:17$8NL8&%"EP 5)PRY))Z#
MN>?\0_&C1?%_PVUV2/P[XUTW25@;S=3L88XGC*2[659-Y4-D<^Q-%@/;SX<T
M!M174'T6P>]4EEN#;H9 223\V,]2?S-69M+T^XOX-0EL;>2\MU989VC!>,-]
MX*W4 ]\=:\-\6^*=2\)?';P_<6MOXBU^"ZT";&DV>Z3>ZR)B0ID*#C=EC[>H
MKK_#OQGT'Q)J'ARRL]-U&.37&N85$T:H;6>W7=+#*I.0P'ID<CWP6 [RWT'1
M;34)-0MM+M(+N0L7G2%5=R>N6QDYP/RH_L+0_P"T)M1_LFS^VSH8Y;CR5\R1
M#@%6;&2.!P?2O,-<^,-W'H%C?:'X5N[B:7Q&/#\T,\D:LCK+L?&&P=V"%)(&
M>3QUGL?&6AZ3X_\ '6H:I<:U92Z786D][!>2*UK&FQBOV=%)R3T)[G@46 ]"
M'A3PR(8H1X?TWRHI/-C3[*FU'QC<!C@X[U7T/PCI>@ZYK6LVJ@WNL2K)<2>6
MB9"YVK\H&0-S')R26.2:YRR^*%O)X@@T+5O#VJ:1?WEF]]8PSB-S=HHRRKL<
MCS!P=I[$5C:)\=-&UR]\.A?#NM66G:].;.WU"Z@581<9.V(G/).T\C(SQU!P
M >DW7AW0;[4CJ5[HUE<WIB,'VB6W5I/+.04W$9V_,W'3D^M,_P"$;\/">.?^
MP]/$L<0@206R;EC P$!QPN"1CI@UKL^V(N3@ 9->*^(/B')XK^&_B,:?I^K:
M1'+H,^JZ?JD$R 2(N=N&4Y1\X)0\@=Z /3O^$0\)_P!FQZ;_ ,(WI?V&*3SH
M[?[)'Y:/_>"XP#QUK0L=+T[2XI(=-LH+-))#*ZP1A SGJQ [GUKQWX>_&"Q?
M0-&T?6].U>WG305U"._NX^-16*)?.:,$[CZ@D#=U'OT^@?$:W\8:C/X>DTO4
M-&N+O2!JEL[R)O>V<[0XVDE'!(X/2BP'72>%O#$UW/=RZ!I\EQ<C;-*ULA:4
M''#'&3T'7TIG_"(>%U-JR^'=-4VC;K<K:QCR3G=E>/EYYX[UX3HFH:U)\.?@
MKJ<GB'4FGNM:%M=%[IB+M&,QQ)W?[@P#VKZ,NH?M%I+!YKQ>8A3?&<,N1C(/
M8T 1:AING:OITVG:E9P7UI,,203QB1'&<\J>#S65;^"?!]M+-+;^&-)CDF0Q
MRLEG&#(IZJV!R/8UXA\//C&OA[0],T/Q)IOB.]MWU:YTT^(KJ/=;^:;EUB5I
M&.>F 3CC'L<=KJ?QZ\(Z7K*6C0W%S8KJ0TF:^A,96*X[CR]WF%0>"P7&>F:+
M =_-X1\+W&G6NFS^'=-DLK20306[6J&.)P<AE7& <^E;H4!0!P/:JUU<M;64
MMPL$EP8T+B*+&Y\#.!D@9^I%>/:7^T-X=U.\TGS/#?B#3M+U6<VL.J7EJ$ME
MFW%1&7!/)*D<9P:5@/5H=!T2VU6YU2WTBSBO[H!9[E(%$DH_VF R?QJM:^%/
M#5B]M)8Z#IULUJ'$!BMD4Q;B"VW XR0,XZUQ^G?%[3=2\7:5H::)?P6^KS7=
MO97\WEJDSVQ(E^3=O494@$@9K(TKQWH6@7/Q"UN\N]?F6QU2.WEL[W:Y$Q55
M2.U0'.U\K@'&=V:=@/2=)\*^&M#GFN-%T+3].FGXEDM;=(VD^I4#-2:7X;T'
M1)[N?2-&LK":\?S+A[:!8VF;U8@<FO+/!WB#7-4_:*\066H1ZOIMLFBPS#3+
MV=9(8Y#+C?'L)7D#![YW>E>C>+/%5GX1TVUN[BSN;V6\NX[*VM[907EF?.U<
ML0%'!Y) % &CJ^A:/X@L&L-<TRUU*S8AF@NH5E0D=#ALC-5[CPGX9NM#@T.Z
M\/Z=/I4&WRK*2V1H8]OW<(1@8KDE^+6B?\(7JWB2XT[4+=M*OSIES8LJ&87/
MF+&$!#;#DNN#NQ@Y-=%X7\4_\)(NH))H]]I-S87'V::"\5<D[%<,K*S*RD..
M0?6BP&U8Z;8:5I\>GZ;9065K'G9!;QB-%R<G"C@<DFL:Z\"^#;W4[C4[SPOI
M5Q>W)4S3R6B,\I5@R[B1DX(!_ 5SWC+XL:3X+\46?AJZT36]1U"^MGN;9;"T
M\X3[>J+SDM^&!D9-<VW[1G@S^S;"^32]>F-[-+:_9XK'=+#<1_>A==V0_< 9
MXYXYH ](;P1X0<WY;POI).H9^UYLXS]HS@_/Q\W0=?2HX? ?@Z#P_=>'8?#6
MFQZ/=N9)[);91#(V0<E<8S\H_(5S$_QATE;6-K+P_K>H7HTQ=7NK""W3S[.W
M/3S%9Q\YP<("6XZ4RW^-'AR[UKPKI]G8:E<1>*8S)I]['$GD,5!WHQWY#KCD
M8_.BP'8VO@[PG8WUU?67AW3;:YO(_*N)(K9%:9,8VM@<C%,A\%^$;;0I]#M_
M#NF0:7<,7EM([9%BD8]6*@8)]Z\U\7>/-+O?%OAK3Y+OQ-HOD^)1IRR64:>1
M?2J%!CD;<?W9W_7AN,C(Q_C1\3+B+P5J\/A-]:M[C3-2@LY=4M%06Z2EE+Q.
MQ.[&U\$@8#8!/:BP'LEEX/\ "^G:#=:#8:#96^F7@;S[:.!0DNX8;<,8.1QS
MZ5!I/@3P?H$\<VC^'M.L9(H/LR-%;JI6+).W/H2S9]<UROBKXT>%/!US=6M]
M%?W8TU(FU![2)7%D)" F_+ DG.<+D@<GM67\2OB?8V_A+Q-8>&FU6XU2ST@7
M[7FEPJZV8D7,3.6/&>"0 2%RW'6@#M8?AI\/HH[-(?"&D*MG*UQ;A;5,12-C
M++QP3M7_ +Y'I5RX\$^$[OQ&GB*ZT"QEU9"K+=/"#("OW3GU'8]:K?#>^N]3
M^%/A34KZ9KB[NM*M9II7ZN[1*68_4G->;^+M<\0>(/B_<>![>\U[P_8V^DBZ
MCN[ 1+B9I67SY"6YB4+TZGGCI0!Z7>?#[P7J.IWNIWGAO3Y[R^C\JYG: ;YE
MXX8]^@_(5GS_  E^&]Q;VMO<>#=+DCM(_)A5H!\B9)V>ZY).#QR:R]&^*_A]
MCHUG>'4!'J2O#8ZM<6ZI;ZC)$,,4*L<%\$J"!N[9XK&7]H7PG>6NI-I>CZ[>
M7%A!<2O&+%DPT.=Z%FX#8&<=<=L\4 >B>*]+OK_P+JNAZ$MM#=7-F]K!YS%(
MX]RE<_*"< '@ =JY#X9?"G1_!OA"RMM1T+2CK/V/[%>W5LA<7*=#RX!^8 ;A
M@9/K7 77Q<U9?$OPV\178U6WTO6M/NI[K1;:W$K3R+"K*T:J-[#,A(R<8 Z8
M->V>"O&6C^._"T'B#0VE^RRN\>R=-DB,C%65E['(HV RK'X7>!="G@U#P_X3
MTNPU&S$GV6=;<$QLXY.>O8>X&0,9I/!'AOQ'8W%[KOC;4K'4/$-['';NUC"T
M<,$,>2L:!B2<LS,3QRV,8 H\5_$WP_X2U*>POK>_NY[:Q.HW LK<RBWMPVW>
M_(QR#QUXKA?%GQ5A\(_&'29KW4K^[\-ZAH+W,-C9VWG%YC*A5PJKN^X&.2<#
MGI0!WL?PG^',>H2ZA'X/TP74MV+YY3#EC."6#^W+$XZ<]*M/\.?!+>*)/$Y\
M.6?]KR2+,USM.6D4':Y&<%AD\XS6=#\5_"5WX5T?Q'I\USJ-MK,I@LH+6!GG
MED&XLOE]05",3GICZ56;XR^#AH%IK2G4'MKB^_LQD6S?S+:YR!Y4J]8SDCKU
M[46 W--^'?@W1]4U74M/T&VAN=75EOFP2+@,<D,"<8_#O3O"?P_\'^!Q=KX5
MT*WTU;M@TWE DMCH,DDX]NE5[_XB>'=-OM<M+^2XMO[#M8[N\F>%O+5'SL"M
M_$Q(.%')Q3O"/Q"\/>,K[4]/TK[7!?Z6R"ZM+VV>WFCWC*L48 X([T =C12
MY)%+2 **** "BBB@ HHHH ****  TUAVIU,8=* /B_\ ;661=:\&'9N3[/=
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M=KOD>AQ@<X- '*77PUU+Q5X\/B;Q=#IED$TFXTD0Z8[2O<+,-K,[NBX"@M@
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MREV3<R#:1G@\Y] >*G\1?#7Q5XTU[QFNHVEMI=KK^C6UK!<1W D,5Q"Q<%@
M"5W'&>N!TYX]]HP*+@>/1>'_ !EX@\3>%]?\3:-;:?+X;M9RL4%RLOVRXD0)
M@''RQX!/."25XP#7+6/@#QY:_#OX<^'Y- MOM?AS7DU&Z9+Q"IA1G/RG'4^9
MT]NM?16**+@5WW/;-M52VTX#=,^]?.Z_#'QDC>)+K2]'MM#M]6T*:SN-%@OM
M]K<7TF09D!&(U ))[G/3J:^D**$[ ?..J> ?B3+)X+ETNPM+:[T+PU<:6UP;
MT#R+F2(1AUPN2!L!SCOZBK7@3P3XZT/QY::]=^$=-L+?^P'TZZ\O4_/FGG#J
M_F,Q7+%B#C+< \D8P?H3 HQ1<#Y[TSP/X[LO GPUT.30(&N?#>LK>WI6\3!C
M4R<IGJ3YG3C[O;M] C=L&0-WI3@ !P*6BX'@=MX$\:77@T_#O4M+M(=/;7&U
M&?55O/,5[?[6;G:J@!Q(>!V Y.>U4]%^'?CCPOXHU31;'P]H&KZ-J>I2:A#K
MMT%,]BLC;F4H5)=@>F#CO[#Z'VBC:*+@1'*PG/85\S^#=$\1>.O@OX>\)IHJ
M66CKJC7<FJ-=+\T45V\F$0?,'8C'. !DYZ"OI:YM;>]LYK.ZA6:WG0QR1N,J
MZD8((]"*I:)X>T7PWIPT[0-+M=,LPQ;R+:(1ID]3@=Z /G[0_A_\3K;Q?X;U
MS5?#NE7M_I.K7+W>JS:B3->PRAT5D&T^7&BL/W><D@<#DU<UKX<^.]:N/&-U
M;6,.FWCZ_::]I+2W8:.Z:!%412!?N@[,@D=2/3-?1..<XYH/TXHN!Y!X3T_X
M@77QBN?%GB/PQ:Z-I\^BQV&V/45N'61)F?G"@'.X^P&.2>!N_%32?$^K:!I<
M7ANT_M 1:E#+?6(NOLS75N VY!)VY*D^H!'L?0@J]A2T7 ^=/#_@CQCI'@[Q
MIH=_\.]'NM,U351?1::M^I66%S&)(E)4!615)#$CYN@P,UW'PC\,ZYX;TW6;
M?4$O;+2)+S=I.G7]T+B:S@" %2X+#&[=@9)  R:]3P*0  <"BX'B/Q%U#4--
M_:"^'MQIVBRZO+]AU!6MX71'VD1Y8%V5<CT)&:Y^Q^'7C72_&&B^*%T&.>:Z
M\2W6N:A;P7$2+9Q21&%8P68;W .YB!@G/7J?<+OP?X8O_$MKXDO-%M9]8M!M
M@O'3,D0YX![=36]M&,47 \=OO#_BWPM\8->\:Z'HA\0Z;X@T^&WEM8IXXY8+
MB($(3YA ,9'4@D@D\&LRX^$^M6G[/^G^'-*N(O\ A+-(N!JMC*N D=SYQE,:
MGCC#,F3Z\^E>Z[11M I >#^*_ /B*TT;X;Z9H>E-K$FC:W%JNI7*S1QEF&XR
MOAR"2S.Q_#'I7*^(? ?Q2@\$>+OA[I?A>WU2QOM4.K66K+?)"2KW"3&)D;G>
M"",Y _K]1T8%.X'S;J_@/Q=I/C_6M6M/AWH7C.W\4"*7.HR1 :5.L84JQ926
MCP/X0"<?2G:]X3^)>@:IXZLM%\+VFO:9XNTV.,2VMQ';"SG2U\E@4?DH<9 '
ML..:^C\#THP,T7 Y#X<V&JZ3\+O#6E:Y:K:7]EI\-M-$LHDVE$"]1QVSQG'J
M:Y#5=(\1WGQLU.[.@W2Z)J'A[^QQJ221%8I-[N7*;MVW#XZ=>W>O7P,"D*AN
MHS2 ^<;;P7XOU_PGX)\ ZKH)TX^#]0MY[G5#(IBN(H%8)Y&#N+., Y"[>]='
MX%T/Q%-\+?&7AG4O#%QHM[?3ZA+;_:)$*S"Y>1DY1CC:& .<5[7M%&U:=P/F
MOPSI?C<^*?A5=:AX"O[&W\,Z=<6-XS31, 6A2-&QNSC*$X[ CZ5Z)\';'6=/
MT+7X]9T&[T66YUZ]O8XKDH6>.9]ZG*DCO@^X_&O3]BXZ4N!G/>BX'SU\7/#O
MC'Q%XTU/3K7PQ=:OIEUH306,L-V+>"*<EMQG((+X^7:AR.3ZY#],L_%.A^)O
M OBW4/!NHW,">&AI%Q;V826:VF+(R[U++A2$Y/12<$U]!;11@<47 ^;-,\">
M*/!=_P"&/'L>BR7PAU#4;N_T6S4/-;17I!41@X#-'A=P!]<9%;,/PYU+Q/X/
M^)-U+8RZ+<^*KI;O3[:X&)8&A1/*D<#A6:1-Q )P",\Y%>]XI H QBBX'@.J
M^ /%VM? ;41J%I%=>,M4N(-6NK260;'>)XV6VW=ALCQCIN)YYKH?A1;+<:CJ
M6MP_"X>!Q)&D#O<X%S<N#R,#I&,#!/4]J]=VBE Q0 F*6BBD 4444 %%%% !
MWHHHH **** $QS28IU% 'Q?^VO&O]L^#&SU@NOE_X%'S^M%-_;3/_%1^#QG_
M )=;G^'/\:=Z* /K_P /KM\+:4OI:1#_ ,<%:=9?A_CPOI7&,6D7 .?X!6I0
M 4444 %5Y/\ 6P?[_P#[*:L57D_UL'^__P"RF@:+%%%% @HHHH **** "BBB
M@ HHHH **** "BBB@ KP;Q3_ &<O[0^J6\VI/ +KP7<M/']K= &$J@$?,-AV
MC/RXZ9]Z]YK-FT/1[F[:]N-*M);IUVM,\*ER/3=C.* /F#P?#I>CCX)>(+'5
M9O[2UB1[6^EDOW<SIY#@(49BNT-M  Q@X[U[#\8(_!>H:)H^@^./W-CJNH+;
MP7XF$36,XCD=)5<C@Y7;Z?-^![M?#^A1FW*:-9*;8YAVP*/*/7Y>./PK$\8>
M%=9\2&W73?%!T>&)6WQ?8(;D2L>A/F XQST]:>X'C=KJ'Q \/6'CSPQIOBA?
M&)TW0!>Z;JP16N+=B7"P2,I.Y]H++GDXSWKC6U"&T^'>H^)/AW\0I]2UW^P?
M+GL;&#:T2B1 \L_)/G+N;:QPQYQD5[I9_#GQCIUO)%I_Q+:T$C%B(-#M$4Y]
M0!R?>H[3X9>++!)!9?$DVWFX\WR=#M$W_7"^] ' W2?#77/ WC&Z\':G/J0N
M_##O<6,<S26T+1IE'<'[LV2/?Y<D=ZKZ3>^'X_'7P4/A_6(3#)I]S#/%;W9:
M)V6U! *YQN#LW;/.#T%>D6_PV\6VD$UO9?$AX+><'S8ET6T"N2,,3A<'-11_
M"OQ!%/;2P^/EB-L,0E="LPT?^Z=O'.>E.Z \CDNI;OX=ZWK.IWL]M\4-/UYD
MA7[0R77F&95AA$8SNB,3 ;0"I&2.<FL_Q)!I<WASXQZQ-K=X+W1=40Z<4U.0
M""4JA.T;L'+[QCV(&*]R_P"%<>+CJ#:@_P 1O,O&78;AM#M/,(&,<[<\8JJ_
MPG\12"=6\=PL+AQ),'\/VC>8PZ%OEY(R<$YZFG<#T(ZUIMCX8BUO5-2M[:Q6
MW2:2[FD"Q@$#YBQ.,<_K7COVC4H_CS<WOAOQ$OB:UU30+B25ML4G]G;#N@1)
M8U&%9F.%)).,G. :ZRY^'WCBZTQM+F^)BR63)Y;6\FA6S1LF,;2O3'M2:;\-
M_%^CV/V/1OB%!I\&<^5;Z!;1IGUPN*6@'EBPP']A*&1)F0S6Z/<2!MK>8;P>
M8S-ZYSDGICFNQ\,:19Z)\<XK?PAK-W>Z/<Z-)/JL#WS7<4,WF+Y,FYF;:SYD
M& >BGM6CI_PL\::79WFDVGQ&B;2;R26>6VET2!P7D8LXP3@*2<X^M6+'X:^-
M-$LVM?#OQ L-*C=PS+;^';>-2._"D<XZ&@#RCP(+D?%[2;!U#>'(/%FN&PW$
M&-7$(VA>O0F; XYR>U>O?%6YMH]0^'\;31H__"46QV%@#@13?XX_&LBW^#?B
M>ST?1M-M?B0571KK[99N='AWI)\VXEMV6W;VW>N36G>?#?QAK,5F^O>.=.O[
MBV^96F\.P2!&XR4W,2O(H 7XYM-'\-([C3SC4H=4L)++:,GSA<Q[<#!SWX[\
MUZ'INNZ3JUY?VFG:A#=7&G2B"ZCC;<8),9VMZ'!KS;5/AO\ $#6[JP.J_$R&
M>'3KF.]ME&B1C]\H8 L-_(&00/7GL*],T_2;'37N9[>U@BNKQA+=311!&N)
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M -E- T6****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7MU/8 ]YI.*\3U7XA>(O"'CGQ'I_B>ZB?3Y-&_M+0UAA >60-M>#.?G<.R
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M?.: 1,AED:0M@'DAVR/I3=8^$6F7_P .] \*Z;JESI-QX?DBN-/U*!5,L<R
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M0>HJ2SO['4(3-8W<-U&#M+PN' /ID4@+=%%% !1110 444=Z "BBB@ HHHH
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MK%W!'RK^\7D_[6.E?45<[JWC#PGH.HQ:;K&OZ?87<PW)#/,J,1ZD'H/<T >
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MM&6VCJ<#K3N!\V?"?3M(N-2\+^']7\(^)D\5>&)9$FDNI)A96I"D-*ISM(?
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M"J^EC+_Z,HH ^TM/_P"0;;8;</+7D]^*M56L_P#CSBPNT;!QC':K- !1110
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M<C8&VG.3U%7;/P]I%AKFIZU:V21:AJ@B6[F'641J53/T!-%P/GS6?&GCNS\
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MU9?F9(U48!ZG/K0![&3E:\0MK6^_X6M\5;F?7KZ>"VT^V"6CE?+VM!*P7[O
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M[Q!J>J^'/$FKZ!'JLYN;VSLVA:&68@!I%62-MC'')7&:D# F:?PEXLT3X6^
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M,_LWC0>*AXJU62Z&D+HQ200E6B'.\_)]_=\V>G;&.*- (/@-&(_@-X6100!
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MT9VJVTXSDY8FNOA^!NLV_@C2/"T/C"U6/3=;.M+-_9IS(X8NJD>;C&YCG';
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M44AH ^(_VTC_ ,5KX6^;_EPEXVY_Y:>M%1?MI,R^./"XW8QI\G'_ &T/^%%
M'VU:\VD)(P=@X_"K%06O_'I%\N/E''IQ4V3UZ4 +1110 55N/]=;_P#73_V4
MU:JM-_K;?_?_ /9330T611112$%%%% !1110 4444 <-XUUO^S=<\*V,?C"U
MT"2^U!8_L\UKYSZBHP#"AS\A.X?-[URWQ;^)Z^&M $/AK6[>/6H]0MK=T:U:
M=2'D :,MC8K[3NP3G ]P:/C0MTVM?#N6UTJ_OA9^(H+J=[2SDG$,2JP+-M!
M&6'7W]*\EU^'Q)I'PNUWX>7?@O7KS6D\0#4DN[.Q,\%U"UT)1()%R =HV[3R
M..V<,#Z5UGQQX4\.WD5GK6MP6=P^W*ODB/<<*7(&$!/ +8SVK.OOBM\.M-O;
MBSOO&&G0SVTRV\R&3)C=N@..GN>@[XKQ+7M*CM/BEXKC\7> _$?B:Q\5+;W&
MFG3S,(SB-5\B8!U5"".K=!]:9J%L\&G_ !N@_P"$:U%3?VL%M8+%ITK^:4M5
MBVHVWYE#XY].1Q3L![/J'Q/T+3_B7:>!I'8SW%@]^UUM8QHH*A1D @Y!8YR
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M313?VT-O_"P?#.5P?[-?GU_>FBJ ^V[<,+:,/][:,_E4W:FQ_<%.J0"BBB@
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M.EZCJWB6ZT*/3!:I9O&MNYB$3-(SJ%55))]P/QINJZ!;^!E^!_ABX)GO=+U
M)-+'"S?>B97.5'"^8X_3->DK\+]-:<^3XS\6!EZA=:E.*D_X599\'_A,O%I/
MOK,M,#QK2+BUMOB]:P^%8KK4K&ZU^YEO=#U'3W$NE3*'$MW#-T"-Z$_Q8'/
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M]I>ZW9VR[]UEY2B1GC489/-7+<<[6SDU[+_PJG5 0T?Q4\5K[[[8G_T33_\
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MS<:0FCS^'M-ETV-MR6CVJ-$K>H0C /O6E965GIUE'9V%K%:V\0VQPPH$1!Z
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MMS,-TA))(+'CT-=/HOABX^'2>+_$MQJE[KT>I2MJ4MG#9KY@=4"D1JI^8E5
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M"[CL(8D''.T@''I7G/B_0_&FFZ%\3/&7B[^Q+2'6O#(MEBM97=XY4C<",%@
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M%>$Q^#_$5YX$\2);_!/3?#>J2Z//IY:VDA>:]GD4)F+# )$.6.YB2,8S@U]
M>#H[V'P1HL&I6#V%W#90QRV[LC&-E0 C*$KV[&D!T%%%%( HHQ10 'I1110
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MUN6TGO(K*%IGBMU#2,JC)P"0.G-2:!K5OK_AC2]?MHWB@U&UCNXTEP&574,
M<<9P:\+UZX;QE>_$N'4]>U"W_P"$=TU(+6VLKY[>([[4RM.R@C?N)VX;( 'N
M:];^&S"7X1^$MI!']CV@R#G_ )8K2L!T4.H6=S=W-K!=0RS6K*LT:."T1*A@
M&';(((JX"O8BOE/4FF\')\5M3T;5KZTO'U^UL&NS=O)]F@F\@/+M8D%E#L W
M5>.>,5W]E-JOA3]H+1O"VFZUJ&IZ#K6E2W4L%_=-<&VDC/$BLY+ -D#;G&>P
MQ18#V&^O[33+8W5]<);P*0&DD;:H).!^9('U(K M/&UG=?$6\\#_ -GWD-]:
MV2W_ )\BJ(I8R^S*G.3\V1R!T->??M$:3'?^#_#LSW%Q#Y/B"Q7]S(R@AY-I
MS@XXSD$]#]:S->\*MKW[0$NEP>(M6TF.'PDA$]C=E)6Q<.HW2$;CU!Z\XY]*
M=@/?]P]12,<+FOE&Q\3^,?&D'P_\*3>();'^TO#<E\;QKJ6W:]N@Q0 R(,DH
M!OV@\]3QC/T'\/8]4A^'^DV^MZY#KNHPQM#-J$/*SE79<Y[GC!/<@FE:P!X:
M\:67B76_$.DV]E=6L^A72VEQ]I4*'8H'#+@GY2".3CZ5U>Y1W%?+?BS3=2^W
M?&KQ-IGB;5=(N-&F@N+=+&;8CRI:1/E\<L.,8/ !.:['?J7C[QWKFAW^OZIH
ML6F:-8W%H+"=HLRSJ[-.V,;MI55 / P?6G8#TK4/&=GIWQ"T;P7)8W;W6K03
M7$5PJCR56( L"<YSR.@[BF^-O&%AX.T>VO\ 4]/NKR"ZNX;+;;HK;6E8("VX
M@8R:\:\&^(-6\3>(_@YKFM,LNH2:7JRR28QYQ0(GF?\  @H;WSD>V#KDDOB[
MX467C[4-=OWOYO$\ DL7NV6"!%OA&L'E9 !50K<C.>>^:+ ?3]CI6EZ8K_V?
MI]M9ASEA!"L>[ZX S5_<,=J^8;"X\=>+-6U'Q-;>+;;2FT7Q#);S1RW\RK%;
MI($\AK?;L;<#D,>22,>E6O .E>*M;;QSK3_$K7#+H6KZCIUE!=7(^RA1%A'E
MRO(4N#T &VBP'T/?:;INJP"WU*RM[Z$-N\NXB61<^N",5/;6]O9VL5K:V\=O
M!$H5(HE"J@] !P!7B7P=U35?^$OU?0_$*Z]9:Q;64+36E_=-=6ER=Q!N;:1C
MT8]0..1Z''0_%35[V/6O!?A>#4+K2K'7]3:WNKZTF,,JA8F=8U?^$NP SUX(
M[TK >CZCJ5GI>FW6I7\Z06MI$T\TC=$102Q/T -<CX.^(<7B_4KBS'AS6-(*
M6\=Y!)?P!4N8),[75@2 >/NG!_6O)O$4>I1^'/C/X+N]9O\ 4=*TO2QJ%G/-
M<NT\'F0.YMVD)+,H* X.<JV#D&O:? .GPZ7\/=#M;>XN+B/['$X>XG:9CE ?
MO,2<>@Z 46 Z=W"J6"[B!G:.IKE?!/CC2_'5GJ5UI=K>6PTV_DTZ:.\B\MQ+
M&!N^7)Q][OS7D'B/6->T/XUVUUK^NZC%H=]K$-K8WFG7C26D>%"FQN( 0$=F
M.[S.3SZ BN/M_P"WM%L?$WC/1_%&H6?V7XA2VO\ 9T3JEM,DDZ*_F CY\AA@
MGIBG8#Z\W#U%)N'J*^7M1\0>)H_']CK5CX@U:ZTZ?QE'I+3RW0BLC$Q9&MH[
M?/S[,<R$#+#C(%;&E1^+KGQSX]U)O'>M3VGA6]$UOIRE&CN0;;S#$X51QDC
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MW=CI]Q;V$5P[,UI"ZH&+ ;F*+USCDXK78JB%CA44=3QBOGIAXJOOCK\*]?\
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M@[E_ T:A\._!^I>&[;P[=Z!;RZ;;3BYBA)8;902?,W [MQ+-DYR=QSG)K/\
M 7CVZ\:QS3-HJV5J(8IX;F&]CNXIM^[*;D^ZZ;?F4\C([<T[7O'<UGXN'@_P
M[HTFN:[':_;[B$3K!';PYVJ6=LC<QZ*!V).!0 __ (59X!CT?4](@\+6,%GJ
MA4W4<:;?-*G*G(.000",8P:+KX3_  YO]0T_4+KPCI\MQI\:Q6[;" J*<JI
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M//U-=CX.\9Z/XVTVYO-':Y3[)</:7-O=0M#-!*OWE=3T/(_SF@#J<T4F*6D
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M:@>-V]A\6/AK#JE];PZ'JM]XC\3)<M:6T4[M)'(@$@3LA! .6. %8D]J]?\
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M#'I3N!XQJUGK?_"5W?PXC\;SV\NF:)"UA=ZGJ$L,TKR-*7N-T9'F,I5%P>
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MGGCT%=!I>@Z9HNB)HVEVWV:S4,-J,V[+$EF+9R6))).<Y.:+@?.$6I>/])\
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M_%W]%_[ L?\ Z/FHJ+]LK'_"Y=(93D_V'$"/3]_/10!]Z+2T@Y]J6@ HHHH
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M1HC1/O"E3AL]>@R*8&UIGQ?_ +7^)MOX=L_#>HC3VT7^UFN7B'F88C;\@.0
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M < G:#GMG..9++XB>/H / LNKOJ6KR>);K28]5"Q0S&WAB67HP\L2,#M!(_
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M1-'NM1CU*ZTNTFO8U*)<20JTB@]0&(R!57_A$_##:<^G_P#".Z8;*1Q(]O\
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M;VG?%+P=J6JP:9#J$D4MU;O=6KW%O)#'=1+]YHV90& '/';GIS2LP*UE\'O
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MCJ.:6I **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^V ?^+WV/#+C18!D]_WTU%)^U]N_X7E:;NG]CP;><\>;+_7-% 'WVO2EHHH
M**** "JTO^N@_P!__P!E-6:KR?ZV#_?_ /930-%@=****!!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,_>>;V\O'XYI]% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 '>BBB@ HHHH ***.] !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !WHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***3F@ Q0>E+36YH ^!?VPL'XX6
M0#9QHL''I^]FHJ/]KY6'QSM]TI(.D0%1C[H\R7C\\G\:*H#] **!14@%%%%
M!5>3_6P?[_\ [*:L57D_UL'^_P#^RF@:+%%%% @HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ,T48HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% "9YI:** "BBB@ HHHH *.]%
M% !1110 4444 %%%% !12<YI: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I,>]+10 G:D]R*=2$4 ? 7[8#;OCE:[1@C1X 3Z_
MO):*A_:Y/_%]U!^4#2X,'U^9Z* /T#!I::HIU !1110 56F_UT&/[_\ [*:L
MU6F_UL'^_P#^RF@:+-%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0YH%+28H 6BDI: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #
MM112=Z %I#2TUJ /S]_:[Q_PO5%^\1I5OD*.1\TG6BH_VN/,7X\-N^8'3;?:
M .@R_P#7-% 'Z#CK2T"B@ HHHH *K2?ZRW_W_P#V4U9JM+_K;?\ W_\ V4T#
M19HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"<[O:EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 2EHI* "EHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***3/:@!:*** "BBB@ HHHH **** "BBB@ [T44AH
M_/\ _; &WXXP>9C:=)@(Q_OR_P#UZ*B_:Y8M\=^0.-,M^GU>B@#]!5I:8IXY
MZT^@ HHHH *K3+F6#_KI_P"RFK-5Y/\ 6P?[_P#[*:$-%BBBB@04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !WHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BCO10
M4=Z0]:!0 O>BBCO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4@I:,4 %%%% !S1110 4444 %%%% !1WHHH *1LTM)0!^?/[6WF?\+X
M;?\ =_LVWV?3+_US11^UN[-\>6#=%TVW Q_P(_UHH _01=V3D4^D44M !111
M0 57FXE@_P!__P!E-6*K3_ZZW_ZZ?^RFFAHLT444A!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 '>BB@T %%%% !1110 48HHH ****
M "DYI:* $%+28I: "BBB@ HHHH **** "BBB@ HHHH **** "BBCO0 4444
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M@ HIN[@^M.% !1110 4444 %%%% !1110 4444 %(U+36H _/7]K8@_'N?\
M[!]O][IT;I12?M7A/^%^W6WK]AM]WUP?Z8HH IK^U1\9?*8_VY:9W?\ /C%_
MA4C?M5?&3!_XG5E_X 1?X445NP)8_P!JGXQ;&SK%B?K8Q_X5)_PU=\8,#_B8
MZ=U_Y\4HHI6)(A^U7\8\_P#(7L/_   C_P *3_AJ_P"+S+&TE[ICE6W#-BO7
M'UHHJ8[E%J/]K;XN>809-'(][+_[*E'[7GQ;#;O^)*1C[ILCC_T/-%%59"%'
M[6WQ<WLWF:/C/W?L7';_ &J(_P!KKXM;<G^Q3SWLSZ?[]%%%A$\7[8GQ6"1[
MK'P\^#SNLY/F^N)?Y5?_ .&P?BAY,S?V3X;RK8'^BS<?^1J**@96F_;#^*:D
M[=-\.#YNUI-_\=I\'[8/Q2?[VF^'3U_Y=)O;_IK110!,O[7GQ/:*%O[-\/ M
MUQ:S?_':U+/]J_XD2YWZ7X?/[S;_ ,>TW3_O[115I%ED_M5?$;$O_$K\/_+T
M_P!&F_\ CM20?M3?$25XU;2] PRDG%M-Z'_IK1119"+ _:@^('V0S?V7H&[?
MMQ]GFQC_ +^U8L?VF_'UP8O,TO0?FZXMYA_[5HHJ6,U3^T7XWP?^)9HG_?B7
M_P".U5N?VD_'4-E-,FEZ%N4X&8)L=O\ IK114L"C;_M/>/YKH1/I6@;2#TMY
ML]/^NM;4/[17C:1-S:9HF=IZ02^W_36BBF22)^T1XV;KIFB#@=()?_CM3Q?M
M >,W:ZSIVC?NFPN(9?0=?WE%% $L/Q\\8R2JK:=H^/:&7_XY6TOQF\4L>;+2
M^A/^JD]?]^BBA#))/C%XG2S\X66F%O>*3'_H=36?Q>\37%H\SV6FAE'&(I,?
M^AT44#+<GQ5\1+<2Q"ST["OM!\M\X_[[I(_BIXB968VFGYSC_5O[_P"W112,
MS;M?'^M36<DS6]GN7IA&QT_WJAF^(FMQR!5M[+'F%>4?I_WU113&-E^(VN1G
MY;6QY'>-_4_[5=3'XDOV5-T<'S#GY3Z?6BBDP,W_ (3/5,1GR+7YL9^5O;_:
MJS+XJU%+IHA%;[1ZJV>WO111U&26_B?4)92K1P8 [*?;WJ]_;UYE?DBY_P!D
M_P"-%%,"6#6+J1FW)'QZ _XU8CU"X>3:VW'THHH*+2W4K#G;^51&\E^;A?RH
MHJ2"N-4N#CY(^OH?3ZTO]IW&3\J=??T^M%%,9:BNI7!W;?RJ7SI..G2BBCJ2
M"SR'.<4\2-CM1104()6]NU*LC<=.M%% #O,;!Z=*B\U\MTZ#^M%% #_,;;VI
M/-?';K110!)O;'X4N]LFBBD F]MHH5CY=%%,!032EC110  G]*0L:** ';C3
M6)P:**0";FW[>U*:**8"%C3%9F!S110 J,2!]:>>E%%'4"&1BOS#K2[VV!N]
M%%/H ]&9AS1(S!>/>BBD ;VX]Z&=LT44 +N.P'OBC<<"BB@!Q8[:;(QP:**
M L>!2ECBBB@ 7H*=DYHHJ0 DX-1L[9%%%- /S\GX4JT44@'"FYYHHH /6C)P
M*** &EC@TH[T450#68X-.]*** $)Y'^]3VHHI -':AB1C'K113 1>IIV3110
M  FE[T45( *7O110 =Z*** $HHHH 4]*8>OX444 ?GM^UD-OQZF9>"VGV^?R
'-%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>skye_ex31img20.jpg
<TEXT>
begin 644 skye_ex31img20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M^$#L/^^I/_BJ5/@#\'8V++X"T\Y_O%R/U:O3Z* /,C\ ?@]C_D0M-_\ '_\
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M!3_H1X>F/^/RX_\ CE)_PS7\%,8_X0>+_P #+C_XY7KM% 'D'_#-/P3";?\
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MN>1X=NE^FH3_ /Q=>X44 >&)^RG\&E4AM#O7/J=0F!'Y-2?\,I_!G_H!7O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%'>@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /F7]LR<Q_"70XU^\VM(W)&<"";_ !HJ/]LYMOPMT#Y<
M_P#$X7G;G_EC+WHJ@.R_9:;=^SKH0Y^6:Z'/_7=S_6O;*\4_9;&/V<] Z?ZZ
MZZ?]?#U[74@%%%% !5>;_70?[Y_]!-6*@D_UT'^^?_030-$]%%% @HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHQ10 F>:6@44 %
M%%% !1110 4444 %%%% !1110 444G>@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"*6DS0!\P_MH,G_  JK0(V
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M*0!4#_ZV'_>_]E-3U7E_UL'^_P#^RF@:+%%%% @HHHH **** "BBB@ HHHH
M.:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4XH$BG&#G- #J*.HHH ***:74$ GDT .HHI-PH 6BDW+G%+0 444A8*,GI0
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M-=0MY+J'8D\#-M5U.3U]#@XZBI/%/C[2O"ETEI=VFH7UTUM)>-#8P>:T<$>
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M8#Z=S1FODQ8M1T?P1H/BZW\5:U<W\?C(Z<HGOF>/[,;MXVC*DX;( )+9/ Y
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MQ7@/CB:Z\:?##XA>)+SQ!J%K<Z1J,VFQZ9!<%;>.**9%VR1_Q,XRQ8\_, ,
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M\]!TQDFO/=0U#Q=H<GQ6\4Z!KJ6%OH^OI,;06JR"\/EP!U=FY5=I_AP<Y/-
M'L[_  H^&<F W@/0C_VXQ_X4P?"_X:V,J7T7@;18I8")4>.Q3<I7D$8&<\=J
M\[N/&GQ+\0Z_XAF\(K:QVFAZJEEY<\T*0^6B(TIFW*7^;<V&5AC:..#GWD?,
M@/'X4K6 X2'XO?#J:)WC\40+%#)Y,LLD<D:1.."KLR@*?J17;6\\%W;17-O*
MD\,BATDC8,KJ>001P17S'X4C\92>!/BE;^%])TG4XKKQ!J:&.[N'20D\$!=I
M4G'(^85O?#/7[S4?#?@3P/X5U:72[7_A'&U"2]FMUDFD9)1"8PK950'+'//
M7I3 ^A>*.*^=_P#A97BV\@BTAM6A@U.PU#4--NAI]H)KR_:# CDAB;*(GS N
M6.!C /-&D?$'XA>(O"WPNFT_4K&QOO$YN[>\EFLO,"M$CE9 NX?W,[1P3CD#
MBBP'OVH:A9Z5IMQJ-_<+;VMNADEE;HBCJ346D:M8:[HEGK&EW N;&]B6:"4
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M'0L.S$9'K7,V'QS^'FH75M##J%Y&MQ=?85GFL)HXEGW%1$SE<*Q(. :O:/\
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M%!]R1S^-(#R;X9>#=9\2?##P'?7GBN"XL](LQ/96BV.!'<^640RG?\_E;F&
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M=0M!I?B"[TNYMUCAC6WVN^\(=HX0L"I(XP2>E<U:6>K>*K[X8PV?A[4="O\
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M8498DY!SGG/%7+KX+^&=2\'ZEX?U.[OKZZU.Y6^N=6E=1=M<(,1R!E 4%1P
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M2J8[F-<M#(K!T<#V90<>U&@'CFH>(M0\%_&WQ!XJ\66=@;BT\'K/MTW>!/\
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M3BK>L?#/QA'KFI7OA3Q=:VUMK.FQV6H1ZE:M<.TD:%%F4JRY8J2#GCOSQ@T
MZ7X7B6/X(>$O)5)9?[&MBJEL!CY2\$XXKSS0O'EUX7\"Z(/"_P /X$&K:_=Z
M:UDFIG]U/YTN6W.GS E#Z8&,#M7JW@WP_J/AGX>Z3X;O-1BO;O3K1+5;B.$Q
MHP087Y22>@&>?RK@+#X7>++72_#=G)K.E9T?7YM:=D@D_>K(TC>6/FX/[Y^?
M9?>D!V7@+QAJ7BA=<M=9TF'3-1T:_-C/'!<&>-CY:.&5BJG!#CJ*J?%+7YM-
M\,Q:%I]Y':ZQXBE_LVTE=]OD;E/F3GD<(@+?7 [T_P &^%O$&@^)_%FHZK>6
M4UKK=_\ ;84M]X:+]VD>TYXZ(.G>N USQ;X<3XS:C-XP:.^TW3;7[%:6O]BW
M=RUO*2&=PPB:,EN!D'@*!W- &A\/_B)J$7P#NM4FMDU?6O"B2V-] LX0R-;\
M%MQSU0!L]ZP;[XN_$;5;7PU<6G@-="M-6U6RBMY[O45+7:2*S[0%0[ =F"3D
MX;IZ</=:UH]AXA\<S^']8AL-%\66WV?[%)H6H1B!_+V>9A8<9()) [FMK5O&
MF@WGP[\%:;#KRQ:]X8NK:Y4RZ-?FUF,*,F#^ZW#(.?J/QI@=]8^+]&\.^*OB
M?X@U+0I;*_TN.RDOF2[,XNB8B(UC4@;,\+[D\XI/%_B77]=^&WCC1_$?A2XT
M&6#P^VHP7$%T\J,2KD)Y@5<2*R#*\YSZ5YA?>(O#_B"7Q[;ZKXIM[:V\6V]N
M%FMM+O=\,L"JJ-M:+&TD9.&XZ GK5MOB!-JG@#7-!\3_ !!L+J[N=,?2[5;?
M3+Z.)MPVM/,3&27QT &.OKP[ >I:W\4(?!NG:1H=K8PZCJ8TB.]ECN+Q;4*F
MT*H!*MN=B&PN.W)'%>@>$_$-OXN\'Z9XBM[>6VBU"!9?)F4J\9/53[@Y%?-.
MI>.[6Q\2:-XJ\*>-=(AU5-,32=1L+^QNS;2HC$I(K"(/D%CU]3SUSZCH?QF^
M'VE^'+:PU'QVFHZDD?[ZXDM)XQ)(>3@;/E7)P!V&.M*P'&>*8=0^"_Q-76K2
MZN-7T/Q4ITZVM-0U!REA=,00?F8XB/<@94=/>]XK\!R>$/AGHUO-XCU.[U.Z
MU^R6ZO!?3H&$LP5XU&_*QX. N??K6!_PEG@7Q1;^+)_B'XBTB]U#58&L[%(&
MN6AM(, JJ[X1L;> S. <D#I@"L"/QI=/\-=#\):KXX\+W]WI&HVUVM_)=7(:
M2.&0.J%3;GG@+G/2@#W'6]6G\"_%?PY;I<32Z+XM=[*2&60LMK<H@,;QY/ =
M<J5Z94'KG/JW:O%-2O[3XF_$WP*?#MTEUIN@.^L7]S&I:-'9-D$08@?,V7..
MH49(Y%>U]J0!1112 **** "BBB@ HHHH **.:* "D-+10!\F_MJ''ACP@-F[
M_3+CZ_<7_/Y44W]M1O\ B1>#1Y>[_2+G_P!!CHH ]1_9F4?\,W^%MH(S]I/(
MQ_R\RU['7D/[-/\ R;CX5Y)^6XZ_]?,M>O4 %%%% !5:7_6P?[__ +*:LU6F
M_P!=;_[_ /[*::W&BS1WHHI""BBB@ HHHH **** .4\2>._#_A2Y%OJTUP9?
ML[7<B6UM).T,"\-*X13M0'C)KA9_B=9^%OB3XFM_$_B">318M.L[VSB2S,AA
M#F7S&_=)NV@*F2W3UJ#XMZ+JNI^(DFT71=<BU>+32NGZOI+H4>4L^;6X1R%:
M(_(QW CDTS[#XE.O>.KJ_P##-Y+)?>&[6SC>"-/+N+A$F$BQ_-TW2KC.. ?2
MF!W6L?$WP?HB0R7NIN\4MJM^9+:WDG6*W;[LKE%.Q#ZG%8E]X@UM_CCH>C6.
MN-_86JZ%<WBPK%&0LB-&%D5MN3P^<$D>U>1ZUX8\>7_@YM%/@O5")/"%MI]N
MMHT4)-RB%76Y?<&=5ZHF2IW'C/3N=)MO$"?$SP3JUUX4U6WMM-\+RV=RS1HP
MCF;RRJ?*QY(C/XD#Z,#L/A#K6M>(OAA;:EKFH_;=0:ZNX6N!&B;@EQ(B_*H
M'"BN.\$_&71[.[U?1?'?BZ-]3C\076G6K26WEA8U8+&KLB[%S@X+$9Y]*Z;X
M*V>K:;\,X=.UK2;K2[R.\NY&AN5 ;;).\BD8)SPX_$5YY)X6UZ[\&>-_ 5SX
M/OI+_6O$$]Y:7;JGV:.&29&6;S<D J QV_>SVYI >O7_ ,2O!NEZQ_95_K A
MF$ZVKR^4[01S-TB>4+L5S_=)!KHM4U;3]$TJXU75KR*SLK==\DTAPJC_ /7^
M=?.4/@O4M/\ %'B;PYKGPVO?$Z:EJS7^G:L;HK:;7;=F<"08V>P).  .E>L?
M%C2O$&J> (QX;L4U'4+&_M;X6+,$%TL4JN8^3CMGD]J ,7P_\2(]2^*'BKSM
M>=?#&F:5;7:I=69MOL[.S[B2ZAF!"J0>AW<9KHIOBKX/71=9U.WO+B?^Q81-
M>6HLYEN(U*Y4^6R!MI'.[&,<YKR7Q5I/C#QMJ_BN^TWP/JUC_:>AV*VZWQC@
M\R6"Y:5X6P^5W#Y0?Q. 0:V=%\/S:QX4\7W&F?#C4/#>HZAH<MBS:K<,\]U.
M48"--TC'RQ_>..O'0TP/0+;XJ^%?^$0TOQ#J5Q/9I?VXG6#[+-)(H"JSD*$W
M%%W#+XV^])J'QA^&NE?9OMWBZQ@%S;K=1$L3OB8@*PP#QS^63V->2S6.L+>>
M$M=U3P!XGU#2(]!71KJSLV:*YMYT*G?Y:2J3&W(R2/NC/;/0>']#%M\3/"\-
MQX!N-,TJWT"XM/)-M]H@M&DG1TC,OS#.P-DYQDD4@.XN/C#\-[.\GM;KQ;:1
M307(LY5.[Y)#V)Q@#D?-T!.,U=L?B)X.\0VNM)H7B:VEFTV(O<2H"1",'$@R
M,.O'5<@XKQKQ'I.K7^B?&.WM_!VJ//K%[ UC_H+?Z2BI&F0<= 48^V<UTVF&
M\'QBU;5T\,:S;Z=-X6AM8Y38NJF5"\ACQ_>PP&/7(H Z3P_\1O#VC^#M ;Q9
MXWL]2OM1@DFBOEMVMTNU0G+*F.,# 'KQCK70P_$;P;=^%H_$UKKT$VF2R_9X
MY8U9F>7./+" ;R_^R!FO#O"NDZY;CX+V]_X1U=!H9O([_P RR<I SH C,<<<
MD'T&#SQ5%=!\3QZ1=ZM;^"]:N;6P\8W>IOIT;26<\MK/&R+)"RL&)&[) P>2
M.E/0#Z"C^(/A&;PI_P )/'KD)TKSOLWG;6R)=VSR]F-V_=QMQGVKG/AMXROO
M%7BSQQ&VJB_TK3KV&*Q_T7R&B5HMS(P(#$AN/FYX]ZX*?1;_ $G3=#\5>'?
M&I6VFV/B(ZE=:0\C37URCV[1FX=6=OG#MG;G.!GZ=E\.)-3F^(WC_5KOPWJ>
MDVFJW%K/:R7L'E^:J6ZHW<X.1T_/D$!6 H^/OB+-:>/F\&Z=XJ7PT]OI<E[)
M=R6!G!F+!8U.4*B,9W,P^F16_P"'?BSX(U#0UDN/&FD7=W964=Q?S0N4B!SL
M+C=T!?@#KR/45BZQ>7-I\>+C5)=!UF;3HO#AL_M%OI\LT<DIFW[,J"#P1TSS
MD5YMI7@G7V_9T\'-I_A6YM]:\/:O!?7^GO;&*>\BCF:1D&X O]X,!R"01UH
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M%!H ^1/VUF*Z1X+&?E\^[)X[[8O_ *]%._;75#I7@LGKYUWT_P!V*BF!ZO\
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M2.9%#(R)(XX."",5U]YXN\1^$O%W@NUU*:U@\$ZIIXA:Y,)$EO<I#N5'DW8
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MHA;S-)*@,<1,4A*C.W/4<$D\"NU^,MO!<? _QFEQ$LJKI5PX#*#AE0E3SW!
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M&#S5N&SMK<$00)$"22$4#)/6O*[GXQ1OHGA>_P!(T/[5=>(M.EU""VN+Q+;
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M?AVS7;Z?\6O"NH>*;308VND^W326]G>O 1;74L?WD1^YX.. #@X)HU V-6\
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MT,I!>%F51E#R>Q'8^D_B7XDZ+?:%(G@KQ[X:@U;S+=E>^N T?ER.!C Y)89
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MYBC%%P/"H?"WQ,\-^.[;Q9I>CZ/JO]HZ:+"_L(;C[+':,LKO&T;%3N0!]IP
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MO'FK[5[_ (YS2XH ^69?"=G9?LPZ&+3P+<#Q*KV4=PJZ1)]J+I<*\F[Y-Q&
MW/3L*[+5K:\3XW:[<-H.HW%KKOA5+.UGCLW:(R!I69';&$."OWL'D"O<]O-&
MT4[@?)^GZ?K\'PL^&-W)H/B(6/AR>6#5[.UMI(KM&9&19D3 9PA8YV@]?:M&
MU\*Z%;>,/ ,5EX%U>'0%U&_N'74;*6X<K)"H624$'RP9,D*<$8!(&37T_MHV
MT7 \?^!\+VFF>,+0:;=:?"?$-W/;13VDEN#"Y!0JKJ !CL/QQFN%\1:#H4_B
M3XL6GB/PA=:CJ^L.BZ0ZZ:\KSC[,H7RI-I5<..3N&,<]*^FMO'6D*@F@#X[N
M=/\ $&F^']2T;4=(UB#5+*^TN2:&TTV:Z%ZL MP]R\^UA@!6PJ%3QT.37LVC
M:B&^.OBC5)+/4(K230;-8I9+&959D:5W4$K]X!U^7KSBO7]HI BCW^M%P/EG
MP+]MT+PQ\,=1U[2=131M/DU&"]CFLY?]$N)'S!(T>W."I90V"!O[9INI^']0
MA\(^+]572;G_ (1>X\66=_8V@M78I;K*GGRI#C<$8[C@#D#.,&OJC:*4*!TX
MHN!Y[\2+,^)/@7XAM]+L9;AKO29&MK8V[+(QV;E41D;@W P,9!KR%=2L=8^(
M^FZBN@ZLVDKX+GTV:672)PKR<'R^4YX!'/'89KZ@VC&*0H"V[O1<#Y.\+Z+9
M:3<_ Z[LM"NK.]B$XU6=+*1)%)AVXF;;G&_@9./3BJLRZ@VD7VH'2-=N-+M?
M'ESJ%Y#:6;I,+>16$4Z(R'>%;#=.H[<5]="-!T&*78*+@?-IT7P\O@ OI3^(
M]'L[[Q$M[9ZG=6GFM]H\ECY[VY0;8205Y R2&X'-97EW5UX<T.>]5?#FKVNH
M:E+::A!I;RZ;?<!6:6%AE!,&;'3[K8ZBOJC:,8I#&I &.G2G<#RGP[%XAOOV
M;8[;3=(&@:W-H\T=K9QDH()2KB/;N^9<G!&>1D>E>?Z3966N0?"B+P=I<VE>
M(='N$75@+5H7MK98R+F.<D<[W "YSN)R.]?2VQ<8' H6-5Z<4K@?(.JR:;:>
M$?$?ABZTBYANSX]-S)"MA)AK0W:ONW!<%=@; !Z"KWBS1A;ZY\5-*\$Z7-!:
M7.EZ<PMM.B,0N5C?-RL0QM+^5D'@DYZ'-?6&T=^:-@HN!\@^(=/\&ZAX#\6Z
MYH%MKUS+>:?!;S+J%F(4CG611'$L:1KNF5?,RPSM'?FO1OB!\.]!TKX<6?BC
MX>Z+%!>^'KU-?M8K5=WVG&WS4[DAXU[<Y45[QY:\\=:-@QZT7 ^7]!\&^(E\
M<3^'=6T:*/0O&DD7B:]B6(%; Q/NEM3V)+&!2>XW'%1Z?#X=E^&/B[13J:Z'
M8_\ "9RR6\RVXF@@02J\3R1G ,!\O&?NU]2;!33$FPIM&#UXZT7 ^07U"]3P
M[H$^K:8MCX6L?$5TNK7WA^W\VTN#Y*B*[$;JZ^7N)R-I4,I(P<5[=\'M-T'3
MO#6H+X5NM3NM%EOY)HKB_01K(752WDH$0+$&R  N,AL<8KT\P(R[6&1Z4]8U
M4848%%P/E2S\+:3<VOQ@USPM:M)XFTS4+D:6UM.X>%7MU5S& >K9D'3JHQ]T
M4S16T*;P_KWB'X6ZMJ]WXD;PY+;R6L=JD$=NR $>;MB0-."2%)). :^K!#&,
MX4#)R<#K2)#%%N\M%3<<G:,9-%P/F#P[>> -=\1?#&V\.VD$U[]CO(-3#VQ\
MQF-H=Z3.P!=BY;(.<Y)[\X7A?6-!@^&WPKTBX(37]%\3*EW$8&\ZR4SS;D8[
M?D!^7@D9P/2OHK6_!U]JGCSPWXBMM5@L[717ED-K]CWM.9$V/E]XQ\O3Y>#Z
M]*Z\VL)!_=KR=Q..2?6BX'R-XGD\+GP'\:(X;ZVPFN126OEW)+;F2,$J<Y//
MF<<C@CM73>/]'\*>$_$'A70[N[32/ EW:7<J2SQ&]MS>.R-ES(6 )3=M;L2<
M5]'-IE@RLK6<#!CE@8U^8^IXI\MC:W$(AG@26(?P.H*_E1<#YNL[WP_IVK>!
M=!\6ZI/?> O[)N/L5YK2;(;RY\TJAEW84CR<E W8@]<5W/P"N-&;P+K%IH4R
M26=OKM^L2JQ;;&9F,?)Y(*XY->K7&GV=U$L-U:Q3QHP95D0, 1T//>I8;:&W
M4K#&J*220H R3U-%P/ECQ)HOA/4$^*][J5]+'XIMM6=]&ACO7BG$_P!GB\HQ
M0JPW,S\9P20/:M;4-"\0>%?&"Z5IEF\S_$33$MK@DETL;Q,?:).3POEO(^.[
M+TKZ&ET?2YM334Y-.MI+U!M6X:%3(H] W45R^A^$=>M_&E[XB\3>)/[9$;S)
MI5NMLD*V4,A4L"1R[?*HR3T!]31< \8>']-C^#.M:!'9F:SM](DBAA;<Y^2(
M[.>22" <]<UX7X?7P;K6E_!3P_;ZI 86BG6_CMKSRW,IL1N5BK!@2?E(XSG'
M>OJPJI4KC@UAQ>$_#,+Q21>'].1XL^6RVL8*9))QQQDDGCUH ^:(]872? XT
M6#7?L?A2V\9W6GS74TC7,=K; $PQO\P/E&3&26 ]<C->Q_!NUL=/\.:I9:9X
MS?Q981W[F&Z$9$4(*J3#$VYMRK[$XSBNW7PKX;73KK35T"P2SNQMN(%MD"3#
M_: &#^-:%CI]GIMC%8Z?:Q6EK$-J0PH$51Z #I1<#YYT5A??';XMM:^./^$=
M(-BOFQ_9SN(@8$GS5/W3Z8Z\USVD:?JJ_L^Q>)-#60W/@_6+BX\VTF=(]=MD
MFS-(P!.[>-S>Q7CBOHR3P%X)FG>XF\):/+,[%W=[&(EV/4D[>365XP\*^(=:
MLK'1/#NN6^@Z&RO!J,<5J&ED@( V1'I&<;AG'&<]L47 \T\6SOJ7[./C;QG=
M&2W_ .$B075M%+(?W=ME$A&TG"[E&\@=W-<K\7M>\J^UV?2/$'DWNCZ?8E6G
MU)H!;NQ# VL2$;V92-S-P  .<G'TM>^&M"U+0H]#U'2K:\TV-55;:>-70!1@
M<'TJB_@#P7*VZ7POIDA^R?8/FM4.+?IY0XX7':G<#S7XB:Q#X9\3^%OB%'<7
MFI:'J,4FCWL%E<.Z2-*F8)$56"[BRLFX?WQ7._#F?Q*VK#X>^+6O8KSPK=R:
MQ/>?:96$UL\9, :0M\_SR'@Y!$/2OH5M,L)+."S>SA:WMRC11;!MC*$%,#MC
M QZ8IW]GV/VR>[^RQ?:+B-899=@W2(N<*3W W-Q[FE<#Y[^'&N+H'C15\7:L
MQ"Z++>1ZS'JK3:?J,'FH?M$B2-F&4$@= #DCL*^BK>XANK:.YMY5FAE4.DB,
M"K*1D$$=17,6GPW\":?9ZA9V7A/3(+?4H_*NXTME F3^ZW'(]JZB&&*W@2""
M-8XHU"JBC 4#H *&!-1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC% !1110
M4444 %%%% !1110 444=Z "BBCM0 =Z0BEHH ^1_VU%_XE'@QCG_ %]T..GW
M8J*9^VH9/L/@E58;/,O"5SU.(<'^?YT4P/7/V:L']G+PM_NW';_IXDKU^O(/
MV:@/^&<_"V#GY;C_ -*)*]?I %%%% !4$O\ KH/]X_\ H)J>H)/]=!_OG_T$
MT#1/1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBD/M0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?('[;+
M[;7P0HW??O3QTZ0T4?MK!/+\#Y9@VZ]X'W<?N/UHI@>P_LV-N_9S\*]1\LXY
M_P"OB2O7J\A_9O3;^SMX5 S@QS'\YY#7KHI +1110 57D_UL'^__ .RFK%5Y
M?];!_O\ _LIH0T6****!!1110 4444 %%%% !1110 4444 %%%% ",V!7D\W
MQ5U-_"^I>,--\,Q7GAVRN9;<3&_"3N$?RVD\O80%W _Q9QSCM7J[@%"#7ROK
MQL]#T?4/B3\*?$BV4UW<YU'PK=ND\5W*9 AC6$9*2%LD8Z]L"F@/J99%**V?
MO<@4\L!U-?*.NW-MXB\9^)[7Q;XX?PGK=K>0R:=:FUS="'RT9%MFW#)+;P0H
M.2><UT>H7WA?4/&OC72?B)K=QI>LV]Q;/HLGG^5<"V$:%/LPZ%VD#[@H)).#
MVHL![@WB"RFOM8TO3C]LU33(4EEME.WEPQC3<> 3M_#(/>I]!OM0U#P]87VK
MZ;_9=]/"KSV9E$GD.>J[AP<5XAI=EX7T_P >_%V"4P:=>SV\,L8\WR9A&;;<
M[## _?Y+#O5'PMJ46JK\+-%\37!N/#U]X::1&DG)CN;Y0@*R-GYF5-Y"G/))
MZCAV ^D2P H# ].:^6C+._A/P_I^HZY=_P!ECQVUEI=PMY)&\VGAW &\,"Z@
MY ;)P ,5Z9\*/L.G^)OB!X>TV[>33M.U:,6UN]PTQA#V\;.!N)(&_=^.:5@)
M=<^+=QHEQ=:@W@S4[CPK8W)M;O6DDC41LK;'81$[V16X+#T)&0*]21UD174Y
M5AD'UKQOQ]XR\'Z[JK^![KQ=H]CI<#";76N+E%8HA#"W0$\LQ W8Y4#'5A7J
M%KKVBW.JC1[;4(9+\6J7GV<'Y_)8X5\>A/% '.>,/&U]X2UW0+%M!^V6FM7B
M6$=X+H1K!*V2 X*\9 .,9R1CCBKNM^*+G2_&/A_P[!I)O6U?S6:59POV>.,
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M..]>965]XXT9_&7@'Q3K$>O36GAJ;4-,UZTW172QC<%24J<AMP!!SSMSDYX
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M&F.%&3M'0G&=N !Q7H/AC7?$%G\7M:\ ZMJ#ZO:1:=#JEK>RQHDD89RC1/L
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M^5"ZLFXLY8_+T'&*+ ?4>:,U\_7VK_&"UTKP;H]UXFTZQUO4M5FTRYF6UCN
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M?X-^)7Q#CU'P)?>*M5TZ_P!.\5:;=W!MK>T,;P&"/S P;/S,P.", #'XUO\
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ML9=SWDE&1C&?O>_(!N>$?!#6_AC7;3Q;:6=W<>([V:^U"U3,D"^8%7R@6 +
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M,#4D^&/A:;6=6U>XCO9KK5]/_LR]\R[D*S0;=N",X!QGD=R3WK,O?@MX'O\
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MC4^H_%GP;:>'-6UBTU/[;_9MK]L>"*-][QD$HP&W)1MN X^7WK2A\?\ A_\
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M06RQ7%LMXDD>Z11 W E8J"%0_P!YL#WHLP+7C'P7H?CC0TTK6H9=L,R7-O/
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MV-[IPL2,L.07;LN0,GTKF-:^"GA37;W5[B74M:M4UJ()J-O:7IBBNG"[?-=
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M .3C)ST!Q7-0_!KQQ9Z!;W%CX@TZV\2Z;KESK%A.D;F!A/\ ZR&4'D@^H_\
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MU)=,\+Z?X4\*KX7\5/:PIJ=]>:5<>([=6L;Y3&OF1E,+Y:$L0I"CD-C[PIV
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MYLXP.GK7SKK/C'5?#_QQD-Q?6<>NZKX8L]-.IVZ[[.UNGF8&5B?X P. 1R<
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M!7DJ/X<\X-0:9\9[K6-;L7TOPM=7WA^]OFL%NX(YFE3#E/.8>7Y?E;E/(<D
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M=-FT1D@\AR0,$@5SG@/Q?8^ /A_K<BV;W;77C&\TZT@C) W%OEW'!(550DD
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M&4./D!QD@')Y[YI@>^?\(!X'^R+9_P#"(Z-]E67SUA-C%L$G=P-N,\#FI?\
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MO'-EJEUH%O8Z?>3#6[-K^.5!&4MXAMP92'XSO4#&<G/H<=?2 **** "BBB@
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MVG^,/A9XKU&S^'^IZ?>G0QI\L]WI[I+YI8>7;Q@#+J"6)8# ^7UX^E>*3 I
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MI%P8QXXDNI(I=.E(CM_M,K9;*<+M=.O7-?45KJNFWUW=VEE?07%Q9L$N(HI
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MEO+4,!\Q!QGTJUI>CZ;/\5O #3^)+S7U@T6]C_M.2Z>,W#0W$:AN&Y&<@]F
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M. #76^&OA7J7AJ Z?;^.]5N=*ME9=,LYXXRMF"I4 MC=(%!.T,<#KC(%0?\
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M %JE 5'4X&#^.*@NOAWX^O\ X/\ C70FT..WU34?$3ZQ:P-=HRSQM,DFPL.
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M=% &9#HFE6\44=OIMK"D4GG1A(54(^,;AQP<$C/6M,# HHH **.]% !1110
M4444 %%%% !1110 4444 %%%% !28YZ_A2T4 %%%% !1110 4444 &**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+32#F@#XI_;4,O\
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M]%(#D4M !1368*,G]*XS_A8^@G1Y=5\C43!%JG]D,JV;M()]^S[@RVW)ZXH
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M8[?-)9OE4#;AE!( KTP>#?C%'+))#\2M&WRX\QSX>4&3 P,XDYXXK-@^%GQ
MLS%]C\5^$[=8F=E$?A2-=I;AL8D[]_6@#0^#GB#1]/\ A-H<6H:G;6LE[J%W
M;P"60+YLK7,K!%!_BQVKUJ21(XR[L%4#)). !7G_ (,\#WFD020^*&\/ZIY=
MREU9+8:.EHMO* 09,9;Y^0,C! 'O7?3V\-U;O;W$*30R*5>.10RL#U!!ZBD!
M\X^,M'\2_$C3/$WBS1M-TN>"%U71+Z6]82P"SE9BR((F&9)%?^,979GI4WB;
MQ@WCWX7_  P\36>KW6ESZEX@L;:[2QNVB +,RRH<'!P5R >G'K7O5GH.BV&D
MMI%CI%E;:>P96M8H%6(AOO J!CGOZUF_\(%X'6VCM5\'Z*((I/.2,6$6U'_O
M ;< \#FBX'BNG^$+W6;;XI?#_2/$^KP?V9<VTVDSMJ$K2PS/;;B"Y.XHS<$$
M]">_-=C\)]7N/'#Q^,YK6\L(;*QCT=+229BIG3FX<J3@X;"!CR=K>M=%XG\+
MZO;V<UY\-8-!T'7[NX1KJ^N;('SHN2P.P99LX//O]:Z+PQHJ^'?"^GZ0)S<O
M;Q 2W#+M:>0\O(?=F+,?K1<#C_B[K-YI6B:!:QW$MG8ZKKEKI^H7<3^6T%O(
M3NPPY7)"KN&,;C7E?CE]9\(#QYX7\.:]JBZ)9Z#%JD4K7DCRV%TTNP1B5B6V
MNJEMI/TZU])ZAI^GZMI\VG:I9P7MI.NV2">,.D@]"#P:R/\ A!_!YT>;1V\,
MZ8VGSL'EMS:H4D8="PQR?>BX$?A#PW_PC>G749U_5-9-Y/\ :3+J,XE9"54%
M5( PO&<>YKY]^*7B_6(/%GB#5]#\0Z@IT'5+"R3-U]GAMF8KYD2Q*2)]P8EF
M<#;C S7U#;6MO9VL5M:PI!!$H2..-0JHH&  !P !7,ZI\.? .L:M<:IJ_A#2
M+Z^NU"S3W%HCM(!C&21UX'/7@4@/./MD;?'?XB3KR%\*VV"#_P!=6X]?K79_
M!0C_ (49X-7!W?V7#G/^[G^M;/\ PK_P69KJ?_A%]-$EW +6=EMU!DB P$./
MX0 !CVK8T;1=*\/Z5#I6BV$-A90 B."!=J("<G ^II@>57DEUXR^*GC'P[>>
M)-3T:/P]:VLEBEA<F 'S8V=IGQ_K,-@8/RX7IR:X"[N-5\>^'_@UKWB*]OK7
M4;W5V@D:UD:!9%"3;9E4?=9@H(([,?6O?M<\#>$O$6I0ZGK>AVUU=PH8A,P*
MLT9ZHQ!&]/\ 9;(Z\<T:IX'\):Y<Z?=:GHL%S)IR[+3.0+<?[*@@ \8SC/:B
MX&TUJK:6UD9YL&+R_-#D2=,9W>OOZU\R:?I4UK^S5I.S6+UYKOQ+;KYMQ+YW
MD$:F0&P> >A/J:^IAM"A!].*XEOA1\/VM+BT_P"$9M4AN;L7TJQEDW3 DA^#
MV)) Z#)HN!Y'XA\6^+?!?B?Q5X>M/$MS?VWVG2MEYJDB;K/[2[)*=RIA4PHQ
M\N%SD"O3OAY9>*M)U/6M*\1>)+;5K<>5<V<(N&N)[9'W!@\C(I92RDKD9&",
MX K3N_AIX)O[W5;V^T&*ZFU>(6]Z9I'<3(,8!!; Q@$8Z'D5?\+^"_#'@O3I
M;'PSI,6G02L'DV%F9R!@%F8DG Z9/%%P.:\=:U?'QWX2\%V^L3:-;:RMW-<7
M=N565Q"B[8D9@0I8ODD#.%X(KS.+4M:\-_#G4GTCQ'<+=IXZ:TDN'6-GN4>Z
M5&#G;@$@]1BO<O%/@OPUXTL(+/Q)I:7T5O()H269&B?^\K*0P/T-8LGPA^'L
MFA-HH\/)#8/="]:&&>6/=,.CDJP)([9Z4 <C8WOB^_\ BCX[CC\7W<>E>'IK
M2:"P2VB82AH/,>$L5SM/3CYNG)Q7*Z!XZ^)5YX3L?BA)KFD/I4\%P\^E27&[
MS&4.4BA00@K(I7!S(V1G\/;]*\%>']%\0ZCKVG6\Z:AJ6/M4KW4KB7 PN59B
M.!P#C@<"L_3?A;X#TGQ-=^([#PY;1:C=,SN_+(K,,.40G:A;N5 S3N!S'@MM
M<U73-$\03?$>:^M=?TXF6W,<0(N&0.&M\+\FP;\J=W09Y!-<-X US6=/\&?#
M;PO!XDO(O^$GN+YYKUQ&\L0B9W*1DH1EV.26#'[V,=O8/#'PO\#^#-5N=2\-
MZ#%8W-QNW,'9@@8Y8(&)" G&0H'0>@JI'\'_  ##I,^FV^BF"*6Z%ZKQ7$JR
M03 DAHG#;H\9. I Y/K2N!Y7JWCCQ_I][JOA>U\13%]+\3Z?IL.K26\3-<07
M(!,;C9M+ID9( )R,UM_$#4OB%X+L+*:3Q)J>J:3:6DSWVH:9;6YNX96<F*:6
M$KAH57((7;G:2:]$N/AAX.NM*MM,N-.E>&&\&H;OM<PDDN1TE=P^YV'JQ/05
M/X@^'OAGQ/J(OM5M;IKC[*;-I(;V:'S("<F-MC#<I).0:=P-W1;V/4?#VGW\
M-T+Q+BVCE6X"[1*&4$-CMG.<5X1X=\5S>&/@Q\0/B@+,7>M3:K>2N&^;&R7R
M8D)Z[$ !P#TSZU]!6]M!9VD5K;1+%!"@CCC085% P !V %<!H?@FXT7Q'XIT
MV2""_P#"?B.:2_:&3[T$\@"S1E>C1OC(]#D'J*0'/2:SXKTGQ=X.TV3Q5<:Q
MI_BNWGCFW6T*R6<BP>8)8BB#Y>V&# <<UPVE6VJS?#SX2I#KL\EY>Z_),MS<
M1HQB^6X)(4 ;B02?FSS[<5[7X:^&_AGPMJ$5[IL-W+/;PFUM3>74EP+2$G/E
MQ!V(1>!TYP .E4[?X1^";6:REMK&[A-A?/J%NJ7\ZK',Q))"A\8^8C&.A([T
M[@><W7Q&\9:-:WV@G5(-0OU\61Z##J-U&D!6)X5ERV%*!P25!V$<]#BF>)O$
M'Q@\+V>GV5[XDTV*XU#Q#96-M(D:7,RV\WF9$H$<8/S)P54$@'ZUZ?+\*?!=
MSIVOZ?>:;+=V^OS"XO5N+F27=*!@2+N8[&'&"N#P/2L__A2G@+^R++36LKXK
M:7*7B3_;YO.:9!A'9]V25&0O9<G&,T7 [;0;/5+'0X+76M6_M:_3=YEWY"P^
M;\Q(^1>!@8''I7S]K2ZA_P +"^.3R^(+R6*T\.QB.%UC*!7MI6"9VY 4DX P
M3GDFOI.- B!02< #DYKA->^$_@_Q#KVJ:Y?6]VE]JEJ+.[:VNY(1-&!M&X*P
M!.W*Y/8D4D!Y7HOBWQ9X/7P3IDWB&UETS5/"<UX%NK=5AL'@MU>-MR_,4P0&
M))S@D8Z5O_#WQ=XPO/'XT/6K^\FM+[0AJ<,E];0Q.)/-V;HT3!6,YR%?YN!G
M&:ZVX^#7@B\_LQ;NWOIX]-L7TVWCDOIF46[)L9"-W(*\'Z#TI^E_!_P;I.J6
M.K6T6HOJ%E;/:1W4^H322&-N@)+<[?X>R]J=P/.=%\;^/O\ A&_ GBO4O$D=
MU'K&OG1[BQ^PHB21/+,HDR/F#CRQC!  Z@\FO;O%"2R>$=5\B^GL'%K(PN+<
M R1X4G*Y!&?PKE+?X-^"[;1],T>%=36STJ\^WVD?]I3_ +J;^\/FZ9R<=,LW
MJ:[^XMH;JTEM+B-989D,<B,,AE(P0?J*0'S3HMMJ;_"KX*>3J\SWUYJB2I<3
MQK*8 UM,S # W=#@MDY/)-:=S\3/&FE:==>'5OH]1U8^+O\ A'8-1N(DA(B,
M*RAFP-@?DJ/EQWP<8/HUE\(?"&GVFB6EJ-3CAT2Y:ZLT_M";".1@?Q<@+\H'
M0 D=S2S_  A\%WFFZ_I]_:W-[;Z[=?;+E;BX=]DV,"2/)^1@,#(YPH':G<"3
MP _CJ&?5].\:7=E=>3(DED\4JO<>4P;(FV(J_>4@$*,\^E0>*-?U2X^(FB^!
MM)U!]*:]LI]0GO$C1Y-D;(JQH'!7DMDG!X''7(Z#PEX*T/P982VNC1SDSL&F
MGNIWGFE(&!N=R20!T'0<XZU5\8_#W0/&S6$^IM>6EYI[E[>]L+AK>>,,,,H=
M>=K#J/84K@>+>%-8UWP[X5TE+?48YOMGQ NM/O7DME+7"O<2;G'9"=IZ#^+C
M&*ZNU\2^/IO$WC34)/$5D-#\)WCAK%-/'F7<8MEEV>9N^7EA@\G.>V!6['\$
MO!L5A:6=I<:Q;1VVJ'6%\O49"3<%B0QW$],D>OJ2>:Z'P[\/]%\-ZGKE_:W%
M]=/KDOG7<=W.98RV,9"D<< #Z >E.Z \ST/QI\3;>VL/&.LS:;=^'+_39+V2
MW,B+)Y@A,J);!%W-T(*N2< G/%:N@ZMX_P!:\,Z3XF;Q58BPUO27N7A2V57M
M)V3>@@X._;\X8.3]W/K70>&O@YX)\*ZG+?:;9W,V/,^SVUU<-+!9AQAUAC)V
MID$CUP2,X-)X4^#OA+PCJ$UUI[:A-&=XM;6ZNWDAL5?(=84)PN02,\G'?K1<
M#@O!OB+Q)8?#KX8Z';:T!>^*$=FU"Y@5S;QI"TK*.S,Q  +9ZDX-&M?$+XB:
M4FMZ!#?6$VJZ/K6G6,=_)9G9=Q797 95X5ESR5ZCH >:[F/X,>%[?PE;>'+2
M^U>!+&Z^V6%X+QFN+%QP!$S9"J!D;<8(/.:?>?!WPU?:)_9LM_JR3/=I?W%^
MEUBYN9TV[)'?'5=JX   QP*5P.0\=>+OB%X#L]/;6-4$U@89VN-<L=+$D<,_
MF?NEGBW$I%LX++R3W]?:=-N6NM%LKIIXKAI8$D,L)RDF5!W+['J/:N0\3?#'
M3?$MVEQ<:]K5GNLAI]U':7(1+V %B5E&TY)W-R,'DXQ7:6=G;:?I]OI]G$L-
MM;QK%%&HX1%& !^ H \3\/\ CKXH>*)K#Q'I6EZ?_P (_/J4EO-#-)'&([99
MC'NW[]_G# .-N#R,=*S(/%&K>%;[QM_8EO#+J&L>-4TV R@%4+VZ$MR5!("G
M + 9(!]*[VP^#7A;3/',WBBSN=3CBGN#>-I'VD_8?M&<^;Y6/O \CL#SV%13
M_!;P[>:9XBT^^U;5[J+7+T:BQ>90UK<@\2PE5&UA@#OP*+H##D\=_$'P]I@L
M_$UC907NH:W:Z9IMY)LXBFSEY8HW(RNU@,, W'H:S?B-)\1K7PQ%8ZCXFTZ,
MC7K"*&:RA*R7-O),@7S4+?*0X/"G#!3TKM/^%.^'9_ M[X6U2_U757O9$FFU
M2\NB]Z9$/[MQ)VV8^4 8Z\<G,3_!G0[CP3<>';O7-:O+NXFAN&UFZNC+>"2%
MMT1#,, +S@ 8Y)ZG-%P.9U+Q]\3M3\2>(M&\#Z3:WLOAR6*V8RQIMO)3&'8O
MNF0QK\W&T-T_"I]6\7>+/%:>,M'TMM-TE/#VGI]KBNH6N3<S20>8T>0RA4 .
MW<,DGGMSN:Q\%=!U37X=;M-=UW1[IH$MK\V%X8SJ:* !YYQEFQD;N#S2>(/@
MKHFL:[-JNFZ[K'AQKRU6SOHM+G$:7D:KM3>"#RJ\9';BBX&S\'\?\*1\'?\
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M;4DC3R_/A ?ABG\+9&0#GM3 S[S6M)U[XG_##QI8MLM;W2M0N/,D^5A%Y,;
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MQYD6&)*'LQ SU%86M_%#0]%NM35K+4;ZRT=E35+^TA5X;$L </\ ,&; (+;
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M4=\XCM_!?C#3_&&JVDWPGT?7K#7KA+V'5=1,#/IS.JB1)ARS["#@(>>,'GA
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MS67XYT7Q?>:EXCBC\&Z],(O$EK>0Q:="B6<MI%Y1\T@$>=*P3G=G&%^[BBR
M]JL_BAH=QXU\1^';A9K&/0+>.>XN[F&2.+Y@S,2Q4 * %P21N).,XS3-3\>V
M&N^%O$\'A#7/LFO:;8O<JMY9O&\0VEED\N55+(>F[!'UZ5YCX]\+^,/$&M?$
MS2M*\/WJOK=CIMW9SNJB";R.7@9]PP['Y=H)ZYZ<UH:<JWWA[Q+K5C\+]=T7
M57T"2SN+B_$LUQ-*P.((59F,B Y);CM[T6 [?P+\1]/U+0/!FFZYJ1?Q/KFD
MQ7HC^SNHG/E[G8,%V#&#QGC\179Z+XATO7X;N;2;DSI:7+VDS&-DVRI]]?F
MS@G&1QFO#-0T_5+;X%?#[5-+A;3_ !CX<%FEK:WD9CD9VVVTD3*P#;6W_C@<
MXKVGPSH8\,^#K724E-Y-!&S2S/PUQ,Q+R2'W9V8_C0T!2TKXC^#M:UY-%TW6
M%GO)?-$/[IUCN/*.)/*D*A9-IZ[2:DT?Q_X7US6UT?3=1::Z<2-%_H\JQSK&
M0':-V4*X!(&5)%?._A>U\3)X[^'>L77@GQ)$-/:^2^@%EY-I9/+'M5(4  V
MG)<YW9SN)&!UOPST_6;'QYH*Z;9:[%H L;A[K3M:L74:+*VT^5;SNJ[D8\;0
M6X7/?A6 ]:USXB>#_#>IMINLZY';7**DDJ['<0([!5:1E!$8+$ %B!6SJVL:
M?HNBS:QJ5VEM80)YDDS9P!VZ<DG(  Y)-?-'QFT[Q+JFM?$'3[3PGK+)<V-E
M]AFTNS+1Z@$.7,TF,G9N(5%(^AQ7LOBU8-0^"[1ZAX?U:ZMIH+=);"T1EO(T
M+H"RJN2'3[^.?NXH V8O'WA>;3;G4!J+106LJ02K/;R12+(RAE3RV4.6(92
M!DYJA)\7/AW#IUKJ,WBJQA@NIFMX_-8QOYB_>4HP#*1GG(&,C/45X7JVC^,6
MTZ'7'TW6/$VDZ%XCCO-YM9++4K^W^S>69" J.SQD[0V 2%[@5?U?2]+DO_"F
MHZ5X!UVUTV;Q4NJ79O;:XN9Y56%E:>53O9!N( !()VYQ3T ]=T3QE9^(OB)
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M%SG@>Y8'L_04<5XKJWQ5\3:#8>.-/U'1]-FU[PO9QZBC12NEO=6[@D, 06#
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M2>G6N;T+XIZCK/Q,N-'F\.7>F:)!H\>I//=M$KQ!RQ#R#>=JX4K@9(/7 YH
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M%G+XWY4#Y3QR*W_&'Q%T+1?!TVI67B/28KVYL6N]/^TS#9,-N5; .=I]>!G
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MK$C;(54?-@]S[5Z<NOZ-Y%K*VKV:+=#]R6G0"7M\O///I4]QJVF6K,MUJ%O
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M=>(H&TF73FT34GTUUEE5S(516W?+P!AQQDUU]( HHHH **** "BBB@ HHHH
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M5Q\^=XYXZ9/O[KD5SOB[Q98>#M!_MK4;>ZGMO.B@*VT>]@TCA%)Y&!DCGWH
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M3QK<>*/#UIXC>]FTU;:\N-5C>*.#:R[( &50SC#<KD #KR*]IVC.>]!49!H
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MT3M4@%%%% !1110 4444 %%%% !1110 =Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H-%% 'PW^V>J_P#"Q/#>2V?[,/3I
M_K6HI/VSMW_"S/#O3']E<?\ ?YZ* /K/X5_\D;\&=/\ D"V?W>G^H2NRKB_A
M2L@^#7@OS4"/_8MGE5Z?ZE:[2@ HHHH *KS<30?[_P#[*:L56F_UT!_V_P#V
M4TT-%FBBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH :>:4#BEHH **** "BBB@ HHHH
M *0 #I2T4 %%%% !1110 4444 %%%% !1110 44=Z* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0
MTM!H ^&OVS2?^%F>'=S?)_9/IW\YZ*9^VAM'Q,\/-N /]DXQ_P!MI** /KOX
M9J$^$?@] ^\#1K,!O7]PE=;7(?#)=GPA\'(.0NC68YY_Y8)77T %%%% !5:;
M_6V_^_\ ^RFK-5I_];;_ /73_P!E--;C19HHHI""BBB@ HHHH **** "BBB@
M HHHH **** *M]>VNG:?<7]]<1V]K;QM)++(VU44#))/88KF]+^('AG6-3L]
M-M+JY2YO@S6RW-G- )U5=Q9#(@##'.1ZBK'CRRT?4OA]KNGZ_=FSTNYM)(;B
MX'6)6&-WX9S7D>GZYXT^'_B#PYX7\?:=#XCTY&ECT7Q!9DB9I$@?"31\_,4W
M#(.._.": /H+-%> ^#_$'Q+UB'0/'DFK6;Z%J,$LU[8RW2L#\K-''"@A!1U/
M!!=LXYZ58\&:MXN\7>&= \;MX\BM+/6EGCOM/*(HA=MPB2V.W(D0KSN+9Y..
MU.P'JOB+Q;HOA?28]4U2=_LDEREJ'@C:4^8[;0,*#QGKZ5T"ME0?6OEKP[JW
MB7PW^S-X9US2?$5RMQ=ZS''-Y\4<I9);PHX!*]\DYY.3QBNOF\4^+?%%U\1[
MG1_$0T,^$)VMK.V6&.1)F2/>TD^X%L-@J-I7&.YH ]VR!WI<U\[MXN\>>+?%
M.D6&F^)U\/VNJ^$EUR2);.-GMI<IPC/ZG/)S@9XS@CO/ /C;4-2^ FF^-]:A
M>\O5T^2XN%MHR7F:/</E4=2VWMW-%@.U?7](C\20^&WU",:K- UTEKG]X8E(
M!?V&2!SUY]#6L3@$U\J^#?'&G2?'30=4U2+6IM:U>QN8KDR:;-&D<DDL CBC
M5ER(D"8W=,Y8X+5]4JZLO!!H8'&7'Q.\$VNKWVDS:X!>V!Q=0K;RLT/INPIP
M#V/?M6I#XP\-7/A2Z\46>LVUYI%K$\TUS;OYJHJ EONY.0!TZUY[X-(;]IKX
MH+Z6NF=O^F)Z5QNH7FI:/\8OBW)X.O5LK2V\/+J%VPB$L<>H*F5.T\;FC!S[
M]: /H?3-2L]8TBTU2QE\VUNXEFA<J5W(PR#@\CBKU>!+KGQ&UK7_  ;H>C>+
M;;2VU;PN-1GFFTY9RLRF/+=0/FW8QT W<9P0V;Q?\4O$FK>()_!\MI%'X?U=
MM/-O<O$D$J18\UI2P,@+9)4J0  .IR:+ >_YJ,21L[(K LO4 \BO%+;Q?XT\
M5:YXJO-#US3](MO"^K1V#65VBF.:) #/+*_++D,=FW ^3G.3CG+/Q)JW@U?B
M_P"-I-8EU5K+4X[6*VN%01AF2%(W)4 A5W@8!' ]>:+ ?25&:\-\1^*_'GA#
MQ#I6CS:Y:ZLNOZ9=S0W,EF%^QW-O%YA(52NZ)@<8))'J>\5KX@^+,/PCM/&%
MQ?0:M-J<-A<K;:78J)[2W9=T[(K$B60J00.@P<"@#W1W6.-I'.%4$DGL*XO_
M (6M\.3&TG_"::3L7@O]I7:".H)IGPQ\0R^*/ ,&KS:[!K9EFF"W44/DDH'(
M57CP-CA<!AZYQQBO-?A]-XRC\,^(X=#\/Z5?V4GBN^CE>6[(E\MKO$N(S'M.
M%+8RXZ?A0![(/%WATZWI^B_VM;'4=1A-Q:VZON>:, MO7'\. >>E=!WKP_QE
M)I^B_&WX8RVL*K::?I6K^7'#R%2.&/Y5^@!%5?!OCWXH>(G\/^*AH]O+X6U5
M));T'RD%FG/E^4PD+N>-K;DY(X H ]ZS2!@>AKQ_PMXA^(7B;1=&\4QZIHL>
MCZY!+(8O)(?3LK^X"G=^^;/WP<#(XKDO"?C3Q9HGP8\#K#/_ &OK'B:[DCCD
M%LOF0C][+(Q4R*)&^4XY4<YYZ$ ^CB<"LK3]>T;4[^_L-.U*VNKG3W$=U%#(
M&:!CT5@.AX/%>5VWCWQ]#;:9H.N:5;:9K^K:PUA8W5PJLCVZH93.\22G#;5*
M[0W+$=JL_#"WU&U^*WQ-AU:[@O+Q;BPW3P0^2L@^S<'9DX..O/)H ]*M]?T>
MXUVXT*WU*VFU*VC$LUJD@,D2GH67J,^]:H^M>&:XOB[_ (:)UL>"VTB"\/AF
MU>2348W=>)YMH"H0<GIDG@>O2IM(^*NL3WO@G5M86ST_P]XELYO-8QL7M[R)
M23'OW[=C!6(^7/RX[Y ![1/<16T$D\\BQQ1J69V. H'4DUDVGBKPW?6EQ>6>
MO:?<6UL-TTT5RC)$/5B#A?QJGX*U'5M9\%Z?JVN1PI=7T7V@1Q1-&%C<DQ@J
MQ)W;"N>>N:\C^%NHZA9^'_%]KIW@J74K2;Q#J0DF2:"-#^](VE68$@#';VH
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M5P5X*MNZ'G%=)\7O$GB;PSX(34/#<5KYTEY;6LDL\K*T:RS)&"H"G));!SC
M.1DC%%@/1!/$93$LBEP,E<\@>N*FKYTN-6\1>&OCCXRU;2_"]MJ5^/#]E=WT
M"7ODQQA3*7*NR9=L  #:,XYQWZ/Q%\=;#2],TR?3-+6[N[W1H]<-O<W/D8A<
M96-2$;=*?FP.!\IYHL![143S1QL%9P"3@ GK7,Z/XTT_4_AO;^.)XI;"Q>Q^
MW2I.,-"H4LP/TP?K7C?B+Q!JWBKQO\*?$C^%#865]J7G6-Q+>YD9#!*RQRQA
M<(6X8$%L &@#Z/HKQ^U^,%Q=>#?#OB4>&_+CU77!HDT(NP3;N9S#O!V?.,J3
MCCM45G\7=<N_$?B#3(OA_J$MMX?NI+>]NH;F-BH6(R*50\L6QC:#QN7UQ18#
MV6F-(JL%+ $]/>O'=.^+NJ:E>:MHZ>&[>#6+;11K5O"VH;T*$X,<I" QNN1E
M<'TS6!8>)KSQ'HWPFUOQIX=DFO-1U!)+6^M;\1QQ2-&65FC R01N&TYQMY;G
MDL!]"45Y3K?Q4NM+BUW6+7PS)?\ AW0+HVE_?+<A9 5V^:T<6T[U3<,DL.0V
M!Q4.M_%S4;/6]6TO1O!=WJ[:=IT>JF>.\BCC>W<,=PSDYPAP,9/H*+ >N45@
M:3XHTW5/!-IXL\SR-.N+);XO)QY<93><_0=:XVQ^*_VB?PW<7^@2Z?HWBB3R
MM*O7N%8R.REHA(F/DWJ,CD\D XHL!Z<9%5@"0">E/KYWT/2KWXB_%+Q5<^)M
M*O;-]&U6W2VN[35,&R\N*-Q"JC@JY8EB!SNQU KM?&/Q:A\(:KJ<,VAW%Q8Z
M5]F^V7/FI&29C\HB5O\ 6D#D@8Q[T >IT5YGK_Q.O-'\;S>$;'P3JVKWXL?[
M0B>&2%(I8]P4G<S_ "@'CD YZ U5T/XPV^O>(/"]A%X?O;6R\26CW5G?3R(L
M9**2\9&<[U(QCOUZ46 ]6HKG/#/B%O$FAR:LEA);QBXFAB5G#><L;LF\8[,5
M.,]L&O-U^/EFCW<USX+U^#3+#4_[,O[]TC\NTDW!1NPQ)Y(SC.,CGD"@#VND
M9MHS7C^O_'GPGX?UJYM)DEGLK.\73[J\BFB/E3'J/*+>8RKD L%P.>N*IW'Q
MFTKQ /$&@V_A7Q48[.2[L;J\LHD_T=HXRQ(D#X4D [3[#UHL![8&##(YI:\F
M\->-=*T?X7^"8],@U?6[O6;55T^VGD1KN<!"[/(Y8*, <MGT'>M"W^+6AW/A
M^2]_LZ_CU*/4AH[Z2R*+D79Z1_>V_=^;=NQ@'F@#TC<N[;GFEKQ_X8:AJ5_\
M4_B0NH1ZI:K!-9!+/4)Q+]G)C=FV;6*A3G(QVQ7L%( HHH[4 %%%% !1110
M44=Z* "BBB@ HHHH ^%OVSOE^*'A]O72 /\ R-)11^V>Z_\ "SO#T>SD:3NW
M>N9I./T_6B@#ZZ^&''P@\' =!HUG_P"B$KKA7*?#7GX2^$&*%"=&L_E/4?N$
MKK* "BBB@ JM,<2P?[__ +*:LU6G_P!=;_\ 73_V4TT-%FBBBD(**** "BBB
M@ HHHH **\6^+GQ FL?"FHQ^&KK5;6[L+V"UEOK6!3 DC.F8F9@3]U^JC .
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M(ZC-;I=O8-!*[F4JL"P@;F8'Y1@9.*  _!7P,OA^305M;U-->\%\(5OIE5)
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M< /+O4JSXZ \GCH*\PTWX5_$6"/P9IU_XOT>YL?"-ZLUL_V&02S1+&R+O^?
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MME*^9&K2/G[I92=WU-0:MH7P^\4?%ZUTDS6DVA0^%'EBM[2Z\N#BXX;]VPR
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MGBE4"2-U!!QP""#P17-ZI\(KJ]T1VMM?C@\22Z['KTFI-:[D,J<*HCW?=5,
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MJII/Q2U#_A)?'DGB+2OL&@^&"H,Z2*Y7$>\Y'5F8,, #C@=36?#\._B'X?\
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M ?0XU33V,FV^@;RT$CD2+A5/1CSP.O/M4]I>6M] )[2XBGC/\43AA^8KY?\
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M'=%%Y:;CYC?PY'3U-;XZ"O%5TS6?"/Q$^'^D2>,M9UB&]EU!K@7UP#YQ\G<
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M2.G%?,/G^)-3^!?PYUC4-3BU;6)_$5E+;37D6/+<RL &8$DC/7&...U=!/\
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M3$WSQ?+F4MC=TQTQF@"K>? 7P%J$%Y!<MJSQWD,4,Z?VC+MD\H 1.5S@LJ@
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MSUT_"?CB7Q!XB\5:/?Z8NF/H-['9AS.'$^Y X/08."..>M=L3D?+0!Y]XT\
MZGXMN[Z'_A)OLNC:C8K97-A)9K..&8^8A8_*^'QG!Q@'M6?+\*[JQO\ 4Y/"
MOB9M&M-7LHK&^A>V\]F\M/+65&W#9)LXR01P#BNAT;QE+J?C[Q-X6NM,^Q?V
M(MNZW!F#"X696(.,?+C;ZUU[21H 68 >] &9I.C6NA>&[30M(1;>VLK=;>W4
M_-M"K@9]?>O+/^%-^(?^$,?PXWC: @ZS_;2SC2P&$GF^:5(\S!&_GZ<5WFN^
M+FT3Q?X8T#^S'G3799HOM(D"B QQE^5QDY ]JA^(OC9O ?@JZ\2#2WU(6S(K
M0)(L9PS!<Y/H2.F>M(# \3?"VZ\62:W-JWB+S9[J.)-*<6N#I#(0WF1$/DL6
M 8G@\ =.*H:W\)O$U_K^F>)M*^(EUHWB&&Q_L^]O(+-6CO8P25)B+8##<>>>
M>>*]:CF5XU+?*Q .T]:D\Q,_>IZ@>47'PJUNUUDWWAGQK<:;'>6$=AJ:W4/V
MM[K8"!*&9OE?#$9Y'M79>$?"K>'/A]IWA&^OO[5CL[069F:(1^9&%V@%03_#
MQUKIE=6/!I2>*0'E6D?"O4+&VT30;[Q(M_X9T&\%Y8V9M=LV4+&%))-Q#+&6
M!&%!.U<UTG@SPEJ'A>]\1W%WJT-^FLZD^HA8[?RC"S*JE<[CN&$7T[U+XT\7
MCP?IEEJ+Z7/J$5U?P6+"%E4Q&5P@8Y/(!/;].M=6&!%,#PKXGWUP_P"T%\-;
M/2]8L[#48H;]E:YB,J$NB*J,H93\V& YZC\*U/\ A46L+JVCZU'XF@.IV^M2
M:W?3269874C1^4$4;_D18_E'4\9KN_&GB2+PCX.U3Q1)ISZBNF0&X:&)E5RH
MZ\MP.,G_ !J&X\8?9O&GAWPS)I<Y;6[6:Y2YWKLC\I5+(1G)/S+VQS1J!@:C
M\/-<@\8Z_K_A3Q%#I2^([>./4(I[8S%)478LT1##:VTXP<C(!J7Q#\*-)U?X
M7:=X#L;A].ATUK=K6Z09DA,;#+ C'S,N\9_VC7I%-W*.II <%XB\#WFH:GX-
M?1KRST^P\-78N5MG@9O, B:+8"& 4!7..#SBN)O/@YXLCT7Q/X8T+QE:V_A_
M6[UKY(;NP,LMJ[.)'16#@;"1W&>?QKW/>OK1N6@#R"Z^&?C.R\9:GK7A+QM#
MI5KKP5]4MY+,RXF"A3-!\WR,0.^>W7%9>O?![Q==:=XO\.:#XLLX/#OB5C</
M#?6SS36\S;?,*N&'#E<G(X).*]TW+1D4[@9.FVNH6/ANTL9[B&YOK>W6)I0A
MCCD8+C.W)(!],FO((O@WXA&AV##6K"+7-)U^?7K*=$D\EVED9GBD&<[<' (]
M.GK[KD9I-RYQGFD!XQXF^%GB;Q)H?C)I=0TN/6?%"VULS;7,5K;PC(4'&YF+
M%CG '(XXY]:T^.ZM]*M8M0,7VE(564PYV;@.=N><?6KI=5!R:YVY\46B3:&M
MI9WFIVVM2F**XM(O,BA 0MOD;/RJ<8SZTP/&?#.C:EXWTKXA^&K.\TT:)J'B
MJZ%W,)"TZQ;XRRJ@&T[P,!B1C).#6SXF^%GC34#XZTO0=8TBVT?Q68IF>YB=
MIH76)(V0 ?+M(C'/49/%=_X.UK0=4OM?L]"T4Z6=*OC9W0-LD/F2[0VX;3R,
M,.37947 \YTGPGXEM?BC+XJO9-,>TFT6#3&2%G$@>-V?> 1C!+$8ST KC'^$
M^O:Q<:W)J%EHV@W.IZ+<Z7<W&ERNRZA,[*4GDCV*$V[6_O']YUKWC<*-RTK@
M>$GP#\4]0\26NM7FH:'I<UKX=GT:$V3RNT4KXVR E1W53[<UG^&OAI\0M#U:
MWU'[#X:B,>@2Z1,D$\H>XE)!\]W,?S,[#G/3GK7L?BGQ?I/A"RL[S6/M'D7=
MU'9H8+=I<2.=J[L?=&>YKHP01FG<#P#2?AIX[LM-^%=G/;Z1CPC,\EVPO')D
M!4H-@\ODX;//?CWKN?AMX6\2>$KWQ/8ZDM@^EWNK3ZE:3P2,97\YLE74C"[<
M <$Y]J]'KF9_&6C6_BY_"LK3#4TL7U$H(&V^2K!20V,$Y(X&: /.M4^&7B'6
M/$'Q)TZ\ELXM!\81PLEW',WVB!XX@@7R]N",C)^;I]:T-&\+^,M4U#P4OBRQ
ML+.'PH#,T]M<&4WLPA,*E5VC8N&9SDDYP/>O1M"UJS\0^'[#7+$2+:W\*SPB
M9"C[6&1E3R#BM6BX'G7Q*\-^(=9OO"6K^&X;2YNM"U3[8UO=3&%9%,3I]X*V
M,;L]*X74O 'CR\\&?$O2H])T];OQ1J7VJV/V[*B,JBG<=G!'EYQ_M>U>_P!1
M^8F\IN!< $KW% 'A/_"">/-'\>:UK&DZ!H&LV'B-())HM2EP^FSK&(W8$H?,
M7&3@8S[5Z#\0/#&I>(OA%K/A7398FO[JP-O$\HV(SX'7'W<X[=*[CM6+XD\3
M:'X3T9]9\1:C%I]@CK&TTN<!F("C@$]30!XJOA#XE67C&'Q5%X+T/54U+38;
M*\TV^NT)LY825219-A!!4Y( [D=A79:/X>\5V7Q2TC5KK3;%]/@T'^SYY[1Q
M$J3-*)"$C/.P8P/K7IL,L4T*31.KQNH967D,#R"*FHN!X!XH\%^.M8T;XFV%
MOH,0?Q-=V[V3F\CQL1$0EO3B//?[WM6QK?AOQA>^.[K7H/"MG>6\WA@Z7]GO
M+E#'),91(R./[I&5S].U>S<4<47 \G^%?@_7O"VL^(?-2;3_  Y<M$=.TFXN
M1<M:, ?,VN"<1DD87)Z=J2ZT7Q=X:^*7B;Q%HVBC7=+\26L&Y$N$B>UN84,8
M#!R 8V7&2,D'/!KUGBC(H ^?H_ACXF\.:;\*])TW31JL?AF^>_U&=+A$ +AL
MK&'(S@N<=.%]37I_Q$TNXUKP?)IL7ARW\0Q3S1K<6,\HC+1;OF9&) #KU4Y'
M(KLZ*0'SSIG@OQ]I6D:'>_8[G58M#\12WMCIMW=1F[6R:!HE5I22I92^<$GC
MO5+_ (0CXEBPD\00:%;P:SIOBV?7K?3FO5:.[@E&QDW@8#!2<$^_%?27%'%.
MX'BWB[3/'7B3PYI%Q+X3CBN!X@LM2?3X)XF:WAA<,S.Y*AW;';( P,\9/1^'
M-)URT^,?C+6[O27@TO5+:RBMKDRHV]H5<,-H)8??X)':O1Z*+@>"_$KPCXJU
MWQ=>:EX;\.W%EK4 MX].URUNXTBN$ZRQ74;-\R+EL?*:J6_@OQ=H?C/Q!9S?
M#O1/%-EK.H'4+?6;EXE%HSA=XD1@7(4C( ZX[9X]JU7Q/H>B:AIFFZIJ45M>
M:I-Y%G Q^>=^,A1[9&3T&:VN,47 \N^'MGKVD?\ "9W6J>&KJR>]UB?4+5#)
M#(9XV1551M8X;Y.Y Y'->3:5\.O'VD^"_!%Y+X)MM4O=!O-1%YHUU<1'[1!=
M2;MZ')4,HXY]Z^DM?\1Z+X8TU=1U_4(;"U:585DE; 9V.%4>I/I0OB30V\4_
M\(O_ &G =:^SFZ-F&S((@0-Y'89(H \FU?P;<ZCX:T^ROOAQ#9QSSRW:Q:!/
M%!<Z1*0@BD$FY%=^&W$9'0<@<['A36?&OAF+P/X3\3:4VISZA;O'=ZD+E/,@
MD4.RJ\8Y;"* S@D;OKSZA>7=K8V4U[>3+#;0(9))7.%10,DD^F*SM'NM#\06
M]MXFT=K>\BN(ML-ZB?,\>3P&(SMSF@#@?%L4FG_'[P'XBFC/]GSVUYI+3?PQ
M3.%>,-Z;MC*/?BHK?3O$5K\0?B7JC>&;N2SU6SMH[.1)8<W+10LA &_(R6XS
MC@5Z9JVDZ?K6F3:=JEJMS:S##QL>O.0<CD$$ @CD'I5]55$"CH/7FBX'S;XC
MTW6;;]E30OAQ>Z5+9>(M2:UT:.T9ED9G$JEI 5)^0(C-GL.M>E_%CP?J_BKX
M277A_0S')J$?D2Q1RG:DYBD1MC'L&"UVLNBZ9-KL.N36:27\$+01S-DF-&(+
M!1T&2!DCDX%:G %(#YMO-#\67GA:[O\ 2OA+9^&+S=;1721/ ]]=()D>3R&'
MRKM"Y4L<[L$8*BJ</@/QAJVD?$S1;?PO>:(FOBWN[&:^NTFW-&B8C=MS$LQ0
MYZJ,U]#Z3XBT77I+U-'U&"^-C,;:X,+;A%* "4)'?!%:_P M5<#Y[\12^./&
MWPN\2K-\.9]*U.ZT]=.\LF)[FYDW9R#D#R5^;&3DEN!QST^DPZM/\<M*U1O"
M^HV>G0^&VL&NIDC"),TJ2;#AB> I'U_.O7>,T<4K@>0^*;7Q-X>^,UOXUL/#
MMWXBTJ[TG^RWM[%T$MK*)3('PY VL."<\8'M7"V^C^++?X5^%])G\&:DM[:^
M+/[1F@B,;F. 7;R[OO<<. ![9Z5],U4OKNTT^QGOKZ>.VMH$,DDLK!511R22
M> *+@>/^&?#VIZC?_%6WNM%N-+;6;QS97<Z*!(AMQ$&4@D\%2>W##U-<1I7@
M?5?$7@Z\\,R?#,>&]>L](GL6UBZD#)(YC,:K 022'/).  /4FOI33-3L-8TN
MWU32[J.[LKE!)#/$<K(IZ$'TJ&^UO1]-OK*SU#4K:UNKY_*M899%5YV_NJ#R
M3]*+L#RGPI>>)/%.F"WU+X<R>']0L-'DT^:]OD0&5BNT10$')0LNXDX' ZYR
M.=\-Q>(_#_\ PK_Q-J?A+6?LVD:3)H%Y9I )9H'Q'BX5%))1C&5SC.,'I7T6
M.:7% 'S!+H.IV6M>'M4;PKJTUMJ7C&;7S:QVA;[%;F/8ID X5BV'V]1D]Q7T
M5J*K'X;O4@L1=!;>0+:I\HD^4_(/3/2M0X R:HV^J:==WMS8VM]!/<VVWSX8
MY SQ;L[=P'*YP<9]*0'R9<>#O&.J>'K_ $_PU9ZW<Z/86]I?6]AKEJ8IX'CF
M#M8Q2-@RIM!..@*J*]9\.I<>,/CC:^.+/P_J6C:?8Z*UE<2:A;&VDN9GD5EC
MVGE@@!.>F2,5[0 HZ"DP.M.X'A'Q<T^XT_XF>'_&&H>'=6\0:!'83:?<0Z2\
MGGP.SJROM1E+*<8/;UZ"L6QT5K'XB_#"WTGP;J.@Z9:0:F_DB.25;(3K^[$L
MG(5S@DKGY20*^DN"*8YCC0LY"J.23T%%P/E'P/X?N9+.P\#ZO\/=9/BG1+N5
MH=6N+B9;&$%F_P!)5MVTN>R@<GKCFNU^&.L3:D?#'AO4OAWJ5EK_ (8M7L[B
M_NK?R[>W7R]C-%(?OF0JG&/4YXY]TM;BUO+=+NSFCGAD&4EC8,K#U!'6K&!1
M<#Y%M6U&S\!^%VO?"_B.:W\*ZY>'5K>VAEAEV3O,$EB*D&3;N!.W^]U'-=&D
M&GZ#:^%?&^B^"=9L_"L&N7%Y>6L\4DUV[RP>6EVT3;F&'W8 YP0W?%?2^!2$
M"BX'C/P5NOM/B'XAW2:-J.F07NM?;(%O+1X-\;Q+A@&'4D$D=>:]HJO#<V\I
M<0RHY1BC!3DAO0^]6*0!1110 4444 %%%% !1110 4444 %-8>M.I#0!\$?M
MD%3\:=, ZC1(<_\ ?Z>BE_;&.?C9I@!Y&APY_P"_\]% 'VQX+P/A_P"'5!)Q
MIMN,GO\ NEK?K!\'((_ >@*&W :?;\^O[M:WJ "BBB@ JO+_ *V#_?\ _935
MBJTW^MM_]_\ ]E- T6:***!!1110 4444 %!Z444 ?*UUHOA.^TCQ/;QV\7_
M  L(^*I_[-V$K>HQN%*,!G(BV98_PD9/6NOF\$_8?BI?>";/3H1X9\4>5KES
MMC&V)K=@)HL>DCF#Z!GKW/[/#YIF\I/,(QOVC./K7+^%O"5[H5_?:EK'B6]\
M0WUPQ2*:Z1$^SP;BPB4* .IY/4X'I3N!UF L> , #%?.7BZ;3;/XN3ZA;WFF
M:^+C6K"UO='NQY=_9S#RO+DMFSEDY5BN-OWN>M?1YY%9S0:2=0:>2*T-Y&-Y
M<JOF*/7/4#I0!\OZGKGA_2O"D_AO4+R&TU>S\>K<"T?/F0Q&\#AP/X5,;'GH
M0:V='U#PGJ7C+7M-^()N%\:VWB(7FE^4K+<SVXQ]G$)_YYE<@C.WDDXZU]$-
M;Z5,AOFCM75]LAG*J0<?=;=[=C38;?2;R[CU&%;6YN8UVK<*%9E4\X##H*+@
M?+7B:V\*ZE%\<-:O;FV?4M.O8Y-.F^U;7BF6W3:4P1\VY2..3@CUKZDT&Y6\
M\-Z;=).)Q+:QOY@.=V5'.:1M!T1UF632+-Q.=TH:!3YAY.3QSU/YU<@CM;6.
M.TMTCA1%PD48"A5'H!T%# ^=?%ECX4UKXA_%R76;B&673]%M9(%:Z*".589?
MFP& W*VW&>03[TWPQJFE^(M=\*V_Q N[:[TBY\'V\MB][,/)ENMP%P23P90-
MGN!GUKWZ3PYX?DDN))-$L6>Z_P!>QMT)EYS\QQSSZU'<>%O#=YIT.G76@Z?-
M90-OBMWMT,<9]57&!U/2BX'SKX/OKR&_^%\.M:DTENFN:HFF27<G[R6S$3+
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M]4&%$R_Q<<'D9'7J:=K7PA\+:UXLN?$<EQJ=G/>HD5]!97CPPWR*  LJKU&
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MPHOPJ7=I&-IDLQR3EV]:O+X+U9?&C^)AXE#SOHXTIEELE.Y@Q?S>&'\1/R@
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M)O8 Y]\9_&D!PFL?$*W\3^#-$UAM)\5Z#I=[J6G/;7D+6R-.)91M5@)21&2
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M\,VBW U6[L(?,"7DNUO/D38WRLWF#."1OXQ18#W=]4TZ.%9I+^W2-U+JS2J
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M9Q9)>G4%B%]<8%QG/F??ZYY^N3U-3Z]\*_ GB7Q#;Z]K.@QW.HP*%,OF.OG
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M9FA*J^'=-"A0HMHP O3&P=*TZ; ****0!5>7_6P?[_\ [*:L57F_UT'^^?\
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MNR;EP7.1A!BNS^(/C9_ NB6.J?V7_:"7%_!9.HG$?E"5P@?D$M@D< 5V(=0
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M$4@/E;P3I>G:SX?ATW2? ?B&P\9:7H]W93WNHRW'D6,WV=H\1%WV@NVW"@#
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M;4/$/A7Q+KWP1\AX[RRADE#K-$P4,MN$!(8#@2# ;ID<=*^E]H/6F+%&H 5
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M9;R6:F5;>59H65%$;HT90A1&N.,]<YS5%?@9H$+:>EGK.JV=M;Z.^B7$$$B
M7<#,S'>=N0=SL?EQV[#% &)\/_BKXJ\0>(+S3=273;ECH;:M UO#+%'%()-A
MA\PLRS*#_P M$X.#BIO"?Q.\:WUUX#O/$FG:1;Z5XLMI=JVID\Z&1(S(&);C
M:R@_+R1ZFM/1_@I#HU[:7EGXWUXSVNEG1TW^1M^S]57 C'W3@^Y'.>:NZ?\
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MZ$4ZD/3- 'YZ?M:,[_'N92?N:?;@<=OF/]:*=^UKS\>Y<?+_ ,2ZW[]?O44
M??&AH\7A[38I,;TM8E;'3(09K2JEI:A-)M$#%PL*#<>_RBKM !1110 56F/[
MVW_ZZ?\ LIJS5:?_ %UO_P!=/_9336XT6:***0@HHHH **** "JE_/-:Z=<W
M5O;M<RQ1,Z0IUD8 D*/<GBK=4=4M)-0TB\L8KE[62XA>)9X_O1%E(##W&<T
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MOVK_ #?^&@+W>1C[#;;<>FS_ !S10!^@]FVZRA^7'R+Q^%6:K6BLMG"KXW!
M#CIG%6:8!1112 *JS_ZVW_ZZ?^RFK55IO];!_O\ _LIIK<:+-%%%(04444 %
M%%% !44T<<L31S1K)&PPRL,@CZ5+6!XRMH;OP'KUO<+NC>PG##<5S^[/<<T
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M^GKVS0!H>'? ?AGPJ^JG1K.>,:M,;B\6>ZFG6:0]6(D9ADYY]>_2LOPS\)/
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MRA86T CV^6H4\D_*2S=26SCCFS:?#SQUH?BI_%FC:SI%QJNJ:>MKJL5S%)'
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M_P"/-7\8:?IMAJ,OB>UMDO[(WAB6RN(4VJR.4.^/!.> V1D=>/7J:2* .5\
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MIT8_*5?(P@/.>A JWX4AOQ<#3M#EN];T>YTC43#:WEDT=WH;N%/V<R<!P[<
M$9^7(XYKZ>Q2%11<#Y#M+F2V\/?#35]2M/$UIH6F:7+I%_)I]K+'-:7)2,[S
M\I9D(&S('4&MW3[>T\#ZS\/M8CT/68/ EH+^%5NXI)9K.>5ODN)(P"R[QN"Y
M&0'/<XKZ/N-5TZUOK6QNKZWAN;MBMO#)(JO,0,D*I.3@<\5H?+BG<#QKX$2J
MVE^,MFGWEC#+XDN[B%;JU>WW1N$92JL!V_&N6DNK?1?&/Q9TGQM922S:[MFT
MMVMVD-] 82B0Q8!+%&P-H!P3GWKZ.XI/ESTI7 ^?+$7.E^(_@AI&N3.^K6-E
M.EZK EH6:U"J'/8[AMR3R0:]#^+D>GR_#2\@U.\N;&VEGMU^UVT?F-;OYR%)
M"N""JL 2/0&O0?EHXHN!\HW.HWT,VA>)-:BM+RQTOQBDMUKVF6["&\C-J$$[
M(,XP=J$K\NY>.:S_ !#JD][=>+/$%AX?U&_TRU\6Z=J]Y:?89$-Q9K;?>(*\
M@, V#Z D8KZ^VKC&T8I#CTIW ^5_'VH^#M9^%GC+6?"^C7R6.N:CISSW4T<D
M:ZA,)5,GE1L,C:B9+  ')]*['PDNAV7[3^JIHD-K:V4_AFVV+;1JD<CB3/&
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M9V-G%:V-M%;6\2[8XH4"(@] !P*M4@"BBB@ HHHH **** "BD]*6@ HH[T4
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M]/DN=1GB,4'E*YF54.V8,Q8%GW=,8]?;?^%?^"_[+N]+_P"$7TS[%>3?:+B
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M25&2QX&<<DY[F#P]<:E\-8O"_BJZ:^N+C319W\ZG!E8Q[78'U)R:&!XS=_\
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M K-N_@MXCNO 7B;PY-XX6>?Q!JB:C/<2V*A4(*,P"JPY+(O?  _&NFT;X?\
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MN,C&3&P/'.&HL!Z[<?$;PC#XRT[PG_;5LVIZA ;F)5E4C9QMYSU;/RCO@UV
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MKGB_P7J^M:#I/BK4+ZTN?"]SJ\5U.RRSV-Q!SN#%<;).!@C@DXQ18#Z-^6C
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MV3Y=KD>G^CQT4 ?HZOW12TU3Q3J "BBB@ '2JUQ_K;?_ *Z?^RFK(Z56N/\
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M"@D\ <]R:-0/*H?"/C;P3\!QX7\.>(/M&OV1 L[NWL0V_,N[849B!G+ L3@
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MI <!I'PS^(V@:S>:7I/C#3X_"=S>-?!'M6:[@+L7>*,YVJI8GYCD@$X&:T]
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M2 6XSZXKQW5_#M[8>-K7X@7&EZY'X.O-6O&$6EB6*ZM!)%%&+G8@#!7:-SC
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MJ<%K<V32S6[><LK('W ;=P)__630@)[CQSIOA3Q5\4M<@\(W#:CHD5I->/\
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MX:7:'55VME%QC8.>^:V/B)X>O?%7PYUOP_ILD<5[=VY6!I20GF AES[9 S2
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MHVD-;@GU_P!&BHH _2=>E.IJ]*=0 4444 %5IO\ 6P?[_P#[*:LU6F_UMO\
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MJ+"/:JPE>5#X^8MVX[\(#U'P[X^\/^)K];/3/M@EDM1>Q&XM)(5F@) $B%@
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MM<U>WL1+DH)&^9@.I"CD@=SC [U0U'XC^!=*L[:[OO%NE0PW4)N(&:Z3][&
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48YS110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*80:?2&@#\U/VCF0_M&^+3QM\V <>OV>+-%'[1P"_M'>+0%Q^]@X'_7O%10!
M^E:]*6D44M !1110 57E_P!;!_O_ /LIJQ5>7_70?[__ +*:!HL4444""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.] !1110
M4444 %%%% !1110 4444 %%%% !1110 444=J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***.U !2'&*6D- 'YH_M(#9^T5XMYS^^A/YV\9H
MJ+]H@,G[0WB_S"9#]IC.6/8PH0/P'%% 'Z8H:?2* !Q2T %%%%  .E5K@_OK
M?_KI_P"RFK(Z56N/];;_ /73_P!E--#19HH%%(04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$9I:** "BBB@ Z
M4444 %%%% !1110 4444 %%'2B@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%%% !111F@ HI*6@
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M (K8CZ:?:_\ QJBBI8#1^TM\;8SQXW9O]ZPM3_[2JV/VGOC5Y1/_  EL>?\
ML'VW_P ;HHI$D0_:9^-N3_Q6GI_S#[7_ .-4G_#3OQL_Z'!?_!?:_P#QNBBF
MBB9/VH?C4)MO_"4Q$>^GV_\ \12K^U-\:,-GQ';'ZZ?!_P#$T450$A_:F^,W
MENO_  D-KG^]]@AS_P"@XH7]JCXSY/\ Q4%K_P""^'_XFBB@!9/VIOC-V\06
MH^FGP_\ Q-!_:G^,PVXU^T_\%\/_ ,3114L"2/\ :K^,85E;6+%^G+6$>?T%
M-;]JSXR8_P"0S8]1_P N$?\ A112 ;_PU7\9?-7_ (G=ECT^P18_E4Y_:S^,
M!S_IVF#KTL5_QHHH)'?\-8?&#=_R$--^]_SXK0/VKOC#YO\ R$M.QGI]A3%%
M% %B/]K#XN"/YKK2F^MD/Z&FK^UK\7-H_?:1W_Y<O_LJ**90X_M;?%O^_H_7
M_GR/_P 50O[6WQ:P<OHY^MD?7_>HHH 1?VN_BWS_ ,@7I_SY'_XNE;]KKXM;
M)/ET3.>#]C;(^GST44B1G_#6WQ<\_P#UFCX_N_8N.G^]2_\ #7'Q<VO^\T?K
M_P ^1_\ BJ** 'K^UO\ %O ^;1N?^G(__%5.O[7_ ,5L<VF@'ZV<G_QRBBFB
MA3^V#\5"Q_T#P\/E'2TE_P#CM./[8/Q4_P"@?X>_\!)?_CM%%,!1^U_\4LQ_
M\2_P]VS_ *)+\WU_>TJ?MC?%-CSI7AO_ ,!)O_CU%%)DDEK^V%\49)%1]+\.
M$<\_99L_^CJLV_[7WQ-=XU;2/#A!C#'_ $6?K_W^HHI 5)OVQ/BDD@"Z5X;
MR?\ EUF]?^NU65_; ^)QB$ATCPWG'3[+/C_T=110 ]OVOOB:N[&C^&^A_P"7
M6?\ ^/57B_;#^*#YW:3X;Z_\^L__ ,>HHH0%]OVN/B4L\:C1_#F&&3_HT_K_
M -=J2X_:Y^)4=T(UTCPYMXZVT_M_TVHHJBC2B_:K^(DDD2MI'A[# YQ;S>O_
M %VK1M?VG/'\VPOI>@_-C.+>;_X[112 5/VG/'S2;3I>@@;]O%O-T_[^TR^_
M:>^(%O?M!'I>@[=V.;>8GHO_ $U]S110P+>E?M+>/+Z[,,VEZ$%QU2"8'I_U
MUKI'^/'C!;2WE^P:06D'S PR8_\ 1E%%" OV_P ;/%4UJDSV.E;BV.(I,?P_
M]-/<U<O/C%XHM[,31V6F%LCK%)C_ -#HHI@::?%/Q"TDBFTT_"L0/W;^A/\
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G>DR<T44 +WIC=:** /RW^,J+%\</&BQC _M:<_B7)/ZT444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>skye_ex31img21.jpg
<TEXT>
begin 644 skye_ex31img21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M^%>Z&0/6S4G\\9J3_A3/PGP?^+>:!S_TXQ_X5WM% '!_\*9^$^3_ ,6[\/\
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M$>/RQ7?44 <"WP9^%3(%_P"%>: ![6,8/YXI@^"OPI4Y'P^T+\;-#_2O0:*
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MTTN ?^RUVU% '$'X1?"W_HG?AS_P60__ !-)_P *A^%IX/P[\.8QC_D&0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!10#D44 %%%% !1110 4444 %%%% !111W% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111B@#A_B5!#<>&
MK9;C&T72D97=SL>BKGCME30H,A/^/A?O''\+450B+X8L6^$7@]F()_L>SY'?
M]RE=CBN/^&**OPD\'A5(4:/:8![?N4KL*3&%%%%( J%_]9%_O?T-35#)_K(O
M][^AH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $QS2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I110!Y
MS\7)'3PC:>7MS]M3[P'3RWHK4^(2P-X?M_M#;5^U+C*[N=C>QHIB'_#,LWPC
M\'L6))T:SS_WY2NOKD/ABH7X1>#U&,?V/:=#D?ZE:Z^AC"BBBD 5"_\ K(O]
M[^AJ:H9/]9%_O?T- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%)SGVH 6BBB@ HHH- !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F:
M4=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0C)% "T444
M %%%% !1110 444AY% ' ?%34[C2_"UI<6JJS->*ARA;C8Y[$>E%4OC+,MOX
M,LV)(!OT'RC/_+.2BJ)-WX9ON^$?@]MI!.CV?![?N4KK06)Z8KDOAB#_ ,*@
M\';B<_V-9_\ HE:Z\ 4BA>U':BBD 5#)_K(O][^AJ:H7_P!9%_O?T- $U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HH[T4 %%%% !1BBB@ HHHH **** "D[TM!H X;XF2K!X9MF
M/D\W:C]]C'W']0>:*ROC,\*>#+,SV7VQ?MZ?NP2,'RY.>#_G-% C:^%F[_A3
MG@S<<_\ $FL__1*UV8KC?A6"OP:\& C_ )@UGT_ZXK79TV,*#GM112 *AD_U
MD7^]_0U-43??B_WOZ&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "C-':DQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%(!R>: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**:2VX87([GTIU !111WH *#110!Y;\;5SX+LOWAC_T].C8_Y9R45)\:+R.S
M\&6<C*K9OT7YL_\ /.3THJ@-GX5EO^%.^#0V<_V-9^__ "Q2NTKC/A5S\&O!
M>#D?V-:<XQG]RM=I28!1112 *AD.)(O][^AJ:H)/]9%_O?T- T3T444""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!,<TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH[T4 %%%% !1110 4444
M%%%% !1WHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)K_@GQ+)\2?#?B?P[)I$5CH5E-:1V=R9$+"0 =5!  "C'%0>*/!OCWQ3X/\
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M++H5G>S&4B##+)@%B51B1A?8T?!OP#X=\2? 7PBVLVKW"++/>/'YA"SRF21
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M8[N+ ),9/4C<,B@#O:*Y_P 4>*=/\*V%K=:A'<S-=W4=G;PVT>]Y97SM49(
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M;/\ PKO3\;/^0I']]B/^64OI13OV@P/^%>:?G_H)Q^O_ #RE]**8'1?!YO\
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M!-=6.WOL)Y*OOV@%!@= ._!) S7TF"#TYK%TKQ-HNM:EJFG:;>>?<Z5*(;Q
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MG(9E1P,Y YQS@5?U?X8^#M=ETV74]+:>33K<VL,GVF57,1QF-V#9=>.C$T7
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M%>-/&DGQ!N/#_BW5;JPU[[+=RQZ;=0QK8WN#F*6VE5,E54?,"W?([@>AZ/\
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M'.?&OQ%XJ\-Z7X:F\+ZQ'IUQJ&MV^FR"6V69764XYST Q[9]17FOC#QE\4O
MD?BGP_/XW&J7UI8V>K66HOI\*,%DG\F2%U"[1S\P/7CZUZ)\==#UGQ'H/ARQ
MT?1-0U)K;6K>^F>R=%:&*,G<068?-AN,?GZ[%_\ "#POK.AZCIVIW&K7#:H8
MC>74EZWGS+'RD9;IM!YV@ 9YH Y.*\^(4?CZQ^&^I^/M]U<VL^L/JUO8Q0N(
M@ZI';HC!EX)9BQ!)& ,8)K!N/B#\1KCPUIMG;ZU:6NLVWC$^&;J]^RJT5TF3
MB782-O Y48)/<"O7];^'NB:\VD7-U<:A!J>DJ8[;4K:Z:.Y"D ,K-_$&P,@@
MC-<%\2/ QLO"GA3PYX5T'5[Z"#7X=1NI;*8&< %S+*TCL/WC%\Y]?3%.X'.:
MK\1_'7@^^\1^#;_5X]=U2.YT^+3]4^SQP%!=MM(9!\N5PVW)QTS[VM8UKXR>
M'?!^IWFH:M#;.=4L8M/FN8X)I3'+*L3I((P$"@L"#UZC->ER_"OPC?>'-4TC
M5K2XU1=7DCGO+J[F+7,CH (SY@P5*@#&, <^ISFO\$_"LGA]M'EU'7IO,N(K
MB6[FU)Y9Y3$VZ-2S9^53R  !GGK2N!QO]G>)++XZ?#ZW\5:]%K.K"TU9TO(X
M1  AV[%"#CA3WZ^^,U!H?C'XA7.IZK\-[WQ.I\8VVNQQI>?8XPITXIYIEV;<
M<JK#ZL!GD&O5=1\ :9?>,-)\727>H'4]'@:&V5+C",&'S!ACG=W_  K \!Z;
MK.O>-]1^(GBCP?\ \(SJ#6::7:VTLZS2F-79WD8KQR2H'?"GL>6!T?Q(\57'
M@KX9Z]XHM;=;BYT^V,D4;YVER0JYQVR03[5YSK7BKXB>!_">H^,;_P 0:;KV
MDS:3#-;(T(BDCO)'1?E5!\T(W@\DMT&>Y]DUK2--U[1+S1=7M1=6%Y$T,\+D
MX=3U''/XUPFD?!+P3I>D7^DS0W^JV5Y ;3RM1O'G$$!(/E19/R*"!C'/ YX%
M(#G[KQ1XV\+_ !!TCPIJ6NQZS;^(=+N9;:_-HJ&SN88RY.U,!D/& ><]ZXG1
MOB)\6KS1OA[K;^(]+8>,+B2P:U;3\BV(W8F!#99OE/R\+T]Z]@TKX2Z#I9\U
M]1U74+J&SDT^RNKVZ\R6P@<8*Q''!_VCEL #..*S[3X(^&+&T\,6EMJFKI!X
M9N'N;!/M*X1F()W?)\PX(^C&@#A(_BYXWL/".L:?>-:W_B"U\5CPW!?) (T8
M-@^88RP&X#( W $XST.?3/AU?_$":75[/QU:0QK#,O\ 9]P&C\Z>,YSYB1DJ
MI&!R.#GVK/'P.\'R:/KVEW\VH7]OKEY_:$_GSC=%<_\ /6-E4%6_.NG\(^"=
M/\'VTJ6]]J&J7=QM\Z]U*Y:>>4+PH+'H "<  #D^M 'EOBVV\3W7[44$?A/4
MK'2]0;PJ^Z>[MS."@N.@0$<EMHR3C&[&2*R-/^,'Q \1?V7X8TW3UB\1F*^%
M]+:0QR#S+>;R08Q+(J;2?F/)]!ZUZ]XA^']EKOBNV\3V^L:GHVKPVK6+7%A(
M@,L#-N*,'5AUY! !'KTK$U3X(^#[ZRT:+3GU#0[O1C(;34-/NF2Y'F-NEW.<
M[]Y))+9/)]30!YI\0KCXBZUX)^&S>*5M= UQ_%-I#-! JW">8&?RY>'((Z'9
MD\]Q6C:>,O%\GA;QSXL\*QZ'86_AS4IUGL_L.Q]3:!1Y\TK*XVN_5>#C !)K
MOM7^#NBZIIV@:=#K6K:?#HE[_:4+0S)))+<@DB:1Y$9F?+'J<>W3$5]\&](N
M=2U62RUO5-,T_7&$FKZ=:.BQ7S]&8G;E"W1MA7<,]*=P.9T'Q_\ $?Q-\2M7
MLM/FT*#PYI*6-[-YL,AG:WGA,A4$/C<!WX&0..HJ;P?\0/B3XHU'P]KUGX?\
MSPQJTSB<.L2?9H26"2(_G%G((&X%!GMBNW\/_#BP\.^-=<\46VK7TSZRD<<U
MI-Y9A58UVQA<(& 5>!STZY/-97AOX-Z/X9\1"]L-=UEM(AF-S:Z')<YM+:0D
MME5QD@$Y"DX!YYXP7 ]1!S1114@%%%% !1110 4444 %%%% !1110!X]^T&T
M"_#^P^T2+&O]IQX9@3SY4O%%0?M&0V\_PXTY;I6*C5(R-IQSY,M%,#JO@[_R
M1'P7CI_8]KU_ZY+7?5POPA!_X4EX)R/^8-:=?^N2UW.<4,!:*3'2EI )44G^
MLB_WOZ&I:B?[\7^]_0T#1-1110(**** "BBD P<T +1110!Q?Q,\83> _AOJ
M_B>VL9+R:TA)C15W*KGA6<9'R D9P<XZ5YW_ ,+%O-)^*<=]JBZW)I][X6CU
M Z1!;&=HYA-AG"+G:-HR23W]>*[_ .+'A_4_%/PC\2>']'B$VH7EH4@C+A-[
M @@9/ SC'/%<+H^G^./^$\B\0:CX&N[2%?"O]EE$O+=R9ED+A>'[@X!Z G\:
M8':S_%?PG'H&CZQ:S7-^FLP/<V<%K#NE>- -[$' 4*2 <GJ0!DFNA\+^)]&\
M8^'+7Q#X?O!=Z?=*2D@!4@@X*D'D$'((KYOL/AKXWTOPOX U"Z^'-IXBFTFT
MN-,U+1+Z>W)"/-YB31LQ*9]>_3CO7T#X#TNYTCP98VEWH6GZ#+\[G3=. \FV
M#.2$!  )P1N/=LXXH Y[4OC7X)TJ[U."\.IH-)NUL[Z4:=,8[5VQAG;;@*<C
MGOD8S6EIOQ2\(ZC>:S:27-UITND6XO+@:A;/;_Z.>DR[@"R>]>3^*?"/CC4M
M#^+EM9^#+N67Q%J%K+I^ZXMP)DC$:EC^\R/N%@#CJ*T?$G@GQ5XP^(/BF230
M[G2]+UKPHNDQW<TT3!)PYDPRJY./FQGIU[<T >A:;\6_!>H:I/IK7TMC/%8G
M4Q]LB,2R6HZRJ3Q@=P<$>E9Q^-7A*2UU![2._EN+>P?4;>W:W*O>PJ,EXLGY
MA]<''/2O.=#^'OB;7O#NI:/J7PKT+PC>?V3/8S:M$\337DS)M7RM@^1"3EB<
M\]!UJSX-\%^)9/#M[IM]\)]&\,ZC!I%S8R:A$\3->R-&558@I^53P6+'';UI
MZ =9:^-E\0:O\-+JXU75]$N]5CEG.FK:X@U#_1]Y#L> H^\O.3TQGD:%Q\=/
M =J;TRMJ@BT^_P#[.O)_[/E\NUDW!<R-C"KD@9//M7&V.E^-KS4?A!=7?@B_
MM!X<\V"^,DT#-&/LPA#\/T+9/K@9[XK%U;PGXUO? 'Q8TK_A!]0>\\0:U]JL
M$:2W(DC)3#$[\#&S/J,CWI >RZ]\3?"_A^\U&UNI+JYDTJU6\OS:6[2BTA8_
M*SD=,C)P,G )Q@5TVB:S8^(-$L]9TYI'L[R)9H7DC:,LC#*G# $9'-?,7B6+
M6=0^)/B^VTSPQJMQ:7FC6>FZTFF7MJ)0=F2'$AX8(=N5)&#[UZ=X/^(ZS^(_
M"GA#2?"EU;>'[[1_,M+R>5?,A,&4:)XQG &T#=G!)&,YHL!Z)XB\3Z;X8LH+
MC41/(UU.MK;P6\9DDGE;.$4>IP>N!Q7D?BWXD,/%OPVU[3-4U>VT34;R\MKO
M3OLI#2M$C#:8PN\MOX R1P/Q[CXIZ-_;WANPT^7PW=Z[:?;4DF%C.L-S:!4<
MK/$2R_.K;>,]">#TKS.T\,?$MM7^&5UKFBWVJMHNHWDUQ<R36XEAMG!2'S,.
M TFW!;&?J3F@#TJU^+OA2^TVUN;&/4KFZNKN6QCTY;-A=>=$NZ5#&V,;5Y.3
M6+XI\:MK&C> O$/A/6+JULM2\16]G/%Y80RH2ZR12!AN4AD(('<'K7G_ /PC
MWQ!B\22F;P-J\FBR>)+_ %&5+:\M8YY(Y540[7\S*H2'#J""0>_(J72?#?CG
M3_AIX0T*;P'J,<^B^*_[0DABNX),VPFEDW F09^^!@\G&>].R ]3\$ZGJEQ\
M3?B'I5]J=Q>VNGW5I]ECEVX@62#>RK@#C)[\UD?%KQ)J'A/Q1X$U4:U?6VD3
M:F;:^LK:#S!<*8G9?NJ7)RH&T=<]*T/!=GKEK\5_'NHWWA^[L;#5)+22UN9F
MB(E\N$1M]UR1R.,]J/BKIFLW5WX-UG2='N=671-:2]NK>UV&3RO*D0LH=E#$
M%QQFD!;TSXN>"M4T"YUJ&^G@2VNA8RVMQ;/'<K<,1MB\HC<6.>!CU]#6SX4\
M<:#XRCU :/-*+C39_LUY:W$1BFMY/1E/3/.#T.#7A_C/X8^*M>CU[QM8>'0]
MW/K=GJ</AZYD13=0V\7ED2%6VAGW%L9.  .M>F_"W29+.WU34!\/;7P1%=R1
ME;92C3SD Y>0H2!RQ '7J3UQ1H!A>)_&5YX3^/\ !%J&I:K>:'-X?ENO[+M+
M8S[9EF10ZK&NX_+NSNX'K77-\4/"O_",Z5K]O/<WD.JQF2S@M[=GGD"_?^3J
M-O1L]#^%8&JZ=KB_M&67B*+0KRXTBW\/S6;748CVF5I5<* 6!SA<9QCD5Y5;
M^ _&6F>&? VK3_#LZNVC2W]I?:-)-&K^3/.726,[L<#L3W_$ 'I=WXZC\1^*
M/AOKGA'Q%+)H6K7UQ:W%J%51+MMY6^8$;PRLO3./:J/Q<^)\5GX4OH_"VK:C
M;W]C?PVLM[9V?FVZR>8H>%Y2I53@\X.0<#.>*JV_AS7;74_A]/9_#\Z1:VNL
M7%[<VMFT+BRCEBDC'F-N^9R6#-C..G.WGEM1\/\ Q"TWX;^*OAJO@2_UB2XU
MAKVQU.WDA6&:%KE9MS%F!#\$8QW]!FF!].3W,%G8RW=S*(X(8S))(W15 R2?
MPKB;'XJ^%=3\\6(U&61+ ZI#&;*16N[8''F1!@-XR1^8/2NEUX:G-X3U%=)M
M8I=1>TD^SPW&"C2;#M5NV,X!KPCP/HWB:/XD>'=2N/ ^NV5K_P (_+IMW=7L
MT6V.<^6?EC#XCC&PJH4#.1@8YI >P?#WQK;^/_!]KXBM;*ZLHKC<RI<1,GR[
MCM()X;@#)!(SD4:O\1?#>B:W+I-])=M+ T*W$D%I)+';&5ML0D900NX]/UQ6
M#\$[?7-+^%FE^']=T&[TFZTE#:M]I*?OB&;+)M8Y7I@G&>HXKB/B%X?\07'C
M[5-:\(Z'KEEXE\RTCM[JVVOI^J0@(6%PKG:I0[N3@\+C)H ]+F^*G@V#0+W7
MI+ZZ^P6&H'3+MQ93$V\X(!5UVY R0-V,<CFI_$GQ(\*>$[R2TU>[N/-AA^TW
M'V:UDN!;PDX$DAC4[%)SC..A/0$UXGXET7QI9^%_B+X-LO ^IZF^L:V=5M[N
M#RQ \3/$V-Q8$N-A&T X/L*Z*[@\7>$_BUXGUL^!]1\3:%XOL;8^5:K$[VL\
M4>PP2AFQL(+9.<<\9YH MO\ %.U\,?%;Q,?$GBB>Z\-#3;.\L4BM/,$ E+[C
M^Z0L5P%.YNF0,U[-:ZA9WVF0ZE9SK/:31B:.5.5=",AA[$5X!?6&OR>*?'TE
MSX.U'_2/"<.FP_9K7S(9)E#[XX>GRYD7 Z$ GC%>L_#*.\M_A-X7M-1L[BRO
M+;3H+>:"Y0I(CH@4@@^X/X4,#%?XX_#6.Z:W?Q%L*7!M99#;2JD$@(&)&*X0
M9( +8!JG9^,KC2?B5\0E\4>((_\ A'](M;&ZMU:)4%LLBR;AD#+DE1ZYX&*X
M%HI]<\'?%7P38Z!>:A?ZMXBNX89/LV;="WE#>TOW5V?>P3G@8J;Q5I/B>'4?
MB/\ V3X7OM3$^G:9;0-/9B2.[\EB)2@/WV4/D#H2"><<@'L&F_$7PIJEEJMW
M'J9M$TA5>]%]"]LUNK+N5F60*<$=#^'6HM+^)W@O5FU18=6-N^DQI->1WD,E
ML\4;C*/MD4$J01@CU'K7@6M>"_%OB*/X@V6B^'=>MGU6TTVXM+C664-<M;NS
M-&S;OE+< +QCJ< UTOBZ+Q+\4OAIX@CLOAQ>Z-K+V-LDCZA''&]U)%<+(8$.
M<E!M?DX'(XIV0'LWA[QQX;\3W]YI^DW[-?6>UIK6:%X945AE7V. 2ISPPX-=
M,S#8Q[ 5\^>'-0AT&+4?B-%\)=<TVYMM-6&]>ZD8W=PQ=-R1H\AS&H!8N<=!
M@=:]RT;5+?7/#]AK-HLBV]];I<Q"1=K!74,,CL<&DT!Y=;_$";1?A5XM\67'
MB)/%$MC=7HM'@L7C6'8N4@<*O 7&&<\<]:WOAO)XJO[3^W-4\4-K&EWUK%)%
M%<:>+66WGY,@&%7,?*@9!/!YKSRTM-8B^"/Q4TV3PUK(O-3U+5!8VQM',DZ3
MKB)E&/N\\^F#7MGA6X:X\'Z4S6T]M(MM&CQ7$1B=&"@$%3R.: ,FW^)7@V[\
M4GPS;ZSYNHBX>S(6"3RO/12S1>;MV;PHR5W9JDWQ@^'"7K6C^*K994N_L+@J
M^(Y<@;6.W"C) R<#/>O%+>S\21>*=/U&\\(^(5FT[QA->SVMGIX6T2%_- E3
MD>:[;E)<EMH/88!L:II>J7/PV^*ME%X7UE[W5M?%W91C3) T\?F0E67Y>VQC
MZC'TR >\)X\\+RZ[J.AQ:ENU'2XC-=P>3)F! ,[C\N,8/'KVK5T76=/\0:):
MZUI-Q]HL;M?,AFV,H=<]0" <'MZ]:\<^)'AG4+[QSX:\1>&+AK>X\21?\(]J
MD$BE6>T=&D,FUL%715?J,\CCC%>BV/B?3].\=6_P[CT>_M#%IXGM;HP_Z+(B
M84QJ_P#>4%?SH V-?\2:/X;LH[K6+Y;2.2188L@L\LC?=1% )9C@\ $\&L1?
MBEX%_P"$<N/$#>(8$T^TF%M<O(K(UO*3C9(A&Y&SV8"N<^*UKK-IXF\">+M/
MTV[U73]$U&1K^TM8_-=8Y8C'YP0<L4ST )^8UY=XN\-ZKJVG?%;Q%I?AG4SI
M_B.73(K*T^QOYUV\3*TLWE8W(O7D@9QFC0#Z!\/>//"7BS4K[3O#^M0WUW8[
M3/$JLI"MT89 W*?[PR*M>(O%>A^%8H)=:O&B-RY2&**%YI92%+-M1 6.%!)(
M& !S7G&CVE]_PT[<ZS'HNH6^ER^&8K-;E[1TB,HE#["Q  (7^HZC%7/B]IL=
M_=>'V:UURVNK=IY;76]%A>>33I0@P'C4'>CC*D'KCMUH ZW2_B)X1UN5HM)U
M;[5(MG_:&U89 6@W%?,4%?F&01Q4?_"QO![>&K#Q&FM1SZ;J+%+-X8WD>X;D
M%4C4%V/!R .,&O'?"4_C3P_XIT#Q!XE\(:I=37_AV73Y!IMD %F%XSH9%7B(
MNA5B3@98^^,7PY8^,O"O@CX9>)#X)U>Y7PY/?PZEI@MQ]H5)R2)DC!R<<CG!
MYZ<YIZ >C>(OBK9KK'@36= \21?\(QJ5]<VVH?Z,6<[(6?:05WHP9<%< \]*
M],\-^)]#\6:0-4T"^%Y:>8\1;8R%74X965@"I![$5X]/;ZC=>,_ NI6G@B]T
M?2UUVZO?*2T;>J2P,IGN-N1&S2N>"<X.3CH.J^$ZW4.H>.(KK2;[3UN?$%S>
M0&ZM'A6:)PF'4D ')#>_L*3 Z?Q;XTT'PQ!]FU#5?LE_<12/;QQPO<2D*I)<
M1HK,57N<8%>>_#OXP:?_ ,*D\/ZUXYUHRZOJ$-S=2&WLW=O)CF=3(R1*=B@!
M06.![T>)WUCPU\?9?$]SX;U+6=%U/05TV&XT^W^T-:3"4L48#D*VX<],]>G'
ME'AK1?%=MX9T30-4\(^(K%%T2_M,V%L$FGG>X=E@DE.=D6UE.?ER2<D@8IJP
M'O\ J7Q;\+6/BOP[H,9N;PZ[ ;J&XMK:66/RMN48%5.[)QT^Z.3BM:U^(W@R
M[\2Q^'(-:5]0EE>")?*D$<TB??1)2NQV7N Q(KQWPQ%KVGVGP>U*Z\)ZY"-,
MTN\TJ[B%FQE@D*1(K,HY5&*,0QQQSQFJOPU\/3Z??:/X<\2?#S77U[1-0:6+
M5[BXFDT\*';]^NZ38&*YP%4Y)!Q1H!].5QNN?$KP7X<U5]+UG6/L]Q%Y8F(@
MDD2#S#A/,=5*Q[NVXBK/A+QA:^+4U3R--OM/FTR[:SGAOH?*?< &##U4JP(/
MO7@OQ4TCQ'JFL>/K9?#.MN;E;-K)=*L<P7RQ^63+-*.7=3E53/1>AZA) >XZ
M]\2O!/AK4I=-UO7H[6]BMQ=-!Y;N_E$X# *#G\.>#3[CX@^$X]!L-7764EM=
M3C+V9MXGG>91U98T!8A<C/''?%<4)KH_&B+6I_#>K_8O^$5-N)FL9& D\TR>
M6< @,5'3KG ZG%>9?"N'Q'X'D\*:UK7@S6VL(]*O-+=8]/D:6SF:[,RGRMN[
M:Z[1N P<<XQ0![+\%_%&K>+_ (<1ZUK&I1:C<M>W4*W$4(B#QI*RH=HZ< ''
MO6UK/Q*\$Z#KC:-JNN);WD;1K*/+=D@,F-@D<*5C)R,;B.H]:Y;X%V^HV7@;
M4K/4M!O]&D&K7DR0WL'EDI)*SKM_O#! SZUY/\5M-\2:IJ7Q)T^'PKKIDN9+
M.2S&F6;>1>I&J$RS./\ 6,-I4+GC'W<T >\6?Q)TF^^+%[\/8+:[%Y9VRSR3
MM;N(RQR0H.W&-H)W$@$\#)K=\0>*M#\+V]O-K=\+;[3)Y,$:QM)),_7:B*"S
M''. *\XT.;5(?C_<ZG+X;U5-.UK0+-(KIK9@D#QM(S)*3PC88<=<U=^,6G6N
MHP^&DNK#73)%>M+#J6B1M)+IT@C;;(R*&W*3P000>G>@#H]'^)G@O7;NSM=,
MUH3SWL4LUO&8)%,J1,5D(W*,E2"".OM4Z_$/P;)X4B\5#7K;^R))?(CG.07D
MR5\L+C<7R"-H&37A.@Q>.-)UGX=^(_$'A.\F^RRZO:S_ -GV!5R)F4QS21*/
MD+D,3D#DY.,UFVNE^.+'X=^&=6@\'ZO+<>'?%MQJ-WILMOB62&1Y?G1<G?@/
MU'=LC@9IV0'J7Q!^)9A\#Z-XJ\%>(K9;,ZW;V-[)+!N 0R;9$<-@QD=^ <9Z
M=:] \,^,_#/BW[;_ ,(]JT5\UE((;A4!4QL1D9! .".AZ'M7BOC+[1K?@.VO
M--^'>IZ?:W'BFTOVMDL7-Q.BNK37$L2Y(R00 >2 /7CL?""S)^T!XZG72+VV
ML;ZTL##<R64D4<KQHRMARH!X*C\..E(#H-4^).BZ9\4K#P%.LPO;NSDN_-,;
M[%PRJJC"\EOGYS@;<=2!6/H/Q%T?3=-US5/%7Q"T:^L1K$EK:3PKY2VZ[5*P
M,<?,X!))YZCFH?$KWFE?M#>'=9;1M3O;&?19]/\ /L[5YDBE:>-@'*C"# )W
M'TKRG7;'4KCX=_$K3AX4UN:75O%D=Y:P?V1<?OH=T!+@;/N_NWR3[=R* /<)
M/C'\,TANIO\ A,; K:2>5, Q+(W7[N,D8!.X#& >:VM:\<^%?#]E;7FK:U!;
MPW4?G0D9<R1XR74*"2N"#G&*\<U*T63XC_$N\A\+ZHT&H>&XK>"1=)N-MQ*J
M2 JOR88X:,?A['',?V1JNFZ_X*\4:]X9\476@MX3@T6>+2DN8[FRN4(W*\:%
M9-K8QTP< \\4 ?46G:I8:MI=OJFF7D5Y97*"2&>%@R2*>A!%8&F?$7P9K.O#
M0]*\1V=WJ#;]D4;Y\PI]\*<88CO@G%0>!=+M]$^&UE8:;H,^E6L,<C6^FW,C
M/*BEF8*Y8DACG)&3C..U?.7@NUUNW\>_#:_N_"&NV!L;[45O;1-)D2STXRA@
MB1M@DJ2=Q<LW/< 8!8#Z9MO'W@Z^UY= M?$5G-J32/$L"29+NG+JIZ$KW .1
M6MJVM:7H.FOJ.L7T-C:(0#+,P49)P /4D\ #DU\Y>&[34K#XL: _AK1=7;2+
MC5;N:\TK5]-?&D.VX-<P7!4#:X)XW'[V,$XQZW\7;33KSX?M::I::M-;O=VY
M\[249Y[1A("L^T E@A 8C!SCIW !A>)/BE:VOB3P9J>D>)-.;PI?WEU:ZE*Z
M?<,<#ORY/R8*\C&?Y5V4?Q'\%2>&E\1KXDLCI33FV6<29W3?\\P.I?\ V<9Q
MS7@VCIXBO-9\!KXFT>ZOX[/Q'=N=131Y8OM<)@*1W$R;?W99R <@?=W>]5I&
MU.W\07ZP^&-7ATZ3QK<7RZA#I4LLUJAMP!)%'MP=[;U#$$#D]<&@#UWQO\0I
MH_!^A^(O ^KV%W97FLVNGR.%\S>LDPC95.?E8<]0:T+#Q%X@;X\:KX3NYK=]
M&CT6+4;=4CQ(CM,4(8]_NGICM7B-E;:A9?!^;3+C0=>%Q#XYBNS'<:?(\SQ?
M:ED+MM7YOD4DD<=!GFO6+.=O^&H;^X^Q7OD2^&X;9+DV<GDF03O(5\S&T':0
M>OMU&* +?Q?\7:]X)T71-8TF\LK:TEU:VL[XW46[$,C8)4[@!COQT^E=1I?C
MSP=K&D76KZ7XFTV[L+($W-Q'<H4@ ZESGY1QU-<5\?K&:_\ A[IQCT^>^AMM
M:LKBXCA@,Q$*R9=BH!. .O%>5^*?"^H7M]XT\:>!_#]XOA]ETQS;6L36LFI-
M!.LLS1(5#<+QNV\G.,T ?2N@^*O#OB>*:7P_K5IJ2P-LE^SRAS&WHP'(_&N#
M^*7Q*'A76O#WA?3]9TW2]3UJ<^9>7^'CLH%5B9&3<O4@*,G&<^E5_A3:^&+C
MQ+K?B;PYH_B*!M2CA%U?:R)4^T.HP$59.25 Y8#';-5?BG<6\7Q@^&4DUO-(
MMI=W,L[I;.ZQHT#(I9@I RV!C- &GX%\<7L?A+5-8^('C3PG<):WQMQ>:5<@
M6\(PN%=V. Y+9QZ$=:[J'Q1X>N=2BTR#6K*6^FM_M<=NLZ&1X>,2!<Y*<CYN
ME>%^%;WP]I_A7XNKJ6BW-WI<^MW$R62V<B_:HY(XU4(-HZN",CIU/'-<WX+M
M/$.AZ5X]^'6K6\T_C*71#'IFI(SS+)!]G/EVRR$84H3[9Y/44P/I72_&'A?6
MKJ>TT;Q%INHSV_,T=M=)(T8]2 21S7$ZE\3$D^+/A3PQX=UG1=2L-3>XCO8X
M9!+<0F.(NI!5\ 94@Y':O(=,L=.\0>&-0U3P+IOB4>-[?PW)IT@NHV@CM-H'
M[A3M56;(^4 DX&>,5I>'/$7A[4/%OP?AT71+VVGT>.>SO8O[/F3[&YMMA1FV
M 'YQZ^YI ?45% Y%%( HHHH **** "BBB@ HHHH **** /&OVBOL_P#PKK3_
M +3OV?VI'C: >?)E]:*=^T-<BV^'FGNR,^=4C7Y<?\\I?4T4 =1\'R[?!#P4
M6))_L>UZ_P#7):[K'K7#_"%67X)>"<G_ )@UI_Z*6NYH **** "H9/\ 61?[
MW]#4U0R?ZR+_ 'OZ&@":BBB@ HHHH **** "BBB@ I/E]JX+XJ>)M3\*^"X[
M[298H+JYO[6Q%Q.P5(%EF5&<E@0, G!((!P2"!BN+NH_BEIOA/Q5=7GC"TL)
M+6-;_2BT\=T^T*=Z3,84!1R %(&03U/ IV ]QXK/U;5;/0]&N]7U"1DM+.)I
MIF2-I"J*,D[5!)X]!7B^G_$K7KGX/>*OB2UV]O>VZF!="E163294*H=YVJ['
M)\PY(&U@.V:Z>^M=<L=*\1?;O&R:YI=YH4EQ;V\L<:SB0(?,D0H%!B(9,#!P
M6Z]*+ >A:3J5GK&CV>K6$GFVEY"D\+E2I9&4%3@\C@]ZO\5XSX/U34[-/A-I
M%OJ)&GZGX;=IX-HPS100%"I(W _.>]9"^,O'+_#RSUJ-]3U;[)K]]::B=,MX
MC>-:123(C1H5VG!5-V%R0#18#UZ;Q5HUOXUM/",LSC5[NU>\BC$;%3&K!22V
M, Y[>WTK?XKP;PMXRUG6/B-X3T^U\7_VQI&K:!=737*V:0NTR2[-WW?E(Z;3
MD @\<TZQ\7>+AJ.H_#N\\07#>*EUU8;>\^S1[O[/*"7SR@7:!L#ID\;R/I3L
M![O\OM6%HGBG1?$-]JUCI=RTT^D7'V6[5HFC\N3&=OS 9X[CBO%[?QE\6_%.
MJZQ>^%TLK>RTC79K!Q<7$2PB&%PKB52I?<1D[E<#D8'>M+PI:ZQ>^)?C%#H.
MI'3=6.K1FWG"JX#BV3:&# C:3P>]*P':Z]\(/A[XF\0R>(-9\/1SZC-CSIHY
MI(O.   #A& ?@ <BM&;5/!_ACQ'HOAWR8+'4=1C-M8QQ6Q&Y(P6V!E7"@ $X
MR!7&_#?QOK'C:[T1/MDRMIFFL=>B:-,_;BWEB%OE&T@I*^%QQM[&HOBU;ZA=
M?$7X7V^E:@=/O'U*[5+GRQ+Y?^BOD[20"<9Z_D>A /9 01FEKYPU#Q9\2]%L
M?$?VGQ+)?)X,UBV6]N8;.%3>V$B)))N&T[716R2N.,\=,>L^!M5U+Q NK^()
M;YYM)NKQH]+C(0J((P$\P%0"0[AV&2>"M%@.VI/E]J\?2[\?:M\8_$FC6?C(
M66CZ,UA=BW_LZ.1I8I%D9XM_!&=F-W7IZ<XW@7Q7\4/%%SX>\4E[1-!U&60W
MD4MU#Y<<9W!$B41B1900H(9VY#9 SP6 ]YXI'950L>@YKYCOOC!XJ\,_VS/X
MBU&ZL-;M4N7@T?4+)!9WJ;]L,MM-&N2J##.&=B>>1V[U]9\8>&?B%X)T^Z\0
M_P#"1:5XF\Z"X$EK%&;>5(C(KQ&,#Y#@C#;L#O18#T7PWXHT/Q=I!U30;T7E
MF)G@\S8R?.APPPP!X-;)94!8D =\]J^9?#_B#7O#/PXTVZT?4#;-=^/9["XC
MDC1UDAEO65AR"1T/((/)]JO>//$GBJYM/C1HH\1W,-IH-A;7-DT21(ZK+"S/
M$6"Y(/0'K[]:=@/<Y_$6CV_B33_#\MQ_Q,-1ADN+9%0D.D>-S;@,#&X=^];6
M!NQ7C?\ ;6N>$];\)VTNKSZGITNA7MW+!-!'YK-!'$P =%!/WR, =AG/6LB'
MQMXRA\#^"OB,=<%Y'KM]:P7FDB"/R4BN)-@6)L!PZ$J,LQR0<TK >]\$_=I<
M#TKYW\1>,OB)9:?\1-<M/%4,-MX5U6.&WM#81DSQE86\MFYP")",CDGNM>J_
M$CQ7<>#?ACJ_B:SB22YMX5\D2?=5W945FYZ L">>@- ':=!7)0^/O"<_BA/#
M<.JH^H/-);*HB?8TT:[GB$FW87"\E0<]?2N6@U?Q;H/Q.T/PIJFO#6M/UZPN
MIDN7MHXI;::'83MV  H0_ 89![FLSX#Z9<)X5U6\OM4;4,Z[J!19(HP$D%PZ
MM("%#9;G_OH\4 >IZUKVD^'M'N]6UB]CL[*T0232ODA%)QD@<]:LZ=?6>JZ7
M;:E92+-:W4:S0R 8#HPRIY]C7SMK"ZJ?&7QX6YUR:ZMK70HE2VDB3&Q[65U3
M.W@*6;&.3GG-6_#/B_Q=X0N_ >EZKJ5K?Z+JGAN6[^S1VNR2W-O;J^%D#'>2
M#@EN_2BP'T3L0G.T9KGO$'B_PMX3-M_PD>L6NEK=,4A:X;:)"/X0?7GI7D?P
M_P#'/Q9\1:OX7UJ]TN!_#&M0N]V\DENB0,02GD;7,C<C:0^3_N\XTOV@?.;1
MO S6L4<ES_PEECY22L55FP^ Q ) )QVH ],T7Q?X6\17,]IH>MVE[<VX!E@C
MD'F1@]"4/('OBMYU#(5!VY[CK7SO?WVOV?[3'AW5?&&C6FDHNEWL5A+IDWV@
M7S*@=TD9E1AM7) V]>_-6X_B!XU_X5[X>^)C:A;3V&J:A##<:1]G $5O+/Y2
MA''S&1<J3G@G/'2BP'K'A7P9I/A%=1&ERW<@U&[>^G-S,9<RM]YAGIG Z5TQ
M5?[HKY_3XF>+X?B#I-C]NAOK*_UZ;2Y4@LR;6&(*VP"?@M,-N6 W#.1Q@X?I
MWQ"^(%KI/CSQ=K&H:5=:)X8O;^RCLX;5HY)VB"^62^X[1D@'@GD^U.P'LMSX
MBT*U\16?AVXU&"/5;V-Y+>T)^>15&68#T K8VK_=&/3%>$B'Q$OQK^&=WXBU
MBUU"2YL-1?%O:")8G,41(4Y)*X/&3V/K7>^,O$>IV7B;POX5T>X2RNM?EN!]
ML>,2^0D,6]L(2 225')X&>*0'6W^GV6I64EG?0)/;28WQ.,JW.<$=Q[=ZMHB
M(BHJ@*HP !@ 5\]:E\3/B'97&K>&HYM).M:/K]CIINY;9S'=V]T?W;% PV,,
MC."?;'6O7=/D\4Z5X'N9O$E_IM]K5M#-)Y\*&WMVQN*;MQ.T8QDYXYHL!U6U
M?[H_*DP$'' KQGX;_$'Q)X@\:PZ+JMQ%?6EWH$6K+<):- $F,FQTC)/[R/GA
MO;J<YKJ?%WB36(?&?AWP9X?G@L[S5DGNIKR>+S?)@A"[@B9 +L74#)P "<&B
MP'2:#XF\/^)1>-H.J6VHK93FVG:!MPCD !*D^O-6-8U;2- TF?5-9OK?3[&$
M9DGG8(BY..2?<U\[>"M8\1^%-6\2;;JUGN+[X@IIUXWD;4ECE1 650WR-T/4
MCJ,=*V_'/B75-:\+_&[PSJS6L]IH%A&UF\<1C;$UNTFULL0Q4@#.!TZ46 ]'
MT?P#X6@\<77Q"M?M%SJ6I(&266X9XHU95!,:'A=P"\]>W .*Z>/2-/77)-9%
MJO\ :#PK;M.<EO+!)"C/09)/'7O7E%YXO\2>$=7^'R7$EC#X)U:T2UN;EXCO
MM;@0YC'F%@ KD #*_P )]17;>#-:UO6O!B:]J"Q;KR2>>U4H8<6V]O(W YY,
M81B>/O=!B@#M,"F[5&,* *\&\#?$_P 6Z]XPT'1]4O-.N4UFRO)G>QM&\BUF
MB9=J1S;R)P V&QQGO5W1OB%XNOO!'@_6KBXL#<ZCX@;2+U4MVVR1>=+'N7YO
ME8",'N.318#UO5]9TK0-'N=8UB\AL;&U7?-/,P54'09/U('U-6;2ZM;^Q@OK
M299K>XC62.1.0ZD9!'U%?/UV_B"\\"_'276-86]M(&OK>.$P;2-ME&5(;=@
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M9I=J_P!T4M'I0 FU?04;12T4 %-"J,X44ZB@!-H]!1@$]!2T4 )M7'2C:O\
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M#R9#[=BJ1D8ZY^Z,8KT.B@#R/0O@G;Z+K^@ZQ+XZ\3:E)H*R1V<5W<QLB1N
M#&<("1A1GGL/2NQ\8>#;7Q9'IDG]H76EZCI5T+NSOK3;YD+[2K## J596(((
MP:ZNB@#R_4/A#I]]I4<'_"0:G!>MJL6L76H)Y?GW4T?^K#$I@*H"@    5W.
MMZ);Z_X6U#P_?22>1?VLEK+)&=K[74J2#V/-:]% 'E7A;X/KX;\6:?XC/C;7
M]3N;.R^P>7<R1^7)"""J$*@^4=<=SSFMSQW\/K?QM)I5]!K5]H.KZ3*SVFHV
M!42QJZ[9$^8$%6&/R%=S2=Z /'(O@1I\.CZQ9KXQU][O4M1AU47TDL9EM[F-
MLB1 $ R1P<YXQZ5&OP(A%IXJBD\<:]<3^)[:*VOYIWB<N$4+D IU(R/0 X'2
MO:**=P/$O%MA=:Q;Z5\$[[0-5UVWN(;::X\07$2I;)%%*&?<R8_>;4"@ <EQ
MGC)KUVXTVTN-&ETEH@EK+";<I'\NU"NW ]..E:'>BD!XMX;^!@T'5O#>H3>/
MM?U ^'XV@M8I&C5!"P7,7"Y"_*,\YP .,"GM\"XO[0B\KQQKMII=KJAU:RTZ
MW:-8[20LS$*2A)&YSC/0<=S7LPSWHH \HO\ X0K=3^,5A\7:K:67BA6$]D@C
M,43NBI)(,KDEE0 9.!D]\89-\&;6]U/PW<ZIXDO[ZVT/3'TH6LD402ZB=-D@
M?Y<_,N!QZ<$5ZU13N!Y1HGP<BTE-+CG\5:EJ*:#'+'HBW.PC3RX*A^ /,95.
MU=V0!VJQHOPJ.A_".^^'%OXKU![.Z6:-;MHX_-B24DN@^7!!+-R>?FZ]*]/H
MI >1_P#"F2-8\/ZLOC;5?M7A[3AI]B6B@981M"F0*4P'*@ GTI=4^"\6H2:9
MJ$/C37=.\062RPRZQ:RHD]W%)(TACD&W;M!8[0!QQZ5ZW13N!Y1JOP9L)[W1
M-1T7Q1K.@ZGI5G_9[7MM,KR7<&<D2[U(9LEFW=BQ..F.F\ >";3X?>#D\,V.
MH7FHVL4TLJ/>.&<;V+%1@#C)_,FNQHI >3Z!\%=%\/\ BEM2M-=U9]&6\:_M
M]!DGS903GG>%QDX)+ $X!P>HI]G\'[2QOKBWA\17X\,S:@-4_L%DC:!)@_F8
M#%2PCWX;8#C(Z]<^JT4[@>.:A\#X]1TGQ3I<OC75Q:^);P7MX@CM_OC' /E]
M/E3_ +Y]S6E)\*)I/$]SX@/C351<W&DC1Y%$5N%:( X./+Z[B6^OMQ7J-%%P
M/(=(^"L.D3>#Y(/%VK2)X369;*-TAP1+D-GY,G@X^@%4Y/@2DO@K6O";>-M6
M-CK&J?VK.WEP[O,+;V4?)T+!6^J^A->U447 \YG^&:W'CO\ X2Q_$6H_O].7
M3[ZS78L=ZJAPK/A<@C>3A<<@?2L.?X'VTO@?1= 7QEK4>H:%-YNFZNK(MQ:I
MMV>6NT ;=H QWQ^%>Q447 \FU;X+V.J>&]*L?^$FU>'6]-O#?1Z^)@UVTK#:
M^21C:5"KM&  JCM7:>$/##>%= 739=6N]8NGD::YO[QMTMQ(<#<>P  4 #H%
M%=+12 \>;X(QQ^%O$7AJU\8ZK%IVM7POA&5B86Q\SS&5<KW;')]![YU;[X5P
MZQXGU76=8UZ[OH]4TC^QI[8QQHAAY.00N=VYF8'U/I7IE%.X'BL7P*=O!^H^
M'=2^(&NZJ+JT&GPS711S:V^X,R(I!&6VJ"QYPHQC%;^O?"FU\1>!=!\/77B"
M_AU#07BDLM8M]J7$;(-H/ QRO!]>M>E9YQ2T@/*+SX.6=_X<LK2Z\2:G<:]8
M:@NJ6^NSE'N%F7 &1@*4V@+MQCCUYK0C^'%T=(\2QW7BFYGUGQ%&L-UJGV>-
M6CB5"BQQIC:J@,^,Y.6)R:]'HIW X+P_X"U#0E\+P#Q??SV?A^V>U6U"+''=
MH8PB>8!U*8R#[UWM%%( HHHH **.W%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %(<TM% 'A?[3FHOI?POTR=?XM7C7C
M'_/&8]R/2BF_M0^5_P *OTOS&*_\3>/I_P!<9J* .]^$:D?!3P6"-I_L:TZ'
M/_+%:[FN'^$2[?@EX)7G_D#6G7_KBM=Q3 ****0"5%)_K(O][^AJ6H9/]9%_
MO?T- T3T4=J*!!1110 4444 %%%% !1110 4444 %%%% !115*^U/3M,A$VI
M7UO9QEMH>>58P3UQDF@"[15:SOK2_MQ<65U%<PGI)$X=3^(JS0 44A8"J0U/
M3_[4_LO[=;_;Q'YWV7S%\T1YQNV]<9XSTH O4444 %%!.!6;;:SI5]>36=GJ
MEK<7,&1+#%,K/'CKN4'(ZB@#2HH[5G7FM:3IT\4&H:I:6DLO^K2>949_H">:
M -'O14<4T<\2RPR*\;#*LIR"*DH ***IWE_96/D_;KR"V\^188O-D">9(>B+
MGJQP< <T 7**3/&:IVVI:?>7$]O:WL$\ULP6:..0,T1/0,!T/UH NT57N;RU
MLT$EU<Q0*> 9'"@G\:D61)(UD1@RL,@J<@B@"2BJT5Y:SSO##<Q2R)]Y$<$K
M]1VJSF@ HHJL+RU-V;/[1$;D+YABWC>%SC=CKCWH LT444 %%%% !11522_L
MX;J.UDNH4N)/N1-( S_0=30!;HI"P5=QX'O44=Q#-&LD4R.C=&5@0: )J*,T
M4 (:7M44DT<6TR.J!B%!8XR3T%+)+'#'YDC*B#JQ. * )**16# ,IR#02 *
M%HJ*.:.9-\<BNN2,J<C(ZT+-&\C1K(I=?O*#R/K0!+1110 444UF5?O,!]:
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MR,#K7M=<7XB\)ZQJ/BFP\1Z%XE.D75K;26KQ26JSPW",RM\ZY4\%1C!'4^M
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M\G/->*>(/%TFA^-_%*:/K6K(M_.JW5M<>%[B\AB=(EB+1.C+D$)GG(../4B
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M69621%)5@0<]:H_!_2]2T_PEHMIIOBRQU[PG;Z=Y$4\4+B:6Y$SESN)X11A
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M XQZ]-^Z\ ?$"\\<>"O%%WK6D7L^C37$MYE)(E(F5498E^;A548R1DY/&:-
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M[L%'"CVKA?#/@OQ#8_$#QSK6MG3WT[Q*81'';R.9(ECC,8#94 Y4YX.0?7L
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M^TW]F'PPTS[3N*?VO'C&.ODS>H-%2_M*VT%S\--.2<R!1JT;#RRPY\F;THH
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MYLPUM)= S-'%=8 4J5'7G&%KWWX(:HNJ_#821Z+;:4L%]<P[;)F:UG82DO+
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M[RV*_P#$UCZ$C_EC+Z45E_M4^?\ \*JTO[/&9&_MF+($A3 \B;THH ]%^$;
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MEI);HT2D=PI& >3^=<HWQ;T&'2O$EY>V.IV<WAQ8Y+^UDMMTL:.NY7 0L"N
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MMZQ74*RJ&P1D!@><$_G7E'@?QW#X=\(:O+XLUZZU"9/$EYI=FT^))[C:^$C
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ML;!E XV@@\\Y-='9?%#PSJGAG3-?L?MUS::G>_V?;HEJQD:;+ @IU &ULD\
M*<UL^-/$@\(^"-7\3-9SWBZ=;/.8(5RS8'Z =2>PR: "_P#!'A#5/$<'B+4?
M#>G76KVX417<MNK2)@Y7!(Z@\@]J-0\#^$-5\16_B'4?#.G76K6^/+NY;=6D
M7'3DCG';/3M7GVC^.HO$7B/X>7E]K&K:-?:KITMR-$6T(M[QO+#,QD8<JHR5
MYY^4_72?XZ_#]8IYFO-12WM[TZ?<3MI=PL=O-D#$C%,)R1UP:+ =3)\._ TK
MZH\GA/2W?5O^/YC;*3<\Y^?CGGGZU5C^%OPYBBNX8/!.CQ17D*V\ZQVJJ)8U
M8,%.!TR ?? ]*AT7XI>$=:373#>SVCZ%&)KU+ZUDMFBB*EA)MD .TA2<U+X<
M^)?A;Q/K\N@V%W/%J:0BY%M=VSP/)">DBAP-P^G3O2L!TVDZ3IN@Z3;Z3H]G
M'96-NNV*"(85!G. /QK,U#P5X4U;7QK^HZ%:7.J+"UN+J1<N(R""N?3!/YU+
MXA\3:3X;M[>?4YW5KJ406\,,;2RSN>=J(H+,< G@< $US5S\8/ ]GI%QJ5WJ
M4]O%:W:6-PDMG*DEO,XRBR(5W+GL2,>].P&DGPS\ PV^GP1^%-.2'393/:(L
M6!!(2"67T/ J;_A7_@IO%P\7?\(OI_\ ;@.?MODC?NQC=]<<9ZUQ/BKXE6NM
M?#+QM/X/U:^TW6M LWN&\ZQ,4J80NAV3+RC!2-V*Z;2_'FCQ:KHGA34KJ;^W
M[W3TNPAMWVRKM&Y@^-IP<YP:+ 7U^'?@=?%S>+E\+Z>-=8[S>>2-^[^]Z;N?
MO=?>H;KX9> +T:H+GPGITG]JRK->_N@/M#J20S8[Y)/UK7T#Q#IOB?2%U727
MF>T9WC5I87B+%6*G 8 D9!YZ&O+KGXE1^$?C1XMTWQ1K5Y+H\-A:75I;1V33
M&$L7$A'E(6V\+EFX&>3TH ]&D\">$I=5&K2:%:F^%K]B$^"&$.,>7U^[[5Y+
MX\^"9GN]"3PAX=T"]T+3(YE.AZC)+"H>0@F5)$R<\ 8/'IST]%L?BIX)U/Q!
MI.AV.M?:+W6+<W5DJ02;)HP"2P?;MXVMD9R#QUK=\-^*-(\5V$VH:--)/;13
MO;&1X7B!=#AL;@-P!R,CC@T >?>#?@[ING^'Y;'Q1I]C-OO!?6]E9RSF'3W"
M[?W3.V[/)RPV_3U]-TC2--T/3(M-TFRCL[2+.V*-<#).23ZDDDDGDDY-<]KG
MQ)\'^';VYL]2U1_.LU5[O[/;2W"VBM]TS-&K"('K\Q''/2J&J_&#X?:+K*:3
MJ/B!%N7ACN$6."6421R$!&4HI# Y'(XY^M%@-KQ!X$\*>*;VWOM:T>.XNX%*
M1W*.\,H0C!0NA#%3DY4G'M575_AIX*UNWTFWO]#3R-'_ ./"*WFD@2V(Z%1&
MR@$=CVKH]3U;3]&T>YU;5+I+2QMHS+--(<*B@9)-<?<?%?PDOAS6];M;B[G7
M1;875S;&RFCG"$$JWEN@;:<??QM R20 :0'>JH50H[<5Q=]\,? ^I:OJ^K76
MAI]LUF'[/?2QS21F=,8(.UA@D  D8)'!K5\)>(E\5>$=-UV."6V^UV\<K121
MLAC9E#$#<!N SC<.#VK@M0^*D6M)\0M%\.27%CJ'ABS9TO);5MK2JCLPPZX&
M"H S][.1D<TP.L@^&_@^TU32-4ATM_M6CVQM+)GNIG$,17:5P6((QQR#5;PW
M\*/ ?A/Q#+KN@Z!%97LF_!5W*1[L;MB$[4SC^$#C(Z5G^ _BIX7\1:)IEK-X
MBMIM;&F1W=XNUD7(0>:P) 4A3UQTKH]+\=>$]9UE=&T[6H9K]X1<QP$,AEB_
MYZ)N #K[KD4 =11CG-%&:0!1110 4=J** "BBB@ HHHH ***3F@#P;]J6X^S
M_"W2VV*^=8C'SY_YXS>E%0_M7)8M\*M*^W2LB?VS%MV^OD344 >D_",J?@GX
M*VC _L:T_P#1*UV]<3\)?^2*>"NO_(&M.3_UQ6NVH **** $J*3_ %D7^]_0
MU+4,O^LA_P!_^AH&B>BBB@04444 %%%% !1110!RWCC2]<UCPM-I^@KITMQ(
MZ"2#4TWV]Q%N_>1N,$X9<CBO*=+^#'B;0VT'4M'OM(LKO3M:GU%=.VRR6=G#
M-#Y;QQ'(<XY;!V@ECTQS[_G'6N%OOB ;76_$^CP^'-1O+S0;"*_6*#:S7RR%
MP%B&>N8R.<'T%,#EM0^'_C&SU/Q98>&;K3#H7BXM+=->LYFL)I$V2NB@$2 @
M9"DK@^U17OPW\:>&?%MCJOPTU/38;.XL;;2M1MM4C9@L<(*I,FS&6"DC;P#^
M->N6%TU[IMK>26\EJ\\2R-!,,/$2 =K#L1G!JWN7.,C-(#P+Q/\ !OQ;KWCV
MZ\4Q:Q9Q:A:Z;!!I.I"1TGAN8F9MSKM*E'W,K+SP?;GIX_#OQ&N_B3X9\2ZM
M!H?DZ=I=S:W7D7$A+RR[3E%*<#,:=^[>@SZJ74=2*Y[6_%,&EZ'J]_I]C<:Y
M=:6566PL 'G+D*0H7UVL&^E.X'CFF_"CQ[I6FZ+KD,NE'Q/X>U*]NK6!9G:W
MO(+IRTD3,0#&?F.#@]/>K/B'X8>-M=\->(+OR=)A\2>)=0M)KN,W#^1;06VW
M8BG;ER0O)P/O8Z"O<[2Y-S8V]R\+V[31K(8I1AT)&=I'J.AJP'4CK1<#QG6O
M!7Q"L_&FMZMX3GTAK+Q1:QQZE%>O)FTFCB\L/$5P6!'&#CIFL'3OAE\3_!L>
M@:IX1N=!N=3&D0:1JMM>[Q PA!\N56')8 E3TSFOH3<",]J3<,]:+@>2:1X*
M\;67QQA\8:A-I][IPT(:3+,KF.5WWK(TFP+@ L" ,\#%9H^&OB>Z^,5GXNN+
M+2-.-KJ$D\NJV,KI/?6N&$=O+$ %)'R9<D_=KO\ Q?XU'A;[+:VFC7>NZI=1
MRS0V%D5$C1Q &1LL0.-RC'4E@ *F7QKI<?@FR\4ZE;W>F0W:1E+2ZA*W(D<X
M6+RQR7)XVC- %?XC^$9/&O@.\T2UNQ9WV^.YL[AAE8YXG$D9;VW* ?;-<[I/
MA?QAJ'BF+QSXIL]-@URRTM]/L;*VG9X2[D,\C2%<C)   ' !Y/%>E65PUQ80
M3RV\EL\D:NT,F-T9(^Z<<9'M679>)K&Z\27OA^2*6UU"U42K'. !<1<#S8R"
M=R@G:>X/4#(R <W\)/#?B3PE\/K7P[XCBL5N+220I)93-(L@>1I"3N48Y;'?
MI5'Q7X;\:K\4['QAX573+F$:3-IMS!?S/'@&02*4V@\DJ%YZ=:]#N]1LK"2V
MCN[J*![J40PK(P4R.03M7U. 3^%8'A/QI9^+KWQ!96^G75G)H=^UA,+D*#(P
M .Y0"?E(/&>HH \JT_X>?$BS\&> _#[V.B2#P_JS:A<N+V0;QN<JJ_NNN)6R
M3_='J:U/#/@?XF^$_$<OAS3+_1CX):^>^CNY49KZ"-Y#(T"@_*3DL-QS@,3Z
M"O;,_2LCQ+KUOX8\,W^OWEM<7%M80M<3);('DV*,L0"1G Y_"BX$NM:-8Z]X
M?O\ 0]21I+2_MWMIE5MI*,I4X/8X->6>&M-^,7A&PM/!\&GZ%K6DV*K;6>L3
M7+PR+ O"^9$ =S*O'! ..O>MJW^,WADPZ1=:IINLZ+I^L>4+*_O[(I;RM(,H
MN]2P4D=-V![UZ7N7 Y'- 'CU]X(\:Z#\2F\<^&);+6;C5-.CT_4[:^;R/G3&
MR=&4'CL5_4YXS=#^&?BOP[XL\"S6<6F7>G:0M[-J,[3,C//=-ND\M-I^5?X<
MGD=?6O<]P]J3<,=A2N!\_7-SXHD^/WC^S\&V^E7MU/IEE#(+NX,;0$JX$F #
MO5<_,N,\@9'?1TWX:^)OAMJVE:AX#MK;7(?[)CTF^M;VX^SMF-F=)T;!'WG8
M%2.A&#7>>+M2\.?#[0]3\=2^'EEFMX_W\ME;)Y[JS <MP<9P3D]J[.-_,B63
M:1N .#U%,#P_P_\ #7Q9X5\4>!&L;6QN[#1H+TZC<-=%"TUW(K2%$V]%P<>H
MXXKG->^&?Q4U#QM?ZI]GT?45@\10:IIU_>W3F1+97R+=4Z1JO4XP2<]>M>]Z
MEX@L-,U'3]+E+3:AJ#E8+6$;G*KR[GIA%'4GU Y) .=X/\<:;XREUR/3[*\M
MO[%U!]-F^UQB,O(BJ25&2<?,.N#[4 >8ZQX(^(<'B3XE2:5I.EWEAXMTY LK
M71C=9A (2FW'3+,V3V '4\0V/P[\;Z&OPZ\4Z=IME<:]X:TO^R+[36N@J3P[
M=NY)-N X///!SC/%>RZ7XCTK5=5U#2K:9DU"PDVW%K*I211DA7 /5&QD,.#]
M<BM*>\M;:6WCFGCC>X?RXE9@#(V"VT>IP"?H#0!X#>?#7QS_ &SHNOII=A/?
MR>*6\17\,=[M2W7RUB2)25^<[1DG Y!QZUV7PS\.>+M%\;^.]6\1:5:V=KKU
M\EW;-#=><V%78%88&. #^..U=AX:\8:;XHN=:M;&WNX)M'O/L5PEU#Y1+[%<
M%0>=I##!.*Z7(]J0'FWQ3T?Q/K2>&E\-Z-;ZC]@UB#4K@SW(AVK$<@+D').3
M],&N,F\$?$:Q7QUX6T[3;*Z\/^,)9;B*[EN%5].>X4+.'3JX&25P3T [\>^5
MSWB[Q38^#?">H>)M4BN);.PC\R5;:+S'QGL/ZD@#O3 X#P5X.\1^$_BK=F/1
MXSX871;32K6^>[5IO]'!P63&?F+G_OD>O'3_ !2TWQ9JWPZU*Q\&2;-7D\LH
M/-$1D0.I= Y^Z63< >Q/45U]C>PW^GVU]#D17$:RIN&#M8 C^=,U"_CT_3+K
M4)8II4MHGF9(4+NP49PJCDDXX'>@#YL_X5W\1[?3/B#:Z?X'T^V3Q3I=O;Q6
M\>JAO(D5&1MS-R[_ #%BW / S7<KIOB+3?'G@[Q1KFEP:?HNB^'9;74;NXO8
M]MI,X0G//('E ;NGS>U>J:+J]OKFA66KV\$]O%>0K,L5S&8Y$##.&4]".XJ;
M4]/T_5]+N=-U.VCNK.YC,4T,J[E=3U!% 'D/PG\-V\/C;Q3KFDZ@+SPHEXXT
M1(G#0H\P5[HICJ/, 4'.!A@*Z/XZ,J_ ?Q:6QQ9'&?7<N*[S3=.T[2=.AT[2
M[.&RLX%V100($1!Z #BJGB#P[HOBC2'TG7M/BU"P<AG@ESM8CIG%*X'CVO\
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M=R,Z8!?WB(?N/<I#A"?4J&8CTSFO19O"/AFX\21^))M#LWUB-0JWIC'FJ!T
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M&Y2 #@')()')'!S7H&F^%+H^/[WQGK5TLUWY)L;""/.RTM]VXGGJ[D L>P
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M+[_2]%@Q.)@);?? O$; ?+M_AZX]ZV%^&_@X:'J>CMI3/;:L5:_:2XE:6[P
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M/]9#_O\ ]#30T3K2TBTM(04444 %%%% !1110 4444 %%%% !1110 5Q^O\
MC:'1?%&G^%[72[W6-7OH)+I;>V\M1'"A +LTC*!R0 ,DDUV%>1_$CPUX?\6>
M,M)T]?$5UX9\9V5LUWI>H6TBJQ0MM9"I/[Q=VTE?ISUIH#N/"OBNV\5:?=74
M.GWFG-:74EG-!>HJR+(F-WW688YZYKH]RXZU\F7?CWQ==:#I-GXDOK#1H8O%
M,FEZSJ]FC&TN@D*[&D*LIPS$*Q#*/EP?2M*^OAX6T72M/G^(,^O>$+WQ-Y&H
M7<#,D5G"T>4MA-O8^5NQG#= 02.:=@/I.^U73],^S?;KM+?[5.EM#O/^LD8X
M51[FJ5OK-U+XLO-%;0[R*UM[=)UU)MOD2LQ(,:\[MPQD\?TSX-XFTWP5%'X7
M:SU^36-(A\91GSI;PO!8I)"[-"D@(^4,H(Y)!(&:7Q7K6J:+X\^)$_A*^EFF
MM_"$%U9QI.91 Q9@7B0D@80!N.X'K2L!])A@>AS1N%?.]O\ V?I7Q'^&DG@C
M5KF>V\0VMP-3C%T\JW4"PAOM$GS'#AOX^#DD5Q^BJ;'P9\./%T?B'4FU6;Q6
M-.EEGU*1E>V:XE4QE68J1M [9.>3S18#Z7\3>(SX<T^&XCT34]9N)I1%':Z;
M"))&."<DL555 !Y8@=NM1^#_ !=:>,M)GOK;3[W3I;6YDL[BTOHPDL,J'#*<
M$@_4$BM'5+ZQM+=;>[U:'3IKO,5N[R(K,_\ L!N&(SG&#]*\M^%>K-X;TOQK
M%XEUNUETK2];E"ZY/Y</VMI KNTA&%+!G"Y'L.PH ]7UC5;+0]$OM9U&40V=
MC"]Q,Y_A15))_(5R%C\28KQO#\LGAC6;2S\0.JV5W*L+1G<A==^R0E,J,C(_
MK70>*;K1D\#ZQ=:THN-&^PRO=!?F#P>62_3J"N>E>"Z;9ZQ\,];\)VOAGQ1;
M>*OA]K6H16UMIUZRRW%D9,X:%QU51S[<\<YH2 ^B+'5M-U,71T^]BNA:3-;3
M&)MPCE7&Y#CN,C([5?#JV<-G%?)>G747A'X3_$6?PS=FQO8O%4]M=-!<'S;6
MR^U*C. 2=I52V'QD<G.179:M)>>"_B!<6WP_OIY[&\\*W=^]D;A[F.*:+F&=
M=Q."Y8CKAL46 ]NU[5TT/P]?ZRUM+=)90/</# 5#LJC<<;F49P.Y%0Z!KT/B
M'PAIGB.TMY%BU&TCO(X&QO = P7KC/..N*\ T>Z\'3?#Q_%&C^-YY]7O/"]R
MM_927QF^T2^26>:5&)*,K @$8^\!TXIGP&U^'5-4T?3_ !A/<6&N:?H\"Z+:
MF=EM[FR\L?O5 P)),AMV<XY':BP'NW@SQA9^--!;5K.UN+-%NIK4PW(42!HG
M*-D*2.H]:Z8R*/XN:^2O#-O!I_AC3/%\&LW<6H'QTUH/+O"8?)DNRLB;,A2&
M!))()[^E;%YJ-SK?@'XF^*K_ ,07VG>+?#VJW2V16Y:,VJ18^SPB,$*RN,CD
M'<7)Y-%@/=M)\8V6K^./$/A*&RNH;S0DMY)I)0OERK,K%"F&)Z*>H%2ZCXJM
M=.\7Z'X8GM+EKC64G:"= OE*8E#,K'=D'!XP#]:\3A\2ZUI7C/XLZ[#$#KMG
MX9TVY$!^;RY1!(S#'H&.<40R^'%^(?POUS0]=_M*^OK&^:9Y+\S&>0VJG)5F
M.&+9X '.>*+ ?1^Y3WI ZDX#9-?+_@&]U+Q5#H'BBY^)MI::C--+!J.G1R2B
MYG),@,+(9MJE>2I5%VA01Q75?L]:7=7W@RS\;:GXJUS5KVZ^TV_V>]O#)$B+
M.P!V'^+Y0=Q.>:+ >U:GJ5EH^DW>J:C<);6EI$TTTK\!$49)/X56\/Z]IWB7
MP]I^NZ5,9;*_A6>%B,':PSR.Q'0CL:\Z^*EUK&NZEI7@70M)&L1W#"^UBV\]
M8LVB,-L;,W02/@8[JKCUKB_A'K&O>$;+QY\.[ZP:WU'P^LNHZ39R2"7-M(K.
MD8<<,%; X_O8[8HL!]&-+&N=S  #.37/W'BFUVZ+-IMC>:Q::O.(H[FPC$D<
M*E2WF2'(VIQ][GG'J*\+T>'0?$OPML==_P"$[O[O5-5T.Z.HV1U%W^USF+<Q
M*;OW7ELK8"@#'!XZKX6F&E_#_P""/]CZS=Q_:[V"&\@6\=TD#VKNRLI/ W*#
MMZ#)XYIV ^E=P &3S2[E]:^=-0U2_P!<\.?%/Q)=>)-1TS7?#-Y=06$<=V\4
M5K'%&KQ9B!"-YA!R6!)#>F*J7=QXD\2>)O$:WWBC5]*$/@ZTU0V=I<F%8KID
M<G ZJ R#@$9[YY%*P'T?<3&&!Y5B:4J"VQ,;F]ADCFL?PEXHL/&7A6R\1Z9%
M/%:7FXQI.H5QM<H<@$]U/?I6?\/=6NM:^%7AO6+^Y^T7EWIL,TTA &YS&"Q(
M''7-?/\ X1TW6-+^&?@;Q-I_C#6)9=0UC^SY-+,O^C/;RW$B.BHN#N49??DD
M8)^A8#ZOW+ZUB^)O$%KX8\-7NOWEO<W%K9QF69;:/S'"#JVW(R .3["O$_#-
M]KB^+;OX0ZEJNL2ZI:ZP-2%_)</OFTO;O4^9_O;8B!CJ?>O>[ZSM]1TRYTZ\
MC$MO<Q/#*C#(96!!!^H- '"K\6_#K:AX6L_L6IA_%,8ETUOLXVRC&3D[OE(&
M"0>Q%=$OBFS?QQ)X1%K=F^CM%O7D\H>2L;,5!+9ZDJPQ['T-?)_D>)(_"W]C
MV[SIJ7P<NI;QG\A1]J0RAH@#V!@#D^O&:]=FNM0USX.>.OB1;S7FD76KVKW.
MFRQMY4\5I!'F $G.-S>8Y_ZZF@#US6M>BT633%DL;VZ&H7B6:M:P^8(68$AY
M.?E3C!;MD5<_M331=7-J;Z 3VL:S3Q^8-T2-G#,.P.UN3Z&O"X[#Q+X?TKP#
MK,_Q US5&UO5]/%Q#<RH(BLD+%U "@[20#M)[>IKE]>TF$^*OC_/)J^I1R6^
MFPRQJE_(N2;5WP0&^90<X4C ' &.*+ ?4=M=6]W;17-M,LT,JAXY$.5=3R"#
MW%3[E/>OE^^USQ/9+\-?AYH6I?9[;4]#-U)-=:G);//-L&$%PJLWRY)"J #Q
MVXJQH=KX^O?&?AGPAX@^)%ZTKZ/??;+C1KQ&61H[A50AFC_U@5PK'&?E[<Y+
M ?3&1C-<5??$;0;;Q!=:#80:AK>HV6#>1:7:M<?9,]!(PX4GG"YW<'BN>^!7
MB+5O$7PCL;S6=0EU"^AN;BU:>;!=UCE95W$=3M Y[]_6N;_9UDMTT_QM8W\@
M'B&/Q%=/J*R<.Q)&QL'G;P<<#O0!Z[X:\3:7XJT4ZMI+RFW$TD#">%HI$>-B
MK*R, 5(((P16[N&,UXUXNUBQC\9^%?">BZF-/TK7M4N_[3NK&<(SSQQ[Q#O!
MRK.V,XP>,#%<3XDUWQ9HOAGXCZ+9^*-3$7AW5+ Z=J32!YE6=HRT#NV2X3?U
M//(SFBP'TWN7UHW+ZUX#))XNT7Q+\0/#>D^,KJ[G_P"$?@O[2ZU::-1:W#F5
M"0P4*JG:IZ8!-<=K'Q$\2Z!X<U"T,VI^'-=DO=.M+ZVU:X-U'8QR&0-/%,"0
MR/M S_#@T6 ^KMZ^M1RSPPPO--(L<: LSL<!0.I)["OF#Q)-X^\,_#CQQ>R_
M$**>0&RN]/BTZ\:>2T5Y1&REWYV/G(&>WID&+QL=<TBY\<^&[CQ=J^I64W@Q
MM6 N+CYDN!)M)7:%*+_L]",YR.*+ ?45O<V]Y:Q75M,LT$RAXY$.5=2,@@]P
M14[$ <G%<1\.IM-L?A]X8TM-062X;389%CEN1)*P\M22,G) SVX Q4/Q,\0W
MVD^$9-/T&)[GQ#J_^@Z=;Q,JNTC Y<%B  BAF)Z#%%@.A\-^*-#\6:;<7^A7
MR7=O;W,MI(RG[LD;;6']0>X(/>MS<!WKYX^&D2?#[XQ:IX+_ +"NO#NC>(;.
M/4-+@NYHY"9XE5)P"CL,L,,1G/'I7+:CJOBZST#XC^*(_'6M2/X9\2);Z? U
MPOE,GF1!ED&WYU(DQMSCC.,DY=@/K#<OK1N&,U\]^,M5\3> /B7)?R7VHZIH
MOBFPDMM-M&NI&2VU/'RQC!&U7['C&"01BO3;PW/A'X.W37VO3)=Z=I3M-JES
MF9ED$9)E(S\V&YQ]!2 [;<I[TN1BOFSP%XL\3V?B?4H)KW4;RW/A--5MDU"<
M2O=RAV G";B8MXQ^[!Z8S@UJ>"97\3^%?#OB:3XG7MQ+JNFS1ZG8_: 1/,RY
MQ$H8>28V#CY1DC%.P'KFH^*]/LGTCR(;O48]5N_LD4UA#YR1MSEI&'W4&TY-
M=)7ROX1FO="^&?P?GTGQ#J41U/6X;>\MVN?,26-_,)4J?NC*C@8 R<Y-=#>Z
MSK7B:S^*>I-XNO\ 1]2\+W$T.GV\$_DQ0+%'OC>1/X_,.[);((Z 8HL!]#;A
M2U\OV>K>+/&GC?PM;7WBS5](35?!HU2ZAL91 //# ;EX.W/!./3TXKTOX0ZW
MJWBKX$:1J&L:M+-J,T,T4EXA D)21T#9QC=A1SCD\TK >J;A0&4C.:^4-#UC
MQGI7[.LOQ(F\?:M?:A?1+9;+R0-!:[KP1F8<9W*I/S9]_86=6U_QY\/[>ZAN
M/'EI=Z?K=[8VL!6Z:\ETM)&Q)-OD'W2HX)) )R!QR[ ?4VX4V1]D;-@G S@#
M)_*OE7Q7JVO>&M=^)VDZ+XRUBXM-(\/PZA9M/J#R/;3M)AL-R3GT/3.*[.WU
M[6+CXP^#M)7Q->?9-4\*/<74*RC'G *!,%.0&.3UXX[\TK >O>&/$5MXJT"+
M6K6SOK*&5G40WUN8)E*L5.4/(Y%;>X5\CZ;KGC?6?"'PL@C\>ZO9W.L:O?6%
MY<12(79%DEP>5^8A1@$\#@[>*Z?5)O'EYXYU+X=Z;XP>*70]'@:WO;_4&M)K
MF63)-PWEQGS0N -IP/7))-%@/HFZN5M+.6X97=8E+E44LQ &< #DFLOPKXFT
MOQCX6LO$>C/(]A>J6B,J%&(#%3D'IR#7D&G:UK?C#QJ/">L^+);>+3O#UO?>
M?H\YA&HSR<-.&P#L7;PHX.[)R.*ZCX"[X_V?O"Q4^8RP2=#G<?-?O18#U/<,
MXHW"OF,>,O%EQ\+;#XJ6_B2^35Y-=%O<:0T@^S"$W1@^SB(CA@I4[OO$Y)/3
M'6_#FR\5:Q\2/%.K7WCS5KC3-%UJ>QBTN388I4\E"-Q &-I?C'I[F@#V\D>M
M&Y?6O$?BC-XHD^+_ ("\/Z/XROM!L=:CO([I+81DGRHPP90P/S'<1DY P"!D
M5Y^OCWXA6MS'X!FU\73IXBN-*CUBYD^S/<QI")$B:4*P5R7"DA<\<$'FBP'U
M=N%&17S0\GQ.B_X1+P[J'Q$>UO+_ %F\TZ:>Q:.X9(!;M*BNS1@F5<8S@=0<
M9%7+^W\=P_$VX\&+\3-96VLO":Z@TRPP!Y)UD,>[)0D9VY/<\\T6 ^B]PKG-
M!\8Z+X@TNXU*SFE@M;>[>R=[R%H/WJL%(&\#(W' /<\=:^??!'B[Q]<ZA\)]
M7U3QE=W\/BQ+R"\M'AB$2>4A*,NU0=V5R3SDY[<5DWFHZ_X@^&E@^L^)M2GN
M+3X@IIBS>8(VDC$ZA<A5P2N,CC /:BP'UK]IMS="V$R><5W^7N^;;TSCTY%3
MU\Z:Q<:KX9^,7C36[76-1NY-*\))?0Q3S;XW96EPC#;]W*[L#'.>>:I6GBSX
MJ>%=#NO'&L:UIVJ:+-X?:\ALY;\3R2704.)(]D*80[@"H) &>>E%@/>+_P 6
M:-IOBS2_"]U-*FJ:HLC6L?DN4D"+N?Y\;<@#IG/(]:V9;B&W"F:18PS! 6.,
MDG 'U)KP&"SU*/XM_"34]0\77NO37UI?2RF81B(,;969HPBC"G(XR1POX[WQ
MGL;JZ\1?#I8=;U"RCGU^.%H[9U"Y\MV$F"I^8%>"<@9Z46 ]GK+UW7-/\.Z%
M>:UJTSPV-G$9II$B:0HHZG:H)/Y5X,?&'C3Q)X'\?>.M,\47&EW/AF^N;>TT
MM(HF@:.V 9O-W(79G&[/*XXP.*]/\5:B^L? /6]4:+RGO?#LTY0_P%[8DCGT
MS0!V&FZA:ZKI=IJ=E)YEM=PI/$Q4J61@"IP>1P>AJ]7S!:^(O'7PWMO!>HWG
MB8^(=%U?1I';3#:I$;9HK43+L*C<RX4J23[GKQTGPYUCXIZYJGA?Q3J&J6TG
MAW6(':ZMWN86 9DW1^0J1AEP0<JSL< YY%%@/>Z*1>E+2 **** "BBB@ HHH
MH **** "CM110!\]_M9K;M\)M)^T-M7^V8L?*&Y\B?UHIO[6<C0_"G274XSK
M,0^]M_Y8344 >I_"D*OP8\%!?N_V)9X_[\)79UQOPLQ_PIGP5MQC^Q++&.G^
MH2NRH ****  =*KS?ZR'_?\ Z&K Z5!-_K(?]_\ H::&B9:6D%+2$%%%% !1
M110 4444 %%><_&+QCKW@;X>3:YX?TV.]NA<10$R/@0AW"[\?Q<D+C_:R> :
MRM;^,$WARZ,>K^$[J&VM/LB:A<FXC"PR3D )$#@S[=PW;>GO3 ];HKQ"^\0Q
M^%OCYXEN9I[J[$^@6TMMIJRL[7%P99%"1(20"P4#@<<D]S6_XG^+5MX52ULK
M_1F&M3637\MA)?00B"(-MYD=@&8X. N22.W6BP'J%%>1R?&NUNI=%B\/^$M9
MUI]:TU]2LQ"L:;PC!60[F&"I/)/'3&<UW'@_Q59^-/!EAXFL(9K>&\0GR9UP
M\;*Q5E/;(8$9Z<4@.DK UWPCX9\2D?V_H5EJ3!0JM<0J[* <\$\CD]JXO2?C
M!::IXNT[09/#NH62ZN+C^SY9V0/,8<[MT>=T8.#M+=<#IFK7PR\<Z]XU'B"3
M6/#KZ2FGZG+9Q?O4< )M!0X.2P.<G&#GBG8#K9/"OAR7PT?#4FAV3:,4$9LC
M"#$5'0;>G84T>$?# \,?\(N- LO[%V>7]A\E?*V_[O\ 7K7%Z_\ &"QT'Q+)
MIT^@ZB]A!J,.ES:A\B*L\J@J%1CN=1N7+ <9XS4>O?&!='\6ZOX9L_!6O:K?
M:7;)=O\ 98X]CQ$X+ E^ ,'J,G' HL!V,W@?PC<>%X/"\_AVPDT6 JT=DT(\
MI2IRI ]<U-!X0\,VOB&7Q!;Z'9Q:K-"()+I(@':,  *3Z8 %<GHWQ9T_6_$^
MB:1;Z+J$-OK>E?VK9WTP012( "R=<[UW#(_IS74^$_$;>)O#,.N'3IK!)C(8
MXI2"S(KE5<8[,!D>Q%*P$>C>!_"/AY[EM$\-Z?8-=!A,8(%4N#U'3H<#CIQ5
M'_A5OPZ%K!:CP7I/D03M=1Q_9EPDK8RX]SM7\A7.:+\9K/5?%^D:#+X9U2QC
MUM+A]/N9_+4S>3DMNCW;X\@<;ASD5E6/[0.GWPM;I?!NNP:5)JG]DSW\R1JE
MM,7"*&&[)Y(SCI[T[ >E^)/!GA?Q=9V]GXET2UU2"W?S(4N(]WEMZCTJ6?PK
MX<NO#'_",7&BVDFB[%C^PF(>5M4@@;?8@'ZUYKK'QWL]'U#Q##)X.UR:T\.W
MD=MJ%VB1^7"C@$2?>R>HPHYQ@G&<5J77Q>M;>7QG&/#>H22>%+6*]F4/'_I,
M+KO#)\W]W)P?3UXHL!W&NZ9-J?AN[TFS-I&9XO*Q>6QN("AX96C#+N!7(QD=
M?PKSC2OA-J&@ZY_;6BR>#;#4>0L\7AZ0,@(P=O\ I/RYYSC&:EU[XUV>CV%O
M?6WA?5-0@_LF/6KEU\N-;>W?IRS ._7Y5ST-9^LZI_:'QY^%FJ:9J5W_ &;K
M&G7TS0>8PBD40*T;%,X!^?TS0!JVGPY\0V=]J]]:W_A*&YUC/V^1?#LF;G(P
M0W^D\@Y.?4DTWP]\-?$GA))X_#.J>%M*6?;YI@T"4&3&< G[5G !('/&:ZWQ
MCXVT_P '6MAY]K<7]_J=P+2QL;4 RW,I&<#)  QU8G KA[[X]Z'I.CZS=:QX
M=U>QU'1+F*VU#3G2-I(!+C9)N#%60Y'(/IQR,FH#;;X/WUBNI+9'P9 -3!6[
MV^&W'G@D':?])Z9&<>O--A^#^J0G3#'<^$%_LL%;/'AV0?9P6+';_I7&2<UZ
M'X3\2/XIT(ZI+H>HZ*1,\8M]1A\J4A3P^/0C!'_UJY#2?C%:ZQ)<3VOAG4WT
MM8KJ6&^B:.03>1]Y2H;,;'!P&Q0!C_\ "F;MM-73UC\%):I.;A8!X=DV+)_>
M ^T\&M"Z^&.NZCXCB\1:E=>$KK5H=OEW,FA3$C:<J2/M."1V)S530OCUI&L7
M?AQY_#.MZ;I'B!_(M=4NH0(//.=L602<G;P>GY$U9M?CQX3NO&6GZ$MO<K::
MG<O9V6H[HRDLRG:5*!MZ@GA6(P:-0)[7X>^+;'Q-?^);34/"<6KZ@GEW-TNB
MS[Y5XX;_ $GGH/RK'TOX,WFB:HNHZ/;^"K6ZCD,R2KH<Y*2$_>4&YPOL!P.V
M*Z/3_BUI^J:_I]C!H&KKIVJ2S06&JF &&Y>-2QP =P4A3AB!G!Z#FL'PIXZT
MO0O YO=.MO$^MSZAKMS906NHNKW)F!8LNYFVI&H1NIXP: $M_A'K%KXAOO$%
MNO@N+4]0C>.YN$T6X5G#YWX_TG@MGDC!-;'A[P3XT\(Z2^F^&+[PEIMH96E\
MB/2+@)N/4_\ 'SQ_]:N?\7>-H_%_PGTGQ5X=N]3TETU^SLYH1)Y4@;[4D4D3
M;3AAR>AP?TKU;Q1XBM?"GA;4/$5[;7-Q:Z?"9Y8[6/?(5'7 R/K],T <1;^!
M?&EMXMN?%45[X236;F(027@TJYW,@Z#'VG%55^&?B)?&+>,O.\)#Q X*M>C2
M;G>1MV_\_6.G'2I;?XWZ+=W"6UMX;\123W5B+_3XET]MU_'QN\L9X"Y7+-A3
MG@GO=N/C#X:B\$Z/XGBCN9O[:8Q65D BSR2+G>AW,%7:5.XEL#UZ9 ,'2?A-
MK'A_4[_4]%M_!5I=WZ-'<.FBW'[U6.2N#<X )Z@=:I6_P:U:SMK"VMK/P9#%
MIUR;RU5+"[412D\M_P ?'/3OVXKH[/XX>#]1\+IK%FMU)=->G3?[,(1;C[2%
M+-'EF"< $[MVWCKGBL>Y^.EI>#PXWAOP[?Z@NI:NVE72_NPUK*@):/A\%\8(
M.=NW/-/4 UCX8>)M6\0G7[Q/!USJ3",/(;&[C67RSE-Z+<;7P>FX'TIE]\,_
M&.HZOJ&L7EMX0FO]1@^RW,^+Y&DBZ;.)L 8XP/4UJ:;XTT71[OXC>(9KKQ!=
MII,L4M[8W$1;[)B$$B!<_=(^8G@=\XYK5\._%OPSXBUHZ6EOJ.G.UA_:4$NH
M6K01W%OQND0MU R,G\>E &=X?\-?$SPMHMOH>A+X/M=-MUVQ0[;Q_+'H-TA.
M,^]8FA_"[Q5X9U=M5T33_!]I/YCS1KB]:.)W&&9$,I521QP!QQ74Z5\7?#NK
M:SH^G1Z?J\!UQ6?3)I;,B.\1>2ZD9PN"&^;'!!XKJ/$_BK2_"UG:S:AYTL]Y
M.MM:VMNF^6XE()VHO<X!)]@:6H'FVG^&/C!;>++[QE/-X.;5KRSBLS%Y=QLC
MC1F;"L#DY+9Y]JW]_P ;B<!O!6/]VZ)_G5?6OBQ8?\(%XMU31+2\.MZ!;R&X
MTRXM]D]L^PLCNA/W,#=D$@C/?BL[X06.M7VD:?XVOO$6NRKJ.G1M=:?J>TQ2
MSD*YN(A_ I!("C YZ<4 2-X<^*F_6'73_ SMK0"Z@6%V/M $?EC//]T8^E1:
MEX3^)FJ>$5\)75GX,.AF!;5K:.2]C_=*H 3*L#MP ,9Y%:=O\:-!U"PN;W2=
M'UB_@6UN+NUF2V"QWB0L%?RR6]3W XYJMX<^,EIJ7@+0];U+0]135=9W?9M-
MM8/-EN=JAF>,9&8P" 6.!DT]0,:;X=_$*\TC1=*NK/P>UIH4JRZ>BW.H*864
M84[@^20"0,DXJ+4/AGXSO_$]_P")KO0_ TFJ:A:M974YDOE\Z%DV$%0V,[!M
MW8!QWKN+?XK^&+KPI+KUL+QY(KS^S7TWR/\ 3%N]VWR#'G[W?KC )S@5QGB/
MXC-KL'A/5/#&IZCI/D^*X-'U;3[B%8W .=\<H(.. ""#C#?D:@8\WP7\17/@
MFQ\(W?A_P5-I=E+Y\"&XO_,CD/!(DW;QD=LXZ>E7+3X5^,M/O=-NM/T/P=:3
M:=:/96KPWFH)Y,3[MP #\D[B2W7)SG/-:_Q,\=R:A\'?%FL>$[S4],ETAL1:
MA'&J1W#+)L<1L<[ESD$C';!ZUTFB_%;POJD>LQ&>[LVT*W2YNWO[5H 82"?-
M4, 2IVMVY[4:@<YX5\%_$7P/I4NE>&+'P?963R&8QFXOI!O/4_.6(S@=ZS=6
M^&?CC6/$9\37&F^$+?664))=V5S?VKRID?+(8V&_[H'.> !7;Z=\1]'\17K>
M'UAU31=0O;1[BQ-[;>0UU&!R\.[.2N0<$9&1D=:Y[X>^.S8_ WPUJWB&ZOM6
MU/4&D@C2)?.N;N7S)#M [D*IR> -I/2C4"E>?#WQQJ/A^P\/W6E>"A8:=*DU
MIY3WB/;.O1T=2&#<L2<\YYZU#>?#'QI?>%KCPW>:9X/N-.N9_M5PIGOE>>;C
MYY'#;G/"_>)Z#T%,^'_Q$6S/Q$UKQ-J>J_8K76D@MK74$_?P%HTVP+&HP"6;
M  ],GU/23?'/P?9Z1JE]J5OJEA-I-S':WEE-:9G@:3'ELP4D;6SP<]>.M&H'
M-WWPN\97UY?WEUIOA&YGU&T%C=/+<Z@3+ %VA/O?KP<DFGQ_#+QE_9&IZ9=Z
M1X.U"#4U2.[^V37LSS*GW 7<D@+GC!XKJG^,7A_[-;/;Z1KEQ<3F=A:)I["=
M8XFP\A1L';DC'<YZ5VEOKVG7'AB#Q&;@6^G26JWAEN!Y>R(KNW,#]WCKFB[
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M%%( HHHH !1110 444GUH 6BBB@ I*6CM0!\W?MB/&GPAT;S-V/[;BQM./\
MEA/12_MA;1\(M'W3>5_Q.XN<9S^XGHI@>O?"M=GP9\%+QQHEETZ?ZA*[*N0^
M%XV_![P8/^H+9_\ HA*Z^D 4444 %5YO]9#_ +_]#5BJ\W^LA_W_ .AIH:)U
MI:04M(04444 %%%% !1110!Q/Q0\(WWCCX>7_A_3+J&UO)7AEB>X!,>Z.59
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M GB+XG>*Y?"WC:'5K?\ L?47>/4H9+Q# %8X58HPFY9$/').3UX->H67PO\
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M7=MX';Z\4-2\8Z7X2^,VLRZ_!K$NF7\J+!J-D&C*I#$1\H(&-F5QC!(SZT6
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M*20QQS-_"><$J.F< FN3U#Q7XN3X1_$C6?%&FZ'XGL['69[;['<;Q'B.2-
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MLG3CD<]>]6_ GQ>O?%/C*/0;[P^88KNT%Y:WEF998DZ[HI6>-=KCCID=LT6
M]=6&-)"ZHH)ZD#DTDD$,DBR/&C.O0E<D5YWX\\>^(O#'B71M \/^#V\07>L6
M]S)"!>I;X>%0Q4[ATPPYS]*Y+Q)\>+K1-1OXK;PPUY%H\D4&H(L[&9I656D2
M$+&RMY8<9+,N<'%%@/;I+.VDW;X4;=PP*YW?7UIK6-F660VL)9055O+&0#U
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MU[%%+'/")8G5T89#*<@USUKJGB&3Q_J.DW&DPQ:%!9Q307XF!>65F(9"G4
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M+=:%=?!;P]_8<EL[Q6<,=Z;<#(N!&H</C^,<9SSTKTR.SLXV5X[6)&1=BE4
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M;*[P6WVN?8)D .Y<;!ANPQC%?7'V2T7RB;:+]S_JSL'R=N/2HDL-.6.:-;.
M).2TJB,8D)ZEO7/O2N!\DZ_I/P[.B^'QH/B%=0TN\\9V;-+'MM(859,2K;A
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M&)4 ^F<'-8VG?#NRL?#>O:;)>&ZO?$$[76H7D\*R>;(P"G$;94* H"J<@>]
M'86UY:W]C%>V=Q'<6TZ+)%)&P975AD$$=00:^3O&&J68^(DGB:TU"*WFM/&-
MO:RWM[?;;I%4A'BCBX"VX4,26Y/7'0U]5:)I%GH&@6&AZ>A2SL8$MX5)R0JC
M S^59]UX+\(7]S<75[X6TJXGN2&FEDLXV:4@@C<2,GD \T ?,GBC3[.ZC^,V
MM?V]J<CZ'>0WVFHNHR"*"9HD?S%7<0?F) !XQP,=NBUZ_P!!\7ZWXJM?'5^L
M-SIWA^"7286NFA1O,@+RSQX90[>8 N?]D#'6O=_^$(\'[;M3X5TDB[.;@&SC
M_?<Y^;CYN1GGO3KKP3X1ODM([[POI=TMG'Y5N);.-A"G]U<C@>PHN!S_ ,&;
MFWNO@GX0DM9TF1=,@C8HV[:RH RGW!&,=JYOP#+-=?M!_%:74&?[3;_V?;VT
M;<A+?RW8%>.A8D_6O6=-TO3M'T^.PTNPM[&UB^Y!;QB-%^BC@5S.H>%)Q\0K
M/QAHUU';W+P?8=2AE4E;JW#;E((Z2(2<'IAB#VH ^<+W1Y['X;>(/'6A^(-5
M@\26/BJ\CTVS@NF:&5VO2OD_9QPQ8%B>"3].*]=O ;?]J;PU/"<75[X;N([Y
M0>-B2*R'_OIF%>@P^#/"L&N-KT'A[3XM49S*UTMNHD9R,%B0/O=>>O)]:S]!
M\(O:^-]5\:ZO="YU>^A%G$B?ZJTMD8E8TR <DG<Q/4]  .7<#M****D HHHH
M *.]%% !29I:* "BBF]* %-'2B@T ?,/[9@_XMCH&U5+_P!KCD]0/)D_^M^5
M%-_;/C_XM7H,F<$:PHQGU@E_PHJ@/=_AS_R2WPIQC_B4VG'_ &Q6NIQ7+?#O
MCX5^$P!TTFTZ_P#7%:ZH=*3 ****0"5%)_K8O][^AJ6H9/\ 61?[W]#0-$]%
M':B@04444 %%%% !1110!R_B[Q.WAJRL1;6!U#4=2O([&SMO,$2O(V3EGP=J
MJJLQ.">.G->0V/BN;P/\0OB?KNNZ7 E[-)I$*6]E([I/)(LB(V=FX9SS\IZ'
MKQ7J?Q!\)7WBO1K'^Q]4&E:SI=Y'J%A=/'YB+*@88=>ZE68'ZUP=_P#"'Q9K
MTOB'4=:\664&J:HMC-;R6%FZ+:7-J28W&YR6&3R/<TP*OBCQHWCCX3?$W2=4
M\/R6ITK3))8KC9+]GN08BZ/&TB(=RLO(QU QG-:UK=6+?&#PU;_\(TC:S_PC
M+26>I/>LBK&"H:(Q $=6'/)QTZ5H7?@WX@ZS\./$FB>(O$VG7FK:M9FQA:"V
M:*VMT(*L^,EBY#$D].  .N;%OX,\2Q_$;PYXFFO-.:VTS26TV:)5</(6VDNN
M?=1@'MF@"EHGQ4U'5_#T]Q)H-K9Z[!KG]B/I3WQ)60, 3O\ +_N[G&!@J.M4
MM+^-B:QXDTNQL= :XL-1O9;(3Q22-+ 4+ 2.GE[0A*GD.3R.,\5T-G\,K&Q^
M,>H?$"&X*)>6JHUDO"&YY5IR.FXQX7\3ZUC>%_A[XY\,:E_8]OXKLO\ A#H;
MZ2]@@2V9;L*SE_LY?.T1[CR0,D<#&>'H!07XU:Q##K>J:AX!G@T+1;JXLKN^
MCOHY")HR%4+'@%@S%1GW[XJUI'QLMYSK[ZUH[VMMH]C_ &A]JM'>:*9.08PS
MQQX?..V.1R*?!\+];OOA[XT\*Z[J5G&^OW]Q?6]Q9JQ^SM(X=00P&=K*.G4>
MAIUO\//''B'PAJWAWXB^)K&\ANK+[' =-MVCP<Y\Z3<?F<87 &!UZYHT PFN
M-6N_VF?!FH:QH,&G37&B7A5H;LRDK\AVL-JC<N2.,@[L]A77^+O%'BO3?BIX
M.\.Z39V<FGZHMU),\LQ5G\N/.T_(=H&X-D9)(QQWQ])\#_$J;XB^&?%?BC6=
M!8:-:3V<D=C!+NG63;SECA3\H/'3&.<UTGC3PIXBU;QAX3\2^&[RQAN-%DG2
M:.^5BKQ3*JNR[>=P"\#@'/44@,36OB[<:;HFL>*+'PV=0\-:)J#6%[=)=!9C
ML;;+)'%C!56('+ GDXP,G8^)7BW4M%^#NJ^+/"ZP3W"6@GA>8D*J-CYP,')
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M!32?#%KH]M!HKZQ+<S:F]VK'RXKUI=J1@;@Q9=H)Z#G/:NTC\)^-[GX1>/\
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MOV>[\@_.5(8L!P2"0,@&L&?0?%NJ?%[P_K<WA>>TTJ'0IM,NI6N8"T3RLIX
M<D@;>H]?PJC\/?#WQ2TK2+?X?:YI.GP:+ID<MNFN)<"1[F'!"*D75&^89)Z!
M>A)H W;?XZ>%[C6+"Q2PU$0ZHD[Z?<)'&_VORLE@J*Y=2P&5W*-V:O\ P_\
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M]*L4#I12 **** "BBB@ HHHH **** "D;I2TAZ4 ?,7[9:G_ (5?H#[OE&L
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M@SZ_N5KJ* "BBB@!*BD_UD7^]_0U+44G^LB_WOZ&@:)J*.U% @HHHH ****
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M266)7)$8)8Y" 9_"H])^%W@70M7.J:7H,5O,'>2)!(YAMV<8=HHB=D9(')4
MU#I_Q6\)WWA_4M8>6[LETRX6TN;6[MFBN$F;;L3RSR2VY=N.N:T_"WCC1?%M
MSJ=II[3PWNF2+'<VMS'Y<D>X91L=U8<@T]0,%?@G\-X]+M-.CT!TM[.^;48
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M4%3[;/D7!ZR9WYS7GVK^+=:\0_$'Q=:Q7'B72T\+26YLTT^WS'*0OF2><O\
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M#N7=MR,T;E]13 \FA\+>,8_B%X/UR;3=,%KIMG>0W:V<WEI"T[J0(TV#<%"
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M/2O2?A_::NL-YJ&J>"=-\(O<[!]DM7265V7.YY'157'/RCGN>^!W;/&JEF8
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M_2=$U1-$U&TBBTO1]3OH9Y[:<M^\$<@<CR1P1N;)(Z=<_35<YX@\7:%X8O\
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MT^P34WU-;2(7KQB)IP@WE <A<]<9/2BX%VBBBD 4444 %%%% !1110 4444
M!Z4FW(I:* /EK]M#=_PKCPY\SA?[5/ ^[GR7Z^_I]313OVSWD7X;^'0/N?VK
MS\N>?)?']:* /?? (/\ PK7PR3D$Z7;'GJ/W2UTU<UX!9F^&OADO][^S+;/U
M\I:Z6F 4444@$J*3_61?[W]#4M0R_P"LA_WOZ&@:)Q1110(**** "BBB@ HH
MHH \Z^)FL75A+X2TB.YGL[/7-:BL+NY@D,;JA1W"!@0REV15R#G&?6N"UK2_
M%IO?'W@_PQKNL2)I=G::MI4IU"0R0SMYF^U:4G<Z.(\@,2%SU'%>W:QH6D>(
M=,?3-;TV#4+-R&,,Z!ER.A'H1V(Y%,T?0-'T"WDM]'T^.TCE?S)-N2TC8 W,
M3DDX ')[4[@>.7'CR^U[P%XF^*?ABXO8;.RT(064$CN42Z 9YG:+.UC'E%W8
M/*/U%<_K'_"<:3X7\2ZM'XZBBT^Y\-3ZC:P6>J37TQFCP1.DLL8*1L' *J0,
MXQ7T-8Z%HNFZ.VC6&F6UMIS>9NM8XP(SO)9_EZ<EB3]:YNR^%'P[TW2=1TG3
M_"-A;6.IJJW<4:$"90<A2<YP#SCI1<#SOQ1I/B+PUX;\*26OC[Q#<76L^(K.
M.6:2X0LD<R_.BC9MV KN"XQU]:Y[6=8\2Z'I'C_1K3Q9K$Z>']>TP6<KW&^X
M,=P8C)&\A&67YVP!@BO>;[P3X7U2PTRQO])CGMM+97LXV9L0,HPK#!ZCL:SK
MKX7> [Z6_FO/#<$SZC,MQ=;G?$TB_=9ANQD=O2@#SWQYKFK'XGZGH<^H:U%;
M)X>%SI,.BL^XW>]LF0)SNX7:'^0@-U-9<.A^*+[QO\--+\1^(M4L]9?P_?OJ
M%S!/&)MY: NBMM(ZX'RC( X-:?C+X9:MJ?Q"OM6_X0O0O$NG2VL%O8M=7\MI
M-9"-2-I*@[EW,6SU.0/X179>$?A=HNBV&D7&JVJW>MZ='+'%<B>5_LZ.S$Q1
MLS;M@#;1GG &:8'BOVS4O%'A3X1W>N:S>37,/BV33Y+@3LIF6-I0CMMP"^(Q
M\V,\GWKV?XS>*=0\&_"J_P!8TB8VT_F06_VK;O\ LR22JC28/&0I.,]\5I/\
M+/A_)H,6A2>&;9M-BNOMJ6Y9BJS8P7'.<GOZ]ZZB\TS3[_2Y=,O;.&YLI4\M
M[>5 R,O]T@\8I >#^.-<USX=^$/%6H:'X[FU..YM;.2RAN6^TRZ>KRK%+<&0
MY^5@V5!XR#CO1XPU+7O"OC"/0=)\4:E>Z1K'AJ]O&:6Z:2:TGMXMR7"R=5#D
MJ,9VDYXKU?1?AQX'T#0;[0=+\,V4.G7XQ=0/'YBSCIAMV21Z \#M5C1O GA3
MP^LJZ9H\:>= +5S,[3,81G]WF0L0G)^4<4 >2V?B+7I_%?P2@_X2*^*ZYH-P
M^HJLN1.ZVB,LC \%MS,<D=1[5SNA/XSF_9TU[X@7GQ#U^:_CL+Y88C(BK&8I
MWV-G;G=\O)R#@@#@5[-8?"'X<:9<VEQ9>$;**>S+M;R ,6BW8SM)/'3C^[VQ
MFKUK\-O!5GX1N?"=OH,4>B74ADFLP[[9&.,D_-GG SSS1<#SCQ/J7BS7?%]K
MX0T/5!9SQ^'8KZ+S-4>R>29V93+N2-S+L"+E#@?-SG/&9I=OXT\3_$>Q\/W7
MQ.O4C_X1JVU&>72&40S3BX\MF0E<[&"'/J3GIQ7K&M_#+P-XD@TVWUSP[;WT
M>F1F*U\PMF)" "N<Y(( ZD]*N6?@GPMI_B6/Q%9:1';:G';BS2:)F0+".D80
M':%'ICWHN!SWQ4U_4-#T+0;2QNY++^VM<M-*GO(P-]O%*QWLIQA6(&T'L6]:
M\U\=:UXI\):EXY\,:3XGU2:TA\-_V[:W3S"6>QF60QF(NRYVOC(YR,-BO?-;
MT32_$6CSZ3K5C'?64^/,AD7@X.0?4$$ @CD$9%8(^&O@S^QM1TF;2#/::D5^
MV>=<S227 7[JO(SERH[+G')XYHN!9\&:'JNAZ1,NK^*+W7[B[E%P9;P*/*RB
M@H@4#"[@2!VSBOGX6'B&'2OC#XNT'QI>Z'/HGB.]N8;6+9]GF9(XF?S01EMR
M@*!G ZX-?3]AI]MIFGP6%G&4MX$$<:L[.54=!EB2?Q-<S<?#3P1=:S/JT^@1
MR7%S,+F=#(_DSRC&)'BW;&;@<E2: /*=5U_QAX7\6_;KC4-0O+/QCHNS1K(R
M,PM=58*?*Q_"IW%@?X0K=,5[7I-K=:!X-M;6\OI]4N[*U'FW,S;I+AU7+,2?
M4YKFH=%\7:Q\1#<^)K/24\.Z-<-=:.UNS-/)(T?EAI 1@;5>7IU+#^[D^@X!
M7&.* /F[POX@U[5/ &C_ !:B\<2_:S!?-?Z5/)FUN'"R>5"D><(4**01R1G)
M[T[P[=?$&ZTO0_%8\9PKINM:3.;I3J!N7EN3"TBM C1!8BI!RH. !CM7K>G?
M#'P#I'B2?Q#I_A:RMM2G+,\RIP&;.YE4_*I.2"0!G-5M/^$'PWTE[U]-\*6M
MJU]&\4QC9P=CC#*OS?("#@[<<4 >&^)M+\17'[,4?B?Q%XZU75GUB/2IC;LZ
MQ)!ND567*C)!#Y.>ZYKUK39M5M_CK=>%WU^^N])'AF.X2&:0%HY#/Y9?< &+
M$+G).<EJZQO /A23P0O@J;25ET%$5%M))78*%(*X8G<,$#'/&.*99_#SPGI^
MKC5K3398K\6?]GB87<Q(@_N<O[9SUSSG/- 'A6CIK'ASX1/X@T?Q1JD4J^+9
M+61))5>*>-]4\MB=R\%@3EE(YS73>)M6\?>)O'OC+0_">KIIL^@1VWV,M>B!
M$+Q"4RR1^6_FJ2VWD@ *,<DFO0U^%7@9=!&A#2)1IHNQ??9_MT^WSMV[?]_K
MNY^O/6E\1?"SP'XIU6'5M=T%;J]AB6 3>=(C-&,X5]K#>.3][- '(MJ6L>--
M;\0Z%+X@N-+72-'M)@=-8+]IFFC=VE5B,M&-H4#IUSSC'3?")U7X$>#I%^?;
MH\!(0YR?+&?QJYKWPU\%^)-0BU#5M%WW44/V<2P3R6[/%_SS?RV7>OLV0*W/
M#WAW1_"NA6^AZ#9_9-/MUVQQ!V?:/JQ)_6@#PVU\:>*W^&GAKXI1>(+F[N-5
MU:&"XTE53R/(FN#$(44+D.ORX;.20<]<5TGPX7QOK7BW7=2U7QW<7>EZ/KE[
MIR:<]K$/-157;O=5'*DY&!_.NQT_X:^#=+U)KVPTEH?](-XML+B0V\<YS^]6
M$ML5OF/(7CM6EX>\(:'X5GU&31;>: ZE<-=7(>XDE#RG[SX=C@GN1C/'I0!Y
MW\3;[Q>?BOX(\+>&_&$VA6^OP7Z3;+>*78T40=7&X9S\WKC@5SMQXB^)FL:[
MXGM?#NLAKGPW>V]DGFS0PP2[(T:9YHRA<ARS\JPQA<=#GV75/!V@ZOXGTOQ)
M?VLLNJ:4'%G,MQ(@A#<-\JL%.1P<CD "LC6?A7X)U[Q<GBG4M)9]3 59&CGD
MC2X"_=$J*0LF.V0>@]*+@>2>+?''CR74?%VG:'KUSI_B?3]7M+32=)MK>.:*
MYMY-GS,60\D&1B21MV<XKT5;_P 1V?QJ_P"$>.N_:K1_#+7BQS1(H6X69(_,
M8J 3G))&0.3@"O-9OA;XMD\3^(;ZZ\,WAU&_U":ZMM3TSQ$UI;!3@1%X@=V0
M ,X4Y.:]FM/A_I U2#7M2FN[S6AI@TN>Y^U2!9(RH#X7=A<D;N.<\]:>@'S[
MXD\5^)[[P5XFT37_ !)KVDZY;^'Y+F\TRYBA6.9]RAI+>9%^:$@L"N2<%1US
M7<ZEKWBZS\1>&OAKH>L7$LC>'O[0:^$D"7,KAMB[=Z%"J@$D;02,<]:[FV^#
M_@FWL;FREMKZ[AGL'TM1=WTLWDVS$$QQ[F.P9"XQSP*CU3X,^"M6T/2M+NX;
M_P S22QM;]+^47<>[[P\[.[!].GH!1H!Y[!J/QFUK7?#GA.?QI8:'J=SHMS/
M>S6MK%=*)H;A8]RG@;B",CH/FXI]YXG^*WBC4_$=YX*U"*(^'=9.FBVE>!+:
M1(E7SFFW*7RQ9B""  !WS7IUG\,?"VG^)]*\06$5Y:W.E6QL[:**[D6)8B<L
M"F<-EOF)/4\G)J'5?A'X'UKQ=)XFOM.G^VS[/M,<5U)'!=E/NF6-2%<CCJ.<
M#.:0'BGQ&USQ!XW^#/CGQ'+XB6#3+#64T^/2H8XS'Y,5RB,97(W%F8A^"  H
M'.37T5X@FOK;P)J-QI5VMG>PV+R03-&)!&ZID$J>#TZ5R.M?!#P'KM[J=Q=V
MM]%%JDBS7EI;7\L-O/*&#>8T:L%+?*.?KWYKM[OP_97?A:7PVS7$=C+;_9"8
MYV$@CV[>')+9QWSF@#YWT;Q-\6KYOAI,_CZ#'C2VE65)-+B(MBD?F;TQC<Y7
M/7Y<\XQQ6Q;^,O&TUEIF@2>*9IM0BUO4M.GDLK2$WVHQ6Y.QHU9/*3' =CM
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M6*_<RO)Y.,8[Y[F;X4>#Y-'TS26M[Y;?3[W[?&ZW\PE>XQ@2R2;MSMZ$DXX
MQ7,6_P /K[6/BWXTU'6K'5;'1=5MK6W@GMM0\H7*QQE9$=4DW8.1@D X!Y&<
M$N!S'PA\0:SXY^)UOXJU+5KJ&2?PO:S262E/*+F>6-L KE5)BW\'.6ZXXKMO
MBCJ7C"S\2>#--\*^)4T@:U?O93!K6.;I"[[_ )AVV]!C/K73)\./"UOXJT[Q
M)9V<UC=:=:+90Q6EP\,!A0DHK1J0K!<G (QS[#%SQ!X+T/Q-J>D:EJBW1N='
MG^TVC0W4D0CDQC<0I /''/8GUHN!XA)XG^+FIZKXE\+:-KB7.K^%EM(1=1_9
MK>.YE\O>\DZ2 G8^<80KC:?6NBNO$?C/Q-JOCFUL?$_]@CPQ80^3%9Q12--<
MO;"8NY=23&"=H QGDYXKMO$'PH\%^)?$R^(=0L9X[]H_)N&M;J2W%Y&, +,$
M(\P# '/;CI61XV^%/AO4IM7\5:?HMU+X@N+!K;RK*]:V6[^38@D&]4; QC/H
M.N!1<#DO!OC;QAJ_BKPAI]_XAG:'6?!?]ISKY$(*W6Y%\T'9Q]XG;R/;TR--
M^)OCW5_ OPUT_P"U&76_$KWQO+J+R8)'6WD8!(RR^6K'Y>=O13CDY'=>&?A5
MINI>!_!'_"6:;=6.NZ#IL=D_V:\:)R H#1LT389"1G&?ZBM63X)_#YO!-AX1
M_LN==/TZ9KFT=;N436\K')9)-VY<GL./:G= <'<Z]\8-'\!V?_"07,\MQ9ZK
M*-3FTC[-/??8!'N1PFW86!9=P"YQ@]ZK^%;O5O$/Q4\%ZU_PGU]J\4_ANZNC
M-!;Q11RA+J%67RRGR[APW\0*X!&*]./PI\)II^FVMG_:-E+ILDDT-W;W\JW!
MD=0CN\F27)  ^;/2I5^%OA"&?0)[6UNK1]"1H[0V]Y+'E6D61EDPW[P%U!(;
M.>:5T!Y9X9\9?%+7(M&\>P-YOAVYEG>^M))[8Q+!EE18E4>9YJD 88G)..*J
M7]UXB\3:#\,/'>H>)I;FWU;Q+9SG2TAC$%NKL_EJK!=^4 VMECN)/2O5=%^#
M_@;P_P"(I=:TW3YXV>5YULWNI'M8I'SN=(2=@/+=N,G&*HP_ OP!;W%NT4&I
MI:6EV+VUL5U.=;:UE!SNCC# +SD_B:+@>H(P9>M>2ZC\W[5NEQJ0#_PB=QSU
M(/VI,5Z%I6@6.CZAJEY:R7#2ZG,L\PEF9U#! @"@G"C"]!WK&O/A[HM[X^3Q
MM)=:FFKI;_95:.\=8UBZE0G3!(S]>:0'C$'C;XFV_AZT\4WWC"":UM?%AT66
MRCT^,"ZMS=^22S=0P&=NW;P!G)YKU3XSZ[K_ (9^$6L:]X:U*/3]0L_*9)7A
M64$-(JD88$<[O0U&_P &?!\GAO\ X1]WU4V/]H'5,?VA)N^T;BV[=G/WB6^O
M/6ND\7>#=(\:>%W\-ZTUU_9\C(TBP3F-GVG(!8<XR ?J!0!Y/=>.O&O@(^,!
MXBUR'Q)+9^'8M<M4%JL"Q2M(\9C 7EH]P4Y)R!6C;^(O&OAGXD>!-,U;Q1'X
MBTOQ;#,LJM:QPM!.D?FAXM@'[L@@88L>^>:[*3X8^&;G6KG5+S[=>O<Z:-)F
MAN+IGBDML8VE3UZDY]23UH\-_##PWX9U*ROK674+V73H6M[ 7]VTZV4;<,L0
M/3(&,G)QQG'% &3\5-:UK1=9\!?V;=0QVU_XAM[&ZCDMDD9T?)RK,#L^Z1D<
M_-U%>:ZUXX^*EK8^.O$$'B^S2T\(ZZ+=;)M/C!NH3Y?[MCR0,2<$<D]QQCVW
MQ=X$TCQI=:1<:I<7T3:1<B\M?LMP8@LHZ.<=2.WU/K7/W'P;\+W&C>(-)DO-
M6:T\070O+Y/MA)>4'.1QQG SCKM'I0!RGBCQQXLT7XL"RU36+OP]H,M]91:;
M,]C')8WJ,$,\<LNUGCDR6"\J.!GCFLM-4\3>';?XJ:['XTF-S!K45G;B^C22
M.,.MM@HJIN+A'*JHX)QE2237I4_PJ\/7UX\^I7>JW\$LT%Q+9W-XSP2RPJH1
MRF.OR)GL<<CK46L_!_PGKFH:O>W;ZG&^JRQW,R07TB1I.GE[944'"O\ NU^;
M&<9]:=P//K[Q]XZLO 'Q+N+;5[N.]\.R026-SJFGQ+,8Y(4<JR( N<DXR,C(
MR.U:;^-O&W@KQ9K]KXHU:WU^VC\+R^(88X;06X@DC?:T*X+$J<CEB2*Z:7X*
M^$IK/6[:2YUAEUR*.*^9M2E9IMF &.2<L=HR?08& 36S)\.-!N/$B:]=SWMW
M<C3FTETFGW1RVY^\C+CG)Y)ZYI <A:Z]XW\/^'Y?&6K>(K/7-%D\.RZFUN(4
MB=+I8_-58-HYB*!AAF)^7.:=X!UCXIWOBO3[C6X?M/A?4M,2=IYC;(T-T0&Q
M$(F),1!X#9/O6_X>^$7A3P[#<6\!U&]M9+:2SCM;^^DN(;>"3[Z1HQPH(X/?
MWJ?P?\+_  _X)O%GTR\U:Y\B,PVL-_?//%9QDC*Q(3A<X SUQQGK1<#/\;>)
M=>\*_$7PO<76KQ6WA#4VDL;A#;C?#<^6[QL9"#\K;<>Q ZYXXSP3\2O$7BJS
MBT'^W VOOK05)GL5B\[2_+$RS^6<[0\?0_WF%>Q^*/"VB^,-#;1=?M!=V+RQ
MRM'TY1PXY^JX/J"1WJO#X+T&#QI/XNM[-8=7EL4T_P Y !MB5BPP,8SR!GT4
M#M0!\[>"M;\=^%O"B:]I.I::OA[_ (3&6QNM-:U+33+->>6S"3/!&X8 ';))
MZ5UTOC_XIZ]XJO;CPCI#3:1I>O'3)8&C@$<L$;!9G:1Y0ZOG<5PN,8ZFNPC^
M"^@Q^%D\-IKFMK8+J7]J\31;VGW[\D^7TW_-CUIS?!GPR/%UYXALM1UG3QJ,
MPN-0L+.^:*VO90<[I%7DYYW $!LG/4T <=IWCWXE6MGXO\6ZW?:-<^'/"]UJ
M%M+:06[QW%RT*_NPK9(4$E>N3U]L;G@+Q'\4]6\4Z;-KVFA_#NHZ<+B2=HH8
MA;3D!@L925FD0@D?, >,UU^B_#S1]'T[Q#I;W-YJECX@N)KF\M[UD92\H(EQ
MM52 P/3/;C'.:7@WX6Z5X,N8WL]:UJ_MK7>MC:7U\TL-FK<;47CH,@%LD"@#
MT*BBBD 4444 %%%&: "BBB@ HHHH **** /ES]L[+?#;PZ W35C\HZG]R_/^
M?444?MGQH?ASX=D*Y*ZIM_.%_P#"B@#WOX>[1\,/"VTY']E6O_HE:ZBN9\ E
M/^%:^&?+&$_LNUV\8X\E:Z:FP"BBBD E0R_?B_W_ .AJ:H9/]9%_O?T--#1/
M1112$%%%% !1110 4444 8/B+Q+I_AJUM);Y9I9+VX2SMH($WR3RL"0JC@=%
M8\D# -8L7Q,\-3Z%'JBR7(>6]?38[(V[?:7ND8AH@@ZD;23S@#DG%9WQ6@\5
MS:;HI\,Z1<ZM;)?@ZE9V=RMO<2P>6X 21B-HW%<D$'' .":\CTOP1\1O#FG6
MVO:?X+5;OPYXEN]1MM)%\LGVRUN8]KA'/0H#P6Y)W<<8+T ]+UWXS:;::;HE
MSHNFW][)J&N+HLT;6C!K:16_>HRY!W[0VT#()YZ"M;P[XET-O$?C>\;Q)J#P
M:?)$UY;ZE$T$.F[8LGR]Z@[2!N)Y'<=<GCO%EMX\\0^%?"WB:/P0]O?Z;XCA
MU4Z';SQ^<(%1E.]V*KO+$DXS@$>A-0'PAXJ\53_%S3[_ $&YT*+Q+' MA<S/
M$ZN4@V$':Q."P].C&@#T*S^)WAFZOA9RF_LIY+1[ZW6[LI(C=PH,LT61E\#G
M:/FP>E0^'_BSX0\3:KI>G:9/>%M4A::SFFLI8HKC:NYE1V4!F Z@>]<1<:5X
ML\82^%=1U/P??:/+X9LYY9H9)8MUW<-"8A%#AB"N1NW-M_AJMX;T;Q7:Z=\&
MK:\\(:A"^@K)'J#,T3"W_P!'>$$_-ZD'CH* /1?&FL:?9^(?"-C=>)+_ $>X
MNM44016L#.E^0K PR-M(53G/)'3/;(GG^(WAVW\3+H#/=/<F]33C+%:R/"MP
MR!Q&7 P#M(//'/6L+XH6>N7FL>!?[(T&ZU&.RUZ&]NGAV[8HE5U).3V+@_A[
M5R&HZ+XL'QD35O"_A_5=$NIM9B74Y]ZOI^I6*H,RL#]V7 VC:,_T /8?$'B?
M2_#BVJ:C,YN;R3R;6VAB:26X<#)"*.3@9)/0#J:\@^'7Q0ALY/%<WBC6M3NK
M23Q8VE:>]W;G="65=L3!5&P YZXK?^*-CXJL?&_@SQSX=T";Q%#HS7-O=Z="
MRB7RYE4>8F>I&WI[CMDCRUO"OQ&O-!\4ZE)X#O+:X7QA;>)+>S:>-I+B-2"T
M:$'[P !STR<#/- 'K?Q!\<6USX%^(6F^']6O--\0>&K SRND1C:(E"\95F&"
M&VD9'Z5=\.?$328D\'>%]8NKEM?UK28+J)I(6*W!\K<YWXV[N"2/<>M>3ZAI
M/Q!UV[^+6J3> ;^R'B;1+>WLXC-&S;U0QA",]?GW'L,$9S72>,]$NYO@QX-F
MM0FD^.?#Z63:?#*J/,DQ"0O%MS@ALG/;Y1GI0![%H/B+3_$=K<76F-(\-O=2
MVC.\90-)&VU]N?O ,",CC(/I7-:5\6O!NL:W:Z59WDY:^DGBL[AK9Q!=O#GS
M!&^,,1@_7MFNGT#1TT'PS8Z1 WF-:PA#(PYD?JS''<MDGZU\PZ!X?^)$?B_P
M9K&I_#S4IKW2=6O!?3-<Q1VP$@(#0Q+A4C&2V[&2<\G- 'M-M\;O 5U?06T=
M]>#SKXZ;YK:?.L<=QG C=BN$+'H#S7._&WXD0:;\/O$UGX;U;4K?6=-6,27F
MGVSO':R,RXCDEVE5)4]CD9'3(SP?_".^,V^'5_I__"#ZS]K/C8:TD96,%K;S
MO,W#G@X!X]3[U:\9:5\1+?PM\0/ EGX%O]6B\07DFI6>JVTZ!0LKJQBD!YW+
MMVXYR,#@#-/0#WN]\26/AOP,/$>O7$BV=K:I-<31Q-*0-HRVU 3UZG&!UXKG
M+7XW?#RZU V<>K3J_P!D:^C:2QG1;B%5W,T1*?O,#^[GH?2F?$ W1_9Q\1?;
M+-K&Z_L&820%U9HV\DY7(X/X5YY/9ZWXQ@\&:I%X-U2U3P[HL\CS2*@DN));
M80I#%S\X.=Y/ PHZ'BD!Z7I?QC\ ZQIU]J5EK3-:6444TLKV\BAA+G8J97+L
M2"NU<G(QC-/D^+O@Z&TU>:\N;RQDT9%EO;>YL9HYHHV^[)LVY*'^\,@=Z\_U
M#PIXFU?]G_P8NGZ+=6>O>%Y+*[?2[@*C79MP \?I\W)7/4@5G>.K'4?$-GXX
M^(5QH]]H-I#X1FTE8-0B$<L\A<R%\ GA0  >Y;V- 'J>@_%WP+XBUJ;2K#6"
MMQ';&\#7,$D$<L(QET=P ZC/4=LGI4$?QE\"M<31R:A<6X2S;4$::SF19[=?
MO21DK\X YX[<]*X&?0=4^*6BZ+;6VB:CX?BL?#US;F]OX50227$"1K&@SEE&
M&8GIPO<\87ASP[KB>&[ZQN/@N-+UC2M)NK0ZJC*QO)/*,2BW&1]\D,3TP#ZB
M@#K/&'Q6T?Q5\+=?U#P'XBO+>\TV*UN6FC@:$E))  !YB\@C.<<CID9KT6T^
M('A^;Q%J_AWS+F/4=%MQ<WB2VLBA8\<,"1A@><;<YQ7E5UHGB,?L@V'AJ+PG
M?/KRVMM:/8>4HD#1RJ68C.,84G/N*U/B1HUYJ7Q \(7F@7BVM]K*/H>K6I7<
MYLF0RNQP<JR8(!]9!3 ]6L?$VDWWA*+Q0MSY.E26OVP3SJ8]L6W=N8-RHQSS
MVK M?BEX1O+:]GBN[I?L=@NIO')93*[VK=)D4KETXZKG'>M/Q=::C#\.M6L_
M#>GVUQ?)821VEK-&&B=@A"H5Z$'I@\5X9X3T'Q;J'C&>:3PCX@TV'5/"4FFM
M=ZM+&5CN-P_Y9J<1KV" +W^4#)I >W0^/O#,T>@20WS.OB&%IM.(@DQ<*(_,
M./EX.WG!P37E_B;XK7&L?#V[\1:'?76@1Z;XDM["626W*"6 7"1R9,BX[L2%
M.1CG'(KG?"K>.&D^%&E3?#C6[.'PK*UI?7,WEA68V[PLZ\_<&0V[OR!FH=1M
M?%=GX)UOPH? 6MW4L'C :DEQ# 'CN(#>>?N4Y!/R+@^Y%,#W+2?B1X/UK3]9
MO;'5U6#10#?&XB> P*5W!B) #M*\@XP:9!\2_"4IO5>_FM7L[?[;)'=VDT#M
M!_SU164%T]U!]^M>3^,/"_B3Q3XC^)]CIV@WUJ-1L=/:RN9X2L-W+:DNT8;M
MNR$!X]>E:/B"35/%WB73O%%OX-UJQ71] OH[J*>T*2W$TZ*B6R*1E]I#,6'R
MCUZT@-[4OBMX+\4VUG:^&_B%_9<WV^RS<1V;OYPD<[81N7'S[2"?X>]==K'Q
M&\)^'SJ)U;4)+=--*B[E^RS-'"6"E075"N2&7C/<5Y%?:9K$/[.?@72X_".J
MOJ&GW^F_:[*.S/FH() \K%.X.TX['<*TO&5QJ7B+XBII>M>$-:3P;I3QW\GV
M.Q>;^VKH*IC5PH_U:?[7WBH':F!Z-J7Q0\%Z1:Q75_JYCB:WCNW(MY6,,4GW
M'D 4F,'_ &L5S/Q6^)NFZ#X$U^/1/$'V?7;6Q^T0R6UN;@1,PS'O(5D3?V+$
M=<UYCK6EZY=>/[[6?$'PKUSQ!IGB^QM9(;:VNI(O[/D6,1M;S@,J[<X8EAQG
MH<&FZ_8^*/"OA[XD^!_^$#U?56\1H)M/OM*M3- B- L8A9NH$>S:.IQSCFC0
M#Z&N+C4KCX<F\AOA;:BVGB87 C5PDGE[MVT\$9KS_P"'GQH\*ZEX,T6WUKQ1
M%<>(1I0O;T>4V253=(1M4*2.20O3!XXKO=-2[U+X;06\MC-:74^G"(P7("NC
M&/;A@"<&O'_!6DW>J>'OA=H3^&-1TN]\,R_:+^>\L7@2#RXG1D5B ',CN#P3
MQDFD!ZW8_$+PGJ6B:;K=CJPGT_5+K['9S+#(?/ERPVJ-N?X&YQC@\\5I>(/%
M&A^%K&&]U_4%L;:>9;=)71BID;[J\ XS[UY5\/\ PGJ6F_$O6M$62)_"/AR^
MDO-,5#REQ<Q!FC(Z 1AY,#'_ "U'X>A_$;PL/&7PXUKPZI*S7-N3;LIP4F0A
MXSGM\ZK0!9C\:>&WU/6-,34U-WHD0FOXO+<&W0J6#'CG(&>,US]O\9OAG>7<
M-C;>,+%KB>011I\P)8KN .1QQZ_2O+5\*?$&\U;PWXIO+.3[5XSM?[(\26VQ
ME%C;;0R-C/#!%D4D_P 4@'I79>";6W'Q<^(VIS^&KV"$O:-:7%SISH)%CA*/
MY1*_-\PXQU&,4 26OQ-L_"WPU\.:KJWB+_A*Y=5OQ:+J5M9M''(#.5<X5<+L
M3=C^]LXZYK7T'XO>&?$'C77/#EK)+%_9$"323SP21*<JS/G<H"A0 <MC.>,U
MY3ID>KV/P!\(/)X5UMI]!\21W=W8+82?:!$+B1MRHP!?AUY'^.+FL:9XCU?Q
M+\6-*M?#>K03>+M)MI-/N)+?;""EKAHI),[5<L=F/7/I0!ZW!\4? =RMZT7B
M:T LH?M,WF[H]L.<>8-P&Y<G&Y<CM5SP]\1/!?BO4I-.\.^([34KN.%;AHH6
M)/EG&&&1SU ..AX.#7SW:VT&N>%]6U%OA=XNL-=M?#MUI\UUJ;W$Y#.AC6"!
M68F3<S$Y"@*.?2NK\"6-S8^,_AH__".:A8Q6WA.2SN'DL)56&8M$=DC;<*25
M<\]?Q%.P'M&O^*M!\,I"=:U!;9I]WE1A6DDDVC<Q5%!8@#DD#BLVZ^(O@ZUT
M73]:;7(9;'4$,ML\"/,TR 9+*J M@=SCCH<5P_Q%N-:\*_%OP_X[A\,ZCXDT
MC^S9])GMM-@,\UL[NL@D">A";2?;Z5E6%OJ'A3XB>'O%3^#[VST"]T&73DT^
MQM'N'TIQ-YRJZ1YYD7@X! 9<9[TK >F7WQ)\$:?I&F:O>>);.*PU5MMG.6)6
M<XS@8_KWXHLOB1X+U/PQ<>)+'78IM,MYOLTDFQPRR[@HCV$!MQ)&!C)R,5XI
M9^'=3T70_A[!<>&]2,<GBZXU=K2*S>06%LYF\L2;0=F/,0X/3)_NU8O+*.[D
M^(EGJ7AOQ(EE>^)+2XM[C3[*9)HPJ1K]IB.P[MKQY. >/K3L![/'\0?"<FC+
MJZZL/LK7!M5W0R+(\P.#&L97>6Y' %4C\5OAY]ATV]'BRP6#4F>.V8L?WC(,
MNN,95AQD'!R0.I%>#:II/CB&/0/$^H:#K/B33]&UF]25[.WDL+^[@EBC5;HQ
MH5;>"'7H,@#(P<UM:9I%G#XC^'UYI?P[UO1M/.NWM_-'>033RQE[?9YTQ^;8
M6?! )[ ^M%@/3-:^,W@VR\$Q>*M,U!-3LY+Z+3U\N.0!)&<*P?Y<IA23R.<8
M&<UV6I>)='T?PX_B+5;Y;+3$C$K33(R[5/3((R/IC-?-M[I^OQ>'_B#=_P#"
M+ZY(D?C2VUB&&.P=7NK99TRT0(^;A"?H >]>R_$NXFUCX#>()+?2+Y[C4-+=
M8['[,7N [I@*8QD[@2,^F*0&MH?Q*\$>)-7DTG1?$=K=WT<'VDQ+N4F/^\"0
M 0,C.,XSS4]C\0/".H:E=:;;:W"+FV@-TXE5HE:$'!E5F #H#P64D>]>%W6C
MZGJ'BGP#9:9X>U>R0>#[G3I9QI\B1VLTD "(Y(4 A@>I'.*Y_2? NJ>(/ EW
MH?\ PK76M.\5:?H<]A)J6J7DK0L_\,5ON<J0_.< *,\&G9 ?3.E>.?"VM7=U
M::?K$3SVD(N)8Y%:(B$])1O RG^T,CWKBIOB(=3^,OA'1O#NL>?H^HVMY+=1
M&S95EV(#'(DK*-RY)&5...]>::?X:N/&WA'Q/)H7P\U_PSXBN-$DT^:^UR[G
M<RON!\B+S&8E3ALG QD#O6]H/B+4?$GQ,^&]Q;_#_7]'@TNUO+6\%S8-##:,
MT*  ,>"H*$#\*0'M.L^*=%\/RP0ZI>&.:XW>3!'"\TLFT98JB L0!U(&!5W3
M]:TS5M#@UO3;Z&ZTZ>,31W$;91DQG.:\A^*G]K1_$/P[+;^&M5O+,V-W&+[1
MK4277FOM @,C?+#&PY+'GC&1S6]\%&U&R^#&C6&K:)?Z5<Z>CV[PWL>V1BK'
M+ <G') SR<=,$$@%]OC-\,1<10-XST]&ED:)2S$*'7.5+$84\'J1GM6IHOQ"
M\&^(-'U#5M)\06L]AIKE+J9B8E@(&?FW@8'<'H1TKY_O;.]D\%:<J^$]99A\
M09-6EC&DS!OLQG=Q(R[,D;"OZ ]#6CXO\.Z[XKE^,&GZ+HM\LMU)IEU;136T
ML$=^+=%\Q4<J,L2F!@\_+SZ.R ]KTWXE>"=3CU$VOB"WW:8JO=B56A:)6&5;
M:X!(.1@@8.>*Q]?^,/A#2O ^N^)K*]-^='&R:T6&194D8?(KH5W(&./F8 >]
M>'ZEX7N/%W@S5M=\*_#/Q#I.KVJVLET=8NI_M&H>5*KO;1;V+$#;PPP<A0.]
M:TWAMO$?PD^(.H^'OAOKFD7^KZ?$A.KS32WE](ASM"R,QPJ@ '@MGV%%D!Z?
M:^-(=:^(WAV2Q\9P6ME/I4MU-H;VK"2?N)=S %0O/IG&>0:U+3XQ_#6^U2PT
MNS\76<UWJ$I@MD4/AY 2NW., DC !(SQCJ*\]L]2O-8^,OP[\1?\(IKEC:QZ
M%=0W#7.GR+]F9A\H<X(&=AP,_P 0]:XM=/U _#K0O+\'ZU]O7Q^=2,9TN19(
MH!.7+D;>%\L@9^H[46 ^@=0^*/@72[YK34O$,,#)<?8VE,;F%9\9\HR % ^/
MX<YKJ;K4;*QTR74[RZBM[*&,RR3RMM1$ R6)/08KY!MM;L5NM8TO4M,\0P^$
M$\5R:R][!I)N%#1S D_:4;&S>I).TD#(S7T#\8M'U;Q1\&M4M/#J&XNL0W4=
MNI_X^DCD61H^.NY5( [G%#0&YI/Q#\(ZW-=VNF:MYUW9P_:9;7R)5G$1Z.(V
M4,P/&" <Y'K7G/@'Q3XP^(/B%?$FD^*3%I%OJ=Q#=Z--IVR,VJEDB9)2FXR$
MKN(W=\$#',]C*?%'QBT;QY8Z#J>FVFE:#-'>RW-C)"T[2$%(%5E#.4*N3@8R
M1CK6I\"YKC_A ;RUN])U#3[A=4O)BM]:20,ZRSO(K#<!N^5AR*0'5-\1O!\>
MMR:'_;&_4(S*IB2"5P7C7?(@8*0SJO)4$D>E8_ACXP>%/$7@RX\53W+:9817
M4ENIN8V4R8D9$V\?,S;?NKD@G'6O.=)CUVS^,MM!X?TC68M.NM7OIM3L-1LF
M-O9CYA]KMYRHXEZ[<GEC@<5R'AZQ\66'@[PI-/X3UAH?!'B2XN]2M'MB#<)+
M++B:$=93&&)X'\7!IZ ?2VG>.O">JZ+?:Q9Z[:FRT]F2\>5C$;5AU$BO@H?9
M@*\_^(GQ0C_X5OJ>N> ?$4"ZAI=Y:Q7*26^Z1$DE5=ICD *Y#@@D<X./4>?^
M*/"?B/Q//\0_%_A/0;I+:YFTRXM[.ZA:'^UFMFWRD(P# 'A0"!N*YH\=:I<>
M+_ACXHUS1?ACK6A76JR6$;W+V3?;+N:.56/[M02$C13\[8!/ I >P>-O&20^
M"O&*^&-8CC\0:!I\ES(6MS(D++'Y@4DC:25QQDXSTH^'?Q*\.^)]'TK26\26
M=[XE738+B]MT<;]YC4NW "G#'G;TSSBO+["^UK3?@]\0? FL:)J=SJB6=RUO
MJ5OIDQ.K^?$2KM\G^N&Y58'ICVXIZ587D_B?X91Z9H]_I4Z>$KFPEN#I\L:V
MT[QA$W_)A3O5S@X]>XH ]SM_B/X+OM<CT6S\16DM]+(T,2@G;+(OWE1L;6([
M@'-<Y\-_&.J77AWQ7?>-M9LV&BZW>61NU18(DABVXX_$]23[FO)K&SNM8^'?
M@#X>GPGJ.G^*/#VM0>>WV22..V2&0F2Y$NT(P=02.3N8]#C-+<6FM7WPU\7W
M&GZ+J-TMIXU.M3Z=):R1O?V:S))M0,HW9"Y_X":>@'H'AWXI?VG\:/$^GS>(
MK4^%-.TJ*[C:2#[/Y#LPW;V?#'CGL,$<5W</Q&\%SZ5J.J+X@M8[32R!>--F
M(V^>5W*P##/;CGMFOF?Q<==\=>.?%>N>%?"FN^3<Z38RHLUG+;&Z^SW"R21!
M\ JQ P,')V\5LW"Z;J_PD^(.O:9X(\46%]?Z5'9RS:MYTTUW*?E5$0DDJO +
M8].PHL![N?BEX ^PRW\/BJPN(HIC QAD\P[@@<X"@D@*021P!U/%;SWYUCPH
M=2\.ZA;L;NV,MG=,A>/YERCE<@D=#C(KY^U[2?#UIIG@.X\/Z7JGA74AI\]Q
M:ZG8Z2[QP3"*-'BNK?RR6W].1GY??->S?#XZQ-\*-"&M:/%H^H&Q57L8%VI#
MQA0%/W?EQ\O8G':D!S'PK^+.B^*/#&@:?K?B;3I/%U[;M)-:(RHY8,W 7L<#
M..N.<5V\?C?PG-XG'AR/7K0ZJS,BVP?YF91EE!Z%@#R.HKYQ\/\ A.VU;P+\
M./"^G^&Y[3Q3H^MI>:A<36+PM9I%*SRL\A4!MX"A0"=QQZ<3> -.5?%&C^%?
M$WACQ;<>)=$U>:Z5WED_LX,7=OM6XG;@ANG.2WN:=@/IC5]>T?P_9?;=9U&&
MQ@+! \S8W,>BCU/L*Q[KXB>![/1[/6+CQ3IJV%ZK-;S+.K"8+]XKCD[>^.G?
M%<+\6K[4/#?CGP-XT?1KS5M#TZ6ZM[R*SB,SV[31A4FV '. &&??'>O,=8;3
M=/UG1TT7P'JWAO2Y]*U V5S#I\T]TYD=B81&=RP[^6^920& &VE8#V?Q?XRU
M73O&7P^AT.\L;C1?$-XUO,XC,CNOE-(K1N&P%('H<\<TGP^\;:IJEUX[7Q5>
M6,4'A_6)+..>)?*18516!8LQYYY.:\@T34F;PU\"(7L-3BETR\,=T);&5/*"
MQ-&6/R_=W, &[\^AQ!>6NJ:KX7^+,>EV-],T7BJ+57MXH6C>ZM4:,MY>X<G$
M;$8S]WH<B@#Z6T_Q?X7U;2[K5--\0:?=65IN%Q.EPI2' R=YS\O'//:N$\-_
M$J;Q'\=K_P +Z7JFE:CX>CT87T,MH"TBR^:J%7;=CID@ ="#7D5Y8VNJ?#_Q
M1XO\'>'?$NI6]Y=:=<:G_:C,9=2CBE#30I'QD*N S=#R 3@UV'@_Q%H6O_M.
MC6O#^GWJ:?=>&$M1,VGR0IY@FW[22H PJXR>,K@$XH ^AZ***0!1110 4444
M %%(:6@ HHHH **** /E_P#;-3/PO\/2A0 -7 W$XQF&3C]/THIG[:'F?\*W
M\.8<*G]JG(.,Y\E\?UHH ]]\ LI^&GA?;T.E6N/^_*UTU<QX!P?AIX8P,#^R
M[7 ]/W2UT]-@%)WI:*0"5#)_K8O][^AJ:HI/]9%_O?T- T34444""BBB@ HH
MHH **** "D_*O.?B5KFHV=]X3\/6-]-IB>(=4%G-?0;?,A01O)M3(.&8J%SV
MR:\S\5ZYX\\.Q>,?#NF^*[XC1[K2[BROIA')+Y5U,(V@D9ERP!!((YQU-.P'
MTEQ2USOA/2-6T32&L]:\23^(;EIWE%W/"L3A6.0F%XP*YWXPZAJFC_#>XUK1
M]4GTZ\LKJV8/#@[U:=$96!!!!5C2 ]#^7VJ&:588))BK,$4L0BEF('H!R3[5
MXAXOUWQ1IOC'XB6NE>)[F&*S\+IJMJC+'(+68&0':",X(0=<]:L>"[[Q99^-
M?"D>M>+;G7K3Q)H,E[+!-%&BV\L8A*E H! (E(.<Y(!IV ]2\+^)=+\7>';?
M7]%D>2QN&=8VDC,;$H[(V5/(^93UK;XSGBOFK1?%&KZ/\*?!>B:')]EEU_7K
MZS:Y+B)HT%S.V%)4A2V H)!ZCKFMF^D^+V@_#^\MKB_.K7-MJPS]AN(Y-0?3
M]F2JDHJM-W'RY(HL![YP?2EKY:O/&WBZ3P3I?B+3_%&NZGX?A%TEYJ-A:1B\
MLIQ)B/[3 R\HB\,%QG!.<8KZ/T"\6^\,:;?K>K?">UBE^THN%FR@.\#L#G/X
MT :OY5P7BK3/ FD:S+\3_$&GQR7^AVGEM=A&F>"/.[(09P1N;YL9 8\XKRO4
M/'7C!?A<_P 9+/Q%)MAU$I)H!CC-L;?[28/+SMW^9]UMV>O&,&JUK9WA\-_'
M+4+K7-1NL+=1F&Z8,N#9*R\;<Y4':,8  Z46 ^CM-O[75-*M-2LVWVMW"D\+
M$8RC ,IQVX(JY\OM7S/H?B3Q=X'U;PJEUXD.L:/JGA.;4/L#PHBVTEO;HZB,
MCG!&!SGN>M:.CWWQ5NM.LO%!\3V<>CZMI;2RK+=I*Z3^471K=?) 7G(*%CP.
MO%%@/H?*^HH^7FOFVTMOBY<_ <>-K?X@W%]JT^GV^I1V@MXXU55!>1 P7)+1
MG_OI1TS5;_A;]Y;>+;[6%U35+OPIKNDA-' 6,A=1$<;-%&0I)/S@<Y&_>,';
MP6 ]GUIO"OCJYUWX<ZD+F9H+>*2]A1I(0T<F2H$BXR#MY /UKH]'TFQT+1+/
M1M/C9+.RB6"%9)&D8(HP 68DGCU->2>%;SQY8^+?&/A6Z\2MK5_8Z%9W-I+>
MPQQJES(LV<E%&5WJ.O0 #L37$V/Q0\3>']"\5PZUK>I_\)3865NKZ7K4,2_9
MYWF$3W,3QJ%D@!D4CK]T=C0!]1#!K"\4>%](\7^'KC0M<BDET^XXECCF>(N!
MV)0@X]JY#P'#X]L?$&H0>)]5AO\ 2+F".>Q$MVD]RCCA^4BC!0Y!''![\\4/
MB;?>,(O'/@K0O#/B;^QH]:DNH)R;9)MNR(N' ;G([<XSC.: /3-+TVTTC2;7
M2[)66VM(EAB#R%V"J,#+,23QZU?XKYSO-:^*NK^)_$7A'P]XG@CU;PQ;V2":
M7RH4NY7CWR2R(48[#G&%(QQU[ZS>+/%GBC7O%6F0>(HM$;PSI5O<_P#$OV2?
M:9Y(3(S;I%(\H8P, 'N<<46 ]V_*O/;FS^'_ (!\<KKCV MM>\87B68N$C>5
MII<9"YY"#Y<GH.,GI7G'@+QMXOUKQ!X%L]2\0320Z[X5FO;C]T@_TA7"B0$+
M@$9/'3VJKIOCGQE=>#?A5J]QK?VB?5/$;Z;?,]O&//C\R50>GRD*F.,9S0!]
M)YR*,+[5X)X9\2>/KC4_&OB+4O%"W&B>$]3U"V;35L45[M(X0R#>#D8)&/7G
M/7BI#XV^(F@^$T^)NIW=OJOA^ZT=[R2P::-?+F*AXQ!MCW;?O AV) R<\46
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MA)!V2Y4AAE0<  =NG%5U^#OAT^!/^$2GU#5)88[YM2MKSSE6YM+AF+>9&ZJ
M#N9SR#]X]L8].HH \OU#X/Z3JV@ZCINJ:[K%U=:G);O=ZBTT8GE6!MT2#";5
M53SA5&223G-;6F^ H+'Q\GC)M<U.YU#^SDTQXYFC\J2)3N!(" [MQ+'!')].
M*[:BD!Q'C#X?6WC#7?#^K7&M:C8R:%<&ZMX[5HPK2$8W-N4YXX_$U0\0_"G1
M_$'BY?%,&K:QH>I21"WO&TN[, OHU^ZLF!GCL1@XKT:B@#S?6/A)H.L^)'U:
MZO\ 41$^DOHK623 0FV88(^[NSG!SNZ@5F>'O@CH^@>(=(UM/$6NWESIEFVG
MQK<70V/;G.(R !\HXP!Z G)%>MT4[@>16?P/TNQT?2M%MO$VM+IFDZH-4M+9
MI$9865MR1@LI.U26]SN.:T+SX4Q75_XNOAXGU5&\50BWNT40[40*5 7Y,\*6
M7UP?4"O3:* /E?7_  ;XBTSQU);LOC6.QL;.VT[3+W28(+O[7%&I):3<,(P8
M@8PH(7)R>:^A/!L.NP^#=+B\33F?51"/.D<*';DXWA?EW[<;MO&<XXKHRH(P
M0,4N*+@>6:G\&=%UC5O%5Q?ZQJ4NG^(]DDVG"15B@N%"@3H0,AQL7]<YXQJ^
M&?AY_9'B!?$FN:[=>(]<AM/L-O>74:1^1!G)4*@ +$]6/)QVKOJ*0' ^./AT
MOC'6] UR#Q!J&AZEHC2^1<66PDK*H61<.",D#@XXKF8/@?':^%=,\.P>,-6-
MIINKKJ\'F+$^UU<NJ?=Z!B23U.?PKV2BF!XUJ.BW'PWUSQ%XNCL]>\:2>++B
M.";3+*SBD$.(V"$\C" #:3TY&:['X8^$H_ _PWTG0%@$$L<9EG16W!97.YE!
M[@$[1[ 5VF!12 **** "BBB@ [T444 %%%% !1110 444F<]NE 'R[^V<#_P
MKOPW\P_Y"C?+G&?W3<_Y]:*=^V:Z?\*T\.HS $ZMGG&>(7_QHH ^@?!08> /
M#VYMQ_LZWR?7]TM=!6!X,7R_ /A^/).W3K<<]?\ 5+6_0 4444 )44G^LB_W
MOZ&I:AD_UD7^]_0T#1/1110(**** "BBB@ HHHH \U^+%K8W6GZ*+MM:LY8[
M[?;ZIH\322Z=)Y4@$C!58E""4(Q_'7D,%OXHLM6\.^*/''AK5[[2);.\TZ:3
M1H)K>=6:YWI<2P1%67SA@LN.N,XZ5]3LJMU%&U?2G<#YITGPUHMK\7? NGV_
M@:_TW08=,OHX[:\LY9HX3)(6C\QV#*&8!CM+?+GG!XI^K:7K6N-\;-/T/3=0
M%Q>_9&LUELY($N1%$%D6-F !Y4@8/.01P<U])[5]*-HS0!\Z:;:>%M=TC7]9
M_P"$'\7*LNAM8ZE<WS7'VD L#]F@20DOC+G<HXV@<[C74?!^3Q -4\20W_F:
MGI220"RUNZLFM+F\41CY9%95+%!A=V!GW[>Q[10% H ^=M4\[29OBSX9\0:/
M=WM_XDDDN-*D@M))!?1R6XBBB$BC *,H&"1CD]#FF6]KJ'AWQE\$])UR.^FO
M-)T^YCOYA \B1/) J1JSJ"I.5*]>,=>F?HS:OI1M%%P/)?V@G\WX,:KI4-K=
M75Q?201QQ6L$DKMB9';A <852>:U4\(^$='T/6/%.FZ7,;R^TQDEN9_.GG>+
M82$VOE@.?N@#W'%>B[0:,#&*0'R[)X5DM_V<O!FK:!X5G;4-/FLKG6;:VB>W
MN[E(0P<,0 Y*NVX?3(K4O(-%G^#OQ$U;PQX=UZ$:Y8>6+C4$N)+B^N#&4 $;
MY8* 5&[H<GKBOH[:!VHVKZ4P/F35(YK#Q%X,\3:IHVN77A.X\.QZ7*VFI.)[
M.<<D/&F'(; 4Y';\[GA7P_X>MOB]H6FS>";FSTU/#AM[:WO;.2=8G\]I%5Y"
MI4-LYY/?!P>*^C]HQBC:*+@?-'ACPM_;?A3XNKI.AR6_B&^U/4%L;FYM&BD>
M&1<($=U&%;YA@'C\:PM0T2'QA\/;W_A$?!WB6+QA:Z,ME>/J,ES&(XT>,O:H
M9#M<OM. HP!GIFOK3:*-H'2BX'SUI.M6^O?'?P1K.E>&=:L["'1;FSDDGTJ:
M".!R5Q&25 &W!&<D<]:[WXH3Z3-!I6@^)?"LFM^&]3>5;^5())OL6U,HY$:E
MEY.-P(V_CD>D;5]*",T7 ^4SX=UNW^$?Q/T+P[)K>L^$E@@DT7[=')YN00TT
M<(8!BBA0!QCTSS7;2:TVG_%O0_&^HV>H?\(I?^'S86UQ)9RDVD_G!SOCV[H]
MZJOS$#.T9KW8* ,4FT=Z+@?,.GV6K^!]*\/^+Y_#]\_AFW\1:G=_9(8'::RL
M[@,D$@B'( R3CJ!)4'C_ $^ZU_3O"=EX'TK4/##7FKWEU;3&RF!!DA<><XVD
MQ!Y'QSC .[@<U]3;1C':C:,47 \6\(_$_2_#_P (K/4O$7AG4- ETV1;"]LH
M-.D"6\F2"ZY'^KR"=V3UQR:Z?XQA)O@GXKC-N]R\VG2)$B1&1F=AA< #KDCZ
M5UVK:-8ZU9BRU!&EM_,61HPY4/M8$!L?>7(Y4\'O6IM! R.E(#YMN-,W>.;.
MP\*V;Z?J%YX FLX76V>)1,2AB1FP &^5^IR,?2IO#XAUW3/A-I6AZ?<VNN^&
MID_M6/[*\1L8UMG2=)"0 "[E0!SNSGH#7T7Y:?W: BCH*8'RA%<0V7P.L-*O
M=,O(=0T?Q9')<!["7]V?M[.2&VX/[LDDKG@^^*Z?7+W2=-^)WCW0?''AK4=3
ML/%D=F=-:VM991=HD(0VX9.4(<%AR "23CJ?HC8N,8XHV*2#CD47 ^8=>M--
MMO&_BO0_'VF^(X[/Q);VK:;!I:2RQSI' %:W^13\ZL._'S9R*]MU^RA7X0ZE
M82"ZLHDT>2)@C^9-"!"00"3\S#Z\GO78[1FL/Q-X=L?%?A;4/#VIM.EGJ$)A
ME:!]C@'N#_\ K'KD4@/GKX:^)O#^O>)O#LWB#4M+MKW1-!?3K:"&TN4:YRL;
M,S--$@^5(\A%)^\QSBM+0M!N/$/[)]E'HH>+6]"E?4;%&A97BN()VE1-O^TO
MRCV:O5-%^'LUCJ6GWFN>+=5\1'3&+V<5XL*)$Y5EWD1HI9@K$#)(&<XSC'=A
M% QCBF!\U^(H]>UCX2VGQ$U'1M0M9]0U:TU+4K*T3=/;Z?%E54 CG;@2=/XC
MGIQCZ[I_@-OA;J&H:(NIWMAK/B*QNGN-5A*_:G\]/.>)652!MW;FVC/S<FOJ
MS:,8[=,4GEJ%"J  .@HN!X+I_B3P?X#^+_Q!U*5HK#3(=-TQI%M;=B-VYT)"
MJ.3\T0./45[Q%*LT"2+G:ZAAD8//L:/)CYR@.>N>]2*-HQ2 6BBB@ HHH[T
M%%%% !111B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% 'RS^V>V/ ?AA<]=1<^G2(_P"-%)^VA(Z^!/#(#80ZBY(]_*./ZT4
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M^(/PYC\77NM02W_A^6;5;/3Y+CY[E%BP3%#DC#,_*CZ\"NV\.Z3IOBB&XO\
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MF7EKXYT'5M6DU9=,U3PR]\^E6]JT^VX$T8+HB*7QM9CDG&,=*])^(NCW^O\
MPM\2Z)I</FW]]IL\$,98+O=D( R>!DUYQX5LO&"^,] UG4O VI6D5CX6?39"
MTMNS&974JO$G\0C..P+#)'8 Z'5?'.@:W<^ [[2O%NI:?;ZU>;K1;6U)BOP%
M.8I692$Z=,@\=.XW[3XB^'KOQ7)X<M3=RSQWAT]IUMV,"W C:0QE^@(5#[=L
MYKQSP[X.\<V'@_X36-QX+O([KP_J\]S?@7$#&&,^:%.3)R&\T' R1@^V>AL_
M!VNV_P 8AXDT+PQ?>'9Y=5D.K7"W<;6.J6>'VRF/<6$Q)3&%'.XGK0![E+(D
M4;2RL$1 69F.  .]>-> _BGJ6O?%S6O#^KV[P:9J-N-0\..4 $]LA,<C>OS,
MN\9['MQGL?B9#KMYX-;1]!TZZNY-4GCL[I[:1$>WMG8":0%R.=FX#'.2*\^\
M<?#.^T*[\(>)OA_I>J:MJ^@WJ*MO-J)9%LRI66,>:^ ", 8H0';7'Q;\*P^,
M)_"<:ZC=:K;SK;316]C*XC=EW+N;;@ CH2<5P*?%B'Q3\.;?7]6U+6?",<GB
M 6<,MC;;VD42%5A<D, 3@AO3WKL? FEZ];_$GQ[JVJ^'[K3;'6)K6:U>XEB?
M=L@$;C",V#D?3'>O)O\ A"_B-;?!^7P3_P (3<S7%EXE2\BECNXBL\(N#*77
M+# P ,'G+=.*>@'M_B+XI>$_#-S?V^H7,\ATR..74&MH&E%DDC;4:0KTSUP,
MG'.,<US>B^++R/XW^,[?4O$4C^'++1[34(8IE416X?<68, #C"]\YSUXK&U#
M0?B!X6^*GBC4_#OA.W\4:5XOAA9_M%PD2V<T<?EXEW?>C(.<#)[?5+SP#XH\
M0?$+Q_'J5C-8Z9KOA^#2X-221"ID52'PFXL!ESC(Z ^M&@'?:'\4_"FO^)+?
MP_:W%Q#J%W;?;+2.XMVC%U#_ 'T)_/!P<=JL^*/B!HOA?46TV[@O+N\2QDU*
M6&T@,ABMD.&D8\#&>,9R?2O/_A7X>\16&I:?#KGPIT;PW-I=L;>76('B>2[(
M4*/+V?, W4[C_.E^*7AGQIX@\9O;VGAUM;\/S:++;0JMXMO'%=L6^:89#.H7
M;@<@'G&0#2T ZS6/C!X-T5]-2:6_N6U2Q_M"S%G833^?%@'*[5Y(!!([#KBD
MU3XQ>"='G9;Z\G6&%HENIUMV*6C2@%%D[ACD< $C/.*XKP9H/CRUU[X:S:OX
M1FM8-&T.;3KR1;R%_*=O+521NR>(LG XW#J016;J7P]\4:9\2O$AA^'.@^+]
M.\1W@O;;4]2,9.GL0H=)%8;F48R O7UY.'H!] 7&I6-GI,NKW%U''8Q1&=YR
MWR",#);/ICFN'A^+?A.2UENIFO;.'[+'>0M<6S+]ICD<(ABZ[BS,HV]<D9 S
M75:M;W:>#;VVL=/@O[D6;QQ6DGR13ML("'T4GCZ&OG.;X4>.9=#U"P\-Z/+H
MVC1PV]]'X?U:YBN8)+])EE>.+!?;"0"OS, 6(XQDT*W4#T+Q)\<-*T_P/XFU
MC1=/N[K5=#\M+BQFBVM 9 #&[\X\LYZ@D\8^GJ6E7\FH:/#>R6\T#.F3%*A5
MU/N*\.N_!OBCQ+\'O%^GQ_#'2/"5_J%O$MMI]K)%YEQ(C;F+N@"@8X4'GDY(
MKVCP[>:K>>'K:XUK2#I%^R?/9F99C'Z LO!..3CIFC0#Q'2_'6H:WXA\;ZIK
MOB;6O#FF>&=53R0D"B%($5=T,@*DL\A)P#D\C;Z5Z*GQ<\+JU_#?6^JZ=>V-
MD=1>SN[&19GMQP9$49W#U Y'<"O+KCX;>.->\-?$[39M%;2KG6-:76-+,D\3
M1S;'4JC;&)4MY8R3Z@UL^*/#?C/QW?)KUQX/DTN73=!OK**TFNHB]U=7$:QE
M?E8J(E )R2">.*- -:^^/&CSV&EWGAS0]8U&"^O;6W6X-BZ1,DK8RI;&YN"
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MW>HVN1LNGCM%D#D=F+-^E%@/H7-1131RJ6CD5P&*DJ<X(."/P/%>)> Y-?\
M$FB^#_'5Q\1)S#K,4RZAI^%\J220,$CA _U;1-QW)VY/>KG[.-O(GP@AO)M2
MO;V2XO;K/VJ0OLVSNO&>><9/J: /9JYOQ+XNTKPS% +Y;JXN;C?Y%K9P-//*
M$&7*HHR0HY/X>HKR+4M>\5>*%^)>I:;XIN= F\(73P6$$.WR7$48D9I@0=^\
M@CV'09ZV&ANO%7Q3^&/B&;5-0TZ75-!N;XV\,@58&V6Q*J&!X.[D'.<46 ]@
MTK4M(\5>&K/5K)EO--OXUEB,D> ZGIE6''T-3-H.B.V]]'LF;U,"D_RKBOB-
MXCN](O?"/AZSO)-.3Q!J@LI;Z/;NAC$;/M4G(#N0J@XZ$XYQ7,>(=0\7>$="
ML?#K^*1JEQJ_B#[!#J$KK%-:V[QM)'$[A& D)7:&V]&''2BUP/6_[!T':5_L
M:QVYR1]G3_"H)/#_ (9E<P2Z+IK&13\C6Z$LO0\8Z<C\Z\"UR;XM^'[31-+U
M+QW##<7WBF&PA>UVW,BVLP8JLK&-,LNW(./FSSQC&E8Z/K'AGXXW#:QXZU#4
M7LO"KWANKXJL(_?E<.J@80;0QP<D@\XP*+ >SP^$_"MA;21VOAO3+>)LETBM
M$4-QSP!S5+PT_@_Q/H$6L:+I=H]C([HC-:!#E'*'@CU4UY#\,]>\7ZEXTT_3
M=3U_5);36O#,E^)[MX<F=95030Q[ 8TQ)E0PY&TXX-0P^(O&UQ\#?"6H6_BZ
MXM]9NO$G]FSWAMXR9HVO)(N4(P % X&.!C-*P'OHT'0\Y&D61.,9\A>GY4A\
M.Z >NBV'_@.G^%>>_#>;Q!I_Q \:^%=:\27>O0Z<;.XMKB\5 ZB:-BR_( ,9
M7C_.>+\<>+?%5MXBU[5-!\0WDUEI&LV-EY5LL:6L <QK+#+O7=+(6<YV\*&7
MG.0"P'JNM7G@;PG<PS7FDVL=YLDN(DM+#S9MD>"\@"*2 N1D^X]:BC^*O@::
MZTVWM];68:D\44$L<3M'OE7=&C,!A&8= V#7&ZUH%Q=?M*Z2Z^)=3@1]#N9U
MBC9"L8$T"F-04.%/4YR2>_:O.-,CUCP_-\1KC2?%U[;7#>*8M.C00I/)-D(?
MW2!,&?;\JY 4 $GID.R ^HM6U:QT71;S6-2G%O96<+3SR$$[$498X')P!VJ3
M3=0L]6TNTU33YO/M+N)9H9!P'1AD'GGH:\-T?Q5XQ?X6?%&.XU:[@U7PY)<"
MSGO8X99XD6W655?:!&QZC//7OQFA<:W\1?$'B/X>:'H_C4Z,NO\ AEKVXD^Q
MQR$3HB'?@J#DEAQD#K]* /HZBO =5\4>+=!^,EEIOB/Q'J.F:9=ZE!!I\D5G
M%)I][$4 :%W"[XIS)NY+8P>@'-=K\3/$^JZ/+X5T/2;K[!<>(]46P;4-@<VR
M;"S%5((WG&!D$#J<XI =8OASPU:>(;CQ0NDV<&KR1^7-?B-5D9,#AF],*.OI
M5/1O'GA7Q!K(TC2=4$]XUL+R-#&Z":#.WS(V8 .N>,J2*\CUJ]\510?$CP#J
MGBBYU"*PT/\ M2SU/RXTN!&ZN&AE 4*W*GD ''H>GH'PFTJ2U^#?A?S]2N+R
M:72;=HYI5CWVZ-"F(TVJ/E&!C.3ZDTP.KUWQ)HOANTAN]:ODM(9ITMD=@2#(
MYPJ\ XR36R#D"OE.[L-8C^"?C5KGQ-?:G/\ \)<EG"U]L<(T>H1*)/E4$L<#
M/... *Z^;QIXX\(V_P 0-'U37(]=OM,>P_L^^>V2 0_;&*#>J\;8SSSV'-%@
M/?JQ]9\1:-X?ABN-8U"*T29_+CWG+2-C.%4<L< G@'@5R'@(_$.W\0:Q9^,)
MDN=+*1S:?-+)";D' $B,(@ 5!Y!QGG&37/V3277[76J1Z@69;#PW&VFHY!50
M\H$KJ/7("D]<<=Z /2=(\6>'=>O[BQTG5[>[O+90T]NC_O(03@%EZKG'<5N_
MTKS3XD:AIW@/1]4^(&GV$#^('MX=/65\X*-,JJS@<L$+Y]3TR,UA3Z]XW\*_
M%+2O"-]XC36K/Q+I]S):W,UJD;V5S"FXG"8#1D$<'D>M%@/:<T5\R_\ "9?%
MZ+X-:;\1I/%6E.=26TBBLAIN0K27'EEBV1U5AGMQQ[Z>O_$7QU\+]0\1VWBK
M4[3Q+$-&_M:PFBM1;>1)YRPF)D4D[-SJ0Q)..]%@/H8FC(Q7AVL:YX^\*ZCI
M]F_BJ'5X]>TN\FAGELXU^QW,,(E!4)C?$?F&"21Q\QK*TKQ1\3T^'^A^+-;\
M6:<8_$?V*."RM]/S/%O#%Q".?,E<;>&^5<$\ ')8#Z&W#&:S+?6]*N-=N]!@
MO8Y=1LXDGGMQDM&CD["?KM./I7SYJOB3QKKWP?N#=:]<V-]8^+(](DF^S1K)
M/%]JB53(JY4$;N=O#8QT//97WC+6O!^N>.IM4GAU>#0/#]K?Q%+=89I7)G!#
MD=1F/.0 %W'BBP'L@.11FO&!XF\:>%]?\%+KFN0Z[:>*W-K)'%9HGV.=H_,1
MHRIRT?# [L\<YK!T?QQ\1S9>']?U+7-/GM+GQ.V@S645B$,L?GO%YF[<2K#:
M#M]!S18#Z&I,UP_Q1NO%6G_#G4=7\(78@U/35^V%#"LOGQ)S)'@]"5S@CG('
MK7ES?&R6W\>P7RZH]UX+U/23):R?9D5HK\0K*+?.<LY0CY?[S8[<%@/=(M?T
MB?Q%<^'HKZ-]4M8$N)K89W)&Q(5C[$@U%?\ B70]+UK3=&OM0CAU#5&9;2 @
MEIBHRV,#L/6O*-#NO'W_  DWB#PSXCU^&34X_#-O>B\M+..*2">1I05SSO"E
M#C/'/2N'T6R\23>%/@AY'B%GU*[GGFCNKNW#B%6MV)7&07.#QD\]>U 'U3U
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MN-0U6>_EN;59PTJ*IC##.T8'(ZG+9)SUHL!Z:'5B5!!(ZC/2G"OG&W\2>(/
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M"S(K_*C]6.3@<#DUZ7%XI:S^% \8ZA)#J#6^D_VC,UAGRYRL.]O+SS@X.,T
M=<=HKG[[QEX5TO68-%U#Q!86FHSR+%';S7"JY=ONK@GJ>P[]J\WL_&OCC36\
M"ZUKEUIM_I7C":&W>UM;=HVL))83)'L?>?,7Y2&R!ZC'2H/A;I%Y?>.OB-<:
MU>6>IPQ^(2#%+9#?YL<4+1N&+' 48"C!QC((HL![A1112 **** "B@T#I0 4
M444 %%%% !1110!\H?MI(O\ PBGA1^K"]F 'L4&?Y#\Z*?\ MI;?^$/\*?.J
MO]NEQGKCRQG^E% 'TIX9&/!^C#_IRA_]%BMBL?PPNWP=HJ]<6,(_\ABMB@ H
MHHH 2HI/]9%_O?T-2U%)_K(O][^AH&B:BBB@04444 %%%% !1110!R_C3PY/
MXBTFV&GSQ6NK:==1WUC<RIO6.9#T8 @[64LIQV8U&_AFV34'\90Z' WBXV(@
MS]J<(3C/E;NFS=WV^^,UR7QBU&ZT6Z\"ZS:KJ4QBU^.*2ST^1MUTC0RDIY>0
MK\HN,].>F34EA\8K*XG2SOO#.J:9J,>JP:1=V=QY>^VDG&89#AB&1AGYAZ'\
M6!UW@_PW)X;TFXCO+I+S4[^ZDOKZZ2/8)9G/89.%50J*/1!4-W\/_"-]JFK:
MI<:.C7>L0BWO7$CKYR!=O.#P=O!(P2  :S;SXFZ3IL_BJ/4+&YMV\-O;1RDE
M")_M&/*V'=QDD [L8[]*YKQCXXM[OP%?-X@T+Q-H8M=6MK&8Z=,BRHQ,3HXD
M1\&)MZJ<<\D8%(#N8OA_X6AO-'O$T^0SZ+#]GL7-U*3!'W4?-R#@ YSD<=.*
MB\/?#?P7X5UB?5O#^@PV%W.6W&,L53=@L$4G:@.!G:!G KG->^,%KHNN>(-'
MA\)ZUJ4_A^*.XOFMTCV) RLWF LXR %/'4^G%3>)OC%X;\.PF18;C4O)T]-5
MN%MRBF&W?[K8=EW,>2$&3A2?3(!U/BKP3X9\;6$-EXFTM+Z*"3SH269&B?&,
MJRD$?@:IW'PY\'W'ARS\/G1XX;*QF^T6ODLR26\N[=YB2 [@V2<MG)SS6#=?
M%_25A2;1])OM9A&DQZU*UOY:-';R9*'8[!F8A6)"@XQ[BKU_\2;>U\42Z+;:
M#J.H1VMQ:VUY=6P0K;/<8\O<I8,5 92S $#/UP[ 6+OX6^"[[2H=-NM+DDMX
MKO[</]*E#//Q^]=MV788&"Q.,<59D^'/@Z:[URYN-%6XDUR%8-0\^5Y%N$7[
MH*LQ QV( ([5H>*/%&F^$](34-1\QS+-';6\$2[I+B9V"I&@[DD_D">U<7>_
M&G1='TWQ)-KNAZK8WWAP1/>V C267RY/N2H5;:R>I!^7O2 U]'^$W@'0]074
M-/T,?:5MVM?,GFDF)B;JAWL<KCC'3%-TGX1^ -%U#3K[3]!"W.F%S:RO-)(8
M=P (&YC\N ,+T'.!R:R-/^-FB7VLZCI<GA_7+*>VL3J5N+BSVF^MQC+Q#//W
M@<'!QGC@U4T'X\:#KVHZ+!)X?UO3++74/V'4;RW"VTL@4L8]P8\X!YQ@X].:
M8'4Z)\+O OAOQ$_B#1?#\-E?MOVLC,4B+_>*(3M0GN5 XR.E:?AGP;X>\'Q7
MT?AVQ^QQWUPUS+&'9EWGKM!.%&<G P.37+V/Q;TFZU+1TFTG4;32==F-OIFK
M2HOV>XDR0JG#;DW[<H6 W9%8EU\>+.5=7ATCP9X@O)M,>\AGD>W6*")[>/>V
M^1FPH/;OQTY% ';:I\-_!NL:O=ZM?:.&NKY%CN_+FDC2["_=$J*P63'3Y@>.
M.E7;CP9X?O/$]EXEGM93JEBICMY5N95$2G&5"!@H!P,C'.!G-<SX2^(]UJMM
MX4L]8T"]M-1UW33>QRMY7E2%(T9\;7)&?,! (!QUQ@U7E^-&AP:3I.H2:-J[
M#4M5FT988H%D:.YC=D*MM8@@E3@@G/M@T@.T\3^%= \8:(^C^)--CO[)F#['
M)!5AT96!!4CU!!K)?X9^"IO!LGA&?0XY](EE\^2*21V=Y<@^89"V_?P/FSGM
MTXKB_$/Q,T/6_A_JMW>6?BC0SINJP6%W%;*L-Y;R[XW0DABHC8,H)S@AL=Q6
MO??$74K;XWQ^ X_#MU+9KI3W\ES%L9F^=5#J-V=H^92,;B2,# S3 U?^%3^!
M/L>FVG]CND6FW O+?;=S*PF P)&8/EV & 6)(%:6L^ ?"FOZY#K>KZ2MW>PV
MSV89Y'VM"V<HR@[6')Z@UQ7@OQ]X;TGX3Z%J5O=ZYJB:E<R6MFFINLE[<S;W
MRK$MM7[K'E@ !S@\5>L_C1X<OM">^M;#4);]-5&B'3 B"<7>"=F2PCQA6.[=
MC ZYXH U=+^%'@71[BSN-/TJ6*YLH'M8)C>3,\<3  H"7S@ #']T\C!J2/X7
M^"X_#5EX<739O[,LKO[=;P_:YOW<V[=O#;L_>)/7&2?6MCP]XE@\0^'?[92S
MN[!%DFBDM[M LL312,CA@I(ZJ>A/%<KX=^+VB^(-?LM+72]2LHM2M9;S3[JX
MB7R[N*,_,PVL2G&" P!P1G!(!0'4V'A+1-+\2ZCXDL;>2/4]11([F5IW82!!
MA?E)*C [@>OJ:Y[4_@]X!UBYU.>^TAV?4[A;NX5+J5$,P(/FJ@;:K\#Y@,^_
M-'A/XH:;XNUJUL++1=4MX+ZTDOK.^FB3R+B)'5&P5<E6RXX8#BG^*/BAI/A;
MQ5%X9GT?6=0U.>S>]ABL+,S><JL 54@_>^N .Y&1D T?^%?^'AXH@\3 7RZI
M;P"UCE6^FPL(*GR]N[&TE02,<G)ZFLAO@YX&DM]1CDM+YCJ-VE_/(=0G+_:%
M)(E5M^5;DC(P<<57T3XS>&=>U30+&ST_68H]=5Q:W=Q8M'!YJ;MT);/$@V-Q
MC''6K>D_%70=7\3VFBVUCJ0CO[BYM;+4)( +:YE@W>:JMN+<;&P2H!P<4 20
M?"?P7:6VOVMM97447B!674 +^?\ ?[AAOX^"0.2.2..E/LOA;X5T_7]$URT_
MM%+W1+?[)9EK^9U6';CRRK,05Z?D/2JMC\5]$OM,\67L>G:G"WA>9H+VWE@4
M2NXZ"-=_S9XQTSD8ZUK^,]6M[+X8ZSJU_+J.F0#3Y'EEM(]UU:@IRR@$C<N<
M]<#% %=_AGX8DU[^V)%OI'^W#4S;/>RM;FY'27RRV,CL.GM6QXE\*Z)XNTH:
M;KEJ9X4D6:)T=HY(9%^ZZ.I#*P]0:XNX^+GAKP])I>AS1:YJ=_/I<=] (;!Y
MI;M#M4'Y>KG.3V'.2,58_P"%P^&3'X3GCM]0EA\5MLT^6.WW*'R 4D.[Y&!S
MD>Q]* --/AIX9&A:OI<GVZ8ZTBQZA>27DGVFY51@*T@.0,9&T8&"1CFM[P[H
M-CX7\.V7A_3&G-E91B*$3S-*RH.B[F.< < =@!7.W_Q,T+39];2]M[Z,Z1<P
MV;!8-YNIY0"D<(4DNQ!'& 1GGBN7\7?$JSUCX:^.X=#NM2T#Q)H%@\\MM<1>
M1<P'871AG(*G'52?PI@;-_\ !OPE?IJ\;2ZK!#JU^NI3PPW\BQB8,'RJ9PN7
M&XD#.>^ !5R7X5^%KJ^\1W=^+Z^;Q% MM?17-RSQLB_<VC^$KSM/49I+/X@:
M=9^)/#?@O4(+XZMJVGK<PSF+,,NV,M)^\SC(QDC_ &AZTV\^*WAZVLI)X;35
M+R87-U;):6UFSS3&W<),Z+W16(&[IGCK1J!<\"_#S1_ =I/'I][J6H7$^%>Z
MU*Z-Q*47[J G[JC). !R34WBSP'I/BVZL=0N+B^TS5+#=]FU'3;@P7$2M]Y=
MPZJ>ZD$5HZ'XFT7Q'X5M?$VD7\=QI5S$9EGY "C.[(/((P00>F#7/^'?BGX;
M\3:HMEI\6HQ^?9/J-I-<V;Q1WENK!6DB)Y/)7@@'!!QS0!;7X>:!+H5_I.J&
M\UE=1@^SW4^H7#32RIUP"3A.3GY0.<'M5/1OAAI6E2275QK&L:MJ7V,V$%_?
MW(DFM83U6,@#!)P2>2<#)XJAIOQN\":KJ&EVMG<WQ&IW364-P]C*D(F#,HC9
MR %9BAP#STSBM6W^)GANXL_$UW_IL2>&<_VB)K5T>(A=W"GEOEY&.HHU XWQ
MO\-+RS^!<7P^\'V^IZNBW5N8S)=Q+)#$EPDC8=V0<*#MQSP*[2V^'.@-%JIU
MA;G6Y-6MUM+IM3E\TF$9(B&,!5!)/'.3G/ KH;S7-.T_PX_B#4+C[)81P?:9
M)9E*[$V[N1U!QVZYXK!T3XB:#K>HWNF6\6H6>HVL!N_L=[9203309($L:, 7
M4D=N>1D F@#.B^%&AQVGD3:OK5T\=C)IUK-->;GM(9,!A&<<' 4;CEL#DTVY
M^$7A^X\'>'/#*ZIK%O#X>N$GL;J"[V7";05V;P/NE6*\8('0BN1^%_B/7/B%
MJS>)O[<UNQ2VU"[273Y[+;9S6P=DBB5BH'F(=K%@2WW@?:76OBI)XB\%_$F'
M0X=6T._\-6]P8+I[0KN:*+?\Q=2JDMD;?O;<$8SP ;Q^"OA=O#VOZ%!J&L6]
MOK%\NH%EO&+6LZLKAXLYP=R@Y;)/TQ6O:?#31;?6M4U.ZOM2U,:II\6F7-O?
M3B6.2!%("G*[B3N<DDG)8^M9W@7XK^%?$::=H<>K/)K!TQ+R1I;:6*.90JB1
MT=E"N QY(/KZ5KZ#\2?"OB775T?2[R9KF2%KBW:2WDCCNXE;:SPNP D4''(]
M0>E&H%/P[\+='\/WUI<-JVKZK_9R-%IL=_<B1=/1EVD1X ).WC+%B!T(R<TH
M?@UX?M_#MAH<6M:X+>QU(:O&YNE+FYW%MY.WIN8MCIFMOQ7\2?"?@O5+32]>
MO9X;N]B:6WBBM)9C(%Z@;%.3[=:Q]'^-7@#7=1TNRTS59II=5D,,.;615CE^
M;$<C$81SM;"GDX],4:@>BO#'+ T,@#(ZE64\@@C%<?!\,?!=KX9TOPY::.D&
MFZ7?)J-M$I)V3+(9 23DGDD<]N.E0W7Q4\)6?B>+09[JY626\_L\77V63[*M
MS_SQ,N-H?/&,]>.M9>H?''X?Z7?7MK>:A=H;"\%E=O\ 8)BENY PSMMPJ'(
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MSCCUK#\0?%#3?%?P>\8ZUX!\036FH:):R3,S0;)8RJEAE)%^ZP4@''KT(HU
MXCP3\./'FC2Z')9MXOTN\AFA-]'J-_9RZ?L!7S5"QR-(ZD;]O /()Z<^G6/P
M=T.SOD0:AJ$FAPWW]HP:&S)]DBGWEPP&W<5#'=M+$9QQQBM'5/B+H/A/1]-&
MO7-W<7<MDMU+':VCW$BQ!1OF=8U.U 3RW3TZ587XE^$)/$VBZ!%J33W>N6_V
MK3WBA=XKF/#$D2 ;> N2">,CUIZ@,T3X>V^@V7B.UL_$&JN-=N);J1IGC8P2
MR??:/Y!C/OD<5RC_  #T$>%=!T>S\0ZU9WWA]W-AJT$J)=1(YRT9(4 J2<X(
M_&NSN/B)X6M=-O\ 4);^7RK&\?3G"6TC/+<*2#%&H7,C9!^Z#T/8&H[?XF^"
M[SPE'XHMM8\W3Y)_LJA()&F,^<>2(0N\O_L[<XYZ<TM0,VX^%MNMEIMOHWB;
M5](DL89HC+$T<K7/FLK2-+YB,'8E<Y]2:Z?1_"FD:-X)M?!\,'G:5;V8L?+F
M^;S(]NTAO7(SGZUCK\4/!<GA:+Q)#JQGL);G['&L4$CSM/G!B$('F;QSE=N0
M!GIS70:#X@TGQ)H-OKFD77GV%P&:.4HR9 8J<A@",%2.1VHU XKPW\);+P_)
MI4<_B+4M8L-#=WTFRO?+,=D2"H(*J&<JK%5W$X!XK1\&> 9O!_B#7]2'B6]U
M*/6KEKN:VGBB5$E.T;@54'[J@8Z?C5C2/B9X,U[Q FA:7K(N+R4.T),,B1W(
M3[WE2,H27'?83QSTKSJW\::_XZ^+FN^'_#OBNXT)=!N[98;8Z8TD5XFW?/YS
M,H*9Y5?F7H",YH ]YHI!G'-+2 **** "CM110 4444 %%%% !1110!\G?MJ.
M5\,^$1NP#=SG_P <6BE_;27/A?PD^Y<"\G&T]3E%Y_3]:* /ICPUM'A'1PIR
M/L4./^_8K8K)\-@KX4TA3U%G#R/]P5K4 %%%% !4,G^LB_WOZ&IJ@E_UD7^]
M_0T#1/1110(**** "BBB@ HHHH X/XC>']:UF+PW?Z#!#=76B:Q#J+6TLOE>
M?&$D1E5L$!OWF1GCBN.UGX?>+]4;4_%D=K8)XAFUC3M0M]/:X)B\BT&%C:7;
M]YM\IS@@94<XKV::XM[<)YTR1AV"+O8#<QZ >I-8OA[Q5IGB6;6(M-6X5](O
MFT^X6>(QGS556.W/5<,,'O\ 3!I@>91^%OB1)J/C75M2\/\ AVZ_X2 6&-.:
MZ:1&BCPDT+ED .8RV&_O'IBL>Y^&GC"S^&>M>'=#TK;!?:Q:WMAID^J>9_9\
M,;12./-8'[SQMA02!N'7FOH7\JBFGBMK>2>>18HHU+N[-A5 &22>PHN!Y!)X
M5\:7/B/XGWTFCVT,/B'2XK.P_P!,4EW2)X_F^7Y0=^?PK!B^'_C[0?$NG:]I
M/AS1-72^T>TTS4K'4K@8M9H%*+,C[6)3:>5')^N"/1D^+'@][)M2\S4AI()
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M(A)Q_M8KJ=3T3QA!\==/\8:7HL-YILVA_P!FW)>Z6-K=Q/YA.,?/D<#'&>I
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MT/5]0U'3]+U.VN[O39!%>10R!F@<]%<#H>#^1K6P/2@!:***0!1110 4444
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M)VUB"."\:X\0733F)>1$7VG"Y)R%.#G)R: -FQ\3ZGJ/C#PK\-;'5+C1(?\
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M-?%S^#+OPI<?#/P]?6%W(LT[S^(KEYWD485_-,>[@<  @#GC!.0#T'X:W'Q
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M*5QN7&T=CA5YXIZ 5(?$GBNZ^(TUF\FGVLL_A!=4A"0+*8)S)M*F0-^]3.2
M"!_.K?P=U7X@>)O#%GXK\7:MI]Q9:I8Q26UK:VWEM"^YMS,V>=R[3['('3GI
M)OAYHDGB1?$%O->6=R--_LD);RA8UM\Y"!<$#!YR/2M/PGX6T_P=X9M?#NE3
M7,EA:+L@%S)O9%_N@X''^-(#RK3_ !5\1KKXO>.-/;7+!O#WA.>":6V6RW37
M$,EN\@C0@\,#MY[D>G!K>!?&OQ0\27WAG7Y[%)/#>M+(;Q96MT2VW F+R65_
M,)_A97!/!Z=O3M'\ :-H_BSQ!XE@FO)[S7]GVU+B;?&VP87"XXP#@>U8WAGX
M.^$_">L)?:3+J?D0R236VGS7C26EH[Y!:.(\ X9@#SC<:+@<#I'Q$\;2Z_/I
M.LZT=,UD:7?7,NF7FG*$CD0AH9+=U&)HPF<Y?/&3Z5S\'Q<^)7A?PGX/\>>)
MK^SUS2/$5K.9-/M[,0R6[I$TD;!QG=G:=W  KT^]^%NA>'M$FU2Q35]8OM+T
MNYL]-AFN#.T*R)AEC7N3P.<\<"LGX3_"^QC^'OA6Y\6V.I2ZGIUE+;K8:G)N
MCM3("DFV/I\RDCG/![4] *7A[QS\1H;>'Q-K$"7WAJYT234'=VMTV3K'Y@$'
MEL6:,@'A@6'&3UJ4:E\1M2\ P>*$\860T_5M FO)&BAC5[.X\H2QK -I+#&\
M-O)("Y&#76>%O@WX0\(7;2Z:-0N(/*>"&TO;QYX+9'^^(T8X7=SD]>2.]-\-
M?!?P?X7DN19R:G<VDL<L,-G=7SR06B2C:XB7/RY'&>N.]%P.)TN_\0Z+\(/A
M->1ZI%?+J5_I\%R+RV1V\N9.BG PPQ][ECN/-6M3\=>*?#OBSQAX,U;7(FU>
MZ@BF\*G[.J^<),H%X!W%9, @_P ()^G6CX.^'QX9T/P^NL:Y]CT2ZCO+,M>[
MG22, 1\D$;5 X4 #DUTVI>"]!U7Q7HGBF_M/,U711(MK/G! ==K COZCT/2B
MX'DNK>*/BA<>)==\.>%7>\O_  Y:VJM+LME2ZGDC$C-+YC*5C(R!Y8'0\U[?
MI-U=76AV=W?0I!=2P))-'&^]4<J"R@]P#D9KBO$WPA\*^)_%I\2W%QJNGW\M
MN+6Z.G7C6XO(A_!)MY(QE>".#CTKK=2T*&^\-OH-M<SZ;;M"(%>R;RWB0#&$
M.#C@8H;N!\V^,O%&M-XEM/C-:PZE-8Z'JGV6TMTM9/L\FE%2D\^_;M)=OF4Y
MZ*O%>A?%V.ZU6Y^'=UI6N-%:7/B&T">5&DB-E79902#G '';GI7<S> M+G^&
MA\ R7=X=+^QBQ\SS0)O* VXW 8Z<=*PF^#VB-H7AO16U[71:^')UFL2+L!D*
MY"9.WD*"5'L<47 X<^&[C_AJ*\LSJN]9_"OFS"2UB*3 W&UE=0 #DC)/7MG%
M<U/?76J_"KX:7-]#9K/%XY2#%G (H@$N)D^51P 0O/>O;O\ A6VG_P#"?GQM
M_;6K_P!J&S-AC[0HC\G^[MV_WOF^M8H^"'AO^P-.T7^VM<:WTW46U6W=KL%U
MN"V[<3MYPQ8_5C3N!D>(/%NO>'_'?C]([O3=NG^'8-0LY+F%8E1RTH"R2?>8
M KD#/\1 QFN?B\9>-[Z/QUH-QKUW%]B\.1ZO8WTUC';3HQ5RV$V_=)0XW ,/
MR->C:Y\(_#OB'6-<U+5+[5)7UJQ73[B(76(Q$IW+M&."&^8>Y/K3=/\ @_X8
MT_6+[5/M6K7EQJ&G_P!FWGVN^>07,>-N6]P,@8P!G@4K@><Z;XN\:V]IX.\
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MIM@7U'"#$FX#]V%(8X&,YQ7-?%VUEM_&7PU\3R*QT[2];\J[8=(A,GEI(WH
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M "YSDCG'6N$\5>/+^?XBGP#X7\1:/INIIIYNM]XOF[YRX2. KN&W(^8]3@C
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MJ ^JM'7;HEBO&! @XZ?=%7ZH:/D:'8!L;OL\><=/NBK]2 4444 %02#YXO\
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MFHZCH]GI5[H\]_H]U+:N2)8MN])?W@#;1N;Y<$@CTY /6)&CCC9W(5%&23T
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M51CY<+AMPPHXK<\'_#[3?!NJ:OJ=GJVKZC>:N8VNI=1NO.W,B[0P&  <8'T
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M"C;C/JP'>L7PQ\09-3\3>*](UZ.QTQ-&U*.QMI1<<7.^,2#[V/FP1P/PS3U
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M]A7=(XD9PA&[ &7;].F*[SQMX0T_QSX-OO#6I220Q7*J4GA.)()%(9)%/JK
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M2;A68C9*=Q^8 @<<<"M?P5\0I/%?BWQGI1CLA9:!- D%W:3F5;A)$9]Q;&.
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M-$#W']H6XAC8H\AE7:K#J"<X!I ><:E\*;O5/@E9?#NX\0A;FP6W%OJ$=J,
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M"'0JRKB)CN4_,Q]C7L_CSP)JOC&33(;'Q?>:!ID2R17]I:(/].B?;\A;/R\
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M>6!M'H/2G+I]BJRJMG$$E_UBA!A_KZT7 ^6M&\0:7-XG^*^F> [BV-SXAO\
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MI_B/4&\7V^IM&UB9V-ODW?E?9?L^2I^0KC W9YS0!]2;U_O#\Z;))LC9@I)
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MUKE/'GB+Q+XD^&_Q:M]<L[2&RT*[^SVK6ET_F1NJQ%0,(-P.\DDGJ<8(&:+
M>]:SX-\*^(KN"]US0;+4IX%VQRW$*NP4G.W)ZC/;I4EWX2\-W>N6&N7&BVDN
MI:>NRUN3&-\(QC"GL.:XWPC\0M8NO'$/@7Q%X6.CW<NE+J5K(MXMQOB#!&5P
M%&UP3TYK<\6^-&T#Q!H7AK3=+&IZUK;2_9H'F\F-$C7=))(^&( !&,*22<4
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MF\YTVLQ7"*BH26).0"<<@5VWP[^(UMX_AU80V/V2XTJY^S3>7,)X9"0"KQR
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M#;=W?'.T<]>OJ:SO%_CJ2S\1OX,T70+K7-7DT][V>*WN$@$$&2@)=CPY.=H
MY]17C'PXUZ!_"_PD76I->FO+[5+TV\\5\?*9][_)<;CNDP-O'L>>HI@?0.O_
M  ^\)^*-6M]4UK2%N;V",PK,LCQ,T9.3&Q0C>F?X6R.OJ:='X!\)0^*+;Q/%
MI"1ZM;0"V@G21P(H@,!%4':%P.F,5P ^/>GKXDUC3;GPGK%M9:)<2V^HZA(J
M&*VV1L^YMI/WMN!]1ZT_0_C_ .&=2U;4+/4;5],6TTPZMY_VB.>-H!U!,9.V
M09Y0\C^98#V7^'!KC-1^&O@S5/$DGB"^TMI+^9HGFVW$B1SM']QI(PP1R./O
M ]!7#:M\;-2MO#&MWEOX%U*UN[;1SK%DUVR>3/#P-Q93@,NY28^N*Q]5U[Q%
MJ6L_!K7;MK_3[O4)Y%N;*.Y"PW -L7RR X.2.,],\XHL!ZGJOPV\'ZUX@G\0
MWVELVIW%I]CDN([B2,M%@C'RL!G!(W=<'K52W^$_@BUCT!+;3;B-?#[E]."W
M]P/LY)R<?/SGH0<\$CIQ6)IOQEL]2\-:UJJ^&[^VO-)U1-)DTR66);B2=G5
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M0 YP!W)R:]M5&:';)C<1\V.F:EHH \=\*?#7QEX7N!X=@\70?\(9#?->00I
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M7YKFUD7$L!]FVKUR,9XK$T_X0R:#J'CJ\T*]BB37[=HM.M9-PAT]I%/G$*.
M&?:V /X0.E>P447 \97X9>*K7P-\/M/LM4TV/6O",R-OD21[>=!$\1XX;.UL
M^F:K:E\+/%U]X1^(.B#4M)B;Q7?_ &R.0"4BV!"*P(Q\QQ&,>Y/TKV^BBX%&
MUCNO[,CBO6C^T^6%D,62N[')&><5X3H_P;\<Z;H'@_0YM<T::V\+:P;^W<1R
MAI8LN0K=<-^\[<# ZU]"447 \#U#X+^*-0U;Q5J/_"26EE=:AK%KK>FS11LW
MD30 JJR*<9#*><'K[<5T2^ /%UYXDU3QEJ&K:9:^(I-'_LK3XK>)Y+:W&_>S
M/OY?<P'&.!GK7K5%%P/ %^!6I3:9KIM]4LO#MY>3VEY8P:3&YM+2Y@.[S@C]
M"Y." . !R:]/\&Z5XNL[:YN/&6L6=[?3;%6*PB:."%5SR-QR68DDGCL.U=A1
M1<#SZ;PCK@^,I\;V]S9BQ_L5M+$#AS*7\WS Y/3&>/6N3T[X7^,K+P5X.T,Z
MEHYG\/ZX-4:01R[)8]TC%0.S9E;VX%>VT47 B>,2P&.1<AAAA7B$W[/]FO@G
M4M$L=<DM[]M2^V:7>A"&TR 2%E@CP<[0KRC@C[_L*]THH \N'@/7--^)']O:
M*^FQ:/%H*Z+!:2>8&3:Q=6) Z;B%Z].>M<EH_P (O&VC^%/ 6BQZGHTC>%=4
MDOF;]Z!.C%OD'RG!Q(W/TKWZBBX'C'AGX:^.?"NL7VE:;XQME\'W&H-J$<+0
M,UY#N8.\*MG:$)W9/)Y)QDUEZU\)O&FI>!_'GAJ#4-'C/BC5?[020F51 A=&
M93A3DXC7GW->]8&<XI:+@<_?:/<:MX%NM O)D@N+NP:TDDB!949H]I(SR0,]
MZ\G@^$_C:/2?AO93:QHTC^#;@29$4H$R*NQ0/?;R>G)]LU[Q1B@#P;4?@SXD
MU.7Q/>+KFGV&H7>MQ:[I4]O"[?9YXTV!9 W#*R@9QWSU'%>E>#=,\86L-U>>
M--8LKR_N=NVVTZ%H[:V5<\*6)9BV<DGZ#@5U]%%P/+/$'P^UNS^)<GQ&\#ZE
M:PZO=VRV=_8Z@K&VNHUQAMR?,C@ 8/(XZ=<V-4\%>(O&GA+6-'\8:O;6RZG9
M-:+:Z;&6AMR3D2[G^9V! X^48'XUZ711<#R'3/AWXJN=:\+:IXLU:PNYO"5O
M-'8M:HX-Y(\?E^;-G[F% ^5<\DG/2N'U_P *ZE\./V3O%7AWQ)J&F2/B9[9X
M&90YEEW[,/CD,3C'4"OI:JUU9V=]#Y-Y:PW,><[)4#C/T-%P/%-6^%^I?%32
MK.Z\6ZKIL5O%I+V^GMI.Z5?,E\MOM!9MO \I<(..3S6Y8^!?%U]K_AK6_%E[
MI<]WX8M9X[,VOF$W<TD8C,DI(&P87.T!N23G@"O5(XXX8UCB1411A548 %24
M7 \+M?A5XOM?@S8>#?[2TK[;8ZE]M,:B3[+>Q><TIAEXW 98],YVCU-,F^$G
MBRY\&>,=%?4M#MI=;OH-2M%MK:18;>5!#\A&?N9A R >N<=J]WHHN!Y8W@;Q
M%J'Q(/B+5YM+?3[C0#H]U';^8KL68NS*"/NY) ^;.#D^E8>G_"OQ+)H/ACPC
MX@U#3[K0?#%_'=VUS%O^T7:P[_)1U(VIC<H)!.0O&,YKV^BBX'@__"K/&Z_#
MB/PZMYHPO(O$G]MB3?+L:/SS/L^[PV[CIC%=]X(U/Q;J6H^(HO$D-B+2UOO)
ML)K1)%\Q!R0V_&2ORC<!@G..E=UBDP!1<#RGQ)X&\70?%;_A//!.H:>'O;!=
M/U"RU+S!&P5B4E4IGYAG&,#Z\FN/T/X/^.-'T_X=V$EYHMTGA;4Y[V=@TL9>
M.0GY5^4@D!FZXSA?<U]#TF.: /&-/^%>N7$?Q+TW7KFQ73O&,TDT+VLCO);$
MKM&Y2J@] >#[>]-M_A[X\\1>#]0\)>/-4T>/3VL7L8;G2X6\ZX/1)90V N,
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M.,$'J"17/^'_  !?6.O6.M:]KZ:M<:<CK;"'3X;0*67:68IRQV\8R%[XZ47
M\[^$5SX-O-8MO%&D^+]0NKV'1Q'J-AY*Q0VX7!9YP%!,F[.&))(SU%>ZZ+K6
MF^(-$M=9TBX^TV-VGF0S;67>OKA@#^E68K.U@,K0V\<9E.Z0JH&\^IQUJ:.-
M(HUCC4(BC"JHP *D!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MF.2?6EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[T44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 448YS10 4444 %%%!Z4 %(<XXHYI:
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M(?LQ<XC\]%),88X&>0-PSBO1\Y'%>0_&+Q'X?U+X(:G9V=Y!J,_B&V%MI5O
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M=AEFRZG=][&,GFND^#]K'8>+_B;8I>S7OE:\N))Y?,<@V\1 )ZG'3)]!Z46
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M&@NJ2Y['$@W#DCG''UJ*W^$_CVST>\TFTO\ P):V%]C[3;1>&SY<V.@<&7#
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M^"^I7>B7*CQ5';:VFO2Z_8:C;V6W[+)(?GC*ESO4CCJ.W7%=M\2/&<OP_P#
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MWJ&QGOC/6@#SK6OA5J^N:/XP>XUZU76_%!MHY)EMF\BVA@QL14W9)/S9)/\
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M2'2BBX!1112 **** "BBB@ HHHH **** "@T4&@#XW_;;"^=X%;<!\M\,?\
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M\4"JRIG.T$#@9YQ5N.W@CEFDCB17E;=(RJ 7.,9)[\ #\*+@?+'POGL]:O\
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M7XH:M=^*+_0M9\*7TL>FPV]VT,5O%%&&1FC^[()2&R6!ZX'&*^C(HQ'$JJN
M!P!VKG]3\#^$M9UA=7U7P_8WE^ %,\D(+, 00&_O $#&<XI7 \0\/6OBSQM\
M4[?[?XZU[28QHNF:U-IUO*$03,3OBVXX3Y3D=<GDG@5W7QWOM3TWX;17VF:O
M=Z9/#J=FK-:R^69$>9496/7&&)XQT'TKOK?PIX=M?$L_B6VT6TAUB>/RI;U(
MP)77C@MW' _*I=>\.:'XGL%T_P 0:5:ZG:JXD$-S$)$##H<'ZT[@>$>-(-;U
M?XS^)='A\;:WI6F0^%1J/DV=UY06978+M]!QDXY/0G'%9G@?Q)=_$1+#3O%/
MBG4+)K7PS!=0I;WIMC=RR;UDN&9""Y38!M.0"22,FO>)? /@Z;4Y=4D\-V#7
MLMN;5YS"-[1;=NPG^[CC'I56?X7?#ZXM-/M)_!^DR0:=G[*C6JD0@MN('L3V
MHN!\\_#74KRU\/?!&VT_6;FWM;F]O[>[M8IBL<VWS&!9>YR>_'(]15R.\\8:
M?8_%+QE;>.-;O)/"NJWEK9Z?/+O@*F-!O<8Y"!L@# !4GN:]^A^&W@6WEL);
M?PIID+Z>[26S1VRH8F;&2,#KP.?:KVD^"_"NAF__ +(T"QL_[1S]K\J$#[1G
M.=_][J>OK1<#Y_76?%'AG0]<\9Z#XWBUFUN?#9NK72Q=27C^<A0&ZS(,KC<2
M5P 3GCCB+48K:;X:WM_:?$S4]7CU;PE-=2:;+<M)))<(GF-<[]V8AD[2@ 7H
M/:O?M \ ^#/"TMS+X>\,Z=IDET"LSV]NJEP3G:3_ '?;I3-'^'O@GP_'?QZ+
MX7TVQ34%*70AMU'G*>JM_L^W2BX'AX@LK>S_ &?X[*[GFC-R'+7$K2,&:TW%
M<L25QG 7H!@"M/5KSQ'X3^(&O^ Y->U>^?QO$K>';N6Y=CI[DLLZJ>B^4&\P
M8Y(4#K7JT?PS\!0PZ='%X3TV-=+D\ZS"P >0^0VY<=#E1D]\5D>&/#7C2?QM
M=>(O'MYI=V+$S0:-'81LOE12-EI)-W\95448Z#=R<TK@9OQVN]1T']GKQ!_9
M<\_F+;Q6KS[B\@B>18W;/4G:3D]>2:I^/IFM=0\"^$]"U&YM4G28C3;.Z-HM
MS#%!@;KA3NC5,J<*"6XXX)'JVM:/I^OZ%>Z+JENMS8WL30S1-T96&#7%V/PY
MT_4_#6EZ/X_TVP\2/HDA6QNKB/>SQ@ *T@( W%0 PY4E0?H >:PZI?:Y^QMK
M-_K&J27>I6=M<NMUYOG2K)#.QB8OU+ HOS=:];FU_5;?X/-XF%J'U2/13?&%
M1D&80;]H Y/S=JRM6^&&DW6ECPQHNGV>B>&[R[%YJD5DGEO=E6#"/ & K$#<
M<@@# '.1Z*(HQ$(@B[0-N,<8H ^7/#>H>+;K3--\26_Q+66TU?1[A9H/MCW$
M\ER(GD+QHR!83&RXZ8VKCDXK6^'\_BFUU_X8ZMJ'C+6-6'BC2[C[;:WDH,*E
M(5D0HF!AAT).2>3ZUZU9?"SX>Z9)J#:?X1TZT.HH8[DPQ;?,4]5XZ*>X&!4G
M_"MO!]O%IGV'0;6"?2$9=-DVEC:;NNW)Z9QQ3N!XCX?U#QAXFU'P_)::]KRZ
MI'KMTFM2Q7!^PM:))(?W9Y3!VQJNT9^]GU,&G>+M<D^(?AC68?%%[<Z9J7B6
M[L&:6\VI<PXD"H+;)"*A50'ZDG) ) J]H/P+\01W-C;ZCX>\,Z;<6TRR3>(=
M.GG^USA7W96/Y51F[Y) R>#TKUYOA%\-I+]M1D\%Z4UT]Q]L:5K<%C+UW9^O
M..F>:+@>2^+M:\7:MXD\9Z3H&J:S%XCL]3LK?2392-]EBA=(BXD RF<%V8L.
M..V =W4K[Q'9^./'NDKXLU)HK7PI#>V[%TS!,#*"R@*!D[ 2<=_I6-XD^#'B
M/6/%WB"XD\*^%]1_M2Z::WUJ>ZG@GM4( 53'&/F9 ."#R<$UZS%\+O![K+-J
M&EB_OKFR2PN[N>1S)<Q*H&&.>^*0'EWA"^\5:7XK^&EW?>,M3UA/%>C337EK
M=NIA1H[>.160 #:?FP3U/4]ZI>$-:\:>+-1\,BUUC74U3^TKG^WI$#&Q^S*S
M[3$Q!C()$87;DXSGU/L,WPW\*)'ILUAI,5M>:/ T&F3;G/V0$<8&[D=,@]0,
M5X]X7^"OB.SN])COO#>@Z/>6-Q'-/XBT[4+AI[C8^XE(=JJK..#DD8)^7H*=
MP/2_C-?ZIH_PW;5-(U6XTZX@OK3+0 %I5:=$9.0>"&[8Z#MFN+\6_P#"8:M\
M:->\/Z9X\U+1M.@\-IJ21V@0E9!(RX4E>,[ 2>3R1D5[#XD\*Z'XOT?^R?$5
MC]LL]ZR>49'0;AT.5()Q69<?#3P9=:K-JDVDLU[/:?89)OM4P9H-NW9P_3'Z
M\]>:0%+X9:UJ'BWX,^']7U:>7[=?6"F:8?*S-C!<8]<9_&O K&RO6^!W@MH]
M?NY+JZ\;0QI)=.)3;.+Z8!U&!DD_,=Q.?:OJ'PWX9T7PEH4.AZ!9_8]/@),<
M/F,X7/)P6)-<O)\&OAN]RUQ_PC21R&\&H9CGE0+.&+!U < 8))P..>E 'D$W
MCSQGX1TGQQX?N/$\NI3:5K=CI]OJ^H%$,$=PH9V<A2 !D@$J0,CCC%>G_#O_
M (3#3_%NN:1XB\266K:>\45UI\1O/M%W"I^5]["*,%"W0XXZ5N'X6^!WFU^2
M;0DN#XA"C4EFEDD6XVG*DJS$ CL1@CM6AX3\#^%_!-@]EX8TB.PAE;=)AF=F
M/;+,22!V&<#M1<#IZ***0!1110 4444 %)FEHH **** "BBCM0!\;?ML,IO/
M R%23LO3G\8**/VU@OV[P/QD^7>\_C!15 ?8Z\BG4U!A:=4@%%%% !4,G^LB
M_P![^AJ:H9/]9%_O?T- T34444""BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH !G'/6BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** #O1110 4444 %%%% !1110 4444 %&*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *#12'C- 'QQ^VP/\ 2? WRL/EOOF'0\P44G[:[8O? ^5R=E[S
MGW@HH ^QTZ4ZFIZ4Z@ HHHH *@D_UD7^]_0U/4$G^LB_WOZ&@:)Z***!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %% HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!.A^M+12"@!:*** "D/2EHH ^-OVV%?[9X&8,
MH&R]&#UZP44?MK-)]O\ !"AL*$O<#'?,'_UJ* /L=>E.[TQ*?0 4444 %02?
MZR+_ 'OZ&IZ@E_UD7^]_0T#1/VHHHH$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4=Z** "BBB@ H[^U%% !1110 4444 '>BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHYH *3'.:6C^5 !2'I2]Z:>2: /C/\ ;49_[7\%J%<J(;O&WUW19_I^
ME%-_;6XU?P8"V1Y-WA?3F*BJ ^SEZ#C%.I%Z4M2 4444 %02?ZR+_>_H:GJ"
M3_61?[W]#0-$]%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *.]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4=Z3-+0 F>:6BB@ HI#1STH 6BCO10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5&S;0<G%/--9=W6@#XQ_;6'_$S\%/N&3#=C'IS%11^VH^W6O!BA2<6
M]UR.GWH_\**H#[04Y%+35Z4ZI **** "H)/]9%_O?T-3U!+_ *R+_>_H:!HG
MHH'2B@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'>BB@ H
MHHH **** "BBB@ I,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4GX4M% 'QA^VQ
M'MU7P5)Q\T-VO/7@Q?XT4W]M<+_;O@T]_L]U_%C^*/M10!]GJ,"G4U3D#%.H
M **** "H)?\ 60_[_P#0U/4,G^LB_P![^AH&B:BBB@04444 %%%% !1110 4
M444 %%%% !1110 4444 '>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.] !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '2BBCO0 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?&?[:['^U/!2[1Q%>'/U,/^%%-_;79
MSJ_@I0 5\F[(/ONB_P#K44 ?92@CFI*1>E+0 4444 %02??A_P!_^AJ>H)/]
M9%_O?T- T3T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HH)Q10 444=: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHH% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!I!
MCG Q2T ?&/[:X_XFO@KG_EC>?^A145'^VON.N>#%V97[/=$-ZG='D?R_.BJ
M^T%Z4ZD4Y%+4@%%%% !4,G^LB_WOZ&IJ@D_UD7^]_0T#1/11VHH$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% "?Q4W<>/K110 ]NHIA)W?G110 X?=%+110 4+THHH *0=?PHHH 7O2T44
M%%%% !VI,T44 ![4>E%% !WHHHH *8>,D=:** /B_P#;5YUOP:?^F%U_Z%'1
&115 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>skye_ex31img22.jpg
<TEXT>
begin 644 skye_ex31img22.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M;^T)_P#XJO;Z* /$?^&5_@OC_D7;GZ_VA/\ _%4A_97^#'/_ !3]W_X,)O\
MXJO;Z*D#Q/\ X99^"NW \,7 /K_:-Q_\743?LJ_!HD$:%>+CL-0FP?\ QZO<
M:*H#Q ?LK?!@#GP_=L?4ZA-_\53#^RM\&F/&AW@^FH2__%5[E28XJ0/#?^&5
M/@V5Q_8E[G/7^T)<_P Z1?V4_@VIYT6]<>AOY?\ &O=**H#P_P#X95^#.W']
M@W?U_M";_P"*J&3]E'X.%?ETB_0^HOI#_6O=J,4 ?!'[2WP@\&_#/2O#MUX4
MM9[=KZ::.?S[AI<[54KC/3J:*]#_ &U53_A'?!^02?M5QS_P!**H#Z*^'/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 ?)?[:A;^P_!JC_ )^+D_\
MCL=%+^VFJ'0?!^8U<_:;CJ>?NI13 ^AOACN_X5#X.W=?[&L__1"5UM<A\,#G
MX/\ @T^NC6?7_K@E=?2 **** "J\G^M@_P!__P!E-6*KR?ZV#_?_ /930-%B
MBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !110.E !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 44AH% "T444 %%%% !1110 4444 %%%% !WHHH/2@#Y'_;49
M1H?@Y&')N+DAO0;4X_7]**7]M;!T7P9_UWNO;^&.BJ ^B/AAC_A3_@W;T_L:
MSZ?]<$KKZX_X7G/P?\&D?] :SZG/_+%*["I **** "J\G^M@_P!__P!E-6*K
M3?ZV#_?_ /930-%FBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%'>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH .]%%% !BBBB@ HHHH **** "BBB@ HHHH *0D]
MJ6B@!!R*6DQS2T ?)7[:8_XDO@[YE'^D7/#=?NQT4G[:NW^Q?!H8$_Z1<_\
MH,=%,#Z$^%>/^%/>#<9_Y UGU_ZXK795Q?PI7;\&_!G)_P"0+9]>O^I6NTH8
M!1112 *KR?ZV#_?_ /935BJTG^LM_P#?_P#930-%GM1110(**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .
M]%%% !1110 44=Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !111F@ HH[4F: %HHSSCO10
M4449H **,T4 %%(6 I0<B@ HHHH **** "BB@G% !1110 4444 %%%% !111
M0 4444 %%%(6 H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [T49I#0
M!\C_ +:Z_P#$G\&,%8_O[H<#C[L=%2?MIKG0_!IQE?M%S^>V.B@#Z ^$Y_XL
MSX,XP/[%L_\ T2M=K7$_"<8^"_@S!S_Q)K3MC_EBM=J*; 6BBBD 57D_UL'^
M_P#^RFK%5Y/];!_O_P#LIH&BQ1110(**** "BBB@ HHI#TXH YR;QKX6M]<&
MAW&MV\>H-,MN(6)!,K+N" XQNV\XSG'-)H_C?PGX@NI+;1=>M;V6.,S%8FSF
M,':77^\H(QD9&:\8\4PZ]:_$"_G\*:1J>K/=:KF^T'4;)FM9<0 ?;(+@@"/A
M0OWNO&.@JA\/)=0A\>^"=1DT7Q$(8]%NM-FB;26M[73I-T#"%%(#!%"MEV+%
ML<$G@.P'LL/Q4^'%Q<VUM!XUTAI;H.T0%ROSA,ACGH,;3U]*OZ?X[\&ZMH-Y
MKNF^([&ZTRR<QW%S'*"D3#'!]^1CUR,5\^#1;.3X>:/'+X1OVG7QR;VXB.BS
MES;&[D;>P\O)7R6'X''M4VNZ3JDVO?$.XT?P[K4MG%KFF:F;2VMI;0WL$$:K
M-Y#X7+AOF^4Y8J",]:+ ?1>A>)-$\1V\\VB:E#>I;RF";R\@QR  E6!Y!P0?
MQI^M:]I'A[3OMVLZA%96Y=8U:4_?=CA54=68GH!R:X/X5V>CM<ZQKNA^&M:T
MJWU+R?.N=<FG-S=2(K ?)*S$*JD#=GGIR #2?$ZSU:+Q?X#\56^G7&HZ1H=]
M,^H6]M$99$62(QI,$'S-L)/"@G#$XXH Z*?XE> K;0[36KGQ9I\-A=S&WAG>
M7 >0'!3'7(/4'IWK:T'7]'\3:1'K&@ZC#J-A*6"3P'*DJ<$?@017S'XN\+ZG
M.GB7Q!9>'=2ETG6O%6FW=I8Q:?(7=(1_I%P8@NY Y+?> )QGG(KZDTZSL[.Q
M6&QM8[:W.7$4<0C W'<?E &"223[FA@8U]XY\*:=KRZ%>ZS'%J+2QP>258[9
M)/\ 5H6 PK,.0"02*Q=*\8V%K>>,=2USQMI=SI.F7B1J$4)_9R[%!CE;^)BY
M/KV^@\_\56NK6_Q5N[KPO!K2W<^JV+7FEW&GO-I^I*JQ9N4FV[861< G>,F(
M#!S2:I'>2:=\<X5T+53_ &@A6S4:;,1=-]C6',?R_/\ O%[<8YZ<T: >A-\8
M_ADHN_\ BM--8V:AY0DA8X)(^4 '<<C&%R13M2\56]]KW@HZ#XQTV"TU>224
M6S+YC:G"(B1Y1[;3@GIZ9['AM/LXXOBEX-U#_A&K]+*S\*2+)*=+EV0RLT9V
M'Y/EDVJ_'7GWYP/!]OJ5MX.^#=O<>&=8@N=,U2X-VKZ9,/LR&.= S_+P"9$P
M>_7L<&@'HOA;QT]GIWBVZ\;ZY!Y>E^(9M,@F6'9N7$9CC"+DLV7Q@9)]ZZ%O
MB3X)C\/#7I_$EK;Z;]J^Q--/NBV3YP8V5@&5O8@8ZUX]<C68;#Q4L/A?5W63
MQJM]Y_\ 9CR306Y"@7-NK*0[*R<<' 8M@UF'2]:'PT\::4_@WQ'.USXJMKZ%
M+RU::6YA\RWD9B1DM\L;Y[#A>O%%@/HCPWXIT'QAHQU?PWJ4>H67F-%YR*P&
M]>",, :\VOOB=:^#?B]XGTOQOXHBMM$CL[2YT^-K?!B+F0./D4LX&P?,>!G!
MKUNSAMX;8?9X%@1_GVA-G)Y)(]?6O)M8@DTKXR^(M4U#PGJ&K6&KZ%;VEN]M
M:&X69TDEWPEA_J@1(GWL*<9SQ0@.VM?B'X1OM2N-.M-6%Q=6]BNI-'%#(Y:W
M(!$B$+AQ\P^[G]*&^(7A-?#VFZ^FJ>=8ZGN-FT,$CO.%!+%8PN_ "DGC@#FO
M(/"OA?Q-\.?%?AF6X\.W^K1/X4_LEQIZ++Y%T)_-\MF8@*H#8#L<';VJI8^'
M]33X2>!M*USP_P")]&U73UNF34])C:2?39<DJ3&F[=&X8K@CG'3O1H!Z=I?C
M73==^(=C+H_C6&;2I=$DO#I(M3ND F"_:/,*@@#E=OZ4^Q^-GPQU*]L[*S\5
M02SWES]DA7R90#-D@(25PI)!QDC/:N&\#P^+K?X@>%-2\1^%[V"9?#MU:WD\
M%D$B25[E9$W!?E5F5,L!T+<XKD8O#^OK\(K2TC\(:R;]/&?]J-!]A8/]G%P9
M-^".FP@8SG.1VIZ ?0%Y\0O".GZZNBW>L1QW9G2U8F-S$D[C<D32 ;%<CD*2
M#TXYIK?$+PO'XC30C?R_;7NOL((M93"9]NXQ>:%V;P.2-W'->*Z?X3U73O&7
MB'1=5^&][K;:EK[ZQINKM)_HB))('W3#>-IC X7&6( XZUL+HFM1_%&+4M!T
M?6[(SZXSZEIU[#YVFRQ*7!O(G8?NY64*?E.23C!')6@'JFE?$+PIK6O)HNFZ
MD\UW+YIA_P!&E2.<1-MD,<C*$<*>"5)K2\1>)M%\*Z;'?ZY?"VBEF6WB&QG>
M:5ONQHJ@LS''  )KQWP)I>N:5\1]+30]#UG3/#TR74NI:9JL.8--F).UK64\
MX=C]U21@DD#MU7QB@URXT[P]_9>C7&HV<6J1RWTME L]W:1@'$D"MT?)QN )
M )(QU !U,/C[PG/X6G\3+K,::9;R&":2161HI0VPQLA&X/N(&TC.2..:Y[5O
MC%X5L](CO;"2ZOI3JD&E2P)93"2WED=0?,39N7"DD#&6(P,FO(U\*^-O^%=Z
ME'I?@_5$O=(\:?\ "00V=^R,]]!OW!=Y<[VP02<GD<$D5UOB&36M;\//XCL/
MAOJ&F01ZYINH-;?9U74;PQ2#S9&C4GHH4+DY.#T&#0!V-CXNM8?''BZ\O/&!
MN-*TVQM[A])%@ZOIR[6+R.VW<Q;&=O48Z5M0?$;PC=:+HNL6NJ-+8:Y<?9;"
M9;:7$\GS< ;<@?(W) '!YKE_#JW]Y\:O$>I77AW4;.QU#2+*-)KFUVHTB&0O
M&3R,@.!W'!YK/\ ^!-6\-^--4L;RU_XI70;F6?PZIR<?:0'D 'I%\Z+QG$C4
M 1CXIV_A'X7#Q#?>()?&3W&KO8V]U%8M" 6FP(V"KQL7//5BN!FNKTGQ%!J7
MQ3U"S@\8>;%#ID<KZ"]F8GM6+9\YG8!N00-AZ5Y'<^'O$T_P1OX8?"NJF]MO
M&+:K]C-OMFEM_MGFAD4_>^4]/8UT^KZ/KWBKXB>)6L]%U+24U?P;_9D%U=P^
M6D5PSR-M9USR XSCW':@#T'3_B;X)U/4O[/M==3SS:O>QF2)XTF@7[TL;LH6
M11@_,I(XJSX>\?>&O%%^;'1[V:2X^SB[5);2:'?"3A9%+J RG(P1G->,^$=(
MF_L"TM=1^#.HC7-%TNYM;JXO928)L0,AC@8R,6\TA1PN &:M_P"%FC:]H_C5
M[;3[;6!X/73 L:Z];;+G3I]PQ;12-AWBVC/\2C YS1H!Z]K&M:=H&FMJ6K72
MVUJC*FX@L69F"JJ@9+,20  "23@5S,WQ9\ 6VCR:K=^(H;6WBNA9S">-XY()
MCT21& 9#_O 5C?%W0]=OG\(Z_H]C)J4?A_6(K^[L8>9)H<%6*+T9ESD#J>W-
M>7^+_#.N:MJ/BWQ19^$]5-GK6L:-Y%H+5A+-':D--,\6,H,?*-PR=O3I0!]$
M^&_$NB^+=!AUSP_>"]T^<NL<P1EW%6*MPP!^\I'X5Y[J7B?6]/\ BIXUTJ_\
M31Z?HMGX=BU"U>6"/;92.TB&0\;I,%,X)QSC%>H64%O%:K]FMUMD?+[ @3!;
MDY'KDG/N37CVOQ:HOQ<\:7PT#5)K.\\*K903PV;2QS3*96* COAUQV//(H W
M]$^(WA[0_!7A4^+?&UM?WVK6X:"_%JT(OCUW! ORY_#/XUNV'Q(\&:IX;N/$
M6GZY%-IMM<&TEDV.K+-D#R]A 8MEE 7&3D8KQ;3]#UQ/#OP.M[KPKJCMH,Y;
M4HWLG/V4"/RPS C^\01C/3/-4O$'AOQ+>OXCU32?!^JW26OC&+618,C6S7MN
M(!$YC.02P?<1@YZ&@#W6#XD^#;G29]2MM6,D<%R+.2%;>7SUG/2(P[?,WGTV
MYK:T'7]-\2:7_:6DSM-;^9)"2\3Q,KHY1E*N 00P(.1VKQ(:+IM_X6O+N#X=
M^)_#UC?ZK;S"Y@>5M3BE2-O]+,>YV 5MJ8Y)!8X/%>@_"6/Q)#X,EA\2),9D
MO;@6]Q<VXMY[F#?\DLL8^Z[<DYP?7F@#>\1^./#?A618=:U#R)FB:?RHH7F<
M1*0&D*H"509Y8X ]:XKXD_$V#1](\,1:#J,@/B2_MH8]0MK5KA8[=_F:2,A2
MK.5'RKR><[2!574X]4\-_&_7=<U'P_J&K:#KFCP6T5Q96K73021,^8"J@E5?
M=G.-N>IXKAH_"7B3PM\.?A1H-[HFHWMWI7B"/5;Z.RMGN%LX 9#L+ $$J'48
M!).#C(H ]T\'6GB.R\-O'XB\0?VW.\KR6]XUJ+>3R#_JPZ * X'7@<]JX;X>
M?%32;B!/#GBKQ7#<^*#J5_:*GD>6T@BN)%1<*NT-L4';G)XZYY]=W,\*,J$9
MP<'@U\]1^&=2U+1++P:_AJ^M=5@\82ZJ]]):LL-O +R283"7&V0M&50 $GYN
M0 #0!Z_'\0?",NE6VIKJW^B7-]_9L<A@D&+G?L\IAMRC;N/FQS2:G\0/"NE>
M(!H=]JACO#-#;L%MY72.64@1QO(JE$9LC 8@X.>E>*:AI_B6S\-W7A*'P;K=
MY=1>-%U0SPP#R#;M>K.'20D!OEX_V3G. *VO$FE:PWQ.GU;P_I>N6&I2ZC9&
MXM9+4W.G:K"!%F9FQLADC ^]NZQ+C)- '5>'?B#HNE^$_$'B/Q)\0K75]-@U
MF:W2\6T\A+0';LM\*,N5S][G.?:NDT;XD^"=?NM2M=*\0VT\NF1B:YSNC"1G
M_EIE@ R?[0)'O7A.J:+KUW\&OB=I5OX1UE[O5O%,E[9VQL9%::%Y8F#@8Z81
MLY^G>M[QQX;UKQ9XM\16>@Z/?6O]H>#QIT%Q-:/!"9O.\P0ER.,IQZ DC/:@
M#U6P^)O@K4&OTM]=C4Z?:_;KCSXWAVV^,B8;P-T>/XER.GK1;_$KPA<:=J%\
MNHS11Z>L3W"SVDT4B"4XB^1T#'>>%P#GM7D.A:';WWAW4[V\^#>L6]^FBR:?
MJ(O+A]]T#MS;VV9&+*2&;=@=% Z\0V'A[6UTCQ/I^IZ9XDU_PLZ6$4$]Y;M#
MJL16;)"$ /(L&=ZG'7(&>:>@'O7AWQ1H_BBVN9](GE<6LWD3I-;R0212;5;:
MR2*K X93T[UC7.LE?BS9Z0OBF../^SI9I-%^R[FD(=,3>;_#@'&W/.X'%8?P
MCMO$EM;:['K#WUU9"_!L;_4[3[->7<?E("95P"2I&T,P!(7TQ2:P+S_AHC0K
MZ/2;^2R@T2[MY;R.U=HDD>2)E7?C&2$/YCUI :.G?&'X<ZIJMAIMCXJMIKJ_
ME,%N@5QODW%=N2, DJ< XSVSQ7=W$R6]O).X;9&I8[%+' &> .3]!7S6-'U:
M#X5:3;+X1UC[;;>,SJ4D(T]S(81>/+YG SCRV7G&?X<5]+QOYD2MM(##.&&"
M/PH XJ/XK>!)-(TG5X]<W6&KW1L;*<6\NV:?=M\L?+P<\<XZ'T...^)OQ(;P
M[XU\+VMCXB:QMH=6BM-9MFM<HT4L3NOSLG)PG1#GGZ5@Z_\ "WQ+K6I^,O#4
M+RV?A^.<Z]H;Q-LW:A(F0F1TC256<C'64>E1ZAHWBV2'X<:CKV@WUYK-SXA3
M6M72UMFDCLP8C&B$]%V+Y8//56-/0#L_$_Q*\.ZM\+]0UKPUX\CT,Q7"6QU$
MV+3M;2AP3&\+ -EER,$#[P-=#K7Q*\(^&&^R:UK6R:&".>X9+>200QN=JR2%
M%(C!/3=C]*\1\1:)XDN_!?Q=TN#PIK#3ZUK44]@JV3CST#198'T^1CG_ !K=
M:U\4:'\0O%EQ=?#JZ\3Z)XMLK4VRB&-PDL<*H8;@2$;$R2?FZ<\&C0#>U/XF
MP^#_ (P:_;^*?$3Q>'DTBUN[6W-MO\N1FD#D"-2[#$9))R!S7K^GZA9:KIEO
MJ6GW"7%I<QK+#*G*NI&01^%>+G2]<3XB>)[V^\-W#O<>%;>Q2>TM2UN9U$A>
M.-B0<9=0.!G'/2NW^$=O?V7P?\,Z?J5A=6%Y96,5M-!=1['5T4*>.XXX/>A@
M4C\1H=5\?^(/ 5C%>6E]IMCO:\-J^%E8-@KE2NT  AFP&/ W"L/X4_%G2-<\
M+^$]'UK6YKKQ-J5H6:1[5TCGD4%G42!!&6 !RH.?QJ=;+7M)^.?BO5&\/WUU
MI^L:/;B"ZMU5HU: 2;T;)!#$NNT '.?8XY31O"_B:/P%\)=*D\.ZE;7>D7$@
MOV54W6@:WFB#9W?WI%/';-&@'J5C\3_!^I>);+0;74I#>7XE^R,]K*D5T8R0
MXCD90KXVG[I-:7C?Q9:>"_ FK>*KU=\.G0&79G'F-T11_O,5'XUXE\.?">I:
M9J?A[0-5^%\D.I^'YF1]?GF+6IB ($T0WD^9)@ @+QG)]O8_B)X2_P"$W^&>
MM^%6F\J2_MRD<A'"R AD)]MP%# XY=%^+E]\/7UV'QQY'BBYM_M,5@EC ;.,
ME21#AD\S/(&XMU[8XKL-:\>:%X7\FSUBXE%_]D-Y-!;6\EPT$*X#2N(U;:@/
M&3Z'&<&N8T+QIXVA\)VVFWWP[U1/$MO"(3%E?LDCKA?,\_. AZ^HZ8/6J$FG
M^(_"WQGUSQ-=:+>:_I>OZ3!#OL8O,-M/#D&':6RJ/N+ GC/7UH W=6^-GPYT
M5[1;SQ&/],M5O8#%:S2B6%B &4HA!Z]!R.XI-7^-WPWT.^O+'4O$7E3V3*EQ
M&MG.[1EAD$X0_+@@YZ>]>=>!O!7B'PUXP^&\&J>&[B2+3M+OH[JX5!*EI+<2
M"18RW^R,J2..3ZU=^T>1\5OC!:0^&[G6+B\M;*&,6\ =78VA C=C@+G(Z\8%
M 'J&J_$?PMI(M=]W<7KW-I]OCCL+26Z;[-_SV(C4E4YZGKSC.#65K?QJ^'.@
MVNG76H>(0L&I6IO+62.VED$\0(!*E5///3J,'.*XKPAX7\0_#'Q%8B\TF]UO
M3[GPU:6$US91^<T%S SDQX)W!&$G!Z<<X[9W@[P5X@\,:]\-+74=!N[J/3[7
M4FNWCC$D5B]RZ-''G./E 925SCZ4: >E6OQ=\&W.J6VGQW]P_P!IN([..Y%G
M-Y'GNNY(3)MVB0@CC/<=ZYW5OBK;:A%\0-(-Q?\ AJ/0H!$-7;3IG-N[1@^:
M1MQU9=JG!(^;H<UYUK^@>-;CQ-=33>"]=NI;+Q=#J42V0BBLGM(W 610&'F3
M,,99LD8SE0,5U6L6OB:VNOBSH\?@[5;S_A)8#+8W$"(T;?Z#'#M)+YW!QC'M
MGI0!Z!:^/-%T7P=X9DOM8N=<NM3L4FMY+6RDDGOU6-6>81("5&""<],XZU6F
M^-7PXAL=+OF\3120:JLAM"D,K>;LX90 N=V>-I^8D@ <UR&AZ=XG\->(O WB
M*X\/ZE>V*>&QHM] D0::QF1E82>6#DABI!*YZ+7.^&O!_B#1?%_A?6+WPK?)
M;3^(=6U>2V2$2+IL5R@2$-M.%(QDA<XR>XI >]^%/%V@^--#&L>'K[[7:>8T
M+$QM&R.OWE96 *D>A%.\0>*=)\,QVS:E._F7<GDV\$,+S33O@L0B("S8 ).!
MP*X'X,Z?J^GS^/GU71;S3$U#Q)<ZA:BYBV>9#(%VL!GV.15KQWI^LV/Q/\&^
M-+'3;K5K"P2ZLKRWMEWO"LRKMF5,Y.&7!P"<&@"[=_&;X=V.AZ?KEWXDBAL;
M^5X87:"7)=#AT8;<HP)Z, :ZWP[XATOQ3X>L_$&BW'VC3KQ/,AE*,A89(/#
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M79%C^V+;EDX!9N>^!WQQ@^H7WB#0]+O;:QU+6+.SNKHX@AGF5'F/HH)RWX4
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MM6CR7NCR0W9:)G@;S,1R'!Q\P!XSW - &-#X%\.VOC2/Q?:Z>D.K1V TY73
M41!@1QCJ,8SZ<5C?\*NM8])O[&W\3Z[ ]WJC:O\ :HIHUEAF8Y8(1'C8>ZD'
M-6?!7CF+6?A=HWC#Q)<6.DG4(?-<F8)$F6. &8^@KJ/[:TD/;HVI6X:Z : >
M:/WH/3;SS^%&H'GUY\$O#%YI$5O+>ZF-5AOY=4CUJ*X$-VES)M#R HH095%7
M 7&!TSS7:>&_#EKX7TC^S[>ZO+PNQEFNKZ<S3SR$ %W<]3@ =@    !5U=:T
MIHIYDU*V:*W)6:02J5B(ZACG"GZU?W*RA@05/((H \XL/@_X=TOQ?=:]87NJ
MP6UW=?;I-(6[(LC<9!\[R_[V1NY.,XXX&"W^$.@VU[(L=_J7]AM=_;QH)F7[
M$LV\2;MNW=C>-VS=MSVKL[GQ#H=G<M;W>L64$JNL;+).JE6;.T')X)P<#O@U
M)J&N:1I,,<VJ:G:V,4AVH]Q*L:L?0$FC4#A]6^$>DZP/%*W6N:RL?BC8;Z*.
MX3: @"@)E,@;1MP2>/?FIIO -KI6N1>,%U?7K^]T[2_L"VXE1_M$2X."H4;F
M9E!ZC)/:NUO9[M](FET;[--=%"8/.<B)F[9*@G'T!KA_A;X^O_'G@$>+M9T^
MUTBWDDD6-$N"X"QLRN[,0 !E3^ IZ@<A\)OAEGP3X;N?%C:VMQI,AFCT:_E4
M6]O.KDI*%49)&<C<Q ))P.,=?IWPA\,Z3XNGUZRN-4CAEN?MO]E"\;["+CKY
MHAZ;MWS<\ \@<#">'_B VO?%;5O#=I<:3>:-;::E]!=V-QYS,QE:,JY' (*G
M@9QQS76V/BOPUJ4%S/IVO:?>16A(N'@N4<0G_:(/R_C2U Y"X^#_ (<N+35+
M)=0UB"SU+45U.2VBO2(XY1()?D4@A09/G..^.<  :DWPYTF;4]5U*35-6^T:
MK8)IUPWVL_-$F[;CC@_.W/\ M'UK1D\=>#HUESXJTHF*U%ZX6\C)6 XQ*<'[
MIR,'H<CUKD#\19/$MCX5U?P3JFBKIU_JIM;M=3G\N62%6*D0@'F0@!@I[,O'
M-/4#@?&/P\O/#VK>'K;3=.\7:GX?TJQEM;6?0KY/MENSR*?*96*YC"HN#R?[
MW0&O6/AII/B?2/#,\/B?4+NZ>6Y>2TCOIEGN+> @!8Y)$ 5VR">,X# 9.,UR
M'C#XC:M)XUNO"/@/6_#Z:M96)NY!J<VY;B7S&0VZX<;64([-UQP"!R:[K1/%
M4%M\.],\0>,-;T:U9[=&NKV"Z469D/'R2,<8)Z<T 6KCP5X?N?'D7C2:R#:Q
M'8MIZS9X\HMNQCUZC/H2.]<[)\'_  I_PKM/ =B;NPT9+@W.VWE"NS^9Y@W'
M'S -@C/]U>N*Z^X\2:%;Z"->GUFQCTMD5UO'N%$+!OND/G&#D8-<I\,O&FI>
M,HO$LFH?V>T>FZL]E;26#EXY8A'&X;<3SG?UP!2 FUOX:Z;KFNQ:T^L:Q9Z@
MFGG37EL[LQ>?'DLI<8PQ5F)';GD$<5!#\)=!M['PO9P:CJR)X98M8$77*97;
M@Y'(VDK]#6-?^-?B''\0O$7AO3--T*XCTJQCU&+SII8WFC=G"ID9 ;]VV3C'
M(^M=!X;^*'A;6OA[HWC/4-2MM#LM37"?VA<)%MD#%63<2 3E3TZCFGJ!K>,?
M!^G^,]"M]+U"XN[;[-=0WL-S:3>7+%+&V596P>>HZ=ZY^3X1Z%):^(K=]5UE
MT\10K#?[KO<9 J! =Q&<[%"YSSSGK76W?B?PY8!6OM>L+57C$JM+<HNY"0H8
M9/3+*,^K#UJ-O&'A6/Q$/#LGB/34UDD!;%KI!.<C(PF<\CGI2U X^^^#'AN[
M.ES1:GKEC=6%JMBUS9Z@\$MW;K]V.5EQN YP>",UZ#;Z=9VFE1:7!;HEG%$(
M$AQE50#:%QZ8XJFOB?PZWB%_#RZY8-K"+N>P%RGGJ,9R4SNZ$'IT-0W'C'PK
M:7(MKOQ'IMO.;C[((Y;I$8S<8CP3][D<=>11J!RVG_";3M'=K71_$6O6&B%B
MPT>"^*VZ L6*J<%T4DGA6%2WWPF\.2:DFIZ+-?>'+S[&NG2/I4HB$ML.D;*0
M1P. P 8=C7<W5]9V-G+=WES%;6T2[Y)I7"(B^I)X KS_ ,6?$/[/H^@:UX-U
M#2=9TZ\URTTR[G2?S52.6148J4.-XW#J>,]* )['X4^']+\3:+K>DW-_IPT:
MS-C:VD$R^2(2064@J6.XC).<D\YKB[#PM?\ B[XK_$![R3Q+H&F7QM85=(Q#
M%?QI"8Y &921ST*D''>O7K?Q1X<NM+N-6MM>T^:PMF99KI+E#%$5^\&8' QW
MSTKEO'?CO^R_A'K?C+P3=:9K+V$)EC<3>; <$;N4/) .<9'U%&H$FI_#'2;K
M5[+5M'U#4/#MY:V:Z=OTR1$$ELIRL;!E8<<X(P1G@U7L/A+H.E>(]"UC3+_4
M;/\ L*V-I:6D<B>2(VQO# J2Q<C+$G)//%6;7Q1KC?&3_A$KB"S72VT3^THY
M%9C,\GG*AR#@*!EN!GL<]J;XQ\7:OX;\;>$-/CALET;5KJ6WN[B>1A)%MA>0
M;1PH'R\L3[8YS0!C77P/\.7%Y-<#6==@C?5AK,=M#?%(H+C?O8HH'\1SUR1G
MC%7=4^$&CZE-XH9=<UFRM_$R;;ZTMIU$))549E5E."RH <Y[XQFNYBUS1YM%
M.LQZM9OIH0R&[2=3"%'5M^<8]\U+9ZE8:I8)?:7?07MM)G9-;R"1&P<'!!P>
M: .,O?AG9S:EI>L:?K>J:7J^GV*Z<+^V:(R36XQ\DBNC(W(W9VY!Y'I3+;X4
MZ-I^K>&]0TO5-3LO^$?698(D>-EF:;_7/*60LS.3DG/7IBN<TSXB^--;^&OB
M[5M/L=&AUW1]9N-+MTNKCR[;;$Z*7=V([%C_  YXZ5ZA)KFEV<UI::GJEE:7
METO[J"2=5:4]]@)!8?A0!B^"?!$'@BUU*VM]9U#4DU"\DOG^VF,[99#ERNQ%
MQD\X_*L6X^$>D3:GJKV^L:C::)K%TMYJ&B0^5]FN91@L>4+J'*J6"L W/K3X
M?B'+;_%W7/".N?V=IVF:?IT%[%=O<$,YD?;AMP 7D'CGMSS@/U+QOJEG\9_#
M?@V*RMGTK5;*XNC=^86D)C7[H'0#E><G/M1J!IZ/X'ATCQ[K'C!==U*ZN=5C
M2&2VF,7DHB9V!0J!AMW-W[G.:[*J$6K:9-?2:?'J%M)>1@%X!*ID3ZKG(J_V
MI %%%% !WHHHH **** "D.ZEHH 3TI:** "@T4'I0!\B?MK,JZ7X+W,1^^NN
M/^ Q44G[:P_XEW@KYL?O;OC\(J*H#Z$^$BC_ (4IX*P?^8-:?^B5KN*XKX3D
M'X+>"V&>=%M.O_7%:[6I **** "JTW^L@_W_ /V4U9JO)_K8/]__ -E- T6*
M***!!1110 4444 %%%% 'R=\0M:T=/'FL7D-Q:6%SI/BK3)KDSHTEV%'DJ\P
MD_Y8P;3M Y#$MR-P%-\9Z9X%OK;XWZIC3Y;NT%O+9RK("T-P8<EH\'Y7,@8'
M'.0P/<5]426%G*SO-:PNS[=Q9 2V#D9]<'I2-IUBZ2*UG"RR_?!08;Z^O4T[
M@> :[X>-GXLTK7?"-G#-'\1=-_LJ^N(U1TBG*+(MT,CG]TLQ('#%%R,G->D>
M/],O](^!FLZ3X)AEM[FRTUH;*.UXD557!"8_BVYQWS[UH:?X1U&'QM<:]J7B
M>YU&QC9CINEF".**PW*%8@J,N<9 )Z!F]<UV65)*]: /G&R/A/4?'GPXOOAP
MMM!&+29=9CM=H1;$0_=NL9&X2<#?SNW<]:W_ -G\^&VL/&#Z3_9QG_X2*]VF
MU"!A 7!CQMY"'' Z>E>SQVEK"TAAMXXS*<N54#>?4^O4TL-I:VY)M[:*$GJ4
M4+G\J /#=6CT"X^-'Q$L+9;.>XG\*1/<6ZE"7F5YCEEZEP/*YZC*^U<XTWAG
M4/@Q\/'\/Z]H6E7=K"##_:=JITZZNEM0LT4^< /AC\W/(;J:^E!:VD<K3+;Q
MK(V=SA0"<]<FF#3]/-D+/['";8?\LM@V?ETHN!Q7@3Q!IEM\&=-\1:A:P:'8
M06KS2HK'RHD5FRR$\E#C<OL1BO'O$>AZQXO^$VJ?$Z/6=)@EFNAXCL6,+--;
M^0-L$(F\P*IV)@@K]]V'7FOIXPQE-A4%,8V]L4>3#LV>6NWTQQ0!\^^//&7@
MGQ?X/^&_B.:?3FCN?$%DSK=!2T*C/G(P;D!25W9XY!/45H+_ ,(*_P"U(D$:
MZ,<>&=NT+%CSOM 90/\ ;V<^NWVKVY[.UD0))!&Z@Y 9<@4[[+;[@_DKN'0D
M<B@#Y9T_6/#]E\$_"RQWUK%:V_CL':'55BC74'D_ ",JWT(K7\::IH-IXV^+
MT=O"M[-=>&K426MI)Y<D[CSE<97DE59"V.=O8U]'"UMPNT0KCKC%/:&)OO1J
M?K1<#Y6TL:?J6I>/K"R>+66U'P:GV7[%IK003LGV@#RTQ@[?W:AB221P>,!L
MVI>% W@N]UJZN]+\(S>&?L,=W;6"F$7IV><C*\3X9U PV!G80">:^IHX[=7*
MQJ@9%"D+U [#Z=<4\6\(01B)=@Z+C@47 ^7?&UIX>TW1-!?2M3:RO+#072UT
M[Q1;>9#J%D9 /*+$!TG(48 ^;&T8';V;P5XXT*[?2_!SQRZ7XABTBWO)-*EB
MD!@C*+\H=AAMN0#SD=^<UWK0Q.<M&&/OVK,70;#_ (2;_A(F5Y+\0FVC:1R5
MAC)!957H,E02>IP.< "BX'S9\9+G3[C7OB'9^3-9ZE#964B*MF]Q->A06$B/
M@B&)"0"5P=P))'%==?)X1\0_M#Z#=ZE8VEW:R>%YI/\ 3+?[TWFH5W*ZCYO+
M\PC(SC)%>]&*-CDJ"?>E\N/.=HS0!\I> ];T;3&\%77B(&7PO96&H6,#20O+
M':WK77RHZX)5C!@+D="0.M=Y\*_%OAOPK\,[;[<ESIEI>>(+RTM%>RE3!DN9
M&B!&WY%VE>3P.F<\5[6WV>,HLFP%VPH8]3UX_+-4-2T6RUA;:.\\UH()EF\E
M7(21E.5#CN 0#CID#.: .'^-T%K+\,&O+JV6:&SU&PN96,>\QQ+=Q&1N 3@)
MNSCMFN OK[PVVO\ Q#M?&-M"T>M6D!T 75N0;JV^S;1%;@J3D2[CM4;MSYQR
M*^C&167:5R/2FM%&Q5F0$KR">U(#S2UTG6#^S;%I?B*U:_UE?#NR6&5-SF80
M'"GK\P.!GKD9KSRTO?".N:)\%;'[+;75BDNVXBEMF1-ZV3(25*X(\T@9/!88
MSP:^D#@@KVZ4T0Q@#Y1D=/:F!\I7,EO:^&=7DTR&Z?PWIWCQ[N^M["#?Y-EL
MQYBQD$/&)-K\ CY>G%>L_!RU\*QVFMZCX-FU>[TS4;H7+7E_&(HKB4K\QA38
MF !M!.T GH3@UZKY<:KTXJ.'[/Y>82I3I\IR..*+@>&ZI:Z!J/QH\=6D%I9W
M%Y-X:B@B18%9GN<W)=5..7PT9(]",US7A?Q-H6H:]\$[>S\Z6ZTNQGL[V1;2
M7$$GV01F)F90,[Q@^F.>M?2\?D2LQC*N4.TX.=IQT_(BG^3$ /D''-%P/FE=
M7L'^&&K.EPKC_A8*W.5!_P!4-3CDWX_N[!NSTQS4'C*#PW<?%3QEI'Q"DUNV
MM]<2U.DO96GG+>1+"F8HW\IRK"4,< KRWN:^F3]G681';YC#(4GD@>U.=805
M,FT$'Y2WK[47 ^:?B-#::?XIEOM+FMM3N1'8VU_X;U>#=<784+Y3VLJ_-YHW
M\X)&>3U&>[^#K:39ZKX\T>VM8[34XO$-W--$L+(1$S QDG:!@C. #C'(KUTP
MQ$Y,8)]30(XU<LJ@,W4^M 'RI=V7A;4O&WBOP]X\?6X_$<FO-=Z?;V=N/,OH
M]R^08I_*+* NU3\X"@=N:M?$&WTFS^(VI>+-*MXY/"5O=6ECXRLHSD7LOF!H
MV\L*2VPLA8C[^2O.&KZ?-O"91(8P77.#W&>M+Y$.6/EC+')]S1<#YWEET=?B
MIX^3088(M7UGPY:S: \%L0TDGDW"EXV &T_=!.1Z5G_"]/AS?WNC7]M<:K)K
M&FZ3+:ZM:7-JD$%G&8_WPNCY2!P6R1N+$DD] Q'TP(8@VX(-W3/>FK;PH[LL
M:J7.6(ZL?>BX'REX/M?"5CH7P=U*WMK*VU&?4KBVOY=N9'5HIE,<A/)4L8Q@
M\<K@<UZI\"7T&+PEJ.EV%O!!JMCJ=]%>I'!L=!]KF:-6; S\C @9. :]=\N,
MC[HIJPQQ[C&H0L<L0.IHN!\H^(-)^'_VOXRVEY96*>)3>EM(@6,"Y\YK6-D-
MNO7<TI))49/4TNO6NAKXXUS0_BSJ>IPW.HZ?8II_DVBRFZ185#)$WENRR";S
M.%(R6KWWPSX+N- \1>(M7NM874?[:O/MGEFV\LP-Y:Q@!MQR-J*.@[UU[6\+
MLK/&K,O*DCD47 ^<O!&A> M:^._C)M2M+>>\TZ#3+FV2>0&2*5(CYSL5.&</
MM#GGG.>M<S8Z3\//[!\&WTUOIR>?XUU&WFDSL/V3?=XB)SD1;3#\OW2&&1\Q
MS]9BW@$AD$:AVZMW-'V>WVA?)7 ;<!COZT ?)NL3>%;7X>_$S3+)[&"WT_Q=
M:SV-O'A5@!>WRT2CH/EFZ<<-[UZ%K"^%V_:%$NH6EC<_VWX91+%F@$@NYA,W
MW2%.3LQSV7':O<#;VY&#"I'7I0T,)E1O+&]?NGTHN!\BZ??:);_"#X97$YO+
M;P[ID[Q>(I+2Q#?9[CRBJ-,K1L&VMG)*M@XZ'%;5NWA'PQJGAK4(WU6Y^&_]
MIWMU->:G"?L@NG@C,,BIL4+%DRA?EV[\D8X-?3TBVL<#^8J+$<E]W"^^:9)]
MB\E8I/*\M_E56(P?847 \N^"UYH4D'C*WT%5BM/[>GGACCMS"@B=(]K*" ,$
MAL5Q'B>P\"3?$;XJ1>,K&VDO[NUMO[,2X@S-*1:;2;;NS[B!\G.<?A]%J]NI
M!5E&[@8/6D,=O,W1693UZE3_ $ZT ?,=WX9\5>#I? NI6<&[6?$^DKX7U=Y$
M#&.=HMT4[#J60!PQ.<A>]?1MG9:9X=\+I8VL<=GINGVVQ%^ZL<:+_0#K6'#X
M,F;XA2>*]0\1:A?6\)W6.ER%5M[-S'Y;.N "Q*EA\Q.-S>V.SVKMQVH ^2='
MUC15\%_"JUU$K!&EC>QF^N;=[F.-P0K0K!@JTS C!(.%W8!R*V[/1X;[]F?P
MEXNTNP\[7?!S+?0GR&$A6*0^=$ P!Y0'C&,J,=*^EF@A? :-3CD>W:I%C15"
MJN!Z47 ^9]+T;Q.WCV30;S06@T7X@&/7;R!8P@L%BDS+#)C@ET^SJW<L[\]Z
M]TT#QAX=\1:GJ^DZ+?\ GW>BS"VO83"\9A?D ?,!D?*>1D<5T,DD,*[Y76->
MF6; K)TW0++3=5U'5(VFGO-1=3-+,^XA5SLC4# 55W'  [DDD\T7 ^8_$VD^
M%+SQ+^T#<7&EV,]Q'9P-8.\"LRSFV(D:+CAO-P"PYW'WK;T+4-/_ .$^T^_\
M>C[1X;OO!]M!I]U?Q%[7S0H^T1Y;I(V.<_,0,>@KZ6_=;]F1N.>-W-*\,;C:
MRY'O1<#R[X-V\F@?!>W_ +0DG@T^&6[FM/MF5>.R\YVB+;N1^[P>><$5Y!X=
MFO)/V4M.AL;>>XM[#6Q)K=E%$QF>Q^U,[@IU(9"I.,@KD>M?60C4+MQQ412-
M7RQP,="<47 ^:M8N=-USQ7XWE^&]E/'+JW@_;!-9V$MNES.LLN[#; "^W"@^
MHQG(X9I=K\.]2T/7M>TN#69+L^&YK*^%]9&.*V.%\N HL2!Y _3&XC:?:OII
M1"P^7!!'8T_RH\$;>M%P/E31]'\.6EQ\$WM-(CBNKC2+F+4#':$-([6>T+*<
M9)\T, #W!K(\/R:3;_#GX,I+9O;ZCH_B(1WP-HZO!AGW[B5Z9:+)''(S7V$(
MHP -O2F^3'_=_4T7 \&U"3PNOQW\:-J-G;&W/AF.-FEL]R&17E:09*X)VLA/
MKD5QD<RQ_#_X-ZCJ<NH0>&]/M);34)K6#S6L[IH56-GC:-\@8D7.TXW>_/U=
MY:?W:7RT_NBBX'S(D6A^$C\/K^/2=6/P]M;Z_?=?6[R&.5P?)N&B"#9&6:38
M"HP&!P,UW/P5FTX7WCZ/3;%[*TD\027,*&U>%#&\48#+E0#DJW Z<>HS[ R)
MC:1Q5=9;7SVM1(GG!0[1[OF"G(SCKC.>?K1<#PZ2TT'QA^T/XITZXU+4%C.B
M6UIMLIY;99BKRF5&92-VT.N>>-Q]ZSO&FE:'X-^(FAV>J6E_IG@G^P6TNUET
M^U%Q'!-YOS(ZF-R-ZE?FQDD<D\X^B_+4,"!C^M*55L9&<47 ^7=$\(_#^Z^+
MGA;P_<>&VFTQ/#MQ&L6J0EY2YG5H/-.T8?R@S*&Y48'!%3S0_8OC+#!X9NH-
M5BNO$+276CWUGB[TV8(4:ZAD7!,.%!PQ*XP._'TUY:YR!BJDE[IUO>QV<MU!
M'=2\QQ-( [_09R:+@?+-E8R7GPNL_#-W9W*?$[2_$BSM(\!-QYK7>XW!<#!C
M,+'DMMP,9/%1>--/\&7NE?&F\BTNSDU!KF :?,EOMD,HC4L8B%SGS4DR1U*G
M-?6WE(3DKWS4?D19^X#SDY'7_/\ 2BX'F?Q"_L35O@C<C5+ZZATR]AM5:]M8
M][Q;I(]LFW^)0Q4L/[N17C,MQ!)X"NM)UZ#3[JSD\9V&[4[6(QP:M"IB\V8Q
MCY1MC4!RN%SGOG/U>9K9+E;8R()F4LJ;OF(R,G'IDBI?(CV[=@(]*+@?)_BJ
MZ\.>']>\=:3I>FVD.FS:GHS*D,#+:VI4?O)V2/&Y58+D="2 ?>./4+&/X3?&
MO3(9KMVN[YI+02V1MC.)(HPI1 @'S%6P ,D#)[FOK0V\;?>4-]12^4OI1<#R
M6QU;3;S]HBP>WO(Y5E\* 1NO1V-P' SZ[1G'IGTIGQGM]#N-4\!2>*((GT&/
M6':\>Y7,$:_9I0ID/0+N*\GBO7?*3<&P,CH:C9[>9WMRT<C+C?'D$@'U'YT@
M/E;6-)71=+U;5-#MKFW^'+>+;.Y*V,*NB6RP!9IHXV5@8A/L/0CY,@8YKU[X
M1Z=X6L-)UR[\'76H7VF7E^;EKN[C6.&:4J-YA540! >"0N,@XSBO3S&A79M&
M!VIPC4)LV_+Z4[@?(.J?V7??LU_%03^3/,_BF[NK17&6)>=#&Z \\KNP1VS[
MU#\9M2TK46\;K;;;>]AT[39()3;M/-? $,'@?!$42ACEAR6)R>,'Z\F:VMXR
MUQ,D2GC<[ >PYI_V>!CO\M22,9QV]*+@?-FMP?#_ %WXXZCJ'CB"VN=*N?"M
MLUB]^K)',WF-DQYQN?!&,?-SQ6)X/M]4TSQ=\+M)OIKB+5H]"U58([LD30B1
MB;97!^Z2@'!/;':OK PQ-C<@8CIGG%*88RP;:,CH:+@?*'PHM_"5_J7A!KB]
MUZ/QYI,\L%[IMO;QHR.>)I+A_*4O&< DL[<G R:^LE^Z,]<5$(85E,BQJ)&Q
MEL<G'O4U( HHHH **** "BBB@ HHHH **** "CM110!\B?MK<:;X*P<#SKOC
M\(J*3]M=_P#B6>"UW ?OKLX/7[L5%4!]"?"1BWP7\%G_ *@UI_Z)6NXKA_A&
MV[X*>"R3_P P:T_]$K7<4F 4444@"J\G^M@_W_\ V4U8JO)_K8/]_P#]E- T
M6****!!1110 4444 %%%% 'DDGQ(U;1O%WCYM>LK?^Q?#L-FMLEM,6EFDE#%
M5P5 WN61<9 7 ZY)KI-)\9:@WC=?"/B318M*OKJU>]L7M[HW$5S&C;77<40J
MZY0E<$8;@G!KFO$GPNUCQ!XF\6LNM6]KHWB2VM68B%FN+:ZM_P#5,G(7:"JL
M<\D\<=:Z/2?#>O77BRP\3>+)M/:\TRSEL[5-/W[&,K(9)&W\@_ND 7G&6Y.1
MA@0_%3Q-X@\*>#[?4O#MK:SW+ZC:VLANG*JB23*A( 4YR6 ]@2>2,'S[5M3U
MWP[^T9J=]HGAIM6O[CPE'<W-E'=B.)9%G.3YC#KA0HPO/' Y(]2^(7AJ_P#%
MO@R72-+NX+2^6YM[J"6XC+QAX9DE 8 @X.S'XUSL/@SQBWQ#O?%UY?:09+CP
M^-)V1Q2 ><&+[\;N$W,1C). .: *,WQLTV;0/#=[I-C%+>Z_8OJ$-O>W8MXX
M8TP&#R!6^;<=H 4Y.>PKN/!/BJ'QKX*T[Q+;V%SIZWB$FVNTVR1,"5(/MD<'
MN,&O*])^#?B_0= \'W6B^)-/M/%/AJWEL#*T#26M[:O)N\N1<A@1P<C'/X$>
MP^'[#4M/T2*VUC5#JE_EGFNO+\L.S,3A4R=J@$ #)X Y- 'E'A?;\3OB;XUG
M\3DW6D^&[\Z1I^F;R(0R_P"MF=1C>Y. "> "0.M=/+'9_";2/$&L>?=7^GWM
MW"VGZ8KM)*LSJL0@C+L>&< @<!<GL*@D\ Z_X<\=ZSXL\!ZA9*->9)-0TS4U
M?R6E7CS8W3YD8@G((()/:K'B#P%K'B[PEJ5CKGB1XM4NI(;BUDM8\0:=+"V^
M,QH>7^898L?F[;1@4 96M_%W4/#<NOZ=K?A'RM9TS2O[8AMX+X/%=VX.'(D*
M*0R'.1M/L3FJMY\8O$FGZ%I.M7GPSO(;?5]1M;&SC;4(O,E$Z!E?&, Y)&TD
M<CDCM-KGPR\1^*1K6J:YJ>FQ:Y>Z(^@VS6L+M#!$[9EE(8Y+-Q@=%QC)R36/
M\6EU#1_A[\/](N]2T]=8A\0::D<K(4@9HV(WE2V=HX)P?QH U9/C7-HL'B"W
M\9>$Y]#UC2EAD@L8[E;G[<DSE(MC@  EQ@YZ58U;XJZUX<O-6TWQ%X02#4+3
M2)-9M5M;_P V*\BC(\U-YC4JZY&1M((Y!Z4WQ+\)[CQO%KE[X@U6.VU6\AMH
M=/FL4)6Q$$AE1OF.7+2-EAQQ@#IFEU[X<^*?%1N[[6]<T]=0_L>XTBU%O:L(
MXO/V^;,Q+9)(0  8 YYYH BM_BKXJFT*TU2X\!'3(-1N(UM+F^O@MND#0F1I
MIV5"8@,;0".2PK-O/BCXJUSPGX+U[PYIVG11:QKBZ;<AKPOEDF=2J,(R#&WE
M'Y^N#P,UT&K?#WQ)?>'_  5:V^MZ='>^&W7S$GM&EM;D"(Q@F/>#N489>>#G
MVK+MOA3XFM/!EAH:>*+&2[TSQ!_;=I<-8,$;,KR%)%$@SS(WW2!P![T] 'Q^
M+-)\+^*_BCX@U#019W>E064EU/%>-*;_ #$PB54( C/10!U)YK1N/B-XHT?5
MO[*U_P (VD-W=:9-J5@+?42R2F+:9+=V,8Q(%;.0"#BH=4^%6I:]/XX_MG7(
M'M_%%K;VZ"WMBCVK0@['R7(;GYL<<]ZM2^ _%6I&SN]<\0:?<ZCI^EW%A:O%
M8L$,DRHKSN#)DG:F  1]]N>U&@%/PG\4O$>N:MX2CUKP?%I6F^*[-[BQN$OA
M,ZLL0EVNFT8#+D@YZ8R 3@=_XL\1V/A#PCJ?B74%9[:PA,K(GWI#T5![DD ?
M6N'TGX=>(M/_ .%=H^O6$D'A"W:!U%HX:Z!A,.0?,^7Y,=CSD^U=MXP\,V/C
M'P9JGA?479+;483"SI]Y#U##W! /X4@.%F^)WB#1O$-IH/B3PO;6E_JNFRW^
MF+!?%TDDB7=);R,4&U@,'< 0<UI?#/QQXH\<Z<FKZOX..A:5=VD-Q9W!O%F,
MY;.X%0 5'0C/4'\!FQ_#?Q1>W&EWWB;Q+8:G?Z+IT]EI\J6+(/-E0(T\H\PE
MFVKC"[1\QKKO 'AW4/"7@'2?#6I7UO?2Z; MLL\$)B5D7A<J6;G&,\T 9?CB
M[M[7Q/X'%UH,6HK-JYBBN)+AD-G*8)"KJ@!WY4..>G'X<;I_Q(\6:;HOQ&\3
M:Y9V5Y9Z!J4EK!;VTKJ5V+"N#E?N?,7+=<EN,5W_ (Q\,:QXBU/PS=:;J5K9
M1Z-J2ZA(L\#2&;",FP$,-O#MSSVK"A\!^*-+OO%;Z+XIMK6UUN^_M"!)+'S&
MAF8Q[PYW@.A$97: #ASD\4 ;_@GQ-?>)[*[O+A=,EM5D06MWI=U]HAN4* D@
MX!!#$J0?2L;QY\0[GPIXCTO0;.TL#<ZA:SW$,FI71MHIGCP! C;3F1BPZ]OK
M5OP!X#;PA=:[J$LEBD^M3QSRVVFVQM[6)EC"DJA9N6.23WXJ+Q]X+USQ<TUK
M!J&EOI%Q8R6LUAJ5D9U$C$XF1E92K $C_.: .<@\?>*8_BC?P:Y:V-AH.G>'
M4UB:,3,9(U8DL3\N&93&1C(&.F2>-6S^(VN1WOA.?7_#UM8Z5XJ^6UG@NS+)
M;2M$98XY5* 99%(RI.&!'3FHW^$TG]K6[1Z\9-*?PZGAW4()H-\UU$@8!Q)N
M&QCN.>#4NB?#W7X8_"^G^)/$%IJ>F^%W\RS\JU:.>=EA:&-I6+D?*KMG Y(!
MXZ4 0:3X^\1>)KG2;B'P;'=>#]<DN+=;V.X,DD,:[@LDT>S 1]IZ$XR,GG%<
M=\"_$MY_PC%AX1\,Z?;WB6=]>MJDTL_EBPB-S)Y2X .YW .%XP!DXR,]1X3^
M%_BSPC<#2+'Q\S>$K6Y>XLM-:S'FIEBZQ/+NR8PYR0 "1QD UE>&_@OXF\*W
MFD:MH_BJPM]5M+B?[:\=G(L.HVTKF012)YAY1W<JV>,T: 8J>,-2^&FK_$:\
MT7PE#=Z!9:_'+?2FZ$+1>;;VX_=KM;<=S$G.  PQWQZ#J/Q$UJ?7/$>D^#_#
ML&MR^&X(Y+WSKLP>9*ZEQ#'\A&[:,Y.!DJ/4C%UCX4^*-:\->-]&N/$6FP_\
M)3?17F^.R<B (L:E<>9\V1$G/'.[CD8TU^'?B72O%&L:]X9\065I)XAM8H]4
MANK1Y8UN$38)X0) 1\N1M)QT.:>@&!8^(-&\1?&?P1XUL4$$&I^%[RX>1\!E
M4/"=K'U7YA^=9'BGQ)J'C>V^&_BQ?#UI%H<WBBU-G<R3,;I8_,90Q3;@*^W.
M QXV_AV6G_"B?2_$OAJ6VU"V?0M$T>;2&M9(&\ZY64#>Q<-@$LH/3N?K7/Z?
M\'/&UAI/A_PU'X\M)- \/:I%J%BDNF[K@HC%EC=]^.,D9 [^V*6@%J\^.=PF
ML3C3?"\VHZ7:ZO\ V5(T/F-<M@E))E41E-BOQRX)P>E3Z?\ %WQ1=IXDU"X\
M &'1_#TE]#<7B7RN7DMP"$5-H)W9QGH".^*MV?PQ\4:'XHU)?#GC06'A75;P
MW]SI[6N^>*1R#*(9=WR!R.X.,G'/-:/AWP1XIT/P_P"+K$:UIXO=:OKC4+6Y
MAM6 MY9?[RLQW@$#T[T] -'P'XRU'Q=]LGN+"S2Q2*&6UO;"[^T0W.\$LN[:
MN&0C!'N/6K/BCQ>VB:_HGAG3K:*]US6WD^SPS2&.-(XUW22.P5B .  !DEA[
MFLCP!\/9_"GB/7_$$\EA!-K"PJ]GI<#06RM&#F782?G8L<XP, =\FM#QAX+N
MM<\1^'O%>C7D5IKN@22^0;A&>&:*5-DL;@$'D8(/8J/>D!Q5_P#&W6K&SBA_
MX0*6?6X]>70+O3TOE7RYG4/$Z,R@.CJ<@G;COQS7IWA/5->UCPS!?>(_#Y\/
MZFY99+$SK/Y>&(!WKP00 ?QKS;5OA1XBU"Z@U2'7=/75I?$,&OWLCVK^7NAB
M6.*&,!@=H4<DG))[5[.N=O(YH \/T_XH:[H?_"S=>\76MJVE>';];:""SN&>
M3=LB"1J&10=Q<$MD?,3\N.:ZO3?'>NP^.]+\)>+O#L&ES:S:276GSVMX;B.1
MXP&DA;**0ZJ0<C(/K6%JWP>O=;/Q TJ_UR$:%XKF6\C2. _:+>X"Q!6+$[2H
M,0XQDYZBM_2O!_B6Y\5Z#X@\8:I87DV@VLT-JMG;LGF2RJJ/,Y9C@[5("@8^
M8\]* .A\8>(+SPWX<;4K#2_[0N6GAMTC:3RXT\R14\R1\':B@[F.#@"O/K?X
MT33?"[Q9XQAT&WNYO#5Y+:RPVU^'AN%0*?-CEV\J0X.,9Z]^*[/XA>%=3\6>
M&8-/TG4H+*X@O8+S;=0^=!<"-]WER+D$J>#UZ@5P4GPE\6S>#/'_ (?N/%&G
M3MXKN3/'(+%HU@W*JN,!SV10/3!)SG@ VM-^(_BR\UR_T.[\#+8ZD=';6-,A
M>_5OM*!@OER%5(C?+*.-PZ\U>\)?$2\\66?A2XM=(CA_MJVN;J[3SV8V*PLL
M97[@W-YC*I!V_P 1!.*S]2TS5O#7BE/B/KNJ6*Z5I&@-874<%M*TA&])'D7!
M/=!@8/'K2_";2=,FG\1^.M*:[&G^(KUI]/CN"RA+?@LRQM]SS)C*_3D%?I0!
MZJW2OGEOB'J$7QXT?71J5O/X5UJYF\-1VZR8,,D9!2<C/)>;S$!Q]T#UY]E\
M8Z?KNK^#M3TOPWJ,.G:G=PM#%=3*Q$.[@L-I!W $X]#BN'\2?"+3]2^%"^%=
M#T_2-%U2&.W6#4(K7)@>-T;>I^_GY>I.?7-" H_%%M>U'XE>!O#L.CZ7JNDW
M;W<S6E]<O''<R1P' D C8;5W9'WLGJ!@&O,+KPW&FK?$[P[K'A2SU7P[X6TJ
MV-M;G4Y!+9PE9I_W#F,D,QSNSC 55^8"O;=5\*^,]1\7>#O$#:EI!DT&*87"
M&&0?:))8PCE<'Y1@< Y_&LB[^'/BZZUGXB7T>J:1&OC"R2S4>3+NM]D;QHQY
MPWRN<\#GVX)<#+EATZZU3X%:A86"V22*_DPA_,\F(Z<[!-QY.,#GVJ?P[XL7
M1]'\8ZKI'@O[+>CQ2]I=Q&]:2,R,(P]S*^"(T ;)V@@ >^:V8/ 'BJ-/APIU
M;3#_ ,(@NV;]Q)FY_<&#Y?F^7Y&)YS\P].*R+SX3^)[O2]<MCKVFB2^\1IK\
M6ZU=H6PH!AE3>-Z_*IZ]13 S=0^+?BC7?A7XAU;P]8:=:ZEI&KKI,TJ7C30R
M9DB420N$^;/F#J..>O2M[Q/\8+KP_J=YH=OHUI>ZQI>GQ7E] ;J1$+OR(8F$
M1+-@$Y8*.5]3MK0_"3Q-'X<\9:7-XJLYY/$&HQZK#*MBT8@N%:-CD>8<I^Z4
M #!QG)-:&I?#_P ;P>,%\6>%/%6G:?JFHVD5IK0N;!I8+EHP0DT:!\JRAF 4
MM@C&3URM /0O#NKIK_AG3M;CMY;9;ZV2X$,ZE7CW*#M8'H1G%<#K7Q2U+2]-
MUKQ)!X?CN?#6AZBUA>7!NMMP0C!)9DCVD%4<D8+ D*3Z5Z/IUK)::9:VDUU+
M=R11+&\\N-TI P6..,GKQ7E^H_#'Q%<6GB7PU;Z]9KX6\1WTE]<![=C=VXE8
M--%&0VTAB&P2,KO/7% &1XBM)O&_QS@T+5-(TW6/#W_"-M<0Q7%Q(HVRS*C3
M!=AVR;00,<@<[AFNJ^)FI:K\/O@C?W7@^.!9=+M8X(3=R,WEQ\1AAU+,,C&3
M[G/0V8O!VN6OQ<A\6VE[IZ:3%I2Z0MD8G\Q8Q()-P;=C.>,8Z8K8^('A9_&O
MP^UCPO'>"RDU"#RUG,?F"-@0P)7(SR* /./$T_B&S^./@N^T[0;6]URYT:_C
MEA^VF.!0'@.YI"A.T>R$Y8<=ZOV_QG$W@[0-2ETM+35-7NKFS:WDD=XK=[=G
M65BR(69<H ,+GYUSCDC<7PAXJD\8^'?%%[K>FRW6F:;<64T<=FZI*\I0EE_>
M$JH,:<<]_;'+1?!_Q+9>%M+ATOQA;V?B'1]4NM1L[Z.Q/E%;AG:2%T+G*G?U
M!XP/K3T [SX?>,+KQKX8?5;S19M(N8KJ6U>!]Q5MAP'0LJDJP(()4?I7%WUO
M#X^^/NJ>%]?C^TZ!X:TVWG2P+'R[BXF;=YDB@X<*J@!2".37H_A;3-:TS1C'
MXBUH:OJ<TK2S3K#Y,:YX"1ID[5  '4Y.3WKG?$G@75+CQQ:>-O"&KV^CZTEN
M;.\6YMC-!?09RJN%92&4]&!SSCI2 KS>'/#GPPN?$/CZP#66F1Z86NM/B'[O
M,67#1KG"$C((  )(/7.:B_$+Q5I^NZ%IFO>&;*%O$5M++I[P7K%8YTC$GD3%
MDX)7/S+GD?=[UOW?@_4?$F@ZQI7C+5H;R'4[1K/R+&W,$4*MG+ ,[EG^[\Q.
M!M& .<Y%GX \3-<^'KK7/$UE>R^'+66*R\NP9/,F>+RA-+F4[B$+#:NWEB<]
MJ .4LOC)XZN?AE>>/)OA]:Q:9':QW%NQU'F<F8QNH79D<#(SC.1ZX%N[^-&N
M>'+W5;+QOX+.F7<>FKJ>GPVMV+C[0ID$7E.P4!7#N@.,CYN^.:7C+1+GP#^R
MOJ/AS5-:MKB2TACMK>YCA,.<S+M&UG;+#)/7H.E;6K?"T_$+3;W4/%&OVM]/
M?:2MC8W.GVAACM@76;S@&=BS%TC/48"X'4FGH!)JGQ%\7>'-:DT76O#>GW%W
M-I4^J6,EK=ND4WDE?-@8LA(95.X'&#P,"LS3_BI\0+GP[9ZYJ'@FQTC3M3^S
M/:7UQJ :"&*2%I7EF(&44;0HSC)=1UZ[UU\/?$VK2+J&N^(["ZU2UTJ;3;22
M.P9(D,V!+,Z^82S%54  @#!ZYXKWGPRUZ;POX(TVU\26<=[X5>,K)+IYD@N
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M<D'!YP<"L*]^"OB^XFN_L_C:RCC_ +>37K>2;3C-.TBL"J2R&3+*H& !C\N
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M<&F>(=0:XT^*Z0H4M\9+*C<JKR&1AD#*[:]?YH ****0!1110 4444 %%%%
M!1110 4AZTM(?6@#Y!_;5;%EX+7<!^\NS@=>D7^?RHH_;6?%GX)CVY)DO&SC
MT$/^-%4!]$?"5 /@QX+_ .P-:?\ HE:[>N*^$_R_!GP8N!QHUIT_ZXK7:TF
M4444@"H)/]9!_O?^RFIZKR?ZV#_?_P#930-%BBBB@04444 %%%% !111U'-
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M*)C 0T8SE4VF3I\HR17H.EZ5X/U#]H/QOI][#9^9J6EV4EMMDV2S[UE,DD3
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M;Y9#9#J6';KQ1XN^+EYI_@7Q%KWAOPM?7ZZ9=?88[QVB6WE;D-,AWY>-6PO
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M(&U5(R>#6Z/'^GZ-HGA^QL++6?$E]=:6E]'!"BR71MPJCS92S*NXD@=<LQ(
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M9YV[U7=CC/%:G@[XH6GC+6DLK+0M0M;6XMYKJSOYS$8KF..14.-KEE.7!VL
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MXM[=(Q, , -@<\$]:XFX^-G@^R\4KH\[7"6C7O\ 9O\ :FU?LPNMN?*^]O\
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MT[4IK9K*9YXI"ZPPB+Y@K$J3@$=L>G?U.DXI: "BBB@ HHHH **** "BBB@
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M4#!HN!YMI?B#QEXG\36W@?6/'-OI6J6_AXW?VK2=A2]O/-DB,@9ARL>P;D
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MZ6V^5?,2+>Q5 2HSM X '047 X&U\3^+AX3^'7C6'Q7<WLGBB_MK+4+%XX3
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M219(U0>K?O(R>RN?:N6TOX<^,M ^%?C?P[<(=9N9;.;1M#CBD4$69\PQEB[
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M%;PSHE[>QW*7\UEILPM[_4;>U:2ULI" =DD@[C(SC.TD;L4RX^+W@^W\4_\
M"-[[^:_#6ZGRK"9XPLW^KDW!<;"<?/TY'-<7=^#?&]KX5^(7@>+18=1M/$M]
M=76GZE]I18X%N3EUF4_."AR1M5L\=*V_A[X3U[PK\0=76ZTMVT=])T_3[;4&
MFC_>-;1E#E Q<;MV1D=CGM3T LGX[^!TODMYAJMO%]L-A+>3Z;-';VTV[:$E
M=E 0D^O3OBM35?BQX5TB>Y^T->2V-G<BTO-2@MFDM;64X^1Y!T(R <9"D@$@
MUYA;Z9XB\9>"_''@FQT0-;:AXJO(9-4FEC6*"+SP[MMSO+C;@#;@DCG@U8A^
M'OC?3/A]XR^&,>E0WUIK=Y/-8ZNUPBQ0Q3,"WFH3OWKR1M4@G'(ZT@/09/C%
MX13Q7=>&E_M!KVTE6*X;[!+Y<.Y'<,S;<!2$.&Z'((R,D/T'XKZ!XDU/^SK&
MQU..>:P.IV?GVNP7]N#C?#SSU'!P>1Q7(Z#X/\;:3KWQ%;3K%+4ZGI]M;:1?
M74D;(\D%N8@SHN2,L0V".@Y Z5D>!/!/CC2?B/X9\1:IX82 1:1+INI7,VIK
M/.\I=&,I&"-IVD*JG@'^'&*- .L\*_&6SU;PG<:WK&C7^FO_ &G+I]I:F'=)
M<L'951,,0[@(2V#M7!R<#-=OX1\8Z+XVT>74M$F=EM[A[2XAE0I);S)]Z-U[
M$9'J.:\,E^&WCJ+PY:0?\(GINJOX?\07>I1VE]<(R:O!.TA("X*HP608W8&Y
M3QZ^R?#[3KVQT*X>\\):9X4-S<>='IMAL/EKL49D9 %9R0W08 P,F@!GB#XE
M:#X?O;ZUDAOK]M,19M1-C;-.+&-@2&DQTX!.!DXYQBJ>M?%[P?HEW86<DE_?
MSZC:&]LUT^PFN/M,8 /[LJN&.#VZ=\5R]OX;\9>#_'GCR]TWP^/$.F^*2MW;
MNL\4?D3A"C1S*Y!V'CE=QQVS6!8Z+?\ @+XC_#+08K"36KC3O#5W;2K;R1QL
MS!H=S*9&48W8 &<X- ';GX[?#\Q:-)#=7UPVLQRO:I!I\TC,T>=\9"J3O!&"
MHR>5/0@UHVGQ:\(ZAX4?Q!;373*E[_9IL6MG6[-UG'D>4>=YSG'IR< &O&FT
M35/!_P 8?AM=7.E"74M6U37]4>PM)$S")T0A S,J$JF"<$#.<9[[FJ_#/QA-
MJY^(5EIT$>JIXECUK^QI;A0S6ZPK"4WC*"5L%O3D#=Q1H!Z#=_&CP9IN@7VJ
MZHU_8'3KB.UO+2>RD$]K(X!3S% (53GAL[3V-9B_&O3[_P :Z'H6DZ!K,]O?
M&Z\V>73I8R/) !V*V&/S,,G&!TZ].0\=> _&?B*3Q1KVG>&76ZUBXTR*&Q-Q
M"KK%:N9'DD;?LRV=H4%N@SUX[SQ1I'B:;XG>"/%&D:*MW;V4-W:WB27"QFV\
M]8\.>NX H<A<GGBGH!JQ_%#PW)HFGZP%OEM+_5!HZ%[5PT=P9#%M<$94;QC/
MK5/7/C)X/T#4]8TV\&J2W.C"-[U+?39Y!#&PSYA(7&P 9+=/3->>S>%_B+!I
M2>'(/!L4]O9>+5UQ;]M1C1+B'[89\*I&X-@X.<8[9Z5T.J>'/%=YK'Q8>'P[
M*(?$.EQ6FG2FXAQ,ZP/$<C?E>7R,@<#GGBEH!L7'B[3$^(TUQ:ZYJU]Y/ATW
MZZ/;6I:WGC\Q2)XWQ\[D,%P&QUSBH- ^,^C7/ASPC?:[8W]A=>)RL5L!92&%
MI6QA ^".<Y!SR 3V-9/AWPWXNC\>Z!>7_AF:SL;?PC_8D]P]S"VV?>C?=5R2
MOR=0.]8>IZ'J"_LPP>&O%5M#X?UW0;1'TQS=(\C3VH&R5-O3<1C')P_/6@#V
MS1_$ECKFHZK9V,=SNTNX-K-)) R1F0 $A6/#8!&<>OUKSCXD>,-03XF>&?A_
M:7&JZ7!J<-U-<WMA;LTOR1?N_+.T@@,VYL=-H!X//H/@O1;K0?"-C8ZA*L^H
M;6GO)4SB2XD8R2L,]B[-CVQ7 ^._#OB/6OC1X4U*ST*XDT:SL+ZRNK])80(V
MN(PBD*6#$+CGCOQF@"_X9^)&@6>G:-H^L>)IM5N;F1K*'7)+%H+74;A2<K&X
M&PG@@8/)!QDUK:!\5O"'B;Q(WA[2+B[EODEFA=9;&:)5>(*74EU&"-XX//M7
MEUCX"\:W?PK\,?##6?#PADT?4X))M8CN(V@^SQ2;P\8W>9YA&%VE0.I/%=W\
M)=&U_17\9KKN@R:8=0\07.I6I>2)P\4H7 ^1F((V<Y]1C/8 ZOQ-XTT;PM=6
M-G?BZGO+U97M[6SMI)Y95C +L @/ ##.?45F7WQ3\&:?X?T+7KC57_L_76"6
M,J6\K^8Q4G:0%)4\'@\Y&*Y_XEZ+XGU;QCH$EGI$VJ:#':W45S';WBVK+,^S
M897R&,. <JF<D#((XKE=)\+>-+?P%\+=#F\)SBX\/:LEQ>K'=0%5BC5UW\N,
MY,H( ).%Y]* /7?"/C71/&MI>7&BO.&LK@VUS!=6[V\T+@ X9' 89!!&17*7
MU_KZ_M#:;H,?B*YBT2?1I-1:Q6&+;YD<J1[=Q3=M(;)&<Y'!'2K'@/2]<L_'
M?Q O]4T:>PM-4U&*XLY'DC82HL"1$X1B024SR!P15/4M/\12?M!6&N1^&[N7
M1H=%ETUKY980%EDE1]VTN&V@+R<9ST% &'\2OB5M/AR+PEJU_"6\36NGW$\5
MFXMKA#)LFA\UDVD@\?*>H(YP<>@77Q&\*V'B&+0[N^:.2:[&GI/Y+_9_M)4,
M(#+C9YA!^[GMCKQ7A]QX9^)B?#;PO\/QX%GN)_#&M6MQ_:<5["L%U%%,6#ID
M[@Q5N=RX&#U/%=%H_@O7-,\=W]K??"_2-6CN=9DU2T\13R1-]GCDE\PAU(+^
M9'DA<<$XY YI@=U<?&3P%:WEU:S:K.K6EZ-/NF-C/LMI3M \QMF$&6 !) )S
MCH:R-5^)UO>WGQ!\/NVHZ!%H%DJG5X[*25H7=')E"A3POR%<XR,GIS7,:QX3
M\8WG@/XJ:;#X5N9+O7-:%W8 3P#SHL0C/^LXQY1.#@G(Z\XMWVE>,O[6^)CP
M^#;V6V\4Z7"+60W-NICD%H8C$P,GWMY'0XQD@GC)H!<\>>.[W2_#7@+3=)U#
M577Q%<VL$VK06>^9X&C+,R#:0)7P#@#(R2!Q6CX"U3^RM?\ %EKK?Q(OM=&F
M11SO:ZG8?9/[-@.]E9I-H#DJ.6X^[TK"U[1?&$WAGX46]KX3OII?#][9W6I1
M)/;YA6*(Q,.9,,<G/!QBCQ+X+\4^*O%/Q,M1I$^F6FN:';V%CJ$DD3)+)&7)
M!57+ -Y@'(['VR =W9?%KP3>7EY:OJ4EC+:61U)A>VTEOOM>,3+O4;D.>._M
M7+6OCF\U?]HK0M&T^_U.'1[K1;BZDL+RS:W5F# )*N] YSSU/&.@S7'-\/\
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M&<*>AXKTKX>:7J.G_"+0-#UBU>PO[73([.XC9E8HRIL)RI(QQD<]".E %/\
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M>@%>4_"/X=R/\//!\WB"\UP7&CQL\.FZC$D2V-SM*[U4IN;;N;869@-Q( X
M]-O/$6F^']$M9/%&O6%K<S+M$DG[I97"[CM0L2< 9(R>E<7\.OB=#JO@G4?$
M/BS6M/A@BUFYT^VN(_W<<R(P6/:,L22,G@FC4#2L_A'H=O\ #RZ\#W.IZI?Z
M=+.;J*6:9!/;2E_,#1NBK@B3+@D'DUJ>'O 5OHNO-XCU'6+_ %W7#:BQ%]?,
MFY( 0VQ515498 DXR3WK1;QQX-6QLKYO%6DBVO@QMI6O(PLP49;:<\X'7T[U
M@:]\6_!NC^&K#7[?6K34K2_O8[&!K>8%6=I KG<,@; 2QSV7WH U](\#Z/H6
MI^(]2TGSK6]\0SBXN9U*ED<1A 4R"!@@M@YY8]N*Y%?@;X<7P+IGA0:QJ^-(
MNVO=-U 31K<V4C,6.QE0 @DDX8'K[#&\OBI+CQQ)';^+-%?2(=*^URV"G-U&
M=P/G,0>(]A'! /->::3\5==\53)J>F^.O"^B68UE[%["_A/F20++MC,;;\L[
MA6XP!@]L<@'4?\*%\+3:/X@T[5=4UO5O[>N(KNYGN;I?,69!Q*FU0 V?;VZ<
M5)/\#]$O?"[Z9J.OZY?ZFTL4L>M3W>Z[MVB)\ORSC:H7<W&.=QSS@CNM3\9^
M$]%U&+3M7\2:?87<F L5Q<JC<],Y/&>V>O:N+^,/Q,M_!/@G59M$U[28?$EK
M&LD=I=,)&8$]-@8$$C)&>N.AHU U?!GPWM?"7B74O$7]O:OJNI:K#%%=R7TZ
ML)#&,*VU5 ! XXZ<^M6_%'@&S\5^)?#VNW6L:E93:!<&YM8K1HA&SD8)?<C$
MY'& 1P:ZG39I+G2;2XEQYDL*.V!@9*@FO*[CQ9X_F^)?BKPQIU_H:0Z-8V]]
M!]HLY-TWF[OW;L)1MQL/S =\X[4 7-5^#>GZQHOB?2;SQ3KAM_$MXE[>[3;J
M=R@ *I$7 PD8]?D'(R<[GC339I/A?J.A266J:V+FT^PN+(PK=.K#87&[:@8
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MZK]A8VY5S(L:98_*)&STW' YQQ7N-Q\1/ =I<-;W7C'189UF^S-&]]&"LO\
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MVUO;Q%+F;;M:7YA\F\?>"XSD]*]4T'2FT3P_I^DM?37ILX$A\^8*'DVC&2%
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MB5,RXX8Y*[?6M^?2/#GB#XH?#C1KB^O-1T@>%[M5DNIFCENT5D"M)M(R& W
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M^S)MMV]4&/E/N,5PR_%RQN/#FDZQ8Z#J,RZA%<2NDK1P+9^0^R199)&"*=_
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M@5@:7\3DU>:QNK+PWJLVA7\L\5OJT40DC?R@QWE%)=$8HP5B.<#@;A69X?\
MC-8Z_P"*+7P]'X?O;6]O[*6^L8II(M\BISME4,3"Q&" W8]J /1-3T#0]:$7
M]L:/9:B(CF/[5 LNP^VX''0?E1=:!H=Z8VO='LKDQ1F*,RP(Y1",%1D< CC
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M.\36VC+X8T>[U#4M3CFE:RE*P-:+$VR0RL3@8<A1C.<^QH [3_A#_"FR1/\
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M&^/?&_B+P_\ %#P'X9TG2S<VVMS7!N'$D8,JQPD[ &(Q@E7)R,[<#J: /45
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M^TEMA)MW;-Z%<X[XS6IE<=152*^LYK^YL([B-[JV5'EB#99 ^=I([9VG'TI
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M^'-'C\N"ZM(V-W>HHQ&CYP$ &,D#)V@<Y)KV@=*3BEJ0"BBB@ HHHH ****
M"BBB@ HHHH *#THH[4 ?''[:_%WX&';9>]^^8**3]MC<+SP-R?N7O\X** /I
MCX7#;\'?!B^FBV?7_K@E=A7)?#/_ ))%X.[?\2:SZ_\ 7!*ZV@ HHHH 3M5:
MX_UUO_UT_P#935GM5:Y_UMO_ -=/_9336XT61UI:1:6D(**** "BBB@ HHHH
M \@\#;M/^/WQ,L]4 2]OS97EF[]9K41%!M]E8$'W-+\6O$EOI<.EVVGZ@U@U
M]K5AIVL7MH=DL%M(9" 9 /DR1C.<J'SQN!KT'7/"?AOQ,]N^O:)::A);9\F2
M:,%XL]=K=5S@=#VH7PGX9C\/S: F@V*Z3,");,0+Y<F>I9<<D^O6@#YW^+1U
M?PE_PFFE>'O$&KV^EC0[;551;Z0FSN#>"+:CEB0KINRI./EXKJO%7A&71;[P
M'I-KXP\2F/5]=D%U.^J/O=6M9'* ] -R<8&1N.,<5Z@?A[X(.E7&E2>%=->R
MN61IXG@5A,4^Z7)Y;&3C/2L3QG\-QXJN?"EO#/86ND:!="X^PS6C2B4!#&%!
M#KM 5CC@\@'MBG<#R:2ZU3PUX[G\!GQ!J5QX1NO$]I9^=-=2/+");5I6M?.S
MO"F3RQUZ-C/)J#QN=8TNZ\6>&=+\3:M:Z79:SHXLY4O9/,MC=.!+"&)RZ@88
M*2=NZOH4>#?"R^'I/#ZZ#9?V7+(97M?)&QG)SN(_O9P<]>*AD\">#IM+32Y_
M#&FS60F^T>2]NK+YN,>8<CEL #=UX%%P/'?%.F-HFM3^$=.\1:IJ?V'P_=ZA
MMU'49(UM"TK,D[2J=TDF?D52,!023D\LT>"VUKQQ\&-<U6[DN=0O/#L\TT[7
M$B^;(L,!!QNQG+,2,<]\XKVO5/!GA+6M0M-0UCPWI^H75FAC@EN;=9&C4]0,
M@\5"O@/P:EGIEBOAG3?LVDOYMC$;9"MLW=DR.#GGZ\T7 \3O?$&K:=HVMV3:
MM?\ ]GW'Q 32;J[:X8RVMHWEY <G**3A,C& YQZUK:U!J&@Z[\1O#NEZQJ T
M6/PL-4B7[5(6TZY'F@"-R=R[_+W8SV/K7K7_  A7A'[+J=G_ ,(UIQMM5D\V
M^A-NI2Z?KN=<89L]SS2V_@WPM;:/>Z/;Z!8II]_Q=6XA&V<8QA_[W  YZ#BB
MX'EW@RQN]'\7_#NX.NZOJ$NN^'YY+\7UZ\JR.B6[HP1CA2"[#Y0.#SGJ>B^)
M%]<MXT\!^')[R>TT36+Z>.\DMYFA:1T@+Q1%U((#-D\$9VXKKX?!?A.WN=-N
M(/#]C%+I:&.R=(0#;*>2J'^$>PJYK7A_1O$>F_V;KFFP:A:[A((YXPP5AT8>
MC#L1R* /F_Q"?$$-_KOA:+7=9BT:R\7:5;6%]'?2"5%N2AFMRV<LL>X8W9QN
M KZ&T31[3PGX2BTN*^O+JVLD=O/O)FFF89+$ECR>O'X5%-X%\'7&DP:5/X9T
MV:Q@F^T1P/;JRK+WDP1][WZUT'E1^3Y)52F,;3TQZ47 ^7_A[JM])X\\ WG]
MK74]CKMOJ9EN;J_:2XOT4[D:6($I#M) 4*<@ @XY KZ=;ZEIWA#P3XMC\4:U
M-J4OB]M-)N-0D=3:M<S1M$8RQ#9V@_-EL]\"OH&U^'7@"SEBDM/!FB6\D,C3
M1M%8QJ4=A@L,#@D4B_#?P ME'9?\(;HQMXI?M"1FRCVK)_? Q][WZT[@>0:E
MI^K:3\2=>^&(N+^2Q\9F&\TZ],\CM9QHV;J,.22NT LO/!=?Q]@\:7EWX=^%
M^O7VBQL;O3M+GDM0 7(9(B5Z\GH/K4/A_P )ZE8Z]<:UXB\1R^(+M6FCL-]M
M' EC;NP)C4(!N;Y$!=LD[1C'.>P90P*L,@]J0'SCI\T]C?\ P>UWPMK%_=R>
M)OW.JK/</*+V,P^9)+(A) 9&!Y&,9QTKK_A)I&EVOC/XCW5I"5FBUYK<'SF;
M">1"<8)_O9Y/->A:7X/\+:'=R7>C^'M/L)Y P:2WMU1B&.6&0.A/)%+HWA#P
MKX=NI[K0?#]AI<]Q_K7M8%C,GUP.>E%P.0\2QL_QQ\*6?VNY%K?Z1J:7%J+A
MQ%)M,&UMF<;AO;D#/Y5YEX7T<K\"='LO"MY9PZQ<:U*[65W=/&-0$=Q.?L[%
M3\A9(V/3&4Z5]!7'AO0;KQ%;>(;K2+2;5[5#'!>O$#+$ISD*W4#D_F:SG^'W
M@>6VGM7\(Z289[G[9*GV1,/-S^\/'+?,W/N?6BX&#\'[^&\\$W,:V-[ITUIJ
M5S;W%E>W'VAK60-DQK)D[E (P<]*Q_&MC>?$#QC+X<ATVUU/1-%MW6^AN+LP
M*]U/&0F,(^3'$6;!Q@RJ>JBO3=)T;2M"TQ-,T;3K>PLXR2L%O&$0$G).!W)Y
M-0Z9X;T'1;R]O-)T>UL;B_D\VZE@B"-._/S,1U/)Y/K0!X_X.U!-=_9]\0^$
M=>;S=4\)P7.CWRQR$DO I\N0,,$@JJD'N0<UBR>%=#D^#OP=62VD/VC4M-9_
M])EY:2 [R,-P3M'3IVQS7M"_#WP,C:@T?A/2D.I9^V%;5!]IR<G?Q\W///>E
ME^'_ ()GL-/L)O"^G/:Z<Q>TA:!2ENQ[H.@/':D!Y3?PG3[?XY:9%=W3V-II
M$0MX)KAY5@!L7)"[R2!GM4$DMQ$WP#EMKZ>!)XDCFABNF6&5!9A@"N<-@C@D
M$UZZ? /@EGU"1_"VFNVI1B*\9[=2;A!C"N3U' X/I3U\!^#%.EM_PC.FYT@8
ML3]G7_1><_)Q\O//%.X'@?@W6;J;QWX(U6/6;B:PUR_U9)+RZOF\^^0"7:'@
MR4CC4QJ%P<\#A=Q%4K.XM_!OPL\6WFDW\NF!O&4UA=W+RRNMM:_:]I.T-N V
MD*64AB&SG/-?0$'PU^']O<_:H?!ND+.+G[8)/LJ%A-R=X..N2:MQ^"?"44FJ
M2)X9TT-J^[[>?LRG[5N.3OX^;)Y.>_-%P/%(=$UNUL/$.GZ/\3],OI=1-A/:
MZ8MQ*((095!3SC([@3A67KR2<5Z!\(=1%WI6OV,VEW^D7VGZHT-UI]Y=FZ6V
M?R8SMBE)):,@AATQN/&,5TL'P_\ !%MX>FT"W\*Z7#I4\@EEM([95CD<$$,0
M!R00,'V%:VE:+I.AVSVNCZ?!8PO(972% H=SU8^I.!R?2BX'R_JNN7K>+=.\
M2:;K]Y+;'QVNGR7=W?M$S1%]CVJVX)7R5_O-@GKMQS4NM0:A#HWQ5\51^*M<
M%YX=\1QC3XO[2E$40_<;@5S\RD.5PV0 . .<^_W/PS^']Y<7%Q=>#=(EEN9A
M<3.UHA,D@Z,>.O)_,TDWPR\ SVM]:S>$].:#4)!-=1^5@3N#D,V.I&31<#QC
MQO/;^*M&^,O]M:W>V][H,+065A'>/#'#"MJ'278I ?S69P=V<C"U[-\/=2L)
M? 'A?3XKR%KM=&M)&@$BEPOE*-VW.<9[T_5/AKX"UNZ2[U;PGIMW,D(MP\L
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MIR!SUK0\/^&- \*Z8=-\.Z3;Z7:%S(8K=-H9B "Q]3P.3Z47 \Y\:>'[&_\
MCOX&DF>]0W%GJ6_R;Z:(#:L.,;'&WECG;C)QG-<CIVM:A_PC7PVD;7KTWDGC
M"YL9FDO9"\UN)+O]W)N8[P/+C^]G&!7MU_X.\,ZIKUOKVH:1%<ZG:_ZBY<MO
MB_W3GC\*RS\,? #:M)JS^$M/DOI+O[<TKP[B9\'Y^>,\GV)YZ\T >1^*6/\
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M9K>\A2>(L,$JRAAD=N#7$ZM\5--TM-6OH]%U._T?1;AK74M2MEB,5K(NW?\
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M\C(SU)-;]I+<Z%9?#'Q=X3U?4-7OO$ES#:ZK#->/.EXDD3/++L+;4:-E)^4
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M6^506P"<8YK*MOB[H-]>Z;'INBZYJ%GJ5TUI:ZA:V1DMY'1]CG<#E54Y^9@
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M2#QUR, UJ^!]1TOP[XL\<MJ'B3Q0\6F6\-Y<6>O,9(].B82/^[?<Q?@-SD\
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M..21V .<5?L?BEX8U'7XM(M9+J0S7LNFQ78MV^SO<QJ6>(/_ '@ ?8X.#1J
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MUROZCTHL!I7GP]\*W_BC2O$MUI:'4M)A$%H\;M&L<8.57:I"D ] 0<5UH&%
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MD!1NC _0T >)Z=IOC#PGX^O]=O/#)UBU\0:3:V\D6D[%6RN(5<"+:[+B,J^
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MV'CFV?X>>)&\#SRW>BZ=<:7<Z<MY LBEXX@)=Q;;MW1-D D@$'!Z#'T#P?\
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MQ%X/\5^)-0\<>,(?#5S:76I>'/[!L=+EFM_.E=F8M*[+(8PH+ #YLD*?8'Z
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M$C/?KFE\*?#32/"6HP:A#J6JZK=6MF-/MI=2N?.-O!N#%$P!@$JO7)X Z47
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M#@XZ<5LI\,=$@\6:;XBT^_U+3YM.T_\ LNWMK:<+ L&#\I4J23G#9)SE1Z4
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MKT3M28!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZJ"6( '))Z"O#9O'WQ-U?Q/J+^$_#ZW6E:5K!TZ5', CECC8+,S2-*'5^20
MI&,9SS6Y^T!J=YIWP/UF2UG:!+AX+2XF4X,<$LJI(?Q5B/QH ZH?$KX?O<M;
MCQCI =7\K)NT"E^ZALX+>P.:ZX'(!KE+[PAX8U3P*_A62SA31FM1;JD6%\I
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M-._LLS?9OM)G4)YO_//G^+VZTKL#PO\ X0_Q$/#6I:./AQXN)OM4&M"Y.N6
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M# +$# YKT+P_XJ6>"TTOQ'?:1:>(IM[+9VMXLGG1AFV2QJ?F*LB[NG'/I3U
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M% !3.^:?2=NE 'Q;^VMQKW@UB!DV]R/_ !Z.BC]M12?$/@YL=;:Y_P#0HZ*
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MS$8UN[.39-"3_$C=B*RO"FB:7X/TR'08=6GOKR8M<237]QYES=.3EI&]?P&
M /2@#D?BM]NM_$W@+5KBTN;SPU8:G(VJ101-*$+1%8)710251SG..#@UPD^F
MHOAOXSWEGITZ>%M50?V1 ]K(4>Y^SL)I(HB,@-*1\P !()'2OI3Y2*3"BBX'
MSYKTNBG2?@]''I>X0WUO-.#9.WE1BVD4[QLX^<KUQSSVK @TK2+[QIJNC^*K
M/Q0VK)XD.H:?'96 %O-'O4P.L_E?*JQ[0V7  4]:^FYKBUMVC6:9(S*VQ [
M;V]!GJ:G*J!TIW ^9/#7@_2]0T'XIZEX7T5(?%"WVI)I<_D/#(D<L0""(D#
M)#XQT)[5@W%BNN>"K_4/AW9^+5\56VCBSN(KJU6T$$ D0R0?+&F^0A7V!2Q&
M2>,U]86]S:7#2K;S1R-"VR0(P)1L9P<=#@CBK.U?2BX'S_H.J>%=3^-W@K4/
M#'AZ\L;8:'=6<DATN6W6)LQ&.)V* 94*XZX!/7D9Z3XB+;V7Q<^'6N7FFO+:
MPRWL$T\5JT^QGA B4[5)&6Z?C7J<EU:0W,-M-<1QS3$B*-G :3')VC.3BK.%
M89Q^=*X'RWJ5O)/\-_&?A+5-$O)/B%<:M+/;316C%[B1IE>WFBF"X"*@09R-
MH0C@"O4_C!)=0_!Z[BN-*?697:VCF6*-W6/]XA,S(GS.JD;BHZ@8/&:],FDA
MMX'FN)%CC099W;  ]R:2*:&XMTN(7$D3J&5E.0P/((]:+@?'%];E_"/QFL6T
MO5K]]3>SN-/DDT>2'[0Q0?.D83"'J>QV]:](TO2/#X_:+2QL= ^SZ!J'A!;6
M6(:<\=M-*9@X5_E"[O+SUYXQUXKWNSO;'4;5;NPNH;NW;(66&0.AP<'!!QUJ
MCXDT*/Q'X:OM#>^N[!+R(Q&XLY/+FC]T;L:=P/(_A7X5UBU\37.DZPL3Z1X'
MN+BRTEE8,9/.Q(K'C@QPN$Z_QGTKH_B!=:=_PL;P/8ZA93W=O))=K,HM))H]
MDENT8#$*5P2<8/\ *NR\*^&;'PEX?M](L9)YECR\MQ<R&2:XD;EI'8]6)_P'
M%;^U3UZTK@>!:;X)\3>!OBQX;T723/>^ +B\EN[526D;2)1:3*8MW:)M^5).
M 1CJ>>0U33;^3PE\2/!>K^'[N7QIJVLR76DW MV8WBM*IMW2;&%$8!SE@%&>
MG-?44]]8VDL,-U=PP27#>7"DD@4R-Z*">3["K*JI^;'7FG<#Y$O]%LVF^,/]
MM>'FO-2;1K2.UN3I;/YUS]GV2/$VS[QE*Y([\^N/5](T_P")>L>'/"^H>'/&
M]MI>EKIML+FSNM),LS2*H$GS.0PSCC(KV78F3\HYHVJ!TXI7 ^:]-A\'ZUXO
M^),OB-M=M8-6OU2WEMX[ZW$\(MU0D+& 'PVX?,#GCC!J[JSZ'KOQ-^'&H:AX
M9N&L8;.^3_3=-DD81\+;-(-F%+;"P#<J3T!KZ&VKNS2[%SG%.X'R=H>F:7I?
M@KPYJ%OX?N+34+?QMY\DD6ERB:.V%S)SPF0GDLO'3!]:V=4L?!,OQ%^+=CJW
MAE;Z^NK>U6VCBTYIG9WM>0C!"%<N0<Y!SR3QD?3&U3GC-<AH/@F/0?%_B#Q*
MNM7][-KCH\]O/Y7E(47:A7:@884;>6/'7)I7 \<\):3XFT^\N/#-Q'=1^)!X
M#AT]+DJYC6Z5IB(_.QMW*'3H>.W2HM$TY=9M_A39>&="O=%U[P]=*NL[[.2W
M^SP+$5N%D<@*_F.!CD[LD^M?2S!54MMS["J-O=V&I6LKV%W%<1;FB:6"0,%8
M<$9!X(].U 'A6G^![O3/B_JG@OR[>X\%:A-'XH>%FP('4LI@*]-K3".0=@(S
MWS6-H>E6$GQ!N-!\2Z/XG?Q';^(Y=3LFB1A9RIYQ:.82XX58\*06Z+M&3Q7M
MG@OP#IW@R*\>#4-2U:\O&'FWVJ71N)V12Q1-QQA5W' ]R>IKL%CC7[J ?2BX
M'RKI.CV3^+IM!\8Z7XKG\30^)7O[86T;?9ILRDQ7 G"X"*A&[+ @*0!V'I?Q
MYOEB\)Z/9K%<33R:Q97&R"WDE(CBG5W8[%/  KV HG]T9H*JWWAFBX'@GQ:N
M)?BQX?LO W@W3;N\^TWT$UYJ<MK)#;6<*'<QWNHW/T^5<G&:X[Q=8VK:G\<=
M/M]'N)_MVGV2V@%C(1<3HC*S(=F&<2$9(ZDY'K7U9L7CY1QT]J3RTY.T<\GW
MH ^9?$'ARQT7X5> ]6\.Z/=6N@)=6]YKW]FVY-PV(-GG,C*2Y5N3D$Y^;KS6
M=?6.F>'X?"WB32=!UZ^\$1:_-J%_%=VC%G9X5 N?(V@B-7R1\HYR1U!/U'<7
M5I;&..>:.,RML17< NQ[#)Y/M20W5E<R300SQ2R0,%E17!:,XR P[''/-.X'
MS?<0>$])UGP#K6F^$-0T_P -0ZY?%?/L)9)'\^W)4B$J713*2%7 ^[D#G-9V
MO6+3^&/B?X;\2:/<W/C'4=9DN=$<VS/+<1L4%HT,@! "8((!&T;LXR:^JE1
M/NBEV*2/E'%*X'S1X%\(Z1??M :U'XHTF&]U&QTG3)A/);G8UY&H\V4-C:7W
MXYSZ^]>B?%'^SU\6_#FXN+/S+J#70ZSK"6:&+R9 _P P!VJ6,><X!P/2O4MD
M8;=M&[IGO2[%]*+@>->$5T/_ (:/\=R"SBCF:VL4MW:VV[I%67SMC$=?F7.#
MSGO7L_:FA%7&!C%.I %%%% !1110 4444 %%%% !1110 4=J** /BO\ ;7'_
M !/_  <?,Q_HUS^'S)_G\**3]MB1?[?\'*%R1;7))^K)_A10!]:^"3GX>^'"
M.G]FVW_HI:Z"N>\#'_BW7AO)R?[,MO\ T4M=#0 4444 %5IO];!_O_\ LIJS
M5:;_ %MO_O\ _LIH0T6:***!!1110 4444 %%%!H \CG\>>)6^*<OA-KG2M)
M/VORK>VU"VD#WML80WGP2[PDC!\@Q@ @ \YK)TWXJ^*;OP9\/?$4UOID;:_K
M[:+?PB"0@+YDJB2,^9\I_<]&W?>]N>PN_AG!J7B.VU+4O$%_=V=IJXUJVL9%
MC*PSA< !]N[8"2=N>O>N<C^!5C''I=I'XPUM+#2=8.L65HGDJL#EG8J/DY&Y
MSR<X&0.I- &CX>\5^./%$Z:]H]OI#>'SJ\^GR6K!_M MHY&C-QYA8 -N7/E[
M/ND<YKAM+\1>*?!^F>+-<T>WTHZ):^-+B*\BG63S94EGC1C&00J$;\\ALG/3
MH>[T_P"#MAI?BV\U2Q\1ZK#HU[>'4I]"#+]F:YSG=G&X+N ;;G!(&<@8J.?X
M1-<>%=:\/R>++PQ:SJHU>:4VT1>.7S%D(7C&TLB=0>GO3 ['QKXF'A#P1JWB
M1K<W)L83(L(./,?.%7/8$D9/.!7":UXR\;>#]=M=&UUM)U&;5]-NKC3Y[6VD
MACAN;>+S'CD4R,60KT8%3QR.>/0=<\.VOB/P=>^&=:D>XM[ZV:VGD7".P(QN
M'& V>1QC-<)JW@672?#USKFNZ_?^)+W2-'NK+3P;5=Z>:@4MM09>0[57=QQG
MIDT 8FC?$KXB1IX#UGQ)I.C-H?B_R8$6Q\P3VLTD6^-F+'#*V"2 /E'&3C)H
MWGQ6^)6F^!;CQ[>:7X?DT?2]2FL[^UB\\3R1I=- 9(R257'RG!SGD\=*U_AK
MX/DD^'O@G5O$VI7US#H5C'/;Z;<V8B^S3K%L)9=NYRGS!...#R>:R?ASX.N/
M&/@W4+76-2U.UT2?7KF]ETFXL/(:11=--&N]U#^6W[MB.O49'(I@;>I_$GQ7
M-X8\7^,O#L&ER:3X9NI8?L<Z.9;R.#F=_,# 1G&=HVM]WGK@1:;X]^(GC'Q?
MJ&G^$;?0K?2(K73]0CN=128RB"X1GP45@"_R^H'&.^1N:A\);>YD\26MEXAO
M;'0_$TWGZGI\:(=[D!9/+D/*!P &'.><$5LZ+X%_L/QUJWB:WU5VBU&V@M38
M>2BQ1)""(]I'/&X_@<=A2 \B\%_$+Q]I_@3P;K&J:I9:LOB'Q1)I,XN+5Q-$
MK33@E7$FWCR\*NW ! YQ6OXH^*WC+0].^*$EK;Z5/-X0GM!;O)'(JR13J&(8
M!S\R[ASD _I6NGP-CA\)CP_:^,-0B2SU@:SI<AAB;[!*'=R ,#?GS&SNXZ8
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MO%6E>._#^CV&FK9Z-I06]34HVD::>6$R^4 K )M3'S'/S,,=":Z7PU)J%O\
M ;0Y](DACO8M MVA:9"R!A IY4$']:S-8^%%W<>(M6U+PYXLN-!M=<LUL]3M
M%MDG6?8FQ74M]QMI*D\Y&/2NQT'PTNC^!++PK-?27L=K8K8^>RA&=539GCH<
M4 >8^$?'7BK_ (5U\/+.XN+*_P#$7BM?W-S.'\N*-(C+))(-V78 8P"H)(Z"
MNT\"^+M4UC7?$WA;Q!:V\.L>'KB-));7=Y-S#*F^*10Q)4D9!7)P1U-<Y9_!
M^^M?"OAS35\72/J7A>Y$VD7QLT401!=GDNBD&163ACN!/48KL_"OA-M!U#6-
M8O=0_M#6-9ECEN[A8O*3$<8C1$3)VJ .Y)R3DF@#C?%OQ)U;1O'USX9M9=*L
M)8X[>2TCU3<AU,2$A_)D+*BLFW&TY))[5EZA\5_$VG> O'6NG3=,EO/"NM?V
M>T69!'<1$Q -R<JW[WIDCCOG-=)XR^&FI>,I]3L[SQ+&NA:C)!(UG+8":2V,
M87)AD+X0L5R24/4^M8GB/X)WVN)XLT^Q\8SZ7HWB.Y2]FM%M$E*W $89M['<
M5/E@[1C!Z''! -37/'OBF;Q#XCT7P)HUGJESX:MK>>\@NI&5[EYLL(8L<*0B
MYW'(RP&.M>>3ZMXHT#XT_$?7_"^@Z:+B+0['4;Z*^E9 -L<C,HV*=SG!&20/
ME[UW^I_"S6_^$S;Q/X<\=76A7M]9QV6K,MI%+]L6-<+(H;A)!S\V&P,4Q?A+
MJ%OJOBNZL?%$<4.O:1#I"QSV)E>!(X_+5RWF .Q#/G@9)'H00#OO#.N?\)1X
M&T?Q)#:B$ZI8Q7BP,V0GF1AMI./?&<5X9X?\>7WA'X=Z;=>&/ >EVKZAXNET
M:XL8;R0()FE*%U9EYR5(R<!1MXQP/;/"'AZ[\,> M(\,R7\=W-IEFEHER(?+
M#!%VJ2FX]@,\\\],UYG#\$]=C\-Z?HS>,[8_8O$1\1B7^RV^>7=O$9'G\+N9
MNG/(],D ='\8]:TVS\7V?B;0;-=;\/W=I900V%PSPWDET!Y(#,H*]1GCIGCM
M7">)/[6TGQG\5=0\1>&M&OY&\,VL]U:VTLD,%U'OD!9V^]O^7&!C(0<BO1-3
M^"1US4_&EUJGB+">))K6YB-M:[);&:V $+AB[!NAW @9SU%0ZE\&_%&K2Z_=
MZIX^BNKS7-'31;AO[+5$6(,Q+!1)][#'!)X))] 'H!:M_&VL>'=:^'6AMH5E
M9^%=>L8H8[H.X-I,+?<L')(YP N3S@]367JGBB;6_$G@._U3P[IM[97?B.X@
MTJ\\^4/"B"0),$'#;PA().,$''/'8ZW\,X?$GPHL_ ^KZHPEM$@$5_:1F)T>
M$C:Z@LQ!VC!^;N:7Q!\.)-0NO!2Z+J%OI.G^%;I;F&U^RF3S J; @(==HVEA
MWY(/;!0'E/QH\1:AXZ^#GCN;3M+TZ30M#O19":Z+&=Y8W3S98\<*%+;1G)8;
MNG /H,GCSQ%9ZGXYTE-.LG?PSIMOJ-HSNX%S&Z.Q5L X(\LC(XY'%96N? _5
M+RQ\4Z'H'C4Z1X=\23F[N+&2P$[0S,5,A1RX(5MOW<<=C6EJ_P )];OM<U34
M=/\ &KV/]M:7'INIYLED:8QJRK(F6 C.'.1@@\]*>@&%XB^-.N:9H&GZQ#I6
MFVUM/X=CUPO=SL6N9&&3;0JGS9 R2Y! !&?6IM1>PU']HOX7^(([013ZCH=Y
M(69<N5\M652>Y&]OS..M0O\  75UM&MK3QT88[GP[%X>NR^GJ[/%&I53&=_[
ML$'D<]SG)R.ET[X8ZU:>*/!FN77BN.[;PS826/EG3]IN%<!2<B3Y<!5 X/3)
MSFD!J_$GQM-X)L=(N!]FM[>_OEM9M0O59K>Q4HS;Y-O."5"CD#+#)K,L_'FO
MZE<^'-!LK#3TUS4]/EU"[?[09K>UAC8(&4K@R;V9<8(XR2>*ZCQ5H.N:R]A)
MI.L6]A]E:0S075L;B"[1D*['0.G SGJ:XC3/@W+X9B\+W/AC75MM5T*"XM6D
MNK<RP7,,SF1XS&'4JH<Y7#' &#FF@,#5O%,7C1/!5YJ.FQV.N:)XVCTNZCR6
M"2JDF_RSC.U@%89QP/;-;6K?%;7(_$,R:-X;GU;3[/5AID\5O97,DKJ"%DF6
M54,0"L3\A.<*?F&<5H2?"J_&GZ7':^(H8[VWU]O$5Y</9%UN;@[AM5/,&Q &
MP.6/RCGKEH^&'B"S\6ZM<Z1XXET_PYK-V;Z]TM;17<RMM\SRY2<QA\<\'&3C
MDY!H!SFF7>L>%A\7]8\'Z/:WMY::V+HV#%E\X?987DV[>=QRS#U.1WKO?#7C
M*?Q-J^D+IIL[K3;G1TU*ZN8B28G=ML:+]2LO7D>61WK&E5OA/'XN\8^(+J?6
M++6-0CN1;:=I[&6 E5A /SG<-JISQSGU JW\&_!\7A7P;<S?V=+ILNKWLU_]
MCF.7M(G<F*'VVK@X[%FH8!XPNH[;XN_#V";0K2\>YFO$MK^25A+:.+=F?8@&
MT[E4#))[\5R6J_%KQU86GBG5D\-:5_9GA;5OL=X[7CEYXB8L",;1A\29); '
M P>:]$\2^$-2USQKX5\16NLQ6D6@32RFW:U\QKCS$,;#?O&WY2>QY_*N2U#X
M0ZOJ'AOQEHC>+(HT\4ZB-0DD^P$_9CE,J!YOS9$:#/'?KTH0'<^.(;74?AKX
MAANK=;BVDTV??&RAMP\LGZ9]/>O*? _CGQ9I47PT\-WFBZ='I/B+2/*L66Z<
MSH\%LK[I/E  8=ADCU[5[!J6CWVI^"KW09=0C2[N[1[5[H0?*-R[2P3=Z'IN
MZUP?_"J=967P)-#XKA23P; \-N3I^X3[HA%EAYO'R#H#UYXZ4D!S>B>/'\,_
M!#0=8TW1]-T*VN=7N+.Y*1S36NGIY\V^9@/F(+(!U !?L.*]9\$:QJ&O>$;7
M5-3>PDN)6E'FZ=+YEO*BR,J.AR>&4*V,Y&<'I7(:)\,_$?A_P=I>A6'C1#-8
MZC->^:^G_NYXY1)OADC\SYANE9@<\8''&:ZKP+X/M_ _A1-"M9A./.FN'98_
M+3?+(SL$0$A%!; 4= .]# \]U+XJ^(8/#>I^/;*RL)/"VF:J=/FMBK&Z>))A
M#).'W;1ACN"[3E1U&:U=)\7_ !$U;XEZIHMKH>DG0=*U".VNKO[2_FF-[=9E
M91@ GYAG_> &<$E+CX0SM'JNB6WB-HO"FK:B-2N=,:VW2;C())(TEW#;&[J"
M1M) ) /-=5X<\+7NA>*?$FL3:HEU%K=RER(%M_+\@I$L2KG<=WR(G8<Y/?%
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MRWQU*/0Q#&$2<MNQYN-YC# '8,=.2:RH_@AJ,/@V/15\7A;ZT\0?\)#9WRV
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M #X>^'.<_P#$MMN3_P!<EKH:; ****0!4$O^L@_W_P#V4U/5>4_O8/\ ?_\
M930-%BBBB@04444 %%%% !112-TXH R;KQ'H%CJL&DWFMV-O?W'^JMI;A5D?
MZ*3D]#7$>+OB$]GXRM/!>@:QHEIK$UK+.7U20E/-#1K%;[592'D,F0>P7@-F
MO/M=CM1I/Q0\,>)=-EG\4:O?RS:+^Y+RWB-&BVODO@_ZMA@\_)@DX!KH(=2T
M>P^/GAK3M=N8)-7C\-FTN)7A)\R[:: J-V,;CM<C^E,#O=;\<Z;X/\-:3?\
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M@'GJQ;Y1WVMZ5L?VEIXU#^SS?6XO-N[R/,&_'KMZUY+XFFT?2/VDO#E]J]J
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MYL=Z\N\.ZCX7MM0%K]IT?Q#I,VBZC+!K$7[F^LD92SQWRY*L2S *S?Q<]Z+
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M(+32<JAD20LJ.Q.)IECR2V%XSP*^GQTH ****0!1110 4444 %%%% !1110
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M#'7C6\+_ !'UC6/&=MX=USPI_8IO]+_M6R?[8)F>,.%97 4!6&X' +<$=\@
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M=CX6N;O3-2OY+%+FW>1Y(55]BS.@BV^6Q!.0Y('7N!I^%OBQ/XH\13V%IHL
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MO8=!^IKQ>X^)7C;3_$?Q'D;PS;:KIWA9;8QVT%VR2%6B,CL"8CN)4@D' &W
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MKUZXQQTKQ%?'.N>!?'GQ)^R^%];\4:=97<%S-*+O<+*$VR.P3S&);EG;8O
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M:QMWCA;?&C1J0A]0,<'Z5Y'X7U'7+S]I/41J^GW&E[_#23+:&]-Q#S< !U&
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M>:##+AF!VDG! 4'GI7KV]2P'&:QO%&IZGHOAF\U+1=$DUS4(%!AL(YEB:<Y
MQN;@8!)_"BX'FVG?#+Q;I]Q\/+Y=:TEKOPQ8RZ;=9MI-DT+B-04&\?,!&.3@
M$DG Z4[PM\-?&_A*>X\/:7XHT^/P:U\UW @M7-[!&TOF-;JV[8%SD;B"<$X
M.,>L6]PSVL$D\7DS2("T9;)0XR1GOBK6[C- '.>,_"]OXR\#ZOX7NY3%'J-L
MT/F[=QC8_=;'?! .,]JXC_A$-?>?0M<\<:AI03PK9SB%K/>!-(\7EF:0R8V
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M*VT9([4P/$/%OPJ\6^,+#7KVZN-(M-8U@6-OY:RR20VT%M)YHPVP%V9R?X5
M&.I%>T6HN?L47VJ*)+@H/,6)BR!L<@$@$C/J!7DTOQL\OP:GB,>%YS_Q4)\/
MRVYNDW0N)-A<G&#S_",]N<<UZ^)EP2>U 'DFH?#_ ,9R7_Q(M=/NM'_LKQ9"
M3"TYD$L<K6RP-NP"-HV[NY/3C.1G77PG\2:I+X(AU&XTR.TT'1;K1[PQ2R%Y
MA/ ("Z Q@# 7< >YQ[U[@K!AQTI-ZYZB@#R[P'X6^)>BKIVF>*O$6E7>EZ0O
MEP26,+K<7BA2B+,6^50%(.%Y+*ISP=WJ8Z4W>OK3NHI %%%% !1110 4444
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M[^66.,?;PI8(6P#M8C/7D^IKZOL? W@S34O%T[PKI5HM]&8;E8;.-!,AZJP
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MB.02K BBX'SM\5!]HO?[2\^+6]/TWPVDE_I9NFAN+2-BY-[;,?D:0;<'J?E
M[XKZ&M)H=3\/PW(66."YMU?;)\CJK*#SCE3@_A6;)X%\%7$MO+-X3TF62UC2
M&%FLXR8D1MRHIQPH/('2N@:WADMWMY(U:)U*LA&00>"* /D#P]IMOI_@3P/X
MNM=4O!K'_"9FQ626^DE#0-<R(8]I;;@KR3C)_&I_!]S;ZUJVA^(-0^(EMIOB
MFUUJ1+S38;5S?7+M,RFV?][S&548&S"@#\?I-?AUX"CLTLU\&:*+9)#,L/V&
M+8KG&6 VX!X'/M5Z'PAX5M=??Q!;^'--BU=\AKY+5%F.>N7 SS1<#YN\80:7
M<?"3XH17Q-S'9>,H=AN9RYB4R6BGYV)P-K./;)KH=9\/^$_$W[0ND:,LBS:%
M_P (C*L<=E=E(Y +@K@LC98#D]<9'K7M2^!O!L<&HP)X5TI8M3.;Q!:1XN3G
M/SC'S<\\U'_P@?@G[8EX?">D>?'!]F23[''N6+;MV X^[MXQTQQ1<#Y*\.:I
M_;&C>'?#7BOQE8Z;I;Z)<+8W&KPF>*1UNYXR5;S$42+&L6UF/ '&,\]W#X3T
MWQAXT\"Z%JWBC6-;L;GPY=R27BSRV;7H66-8Y#&&! (;.3]_ )SUKW67X<>
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M<#U/6LWXB3>--#^#?B.?QMK>DR3:A'!IL0M+*0VMLLCA))9-S%B2'/(X7:"
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ML.),?*&[\T :OB[XZZ%X/U74K*\L6N/[(\@:@8[J%9(VD ;;'&S!I2JLI;'
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MG'-K0O"'C.R^,X\4:HEA/8/H4>ERSQ2LK^:K^866+9A4W$J!NZ ')/%<U?\
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M-$(0P!(#F-,GJ,G@9QZ]X1\/Q>%_"5AH<3-*]NF9IG)+33,=TDA/<LY9C]:
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M[3)90NV4A61@"P4=R!R30P.:USXT7.C:IXILH_A_K5ZOAAU:_G22%46 IO\
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M; L0.^%=V$CV_-U)Q] !NZ/\7M/OO$,NEZSH.H^'H?[+;6+>[OU4)<6R[=[
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M:CP)KOBJ]\?:!#=Z]JEU8>(=+U"X-T[I]GF=)D\N:VB8%HU"N -PP00<=:+
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MI%)4L,@=<>@YSBO"]:\0>+8?AMXXN;3QEJ45]I_C0:?;W6X,T<!DA3801C:
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MA74KRQB31?$$$%UJ TMKJXL#'%;7)<H(Y&)X;/89QD9P>*+ =EK?@'PAXBU
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MDGHW&,"M_4OBOI>C65JU]H^I-?R67]H3V,:Q>=;0 XWN#)CG#852S':>.*+
M;+_#WPC)8:98_P!D^7#I43067DS21-!&P 9%96#;2 .,XX%=!INF6.CZ7;Z9
MIMK':6=L@CAAB4*L:CH !7G-]\</"-IJEIIL%IK.H375O;W:/:Z>[IY,S )(
M3Q\O(R1QDXZ\5IM\5O#:>)H-&:*[$-Q>MIL6H^6/LKW0!S"'SG.0RYQC<",T
M :L7P_\ "$.L-JD>AQ).US]M(#-Y1GX/G>5G9YF0#NVYSSG-6H?".@V_BR;Q
M/%9LNK3)Y<ESYSY=>RD;L8&>!C R?6N6NOBYI4-]+:6_A_6[Y1<7-G#<VUNK
M0W$\".TL:G<""/+<#<!DJ<9Q5KX5>.;OX@^ +/Q+>Z3+ISW)<J& \MUW,!L.
M26   )('.<4 =!XB\(:#XJ^PKKMC]K6QF%Q /,=/+D'1QM(^8=CVY]:HM\.O
M!LESK5Q-H<-PVN +J*S,TB7('W=RDXX[''':LK4OBUX6TV_N8YA>2Z=8W2V5
MYJL,&^TM9R<>6[@\$' )P0I(!(-+'\6O#-QX\D\&00:G+J$5U':RLME)Y4;.
MC.I+8X4A>IX/;(R0 ;VB>#?#OAZ[-[I6F^5=>2MMY\DCRR"(<B,.Y)"@\[<X
MS7%?$CPAKWBCXC^![RUT9;G1]'GEEN[@7_V>0"1"A"A<-\O#9!&>GO71^,_B
M7X=\"WEE9ZVNH//>QRR0):VCS>9Y:[F4$#&[';\>!S6;JWQA\)Z1"MQ-%J$U
MJMM#=W4\%MO6QCE *&;G*G!!(P2 02,<T :LGPP\$306$,FA@+871OH#'/(A
M6X/64E6!9_\ :;)]ZKZK\)/A[K>IZCJ.J>&X9[G4BC73"61!*RXVN0K !A@?
M, #UYY-0ZQ\6/"^BZE/:3+?74%HUNEY>VT/F6]H9\>5YC9Z$%3D X# GK4VN
M?%#P_H/B"31;J"_GE@DMXKF:VMC)%;23MB%)&'0MQVP,C)&10!/K7PN\">(+
MNVO-6\-VUS<VT0MTE)96:(=(W*D;U]FR*N-X%\,-K?\ ;']EB.^^RBR\V&1X
MOW(#*JX4@9 9@#C(!X(K(U;XK^$]%U&XBOGO!96ER+.ZU-+5VM+:8X^1Y0,
MY(!QD D X-4]0^-G@33=3U/3[BZO&FTJ9(;PQV4K+ 'QB1F"X$?*_-T.X8S0
M!=E^$7P]G\/66@3>'$?3]/F:XLT\^7?;.QR3&^[<F3S@$"K)^%_@4#3EC\/Q
M0C3U>.#R9'CPKG<ZMM(WACR0V<GDU4U[XL>%?#NMOI=[]NE$$D,-U=6]J\D%
MF\N#&)7 ^7<&7U^\/6N8\3?$9O!/QMGMM;U+4)]#ET%;J&PM;7SBD_GE690B
M[B-J$DL2!STSBBP'9VOPP\%V(T);/27@&@NSZ>([J91 S##'&_G(XYSQQTK;
M\0^&]%\5:,^D:]9"]LV=)-FYD(=6#*P92""" <@BN!D\7S:O\4/ -]X?U^6X
M\,Z[I]],UN$41R&)4*ORN\'YR"">,#CK6]%\3_"\OB*TT=9;M#>W4EC;7CVK
MBVGN$^]&DN-I;(8>A*, >*+ /MOAAX+M/[5\O1O-_M:!;:]%Q/+,+E NT;P[
M')P!\WWCZTND_#+P;H>KV>L:;ILZ7]E$8+>:6]GE,<9 &P;W(V\#"]!VQ6SX
MA\2:9X8TY+S49)<2R+###!$TLL\AZ(B+RQP"<#L">@KE&^,O@9=!BUW[;=_8
M&O#I\LGV.7_1;@,%\N8;<Q')'WL"C4#JK3POHMGXCU3Q!;:;!%J>JK$EW<JO
MS3K&"%#?0''O@9Z"N<TWX1> ])NK*ZTW1Y8)['S%MY!>S[H4< %%._A1@87H
MIY !YIFI?&'P1HZ:M-J5W=VUMI5V+&XN6LI?*\X_P*X7:Q]<'C(SUJ32_BYX
M%U:QU:\M]6:--)*_:DG@DBD57.$8(RAF5CPI .21ZT 31?"SP9!I>EZ9#IUS
M'9Z5=F^LXEO[C$,Y8L7'SY)R3UZ9..IRRZ^$_@>\FGEFTB59)K_^TR\5[/&4
MN>09$VN-A.XYVXSWZ"IK7XF^$;FRUJZEOY+ Z&H>_@O8'@F@5EW*Q1@&(8=,
M YZ=:YGQ-\<- T;PKJ^H:?INIW>I:<T,;V$MC+#)&9O]4[AE!5#_ 'NYXZFC
M4"AXZ^$=K%X(OM.\!>'K5YK_ %&VOK^RENY(Q>+&^YE1RQ\IB0.1COSG%2>!
M?!.KMJ]U-KGA9M T26SDM9=*N];EU5;QG93N978H@4*PXY._G&,5TNK?%SPA
MH;D:D=0B,,,5Q='^SYC]ABD)"//\O[L$@]>>.E7?$'Q*\+^&M8AT;5+BZ&H3
MVYNH8(+.6=ID! .S8IW'GH,G&3VHU G\,_#SP?X,G>?P[HZVDC(T88RO*4C)
M#%$WL=B9 .T8&0*N:_X/\/\ BB[TR\UJQ,]QI<QFM)4E>-HF(P>5()! P5.0
M>XK'D^*?A&/P_I6M1WLUU#JL#W-M%;6\DLS1(,R.44$J$Z-GH>.I I+7XJ^"
M[[6/#^EV6H2W$OB*$SZ;)';2&*X502V'VX!7!RIP1W H LW'PU\'W&K7FI-I
M;J]]*D]U;QW$B6]S*IR'DA5A&[<#)93G SG%=7<6\=S:M:S1K)#(ACD5NC*1
M@BL?P_XITOQ/]N;2_/(L;N2RF,L#Q@2QG#@%@ P!XR,C.:Z"D!P5K\*/!=GI
MVD:;;V-U'::/<F[LXQ?S_NI,8!SOR<+\HST' IMY\(_ FH6%_87VCO<0:A>?
MVC,)+J9B+CO*C;\QL<#.TC( '05W]%,#$\.^&=%\*Z2-*T&R%K:^8TI4NSLS
MMU9F8EF)]235'Q!X'\.^);^WU+4[.5-1M5*07UI<26T\:D@E1)&RMMR.A..O
MK74T4@.2D^'_ (2FT&_T6[T=+ZTU$*MV;MVFDN-IRN^1B7)!Y'/!Z8JK_P *
MP\'FQO;2;3I[A+ZT%A.\U[-)(]N#GRM[.6"?[((![UV]% 'C_P 2/ ][=>#O
M"WA7POH,U[IVFZM:7,J_;5C,-O"V2H=W#%L<+@\>HP*[B+P/X8_L_6+.73!=
M1:R E^;J1YWN %V@,SDM@#H,\9XQ73X%  '08H XQ?AIX073[FR;3YWCNK1;
M&5GO9VD-NIR(@Y<LJ>J@@'OFEO?AMX/U+1](TF^T?S[;1O\ CQ#7$@> ;=NT
M.&W$;>,$D8 ':NSHH X%?A)X!31KG1X?#T<-G<W@OY(XII$_? DA@0V5QDX
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MG)) )R1FNP[444 %%%% !1110 4444 %%%% !1110 4'I1WH[4 ?$/[9Y/\
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M1'1SMVYLH>/3]V*V*R/#6W_A%-(VG*_8X<<8_@%:]2 4444 %5Y/];!_O_\
MLIJQ5>3_ %L'^_\ ^RF@:+%%%% @HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH[T4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %&*** "BBB@ HYHHH 2EHHH **** "BBB@ HH[T4 %
M%%% !1110 F.:1LTZD;I0!\0?MGM_P 5OX77<I(L).#U'[RBF_MH/CQWX87;
MG&G.<X]9#_A15 ?9GAT?\4MI1_Z=(>/^ "M:LW0#N\-:6P[VL7_H K2J0"BB
MB@ JO)_K8/\ ?_\ 935BJTO^MM_]_P#]E- T6:***!!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** #\:*** "BBB@ H[T44 %%%% !1
M2'VZTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4=Z** "BBB@ I&.!TS2TG- 'P_^V<__ !<#PR.F--;_
M -&G_"BD_;2W?\)WX8P,C^SGYS_TT-% 'V?X?_Y%G2_3[+%_Z *TZS- &/#6
ME\8/V6+_ - %:= !1110 56G_P!=;_\ 73_V4U9JM-S-!_O_ /LIIH:+-%%%
M(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:+HLT6GV,>H)<W5S)&75R56,X4X8E6YZ"@#U2%9EA1;AEDE &YD4JI/<@$G
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MQRVT]AUS0!ZO17E/A_XE:BUMXUU/Q;#I^GZ5X5O);*26V9V>8QJKE\-T!#*
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M?[__ +*:L57D_P!;!_O_ /LIH&BQ1110(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **.]% !2'I2T'I0!\+?MG,O_"Q_#RY4$:8>#U_UKT5)^V<(S\2?#I_B
M_LLY^GFMC^M% 'VOI*_\26R_ZX)_Z"*O50T<,-#L0S[V$$>6]?E'-7Z "BBB
M@ JM/_K;?_KI_P"RFK-5YO\ 6V_^_P#^RFA;C18HHHH$%%%% !1110 4444
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M$_Q"\?7_ ('MM#N+?P[_ &H-7OXM-"FZ$+132?<S\K9'!R1TXZUR>BGPK/\
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M#+JTSV]O_P )/:V\TRW#0A(7#;\D$8^Z/FZCKD<T >X^:F =V1ZBD\V/ .[
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MK6U+-,PM9?M#8C<3-&I"CG=E,KCH<BEJ!;NOA?XWOA&M]\6;RZ5#N"S:-9N
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MY# V^,L@.PXQD>AQD?C2W$%K>V\EO<PQ7,+##QR*&5OJ#Q7F>G_%LZAHLO\
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M.BKM2 4444 %5I?];!_O_P#LIJS5>3_6P?[_ /[*:!HL4444""BBB@ HHHH
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M-;,[;.<N 1NP 0>=P.,4:@9O_"M-8L=7\*>(M%URVAU_1M,71[N6>U9H+ZV
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M;:@+8SRQ!YP*]]_X5]X)_M!=0_X1C3A=+;?8UE$"[A#MV>7G^[MXQ4$GPR\
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M/\P,S+C!."/[JYQU*J3D@47 \M\3:CK/PYUKQY'I'B#4]0*^&8M5C;49_/\
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MI\/_  T\,W^MA8=:L[UY[N>\DM6O989&2-#+&-V< -@8+$#/O]%WG@/PM?\
MB"3Q#=:6'U66!K5KH2R*YB8$%.&'&">/7GKS6?-\*/ $WA*/PK-X9MI-&AE,
MT5JS.1$YZLA+94G)Z$=3ZT7 \870_%E]XJ\!^#M2^)FHW#W-CJ=I?7>DW6W<
ML.W9RP.91N 9S\V5[')J#4X_&7B[Q9XQT[3_ !HND77A&XA@LIKC49H'MXD1
M7,SQH-DOF?-N+@CC QW]XM_ASX+M;_2+^U\/V\%SHT7DV#1;D%NF22% ..23
MDXR<\TW7/AGX%\2:[%KNN>%[&_U&( ">6/)<#H''1\=MP..U%P/#M9U[5_\
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M/#\'EG[)"%D>.,())#R[[1P-S%C^-=%2 **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" >M+110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2&EH/2@#X1_;)^7XNZ(<]=&3_P!'RT4W]LM\?%O1%VXQHR'/KF>;_"BJ ^Z[
M<8MX^<_**EJ* Y@3_=%2U(!1110 56N,^;;X_P">G_LIJS5>3_6P?[__ +*:
M:&BQ1112$%%%% !1110 4444 %%%% !1110 4444 !.*:KJP!!%>??& ^*5^
M&]W)X1CNIKV.:*2>.RD\NXDM@X,RQ-U#E00,<]<<UQ7@?Q=X(N=1O?&'AOQ9
M>QZ#I.D7!U31=0NIY)K.16C?S?*D+'A5D4D$C. .2<L#WBBO)=*^/'@W4-6O
M=/N'>S-KISZKYIFAG0P*,L&,3MLD']P\U/>?%:ZATG4IU\$ZQ;74&COK-K'>
M"-$GB7KN8,1&PX)1OFP1WXHL!ZB6"]>*=7CS>*$U2'X9:AXJTS6;+4M1N5-N
M+2XC2V>9K<MF4+)RA&YE7D_+SZ'5O_BYH^GVMYK$FDZC+X9LKTV%SK48C,$4
M@?RV;;NWL@<[2P4\Y[4 >F45Y=K'QBTW2]8\0Z9%X8US4'\/01W=[-;1Q&);
M=T+B4,9!D;5)QU.#@'!KM[N>XUSPC+<>';]+>>_M"]E=NFY8RZ920J>N,@XI
M ;&X%L TZO%M+T;6/"7QMT/1]%\4ZSK5A?:=<W.L6^K7C7/E!2JPS)G[A9R5
MP."%; XKV@'B@!: <BO/OBE?:\?"+^'?"-P(/$NM[K:RDWE/(4+NDEW#D;5&
M ?[S)ZU%X1^(46H_!&S\=7T-Q<R6]D7OXH$!D$L65F 4D#AE8_2F!Z-17E%K
M\:])OI]-AM?"OB*2?5K'^T--C%M'F\C !.W]YA<;AR^T>A.1F:'XU^%;SPYI
M&L6<-TTFJ//'%9S-#!*C0G$N\R2*B[3@?>YW#&><%@/4:*\JM_C?X7O]+T+4
M-+L=5U!=9NI;&**VA1W2>-2S1M\^,X&002"#G.*TK+XJZ)=>'[S4IM-U*TN[
M34!I,FFS1+]I:[.-L2A6*DG<"#NQC))&#18#T+<#T(I:\)T?QM=:3\0_B1KF
MM:?KUI9:5I-E>2:7<RK,\/$I=H@LC1A2H!.#U#=,8KI'^,FDQZN-(_X1KQ&]
M]-:_;;.%+)2;R'NR?/A0/5]H],Y%%@/4J*\YF^+?AD:1HU]8QW>H2:O9F_M[
M6'RTD\D ;F;S751@L!C=DGH#@XJK\:/#-S%X??3=-UG4V\06LMW8):6H<RB/
MB1#E@ RG@@\#UHL!ZA17C^I_&177PH_A_P .ZG=)KFIOI\GF+%&\#Q;Q+"0\
M@Q("G^[@'G.!713_ !,TR+Q!+I*Z3JL_V>_@TRYNXHXVAMKB;9L1_GW8_>)E
M@I'.,T@.^HK@OBCXXN/A_P"!Y-<MM*FU&=YH[>(+MV1.[!59\D';D]L\XZ#D
M6[_QU:Z?J%OI2Z/JE]JLEK]MELK2.-Y+6'.-\GSA1DY  ))P< XH [$D <\4
M;AC.16)X?\0Z5XN\,6>N:-<&>QO8]\;[2K#D@@@\@@@CZBOGZ/Q=:V.@>/FU
M;XN76D:YHVKWL.FQ3W\;/Y<8'E+Y#@^8"V1T)/:@#Z=!S1D#J:\LT?XFR:;X
M$\&ZCXVTN]L]3\0>5 5A@W(D[D!0YSA-V00#TY';%87Q6\:WDFBC_A&M2U#3
M;G2/$UAI]S*B[$G+LI:,-SN&UU) QZ'TIV ]PHK@;OXI>&;'7)=+F^VE(+^+
M2Y[U;<_9X+J3&R)G]3N7D @9&2,U/<?$31;36==TB:"_-[H5FM]=Q1VY8F)N
MC)@Y?H>GH<]J+ =O17GX^*?A?^Q]%U?S+M[#6+6:]AN5MFV)#$NZ1Y.Z  ]_
MYXSK^'/&>F^)KV>SL[6_MI8((KHK=VYB#Q2%@CJ>A!V-WR,<@&@#J:0G%9'B
M&UU>^\.7UGH.HKIFIS1E+>[>,2"%C_%M/!QZ5Y2O_"9W'QPU/P/'\0-6BL8/
M#\>H13""U+K.TICR<Q8(P,XI >W9%%>"+XZU;P'\4;K2_''B"]U:"+PO:7LL
M=M9[U$ZR-'/*B1KD*=A8[NF[L,"O2=1^(7AS3["UO%FGO4O+,W\*V-N]PQ@"
M@^:0@.%P1UQGH,T[ =E16-I6L:;XH\-V^L:'J'GV-]#YD%S%UP>XW#@CT(X(
MY%?.(^(WC;2_@:GQ$E^(D5WK5O>R0MI-Y;V_E7BK<M$(U6-%D5RJ[LANQ[<A
M ?4]%<9<>/-+TO3-';6(;F'5=4MQ<1Z7;V\EQ<CY0TG[M%+87."<?J<567XJ
M>#)=,TR^L]0GOAJC3+:PVEI+--(8?]:/+52R[>^0,9%,#O**\^OOC!\/],T?
M1M7OM>$5EK2.]E(89/WH098?=X(Z8.#GC&:P?'OQ4T7_ (5KJE]X6UZ[BU%M
M)&HVUS:6#S_9T<$Q-*"A6,,01\^.,GMD%@/7Z*YWP;>75_X T#4+Z1Y;JXTZ
MWFED<89W:)2Q/3G)-8EO\4O!UUJ]K8Q:JYCOKEK.TNS;2"UN)U)!C2<CRV;(
M.,'D@@9Q2 [W(I,@C(Y%>'ZGXD\1>,?BAX@\(^']=U;P[/HT-K]DE737>!YR
M7>0S[D_U9555<L <DC-=SXD\?67AKQ5X>\.7%C?SSZQ(ZK);VDLJQJL;,3\J
MG)W!1CL&W'@4[ =Q17A^B_%C3_#GB7QEI?CGQ%([66M+;VS&U)%O \<93>8D
MPB[F8;GZG/O7=:Y\3/"'ANZFM]7U)XA;F(7$T=O++#:^80$\V15*QYR/O$<$
M'H:+ =M2$C'6N>\6^*+'PCX)U3Q5J&Y[33[=IV5.LG]U1[DD#\:X3^S_ (OW
MO@&?7K?Q;;P^(YX3=0:6MC&;6(%<K!EAO+]MY;&?X<4 >N YI:X_5O'6A^&U
MAM];N95OA:_:IH;:VDN'BC! :1UB5MJ[CC)XSG&<&LO6OC+\.M!M+&ZU+Q+'
M%!J%L;RUE6&1UGB]5*J03[=1W%%@/1**\RU#XY?#72[JZM;SQ%LN+18WFC6U
MF=D1U#*Y"H?EPR_-TY'/-;&K?$KPKI+1>;=7%WOM!?M]AM9+D16YSMF<H"%0
MX.">N#BBP':T5YUKGQD^'OATVQU77O*2ZLQ?P,EM+(LL)QAU*J01\P/TYJW:
M_%'PE?:['H]O>7'FS7CZ?#.UI(();A 2\2R8VEAM;C/8T6 [K-%>.ZA\4;+6
M=!\?6L-WJ/AW^PO,MQJK:?(X@81IE]N#DJS_ '>#@9P.M;UM\1-"TGPYX?CO
MM6O-:OK[3([U9;33Y));B+8";AHHU/EJ>3@@=P.E%@/1**X.[^+/@.SL-#U"
M;7D-GK@<V,Z0R.DQ49*Y"G#=MIPV>,9XK9\+>,O#_C/39[[P_?&YCMYFMYE>
M-HI(91U1D<!E/(ZBD!T>:*\TL_$,<?QJ\264_C0/9:?I4<TVC26I06ASDS^:
M0 5VXX!/4YZ5N^&_B#X7\6:@MCHUW.]P]HM]&D]K+!YMNQPLJ%U&Y2>XI@==
M17*^(O'/AWPM<BWU:YG\XP/=&*VM9;ATA7[TC+&K%5&?O' Z^AJI:_$SP9>:
MS;Z5;ZQON;FQ_M* ^3((Y[?;N,B2%=K8'4 Y'0T@.U[4?I7G=Y\8OA_9:?I5
M]>ZXUM#JT33V1FM9E:=%SE@NS/;CCG(QU%1?\+O^&?\ 8MKK+>)5CL;JX>T1
MY+:92)EZQLI3*M[$"F!Z317GC?&+P%_8=OK<.K3SV$]NUV)(;&XD*0JQ0R2*
ML9,:[E898#[I/0&K>K_%'P7HAA%[JCD2VT=YOM[6:=(X7.$D=HT8(K'."V,X
MHL!W%&17&S?$3PJOB0^'OM\K7ZW*6;>7:RO'',Z[EC:0+L5B,<$]Q7*>&_B%
M#H7AW5+SQUKTDB)XCN])M[IK4_.5E*QIB)..!C)[]Z+ >NT5B0^)-+N/%$_A
MN&=WU*WMTNI8Q"^U8W)"G?MV\D'C.>#Z5E>(_B-X1\*WK6>MZH8)TM_M<J1P
M2S&&'=M\Q]BG8N[C+8Z'TI =A17,#QKX?;77T.._,FHI9?VCY"PR$M;Y \Q2
M%PP^8< DUS6H?&/PG:77A9;*2YU"W\1M*;>X@M9641QHY9ON9)W(%V]1G)P!
M0!Z9D'IS17C&D_%33M \<^+] \<^*H56VU6*#3Q) $\N*2&)P&*C@!I,;F[]
MZ[;6OB+X1\.ZC+8:MJX@FA1))BL3R+;JYPK2LJE8P>Q8@'K3L!V-%>?ZE\7/
MA[I>N_V#?>*+6#5/-2$6_P Q;>^=HX!ZX[=,C.,UF:%\0M)L;77M2U[QO:ZM
M8C6Y;*T-O;$&T^0.+8[5R[J Q+#/'?BBP'J=%<19_$_P/J%IJ5U:^((GCTQD
MCNM\;HT3N<(N&4$L3P%&23CUJ>'XB>#Y_#M[KZZY;KI]A*8;J20E# X(&UE8
M!@WS+@8R<BBP'89%%>4^ /&E]XF^*'CG2?[76^TC2ULFLXS;>2\!D$OF(X(#
M$@H.O8#WSZM2 **** "BBB@ HHHH **** "BCO10 4=J*0]* /@_]LH-_P +
M@T9MW']BQC'I^_FHI?VR)?\ B[^C1[5RNBQG)ZG,\W^%%4!]TP?ZM/3:*GJ&
MWP85[C%34F 4444@"J\G^M@_W_\ V4U8JO)_K8/]_P#]E- T6****!!1110
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M%>^;E]:,C/6@#PB^\!^-$UGXG-I^CVKV?B+1;?3-/+7H#9BA>++#;QD2;O\
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M1C]VI!+;<$KACD=.:+@8OP8AUR\^'UIXJ\3NDFNZ[''//(!_RR5 D0_%1O\
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MJNH>']-O-1M?]3=36R/+']&()%4=$\&Z=H_C#7O%$7EF_P!8*+(8X5B"QH.
M<??;).6/.,#C% 'G?Q1T^[U?XQ^ O#\7BC6M)M=8M]1CN8M.NS"&$<(96 Y
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M<%W:FYU&9)+FX9Y%+^8/FD*!00I.!UP<<>YMX+\)NFIHWAO3"NJ B]'V5/\
M20>H?CYOQJI=?#GP)?Z59:7?>$=)N+*P_P"/6&2T0K!SD[>.,GD^O>G<#QO2
M=*\2>*O'^G^']1^*&JR1_P#"-+=37.CS"*.:=+HQAU!!&"$Y.,,<D<&OH6"[
MM;AYHH+J*:2!MDJHX8HV,X8#H?8UFQ^%/#4.L1ZO#H-A%J,40ACNDMU$B(!@
M*#C(4 # Z<5F^'O ]AX?\5^(?$5N+>.?6F0R1VUN(4 0L0S8)WR$N=SGK@8
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MX."BG'3(&17=8&W:*5P/EZW^-'B&-/ 6ISZE)]E\W['XM@>VCV6$GF^2'D<
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ME<E:^%?%VM^+_#WBKQ5:6$%WX:M+F*"&UNF=;VXD54,A)0>6F%.!R?F]N0#
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M-0TN6]\1WFHPB\MC%YD,I!4CMV.1VKV*D 4444 %%%% !1110 4444 %%%%
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M!H0 D^M*%P:6B@!"N:,<8I:* $  I<444 -VTNWUI>]% #2@/KCTI0H%+10
M4FT4M% !@4FWG-+10 W:N<_C2[>:6B@ I ,4M% "8'I1@>E+10 FT'J,T!0!
MBEHH 3:,TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z0TM!Z4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 &D'2EHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@#X$_;&D_XO;I^WJN
MBPJ?^_TYHIW[88_XO?8?]@6'M_TVFHH ^]TX4"G4U>G3%.H **** "J\G^M@
M_P!__P!E-6*KR?ZV#_?_ /930-%BBBB@04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1WHHH **** "BBFL3F@#X&_;$_Y+?8<Y_P")+#_Z.FHIG[87_);K+/\ T!H/
M_1LU% 'WXIXIU,7GBGT %%%% !5>3_6P?[__ +*:L56D_P!9;_[_ /[*:!HL
MT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CO110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z8WS*:?36'Y4 ?
M?[7_ ,OQOM,]]'@_]&S44O[7RX^.-HWKH\'_ *-EHH ^^UIU1HWR]<T_\* %
MHHHH *KR?ZV#_?\ _935BJ\G^M@_W_\ V4T#18HHHH$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(1G
MOBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *.U%!Z4 ? /[87S?'"T'IH\'_HV:BC]L Y^
M.-KSTT> ?^1):* /OM !D4^FKT%.H **** "J\G^M@_W_P#V4U8JO)_K8/\
M?_\ 930-%BBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%'>@ HHHH
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M HHHH **** "BBB@ HHHH .U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2&EIN#0!^?O[7O_ "7./_L%0?\
MH4E%+^UW_P EUC_[!4'_ *')10!^@2\#%+313J "BBB@ JM-_K;?_?\ _935
MFJUP<2V__73_ -E--#19HHHI""BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*.U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%'>B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *#10>E 'Y^_M>$'XYP[5(/]E09/K\\E%'[76W_A>L8"XQI4&3ZG?)15
M ?H"*6D'2EJ0"BBB@ JM/_KK?_KI_P"RFK-5I_\ 76__ %T_]E--;C19HH%%
M(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !111S0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 44=Z* "BBB@ HHHH **** "@]**0T ?GW^UTL@^.:
M!CD?V7 5V]<;I.OXYHH_:[8_\+T7+ XTN 8';YI** /T#4TZD7IS2T %%%%
M!5:;_6V_^_\ ^RFK-5;C_6V__73_ -E--#1:HHHI""BBB@ HHHH *0G S2T4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%':B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BD.:6@ H(S10>E 'Y]?M<ON^.^WGY-,MUY^KG^M%'
M[7/S?'?''&F6_P#-Z*H#] USWIU-3..N:=4@%%%% !56X_UUO_UT_P#935JJ
MT_\ KK?_ *Z?^RFFAHL#I2T44A!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444GS9]J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***3'6@!<T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4GUI:.U 'Y\?M;$#X\,5SDZ;;YS]7HI/VMBK?'>3:Q+#3X 1
MC@?>HJ@/T&6G4U:=4@%%%% !5:?_ %UO_P!=/_935FJMQ_KK?_KI_P"RFFAH
MM"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH #TI.1[TM% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 '>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TG:@#\
M_/VN% ^.XVC:3ID!/O\ ,]%0_M9$GX]39R<:?;C&<X^]10!^A"GBG4@I: "B
MBB@ JM/_ *VW_P"NG_LIJS5>3_6P?[__ +*::&BQ1112$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=Z** "BBB@ HHHH
M ,T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4=Z*.<T %%%% !1110 4444 %%%% !1110 444
M4 '>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH'2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "CM110!^?/[6@V_'MVSUTVWX].6HJ/
M]K1MWQ[EW#:!IUO@^OWJ* /T)%+313J "BBB@ JM+_KH/]__ -E-6:K3?ZVW
M_P!__P!E- T6:***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4#I110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !WHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBB@ HHHH **** "C
MM110!^>O[6AS\>Y?;3K<?^A44?M;'=\>I !C&G6__LU%4!^A"]SFG4Q3SC-/
MJ0"BBB@ JM-_KH/^NG_LIJS5>;_70?[Y_P#0330T6****0@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)Q2T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !0>E%(>E 'Y[_M:1Y^/<N/F+:=;L1Z?>%%
M-_:Q7;\?+@H?,+6%N2O]W@\?Y]:*H#T!?VH?B" ?^)7H!^8=;>;_ ..UKQ?M
M)>.GMC(=,T/=QT@E]/\ KK115LH7_AI'QU@_\2S0_P#OQ+_\=K5MOV@/&<N-
MVG:-^$,O_P <HHJ6 ^#X_P#C*0_-IVC?A#+_ /'*OR?&OQ6T"2_8=*#+(,8A
MDQT/^W113B!97XU>*B5_T'2^3C_4R?\ Q=7;?XO>)I+AD:STW&_;Q%)T_P"^
MZ**8S0'Q3\0X_P"/33^__+-__BZT[+XA:U<6@F>WL@QSTC;';_:HHJ6!<C\<
M:L^TFWM/NYX1O;_:J_'XLU)ID4PV^&SGY6]O>BBD(M0^);^2[$31P;?93_C3
MY_$5]'$66.'..ZGU^M%%(D?#X@O9(MS1PYSV4^GUJ2+7;QX\F.'/LI_QHHH
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M/E@]\444"%!.*1F(C)'6BB@ R<BER<FBBF 9YI:**D!,G%*.E%% "TG:BB@
M[TA/(HHH 7-%%% !FD'0T44 )N/%.[444 )FC/%%%  ">:4T44 %(/O444 '
M>E'>BBF O:F@\FBBD O:CTHHH 0'I2FBB@ I/6BB@!3]VBBB@ /6F%CQ110!
7^>W[5['_ (7S-_V#[?\ ]FHHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>skye_ex31img23.jpg
<TEXT>
begin 644 skye_ex31img23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M2!\9_P##$M[W^(D/_@K/_P =I1^Q+=]_B-$/II1/_M:OLNBJ ^-_^&(YL_\
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M'?PJ_P"?SQ!_X&1__&Z/^&/?A6/^7K7C];Q/_C=?1=% 'SNO['_PI[S:X?\
MM\7_ .(IP_9 ^$_.9-;_ / Q?_B*^AJ* /GL?LA_"4#G^V6/J;T?_$T\?LC?
M",,"8=7(]/MW'_H-?0-% '@0_9)^#X_Y<]5;ZWS?X4[_ (9,^#X_Y<=3_P#
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M10!YA_PH'X._]"#IWYO_ /%4X? /X/@_\B#IOXAO_BJ]-HI6 \V_X43\(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N:\>KO^&OB=1WTNZ_]%-72USGCH _#GQ*IZ'3+
MD?\ D)J /R;-%*W6B@#]>=*;?H]G(>K0H?\ QT5=JCI!W:)8]#^X3_T$5>H
M**** "J\O^N@_P!\_P#H)JQ5>;_76_\ OG_T$TT-%BBCM12$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4=Z** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBD(H 6L#QH W@#Q$O8Z;<CG_KDU;W:L/Q?C_A
M!=?_ .P?<?\ HMJ /R5;K10>M% 'ZY^'SN\,:6P_BM8C_P"."M2LGPVV[PII
M+=C:1'_QP5K4V 4444@"H)?]=!_OG_T$U/4$O^N@_P!X_P#H)H&B>BBB@044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 )C@UA^+EW>!M=7/73YQ_Y#:MV
ML;Q5SX-UL?\ 3C/_ .BVH _))NM%(W6B@#];?";;O!>B-ZV,'_HM:VJPO"!S
MX&T$\?\ (/M^G_7-:W: "BBB@ J"3_70?[Q_]!-3U7D_UT'^^?\ T$T#18HH
MHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0+O\ #.J)
MUS:RC_QPUIUFZYG_ (1[4B!D_99>/^ F@#\BVZT4-UHH _6'P$P?X9^%W4Y!
MTJU.?^V*UTM<O\.\_P#"KO"A/?2;3_T2M=10 4444 %02?ZV'_>/\C4]5Y/]
M;#_O'_T$T(:+%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6/([;B"!GK@UO_%'6@UMIG@.QU&"QU7Q5*;-))<D10A296P""<J-@P1RPYH
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M^6"#MW8YYP/R -[4?%GQ<TC7/!^DZFWARWNO$MS-!Y8M9I!9[$+C+"4!R1[
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M-3U#)_K8?]X_R- T34444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 0@,,'D52_LK3?):'[!;^4QW,GE+M)]2,5>HH C,
M,9B\HH#'C;MQQBHUM;99VN%@19G&UI HW$>A-6** *YL[5G9VMXRS=6*C)IT
M5O# A2&)(U/9% %344 5X[6VAE::."-)&^\RJ 3]339K"QN'+W%G#,Q&,N@8
MX_&K5% %(:9IXA:$6, B9MQC\L;2?7&.M2_9;86WV<6Z"'&/+VC;CZ=*L44
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MSKVHZQ:_8K? 9HI5<DDX"@ \D^E:CZ]HL,%M--JMI"EUCR3).BB3/3;SS^%
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MU[<7^L0:=J%I)<;KB".1L;E16X(P<EO45WR^)/#[:LVCC6[%M27.ZT%PGFC
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MQMW;:-Q!RQ?KDX7V-=QXN\/^%/%_QWU*R\6WTD.G/X7@EAVWIMUD/GR_/D,
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M[.WF*ZJ5P-C]_P"=;?BK7?#*_$7Q):>/_#VIZAI'B;1;+^R'BL9'<JH8M @
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M!26N6L5$882B(KNWXW GM_.MG2?CKX7O]3U/3]4TS5O#TEC8MJ0.J6XB\ZW
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MM= \4G3_  5J-EJFD:>-1@342D:RV[9 FP"?ND'Y.IQCCM3UCP;\2/$/PO\
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M(RH)R&4'_.*6@$EM\4[C4=(\,+IOAF8>(/$$<TD>FWLOV<6ZP_ZUI'*DX!P
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MI)I5;REW##D <^N*X'Q5\,/&WB;PQ9^'KN\\/W=@-'CL9([J"0_9[I,@7,+
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MA$^\WL,]Z^59O$.L>-KGPQHFN^-(-#BNO"4%]#=7$TD(FNGW"20%)$W.NU2
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MYB]F4EU]#SFJH^*]_I?C#QVOB+2A9Z!X9AMV66*4.\C2!B..,E\J .,8]Z+
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ME[F.3R& + +DCG&.G->O8HI@>*?#SP?XE\)_LY7&AZQ'J%[JLEK<J-/9HV:
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M4@%%%% !4$O^N@_WC_Z":GJO)_KH/]\_^@F@:+%%%% @HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ",T444
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MW-=1X]\.Z1KGAY[C5?"__"4O8!I;;32P E<C'1B%S@]3T[5YQ\(_#7A?Q?\
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M9O)DN?+*HY54^7:H(&U%&#GI7/7GP?\ #%QX2\1>%[2XOM.TWQ!?MJ%TELZ
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MYHN!\>2^)(=%GT*3[+)(U[X)@TN=+RQGE6%\LH.$1F&"&R"!G P3V^BOA/\
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M08[1[B/4;6[<W<K1J$BE60@$*W)V@?C67>^%/%!^(OBCQ!9V^GR6NJ:)'I\
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MX$C&3O!W9Z  #GK6)!\*?$FF^'/%7@G3]0T^7PUXBNI;CSY_,%Q9),?WL:H
M5?C.TEEP3R*Z7P?X&U;PG\0_%&I0W-D^@:UY$T<85_M$,D<:QA/[NW"YSG/0
M8[T 4O'7Q@B\%ZEJ4,WAR[NK#28X9+V\,B0K^].%6(.?WK#() Z4[Q1\5K_1
M/&-KX7TGP3J&NWE[IIU&U-O+&@E4, 0<GY<#N>^  <URWC[X0^,?%GB'QC-;
MZAHTECKMI!#:2WRRO/I^P#>D:CY5#D$EASST.*CO)->L_P!H?P?I\,VD7.MP
M^&)XKB,R/%%GS%^[PS=N,CD ].ST V)/CQ!+IOAFXTGPAJNH7.O2W%JMJ-D<
MD%Q"#NB8,>#D#).  <YXQ7)^-O',/COPKI$\VE7V@:WH/B[3[:\TZYEP8F9^
MY7AE(/!QVIOBC1=2\&^*_A=:G4-/N=<O->O[ZXDD_<6[23(2RKC+ <[5R#SC
M/I70:W\)O%VM1WVJ37FE1ZQJ.NVFJ3JK2M#%#;#$42DC+-URQ '/3@4P.F/Q
M9\FX\;V=UX=FAOO"S1!;<SJ6OA+_ *LIQQNX '/)QUKJ/$VN:OH_PTU/Q%;Z
M;&VIVFGO=_8Y9OE5E3<5+ <XP?KBO/)+?PSX^^/NE:IHFJ237'AV">'6(HE8
M1ETD7R8G) !*R%W'7[E>K^(M);7/"FK:*LP@-_9RVHD*[MF]"N<=\9J0/-_#
MOQ*UJ3P/X,^W:3'?^*_$=L)K:S2?RUEC6(.\[MM(C7!Z8)R0!GG'6^"/&L'C
M+3]0W6$VF:II5TUCJ%A,P9H)E&>&'#*000PZUPFE_#'Q;I]GX'U+^T=,;7_"
M,3V,:()%M[JT9!&5<G+"3"[MP&,\8KMO!/A.[\/WOB'6=6NH)M5U^^^US_9U
M*Q1JJ!$1<\G"KDD]R>!0!YY_PDWB/QI=?%?PUX@T>W@T;18##$8KL[T<1%U.
M0H)W?*V01MQCG.:J_#_XOKHOA#3-)\6>'+K1K2P\+PZI;7S2I+]M@C2-&(1?
MNL2PP"<X(SBNH;P%XNL_$OQ O-,O]*EL/%48:..XCD$D4OD"+DCY=HY;H2>!
MQUKG=1^"OB#6[?1M)U+4K&+3[/PNWAZ::$.\A8B,B5588X:)>,@X)YI@=-X%
M^,%OXP\7MX9FTC[)<O9"_@EMKD743)G!1V50$D&1D<CGKZP^,6F\6_&G1OAS
M<W4D.@1:7)K&H01.T;7A$@CCC9A@[03N(!YQS6UX'T#Q_IK0)XP\1:??6]C!
M]FMTT^W>(W'0>;,6)^; X"\<D^F&>,O >J:KXRT/QQX6U:'3-?TJ.2V87,1D
M@N[=^L<@4@C!Y!'0]C2 ?:^!]$\%^*&\6:3.VEZ5!ITT5Y9>8[0G!1Q*JDX5
M@(R#@<C'I67:_%74/,\.W^K>&&L=$\2N8M-NQ<AWWL-T*RK@!/,49')P>#73
M1Z/XDUB.[A\47EI'9W%H]H;/3PVT[P SL[<DCD* !C)SG/''Z7\,?$*Z)X2\
M.ZYK5E>:7X6NDNK=X862:Z,2L(5?)(4#(SC.<8H S+?XT^+IO#VL^(V^&DZZ
M5IEO=-)-]OC(\ZWD*.G3I@$Y&<D$"EL?CI?6NIZ>WC3P1<^&]&U6PEO;&^>Y
M67S/+B\QU9  5.W. >3QQZ3:]HM]X+_9T\<Z?X@U&RD,T&H7$<T.8@3.SN$^
M;ON? ]:SK'X<77Q0\!^$V\3ZO:'2+32&C@ATY&#-+) (Q(S,>-@+?*!UZ^E
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M)4M]RR$NQ,#"3CY=N<$4RSNKI?V1'\91^*-7?69K")Y[[^TI2T;+-@X&[:I
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M"TMK<RM;V\<)E<R2;%"[V/5CCJ?>K%%% "'...#2T44 %%%% !1110 4444
M0SP07,1AN(4FC;JCJ&!_ TL,,-O$L,$:Q1KPJJ, ?A4M% !1110 4444 %%%
M% !1110 4444 %%%% !2%5;J,TM% !1110 48!ZT44 -557[J@?2G444 %%%
M% !1110 4444 %%%% !1110 FT ]*6BB@ HHHH **** "BBB@ HHHH ****
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M@#.T[3K>QLUC%M;QRLH\TP1!%=@,$X_QJ2'2].M8GBM;"W@CDSO6.-5#9ZY
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M4_V32&2.;5/.0PM(R!O+ Z[@#R.W&>M '94444 %%%% !1110 4444 %%%%
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M*GEMM 0_='(YY/'% '*>.?"=CX?\1?#;3[:\U$PS:X\#>9J$Q+1%7D$9.[+
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MH **** "BBB@ HHHH 0"EHHH *3'-+10 4444 %':BDSS0 HI*6B@ HHHQ0
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MZ7XDL;BZTF:26&"XDM9&>)HR)$.UAA@,\]^E(#:HKYEU#QYXPL[3XGW8\?\
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MN+L%!!XQGD_G75^"_&6C^//"=KXDT1Y#9W&X;95VO&RG#*P[$$46 Z6BBBD
M4444 %%%% !1110 444'IQ0 4P]*=FFL<].: /S"^.R,OQY\8*WS'[>QR/\
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M(K7 &*8'@7BB/Q%J,'AGQ=9_#V^LX;/Q*E]+IL,*?;)(S$R-.ZAL;B2O!.0
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M/F$R(RDC?"!C P3P>YKN/"&C>,=#^*'BTWVF02Z%JTL-\FIBX =I1;Q1,GE
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M& ^;&S.!US7M9*UQ_C#QQ:^$Q;6ZZ9?:QJ-TLDD-C9(&E=(P#(^"0,#(^I(
MHN!XW<?##XBKIVIPZ?IVG+-I/B*77M):>?<NH>83NBD7'R#:<9)Z^W-;.M^"
M/B+XA\*V.OMH^BZ/XHTC5(=3L]*M7S#((UP4DDQRS D>@P.>IK:O/CI8I8'4
M=*\'^(=7M8S%'<&UM@9+6:10RQ.A.=V"N<< L!FO7(9!)$KLI1F .UNHXZ4
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MGI?C30#HVL&X6#S8YUDMI3%)'(C!E96'(((KFA\(?"Z_V\BW&K@:[;K:WO\
MQ,)"715"@9))^Z-N?3([T7 XG5/&OQ$\2:N^D^#1%:W=MH5IJFW,0$L\X8A6
M\S/[L; /EP>3R.*]F\/W-_>>'-,NM52!+^6VC>X6W??&)"HW;#W7.<'TKB+_
M ."O@G4DT@S+J,=SI5NMG%=P7TD4TENI_P!5(ZD%U[8/:O0K*QM=.LH;"SA2
M"V@C6**-!@(J@  ?0 4,#QCP9)]N_:K^)#ZM@W=C8V4&GHQSMMV3<Y7ZMMS[
MFNB\?:C;>#HK[7M#:"'7]8GL-.D>4ADB5I_+69D_V1(W)X.%%;7BGX;^'_%6
MJ0:U))>:5K=NGEQZGIDYM[@)S\A8?>7G.#FF+\,?"\GA:_\ #VIQ76KQZB%%
MW=7]PTMQ,5.Y3YAY&T\J!@ ]!UH \\\4^+_'/@^^\1Z*FN0ZD8_#LNN6-[/:
MH&A:)]KQNJX# Y&#@8]ZC\1:[\5O#O@SPYJL_BK3KB[US5K*W55TT*L$<R\K
M][YL-WX)![5W?_"I/#;Z'J>FWUYJM_+J5JMC/?7-V7N3;KTC#]EY.1WR<YKF
M/BIX#U:]^'OA;PGX:L=0U6+3M4MII)3=()DABSD[V9?FP1C'I3N!S^L?$?Q[
MX)U37?">LZI8ZG?AM/-AJQM1$D*7,QC8RQ@X^4AB.>>,U)XQ\9?$#P3K&M^'
MSX@CU-9?#MQK%C?26*B2UDA/S(RK\I4YX)'!(ZUZ=#\,?"\FA:MI>JVTVK#6
MMIOY[Z4R33[?N MV"8&T+C%5$^$7A5M*U*ROIM3U"74;3^SY;VZO&DN%MN#Y
M2O\ PKQR!U[YHN!P,_B3XCV?A_PHVH^,+>6]\32)+':Z;IJ?:40V^\QQ!B4(
M#8+.^ !GD<5RD_B?Q9XT\)?"+7+_ ,02:?>W?B-K6X2") C,CRJ)"ISD@)T^
M[SG'2O:[_P"$7A'4M(\/Z?>+?NWA\;+*Z%Y(LZ)@!D+@@E64;2/2J"_ OP''
MX3B\-16]]%9P:B=4A=+QUD@ES_ P.57!(P/7/7FBX'(7GQ0U[PG+\8+W4WCU
M1?#)LQ8HD"QY,R<;RO4!F7)] >E:9\0>.-+\;Z?X=N?$<&JV>O:)/?6EZUK&
MDEI<1!2QPH"F,AQMSSG//'/:Z7\,?"VEZQK^I1PW5R_B",0ZA%=W#313*!M
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MG&<D=AS]31NK1C:<C'6N/U7X7_#[7=5N=2UCPCIUY=W(7SI9(<F3:003V)X
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M 52,X )#?B6 ]5NOBAX9G\1Z]X3TW7+"'6M+M/.,EW*JP)(0Q"L<Y.W +8Z
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M!9M ]R_FL%B2$#<S#&  "3C/2O.?#>A^(-.MO@XL_@[5DF\/QW2W^V!3Y)>
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M!\N)45E]"2Q[8X.:+ >BZ;JNFZSI<6IZ5?0WME,"8[B%PZ. 2#@C@\@UG?\
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MN?AKJ=YX?\8P7/B*(ZUXK00W-ZMH1'!$(_+5$CW]@6Y+$Y:M;7O'C:?X]L/
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M=[;V\*/YJ*S,I#-DH/F(('7VJFGP:O+6XT+5-+\=:E8:YIVGC2[B_2"-OML
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M#<;+6ZG4 ;W4#OC)'0GVXK)\%_$_5/$3CQE<^)/#L7@K]^MY;R,8[G36WE8
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MG_\ 1<5?1=)@%%%%( J"7_70?[Y_]!-3U7D_UL/^\?\ T$T#18HHHH$%%%%
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M$]!M+Y84MKK6;:'S;QR+2' 9\SC^./Y?N$C)QR*]3;3[&2Z6[DLX6N$^[*R
ML/H>M/GM[>YC\JXA29,AMKJ&&1R#S1<#Y=\.7.C7GP>\?>'Y_%5G81Q>)LPW
M9M2EI&'DB>',1)"PNP(()QM)/(KTWX'7DEQX=\00SZ7IMI-!JSK-<:0V;*\?
MRH\RP]@" ,@<9S[UZE]BL]LJ_98L2D&0;!\Y' SZ]!3[:TM[. 6]K;I!$.B1
MJ%4?@*+@?*'C.Q\"7%W\<[ZZ6PEN[:.V:T)<;HI_)(W)_M>8<$CG/%:6JS>#
M/#?B&>?1[5;L:CX'FGO(-/F(EOGWHP9G7)+E3(=WWL ^E?3+6%B^_=:Q,)""
MV4'S$<@FIA;P*05A0$#&0HZ>E%P/E+X81>&]>^)>H:#-);76DZYX3MX/L]K:
MO'#E&P5#-_K&0<>8><^A&*[?X0^&]<765T?Q)9*+;P"TVG:=,R*WVHRX99=V
M."L)1>/[Y^@]DUK1FU+0[G3['4)](GEC\N.\M HE@YSE=P(_2H?#/AV'PSHX
MT^.^N;^5Y7GGN[M@TL\CG+,V !Z      47 X+X]6MI<?#[3_P"TH3)ID6M6
M,EZ>=L<'G .S$<@8/)[9KR+Q=X>^SW'CB\^&=A.OA!X].^W1Z,-T=TPF+3^0
MH!5L1$;MN5['/('U@LUM<-)$LL<NP[756!VGT([5((T4;0,#T% 'B_PAC\&3
M>(]=UWP=JVMZL=0BA-Y/>6XM[=67Y5556*-3( #D@''<\UR7B6P^&[?'+XAV
MOC*ULA]KT:TF@61,L\FR0.T8'67[F/XCV[U])8AMXS]V.-03Z "N'L-'\/Z=
MXTUKQZ?%2SIJ216LL<DL MXS%G: P .X9;JQ/)]L" \,^&?A'2+SX@Z!H_C[
M3(;S54\)V[^5>*2PF$[LH<'K(L6P<Y( ]JCU6V67P+\0/"_B.P=_B'<ZVUQI
MI*$W%UEE^RR0L!G8H!'!PH!SC)KZJM+FSO8OM5G<17,9RHDB<...HR/>K)CC
M+!BH+#H:+@?/FO>$=;T7XCP66E68:V\?Z>NGZO+%D"">(9EFW#'+1&0#IE@#
M4_C+38=,^+^BZ?X6LUM=13PIJ%C:&*' 5PJ^0I8#'&#@$\?C7OVT&DV+1<#Y
M*T'6= N#\'=/M=&OK?7="O3!J:-IDHEMW,#[P[;.=S?/U/'S'H:C\%Z5I%UX
MFLM#\96OBK_A.=)UQ[M+:*,>0[M(6%QYHC_U>T@G+<@<>E?6YCB3<^T+W)JK
MI]]I^IVB7VFWD%Y;29V3V\@D1L''# D&G<#Y*\2ZE90?"_7O"NN>'[X>-(/$
M:ZA+_P 2^61KA3=@B=) I##RSL'(]*^L+R^LH=$DU"])2U$7F-OC;*@CNN,Y
M]L9K1V+G..:7 -2!\M^&Y/LOPQ^%VJR6<DF@Z'JLPUJW^SN# S>8L,SIC)5"
MZMG!QD'MQG^-]/TV<>)=2_L]KGPWK7B72Y=/2.T9U<1A!>2H-OR@X()Z-M;K
MG)^L]BXQC-&Q>PIW RM$T?1-#T>.Q\/Z;:Z=8',B06T0B3+<D[0!R<U\W>&=
M"T/4/#'AW0M/T/R/'.G^(OM-U(;)H9K>);J1WD=RHRAB^4<D$L!UZ?4_!ZU5
MO+FSL+22\O;B*V@C&Z2:5PBH/4D\"D!X3+X/U'3?CI=>%M-@1_"'B8QZY?(,
M'[++ PW*%[+(XB_\>QTKT_XE6$VH?"7Q586ML]S--I=PL<4:;F=O+. H'4YQ
MBF^#?!WA_09+O7M*OKO5KC5AYC:A=W9N6>(L75$/0(-QP!^M=+::EI^H7%U;
MV=[#<2VDGDW"12!C"^ =K8Z'!!P?6F!\\W&H:)XD\;?!IIM&NIK&"SNA+%=:
M;($C<Q*B%@R8^^C8..P/<5Q^EK/HL]IJT^BZZWAK2_$.K"2/3K69)+9)L>1,
M@*@E2 Z\= W8D5]A^6OI1L0#[M%P."^%NG:7IO@5(]$TK4=,TZ:XFG@BU+<)
MF#MG>5;E Q)(7CCW-<5X6U!OA9XZ\9Z3XDTR_BTK7-5DUG3]4M[22XA?S0-\
M;F-2492!@$<C]?8K76-*O=0NM/LM2MKFZM,"XABE5WA)R & .5Z'KZ5?;8!E
MNU(#P?XD:AJ^MS^!_%UEH5_>>&=(UI;F[C-N_FR1;<"X\@C?M0DD9&>AQWKA
MOB-I"ZF?&>MVNBWLVA:IJFD+"JV4O[Z6,_Z1*J!=P&S:-V!N(P,U]-:3XC\.
MZY+<0:-K5AJ4EN0)TM;A)3%GIN"DXS6QM7.:=P/!?'6B>"-)\=?#$KX=LH='
MDN+]VACL?D^:W+!FC"YQNY.1QUKG;/0=3T6>W\66>B74?@U/%SWRZ6MJX>&W
M,)B^T>3C<%$I+XQD#! KWC6/"-CK'BO0_$ES?7L=SHC2-;112!8B778VX8R<
MCCK5AO%7AB..ZDDU_3UCLYUMKAC<IB&5B J,<\,20,&@#YW\8Z.VHP^.M>M-
M"OYM"U?5=)$%NMA(WGM$ZFYF$>,A2H(+$#=M[\9U/B1ID>E^*Y]+T'PW?Z98
M7_AZ>*WFT/2C*UW-(Y9H&X*1C W$X#'/4=#](84K@]*-JT ?.GA^\N--U;X0
MZE?>'=7,'_"/2Z9)MT^1WCF(@ \P 95?E8Y/;FLB'3-6D^$UU]BT'4;JTTSQ
MM)J5WIIL71[FR%PSX1&4;QRK;?;V%?4>T8]J,"D!\H?$K3;CQ->>./%'AO1+
MZ?1+K0+:S*II\BF]O!<;@0A4,2B<%P..1GM7HWA[^S+/X]6<VE:7/96-UX62
M!62PEBB:03>8%8E0 P0D\\]0>:]IVC' J.3RT0LV HZDG@"G<#R#XG75O9_%
MGX9W<EG<R"WN[IIIX;62011M"4&YE!P-S#C\:\J^Q:9#X+OKZQ\,WL>J?\)X
M+OS4TN83&!;D,) =FX+Y>>G3FOJC2M5TS7-+BU31]0@O[*;/EW%O('1\'!PP
MX/((I-4U;2M$M5N]6U"WL+=I%B$MQ((U+L<*N3W)- '$?&*TGUCX)ZXMA9RW
MDA@CG2**,L[*KJYPO7.T'CK7#ZC-IOB'XV^$M4N/#E_+HR^';D W.E2F.-F8
M%<@I\K%58@$9Z>M>WPZQI4VJSZ3!J-M)J$""26U653+&IZ%ESD ^IK0*KU-
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ME;D<'K7):I\(?$5Q\-]5T&WUK3YM8UO61K%_=SPLL:L)$8(BC)P BC)/KZT
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MSD<$5<U+X2>(-<\%_9-:^(%Y<>*(KQ+^UUF.W6,6DB JJI$#@+M9@>><\T]
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M*H#Z5_8[_P"2)W_?_B<S?^BH:^C:^;_V-V8_!;4@>@UJ;'_?F&OI"I ****
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MUIV,FFV?B[P7X)\3^-;G7/#26%W-#J%S=&*+4+E9-OENX/[P(N<#<>2.N*+
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M>(O!RP:;+8^$WCAT^WU&.>66_"G,OEQR-D@8&YN6)'<4[ ?42SQ%BOF+N'4
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MWOHX[F1H5(\YB@^=L\D_6A@=A1112 **** "BBB@ HHHH **** "D:EIIY%
M'YP_M.!!^T7XBQG[EMGZ_9XZ*/VG_D_:*\0>\=M_Z(2BJ ^COV-B/^%,:H >
M?[;FS_WYAKZ2KYM_8W(_X4QJF,\:U+U/_3&&OI*I **** "H)/\ 70_[Q_\
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M(;=W' YS6KJOQCL-+L]2UJ/0KZ^\.:5>FPOM4@*%8I 0K$)G<R*Q )XQ[T6
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M)((H]!TO[&)&==I,C%V+ #.%&.>?:K"_&;2X?"L^KZII<VEW\&KOHC6-S-&
M+A>2?,SMV;>=WIV/%;_P_P#B#:^/+/57M[3[-/I=V;2<1S">)S@,&CD& RD'
MK@?2C4#H;#P[X=T6[NKS2M%L;"XO&W7$MO L;2MZL0.3SWJ"T\(^$[/4I+ZQ
M\.:9!>/+Y[SQ6L:N9/[Q(&<\GGWKR[P^!\4_B;XRD\027!T;PS>#3++34F:.
M-WP2\T@4C>2?NYZ#ISS6PENOPD_M.Y2\O]<B\0:G;V^E:;+.SR12LNTQ!W)
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M<\GIBN:L_C)XX\4>)]*TKP7X8TJ9-4T6/6(S?W4B&)?,".K87J#N QUX/M3
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M58=3:*>659HK<P\.Y?!!9NY/X8KI]0U#['I5U?0P->/;Q/((8F4,Y4$[02<
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MX6\#R:3H_AR2&2UU R1,TL,1P/W(!QDC>.>Y!KO;.U@L[*"SMHQ%! BQQHO
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MMG$8?D^6SD85_E/R]>GJ*U=1^)OA;2_$<.B7ES.DDMT+$7/V=C;K<$ B(R=
MWS#^76O*;?0?$">$_"=JW@W5(IK+QA+J4T2HF8H#-+(&^]Z2+T/8TW2_!.J:
M=XNU/0]6^&*>(&FU>34K37YYU$*H\F_=("<ATSP .?U)H!W<GQZ^'"7BVO\
M:EP3]N.GN_V20)#*"!\Y(&T9/!/7!]*N6WQ2L9?B+XB\,7.G7EI:Z%:+<SWT
MT)$9R'8MD=$VKP3U.?2O)]4\+>+KCX<_$?35\%ZC)>ZQXB6_M%VQ9DB+1G/W
M^PC/YCWKLYM*\3V?Q-\9:D?!\NKZ9K^B0+$KR(B;HHG#029/!8N!P#U//%+0
M#O/"WQ"T/Q9J=SI^GPWT$T%M%>#[7;F(2PR%@DB$]0=IK$\2?&SP/X6U;4]*
MU.YO7O-+,?VJ."SD?RU<9#D@8V@=6Z<USOPGT#Q/HOC#5 MCJNG>$#9QBUL=
M8E626TGW',<+ L?)"^I[C'>JWBC0_$U]JWQ72U\(WMS'KFDPVMA,&BVSND+(
M1RX(&7!''8^U ';Z5\6O!>KZSJ&FVM].GV*S:_:XFMWCAE@4X:2-R/G49'(X
MP1C-6/#OQ,\.^)=1FLK<7ME+'9IJ*_;K<P"6V;I*I/5?RQGFO--5T?QT]_X?
MNM)\(W9GM?"=WIN^Y,!2*Y=4VAQO.03%@]1\P]\8UAX%\;:K?S6\GAG4-,CU
M7PG/HLVH7]\DKQW!;=O958[5)X"KP!C@8Q1H!U[?$QM<^,7@G3]$N=5AT;4%
MNV=+BS$5O>(D3%)(W(W,,]L] #CGGKH/BMX3N/%MGX=6>X5[^62WL[QH2+:Y
MEC.'1).Y!R/0]C7!Z?;_ ! U?Q3\/SJ'P_GTV'PYY]M>7+7<1C.Z#RM\8#;F
M7C(XSS^-4OAWX.UO0M9TWP]K'PMT^2ZTNZ>3_A*&:,H\6\LLBC&_S"#CV/-/
M0#I/B]XNO?!OB[P'J;:Q=6^BS7TL=]:01;_/ B)7H-Q.> O<U9_X7YX&_P"$
M1/B4KJ7V6.^&GSQ&U(EMIB,J)%)^4'L?ZU9^)VAZ_>>(?!'B#1]'?58M"U)[
MBZMH9%64HT94,H8@$@GIFLRW\$C7;;X@7WC&RCT>W\5B*!+261"\2PQ;5E8@
M[=Y/S8!.-HI >B6_BBSNO%]QX7AM[HWEO9QWLDACQ$$<E5&[/WB5;CV-<%>?
M$74M8UGX@^%+/3+_ $F70;(M#J(C!"R&)G#')/!PNWCD9Z5I?!G1M4LOA]::
MQK]T;S6=82.XGF8Y.P(%B7GT0 _5F]:Q;O0?%]GX_P#B1-:^'#>6'B+38S:7
M:7**/,2W,?E%6(.XL>O3'>@"O\+?C%I&J:%X4\/ZQ/?G6+S2Q.=0NX2D%T\:
M9EVR'[S#DGMP>:ZSP_\ %;PQXB\26F@VZ7MK<:A;&\T]KJ'RTOHAU:,Y)XQG
M! ..1Q7E3?#GQQ?^'OAAI3^'9+3^Q]-N['49FGB/V=IK<P!@ X+ ?>X['UXK
MI_AAX6\2:7/H]GKGPWT+1;G1H3#-K4)B>2['EE 8=J[E)ZL6(] #G@ Z7Q7X
MBUN^^)6C?#KPW?C3)KBSDU2_O_*$CQ6ZL$5(PWR[F8]2" !T.:T;'2_%N@>)
MTN+SQ8^J^%ULI3<?;XXDFAF#(5?>BKN7;OXP,>IXQB>./#WB73?B/H_Q(\*:
M:NLW%M9OI=]IIF$4DT#.'5HV8[=RMG@]0?:K.KKXF^(G@[7-!D\/7'AFTU"Q
MFM?-U%T:8NR$#:D;, H)SN)YQC'>@!^G_&/PG?ZO;V'E:E:I>Q236%U<6;)#
M?H@)8PM_$<#(& 2,8SFL7_AHOX<M:W-Y&^JR6]NCN\JZ=+L&U]A&[& <D=>Q
M&<5C6?A[QIK6E^ ?#^K>$I=-;PE<0W-U?-/$\<_D1%%6':V3OR.H4 #FL6YT
M76O#_P"R;XQTSQ)HLNFW4;75PL<TD;^8LD_F+RA(S\P!'K1H!ZCX:^,7@WQ/
MJ>HZ?:W%Q9RV%N;QC?P-;K+;CK,F[[R#UIMG\7?#5S>1VUS9:K8?:+1[VS>X
MLVQ?1*,L8MN2QV\[<!L=JXG7/!?B#XH2O=MH\OA>*/P]<:9'+=%/,FEE,9
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M)8#6+_Q?-H$%S';"&&(F0 S,@ZD<GDY)QDT6 ^A>#1@5\^^,/''Q \$S>*]
M;6HM2N+711K>G:A)9H'15DV212*N%/.,-CUX-=+X0U[QU;_$ZUT#Q9K%GJ5M
MJFBG4XT@M1";617160$$EE^?J?046 ]=(HXIK,1&2O7%?--Q\1?'D,6N1ZKX
MCDT/Q!9Z=?7/]D7%C&$=H_FB>VD*$2)M'S98GYCTQ0!]+.P52QZ"L7P]XFT7
MQ5H46N:%?+=:?,[)', 5#,K%2,'!ZC\:\ZC\7>)[CQS\.K./5%%IXBT6>YO(
M3 A594B1E<?Q#F3E<XX'O7!?VEXGUSP3\+IFU^6PEO/$DMM<+96L4<;;))MK
M[-I QLZ=.<G)&:=@/I[BCY:XGXE>++OP-\+=9\36=NMW=6$ :-9/NLQ8*"V.
MW.>WX5P%WXI\<>&_%'AJQN=?75['Q5ILS++);1@V=VD)E#($ S&1_"V3QUI
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M&X \]>F,=P#VH[<TF%KYP\+^-OBMXRO-%\9:0T$/A^?4)(;VUGN(/)2 2>6
MHQY@E&">3R2,#%:OA3Q5X[\5Z3;>-[7Q-8VUM'K$MI>:1<(JQ);(Y0*#MW^>
M?E(RV#G'3BG8#WK(Q6+H'B;1_$]M>W&CW#3QV5W+8S$QLFV6,X9?F SC/7I7
MC7@/Q1\5/$VI^'O$TC)_PCVI-*+Y'FM_*C4[O+$2@>8'5A@@DYQS6?+XH\>Q
M^ KR?3_$BVNI)XV?1_/-E$5>%IQ&,K@=,Y)')YHL!]&221Q1M+(P1%&68G
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MX./6A(#Z2\.^-&U>'6&U;0[[P^^D/MN!?A0A79OWJZDJRX/4'BB?QYIL6O\
MA73;:WEN[?Q,LCVE]&1Y0"Q&7G)W<J..*Q?BWI5I'\ O%=FIF,4&E2LC&9RY
M*KD9;.YN0,Y)SWS7G$6DZ1J6D?!32;?4KJ""9)-[V]XWFJ38DL@DW$KSQ@'C
MH,4 ?2&]1WIP8'I7R7<^)=<TCPG#X?C\2O%I$/C.YTF74;Z>27RK9 &CCDD#
M!MI)QG<./QKV?X1V=UINDZS8W'C2W\41I?N\3V[,ZVBL WD[V9B<9S@DX!%
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MLTU[!%NU-B%E0N-T:8()D(SBC4#%T[X4Z'I/B&/7+'4]6CN(M-&DQJUPKJL
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MP,_7VJ:\UB\7XCZ=H]OK6E+;-:2RW&GODWCL"-CK@X"#/)(HU I>+/AEX?\
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MX(F\'631P2O-&K;F"NV-QY/? XZ<4RR^,_@K4/"*^)+:YN6B:Z-BMH82+DW
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MO$6M3ZSK/A'3K[4+A/+EGECY<<=>Q/ YZ^]0/\(?AQ)/=SMX4LP]W;BUFQN
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MM)"#T+*#D9]ZT\ T7 \+U35K!OVM/#[,LC(-#EMO-$+%!*\F]%+8P"5!(_\
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M@@G<1QUSGTKZ&VK^%9VKZQI.A::^I:SJ%OI]FC*KSW$@C12Q  )/')('XT7
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MZ1&BO)<$M^ZN)B05B P=N0"3WZ5W_P ,1J3_  @\/VFI:7=Z3=V^G0VK0W0
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MP.G3G%>VXI-HSTHN!\TZ3X-\01? >#PYXD^'=UJ#IK,\LMI#<QI<PQ.[R+/
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M: 11*LL;J [$A<@G /'3%5-/^$,EC#X0AE\7ZC>1^%9C):+)#$ 5V>6J'"]
MF1ZY).:=P./U6?7=8^"7Q;_X2>_@U1;6YOX( 8,&/RT79CD@ <8P,@Y.236E
MJ'Q \86[_P#",^#=)^U7>EZ':7C.;5IQ-+(IVQ'#J$!"'YN>O3BNIN_A:EUI
M7B_1U\27\6G>)I9)9(%2(BV,@'F;<KSNQWZ#IZU%J/PD^T:OIVL:3XNU?1=3
MMK&/3KFYM?+S>0)]T.I4J&'.& XS1H!GS^*O$/C&ZE\(65GI^FW2:%'?:I#?
MQ_:1'+,"%M]H89'#9;GC'K6C\#%D_P"&?_"\:8B?[(R@XR =[<XJQ??"G3VU
MJQUC0=<U/P_=VUBNF2O9NC?:;=>55]ZM\P.<,.>:W_ OA"#P-X-L_#-KJ%U?
M06H(22YV[P"<D?* ,9)I >.>&O'7C/2_#+1WFJ6^JZSKGBV?1K22Y@98[?#L
M&<@/RH5/E08YXR>M>E^%/$^N3^/O$/@KQ$EK+<Z9!;WEO>6J-&MQ#+N'S(2V
MU@R,.O((K.;X.:2;'4+1=:U)5EU7^VK%LQDZ;=;RY>+Y><DG(;(()'O75^'_
M  O'HVH:CK-Q?3ZEJ^I")+F[F54)2,$(BJH 51ECZY8Y/H >::Y;>+(/CWKL
MW@2/1X+N3P];RSM?QL1*XFE"C"$<G&"QZ8%9MK\:?$_B2RTK3_#NAXUR729-
M0O$2W-PL<JRF$1JN]?E+HY+9.!MZDUZ9K?@6;4/&#^)])\1W>CWL]FEA<B**
M.59(59F&W>#L8%VY''J#6+J'P;T8KH4WAG6-1\,:CHML;.&]L65GEA8[F20.
MI#Y;+9/<DT ==X7U'7M6\$6%]X@TM-*UN:#-Q:%MRQ2\@C@GCC/7H:\9L_B!
MXHTCP?H4VB:+X?LYM3\73Z+<0Q0211;O/=?, #9R2I)SGK7NVFZ5'I.AQ:7:
MS2D1H0)I6WR,QR2[$]2223]:\U3X+*NDZ98GQ=J1_L_6WUY)!#"K-.S%B#\N
M-N6;CWH RKCXH^+?#]GXATK6[?3+_7;36;32;&6V5XH)6N45D+@DD;06)YYQ
MCWK%U+7M7^'WQ/\ &OBC7FLM1N+/PO!/&;6 VXF_TAU ?YFYW<9],>E=WJOP
M>T_7?^$E_MC6[Z<ZW=0WB,BI&UE-"NV-XV SD#'7.<>](OP>L+R]O[SQ+XDU
M;7Y=1TO^RKK[0T<:R1[BP.(U&"">,=^N:=T!B?\ ";?%.UL]7U*XT.S?3(M%
MDU""[FC$(CN%3?Y142DNA&<,,'CFLG2_B%\4M2UKP78J-!5?&&DM>1/Y,F+%
MT0,Q(W_O,AA@<<GKQSV&E_"&/3?#M]HTOC37[ZVELY-/M1<S1L+*!P 0@VX+
M;1C<V<#IBI]/^$UOINH^$KV'Q)J+/X6M)+.TW)#\\;KM.[Y.N-HX_N^YHN!P
MEO\ %OX@7WA;PG-:VNBKJ>I>(I?#UVTL4ACRA8>:H#\<(21D^Q%1>)/'GB.Y
M^$WC+_A(M%\/ZM>>&]<CTZ>.:V=[>Z3=&5DV%OE8>8IZD#%=;8_ VQT^/2(H
MO%VL-'I6K/K,*LL'S7#G+%OW?0Y;@8^\:?J7P5M]5T;Q5I-YXKU1K?Q+J":C
M<;4A!C92"%7Y.GR)U_NCWI 4/&%CJNH_'_PO9&ZLVMI-$OWC@N;0RQ*<PJ^X
M;QNR#C(Q@9'.:S/#OC6_\/\ PT\.V>C>'].MKW4->N=)2UTVV*PQ+%)-O=4+
M LQ6(]6ZG/M7HEYX!DN_B'IOC)O$VH)/I]F]E';!(3&4?;O)RF<L54G'H,8K
M''P>TX^!AX;&O:F)[?47U2SU-3&MQ:3LY?<I"@$99N".C'VH P=-^(7Q!DUO
M2/"NN:+9Z=K&IZE<1P74L;!&LHHPYF$0D)#G=C!;'!K2^#UO>6GB;XE07QMC
M<+KPW&UB,49!MXBI"Y.,@C/)YS5^^^$-CJ%CITMQXFUEO$6GW#7<.N^:GVD.
MRA2"-NS9M"C;MQQ]<[G@[P+%X0O]:O8]<U+5)]8F2XN&O70_O%0)N 51C(7^
M7I0P/,[[_A-=/^,GQ*O? <>CBXAL=/N)HKZ)V^T,(Y2$!5EVDX/)SVJYIOQ:
M\1?VCX/US78=-L?"'B33'E\X1N)+:[2,N8V8MC:0K%>,G&.V3V^K_#[^T?$V
MHZU9^(M2TO\ M:VCM-0@MO+*SH@8*59E+1L Q&5/?\:Y77M'36M7TCX36_@>
M[C\-:4UI=?VM+S;I%#AA$I/+.=H0\GAF- '>>#KSQ%JW@BRU+Q#'#:ZG>1F;
MRHXBHA5N4!!8G(7&>1SQ7SE>7GB;6/@?>:IJ][;ZUJT?C2..U-Q#L*2I=J@Y
M!.T$ +@#@9Y-?6P'R8' KR*;X'Z<VG7NEV_B[7;6PN-6&L);1M"R03"3S,+N
MC)QOY_#ZT 8VL?%GQ-X/F\>6?B&WT_4;G0HK*2QDM(7A65KHE55PSMPKXYR.
M ?6NR\#:YX]U+Q#K%EXLT+['IT21O8W;QI#).Q_UBF-99.%/0YJOJ/P>T37-
M>\3ZAKVI7VHVWB.UBM;FRD\M8T$1S$R%5#!E.2#GOSFMGP;X$C\)!Y)O$.KZ
M]=M"MNMQJDPD:.)3D(H4  9ZGDG R>!0!PVE0V_B/]JCQ3'KQ%Q_PCVFV@TF
MUEY1!*NZ695/&[=A=P['%=!XV_L_X?VNK^-M"LX4UO5?L>G%&XAD<S>7'(RK
MR2/-.3W"@5J^)OASIVO^(K7Q19:A>Z#XCM8C;QZE8%-[Q$Y,;JZLKKGGD9'8
MTVY^&^FZMX:U'1_$FIW^MR:E$L4]Y<2*D@"-N3RQ&%5-K?,,#KUS0!STWBKQ
M=X?\=7?A+4KZRU))]#GU2ROOLWEM%+$0K1NBMAE^8$?=/;)ZUQ__  G'Q?C^
M&GAOQB^J>'C_ &]-I\,-K]BDS&9G(;)W\Y!4GZG&, GU&V^'=O&+ZXOM?U34
MM4N[%M-&H7!B\V" DDA J!,DX))4DX'I7$_$#P7>:'\*?#'@_P .PZWK,-AJ
MUEMDA"//!!&V2V0 /E X..N* ,C6OBGX]\#ZOXE\.^(O[)U&]@@M)],O8H6B
MC/VB80_O5W'A&)[@D+UYXT_$OC;QSX,\477ANZU&TU476@W6JV=Z]H$:&>!=
MS(RJ<%",8[@GJ:[*3X5^&]2TK6[?7)+S6+C78HXKN[NI%$VV/F()M ";3R,#
MKR<U$_PET:ZBN6U36M7U&\FL&TN.\N)E\V"V;&Y$PH&6QRQ!8^M.X'#_ /"6
M_$RT\.>&+_6-?TLGQ,\+)%86#-<P(8&=EB0EO,;.S+'A06/'&,74O&'C'Q-\
M-/A]JESK$FEWUYXL33+I;>%!YH2>158CGD>6,@':3G@C%>K7WPIT?4-'\-Z?
M)JVKPR^'&)L;V&X5+A5*[&0L%P5*\=,XJBOP5\++X<BT%=0UE;:#4QJMM(+T
M^9;3!F;*$C@9=L\$G/)XHN!S%YX\U7PGXD^+=U=6EA>CPY8V-S T5N(99R\3
M$"5QRV#CZ#IBK=OXR\::3XN\):5?ZG::I:^+-+N+F.06H0V5S'#YOR[6^:+!
M PQ+>]=E:_##P_%JWB#4+R:^U$>(;9+34(+N8-'-&J;%&  <A<C.<\^O-1:5
M\*O#NDO;21W6I7,MC:/8:>]S<>8;"!Q@K%QQQ@;FW-@ 9Q1<#S3PS\1/B%<:
M7\,_$6KZS83VWBC4'T^YLHK((JKF3:X?=G=\@&.![>OT6I!'6O-;3X->&;+2
MO#>F6]_JPMO#5TUY8*;H91R<\_+R.6_[Z-=9X9\,VWA>PNK.UOKZ]6YNI+MG
MOK@S.K.<E5)Z*.PI ;]%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\]?VM%8?'N;/?3[<_P#H5%._:U_Y+W+D_P#,.M__ &:B
M@#V3]BYL_#[Q(O<:DO\ Z*6OJ2OEC]BX'_A ?$W_ &$4_P#10KZGH **** "
MH)?]=!_O'_T$U/4+_P"LB_WC_(T#1-1110(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNN=V!18#WG-56NK9+Q+-KB,7#J76(N [*.I ZD#(KPO5_BEXNO/AG\0GT_\
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M *>5*]EV\=>/0M6\4^,-:\;^*O#OA/4['2_^$;L89L7%OYK74\B%U4_-\L8
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MW2N1G@>G'7Z>HI@?/>B^)O#]CK/@G4I/$E_,/#%@]AY2>&;T?:%=54MD@[2
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M&Q7)3KDYS7N*7UI)</;QW43S)]Z-7!9?J.U,^WV?F>6+J$OM+;?,&< X)QZ
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M9F))*YX[5T/@SQ%XFO;6[U[7=:T+4/#1LTN(;VP5HVBD )E1P68%5QUR#[4
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MYSD#OU]ZXB2^M(/@MK6G:6TR2Z5XMDEUJWT^/]_'9&[<89<$8]%/&!TQFOL
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M/O6_L4C!'%+P!CH*0'QI:ZEI[_L]^$?#]Q8W44^F^*H8KZ.6S?:-MPSR9XY
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MWI8L=A'F\???]/3E^O?!C7-:;Q]M\5VT4?B_[/N4V))@$) 49W\Y48/N<TM
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MVSR=&@X]/WLM% 'I?[%?_(I>+.1_Q^P\?]LS7U=BOE#]BO\ Y%;Q;_U^0?\
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M_,T$BLQF5T&[D=2>2>_(Z&JT.I?$;QOJGB35M#\76NB-H6N&S6*XO66.."'
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M&P'N%!I6 ]4W"O._$WQ*.@Z]<Z5IOA?4_$!T\6[:@]@%;[*LS%4^7.YSA2Q
M' P:\?L-7U:W\$?"_P >:7XIU"_UC6]3@M=3AEO'>*]$K-YJ^7G:FPC VJ,
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MWKL^7Y@1TQU[57'QR\$-;RSR+JL26UR+6[\S3I5^Q.6 'G9&$!)'6@#J-?\
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M3/SGYSCYN0#SWK>HI <\/!GA%9;>5?"^E![9/+A86<>8EY^5>.!R>!ZFHO\
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M;4)[NX)EDPZN6PJ?)Z,1VZ"FR_!OQK?Z/XFCFU33]/U*Y\1#Q+I5S;N[B.<
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M** "BBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !113<G=C''K0 ZBBB@
MHHHH **** "BCO10 4444 %%%% !1110 4444 %%)N%&X4 +11FB@ HI*6@
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M-K5G\,]%MAX0U9+R+QM_:<EN+(JZP"Y+[R!GC81CGMCM18#Z$\0-K2Z!=?\
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MIJ\NLZ3K-G]HWVQ;?!#)N\S/^X #W)S6AXFTR_O+CXQM;^&;V7^VK&W@L'6
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MI5THC ,$K2JRE\D83:/O>V*+ ?0_B#Q)HWA?35U#7;]+*W:1849@27D;A44
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M[17[)8B":V'E,5=2'P4WJ <C/S#K6;\7/#&KZS<^%?%OAE8[S5O"M^+Q;$L
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M=NUK<V"A4CF=Y#YTOS?.A"* #Q][IVM?%SQA>>$]9\+VNL:MJ>C>%KKS$O\
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M)&:4,%&0,*IZ8.>HJQKUQ'XL\<7EU>WFE:;8:IX5ET::[36+=OL\[R;^F[+
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M=KB6+5KY'E<89R)VRQXY)ZT6 ]AHHHI %%%% !1110 4444 %%%% !111VH
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MK 94X//;!S63I_C0>(O%W@::+6[[1QJ5A<7#:+<6#K]M_=H0_F,  $R2/7-
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MZ^W_ -\_^@FFAHL"BBBD(**** "BBB@ HHHH Y7Q_P"(KCPIX#U37+.W$]U
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M<[2,XZ$]1Q4-GJWB2V\>?$+1VU2WDGL-'M)[.Z^Q('5C')S(1]\[ES@D#G@
M5W/C3P?8^-M#ATF^O+NR\FYBNX;FRD\N6&2-LAE.#CN/QK#C^&%G'JFO:@GB
M/6_-UNP6PN-TR-M54*HX)7.X98Y)/+'- 'E?A_Q=\5M2D^'OF^,+%5\96$V\
M'3D)M&B3=YB88;G.>0?E'I5BP^*7C3_A!].TMKB/4/$%UXDNM 6_$<<)=(@Q
M\P*Q"!S@ #IGL:]&TOX0Z+I+>$FAUC57/A:*6&RW2I@K)P=WR<\8'&.!5.'X
M&^%5\(WGANYOM4NXI]1;58[J2=1/:W)Y,D;JHP<Y]:=P-+X9M\1$L]4L_'ZJ
M_DW'_$ON6:+SYH#G!E$1VAATR,9]*YC4O$'C+Q3XA\<Q^'?$7]A)X098[>V%
MND@O91%YC&8N,A#]T;=O<Y->D^%_"EIX5TPV=O>WVH3.0TUW?SF>><@8!9CZ
M=@, 5A:M\+=#U+Q/J.O07^I:9/JT*V^I16,_EQWJ*,#>,$AL'&Y2#BE<#RN\
MU/6/'WBKX*>(O[6N=';5X+J=H+=(V6&18"6=2Z'.X$K@@\=/6O6OB!)KVA_#
MJ]D\$6>+^$HXBM8D,GE^8#*8U(VF3;N(!')]:+[X:Z'>>(/#>KP75]8'PXAC
ML+6TD5((U*A2-NT]5&WKTK:\5>&H?%6BC39M0O=.9)H[B*ZL9!'+%(C;E()!
M'4=""#0!XYX1\>ZSJVI^%)]/\<2:YI^HZW<V,T%S9Q03Q1"T,HCF4(N)$=#R
MN 0U:$/C?Q*HO]%DUC_3+OQE)H5K?RP)FV@$2R\*%"LV 5!(ZD9SBNEF^#GA
M^72%M4U75[?4AJ7]K/K,$ZI=O<%=A;<%V@%/E("@8]\TT_!;PN^A:II,E_K+
MC4-0&J"Y:^8S6UR,8EB8_=;CKR3WIW Y'XE67BNS^$UYI^N:U;:K=)XAL!IU
MXT:K)Y1N(=AF50J[PVX';P1CI78>"-0\46_Q*\6^%?$6NC6X;6&UOK6;[,D!
MB68R QX7J 8^"3FG7'P?T6Z\)Q^';C7]=FQ>QW\U]-=B2YN)8RI0N[*<A=JX
M   Q6[I7@FTTKQUJ?BV/5]2GN]1MX;:2":13$%C!VX 4'/+'KW/K2N!Q'BJ3
MXBZI\9V\+^&_&B:'IJZ1'J#?Z"DK*WGE"H+==P!Z].PKG[+Q7\6/$VMMXB\.
M>6=*M-;EL'M))($MS:QN8W+DYD\PD9!&!TX->MGP79-\2/\ A.?[0OOMWV'^
MS_LXD40>7NW?=QDG))Y/>N>C^#?A>U\9WGB:SN=4MQ>7'VRZTN*\9;.YGSN\
MQX^YSSC.,BBX'F]YXF^*4'AWQ9XP7QA ]IX4UJXB^P"Q0?;H(V7<C-_#P3C;
MSGK6A?\ BCXI>)]4UO4O!;&WM]&U*.VBMY9;=;>1%C1I?.W9?D.<;2,8'6M;
MP;\.]0U"_P#$[>*H]9T^PNO$$VH1Z:UQ%]EO(BRLA95W'&5!*Y&<<Y'%=-J'
MPC\.ZAXYE\4KJ.KV3W91KZQL[QHK6^*C"F5!][C Z\_G3N!YKX@\>>-=/^(E
MFT/B%[BT/BBTTF2UL[>-K**WE(!C>5EW&?J2%)"\9QD5WGP_\O\ X71\52@
M)N=/S@8R?LU%Q\"_"<\EZ5U#6K:&XU1=8C@@OF2.UN0P8R1CL21WSCMBNK\/
M>";#P[XEU_7K74;^YN=<E26X2YE5D0HNU=@"@C XY)Z4F!RFO:YXAU[XPO\
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M9-A&['(SUP<9IW \GTSQ_K6G:QX*\<>)];N+?P[XET65IK1V @M[Q$\P$9Y
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M,\8JG#\*/ \'ANW\/Q:2Z65I=&^M<7,OF6TQ.2\<F[<AR3T..:=P/&/$FO\
MC71= ^)GAJU\7ZAYOA:XL;FPU*1E:<Q7!'[B1B,L!G[W4UM"7X@:#X_\;>$;
M#QE=ZS=2^&UU.Q>_\M1!=&0Q@)T55] >.F>F:]4N?AGX/O-&U#2;K399;;4Y
MEN+UC=2^9=2* %,CAMS8P, G QTHU#X9^$=4U.[U*^TZ6YN[RQ&FW$CW<W[R
MW!!V'YO49SUS1<#C?@WJ]U?:GKMAJ6I:VNIVD-J+G2=:8O+:RX</+')DAXI#
MT(_NGM@4FK_VMXV^)'BWP[%XGU+0$T"RM?L@TZ?RBTLRM)YS_P!\#:%"].M>
MC:'X1T/P_>W-[IT$QN[I(XIKBXN))Y&1,[$W.Q.T9.!TY/K537/ 'AG7]8_M
MB^M;B*_:#[++/:74MNT\.2?+D\MAO7D\'/6B^H'@7VW4OB/H/P8US7;Z^M=0
MO-3EM9FM9C"&,<<H,R@<!FV?>'J<<5Z-^T!I2R? ;4HX[ZZ@%J]N=T<I!F!E
M1"'Q]\$-DCN0#7;7WP]\+:A)H[SZ>T8T7']GI;S/"EK@8&Q4( ..,UJ^(/#V
MD^)_#USH.MVOVK3[E0LD1=E)P0P.00000#G/:E<#Q/Q3X7O-0^,GA#P[IOB7
M4=*V>'+R-K^%P]T5#Q?QL#@Y(.[KP16;X6UOQ9<Z=\)KK4/$U].9M7O-,O(F
M9<78C,X5Y&^\6_=CC.#7LL/PY\+V^K6.K1V4YO;&U:S@F:[E9DB;[R\MSGU/
M.>:JV7PI\$6']F"STN5%TNX>ZM%-Y,PAE8DLP!<\G)SGU-.X'F5MK.N67QSM
M--\2ZYK-C+=ZM.VGM#/YNFZA;;&5;;:#A)$/)R,Y!]J]3^)'B:X\+^";FXTV
M%[K5[PK9:;;QC+27,GRIQZ#[Q] I-2VOPX\(V>O)K<.EDW<=S)>Q[YI'CBGD
MSOD5"Q56.3R!W-9'C[PYXHU;7=#U3P[INB7;Z6S2QOJ5W<0M%(1MRHB^4_*2
M/F]:0'F7PWANO 'QJN?"1T[4]*T?Q1IZ7%FMYY;;KR% )F&UW&YURYR<Y[8
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M$Y+$,O#9[@@\#T%:/A7PA\4?!EF\'AWPUX&LEF.9B+N[=WQTR[*20.<#.!2
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M]@5\??L3L/)\;KWW6?Y8FK[!J0"BBB@ JM/_ *^W_P!\_P#H)JS5>89FM_\
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MFO77@GXN6:>$]4BN=7NKF2QB>-5-PLEND2LN6QU0D^U9VEV'B[PQK^FZO<>
M]0U[2]5\-VFCW%I'Y7GVDT6X%75F"^6P8Y.<?U /4-2^)_@?28X);S7$$4UO
M'=^9%%)*B0.<)*[*I"(3P"V!3&^(>E_\+,3P,MM=M<FP-\UP+>0QA=P"X8*1
M@_-\V<9 '4UXMXX\)>-]2M-=TQ? \\27/A^"WLX]#DCB@#)N)BF<L&?9DA4
MVG)XZ8]#TVQ\06GQ6T'7I/#-Z+&Y\,II\A'E?Z%*L@<K+\W'''R[LGZ4] -O
MPYXRL8/!S:QKGBF#5DDU*>UAN+>U9"S>:RI L8&YG4#;P"3@GWJ])\3?!,/A
MV^U^ZUC[-8Z=,+>\,UO*DEM(<862,KO7.X=1CFO++'PKXQM]+\.ZT?#-T9=%
M\57^IS:9(\0DGMYVEVR)\Q&Y1(#@D=ZG\7>%?$FL^'/B-K.F^'+P2^)?L,%K
MICLBS.L) >1QNVJ",C&[.%[9HT ];T'QQX9\2:G<Z7H^H>==V\:S/$\$D1:-
MB0'7>HWJ2#\RY%6-<\3Z/X>DM8M2GE$UXSK##!;R3R2;5W-A(U9L <DXQ^=<
M=9V.M?\ "^UUUO#MU#IDOAU+(W;-%M243&380')X!QP.N?K4?Q4T&ZURYT4V
MNDZT;BT$\]OJ^BW*1SV$P"A04=@'1QN!'/3'>D!G:E\25L/BAX?F'B S^%-8
MT66]AMH;-GD>0-&$*A5,C9#'Y0.,'(X-=:WQ1\%C2=.U*+57N8=2BEGM4MK:
M6:61(_\ 6-Y:J6 4\'(&#Q7#:'I?CA/B5X0U3Q!X;FD-AX<EM;R[@,(A6Y=D
M; 4,#G"$' QEN..:XK3?"OCY5TFSNO =[%8K'J<;&VG@BN%>>X:1%>3?N6$J
M5)VG)8=".KT ])\2>.;R;Q1\,[SPKKD<GA_Q%>R03JL(83IY3,I#$97E2.,5
MM?#O7=9U;6/&UGJU]]L32M;>SM3Y:ILB\J-@ORCG!8\FO*] \*^-+72/@WI]
MQX0O8#X<O9O[082Q$1+M9 _#\@EL^N![XKTSX;Z7K&F^(/'<^K:+/IZ:CK;W
MEK)*T;":(QH@(VL<<H>#CJ*&!T'B3QWX9\)R%-:OGBD6!KITAMY)VCA4X:1A
M&K%4!/WC@4S4OB!X6TZ.T+W[W37EO]LBCL;>2ZD,''[TK&K$)R/F(Q7#>*-+
M\8:'\6[_ ,1:5X1_X2[1-?TN/3[FT$\<;6[QL^-WF<&-@YSU[\>L4>A^+O"W
MQ67Q=_PCG]KZ?J6AP:=-;:8R;K&>,[MJJY4"(],@]>2!2 ["X^*W@.U71I&U
MQ9DUM'>P:"&647 7J%VJ>>VWKG QFB'XJ>"[CP_:ZW#J,SPW5XVGQ0K:3&X>
MX7.Z+R=N_<,$D8XKR_P_X#\7>'-8^'!N/#TETFGWVI7U_P#9IHVBLOM._P M
M!N8$[=PS@''.":JP^#==G\/:M9:Y\/=7=;GQ9=:M!+I][#%=62NH,5Q$?,P6
M!X*GU]J>@'IS?%OP[+XAT/2[&VU.[CUB*XECN$T^XPGE-L92NS=D-D'CY<<X
MR*RU^)UAX?\ AW=^*+S6)O$\/]L264<EMI\D/DEI]BQ,NW(V9QN/WB,#)(K$
MT#1_B)INL>!]8UK1)=6GM8=1L[EDD@CEA6::-HI)L,%)V1DOLR=Q[YJJOAKQ
M=)\'O$-@OA6^AU-_$S:M%9/-"9)H3?+/\K!RN=@[D<T: >IV_C[PS</JB+=7
M"3:3:K>7L,MC/')#$P)#;60$Y"G@ GBL27XL^'CXE\*:5IL%U?V_B2WDNK>\
MBMY"@C49!^[DY)Y_N]37):S9^.(_&_B#5;'P1<WD7B;P_#:QG[3"OV&=!+F.
M4[NF''*YYXK,\.^&_&VDP?"B>X\*71;3-)N=+ODCGBW6C2",+(Q+8VX4GC)'
M3%(#UFU^(?A&\UZVT2VU827=TTD=N?)D$4[1_?5)"NQBN#D D\5JZ[XCTGPY
M:0W.K7#1)<3+;0HD;2/-*WW41%!9B<'@#L:\1^%_@/6]$OM(T'Q)\.[9KK0+
MB22/Q&]T)(Y8SG:T:YW"0DCJH  R><5WWQ9L/$%]I&AMH>C3:J+?5(YKI+-X
MTNHHPCC?"TF K9(!.00"<4 =CH'B/2/$UA+>:/<--%#,]M*)(GB>*5#AD97
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MPK)Y-SYIC?F3;@;QG)!Z_CI6N@>*I/AQ\488O![1:GJNJW-Y96]ZD+_:8W"
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M;D(^&P.X.3S5KX0^$=;\+WVOB32[O0?#\_D?8-'NKU;K[-( QF,;*3MC)8
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MM#\4>'?"%_IWBG28M/N9-3NKN,17(G#++(7[ 8QG'OUXSB@#TVBBBD 4444
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MZC'0XKT\>)?$7A+XGZ_IFH:M_;5GIOA,ZO\ /:Q0RS2JY'S.@&>%^@STXIV
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MW&J>!;[58=9U8:O:Z?:ZU(D=L!'/$SY8<H'&P@9XY&0>E%@/I6DXKSWX<_\
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M_@;CBLK;JGBCP1\+[O6/$&JR7TGB>>SEN(9O*,@1[G:Y X#*(QCCCGUHL!]
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MS1/)J<>RYB(<_NI?5EX&>^.U%@/0Z***0!1110 4444 %%%% !1110 4444
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MXFT&9=,:'4X)%U7/V(JV1<87<=OKP,U)K'B#1O#UK'=:YJ=MIT$DBQ))<2!
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M0"!T'!.,?SH U%^$?A1;/P_9Q2:G%%X>+&PV7T@,61CKGG@D>PXJI=>&=5\
M>%CI?PUT+^V)=1OG:Y74]0;;") 2\Q+9R-V"5')R:ZKPOXV\,^,[:YN/#6KQ
M:A':R>5-LRIC;T((!'MZUC:C\2-'MOB;:_#R/[3_ &M<VSSF3[+(T<739D@8
M(.>3G Q@D$T:@;O@SPS:^#_!6E^&[0)Y=E"$8HN [GEVQ[L2?QJQKGAO1?$B
M64>M:=%>I8W*7D E7(25/NL/S->:^ OBWIL^- \9>)+1_$DVK7=C#'%$45PD
MS)&.!A20.,G)]Z[._P#B/X.TO75T6^UJ.*[,RVY)5C&DK?=C:0#8KG^Z2#TX
MYHLP-.'POH=OK6JZS;V$<&HZI$D-W<Q91Y50$+DCN QYZ]/05ST7PG\&0^%;
M3PVEC=#3[.\^WP#[;-YD4W.65]VX9W-D X.3ZUT_B"2^7PSJ,VF7:6EW';N\
M4SQ>8$8+D$KD9^E?/EU\3?B+H?P<T+XG7GB32-3%UY33Z+]B$3RB1MNV-U8G
M>!ST['Z4 >NR_";P7-9ZW9R6EZ8-<Q]N3^T+C$V  ,_/Z*!]!BNBB\-Z7'X3
M/A:2)[C2S;&S:.XE:5GB*[2K,Q+'CC.<UEV/Q \.WOB9?"IN)H=>^RK>264D
M$@:.,J#DMMVXYQUZ\5QC>/+W4OB_X0AT;70_A36+"]F:"2S\MGD@P"VYP& ^
M;TQ\IZYX+,#HK7X2^#+,Z&UO;WJ-H;.UD_V^8LF_ ;)W<\#;SVXJJOP1^'BW
M377]EW1F:[DO2_\ :%QN\R1=LASOS\PZ^M:_A_XD>#O%&K-IFAZQ]JN?+>6,
M>4Z+.BMM9XV8 2 'C*DBJZ_%?P&VB-K2Z]_Q+TO1I[3&WE 2X/'EG*Y!R1UX
MHU JQ_!KP!#X<C\/Q:/(EA%>+?QJ+J7='*I)!5MV5')& 1P3ZU/\3]#U+5/@
M_KWAWP]IYO;V[LS:V\ D"=<#)9CC@<\FK^I_$/PGI&J76EWNI-'>VJQ%X5@D
M=CYIQ&J[5.YCV49/M6IX?\1Z1XHTUM1T>X:>W65X&+Q-&RR(<,I5@""#ZB@#
MF_"/@'1=+TBSN;K2)(]1;3DL)H[RX:Y,<6!NB!9F&TGKCK4>D?!SX>Z%;WL6
ME:";5+R%[>0+<S?+&QRRH=V4![[<9K:\<KK8\&:C=^'=6&FZA:PO/'*T*RJV
MU2=I#=CZUPGPV^)U[X\\+ZAHNI,WA_QII]N/M,3QJ<%ERD\:GAD/!].0.X)>
MX':2_#WPQ)X8TSPZ+6X33]*D2:S6.[E5X&0$*5<-NX!.!G%0M\,O!KZ)!I3:
M3F*"[-_'-YT@N%N"<F7SMV_<>YW<CCI6-X<\>0Z/\,O#>K>-];DO-6U:T6ZV
M069>5\J'8)%"I)501DX^IJ+5OC9X2L+OPO#I_P!KU6+Q%+M@N;6UDDC51G=G
M:I)<%<>6!N'<#%(#<N/ACX/NK6VM9-/E*6UZ=25A=2AWN<@^:[!LNW P6SCM
M6SI'A71M#U;4]6TV&5+O5'62[EDN))?,*C"\,Q P..,<5C3_ !/\&6=MKT]Q
MJ<L2>'I(X]2W6DV;8O\ =R-O(]QD 5B?$CXA:3IWAJ2QLO&2>&M6N;6*]M[V
M:R>54A:0#."I&6&5 /.3TH Z?Q+X$\.^*[J.[U:*Y$Z0M;>9;74L!:%F!:-M
MC#*D@9!K=ATO3X-&CTB&UC33XX1;K;A?D$87;LQZ8XQ7":I\0X8?'EO\/+9;
MI-5N-/DN?MQLG>*-AM"-@##*2QR<@#&"<FL'X5_%O3M8T+P[HOB7Q$EWXKU'
MSP=MOL21DDD^7*C8&V(#C.?;F@#K-!^$OP^\.274FD>&[=/M,;Q.LI:551L[
MD57)" YY QGO4V@_#/PGX;N$FTRTN \,+V]OY]W+,+6-\;DB#,=@X'3'053O
MOBYX+L]5N-+^W74]U#YRA;>RFD65XE+2(CA=K,H!R >O%4-#^-/A74O!VF:_
M?&[LI=2+B"S^R322R[1N.Q53+@*02RY4>M %]OA#X%;1;#16TRX-CI]V;ZVC
M^W3CRYB2V\'?G.23]3[UH6OPW\)V>MIJ\5C*9X[F2\2.2YD>))Y-V^18V8J&
M.]N0.]0W?Q2\!V&C:-K%YXB@AL=:;;93,K;92,Y[?+T[XYI^E_$SP1J_A.\\
M4V>OP?V38R&*YGE#1^4XQ\K*P!R<C QSD8H I6GP?^'FGZY=ZU9^'Q;WMP92
MSQSR*$,H*R%%#80D$C*@'DXI]O\ "/P-:VNBVT.FW"1:)(9;!1?3@6['))7Y
M^O)KS:Z^*M]J/C'QU%8^,'TG0[#1(;BUN;S36C^P3R-MW,CH'?L1D$?-[5Z*
MWQ*\)^&]+T2S\3>*X9M2O;!;J.80,IO%"9,BHJG&[LHYYP!1J!O:'X+\/^&]
M:U75M'LC:W6K2>==8E<HS]V"D[5)/)P!FL[6_AEX1\0:[-K5]8S)=W40@NS;
M7,D"WD8Z+,J,!(!TY[<=*=#\3/!EUH.GZY9:S]KM-09H[9;>&2665E^\HB52
M^5[\<=ZU?#?BO0/%NGR:AX=U*._MT?RW9 04?&2K @$$9Y!Y% %2Q\">&=-\
M4Q^)+&Q-OJ,5HMBC1S.$6!?NQA,[0H[#%6/%/A'0_&5A;V.O6KS16]PMS"8Y
MGB>.1<@,&0@C@D=>]4=;^(O@[P]J[Z3JVM);W<8C:5!&[B 2-M0R,H(C#'@%
MB*KZ[\4_ ?AO4+S3]:\26UI=V2H\\!#,Z*_W3M4$D8Y..@Y.*0%2U^#_ ("L
MX&AL]'DMU-Z-04QW<RF.<#&]3N^7@GIUSS75:!X=TGPUIK6&BV8MH'E>9QN+
M-)(QRSLQ)+,3W)K/3Q[X3?Q)9>'8]9B?5+^ 75K JL?.B(SO5@-I&!GK6CH>
MO:9XBL'OM'N?M%NDSVYD",HWH=K 9 S@@C/3B@#8HHHH **** "BBB@ HHHH
M **** "BBDW4 ?#O[://Q"\-?]@QO_1K44_]L]-WQ!\,MZZ:W_HT_P"-%4!M
M_L3Y\SQOZ8L__:U?8M?''[$__'QXW_W;/^<U?8XZ5(!1110 57E_UT'^^?\
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MN;_9_>)^'T-?29P!7'O\2/!<>D:EJS:[%]BTV\%A<S!&(CG) "=.3EATXYH
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MKA(WA'RL"K]P1\O..Y/2O0?B)K7B;PW\/?[6T>:Q_M.&:VCD,\3-&^^5(VP
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M27K6J7=P-R6R(F]VVY&YB. ,CD_@?//$OB_Q9?\ @WXK^$=2OK6+4/#5EO\
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MN* ,%O$WQ"O?BGX@T'3Y-$BT;0WL[B:22*4S/!*KLR#G&_"\'IP..>,+P?\
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M:\_\LK/C\9:^RZ^-/V)Q_P 3'QL<_P#+*S_G-7V70 4444 %5YO]=;_[Y_\
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M<XH 6BCM10 4=Z*.] !BBDI: "BBB@ HHHH **** "BBB@ H[T44 %%%'>@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 @.:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *.]&:*  ]*2EI.]  *6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3I0!\8?MK?\AKP
M6/\ IA=_^A144_\ ;8'_ !-/!)QUBO.?QAHJ@*'[%G_([>*>./L$?_HROMRO
MB']BUL>./%"]SI\9_P#(E?;U)@%%%%( '2JEQ_K[;_KH?_035L=*JW'^OMO]
M\_\ H)IH:+*TM(*6D(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2"EI!0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11WHH
M*.U%% 'QE^VR?^)AX(7;G]W>'/XPT4O[;/\ Q^^",+QLO>?QAHJ@,W]BTG_A
M.O$XXQ_9\?'_ &TK[>KX@_8MV_\ ">>)N?F_LY,<=O,&?Z5]OU(!1110 #I5
M:?\ U]O_ +Y_]!-61TJM/_K[;_?/_H)IH:+ I:04M(04444 %%%% !1110 4
M444 %!Z444 ':BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 449HH ***3K0
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M>7A__P !)/\ X[2#]L+XK?\ /EX?_P# 23_X[112 0?M??%?=_Q[Z#_X!O\
M_'*3_AKGXL9_U>B?^ ;?_%T44T 2?M<_%C:=J:(OTLV_J],7]KKXM>FB_P#@
M&W_Q=%%# <?VM/BUM^]H_7_GR/\ \536_:V^+7E[MVC Y[61_P#BJ**8$/\
MPUI\7/W?[[2??_0NOU^:ED_:T^+GF\3:2!CH++C_ -"HHH <?VL?B[D_Z5I0
M^ED/\:A'[5OQ@Y_XF.G?^ *T44(!?^&KOC!Y3'^T--R#_P ^*U _[5WQBW_\
MA33_ /P!2BBID G_  U?\8L?\A33_P#P!2C_ (:L^,F-O]L6/U^P1Y_E113
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M_P"1^U+_ ,<_^)H;X\?& L,^/M2_\<_^)HHJ &GX]?&!4_Y'W4S]64_TI/\
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M?B%K_P#X'R?XT44 +_PMSXI9;_BX7B#_ ,#Y/\:3_A;GQ1Q_R4+Q!_X,)?\
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LC77C_P!Q*;_XJBB@#'U'7-9UH1MK&K7FHF+.S[5</+LSUQN)QT%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>skye_ex31img24.jpg
<TEXT>
begin 644 skye_ex31img24.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 2D Y8# 2(  A$! Q$!_\0
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M /;Z^S*AN/\ CUE_W30-'QZG[$<A )^)8_\ !/\ _;Z>/V(FYS\2_P#RC_\
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MEK^Q/H@^]X]OC]+)!_[-3O\ ABCP_C_D>M0_\ X__BJ^LJ* /D__ (8H\/\
M;QSJ/_@)'_C33^Q3X?R,>.-1]_\ 1(_\:^LJ* /DX_L4^'L<>-]1SZ_98_\
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M8?\ AB[X>_\ 0S>(\?\ 76#_ .-4X?L7?#O//B7Q)C_KK!_\:KZ<HH ^9?\
MAB_X<[?^1D\2Y]?/M_\ XS2']B_X<XX\1^)?^_\ ;_\ QFOINB@#YD_X8O\
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M:KZ-HHL!\Y_\,=?"S_H(>(?_  +B_P#C5 _8[^%G_00\0G_M[B_^-5]&446
M^<_^&.OA9G_D(>(<>GVN+_XU2_\ #'OPKQ_Q^^(/_ N/_P"-5]%T46 ^=?\
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M;_42?[IJ6HIO]1)_NF@!Z]!]*=35Z"G4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\@?ML#_1?!'S*/GO>#UZ0T4_]M?_ (]? _W?OWO7KT@H
MH ]!_9/8?\*"LEYS]NN?_0Z][KP3]DT@_ &T[D7UR/I\PKWNFP"BBBD 5%-_
MJ7_W34M13?ZB3_=- $B]!2TB]!2T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\@_ML'_1_ ZCIOO3^D%%-_;97-OX&.['S7O'X044 >A_LE_\
MD%MMH_Y?KC/UW"O?:\$_9+_Y(%:_]?\ <_\ H0KWN@ HHH[T %13?ZE_]TU+
M44W^I?\ W30 ]>@IU-7H*=0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%)NHZT ?'_ .VTQ\CP,NS/S7QSZ<0<44?ML[A#X%QR-U]_[0HH ]"_9);/
MP%A'IJ%QC_QVO?QG'-?/W[)!!^!$8'4:A<?^RU] TV 4444@"HIO]1)_NFI:
MBF_U$G^Z: 'IT'TIU-7H/I3J "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**0T8- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@5X+H]GX@M/AW\,=4E\-ZL%\'7_DZI8O:-YC+Y;Q--'&,F0(7R"!TR1FO1O
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M6709YQJ*^0F80T31[CAN06<'W )Z\5])K]T=J %HHHI %%%% !1110 4444
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M4 %(W2EQ10!\>_MKK\G@9M^.;T8_[\44[]MAAY7@9?\ :OC_ .B** .W_8_
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M;TN;S;*^A2XA<C!*, 1D=N"*KZ-XFT3Q!<ZK#I=ZERVE79L;DKT64(K,H/?
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M,.I8_*^0#NZ\#)[563X*Z OA5M!DUS7[AC<PW,E_-?&2YD,3;HE+L"-B'D*
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MB5M/MF<)Y88PKD)C&W..F"1CWKDO%'@.]\07EG:6?B!M(\-F-XM1TJVM(_\
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M+:.9K:8'!5U7.WJ#G.,$<\TZ'XK^&9H->D\O4XVT.W%Y<136$L4DD'/[V-&
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M^(;SQ%9^&["'5KT%;B[6$>9(#][)]^_KWKSKQ-\0/#?BKP?H.J0:QXCT./\
MX2*&Q86<+13K<JV#!.#]U#GD'K@<'I6]X1^(U_XF^)WBOPK)X=NK&VT/R8UF
ME R78,26(. &&TJ!G@$GKB@#?C^&GP]AM/LD?@O1U@\[S_+^QH5\S^]C'6I[
MCP'X+N]7N-6O/"NEW%_<JB37$MJC.X4@KDD=BH/X#TI?%/BVQ\*Q622VMUJ%
M]?S?9[.PLT#S7#XW':"0 %4$DD@ "N3NOC7X7M/#J:M=:?J\3#41I4]G]C9I
M[:X)'R2*#QD$$8)W \9HU ZM_ ?@N6>]N)?">DO+?@K=.UG&3< D$ASCYAD
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MU\-Z;!I=WGS[2.UC6*7/]Y0,'\:T=(TG2="TR+2]%L;>PLH<B.WMT"(F3DX
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M328!1112 *BF_P!0_P!#4M13?ZB3_=- $B]!2TB]!2T %%%% !1110 4444
M>5?%3^T)-?\  C66AZCJ$5AK<=_=2VMNTJPQ".1"3COEQQ@G%<AXCL=8N]'^
M-%O;^%=6>;6"B6)6T+?:3]F2+*YZ@,I/H!R*]OU'7M(TK4M-T[4+Z*"[U21H
M;2-SS,X4L5'X"M3 I@>$S7GB+P]XYNM6D\!ZIXBT7Q5I-G:B"&)2UO-&KJT4
MR2$;$82$DGCKG-5X8=?\&^(O&4>L^$+S7+?Q39P2VJ:7;F:%9%@\I[5B2/+4
M<;2<#;GOQ7OV!Z4FT>E%P/ /A]X4UCPM\3?#]AJFBW<\.G^$X]+DU 6^ZV%Q
MYOF%5?T &,X[ >E9LCSZQIWQ9\%6/AW4;N_UK6IK:&Y2U+6R,\,2AGEZ+L^\
M<\^E?2)56&.*YWP]X0TOPS=ZI<:;)=N^JW)N[G[1<-*#*1@L Q^7@ <>@HN!
MY5#IVN>!=8\:Z3>:!J/B*T\2*)M/GM+82J[^0(FAE[1CY5P6^7!/>I/!'A[4
MM ^)VD:3J.CW]S#IWA2#26U)[<FV:='WL%?N,>O<8%>Z<4<47 ^:/#NG>,5\
M9>&-6U#P7K8N;'7K\7K I':QK,LJJT,6X#R^0S28!8D\L35N^L/%$/P\\=>&
MQX/UB:XEU][RWEBC1EN8Y+M904^;D!!SP ..]?1F!2T7 \=NKC6/#/Q0U;Q)
M)X7U76-)\1:7;QHME;>;+:2P[_W4BY^4,).O3(.?6N7\!^#];\$>)_!%A>Z-
M?7,>GZ3?)<W=O$7A@EN)ED6('/.T*03C&<>M?1/%'% 'G/P>M]0L_ !L=2T6
M]TFXBOKN0Q7<80E9)WD4K@GC:X'U!KD;S0]<?XS#5O#NCZUHUU)J:#4G=@^F
M7]HB']\1GB8_*!@ @J/<U[K28%%P/GQ=+\3CP-JUJW@W57O)_&:ZK''B,,T
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M$\-:]K7ANUTG3K30[C2+A1J*S2Q%P!YGRK@Y*\ 9XZD=*L?#WP]\5-(T/3O
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MZ'P<'G&.?6H?$/@/XE>.=<UW5;[P]IFAM?Z)!:0I)?\ V@K/#<>>H8*N"K$
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M@%CR6S@8Y];T^_@U/3K;4+7)M[F)9HRPP2K $9';@U<_*BX'AVA^&O&=C/\
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M=-O++[!'''LW3@2;AR&'E#N!CJ"<DR>%_B)XTN/'/@NUN-8;5=,\2/?)-/\
M98H[7,:EH_LW E( &"SY![$UZ#:_!OPQ8^'-'\/07VK?V;I%XU[;PM= _O&)
M)R=N2/F?C_:-4M/^!?A+2Y]$FM+[7=VAS/)8!M2<K K9S&HZ!>?J>A.*=P.#
M@\8?$BS\.V/BNZ\717D*>*FT6:P.G1H)X3=F'+..00,$;<>^>M:VK>+/&&F_
M#SXLZE::Q!#J.@:E(MG<1V<8 01Q-AAC#'#$9.3]:[/_ (4YX;.@+H<FHZQ)
M9KJ?]K@-= G[1O\ ,SG;TWG=CUJ67X2>'Y]%\1:3/J6L3VWB.437X>Z!+M@
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M3M8D @<#':G<#Q[PMXE^)>IV&@_$#^V;*72;M)7O+!KQ668E&988HA$"DBD
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M#G=M7=A5;)R!@'CT%7+[X/\ @>_EUQYK&[ UR19+U(KZ:-'8,&R%5@%R54G
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M 6?PG\)6*^&UM4U%%\-LS:<O]H3$1;A@Y^;YACC!XP2.E=_0 4444@"BBB@
MHHHH *3FEHH **** "BBB@#XY_;;W>;X$ZXQ?_\ MO13OVVMN[P)NZ_Z?_[;
MT50'=_L?M_Q9"X'_ %%I_P#T".OHFOG;]C\#_A2%QQS_ &O/_P"BXJ^B:D H
MHHH *BF_U$G^Z:EJ*;_42?[IH >O0?2G4B]!2T %%%% !1110 4444 9NIZY
MHNBQI)K&K6>G(YPK74ZQ!C[;B,U6NO%/ANQ^R&^U_3K7[:H:V\ZZ1//4XP4R
M?F!R.GJ*\O\ B\UK'XCTJXMK^;3->M["ZDMIYK1KBSO(CM$EG*HSR^%QCGY>
M,GBN!-SI]OJ4T'Q!\,>(+#3O$V@V$=C9:6D\B1A(BCV9"?,&W'(S_>Y(ZT[
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MY'S':N(VF\2_"Z+1M)U#3V/AZ\LYKA-,F1+66:%(X_,.P!?WBG.<8ZG .:+
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MQAJGCSPK\)'UB/Q9;7FIQ7L(CNFTY8Q+;RS)&H>,GAP'SD8Z=*XL^']<\+^
M/AOHT_A[5;JZM?$2ZG-%9VYG6R@,DK[&V\#:)%&.G!QTKT'XW&^F^%LVG:5H
MNHZI=W=S;%(K*V:9EV3I(Q;'3A3U[T@.@UGQ]X5\'366E>*/$D,.I2P&15=#
MOG"CYB%4'DGHHY/09JS_ ,)[X6/AO3M?AU1;FQU(?Z$;>)YI+@X)(2-07) !
MR,9&#G%>?^)I[Z\^-WP^UR+PSJTFGP6%WY\PLF(@:95"*_\ =;Y3D'IFO/\
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M]Q]E@F8-@RYP488RA!Z[L8[U2D^,OPYCTR#5%\1B:TF@-SYD%K-+Y<0<H9)
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M%'PN?P1IWAO4S>3>(Y;A=36VVVT")?\ F-,)>FY54J!RQ/&,5K0V/B%_AO\
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MBN^O[^RTO3I]1U"ZBM;2WC,DLTK!411R22>@KSO_ (6?'?>)?!*Z4]C+X?\
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M\D/N ;\,>]6_"OPXN='\92>+]=UYM:UG^STTU)Q;+;@Q!MQ+A2=[D@?-QP.
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M6QL!P"N#@YKB[JQT'5/"FL:7JW@SXA7NIZI?#4I=5.BA)HKE5"QR(%.U=JC
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MHH **** "BBB@ HHHH **** "BBB@ HHHH .]%%% !1110 4444 %(5!I:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 449HS0 449HS0 449HH **,T4 %%%% !111F@ HHS1F@ K
M\7:XOAOPG?ZP(O/GACVV\ .#/,Q"Q1CW9RJCZUOUAZYX9T;Q)':)K%O).MG.
MMS"$N)(MDJG*M\C#)!Y&<X- '@?A2U\0_#OXL>&M0UO1[FQM_%5J=-U>ZFEA
M;[5J>7F68A';&<L@Z<8&.!4WC"]\:Z?XV^+>H^"H[.::&QTXW$4B,TQC\F3<
MT0SMW@9(!!S7M_B7P;X<\80VEOXBT]KV*TF%Q"HN)8@D@Z-\C#)'8GIVJOHO
MP_\ "WA_7;W7-+L)HM1OD"7,\MY/,9@.FX2.P..WI3N!G_"RQ\,6?PI\.0>$
M[C[5I"6H:"9\%W+9+%L=&W%LCL<BL;X,HO\ PCWBC<N1_P )1J1 Q_TWKKO#
M_@?POX5;4/\ A'M-.G+J#M)/'#<2>66)))5"VU#S_"!1X9\%>&O!\5U'X>L9
M+2.ZD,TJ-=32JSGJV'=@">Y&,]Z0'A7BR.^F^&WQW735F:4:P&81YR8EBMS+
MCO\ <W9]J]NTB?PQ=_#33IO]&.@R:?&<R$"(1;!C)Z#BI=%\"^%_#U_J5[I-
ME)#-JDC27GF74TJW#'JS*[E2>V<=.*HZ?\,/ ^EWRW5AH8A"2^>EO]IF-M')
MG.]("YB4YZ$*,4 8F@N&_:-\8_-\HT73AC_MI/5+XTZA:ZA\-YH;"\C,UKKF
MG6\I(W"*3[3"V".^ RD@5U%S\,O!MYKMWKLUC>C4[P!9[B+5+N-G4=%^6484
M9X X':G7'PR\$WGAV#P_-H[G38+DWBQ+>3J3.6W>8S!PSMGG+$X-,"OIMOXI
MTOQ<+SQ7XFT^^TZY@2ULX+>V:W(N-S$G:7?<2HZY['BMWQ;=Z)9>$-3N/$4:
M2Z5Y#+<1NF\2*PQLV_Q%L[0.I) [U1T_X?>%M+UFWUFVL[J2]M@PADNK^XN?
M+W##%1)(P!(XR!G!([U:\1>#?#WBF6PFUVSENGT^43VZK=31*D@((;:C $@@
M8)!Q2 \4^#<4W@WQU+X/\:13#5[JQ6?09;FY,_EV&XDV@)  >,XW =<>BBNG
M^$;*WQ0^+C<?\AR/'!_YXUW?B'X?>$/%>KV.K:]I)N[[3QBUF%S+&8.<Y78X
MP<@<]>*?X>\!^%?"NI7VI:#ILEK=WYW74ANYI?//]Y@[D$^_6@#J:*** "BB
MB@ HI,TM !11FC- !11FCM0 44TN *-PH =13=ZYQ2AE;H: %HI-W.*"V* %
MHI-PSBEH **** "BBB@ HHHH .]%%% !1110 4444 %%%% !1WHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#XY_;:QYO@3UQ??^V]%-_;;_
M -;X%_W;[_VA10!Z#^R!_P D.G_["T__ *!'7T/7SS^R"?\ BQLP_P"HM/\
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M=\%6=UX@UNX\5)?:BMO9:E9PK*9X96'DNPC 4  \D<<9[XKH/'GBF'P5\/\
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MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'!- 'J%%>&?#GQQ:^&?A!!J7B+5+K59I]9N[.U,LXDFN6$\@50\K 8"J3EF
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MHIM_X5_H."<_\>2?X5>T;X;^ ?#^K1ZMH?A#2=-OX@0EQ;6JHZA@0<$#N":
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MVB29P2%W,%'0$]6 _&M488 TP/G_ .&_P_\ 'OA9M,\-ZEX?\/'3](NS(GB
M(DEQ<6X)*QA-NY7.1EB>!P,FOH$#@"F[DW!=PW>F>:?2 **** "BBB@ HHHH
M **** "BBB@ I".#2T'I0!\9?MKY^W>"#G'[N]&,>\-%2?MK_P#'[X'&W)V7
MO/XP450'H?[(*_\ %C)3QDZK/_Z#'7T-7SW^R'_R0M\_]!2?''^S'7T)4@%%
M%% !4,__ ![R?[IJ:H9_^/>3_=/\J )%Z#Z4ZFIT'TIU !1110 4444 %%%%
M 'C/Q"N[BY^/OPS\.WLA319VN[QH\_)<W$4?[M6'0[<Y&>Y]J[CQ58:-8B#Q
MS>V[-=>&;>YNH3$0K,AA8.ASU!'/;D"K7BOPEI_B[3(;6\FGM9[6=+JUO+5@
MLUK*AR'0D$>H(((()%4K7P8TEVESXEUJZ\1O%&\427<4211AU*N=D:*"Q4E=
MQSPQ QDY .%F\;>,]&TOP/XFU34K"^L/%5W!9R6=O:%19M<1EHF1M^7"D88'
M[V<C;6/'XT^*_P#PIO6?B)-K6@,EK:W3PVL6G2$AX;ADW$F7H50_3CKS7>:'
M\*K#1H-*L&US4[W2]$F:?2[*Y,;+:.595.[9N?8'8*&) XZX&,+QCX+G\,_L
M]>)O">BR:IKDMU!.EM$(5DEWS.6( C4<;F)R>E,#G]?^)/Q"^'J6>L>*+C3=
M<TK5]+GNH(K.V,#6EQ'$) F[<2R'/+$ ^@'2MC5O%OC[PUJWAZSO-0L-2A\2
M6-PR3_8R@L+J.'S1PK@O&0".3N&,Y/2M7P_\.+76?#6F3^+=0U75R=&.FK9:
ME%'%]E21%$GRJH/F?*!N))P./6KMG\)[.&'3X[[Q'JNH_P!DV<UCIC3F+-G'
M(@0D80;W"#:&;/';/-&@'&Z;XP^)B_#;2/%^O>(M!@AUL6041VC[[5)-V\HN
M3YTI!0A .N1@@<X7B;QIXRU[X/>(WDU&;3;K2?$J:0TOV0(]W 98U_>+GY3\
M_.W (&,<UZ;<_"73[KP%H/A4^(-51O#\\5QIVH*T0GA:,;5!^38P )'*FJ,?
MP1T7_A'_ !'HMQXDUNX@UZ]34))))HR\$ZLK;T.S&2RC.<C@#% %36O&VK^$
M?B/J<&L?8[[3=.\*RZJ)TM1'.[I( 5+[CP2,X  &1UQ44/C+QOIY\!:]J&H6
M>H:/XMDAM[BUCM@K6,L\9>(QL#ET'W6W9/?C/'61_#>S'BR+Q'?:YJ.I7 TK
M^R)8KM86CN(2VYB^(P<D\G! ]L5#H?PMT_13HT/]N:G?6.A/))IEG<M$4MF9
M64'(0,^U78+N)P#WHT X4>./B1;Z9>^(+S6M)DL=)\3_ -C36<6GE&NHC<)%
MNWF0["-^1@'IR37H?Q \4WWAV+0+'3);>WO-=U2/34N;E=T=N&5F9\9&XX3
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M"&6TE0RN!(X!5<' < [L'/ Z5W3>//"$'B)/#DWB&S75VE6#[-NY$K+N"$]
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MG1(3$94\J)ER"2<YDP3G&:[.;QYX.MO$R>&9O$5DNL.ZQ"T,GS[V&50^C$=
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MS<0V\H=HQTSQVSQFOG_Q1I$^H:Q\;"OA/4[B;4[&VCT^0:5,YG=8MC"-MF"
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M9-6:5+?R#G(E8 JA(&%9LC )R<BJMGXFU"Q^(!\'Z\8&DOX7O-+N(5*^;&A
MDC=23ATRISG#!O4&O!_&4'B*;7/$ZIX/\08MO$UIJ<5MIVGEK>YC1XMUT9>3
M)(RC&Q3A0.1P2/1O&,-YKGQ\^%Z6,;)-I<=]J-[N S!"T:Q+G!_B8E?S]* /
M2?$/BK0/"MO!/K^I1V8N9/*A4JSO*V,D*J@LW SP.*I3?$3P1:Z;I>HW7BC3
MH+35E9[*62<*LZJ,L1GL._I7&_%HZJOB;P9-9Z/JDUM'/<";4=(M/M-U:EHP
MH1000BOR&<@X [=:\W\/V&J+X'^'.DZIX,UU7T7Q///<"?3GE*19N")#M!R
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MG8W,&I-%I,T*PRO J?O3L&,R*V2>_P V<')^D5)* E<''3TH =1112 ****
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M$9'S'CCG9\9?$KQ'I6H>-H=(;28%\*6D-U]GOHG>2_#H7.TJZ[1_"#AOFIV
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MZ#)XR>E 'FZ_".ZGTR&VU?QA=7\UCILVEZ?*+6.-;:.1!&S%!]]RBA<DXQG
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MA>WLD\3V4EQI,EO>&7]ZJ>8()<H-K%2.1D9XJ*7X7ZUJWBCQC>>(M4LYM/\
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M!(X)QMW'AL47/PL\2-;_ !'M[?4-,AMO%EM%:6J".3-HD<(@7=S\WR<_7VI
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M\Y]6VGPK\2:?IW@^[A\364WB#PJCVMM,UBR6\MJ\8C:)T5]V<*K;MW7MBJT
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M"22%P.,DD\>I]:Q?%WQ&LO"'B#1]#FT/5M2O=8$GV1;&!7$C(NXIDL,'IUX
M.20 :Y>3X]Z!'I^G3#PYK[WMY>RZ:VGI:J;BVND3?Y3KN^\W&,9'/.,&@#<U
MKX<275Q!I_AS4+3PWX:N XU;3;#3XD:_!(X\P#*9 *G Z,:]#CC6.-448"C
M [5YQ<?%6!;::XL?"NMWRV%O#<:I'%%&LFGB1/,V.CN"TBKRR+DC(ZYQ5_3_
M (E:3J7C6P\-VUE=E-3T_P#M*QU$[!;W4.%)V'=NW#>N5*@]^E/4#I]1T32-
M6GM)M4TNTO9+.3S;=KB%9#"_]Y21\I]Q4#^%?#;Z(^AMX?TYM*=B[69M4,+,
M3G)3&,YYS7G\WCC3]8\8^"FDA\1:7]LOKV"U1&C6VNS'&P)EPQW*=I9,>QZ5
MJZ?\3K/6-7:RLM!U6>Q>ZN+*/4(1&\320JQ<$!]Z9*,%W*,_0BBP'7W7AS0;
MVPM;"\T6QGM+1E>W@DMU9(67[I5<84CMBFV_AOP_9WMS>V.AV%M=7:E;B>*V
M1'F![,P&3^->8^"/B!X?TKX9Z))93:_K=SJ=]<6EC;:BZO?7,PE?<K$D*H4
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M^G#[*);B=KF:.QM_(MHW8 %8H\G:N%'<Y.2>37)_$;QG--X7\8:+HPU6RO\
M3=";5/[4M9(UCA)5F1-P8L&.P\8Z#.>0:EN/BQI'A32=.MM4M=4U"2VTRTN]
M2NX$5UM4E^19)"S@ME@WW QXYH M>./A[?>,/B+X6UJYM]&O=#T99A-9W\;2
M-*9=H) P5^4*"/>NNG\(>%[S0HM N_#NG3:3$P:.RDMD:%"#D$(1@')/;N:S
M[OQS9VOCNW\'OI=^;V[LGOK:<(@@N%3[R*Q<'>,C@@=0>G-9&F_%K1=6\.66
MN0:7J*076I2:8\4BQ+);O&',CR+YGW5$;$XR<#I0!NS?#[P)<0O!<>#M%EB>
M03,C6,1#/C 8C;R?>I;_ ,$>$=4O+>]U+POI5Y<VR+'#+/:1NT:*<JJDC@ \
MXZ5E^$_B'8^,+Z&&QT75+6VNK1KZTO+B.,0W40<)E2KL0?F4[6 .",@5U6JZ
MC#I.BWNJ77$%G ]Q)C^ZJEC^@H S=0\'^%M5U%M1U+PWIEY>-";=KB>TC>0Q
MX(V;B"=O)XZ<TV?P1X/NIA-=>%]*GD%O]D#O9QDB'_GGG'W?;I7+^'?%5YIO
MPU7Q]XTNR&U-([J.R@7*P))CR8(EZLY#(#D\N3C P*Y71]3\0>*_C%XIT=KW
MQ)X:C_L:WN+>WNY(_P#1IC*X\R)5+(R$ 9!)R<CTP >FKX#\&1W7VB/PII"S
M>5Y E%G'N\O&W9G&<8XQTQQ4W_"&^%?L5E9?\(WI?V:RG^TV\7V.,)#)_?08
MPK>XYK/^'?BBX\5>#TO-0BC@U6SGFT_4(HSE5N(7,;X] 2-P'8,*RM%^+&DZ
MUXCL-*CT75+6WU.6Y@L+^X2-8;IX,^8  Y=>%8@LHS@T >C;1C%8?_"*>&5L
M+_3QX=T[['J,C2W<'V9/+N'/)9UQAB3W-<%<?'#P_;W%^)/#_B 6NF7JV5_=
MFR"Q6;$J SDMG'S@X +8YQTK<;XEZ7'J7BO3Y=-OXIO#%L+NYWB-1-&59E:+
MY^00AY.!G@XHL!U>D:%HV@V7V/1=*M--ML[O*M85B4GUPH'-.U31M(UVS%GK
M6F6NHVP<2"&ZA65 PZ'# C(K/U#Q38Z1X*E\6:O#<6-I!:_:IHI$!EB&,[2J
MD_-VP#UKG-(^*V@ZC-KT&J6EYH$^@VJ7MY'J C^2%P65P8W8'@=,Y!XQF@#H
MSX-\)26T]K)X9TI[>XE$TL36<91W P&(VX) XS5/5_"-K_9]Y-X5M=-T37WM
M_)M=2%C&[0X P",<K@8Q7&ZI\:([?1M8FM_"FK1WUMI#:S9Q7*HB7=L/^6@8
M.0N,@E6PV.@)(%4['Q@VM>(/A?>:Q_PD.DZAJUO/*EI$T:V=R?)#%I@K-Q_$
M@SD9&0* /0_"'AF;PSH\D%_J;ZMJ=W.UU>WTB!#/*V 2%'"J %4 = HK;U".
M\FTVYCL)(H;MHV6*292R*V."0""1GW%>?ZA\8=!TV:>ZFT[4)/#UM=_8+C78
MU1K:&?.TJ1NW[0Q"EPI4'OWJKKGQHTS2-6\0:;;^&=;U.?08H[BZ-K"A40LI
M;S Q<#: O?!.> >:+,#2^&WPULO!GA*UTW4K/2;_ %.)9(I+^"R$;S(S$X8G
M)/!P><'%=E:Z#HMC8RV-CI%G:VDV?,@A@1$DR,'*@8/%8&N^,5L?A9>>-]%M
M'U2)-/\ [0MXE8(9$*;@26Z #D]^#WXKG-)^)]TW@SPM-J.A7,_B77X ]MIL
M#Q!K@+&&DF#;MB1X.?F(/(&,T >AZ;H>BZ-&\>CZ39Z<CG++:P+$&/OM S4O
MV&S(N(_LL.+DEIE\L8E)7:2WKP .>PQ7/>"_&UAXSM+]X+*[TZ^TVY-I?6%X
MH66WE !P<$@@@Y# X(KD;7Q7:Z/XH^)FI?9?$M[-I MIKBQFEC:-4\ML-;+N
M 52 6.3DXZ=J /06\*>&'T]-/;PYIC6:2>:MN;2,QJ_]X+C&?>GKX;\.I=6M
MTNA:?Y]FH2WD%LFZ!1T"'&5 R>GK7F]E\9VU V:P^!]:B.J:<^H:6;AH8A?!
M%1G13O.TA7SEL X.,\5'H7Q@9/A/H7BWQ%IIAU#69/*M;43Q1BX)RVY69@J*
M%!R7(/R^XR6 ]._X1W0/[7&L?V'8?VD#G[9]F3SNF/OXSTXZU$WA7PT_VPMX
M>TUOMIS=9M8S]H.<Y?CYN>>:\O7]H/0IM-TFZLO#.N7]SJ-U-8BUM(HY6CN(
M@2T1(?#$C!!7*X;.>#5JZ^-WDS7UG!\//%%QJ-C907]Q:"VC#112*S98[^"
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MY[FP@EAF=XW4L"K!PN1M;*DY&.AK)T_XZ6=_/8(W@OQ#:Q:I:/=:9++#&O\
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MVAD+97<2> #US@>A^)_'EGX;OO[/CTO4-7U#[*]^UII\:O(+=&57D^9E!Y8
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M$W(AA9P/NA<C@<@FO:?,7.,UCZ]X<\/^(X+:#7])M=2BMYUN(4N8A(J2#.&
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MVJ.&VLV<219P75NA )P?0UK>%_&?A_QA;W4VAWKRO9SM;74$L3Q2VTHZI(C
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MUDR?"[P+)I=]I<V@K)97]RMW<PO/*5EE'1SENO3\AZ"BX'DWB.X\7>(/&GC
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MNT3!I9(Y@5GS&#D)L$C GIL'->\6=G;Z?IMO8V<0CM[>-8HD'1548 _(4 >
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "$X&<9I,TZB@#XI_;5/_%3>$,#_ETN
M/_0UHI?VU /^$H\(_+G_ $2?G_@:T4 >M_LF,3\ ;08Z7US_ .A"O>J\'_9/
M_P"3?K'I_P ?MST_W^]>\4 %%%% !4,__'O+_NG^535%-_J)/]TT#'IT'TIU
M-7H/I3J!!1110 4444 %%%% &'K?A3PWXF2-/$.@:?JHB_U?VNW64I]"1Q^%
M:&GZ=8Z5I\.GZ;9065I"NV."",(B#T"C@5<HH **** "BBB@ HHHH ,4444
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MX>\5B\_L+4/M+V4@CGC:)XGC)&5RK@'!'(.,$=* .BHKC?$UCXWU+4TA\/\
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M9[X]"\'Z;K5G\9_'>J7NA7-IINJ)9&UNG\O;(8HMC#ABV<GC(Z"O3O,0N4#
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M,,"N]B0 2"  W?%=A\'[.\L/$OQ(M;_5)M5NDUP*UY,B(T@^SQE<A !D @'
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M<8QS7<:I\*_#NJ:CJ=PUQJ-K;:OM.IV%M.$M[X@8RZXR"0 &*E=P&#FM'3?
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M\>?%&ST'Q'XFNO$UI+:^'O$XTD6@T]%-W$9HXSO/48#C;MY/.2>,>EVOP/\
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M^5N 0W3J*ZS4M4T_1].EU#5+Z"RM(AF2>XD$:)]2>!4.AW-M=^'[">S4K!)
MC)E"A P.JG!%<%\9HK.X\*Z7%>W&H6"_VK;M#J%E#YWV&5<NDLB8(:,, "#Q
MR#VHZ@=C8>,O"FJ7$,&F^)-+O)9U9HD@O(W:0+][ !R<=_2I/^$K\-?V++KG
M]O:?_9<3%)+S[2GDJP.""^<9SQC-?.6BZO?Z/J_@SQ7XBT61+&UU35K:2]TO
M3)5%X9%41W'D!2RB0JW;&1D<5EZ;K.H6>G#Q0_A?6YM+TCQO=:G?6C63AO)E
M5TC=01ARC') )VG'L:=@/=?%_CG[-HGAWQ!X7U73+S3+O6;:RN9PPE4Q22;'
M*.K *1SUS]*['1?$.A>(K:6Y\/ZQ9ZI##(8I)+2=955QR5)4D \BO"?$ESX;
MU3P5I=U8>$+RQTC5O%EM?RPSV<CM=('4S3-$ =JGD8/4#..:Z_X?S6,7QD^(
MUO96DUO%--9M&1:O%#)L@".5;:%.&XZ\T@/6W<1J6;@ 9)/:N8M/B!X+OM0@
MT^S\5:1<75QD0Q1WT3/+@D': V3@@C\#74.%9"& 92,$'O7QKI^G:/XF^'">
M%O#_ (>E/BP^*II4OHM/8+:HEVS&4SA<!5C^7 ;.>,4)7 ^J+7QQX1OK]K&U
M\2:7/<C?F*.\C9OD&7X!S\HP3Z9J.Q\>^#-2@O9[#Q5I5S%9(9;EX[R-EA09
MRS<_*O!Y/%?-=GX67Q%\,?BVOA_PS)_PD4NM3W5H\M@T$LEJSH2D3,H/SHDH
MVCGGIR*[C1O[,\=?$KP/J7AW1;RTM=+TNY@U@W-C);HL3Q*B6A+*H8A\G:,@
M!2>].P'L7_"9^%)-*MM5B\2:6]A=3"W@N1=QF.60G 16S@L3Q@<UC^%_%+CP
M[J^J^)_%'AZZM[6_FC2[T^X @AA!&Q)&)P)!G!&>XKSSP'X,U[0_&%WX2OK>
M.+P5X4O)=2TMVRS7)F4F)/<1;IL]]Q0]N>)T.33+CX/^*H+VTUO3K4^+WO(+
MBTL9!+:(TRR03JA3YT!49&,@<>E(#W'Q!XRCNK'0[SPAXO\ #<44^J16\\M[
M<ADN(^DD4.UN9N5P/>N@OO&OA32]771]1\1:=::@VW;;372)(2V=HP3U.#CU
MKYHU34M1N/ _AV[UC2I)KD>.$O!J%KI4T9O+:+:'NS'M)B)X&.,[<@=:T]9>
M2W\+?$[P#KF@W]YXFUW4I[K36ALG=+U)=OD,L@&U=F #N(VXH ^@=2\<^$-'
MFN(=4\3:792VR+)-'/>1HT:L<*6!/ )(QZYK+USQA=/X@T+PWX66"]O]5C-X
M]R6WPVMFI4&8X(W[BRJH!&2<] :\5F@M=/\ B+JMIX@L9M0O;+P'%IKW3Z?)
M(LUVH=I-K["&)4@Y!YSC-3_ 59K'Q=HB:A;3VLLW@^*"..YC>-P\-TXE7:P'
M]]#QQS0![K>>+=";4Y?#MOXCTZWU]@4BMI)5:02;<C,>X$\<XX./3K5?P/XK
M;Q):ZC9:A;K:ZYHUVUCJ,"_=\P $2)GGRW4AESS@X[5XKI[3?\+Y>/P]87TL
M<_B"2?4M,U"S?R[=TC*_;X+@  *5P-A)R6P.U=[\/8VN/C7\4=8MHV6R>YLK
M+=GAYHH/WF/IN44 >K33+#;R2O(L:HI8NYP% [GVKB?#'C.S7PO;7?BCQ?X=
MN;FXGF2.ZL;A4MY55V "EFY(4#=SP<UV-]<6]KIUQ<W0)@BC9Y $+G:!D\#)
M/':ODSP_>:5-X5^'.D76CWK-;>+;FZGAETV8K%"99F4G*;<?/']/PH ^JM&U
M[1_$6GC4-#U*VU&T+%1/;2K*A(ZC*DC-:$TT<,;22,%11DLQP />O&_@M>6<
MFO\ Q&^R6L]I!-KS3PI+:M I0QJNY0P Y9&]_6N^^(3S1_#;Q%);:6VJRC3Y
M\60+ W'R'*?+SS[<^E("SIOC3PKK*W#:5XAL+T6R[YC#<*PB7^\Q!X'OTJM;
M_$#P3<7*VT/BK27G>-IDC6]C+,BY+,!NY  ))]CZ5X#\.-=LX/B E]<V.MW&
MG2>$8K9)9='>&!!$[,RHH&2B\*"VYB3U(.:J^&?['T_P)\)6;09[2\AUZ5[Q
MO[-D61%(F5BY5<X.^,<]>.PI@?2,/C3PE<:<NI6_B33);)IA;K<)=H8S*>B;
MLXW'TZUT$<BR(&7H:\#\->$=1T[XO:KX)ABA_P"$.MKR/Q.@R-T<DA8);X X
M42HT@] JCOFO>T4(H49_$YH RM;\3>'O#<,<WB#6K'2HY6VQM=W"Q!SZ#<1F
ML+5OB-X3TS7]#T*36[,W.M*SP,+A-HCV%ED)ST8@*N.I/'2N*\37]OX7^/BZ
M]XLA;_A'KW0FLK*[,+31P3K)ODC8 '#.N,'^+;CDBO/_  _;W7@G4OAGJ6N:
M5?KIC7&L+:0+:O+);I.ZFVA90/E)7) / YZ8H0'K'@[XDQW.H>(=.\7ZWH]G
M>6NOS:58QHX@,Z+'$RX5W)9B7/3\J[B^\3:!IFI6VFZEK-C9WET0(()KA$DE
MR<#:I.3D@]*^8-6D\/7/P^^*]\--:?4+OQ0DEM-]AD>1TW1%"F5S@!9NGOZU
M+XM6PO/B3XDT?Q%;>*+Q/%!M;C1AI'RP7\(B0)&S%,QE74DDG W$GW /I=/%
MGAF34AIL>OZ<]\9C!]F%TAD\P DIMSG=@'BMT'(KP3X9Z;X3U3XO>/\ 43H\
M4UY;ZE;3V<\MJ04"VPC+HQ&/OF3)'4G/I7O2X"@ 8'I0P%HHHI %%%% !111
M0 4444 %%%% !2&EHH ^)?VTO^1R\*=?^/&;_P!&"BC]M+=_PF?A3T^PR_\
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M4L_"5II=R=;O_L#"^W_*Q1F#94\* I)X)HL!ZAM&>E&T9S7S_>_$;XL"XO\
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M;)8H8I&!A5TD=2 1@LV?F)(Z+CI7KPZ4 %%%%( HHHH **** "BBB@ HHHH
M***#0!\3?MJ'_BK_  G_ ->4W_HP44W]M%L^-/"JC'%C+UZ_ZP44 >S_ +*7
M_)O>F>UW<_\ HPU[I7AG[*8 _9ZTLYZW5SGC_IJ:]SH **** "H;C_CVD_W3
M4U0S_P#'O+_NG^5 R1>E.IJ=!]*=0(**** "BBB@ HHHH X+Q5\-[/Q+XHLO
M$]GKNJ>']9MH3:->:;(JM-;D[C&P=67J<@XR*9_PK.TC\2)KMIX@U6VGCTIM
M)1=T<H\MGWL[&1&9G+<Y)[=*9XB\5ZQI/QB\(>'([BU31]7M;V:X#Q'S%:%
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MD'O;..]CLI+J);J52T<)<!W ZD#J0*G>1(XVDD8*BC)8\ "G<#YJFT?7]3\
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MZU6[3='9W%UOAMOD5&>*/^$D#!/^T1WI@=1H>E6^A^'['1[7B"S@2!,@#A0
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MPN]I&$R,0%[\ G\*]:P,TO:@#YR\7)X7UKXS?"NXN[:SO[,V%RTLLD>Y2IC
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MO*<G,8D &1@X.2,5L>)/AMX;\3GPTE];!(O#\XDMXT'RM'LV&%O^F9PN1WV
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MIHI45<;P2P90@^;;@YZ#%.7X6^);:[TW5[74M,GU9M>.O:I)*DD:.YB,0BB
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MIDO[R_9;,01$B,EPF=\P&5&,<YSVK,O/$5KX[U+X+^,TL?LDNH:A,PC\W<4
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M %%%% !1110 4444 %%%% !3<=:=10!\/?MH,#X]\,+QD:<__HTT4O[:#_\
M%>^&%V]-.<_G*?\ "BJ ]R_98Q_PSKH?<B>Z'T_?O7MU>)_LM?\ )NFA$=YK
MK_T>]>V5(!1110 5!<?\>TG^Z:GJ"X_X]I/]TTT-$J_=%.IJ_=%.I""BBB@
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M;B-P0^".X/>O O"&C^&[C]I76==CN)TN)-&L;FV6:ZD5I&D5P3L+<X4#Y3D
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M$W$#!@4*AMJJ2>%7G@Y]MS6;<:M:1WEQ81R">_@M_M1M(R#(4R0#CW(('N*
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MC<<$X'KP#4U 'S__ ,(7\0?%VO>,Y/$V@V6AVOB;P_'IT;QWPG>UD3S-JL%
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M(M.AFU=+..SFU%E)EN%1 OS$DD\#OFHK+X6?#W3;FTO-/\'Z9!<65PUU;.L
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M@GLN!P*+@9OQ0U74+;PLNA:+ USK.O2#3[:&-PK[6&9G!)P-L8<Y/ .VO/\
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MT[<YX)'3BG^"M'\07&NZCXS\7:'9:1K%];PV<=K;R>>\,49<G=*, EF<G X
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MW>""7RF63*^9N8 MD,,$@#BO4O%?@31_&&H:->ZC<W]M/H]PTT$EE<M S!@
M\;%>2K  $<''?FL>\^$?AJ\UV\O9+G4$T[49UN[[14F L;N=2#YDD9&220I(
MSAMHR#1<"3X@7SZA^SYXGU"2W:W>Z\.W$QA?JFZW8E3],XKRJ3Q=XZ^&6E>%
M;V^UZ+Q#I6I^'[B;[$UFL7V.2WM/.0H4&XJ<!3N.>_?CZ'U?2;'6]"O=#U&'
MS;&^@>VGC!(W1NI5AD=.#7)^'OA?H.@Q%;B[U#7V6U:R@;5YA.;:W8 -$G
M4X&>Y  S@47 YOP%??$R;Q'I=YK]Y:7'A_4K$R-ONXI',Q 9&A"0QX4KG*DM
MCKGU]AKSGP+\(?"_P_U*XO-'GU*XW!DMHKVZ,L=C&Q!9(5_A!(7/4_*.:]&I
M %%%% !1110 4444 %%%% !1110 4'I12&@#X<_;.X^(WALXZZ6?_1K44G[9
MO_)2_#N>O]E?^UGHJ@/??V8/^3;_  WU^_=_^E,M>T5XW^S#M_X9N\,8Z[KK
M/_@5+7LE2 4444 %13?ZB3_=-2U#/_Q[R?[I_E0!(G0?2G4U>@^E.H ****
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MO(RM.L(1(Y5D)RW^YC\: ,"6\UR?XL_$?1E\07\5K#H-O<VB+-@6LC!\L@Z
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MJ8^-OA&73- U&QM-7OX=?>2"T^S699O.CW;HF&>'RIX_'IS7F[> /'UJ=/\
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MVV]C/'&%-O<JA8H_JL@Y4]BI'0BNIUW7=,\-Z'<ZYK-VMGI]HN^:9\D*,X'
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M8S;1RR%D0@=#C!('0DBO.IKJ>Z\:?&/0[?PS>:I<:BT%I"T,.Z-V:S50KO\
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MJ<YKO/"FDM8^ M/TBZTFUTEA;>7)8V;%HK?.<HI/4#.,UY;\-YO$GPH\/S>
M=;\(ZQJ-M974K:9J&E6WVF.X@D<N Y!&QP68'=@=.:0'<:?XMO?#?AG2;?X@
MS%O$EW+/"L%A;/*UUY;M\\<<88[?+"MST##/-)-\7?A_;:+I>MS:\%LM4D:&
MV<02L6D7.Y& 4E6&#\IP<]JYK5_^$MLOB%X8\?:AX9NKBU.GW.FWMC8 7,MA
MYDB21R87E^$"L5SCMFN1A\)Z_I^MZ'J4GA34#!>>-+C7Y;>.%9/L5NT;1H7"
MM@,20Y7G!8]QR >AS?';X8VZ6[MX@D#7-G]NAC%G.7DASC<!LR>A^@4GH#6T
MWQ0\&OIVF7EEJ4FI+JD+W%I%8VTMQ+-&A =MB*6 !.#D#GBO/_$&HV^B_M26
M<C:+>ZA%_P (DZB*QMC,T>;GKM'(!QMSVR.V36%X'\+>*/ASXJT_Q#>>%[J?
M2]4T^XBN+:PA$\NE2O=//'&$3JNU@I(R 1Z8R >G7OQJ^&UAI>FZE<>)(_LV
MIQR26LB0ROYGE_?7A>'!X*'#9XQ4\/Q:\"W&H6UG#J[S?:9H;=)TMI#")95W
MQ1F3;M#,I! )SS7D?A/P7XB\/^//"MYJ?AF^^S3:IJVJSK'%YT>GBZ"I#&Q!
M(W#;EL<+G\:J^)])\6/XEOIU\!ZW,UEXJMKZ$:;#%%:26B.NV0*"#-,1P2V=
MH'50#EZ >J+\5+'4O$_C'PU#%?Z6_A^U#MJ$ME(Z*Y1B6V[>B_*1D_/S@$5+
MX9^(.EV?P_\ #EUKWB4Z]J.IP/)#<6EA(LE\%)+,D"KN 48SP.Q[URMG;>(]
M)^)_Q,O;CPEJLEMKEC;S6ES;QI(N8[8H8_O#+[S@*,],YQS7(>"O#_BSPA=_
M#GQ3J'A;5);'3M#GT?4+6*$R3V<IE+K((A\Q#' )4<#J:0'L]U\7/A[9Z#I6
MN7'B:W73]5D,-K.JNP=QP5.%.TCN#C%;'A7QQX:\:V]Y/X<U'[6+*;R+A&B>
M)XGZX97 8?E7@,_@[Q-IFAZ&[^%[^3[9XZ_X2%K."$R_8;3=P'VY"G&"5YZG
MTKTKX>6NIP?%;XDZA<Z'>V%GJ-W:O:RW$!19PD7ELRGO\P_(YH Z _$73%^*
M?_"!?9;M;I+-KR2X:WD$:_, H!VX*D;B7R%! &235G3?B/X2U;6[71[/4)3<
M7H<VCR6LL<5V$^_Y4C*$DQ_LD\<]*\_\=>'?$&K?%35(-/TV_$&M>$Y=*AU&
M)1Y-M/YC-^\;.5X(YZG/ -4-(TS6/$&F?#+P[-X8U'2M0\*W<,^H7-S;-%%"
ML$+1E4D/RR^8=OW2?E.>,4 >R^)/$VB>$]%DUKQ#?+8Z?$RH\[*S!2S!5^Z"
M>20*Y>U^,7PZN[/5KR'Q+'Y.D(LMV6@E3RXV; < IEE)[KD<CUJG\>BJ_ GQ
M&QC,@"P?*HR3_I$?%>>^.],NO%%QK_B?1?"FLQHOA>XT95_L]XIKN>9UV1B,
M@,509R^-HW'!.*$!ZM!\5O 5WIQU"QUX7D/VK[$HMH)99))MH;8B*I9SM.[Y
M01CFJ>L_&#PCI/AK2=>@GN=2L]4OUT^ VEM(["0OM964+E67GY2 Q(P!7.ZU
M:W.D^.O _C6Q\,7<NC1V5Q:WL%M8L\]D\J1[)3$!OS^[V$@$@#'M6!JVAZ[:
M^$6\00>'=3FCN/&\6N?V9%;EKB.VW*I;RL[LL5WE>"-_('-&@'JU_P#$CP?I
ME[!::AJC6[RM$A9[:4)"TF/+65]FV)FR,!RIY'K4FK?$/PAHFN#1M2U@0W@:
M)) (I'2%I#B,2.JE8RQZ;B,UXG-HMV?&GBC3O$GPQ\0Z\GB"[34=.G$LGV,!
MHXU$5TJR"-#&R<DY.!QGC.T_]O:#XZ\8^&[_ , W_B.T\1WL%_IMT81):?+%
M&NV=R?D"-&#@Y.!P#D4 >D^$OB)H?C'7]<TG2TNQ+HUQ]GD::WDC#$*I)RR@
M#EL8)R<9QC!KMZ\F^'4.IZ3\1_B%IM]H=]!'?:K_ &C;WIA(MI8VAC4!7/5L
M@Y SC!KUD# I !HHHH **** "BBB@ HHHH **** "D/2EI#0!\-_MH'_ (N5
MX<_[!1_]'/11^V=_R4SP[P?^05_[6>BJ ^@/V81_QC=X8_WKO_TJEKV6O&OV
M8/\ DV[PS_O7?_I5+7LM2 4444 %13?ZA_\ =-2U#/\ \>TO^Z?Y4 2+T%.I
MJ=!]*=0 4444 %%%% !1110!AOKVSQ:OA_\ LN^*FT^U&_$/^C+\VWRR^?O]
M\>E:-AJ%EJ=C%?:?=1W5K,-T<L3;E<>H/>O$?&T*7/QJUC2[C4+Z2QNO!%U/
M)9B[=8_,690&5=WRMA><8SW[UQ.F::B_!CP--X=N6U5+72'O=2T&+6);>>=F
MCB5I8G5B \><B,_*-W !(IV ^K\USNK^*+/1M<T31[B"X>?69WMX)(T!C5EC
M:0[B3Q\J-CKTJEH>L"3X3:=KVG-=7X_L>.ZA-R,SSXA##?C.7;OCN:\6TE-!
MN-0^#WBIO$4E]K.K7#RW[37[,'EDM)6<^7NVH5D.P8 V@[: /?\ 1=8_MBWN
M9CIM[8"&YDM@E[%Y;2;#C>HR<H>H/<5L;A7S1>RW\G@%(5\7:K;R1_$!M/%R
MM^PD$)O-FUF/W@%Y .1Q3_$FFWUKX[L?AC_PG5UIFFP:))=65WJEW())[AY7
MRWFHR;VB7;M4DC')&>:+ ?2.R+S=^T>9C&>^*@:^LX[^&PDN(UNI4:2.(M\S
MJI 8@>@++^8KP!;Z+Q-XAN?"/BSQY/;BU\.6]QINJ6\[V"W$C%Q)=A=PWE2J
M8!)7&3_$:2ZTO2Q\:M!UQ]4O=2G'A-[V&Y:^EA6\F22(1D*&  ?@E!\IR.":
M+ ?16X4!E/2OF_2;R_C\+_#CQW8^(M2N-=\1:C!;:G;R7;R17"R[O.40D[4,
M>TD;0-H3GC-2^%=#U2X\(>)_%0^).L0WL,^JZ;:M?7NZUMU\]DC=P02&!4'=
MGC/ P*+ >U>(_!_A7QA#!#XFT*SU>.W8M$+F(/L)X.#VS6EI.C:5H.F1:9HN
MG6^G64(Q'!;QB-%_ 5Y)\*=471=0\2:3XF:]T2]L!:^=#J&JF[M3OWA)H)I#
MG$ASE3W45WWQ&UK4O#OPQ\0ZYHL'GZA9V4DT"[2WS ?>P.N.OX4@.LS7!W7Q
M.T2UO+GS['4QI5K+/!-JZ6OF6L<D()D5BI+@#:PW%0I((!-<5IMO-H_CGP/_
M &/XDU'4[7Q18S_VI%<7KS"4+"'%RF3^[.X[?DP/G'I7'_\ "*Z/:_LU_$"^
MBO=1+B?557=J,SKB.YE"#&[!S@;C_%DYSFG8#VKP]\0K3Q%KXTJ#P_KMH)+4
M7D5Y<V>VWEB.-A$@) + Y"M@\'(!XKM\BOGGPG;R^%_'GAVTT?4]3N+.X\&2
M7[6-SJ$D\)F4PA2JNQQW''&.F*3X?:U'JV@>&/'P\<7=SK][#=K?:5YK2K>S
M[6;R_*SB(1[."JCC SSR6 ^A]WK2;U]:^:/AY)K&NP:%XJD^)4(FU6&XCU&R
MCNI))IYGC+%!&S%8&B()!50 !SQ5SPGHOB:^^ *>);3X@:E)KVLZ?'!&VHWV
MVW1C.  I RCLO[O<"3EO6G8#Z-!!&12<"O(_A3XBLHXM;T?5KBZTO5[?4Q;R
M:=J=\;@P.T*%8X9G),JMAG&.0&Z"K_QGUW4-#\"VK6-XMA'?ZG:V-U>LS(+>
M"1\.Q=>4[+N'(W<8.*5@/3=PQFC<*^9_$-OXE\._#GQ1##\0WE9-1TZ6S6PN
MY9'L4EF5&C,SDL58$L 2<?0U+=:#JC>,OB#X>7X@>*8M.TO2X=6@8:AB19V2
M7(WXR$^0':,#\A18#Z3+*.IQ7.ZUXLTK0=>T31KX7(N=:G-O:F.$M&7"EL,W
M0< GUKQFY&M>*-=^%5O<^-M9TU/$.A2RWR6%QY'FNL$;[EP.&)<Y/7'3%5;.
M;5%USP)I&JZE<ZHNE>-+VQM+^Z;?+<P1V\N&9OXBI9DS_L46 ^DMPI,\U\]Z
MQJ^N7_@KQ_XZA\2ZAI>M>&]3N(;2T%QBW2. KMB:+&'\P9Y8$G>,=!5GQ1K&
MO>#?'\5W<:AJD]GXQTQK:PLGGD:*SU3"A47'W P;CT*M0![YN7&<\4;A7SCJ
M"^+=3\9:S\/+7Q?)I[Z!I-M]ENKJ_E@EN)'4E[HE0?, 8!<'@#/K5?4-6\:^
M,O%TOA"U\;VFG7EAH=K=07,%U):+=3NN7N5"J?,0' VMQSTYX+ ?1&I:;8:O
MILVGZE;)=6DPQ)#(,JXSG!'<>W>K4,,4$*0PQK'&@"JBC 4#H .U?-WB[5O&
ME@FEZ]J.O7^IZ'!IMLMQJGAJ["K:7&27N9(,?O8G&T^F >G%?15K>6MU$6@G
M24C ;:P)4D X/H<$&D!<HKQOQ1=7OB?XIZOX+'BZ\\-'3]&BOK VLODF:=W<
M&5C_ ,M$3;&-F<'<V?;*L=8U/X@>*?$^AGQI?:4GAVPLVL[G37$(NWEB+F[;
M(.]"0 %SMQG.200P/>-PSBEKYVT?7?&'C"/X6_;O$^H:-+K^G7S7XLA$OFF)
M1ME4E#@L&W>@R,<C-5FUKQJOPTT=K;6-5UIM+U;48+];&=(]4O+:">2))$R#
MOV?(64#YOE[=2P'TCD5BWWB/2M/\0Z7H-W<.M[JID%J@B<J_EJ7?YP-H( Z$
MYKR7PEXEO-;\0R6MMXPO-1TJY\'V]ZEVRK&?/WO&\RC'R,=A)!R :A\.ZKJ6
MOZ=\%-2U:\>ZO[Q+J6>X=55G8V<GS<<9YHL![I%<0S%O*E5]C;6VG.T^A]#S
M4VX5\S>&UU/0_A]=K8>+M9%Q?^++NQ2"(I-<W"+<2ADB+* LK!,F1S@!2>.E
M7W\6^,HO@1X[U$ZW<V6K:'K$MI:S2F.>6.,-%B)VV[7/SE=V,Y[]Z+ ?0\DD
M<<;22N$11EF8X 'J:$DCD17C8,K $$'((KYK\=77BBQ@\>^%=1\8:C?0?\(F
M-764I'"T4V]T9%*#/EL%&5Y/7DYK;\877B_PCX5\+)I=]KVIZ+;V#MJ,^FM
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MGH00#ZAW"C<*\3L]0\;:YXK\2>#_ /A-9+"\\+V%IB\@LX5.H7,L;.9I$=6
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MV#71-*J0M(WW5&3CFO$M.U_4M'UCX96*ZQ';:+=>&9I[F*94\L&&"(K(7QD
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M"_[9Q_XN?X?_ .P2._\ TVDHIW[9W_)3O#O'_,)_]K/15 ?07[,/_)MOA?\
MWKO_ -*I:]DKQS]F,_\ &-WA;_MZ_P#2J6O8ZD HHHH *AG_ ./>3_=/\JFJ
M&?\ X]Y/]TT 2+T'TIU-3H/I3J "BBB@ HHHH **** *#:5I;ZB-3;3K5KX+
ML%R85,H7IC=C./:LN3P5X1FM4M9_"^DR6T;%TB:RC*J20Q(&,#) )]QFLO6/
MB%IVDZ_-I']DZE??9&MUO;FVC0QVAG;;%NW.&8'N45@!UQ5+4/BSX7TO78M/
MNEO&@DU'^R/[0C16MTN\?ZDX;?G/RYVD Y&>#0!W\<4<42Q1H$10%55&  .@
MK"A\%^$;>_>^@\,Z5%<O,UPTJ6<89I&X+DXR6/K7):;\9_#FKW>HV^EZ+XAN
MGT[[0)RNG,%5H2 Z9) W8.0O7 /<@';M?B#I5]H_A[5+6PU*>W\01--:B* .
MZ($W[G4,2.,=,\D#J0* -+_A#/"#6X@/A?26B\X7&S[%'M\P='QC[P]>M6M4
M\-Z!KB6Z:QHUCJ2V[!X1=6Z2B,C'*[@<=!TKA?"?C;P_IOPPTC5(=0UO68]0
MNYK6S6_7??7<WG29C ) XVMC. %7G%7X?BQX:N=(ANK6"^GO9KF>S72UA NA
M-#_K5*DA1MX).['(P22!3 ZG5O"WAW79+:36=#L-0>U8/ US;K(8F'0KD<5+
M=:%H]]?6=]>Z;:W-S9$M;2RQ*S0$C!V$_=R/2JGA7Q;H?C3P[#KWA^Z-S92E
MDR5*LCJ<,C*>0P/45STGQ:\)QW&Z7[:FE_;/[/&LFW/V(W&=NP2 Y^]\N[&W
M/&ZD!T=IX1\+V&KW&KV/A_3[;4+C/FW,5LBR/GKD@9Y[^M.M_"GAFSTV[TVU
M\/Z=!97A)N+>.V18YC_M*!AOQKF]+^+'A76O&DOA+3TU.34H;F2UE+6$J11.
MB%SN<@!<@'&>OTYJ3QEXDN8O%/AWP/I-PUOJ6N/)+)<* 3;6L2[I&&?XF.U!
MP<;B>U,!^M_#?PMJW@NZ\+6NEV.F6%ZR-.(+2/Y@&R2!T#=<-SMSD5V2P0K;
M+;JH\M5"@'GBO,-0UW2H=8^(0E\2Z] =-TR#[5$D+%;!2DG[VW^7+,0"Q;D<
M#TX-?\3W7A/P'X<\=6>H7>J:/!#;1Z@MV0KSV\NU?M!XXE4LK$# (+ ]B #M
M-+\&^%-!DN9-'\/:=ISW0(F-O;I'Y@)R0<#D9/2HX? G@JWTR73(/"ND1V,S
M;Y+=;.,1NWJ5Q@GFM'6-3_LWP_<ZHEG/?>3$9!#;+O=^,\#/->-> ?$DD>B^
M&_&FLZYXAN-1\06WE?V&Q$J7LY59/,@0G$:JH;."JXZXQR >M6_@_P *V5]:
MWUGX=TVWNK1#'!-%:HKQ*>JJ0,@<G@>M36/A7PYI>KW>L:=H5A::C>#$]U#;
MJDDH]&8#)KD+KXR^"['2X;ZZDOX2]\=,>W-E(98+D?\ +*15!VM@@@?Q#[N:
MV)O'=B?AG<^.[/3M1N+*&UDNA;FW,<[!,Y&QL$=#^ S0!?A\%>$8+^^OH/#.
MF175^ACNIDM(P\ZGJ&.,D'OGK4J^$_#*:%)H,?A_3DTF4AGLEM4$+$$$$H!@
M\J/R'I7E.K_$2Y67X9^)+^34]*MM1E=;RR$)VW)-FSJ%106?YV4+[]J[/3_B
MIX7U+P]/K%N;U?(U#^RGLY+9EN?M60!#Y?7<<]^W/ HL!+J'PU\,W-EI&EV>
MEV=A8:=J*ZF(X;<;O-4E@5;^$EL9/4J"._'7W^GV&J6$VGZE:07EK.NV2"=
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M%% !129 Z\4M !1110 4449H **** "BBB@ HHR** "BBB@ HHS1D4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M'>BB@ HHHH ***0,#0 M%'>B@ HHHH **** "BBB@ HHHH ***.] !111F@
MHHHH **0X%+0 44TMA@M*#D9H 6BB@T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!\+?MGM_Q=#0/^P2/_ $=)11^V;_R53P_Z?V./_1TE% 'T
M7^S2"/V;_">?[ES_ .E,M>O5Y#^S5G_AG'PF"<_)<?\ I3+7KU !1110 5%-
M_J)/]TU+44W^HD_W30 ]>@^E.IJ]!]*=0 4444 %%%% !1110 4444 %%%%
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M$D"76Y(WE58G;:DC,@(56/ )QD]*VM:U[2?#VD/JFL7JVEFA53(RDY9CM50
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M^4G!Y(&:XS3K/7O$/B/P)JDGA74]&F\+6=P-0DN8PF]S"(A#%@_O0Q&[(^7
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MO0?2G4 %%%% !1110 444&@ XZ45X]?ZEXH\3>,?&%CH_C#_ (1V;PR]LMM
MR1M!*KQ)*\L^Y2Q4AF08( VYY-<OX@\:>+8?&L-]H_B"YU#3D\1VFF2&U2-=
M/2"4HIA)92\DV2Q+*V$RHSGBF!]$9'K6,WB32%\6CPK]I/\ :S6AOA#Y;8,(
M<(6W8V_>(&,Y]J\@U2?XCW^O_$5--\>2V,/AHPSV$?V*!A(3;"8QN2.4R<=C
MZDU<TGQ%XD\2>*M,M;C6)=/L]:\&#5FM[>)%:UG9HP65RI/1B.<_I18#VE)(
MY%RCAAR,@YZ<&L?5_$VCZ'?Z78ZG=&"?5;@6MHOENPDD(R%R 0. >N.E>!>%
M]2\0:7\%_ =KIWB74I9]9%Q(UO;+$]Y,0KMMA9DVH@<[G:3H#][M6G8>(=5\
M6_#+X2Z]K[K-J4WB2%9G50@8H9T#'' .%!XX)]J+ >UZ3XDTC6K[5+#3KSS;
MG2IQ;7:>6R^5(5#8RP /!SD9%;617D_A_5_$6HWGQ$TN_P#$C6HTG4HXX+_[
M/&#;0&*.1NVTG!89;.."<UP\/Q"\=:=X&\4?$2359;[0/,CM= AU"")&E1I%
M0W<A1$.SG*C XY/4&BP'TAD5AP>*-#N?%MUX4AO@^LVENMU-;;&!2-C@-G&/
MR->.WGB;XH>%4N#K&I6(L-6GM;73+F\EBEFM7EE59)'\I$5HPI)&>AV@DYK4
M\*Z?=Z=^TWK5O?:Y<ZQ(?#=NR3W4<:.H,[97]VJJ1G)Z<9Q0![.TD:NJLZAF
MZ ]33_EKQ[Q1:WS_ +2/A%DUZ^AM3I-[-]F3RS&"C1 @ J?O!L$GG@8(KG/"
M_C3XG>*DT;Q?IEQ8)HEWJ#P7<-Q-"L,4!D,:A0%$OG*=O5B"3C !% 'T'N3.
M-PI<K7S]I&N?$J\^%_B3QY=^-H"+*VU%;:UCTZ/ :"5PDA;/)PA&,8P1U.:-
M&U3XD7GC31?#\WCO,.N^'AJ[S'380]K("@VQ<XYWC.X-T..O!8#Z!^6D^7:<
M8Q7@$GCOQM-\(O"'BR26\:"43'6;G2+2.:Y 4LD<BQ,&4IN&7P,@=,"O3/#F
MKZEJ7PFM=7LM7M-;U*73S)%>JOEPW,H4X8CC:"PY'&.: ,SQ)X.^$/A[2[OQ
M!XB\):#;V<9,D]S)IZ/@L<DG"D\DU=M_AS\,[^S@NH?!.A/#.BR1M_9\8RI&
M0<;?0UXW<^*M6UWX5_$#3?$&I:J-3MM =[G2-7M(X9H9=IW2QM&@#PD_=Y/0
M]JWQXA\:>#9++3[SQ;97-M?>%[B_MWU"T6"&QGA6(*2R?,4_><@Y/'X46 ]!
MU'X=?"O2M-N-0OO!>@PVUNK2R2-I\9"CJ3PN:Y>"R^ 5R_A^.W\.^'F/B'+:
M:/[+P;D8.2/DXZ=\5SOA'QKXLUCQ#XN\-:[>7M[81^&UU"&2^LX[>0NRE69
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M)]<T6 ]G.WO0"K=,&O V^)_Q UC69+OPKX=-_IEOK4FER0M:L5>"-PCS>>)
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MGR>(/#.AKHEOIT-W:11B*81LP*;W#;< C:1@]:]^HQ3N!Y?K7P:\-ZC#H/\
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MGS /[N".: -ZBLO1]<TCQ!:RW6C:A#>P1326\CPMD+(AVLI]P:TRP7J<#WH
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M*S;?6M*O-6N=)M-3M;B^M IN+>*96DASG&Y0<KG!ZT :=%%% !1110 4444
M%%0S316T$D\TBQ11J69W.%4#DDGL*CLKZSU*QAOK"ZBN[6=0\4T+ATD4]"&'
M!% %JBBB@ HHHH **3<-VWO4-Q<0VMO)<7,R0PQJ6>21@JJ!U))Z"@">BLW2
M]:T?6H'N-%U2TU*&-S&\EK,LJJPZJ2I."/2M*@ HJE?:C8:79O>ZE?06=M']
M^:XD$:+]23@59BECFC62-@Z,-RLIR"/6@"2BJ5YJ-CIZ12:A>P6JRR+#&9I
M@=VZ*,]2>PZU=[4 %%1R2)'&TDC!%49+,< #UK,A\2>';FX2VM]>T^:>3[D:
M7*,S?0 Y- &O12 Y%4+[5M-TL1-J>H6UF)I%BC-Q*L>]R<!1D\DGH* -"BBC
MM0 453CO[*6\EM([J%[B%0TD:N"\8/0D=1G!_*H%UO1VU1]+75;0Z@@RUJ)E
M\U1C.2F<]/:@#3HJC:ZGI][/<6]G?V]S-;-LF2*16:)NN& /RGV-7&944LQ
M [F@!U%9L>M://J<FEPZI:27\0S);),K2H/=0<BM*@ HHHH **** "BBJ%[J
MFG:8D4FIZA;V2RR+#&T\BQAW8X51D\DGH.M %^BD!R,]J6@ HI-R^M+0 452
MN-1L;6:"*ZO(899VVPQR2!6E/HH/)/L*N@Y% !1110 452N-2L+.YM[:ZOH+
M>:Y;9#'+(%:5O10>I]A5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@7,2L&4DB,<AU5OPQT)%6]-^$=QINMWNM#QYK]SJ%[8"QN)9VA*R[=VURNS
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M@D5<;EP-RKDYZ CO2 Y"WU+6H?'/B/1?">EZ(-<M;6"\UB]D1XTNIF5O(B5
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M!V?CWP;=^-+#2;6WUA=,&GZE!J.3;>=YC1-N5?O+@9ZUE7'P[U:?7O&6K?\
M"4(C>)M/CL!&+#BU"*RA\[\L<.W''4>E(#K_  _JB^)/"&E:TUKY*ZC:1W)@
M<[MF] VT^O7%?'X33=2\!ZUX#3P[%:WVO>++NWLM<NXECM;619MP E7+;L @
M+@9SC..*^N?"^A7?AWP5IGAU]06[FL+5+5;DP[ ^U=H)7)[ =ZX#1_@K'!X!
M\2>#?$6O#6;'6KJ6]61+,026LTAW%T.YN0V"/3GKF@#:O-;U[PQXA\">%A-;
MWUOJ<4UI<W,L;"4RPVY<2#YL?,5.01^-<!KWB;4O%7PRGN->M;(WNE>,[33U
MDM8F5'6.]A&\!RQ!.2#S[5UDWPO\0W6@^'+>X^(%R=;\/2LUKK"V*&1HVC,;
MJZ,65B5/WCSP#S5*U^"]]:>$;C0!XYO9EGUI-:>:XM4=S(LBR 9R.K("2?R%
M/0!/%7Q-\666O>(=/\*:"VIR:!]G#6PT^XG:]>10[(KQ_+#A",%MV3V Z^O6
MLS7-G#.T3PF5 QCD&&3(S@^XKS'7_A)?:GXZG\3Z'XYU+P[_ &E#'!JMM:1J
M5O%08!!/^K;!QN&2.V*]1@ACM[=((AMCC4(H] .!28'C_P /].L=/_: ^*45
MA9QVT3+ITC)$@52[1.6.!W)Y/N<U4\4> ?"MCK_@K3?#^FI'XEAUA-1>^BP;
M@0J6>>6=ARROC9SQN=0.F*[?0_ ]WHWQ'\1^,'US[3_;JQ)):?9@@C$0VQX;
M<<X!.>.:Y2#X1^+HM?OM3D^+.I;-1N$GO(XK"&-Y54\1B4?.B@<#:1@9]: .
M9FU+QMX>^)7Q5U#P5HVCSP6,EI>70O'=7GQ9HS1QJ@P&.&.YCC)Z'FO0[/XN
M^!KK3M%74O$5II.I:S:07$-I-*!(!,!MQZ\G@^U0ZE\--4NO$/B;4+#Q9)I]
MCXFBCBU"V%HLDB[8A%F&3(V':".5;KQCC':6OAW2+'3K.QLM/MXX[&)8;7=&
M&\E5&% SSQ@=Z /'O$7P]\-6OC+P#H?A.S6VU_3M034[O48Q_I!M$SYK3N,%
MS*^U<MU);L#7L?B"\U#3_#.HWVEQPRWEO;O+$EPQ5&95)P2.0.*\NT_X0^,+
M6^N)IOBYJ;)>W7VF\$%A#%)/S]WS!E@, *.?E' Z5Z5XMN8+'P9K%Q=,5A%I
M("0I8Y*D 8 )/)% 'D6A_%#XG3:?X,US6M#T$:/XJV6T)M9)O-@G>-FC9\@@
M(Q7&!DCU-4]%^,GQ N/">G>)-6T30H[76;X:/IZ032^9]K:Y,8:0'CRPH)P#
MN)7MNXF^$_@W6-<^&'@FZU+Q(LMMHT336EB^G>68;G8R*92S9?R][8P%[$Y(
MKHK#X*P0?"<>!-0\0RWDEO>&_L=2%N(Y+2?S/,5P-Q!(8GTR"1[T 5K_ .(?
MCC0+CQ9H.J6VE7FLZ/I']N6=W%%)#;W$ +!T9"[L&4KCAN<C@=:H:;X_^+6I
M:WI6C)I_A>*YUK1O[8M)"\Q2V4;0R2#.7)+KC;M R>6QST]]\,;_ %BT\13Z
MGXF676=<L$TMKQ+':EO:C.Y$C+GEBS$DMUQQQBDT_P"&VM6/B+1-9'BN*671
MM'?1XE?3\!U.W$AQ)URB<#T/KP 9GA_XG>(=6B^'=Y-9V,$/B9[FWO8@CDP2
MQ)(V8VW="8SP0>O6L7Q1X@U+Q-X-N%UJ&S-SH_C>ST^-[:,H'5+J'# ,S%6P
MY!YK=B^#VI6O@CPWHMCXR>WU3P[>R7=GJ:V:G <.'1H]V#D2-SGTJNOP6U:#
M0;O2XO'MS,;G6XM<>>ZLUD<R(5;'##JR*2?08 '.7H!9\6?$C7]+UCQE:Z/'
MIT47A33H;Z1+Y69[TNC/A"K#8 %V[B&RQ]N<WQ9\5/&.A:,FHQV.D6GEZ,FJ
M%+E9)C=R'):"-48.FQ0,NRD98=*X;XB-<Q?&C5[B^U"_TRY>.WM[&)_#0U:.
M]C5.L; '9EV?Y,CGD]>.VNOA+XH\5P2ZYJOBZ?1-0US14T_5;.&V21<A6QM)
M/R<L2R@D9)P: +EOXH\3ZC\:=$E_M&SM="F\,'56M&A=F1'>+>"P?!<8&&Q@
M#(P<YK)TCXV^);Z73=<E\+SR>%[Y9Y))(=/N%>QB0,4E>9OW<@(7G:!C/4XY
MZFS^%NJ66O>%]63QE.TND:;_ &7>;K./_3X X<+Z1\@#N=OOS67X?^!]YH\D
MVDW7CS4+[P?NF,&@^4J+&L@8!&ER695WDA>!D ]J0&!>:OXF\3ZU\)O%FKZ?
MI-OI^I:L)K:.%&:ZME:"4HK2D[6#+\S;0O('6O6?B-XCU+PE\.]5\2Z5%;RW
M&G1"?RKA6*R*",KP1@\]><>AKSS2?@AXDTL^&[)OB9<7&D>&KT76GVCZ=&65
M0&4(S[LMA6(!QQD\=,>J>,/#L/BSP3J_ANXE,*:E:O;^:%W&,L,!L=\'!Q[4
M <5X@\>^)-)\5ZYH]K9Z?<16GAXZY:ERZ/E'VO&YY!S@D$ ?UK*\/_%+Q1_:
MVAGQAINEV>E:WHDNL0RV<DC20"-(W8/N&.0Y( Y'O2_\*C\63:M>ZSJ'Q'-Y
M?WNBR:+/YFFJ(MC9^95#@KC(/7KD]#BM"S^%.H1ZCX3?4/$5O>V/A_29M)DM
M_L+(;N.10C$MYIVG:J]CR#Z\ '"^(-<U[Q1JWPG\::EH^EP:7?:TDUFT66NX
M(VAD:-78G#!UPQ"@8*@<]:V/#WQF\5>)M2TFYT?PJ;C1]6:=8G:TND-HJ!O+
MDEFV&(JQ7D*3MW=R.9].^"?B:SA\.:7)\1&N-$\-Z@+S3[633E,B( X6-I"W
MS85RO0#':KWAOX/:]X5U&>UT;X@W$/A9))I[#1'M%=+=W!(#2;@[1JQW! 5S
MW/)R] -+X3>.O&?C_1XO$6M>']/TS1;NW+VSV]PTDK2+(R,&4CA<#(/^/'JG
M:N%^%O@K4/A]X"M/"M[J\.K+9,X@GCMC =C,6PP+MDY)Y&.,<5W52 4444 %
M%%% !1110 4444 %%%% !2&EH- 'P=^V4<_&'1AZ:+'U_P"N\U%+^V5_R6#1
MOE_Y@L?/_;>:BJ ^GOV>O^3>/"'_ %[/_P"C7KU*O+/V>OE_9Y\(+_T[.?\
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M_#MGX<T][2UEN+DR2&::XNI#)-/(0 7=CU. !V     %;F!110 FT4;12T4
M)M7!XHVBEHH ;L7.<4H4#H*6B@!-H]*38N<[1FG44 -*J>J@TN!BEHH ;M&,
M=J<  .*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBCO0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'P9^V6V?C%HZ\\:)%_P"CYZ*/VS#_ ,7BT<?]02+O_P!-YZ*H#ZC_
M &?UV_L^>#_^O0G_ ,B-7J%>9_ ,Y_9_\'<Y_P!!'/\ P-J],J0"BBB@ J*;
M_42?[IJ6HIO]1)_NF@"1>@I::O0?2G4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%%  >E)CBEH[T ?!7[9/\ R672>G_($B_]'ST4O[9F[_A<VD;NG]AQ
M8_[_ ,]%4!]3_ ,?\6 \'?\ 7C_[.U>FUYE\!3CX ^#L_P#/B/\ T)J]-J0"
MBBB@ J*;_42?[IJ6HIO]1)_NF@!Z]!3J:O2G4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !0>GK110 R,N8U,B[6QR.N#3Z** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^#?VR"/^%UZ2!U&@PY_P#
MB>BF?MDD_P#"Z=*'IH</_H^>BF!]4_ 51_PH#P=_UXC_ -":O3*\T^ HQ\ ?
M!WK]A'_H35Z72 **** "HIO]1)_NFI:BF_U$G^Z: 'KT%.IJ]!3J "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1C@=,_2EHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HH%% !1110 4444 %%%% !111WH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH[4 ? O[89/\ PO"P
MW 8_L6#&/^NTU%'[8A'_  N[3^?^8+#U_P"NTU%4!];_  :7/P/\%$G_ )A%
MOT_W!7H0Z5P/P: _X4=X*[C^R+;_ -%BN_S28!1112 *AN/^/:3_ '34U07'
M_'K+_NG^5-#1*OW!]*=34^X/I3J0@HHHH **.]% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%)WH 6BBB@ HHHH **3O2T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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HO2=J** $7[QI>]%% "TQC1130'P1^V$2?C?8?]@6#_T=-1113 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>skye_ex31img25.jpg
<TEXT>
begin 644 skye_ex31img25.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 1I XL# 2(  A$! Q$!_\0
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M_;^W^%>_T4 > ?\ #(WP?S_QZ:K_ .![?X4?\,C?!_/_ !YZK_X'M_A7O]%
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MQQC[9-_\73U_9D^"@/\ R)BGZWD__P 77LE% 'CO_#,WP4Y_XHF/_P #)_\
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MH \C_P"&;?@G_P!"%;?^!,__ ,<I?^&;?@EC_D0K;_P)G_\ CE>MT4 >1_\
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M44 %%)WI: "BBB@ HHHH **** $5=HP*6BB@ HHHH ****  T@I:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $/2F9]J><^E-R.] 'S_P#LB'/P'B]K^X'U^:OH.OGW]D;_
M )(+%[:A<?\ H5?05 !1110 E0W7_'K+_N-_(U-4-S_QZS?[A_D: )E^Z*6F
MKTIU !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:* "BBB@ HHHH
M*#110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 '>BBD- "T444 %%)GG%+0 4444 %%%'>@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.U%% "'C_ !J)
MOO'FI3TI,?[5 'S]^R+_ ,D(CZ_\A"X_#YJ^@Z^?/V1<?\*(CYY_M"XS]=U?
M0= !1110 E077_'G/_US;^53U!=?\>LW^X?Y&@"=?NBEI%Z4M !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !112?Q4 +1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 (.II:** "BBB@ HHHH **** "BBB@!"
M.:6BB@ HHHH **** "BBB@ HHHH **** "CM110 4444 %%%% !1110 4444
M %%%(1SUH 6BBB@ HHHH **** "BBB@ HHHH **** "B@]** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&J/=4A&:8>O2F@/G_
M /9$"_\ "B5V\G^T;C=]=W^%?0E?/G[(@Q\"5/KJ%Q_Z%7T'2 **** $J"Z_
MX]9O]P_R-3U!=?\ 'I-_N'^5 $Z]*6D7I2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 G0TO:BB@ HHHH **3YJ6@ HHHH **** "BBB@ HHHH **** $
M'>EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%!.** "BBB@ HHHH **** "BBB@ HHHH **** "BBCI0 4444 %%(:4=*
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MM;Z=!Y<T"X.>#\I(92 >3FNYU_2DUWPUJFAS-LCU"UEM6<=5#H5)_6O'=/\
MAO\ $;4?AE/\-?%.I:3'H]OIHL+>[LV=I9]H7RF8,HV@;0#W- '76?Q4M)=?
MTS2]1T/4=,.KPF;3I)E4I<@+NVY!^5B.@/-<[_PT!IS:1J>L1>#=?ETS3#<1
MW5VL \N*2(C<I.?<<U-8^!O&NLW7A+_A,%TN)/"A:6%K29G-Y,$V(QROR+CD
M]37,Z]X:UGP;^S'\0=-\126/G7+7EU"UO,74B9PP0[@/FSQ3 [W3OB_ID^L3
M:?K6BZEH(%B^HV\M]&%6Y@3[S+@]?8\TVW^+4!GTP7WAW4;*VUA';39I-I%T
M54L%QGY68 D UB3> =:\?P0WWB:;38+7^Q'L+0Z;.\HD,H!,I+*I ^5<#FH[
M?X?>.K^S\+6.O_V/Y7A8M+;S0SR$WDHC*1Y!0;!SD]>E %G3_CO9ZCHL.L0>
M#M>6SNV2*SF>$".XE:5HRF[.%P4)).*K^)/C/>+\/-0USP]HDG]HV&J+I-Q%
M,RLL$N\ G(.&'88-5+?X8^.K3X(:#X+CN]*-[IVHM/<PF>06]];M*\AB9@N1
MDR $8P0OOBJ(^#GC1?"?BS0X9] MH]3U5-4LHK?S%2-@P8QD;,!> !B@#K=-
M\268^,&IKJ<^K6-Y:Z$EU<03R#[$L>X9=0/XL]_2M#3OBSI]WJ.AQ7>BWUA8
M>(=W]EWTP'EW) +*#@Y4LHW+G&16&WP[\4:MX^U/6-=_LU=/U;P__8TWV69R
M\;9W;@"HR,C'6JVE_#?QE<V'@?P_X@FTR+3O!]P)H[FV=FDO?+C*0_*0-G!^
M;GMQ0!:7X\:;Y:7<GA768=.74?[,N+R2-0D$V[: ><GGTKV%6/>OGN3X6^/)
M?A_J&@F/2$N;OQ -75A=.56/S-^T_)U[5Z/X%\1>*M;\1>)K/7K6R6RL)TCL
M[BRWE9,@EU)8#<5XR0,<T =Q>7<-E83WEPXCA@C:61CV51DG\A7F=E\8K2\N
MM "^'=0CM/$&XV%RQ0+(J]2>>..:[WQ)>#3?">KW[1"1;:SFE*%=X;:A.".^
M<=*^6OAK)<Z=J_AEGDT?70P:UMX+/5C++9I+GS&6#;@8[\G%(#V&Q^.?AR^\
M366DI;3K!?73V-O=AE8&53CYE!W*"00"13(_C=8B2)[KPOK%M8'5FT66\D1=
MD5R)#'LX.2-P(R!Q5'P9X!^(OA:\313>: _A^"\DNHKV.-A=M&S[_).5QR3@
MMGIGVK/O/AIX_O/!SZ*5T,3-XI?7\K<R!0AN&FV#]WURQ'^<4P-^3X[^&(_$
M$&G);7$MM/=O8I=H5*F9>VW.X#MNQBJUK\>+*XTZ^U,>#M?2RM'EA:<V^4,R
M.J>6".Y+"J/AGX>?$7PO?76EV=UH$FA2737,5U+&6O(PQW&($KCKWIEO\/OB
M-%\&]<\+175A8ZM<ZB]W"]O=.%EB>4.\3,%!3*Y7(_O9XI =#<>.E\7^"_'.
MGQVM[HNIZ+9R&1?-7>I,/F1LKH2.F/UKJOAK<W-Y\+O#EU>7#W%Q+91O))(<
MLQ(ZDUYMH?PY\::/_P )\T6G^'[:'Q%9+':VEG*R)%)Y/E$$E?Q)[FO3/ .E
MZGH?@+1]%UB.%+VRMUA<02%T..X.!_*D!/XL\6:=X0TF*^OUEE:XN([6VMX5
MW23S.<*BCW_*N)OOC3INCV6NMKF@ZE87^B1QS7-DX5G,3D!9%(.&&3CCO6W\
M3O!VJ>+M"T]M"NH;?6-'U"'4[,SY\MWC)^1L<@,"17 >)OAY\0/%T6NZU>66
ME6FJZE9V^GPV2W;,D$<<GF,S/MPQ+= .Q]:8'JW@_P 4R>+-)DU$Z)J&D(),
M(E_%Y;R+@$.!Z&L'XU7%Y:?!+Q3>V5]<65Q;V9D26W?8ZD$=QS7;Z3'<PZ1:
M07BHL\<2HXC.5!  .#7*_%+0M8\5?##7/#>A);M>ZA#Y"FXD*(H)!)R >W;O
M2 YW5]<L;/XG>'([J76FO4T>6YC@MW'V:=5 +;AGEQVJC:?'S1[F+2;A?"^O
MBVU>=K6TE^RY$LZY_=#!R3P:LZOX4\::AXZ\-^(;>PT]8K#1YK.X1[H@B5UZ
M#"\C(ZURNE_#GX@6FA> +"73-.,GAW6GU&X*WN0R'=]WC_:/Y4P-G6OB7HWB
MCP=;7C+KVBM:^)8-*NHH5"30W =<(_.-C;UR16J?BG/8?$?Q/H^K:3+9Z#H%
MDEQ+>L0<Y_BZ]#QCO7(WOP]^(<VD>(K6/2[!YM0\70^((<W@P(4V?*3C[W[I
M>/\ :/I6QXL^''B[7O%OBM;1;&'2O$NEQ6\EU)*=]M+&!@; #N!(Z\4P-S3?
MC9X8O;Z_L[R*ZTQ[.P.IEKA05D@'<%2<''8\U@6?B[6-:_:%\.0FTUG1M/NM
M%GF^QWFU8IL.NR0 9^;!(()R..!4%K\/_'_B#P/JOAWQ%IN@: _]G/907&GJ
M'>ZEP-LK,%&U>.5ZG/M5_0="^*&J_$CPMXG\4Z#I&EPZ387%A<+!>>:\FXIA
MUP. 2G"D\<Y]P#VI<XYIU(N<<TM2 4444 %%%% !1110 4444 %%%':@!&IN
M3GH:=W%0.[;SA30!X%^R(,? D>IU&XX].17T+7SQ^R"/^+&-_P!A*X_F*^AZ
M "BBB@ J"[_X\Y_^N;?RJ>H+K_CUF_W#_*F-$J_=IW:D7[M+2$%%%% !11WH
MH *:[!1DG%.KBOBNF_X/^*R'DC>/3)Y$:.1HV5E0D$,I!ZB@#KUGC<LJR!F7
MJ >1_GK2+/$X.R56QUPV<5\EVLFB:;HOAOQ#X)U+4=6OCX:EE\3BSU"6>>6(
M6JA=Q8D1R+(WR\ JJM@8&*K>%M9T&VO/%%I_;5O#8WWA='B-JTT*/*N=Q,A(
MW2#C+<$FF!]6:MXATG1+>&XU*^C@CGGBM8\MDM)(P1% ]R16A]HC_BE12<8R
M>Y[5\CW?ACP2/@SX&\93%[_S]4TW^U;N[NI+A(HUE ER&8A1@X.,<?CE==3P
M??3_ !>U6VU*;;8):W6E8OYU2"0PIAHTWC!W' _NYP !Q0!]<O/&F \BJ2<
M%@,T>;&&VM( V<8STKY%US4+?7O$:Q^._$EUIME=Z5:R:+?0VKS^9(%&_P @
MJ?EESU.,UVO@_1]%U;X_:I;7VK:M//INGZ=>V\$]],K&=0=S.F[!.-NY2,?,
M>* /=M6U3^S='OKZ*,W4EI"\OD(X#-M&2.3U^M9_A'Q0GBSPAI^OQVIM3>1>
M:+=W#,H]"17S1X-UK3M.UN\FM=4MO$>GW>D7\\>KI/(MU&I.=M]&W!<$[5;
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M^4X&!S[UO^*H=-T'2/"GQ8^&]K_:-GIX%C<VUM*62>"3Y%(#$@E9".>IW8H
M^B$D5A\K CV[4GG1^8(_,&[KC/.*Y7P3X=;PWX-2V0'[?<;KJX+,QS*_)X)X
M],=*\.\!:MX;U'Q-:P>(KW7+?XD6.OS+/!&\ADN8RS;01C MA&0<=!LSU(I
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MU==KGA[6-%^)VH^#]*NM1FTKQV%GBN&NG;^S]C;IPN6X4C&,#(W>U,#Z/!W
M$8Y[T[ QTKGM(UGP_P#;YO"NFZE%-?:7&BS6WF;Y(UZ MGDGWKHATJ0&XYZ4
MZBB@ P/2BBB@ P/2BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#FH65=Q
MS4Q-0D<_=%- > _LAX_X42,=]1N/YBOH6OGO]D7/_"B5YS_Q,;C'_?5?0E(
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M=SB")8PQ]3@<U;HH HW.CZ5=WT=]=:;:SW42-&DTD2LZJWWE!(S@]Q4!\.:
M9DE;0[ R)%Y"M]E3*QX(V XX7!/'2M6B@#SCQ'\.+G6=2L+?3/$/]@^&8\->
MZ/8V<:)>D-N^^,%<\9X->A1QA8P@  7IQ@ 5+10!G7&AZ-=ZE#J=UI-E<7T
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MCJW\(V-A%#-8MJFJ7"6UG#>70@C).?G8\G8,<D5K>&]0\0:AX=6ZUS3[2TU
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MCZ9XU\-ZSX@U;0M-U>"XOM'V?;%5AB,MN.,YY(V\^F13 Z6CO7(^)_&,>E>
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MQ/(R:8' > M3\/ZAJ>M>*--\$7WA>&:RB_M*[U*%K4.\:$>6L;8!"+D%^ <
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MADR>O8^E>]&"$R^:8DW]-VT9H\B+S/,$:;O[VT9H >O2EHHH **** "BBB@
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M*** "BBB@ JG(B^8?\:N56?[YZ_E3 \$_9#_ .2$K_V$;C_T*OH2OGO]D/\
MY(4/^PC<?S%?0E( HHHH 2H+S_CQG_ZYM_*IZ@NO^/2;_</\C0!,GW13J1?N
MTM !1110 4444 %%%% ";1Z4N!110 8%&*** "C%%% !@4444 &*0"EHH ,"
MC HHH *,"BB@ Q1110 8'I1110 48%%% !1110 4444 %%%% !@>E&!Z444
M&!FC HHH *,#THHH 3:/2EP/2BB@ P/2C HHH ,#/2BBB@ P*,#THHH 3:OI
M2X'I110 8%&!G-%% !1@>E%% !@>E&!110 48%%% "8'I2X'I110 8'I1BBB
M@ P*3 ]*6B@ P/2C ]*** # HP/2BB@ P/2C ]*** # HP/2BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***0T &>:I3%O-.-P%7?>JTBOYAPHQ30'@G[(9_XL4
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M[[!=7)MR([>3.!N/8$UZ#XD\2Z3X7\,7?B+5[H0:?:Q^8\G4GT"CN22 ![T
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MX:%5"A0.W''XGUK(G^!7P[N(],5]-G4Z=%Y,3)<,K-'_ '&(^\/8UZB5I<4
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M^*-#^)^I^)IM4L'T_5;2!;JV2-S()HXU0%2?X<+GFN=^.UXT6N?#B.SGMTU
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M\,:3_:WV-[^SMV#WAMV!>VA[R;>K >@YKH+2ZMM0T^"_LI%GM[B-98G4\.K
M$$>Q%?/WP8T#P;;_  /N?%5KMFU&\T^6WU"Z6ZD?*J20I4MM4CCL#BN_^!*7
M2? ?PHEZLBR?96*"0Y(B,C>7_P".;:0'4:;J^L7/B?6+"^T,V>G693[+?M<*
MXNLK\QV 97!XY)_"MQ)HV<QJZ,P&2JD9'X5\S:S<^&X?$WQULUOK*%#9Q2O&
MLXR)/+&\G!R#OZCL:A\"_P#",>'?BY\-8]#U."*;6M!F.H[;XR-=2; 8Q)N8
MY.X':,=1QTI@?4;NB LQ"@#.33%FC=-ZR*0?XEZ'\:\D^/VH:;8^!])BU2-O
MLUUJUM'NDD\JTC();-T<',7'*]^!D=:^?)];\-7'PP\6:0NO66+7Q5&UI%9S
M-:QQP/(,F)=WRH1DX!.* /M]9HL$JZ<<-\PX^M.WQY R.>,=_P J^9M.\&^$
M=6^)'Q!^'FB744>EZGH4%P(([DR*)]QQ-DDDL,J<\]:Z/X+1ZIXKNH/$GB/3
M6L;CPO:_\(W'$2#ON8F(N)N.N2$ !Z$/ZY(![RO2G4B]*6D 4444 %%%% !1
M11WH **** "BBB@ K!OE_P!-D^9^W0^WTK<;VK#OHE:^D.P'I_(4T!XM^R%_
MR0LD'/\ Q,KC\.17T.*^>/V0_P#DA?\ W$KC\>17T/2 ,4444 %5[S_CRN/^
MN;?RJQ5>\_X\;C_KFW\J )D^Z*=34^Z*=0 4444 %%%% !2'D4M<[XWUS4O#
M?@K4]<TG2)-7O+2(R):1YW28ZX Y.!S@<G&!0!KW-Y9V@C%U=0P>:P2/S7"[
MV/0#/4^U61M/:OE_QMXUN_&_@+3-15]$U9+/Q5IGV&YTZ1D69BW*R(^7A8,2
M,'/'/-=O-\5?%NFKXHTW5M"TG^UM%EAVR17;+;^3+T=]_P V5[@=>U%@/:=N
M.0?SKD_%?@/2O&%_IMQJUYJ20V+EFM+:[:*"Z&0=LR X<9 .#Z>G%>9R?&[6
MX? 'B_7%T>PO;WPU>0P.$:6WCN8Y-N&574NIYX!X/7.*N:C\4_'NGZO<>&G\
M'V;^(+>U:^,5JTMU&8BY$2':H(=MIR3P#VYIV ]KCC2-%1%"JH 51T ':G8%
M>*ZY\7]>TNW\.?:O#L/AZ?5;1IY/[:,D<23 X%OYBC:K'J"Q'TKN/&7CJV\$
M?#*[\::M;EQ;6R2_98G#&25L!8PW3!9@-PSQSS2 [(A=OM5'^T=.%^+ 7UO]
MLQN$'F+YF/\ =SFO/;7QUXLL/'%EX2\4Z3ID%SJUG)<:?=6<SM%YB8W1.&&>
M,@[A@$5R/P7T&3Q!IEWXA\46.GW6H6>M74UO=Q-()DE#8.6Z%,< =*8'NMQ<
MV]K"9KJ>."->LDCA5'XG%2KL*@I]T^G2OFG7=6\3^)?A+\9SXH^PW-G8SSVU
MK''O_<,D<94*&SQSNSU+9Z<8['3/BAKF@:@FC>+= M+2V703JUM):79E<I&
M&1P0,-GN,B@#V?:#2X&*\F\$_$SQ-XF\3V5I?>$9K?2-1M6NH;Z.&9!;XZ1R
M&10"3V*\5J>)?''B"'Q?>>%?"&B6FIZEI^F#5;A;N9HA(A9E2&/:#\[%&Y/
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MH(B$A4@R'/ XJ6X^+&KR+?+HO@N2]GT>U6XU:&6]6)[9B"?*7Y2'? )[#WH
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M')/R9ZFO69?$.APV<-Y)K-@EM.VV.9[A CD=@V<$UH1R1O$LL; QL-P*G(-
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M1M[ZZG-NWDQK$05CC7=GMR23FK]]\-?%MWK?CC4O[:TL+XETA=-CC^RN?(8
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MY2.1P*:$>/?LA_\ )"S_ -A*X_F*^AJ^>OV0_P#DA6?74;C^8KZ%I#"BBB@
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MDHU"9+&;S"3'L82G;G'F#')XP".,&J6@V]XNM76B^$E?4FDL+YK62YL7@O\
M2&;.Z.5\!7#'(7/X5]<+'$Q'[M.!D8'3Z4[R88V,BQ*&;JP7DT ?+/@^'PW>
M6RZA_9OB9]4LM"N++4DNM/\ *@@41X,;A8P9F+-\H&X\DU3\%:5IMEI7PDDM
M]$GMKQ[*ZMM28V,JL6:/&V4E?[V<;CCTKZ3/BSPK%I^I:@VKV26FG2>7>2^8
M-L+^C>AK<B-O-%'+%M>-U#*R]".Q%(#X^MY%M_A5X.9M/U6/2]#UF4ZVEII[
M,T?78S(ZE9%!]B!6O;MH&@WWA+6TTW7+OX?G6KRYN6O;-F"W#P*(IA"JY6(,
M6QQUS[5]6&*W6-OW:!>2PQP?7-9VF:IHNM6<DVEWEM>6L<A@9H6#*KJ>5/N*
M /*O@.]J)_'ZV&GW-E8R^([BXM4FM7@!B8+@J' P..F.*HZVL=A^T7JKK9NF
MH:GH ATR9;5G#3ALD[P"!@=2<5[L$13E5V\]N]5;Z[T_3[274;^6*W@MT+R3
MR8 C7N2>U 'R]I$.GZEX7\!V.D:9/9?$73M<B;42;>19XP';[3)*^.8W3/))
M!)4#FO4_CS=16GPXA:XTZ2[B.H6Y>1-Y2WPW^MD5/F91_=Z'C->G64VGWUM'
MJ5@T,\-Q&&2>+!$BGH<]Q5IHDD4K(@93U!&0: /CRSU%(/A-\6--D:^D$TZS
M6TC:7+;I,KX *)MPN2>GXUZ9HNK6<W[36AM'-($E\&)$A:)U#/YROCD==O..
M.E>[-;P,I5HE(/4$<&C[/ '$@A0.. VT9%,#R3XUB6-/"=_J$3S^&+75E?5X
M5C,@,>,(S@ Y4-R<\"O.KZUTM/#7Q9O=-C0^#[VW3^SQY;M%+=;3DPC!XSCD
M#K7TR\EI).;-Y(FDV[FA)!./7'I3_L]L(A'Y,80=%VC I@<A\+4TI?A1X<;2
M(8HH&LH6?RDV@R;%#D\?>W @^X.:^?=1'AZP\&_'71([1+;5VOYW6);=D9H&
M<;,';@@\X -?4]]J>DZ'8K<:A=V]A;;UC#2$*I9CA0/<FK/V>UDW.UO$Y?!)
M*@[OK4@?*4]IINEZS91^ !]DO=3\$W"NMK&ZF:X"*4#''+Y#8[\?2NA^#;>$
M=2\6:-J_A[4-;?4X](%I?V;V0MK>V"X^68A%WODG!)8D=37O\-_H<FL2:3!<
M6C:E;Q^8]NA7S(TZ D=0*T8K>WCW&&&./<>2B@9^M $J\#KFEH Q10 4444
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M,, ?AO+3.%R..*?9_"3PA:W+S7$%QJ1^RO91B]N&F$4+?>1<] :+@8WP^O\
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MB&: E68?-]W(X'ZUW8^#VAV(T6?P[J%[HFH:7"]L+Z!\RW$4C[Y%D)^\2Q+
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MC7UPDQ!"2$ ?+Z#  _"NM/0T@/*/#LY\3_'CQ9<7N73PO%!96<3'*QO*&9Y
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M\,W.D6D%YH)U#S+FW9VBD4X. "!@]!VK:G^#^D7.F>+=-FU:_:W\4R++>C<
M01P=IQP".*N-\-XFUNPU@^(M2^UV>E'2E<,HW(>KGC[V>:8'GWASXG^/-0NO
M!M_JJ:5_9OB.2:Q-K%$VZ.5%)\S=GH<=*YB^\0>+[[P!I5QH^H66@R-XT_LZ
MXCL+;:DG[U0&/J.[>O>O3K?X)Z?:VWA^WM?$VJ1Q:#<27-J,J3O?J3Q[U*OP
M3T9?"EQH"Z[J8235EUF*<2 207 8'*G'<B@#D/%GQ4\:>'O'#64-Q83V=CJ5
MGIUQ;1VY<2K,J[I&DS\C!B<(.W6FQZCXT3Q%\6)KK6++5+738E$5E>6V8L;"
M0O!Z8Z^M='?_  #T+4+J]F;Q)K427EY%J$D23_*;B/&)3ZL<9YK<N_A/I]UK
M>NZG'KNI6W]N6@MKR&.0;'.W;YF/[V* .9L_&^NZJO@CP?X8FT_1]1U?1?[4
MFN'@WQP1J$ CC3(!)+'KT K&7XP>.FTZSLTLM,.L6GB*3P]J#E6,4KJ.)$P<
M@<9(KOI/A38K8^&/L.M7MIJ7AF-H;+44*F0Q,-IC<$89<!?RIEQ\']#FL=/M
MUU&]AEM=2;5I+E&'F75TQ)9Y#WZG\* '_#;Q7XGU;6_%7AWQ8UG-?:'=)&+B
MTC*)(CJ6'!/!&*]"GN$@MI)YI%ABC4N[N<!0!DDGZ"O(O$WPMU)(=;O/#/B+
M58M5UV[@EFE6<(L6QA\W3E0,Y'>ND^)=KJMQ\,+S2K+3=1UBXNXEM9DTZ1(I
MG0C#L"_ SW^M(#PJT\>30?&/2/B==75XFE:_.VER6<L$B16MOG%N^XKM);&>
M#WKU'Q#XR^(TGQ9N? _A.UT7:NF"_CN+LN2/G .X \^V/6N=\4W_ (K\5>"$
M\*7WPB\1Q6RB/]_#=6X?*=".P/TJEIMSXVTOQM:>+&^&OBZ\O8+'^SRDES;%
M98ASS[Y /X4P,G3?$?C.V\#^*]4\3MI7B-+;QFEDT=Y"Q$9#Q)O0;L +E=JX
MXY/.:])UWQKXXU'Q=K/AOP%;Z;YV@VL,\RW@):ZD< B-<'Y5Q_%ZUYC=:'XF
MFM]>L5^&_C."RUK4UUAX8[NV*PW 97)7/J57KZ5:\16'B77/% \1VGPU\;Z'
M?RP+:W;V%[ GVN->,-SUQW% &VVO/X?^.GB7Q1?Z?$ES;^"4O+F"%L@R+*"5
M![\\9KJ/A]XY^(FN>(=/37/#J#1-3TY+Y;R*+REM)& (BY8[Q@CYOK7#1V^M
MQ>)KS5I/A%XKFAO=)_L>6T>ZMRGD YZYSNSWJU\,=(\1Z#XHTRWO/"?C0Z;;
MJUM9_P!IWD+V]A&5'.U3EN1@>F: /H\'(I:1:6D 4444 %%%% !1110 4444
M %%%% "'[M<KJER(]4F3:QQC_P!!%=6>E<?J\5LVK3L\BJQQD$_[(IH#RW]D
M?'_"AXMJX/V^X_'YNM?05?/G[(P<? :(LO!O[C!/INKZ#I %%%% "5!>?\>-
MQ_US;^53U!>?\>-Q_P!<V_E0!,GW:=34^[3J "BBB@ HHHH *P_%EIK5YX5O
MX/#NHKIVK&,FVN&0.JN.F0>QZ5N50U75=,TBT%UJNH06,!8*))Y BY],F@#Q
MC1?B!K6I?L\)>OJLB^,VNFT=_D7>E_YY0IMQC &6_P!T$]:U+6[\86'QCT3P
MG?>*9;NUFT5[RX_<H-TRMMR#CIWK%L+/PK8_&^_\3Q^-='/AV]4:@ED;J/":
MAL\HR@9X_=@\^K&KFH:[ITGQWL/%=OK&C3:3:Z5)9,_]I1AMY;<#MSTI@;_P
M=UWQ#XATOQ#=:_JQOGL]8N-.B_=+&!''MP>._P U9^M?$2;PK\9M3T_6KZYG
MT9-'BO(K6WM_,9'WL&(V\D84'FH?@C(NF6_B#2;V]TR2YU#6+G48%M+Y)F:-
M]O!"\C %7]2T'Q*WQ<UOQ!;Z-'<:==Z"NGPR&95)E!<\CJ =X'X4 ;U[\5/!
M]CHVG:HVH&:'48#<P+$N7:,=6(XP!5*^^-/@.Q-D/[1GNC>VRWD M+=Y2\1;
M;D;1V/!]*\MLOAKXTT>Q\*ZA)X3T[7)K&PDTZ]TVXN,8!<L)$;I^%=GX>\)^
M(;#XIZ#J4WAFSLM*M-%FLW^RR#RX)'E#A57N %P3W)H ZR_^*O@[3-=72KO4
M"&^U"R:<+F))STC+?WJ?JWQ/\)Z-J%U:7=W,RV;*MU<10L\-L3T#L.E>56?P
MY\3:3XNU+3)?!&CZYIEYK#ZG:ZQ=2_-;JTN_YD[LN2!^%7O^$0\;:/IWCGPG
M#HD6J67B*9Y[2_$H41^8,,LH//':@#2\;>.-4U+XE:9X!T#4+S3$O+"6X&HV
ML'F9E+1K$1G_ )9C?EC7K6CQZC;:)9V^K7D=YJ$<*K<3QIL620##,%[ G/%>
M4V'A?Q1H_P 4?#E];Z2+G2M%\.'2#=M.%\R7]V0V.N/W>#]:[?P%XGO_ !5X
M275M6TQ=,N5EDB>-7W(=K$%E;N#C.: /+D^(WBC6?%7B'1[;Q1:Z%KVG731V
M6AWEJNR[B'1M[<DM['BO3/$/Q(\.^$C';Z[<.MXMNMS<1P1E_L\9.#(_HN<\
M^U>.>/88/&VB7^FZW8Z$^OQ7+#2]7@U2&-H%S\KL<Y!'<=Z@\3:?':>-X=4\
MGPYXZL[[0X-+NOM.J1Q.DT6[+GYL%'WDGWH ]DU7XL>#-*DC$VHM/$8XY9)K
M:,R1PH_W&=AP :RY?BI87?C37?"=O!=VATW3?MC:B82Z_,/E95[C'/O7F^G2
M:OX/\4:M%I?_  B>LZ3KD<!XU"*..TD5%0C83R@V\"MFXO#IOQ/U_6;>^T6_
MM=4T.*T66+4HD"3(#E=I/0YXH [7PYXXTW3?AQX9OM:U]]<N]40K;SP6Q$EZ
M<DY6,= !C/T]ZGG^,'@.#3;6^EU9TCN;EK-5\EO,69>J,N,J:\DT&UU#P[IG
MPRUF&_T2YO?#MG/INH:>=5A!$<A&)8VSC=\J_@<57N]',OB.#6X[S1<7_B1=
M7GM1J4(%M$J!1DYY8]3B@#Z#\+^,M$\7VUW-HL[R&SE\B>.6,QO&^,@%3R,B
MN>\=>)O$6@>-O!%EILEM_9FKW[VMVCQ[I& C9A@] .![US/P_P!1L=)^(GC_
M %;5-4TBTM-:O(9[1AJ,3%PB%3D \5)\1M5M=6\7^!KK1M4TJ[MM*U%KN[<Z
MC$H53&4&.>3\V?PH ]?N+F*V@DN+B18H8E+N[' 4#J37(Z7\2O"NKZO:Z;;7
M4J27N\6CRPLD=UMZ^6Q^]_7!J_X@M8/&'@/5-/TK4H7%_;/#'<0R!U#$8ZBO
M+;'PAXNUNT^'FCZSH*:8OA6Z2>XO%F#"3RE*J(\<_/QG\: )].\7>*O'7Q.U
MG3_#NLRZ-;>']0CB:WN+/=%=0>6IE#'J'RQV^V#72:M\2(SXYU;P+I]M=P:A
M:Z<UTMX8=R(_\/!X(]Z/A[I.O:?XR\=ZAJVDM96VKZDMU:LTH8N@B1.0.GW,
M_C6?X@T7Q79?%C5-=TG0QJ=CJNBBP#K,(S X)/S9ZYH ;\*_BMIGB'0/#^DZ
MUJOG>)K^*5F/D-&DS([9"G&,A1T%:OA[QYIMKX:U;7-8\3)J=I'J\UK$T=J8
MWB)D(2#;U9QT)]C7">'O!WB_3].^$]M/X:\I_#]W<S:@RRK^[5ED48]<^9G\
M*<O@O7I_!'B.PUCPA-<KJ7BJ?4Q!%<A)XX'=W66)AT=25X]S0![3H'B32_$V
MG-?Z3,TD*2-$V]"C*Z]5(-<%\7/BA=> +:P;3+ W\HD2ZOU5=WD6*NJRR8]<
MLH%:OPLT[Q/I/@V2W\3O++<"YD:#[1M,YA_A\PC@MBN?M/ MUXVU3Q7K'C:U
MU33?MS'3H;.&[V)+8JO ..NYFD)^H]*0'=>(/'7AKPMH5IK6N:BMM87CK'#,
M%+ARWW1QZURVE_&GPSKGQ L_"6D0W=P]S \WVEH&1%V]N1G\>E>76_AKXF7O
MP9T#P9J_A.>:^T35K:5)7F4B2VC<X_$*0/PKTZ\T36[/XX:7XFL=#\_3)=+>
MTE:-E3[.Y<-R._2F!9\-^.=/M/#VH:CKGBR#5A_;4UC T%NR,K9&RW"=690>
M3]:S/&_Q+=_ -EXE\#ZI$%_M6"RN1-#EU#/M="I^ZPKSRV\'_$72[6/Q-8^%
MVEO=*\7WVKIITLJ[KFUG39\O;<.<9]:ZGQEH7BK7_APBV/@Y+&[NM<@OGL(7
M7S$C5]S/(>A<]30!Z1JGQ&\)Z)JD6F:GJ@AF>182^PF.-V^ZK-T4GWK<UG7-
M-\/Z-+JVK72VUI%@-(W/).  !U)) _&O ;CP+K<?C'7['4OAO!XFL=5O4OK3
M4)Y]JP$@ K*,\[<9&*]/^*UCXAO?AV]KX9L4O;H7-N9(E +B)9 6:+/&\8R,
M],9I@:$?Q.\&MH=YK,NKK;V=C*(;DS1LC0L>@9<9&:FTCXA^#]<CU&73M;@=
M--7S+EI,Q^6G]_YL?+[UX9_PB_C./0?B%;2>#=2D_MR:VDMO.N%FDD VAMQ]
M?E.?K5OQAX&\8>)-=\9QZ3H$UC;:CX;MK2V=RJ1O-&^]HSCID<9I =S9?$Y]
M9^-^E>&=&O8IM%NM*FNG1K9DDWHZA7#,.5(;C'I73:I\0M+T[XBZ;X$,<O\
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M[;<;0.PW_P".:^@,UX#^R5)N^ EJN[.V]N!TZ?.:]^H **** "J]Y_QYS_\
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M!SCJ ?7TKY\U%M>\(:KH?QEUG2?LYEO_ /B<7;3AA]@N"$1 H[1CRV^N[UH
M^H._^-8^J>(;#2]$O-699;R&T)61;1/-?(X(P.IKR*\M]2\5?'C5M"M?'.HV
M>D#2[6]2&RG4AB68$*>RD#GZURFF2?V!\!O&U]HOB*[M]5MM0N"7-UOD4"0=
MCTS^M,#Z;@E2XM(I@K!95#!6&#@C/(KGE\4Z&OC@^ DMY8[X67VH((<0F+..
M#T_"O'+K7&\5>*O$NCZWXTN/"L^C:99W.DSI<"-&W1[Y+@@_ZSYAMQZ ^M6?
M$^N75E\69-9TJ3[5?Q>#7GARF&9MY(;;V]<4 >FGX6?#B24S/X-TLN2228!R
M3UIO_"I_ALQ^;P5I77/^I%>/^#=4\026LFO0?$+3S'J&DRR2PO<M/MG5<B9@
M1^[VG@CI71_!S6=0F\6ZIHNMW&HQ:O#IT$\UO-.+BVGRQS<Q2#H'/\/L:0'?
M_P#"J?AO]W_A"]*XZ?N!6%XC\+?"GPO;6INO!-C//>S>1;6MM:!Y)Y",[5'T
M&?PK"U/4KCQ!\0O&^EZEXBNM(;0;5'TV""7R0 8]QG.?O_-QZ#%<WJ)N/%-Q
M\'=2\374\&IW5TZSK'-Y6X")\/M[$X'/O[TP-^]F^"6G^'](UG4/ /V>'4[H
MV,*-I9\Q)]_E^6R]B67CU'-=S'\+/AK-$)/^$'TQ?,^8JUN 1GUKE_CPT%OX
M>\$1;E7_ (JW3<*6P2 YR?>J/BN'4]6^*7B32/\ A,M2TZPM=#2]%M;3*F)-
MS8P2,@< D=Z .Z_X51\-^!_PA6E<<?Z@<4T?"7X:[=I\$Z5CJ1Y(ZUY%I7BV
MX\3W'A+0?%/BJ?2[&_T.6>.[CF$/VJZ1]O+^JKSCN:V=.U2\\2>--#\&ZQXQ
MN)M,C\.K=PZA;-]G.J7'F-&\N[N%"JP Z[MU 'M>D:+I'A_3ET_1-/AL;126
M6&%<*":T/ICK7R[HNK>+O&'B7PCH-]XTU'3A<07\3SVS*#<K$V(Y.>I('6N@
MU;2-7U3XK^(O"TWQ(U73;.ST.UNHV69$V2Y92_/;Y02/>@#Z!R/J,4NX?7%?
M-W@WQ#KWQ%31=/\ &&M7>BN_AB+44^S2>2;B5I''GY[X5$;'^V<UEZ+K7C+Q
MIJG@G1[GQM?:8VI0WL<TMMM'GI$2$D /<@=: /J,\G ]*R-<\2Z9H.CW^J77
MFW$=@JM-%:H991N( PHYSS^5?->H>+]6TSQGI]W:>+[N^2U\46NBS7,TZQ1^
M20B2Q^3U/5F+],D59U*2?0+7XU:OH_B2]M-3M+V/[/NN@Q VPY(4]<;B,^E
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MEODX.<#VK%\&^"/#'A=KW4M"BD:35I#<R3S.9'(8[@H)Z+STKG?B!J6I:/\
MLYZCJ^C7:VMW9Z,DR.T8D'$:DC!XYK%UK4O&=_\ $'P[X;TGQ*VDVNH^'Y+J
M0I;J[1RJ5 89[\T >U'!HXX]OTKS#P%XLU?4O@B_B#6-1A_M"VCG5[R1,*3&
M2 [ ?3FN"\!^//&4GQ#L;74;ZYU'3-2\.R:D$G55,L\9'S0@<JK;@ #[&@#Z
M,XX&*.*\+\'^(/$=]H.C^/I/&\-[#J-G//<:*P!42[2ZPQ <@K@J<^E4M%\5
M^)!X6L/B(WCB.^2[M[@W.C2A=HD )CCB4<JRD '/;-%@/H+(QSV-)FO!=/\
M$7B_2[CX<:\_B:36[;QB?(O;1XUV0N\32B2''W0FW:0>U<];>+/B-I?@[6O&
MU]XP&H00ZC/I,5K]E4)&QGV+,Q'91GCZ46 ^@(O%6A3>,)O":76=7@M_M+P%
M2"(\XSGZFMNOF?5&U3P?\4=>U23QA]MNHO"33P7E^H98F,B>G4'/ K2\)>+O
M&!N_'VB7VNW3_9-$AU;3YKQ4,\#21.6!QVW1Y"GH#[T >]ZEIUCK&F7&F:C
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MHC=:XS67B&L3AK?<?EY_X"* /,?V2=W_  H6#MF_N"/^^J^@QTKY]_9(5O\
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M+9BWTZW4I'#N+  ]1S6)IGPS\'Z1J?V^PTUHG65IHXC*QBBD;JRH3@&NRHH
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M^4#%]<#CO\]?0%?/G[(^[_A1$65 ']H7&".XW5]!TAA1110 8J"[_P"/.?\
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M1C@<8KI6\ >*]:^(-UJ_B/[ NG:EX:;0[P6LK;U9R2S)D=/F(Y^M>Q[11M%
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M HHHH **** "BC-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1WHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $)I:** "BBB@ HHHH ****
M"BBB@ HHHH *.U%% !1110 =J\M\40Z>WB>\::[D1R5RHD8 ?(*]1;H:\I\5
M&/\ X2B\S;Q,?DY91D_(OO3$SF/V3%(^ ED=V<WEP?\ Q^O?J\"_9+V'X!V>
MTG_C\N,Y['?7OE(8M%%% !BJ]YQ8S_\ 7-OY58J"\_X\9_\ KFW\J )5^[3J
M1>E+0 4444 %%%% !1110 4444 %%%% !0>AHH/2@#S35O%GC"'XT67@>P&C
MQV%[ILFHQW,\,KRIL8*4(#@').<CMVK/\!?%MM>\5ZGX+\36]KI^OVD[I;O
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MML!MY;&#[5YOJ7@^X\(^%/A3X7U]=1>:WU22[OFTU+AOLRN"<"2+E<$XR"*
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M&6C6^M7?B4_$32]0F;4+.&U@1=S,V^::=80TD)ZC=(>HQ7U!JYO&T&_&G_\
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ML;2JX]#T%>(-J?CKQ5XA\$6L/BN[\.)KWA^:]O(;>WB+1R(8N4+J2I;S.^<
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M,)%&%;<I!R*J>'_AGH/AS6]3U>UNM2N+G4XA#<F[O))A(H&!D,>N._6NWHH
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MTN4#HZ_R/H1T-:5 !1110 4444 %%%% !1110 4444 %%%% !1110 8HHHH
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M /BJ -RBL3_A+_">0/\ A)M*R?\ I\C_ /BJ7_A+/"__ $,FE?\ @9'_ (T
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MA_D: )E^Z*6D7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?2-!T.]C!VL885.T^A':N6^/$+-)\/6AM4N9!XEM\*^.1M;(R?I6-JNA>+?
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MBD!S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !WHHHH **** "BBB@ HHHH 0C-?-_P 27V_$?5EYX,7;
M_IDE?2-?+7Q3O88OBCK,;*208NG_ %Q2F@.Y_9<Q_P ,\:!C^_/_ .C6KVRO
M$/V65=?V>-$W8P9)RN#V\UJ]OI %%%% !FH+H_Z++_N'^535!=?\>LW^X?Y&
M@"9>E.I%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H[44AZ4 !/%%(,FG4 )]:6DQDTM !1110 4444 %%%% !1110
M 4444 %%%% !112$4 +1110 4444 %%%% !1110 4444 %%%% !1110 4F:7
MM2=!0 C=*^+?C5)?+\9]?$5BLB;H,-SS^XCK[3/2OAGXZ/KB_''Q&+.Y5(-T
M&U<=/]'C_K30'T'^S&A7]G+PP2Q.X3-]/WSU[)7C_P"S0/\ C'#PK_USF_\
M1SU[!2 **** $J"[_P"/&?\ ZYM_*IZ@N_\ CRG_ .N;?RH&3)]VG4U/NTZ@
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M111G- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BC-% !1110 9YHIN "2!2;N: 'T4@/%+0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 UJ^'/CGK5Y:?'#Q%;QVMNZ(8,,Z\G_1XS7W)U%?
M!'Q]N'3X\^)5$^T!K?C'3_1XJ: ^EOV:Q_QCGX3/?RIO_1[U["#FO'_V:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1
MNE?G7^T:6_X:)\58;'S6W;_IUBK]%":_.S]HQ/\ C(CQ3T^];=A_SZQ4P/L7
MX!+M_9^\&@-N_P! 4YQCJ2:]/KRW]GTY_9]\'88-_H(Y'^\>*]2I %%%% !4
M%Y_QY3_]<V_E4]07G_'G/_US;^5 T2I]T4ZFI]T4Z@04444 %%%% !1110 4
M444 %%%% !1110 4444 %%(<]L4M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 44<T4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !11SFB@ HHHH **** "BBB@ HHHH ****  <"B
MBB@ HHHH **0=:6@ HHHH **** "BBB@ HHHH **** "BBC- !1110 4444
M%%%% !1110 4444 %%%% !1129H ,'-+31UIU "-TK\ZOVC4+?M$^*F$RK\U
MMP3_ -.L5?HH><5^<?[2/_)QOBO[WWK;HO\ TZQ4P/LK]G[Y?V??!^$"#["O
M3OR>:]4'(KRO]GL,O[/?@Y6ZFRS^&XXKU,<"D M% HH ,U7N_P#CRG_ZYM_*
MIZ@NO^/.<?\ 3-OY4#)D^Z*=35^Z*=0(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ H(S110 =J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHYH **** "C/.*** "BBB@ HHHH **** "BBB@ HHHH
M****  TF10WK2<YZ4 +2TAI.^* &M7YQ_M)9_P"&CO%?3[UM_P"DL5?HXU?G
M)^TC(5_:-\5K_M6W<_\ /K%30'VE\!5"? 'P:N[=_P 2Y#FO3:\S^ \>SX!>
M#%/?3HVX/J,UZ92 **** $J"Z_X])C_L-_*IZ@NO^/*?_KFW\J!DZ_=%+35^
MZ*=0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H.>U%% "#/>EHHH *3'-+10 4444 %-QZ]:=24 -;M7Y
MQ_M)1LW[1WBLCINMO_26*OT=[<U^</[217_AH[Q9G.=UMW_Z=8J: ^U/@-M'
MP!\&;6W#^SH^??'/ZUZ97F7P%9'^ '@SRU 7^SD''J.":]-I %%%% "5!=_\
M>4__ %S;^53U7O/^/"X_ZYM_*@"=/NTZFI]VG4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T44 (#FEHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%%  :*** "BBB@ I*6B@!OTXK\UOVCYI!^T;XM#HN?,@_+[/%C
M]*_2@DU^:O[2.UOVCO%I"G_66XZ_].T5 'W5\$T$?P(\$JN,'2;=N/= :]#K
MA/@[&(_@=X'4#'_$EM#^<2FN[H **** $J"\_P"/&X_ZYM_*IZ@N_P#CQG_Z
MYM_*@"9/NTZFK]T4Z@ HHHH **** "BBB@ HH/-% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %':BB@ '2BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$(YK\T_VC(O^,B_%O)_UL/\ Z3QU^EO05^:'[1F__AHOQ;\J_P"NA_\ 2>.@
M#[T^$&/^%'^!]I)']B6?4Y_Y8K7=UP?P<##X&>!]R;3_ &+:<>WDK7>4 %%%
M% "5!=?\>4X_Z9M_*IZ@NO\ CUF_W#_(T 3+]T4ZD7I2T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 449S10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (<FOS3_ &C X_:+\6_./];!_P"D\=?I;7YH
M?M'&/_AHWQ;_ -=8/_2>*@#[X^$99O@?X'9NO]AV?_HE*[>N)^$88?!#P.&.
M3_8=E_Z(2NVH **** $J"Z_X])O]QOY58J"[_P"/.?\ ZYM_*@9*O2G4U?NT
MZ@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%(<]J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D-+10 @XI:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDI<T ,8'.:_,K]H8R
MG]HCQ?NSG[1'^7DQXK]-VZ&OS-_:(/\ QD1XN^Y_KXOXO^F$= 'W_P#"<[O@
MIX'(.?\ B167/_;!*[2N*^$X5/@GX'49 _L.RZ_]<$KM: "BBB@ J"[_ ./.
M?_KFW\JFJ"Z_X\Y_^N;?RIC1.OW12TB_=%+2$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %)TI:#TH :S8%?F/^T)_R<-XNW 9^TQ_EY*>]?ILR]#WK\T?V
MA\?\-$>+OF_Y;Q=C_P \(_:@#[_^%0/_  I?P0>G_$CLO_1"5V=<9\*3GX*^
M!_\ L!67_HA*[.@ HHHH 2H+K_CUF_W#_(U/4%U_QZS?[A_D: )UZ4M(O2EH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHR* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K<U^8OQ_>23]H/Q>S;<_
M:E'WO2)!7Z=&OS%_:"4)^T)XO4.3_I2'IZQ(: /T+^%@5?@SX*5/NC1++'T\
MA*[&N-^%8*_!CP2IZC0[+_T0E=E0 4444 )4%U_QZ3?[A_D:GJ&Z_P"/.;_<
M;^5 $R_=I::OW13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% "'I2T44 %%%% !128YI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 1NE?F1^T&R-^T+XO*X(^TH.G_ $Q2OTV)
M'-?F!\?2K?M!>,".?],'_HM: /T0^%G_ "1KP5_V [+_ -$)78UQOPN_Y([X
M*'_4$LO_ $0E=E0 4444 )4%U_QY3_\ 7-OY5/4%U_QYS_\ 7-OY4#)E^[3J
M1?NBEH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !129H'6@!:*** "BBB@ HHHH **.U% !1110
M 4444 %%%% !1110 4444 %%%% !112"@!:*** "BBB@ I#]ZEII'- #2.<]
MO2OS ^.[!_C[XP9>1]MQU]$45^H)!Q7Y=_'**6'X]>,$GP7^WLW'H5!'Z$4
M?HI\+P?^%/\ @L_]02RX_P"V"5V(Z5R7PT_Y)+X/RNT_V-9\>G[E:ZZ@!H:G
M444 )4%U_P >LW^X?Y&IZ@NO^/6;_</\C0!.O2EI%Z4M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 )BEHHH **** "BBB@ HHHH **0C-+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !WHHHH **** "BBB@ HHHH 04M%(#0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !11W]J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH /2BBB@
MHHHH **** "BBB@ HHHH ,4E+10 44=Z* "BBB@ HHHH **** "BBB@ HHHH
M *3^*EI/PH 6BBB@ HHHH **** "@C-%% !1110 8I,4M% ";>:6BB@ HHHH
M **** "BBB@ HHHH ***.] !VHHHH 0YI:** "BBB@ H[T44 )SFE[T44 %%
M%(W2@!*<*3%!XH 6BBB@ ]:.U%% #37Y<_'*4S?'KQB^<_Z>R_D /Z5^HS=:
M_+OXZ*J?'OQ@JK@?;F/YJ#0!^CGP\^;X7>%2!C.DVA _[8K755RWP_ 'PR\+
M;<X&E6H&>O\ JEKJ: "BBB@!*@NO^/*?_KFW\JGJ"Z_X\Y_^N;?RH&3K]T4M
M(OW12T""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **!10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 44#I10 4444 %%%% !1110 4444 %%% H **** "
MBBB@ HHI",T +D44F..:6@ [T444 %%%% !1110 4444 )CFC&.:6B@!,T,V
M.@S1BB@!IZY_2ORZ^.8(^/?C'+;O]/8Y_P" BOU%/IWK\NOC>C+\>/&(8@G^
MT'/Z"F!^D'@-BOPW\+HQR1I=MG_OTM=0.E<UX*3'P_\ #@]--MAS_P!<EKI%
MZ4 +1112 2H+K_CTF_W#_(U8J"[_ ./.?_KFW\J!DR_=I::OW13J!!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12
M"EH **** "BBB@ HHHH **** "BBB@ HI #S2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44&B@ HI ?6C/2@!:.]%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4"BB@ HHHH **** "BBB@
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M"+-)FF]A0?O#ZTQC\CUHIC=*7^*D [(HS3!]UOK49Z4P)2>:=48^[2M]PT6
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?K@_\A!SU]0#7ZBMU%?E[\=/^2]^,?^O]O_010!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208428392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Skye Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,007,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,109,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208482936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,469,410<span></span>
</td>
<td class="nump">$ 1,829,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">190,134<span></span>
</td>
<td class="nump">152,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">7,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,664,385<span></span>
</td>
<td class="nump">1,994,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,341<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,671,726<span></span>
</td>
<td class="nump">1,996,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">364,340<span></span>
</td>
<td class="nump">129,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable - related party</a></td>
<td class="nump">17,032<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AccruedInterestRelatedParty', window );">Accrued interest - related party</a></td>
<td class="nump">44,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">259,111<span></span>
</td>
<td class="nump">420,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">38,567<span></span>
</td>
<td class="nump">410,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtCurrent', window );">PPP loan current</a></td>
<td class="nump">64,062<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">787,199<span></span>
</td>
<td class="nump">970,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLoansPayableLongTerm', window );">PPP loan non-current</a></td>
<td class="nump">52,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Multi-draw credit agreement - related party</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">931,103<span></span>
</td>
<td class="nump">387,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,220,940<span></span>
</td>
<td class="nump">1,448,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at December 31, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 500,000,000 shares authorized; 288,074,415 and 182,895,247 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">288,074<span></span>
</td>
<td class="nump">182,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">38,896,693<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(38,733,981)<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">450,786<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,671,726<span></span>
</td>
<td class="nump">$ 1,996,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AccruedInterestRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AccruedInterestRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayableLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayableLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214852184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">288,074,415<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">288,074,415<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208511880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,944,411<span></span>
</td>
<td class="nump">$ 2,237,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,344,602<span></span>
</td>
<td class="nump">4,394,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,289,013<span></span>
</td>
<td class="nump">6,632,578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,289,013)<span></span>
</td>
<td class="num">(6,632,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(436,270)<span></span>
</td>
<td class="num">(9,734,759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">725,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">706,385<span></span>
</td>
<td class="nump">1,000,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense (income), net</a></td>
<td class="nump">270,086<span></span>
</td>
<td class="num">(7,686,003)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">(Loss) income before income taxes</a></td>
<td class="num">(6,559,099)<span></span>
</td>
<td class="nump">1,053,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income and comprehensive (loss) income</a></td>
<td class="num">$ (6,560,699)<span></span>
</td>
<td class="nump">$ 1,051,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>(Loss) earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares of common stock outstanding used to compute (loss) earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">230,746,878<span></span>
</td>
<td class="nump">135,154,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">231,420,973<span></span>
</td>
<td class="nump">169,560,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfDerivativeLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of derivative liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfDerivativeLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506207997176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (6,560,699)<span></span>
</td>
<td class="nump">$ 1,051,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">302,742<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(436,270)<span></span>
</td>
<td class="num">(9,734,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfDerivativeLiabilityExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">725,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">544,033<span></span>
</td>
<td class="nump">629,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(37,439)<span></span>
</td>
<td class="num">(59,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">7,275<span></span>
</td>
<td class="num">(4,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">234,531<span></span>
</td>
<td class="nump">124,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable - related party</a></td>
<td class="nump">7,032<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued interest - related party</a></td>
<td class="nump">44,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(161,295)<span></span>
</td>
<td class="nump">225,945<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,054,131)<span></span>
</td>
<td class="num">(6,027,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(7,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and warrants - net of $854,078 and $80,628 of issuance costs in 2020 and 2019, respectively</a></td>
<td class="nump">6,085,589<span></span>
</td>
<td class="nump">1,919,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="nump">48,533<span></span>
</td>
<td class="nump">4,080,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Proceeds from PPP loan</a></td>
<td class="nump">116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs in 2020 and 2019, respectively</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">3,990,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_RepaymentOfConvertibleMultiDrawCreditAgreement', window );">Prepayment of convertible multi-draw credit agreement - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,985,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,700,822<span></span>
</td>
<td class="nump">6,004,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and restricted cash</a></td>
<td class="nump">639,461<span></span>
</td>
<td class="num">(23,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, beginning of year</a></td>
<td class="nump">1,834,515<span></span>
</td>
<td class="nump">1,857,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, end of year</a></td>
<td class="nump">2,473,976<span></span>
</td>
<td class="nump">1,834,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">2,469,410<span></span>
</td>
<td class="nump">1,829,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, end of year</a></td>
<td class="nump">2,473,976<span></span>
</td>
<td class="nump">1,834,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">117,459<span></span>
</td>
<td class="nump">371,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement', window );">Beneficial conversion feature on convertible multi-draw credit agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement', window );">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement', window );">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">193,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ExerciseOfWarrants', window );">Reclassification of warrant liabilities to equity from exercise of warrants</a></td>
<td class="nump">$ 26,250<span></span>
</td>
<td class="nump">$ 6,077,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of derivative liabilities reclassified to equity upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfDerivativeLiabilityExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of fair value of derivative liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfDerivativeLiabilityExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_RepaymentOfConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to prepayment of convertible multi-draw credit agreement - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_RepaymentOfConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214657208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet', window );">Proceeds from the sale of common stock and warrants net</a></td>
<td class="nump">$ 854,078<span></span>
</td>
<td class="nump">$ 80,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the proceeds from issuance of common stock and warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ProceedsFromIssuanceOfCommonStockAndWarrantNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208141128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">$ 17,528,947<span></span>
</td>
<td class="num">$ (33,225,107)<span></span>
</td>
<td class="num">$ (15,562,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi-draw credit agreement, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts', window );">Issuance of common stock net of issuance costs of $16,900</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">1,911,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,919,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts', window );">Issuance of common stock net of issuance costs of $16,900 (in shares)</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">144,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">144,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FinancingValueWarrantExercise', window );">Exercise of Emerald financing warrants</a></td>
<td class="nump">$ 40,800<span></span>
</td>
<td class="nump">9,972,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,013,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FinancingSharesWarrantExercise', window );">Exercise of Emerald financing warrants (in shares)</a></td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,051,825<span></span>
</td>
<td class="nump">1,051,825<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 182,895<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">302,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">302,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts', window );">Issuance of common stock net of issuance costs of $16,900</a></td>
<td class="nump">$ 56,333<span></span>
</td>
<td class="nump">6,029,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,085,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts', window );">Issuance of common stock net of issuance costs of $16,900 (in shares)</a></td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">$ 48,533<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="nump">48,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,560,699)<span></span>
</td>
<td class="num">(6,560,699)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 288,074<span></span>
</td>
<td class="nump">$ 38,896,693<span></span>
</td>
<td class="num">$ (38,733,981)<span></span>
</td>
<td class="nump">$ 450,786<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">288,074,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FinancingSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares related to exercise of emerald financing warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FinancingSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FinancingValueWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to Exercise of emerald financing warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FinancingValueWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_StockIssuedDuringPeriodSharesForExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period net of issuance costs value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_StockIssuedDuringPeriodSharesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_StockIssuedDuringPeriodSharesSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_StockIssuedDuringPeriodValueForExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of common stock issued during the period net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_StockIssuedDuringPeriodValueNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_StockIssuedDuringPeriodValueSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506209030184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ShareIssuanceCosts', window );">Share Issuance Costs</a></td>
<td class="nump">$ 854,078<span></span>
</td>
<td class="nump">$ 80,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents costs related to issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214580568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Operations and Business Activities</a></td>
<td class="text">
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><strong>1. Nature of Operations and Business Activities</strong></span></span></span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><strong><i>Nature of Operations</i></strong></span></span></span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Skye Bioscience, Inc. (the &#x201c;Company&#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#x201c;Merger&#x201d;) pursuant to which Nemus, a California corporation (&#x201c;Nemus Sub&#x201d;), became the Company&#x2019;s wholly owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub to form a Nevada company.</span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#x201c;Emerald Health Sciences&#x201d;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &#x201c;Emerald Financing&#x201d;). As part of the transaction, the Company&#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&#x2019;s former CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#x2019;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company.</span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Effective March 25, 2019, the Company changed its name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc. Effective January 19, 2021, the Company changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc.</span></span></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#x201c;EMBI Australia&#x201d;), in order to qualify for the Australian government&#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#x2019;s product candidates.</span></span></span></span></span></span></span></span></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 11 - Related Party Matters for additional information.</span></span></span></span></span></span></span></span></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company is a biopharmaceutical company located in San Diego, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#x201c;UM&#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</span></span></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.</span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><strong><i>Liquidity and Going Concern</i></strong></span></span></span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The Company has incurred operating losses and negative cash flows from operations since inception and as of December 31, 2020, had an accumulated deficit of $38,733,981. The Company anticipates that it will continue to incur operating losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of December 31, 2020, the Company had unrestricted cash in the amount of $2,469,410. From January&#160;1, 2021&#160;through February 23, 2021, the Company received $3,019,800 in proceeds from the exercise of warrants (Note 13).</p>
    </div>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company&#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. As the Company approaches its first clinical trial, it expects to ramp up research and development spending and to increase cash used in operating activities. However, based on the Company&#x2019;s expected cash requirements, without obtaining additional funding by the second half of 2021, management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:black">On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Emerald Health Sciences (See Note 4). On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &#x201c;Amended Credit Agreement&#x201d;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to </span><span><span><span><span><span><span>$20,000,000,&#160;</span></span></span></span></span></span><span style="color:black">which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.</span></span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <div>
      <div>
        <div>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000 and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of the Company&#x2019;s common stock, in accordance with the terms of the Credit Agreement.</p>
        </div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <div>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">During the year ended December 31, 2020, the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. Emerald Health Sciences elected that the fourth and fifth advances are not convertible into shares of Common Stock and no warrants were issued with the advances. The Company used the proceeds from the advances for general corporate and working capital purposes. As of December 31, 2020, the Company may draw down up to the remaining amount under the Amended Credit Agreement. However, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place, however, there is no guarantee of continued funding.</p>
        </div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#x201c;PPP Loan&#x201d;) from City National Bank (the &#x201c;PPP Loan Lender&#x201d;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) administered by the U.S. Small Business Administration (&#x201c;SBA&#x201d;) (Note 4).</span></span></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 31, 2020, the Company entered into the August 2020 Financing (Note 5), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction were $6,085,589. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company is using the net proceeds of the offering for general corporate purposes, including working capital.</span></span></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely. Upon the closing of the August 2020 Financing, the Company&#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.</span></span></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</span></span></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In December 2019, a novel strain of coronavirus (&#x201c;COVID-19&#x201d;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread around the world and throughout the United States and Australia, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&#x2019;s ability to raise additional capital and obtain the necessary funds.</span></span></span></span></p>
        </div></div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Notably, the Company relies on third party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of THCVHS from the second half of 2020 to the third quarter of 2021.</span></span></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></span></span></p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506314827752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
    <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong>2. Summary of Significant Accounting Policies</strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Basis of Presentation</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span>The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Use of Estimates</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Risks and Uncertainties</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#x2019;s ability to attract new funding.</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><em><strong>Cash, Cash Equivalents and Restricted Cash</strong></em></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2020, and 2019, the Company has no cash equivalents.</span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash on the balance sheet represents a certificate of deposit held by the Company&#x2019;s bank as collateral for the Company&#x2019;s credit cards.</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Fair Value Measurements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</span></span></p>
        <p style="MARGIN:0px">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%">
          <tbody>
            <tr style="height:15">
              <td style="width:7%" valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Level 1:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
              <td style="width:93%" valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td valign="top">&#160;</td>
              <td valign="top">&#160;</td>
            </tr>
            <tr style="height:15">
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Level 2:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td valign="top">&#160;</td>
              <td valign="top">&#160;</td>
            </tr>
            <tr style="height:15">
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Level 3:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <div>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The carrying values of the Company&#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).</p>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As of December 31, 2019, the fair value of the advances under the Amended Credit Agreement was $1,877,938, the carrying amount of the liability on December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Consolidated Balance Sheets. As of December 31, 2020, the Company estimates the fair value of the Amended Credit Agreement to be materially consistent with the fair value estimate as of December 31, 2019, plus the non-convertible advances made in 2020. This determination was based on the following considerations: (i) the Company has not experienced any significant change in its credit worthiness or operations year over year, (ii) there have been no repayments or convertible draws, (iii) the facility is closer to maturity, and (iv) the embedded conversion feature on the convertible advances is out-of-the-money at the reporting date. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</p>
        </div>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Income Taxes</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &#x201c;NOLs&#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#x2019;s Consolidated Statements of Comprehensive (Loss) Income in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020 and 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive (Loss) Income to offset pre-tax losses.</span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</span></span></span></span></span></span></span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Convertible Instruments</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815,&#160;<em>Derivatives and Hedging Activities</em>&#160;(&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></span></span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also follows ASC 480-10,&#160;<em>Distinguishing Liabilities from Equity</em>&#160;(&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</span></span></p>
      </div>

    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Warrants Issued in Connection with Financings</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Consolidated Statements of Comprehensive (Loss) Income.</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Debt Issuance Costs and Interest</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Research and Development Expenses and Licensed Technology</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third party contract research organizations and investigative sites, third party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, and other expenses; and equipment and laboratory supplies.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></span></span></span></span></span></span></p>
      </div>

    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Stock-Based Compensation&#160;</i></strong></span></span></span></span></span></span></span></span></span></span></span></span><em><strong>Expense</strong></em></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="MARGIN:0px">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%">
          <tbody>
            <tr style="height:15">
              <td style="width:4%">
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td style="width:4%" valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Dividends - </span></span></span></span></span></span></span></span>The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    <p style="MARGIN:0px 0px 0px 0in">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><em>Comprehensive (Loss)&#160;</em></strong></span></span></span></span></span></span><span><strong><em>Income</em></strong></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Comprehensive (loss) income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220&#160;<em>Comprehensive Income</em>&#160;requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2020 and 2019, the comprehensive (loss) income was equal to net (loss) income.</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><em>Net (Loss) </em></strong></span></span></span></span></span></span><span><strong><em>Income </em></strong></span>&#160;<span><span><span><span><span><span><strong><em>Per Share of Common Stock</em></strong></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies FASB ASC No. 260,&#160;<em>Earnings per Share</em>&#160;in calculating its basic and diluted net (loss) income per share. Basic net (loss) income per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net (loss) income per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net (loss) income per share, see Note 7 &#x201c;Net (Loss) Income per Share of Common Stock.&#x201d;</span></span></p>
      </div>

    <p style="margin:0px;text-align:justify">&#160;</p>

      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Recent Accounting Pronouncements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2020, the FASB issued ASU 2020-06,&#160;<em>Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity</em>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The adoption of ASU 2020-06 will likely impact the way the Company calculates its (loss) earnings per share, result in expanded disclosures around convertible instruments and remove the requirement to assess and record beneficial conversion features. The impact from adoption will depend on whether the Company elects to early adopt this ASU. The Company currently plans to adopt the provisions of this ASU on the effective date. However, it reserves the right to early adopt these provisions.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, the FASB issued ASU No. 2019-12,&#160;<em>Income Taxes (Topic 740)</em>:&#160;<em>Simplifying the Accounting for Income Taxes</em>. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. Because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></p>
        <p style="margin:0px 0px 0px 0in;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Recently Adopted Accounting Pronouncements</strong></em></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) intended to improve the effectiveness of disclosures around fair value measurements in the notes to financial statements. The ASU affects all entities that are required to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The Company early adopted certain provisions of this ASU upon issuance during the third quarter of 2018 and revised its disclosures to omit the disclosures removed by this ASU on a retrospective basis. As provided by the ASU, the Company elected to delay adoption of the additional disclosures until January 1, 2020, which include the range and weighed average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty until their effective date. Upon the effective date, the additional disclosures have been included on a prospective basis in the Company&#x2019;s financial statements, as applicable. Because much of this information was disclosed prior to adoption this guidance did not have a substantial impact to the Company's disclosures in the notes to its financial statements and had no impact on the Company&#x2019;s consolidated financial statements.</span></span></p>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506320453304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsAndDerivativeLiabilitiesAbstract', window );"><strong>Warrants And Derivative Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsAndDerivativeLiabilitiesTextBlock', window );">Warrants and Derivative Liabilities</a></td>
<td class="text">
    <p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><strong>3. Warrants and Derivative Liabilities</strong></span></span></span></span></span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px">&#160;</p>
    <p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><strong><i>Warrants</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px">&#160;</p>
    <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Warrants vested and outstanding as of December 31, 2020 are summarized as follows:</span></span></span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Exercise</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Term</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Vested and</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Source</strong></span></span></span></span></p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Price</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(Years)</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Outstanding</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Pre 2015 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6&#x2014;10</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,110,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2015 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5&#x2014;10</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>100,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2016 Common Stock Warrants to Service Providers</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.15</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>40,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2016 Series C Common Stock Warrants to Placement Agent</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.40</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>125,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2017 Series D Common Stock Warrants to Placement Agent</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.25</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>480,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2017 Common Stock Warrants to Service Provider</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.41</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>125,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2018 Emerald Financing Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.10</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,400,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Multi-Draw Credit Agreement Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.50</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,500,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2019 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.35</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8,000,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2020 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.06</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>116,666,668</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2020 Common Stock Warrants to Placement Agent</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.075</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.99</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8,166,667</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2020 Pre-Funded Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.001</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indefinite</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,800,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total warrants vested and outstanding as of December 31, 2020</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>157,513,335</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>August 2020 Financing Warrants</em></span></span></span></span></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In connection with the August 2020 Financing (Note 5), the Company issued 116,666,668 common stock warrants, 8,166,667 common stock warrants to the placement agent and 60,333,334 pre-funded warrants. The warrants were equity classified at issuance and of the $6,939,667 in gross proceeds, the Company allocated $2,767,767 and $2,146,997 of the gross proceeds to the common stock warrants and pre-funded warrants on a relative fair value basis, respectively. The remaining $2,024,903 was allocated to the common stock. The warrants issued to the placement agent were valued at $261,333 and recorded as equity issuance costs within equity. The warrants vested immediately and were valued utilizing the Black-Scholes option pricing model with the following assumptions:</span></span></span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Common Stock Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Pre-funded</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Placement Agent Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility factor</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>91.64</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>93.86</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>91.64</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.52</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected term (years)</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.0</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.99</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Underlying common stock price</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.05</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.05</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.05</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>2019 Common Stock Warrants</em></span></span></span></span></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the year ended December 31, 2019, the Company issued 8,000,000 fully vested common stock warrants to investors, in conjunction with the November 2019 Common Stock Offering discussed below (See Note 5). The warrants are equity classified at issuance and the Company allocated an aggregate of $722,208 of the gross proceeds to the warrants on a relative fair value basis. The warrants vested immediately and had an estimated aggregate fair value of $1,130,400 utilizing the Black-Scholes option pricing model with the following assumptions:</span></span></span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>At Issuance</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility factor</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>93.08</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.62</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected term (years)</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.0</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Underlying common stock price</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.22</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Emerald Multi-Draw Credit Agreement Warrants</em></span></span></span></span></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the year ended December 31, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes option pricing model with the following assumptions:</span></span></span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>At Issuance</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility factor</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>91.6&#x2014;92.1</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.23&#x2014;2.51</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected term (years)</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.0</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Underlying common stock price</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.33&#x2014;0.69</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      </div>

    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Derivative Liabilities</strong></em></span></span></span></span></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following tables summarize the activity of derivative liabilities for the periods indicated:</span></span></span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="18" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Year Ended December 31, 2020</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>2019,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Derivative Liabilities Issued</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Change in</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Reclassification</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>of Derivatives</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>to Equity</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>2020,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Multi-Draw Credit Agreement - compound derivative liability&#160;<sup>(1)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Financing - warrant liability&#160;<sup>(2)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>276,024</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(237,457</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>38,567</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Series B - warrant liability&#160;<sup>(3)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>134,579</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(108,016</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(26,563</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>501,400</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#x2014;</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(436,270</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(26,563</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>38,567</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>410,603</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>38,567</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="18" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Year Ended December 31, 2019</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2018, Fair</strong>&#160;<strong>Value of</strong>&#160;<strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair Value of Derivative Liabilities Issued</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Change in</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Reclassification</strong>&#160;<strong>of Derivatives</strong>&#160;<strong>to Equity or Extinguishment</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2019, Fair</strong>&#160;<strong>Value of</strong>&#160;<strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Multi-Draw Credit Agreement - compound derivative liability&#160;<sup>(1)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>219,453</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>516,058</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(484,147</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(160,567</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)*</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Financing - warrant liability&#160;<sup>(2)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,251,413</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(9,042,066</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(5,933,323</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>276,024</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Series B - warrant liability&#160;<sup>(3)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>487,500</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(208,546</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(144,375</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>134,579</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>15,958,366</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>516,058</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(9,734,759</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(6,238,265</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>501,400</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(219,453</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>15,738,913</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>410,603</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.</em></span></span></span></span></p>
      </div>

    <p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p>
    <div>
      <div>
        <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em></span></span></span></span></span></span></p>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
        <div>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes Option Pricing model for each payment period.</p>
        </div>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. During the year ended December 31, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.</span></span></span></span></span></span></p>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
        <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><em>Emerald Financing Warrant Liability (2)</em></span></span></span></span></span></span></p>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
        <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision.The warrants contained an anti-dilution protection feature that provided the investors with price protection if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. In connection with the August 2020 Financing, this provision was waived, and the exercise price was permanently set to $0.10. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.</span></span></span></span></span></span></p>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
        <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</span></span></span></span></span></span></p>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
        <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity</em><em>&#x2019;</em><em>s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s.</span></span></span></span></span></span></p>
        <p style="MARGIN:0px;text-align:justify">&#160;</p>
      </div>
    </div>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:</span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="6" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of&#160;</strong><strong>December 31,</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90.9</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.5</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.14</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.62</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.04</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><em>Series B Warrant Liability (3)</em></span></span></span></span></span></span></p>
    <p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p>
    <div>
      <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Common Stock Warrants originally exercisable at a price of $1.15 per share. The warrants were exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B Common Stock Warrants also had a &#x201c;down-round&#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and the strike price was permanently reset to $0.00 on January 19, 2018, as a result of the Emerald Financing. However, because the remaining warrant holders still had certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B Common Stock Warrant agreements, the warrants continued to require liability classification. After the Emerald Financing repricing occurred, the warrants were valued using a Black Scholes Merton Option Pricing Model.</span></span></div>
    </div>
    <p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model:</span></span></p>

      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of</strong></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.2</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.60</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.64</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Common Stock Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options was reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#x2019;s common stock on the exercise dates.</span></span></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2020, the remaining Series B Common Stock Warrants expired unexercised.</span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_WarrantsAndDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_WarrantsAndDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_WarrantsAndDerivativeLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Warrants and Derivative Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_WarrantsAndDerivativeLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506288925624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4. Debt</strong></span></span></p>
    <p style="MARGIN:0px 0px 0px 0in">&#160;</p>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><em>Multi-Draw Credit Agreement- Related Party</em></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">The Company&#x2019;s Debt with Emerald Health Sciences consists of the following:</p>
        <div>
          <div>

              <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%">&#160;</td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>As of</strong> <strong>December 31,</strong></p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>Conversion</strong></p>
                      <p style="MARGIN:0px;text-align:center"><strong>Price</strong></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Total principal value of convertible debt&#x2014;related party</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                    <td style="text-align:right;width:9%" valign="bottom">0.40</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                    <td style="text-align:right;width:9%" valign="bottom">2,014,500</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                    <td style="text-align:right;width:9%" valign="bottom">2,014,500</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Unamortized debt discount</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom">(1,079,821</td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom">(1,622,344</td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Unamortized debt issuance costs</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(3,576</td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(5,086</td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><strong>Carrying value of total convertible debt - related party</strong></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>931,103</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>387,070</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Total principal value of non-convertible debt&#x2014;related party</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom">n/a</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">450,000</td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>&#x2014;</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>1,381,103</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>387,070</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                </tbody>
              </table>

            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
          </div>
        </div>
      </div>
    </div>
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 11). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. As of August 2020, interest is no longer being deferred as a result of the August 2020 Financing. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.</span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Amended Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&#x2019; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of December 31, 2020, the unused portion of the credit facility is $13,550,000. The Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place; however, there is no guarantee of continued funding under the Amended Credit Agreement..</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#x2019;s stockholders (See Note 3).</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision were remeasured at fair value in subsequent periods in the Company&#x2019;s Consolidated Balance Sheets.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">During the year ended December 31, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">During the year ended December 31, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. Emerald Health Sciences has elected that the fourth and fifth advances will not be convertible into shares of the Company&#x2019;s common stock and gave notice to the Company that no warrants will be issued in connection with the advances.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        </div></div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <div>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">For the years ended December 31, 2020 and 2019, the effective interest rate related to the convertible portion of the Amended Credit Agreement was 98.01% and 32.05%, respectively. As of December 31, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 1.76 years. As of December 31, 2020, the fair value of the shares underlying the convertible advances under the Amended Credit agreement was $201,450. As of December 31, 2020, the if-converted value did not exceed the principal balance.</p>
        </div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><em>PPP Loan</em></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing on the date the amount of forgiveness determined under section 1106 of the CARES Act is remitted to the Company, but in no event ten months after the last day of the covered period if the Company fails to apply for loan forgiveness. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before October 9, 2020.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 40% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><em>Interest Expense</em></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">The Company&#x2019;s interest expense consists of the following:</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>

          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>Year Ended</strong></p>
                  <p style="MARGIN:0px;text-align:center"><strong>December 31,</strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Related party interest expense &#x2013; stated rate</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">161,546</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">371,420</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">PPP loan interest expense &#x2013; stated rate</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">806</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Non-cash interest expense:</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px 0px 0px 30px;text-align:justify">Amortization of debt discount</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">542,523</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">616,383</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px 0px 0px 30px;text-align:justify">Amortization of transaction costs</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">1,510</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">12,910</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>706,385</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,000,713</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
            </tbody>
          </table>



    <p style="MARGIN:0px;text-align:justify">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208455528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Capitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit) and Capitalization</a></td>
<td class="text">
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>5. Stockholders&#x2019; Equity (Deficit) and Capitalization</strong></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><em>Common Stock</em></strong></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><em>August 2020 Financing</em></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On July 31, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the issuance and sale of securities, with H.C. Wainwright &amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and 60,333,334 pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, in a registered public offering which closed on August 4, 2020 (the &#x201c;August 2020 Financing&#x201d;). The common units and pre-funded units were sold at a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The common stock warrants have a term of five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full (Note 3).</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">In connection with the August 2020 Financing, the Company incurred issuance costs of $854,078, for net proceeds of $6,085,589. Additionally, the Company issued warrants to purchase 8,166,667 shares of common stock to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years.</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>November 2019 Common Stock Offering</em></span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In November 2019, the Company sold in a registered direct offering an aggregate of 8,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 8,000,000 shares of common stock (Note 3). The aggregate net proceeds of the transaction were $1,919,372.</span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><em>Warrant Exercises</em></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">During the year ended December 31, 2020, the Pre-Funded Warrant holders exercised 48,533,334 warrants with an intrinsic value of $2,104,667, which resulted in the issuance of 48,533,334 shares of common stock.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">During the year ended December 31, 2020, the Series B Warrant holders exercised 312,500 warrants with an intrinsic value of $26,563, which resulted in the issuance of 312,500 shares of common stock.</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2019, Emerald Health Sciences exercised 40,800,000 2018 Emerald Financing Warrants with an intrinsic value of $4,284,000, which resulted in the issuance of 40,800,000 shares of common stock.</span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">During the year ended December 31, 2019, the Series B Common Stock Warrant holders exercised 187,500 warrants with an intrinsic value of $144,375, which resulted in the issuance of 187,500 shares of common stock.<span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">.</span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506294919400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><strong>6. Stock-Based Compensation</strong><strong> </strong></span></span></span></span></span></span></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><strong><i>Stock Incentive Plan</i></strong></span></span></span></span></span></span></span></span><br/>&#160;</p>
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On October 31, 2014, after the closing of the Merger, the Board approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. In August 2020, the Company approved Amendment No. 2 to the 2014 Plan, which increased the share reserve by an additional 7,876,835 shares over the 10% of the number of issued and outstanding shares of common stock and removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of December 31, 2020, the shares available for future grant under the 2014 Plan are as follows:</span></span></p>
    </div>
    <p style="MARGIN:0px">&#160;</p>

      <div>
        <div>
          <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares Available for Grant</strong></span></span></p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Available as of December 31, 2019</strong></span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>13,128,381</strong></span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Share pool increase</span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">18,394,752</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Forfeited</span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,837,407</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cancelled</span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5,830,235</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Granted</span></span></p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(26,400,000</span></span></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Available as of December 31, 2020</strong></span></span></p>
                </td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>12,790,775</strong></span></span></td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>

    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span>&#160;&#160;</span></span></span></span></span></span></span></span></p>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>Stock Options </em></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options granted under the 2014 Plan expire no later than ten years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&#x2019;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to five years from the date of grant.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The following is a summary of option activities under the Company&#x2019;s 2014 Plan for the year ended December 31, 2020:</span></span></p>
      </div>
    </div>
    <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span>&#160;&#160;</span></span></span></span></span></span></span></span></p>

      <div>
        <div>
          <div>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
            <div>
              <div>
                <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
                <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                  <tbody>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Number of</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Weighted</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Average</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Exercise Price</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Weighted</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Average Remaining</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Contractual</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Term (Years)</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Aggregate</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Intrinsic</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Value*</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Outstanding, December 31, 2019</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>3,317,642</strong></span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.33</strong></span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>8.34</strong></span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Granted</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">26,400,000</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.05</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cancelled</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,830,235</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.07</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Forfeited</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(1,837,407</span></span></td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.26</span></span></td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Outstanding, December 31, 2020</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>22,050,000</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.06</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>9.52</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Exercisable, December 31, 2020</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>3,465,000</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.15</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>8.88</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Vested and expected to vest, December 31, 2020</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>22,050,000</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.06</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>9.52</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                  </tbody>
                </table>
              </div>
            </div>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#x2019;s stock exceeded the exercise price of the stock options at December 31, 2020 for those stock options for which the quoted market price was in excess of the exercise price (&#x201c;in-the-money options&#x201d;).</em></span></span></p>
          </div>
        </div>
      </div>

    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2020 and 2019 was $0.04 and $0.22, respectively. The total fair value of the stock options that vested during the years ended December 31, 2020 and 2019 was $168,168 and $473,030, respectively.</span></span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:</span></span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>

        <div>
          <div>
            <div>
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                  <tbody>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Year Ended December 31,</strong></span></span></p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2020</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2019</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2">
                        <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.28&#x2014;0.46</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap" valign="bottom">
                        <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.49</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected term (years)</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2">
                        <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.65&#x2014;6.13</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.65</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2">
                        <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">92.51&#x2014;107.87</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap" valign="bottom">
                        <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">93.72</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                    </tr>
                  </tbody>
                </table>
              </div>
            </div>
          </div>
        </div>

    </div>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>Restricted Stock Awards </em></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 30, 2020, 643,501 restricted stock awards (&#x201c;RSAs&#x201d;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. As of December 31, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">There was no restricted stock award (&#x201c;RSA&#x201d;) activity under the Company&#x2019;s 2014 Plan during the year ended December 31, 2019.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em><strong>Awards Granted Outside the 2014 Plan</strong></em></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>Options</em></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&#x2019;s former CFO. As of December 31, 2020, an additional 869,144 options vested and outstanding with a weighted average exercise price of $0.25 were cancelled unexercised.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">There was no option activity outside of the 2014 Plan during the year ended December 31, 2019.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The total fair value of stock options that vested during the years ended December 31, 2020 and 2019 were $18,252 and $54,756, respectively.</span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>Restricted Stock Awards</em></span></span></p>
      </div>
    </div>
    <p style="margin:0px;text-align:justify">&#160;</p>
    <div>
      <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The following is a summary of RSA activity outside of the Company&#x2019;s 2014 Plan during the year ended December 31, 2020:</span></span></div>
      <div>&#160;</div>
      <div>

          <div>
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="FONT-SIZE:10pt" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Number of</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Weighted </strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Average</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Grant </strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Date Fair</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Value</strong></span></span></p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Unvested, December 31, 2019</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>450,000</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%" valign="bottom">
                      <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.19</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Granted</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Released</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(450,000</span></span></p>
                    </td>
                    <td style="width:1%" valign="bottom">
                      <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.19</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Unvested, December 31, 2020</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%" valign="bottom">
                      <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>

      </div>
    </div>
    <p>&#160;</p>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. The Company recognized stock-based compensation expense, including compensation expense for RSAs discussed above, in its Consolidated Statements of Comprehensive (Loss) Income as follows:</span></span></p>

          <div>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
            <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
              <tbody>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">&#160;</td>
                  <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Year Ended</strong></span></span></p>
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>December 31,</strong></span></span></p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px">
                  <td>&#160;</td>
                  <td style="white-space:nowrap">&#160;</td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2020</strong></span></span></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">&#160;</td>
                  <td style="white-space:nowrap">&#160;</td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2019</strong></span></span></p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Research and development</span></span></p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
                  <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">93,545</span></span></td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
                  <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">General and administrative</span></span></p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">209,197</span></span></td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">680,455</span></span></td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>302,742</strong></span></span></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>680,455</strong></span></span></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>

        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The total amount of unrecognized compensation cost was $688,410 as of December 31, 2020. This amount will be recognized over a weighted-average period of 3.79 years.</span></span></p>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506210928360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share of Common Stock</a></td>
<td class="text">
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7. Net (Loss) Income Per Share of Common Stock</strong></span></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net (loss) income per share computations:</span></span></p>
      </div>
    </div>
    <div>
      <p style="margin:0px;text-align:justify">&#160;</p>

        <div>
          <div>
            <div>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Year Ended</strong> <strong>December 31, 2020</strong></span></span></p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Loss</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Numerator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Shares</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Denominator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Per-Share</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Amount</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,560,699</span></span></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss available to common stockholders</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,560,699</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">230,746,878</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(0.03</strong></span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Effect of Dilutive Securities</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants &#x2013; liability classified</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(345,473</p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">674,095</span></span></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Diluted EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss available to common stockholders + assumed conversions</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,906,172</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231,420,973</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(</strong></span></span><strong style="font-family:Times New Roman, Times, serif;font-size:10pt">0.03</strong></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
                  </tr>
                </tbody>
              </table>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Year Ended</strong> <strong>December 31, 2019</strong></span></span></p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Income</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Numerator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Shares</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Denominator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Per-Share</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Amount</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net income</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,051,825</span></span></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income available to common stockholders</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,051,825</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">135,154,931</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>0.01</strong></span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Effect of Dilutive Securities</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested restricted stock</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">858,856</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392,784</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">447,431</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants &#x2013; liability classified</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9,250,612</span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,706,263</span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Diluted EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss available to common stockholders + assumed conversions</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(8,198,787</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">169,560,265</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(0.05</strong></span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>

    </div>
    <p style="MARGIN:0px">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</span></span></span></span></span></span></p>
    <p style="MARGIN:0px">&#160;</p>

      <div>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="6" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year Ended</strong></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22,050,000</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,119,931</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested restricted stock</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">234,645</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shares underlying convertible debt</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,126,343</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,036,250</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">145,039,240</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,712,000</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506212934440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
    <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8. Income Taxes </strong></span></span></p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The components of (loss) income before the income tax provision consist of the following:</p>
    <p style="MARGIN:0px;text-align:justify">&#160;</p>

      <div>
        <div>
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
              <tbody>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>Year Ended </strong></p>
                    <p style="MARGIN:0px;text-align:center"><strong>December 31,</strong></p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">United States</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">(6,556,280</td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">1,120,521</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Foreign</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(2,819</td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(67,096</td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify"><strong>Pre-tax (loss) income from operations </strong></p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>(6,559,099</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><strong>)</strong></td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,053,425</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </div>

    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The Company is subject to taxation in the United States, California and Australia. The Company&#x2019;s tax years for 2017 (federal), 2016 (California) and 2019 (Australia) and forward are subject to examination by the United States, California and Australia tax authorities. However, to the extent allowed by law, the taxing authorities may have the right to examine periods where NOLs and credits were generated and carried forward and make adjustments up to the amount of the NOL and credit carryforwards. &#160;The Company is not currently under examination by any jurisdiction.</p>
    </div>
    <p style="MARGIN:0px 0px 0px 0in;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>At December 31, 2020, the Company had federal and California NOLs aggregating $30,475,657 and $30,310,672, respectively.&#160;</span></span></span></span>If not used, $13,213,037 of Federal NOLs and $30,310,672 of state NOLs will begin to expire in 2033.<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> $17,262,620&#160;</span></span>of federal NOLs will carry forward indefinitely subject to an 80% limitation against taxable income. At December 31, 2020, the Company had Australia NOLs aggregating<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> $43,349 which do not expire.</span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">At December 31, 2020, the Company had federal and California research credit carryforwards of approximately $76,632 and $40,528, respectively. The federal research credit carry forwards will begin to expire in 2040, unless previously utilized and the California research credits will carry forward indefinitely.&#160;The Company&#x2019;s NOLs and research credit carryforwards are subject to a FIN 48 reserve.</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">Utilization of the domestic NOL will be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, respectively.<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;In general, an &#x201c;ownership change&#x201d; as defined by Section 382 of the Code&#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.</span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. While the Company has not performed a Section 382 study, multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company&#x2019;s effective tax rate.</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:</span></span></p>
    <p style="MARGIN:0px">&#160;</p>

      <div>
        <div>
          <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>As of December 31,</strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px">
                <td valign="bottom">
                  <p style="MARGIN:0px;text-align:justify"><strong>Current deferred tax assets/(liabilities): </strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">State taxes</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">336</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">336</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px 0px 0px 15px;text-align:justify">Amortization</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">180</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Research and development credits</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">54,324</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Other</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">83,056</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">112,222</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Net operating loss</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">7,679,216</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">6,434,544</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Gross deferred tax assets</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><strong>7,817,112</strong></td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><strong>6,547,102</strong></td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Valuation allowance</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(7,590,215</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(6,206,450</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Net deferred tax assets </strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>226,897</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>340,652</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Deferred tax liabilities</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Note discount</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(226,897</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(340,652</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Total deferred tax liabilities</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>(226,897</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><strong>)</strong></td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>(340,652</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Net deferred tax assets</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>&#x2014;</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>&#x2014;</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>

    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2020 and 2019, due to the following:</p>
    <p style="MARGIN:0px">&#160;</p>

      <div>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>As of December 31,</strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Expected income tax benefit at federal statutory tax rate</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">(1,377,411</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">221,219</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">State income taxes, net of federal benefit</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(415,249</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(434,881</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Change in fair value of warrants</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(72,549</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(1,874,873</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Change in valuation allowance</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">1,383,765</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">1,469,187</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Uncertain tax positions</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">470,838</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">436,145</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Change in compound derivative</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(101,671</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Loss on extinguishment of debt</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">33,925</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">117,198</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Stock compensation</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">64,273</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">121,289</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Rate adjustment</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(108,649</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">49,338</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Other permanent difference</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">22,657</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(1,351</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Provision for income taxes</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,600</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,600</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>

    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company&#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses. During the year ended December 31, 2020, the valuation allowance increased by $1,383,765.</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On April 22, 2020, when the Company entered into the PPP Loan with the PPP Loan Lender (Note 4). In accordance with the Consolidated Appropriations Act, 2021 enacted on December 27, 2020, certain qualified expenses used with the funds of the PPP Loan are fully deductible for Federal income tax purposes. Additionally, should the Company receive forgiveness of the PPP loan in the future, the amount will not be considered taxable for Federal income tax purposes.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">Under the FASB&#x2019;s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows:</span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

      <div>
        <p style="MARGIN:0px">&#160;</p>
        <div>
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
              <tbody>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>As of December 31,</strong></p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Unrecognized tax positions, beginning of the year</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">552,082</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Gross increase - current period tax positions</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="text-align:right;width:9%" valign="bottom">585,812</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="text-align:right;width:9%" valign="bottom">552,082</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Gross decrease &#x2013; prior period tax positions</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(3,721</td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:9%">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Unrecognized tax positions, end of year</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,134,173</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>552,082</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </div>

    <p style="MARGIN:0px;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If recognized, none of the unrecognized tax positions would impact the Company&#x2019;s income tax benefit or effective tax rate as long as the Company&#x2019;s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company&#x2019;s unrecognized tax positions within the next twelve months.</span></span></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The Company had no accrual for interest or penalties on the Company&#x2019;s Balance Sheets at December 31, 2020 and 2019 and has not recognized interest and/or penalties in the Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2020 and 2019.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506210928360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><strong>9. Other Current Liabilities</strong></p>
          <div>
            <div>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><strong>Other current liabilities consist of the following:</strong></p>

                <div>
                  <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
                  <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                    <tbody>
                      <tr style="HEIGHT:15px">
                        <td>
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                          <p style="MARGIN:0px;text-align:center"><strong>As of </strong><strong>December 31,</strong></p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px">
                        <td>
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                          <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                        </td>
                        <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                          <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                        </td>
                        <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#cceeff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued payroll liabilities</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">61,547</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">43,830</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#ffffff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued research and development costs</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">93,888</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">148,006</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#cceeff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued legal expense</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">57,596</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">92,237</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#ffffff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued board fees</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">40,625</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">58,395</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#cceeff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Total other accrued liabilities</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">5,455</td>
                        <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">77,938</td>
                        <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#ffffff">
                        <td>
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                        <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>259,111</strong></td>
                        <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                        <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>420,406</strong></td>
                        <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </div>

            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506210999912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_SignificantContractsAbstract', window );"><strong>Significant Contracts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_SignificantContractsTextBlock', window );">Significant Contracts - University of Mississippi</a></td>
<td class="text">
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><strong>10. Significant Contracts - University of Mississippi</strong></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><strong><em>UM 5050 Prodrug and UM 8930 Analog Agreements</em></strong></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">In July 2018, the Company renewed its ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&#x201c;THC&#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&#x201c;CBD&#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &#x201c;all fields of use&#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &#x201c;License Agreements&#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, the&#160;intellectual property related to UM 5050 and UM 8930 for all fields of use.</span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. </span>The Company made upfront payments<span style="font-family:Times New Roman,Times,serif">&#160;for </span>UM 5050 and UM 8930 of<span style="font-family:Times New Roman,Times,serif">&#160;$100,000 and&#160;$200,000,&#160;</span>respectively.<span style="font-family:Times New Roman,Times,serif"> In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:</span></p>
      </div>
    </div>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <table border="0" cellpadding="0" cellspacing="0" style="FONT-SIZE:10pt" width="100%">
          <tbody>
            <tr style="HEIGHT:15px">
              <td style="width:4%" valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">i)</span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application (&#x201c;NDA&#x201d;) to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;</span></p>
              </td>
            </tr>
            <tr>
              <td style="width:4%" valign="top">&#160;</td>
              <td valign="top">&#160;</td>
            </tr>
            <tr style="HEIGHT:15px">
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">ii)</span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</span></p>
              </td>
            </tr>
            <tr style="HEIGHT:15px">
              <td>&#160;</td>
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
            </tr>
            <tr style="HEIGHT:15px">
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">iii)</span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</span></p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</span></p>
      </div>
    </div>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#x2019;s dissolution or cessation of operations, the Company&#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#x2019;s control, or the Company&#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#x2019; written notice to UM.</span></span></span></span></span><br/>&#160;</p>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.</span></p>
        </div></div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><strong><em>UM 5070 License Agreement</em></strong></span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#x201c;UM 5070&#x201d;), to research, develop and commercialize products for the treatment of infectious diseases.</span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">The Company paid UM an upfront license fee of $65,000 under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees of $25,000 that will be credited against any royalties incurred, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is<span style="font-family:Times New Roman,Times,serif">&#160;$700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</span></p>


    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
    <div>
      <div>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#x2019;s control. The Company may terminate the license agreement upon 60 days&#x2019; written notice to UM.</span></p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
        <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2020, none of the milestones under this license agreement have been met.</span></p>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_SignificantContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_SignificantContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_SignificantContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents entire disclosure for significant contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_SignificantContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506210917352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Matters</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><strong>11. Related Party Matters</strong></p>
            <p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p>
            <p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em><strong>Emerald Health Sciences</strong></em></p>
            <p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p>
            <div>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of <span style="-sec-ix-hidden:Fxbrl_20200506114236417">ten</span> years and specified compensation to be agreed upon between the Company&#x2019;s Chief Executive Officer and Emerald Health Sciences&#x2019; CEO on a month-to-month basis.&#160;The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of December 31, 2020, and 2019, the Company has accrued $7,032 reimbursable expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the year ended December 31, 2020. Under this agreement, for the year ended December 31, 2019, the Company incurred expenses of $542,000.</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</p>
            </div>
            <p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon initially received a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#x2019;s completion of a material financing. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to defer payment of 100% of Dr. Dhillon&#x2019;s consulting fees until the Board of Directors determined that the Company had been sufficiently financed to make such payments at which point the Company agreed to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. Subsequent to the August 2020 Financing Dr. Dhillon continues to receive a monthly fee of $10,000 per month for his services. The Board reviews the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and automatically renews thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#x2019; prior written notice to the other party. Under this agreement, for the years ended December 31, 2020 and 2019, the Company incurred fees of $127,387 and $3,871, respectively. As of December 31, 2020, the Company has accrued $10,000 in expense related to the Independent Contractor Services Agreement.</p>
          </div>
        </div>
        <div>
          <div>
            <p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p>
            <div>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">In addition, on August 10, 2020, Emerald Health Sciences, Inc. transferred to Dr. Avtar Dhillon 500,000 shares of the Company&#x2019;s common stock at a deemed price of $0.10 in exchange for the cancellation of $50,000 of debt.</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As of December 31, 2020, Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. As of December 31, 2020, Jim Heppell is also a board member of Emerald Health Sciences, Inc. The Company&#x2019;s CEO, Punit Dhillon also served as a board member of Emerald Health Sciences, Inc. until he tendered his resignation from such board on August 10, 2020.</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">The Company shares the same office location as Emerald Health Pharmaceuticals. However, the Company&#x2019;s workforce is remote, there is no written rental agreement with Emerald Health Pharmaceuticals, and no rent is being charged.</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On August 10, 2020, Emerald Health Sciences, Inc. extinguished debt of $186,667 by transferring 1,566,666 shares of the Company&#x2019;s common stock at a deemed price of $0.10 per share to certain officers, employees and directors of the Company.</p>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506210918472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Contingencies</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"><strong>1</strong><strong>2.&#160;<strong>Contingencies</strong></strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"><strong><em><span style="font-style:italic">General Litigation and Disputes</span></em></strong></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">From time to time, in the normal course of our operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Company&#x2019;s operations or financial position, liquidity or results of operations. As of December 31, 2020, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&#x2019;s financial position or results of operations.</p>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506212884216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>13. Subsequent Events</strong></p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><em><strong>Emerald Health Biotechnology Espa&#xf1;a, S.L.U</strong></em></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">In January 2021, the Company entered into a Collaborative Research Agreement with Emerald Health Biotechnology Espa&#xf1;a, S.L.U, a subsidiary of Emerald Health Research, Inc. which is 100% owned by Emerald Health Sciences. Under the agreement, Emerald Health Biotechnology Espa&#xf1;a, S.L. will provide research and development services pursuant to an agreed upon project plan for the research and development of CBDVHS. The term of the agreement is initially for a one-year period. The agreement will terminate upon delivery and acceptance of the final deliverable under the project plan or if either party is in breach of the terms of the contract and such breach remains uncured for 45 days. Payment for services rendered will be based on time and materials billable at reasonable market rates.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><strong><em>Warrant Exercises</em></strong></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">From January 1, 2021 through February 23, 2021 11,800,000 pre-funded warrants were exercised in exchange for 11,800,000 shares of common stock for gross proceeds of $11,800.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">From January 1, 2021 through February 23, 2021 50,133,334 common stock warrants were exercised in exchange for 50,133,334 shares of common stock for gross proceeds of $3,008,000.</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><strong><em>Increase to Authorized Shares of Capital Stock</em></strong></p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On February 5, 2021, the Company increased its authorized shares of common and preferred stock to 5,000,000,000 and 50,000,000, respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208525496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Basis of Presentation</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span>The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Use of Estimates</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Risks and Uncertainties</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#x2019;s ability to attract new funding.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><em><strong>Cash, Cash Equivalents and Restricted Cash</strong></em></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2020, and 2019, the Company has no cash equivalents.</span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash on the balance sheet represents a certificate of deposit held by the Company&#x2019;s bank as collateral for the Company&#x2019;s credit cards.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
      <div>
        <p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Fair Value Measurements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</span></span></p>
        <p style="MARGIN:0px">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%">
          <tbody>
            <tr style="height:15">
              <td style="width:7%" valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Level 1:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
              <td style="width:93%" valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td valign="top">&#160;</td>
              <td valign="top">&#160;</td>
            </tr>
            <tr style="height:15">
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Level 2:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td valign="top">&#160;</td>
              <td valign="top">&#160;</td>
            </tr>
            <tr style="height:15">
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Level 3:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <div>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The carrying values of the Company&#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).</p>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
          <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As of December 31, 2019, the fair value of the advances under the Amended Credit Agreement was $1,877,938, the carrying amount of the liability on December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Consolidated Balance Sheets. As of December 31, 2020, the Company estimates the fair value of the Amended Credit Agreement to be materially consistent with the fair value estimate as of December 31, 2019, plus the non-convertible advances made in 2020. This determination was based on the following considerations: (i) the Company has not experienced any significant change in its credit worthiness or operations year over year, (ii) there have been no repayments or convertible draws, (iii) the facility is closer to maturity, and (iv) the embedded conversion feature on the convertible advances is out-of-the-money at the reporting date. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</p>
        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Income Taxes</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &#x201c;NOLs&#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#x2019;s Consolidated Statements of Comprehensive (Loss) Income in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2020 and 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive (Loss) Income to offset pre-tax losses.</span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</span></span></span></span></span></span></span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Convertible Instruments</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815,&#160;<em>Derivatives and Hedging Activities</em>&#160;(&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></span></span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also follows ASC 480-10,&#160;<em>Distinguishing Liabilities from Equity</em>&#160;(&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock', window );">Warrants Issued in Connection with Financings</a></td>
<td class="text">
      <div>
        <p style="margin:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Warrants Issued in Connection with Financings</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Consolidated Statements of Comprehensive (Loss) Income.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Interest</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Debt Issuance Costs and Interest</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Licensed Technology</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Research and Development Expenses and Licensed Technology</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third party contract research organizations and investigative sites, third party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, and other expenses; and equipment and laboratory supplies.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></span></span></span></span></span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation for Employees</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Stock-Based Compensation&#160;</i></strong></span></span></span></span></span></span></span></span></span></span></span></span><em><strong>Expense</strong></em></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="MARGIN:0px">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%">
          <tbody>
            <tr style="height:15">
              <td style="width:4%">
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td style="width:4%" valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></span></span></p>
              </td>
            </tr>
            <tr style="height:15">
              <td>
                <p style="MARGIN:0px;text-align:justify">&#160;</p>
              </td>
              <td valign="top">
                <p style="margin:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2022;</span></span></span></span></p>
              </td>
              <td valign="top">
                <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Dividends - </span></span></span></span></span></span></span></span>The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></span></span></span></span></span></span></p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><em>Comprehensive (Loss)&#160;</em></strong></span></span></span></span></span></span><span><strong><em>Income</em></strong></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Comprehensive (loss) income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220&#160;<em>Comprehensive Income</em>&#160;requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2020 and 2019, the comprehensive (loss) income was equal to net (loss) income.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share of Common Stock</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><em>Net (Loss) </em></strong></span></span></span></span></span></span><span><strong><em>Income </em></strong></span>&#160;<span><span><span><span><span><span><strong><em>Per Share of Common Stock</em></strong></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies FASB ASC No. 260,&#160;<em>Earnings per Share</em>&#160;in calculating its basic and diluted net (loss) income per share. Basic net (loss) income per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net (loss) income per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net (loss) income per share, see Note 7 &#x201c;Net (Loss) Income per Share of Common Stock.&#x201d;</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
      <div>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Recent Accounting Pronouncements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2020, the FASB issued ASU 2020-06,&#160;<em>Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity</em>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The adoption of ASU 2020-06 will likely impact the way the Company calculates its (loss) earnings per share, result in expanded disclosures around convertible instruments and remove the requirement to assess and record beneficial conversion features. The impact from adoption will depend on whether the Company elects to early adopt this ASU. The Company currently plans to adopt the provisions of this ASU on the effective date. However, it reserves the right to early adopt these provisions.</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, the FASB issued ASU No. 2019-12,&#160;<em>Income Taxes (Topic 740)</em>:&#160;<em>Simplifying the Accounting for Income Taxes</em>. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. Because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></p>
        <p style="margin:0px 0px 0px 0in;text-align:justify">&#160;</p>
        <p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Recently Adopted Accounting Pronouncements</strong></em></span></span></span></span></p>
        <p style="margin:0px;text-align:justify">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) intended to improve the effectiveness of disclosures around fair value measurements in the notes to financial statements. The ASU affects all entities that are required to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The Company early adopted certain provisions of this ASU upon issuance during the third quarter of 2018 and revised its disclosures to omit the disclosures removed by this ASU on a retrospective basis. As provided by the ASU, the Company elected to delay adoption of the additional disclosures until January 1, 2020, which include the range and weighed average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty until their effective date. Upon the effective date, the additional disclosures have been included on a prospective basis in the Company&#x2019;s financial statements, as applicable. Because much of this information was disclosed prior to adoption this guidance did not have a substantial impact to the Company's disclosures in the notes to its financial statements and had no impact on the Company&#x2019;s consolidated financial statements.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for Risks and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants issued in bundled transactions with other financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208748136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants vested and outstanding</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Exercise</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Term</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Vested and</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Source</strong></span></span></span></span></p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Price</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(Years)</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Outstanding</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Pre 2015 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6&#x2014;10</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,110,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2015 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5&#x2014;10</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>100,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2016 Common Stock Warrants to Service Providers</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.15</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>40,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2016 Series C Common Stock Warrants to Placement Agent</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.40</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>125,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2017 Series D Common Stock Warrants to Placement Agent</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.25</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>480,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2017 Common Stock Warrants to Service Provider</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.41</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>125,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2018 Emerald Financing Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.10</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,400,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Multi-Draw Credit Agreement Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.50</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,500,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2019 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.35</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8,000,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2020 Common Stock Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.06</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>116,666,668</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2020 Common Stock Warrants to Placement Agent</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.075</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.99</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8,166,667</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2020 Pre-Funded Warrants</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.001</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indefinite</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11,800,000</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total warrants vested and outstanding as of December 31, 2020</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>157,513,335</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule summary of the activity of derivative liabilities</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="18" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Year Ended December 31, 2020</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>2019,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Derivative Liabilities Issued</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Change in</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Reclassification</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>of Derivatives</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>to Equity</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>2020,</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Multi-Draw Credit Agreement - compound derivative liability&#160;<sup>(1)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Financing - warrant liability&#160;<sup>(2)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>276,024</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(237,457</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>38,567</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Series B - warrant liability&#160;<sup>(3)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>134,579</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(108,016</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(26,563</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>501,400</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#x2014;</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(436,270</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(26,563</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>38,567</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>410,603</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>38,567</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="18" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Year Ended December 31, 2019</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2018, Fair</strong>&#160;<strong>Value of</strong>&#160;<strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair Value of Derivative Liabilities Issued</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Change in</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Fair value of</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Reclassification</strong>&#160;<strong>of Derivatives</strong>&#160;<strong>to Equity or Extinguishment</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2019, Fair</strong>&#160;<strong>Value of</strong>&#160;<strong>Derivative Liabilities</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Multi-Draw Credit Agreement - compound derivative liability&#160;<sup>(1)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>219,453</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>516,058</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(484,147</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(160,567</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)*</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Emerald Financing - warrant liability&#160;<sup>(2)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,251,413</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(9,042,066</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(5,933,323</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>276,024</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Series B - warrant liability&#160;<sup>(3)</sup></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>487,500</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(208,546</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(144,375</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>134,579</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>15,958,366</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>516,058</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(9,734,759</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(6,238,265</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>501,400</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(219,453</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(90,797</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>15,738,913</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:9%">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="border-bottom:2.5pt double black;border-top:1pt solid black;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>410,603</strong></span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.</em></span></span></span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>At Issuance</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility factor</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>91.6&#x2014;92.1</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.23&#x2014;2.51</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected term (years)</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.0</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Underlying common stock price</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.33&#x2014;0.69</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      </div>
    <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=skye_AugustTwoThousandAndTwentyFinancingWarrantsMember', window );">August 2020 Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock', window );">Fair Value Measurement Input And Valuation Techniques Derivative Liabilities [Table Text Block]</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Common Stock Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Pre-funded</strong></span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Placement Agent Warrants</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility factor</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>91.64</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>93.86</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>91.64</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.52</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected term (years)</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.0</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.99</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Underlying common stock price</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.05</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.05</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.05</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock', window );">Fair Value Measurement Input And Valuation Techniques Derivative Liabilities [Table Text Block]</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>At Issuance</strong></span></span></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.00</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility factor</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>93.08</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.62</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected term (years)</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.0</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Underlying common stock price</span></span></span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.22</span></span></span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=skye_EmeraldFinancingWarrantsLiabilityMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="6" style="text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of&#160;</strong><strong>December 31,</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-top:1pt solid black;border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-top:1pt solid black;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90.9</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.5</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.14</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.62</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.04</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=skye_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text">
      <div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of</strong></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.2</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.60</span></span></td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.64</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DerivativeLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DerivativeLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Input And Valuation Techniques Derivative Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueMeasurementInputAndValuationTechniquesDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=skye_AugustTwoThousandAndTwentyFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=skye_AugustTwoThousandAndTwentyFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=skye_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=skye_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=skye_EmeraldFinancingWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=skye_EmeraldFinancingWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=skye_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=skye_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214938664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible and non-convertible advances</a></td>
<td class="text">
              <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%">&#160;</td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>As of</strong> <strong>December 31,</strong></p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>Conversion</strong></p>
                      <p style="MARGIN:0px;text-align:center"><strong>Price</strong></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Total principal value of convertible debt&#x2014;related party</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                    <td style="text-align:right;width:9%" valign="bottom">0.40</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                    <td style="text-align:right;width:9%" valign="bottom">2,014,500</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                    <td style="text-align:right;width:9%" valign="bottom">2,014,500</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Unamortized debt discount</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom">(1,079,821</td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom">(1,622,344</td>
                    <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Unamortized debt issuance costs</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(3,576</td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(5,086</td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><strong>Carrying value of total convertible debt - related party</strong></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>931,103</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>387,070</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify">Total principal value of non-convertible debt&#x2014;related party</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom">n/a</td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">450,000</td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>&#x2014;</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>1,381,103</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>387,070</strong></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                </tbody>
              </table>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>Year Ended</strong></p>
                  <p style="MARGIN:0px;text-align:center"><strong>December 31,</strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Related party interest expense &#x2013; stated rate</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">161,546</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">371,420</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">PPP loan interest expense &#x2013; stated rate</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">806</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Non-cash interest expense:</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px 0px 0px 30px;text-align:justify">Amortization of debt discount</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">542,523</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">616,383</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px 0px 0px 30px;text-align:justify">Amortization of transaction costs</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">1,510</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">12,910</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>706,385</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,000,713</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
            </tbody>
          </table>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506319725592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumptions of stock option granted</a></td>
<td class="text">
        <div>
          <div>
            <div>
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                  <tbody>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Year Ended December 31,</strong></span></span></p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2020</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2019</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2">
                        <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.28&#x2014;0.46</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap" valign="bottom">
                        <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.49</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected term (years)</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2">
                        <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.65&#x2014;6.13</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.65</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2">
                        <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">92.51&#x2014;107.87</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap" valign="bottom">
                        <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">93.72</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
                    </tr>
                  </tbody>
                </table>
              </div>
            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of RSA activity</a></td>
<td class="text">
          <div>
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="FONT-SIZE:10pt" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Number of</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Weighted </strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Average</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Grant </strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Date Fair</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Value</strong></span></span></p>
                    </td>
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Unvested, December 31, 2019</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>450,000</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%" valign="bottom">
                      <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.19</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Granted</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Released</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(450,000</span></span></p>
                    </td>
                    <td style="width:1%" valign="bottom">
                      <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.19</span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Unvested, December 31, 2020</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%" valign="bottom">
                      <p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></p>
                    </td>
                    <td style="width:1%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of stock-Based compensation Expense</a></td>
<td class="text">
          <div>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
            <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
              <tbody>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">&#160;</td>
                  <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Year Ended</strong></span></span></p>
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>December 31,</strong></span></span></p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px">
                  <td>&#160;</td>
                  <td style="white-space:nowrap">&#160;</td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2020</strong></span></span></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">&#160;</td>
                  <td style="white-space:nowrap">&#160;</td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2019</strong></span></span></p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Research and development</span></span></p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
                  <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">93,545</span></span></td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
                  <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">General and administrative</span></span></p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">209,197</span></span></td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">680,455</span></span></td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>302,742</strong></span></span></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>680,455</strong></span></span></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
        <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of shares available for future grant</a></td>
<td class="text">
      <div>
        <div>
          <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares Available for Grant</strong></span></span></p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Available as of December 31, 2019</strong></span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>13,128,381</strong></span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Share pool increase</span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">18,394,752</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Forfeited</span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,837,407</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cancelled</span></span></p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5,830,235</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Granted</span></span></p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(26,400,000</span></span></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Available as of December 31, 2020</strong></span></span></p>
                </td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>12,790,775</strong></span></span></td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
            <div>
              <div>
                <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
                <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                  <tbody>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Number of</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Weighted</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Average</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Exercise Price</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Weighted</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Average Remaining</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Contractual</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Term (Years)</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Aggregate</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Intrinsic</strong></span></span></p>
                        <p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Value*</strong></span></span></p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Outstanding, December 31, 2019</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>3,317,642</strong></span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.33</strong></span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>8.34</strong></span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td>
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Granted</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">26,400,000</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.05</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cancelled</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,830,235</span></span></td>
                      <td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.07</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Forfeited</span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(1,837,407</span></span></td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.26</span></span></td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:1px solid;width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Outstanding, December 31, 2020</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>22,050,000</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.06</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>9.52</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#cceeff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Exercisable, December 31, 2020</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>3,465,000</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.15</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>8.88</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                    <tr style="HEIGHT:15px;background-color:#ffffff">
                      <td valign="top">
                        <p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Vested and expected to vest, December 31, 2020</strong></span></span></p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>22,050,000</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.06</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>9.52</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                      <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td>
                      <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#x2014;</strong></span></span></td>
                      <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                        <p style="MARGIN:0px">&#160;</p>
                      </td>
                    </tr>
                  </tbody>
                </table>
              </div>
            </div>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
            <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#x2019;s stock exceeded the exercise price of the stock options at December 31, 2020 for those stock options for which the quoted market price was in excess of the exercise price (&#x201c;in-the-money options&#x201d;).</em></span></span></p>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214602136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text">
        <div>
          <div>
            <div>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Year Ended</strong> <strong>December 31, 2020</strong></span></span></p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Loss</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Numerator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Shares</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Denominator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Per-Share</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Amount</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,560,699</span></span></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss available to common stockholders</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,560,699</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">230,746,878</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(0.03</strong></span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Effect of Dilutive Securities</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants &#x2013; liability classified</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(345,473</p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">674,095</span></span></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Diluted EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss available to common stockholders + assumed conversions</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,906,172</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231,420,973</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(</strong></span></span><strong style="font-family:Times New Roman, Times, serif;font-size:10pt">0.03</strong></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
                  </tr>
                </tbody>
              </table>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px">&#160;</p>
              <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                <tbody>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="10" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Year Ended</strong> <strong>December 31, 2019</strong></span></span></p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Income</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Numerator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Shares</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(Denominator)</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Per-Share</strong></span></span></p>
                      <p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Amount</strong></span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net income</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,051,825</span></span></td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td colspan="2" style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income available to common stockholders</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,051,825</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">135,154,931</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>0.01</strong></span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Effect of Dilutive Securities</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested restricted stock</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">858,856</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392,784</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">447,431</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants &#x2013; liability classified</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9,250,612</span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,706,263</span></span></p>
                    </td>
                    <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td>
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#ffffff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Diluted EPS</strong></span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:9%">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                  </tr>
                  <tr style="HEIGHT:15px;background-color:#cceeff">
                    <td valign="top">
                      <p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss available to common stockholders + assumed conversions</span></span></p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(8,198,787</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">169,560,265</span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="width:1%;white-space:nowrap">
                      <p style="MARGIN:0px">&#160;</p>
                    </td>
                    <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                    <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(0.05</strong></span></span></td>
                    <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text">
      <div>
        <table border="0" cellpadding="0" cellspacing="0" style="border:0px;width:100%" width="100%">
          <tbody>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="6" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year Ended</strong></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr>
              <td>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="border-bottom:1pt solid black;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td colspan="2" style="border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p>
              </td>
              <td style="white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22,050,000</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,119,931</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested restricted stock</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">234,645</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shares underlying convertible debt</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,126,343</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,036,250</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
            <tr style="background-color:#ffffff">
              <td valign="top">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">145,039,240</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
              <td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,712,000</span></span></td>
              <td style="width:1%;white-space:nowrap">
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506210760488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income (loss) before the income tax provision (benefit)</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
              <tbody>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>Year Ended </strong></p>
                    <p style="MARGIN:0px;text-align:center"><strong>December 31,</strong></p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">United States</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">(6,556,280</td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">1,120,521</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Foreign</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(2,819</td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(67,096</td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify"><strong>Pre-tax (loss) income from operations </strong></p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>(6,559,099</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><strong>)</strong></td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,053,425</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule for significant portions of deferred income tax assets</a></td>
<td class="text">
      <div>
        <div>
          <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>As of December 31,</strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px">
                <td valign="bottom">
                  <p style="MARGIN:0px;text-align:justify"><strong>Current deferred tax assets/(liabilities): </strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">State taxes</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">336</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">336</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px 0px 0px 15px;text-align:justify">Amortization</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">180</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Research and development credits</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">54,324</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Other</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">83,056</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">112,222</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Net operating loss</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">7,679,216</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">6,434,544</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Gross deferred tax assets</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><strong>7,817,112</strong></td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom"><strong>6,547,102</strong></td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Valuation allowance</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(7,590,215</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(6,206,450</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Net deferred tax assets </strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>226,897</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>340,652</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Deferred tax liabilities</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:9%">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;TEXT-INDENT:15px;text-align:justify">Note discount</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(226,897</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(340,652</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Total deferred tax liabilities</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>(226,897</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><strong>)</strong></td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><strong>(340,652</strong></td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Net deferred tax assets</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>&#x2014;</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>&#x2014;</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate</a></td>
<td class="text">
      <div>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
            <tbody>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>As of December 31,</strong></p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px">
                <td>
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                  <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                </td>
                <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Expected income tax benefit at federal statutory tax rate</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">(1,377,411</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                <td style="text-align:right;width:9%" valign="bottom">221,219</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">State income taxes, net of federal benefit</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(415,249</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(434,881</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Change in fair value of warrants</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(72,549</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(1,874,873</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Change in valuation allowance</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">1,383,765</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">1,469,187</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Uncertain tax positions</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">470,838</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">436,145</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Change in compound derivative</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(101,671</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Loss on extinguishment of debt</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">33,925</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">117,198</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Stock compensation</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">64,273</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">121,289</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Rate adjustment</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">(108,649</td>
                <td style="width:1%;white-space:nowrap" valign="bottom">)</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="text-align:right;width:9%" valign="bottom">49,338</td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#ffffff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify">Other permanent difference</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">22,657</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(1,351</td>
                <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
              </tr>
              <tr style="HEIGHT:15px;background-color:#cceeff">
                <td valign="top">
                  <p style="MARGIN:0px;text-align:justify"><strong>Provision for income taxes</strong></p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,600</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
                <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,600</strong></td>
                <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                  <p style="MARGIN:0px">&#160;</p>
                </td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of beginning and ending amounts of unrecognized tax positions</a></td>
<td class="text">
      <div>
        <p style="MARGIN:0px">&#160;</p>
        <div>
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
              <tbody>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>As of December 31,</strong></p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px">
                  <td>
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                    <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Unrecognized tax positions, beginning of the year</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">552,082</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap" valign="bottom">$</td>
                  <td style="text-align:right;width:9%" valign="bottom">&#x2014;</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Gross increase - current period tax positions</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="text-align:right;width:9%" valign="bottom">585,812</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="text-align:right;width:9%" valign="bottom">552,082</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#cceeff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Gross decrease &#x2013; prior period tax positions</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">(3,721</td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom">)</td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:1px solid;width:9%">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
                <tr style="HEIGHT:15px;background-color:#ffffff">
                  <td valign="top">
                    <p style="MARGIN:0px;text-align:justify">Unrecognized tax positions, end of year</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>1,134,173</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                  <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                  <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>552,082</strong></td>
                  <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                    <p style="MARGIN:0px">&#160;</p>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506212990680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text">
                <div>
                  <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify">&#160;</p>
                  <table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%">
                    <tbody>
                      <tr style="HEIGHT:15px">
                        <td>
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                          <p style="MARGIN:0px;text-align:center"><strong>As of </strong><strong>December 31,</strong></p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px">
                        <td>
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                          <p style="MARGIN:0px;text-align:center"><strong>2020</strong></p>
                        </td>
                        <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom">
                          <p style="MARGIN:0px;text-align:center"><strong>2019</strong></p>
                        </td>
                        <td style="PADDING-BOTTOM:1px;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#cceeff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued payroll liabilities</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">61,547</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">43,830</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#ffffff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued research and development costs</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">93,888</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">148,006</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#cceeff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued legal expense</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">57,596</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">92,237</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#ffffff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Accrued board fees</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">40,625</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="text-align:right;width:9%" valign="bottom">58,395</td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#cceeff">
                        <td valign="top">
                          <p style="MARGIN:0px;text-align:justify">Total other accrued liabilities</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">5,455</td>
                        <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">77,938</td>
                        <td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                      <tr style="HEIGHT:15px;background-color:#ffffff">
                        <td>
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                        <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>259,111</strong></td>
                        <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                        <td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><strong>$</strong></td>
                        <td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>420,406</strong></td>
                        <td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap">
                          <p style="MARGIN:0px">&#160;</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506202792232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,733,981<span></span>
</td>
<td class="nump">$ 32,173,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,469,410<span></span>
</td>
<td class="nump">1,829,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_SeniorManagementCompensationPlanDescription', window );">Description of senior management's compensation plan</a></td>
<td class="text">Upon the closing of the August 2020 Financing, the Company&#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,533<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,019,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember', window );">Common Stock Warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=skye_PaycheckProtectionProgramPromissoryNoteMember', window );">Paycheck Protection Program Promissory Note (PPP Note)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_AmendedAndRestatedMultiDrawCreditAgreementMember', window );">Amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Credit facility advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Principal amount of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DrawDownsLoansInAggregatePrincipalAmount', window );">Draw downs loans In aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember', window );">Fourth amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Credit facility advances per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember', window );">Fifth amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Credit facility advances per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NumberOfCommonStockUnitsSold', window );">Number of common stock units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NumberOfPreFundedUnitsSold', window );">Number of pre-funded units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_GrossProceedsOfUnitsSold', window );">Gross proceeds of units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,085,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DrawDownsLoansInAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents draw downs loans in aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DrawDownsLoansInAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_GrossProceedsOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gross proceeds of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_GrossProceedsOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NatureOfOperationsAndBusinessActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NatureOfOperationsAndBusinessActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NumberOfCommonStockUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NumberOfCommonStockUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NumberOfPreFundedUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NumberOfPreFundedUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_SeniorManagementCompensationPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents description of senior management compensation plan description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_SeniorManagementCompensationPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum month-end amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=skye_PaycheckProtectionProgramPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=skye_PaycheckProtectionProgramPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_AmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_AmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_FourthAmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_FifthAmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementWithHcWainwrightAndCoLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214680056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Fair value of advance under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,877,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">$ 931,103<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203865448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">157,513,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">1,110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember', window );">2016 Common Stock Warrants to Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember', window );">2016 Series C Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember', window );">2017 Series D Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">480,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember', window );">2017 Common Stock Warrants to Service Provider</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">116,666,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember', window );">2020 Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">8,166,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyPreFundedWarrantsMember', window );">2020 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsVestedAndOutstanding', window );">Number of Warrants Vested and Outstanding</a></td>
<td class="nump">11,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_WarrantsVestedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants vested and outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_WarrantsVestedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_Pre2015CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_Pre2015CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203441096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 1) - Black-Scholes option pricing model<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants | Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants | Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">91.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants | Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants | Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants | Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants | Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">93.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants | Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants | Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember', window );">Placement agent warrants | Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember', window );">Placement agent warrants | Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">91.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember', window );">Placement agent warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember', window );">Placement agent warrants | Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember', window );">Placement agent warrants | Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants | Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants | Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants | Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PricingModelAxis=skye_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PricingModelAxis=skye_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203402456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 2) - Emerald Multi-Draw Credit Agreement Warrants - Black-Scholes option pricing model<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">92.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">2.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">2.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PricingModelAxis=skye_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PricingModelAxis=skye_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203747816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(436,270)<span></span>
</td>
<td class="num">(9,734,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="num">(26,563)<span></span>
</td>
<td class="num">(6,238,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">38,567<span></span>
</td>
<td class="nump">501,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Less, noncurrent portion of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(90,797)<span></span>
</td>
<td class="num">$ (219,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current balance of derivative liabilities</a></td>
<td class="nump">38,567<span></span>
</td>
<td class="nump">410,603<span></span>
</td>
<td class="nump">$ 15,738,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember', window );">Emerald Multi-Draw Credit Agreement - compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">90,797<span></span>
</td>
<td class="nump">219,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(90,797)<span></span>
</td>
<td class="num">(484,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(160,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantMember', window );">Series B - warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">134,579<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(108,016)<span></span>
</td>
<td class="num">(208,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="num">(26,563)<span></span>
</td>
<td class="num">(144,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=skye_EmeraldFinancingMember', window );">Emerald Financing - Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">276,024<span></span>
</td>
<td class="nump">15,251,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(237,457)<span></span>
</td>
<td class="num">(9,042,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,933,323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">$ 38,567<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfDerivativeLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfDerivativeLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ReclassificationOfDerivativesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derivatives reclassified to equity or the statement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ReclassificationOfDerivativesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506208755224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 4) - Monte Carlo simulations - Emerald financing<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">90.9<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">2 years 1 month 17 days<span></span>
</td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PricingModelAxis=skye_MonteCarloSimulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PricingModelAxis=skye_MonteCarloSimulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506202774936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 5) - Black Scholes Merton Option Pricing Model - Series B Warrant Liability<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">7 months 20 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PricingModelAxis=skye_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PricingModelAxis=skye_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=skye_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=skye_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506206658920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_GrossProceedsOfWarrant', window );">Gross proceeds of warrants on a relative fair value basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,939,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Decrease in derivative liability through an adjustment to change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(436,270)<span></span>
</td>
<td class="num">(9,734,759)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,797)<span></span>
</td>
<td class="num">(484,147)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldFinancingWarrantsLiabilityMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AggregateExercisePriceOfOutstandingCreditAgreements', window );">Aggregate exercise price of outstanding credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldWarrantLiabilityMember', window );">Emerald Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price, per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember', window );">Series B Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_GrossProceedsOfWarrant', window );">Gross proceeds of warrants on a relative fair value basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,767,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,666,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,130,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember', window );">2020 Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity', window );">Value of warrants issued recorded as equity issuance costs within equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_GrossProceedsOfWarrant', window );">Gross proceeds of warrants on a relative fair value basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,146,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AggregateExercisePriceOfOutstandingCreditAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about aggregate exercise price of outstanding credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AggregateExercisePriceOfOutstandingCreditAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ClassOfWarrantOrRightWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ClassOfWarrantOrRightWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_GrossProceedsOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gross proceeds of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_GrossProceedsOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ValueOfCommonStockCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of common stock called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ValueOfCommonStockCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value Of Warrants Issued recorded as equity issuance costs within equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ValueOfWarrantIssuedRecordedAsEquityIssuanceCostsWithinEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldFinancingWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldFinancingWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_EmeraldWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506209521352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Total principal value of non-convertible debt - related party</a></td>
<td class="nump">$ 931,103<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Total principal value of convertible debt - related party</a></td>
<td class="nump">$ 2,014,500<span></span>
</td>
<td class="nump">2,014,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized debt discount</a></td>
<td class="num">(1,079,821)<span></span>
</td>
<td class="num">(1,622,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Unamortized debt issuance costs</a></td>
<td class="num">(3,576)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Carrying value of total convertible debt - related party</a></td>
<td class="nump">931,103<span></span>
</td>
<td class="nump">387,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Total principal value of non-convertible debt - related party</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_CurrentConvertibleDebtExcludingNoncurrentPortion', window );">Total carrying value of advances under the multi-draw credit agreement</a></td>
<td class="nump">$ 1,381,103<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_CurrentConvertibleDebtExcludingNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_CurrentConvertibleDebtExcludingNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214739320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related party interest expense - stated rate</a></td>
<td class="nump">$ 161,546<span></span>
</td>
<td class="nump">$ 371,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">PPP loan interest expense - stated rate</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">542,523<span></span>
</td>
<td class="nump">616,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AmortizationOfTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="nump">12,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">$ 706,385<span></span>
</td>
<td class="nump">$ 1,000,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AmortizationOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AmortizationOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NonCashInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NonCashInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506202470184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,567<span></span>
</td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts', window );">Convertible multi-draw credit agreement issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (725,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=skye_PaycheckProtectionProgrammeMember', window );">Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 24,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PayrollCostExcludeCompensation', window );">Excess payroll costs exclude compensation of an individual employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentageOfForgivenessAmountForNonPayrollCost', window );">Percentage of forgiveness amount for nonpayroll costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Amount of salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentOfReductionInAnnualSalary', window );">Percentage of reduction in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AllocationOfDebtOnBasisOfRelativeFairValue', window );">Allocation of debt on the basis of relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,684,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,283,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AllocationOfWarrantOnBasisOfRelativeFairValue', window );">Allocation of warrant on the basis of relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,985,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(725,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfWarrantLiabilityInExcessForProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UnamortizedDebtDiscountPeriod', window );">Unamortized debt discount period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.01%<span></span>
</td>
<td class="nump">32.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FairValueOfSharesUnderlyingConvertibleDebt1', window );">Fair value of shares underlying convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=skye_EmeraldFinancingMember', window );">Emerald financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,567<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="nump">$ 15,251,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=skye_EmeraldFinancingMember', window );">Emerald financing | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Maximum amount that can be borrowed over the life of the credit facility</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Unused portion of the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase', window );">Warrant coverage on the debt facility</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Reduced exercise price of warrant</a></td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Amount of capital raise</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc | Independent contractor agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_CreditFacilityEffectedFourthAdvance', window );">Credit facility effected fourth advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_CreditFacilityEffectedFifthAdvance', window );">Credit facility effected fifth advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AllocationOfDebtOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of debt on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AllocationOfDebtOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AllocationOfWarrantOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of warrant on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AllocationOfWarrantOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible multi-draw credit agreement issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ConvertibleMultiDrawCreditAgreementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_CreditFacilityEffectedFifthAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit facility effected fifth advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_CreditFacilityEffectedFifthAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_CreditFacilityEffectedFourthAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit facility effected fourth advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_CreditFacilityEffectedFourthAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfSharesUnderlyingConvertibleDebt1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares underlying convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfSharesUnderlyingConvertibleDebt1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FairValueOfWarrantLiabilityInExcessForProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FairValueOfWarrantLiabilityInExcessForProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PayrollCostExcludeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll costs exclude compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PayrollCostExcludeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentOfReductionInAnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of reduction in annual salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentOfReductionInAnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount need to be issued against warrant purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentageOfForgivenessAmountForNonPayrollCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of forgiveness amount for non payroll cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentageOfForgivenessAmountForNonPayrollCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_UnamortizedDebtDiscountPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of unamortized discount of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_UnamortizedDebtDiscountPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=skye_PaycheckProtectionProgrammeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=skye_PaycheckProtectionProgrammeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506202355304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,085,589<span></span>
</td>
<td class="nump">$ 1,919,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,284,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,104,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,563<span></span>
</td>
<td class="nump">$ 144,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, par value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,919,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NumberOfCommonStockUnitsSold', window );">Number of common stock units sold</a></td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NumberOfPreFundedUnitsSold', window );">Number of pre-funded units sold</a></td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_CommonUnitSoldPricePerUnit', window );">Common units sold price per unit</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PreFundedUnitSoldPricePerUnit', window );">Pre-funded units sold price per unit</a></td>
<td class="nump">$ 0.059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_GrossProceedsOfUnitsSold', window );">Gross proceeds of units sold</a></td>
<td class="nump">$ 6,939,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 854,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 6,085,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Direct offering | Placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate shares of common stock</a></td>
<td class="nump">8,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering', window );">Percentage of total shares of common stock and pre-funded warrants sold in offering</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Direct offering | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Common stock and pre-funded stock units sold description</a></td>
<td class="text">each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Direct offering | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Common stock and pre-funded stock units sold description</a></td>
<td class="text">each consisting of one share of common stock and one warrant to purchase one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_ClassOfWarrantOrRightWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_ClassOfWarrantOrRightWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_CommonUnitSoldPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Unit Sold Price Per Unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_CommonUnitSoldPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_GrossProceedsOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gross proceeds of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_GrossProceedsOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_IntrinsicValueOfWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents intrinsic value of warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_IntrinsicValueOfWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NumberOfCommonStockUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NumberOfCommonStockUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NumberOfPreFundedUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NumberOfPreFundedUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total shares of common stock and pre-funded warrants sold in the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentageOfSharesOfCommonStockAndPrefundedWarrantsSoldInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PreFundedUnitSoldPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per unit of pre-funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PreFundedUnitSoldPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_InstitutionalInvestorAndHcWainWrightAndCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=skye_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=skye_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203416952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated', window );">Balance at the beginning</a></td>
<td class="nump">13,128,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Share pool increase</a></td>
<td class="nump">18,394,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">1,837,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="nump">5,830,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="num">(26,400,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated', window );">Balance at the ending</a></td>
<td class="nump">12,790,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506206634008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest</a></td>
<td class="nump">869,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">26,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="num">(5,830,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,837,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning</a></td>
<td class="nump">3,317,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">26,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="num">(5,830,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,837,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending</a></td>
<td class="nump">22,050,000<span></span>
</td>
<td class="nump">3,317,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">3,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest</a></td>
<td class="nump">22,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the ending</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based compensation arrangement by share-based payment award, options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">9 years 6 months 7 days<span></span>
</td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">8 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and Expected to Vest</a></td>
<td class="text">9 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Expected to Vest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203668072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 2) - Stock options - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.72%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">92.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">107.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506209494888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 3) - Restricted stock awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2019 | shares</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released | shares</a></td>
<td class="num">(450,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2020 | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released | $ / shares</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506209562376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 1,944,411<span></span>
</td>
<td class="nump">$ 2,237,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,344,602<span></span>
</td>
<td class="nump">4,394,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">302,742<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">93,545<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">209,197<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 302,742<span></span>
</td>
<td class="nump">$ 680,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506207912936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">$ 18,252<span></span>
</td>
<td class="nump">$ 54,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">$ 168,168<span></span>
</td>
<td class="nump">$ 473,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203614488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of forfeiture of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of forfeiture of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price of vested and outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,742<span></span>
</td>
<td class="nump">$ 680,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,252<span></span>
</td>
<td class="nump">$ 54,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for future grants</a></td>
<td class="nump">7,876,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares', window );">Percentage of share reserve of the number of issued and outstanding shares</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months 7 days<span></span>
</td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,168<span></span>
</td>
<td class="nump">$ 473,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,742<span></span>
</td>
<td class="nump">$ 680,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share reserve of the number of issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=skye_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203586328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share of Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (6,560,699)<span></span>
</td>
<td class="nump">$ 1,051,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income available to common stockholders, Income (Numerator)</a></td>
<td class="num">$ (6,560,699)<span></span>
</td>
<td class="nump">$ 1,051,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Income available to common stockholders Shares (Denominator)</a></td>
<td class="nump">230,746,878<span></span>
</td>
<td class="nump">135,154,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income available to common stockholders, Per-Share Amount</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NetLossAdjustedBalance', window );">Loss available to common stockholders + assumed conversions, Income (Numerator)</a></td>
<td class="num">$ (6,906,172)<span></span>
</td>
<td class="num">$ (8,198,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Loss available to common stockholders + assumed conversions, Shares (Denominator)</a></td>
<td class="nump">231,420,973<span></span>
</td>
<td class="nump">169,560,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss available to common stockholders + assumed conversions, Per-Share Amount</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutedSecuritiesAxis=skye_UnvestedRestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutedSecuritiesAxis=skye_OptionsMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutedSecuritiesAxis=skye_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutedSecuritiesAxis=skye_WarrantsLiabilityClassifiedMember', window );">Warrants - liability classified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Income (Numerator)</a></td>
<td class="num">$ (345,473)<span></span>
</td>
<td class="num">$ (9,250,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="nump">674,095<span></span>
</td>
<td class="nump">32,706,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NetLossAdjustedBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted balance of net loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NetLossAdjustedBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DilutedSecuritiesAxis=skye_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DilutedSecuritiesAxis=skye_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DilutedSecuritiesAxis=skye_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DilutedSecuritiesAxis=skye_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DilutedSecuritiesAxis=skye_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DilutedSecuritiesAxis=skye_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DilutedSecuritiesAxis=skye_WarrantsLiabilityClassifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DilutedSecuritiesAxis=skye_WarrantsLiabilityClassifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506209484552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share of Common Stock (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">22,050,000<span></span>
</td>
<td class="nump">4,119,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">234,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Common shares underlying convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">5,126,343<span></span>
</td>
<td class="nump">5,036,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">145,039,240<span></span>
</td>
<td class="nump">20,712,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506214695224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">United States</a></td>
<td class="num">$ (6,556,280)<span></span>
</td>
<td class="nump">$ 1,120,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(2,819)<span></span>
</td>
<td class="num">(67,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Pre-tax (loss) income from operations</a></td>
<td class="num">$ (6,559,099)<span></span>
</td>
<td class="nump">$ 1,053,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203423736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Current deferred tax assets/(liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State taxes</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Research and development credits</a></td>
<td class="nump">54,324<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">83,056<span></span>
</td>
<td class="nump">112,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">7,679,216<span></span>
</td>
<td class="nump">6,434,544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">7,817,112<span></span>
</td>
<td class="nump">6,547,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(7,590,215)<span></span>
</td>
<td class="num">(6,206,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">226,897<span></span>
</td>
<td class="nump">340,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DeferredTaxLiabilitiesNoteDiscount', window );">Note discount</a></td>
<td class="num">(226,897)<span></span>
</td>
<td class="num">(340,652)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(226,897)<span></span>
</td>
<td class="num">(340,652)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents deferred tax assets amortizaton.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DeferredTaxLiabilitiesNoteDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of notes discount related to deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DeferredTaxLiabilitiesNoteDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506209527704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at federal statutory tax rate</a></td>
<td class="num">$ (1,377,411)<span></span>
</td>
<td class="nump">$ 221,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(415,249)<span></span>
</td>
<td class="num">(434,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant', window );">Change in fair value of warrants</a></td>
<td class="num">(72,549)<span></span>
</td>
<td class="num">(1,874,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,383,765<span></span>
</td>
<td class="nump">1,469,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_IncomeTaxReconciliationUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">470,838<span></span>
</td>
<td class="nump">436,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_IncomeTaxReconciliationChangeInCompoundDerivative', window );">Change in compound derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(101,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax', window );">Loss on extinguishment of debt</a></td>
<td class="nump">33,925<span></span>
</td>
<td class="nump">117,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">64,273<span></span>
</td>
<td class="nump">121,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Rate adjustment</a></td>
<td class="num">(108,649)<span></span>
</td>
<td class="nump">49,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Other permanent difference</a></td>
<td class="nump">22,657<span></span>
</td>
<td class="num">(1,351)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for Income Taxes</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to Change in fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_IncomeTaxReconciliationChangeInCompoundDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of Income Tax Reconciliation change in compound derivative related to the income tax reconciliation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_IncomeTaxReconciliationChangeInCompoundDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_IncomeTaxReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of uncertain tax positions related to Income Tax Reconciliation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_IncomeTaxReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current period income tax expense or benefit pertaining to a gain (loss) on an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506207925256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax positions, beginning of the year</a></td>
<td class="nump">$ 552,082<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase - current period tax positions</a></td>
<td class="nump">585,812<span></span>
</td>
<td class="nump">552,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decrease - prior period tax positions</a></td>
<td class="num">(3,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax positions, end of year</a></td>
<td class="nump">$ 1,134,173<span></span>
</td>
<td class="nump">$ 552,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506207199176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 30,475,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">California net operating loss carry forwards</a></td>
<td class="nump">30,310,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Expired in net operating loss carryforward</a></td>
<td class="nump">13,213,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal', window );">Expired in California net operating loss carry forwards</a></td>
<td class="nump">30,310,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Deferred tax carry forwards</a></td>
<td class="nump">76,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">California research deferred tax carry forwards</a></td>
<td class="nump">40,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets increase in valuation allowance</a></td>
<td class="nump">$ 1,383,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit limitation on use</a></td>
<td class="text">In general, an &#x201c;ownership change&#x201d; as defined by Section 382 of the Code&#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 43,349<span></span>
</td>
<td class="nump">$ 17,262,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates state and local.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506298254152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll liabilities</a></td>
<td class="nump">$ 61,547<span></span>
</td>
<td class="nump">$ 43,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">93,888<span></span>
</td>
<td class="nump">148,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expense</a></td>
<td class="nump">57,596<span></span>
</td>
<td class="nump">92,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AccruedBoardFees', window );">Accrued board fees</a></td>
<td class="nump">40,625<span></span>
</td>
<td class="nump">58,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other accrued liabilities</a></td>
<td class="nump">5,455<span></span>
</td>
<td class="nump">77,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 259,111<span></span>
</td>
<td class="nump">$ 420,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AccruedBoardFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued board fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AccruedBoardFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506203722248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2017</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AnnualMaintenanceFeePayable', window );">Annual Maintenance Fee Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_OptionAgreementMember', window );">UM 5050 pro-drug agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_Um5070LicenseAgreementMember', window );">UM 5070 license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AnnualMaintenanceFeePayable', window );">Annual Maintenance Fee Payable</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_Um5070LicenseAgreementMember', window );">UM 5070 license agreement | University of Mississippi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_Um5070LicenseAgreementMember', window );">UM 5070 license agreement | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_Um5050ProdrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Milestone 1 | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_Um5050ProdrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Milestone 2 | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_Um5050ProdrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Milestone 3 | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AggregateMilestonePaymentsIfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AggregateMilestonePaymentsIfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AnnualFeesForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual fees for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AnnualFeesForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AnnualMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AnnualMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PaymentForUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents payment for upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PaymentForUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_Um5070LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_Um5070LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_Um5050ProdrugAndUm8930AnalogAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_Um5050ProdrugAndUm8930AnalogAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_MilestonePaymentsPayableAxis=skye_Milestone1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_MilestonePaymentsPayableAxis=skye_Milestone1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_MilestonePaymentsPayableAxis=skye_Milestone2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_MilestonePaymentsPayableAxis=skye_Milestone2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_MilestonePaymentsPayableAxis=skye_Milestone3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_MilestonePaymentsPayableAxis=skye_Milestone3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506202401832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc | Officers, employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">$ 186,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_IndependentContractorAgreementMember', window );">Independent contractor agreement | Dr. Avtar Dhillon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_MonthlyFee', window );">Monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_MonthlyFeePaidEachMonthInExchangeOfServices', window );">Monthly fee paid each month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices', window );">Monthly fee accruing from effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentageOfAccruedConsultingFee', window );">Percentage of accrued consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_PercentageOfBonusForAccruedConsultingFee', window );">Percentage of bonus for accrued consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_FeesIncurredUnderAgreement', window );">Fees incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,387<span></span>
</td>
<td class="nump">$ 3,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=skye_IndependentContractorAgreementMember', window );">Independent contractor agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_TotalExpenseIncurredUnderAgreement', window );">Total expense incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">542,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_skye_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_AccruedExpenseUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total accrued expense under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_AccruedExpenseUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_FeesIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fees incurred under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_FeesIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_MonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_MonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fees accruing from the effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_MonthlyFeePaidEachMonthInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee paid in exchange of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_MonthlyFeePaidEachMonthInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentageOfAccruedConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentageOfAccruedConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_PercentageOfBonusForAccruedConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of bonus for accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_PercentageOfBonusForAccruedConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_skye_TotalExpenseIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total expense incurred under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">skye_TotalExpenseIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>skye_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=skye_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=skye_OfficersEmployeeAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=skye_OfficersEmployeeAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=skye_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=skye_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=skye_AvtarDhillonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=skye_AvtarDhillonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140506206634600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,533<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,074,415<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 3,019,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of warrants exercised</a></td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of warrants exercised</a></td>
<td class="nump">50,133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 3,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">50,133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=skye_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+MH+Z?9%-1M[IWO?*-6L[>.*4>TD1D!_7S:-VK^8";K_%G#Y#U!+ P04
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MXW::41=&:0+H/!5";Q:&H.GKP3]02P,$%     @ T:5A4AP!$JX&!@  *AH
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M,=9Y,26 YZ  $4\GQ@0:Q-A\44)H8&<&-7("#<N)GR: D*D$*I8P=GMB;K0
M&M8"[8&S%7RZWF61VM-#$[?VV)FXE!@U0Z96T+O[.&1I@707Z^;=>EMRNN"P
MY#U:$5,"5&'U5Z21 &A8 OP[45H[:Q<#0Z,4IAY 'C+^F;+ C'+8/*F]V)-T
M(RO0L*SX<4F*S,&/(>J5I*B9^VAX[I^L=-#XFQ,T^DYD88%,%;..%P1Z#4Y
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M;9/VCWZA2_NO" .YR> ?[?V+IIZ!'RF7VF.E-DOA9DR!P9-!-M&6K:U)Q^%
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M$_< C*B:FA*M)'O/Z#T,")R+>&D_ 5[91:Z05RQCB(LAN,SD0L&7V*&,$4M
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M+W=O<FMS:&5E=',O<VAE970Q,"YX;6RU7%N3$T>6?N]?4=$SNP,1DOH"-CV
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M<H*R40A :;9?KE*")T[I\</9R5NI87U27X>UB^2A*;P#INNV90_ CW?JZS%
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M0$GHJJG=@RUW/.IFD9!CE8FO[I02/]6-$DGR]41@^UOHJQ#IC0OK9W:_Q98
MDS_+Q<-:9VLA:;$5LLK!E&W E=TKTD0 S(4LR)3J7#TB3DCQM*Y""@EZCXYS
M9%19W^,!O92M9;52$(-\JC% <$E\"'5/;\*6/D<,U#/]FC?$ P0>$_FCA0:5
M*9Z@RJ?2+]2L(=O "1JH<:B\#'\+14)*>,]&DQ<9J:USGD842F+=V9R<C?Y-
MA(O\VW:%G.*MT='7%EXLBAIR(,<I4@CS1N8A84BE)(''DP$1\9VNH#"LF#!8
ML1F(?XCEK#I6<W#K!VR,C,SQCDV69!/:J*QSO=29I(S=FZI;5LH<RY:-#XE=
M3R$BSFC18#,-&@LUBGGHB,3*VPS;9ST$;@@"2="S>)+.Q08[V;4T_!.47^*5
MNZ;.OD0P2J&L/0C"&U/?ZUR19ALBV:RQ)3'MV7)<X>$69[W4**'@R%4^5-PS
M?MEMR@H-.+&4F2XT C2$N7<BB-1NZ,>S- Z.PHZI"7>LRI X<WC.+A8=9&"A
MI.G]BI2,PJNJ6G;/AK5X]8KW0$%%>;G>PJ@TQ8;-(:WZ)"A"41>-;1H8)?IM
MM9$Z[WDIY=- TP%W,F=22R85WD!+_7C )^@I*Z%X&A@E0D6[^!T,D2I=R8;R
M%D]_QV<7"V0.MX?=P!(PH_N6:S(7@"N"+_HXUO]F[\=/JLE"W XS]@!+VZJU
M!+^4$\&H9W';[##G68+,./=0,*@J1%X[%W5%0[!OMU3>2UU(4J[#H."\1OW1
M*BHQ*#3DAOR.0HZR4P6:#Q7;8$G*RMV&!UT&W $<X.] T$TA,_6M6-</0$_#
M,H*^@Z<5(%+"FJ$  :"TRNU!QGC>.2>3DZ.,C(*GMR/CN!T"N<LXY% >%\$Y
M1W:6P3&-'-J"W9PTZ;]W/HHU,@<#]&Y31V+1-FR'0I>:W)-^RTP-A!F1)1>#
M_Z+;$C5I!W2HX%!Y16#D-_'&G8B_.<8RZ1/#GJPDC;:DOZ6I2WBGRH"_V+Z7
M>B&K+Z;=-!EDH.UL7>"9^V84VD%9>9>-#L)6@&"$&PHDE#CD'<AT[%FZ+&$)
MH .R'Z5Z$(!5#4LG7>^&K1R,0B02X\D+OR/-"R"JSH!KEF6QP8_ :W00R6%H
MF >\P8Z-JCPG<$YET) 1JB&B&4DTASO9J)1?%/,YQ*0+[)FKK."8*8JQ/W"1
MTTN&.K<E P0ED=(&BNKTX-Y[B=S:Q3FCXL,:<H D01=<&<%KV"J.&!(>6^L@
ME =M=T\#MK-$&T!<QDSSSYNBM2*)7T4>0GA'OY.VPJ,T+%X4[+ P2>5;=M:)
MDO2^QYWGY1P7F6LJ".@1!11W"XH^'#+U PIQZ8N736M0VB%P./];ASJ#;$$!
M7 5! (?0"U;-XU=!$57+B(UO!RAP23 2;V^2<OC9L;:6]U R>Q]17&I\?8*M
MK*-'SC6,*/6H3*:MP_ -]@XMTT3\^@)E'@D*K\YA?0.8[O@,5=>*43L/V;71
MI=H"PY!-M@1E\OG Y#LN[511!1G5J'J;QX/JC?"&_.$P\2/=!^3P2@\%X]X-
MIX-RT8DR?LTERT&MT%<((8-T>!8P?JM,<&T#BFFCD2]<E;"OKH";+0B:W!N&
M,,?:KK!F\+/(,T"B#NB-\PZN"88;<-ZP5A%Q]+Y%R\".C+(.FV&IPRPD4"A@
MI\[L)A?\^KHN<NIZAMT0Q[WO!C@7@>0H+DCLYJAOO P.@&MUUO6&X#<#,EAX
M:?.@E#,!#P/6-4&>WW0)4EU&ZS@@7;G^EP)P*;7QW?M"6FUW1.!VF.E[J!P^
MA&9=0*CE4O&8<EA^#L'5#ST$MQX(N<H7&>:+:@8CCCW*'R+/6"EPC]J0;T$/
ME8*3Z&X^POLOE2O5N4$+0YI@8V;(11>YAU&$F.S;KK:AF0D0_IS:8U??NM 8
M37QL-TCP5(.6H^,LN7B@7AA4J)\V^I[M85FC$"[BF',M;3\ZHGSGP,B#Z%$
M:+D^&IMGG/E*A:J%.B6WPZ@ ' E*IB-UKRKF0UHW/4(P]135XT:A^>K<;Y]X
MV_IR9<S*(8FGTYF-C#,L(3G.0PKGHI=URBVY@<B2!J:,UP.O)BQJ%Y: FDIE
ML%+G-L#6MJ^]KZE*U#FS^$X6',-W-*.V' <_P0"<&Y,PEF+O@</(OL6@7I[[
M?0JELW34H [=UT-!2D-%?F&0@;BD>D%Z> Z,O(ZW.TWFI=ON<***T']%E]>S
MZ":-@U]TX,,S"X]+^4Y8G4T3&F7&NZ_!%-17!&A7/2=PQ&="F51P$S-==H]]
M3H9.1"Y<%TBOI_$L2N+43VX*6WO<H/[N UH<'R)4B0@72%L]:W(SAAUG;Q;F
MH1X,.!@80T?EJBO>/SA Y(8;L-$*^EUQB=E-90<+9OV" RXSHH$EW;3L_^A"
M=N1#T9BG@333*+V>1M<W>QQA["]7R664)/\#?TFB.3SX>AX? MW.8;2K=;?5
M>S8':_'\.B"-\YXMQ?WLHJ-[E\>J^_#];)JFT>5LQH)VQ/#9=X8>13N$&B#2
M'8V'R]#?DE,8M:9S1LCPU0]HN;^&_;A5#88[[M72E1.C]'M<G^J18M\/D#LD
MV+%JL]8FYZ'*?QEC/!V"[]Q<SPD>><02=N.&OQE6J9YU0N2N[N_FN^*W86]D
M%!I3X,;6Y&G8^_=!N7 98&]WYT?$?NJ]KS!Q@:H>*9):;=><DXO:33O.KM)Y
M-$OGP<[+F@8'89Q.;Y!20C6^2X*<)Y-%UKITZBV9:R1Z0XW.J#0<I,,P:?-#
M,Y=8N96E2.LV&L?F[C'/N.#D3IE^"MG]*"J_T"5VCEVXAB%9@[)X4J>7S7HT
MG.KAURDZF??I]VP:D!65QL:51#23.-0L4A?.(UOV^#!F/;C[@<FXF]CVO?1S
M52Z37E'C%EK4\?C[8,?JTX/>[ZV!3:!FAV[++DKX')(5=CF%BJY<Y[@@%T(X
MM.Y(A5+N$ (/5]9=([*OC'UI8>I/Q5Y6=OZIVGAR\MT (>TA#V0&>G0ZQ.UN
M4=N9?@MG#C?KD.WF>A(G[I!AFD[B^:MM-WUFI'[@6)HZOH-)/+C.5H]!'2+=
MC&$\Y)J9$R/-RQ]UZ08TR>3JTJGO&<YVX<?'PN!(XB"#!SME.=(=RKPDFLWC
M9UC1R_-^1N58RH%]%+,NM7E<W\D GSY]$C_4P//^<'BV#Z7@K4K?#\;[7;;J
M*/R@6*1-:VB>U84-/0_@</OYXYVXS2!D7L((UATX+Y[XZ=V[6W],MK=\3%"
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MFF)Z/=UYNT'_8?U1M[O("*:3^"1)HYN$;DU>Q;1PSO?\*(JNDNF^:ZP7@WO
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M[H'V)SA_8U7E3DUS9>D,YBXS.O2BY@7T?J%HEC0W[* ]1I_\"U!+ P04
M" #1I6%20M@24Q(*  #+&P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6RM65MSV[@5?N>OP+C9CK-#R[SHFCB9L9UDFYEF[;&SV>ET^@"1D(2&)!B
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MANG:D4=RG#;-ORS.\/4,S9[8M"RZ.< C^ZV;.#_C39S;5#VSB=LO/HM'<K9
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MX/M"H3=O7HA!]_O=Z_\"4$L#!!0    ( -&E85*BZ*XW; 0  $X*   9
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MJ)5OQ/1&ORN?>*MMDAE;ETK\\W)IJQ(>\:\GCABW1XSYB/%_J<*G=\_/19>
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M;K=L<9R"L@"\;Z0TEXT-, WH[6]02P,$%     @ T:5A4A'55?L)"@  #B
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MP^U9V>M^NWO @>B?"#O @[!A Z!QW^'^=/%@<>CGQ=-;:_MR#%/!)$)$>.S
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M*SE"E]:B<G:K<D);:75+D^,P;]&DJJC>D]LJQ!15[7PM,<-9,TW<7-05.@I
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M[9_FQI:8'E/C2_4F.&P.II54'+@5M,YJ[D-; 3;Q88YK$(X#PPY+*<S6V;R
MWXE3;>J2>"S=1,XY#[EI\2@/0V_AJ'ZGJ?OIH^.#D/G0WYMLZ.^M[VKR%S\
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M"",?$&/YK[#,;-?9%?^XU H^AA[ ]W,+;O@/=$#\NSRO_@]02P,$%     @
MT:5A4ID9TJ1-!P  +1L  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MS5E;;^.V$G[7KR#<[4%2*#9)W:R>)$!NBP;8;8--FJ(H^D#+M$VL+EZ2BI-_
MWR%ULQ-;\2X:;!]L213GF^'PFR&'.EX5\K-:<*[18Y;FZF2PT'KY\VBDD@7/
MF!H62Y[#FUDA,Z;A4<Y':BDYFUJA+!U1C,-1QD0^.#VV;3?R]+@H=2IR?B.1
M*K.,R:=SGA:KDP$9- V?Q'RA3</H]'C)YOR6Z]^7-Q*>1BW*5&0\5Z+(D>2S
MD\$9^?F<8B-@>]P+OE)K]\@,95(4G\W#]?1D@(U%/.6)-A ,+@_\@J>I00([
MOM2@@U:G$5R_;]#?V\'#8"9,\8LB_4-,]>)D,!Z@*9^Q,M6?BM4OO!Y08/"2
M(E7V'ZWJOGB DE+I(JN%P8),Y-65/=:.V$> U@+4VETILE9>,LU.CV6Q0M+T
M!C1S8X=JI<$XD9M9N=42W@J0TZ=_,"E9KA5B^11=<BD>F'$3^B#81*1""Z[0
MP1V;I%P='H\T:#1RHZ1&/Z_0Z0YT0M''(M<+A:[R*9]N HS U-9>VMA[3GL1
M+WDR1!YQ$<44]^!Y[?@]B^?MQ-LZY+\^0#]TK7FF_N[1XK=:?*O%WZ'E%H)I
M6J8<%3.T:CS^P)7F4^MX"!>EX4;D\VU.[@?_M<PF7!KH9C*=JT<N$Z&X<\=E
MYMRWBIS;HI0)=VZD@/^#/SF3ZM#YK=,.;SBXE@3HHL@RB)I;722?.^!WB PQ
M=L+__3"FA/Z?8(>XA& 70V.O6&#$@C4QW J%VX60+M MEP]@*;J1Q8.8<ED9
M0 (0=_PU .AG9NUB-])-RA(.V42CLSG\ PX>^F"10VC0X$0-SN77X=  </PQ
M[G#V'E!E!]FT8XRN,BY9.D7O1<[R!.9EW95X2(SAGNO7/FQZ?X1,)(XN)5NA
M"\FGPM@H>67MAGQ@Y",WZ.8@WCEQ>.B9X8U-S[HWQ3V]<6@&0T(W#,UOW--_
MES]Q!.X<QC$H)18DJD" FT?O2Y-(GJG$Q+F&YIG(A>:@W!W7MMX5FJ6O11QB
MR@0/9!9N ZG)+@X)P$?$<STOZ,D!09L#@OUR0+T &IUZP:MU26C[/.VR4=IE
MHVTIH5^7">PJY6X9UK,6$KOH/1,2W;.TY)4GMN5$9Y].Z%JIDD^=BP7+YQR)
MO()^:*36\3[Q)&5*B9E(F%VA-U M.ZZ^E."9YQ93O*?%^P3&$4J*;%D K;9Y
M_PD=D$,@68S=*([@ILY@<'=0M:'#C=;F[F4$'S4\7 >GAPZ-0A=3WVDD#Z@7
MN7Y@@)LF;^P&$ 1U=CK?#N4=.L3SW2"*.RB"(6XA/QX":@@8WAIH%1O;&6<2
M-B8FP6P.V?="ET;8CKE#?(=J S]PI5R4%WE22FF<NRQD,[,[%'5>;-1<U+(3
MEH+G>(_L.^3#TA-BK[-@-_%)_(+XX_\Z\5$!@WG4P)Y2J(6AZS<'[[\7"A1T
M^H'Q>0!9'@=C2XRQ[Q*_"H8#$F(S&>CPIRYR]H\'$K@T .X1K^-Q[&*?NCBT
M3 [<V(.D3 WUFN!Y-33\L5WOUJ(,0B/P+2#Q?=>+ M0%T"NQ 2;&P=CUPG#3
M"[$; 4 4Q)4?(%: EC0,[&,34-\2)+7/C;%MO'Q-G(#!$9@2$V\M:'ZZ6PC8
M]V<PX1HM8!&<<)X#<Y.T-/$#%#;+4\+2I$Q;GIHFOD%)E!9*08&6%+(62XH\
MKXNNE= +*P,EXY(]V?XU2L.(%S0$2Z9<)5),*KA?"\V1#]9!!3GL68C#=B$.
M>Q?'K]DN]:B+6G71&U88XU;+>.\*0^3+4MM=CDD_U=1IGBQR\05R1*G K9!B
MJM3T/%IV;#?ZE9]IF_X,#9U+83:VH/M)\'3JF-T9^M&Y+PR%;#3.8,-32"<F
MPZ:*B.F0.#\ZGX3Z?#2#&8 !:"YAKX8D@_T<'5*O[DF'@>EY];@$?IEA0'F#
M#IZJ,@9*#.=W2/TR?3+Y):FVG,IN.9>VX'D'F]D&"@_#N,?O<>OWN'_HY1R*
M=+LIV;);[U% <%>AXS<D$%D["2"]0UE;1SYRIDI9A<*U9=,9S.A]RZ:[ADUJ
MUW+XESTS@(Z/&IVG, 5_;ST]Z+=H>Y5ARH#9LS+@61G1O=A.Q\W+=G+Z\";V
MAN/07.OG712%DBRV> &U%_NTFZ6F>C7US2ML-:5-L'GIFVC:333M=>ON>J\/
MOCM1(6]YI$*Z,Q72?^[Q/?C:;]$WY4%OB,<]U +FT5XRO4XB2OO\W=6OI+^H
MW'DHT3KRJ4]/MSR3\"WYTZW+)/J>2^8KVL]>'#K80PZGJE3ZLM86#N&A23A1
M/ SZDY3)8;V$@I78<SSSMT=N\JO#**]O-KK]"WEE ]/LX+^*5-TR3>(W)!7M
M%FN*OR>I7M'^DE2HAT\OB00,HOVY".^D#FRH_#U8LYTNH[4O&)!FYO8[C0(,
MJ$VJCQEM:_LMZ*SZ M)UKSXD?61R+G*%4CX#43R,(*O)ZMM,]:"+I?T>,BFT
M+C)[N^ ,[#8=X/VL@(*C?C *VB]DI_\ 4$L#!!0    ( -&E85) P%0";@,
M  H(   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(U56V_;-A1^UZ\@
MM&)( 26B;K:3V@:<I,/VT,)(V@W#L =:.K:(2J1&4G&R7]]#2E;L.C;Z(O%R
MOH_?N9!GNI7JFRX!#'FN*Z%G?FE,<Q.&.B^A9OI*-B!P9RU5S0Q.U2;4C0)6
M.%!=A3&EH[!F7/CSJ5M;JOE4MJ;B I:*Z+:NF7JYA4IN9W[D[Q8>^*8T=B&<
M3QNV@4<P7YNEPEDXL!2\!J&Y%$3!>N8OHIO;S-H[@S\Y;/7>F%A/5E)^LY,_
MBIE/K2"H(#>6@>'O">Z@JBP1ROBOY_2'(RUP?[QC_\WYCKZLF(8[6?W%"U/.
M_(E/"EBSMC(/<OL[]/XX@;FLM/N2;6>;)3[)6VUDW8-10<U%]V?/?1SV !-Z
M A#W@-CI[@YR*N^98?.IDENBK#6RV8%SU:%1'!<V*8]&X2Y'G)G?P\J0BR]L
M58%^/PT-4MJ-,._AMQT\/@&/8O))"E-J\E$44!P2A*AE$!3O!-W&9QGO(;\B
M2120F,;T#%\R.)@XON2<@_=<YY74K0+RSV*EC<)B^/<,>3J0IXX\/4'^B'>D
M:"L@<DUR*9Y &8Z1)$P41$AQ>;!6/#&1@WXKR.=/66C+CX&!>@7*!L>[<\3N
M9BP5S\&ST<)/=.U]D895I%%<Y+S!T1.KVB.!!4;EUU\F<11_4% Q P5IF#(O
MWCM"KU**OSB@41ID]'#\5;!:(L?_"+ <I,#(RE88[R(*Z/@Z0$KRWDY&<1PD
M:8J3(PS7NK6A0$7::.\B";+QR**R@$[LX(XI]<+%YE6[<4[]Z &Y)(?JKS$V
M$4V\9#)&-?1T+'Y,SLEXB)!Y:48#BL[W!CUK?B1REV'2XEU0Q)1 :GP<^&6A
MV);D"@IN"-LH 'S5#,8U"I)))_@=Z26?*<IL*,KLIXN2"P,*M"'PC,^XAK>*
M[SS;W\!4=[D/*_"UX![V W9T(G%1BSX0;9R5PJ]U?10%63JRCH^C($6NY7))
M*LG$SS%,Z&C(QV>;3*;+(^2-M^@JC[D.@/$XK-DLC8,L3KQ1-,),)$?6^$X(
MS;KVT=4JBHZH%\7!=60OQIA:8.92B142C*/DK02&>^]S#6KCNI F3D3W5 ^K
M0Z-;=._[JWG7)3\QM>%"DPK6"*578\R>ZCI/-S&R<:_]2AKL'6Y88K,&90UP
M?RVEV4WL 4/[GW\'4$L#!!0    ( -&E85*OL69W4@4  !,.   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;,U76V_;-A1^UZ\@O'9P"D6F;I;=7  G
MO058U\!I4Q3#'FCIV"8BB2Y)V3&P'[]#RE*<)E&"/>W%ILAS^?B="\GCC9 W
M:@F@R6V1E^JDM]1Z]78P4.D2"J8\L8(25^9"%DSCIUP,U$H"RZQ2D0\"2H>#
M@O&R=WILYR[EZ;&H=,Y+N)1$547!Y/8,<K$YZ?F]9F+*%TMM)@:GQRNV@"O0
MWU:7$K\&K96,%U J+DHB87[2F_AOSWQJ%*S$-8>-VAL3LY69$#?FXR([Z5&#
M"')(M3'!\&\-YY#GQA+B^+DSVFM]&L7]<6/]@]T\;F;&%)R+_#O/]/*D-^J1
M#.:LRO54;#[!;D.QL9>*7-E?LJEEDW&/I)72HM@I(X*"E_4_N]T1L:<PHD\H
M!#N%P.*N'5F4[YAFI\=2;(@TTFC-#.Q6K3:"XZ6)RI66N,I13Y]>:9'>')[A
MOC)R+@H,MF*6KOY7-LM!'1P/-+HQPH-T9_*L-AD\8=(/R&=1ZJ4B[\L,LOL&
M!HBO!1DT(,^"3HOO(/5(Z+LDH 'ML!>VFPZMO?"I32^9A,/9PTU/I&3E C#K
M-)EMR;[<)=O:Z<F&R8S\]0>:)!<:"O5W!Z"H!1190-%3@+#8LBH'(N9DSK@D
M:Y970)C"8ED99,JL*!,K(NP$62!2_2N[-9G=OGX DW5D"/(*Q0RDX=8QW.*/
M/W;>\37/H,S(ED.>.=2CE+QN_J9<W1S.)0#AZ%^"TD0R#;@<C'[_;13XP1'U
MHJ'SVO&]:(P*[V]76('H#:4+TM^B>W7@Q-XPWHD//3^TW\ZUR#$..==;9QQX
ML;\3\&GBC1*T. Z])""O.PB/6\+C%Q,^O9K4S0']/D9GMZ4_*\L@VK'9HISO
MMA'@?B=KD-C8R$<3*8+5">2#B>VUB:WSK5PC=Y"Y]Z) ; "BF+J44N<5LHJ?
M'^M0.SLZVO\I]C:3FTZ_43BH%9ZTC1%NE%\UHPXVARV;PQ>SJ?8:2KI?6R8/
M2@6/,=QM_?F$G8)"F71)&"9M!FL\:U:F6)U79!RZ<13CH-GW1R@Q++D591EV
M5*XT)C >#6AK[/KCQ!F.J!O%1BFD@9M$ 8YV<QUD)2U923=9>U6LR#_D2U'R
M6:7(19DB9,1!+G-6FD2(.KR-6F^C_T>K&[> QB_/%5LQA*T9S\UI0_"60>:5
MKB34_>VQ9'G&?&UR<L^D+2#G;H[9=OJ@[H@?NGXP<L.1[U@[9"7P0.9E*DV=
M$1^7QI&;Q(&#-X(Y<%/EOCL*$S>BB7/.,()YCG,QSE$W"..F=$D_&**,+5)R
M\!R2@!(?\VY,W23IRCB?WAWR].6DU_>O!P=*5PM\QOSS/?#]+<B4(X>7DJ?P
M<'T*Y@;)RP4F:8GUF.H*:_2K/3%^U"?&9+&0L#!=] (E.-X+T[J5OG&^5%II
M+&C4?ZR=AF[H)^[0UC'UPM 9>6'4=M6[R)@C+KX+H]-OXTA,8\40MV%W^FW<
M[5HP[ 1A&E7@TJ:M(PHZ=,9>'.PUIAU%)BT>TP_=:!BWZGZ,FQB-]M2O;<>W
M;0W:$U<0<Q#\)SAOOBXQ/5O.><MY?37ABF@4P&0R83=#5HBJU,HTD\V28S,V
MDS\K88!@PMW@"V-E@M_(FV[$RJWUEQRI73+";0I@6KT1@29K[BFJ>PV4Z4?*
MQQ2]7@KUJ["9[P:WP8KDI86A5./Q%QQ]@SF@1[P\Q-7#0I2P;5S8)?_HP'NL
M;@=[]_0"Y,*^1A0>DTA<?65O9]L7SZ2^Y]^)U\^ESTPN,!XDASFJ4B_!6XJL
M7R#UAQ8K>^N?"8UO"#M<XJL-I!' ];G S>\^C(/V'7CZ+U!+ P04    " #1
MI6%2RF)_FN4#  !#"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6RM
M5FUOVS80_JY?0;C#D*!L)%+OK6T@;\,*K)E1KRN&81]HB;:)4*)+TG'S[W>D
M9,4%8B<8]L7FVSUW]SQW(L<[I>_-FG.+OC>R-9/1VMK-^S TU9HWS%RH#6]A
M9ZETPRQ,]2HT&\U9[8T:&=(HRL*&B78T'?NUF9Z.U=9*T?*91F;;-$P_7G&I
M=I,1&>T7/HO5VKJ%<#K>L!6?<_ME,],P"P>46C2\-4*U2//E9'1)WE^E[KP_
M\*?@.W,P1BZ3A5+W;O*QGHPB%Q"7O+(.@<'? [_F4CH@".-;CSD:7#K#P_$>
M_1>?.^2R8(9?*_E5U'8]&14C5/,EVTK[6>U^Y7T^/L!*2>-_T:X[F\8C5&V-
M54UO#!$THNW^V?>>AP.#(CIB0'L#ZN/N'/DH;YAET[%6.Z3=:4!S Y^JMX;@
M1.M$F5L-NP+L[/0.=#_[31ESCCZVE6HXFG&-YFNF.5)+=*V:!KB;6U7=H[,_
MV$)R<SX.+7AV]F'5>[GJO- C7@A%GU1KUP;=MC6O?P0((>0A;KJ/^XJ>1+SA
MU06*"48THM$)O'C@(?9X\1&\6Z9;T:[,0?I_7RZ,U5 V_YS 3P;\Q.,G1_#G
MT$WU5GI2H8I$A5A;HUK(K>4U:D$%"2*@#7@WSOMS')_V $6*[)JCOSC3'<T(
M2.+- B#W1 5.:71VMVVX9E;I\\"G"DLWO%507MTB</"NX^"R4=O6!G=]?,%/
MZ"S#:1;AK"S1>7#E,[F=S3M@]L"$=#6"K$)55SK&E<Y:R9IK$_Q@3.,(YTF&
MB[QPN-%%%,/J[7()#>MHNG'D0,NB.:^V6EC!3?"5:<U::]#/;PI*R <D!5L(
M*>PCJB0S1BP%KX.S.$EQDCNX+$]P5*;!3<_TJV-%;Q'@ 5$U[+8/L (?D9Z
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M[&&'YP'Q":F7:P 'EX.;1_S)N%%BIAKE%>CI>(?_0#SN#.PG2=[_GK<8^(_
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MC44.@<B/P.;(=RFOR%$,P7Z#CPZZ-G_;]N.#7QE\4V/Q<!2U),"!#_G!U9R
M[N45.;PATG,:',J0OX?K(0VTH<!2U)(%!T+D!V%S%KI65N2 AZY[SH%#'O*W
M<4<KZQ%Y&!XMK<A!$?FAV!SG4VLJ=IC#8;_QQHYRV-^K=:ZIE;[WU53L$(C]
M")S;@7U_9[%E\;D]96X]&%Q[GERQXQ<^]^R*WSV\8H<^[$>?)_Q=JBMV",,]
MCZ_8T0N?>X#%G298[."'_?#R9*%[B<4.<[CG&98XLI%SS["DRPQ+'!>)GXN>
M5'2ML\1!D/0\P1)'0/(_)]@C\F1?9@&$P!8-L]( 12!A.U_A)0?/^_S0]$3_
MU.I+' M)SQ,M<10D/WBB)5TF6N(02?R(+!Y$-S]#\+GIN$9ZGF.)8QGQMVQ=
M(SJK]+V-*&IIT:D#'?6#KCVB73H:ZGA%>YY6J:,4/?.T.JL,ON=QO ,<]0/*
MFX N/0UUU*(]CZKTX&W#F4?5&?U^5!WC83AJR8-#'/4CSIN'[ET-=4RC/0^M
MU/&-^ONV'K(Q^BX;ML%LHY*C(_73T9N,KGU-Y& 8]3S/1HZ#D;]O.];7S([(
M>Y[,!P<OL(M_#_S!U%+D&J1\856%PVM[!ZG]"_G]AI'K\IWVHS1&9N7/%6>V
M/A4GV.,+*<WK1O&:O/Y;Q/1?4$L#!!0    ( -&E85*Y\!"1CP,  '(.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;+U736_;.!#]*X300P*L+9'^
MB%W8!IJX10LT0)!LV\-B#XPTM@F3HDK2=@SLC]\AY4@.("LYU/'!$B7.FS=O
MQ"=QLM-F;5< CCPIF=MIM'*N^!C'-EV!XK:K"\CQSD(;Q1T.S3*VA0&>A2 E
M8Y8DPUAQD4>S2;AV9V83O7%2Y'!GB-THQ<W^&J3>32,:/5^X%\N5\Q?BV:3@
M2W@ ]Z.X,SB**Y1,*,BMT#DQL)A&G^C':S;P 6'&3P$[>W1.?"F/6J_]X%LV
MC1+/""2DSD-P/&SA!J3T2,CC]P$TJG+ZP./S9_0OH7@LYI%;N-'RE\C<:AJ-
M(I+!@F^DN]>[KW H*!!,M;3AG^P.<Y.(I!OKM#H$(P,E\O+(GPY"' 6P_HD
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M!_C>=,1P!V];";65T=&9^U";'!V_=Q_*A..C-K N._&.9+5'LG:/;%'^U17
M:H]C]+S*LZ.OI?;/I3^O_"'A2^4'](3RM5FR=K/\_%3@-@ R@K(K<K$';NQE
MFP2UG['^F=6NK8VU?V151?R-132*UQX_(*'N)B[QT0["[\9NN5F*W!()"X1*
MNE>(;,H-3CEPN@B;BD?M<(L23E>X*03C)^#]A=;N>>#W*=4V<_8_4$L#!!0
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M(BW*?\&ZOM<;@6A5*)'5PMJ#+,FK_]FW.A%; EI/MP"J!=!+ =(C@&L!_$(
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MRAJ8]VLI\69CAXMVF)S_!E!+ P04    " #1I6%23*J2H-H"   2"   &0
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ML7@&?\M2 +W(U+<W9JVBR6%-&;*3JG)FT3%(1\MQF%BA@*1"+$JT!.Z#7,B
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M5KEZX)M?61M0J/TE/)?U?[1I^WH#E%12\:(U!@1%5C:?=-LF8L\ _-@-2&M
M#@Q(GX'?&OB'!D&/0= :!'5FFE#J/$RIHI-+P3=(Z-[@33_4R:RM(?RLU//^
MJ 1\FX&=FCPJGGP[NX',I>B6%U!.DM83\F;*%,UR](EM545SB?!;=(8^/T[1
MFY_>7@X5C*T]#)-VG)MF'-(S#D8?>*F6$KTK4Y9:[&]/V!.'@R$$W45.=I'?
M$*?'CXDZ1S[^!1$/!S9 ;O,I2W;FQ+.83[_;'(\=T?C=//JU/[]O'I=4L+/9
M\3Q>"T'+!8.EJM#L">WWNZ=/=?/UAHH4_?$;N$1WBA7R3P>@H ,4U(""'D"_
M5\6,"<3G",AISC)5":;?I 8@T0)0*7LA-'[#VJ^FK?7$)^&80);6%CQAAR=T
MXOE:,P!$3==, *,AMF4BR21#*Y$EK!?HFZQ$*<]S*B1:04!ULVT!W#;CQWNX
MO7,2VE%''>K(B?H+DS7F,D7OMBO@2GA1'.EF&X3H*'5Q-,9!8 <QZD",_FOJ
MU@8GB(M4\)"5BQ<D;_2"Y,4=[MB)N^&VIM:3_37!MOJ9V7 T'J/]XO/(*" =
MDF9Q'W>+8B\(>P"/.\!C)^#W-!-H3?.J*4 -'_&5ABS;#-L@CX\F'<<D/$0\
M/D(<!J,PL@/&GI$/SPGY$U<T1[3@%1 )@*Y*P1*^*+._#Y.><'O-M@,\SV4<
M8*\'VIZR82>T!P-D<UC!4(P9M\N0VZF/GIBNYC$J&CG" 4KIDW0P)B8&,7$Z
M_UB4V:R2Z*Y,@)=A/X3N<UI:!.JY?Z,1^ <1"6Q4 G^O3+1\"W],K&%@8&,T
MKVHVKL5"6C<=-K'P]$]/]1BYP&Z],,!HFF8Z2U#GK\,8'F$<Q:,H]GO8 AMQ
MP&YUN <:AKG1!;U+X Z;;E!+ALHNC$S*RD+134A6W.[!L7?N>3^[BL#H"W8+
MS.,SIOL'O7(=&%W \0^R#@SS8S?U/S!]2-,3D@"O"#@.P:8;Y=G<JE(GG(U;
MDHIV)#6R<%0C"R<\Q:VG8.>)G&([8J2#N*5CMZTXVY'RW"%_[7[Q!3N*=O3G
M6PJO1_"(417B%H 7[LA:;_N+GQ O[&<H8M2"N-7B=;N%UNF^W.(HAM^#_8*E
M7S#R/;\/MA$AXI^H=*E@VZCSUF"F>D4Y2\JH"0E^C(5-C(Z0[]61TR<?<JP4
M4>"''N[)N1$*XN;J_WNI1;;=>]]2,[) W+)@4B=,S<">$JBHA>S*Y>@HEWVE
M:W2#N \4IP$YUEU\A"=PT8!1#N*FZ-><<LCQ:<!ZS+'TLYYSAGL74 43B_HB
M3P(<.!4T-S)=:W=9>%U?D1VTW^*+:7/E9]PT-Y ?J%AD4)TYFX-+[WP$F13-
MI5[SHOBJON::<:5X43\N&4V9T!W@^SGG:O>B!^BN5B?_ E!+ P04    " #1
MI6%2VF>!VB $  ""$   &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RU
M6-^/VC@0_E<L= ];M;N)G=\5("VPIZMT[:&B;9]-,&!M$G.V@?:_[S@)"0O$
MR\/RLMC.S'B^S^,9S_;W0KZH-6,:_<JS0@UZ:ZTWGQU'I6N64_4@-JR +TLA
M<ZIA*E>.VDA&%Z52GCG$=4,GI[SH#?OEVE0.^V*K,UZPJ41JF^=4_AZQ3.P'
M/=P[+'SGJ[4V"\ZPOZ$K-F/Z>3.5,',:*PN>LT)Q42#)EH/>(_X\)H%1*"5^
M<+971V-DH,R%>#&3+XM!SS4>L8REVIB@\+-C8Y9EQA+X\7]MM-?L:12/QP?K
M?Y?@ <R<*C86V4^^T.M!+^ZA!5O2;::_B_T_K 94.IB*3)5_T;Z6=7LHW2HM
M\EH9/,AY4?W27S411PHX[% @M0(Y5? [%+Q:P2N!5IZ5L"94TV%?BCV21AJL
MF4')3:D-:'AACG&F)7SEH*>'WR!2[OX52GU 7XI4Y Q-F42S-94,B24:BSP'
MLF=:I"_H;L(TY1F(WJ/GV03=_?6A[VAPPIARTGK#4;4AZ=@0$_15%'JMT%.Q
M8(O7!ASPOH% #A!&Q&IQPM('Y.%/B+C$O>#0^&IUG%C<\1I&O=*>UV'O:;F$
M$#7D37BV-4&*9BS=2JXY4Q;[?F/?+^W[EA/CY5%=(K_2#4M=<X5WP_LP"-TP
M 6B[8U+.!;$;X)@$C=PK[X+&N\"*?D053]'3=&9!&C:V0BO2.B#I#H*.SC.&
MM$!I%9#*!.1:9 LFU:=#Y-Y]V^9,4BWDQ;@,KZ7F7-!*3=3 B=X#3G7YE+EM
MA8 ;WXFGVBTX<I-X;N2'<12? #J7Q%Z  S_Q\&5(<0,I?I\3@J1R7R65QUQL
M"WT)3[55?'P^[H/KG6 YEP*A#AA) R.Q!FUY4=GBC;#%;IM372LM)I^^?<X?
M$550/6'?5!0[6(&R=G4PUQZ\CN;$#7%$3@B[)!GC!*(DNLP:/JH=^'8XKPWS
MVH?7<8Y]XB;1:6Q<$,5A G><A!UW%Y,6*[D=UFO"O][_K?CO$.O"UU8M[%GQ
M/8.[REP".!0M>6J&)33;C6AK%O9O4A1Q6W=P8/7_RG :UV:.8R0.XC@(.PAL
MBQ6V5ZO_-N9=:@735@H<W8:N-G%C>^:^FJ[XC"XO(5'L=]#5IER<6!WX2:6D
MA;:A(6W")>Y-^")MJB/V5'<M7^0\!?E^Y'<56M+F'V+//P>^X.V=<3KG&=>_
M49I!NN%+;G]'MSF W.;I2MH\0.R/U^N*&[GPBO7\P#]+^)<$$Q) &20=?+?Y
MA+Q+/AF1\WP21KZ;!*>NGLMY)')#$GHGKCI'W1RPM"J;7 4%!0I'U14UJTTC
M_5BVCR?K(VBPJW:X-5-UYU^I7/%"H8PMP:3[$(%;LFIXJXD6F[)GG L-'6@Y
M7#,*)<X(P/>E$/HP,1LT_W88_@%02P,$%     @ T:5A4B!@A],\ P  30L
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MP)(?J)24:^5#3H<H&4D&Q!XQG&=QGD5^Y*Q#SMZ);&EI4RXK4[ I7WG/1S8
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MAL(8Z.<+SM5Z8P+T_\3T#U!+ P04    " #1I6%24-P:=-L#  "?"P  &0
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M*L^JQXPJ:%1V HW/I32[AG70UN23?P!02P,$%     @ T:5A4B9';IBR @
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M*+L WR^D-"\3>_E2W\X-_P-02P,$%     @ T:5A4M1Q R77 P   @X  !D
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M^6 R@ QS7DM[IU9?L0UHY.RE2IKF'U:;N<EP &EMK"I;,#$H1;6Y\G6;B!T
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M!7VDH783Z'VNE'T9N#-W]]DW^P]02P,$%     @ T:5A4D*]F^"M P  C@\
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MDII=]UD/9B%<UF!_-],+5FW#X44=_P%02P,$%     @ T:5A4I>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #1I6%2
M<"CO*9 $   U)P  #P   'AL+W=O<FMB;V]K+GAM;,6:77/:.!1 _XJ&ETT>
MNF!;)A]3.D. ;C)#@*G9[F-'&!$TL2TJR4G:7[^2':;2AMS9EUN_Q+%LQ/$U
MUKE7\L=GJ1XW4CZ2E[*H]*BW-^9PW>_K?,]+IO^4!U[9(SNI2F;LKGKHZX/B
M;*OWG)NRZ,>#P;!?,E'U/GT\]K52?7]'&IX;(2O;Z!J^"OZL?QUWN^1):+$1
MA3 _1KWF_X+W2"DJ48J??#OJ#7I$[^7SK53BIZP,*[)<R:(8]:+VP%>NC,C?
M-&<.<LTVNFDQ;/.%69!1;SBP'>Z$TJ8YH^F?6<8G;D]N]VHC/XO"<#5EAO^E
M9'T0U8/KQEY%W[N,)@[';1O$:_5_PBAW.Y'SJ<SKDE>FC:/BA0.L]%X<=(]4
MK.2CWO$4PJHMF57&!HG<56U7]EQWI?:K[[;M51N+Z\5070M[0-UM&W \R,ER
MD2WG=]/Q>C8E-^/Y>#&9D>QV-EMG'F , ,:= 9*S%?,@$P R^8V0V=IN[F<+
M"[C\3";+^Y4'20%(VAWD.+OU(%, ,NT0\EOL00X!R&%GD-EZ.?$@+P#(BPXA
M@TA> I"7N) +9FK%B=R1Y8&K]G@S7M[46E3<@[P"(*]P(;.Z+)GZX2@S\5 )
M^S%FA_5QGLO:#NO^0#Z 1O(!+N8_3"G+U<9ORI5X8LZ,9"Z84[2/"0H'V3A3
MOC$^"^26"%DNF9'YXUX66Z[T'V3VO7:.=N&;L(,POEPBR"X1LEX:S \W3'-+
M)DO;DWZ30D!BB9#-LK#]GLVEUN<VP<EER<F**Y+M6?MH^YB06B)DM[RRK=D+
MUSX39)((625+L[>AFM1*N4SQ]5$U(@2$+!(A:\0?\28VA5<VW];D _F[LF.+
M"C ACT3((OGB&NWCL6+*/L+WS)C_P$'^B) %XN)FJQ!>Y>&-C2%=Q,BZR.J-
MYM]K][.;/=F_ 1@DB!A9$*!N@\0E!NL29'> N@TQ(7?$R.YPNB5GMCPNN#[W
MH2!AQ,C">$]HKZ ^)B2,&%D8H-?"6PPY)$9VB.^UD[<:\D>,[(]W!=>2^IB0
M/^(N"Y'P5D,FB;LL1;XE_FP(Y):DRU(DQ(1,DR";!L:D/B9DFJ13TZ0^)C@'
MAFP:&'/H8T+N29#= V->^)B0>Q)D]\"8ESXFY)X$V3TPYI6/"5DH0;90FP5-
MN6&B"-R80-))D*434)$HX((LDR!;QN<B:_YB:A9&C4)RH=B%RZE)&TMK/R[,
MN3_;0"&Y4.PRYMT<MPFLCPG)A?Z.*;#W,(/$AT)RH1U-@;68?D9!P266S@H;
MA^EG%!22"T66"XSI9Q04D@M%E@N,Z6<4%)(+Q9XB S']C()"MJ'8)0Y8S0:/
M$"0?BBP?&--_A%+(0BFRA<*B^T1FD4+R29'E<Y(NS#!2R#HILG5.\\4!'Z2;
M%%DWI_F2@ _R3(KLF5-\)S.U%%S+1]8,,/?CD'U,2#,IMF:@)8X@!4HAS:3(
MFCFYQ/'KYON8D&929,V\65<(?Y\^)J29M-%,__B:UM:F]Q7?+NQ7:-N>LR)?
M*>(V[2(R3=T*SZXNBHEM6U9SR;;'M[Z.;ZQ]^A=02P,$%     @ T:5A4EEV
M ?CU 0  .",  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:NT[K
M0!2%X5>)_ !,]BW $:&BH46\@!4F%Y'$ECT(>'NB4(1E49P&S:JLL>7MO_ID
MC7WWE/=MV77'<;OKQ]G'87\<E\VVE/Y?2N-JFP_M>-7U^7BZLNZ&0UM.RV&3
M^G;UVFYRTOE\D8:?,YK[NY\S9\^???Z?B=UZO5OEAV[U=LC'\LO@]-X-K^,V
MY]+,GMMAD\NR21_[R^DQG0]R=9K<S!Y?ELWP^")-JAVD$*3U@PR"K'Z00Y#7
M#PH(BOI!"PA:U ^ZAJ#K^D$W$'13/^@6@F[K!\D<99P3)$VP)M!:D&LA\%H0
M;"$06Y!L(3!;$&TA4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%LG
M+]L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;
MZFT$>AOJ;01ZVV2SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O
M1[V=0&]'O9U ;T>]G4!O1[V=0&^?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H
M[:BW$^@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VH=Q#H'9./E01Z!^H=!'H'ZAT$
M>@?J'01Z!^H=?ZGW6#[W>;ST?*_Q._=?4EU.]^;+X\_+[Y.(\^*,<X(?9>Z_
M %!+ P04    " #1I6%2%\C,&]L!  #1(@  $P   %M#;VYT96YT7U1Y<&5S
M72YX;6S-VEU/@S 4!N"_LG!K1M>O^1'GC7JK7O@'*IP-,J!-V\WY[RU,331*
M7&;B>P.!MN<]M,ESQ>7CBZ,PV;5-%Q99%:.[8"P4%;4FY-91ET:6UK<FID>_
M8LX4:[,B)F:S.2ML%ZF+T]C7R*XN;VAI-DV<W.[2ZU#;;I%Y:D(VN=Y/[+,6
MF7&NJ0L3TSC;=N67E.E;0IY6#G-"5;MPDB9D[-N$?N3G@+=U]UOROBYI\F!\
MO#-MFL5V#0OQI:&0CY?XID>[7-8%E;;8M&E)'IPG4X:**+9-OB]Z,IX<TP[3
M_LJ/SA_*C 6FF0_>NI!.S-/A<>]'TJ^>NE2(?*S'/_$C,94^^ONH/^V2RE]F
MI^U]MGX]G$=@P^WX/?Y\QA_U#^Q#@/0A0?I0('UHD#[F('V<@O1Q!M+'.4@?
M?(;2"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!(JM D56@R"I09!4H
ML@H4606*K )%5H$BJT215:+(*E%DE2BR2A19)8JL$D56B2*K1)%5HLBJ4&15
M*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%D
MU2BR:A19]7_*^F3M^J]_LNCO>6OJ[CV?#7^R7+T"4$L! A0#%     @ T:5A
M4@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P<"YX
M;6Q02P$"% ,4    " #1I6%2NFUWJNX    K @  $0              @ &O
M    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #1I6%2F5R<(Q &  "<
M)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4
M Q0    ( -&E85(B8O43%P0  "0/   8              " @0T(  !X;"]W
M;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #1I6%2K1)!DJD%  "!
M%@  &               @(%:#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
M4$L! A0#%     @ T:5A4M8VTY[6 @  *PD  !@              ("!.1(
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -&E85*MA;@]
M"P4  'D1   8              " @445  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #1I6%2I4JCK-T'   B(   &
M@(&&&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ T:5A
M4EK-UP:) @  XP4  !@              ("!F2(  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( -&E85(< 1*N!@8  "H:   8
M      " @5@E  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #1I6%2%A>1NV,"   O!0  &               @(&4*P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ T:5A4A#TZ@S3$0  <C   !@
M             ("!+2X  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( -&E85(UO18CN14  #Q    9              " @39   !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ T:5A4L'Z*#Q=$
MLS8  !D              ("!)E8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #1I6%2?.G9_M0/  !R+@  &0              @(&Z
M9@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -&E85+)
M-;(Q< 4  %(/   9              " @<5V  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ T:5A4D+8$E,2"@  RQL  !D
M     ("!;'P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -&E85(71Y>?M <  /@4   9              "
M@?.F  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ T:5A
M4KD>*&LV P  +P<  !D              ("!WJX  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #1I6%2K5B*6#<$  #6"0  &0
M        @(%+L@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( -&E85*\"+<(L!8  *-'   9              " @;FV  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ T:5A4ID9TJ1-!P  +1L
M !D              ("!H,T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #1I6%20,!4 FX#   *"   &0              @($DU0
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -&E85*OL69W
M4@4  !,.   9              " @<G8  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ T:5A4LIB?YKE P  0PD  !D
M ("!4MX  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #1
MI6%2P%$]VFH%  #T#   &0              @(%NX@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -&E85*0'7+FE0(  ' %   9
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M970S,BYX;6Q02P$"% ,4    " #1I6%2N? 0D8\#  !R#@  &0
M    @(%<  $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M -&E85(X.!;"!@4  %<8   9              " @2($ 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ T:5A4I(T[3(Z P  "0L  !D
M             ("!7PD! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #1I6%2;D=C@0<#  "X"0  &0              @('0# $ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -&E85)X9F"/P <
M " K   9              " @0X0 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ T:5A4O]-J XP P  6 H  !D              ("!
M!1@! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #1I6%2
M3*J2H-H"   2"   &0              @(%L&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -&E85+NS@V!D0<   DA   9
M      " @7T> 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ T:5A4H1DG?>[!@  I2$  !D              ("!128! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #1I6%2.^F3+IP"  #-!@
M&0              @($W+0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( -&E85*?V^#/T 0  $H4   9              " @0HP 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ T:5A4ME>&I(]
M P  <@P  !D              ("!$34! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " #1I6%2B>J+=+H"  !Y"   &0
M@(&%. $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -&E
M85(#^(=V" ,  *D)   9              " @78[ 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ T:5A4LW="\<? P  N0D  !D
M         ("!M3X! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " #1I6%2"W\I3"X%  !F%0  &0              @($+0@$ >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -&E85+:9X':( 0  ((0
M   9              " @7!' 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ T:5A4B!@A],\ P  30L  !D              ("!QTL!
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #1I6%2@6&$
MYW\"  !&!@  &0              @($Z3P$ >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( -&E85+10S?W- ,  ,@*   9
M  " @?!1 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MT:5A4O0=E./7 P  Z@L  !D              ("!6U4! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " #1I6%2'*P\3*D"   ?!P  &0
M            @(%I60$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( -&E85)0W!ITVP,  )\+   9              " @4E< 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ T:5A4B9';IBR @
MQ <  !D              ("!6V ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " #1I6%2=7.3*@\$  "I$P  &0              @(%$
M8P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -&E85+4
M<0,EUP,   (.   9              " @8IG 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ T:5A4D*]F^"M P  C@\  !D
M     ("!F&L! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
M" #1I6%2]?I$+$@"  !>"P  #0              @ %\;P$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( -&E85*7BKL<P    !,"   +              "
M >]Q 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -&E85)P*.\ID 0  #4G   /
M              "  =AR 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #1
MI6%2678!^/4!   X(P  &@              @ &5=P$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #1I6%2%\C,&]L!  #1(@  $P
M            @ '">0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0P!#
+ $P2  #.>P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>407</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsOFCASHFLOWSParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Nature of Operations and Business Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</Role>
      <ShortName>Nature of Operations and Business Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Warrants and Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</Role>
      <ShortName>Warrants and Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Stockholders' Equity and Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization</Role>
      <ShortName>Stockholders' Equity and Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Net (Loss) Income Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock</Role>
      <ShortName>Net (Loss) Income Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/OtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Significant Contracts - University of Mississippi</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</Role>
      <ShortName>Significant Contracts - University of Mississippi</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Related Party Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMatters</Role>
      <ShortName>Related Party Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Warrants and Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</Role>
      <ShortName>Warrants and Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Net (Loss) Income Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables</Role>
      <ShortName>Net (Loss) Income Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/Incometaxestables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/OtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals</Role>
      <ShortName>Nature of Operations and Business Activities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Warrants and Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails</Role>
      <ShortName>Warrants and Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Warrants and Derivative Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Warrants and Derivative Liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - Warrants and Derivative Liabilities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - Warrants and Derivative Liabilities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Warrants and Derivative Liabilities (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Warrants and Derivative Liabilities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals</Role>
      <ShortName>Warrants and Derivative Liabilities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Debt (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1</Role>
      <ShortName>Debt (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Debt (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals</Role>
      <ShortName>Debt (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals</Role>
      <ShortName>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - Stock-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails4</Role>
      <ShortName>Stock-Based Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - Stock-Based Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails5</Role>
      <ShortName>Stock-Based Compensation (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - Stock-Based Compensation (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - Net (Loss) Income Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails</Role>
      <ShortName>Net (Loss) Income Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - Net (Loss) Income Per Share of Common Stock (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1</Role>
      <ShortName>Net (Loss) Income Per Share of Common Stock (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - Income Taxes (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals</Role>
      <ShortName>Income Taxes (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0057 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals</Role>
      <ShortName>Significant Contracts - University of Mississippi (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0058 - Disclosure - Related Party Matters (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMattersDetails</Role>
      <ShortName>Related Party Matters (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/RelatedPartyMatters</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="skye-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0059 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>skye-20201231.xml</File>
    <File>skye-20201231.xsd</File>
    <File>skye-20201231_cal.xml</File>
    <File>skye-20201231_def.xml</File>
    <File>skye-20201231_lab.xml</File>
    <File>skye-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001640334-21-000483-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-21-000483-xbrl.zip
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M"?>TLBOX_"&,5C@%A=?7PGMP[@R'S$<>SER-QI6WHC!1:0V_,]__GR!\"NZ
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M#XRN65&BZB<I07([NP>;]H,?.K73=RW]E>:RH0<G-/[;*SW=:: EHVN9W?[
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MA6L8-3\O2!)XP.*VJOLG3Y6YM(*Y] $9]S^)<4NI.,I<.E;F<S77^T/6#:H
M'HJ\1!;KF#T>D2OQ0ON0?^QA&LN(<EC0 84-7G]P@P:[50]%,\8G\J/=\TZS
MWJ-P!#D"#(U:NWJ\]WOD!#%ZVYP,KF?M)QQ7#E^Q'\"F:/QB$"OSK(EF9#@R
M.><<]Q%DKO/ L"LYMY4R5IC!D$^("$*-"I:,;:P1)H?WS+UGR1.FY8@QL+.M
MAU,)/85G5&7GB#R9%W2^N(LK8<-Q  H0H'HF] +QN(SK"6863?!J/YI]..:,
MQQ#">]C)1^?>1WUL.A,;./&"RI.SH/(L:!GR)&,/! (HD<\:=\41]*@M^FBU
M">\IOG>&OW+=BC?5C "ZY"GDQ"+T51P@FS WY'PG3D2/Y?0Q&;(S_*X9$:]7
M/[?+-MU."%&\JSS=RQLRWY]B,_+@(?L;)A^F?XMYOK[_OU_/+S]>__US>HJI
M&RP=5NWK]:?W=]KG][]K7VX^77Y^!>JKFXS_]@H3YUX50!! W(?N<^ES\4V4
M3@AJ]<,X>6UTR@-DC[KIHS3;Z]Y_O4)L I\!$1E.ZUYKQ)UR0<[]_2.>%,U8
M1*:'^4?QC$B*7N*VI+R!I4AO6[]G(D6X_.K%.4@NER=AD.^.Y6Y"C.)DL9U'
MQ_.)_TUY%G<:V<G:Q_\Y"]%<(8D;UPT'( ![#Q+J.2Z D22J=]@Y&9LY)/SS
M: /\O7RF2M)MW@%=_M7M@:U8P0:ED*FDD"*T[?Y^4[$^?N*) &#C!9I0AHJR
MXN>E1$@,9HSO1/4"Y*PZ1/HNSU(1&0MBW*)(6CPX_,T7(Y:6C2G94?#,T G(
M>1Y&40C6 F6EW#_+#PG+$"P_1\D\)?,4*]J>S+.4S%.$MMW?OU7]:+EHB&=3
MD7)XCT':).$R(@A3(2 R)IZ%/RQ]38H"TL5,?@TPS4J4?'0BBZ-!9.5I):G=
M-L'KMY@MY\44FTQ#3",_?-(F+!F';NB'#VEZ9BH2<Z^DDECUK)]_6G'/\8^1
M-BH?;S+SH1SVVG6,HC%18&$&JY?5_\1X/0;S1<B 3>4\6%%D5^.5(K2L5(1(
M2:I/!<V.PQD1_1E/L/6RS%_,%DU#]E/GF?N?<;;;VUO-#QU^J9DK@<-91-FN
MA=A(NZR'8LZ#EZ$F9O5XX+D']8LB=D$3D'_>P?@)0$:99'1EC2?6XM]"(F::
M.1;?U:R?+VH/P,N0SV+BWC4AUZ9=I,D6-7P8HTAH>_!@V%Q*?0*;YZ_&6;_7
M.QM8?3YB=F;RF]04),GB3K#'%6#X2%:_=Z;W=")1+TO_)M?>51@\8H( &1]8
M8^7<C9RG-)CO9!"= _7X9+!@U.KY3 L8@9 *B_RN5LT1+J3AOQ6I"G>8JA#/
MR5Z1<U;R_/!ZY#9BDJ<KX:N11[D[%$R*$\)RRD*D\=*)T.JLW]VI/^-0!&%P
M/I30EVWPQ'%1W-,R\(!Z^6U]'LC#39'B9FAO^B!D<7/36!=WS[[6?O)^KDG>
MJ:87%9*#> @5(/"2+"_C"?C*V LPA0NMU3PG]9F!$ ]A%?3;&<S(IP3F,7:
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MJ_Y@F+Z'T2E4N.G[&,F%&!JZ&R*Z9B'4M;H9B#WPO'[,EZ!;K*B-XL5IRI3
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MCJYKU_@VSUC>&%8 :#1K"HBAD&[1B"P5Y]L$@IXB;(D#&LDL2;4*.D3#5+/
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MW-R,I6*SF8KI-C2C"[Q5XHRD;9CH0&A;-6LF9U4.NX*N1*Q_ B')\OS/0E]
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M2>-LR+PO>#/,DZ!G+@\(J[A@A2LA5SHSI(+9"]@,AB77)?5;BL:K9+)6&2A
M\_]U,.JB%XF> ZG,P\B8CR&-:89<RR5(:\"JEHR<\%R/-F)(7#L:#V6YLC5.
M#^DU5&)V>'*17:L>FCI4)3]JU<LH+\)T6OKK[*V5<%<T1GK'^@#7IH@T&4H-
M\1W:TI?Y!"YQ$-P0T?IXFEH"B'-(#W&_X/;,ESQ 0N*$$3N96)IU@_6"(Z]
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MLU7+U$Q;T?2SMU5&[L#9PBD<-1G#Z?7F:8WI3^JGK'3 CQDC-1[1P]O EA3
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MQ;"-H5Y2EZ9MV&:W^(F\9\)=GSSG 78G'JHX<MH74YBJ:H\J7#VL0K3\JBN
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MY:  )Z\_],%^#I*:X_W<'<T/^7,_JINP54&"36;/9(^IBS/D84G>U'PXSF'
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MBD-FR])K59<U^$?1!RBI'Q)8,W4H ('W0U1A<??1<5UIS.[1,*%6+9P 2QR
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M*,'#M,X6M($!P%P;'=NQ @?E!4'^</7CO?0CLJ93Z?_R4?"?*T#97S@3:6"
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MYZX2%065? +:SOS8M4O40K5"_8*1[N'_/1:6/NWBIY/90LQX0@T2=[CHNT^
M&# !)3.LM0EXK9*MEHK\;UQ"H\3/6HIQ<M?G/G:$S!;F^B+)TQU2]9,'#I\:
MJRDZ57&VOZIFD-2@%6X%#&0#?#( 7,1QB=?%(R!\U@5"06"4"HX()44<>2GB
MR$N,(R]Y',FGA!#& @!@B'B!(48,DHP.*8X&2+('"\>Q?B+V5AS-_  \0Y#X
MYX OQYL9G,X40UL,XES4 1[46I()DR0'SYGY/I]8QHQ'5BEPRRJ&T&6\2'RR
M,+\"WT<5X5\54^?$A?@1[,'$$K\=;KZ04C"1@7VP7#QF0B[RFB.&4\P\\='@
M-A[N _,4NJ3X8A18GL"WBY'7P<#*TV=@_.J_MOJ1%1 ( /CW^;M77*I@>G?%
M#)&:T]R/0@;!Q,/_Y.K 36[L%:2QI+/<]EMATC4W%#US$;PLU5?Z<1RB;MF<
M=ZNL8=U@JZXF"<\C=_M-H%C1[W?-PM:ZC.O*!JA[2,BNS[-7U@$VSA2_'&@O
MVO]WH[3Q03H =Y91JU=Y21T.J0XOT>1U-W5HUAVX&6MV:O5*@M0U06K2+_B4
M!&DKX]JPB*9)&4WC9=7?5GK#<L&33EQK3 7N3^>:+W^_O%W89R_:W>J$35.3
ME>':DRM/C<)=@/&%I6#35@)=(/.^;.>ZZO&#VLZ_!;C%/%V)ERXEO@3C1>F*
MWJ8MD\Y+8]H"8T/S.S3EH4KFEV"LA?$LY_+..[_"@-LL,>#YY*J_DQ9@P@.R
MY'O<K=$:V)N>&2\/M+5[-C8)6?>Y59/DJ$VPCVJ7(8X"Z'YVJG5FWCB:X[\N
M:<)$7=39I4I:L ED8Y!VVP:BZH:L)IU1M@-L/YM!R!%OPO,3$\-B"''20KAZ
MLA!W:I?ZQ:W*WJ3D1EU]Q/&V++U\;9![T+J<C]-"N9<L>;['TO6#-:4WC[QB
M,JF-6[G9J.:00PC2('C$C0@/+#O<$*MX7"R_L\+5@V'Q<=T&HX#-L::M<$JW
M)?8FU>S#*>\2L'U6+%:6\%H(Y.=E9UZ4I0KY1H8T[ S7;J]:1S('RPKYJQYP
M6HH>F0LTF .O9DG-9WN*ESI6#5KDZLRR<5N8-9D$L>4F6\R3XD&>(DAJ!Y?J
MS\M\?&^YO##QQXRAC*T]PIW_@162*$K%TLE"R>)?2U]VO&KY](^LY!W5#X$*
MV(QY(>K)!39'?9-L_LFVLHA*_Q5;T3+HRH6.__G7.+R\MZS%6S'8G?7S)BN1
MO /BOG?]R9^_XI/I@S\F,V;'+OLZ1:!\;+X2?IUFK]^*:NWW0K_OT(AGXV#Q
M,W+L.YO^\NKZ#X1+414U\O$O5=/55Y)C__+JP\]QX(J[NJJI0\54U<% >?5K
MP;IO?H(]U;KEMZDFHRNU;O_$/6>W7)?KG,159-CMHU1:5P::M.]L*Z*HM(X$
M:3U:5%IWVJN+OWE.YH>?UZ)ABPJF+OJR:?9E;:@<$H&36ZYK$0=56=44V6RV
M!-M&&N_+H!UMV>N#:$UR5J;L%->M&UI031ZJ:[M24_T#R=$F,_% 5D;]-@E2
MYUW,<JSP+6DR=N'R[&[::2;PY\6F9 ?+RW1.DD]W=9A[O2-0M]K8\3 +Q,]#
M]68'8$BZVB-=JJR8NFPDY[%1]<'R37%KG]4'^2K;#HMGI46XFV3AFV<GKCS[
MDS^QW!7#;+#J9K.),[?<D*]SE9;@5/C?$/<KZ;HY&OQ17IDSM(&A H->2;'G
MB/%_^W'SZM?+/@3M$+/G>#>!=W^(JJ,4476T&Z*ZH@QT4UU&5(78%D+;/>*9
M!&F'8.4S/-,@3*@BLAZ>?:#0A$GKN7'9'X"'NA,.7]-N=KC"?HT- :=^\&AA
M6^ JZ3>$UM0,S="U96AUQ1B8?7.0P[OZX]O"*"CZ1QSBBQG^5VD;J*N?3IC<
M3&ATC7UV@J?/?!EP W51^H9A*D9%+P9:'_ZK'!(W0?]#X);RS=!451DNXP8&
MPA@U1BR51021URFM?J]D.W80.X#3,&K$3E>5_D"KJDE3T+;&3U1FW?F@AXX(
M:[; ,A7 @09S3;\B@+JF J:#[;"L LAQ#?]\8CN.LRMO,ZS!AAOF:M[N&]3U
MO(8_KN&W$^UJ,=-)6-%TF(V6T1OT^_HZN:T'8QO0O[.0\=ZT.Z"@*\-112X-
M<!>&C5%(P2FA4OOH)V?N1")3\-7[+61;5ER!(.F#P>#5KQ^]I&^LB[UH"UOL
M)N_\1[@>SIR%-)E9WCTK=L;&PDT;)M>D.?:/I-&T/M326M)KWV:Y@R^:O(<B
MV6&)MGR6>,</>*D?$_TV\QOP^X$%^/ L8.R2]VA.MON)T9(6@ #U,J0X$N_,
MS[L7F@J^ARNXUCVVY'>2DCN$TH\C[*EOBR[Q6,&&?1^EI'=\L>\WORM:C(>]
MG,$;,6E%>5U%.% 9'=&P'^BQ76G=T%+'(S95+C6;#2]5E5F7EFT/+PV5V4-X
M;L"TZ9:%=ED<AQ5QES\^_O>MJ.;D/S]<??[XZ9]OETKDWNU0A5T(2X]<R<=A
M6%''MS(/61\3BRA[3:3[4B?6M.%,D^/4[6V0PSU(A[J.,6=]:J6QR.^/.:L3
M[-=)?X^:70-_O7!SR_KF;8,L>\?8=IPBJEUTJEDMWN;LV*E\BDQQ^\6F2>5=
M]\5F"WO\XJ=!<H?KXY>;VR\) "O,-@\]"R= GO;Y>WLMUBH/W6R92-?7+N^?
M"DW;#1UQ?#.:[L?>'?3H<BG]9YVMNYKC(8#_P],!9R[ZQX>N86GK^JKD+B%.
MT&T/W6%:@+:9 J?D:V:I?MP@;;,'YOH+?A;HA.=MS]T!/3YT#7LS&K*N&:>"
M.T&W/71DEI>@;H-+O+%9_HH'KYV!E+8;NF8Z--1EQ>QL0$G0'2V.4C59T];V
M4VXS\J?D#7^IG.A[!M*ZQ\U=+8"ZF>X-Y/Y@)&MJ [.]GS:U9"M)^M[U94,W
M9--H$+"U7OJZX(5O5"Z1MM>O%$MP#/=='-$J'G8+NETV@PWDH3J05;5)*]HN
MT8:@VQZZ7>2J#U8=Y$HY%;GJ@I._PJK_7NU[>P;">\YNU<5 -D<*>/7FP?RJ
MK9HUD.QT0';ZLJ: 7VXV6-L^K.R<C$/]947'\O/SI[=1L/UV6CB$ZI2AT;2^
M/!P-MH:I]8$NB5S;1$XW%+EO;N]RMU[D7LH+/[ZXMHON781N]<%N1"B"CH2L
MW3:Z!>[Z3=%5+VP//#]WO0O0D282="1D737W+:E^\2,FV4XXP4Y1)\BK0\7$
M#?:G[:NI=2&YTH(4);']9=A>3'!01J-5WO*='UEN.;U]UC[S.:\AE27CXH4S
MX?OM9$TRUTF9HU1X"_SN759%SWW&.$K_^0T!VD4S*QOM]J"=6[:?/]N8G23O
M="5OU;P@KM=TJ10W*L<=\,M;G&O0J&OI^MZ\O W4'7:!:M"'5U-5O=*/7-=K
MVL+7?&=K>%:WK@=XC$JS_4;PU/=R+O:-V:%-<=\<ZJ/!'[544_$$A^>_OBV0
MFY_)D -9)>6N(%Y;"P<B5^=_F)VV@@")O<D;05S[8;1++^N!KO8'_3^:$-XT
M=,U8A==F .\?X\W9]2S&#;C8 -O5G=YQ+WDS$](?+$,XU!5SG=+RCVP#QUK3
M,:@JI:K!?W8$9!^G7 !TPPIT@_Y@I*EKZ;3W\Q*:4714.3:D;^B&:1@'@%GL
MH&I"4KA7(>E0'0#3UX#'/[,-).L(I55/ONB;Q@"4>3=(LMT(5^EFA&8$4H=_
MF+JB&<,JH<P16!IS#7C5;^\,ZUH2:L8?AJ*:QK!B3?J:TC?,F@.2MH85P^AM
MSPHQ$513J4"I:?WA:-T9&O#1YE!M>LP/0&4.^WK5>3*4OKE."E.HEF>4@AN*
M*WTWR4+?UF3KJWW=-*N'/*1DV_#[.\&Z*3'[&L@;_/\J8C:!M8;PA<=W(N=0
M&59.K%DCA87/;@/9YL0;PG/]BD%<(XD;0":$M4CHK50X=:]&1G]D*']L1M-U
MEJ<,T4[0;^XSUD._@NY;0I\'J;?3*1Y)\L"R<Z.^0\CUG0'\$WB9V]UMS]?0
M%%VS#W&^!AUS<2Z]U>F8B]8P9XME%A+YS8'JT'$"= I%>X#JD-C0*10%^-N\
M*HVGPDXB9DL.]PGY4O0X.;/6BJ0IL_$8/!C/BN+(#Y[X P&XC6>P0-B: PLN
M5%D?#&1#50\'_,G4>;:&:YJFREIB"#M(U_T8M:/4:(J3='*+QD(9XKT(W??4
MH"4V[LRMV/&A:V@(#=64-6-/.G6V9O#XT#5ENV[(P^%Q9K\..W?7XN!?QY.F
MEA/@!V)^#/"C%0261Z<\'!VZI@VN--DDX]=YZ!H[_\,!F+^!WF'S=Q0W,#=_
M#V?9#+#=T#7LEB_K0UT>]!OT]FLW^@3=]M U%1VC/Y+588-]L^U"O\,>Z&]@
M:8/( A.,><.%'SIHA<GQ/#9TS33(&"CR4!^>"O($W?;0-10<O2^K1F?G[)/P
M?2?^?('@2#8+G <+ZW_.0$[;#=WYG=)'T!TO?Z"H<G] R=.&%A1W/4B^)\%=
MQ[N/G7#&#\CUIV!(Q[1P=&SHFBF!KLLCK;-^"$%WO$,:![(ZZFSDTV$']D<D
MZL_G"^:%/'=[!L+9;N@:GG)GR-J^UBR.CSM!MSUT#4TNEDT-S[QLZB@>+^X&
MDBP;+Z&K>P:2V6[H&L=Y0[E/Y0&=AZYABG4DZ]U-S7?8015]+18LF%L>)@9L
M9SIE 3N/TH)S[KFH:7+?/%P3YN.3J=W0G;/HX480LT$FMPM'%+:@&>>WP']P
M0BP/F_I!:=\ 1Y'Z<9Y<5T15[BNU.UM/HQTBB1R)7$L\>7']\!TXFS<W*75)
MR=\JO9%=QGVR7LC>BVUC5]$'L8_L1[HOMO35#=JFU';.&F+G+%TQS$J'N4M5
M'PP,5<TQWRO +T@*=9228FT3L>'H#U49:H91(86&[=!&1R0$WUV(_5W]B>5F
MS]2V@-J(ZZ/A'[HZ&JJ5CEJ7AFIJQO.HK@)HK\ALQC<07GAVV%='561T8SA\
M7H#7(L/[=6VBZ5]\SP;# (^!QB<2($JB/GH?+"? /G-@-/XA-D)MQ;FE7DZ:
MKNB X1]K&3K03.3G@=!X41)M(@\K2;1&3-3AP!@.],,2Z1D93-_>KHWC)DJO
M:Q7,57VH#_KFLPK2 +A#X[JA3=#[?^B&H5?;\*E&?P3\WCO*7'16C)55I,.=
M;VD]^DX&0'1M&RA#U5"5RG1EP U]F(AS$YCVA$D3/4TP475CI*E53/2^:IB'
MP"3E[W52JGJ35:KNQ3(;)@B:^L=F_%+6([@:U'UBN8UQK<=R!2\O8?C^0-T)
MUU1I;TL%<M@+?QS]#40 "^BRD?>B86 L1KI9;2L_T@IF<R-P]H# -HH%$: Z
MJ#2<5>'.:+@+!BL86#<S_IA9 7MOA<R^+M368#_Q;:<RH\*1OJ'A#+Y7Z%X
MWPVG,[/25U3E <L1$.9K4%?9BOU^YK&1:>C#2O]AL!C#_@;!R#)(>T%C*UT#
M U=MEVV,='UX$"3JN+OS]#52%1T;J"IX@D"-IFE:WWS>?ZH#;6\H-9VKRBA5
ME>D2+CX?)CZ+4M4U7/8>T^GM:KZB'W9C3P,/*1CH^K.>?5/85O3S_<T+@";W
M'AX3 2\F&8[PN^^Z'T2G_NVZ^98U::B8YE!1]6?[]VZ56*P;;-75)"=ZY(;
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M),VL4!HSYDF.-W%CF]GPAQ3-F#2QW$GL6FD=*EX"?!SO/G;"V1RSRZX?AE+
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M!)'A3;0 "'%" _C(F$6/.-WP^22#+L<W1,O/@0TGS+,"QX<KX<K'UW!' -&
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M^EGKW^R"K#K$@1%9_$OM;X3L*EORR;'&C@MN_DJT1@"_9@Y&AJGLS"< 6,U
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M5B1H:]/P2GVL;ED2L/3CU&;(*@-B&X;JFK,3A\X'QJD8D(//W_L:C4KXW\I
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M;E.O!&E!"T=BW<1_P ?8E! E1=M9H&1K=;$E;$IE<J*_,$P.X9(=C<1F=2D
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MZ7>&?AW1UB]'MHZI6SU(P9N29_KE07/?E'M!>W*CG]Y)@9>BG_H>;O<<>&4
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MSZZ)G3^1F:N&JMJLL[,^.Q8$^J9$;R:7Q7D#52:B^B@/BS?UEYK>_&:N+^)
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MOJ012#M?1 "^7G*E#_$#>%-.;SWV7%E((0;A%J#FD\U@50I/"&L_*M).9_P
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MO)&62R\/@>0,SM)D$T;>7ZB5&QKBKSH3Q>O"C)5]CR)BD+CKPJO>S=Q\5=!
M9BZ+M,_3)$Y<K"J#=4X-:]DW&=.9FCG*2#SKDQO]@9(LJH4)V7M73,*YG9RI
M/5=<)\R7_1\)\F'9/I 0:KR?%]&:-?V]OEV4NT+Q(O*R>6]C>U>&MWE]K4'P
MN+)O:_'Y!T0L)?S[RS!((GP:8ZN*O((Y;6/-Z5-CZ5);IE!R[7>51IBN//J>
MZ[ZJMMDE,OG'B_)@-B_#-4Y5%(<'\_!I\W,VK[693Y.S-TRQ5.ZQW6KAOJ\D
M8=4K<GV8C1X^-S;MEYW>QVO5]@K^-%".94G3W;^QA[="7I?J69("Y\S>,U1M
M<-?X#K@5HIPSF G,QL=3>T]O*I+@G/7+MY(&\,&R3"0)<\X E2-1EI)S9L<K
M&E#QAC,K'E:)(4#1"UZ%]-DMM7C&2/P8)JY?_?ME&">?P^3_4/* %N$Z('%&
M0=BLT^\[9U9\L-9XVZV=,-K]BK3CK=EN"7'.QC(D8QF2\?G!\?G!=IFEBY8'
MBAOEPT;=62SS,;[/"%\#U[![/2D*PWS7[0C?!U,U')-YR(X<0!#>]=!&DW7J
M6Y*+5H17&89/K@1K8@@CK,VKRP1E:[.PDO!V=-NS?.J;7HC.[%V-EG.FLZ<.
MU82E )HP0E$"$F!0F/RW&9'1PH^.Y1),(TE/J"""$83J"54XD /&GFJ5@S:
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M!'+C]C).VX2_PNKMC']_*OG]:?%],^=*.>Z9Y/?/BN^;*8C8RMJP6#?VA@0
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M>3+'NT+.P.*M4\W7X4TI.] 7DAL=;_1T!+R*'PPZCYFI)3%@*6P:@?(F6ID
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MXK'T8_-8VOKL>C1#@.3'-M^P-,[R+V$:WM>I=:LK9 Q^.6'%/(_7IGOH 2Q
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MF4D!TD#;[!?2;?@DZMG=8&50^$EY4>U -7LW-'?/GH"@RR/BQI,D>]2D$AM
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MK>$P:H+9^Z%Y!?<2X&@77TT XA-%);7C$ENR-9DD^:)SX!S;:. !($G\R:Z
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M $"2:(_#.4\"BFX_)D<V&SX[$< @B>&0$E5A9TZQW H"$)\FFV]7FE;B;=?
M="LY0".)N)!!\RW/R#G0?IL&0)!$3F@% N_/*9.F&P. 1Q)/(:6[RK,%*PJ>
MYADSYSH/E(80X)!$KJK?:0P<*A,U *-YL:+.PNV6V<Q./'M/DVM/(YG6D7&B
M S DT:&JW++\@:<HBRZ*2[GE73<Q '@T_H)#5OA>E%A3;0)7B#,68HXJIP[8
MK0GH(AI?Q$%^'FEPUP__OF9_;N(B+EE5@XR?Q%Z+1W/X@>WM\KZ;ABZEKW:
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M4?;( 1J5I]:331DL/0B=D@, I/*Y>N)55ZQ2M\:BU+.9?:3)M[LM8U-=S;5
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MY"C523CL^FL %P!*XD=4Y=*Q=B1[8$G&5V9[Y@TC'8 A\22,0HDPQ[&0!#4
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M1:M:R0A5'\H4NH'&6Q3I(42^B.J-[8"<)T[T ([&7X1-.NS*NU$CUELE Q4
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MI5L ARAH]?J&^&V["ZPA:KDU4G0:*2J-54&@.4^/5J=+4[Z&'A",9G@%+;N
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M]?RVB6WB*5;C]"%+'F"6E(]9 )9_E>6,Q^307$UH4:E53(&*>B>G Z#6KFT
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ML/,67!E<L4,\Q70TSO7E0O/";R)O%+K2VQ>VOFGK37UB105-NP9U.WC+_^?
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M<KI8L#G(=!8ORN6A**BD]IC$%%E(NH!)PF"!E'4M)@(]LN-1*I7 4]$%%6'
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MD9LN3,[3^1LO;PQZC02=5GABSS>4#Q"&]H%R CE G$[JS*&(E?-@"&(Z_4Y
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MJ&:1%H!ZZNA[GU*9A(K?9H=1%(N8ZJLPCL[3XW =EV&"/NGMDBG=4LN2W[P
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M+/=%\.U+@/QP]KX^ 8[\32G\$ID&@FLKK;3,3?_RVCX(M4K)OZUJG,B"1Z'
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MIU11].K,4T<VW\Z6*+M6OR0F_9X*:;6'@OA%AMB!Y""SEX+4\\@_+Z_>%#7
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M;+&\24#OV?,-AY/!;:6-]HXN-'.XN?E!RF<&-Q21P&)=2F%S/8%@GPYHZKR
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M=V 2F 8QDU"/.Y[)&=3TU[0%,_;A-&,:TTX#/\OLS@JF/N6 >,[,J/9UNIJ
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MHY>>N0.V3EIKI4;)+>[NB,<=]?S,@18O^2=G+>[Q&,0R557?7\15)+XW@EI
MGJCH!#\Z)$2]:/#251'#2[C*5![XJ;1;*C10U7J=<''8Q1)BC9JNKR[%$QO=
M0D!8 <"/Z2._)[EH<^  81^4FE)93:EPSX\ZTI%.4:@#:4L[,^>.;3)U+_5$
MW$O]0#Z=JN!0@:+8X+;.= X^TQ452ZCC<9M M!-,6F:H$0TJCPEQ/#T& H^D
MY%N"4$27-(J3&#LFWB/@N(D"K;!<#S2>2>%)3O5[FPPH6:([SQ.N?5D'5>+X
MQ+Z*7VF27N_6D"&QE7X(4,,1HLNVCFRL"ME6.5)Y#_()NK3-/1%B5@6_$A<,
MMFO^\!D\$#?9XT1$-,@RMOP3 I?@#=]&&%*8NAMV^R4 \Y'_/0UMZV-;E'53
M[M5^228/\OVKJ>G%.8OB=1"1^3"'*@(SW)W%;:WJ(9*1DOK(8"ADS))W5BMU
MKU_CDI851PQ#(7<=/9B\SW68!0LL-2@C1@-8;K)=R$>P7'MB"/;4P<&F/$G(
MP6%&W:4#S+9W=%" WUJGU)3QG[NZ.(:I(=W6S"$'D4<Q)>PB'FLFL-+Z=^&.
M8_1D!S'#P+9:]X"QI0\\&H:[/6)Q@DEI_QKS#4]?^<NRD#1^J:0H-<X*/S+9
MU9+],*$7X_1UU)ON\MHSUI9.[]0 -BV9/Q4XI/AY)R1T\IF,J(,L\99MI).>
MH]RZE8875\GEUX S+V%K-Q!7XQ^2P.?3*9S'TJ1LUF/ LTP7SP.,[?N:9.;3
M!@.];U* 2)C'^'C[\C2_?NW1\,#T3C.M!X:9"G"LABH''[S(O7#'O!QRQ]],
M=ZNF9Q%Z+I''F)]><LD*[^9BV<R*S_<>\@>,_U+\1%-+0G8E1W/'G0T]ST0<
M,>?N/SZ<S-Z__B V'Z_>O9V=_/0:?EP\Q[F09L*1"KE9Q5-P&#:#&F]P9L;Q
MA237J?=4%UZEHJZNNF=YJV:"@%_U*'](6"UE+PV@:1O*:W^/B8CJ55V3EH/8
M"QU>^:(^OEL%<$JF3TEBGP5?YGPZ\\6=P-#%O>+E$PX\0C 6NV*B"4N,B]FF
MQK.8@Y@_I%GB>II$&/"$\UOQS/]/I,BFH.@-UM@3ET1E%(P\L;J*EG&REF$U
M9B&T*EE&E%T&J>>&_V)N<A'YD X:U[=\V)%/._ X5"\2^:.I=*^3']T[32Q_
MF^(+2DA9Y#GA)?\9?G!=$DB)+I]W1 ,BS>L!M%K 1 #ZJQY8T%_Q@C/VJ+T2
MOH_2S0K?1^4W1=(Y[1Q3RJP80CR_X(*W*GL"P?NH^I[WWJYA>()8K4+(5FV:
M$K)-A?(+?<9?G[CA%=]A?OM?]HSJ4GW+U:..>-;A#Q.I%1<<O:8XH> ]5#VT
M+G<A/E(CVG2]R_[#,+12-R&H'D,DUTZW;!,G<('D+G,SS3>SP*%66V431[:A
MD?\\!H=DF[R_R4<F7X++UU^L6?+(E?1S$G_-5A _[4:M<T[1P)$M'-6$2/IO
M]XD;R<2H\OO7*OHWIWI<?2]IY+X,0I:<\:_T8YRT:EL\Z!1/DLXK39E;)A+S
M,G<K^"K*&&QL@R?&%T-N6UK+<E]<MH#UDVLR0V*W_#?Y0QAXEV'LM@HM'W/$
M<S2"WK+' 'P(4?;)7>,+/R5K]:0#CY)R>4OJ%C)/('6WDN]6+ Q[S,WB.=H9
M^6[MAN%IG@81TUS^+62%!YWB21IA?XG#/,K<1,YMK>*6C\KIC4C@7_GX_F\4
M?XWNF)O&$?-%9#=>:TP)#DU>_@YMG**1C-*?-&,X0+AFCVXHI9I_"S0WP^&9
MPE7Y&SQ&Y5W=EA9-TO[1>7?R[@3._EZ>)_FC\+/R'W[XZ<V),X_<,'YTYH\)
M$Y?0)J>,.)GDXK]Z_7 ?9"$^.8O?P,G4J]<O'GYPBC93R\K79;#'N'M>/\0A
M+JA\PI&/$)&B*29&"?-BZM28_O[,OLS#!S[U?^3/>7GH)K<L96[BK:XB[R/3
M5B64C9RRE5,T@W0'SF^R)84=]H.$'B%]O+V:7/E0J?K&#1IW<"[CCK,D*,$-
MC9JWJAS>SBD:4FF^"P^>0)WCV0 >7^(IZE,XRSCYS\F'I+A%(:>U@*7:+T]Q
MA:)ZU/G--?7]:9=9^2#A0K+:S)1'=JU<HCWNZ\.H7M".YR138+KFJRI6?N5;
MIEGQ8+4>()]84<$QY6\)/KF&/\413"MBA\[2[$*6S6@U!=[$$5-1T<A1K0PS
MI37.I@\8- \9I),!,$$!1E4.F7X^A?!2/JM_C'T6:J=2]9 CGC*XBN\M:8L3
M=DM6 E^LD/8N>(R"9>"Y(F&\H$+:2O!: Z=L03D-8@CNX7[.$/%%@^EE+Z*E
MX2867^4\N>(F4U5QJ'4DRF#W.9R\ELWK%8NHQB7)OIS&D.=D>1XDS(,;[&<K
M-^ ?S:CE.R6:P):P;.04K8Q^L]KGSFXLZ'(T3M=NZGSZIW/]_'M,$3S10W L
M@))J$-JX=+8*V/+B&U\@ \$72VZ_+&DADGC>*1LXJ@4MB=I H"O/Y)_.:1)P
MM=_]T_F8)YL5Q3%,E^1HT10"]7?2YS*(W,@+W+ O?<H&%M%' P(]1@B#/WD/
MV<HYY4LW[\^9<W:YF%KS'_E&=IVO6W2MGJ#5;5-,3)OJ"2(#;,J'F9Q!^5K'
M-XBZQE<^03R^#3'1\95/4(UO0SYT?,W)US:^MY#(3KO=@O"6(,T""+7\R+?J
M>:+\"]-OO I96YBHE99BZ\7E%0<@B^55Y =/@9^[^FUM>512/4NDXQV9?PVR
MU2W4$80$1JM@<Q]W1A^A: C&H%93%>HL@*,Y#OF>O&/753WN%,_3^C=[X- 4
MYYT81\^!*'('=]1$%H]6>8,-!LT,T_^V^"VZ3Z$X+SQK@;9O93'0&S?)NNM1
M;^E>M7548_H:K[VP]1D8BZJD]L*D*63=Q)3%]"6$577JFJNJ3PGT1BUN"TBF
M@8 >SXLJO+%(>>XJ.(8KN0^K*8[@:"N+;K*$^-[DF4=^E32^+Y,($=PD\9*E
MD/S1#2]9/QNHMW&@D366H$.CF6BE"8BP*T4FPI&X<T,WV8=(14-JY;<"P.\Z
M%V594X,0.M7O^R(HW@TAWN,J.G,W 9\H:U=)<.V7S60(2P"'KJ+EK'&=A'):
M[4:&#DN%#()97@9P BM:6C0\;2%=S9%Y68T,9=A!/SP=XR'P7)5X:,;CWWF:
M@=NBRK3TLRSP<1DG=RQY"CQ-*O"J:2-1EFH-05).T9YN+NL'#QNG7[9K JA\
MTK#:W7!A5Q!)HDE@"=B].$KS4&R'4X-JZ#_ Z7VLG4(:68/ !5,5>+]D;I9K
MJBG4.@>UM$^BS3Q0SM= 7+DJ2\.K]UA E0,5A9'IE$5L&8BSGRH_M[.4+9Q\
MP_\1U'+K<&*"]^1L.\F.K0025RP?MLN6W+(_\B -,J;L3(9=WC(O?HQ$+\+$
M#B66KM(.>!'4^XMYJ(A(K8E ^NDPK%AM]0.E+:]>EXARQ5Q7!*"(O"!DC9*"
M][&(X$WBI\!G_NGS9R[_55368IO#9;?N^)8ZJ^YCIWR5LUL>D_]:QC.K5SJG
MS\X+>"M_[@>GJD97O=D2GZT)7>++F(:%)J4N(7>:K-]85'/DOX8?BKB_'%3(
MS3<N->B6[YLT!K!4V!JN5O\IC&"QA%G]/$B%?XO/O>L@Q^OCU5N)T!;XHA4-
MG1>JJ9FRBKT^9IVH-#NX!BH?4/FJ(26I.]&@CJ4M-/7,C<:1#:.=BL*('L\@
MHV!_QI7Y^$0[2]BV!>9XB;8%I _'RKT"!/?7BR2)+4&Q#W!>O"+)WSZ/LD D
MT0^>6'4YY.*;%^;\2P#9!&&5D6<*_W;%<.G@P=E9Z[E^[Z3HN\RV6?0.RL(*
MO9LK4=^/R:-H"*4\[_EEJ2+6T M<+/+<$"Z%E1:A[O!$.\7DCY XI\]X!]KX
M!!V=IH]1&$D#UT'$KC*V'@9WH/4XO\%K'/$>BY0$R09:HC<TX&<B20%M'$?"
MW,7RFD_EN.#\US 0\ #=A%7)B,XZ2D8O3C9Q DEL8Q'GZ:R8Z_^1NTE&6S>^
M)C[Z>57BAX94W,V LO!J*@] W.HG(@$/[%[B*&V+_872CP^@?"!XO?POK!'J
M_Y;EJ[.5&SG-1J1&D*9,MR05OR*K6*(DTY^-N\;DZ\MN*2'&;"FA.0WV&]9V
M;XEXQ!*W1E-<=*J[N[NXOZ/39>M1NWC"[+EZ?Y/ICBI1Q[RV6%!;^,A4 @\B
M00^[*LE@DX%MB]^6 II0U5#P'+*:ZO</\(1(?$JX98"Z4.EBN15%^RS_>\^^
M9:>A+AI!-(6%3]5X)H-JGYW?U)_0@R.ZH.1-3Y#HF5@!\H;+QQGEFCJ/Z1PH
M4<;E.G;Q#8K\M7-MJ,I+KV5^343TVZ>I4>&DJJ3+P[,#.<JXLC^Q=9[^!_W,
M7D-$776C/S_:KAI7+*&[FJ25&+4_L[SNTBH<0O$]%?QQ\4<>/+DA[++D4>95
MY"60J>.<R3_U^89@#R7^4NMC5ISS%MU Y4SY-S,G,GV67H/@HJDS6 8':@J0
M7P""PS2OT 1DU$@"#QR'\#-"\QX$%YL ^L 5?V%5]Q;1N,='OHV_-G[J^R'5
M9M+"D-HS8+>EY;3!'#J.5:_.]S':/=5T%"3H@M;\0>W)SBQXLYY4V/Y9K8$=
MN\)QU(07B93Q(D%U/*_YB)%$A0"4RS#^"B'O(L75$Q<*@F,BOSP5K@)E(!HA
MC.'^;W>"1.AUYJA^G;)C@;SLNAY65'5N#R<.4@T:EI9O-J'P@KNA" 20;<3V
M,"IRABU+]1#'#*FRM2*6KN5DJRPT+ LD4GKQT4*[6O>)MD(RH3<%1=!'^;L8
M#([#_H6<%91!!:OMHU3[.7<+$.*3:Q1,60N^/)0^<\,00B8O7&_5?'887OX!
M$'W+6._RO%]V#\X:>,%.*\I)_V#]H%O:4@E;=RRLH4!7%:66$39<;VC_F::K
MB-+.J-@V*/I<C"T3S/3Y&$L,\7H=9$4, :2(Y)IG$>3'T 0,E,_+_5*]!>4<
MT((#3UC8Q.&9QG' 0/1=P;<-S70K]5& =CBG>B.UQ%TQ##+.5POXJ6[RUJ__
MP):;)4_BQN)E#A?&BK!O[<A5Q>^*J[*J"%[1E0A'EIV50>3$HS<,>?N'2UW+
M3.IHEQ+MHUAG$ ]O:[A8-7PV7'#>E5HWUYN\(C] MS=NLD@@-1OSQ36X(@2W
MA['PIK!BD(T=>0&XC*ZE6\3UP(:-":!Y*BXQ-ZXGJRL)+X+(\2'0,*F%EQLY
M(1O.-2U2-#UL#=P,4A IW-,!',!/.;/-\VP5)\&?#(\M1BN85FWL&*,=)"TS
M@QH;-3&[1I$,& S]#>3F"(CG9K+:F"7:U]_Q;:K\'R?_/#EY55G%?SGO3DYF
M)_)_NP/R7\[K#Q]F)S^^G;U]]4XL_5Y]>#W[\-.[V>NW/Q:/JPD$?AM7NTG'
MS9QSYHFOA//FU<QY??+Z1#RT]=-7/\W@V[QAHD9E2)(O#&Y3)&S%HI2+("_'
M]H_/:C16-X=M/<?KBU/#I!V<ZH8TS9@5J1.4\UW.0"HK _-?:0:K3+A0^.++
M*;5L2CI"7:AZ+78]DU#V'!DY7PX?%@OFV58\O09$39(0L%+V1C<V9=*2EL&H
MLK/0A4EM"8M'$B3),WQORM5M)H/ MR]X3Y!K<Z#R6S=^6PERR*,(<=DUKI.&
MYBW0='4H,43G];NFEJE_!U#;TD_.0'GDLR04IK)M&Q:,D/#(=ZVSMFU"-#*]
MM-IG>+;0H$$.WHKY><BP9!3DWSH=$&R_K0,"2WT1K5'_F?\$#CL2CUN1*:2'
M9[],X&*% [\I>+N-[$ANQ[Y#!P$M3$0T(<%[KR(^SK*2I[:>JDBU4CY'& 33
M%+AFN%5^N7Z)^[8@-=+SS9Q:MCJ+$O3M!7YP,CZKAK58Z<J\(HOE_8I!@&7V
M#!OS.-)=-VT?W7+Y7"7LE9TZ9:_VC7$/3>BOLVZ2(/*"#?];S1\^_5YAP,RY
MKP[T-V2W=& 7S4LKA!JF[;=^.KA=V;/H:N84G5E(:0UJ_09+X-K PU;24X,'
MX^0M7S^*S!E-]X@$1YOK2(OOED&L);>_(OE</?F7O-F$>[K:*5MV6^4/;&05
MDSW;1]]>ZL"X_#ERY9-\KFTD?H-Q-P1U[T&_7_'7K>+0OT]<..,X=Y][+1*W
M!KGLQE'].-"1?8.*PFWW=F8*D,\?=5P1?5<%ZL/RGW]@^7>5?E2+.N6W7)J+
MY5(>/G&B>G#KX+'GUZ8LP@Z]S)RR'Z?JR))1[8*+EO@LX93UV1/KQDY&!1PX
M<"K&P^I1VP&*#=F5Z8'::UG0"@,M$BTOHX=P?=XR[EVWWFG8<0Y<T]YD:,K^
M$?:T4#V1:[*?G10MG'-#RM_#*!HH6E(9"/:L"P"FOCI[&40# EYOU[#8PXC3
MD;1QAS;DR1J;XNNO"-1]U]=Q]/B2\W'M;.%)*>\+@"Q]@E#@.4N#3C (.L?O
M5A)K<8A0?#YHU"\K;ES&"0L>(QGT<N]^NY %$J3S4.=W4\4Z5-LB8H:W=E1S
MYX7J@#+.LB=$;,14$\J!V6M$IAZ)7L$.78APD^F!B&\X8T,%I0923 =-[ZCT
M"X 91T:79*X (%:O\\B_CCTWW(MZH@<QK8D^;)\4>@'&_3I!5L E'3(NKDQG
M^#.D#FL?'!B%(B&C>)Q\,MB2'M.T^,U4AC*0/EOB8W8^J?B#25,KY/J)=9AV
MG3W\87NXLP5"ET_,UC$8JGA8S$,\O/28S\,P_FKJ1MM^XW&D@] 1,J,9#+.Q
M,SW]!RU@VK+:(H/Q?U[4RFK_0))P9@=.6:T+8O'%N? R3B#I[8#/757$##IQ
M&KW88SDM2%N7QWV1VK-4[@-9ERFQ*J<6&EK#C$C1Q@IS'+[.ME?9QS&>34W@
ML>YAP)^. E>4 FJ.L^-!9XY)HQUSV/.'?S,ONX_Y7B)(Q*=ZM,&774.EP:KS
M(Z$ HA7T: Y^+:^3Z(B@NK2#!E#+9,#PPN-6#9B0'QL(8Z(.UC'_RQG_=Y#M
MN0" O\L.S'_\]QT'#<;63S\LW2R<&7$HD.+"3;S5X<,F<HR*ONP?P!)UQS<O
M4<\UU^4V#.XF85[0]A&K'B =CIJ<N-&8E;-;D4GP)*I<0?H=V)Y!U8[6D\>B
M@5.T(#YW+.2I^5S::@'5 !0MGLU6!NJW86Z!T;9A?G##HFJ]7R&K[9A)V=\"
M"MM*G4^&H#^M>N62KSUN[9&P%E#7C=+:N3S)4.Q4M,2' *MA*0/JG#ARH-J-
MAQ3MI+/X75AX?)E,^O")#P#?<<0)X7'IKL2H$>\W$ 8=0<,9UNYXW0^@'>G#
M6[#J(U)%P?-=U#1C5=QI7"SAW@V+4K%XNI6WAT0,BU#W@YLR_\9]7G>6#!"/
MOQ3/.ZI!HRXH\5W4OH!/ZX [/E?5=54^LO5>'=6M# 92"4&:NDFMN>)ZH&;0
M.^*0;.2E:-#0"_7(5SCJ4M7KXYX^[V"5A?H&,*$^V@U6U%\$^;%1DQ%%_RS*
M$#"V_KIR"A2YO)[<(!1*V$Y[24*BG$%U=&43-VZB7T#E3!8Z+Z8 ]3"EA:/"
MHQ7XRKNTFV*6\CD>D8'#R59,9#^&.9QB#+:KT;=^C29?. R57JQO!D*8J561
M!4?3[7!TA3(]X?47OO[R=J21H^B>EM&. KWA(9>E-R0EFG%Q(U\L*IF_)YM$
M:D/9@QV+Z[XP,9;)M'X.*] "S;Q:.B&2P(=M0/N.US2CM)?]]QF;0GR[YX!M
M)-K-.4=BR3R@Q+ENO>+50J@9+$95TBU1? (N&GIA+F[$WG^-Y0^=CRQ;Q3[Y
MW;!M]'T\BQAX*QV,7>!TX7>-K*:U18_<F))F-=^&-'2DC&^4]YKPCGM(BAO2
M960\7'%M5C.<9Y>,+_O=$,)[\BQ.GAL/XX-7WKRN70^ IYUFWS-(LJRZ=\K^
MMQO-BHO-=(,^@I[P<X%D$\.]8'$03'5!^&*]">-GQNY8\A1X#-_<?XI%:43^
M013'U,*[7/\]^(<^Q=F_6 9J>8P@(8;,FW$9)^I'\!R>5*3#:2A*3,K72\?(
M3'C4^$\SYYF;6/7*LEHV> MJKZ6CSK3*U54GE6V<KPSJ1T&R<_X=<A^9P20E
M?3]TT^H'3]]3ZD>JHZC3J1@GRTS$&^B!Q$MO3$?BP[.0P$:R2]E;BWU*W]+W
M9X\-7>JSM[FE:RV/DHIX7MT_[,5F+@M3FV1#1?H[DWU55.:XRV([S;6"VY*U
MN7A:%4F2S]/G:]:#T![TP+J-3PHB?Q#_K0T,WA$>30!,3AB1][#=#21S6MKA
MEVN*BQYT3R%N/[66Z21;PO"V,X8:C<$;I.5MZ5N4/8WTG4K_!G'\>9"N8(&P
M6$)2#/G)QS7?>%Q$1HA$(.96"?L ^)EK$[;OY8YN$!9HK;;_L]K>EI);O3!B
M7!/W5?CWB>U@I<K#?^D&B:@>)2.TX?Y1%>SXD;EP8NTOHEN(LTD@WVSD\[5+
M4OP3#A72\K;M/?-64?!'SM(>^?SAS:JNGGJ/."J%R'75N3A3J;]M5KO86[UK
MHF/^GN281J%=Q_]!M,DSH;^G4F-9T9F3IW+9)S,@%Y6=B:-<2\75V-"_"A?.
M)DO=T_VAHFEW<,,A&;, \GQ<\S6K?Q5E7$B(T97$/WW^Z/X[3L29AS:;OFS_
M4G3@5#VHZRUPGB(Z42<G=+GV6W!6*#O2I+5CG360DF=04ZF=SF 9D3RW[+^*
M[%;B4I(L' @K5_I:M2@"-%HGAT4VG_PH]/PSB\#IS3\"<W_-"0*BP!90I=A!
M5:[:B-F]V:K((42V[>V"@R:PJ<%Q&ZT(V=,%!$UE,RF0+F;)A2@L."%J3=8S
MS_D"0]T^YGOU4[;D-E(N6/GJ)(B$^189]SCZ9B]RJR0/L*^$ TM\>5"6-L_M
M1"Q?)8132>$\"#&*LA/J=+S6>WW1#\'M?+4DXN?B,(2>3*8'[,7Y*16-EG9.
MV$LX_WH1"DT'4EE"X7$I MD]C2FU@QFEXI_2BN*:^E<&;R.<9*;4S9L6$Y7$
MF4@W_>8MD0Q#A#VWN?44@/)A.QQ\.@0M-ZJF0C!0^9"*1!S.Z];O.^(7+0C7
MZAH,+2OS%A2$2_#2ZLME==<P;*W!B4>@+GFW\K=DMT'O/:L%U@!,5C-PT$R$
M0VF9C2:%LL=PM'N"-"#L\/RTHFD?$LK/L7C]C1OX'1IGJ0-/V:!@)6^+3HF7
M.#N)=+$%X-S_=RZ7<'#,T$RG4F:,Z#(#)"4TNA6;.=7KY/E++>/,"_'.'ZH\
M%<0;KA'5AT=]U8J2[2:"+%)=D-*GCU^\HH&EOG M&JMGPV;PZMD*0KJNHIV$
M1^5!3IF&]L" 7_DFX"22#@I+>TL>,3:"RM#8WU(1U0&7:S+7[X'4N(CX DK
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M.U+?\P&#T.MH6*\KY\6_A+_:^ +,]$1I21C?7S!0;\1PO(YPLWI<>$H>C7J
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MQ1O\$&Z_SL@(2P^=C-#TT(D)+PH\%M^&FSSQ5F[YF<'/]+H;$A/9!"1B@IJ
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M&Q__[_]J0$_R2__U?^0_Y)^J,/M__2]02P,$%     @ T:5A4EJ_N"1D70
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M25)<<('=6I22G"2@"Q8:Y&"/>(*;L- & R D 4C#=E5=5VQ\4 B<.7@P^U'
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M ?,Y)$<D7CU(L)61TOVN9QF8LI5I)?J__$30:>B$%$<DYK8P;[#8VV.]%J6
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M R\#C"9O\]4G+X[)_UY>/ CC!^US(H,'KP^0D8/V":%A@]O)L#%#(#,J_$+
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MW=S%84UU*#/YS"J6)Z*^WH7!(K<X<SAC]C&? 9.[GA2>D(*)LLESVT9TO)4
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MDC*_C-.NA@N8K2.4T\ _[@3=M&8C+J8C1HL?UN'K^R7R\$R<?"0_O",_5"8
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M,U376+5J-2.+*,R-+I&F3U0A5FL<Y>K&\#?9[HPI[ES>%/"Z&:I17"-#]BW
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M>64M,C R,#$R,S$N>&UL4$L! A0#%     @ T:5A4J@6TH3>'0  ]G\! !$
M             ( !-%X! '-K>64M,C R,#$R,S$N>'-D4$L! A0#%     @
MT:5A4CA%/:]K#    *\  !4              ( !07P! '-K>64M,C R,#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( -&E85(ARWBWUS\  )S8!  5
M      "  =^( 0!S:WEE+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #1
MI6%2$L?$TW 9 0#3K0\ %0              @ 'IR $ <VMY92TR,#(P,3(S
M,5]L86(N>&UL4$L! A0#%     @ T:5A4EJ_N"1D70  AAL' !4
M     ( !C.(" '-K>64M,C R,#$R,S%?<')E+GAM;%!+!08     !@ & (H!
(   C0 ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
